KRAS G12C INHIBITORS

FIELD OF THE INVENTION

[0001] The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

BACKGROUND OF THE INVENTION

[0002] Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ("KRas") is a small GTPase and a member of the Ras family of oncogenes. KRas serves a molecular switch cycling between inactive (GDP-bound) and active (GTP-bound) states to transduce upstream cellular signals received from multiple tyrosine kinases to downstream effectors to regulate a wide variety of processes, including cellular proliferation (e.g., see Alamgeer et al., (2013) Current Opin Pharmcol. 13:394-401).

[0003] The role of activated KRas in malignancy was observed over thirty years ago (e.g., see Santos et al., (1984) Science 223:661-664). Aberrant expression of KRas accounts for up to 20% of all cancers and oncogenic KRas mutations that stabilize GTP binding and lead to constitutive activation of KRas and downstream signaling have been reported in 25 -30% of lung adenocarcinomas. (e.g., see Samatar and Poulikakos (2014) Nat Rev Drug Disc 13(12): 928-942 doi: 10.1038/nrd428). Single nucleotide substitutions that result in missense mutations at codons 12 and 13 of the KRas primary amino acid sequence comprise approximately 40% of these KRas driver mutations in lung adenocarcinoma, with a G12C transversion being the most common activating mutation (e.g., see Dogan et al., (2012) Clin Cancer Res. 18(22):6169-6177, published online 2012 Sep 26. doi: 10.1158/1078-0432.CCR-11-3265).

[0004] The well-known role of KRAs in malignancy and the discovery of these frequent mutations in KRas in various tumor types made KRas a highly attractable target of the pharmaceutical industry for cancer therapy. Notwithstanding thirty years of large scale discovery efforts to develop inhibitors of KRas for treating cancer, no KRas inhibitor has


demonstrated sufficient safety and/or efficacy to obtain regulatory approval (e.g., see McCormick (2015) Clin Cancer Res. 21 (8):1797-1801).

[0005] Despite many failed efforts to target KRas, compounds that inhibit KRas activity are still highly desirable and under investigation, including those that disrupt effectors such as guanine nucleotide exchange factors (e.g., see Sun et al., (2012) Agnew Chem Int Ed Engl. 51(25):6140-6143 doi: 10.1002/anie201201358) as well target KRas G12C (e.g., see Ostrem et al., (2013) Nature 503:548-551). Clearly there remains a continued interest and effort to develop inhibitors of KRas, particularly inhibitors of activating KRas mutants, including KRas G12C.

[0006] Thus, there is a need to develop new KRas G12C inhibitors that demonstrate sufficient efficacy, stability and/or safety for treating KRas G12C-mediated cancer. The compounds and compositions of the present invention advantageously overcome one or more of the previous shortcomings by providing selective KRas G12C inhibitors.

SUMMARY OF THE INVENTION

[0007] In one aspect of the invention, compounds are provided that inhibit KRas G12C activity. In certain embodiments, the compounds are represented by formula (I):



Formula (I)

[0008] or a pharmaceutically acceptable salt thereof, wherein:

[0010] X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

[0011] Y is a bond, O, S or NR^5;

[0012] R^1 is $-C(O)C(R^A)$ ⋯ $C(R^B)_p$ or $-SO_2C(R^A)$ ⋯ $C(R^B)_p$;

[0013] R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

[0014] Z is C1 – C4 alkylene;

[0015] each R^3 is independently C1 – C3 alkyl, oxo, or haloalkyl;

[0016] L is a bond, -C(O)-, or C1 – C3 alkylene;

[0017] R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6 or R^7;

[0018] each R^5 is independently hydrogen or C1 – C3 alkyl;

[0019] R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

[0020] each R^7 is independently halogen, hydroxyl, C1 – C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

[0021] R^8 is oxo, C1 – C3 alkyl, C2 – C4 alkynyl, heteroalkyl, cyano, -$C(O)OR^5$, -$C(O)N(R^5)_2$, -$N(R^5)_2$, wherein the C1 – C3 alkyl may be optionally substituted with cyano, halogen, -OR^5, -$N(R^5)_2$, or heteroaryl

[0022] each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1 – C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl,

alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1 – C6 alkyl may be optionally substituted with cycloalkyl;

[0023] each R^{10} is independently hydrogen, acyl, C1 – C3 alkyl, heteroalkyl or hydroxyalkyl;

[0024] R^A is absent, hydrogen, or C1 – C3 alkyl;

[0025] each R^B is independently hydrogen, C1 – C3 alkyl, alkylaminylalkyl, dialkylaminylalkyl or heterocyclylalkyl;


[0026] m is zero or an integer between 1 and 2;

[0027] p is one or two; and wherein,

[0028] when ------ is a triple bond then R^A is absent, R^B is present and p equals one,

[0029] or when ------ is a double bond then R^A is present, R^B is present and p equals two, or R^A, R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl optionally substituted with one or more R^7.


[0030] Also included are compounds of Formula I having the Formula I-A:



Formula I-A

[0031] wherein R^1, R^3, R^4, R^5, R^{10}, L and m are as defined for Formula I, R^{11} is hydrogen, C1 – C3 alkyl or hydroxyalkyl, and the piperazinyl ring is optionally substituted with R^8 wherein R^8 is as defined for Formula I.


[0032] Also included are compounds of Formula I having the Formula I-B:



Formula I-B

[0033] where R^1, R^3, R^4, L and m are as defined for Formula I, R^2 is heterocyclylalkyl optionally substituted with one or more R^9 where R^9 is as defined for Formula I, and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula I.

[0034] In certain embodiments, the compounds are represented by Formula (II):



Formula (II)

[0035] or a pharmaceutically acceptable salt thereof:

[0036] wherein:

[0037] X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

[0038] Y is a bond, O, S or NR^5;

[0039] R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ or $-SO_2C(R^A)$ ------ $C(R^B)_p$;

[0040] R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, $-Z-NR^5R^{10}$, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

[0041] each Z is C1 – C4 alkylene;

[0042] each R^3 is independently C1 – C3 alkyl, oxo, haloalkyl, hydroxyl or halogen;

[0043] L is a bond, -C(O)-, or C1 – C3 alkylene;

[0044] R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6, R^7 or R^8;

[0045] each R^5 is independently hydrogen or C1 – C3 alkyl;

[0046] R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

[0047] each R^7 is independently halogen, hydroxyl, C1 – C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

[0048] R^8 is oxo, C1 – C3 alkyl, C2 – C4 alkynyl, heteroalkyl, cyano, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-N(R^5)_2$, wherein the C1 – C3 alkyl may be optionally substituted with cyano, halogen, $-OR^5$, $-N(R^5)_2$, or heteroaryl;

[0049] each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1 – C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl,


alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1 – C6 alkyl may be optionally substituted with cycloalkyl;

[0050] each R^{10} is independently hydrogen, acyl, C1 – C3 alkyl, heteroalkyl or hydroxyalkyl;

[0051] R^{11} is haloalkyl;


[0052] R^A is absent, hydrogen, deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl;


[0053] each R^B is independently hydrogen, deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7;

[0054] or when  is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo;


[0055] m is zero or an integer between 1 and 2;

[0056] p is one or two; and wherein,

[0057] when  is a triple bond then R^A is absent, p equals one and R^B is hydroxyalkyl,

[0058] or when  is a double bond then R^A is present, R^B is present and p equals two, wherein when R^A is hydrogen or C1 – C3 alkyl at least one R^B is deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl or heterocyclylalkyl, wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or C1 – C3 alkyl; or when each R^B is hydrogen, then R^A is deuterium, cyano, halogen, haloalkyl, $-C(O)N(R^5)_2$, hydroxyalkyl or heteroalkyl.


[0059] Also included are compounds of Formula II having the Formula II-A:



Formula II-A

[0060] wherein R^1, R^3, R^4, R^5, R^{10}, L and m are as defined for Formula II, R^{11} is hydrogen, C1 – C3 alkyl or hydroxyalkyl, and the piperazinyl ring is optionally substituted with R^8 wherein R^8 is as defined for Formula II.

[0061] Also included are compounds of Formula II having the Formula II-B:



Formula II-B

[0062] where R^1, R^3, R^4, R^8, L and m are as defined for Formula II, R^2 is heterocyclylalkyl optionally substituted with one or more R^9, and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula II.

[0063] In another aspect of the invention, pharmaceutical compositions are provided comprising a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0064] In yet another aspect of the invention, methods for inhibiting KRas G12C activity in a in a cell, comprising contacting the cell with a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B. In one embodiment, the contacting is in vitro. In one embodiment, the contacting is in vivo.

[0065] Also provided herein is a method of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof as defined herein.

[0066] Also provided are methods for treating cancer in a patient comprising administering a therapeutically effective amount of a compound or pharmaceutical composition of the present invention or a pharmaceutically acceptable salt thereof to a patient in need thereof.

[0067] Also provided herein is a method of treating a KRas G12C -associated disease or disorder in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein.

[0068] Also provided herein is a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein for use in therapy.

[0069] Also provided herein is a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B,or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein for use in the treatment of cancer.

[0070] Also provided herein is a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B,or a pharmaceutically acceptable salt or solvate thereof for use in the inhibition of KRas G12C.

[0071] Also provided herein is a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein, for use in the treatment of a KRas G12C-associated disease or disorder.

[0072] Also provided herein is the use of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer.

[0073] Also provided herein is a use of a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of activity of KRas G12C.

[0074] Also provided herein is the use of a compound of Formula I, Formula I-A, Formula 1-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for the treatment of a KRas G12C-associated disease or disorder.

[0075] Also provided herein is a method for treating cancer in a patient in need thereof, the method comprising (a) determining that the cancer is associated with a KRas G12C mutation (e.g., a KRas G12C-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0076] Also provided herein is a process for preparing a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof.

[0077] Also provided herein is a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt thereof obtained by a process of preparing the compound as defined herein.

DETAILED DESCRIPTION OF THE INVENTION

[0078] The present invention relates to inhibitors of KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising a therapeutically effective amount of the compounds and methods of use therefor.

DEFINITIONS

[0079] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications, and publications referred to herein are incorporated by reference.

[0080] As used herein, "KRas G12C" refers to a mutant form of a mammalian KRas protein that contains an amino acid substitution of a cysteine for a glycine at amino acid position 12. The assignment of amino acid codon and residue positions for human KRas is based on the amino acid sequence identified by UniProtKB/Swiss-Prot P01116: Variant p.Gly12Cys.

[0081] As used herein, a "KRas G12C inhibitor" refers to compounds of the present invention that are represented by formulae (I) as described herein. These compounds are capable of negatively modulating or inhibiting all or a portion of the enzymatic activity of KRas G12C. The KRas G12C inhibitors of the present invention interact with and irreversibly bind to KRas G12C by forming a covalent adduct with the sulfhydryl side chain of the cysteine residue at position 12 resulting in the inhibition of the enzymatic activity of KRas G12C.

[0082] A "KRas G12C-associated disease or disorder" as used herein refers to diseases or disorders associated with or mediated by or having a KRas G12C mutation. A non-limiting example of a KRas G12C-associated disease or disorder is a KRas G12C-associated cancer.

[0083] As used herein, the term "subject," "individual," or "patient," used interchangeably, refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans. In some embodiments, the patient is a human. In some embodiments, the subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented. In some embodiments, the

subject has been identified or diagnosed as having a cancer having a KRas G12C mutation (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments, the subject has a tumor that is positive for a KRas G12C mutation (e.g., as determined using a regulatory agency-approved assay or kit). The subject can be a subject with a tumor(s) that is positive for a KRas G12C mutation (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit). The subject can be a subject whose tumors have a KRas G12C mutation (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay). In some embodiments, the subject is suspected of having a KRas G12C gene-associated cancer. In some embodiments, the subject has a clinical record indicating that the subject has a tumor that has a KRas G12C mutation (and optionally the clinical record indicates that the subject should be treated with any of the compositions provided herein).

[0084] In some embodiments of any of the methods or uses described herein, an assay is used to determine whether the patient has KRas G12C mutation using a sample (e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a patient (e.g., a patient suspected of having a KRas G12C-associated cancer, a patient having one or more symptoms of a KRas G12C-associated cancer, and/or a patient that has an increased risk of developing a KRas G12C-associated cancer) can include, for example, next generation sequencing, immunohistochemistry, fluorescence microscopy, break apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR-based amplification (e.g., RT-PCR and quantitative real-time RT-PCR). As is well-known in the art, the assays are typically performed, e.g., with at least one labelled nucleic acid probe or at least one labelled antibody or antigen-binding fragment thereof.

[0085] The term "regulatory agency" is a country's agency for the approval of the medical use of pharmaceutical agents with the country. For example, a non-limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).

[0086] The term "amino" refers to $-NH_2$;

[0087] The term "acyl" refers to $-C(O)CH_3$.

[0088] The term "alkyl" as employed herein refers to straight and branched chain aliphatic groups having from 1 to 12 carbon atoms, 1-8 carbon atoms 1-6 carbon atoms, or 1-3 carbon atoms which is optionally substituted with one, two or three substituents. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, and hexyl.

[0089] The term "haloalkyl" refers to an alkyl chain in which one or more hydrogen has been replaced by a halogen. Examples of haloalkyls are trifluoromethyl, difluoromethyl and fluoromethyl.

[0090] The term "haloalkyloxy" refers to -O-haloalkyl.

[0091] An "alkylene," group is an alkyl group, as defined hereinabove, that is positioned between and serves to connect two other chemical groups. Exemplary alkylene groups include, without limitation, methylene, ethylene, propylene, and butylene.

[0092] The term "alkoxy" refers to –OC1 – C6 alkyl.

[0093] The term "cycloalkyl" as employed herein includes saturated and partially unsaturated cyclic hydrocarbon groups having 3 to 12 carbons, for example 3 to 8 carbons, and as a further example 3 to 6 carbons, wherein the cycloalkyl group additionally is optionally substituted. Examples of cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0094] The term "heteroalkyl" refers to an alkyl group, as defined hereinabove, wherein one or more carbon atoms in the chain are replaced by a heteroatom selected from the group consisting of O, S, and N.

[0095] As used herein, the term "hydroxyalkyl" refers to –alkyl-OH.

[0096] The term "dihydroxyalkyl" refers to an alkyl group as defined herein wherein two carbon atoms are each substituted with a hydroxyl group.

[0097] The term "alkylaminyl" refers to $-NR^x$-alkyl, wherein R^x is hydrogen. In one embodiment, R^x is hydrogen.

[0098] The term "dialkylaminyl" refers to $-N(R^y)_2$, wherein each R^y is C1 – C3 alkyl.

[0099] The term "alkylaminylalkyl" refers to –alkyl-NR^x-alkyl, wherein R^x is hydrogen. In one embodiment, R^x is hydrogen.

[00100] The term "dialkylaminylalkyl" refers to –alkyl-$N(R^y)_2$, wherein each R^y is C1 – C4 alkyl, wherein the alkyl of the--alkyl-$N(R^y)_2$ may be optionally substituted with hydroxy or hydroxyalkyl.

[00101] An "aryl" group is a C_6-C_{14} aromatic moiety comprising one to three aromatic rings, which is optionally substituted. As one embodiment, the aryl group is a C_6-C_{10} aryl group. Examples of aryl groups include, without limitation, phenyl, naphthyl, anthracenyl, fluorenyl, and dihydrobenzofuranyl.

[00102] An "aralkyl" or "arylalkyl" group comprises an aryl group covalently linked to an alkyl group, either of which may independently be optionally substituted or unsubstituted. An example of an aralkyl group is (C_1- C_6)alkyl(C_6-C_{10})aryl, including, without limitation, benzyl, phenethyl, and naphthylmethyl. An example of a substituted aralkyl is wherein the alkyl group is substituted with hydroxyalkyl.

[00103] A "heterocyclyl" or "heterocyclic" group is a ring structure having from about 3 to about 12 atoms, for example 4 to 8 atoms, wherein one or more atoms are selected from the group consisting of N, O, and S, the remainder of the ring atoms being carbon. The heterocyclyl may be a monocyclic, a bicyclic, a spirocyclic or a bridged ring system. The heterocyclic group is optionally substituted with R^7 on carbon or nitrogen at one or more positions, wherein R^7 is as defined for Formula I. The heterocyclic group is also independently optionally substituted on nitrogen with alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, aralkoxycarbonyl, or on sulfur with oxo or lower alkyl. Examples of heterocyclic groups include, without limitation, epoxy, azetidinyl, aziridinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, pyrrolidinonyl, piperidinyl, piperazinyl, imidazolidinyl, thiazolidinyl, dithianyl, trithianyl, dioxolanyl, oxazolidinyl, oxazolidinonyl, decahydroquinolinyl, piperidonyl, 4-piperidinonyl, thiomorpholinyl, thiomorpholinyl 1,1 dioxide, morpholinyl, oxazepanyl, azabicyclohexanes, azabicycloheptanes and oxa

azabiocycloheptanes. Specifically excluded from the scope of this term are compounds having adjacent annular O and/or S atoms.

[00104] The term "heterocyclylalkyl" refers to a heterocyclyl group as defined herein linked to the remaining portion of the molecule via an alkyl linker, wherein the alkyl linker of the heterocyclylalkyl may be optionally substituted with hydroxy or hydroxyalkyl.

[00105] As used herein, the term "heteroaryl" refers to groups having 5 to 14 ring atoms, preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 π electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to three heteroatoms per ring selected from the group consisting of N, O, and S. Examples of heteroaryl groups include acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, furanyl, furazanyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.

[00106] A "heteroarylalkyl" group comprises a heteroaryl group covalently linked to an alkyl group, wherein the radical is on the alkyl group, either of which is independently optionally substituted or unsubstituted. Examples of heteroarylalkyl groups include a heteroaryl group having 5, 6, 9, or 10 ring atoms bonded to a C1-C6 alkyl group. Examples of heteroaralkyl groups include pyridylmethyl, pyridylethyl, pyrrolylmethyl, pyrrolylethyl,

imidazolylmethyl, imidazolylethyl, thiazolylmethyl, thiazolylethyl, benzimidazolylmethyl, benzimidazolylethyl quinazolinylmethyl, quinolinylmethyl, quinolinylethyl, benzofuranylmethyl, indolinylethyl isoquinolinylmethyl, isoinodylmethyl, cinnolinylmethyl, and benzothiophenylethyl. Specifically excluded from the scope of this term are compounds having adjacent annular O and/or S atoms.

[00107] As used herein, "an effective amount" of a compound is an amount that is sufficient to negatively modulate or inhibit the activity of KRas G12C. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective.


[00108] As used herein, a "therapeutically effective amount" of a compound is an amount that is sufficient to ameliorate, or in some manner reduce a symptom or stop or reverse progression of a condition, or negatively modulate or inhibit the activity of KRas G12C. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective.

[00109] As used herein, treatment means any manner in which the symptoms or pathology of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein.

[00110] As used herein, amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

COMPOUNDS

[00111] In one aspect of the invention, compounds are provided represented by formula (I):



Formula (I)

[00112] or a pharmaceutically acceptable salt thereof, wherein:

[00113] X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

[00114] Y is a bond, O, S or NR^5;

[00115] R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ or $-SO_2C(R^A)$ ------ $C(R^B)_p$;

[00116] R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

[00117] Z is C1 – C4 alkylene;

[00118] each R^3 is independently C1 – C3 alkyl, oxo, or haloalkyl;

[00119] L is a bond, -C(O)-, or C1 – C3 alkylene;

[00120] R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6 or R^7;

[00121] each R^5 is independently hydrogen or C1 – C3 alkyl;

[00122] R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

[00123] each R^7 is independently halogen, hydroxyl, C1 – C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

[00124] R^8 is oxo, C1 – C3 alkyl, C2 – C4 alkynyl, heteroalkyl, cyano, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-N(R^5)_2$, wherein the C1 – C3 alkyl may be optionally substituted with cyano, halogen, $-OR^5$, $-N(R^5)_2$, or heteroaryl;

[00125] each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1 – C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1 – C6 alkyl may be optionally substituted with cycloalkyl;

[00126] each R^{10} is independently hydrogen, acyl, C1 – C3 alkyl, heteroalkyl or hydroxyalkyl;

[00127] R^A is absent, hydrogen, or C1 – C3 alkyl;

[00128] each R^B is independently hydrogen, C1 – C3 alkyl, alkylaminylalkyl, dialkylaminylalkyl or heterocyclylalkyl;


[0100] m is zero or an integer between 1 and 2;

[0101] p is one or two; and wherein,

[0102] when $\overset{\text{------}}{\equiv}$ is a triple bond then R^A is absent, R^B is present and p equals one;

[0103] or when ------ is a double bond then R^A is present, R^B is present and p equals two, or R^A, R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl optionally substituted with one or more R^7.

[0104] In certain embodiments, R^1-X is:



[0105] wherein R^1 is are defined for Formula I and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula I. In certain embodiments, R^8 is C1 – C3 alkyl wherein the alkyl is optionally substituted with cyano or OR^5, or $-C(O)N(R^5)_2$, wherein each R^5 is independently hydrogen or C1 – C3 alkyl.

[0106] In particular embodiments, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ where R^A, R^B and p are as defined for Formula I. In one embodiment, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$, wherein ------ is a triple bond and R^A is absent, p is one and R^B is C1 – C3 alkyl. In one embodiment, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$, wherein ------ is a double bond and R^A is hydrogen or C1 – C3alkyl, p is two and each R^B is independently hydrogen, C1 – C3alkyl, dialkylaminylalkyl or heterocyclylalkyl. In one embodiment, R^1 is $-C(O)C(R^A)=C(R^B)_p$, wherein R^A is hydrogen or C1 – C3alkyl, p is two, one of said R^B is hydrogen, C1 – C3alkyl, dialkylaminylalkyl or heterocyclylalkyl and the other R^B is hydrogen or C1 – C3alkyl. In one embodiment, R^1 is $-C(O)CH=CH_2$.

[0107] In one embodiment, Y is O or NR^5 and R^2 is selected from the group consisting of alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, heterocyclyl, heterocyclylalkyl, and heteroaryl. In one embodiment, Y is O and R^2 is hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, or dialkylaminylalkyl, wherein the alkylaminylalkyl or

dialkylaminylalkyl is optionally substituted with one or more R^9. In one embodiment, the optionally substituted alkylaminylalkyl or dialkylaminylalkyl is independently selected from methylaminylpropan-2-yl, dimethylaminylethyl, methylethylaminylethyl, dimethylaminylpropanyl, dimethylaminylpropan-2-yl, dimethylaminylbutanyl, dimethylaminylbutan-2-yl, 2-dimethylaminylpropanol, or diethylaminylethyl. In one embodiment, Y is O or NR^5 and R^2 is heterocyclyl or heterocyclylalkyl optionally substituted with one or more R^9. Nonlimiting examples of one or more R^9 when R^2 is heterocyclyl or heterocyclylalkyl include C1 – C3 alkyl, acyl, oxo, cyano, alkoxy, cycloalkyl, cycloalkylmethyl, halogen, and hydroxyl. Nonlimiting examples of R^2 heterocyclyls optionally substituted with one or more R^9 include azetidinyl, C1-C3alkyl-substituted azetidinyl (e.g., methylazetidinyl), halo-substituted azetidinyl (e.g., difluoroazetidinyl), tetrahydropyran, pyrrolidinyl, C1-C3 alkyl-substituted pyrrolidinyl (e.g., methylpyrrolidinyl, dimethylpyrrolidinyl, and isopropylpyrrolidinyl), cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, halo-substituted pyrrolidinyl (e.g., fluoropyrrolidinyl and difluoropyrrolidinyl), methoxyethylpyrrolidinyl, (N-methyl)methoxypyrrolidinyl, piperazinyl, dimethylaminylpyrrolidinyl, morpholinyl, methylmorpholinyl, 1,4-oxazepanyl, piperdinyl, C1-C3 alkyl-substituted piperidinyl (e.g., methylpiperidinyl), acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl (e.g., fluoropiperdinyl), dihalopiperdinyl (e.g., difluoropiperdinyl), alkoxypiperdinyl, pyrrolidonyl, piperidonyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, and azabicyclo[2.2.1]heptan-2-yl.

[0108] In one embodiment, Y is O and R^2 is heteroarylalkyl optionally substituted with one or more R^9. In one embodiment, the heteroaryl portion of the heteroarylalkyl is pyridinyl.

[0109] In one embodiment, Y is O and R^2 is $-ZR^5R^{10}$. In one embodiment, R^5 is C1 – C3 alkyl and R^{10} is independently selected from acyl, hydroxyalkyl or alkoxy.

[0110] In one embodiment, Y is a bond and R^2 is hydrogen, heterocyclyl or aryl, wherein said heterocyclyl and aryl are optionally substituted with one or more R^9.

[0111] In one embodiment, Y is a bond and R^2 is hydrogen.

[0112] In one embodiment, Y is a bond and R^2 is heterocyclyl optionally substituted with one or more R^9. In one embodiment, Y is a bond and R^2 is heterocyclyl optionally substituted with

methyl, halogen or dimethylamino. Nonlimiting examples of R^2 heterocyclyls include azetidinyl, piperidinyl, piperazinyl, morpholinyl, and pyrrolidinyl.

[0113] In one embodiment, Y is a bond and R^2 is aryl optionally substituted with one or more R^9. In one embodiment, the aryl is phenyl substituted with heterocyclylalkyl.

[0114] In certain other embodiments when X is a monocyclic ring, R^4 is aryl. In one embodiment, R^4 is selected from the group consisting of phenyl and naphthyl and is optionally substituted with one or more R^6 or R^7. Examples of R^7 substituents include halogen, hydroxyl, C1- C6 alkyl (e.g., C1- C3 alkyl), cycloalkyl, haloalkyl, Q-haloalkyl, amino, cyano, hydroxyalkyl and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from methyl, trifluoromethyl, 2,2,2-trifluoroethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and trifluoromethylthio. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from hydroxyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with Q-haloalkyl and hydroxyl or fluorine.

[0115] In one embodiment, R^4 is aryl wherein aryl is naphthyl optionally substituted with one or more R^7. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro.

[0116] In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl.

[0117] In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^7. In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^7 independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, alkoxy and amino. In one embodiments, R^4 is indoyl, indazolyl, quinolinyl, isoquinolinyl, pyridinyl or benzo[d]thiazolyl optionally substituted with one or more R^7. In one embodiments, R^4 is indoyl, indazolyl, quinolinyl, isoquinolinyl, pyridinyl or benzo[d]thiazolyl optionally substituted with one or more R^7 independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, alkoxy and amino.

[0118] In yet other embodiments, R^4 is heteroaryl, optionally an indoyl or an indazolyl, each of which may be substituted with one or more R^7. In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^7 substituents independently selected from the group consisting of halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl and alkoxy. In one embodiment, the R^4 heteroaryl is indazolyl optionally substituted with one or two R^7 independently selected from alkoxy, haloalkyl, and C1-C6 alkyl. In other embodiments, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7 independently selected from amino, hydroxyl, C1 – C3 alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with R^7 selected from hydroxyl and amino. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In other embodiments, the R^4 heteroaryl is benzo[d]thiazolyl optionally substituted with one or more R^7, such as hydroxyl, one or two C1 – C3 alkyl, or hydroxyl and one or two C1 – C3 alkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl and C1 – C3alkyl.

[0119] In one embodiment, where X is a monocyclic ring, R^4 is aralkyl. In certain embodiments, the aralkyl is benzyl. In other embodiments, the alkyl of the benzyl group is optionally substituted with hydroxyalkyl.


[0120] In one embodiment, L is a bond.

[0121] In one embodiment, m is one and R^3 is C1 – C3 alkyl.

[0122] In one embodiment, m is one and R^3 is oxo.

[0123] In one embodiment, R^8 is heteroalkyl, C2-C4 alkynyl or C1 – C3 alkyl optionally substituted with $-OR^5$, cyano or heteroaryl. In one embodiment, R^8 is methyl, cyanomethyl, methoxymethyl, hydroxymethyl. In one embodiment, R^8 is methyl. In one embodiment, R^8 is cyanomethyl. In one embodiment, R^8 is hydroxymethyl.

[0124] In one embodiment, Formula I includes compounds having the Formula I-A:




[0125] wherein R^1, R^3, R^4, R^5, R^{10}, L and m are as defined for Formula I, R^{11} is hydrogen, methyl or hydroxyalkyl, and the piperidinyl ring is optionally substituted with R^8 wherein R^8 is as defined for Formula I. In one embodiment, L is a bond. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^6 or R^7. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^7. In one embodiment, each R^7 is independently selected from hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy. In one embodiment, R^5 and R^{10} are

each C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from methyl, trifluoromethyl, 2,2,2-trifluoroethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and trifluoromethylthio. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from hydroxyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with Q-haloalkyl and hydroxyl or fluorine. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro. In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is indazolyl optionally substituted with one or two R^7 independently selected from alkoxy, haloalkyl, and C1-C6 alkyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7 independently selected from amino, hydroxyl, C1 – C3alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In one embodiment, the R^4 heteroaryl is benzo[d]thiazolyl optionally substituted

with one or more R^7, such as hydroxyl, one or two C1 – C3 alkyl, or hydroxyl and one or two C1 – C3 alkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl and C1 – C3alkyl. In one embodiment, R^{11} is methyl. In one embodiment, the piperidinyl ring is unsubstituted. In one embodiment, the piperidinyl ring is substituted with R^8. In one embodiment, R^8 is C1 – C3 alkyl optionally substituted with cyano or hydroxyl. In one embodiment, R^8 is methyl, cyanomethyl or hydroxymethyl. In one embodiment, R^8 is methyl. In one embodiment, R^8 is cyanomethyl. In one embodiment, R^8 is hydroxymethyl. In another embodiment, R^5 and R^{10} are each C1 – C3 alkyl, R^{11} is methyl, R^8 is methyl, cyanomethyl or hydroxymethyl, L is a bond, and R^4 is aryl or heteroaryl, each optionally substituted with one or more R^6 or R^7.

[0126] In one embodiment, Formula I includes compounds having the Formula I-B:



Formula I-B


and R^1, R^3, R^4, R^9, L and m are as defined for Formula I, R^2 is heterocyclylalkyl optionally substituted with one or more R^9, and the piperidinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula I. In one embodiment, the heterocyclyl portion of the R^2 heterocyclylalkyl is a monocyclic, bicyclic, or bridged ring system having one or two ring heteroatoms independently selected from N and O. In one embodiment, R^2 heterocyclyl is pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-oxazepanyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, and azabicyclo[2.2.1]heptan-2-yl, optionally substituted with one or more R^9. In one embodiment,

each R^9 is selected from acyl, oxo, halogen, cyano, C1 – C3 alkyl, alkoxy, hydroxyalkyl, heteroalkyl, heterocyclyl, cycloalkyl, aralkyl and dialkylamidoalkyl. In one embodiment, L is a bond. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^6 or R^7. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^7. In one embodiment, each R^7 is independently selected from hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from methyl, trifluoromethyl, 2,2,2-trifluoroethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and trifluoromethylthio. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from hydroxyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with Q-haloalkyl and hydroxyl or fluorine. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro. In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is indazolyl optionally substituted with one or two R^7 independently selected from alkoxy, haloalkyl, and C1-C6 alkyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7. In one embodiment, R^4 is heteroaryl, wherein the

heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7 independently selected from amino, hydroxyl, C1 – C3 alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In one embodiment, the R^4 heteroaryl is benzo[d]thiazolyl optionally substituted with one or more R^7, such as hydroxyl, one or two C1 – C3 alkyl, or hydroxyl and one or two C1 – C3 alkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl and C1 – C3 alkyl. In one embodiment, R^{11} is methyl. In one embodiment, the piperidinyl ring is unsubstituted. In one embodiment, the piperidinyl ring is substituted with R^8. In one embodiment, the piperidinyl ring is unsubstituted. In one embodiment, the piperidinyl ring is substituted with R^8. In one embodiment, R^8 is C1 – C3 alkyl optionally substituted with cyano, hydroxyl or methoxy. In one embodiment, R^8 is methyl, cyanomethyl, hydroxymethyl or methoxymethyl.


[0127] In one embodiment, X is a saturated bridged ring system. Nonlimiting examples of bridged ring systems include diazabicycloheptanes and diazabicyclooctanes. In certain embodiments, when X is a saturated bridged ring system, R^1 is $–C(O)CH=CH_2$. In one embodiment, the bridged ring system is substituted with one or two groups independently selected from R^8, where R^8 is as defined for Formula I. In one embodiment, the bridged ring system is unsubstituted. In one embodiment, the bridged ring system is diazabicyclo[3.2.1]octan-8-yl or diazabicyclo[3.2.1]octan-3-yl.

[0128] In one embodiment, R^1-X is:



[0129] wherein A and B are a spirocyclic ring system, wherein A and B are the same or different and independently represent a 4-6 membered saturated ring systems, wherein the rings are optionally substituted with one or more R^8, wherein R^8 is as defined for Formula I. In certain embodiments, R^1 is $-C(O)CH=CH_2$. In certain embodiments, rings A and B are unsubstituted.

[0130] In one embodiment, the spirocyclic ring system is unsubstituted. Non-limiting examples of spirocyclic ring systems include:



[0131] In certain embodiments when A and B represent a spirocyclic ring system, R^1 is –C(O)CH=CH_2.

[0132] In one embodiment of Formula I, R^2 is selected from the group consisting of hydroxyalkyl, dialkylaminylalkyl, heterocyclyl and heterocyclylalkyl, wherein each of the heterocyclyl or heterocyclylalkyl are independently optionally substituted with R^9. In another embodiment, R^2 is heterocyclyl and heterocyclylalkyl, wherein each of the heterocyclyl or heterocyclylalkyl are independently optionally substituted with one or more R^9. In certain embodiments, R^2 is dialkylaminylalkyl optionally substituted with one or more R^9. Non-limiting examples include dimethylaminylethyl, dimethylaminylpropanyl, dimethylaminylpropan-2-yl, dimethylaminylbutanyl, dimethylaminylbutan-2-yl, 2-dimethylaminylpropanol, or diethylaminylethyl.

[0133] In one embodiment, Y is O and R^2 is selected from the group consisting of hydroxyalkyl, dialkylaminylalkyl, heterocyclyl, heterocyclylalkyl, and -ZR^5R^{10}, wherein R^5 and R^{10} are as defined for Formula I.






[0134] In one embodiment, Y is O and R^2 is selected from the group consisting of hydroxyalkyl, dialkylaminylalkyl, heterocyclyl and heterocyclylalkyl, wherein each of the heterocyclyl or heterocyclylalkyl are independently optionally substituted with R^9. In another embodiment, R^2 is heterocyclyl and heterocyclylalkyl, wherein each of the heterocyclyl or heterocyclylalkyl are independently optionally substituted with one or more R^9. Non-limiting examples of R^9 include acyl, oxo, halogen, cyano, C1 – C6 alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, aralkyl or dialkylamidoalkyl. In certain embodiments, R^2 is dialkylaminylalkyl optionally substituted with one or more R^9. Non-limiting examples include dimethylaminylethyl, dimethylaminylpropanyl, dimethylaminylpropan-2-yl, dimethylaminylbutanyl, dimethylaminylbutan-2-yl, 2-dimethylaminylpropanol, or diethylaminylethyl.









[0135] In one embodiment of Formula I, R^4 is aryl optionally substituted with one or more R^6 or R^7. In one embodiment, R^4 is phenyl or naphthyl optionally substituted with one or more R^6 or R^7. In one embodiment, R^4 is phenyl or naphthyl optionally substituted with one or more R^7. In one embodiment, R^4 is phenyl or naphthyl optionally substituted with one or more R^7 substituents independently selected from halogen, hydroxyl, C1 – C3alkyl, cycloalkyl, alkoxy,







haloalkyl, or Q-haloalkyl wherein Q is O or S. In one embodiment, R^4 is phenyl or naphthyl optionally substituted with one or more R^7 substituents independently selected from methyl, trifluoromethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and methylthio.







[0136] In one embodiment, R^4 is isoquinolinyl which is optionally substituted with amino. In one embodiment, R^4 is aralkyl. In certain embodiments, the aralkyl is benzyl. In one embodiment, the aralkyl is benzyl wherein the alkyl portion is substituted with hydroxyl or hydroxyalkyl.









[0137] Nonlimiting examples of compounds of Formula (I), Formula I-A and Formula I-B are selected from the group consisting of:








,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,



,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,



,



,



,



,


,



,


,



,




,




,




,









,



















,





,



,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,



,



,










,










,










,










,










,



,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,




,




,




,




,




,











,





,





,



,

,

,

,

,

,

,

,



,



,



,










,



,


,



,


,



,

,

,

,

,

,

,

,




,




,




,




,




,











,



















,



















,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,



,



,



,



,



,



,



,



,



,



,










,










,










,



,



,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,



,



,


,



,


,



,




,




,




,




,




,




,




,




,




,









,












,




,


,

,

,

,

,

,



,

,

,

,

,

,

,

,




,




,




,




,




,




,



,




, and




,

[0138] and pharmaceutically acceptable salts thereof.


[0139] Further nonlimiting examples of compounds of Formula (I), Formula I-A and Formula I-B are selected from the group consisting of:




,




,




,




,




,




,





,





,



,



,



,



,



,



,



,








,



,


,



,


,



,

,

,

,

,

,




,




,




,




,





,





,



,








,



,


,



,


,



,

,

,

,

,

,


O
NC
(S)
N
N
N
N
O
(R)
N
HO


,


O
NC
(S)
N
N
N
N
O
(S)
N
CF3
OMe


,


O
NC
(S)
N
N
N
N
O
(S)
N
Cl


,


O
NC
N
N
N
N
O
O
N
CF3
Cl







,



O
NC
(S)
N
N
N
N
O
(S)
N
F

,



O
NC
(S)
N
N
N
N
O
(R)
N

,



,

,

,

,

,

,




,




,




,




,




,




,


N
(E)
O
N
NC
(S)
N
N
N
O
(S)
N
CF3
Cl


,


O
N
NC
(S)
N
N
HO
N
N
O
(R)
(R)
N


,


O
N
NC
(S)
N
N
N
O
(S)
N
F


,


O
N
NC
(S)
N
N
HO
N
N
O
(R)
N


,



O
N
NC
(S)
N
N
N
O
H
N
(Z)
N
(Z)


,



O
N
NC
(S)
N
N
N
N
O
(S)
N


,



,








,



,


,



,


,



,

,

,

,

,

,




,




,




,




,
















,
















,







































,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


























,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

, and

,

[0140] and pharmaceutically acceptable salts thereof.

[0141] In one aspect of the invention, compounds are provided represented by formula (II):



Formula (II)

[0142] or a pharmaceutically acceptable salt thereof:

[0143] wherein:

[0144] X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

[0145] Y is a bond, O, S or NR^5;

[0146] R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ or $-SO_2C(R^A)$ ------ $C(R^B)_p$;

[0147] R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

[0148] each Z is C1 – C4 alkylene;

[0149] each R^3 is independently C1 – C3 alkyl, oxo, haloalkyl, hydroxyl or halogen;

[0150] L is a bond, -C(O)-, or C1 – C3 alkylene;

[0151] R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6, R^7 or R^8;

[0152] each R^5 is independently hydrogen or C1 – C3 alkyl;

[0153] R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

[0154] each R^7 is independently halogen, hydroxyl, C1 – C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

[0155] R^8 is oxo, C1 – C3 alkyl, C2 – C4 alkynyl, heteroalkyl, cyano, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-N(R^5)_2$, wherein the C1 – C3 alkyl may be optionally substituted with cyano, halogen, $-OR^5$, $-N(R^5)_2$, or heteroaryl;

[0156] each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1 – C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1 – C6 alkyl may be optionally substituted with cycloalkyl;

[0157] each R^{10} is independently hydrogen, acyl, C1 – C3 alkyl, heteroalkyl or hydroxyalkyl;

[0158] R^{11} is haloalkyl;

[0159] R^A is absent, hydrogen, deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl;

[0160] each R^B is independently hydrogen, deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7;

[0161] or when ------ is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 4-8 membered partially saturated cycloalkyl substituted with oxo;


[0162] m is zero or an integer between 1 and 2;

[0163] p is one or two; and wherein,

[0164] when ------ is a triple bond then R^A is absent, p equals one and R^B is hydroxyalkyl,

[0165] or when ------ is a double bond then R^A is present, R^B is present and p equals two, wherein when R^A is hydrogen or C1 – C3 alkyl, at least one R^B is deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, $-NHC(O)C1 – C3$ alkyl, $-CH_2NHC(O)C1 – C3$ alkyl or heterocyclylalkyl, wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl; or when each R^B is hydrogen, then R^A is deuterium, cyano, halogen, haloalkyl, $-C(O)N(R^5)_2$, hydroxyalkyl or heteroalkyl.

[0166] In certain embodiments, R^1-X is:



[0167] wherein R^1 is are defined for Formula II and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula II. In certain embodiments, R^8 is C1 – C3 alkyl wherein the alkyl is optionally substituted with cyano or OR^5, or $-C(O)N(R^5)_2$, wherein each R^5 is independently hydrogen or C1 – C3 alkyl.

[0168] In particular embodiments, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ where R^A, R^B and p are as defined for Formula II. In one embodiment, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$, wherein ------ is a triple bond and R^A is absent, p is one and R^B is hydroxyalkyl.

[0169] In one embodiment, R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$, wherein ------ is a double bond and R^A is hydrogen or C1 – C3 alkyl, p is two and at least one R^B is deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, $-NHC(O)$C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7. In one embodiment, when ------ is a double bond, the double bond is in the E configuration. In one embodiment, the double bond is in the Z configuration.

[0170] In certain embodiments, one R^B is heterocyclylalkyl substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or C1 – C3 alkyl and the other R^B is hydrogen. In one embodiment, the heterocyclyl portion of the heterocyclylalkyl is azetidinyl substituted with a halogen. In certain embodiments, the halogen is fluorine. In one embodiment, the heterocyclyl portion of the heterocyclylalkyl is pyrrolidinyl substituted with one or more halogen. In certain embodiments, the halogen-substituted pyrrolidinyl is fluoropyrrolidinyl or difluorpyrrolidinyl.

[0171] In certain embodiments, one R^B is halogen and the other R^B is hydrogen. In one embodiment, the halogen is chlorine.

[0172] In certain embodiments, one R^B is haloalkyl and the other R^B is hydrogen. In one embodiment, the haloalkyl is chloromethyl, fluoromethyl, difluoromethyl or trifluoromethyl.

[0173] In certain embodiments, one R^B is heteroalkyl and the other R^B is hydrogen. In one embodiment, the heteroalkyl is methoxymethyl.

[0174] In ceratin embodiments, one R^B is $-ZNR^5R^{11}$, wherein Z is methylene, R^5 is methyl and R^{11} is trifluoromethyl or 2,2,2-trifluoroethyl, and the other R^B is hydrogen.

[0175] In certain embodiments, one R^B is hydroxyalkyl and the other R^B is hydrogen.

[0176] In certain embodiments, one R^B is heteroaryl optionally substituted with one or more R^7 and the other R^B is hydrogen. In one embodiment, the heteroaryl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each substituted with one or more R^7.

[0177] In certain embodiments, one R^B is heteroarylalkyl optionally substituted with one or more R^7, and the other R^B is hydrogen. In one embodiment, the heteroaryl portion of the heteroarylalkyl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each optionally substituted with one or more R^7. In one embodiment, the one or more R^7 is C1 – C3 alkyl.

[0178] In certain embodiments, one R^B is $-C(O)N(R^5)_2$ and the other R^B is hydrogen. In one embodiment, each R^5 is hydrogen. In one embodiment, each R^5 is C1 – C3 alkyl.

[0179] In certain embodiments, one R^B is -NHC(O)C1 – C3 alkyl or $-CH_2NHC(O)$C1 – C3 alkyl and the other R^B is hydrogen. In one embodiment, the C1 – C3 alkyl is methyl.

[0180] In one embodiment, R^1 is $-C(O)C(R^A)=C(R^B)_p$, wherein R^A is deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl, p is two, each R^B is hydrogen. In one embodiment, R^A is halogen. In one embodiment, the halogen is fluorine or chlorine. In one embodiment, R^A is haloalkyl. In one embodiment, the haloalkyl is trifluoromethyl. In one embodiment, R^A is cyano. In one embodiment, R^A is heteroalkyl. In one embodiment, the heteroalkyl is methoxy. In one embodiment, R^A is hydroxyalkyl.

[0181] In one embodiment, R^1 is $-C(O)C(R^A)\overset{\text{------}}{=}C(R^B)_p$, wherein $\overset{\text{------}}{=}$ is a double bond and R^A is deuterium, p is two and at least one R^B is deuterium.

[0182] In one embodiment, R^1 is $-C(O)C(R^A)\overset{\text{------}}{=}C(R^B)_p$, wherein $\overset{\text{------}}{=}$ is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo.

[0183] In one embodiment, R^1 is $-C(O)C(R^A)\overset{\text{------}}{=}C(R^B)_p$, wherein $\overset{\text{------}}{=}$ is a double bond and p is two, one R^B is hydrogen, the second R^B is dialkylaminylalkyl, and R^A is halogen

[0184] In one embodiment, Y is O or NR^5 and R^2 is heterocyclyl or heterocyclylalkyl optionally substituted with one or more R^9. Nonlimiting examples of one or more R^9 when R^2 is heterocyclyl or heterocyclylalkyl include C1 – C3 alkyl, acyl, oxo, cyano, alkoxy, cycloalkyl, cycloalkylmethyl, halogen, and hydroxyl. Nonlimiting examples of R^2 heterocyclyls optionally substituted with one or more R^9 include azetidinyl, C1-C3 alkyl-substituted azetidinyl (e.g., methylazetidinyl), halo-substituted azetidinyl (e.g., difluoroazetidinyl), tetrahydropyran, pyrrolidinyl, C1-C3 alkyl-substituted pyrrolidinyl (e.g., methylpyrrolidinyl, dimethylpyrrolidinyl, and isopropylpyrrolidinyl), cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, halo-substituted pyrrolidinyl (e.g., fluoropyrrolidinyl and difluoropyrrolidinyl), halo-substituted N-methyl pyrrolidinyl (e.g., N-methylfluoropyrrolidinyl and N-methyldifluoropyrrolidinyl), methoxyethylpyrrolidinyl, alkoxy-substituted N-methylpyrrolidinyl (e.g., (N-methyl)methoxypyrrolidinyl), piperazinyl, dimethylaminylpyrrolidinyl, morpholinyl, methylmorpholinyl, 1,4-oxazepanyl, piperdinyl, C1-C3 alkyl-substituted piperidinyl (e.g., methylpiperidinyl), acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl (e.g., fluoropiperdinyl), dihalopiperdinyl (e.g., difluoropiperdinyl), alkoxypiperdinyl, pyrrolidonyl, piperidonyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, and azabicyclo[2.2.1]heptan-2-yl.

[0185] In one embodiment, the heterocycyl portion of the heterocyclylalkyl is N-methylpyrrolidinyl. In one embodiment, the heterocycyl portion of the heterocyclylalkyl is 3,3-difluoro-1-methylpyrrolidinyl.

[0186] In certain other embodiments, R^4 is aryl. In one embodiment, R^4 is selected from the group consisting of phenyl and naphthyl and is optionally substituted with one or more R^6 or R^7. Examples of R^7 substituents include halogen, hydroxyl, C1- C6 alkyl (e.g., C1- C3 alkyl), cycloalkyl, haloalkyl, Q-haloalkyl, amino, cyano, hydroxyalkyl and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from methyl,

trifluoromethyl, hydroxyl, fluoro, and chloro. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from methyl, hydroxyl, trifluoromethyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with trifluoromethyl and C1 – C3 alkyl or two C1 – C3 alkyl.

[0187] In one embodiment, R^4 is aryl wherein aryl is naphthyl optionally substituted with one or more R^7. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro. In one embodiment, the substituted naphthyl is 8-chloronaphthyl or 8-methylnaphthyl.

[0188] In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl.

[0189] In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^7 or R^8 independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, alkoxy and amino. In one embodiments, R^4 is indoyl, indazolyl, quinolinyl, isoquinolinyl, pyridinyl or benzo[d]thiazolyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiments, R^4 is indoyl, indazolyl, quinolinyl, isoquinolinyl, pyridinyl or benzo[d]thiazolyl optionally substituted with one or more R^7 or R^8 independently selected from oxo, halogen, hydroxyl, C1-C3 alkyl, haloalkyl, Q-haloalkyl, alkoxy and amino.

[0190] In yet other embodiments, R^4 is heteroaryl, optionally an indoyl or an indazolyl, each of which may be substituted with one or more R^6, R^7 or R^8. In one embodiment, R^4 is heteroaryl optionally substituted with one or more R^7 or R^8 substituents independently selected from the


group consisting of halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl and alkoxy. In one embodiment, the R^4 heteroaryl is indazolyl optionally substituted with one or two R^7 or R^8 independently selected from oxo, trifluoromethyl, alkoxy, haloalkyl, and C1-C6 alkyl. In other embodiments, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7 independently selected from amino, hydroxyl, C1 – C3 alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a quinolinyl or isoquinolinyl, each optionally substituted with R^7 selected from hydroxyl and amino. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl, trifluoromethyl and C1 – C3alkyl.

[0191] In one embodiment, L is a bond.



[0192] In one embodiment, m is zero.


[0193] In one embodiment, R^8 is heteroalkyl, C2-C4 alkynyl or C1 – C3 alkyl optionally substituted with $-OR^5$, cyano or heteroaryl. In one embodiment, R^8 is methyl, cyanomethyl, methoxymethyl, hydroxymethyl. In one embodiment, R^8 is methyl. In one embodiment, R^8 is cyanomethyl. In one embodiment, R^8 is hydroxymethyl.

[0194] In one embodiment, Formula II includes compounds having the Formula II-A:





[0195] wherein R^1, R^3, R^4, R^5, R^{10}, L and m are as defined for Formula II, R^{11} is hydrogen, methyl or hydroxyalkyl, and the piperazinyl ring is optionally substituted with R^8 wherein R^8 is as defined for Formula II.

[0196] In particular embodiments, R^1 is $-C(O)C(R^A)$  $C(R^B)_p$ where R^A, R^B and p are as defined for Formula II. In one embodiment, R^1 is $-C(O)C(R^A)$  $C(R^B)_p$, wherein is a triple bond and R^A is absent, p is one and R^B is hydroxyalkyl.

[0197] In one embodiment, R^1 is $-C(O)C(R^A)$  $C(R^B)_p$, wherein is a double bond and R^A is hydrogen or C1 – C3 alkyl, p is two and at least one R^B is deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, $-NHC(O)$C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7.

[0198] In one embodiment, R^1 is $-C(O)C(R^A)=C(R^B)_p$, wherein R^A is deuterium, cyano, halogen, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl, p is two, and each R^B is hydrogen. In one embodiment, R^A is halogen. In one embodiment, the halogen is fluorine or chlorine. In one embodiment, R^A is haloalkyl. In one embodiment, the haloalkyl is trifluoromethyl. In one embodiment, R^A is cyano. In one embodiment, R^A is heteroalkyl. In one embodiment, the heteroalkyl is methoxymethyl. In one embodiment, R^A is hydroxyalkyl.

[0199] In one embodiment, R^1 is $-C(O)C(R^A)$  $C(R^B)_p$, wherein is a double bond and R^A is deuterium, p is two and at least one R^B is deuterium.


[0200] In one embodiment, R^1 is $-C(O)C(R^A)$  $C(R^B)_p$, wherein is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo.

[0201] In one embodiment, R^1 is $-C(O)C(R^A)$ ═══ $C(R^B)_p$, wherein ═══ is a double bond and p is two, one R^B is hydrogen, the second R^B is dialkylaminylalkyl, and R^A is halogen.

[0202] In one embodiment, L is a bond. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^7. In one embodiment, each R^7 or R^8 is independently selected from oxo, hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy. In one embodiment, R^5 and R^{10} are each C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from methyl, trifluoromethyl, 2,2,2-trifluoroethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and trifluoromethylthio. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from hydroxyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with Q-haloalkyl and hydroxyl or fluorine. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 or R^8 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro. In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is indazolyl optionally substituted with one or two R^7 or R^8 independently selected

from oxo, alkoxy, haloalkyl, and C1-C6 alkyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^7 independently selected from amino, hydroxyl, C1 – C3alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^7. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl and C1 – C3alkyl. In one embodiment, R^{11} is methyl. In one embodiment, the piperazinyl ring is unsubstituted. In one embodiment, the piperazinyl ring is substituted with R^8. In one embodiment, R^8 is C1 – C3 alkyl optionally substituted with cyano or hydroxyl. In one embodiment, R^8 is methyl, cyanomethyl or hydroxymethyl. In one embodiment, R^8 is methyl. In one embodiment, R^8 is cyanomethyl. In one embodiment, R^8 is hydroxymethyl. In another embodiment, R^5 and R^{10} are each C1 – C3 alkyl, R^{11} is methyl, R^8 is methyl, cyanomethyl or hydroxymethyl, L is a bond, and R^4 is aryl or heteroaryl, each optionally substituted with one or more R^6 or R^7.

[0203] In one embodiment, Formula II includes compounds having the Formula II-B:



Formula II-B

[0204] where R^1, R^3, R^4, L and m are as defined for Formula II, R^2 is heterocyclylalkyl optionally substituted with one or more R^9 wherein R^9 is as defined for Formula II, and the piperazinyl ring is optionally substituted with R^8, where R^8 is as defined for Formula II.

[0205] In particular embodiments, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$ where R^A, R^B and p are as defined for Formula II. In one embodiment, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$, wherein $\overset{\text{------}}{\equiv}$ is a triple bond and R^A is absent, p is one and R^B is hydroxyalkyl.

[0206] In one embodiment, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$, wherein $\overset{\text{------}}{\equiv}$ is a double bond and R^A is hydrogen or C1 – C3 alkyl, p is two and at least one R^B is deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7.

[0207] In one embodiment, R^1 is $-C(O)C(R^A)=C(R^B)_p$, wherein R^A is deuterium, cyano, halogen, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl, p is two, and each R^B is hydrogen. In one embodiment, R^A is halogen. In one embodiment, the halogen is fluorine or chlorine. In one embodiment, R^A is haloalkyl. In one embodiment, the haloalkyl is trifluoromethyl. In one embodiment, R^A is cyano. In one embodiment, R^A is heteroalkyl. In one embodiment, the heteroalkyl is methoxymethyl. In one embodiment, R^A is hydroxyalkyl.

[0208] In one embodiment, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$, wherein $\overset{\text{------}}{\equiv}$ is a double bond and R^A is deuterium, p is two and at least one R^B is deuterium.

[0209] In one embodiment, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$, wherein $\overset{\text{------}}{\equiv}$ is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo.

[0210] In one embodiment, R^1 is $-C(O)C(R^A)$ $\overset{\text{------}}{\equiv}$ $C(R^B)_p$, wherein $\overset{\text{------}}{\equiv}$ is a double bond and p is two, one R^B is hydrogen, the second R^B is dialkylaminylalkyl, and R^A is halogen.

[0211] In one embodiment, the heterocyclyl portion of the R^2 heterocyclylalkyl is a monocyclic, bicyclic, or bridged ring system having one or two ring heteroatoms independently selected from N and O. In one embodiment, R^2 heterocyclyl is azetidinyl, methylazetidinyl, ethylazetidinyl, isopropylazetidinyl, difluoroazetidinyl, cyclopropylazetidinyl, tetrahydropyranylazetidinyl, tetrahydropyran, pyrrolidinyl, methylpyrrolidinyl, diemethylpyrrolidinyl, isopropylpyrrolidinyl, cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, fluoropyrrolidinyl, difluoropyrrolidinyl, (N-methyl)fluoropyrrolidinyl, (N-methyl)difluoropyrrolidinyl, methoxyethylpyrrolidinyl, alkoxy-substituted N-methylpyrrolidinyl (e.g., (N-methyl)methoxypyrrolidinyl), piperazinyl, dimethylaminylpyrrolidinyl, pyrrolidinone, methylpyrrolidinone, morpholinyl, methylmorpholinyl, ethylmorpholinyl, isopropylmorpholinyl, oxetanyl, 1,4-oxazepanyl, piperdinyl, methylpiperidinyl acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl, dihalopiperdinyl, fluoropiperdinyl, difluoropiperdinyl, alkoxypiperdinyl, pyrrolidonyl, piperidinonyl, tetrahydropyrrolizinyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, or azabicyclo[2.2.1]heptan-2-yl, optionally substituted with one or more R^9. In one embodiment, each R^9 is selected from acyl, oxo, halogen, cyano, C1 – C3 alkyl, alkoxy, hydroxyalkyl, heteroalkyl, cycloalkyl, aralkyl, heterocyclyl and dialkylamidoalkyl. In one embodiment, L is a bond. In one embodiment, the heterocyclyl portion of the R^2 heterocyclylalkyl is (N-methyl)difluoropyrrolidinyl, including 3,3-difluoro-1-methylpyrrolidinyl. In one embodiment, the heterocyclyl portion of the R^2 heterocyclylalkyl is N-methylpyrrolidinyl.


[0212] In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, R^4 is aryl or heteroaryl, each of which is optionally substituted with one or more R^7. In one embodiment, each R^7 is independently selected from hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, the aryl is phenyl substituted with one or more R^7 groups


independently selected from methyl, trifluoromethyl, 2,2,2-trifluoroethyl, hydroxyl, trifluoromethoxy, hydroxyl, fluoro, chloro, isopropyl, cyclopropyl and trifluoromethylthio. In one embodiment, the aryl is phenyl substituted with one to three R^7 groups independently selected from hydroxyl, fluorine and chlorine. In one embodiment, the aryl is phenyl substituted with hydroxyl and C1 – C3 alkyl or two C1 – C3 alkyl. In one embodiment, the aryl is phenyl substituted with Q-haloalkyl and hydroxyl or fluorine. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, hydroxyl, C1- C3 alkyl, haloalkyl, Q-haloalkyl, and alkoxy. In one embodiment, the aryl is naphthyl substituted with one or more R^7 groups independently selected from halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl and hydroxyl. In one embodiment, R^4 is naphthyl optionally substituted with one or more R^7 substituents independently selected from hydroxyl, halogen, C1 – C3 alkyl, amino, and haloalkyl. In one embodiment, R^4 is naphthyl optionally substituted with one to three R^7 substituents independently selected from difluoromethyl, methyl, hydroxyl, amino, fluoro, and chloro. In one embodiment, the aryl is naphthyl optionally substituted with one or more halogen. In one embodiment, the aryl is naphthyl substituted with hydroxyl and trifluoromethyl or C1 – C3alkyl. In one embodiment, the aryl is naphthyl substituted with hydroxyl. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is indazolyl optionally substituted with one or two R^7 independently selected from alkoxy, haloalkyl, and C1-C6 alkyl.










[0213] In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, R^4 is heteroaryl, wherein the heteroaryl is quinolinyl or isoquinolinyl, each optionally substituted with one or more R^6, R^7 or R^8 independently selected from oxo, amino, hydroxyl, C1 – C3 alkyl, and hydroxyl. In one embodiment, the R^4 heteroaryl is a pyridinyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, the R^4 heteroaryl is pyridinyl optionally substituted with one or more R^7 independently selected from C1 – C3 alkyl, halogen and haloalkyl. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or more R^6, R^7 or R^8. In one embodiment, the R^4 heteroaryl is indolyl optionally substituted with one or two R^7 independently selected from hydroxyl and C1 – C3 alkyl. In one embodiment, R^{11} is methyl. In one embodiment, the piperazinyl ring is unsubstituted. In one










embodiment, the piperazinyl ring of Formula II-B is substituted with R^8. In one embodiment, R^8 is C1 – C3 alkyl optionally substituted with cyano, hydroxyl or methoxy. In one embodiment, R^8 is methyl, cyanomethyl, hydroxymethyl or methoxymethyl.










[0214] Nonlimiting examples of compounds of Formula (II), Formula II-A and Formula II-B are selected from the group consisting of:





























,

,

,

,

,

,

,

,

,








,

,

,

,

,

,

,

,

,









,

,

,

,

,

,

,

,

,










,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,



,

,

,

,

,

,



,

,

,

,

,

,

,













,

,

,

,

,

,

,

,
















































































,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

and ,

[0215] or a pharmaceutically acceptable salt thereof.

[0216] In one embodiment, the compounds of Formula I include trifluoroacetic acid salts of the above compounds. The compounds of Formula (I), Formula I-A, Formula I-B, Formula (II), Formula II-A, or Formula II-B may be formulated into pharmaceutical compositions.

PHARMACEUTICAL COMPOSITIONS

[0217] In another aspect, the invention provides pharmaceutical compositions comprising a KRas G12C inhibitor according to the invention and a pharmaceutically acceptable carrier, excipient, or diluent. Compounds of the invention may be formulated by any method well known in the art and may be prepared for administration by any route, including, without

limitation, parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal, or intrarectal. In certain embodiments, compounds of the invention are administered intravenously in a hospital setting. In one embodiment, administration may be by the oral route.

[0218] The characteristics of the carrier will depend on the route of administration. As used herein, the term "pharmaceutically acceptable" means a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism, and that does not interfere with the effectiveness of the biological activity of the active ingredient(s). Thus, compositions according to the invention may contain, in addition to the inhibitor, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The preparation of pharmaceutically acceptable formulations is described in, e.g., Remington's Pharmaceutical Sciences, 18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

[0219] As used herein, the term pharmaceutically acceptable salt refers to salts that retain the desired biological activity of the above-identified compounds and exhibit minimal or no undesired toxicological effects. Examples of such salts include, but are not limited to acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid, and polygalacturonic acid. The compounds can also be administered as pharmaceutically acceptable quaternary salts known by those skilled in the art, which specifically include the quaternary ammonium salt of the formula --NR+Z-, wherein R is hydrogen, alkyl, or benzyl, and Z is a counterion, including chloride, bromide, iodide, --O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate, and diphenylacetate).

[0220] The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount without causing serious toxic effects in the patient treated. In one embodiment, a dose of the active compound for all of the above-mentioned conditions is in the range from about 0.01 to 300 mg/kg, for

example 0.1 to 100 mg/kg per day, and as a further example 0.5 to about 25 mg per kilogram body weight of the recipient per day. A typical topical dosage will range from 0.01-3% wt/wt in a suitable carrier. The effective dosage range of the pharmaceutically acceptable derivatives can be calculated based on the weight of the parent compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those skilled in the art.

[0221] The pharmaceutical compositions comprising compounds of the present invention may be used in the methods of use described herein.

METHODS OF USE

[0222] In yet another aspect, the invention provides for methods for inhibiting KRas G12C activity in a cell, comprising contacting the cell in which inhibition of KRas G12C activity is desired with an effective amount of a compound of Formula (II), Formula II-A, or Formula II-B, pharmaceutically acceptable salts thereof or pharmaceutical compositions containing the compound or pharmaceutically acceptable salt thereof. In one embodiment, the contacting is in vitro. In one embodiment, the contacting is in vivo.

[0223] As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" a KRas G12C with a compound provided herein includes the administration of a compound provided herein to an individual or patient, such as a human, having KRas G12C, as well as, for example, introducing a compound provided herein into a sample containing a cellular or purified preparation containing the KRas G12C.

[0224] In one embodiment, a cell in which inhibition of KRas G12C activity is desired is contacted with an effective amount of a compound of Formula (II), Formula II-A, or Formula II-B, to negatively modulate the activity of KRas G12C. In other embodiments, a therapeutically effective amount of pharmaceutically acceptable salt or pharmaceutical compositions containing the compound of Formula (II), Formula II-A, or Formula II-B, may be used.

[0225] By negatively modulating the activity of KRas G12C, the methods described herein are designed to inhibit undesired cellular proliferation resulting from enhanced KRas G12C activity within the cell. The cells may be contacted in a single dose or multiple doses in accordance with a particular treatment regimen to effect the desired negative modulation of KRas G12C. The degree of covalent modification of KRas G12C may be monitored in vitro using well known methods, including those described in Example A below. In addition, the inhibitory activity of exemplary compounds in cells may be monitored, for example, by measuring the inhibition of KRas G12C activity of the amount of phosphylated ERK, including those described in Example B below, to assess the effectiveness of treatment and dosages may be adjusted accordingly by the attending medical practitioner.

[0226] In another aspect, methods of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of Formula (I), Formula II-A, or Formula II-B, pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof are provided.

[0227] The compositions and methods provided herein may be used for the treatment of a KRas G12C-associated cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of Formula (II), Formula II-A, or Formula II-B, pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the compound or pharmaceutically acceptable salts thereof are provided. In one embodiment, the KRas G12C-associated cancer is lung cancer.

[0228] The compositions and methods provided herein may be used for the treatment of a wide variety of cancers including tumors such as lung, prostate, breast, brain, skin, cervical carcinomas, testicular carcinomas, etc. More particularly, cancers that may be treated by the compositions and methods of the invention include, but are not limited to tumor types such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate and thyroid carcinomas and sarcomas. More specifically, these compounds can be used to treat: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell,

undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic

syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. In certain embodiments, the cancer is non-small cell lung cancer.

[0229] The concentration and route of administration to the patient will vary depending on the cancer to be treated. The compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds and salts also may be co-administered with other anti-neoplastic compounds, e.g., chemotherapy, or used in combination with other treatments, such as radiation or surgical intervention, either as an adjuvant prior to surgery or post-operatively.

[0230] Also provided herein is a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein for use in therapy.

[0231] Also provided herein is a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein for use in the treatment of cancer.

[0232] Also provided herein is a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof for use in the inhibition of KRas G12C.

[0233] Also provided herein is a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein, for use in the treatment of a KRas G12C-associated disease or disorder.

[0234] Also provided herein is the use of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer.

[0235] Also provided herein is a use of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate

thereof, as defined herein in the manufacture of a medicament for the inhibition of activity of KRas G12C.

[0236] Also provided herein is the use of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for the treatment of a KRas G12C-associated disease or disorder.

[0237] Also provided herein is a method for treating cancer in a patient in need thereof, the method comprising (a) determining that cancer is associated with a KRas G12C mutation (e.g., a KRas G12C-associated cancer) (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit); and (b) administering to the patient a therapeutically effective amount of a compound of Formula I, Formula I-A, Formula I-B, Formula II, Formula II-A or Formula II-B, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.

[0238] One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and/or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.


[0239] One skilled in the art will further recognize that human clinical trials including first-in-human, dose ranging and efficacy trials, in healthy patients and/or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

REACTION SCHEMES AND EXAMPLES

[0240] The compounds of the present invention may be prepared from commercially available reagents using the synthetic methods and reaction schemes described herein, or using other reagents and conventional methods well known to those skilled in the art.

[0241] For instance, compounds of the present invention may be prepared according to the General Reaction Schemes I and II.

GENERAL REACTION SCHEMES




SCHEME I

[0242] Compounds of Formula I wherein L and Y are bonds, R^2 is hydrogen and R^4 is aryl or heteroaryl can be prepared according to Scheme I. In step A, an appropriately functionalized dihydropyridopyrimidine (1) is coupled to a heterocycle containing one nucleophilic amine species, with the other bound to a protecting group to provide compound (2). This coupling proceeds in a solvent such as dichloromethane in the presence of a base such as triethylamine or Hunig's base. In step B, the Boc group of compound (2) is removed using conditions known in the art, for example with trifluoroacetic acid in a solvent such as dichloromethane, to provide compound (3). In step C, the substituent R^4 is introduced with a palladium coupling, using a suitable functionalized aryl or heteroaryl system, for example an aryl triflate, in the presence of a palladium catalyst such as Pd_2DBA_3/Xantphos in a solvent such as toluene with a base such as sodium tert-butoxide to provide compound (4). In step D, the protecting group of ring X compound (4) is removed, for example hydrogenolysis by Pd/C in the presence of H_2 in a polar solvent such as EtOH/THF to provide compound (5). In the final step, E, R^1 is introduced to provide a compound of Formula I, for example by treating with an acid chloride having the formula Cl–C(O)C(R^A)$=$C(R^B)$_p$ or Cl–SO_2C(R^A)$=$C(R^B)$_p$, or an anhydride having the formula C(R^B)$_p$$=$C($R^A$)C(O)OC(O)C($R^A$)$=$C($R^B$)$_p$, where R^A, R^B and p are as defined for Formula I. For example, in the case where R^1 is an acryloyl group, this reaction proceeds, for example, in a solvent such as methylene chloride in the presence of acryloyl chloride or an acryloyl anhydride and a base such as Hunig's base. In some cases, the species

R^4 will also contain a protecting group, which can be removed at a subsequent step in the synthetic sequence.

[0243] Compounds (1), (2), (3), (4) and (5) as shown and described above for Scheme **I** are useful as intermediates for preparing compounds of Formula I and are provided as further aspects of the invention.



SCHEME II


[0244] Compounds of Formula I wherein L is a bond, –Y-R^2 is other than hydrogen and R^4 is aryl or heteroaryl can be prepared according to Scheme II. In step A, an appropriately functionalized dihydropyridopyrimidine (6) is coupled to a heterocycle containing one nucleophilic amine species, with the other bound to a protecting group to provide compound (7). This coupling proceeds in a solvent such as dichloromethane in the presence of a base such as triethylamine or Hunig's base. In step B, the substituent –Y-R^2 is introduced by substitution of the chlorine by a nucleophile, for example (S)-1-(dimethylamino-propan-2-ol in a polar solvent such as dioxane to provide compound (8). In step C, the Boc group is removed using

conditions known in the art, for example with trifluoroacetic acid in a solvent such as dichloromethane to provide compound (9). In step D, the substituent R^4 is introduced with a palladium coupling, using a suitable functionalized aryl or heteroaryl system, for example an aryl triflate, in the presence of a palladium catalyst such as Pd_2DBA_3/BINAP in a solvent such as toluene with a base such as sodium tert-butoxide to provide compound (10). In step E, the protecting group of ring X is removed, for example hydrogenolysis by Pd/C in the presence of H_2 in a polar solvent such as EtOH/THF to provide compound (11). In step F, R^1 is introduced to provide a compound of Formula I, for example by treating with an acid chloride having the formula $Cl–C(O)C(R^A)$ ⋿ $C(R^B)_p$ or $Cl–SO_2C(R^A)$ ⋿ $C(R^B)_p$, or an anhydride having the formula $C(R^B)_p$⋿ $C(R^A)C(O)OC(O)C(R^A)$ ⋿ $C(R^B)_p$, where R^A, R^B and p are as defined for Formula I. For example, in the case where R^1 is an acryloyl group, this reaction proceeds, for example, in a solvent such as methylene chloride in the presence of acryloyl chloride acryloyl anhydride and a base such as Hunig's base. In some cases, the species R^4 and R^2 may also contain protecting groups, which can be removed at a subsequent step in the synthetic sequence.

[0245] Compounds (6), (7), (8), (9), (10) and (11) as shown and described above for Scheme **2** are useful as intermediates for preparing compounds of Formula I, Formula I-A or Formula I-B and are provided as further aspects of the invention.

[0246] Accordingly, also provide is a process for preparing a compound of Formula I, comprising:


[0247] (a) for a compound of Formula I where Y is a bond and R^2 is hydrogen, reacting a compound of formula 5



5

[0248] where X, R^3 and R^4 are as defined for Formula I, with an acid chloride having the formula Cl–C(O)C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$ or Cl–SO_2C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$ or an anhydride having the formula C(R^B)$_p$ $\overset{\text{------}}{=}$ C(R^A)C(O)OC(O)C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$, where R^A, R^B and p are as defined for Formula I, in the presence of a base; or

[0249] (b) for a compound of Formula I wherein L is a bond and –Y-R^2 is other than hydrogen, reacting a compound of formula (11)



(11)

[0250] wherein L is a bond, –Y-R^2 is other than hydrogen, and X, R^3 and R^4 are as defined for Formula I, with an acid chloride having the formula Cl–C(O)C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$ or Cl–SO_2C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$, or an anhydride having the formula C(R^B)$_p$ $\overset{\text{------}}{=}$ C(R^A)C(O)OC(O)C(R^A) $\overset{\text{------}}{=}$ C(R^B)$_p$, where R^A, R^B and p are as defined for Formula I, in the presence of a base; and


[0251] optionally forming a salt thereof.

[0252] The compounds of the present invention may have one or more chiral center and may be synthesized as stereoisomeric mixtures, isomers of identical constitution that differ in the arrangement of their atoms in space. The compounds may be used as mixtures or the individual components/isomers may be separated using commercially available reagents and conventional methods for isolation of stereoisomers and enantiomers well-known to those skilled in the art, e.g., using CHIRALPAK® (Sigma-Aldrich) or CHIRALCEL® (Diacel Corp) chiral chromatographic HPLC columns according to the manufacturer's instructions. Alternatively, compounds of the present invention may be synthesized using optically pure, chiral reagents and intermediates to prepare individual isomers or enantiomers. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the


invention. Unless otherwise indicated, whenever the specification, including the claims, refers to compounds of the invention, the term "compound" is to be understood to encompass all chiral (enantiomeric and diastereomeric) and racemic forms.

[0253] The following Examples are intended to illustrate further certain embodiments of the invention and are not intended to limit the scope of the invention.

Intermediate 1




3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate




[0254] 3-Hydroxynaphthalen-1-yl trifluoromethanesulfonate (13.101 g, 44.831 mmol) was dissolved in dichloromethane (100 mL) and stirred at 0 °C. To this solution was added chloro(methoxy)methane (3.7456 ml, 49.315 mmol) and Hunig's base (11.745 mL, 67.247 mmol). The reaction was stirred at 0 °C for 4 hrs. The reaction was partitioned with 1M HCl and washed with saturated sodium bicarbonate. The combined organic layers were dried over magnesium sulfate and concentrated under vacuum. The concentrated material was loaded onto a 120 g RediSep® gold silica gel column with dichloromethane and purified by normal phase chromatography (CombiFlash®, 0%-20% ethyl acetate/hexanes as the eluent) to give 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate (11.785 g, 35.045 mmol, 78.171 % yield).

Intermediate 2




2-bromo-7-(methoxymethoxy)naphthalene




[0255] To a solution of 7-bromonaphthalen-2-ol (2.0 g, 9.0 mmol) in dimethyl acetamide (40 mL) was added chloro(methoxy)methane (1.4 g, 18 mmol) and cesium carbonate (5.8 g, 18 mmol) and the reaction mixture was stirred overnight at room temperature. The reaction was diluted with water and the aqueous layer washed with ethyl acetate. The combined organic layers were washed with water and brine, dried over magnesium sulfate and concentrated under vacuum. The crude material was purified by normal phase chromatography using 5-50% ethyl acetate/hexanes as the eluent to give 2-bromo-7-(methoxymethoxy)naphthalene (1.0 g, 3.7 mmol, 42 % yield).

Intermediate 3




2-bromo-1-fluoro-3-(methoxymethyl)benzene




[0256] To a stirred solution of 2-bromo-3-fluorophenol (1422 mg, 7.445 mmol) in 22 mL tetrahydrofuran at room temperature under nitrogen was added NaH (327.6 mg, 8.190 mmol) neat as a solid portion wise. After 15 minutes, a solution had formed. Chloro(methoxy)methane (678.6 μL, 8.934 mmol) was added by syringe. After stirring for 2 hours, the reaction was quenched with saturated ammonium chloride solution and then partitioned between ethyl acetate (30 mL) and water (30 mL). The combined organic layers were isolated, washed with brine, dried over $MgSO_4$, filtered and concentrated. The crude product was loaded in a minimum of dichloromethane onto a 40 gram RediSep® column pre-wet with hexanes and eluted with an ethyl acetate/hexanes gradient (0% to 20% ethyl acetate). Fractions containing the product were combined and concentrated to provide the product as a clear oil (1.45g, 83%).

Intermediate 4




2-bromo-1-fluoro-4-(methoxymethoxy)benzene




[0257] To a stirred solution of 3-bromo-4-fluorophenol (327 mg, 1.71 mmol) in 5.1 mL tetrahydrofuran at room temperature under nitrogen was added NaH (75.3 mg, 1.88 mmol) neat as a solid portion wise. After 15 minutes, a solution had formed. Chloro(methoxy)methane (156 μL, 2.05 mmol) was added by syringe. After stirring for 2 hours, the reaction was quenched with saturated ammonium chloride solution and partitioned between ethyl acetate and water. The combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated. The crude product was loaded in a minimum of dichloromethane onto a 24 gram RediSep® column pre-wet with hexanes and eluted with an ethyl acetate/hexanes gradient (0% to 20% ethyl acetate). Fractions containing the product were combined and concentrated to provide the product as a clear oil (120 mg, 29.8%)

Intermediate 5




4-bromo-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole



[0258] To a solution of 4-bromo-5-methyl-1H-indazole (0.7 g, 3.3 mmol) in dimethyl acetamide (30 mL) cooled to 0 °C was added NaH (0.19 g, 4.6 mmol) in portions and the reaction mixture was purged with nitrogen. The reaction was stirred for 20 minutes, and then (2-(chloromethoxy)ethyl)trimethylsilane (0.83 g, 5.0 mmol) was added and the reaction was stirred for 2 hours while warming to room temperature. The reaction was quenched by pouring into water and the aqueous layer was extracted into ethyl acetate. The combined organic layers were washed with water and brine, dried over $MgSO_4$ and concentrated under vacuum. The crude material was purified by chromatography using 10-50% ethyl acetate/hexanes as the eluent to give 4-bromo-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (0.87 g, 79%).


Intermediate 6



(R)-1-(pyrrolidin-1-yl)propan-2-ol

[0259] In a sealed tube, R-(+)-Propylene oxide (3.69 mL, 52.7 mmol) was cooled to -78°C and then sparged with anhydrous dimethyl amine for a few minutes. The reaction mixture was heated to 70°C for 16 hours. The reaction was cooled and concentrated in vacuo for 20 minutes to provide (R)-1-(pyrrolidin-1-yl)propan-2-ol (5.35 g, 41.4 mmol, 98.2% yield).


Intermediate 7



(R)-1-morpholinopropan-2-ol

[0260] In a sealed tube, R-(+)-Propylene oxide (2.111 mL, 30.13 mmol) and morpholine (1.490 mL, 17.22 mmol) were heated to 70°C for 20 hours. The reaction was cooled and concentrated in vacuo to provide (R)-1-morpholinopropan-2-ol (2.47 g, 17.01 mmol, 98.80 % yield).


Intermediate 8



(R)-1-(dimethylamino)butan-2-ol

[0261] In a sealed tube, R-(+)-Propylene oxide (4.00 g, 55.5 mmol) and dimethylamine (1.00 g, 22.2 mmol), were heated to 65°C for 18 hours. The reaction was cooled and concentrated in vacuo. The resulting residue was purified by silica gel (0-12% MeOH in DCM) to provide (R)-1-(dimethylamino)butan-2-ol (1.38 g, 11.8 mmol, 53.1 % yield).


Intermediate 9



(R)-1-((R)-3-methoxypyrrolidin-1-yl)propan-2-ol

[0262] In a sealed tube, (R)-3-methoxypyrrolidine hydrochloride (1.00 g, 7.27 mmol), TEA (2.03 mL, 14.5 mmol) and R-(+)-Propylene oxide (1.27 mL, 18.2 mmol) were heated to 65°C for 18 hours. The reaction was cooled and concentrated in vacuo. The resulting residue was purified by silica gel (0-12% MeOH in DCM) to provide (R)-1-((R)-3-methoxypyrrolidin-1-yl)propan-2-ol (775 mg, 4.87 mmol, 67.0 % yield).

Intermediate 10




(R)-1-((S)-3-methoxypyrrolidin-1-yl)propan-2-ol

[0263] In a sealed tube, (S)-3-methoxypyrrolidine hydrochloride (1.00 g, 7.27 mmol), TEA (2.03 mL, 14.5 mmol) and R-(+)-Propylene oxide (1.27 mL, 18.2 mmol) were heated to 65°C

for 18 hours. The reaction was cooled and concentrated in vacuo. The resulting residue was purified by silica gel (0-12% MeOH in DCM) to provide (R)-1-((S)-3-methoxypyrrolidin-1-yl)propan-2-ol (781 mg, 4.90 mmol, 67.5 % yield)


Intermediate 11



(R)-1-((S)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-1-yl)propan-2-ol

[0264] In a sealed tube, R-(+)-Propylene oxide (0.609 mL, 8.69 mmol) and (S)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine (1.00 g, 4.97 mmol) were heated to 70°C for 20 hours. The reaction was cooled and concentrated in vacuo to provide (R)-1-((S)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-1-yl)propan-2-ol (1.29 g, 4.20 mmol, 84.6 % yield).

Intermediate 12




tert-butyl 2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate

[0265] To a suspension of lithium chloride (246 mg, 5.81 mmol) and Lithium Borohydride (126 mg, 5.81 mmol) in ethanol (9 mL), at 0°C under nitrogen, a solution of 1-(tert-butyl) 2-methyl 4-methylpiperazine-1,2-dicarboxylate (750 mg, 2.90 mmol) in dry THF (6 mL) was added dropwise. The reaction was stirred overnight forming a white precipitate. The precipitate was filtered and washed with ethanol. The combined filtrate and organic extracts were concentrated to provide a white residue which was extracted with ethyl acetate. The combined organic layers were washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The residue was purified by chromatography with isocratic 10% MeOH

in DCM with 0.2% NH_4OH to provide tert-butyl 2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate (104 mg, 0.452 mmol, 15.6 % yield).


Intermediate 13



(S)-2-(2-methylpiperidin-1-yl)ethan-1-ol

[0266] A mixture of (S)-2-methylpiperidine (100 mg, 1.01 mmol), 2-bromoethanol (78 μL, 139 mg, 1.11 mmol, 1.1 eq.), sodium iodide (151 mg, 1 eq.), potassium carbonate (418 mg, 3 eq.) and acetonitrile (1 mL) in a 4-mL vial was purged with nitrogen, sealed and stirred at room temperature for 2 days. The reaction mixture was partitioned between diethyl ether (15 mL) and water (2 mL). The ether layer was washed with brine (2 mL), acidified with TFA and dried under high vacuum for 2 days. The residue was washed with ether (3 mL), diluted with water (0.5 mL) and basified with 10M NaOH (0.2 mL). The layers were separated and the upper layer was carefully dried over NaOH. The ether solution was evaporated under nitrogen to yield crude (S)-2-(2-methylpiperidin-1-yl)ethan-1-ol (100 mg, 0.698 mmol, 69.24% yield) as colorless oil.


Intermediate 14



(R)-2-(2-methylpiperidin-1-yl)ethan-1-ol

[0267] Synthesized according to the method of Intermediate 13, using (R)-2-methylpiperidine (99 mg, 1 mmol) in place of (S)-2-methylpiperidine.


Intermediate 15



(S)-2-(3-methoxypiperidin-1-yl)ethan-1-ol

[0268] Synthesized according to the method of Intermediate 13, using (S)-3-methoxypiperidine (173 mg, 1.50 mmol) in place of (S)-2-methylpiperidine.


Intermediate 16



(R)-2-(3-methoxypiperidin-1-yl)ethan-1-ol

[0269] Synthesized according to the method of Intermediate 13, using R-3-methoxypiperidine (173 mg, 1.50 mmol) in place of (S)-2-methylpiperidine.

Intermediate 17




3-(1,4-oxazepan-4-yl)propan-1-ol

[0270] To a vial was added homomorpholine (0.250 g, 2.472 mmol), Acetonitrile (4.943 mL, 2.472 mmol) and 3-Bromo-1-propanol (0.2459 mL, 2.719 mmol). Potassium carbonate (0.6832 g, 4.943 mmol) was added and the mixture was warmed to 50 °C and stirred for 6 hours. The mixture was cooled to ambient temperature, diluted with DCM, filtered and the collected solids were washed with DCM. The filtrate was concentrated in vacuo and the crude oil was purified

via column chromatography (Biotage Isolera, 12g Isco RediSep Gold, 10-20% MeOH/DCM with 0.2% NH_4OH) to afford 3-(1,4-oxazepan-4-yl)propan-1-ol (0.272 g, 1.708 mmol) as a colorless oil.


Intermediate 18



3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol

[0271] Synthesized according to the method of Intermediate 17, using (1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptane (0.250 g, 2.522 mmol) in place of homomorpholine.


Intermediate 19



2-(4-methoxypiperidin-1-yl)ethan-1-ol

[0272] Synthesized according to the method of Intermediate 13, using 4-methoxypiperidine (173 mg, 1.50 mmol) in place of (S)-2-methylpiperidine.


Intermediate 20



2-(4,4-difluoropiperidin-1-yl)ethan-1-ol

[0273] Synthesized according to the method of Intermediate 13, using 4,4-difluoropiperidine hydrochloride (173 mg, 1.50 mmol) in place of (S)-2-methylpiperidine.


Intermediate 21



(S)-2-(3-fluoropiperidin-1-yl)ethan-1-ol

[0274] Synthesized according to the method of Intermediate 13, using S-3-fluoropiperidine hydrochloride (209 mg, 1.50 mmol) in place of (S)-2-methylpiperidine.

Intermediate 22



benzyl 4-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(methylsulfinyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate

[0275] Step A: tert-butyl 4-hydroxy-2-(methylthio)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: To a stirred solution of 1-*tert*-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (50.0 g, 184 mmol, 1.00 *eq*) in MeOH (1.00 L) at 25 °C under nitrogen was added NaOMe (49.8 g, 921 mmol, 5.00 *eq*), followed by 2-methylisothiourea (62.4 g, 331 mmol, 1.80 *eq*, H_2SO_4) as a solid. The reaction mixture was stirred at 25 °C for 16 hours. The reaction mixture was adjusted to pH 5 with HCl (2 M), and the mixture was concentrated under reduced pressure to removed MeOH. The residue was suspended in 300 mL of ethyl acetate and 300 mL of water and stirred rapidly. The suspension was filtered and the white solid was collected. The filtrate was separated and the organic layer was washed with water (1 × 300 mL) and brine (1× 200

mL). The combined organic layers were isolated, dried over Na_2SO_4, filtered and concentrated to provide *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 138 mmol, 75.4 % yield, 81.0 % purity) as a white solid which as used directly in the next step without further purification. **ESI** MS m/z 298.2 $[M+H]^+$.

[0276] Step B: *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred suspension of *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 171 mmol, 1.00 *eq*) in DCM (500 mL) at 0 °C was added DIEA (44.3 g, 343 mmol, 59.9 mL, 2.00 *eq*), followed by trifluoromethanesulfonic anhydride (72.6 g, 257 mmol, 42.4 mL, 1.50 *eq*) under nitrogen. Immediately a brown solution formed. After stirring at 25 °C for 16 hours, the reaction was concentrated to give a brown oil. The brown oil was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1:0 to 10:1) to provide *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (46.0 g, 107 mmol, 62.4 % yield) as a yellow solid **ESI** MS m/z 430.2 $[M+H]^+$.

[0277] Step C: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of *tert*-butyl 2-methylsulfanyl-4- (trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (46.0 g, 107 mmol, 1.00 *eq*) in DMF (500 mL) was added DIEA (27.7 g, 214 mmol, 37.4 mL, 2.00 *eq*) followed by benzyl piperazine-1-carboxylate (25.9 g, 117 mmol, 22.7 mL, 1.10 *eq*). The reaction was heated to 100 °C for 1 hour under a nitrogen atmosphere. The reaction mixture was poured into ethyl acetate (300 mL), washed with H_2O (300 mL × 3) and brine (200 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1:0 to 5:1) to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 96.9 mmol, 90.5 % yield, 92.0 % purity) as a white solid **ESI** MS m/z 500.3 $[M+H]^+$.

[0278] Step D: Benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1-carboxylate: To a solution of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (25.0 g, 50.0 mmol, 1.00 *eq*) in DCM (50.0 mL) was added TFA (85.6 g, 750 mmol, 55.6 mL, 15.0 *eq*). After


stirring at 25 °C for 1 hour, the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 300 mL of ethyl acetate and 300 mL of water and stirred rapidly. The mixture was adjusted to pH 8 with Na_2CO_3. The organic layer was washed with water (1 × 300 mL) and brine (1 × 200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to provide benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1-carboxylate (19.0 g, 46.6 mmol, 93.2 % yield, 98.0 % purity) as a yellow oil. **ESI** MS m/z 400.2 $[M+H]^+$.

[0279] Step E : Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of 3-benzyloxy-1-bromo-naphthalene (16.3 g, 52.1 mmol, 1.30 *eq*), benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (16.0 g, 40.1 mmol, 1.00 *eq*), Cs_2CO_3 (32.6 g, 100 mmol, 2.50 *eq*), $Pd_2(dba)_3$ (5.50 g, 6.01 mmol, 0.15 *eq*) and 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (3.74 g, 8.01 mmol, 0.20 *eq*) in dioxane (300 mL) was degassed and purged with nitrogen 3 times. The mixture was stirred at 85 °C for 5 hours under a nitrogen atmosphere. The reaction mixture was quenched by adding water (200 mL) at 0 °C, and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine (3 × 150 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 10/1 to 5/1) to provide benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (16.0 g, 22.8 mmol, 56.9 % yield, 90.0 % purity) as a yellow solid. **ESI** MS m/z 632.5 $[M+H]^+$.

[0280] Step F: Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate :To a stirred solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2- methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (8.00 g, 12.7 mmol, 1.00 *eq*) in DCM (200 mL) was added m-CPBA (2.73 g, 12.7 mmol, 80.0 % purity, 1.00 *eq*) at 0 °C under nitrogen. After stirring at 0 °C for 2 hours under a nitrogen atmosphere, the reaction mixture was quenched by adding $Na_2S_2O_3$ (10.0 mL) at 0 °C, diluted with water (100 mL) and extracted with DCM (200 mL). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column

chromatography (SiO_2, DCM/MeOH = 1/0 to 10/1) to provide benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (3.50 g, 4.92 mmol, 38.8 % yield, 91.0 % purity) as a yellow solid. **ESI** MS m/z 648.5 $[M+H]^+$.


Intermediate 23



(R)-1-(4-(2-hydroxypropyl)piperazin-1-yl)ethan-1-one

[0281] Step A: 1-[4-[(2*R*)-2-hydroxypropyl]piperazin-1-yl]ethanone: (2*R*)-2-methyloxirane (1.00 g, 17.2 mmol, 1.20 mL, 1.00 *eq*) and 1-piperazin-1-ylethanone (8.00 g, 62.4 mmol, 3.62 *eq*) were taken up into a microwave tube. The sealed tube was heated at 150 °C for 1 hour under microwave. The mixture was dissolved in DCM (80.0 mL), added $(Boc)_2O$ (3.62 eq,13.6 g) and stirred at 20 °C for 1 hour. The residue was purified by column chromatography (DCM/MeOH 100/1 to 10/1) to give 1-[4-[(2*R*)-2-hydroxypropyl]piperazin-1-yl]ethanone (3.80 g, 13.5 mmol, 78.2 % yield, 66.0 % purity) as a yellow oil.

Intermediate 24




1-(benzyloxy)-3-bromo-5-cyclopropylbenzene

[0282] Step A: 1-benzyloxy-3,5-dibromo-benzene: To a mixture of 3,5-dibromophenol (1.50 g, 5.95 mmol, 1.00 *eq*) and K_2CO_3 (2.47 g, 17.9 mmol, 3.00 *eq*) in MeCN (30.0 mL) was added benzyl bromide (1.07 g, 6.25 mmol, 742 µL, 1.05 *eq*), the reaction mixture was stirred at 80 °C for 2 hours. The reaction mixture was filtered and concentrated. The residue was purified by

column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1:1 to give 1-benzyloxy-3,5-dibromobenzene (1.60 g, 4.68 mmol, 78.6 % yield) as colorless oil.

[0283] Step B: 1-benzyloxy-3-bromo-5-cyclopropylbenzene: To a mixture of 1-benzyloxy-3,5-dibromobenzene (1.20 g, 3.51 mmol, 1.00 *eq*) and cyclopropylboronic acid (392 mg, 4.56 mmol, 1.30 *eq*) in H_2O (4.00 mL) and dioxane (20.0 mL) was added $Pd(dppf)Cl_2$ (513 mg, 702 μmol, 0.20 *eq*) and Cs_2CO_3 (2.29 g, 7.02 mmol, 2.00 *eq*). The reaction mixture was stirred at 90 °C for 12 hours under N_2. The reaction mixture was added to water (20 mL) and extracted with ethyl acetate (2 × 15 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1:1 to give 1-benzyloxy-3-bromo-5-cyclopropyl -benzene (270 mg, 890 μmol, 25.4 % yield) as colorless oil.

Intermediate 25




benzyl 4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate

[0284] Step A: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a mixture of 3-morpholinopropan-1-ol (5.46 g, 37.6 mmol, 2.00 *eq*) in THF (100 mL) was added NaH (2.26 g, 56.4 mmol, 60.0 % purity, 3.00 *eq*) in portions at 0 °C. After the mixture was stirred at 0 °C for 0.5 hour, a solution of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (10.0 g, 18.8 mmol, 1.00 *eq*) in THF (100 mL) was added, and the reaction mixture was stirred at 0 °C for 1.5 hours under N_2. The mixture was poured into NH_4Cl aqueous (300 mL), and extracted with DCM (2 × 200 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The residue was purified by

column chromatography (SiO_2, Petroleum ether/Ethyl acetate=50:1 to 10:1) to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (7.70 g, 12.8 mmol, 67.8 % yield, 98.8 % purity) as a yellow oil. **ESI** MS m/z 597.4 $[M+H]^+$.

[0285] Step B: benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (7.70 g, 12.9 mmol, 1.00 *eq*) in DCM (80.0 mL) was added TFA (119 g, 1.04 mol, 76.9 mL, 80.6 *eq*), and the reaction mixture was stirred at 15 °C for 1 hour. The reaction mixture was concentrated, then diluted with DCM (100 mL) and adjusted to pH 8 with aqueous NaOH. The organic layer was separated, dried over Na_2SO_4, filtered and concentrated to give benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (6.00 g, 11.2 mmol, 86.9 % yield, 92.8 % purity) as yellow oil. **ESI** MS m/z 497.4 $[M+H]^+$.


Intermediate 26



4-(benzyloxy)-2-bromo-1-fluorobenzene

[0286] To a solution of 3-bromo-4-fluorophenol (4.00 g, 20.9 mmol, 1.00 *eq*) and K_2CO_3 (8.68 g, 62.8 mmol, 3.00 *eq*) in ACN (80.0 mL) was added benzyl bromide (3.65 g, 21.4 mmol, 2.54 mL, 1.02 *eq*) and the reaction mixture was stirred at 60 °C for 2 hrs. The reaction mixture was filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (petroleum ether:ethyl acetate; gradient from 1:0 to 10:1) to give 4-benzyloxy-2-bromo-1-fluoro-benzene (5.02 g, 17.0 mmol, 81.0 % yield, 95 % purity) was obtained as white solid.

Intermediate 27



SUBSTITUTE SHEET (RULE 26)

2-(3-fluoropyrrolidin-1-yl)ethan-1-ol

[0287] Step A: *tert*-butyl 3-fluoropyrrolidine-1-carboxylate: To a solution of *tert*-butyl 3-hydroxypyrrolidine-1-carboxylate (10.0 g, 53.4 mmol, 1.00 *eq*) in DCM (150.00 mL) was added diethylaminosulfur trifluoride (DAST) (12.9 g, 80.1 mmol, 10.6 mL, 1.50 *eq*) at -40 °C under a nitrogen atmosphere. After stirring at - 40 °C for 2 hours, the mixture was warmed to 20 °C and stirred for 16 hours. The mixture was poured into 5% aqueous sodium bicarbonate (200 mL) and extracted with dichloromethane (2 × 100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100:1 to 5:1). The desired fractions were collected and concentrated under vacuum to give *tert*-butyl 3-fluoropyrrolidine-1-carboxylate (4.30 g, 22.7 mmol, 42.6 % yield) as a colorless oil. ^{1}H NMR (400 MHz, Chloroform-d) δ = 5.27 (t, *J* = 3.6 Hz, 0.5H), 5.13 (t, *J* = 3.6 Hz, 0.5H), 3.77 - 3.38 (m, 4H), 2.26 - 2.15 (m, 1H), 2.08 - 1.85 (m, 1H), 1.46 (s, 9H).

[0288] Step B: 3-fluoropyrrolidine: To a solution of *tert*-butyl 3-fluoropyrrolidine-1-carboxylate (4.30 g, 22.7 mmol, 1.00 *eq*) in DCM (50.00 mL) was added HCl/dioxane (4 M, 35.0 mL, 6.16 *eq*) dropwise at 0 °C. The mixture was warmed to 20 °C and stirred for 1 hour. The mixture was concentrated under vacuum. The residue was triturated with diisopropyl ether (20 mL) and the precipitate was filtered and dried under vacuum to provide 3-fluoropyrrolidine (2.70 g, 21.5 mmol, 94.6 % yield, HCl) as a white solid. ^{1}H NMR (400 MHz, Methanol-d_4) δ = 5.51 (t, *J* = 3.6 Hz, 0.5H), 5.38 (t, *J*=3.6 Hz, 1H), 3.66 - 3.27 (m, 5H), 2.45 - 2.12 (m, 2H).


[0289] Step C: methyl 2-(3-fluoropyrrolidin-1-yl)acetate: A suspension of 3-fluoropyrrolidine (2.70 g, 21.5 mmol, 1.00 *eq*, HCl) in DCM (27.00 mL) was cooled to 0° C. Triethylamine (5.44 g, 53.8 mmol, 7.45 mL, 2.50 *eq*) and methyl 2-bromoacetate (3.62 g, 23.7 mmol, 2.23 mL, 1.10 *eq*) were added and the reaction mixture was stirred at 20 °C for 16 h. The reaction mixture was diluted with CH_2Cl_2 (100 mL) and water (50 mL). The organic layer was washed with 5% aqueous citric acid solution (1 × 50 mL). The water layer was basified by saturated aqueous sodium carbonate solution (20 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo to give methyl 2-(3-fluoropyrrolidin-1-yl)acetate (2.20 g, 13.7 mmol, 63.5 % yield). ^{1}H NMR (400

SUBSTITUTE SHEET (RULE 26)

MHz, Chloroform-d) δ = 5.22 - 5.02 (m, 1H), 3.66 (s, 3H), 3.35 (s, 2H), 3.07 - 2.93 (m, 1H), 2.91 - 2.77 (m, 2H), 2.67 (dt, *J* = 5.2, 8.4 Hz, 1H), 2.21 - 1.93 (m, 2H).

[0290] Step D: 2-(3-fluoropyrrolidin-1-yl)ethanol: To a solution of $LiAlH_4$ (706 mg, 18.6 mmol, 1.50 *eq*) in THF (20 mL) was added a solution of methyl 2-(3-fluoropyrrolidin-1-yl)acetate (2.00 g, 12.4 mmol, 1.00 *eq*) in THF (10 mL) dropwise at 0 °C. The mixture was warmed up to 20 °C and stirred for 3 hours. The mixture was quenched with saturated aqueous sodium sulfate solution (1 mL). The mixture was filtered and the filtrate was concentrated under vacuum. The product was purified by silica gel chromatography using 5% MeOH in DMC. The desired fractions were collected and concentrated under vacuum to give 2-(3-fluoropyrrolidin-1-yl)ethanol (1.20 g, 9.01 mmol, 72.6 % yield) as a colorless oil. ^{1}H NMR (400 MHz, Chloroform-d) δ = 5.28 - 5.05 (m, 1H), 3.68 - 3.61 (m, 2H), 2.99 - 2.73 (m, 4H), 2.72 - 2.67 (m, 2H), 2.58 - 2.45 (m, 1H), 2.28 - 1.97 (m, 2H).

Intermediate 28




1-(tert-butyl) 3-methyl piperazine-1,3-dicarboxylate

[0291] Step A: methyl piperazine-2-carboxylate: To a mixture of 1-tert-butyl 2-methyl piperazine-1,2-dicarboxylate (5.0 g, 22.6 mmol, 1.00 eq) in MeOH (50.0 mL) was added HCl/dioxane (4.0 M, 134 mL). The reaction mixture was degassed and purged with nitrogen 3 times, and the mixture was stirred at 25 °C for 12 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to dryness to give methyl piperazine-2-carboxylate (4.89 g, 2HCl, crude) as a white solid, which was used directly in the next step without further purification.

[0292] Step B: 1-(tert-butyl) 3-methyl piperazine-1,3-dicarboxylate: To a solution of methyl piperazine-2-carboxylate (4.30 g, crude) and TEA (8.02 g, 79.2 mmol, 11.0 mL) in MeOH (50.0

mL) was added di-tert-butyl dicarbonate (4.32 g, 19.8 mmol, 4.55 mL). After stirring at 25 °C for 12 hours, the reaction mixture was filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM / MeOH = 1:0 to 20:1) to give 1-(tert-butyl) 3-methyl piperazine-1,3-dicarboxylate (4.80 g, 19.7 mmol, two steps, 99.0 % yield) as a colorless oil.^{1}H NMR (400 MHz, chloroform-d) δ = 4.10 - 3.85 (m, 1H), 3.73 (s, 3H), 3.71 - 3.65 (m, 1H), 3.47 - 3.38 (m, 1H), 3.10 - 2.98 (m, 2H), 2.78 - 2.66 (m, 1H), 2.17 (s, 1H), 1.46 (s, 9H).

Intermediate 29



4-bromonaphthalen-2-ol

[0293] Step A: 2,4-dibromonaphthalen-1-amine: To a solution of Br_2 (246 g, 1.54 mol, 79.3 mL, 2.18 *eq*) in AcOH (750 mL) was added a solution of naphthalen-1-amine (101 g, 705 mmol, 99.0 mL, 1.00 *eq*) in AcOH (500 mL) at ambient temperature, and the reaction was stirred at 70 °C for 1 hour. The reaction mixture was cooled at room temperature and filtered. The filter cake was washed with AcOH (300 mL), then added to 20 % aqueous of NaOH (1.2 L). The mixture was stirred for 20 min and filtered. The isolated solid was washed with water (1 L) and dried under vacuum to provide 2,4-dibromonaphthalen-1-amine (200 g, 664 mmol, 94.2% yield) as gray solid. **ESI** MS m/z 301. 9 $[M+H]^+$.


[0294] Step B: 4-bromo-1-diazonio-naphthalen-2-olate: To a solution of 2,4-dibromonaphthalen-1-amine (60.0 g, 199 mmol, 1.00 *eq*) in AcOH (900 mL) and propionic acid (150 mL) was added $NaNO_2$ (16.5 g, 239 mmol, 13.0 mL, 1.20 *eq*) portionwise at 5-8 °C over 30 min, and then the reaction mixture was stirred at 5-8 °C for 30 min. The reaction mixture was poured into ice-water (4000 mL), and the resulting solid was collected and washed with water (2 × 50 mL) to provide 4-bromo-1-diazonio-naphthalen-2-olate (150 g, wet crude) as gray solid which was used directly in the next step. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.12 - 8.10 (d, *J*=8.4 Hz, 1H), 7.62

- 7.58 (t, *J*=7.6 Hz, 1H), 7.41 - 7.37 (t, *J*=7.6 Hz, 1H), 7.31 - 7.29 (d, *J*=8.0 Hz, 1H), 7.20 (s, 1H).

[0295] Step C: 4-bromonaphthalen-2-ol: To a solution of 4-bromo-1-diazonio-naphthalen-2-olate (100 g, 402 mmol, 1.00 *eq*) in EtOH (2.00 L) was added portionwise $NaBH_4$ (30.4 g, 803 mmol, 2.00 *eq*) at 13-15 °C over 1 h, and the reaction mixture was stirred at 15-18 °C for 3 hrs. The reaction was filtered and concentrated to dryness. The residue was dissolved in DCM (1000 mL) and washed with water (500 mL × 2). The organic phase was dried over Na_2SO_4 and concentrated to dryness. The residue was purified by silica gel column chromatograph, eluting with diethyl ether/ethyl acetate (60:1 to 10:1). The isolated product was further purified by reversed phase HPLC to provide 4-bromonaphthalen-2-ol (40.0 g, 139 mmol, 17.3 % yield, 77.4% purity) as a gray solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.07 – 8.05 (d, *J*=8.0 Hz, 1H), 7.60 – 7.58 (d, *J*=7.6 Hz, 1H), 7.41 - 7.36 (m, 3H), 7.07 (s, 1H).

[0296] Step D: 3-benzyloxy-1-bromo-naphthalene: A mixture of 4-bromonaphthalen-2-ol (30.0 g, 134 mmol, 1.00 *eq*), benzyl bromide (25.3 g, 148 mmol, 17.6 mL, 1.10 *eq*) and K_2CO_3 (55.7 g, 403 mmol, 3.00 *eq*) in MeCN (500 mL) was heated at 80 °C for 1 hr. The reaction mixture was filtered and concentrated to dryness. The residue was purified by silica gel column chromatography, eluting with diethyl ether/ethyl acetate (100:1 to 60:1) to provide 3-benzyloxy-1-bromo-naphthalene (40.0 g, 128 mmol, 95 % yield) as yellow oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.19 – 8.17 (d, *J*=8.0 Hz, 1H), 7.75 – 7.32 (d, *J*=8.8 Hz, 1H), 7.64 - 7.63 (d, *J*=2.4 Hz,1H), 7.52 – 7.37 (m, 7H), 7.23 – 7.21 (d, *J*=2.0 Hz,1H), 5.2 (s, 2H).

Intermediate 30



3-methoxynaphthalen-1-yl trifluoromethanesulfonate


[0297] Step A: 3-methoxynaphthalen-1-ol : To a solution of naphthalene-1,3-diol (3.00 g, 18.7 mmol, 1.00 eq) in MeOH (60.0 mL) was added HCl/MeOH (4 M, 60.0 mL, 12.8 eq) at 0 °C. The mixture was stirred at 25 °C for 60 hours. The solvent was removed under vacuum. The

SUBSTITUTE SHEET (RULE 26)

residue was purified by silica gel chromatography (diethyl ether:ethyl acetate=10:1 to 5:1) to give 3-methoxynaphthalen-1-ol (2.10 g, 12.1 mmol, 64.4% yield) as a brown solid. ^{1}H NMR (400 MHz, $CDCl_3$-d_6) δ = 8.10 - 8.08 (d, *J*=8.4 Hz, 1H).7.73 - 7.71 (d, *J*=8.4 Hz, 1H), 7.47 - 7.45(m, 1H), 7.38 - 7.35(m, 1H), 6.80 - 6.79 (d, *J*=2.0 Hz, 1H), 6.56 - 6.55 (d, *J*=2.4 Hz, 1H), 3.92 (s, 3H).

[0298] Step B: (3-methoxy-1-naphthyl) trifluoromethanesulfonate: To a solution of 3-methoxynaphthalen-1-ol (2.10 g, 12.0 mmol, 1.00 eq) in DCM (40.0 mL) was added DIEA (7.79 g, 60.3 mmol, 10.5 mL, 5.00 eq) and trifluoromethanesulfonic anhydride (5.10 g, 18.1 mmol, 2.98 mL, 1.50 eq) at 0 °C. The mixture was stirred at 25 °C for 1 hour. The mixture was diluted with DCM (30 mL) and water (10 mL) and extracted with DCM (20 mL). The combined organic layers were washed with brine (5 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (diethyl ether:ethyl acetate=20:1 to 10 :1) to give (3-methoxy-1-naphthyl) trifluoromethanesulfonate (3.00 g, 8.52 mmol, 70.7 % yield, 87.0 % purity) as a brown oil. **ESI** MS m/z 307.1 $[M+H]^+$.

Intermediate 31




7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine

[0299] Step A: 7-benzyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-2,4-diol: To EtOH (600 mL) was added Na (5.56 g, 241 mmol, 5.73 mL, 2.40 eq) in portions. The reaction mixture was stirred for 1 hour. To the mixture was added ethyl 1-benzyl-3-oxo-piperidine-4-carboxylate (30.0 g, 100 mmol, 1.00 eq, HCl) and urea (14.5 g, 242 mmol, 13.0 mL, 2.40 eq). The reaction mixture was stirred at 75 °C for 36 hours, and then the solvent was removed under vacuum. The residue was dissolved in water (50 mL) and acidified with HCl (120 mL, 2M). A white solid precipitated from the solution and was collected by filtration. The filter cake was dried under vacuum to provide 7-benzyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-2,4-diol (22.0 g, 83.8 mmol, 83.2 % yield, 98 % purity) as a white solid.^{1}HNMR (400 MHz, DMSO-d_6) δ = 10.97 (br

s, 1H), 10.66 (br s, 1H), 7.55 - 6.95 (m, 5H), 3.81 - 3.50 (m, 2H), 3.26 - 2.91 (m, 2H), 2.77 - 2.58 (m, 2H), 2.34 - 2.09 (m, 2H).

[0300] Step B: 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: To a solution of DIEA (30.1 g, 233 mmol, 40.7 mL, 3.00 eq) in $POCl_3$ (330 g, 2.15 mol, 200 mL) was added 7-benzyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-2,4-diol (20.0 g, 77.7 mmol, 1.00 eq). The reaction mixture was stirred at 110 °C for 5 hours. The reaction mixture was concentrated under vacuum. The residue was dissolved in DCM (400 mL) and poured into saturated $NaHCO_3$ (200 mL). The mixture was extracted with DCM (2 × 400 mL). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (diethyl ether: DCM=10:1 to 0:1) to give 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (7.70 g, 26.2 mmol, 33.7 % yield) as a brown oil. ^{1}HNMR (300 MHz, chloroform-d) δ = 7.43 – 7.28 (m, 5H), 3.73 (s, 2H), 3.66 (br s, 2H), 2.84 (br s, 4H)

Intermediate 32



tert-butyl4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-(methylsulfonyl)-5,6-dihydropyrido[3,4-d]pyrimidine-7(8*H*)-carboxylate

[0301] Step A: *tert*-butyl4-hydroxy-2-methylsulfanyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of 1-*tert*-butyl 4-ethyl-3-oxopiperidine-1,4-dicarboxylate (44.0 g, 162 mmol, 1.00 *eq*) in MeOH (1.00 mL) at 25 °C under nitrogen was added a solution of NaOMe (35.0 g, 649 mmol, 4.00 *eq*) in MeOH (600 mL) by syringe followed by 2-methylisothiourea (61.1 g, 324 mmol, 2.00 *eq*, H_2SO_4). After stirring at 25 °C for 16 hours, the

reaction mixture was concentrated under reduced pressure to removed MeOH. The residue was suspended in 500 mL of ethyl acetate and 500 mL of water and stirred rapidly. The reaction mixture was adjusted to pH 5 with HCl (2 M). The precipitate was filtered and the white solid was washed with ethyl acetate and dried under vacuum to give *tert*-butyl4-hydroxy-2-methylsulfanyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (33.0 g, 103 mmol, 63.8 % yield, 93.2 % purity) as a white solid, which was used directly in the next step without further purification. ^{1}H NMR (400 MHz, DMSO-d6) δ = 4.19 (s, 2 H), 3.49 (br s, 2 H), 2.46 (s, 3 H), 2.35 (br t, J = 5.2 Hz, 2 H), 1.42 (s, 9 H).


[0302] Step B: give *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidine-7-carboxylate: To a stirred suspension of *tert*-butyl 4-hydroxy-2-methylsulfanyl -6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (15.0 g, 50.4 mmol, 1.00 *eq*) in DCM (200 mL) was added DIEA (26.1 g, 202 mmol, 35.2 mL, 4.00 *eq*) at 0 °C under nitrogen and followed by trifluoromethanesulfonic anhydride (28.5 g, 101 mmol, 16.6 mL, 2.00 *eq*) by syringe. Immediately a brown solution formed. The reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was purified by column chromatography (SiO_2, Petroleum ether / Ethyl acetate = 1:0 to 10:1) to give *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidine-7-carboxylate (16.7 g, 35.7 mmol, 70.9 % yield, 91.9 % purity) as a white solid. **ESI** MS m/z 374.0 $[M+H]^+$.

[0303] Step C: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8- dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of *tert*-butyl2-methylsulfanyl-4-(trifluoromethyl sulfonyloxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (16.7 g, 38.9 mmol, 1.00 *eq*) in DMF (100 mL) was added DIEA (10.0 g, 77.9 mmol, 2.00 *eq*) and benzyl piperazine-1-carboxylate (9.41 g, 42.8 mmol, 1.10 *eq*). The reaction was heated to 100 °C and stirred for 1 hour under a nitrogen atmosphere. The reaction mixture was diluted with water (150 mL) and the reaction mixture was adjusted to pH 5 with HCl (2 M) and extracted with DCM (3× 200 mL). The combined organic layers were washed with saturated $NaHCO_3$ (3 × 150 mL), brine (3 × 150 mL) and H_2O (3 × 150 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8- dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (18.1 g, 36.2 mmol,

93.0 % yield, 94.1 % purity) as a yellow solid, which was used directly in the next step without further purification. **ESI** MS m/z 500.1 $[M+H]^+$.

[0304] Step D: tert-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2- methylsulfonyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of tert-butyl4-(4-benzyloxycarbonylpiperazin -1-yl)-2-methylsulfanyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (14.4 g, 28.9 mmol, 1.00 eq) in DCM (150 mL) at 0 °C under nitrogen was added meta-chloroperoxybenzoic acid (17.4 g, 101 mmol, 3.50 eq) as a solid. After stirring at 0 °C for 2 hours under a nitrogen atmosphere, the reaction mixture was diluted with water (300 mL) and the reaction mixture was adjusted to pH 8 with saturated aqueous $NaHCO_3$ and extracted with DCM (3 × 200 mL). The combined organic layers were washed with brine (3 × 200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 10:1 to 1:2) to give tert-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (11.0 g, 19.7 mmol, 68.6 % yield, 95.4 % purity) as a white solid. **ESI** MS m/z 532.1 $[M+H]^+$.


Intermediate 33



tert-butyl (1-bromoisoquinolin-3-yl)carbamate

[0305] Step A: A mixture of 1-bromoisoquinolin-3-amine (400 mg, 1.79 mmol, 1.00 eq) and *tert*-butoxycarbonyl tert-butyl carbonate (3.91 g, 17.9 mmol, 4.12 mL, 10.0 eq) was stirred at 70 °C for 16 hours. The residue was purified by column chromatography (SiO_2, diethyl ether/ethyl acetate = 5:1) to give *tert*-butyl N-(1-bromo-3-isoquinolyl) carbamate (400 mg, 1.24 mmol, 69.2 % yield) as a yellow solid. **ESI** MS m/z 322.1, 324.1 $[M+H]^+$.

Intermediate 34



3-methoxy-6-methylnaphthalen-1-yl trifluoromethanesulfonate

[0306] Step A: 3-methoxynaphthalen-1-ol: To a solution of naphthalene-1,3-diol (40.0 g, 250 mmol, 1.00 *eq*) in MeOH (800 mL) was added HCl (4 M, 750 mL, 12.0 *eq*, 4 M in MeOH) at 0 °C. The mixture was warmed up to 18 °C and stirred for 30 hours. The mixture was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 1/1). The desired fractions were collected and concentrated under vacuum to give 3-methoxynaphthalen-1-ol (17.7 g, 96.5 mmol, 38.6 % yield, 95 % purity) as a red oil. ^{1}H NMR (400MHz, Chloroform-d) δ = 8.17 (d, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.50 (ddd, *J* = 1.2, 6.8, 8.0 Hz, 1H), 7.38 (ddd, *J*=1.2, 6.8, 8.0 Hz, 1H), 6.81 (d, *J*=2.0 Hz, 1H), 6.76 (br s, 1H), 6.62 (d, *J*=2.4 Hz, 1H), 3.91 (s, 3H).

[0307] Step B: *tert*-butyl-[(3-methoxy-1-naphthyl)oxy]-dimethyl-silane: To a solution of 3-methoxynaphthalen-1-ol (20.0 g, 115 mmol, 1.00 *eq*) and imidazole (23.5 g, 344 mmol, 3.00 *eq*) in THF (400 mL) was added TBSCl (26.0 g, 172 mmol, 21.1 mL, 1.50 *eq*) dropwise at 0 °C. The mixture was warmed up to 25 °C and stirred for 16 hours. The mixture was diluted with petroleum ether (600 mL) and ethyl acetate (200 mL), and then washed with water (1 × 200 mL) and brine (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 10/1). *tert*-butyl-[(3-methoxy-1-naphthyl)oxy]-dimethyl-silane (28.0 g, 97.1 mmol, 84.6 % yield) was obtained as a colorless oil. ^{1}H NMR (400MHz, Chloroform-d) δ = 8.01 (d, *J* = 8.4 Hz, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.35 (dt, *J* = 1.2, 7.6 Hz, 1H), 7.24 (dt, *J* = 1.2, 7.6 Hz, 1H), 6.71 (d, *J* = 2.0 Hz, 1H), 6.48 (d, *J* = 2.4 Hz, 1H), 3.82 (s, 3H), 1.02 (s, 9H), 0.23 (s, 6H).

[0308] Step C: *tert*-butyl-[[3-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]oxy]-dimethyl-silane and *tert*-butyl((3-methoxy-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)oxy)dimethylsilane: A mixture of *tert*-butyl-[(3-methoxy-1-

naphthyl) oxy]-dimethyl-silane (26.0 g, 90.1 mmol, 1.00 *eq*), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (45.8 g, 180 mmol, 2.00 *eq*), (1*Z*,5*Z*)-cycloocta-1,5-diene;2,4-dimethyl-BLAHbicyclo[1.1.0]butane (2.39 g, 3.61 mmol, 0.04 *eq*) and 4-*tert*-butyl-2-(4-*tert*-butyl-2-pyridyl)pyridine (1.45 g, 5.41 mmol, 0.06 *eq*) in hexane (500 mL) was stirred at 100 °C under nitrogen atmosphere for 16 hours. The mixture was diluted with water (500 mL) and ethyl acetate (1000 mL). The separated organic layer was washed with brine (1 × 500 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum etehr/ethyl acetate 100/1 to 10/1). The desired fractions were collected and concentrated under vacuum to give a mixture of *tert*-butyl-[[3-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-naphthyl]oxy]-dimethyl-silane and *tert*-butyl((3-methoxy-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalen-1-yl)oxy)dimethylsilane (38.0 g, 85.3 mmol, 94.6 % yield, 93 % purity) as a light yellow oil. **ESI** MS m/z 415.5 $[M+H]^+$

[0309] Step D: 8-[*tert*-butyl(dimethyl)silyl]oxy-6-methoxy- naphthalen-2-ol: To a solution of mixture (36.0 g, 86.9 mmol, 1.00 *eq*) of *tert*-butyl-[[3-methoxy-6-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1- naphthyl]oxy]-dimethyl-silane and *tert*-butyl((3-methoxy-7-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)naphthalen-1-yl)oxy)dimethylsilanein in acetone (400 mL) was added a solution of Oxone (58.7 g, 95.6 mmol, 1.10 *eq*) in H_2O (400 mL) at 0 °C. The mixture was stirred at 0 °C for 1 hour. The mixture was quenched with 5% aqueous sodium thiosulfate solution (50 mL) and extracted with ethyl acetate (2 × 300 mL). The extracts were combined and washed with water (1 × 200 mL), brine (1 × 200 mL), dried over magnesium sulfate, filtered and the filtrate was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 200/1 to 20/1). The desired fractions were collected and concentrated under vacuum to give 8-[*tert*-butyl(dimethyl)silyl]oxy-6-methoxy- naphthalen-2-ol (9.00 g, 28.4 mmol, 32.7 % yield, 96 % purity) as a colorless oil and 5-[*tert*-butyl(dimethyl)silyl]oxy-7-methoxy-naphthalen-2-ol (9.00 g, 29.0 mmol, 33.4 % yield, 98 % purity) as a white solid. **ESI** MS m/z 305.2 $[M+H]^+$

[0310] Step E: [5-[*tert*-butyl(dimethyl)silyl]oxy-7-methoxy-2-naphthyl] trifluoromethanesulfonate: To a solution of 5-[*tert*-butyl(dimethyl)silyl]oxy-7- methoxy-naphthalen-2-ol (11.0 g, 36.1 mmol, 1.00 *eq*) and DIEA (14.0 g, 108 mmol, 18.9 mL, 3.00 *eq*)






in DCM (150 mL) was added Tf_2O (12.2 g, 43.4 mmol, 7.15 mL, 1.20 *eq*) dropwise at - 40 °C. The mixture was stirred for 1 hour. The mixture was diluted with dichloromethane (200 mL) and washed with water (1 × 200 mL) and brine (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 10/1). The desired fractions were collected and concentrated under vacuum to give [5-[*tert*-butyl(dimethyl)silyl]oxy-7-methoxy-2-naphthyl] trifluoromethanesulfonate (13.0 g, 29.8 mmol, 82.4 % yield, 100 % purity) as a white solid. **ESI** MS m/z 436.9 $[M+H]^+$





[0311] Step F: *tert*-butyl-[(3-methoxy-6-methyl-1-naphthyl)oxy]-dimethyl-silane: To a solution of [5-[*tert*-butyl(dimethyl)silyl]oxy-7-methoxy-2- naphthyl]trifluoromethanesulfonate (12.5 g, 28.6 mmol, 1.00 eq) and K_2CO_3 (11.9 g, 85.9 mmol, 3.00 eq) in dioxane (160 mL) was added $Pd(PPh_3)_4$ (3.31 g, 2.86 mmol, 0.10 eq) and trimethylboroxine (14.4 g, 57.3 mmol, 16.0 mL, 2.00 eq) under nitrogen atmosphere. The reaction was heated to 100 °C for 16 hours. The mixture was diluted with ethyl acetate (200 mL) and then washed with water (1 × 200 mL) and brine (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 5/1). The desired fractions were collected and concentrated under vacuum to give *tert*-butyl-[(3-methoxy-6-methyl-1-naphthyl)oxy]-dimethyl-silane (8.00 g, 24.6 mmol, 85.9 % yield, 93 % purity) as a colorless oil as red solid. **ESI** MS m/z 303.2 $[M+H]^+$

[0312] Step G: 3-methoxy-6-methyl-naphthalen-1-ol: To a solution of *tert*-butyl-[(3-methoxy-6-methyl-1-naphthyl) oxy]-dimethyl-silane (8.00 g, 26.5 mmol, 1.00 eq) in THF (100 mL) was added TBAF (10.4 g, 39.7 mmol, 1.50 eq) at 0 °C. The mixture was stirred at 0 °C for 3 hours. The mixture was diluted with water (100 mL) and ethyl acetate (200 mL). The separated organic layer was washed with brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 50/1 to 5/1). The desired fractions were collected and concentrated under vacuum to give 3-methoxy-6-methyl-naphthalen-1-ol (4.70 g, 25.0 mmol, 94.4 % yield) as a red solid. **ESI** MS m/z 188.4 $[M+H]^+$


[0313] Step H: 3-methoxy-6-methyl-1-naphthyl trifluoromethanesulfonate: To a solution of 3-methoxy-6-methyl-naphthalen-1-ol (4.70 g, 25.0 mmol, 1.00 eq) and DIEA (9.68 g, 74.9 mmol, 13.1 mL, 3.00 eq) in DCM (3.00 mL) was added Tf_2O (8.45 g, 30.0 mmol, 4.94 mL, 1.20 eq) dropwise at - 40 °C. The mixture was stirred for 1 hour. The mixture was diluted with dichloromethane (200 mL) and washed with water (1 × 200 mL) and brine (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 10/1). 3-methoxy-6-methyl-1-naphthyl trifluoromethanesulfonate (7.70 g, 24.0 mmol, 96.2 % yield, 99.9 % purity) was obtained as a colorless oil. **ESI** MS m/z 320.7 $[M+H]^+$.

[0314] The following intermediates were prepared according to the preparation for Intermediate 3, substituting the appropriate phenol for 2-bromo-3-fluorophenol.

Intermediate No.	Structure	Name
Intermediate 35		2-bromo-4-(methoxymethoxy)-1-(trifluoromethoxy)benzene
Intermediate 36		2-bromo-4-(methoxymethoxy)-1-(trifluoromethyl)benzene
Intermediate 37		2-bromo-1-(methoxymethoxy)-4-(trifluoromethoxy)benzene
Intermediate 38		2-bromo-4-fluoro-3-(methoxymethoxy)-1-methylbenzene
Intermediate 39		1-bromo-3-(methoxymethoxy)-5-(trifluoromethoxy)benzene

Intermediate 40		2-bromo-1-methoxy-4-(methoxymethoxy)benzene
Intermediate 41		2-bromo-1-(methoxymethoxy)-3-methylbenzene
Intermediate 42		2-bromo-4-(methoxymethoxy)-1-methylbenzene
Intermediate 43		1-bromo-4-(methoxymethoxy)-2-(trifluoromethoxy)benzene

Intermediate 44




2-bromo-3-fluoro-1-(methoxymethoxy)-4-methylbenzene

[0315] Step 1: 3-fluoro-4-methylphenol (1.016 g, 8.055 mmol) was placed in Cs_2 (3.9 mL, 64.44 mmol) and was cooled to 0°C. Br_2 (0.4150 mL, 8.055 mmol) was added and the mixture was stirred at room temperature for 2 hrs. 10% $Na_2S_2O_2$ was added and the mixture was extracted with DCM. The organic layers were combined, dried and filtered to provide 2-bromo-3-fluoro-4-methylphenol (1.389 g, 6.775 mmol, 84.10 % yield) which was used directly in the next step.

[0316] Step 2: 2-bromo-3-fluoro-1-(methoxymethoxy)-4-methylbenzene was prepared according to the procedure for Intermediate 8 using 2-bromo-3-fluoro-4-methylphenol in place of 2-bromo-3-fluorophenol.

Intermediate 45



2-bromo-1-isopropoxy-4-(methoxymethoxy)benzene


[0317] Step 1: 4-isopropoxyphenol (1.00 g, 6.57 mmol) and TEA (1.83 mL, 13.1 mmol) were placed in DCM (25 mL). Acetyl chloride (7.56 mL, 7.56 mmol) was added dropwise and the reaction was stirred at room temperature for 2hr. Water was added and the mixture was extracted with DCM. The organic layer was dried, filtered and concentrated to provide 4-isopropoxyphenyl acetate (1.24 g, 6.38 mmol, 97.2 % yield) which was directly in the next step.

[0318] Step2: 4-Isopropoxyphenyl acetate (1.24 g, 6.585 mmol) was placed in ACN (20 mL) and N-bromosuccinimide (1.173 g, 6.590 mmol) was added. The mixture was stirred for 18 hr. Water was added and the mixture was extracted with ether. The organic layers were combined, dried, and concentrated to provide 3-bromo-4-isopropoxyphenyl acetate (1.584 g, 5.800 mmol, 88.00 % yield) which was directly in the next step.

[0319] Step 3: 3-Bromo-4-isopropoxyphenyl acetate (500 mg, 1.83 mmol) was placed in MeOH (7 mL). A solution of KOH (111 mg, 1.98 mmol) in water (2 mL) was added to mixture and was stirred for 1 hr at room temperature. The reaction mixture was adjusted to pH 3 by the addition of 1N HCl. The mixture was extracted with DCM. The extracts were combined, dried, filtered and concentrated to provide crude 3-bromo-4-isopropoxyphenol which was used directly the next reaction.

[0320] Step 4: 2-Bromo-1-isopropoxy-4-(methoxymethoxy)benzene was prepared according to the procedure for Intermediate 8 using 3-bromo-4-isopropoxyphenol in place of 2-bromo-3-fluorophenol

Intermediate 46




1-bromo-3-chloro-2-isopropyl-5-(methoxymethoxy)benzene

[0321] Step 1: 1-bromo-3-chloro-2-isopropyl-5-methoxybenzene (952 mg, 3.61 mmol) was placed in DCM (3 mL) and was cooled to 0°C. BBr3 (9030 µL, 9.03 mmol) was added and the reaction was stirred at 0°C for 2 hr. Water was added and the mixture was extracted with DCM. The extracts were combined and concentrated. The resulting residue was purified by silica gel (0-20% EtOAc in hexane) to provide 3-bromo-5-chloro-4-isopropylphenol (575 mg, 2.30 mmol, 63.8 % yield)

[0322] Step 2: 1-bromo-3-chloro-2-isopropyl-5-(methoxymethoxy)benzene was prepared according to the procedure for Intermediate 8 using 3-bromo-5-chloro-4-isopropylphenol in place of 2-

Intermediate 47




1-iodo-3-(methoxymethoxy)naphthalene


[0323] To a solution of 4-iodonaphthalen-2-ol (0.80 g, 3.0 mmol) in DCM (20 mL) was added N-ethyl-N-isopropylpropan-2-amine (1.1 mL, 5.9 mmol) and chloro(methoxy)methane (0.29 g, 3.6 mmol) and the reaction stirred at room temperature for 4 hours, with additional chloro(methoxy)methane (0.15 g) being added after 2 hours. The reaction was washed with brine and concentrated *in vacuo*. The material was purified by chromatography using a gradient of 0 to 10% EtOAc/hexanes as the eluent to give 1-iodo-3-(methoxymethoxy)naphthalene (0.80 g, 2.5 mmol, 86 % yield).

Intermediate 48


3-benzyloxy-1-bromo-naphthalene




[0324] Step A: 2,4-dibromonaphthalen-1-amine: To a solution of Br_2 (246 g, 1.54 mol, 79.3 mL) in AcOH (750 mL) was added a solution of naphthalen-1-amine (101 g, 705 mmol, 99.0 mL) in AcOH (500 mL) at room temperature and the reaction stirred at 70 °C for 1 hour. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with AcOH (300 mL). The solid was next suspended in 20 % aqueous of NaOH (1.2 L). The mixture was stirred for 20 minutes and filtered. The solid was washed with water (1 L) and dried under vacuum to give 2,4-dibromonaphthalen-1-amine (200 g, 664 mmol, 94.2% yield) as gray solid. ES+APCI MS m/z 301.9 $[M+H]^+$.



[0325] Step B: 4-bromo-1-diazonio-naphthalen-2-olate: To a solution of 2,4-dibromonaphthalen-1-amine (60.0 g, 199 mmol) in AcOH (900 mL) and propionic acid (150 mL) was added $NaNO_2$ (16.5 g, 239 mmol, 13.0 mL) portionwise at 5-8 °C over 30 minutes and the reaction mixture stirred at 5-8 °C for 30 minutes. The reaction mixture was poured into ice-water (4000 mL), the slurry filtered and the solid washed with water (2 × 50 mL) to give 4-bromo-1-diazonio-naphthalen-2-olate (150 g, wet crude) which was used crude in the next step immediately. ^1H NMR (400 MHz, $CDCl_3$) δ 8.12 - 8.10 (d, *J*=8.4 Hz, 1H), 7.62 - 7.58 (t, *J*=7.6 Hz, 1H), 7.41 - 7.37 (t, *J*=7.6 Hz, 1H), 7.31 - 7.29 (d, *J*=8.0 Hz, 1H), 7.20 (s, 1H).




[0326] Step C: 4-bromonaphthalen-2-ol: To a solution of 4-bromo-1-diazonio-naphthalen-2-olate (100 g, 402 mmol) in EtOH (2.00 L) was added portion-wise $NaBH_4$ (30.4 g, 803 mmol) at 13-15 °C over 1 hour and the reaction stirred at 15-18 °C for 3 hours. The reaction was filtered and concentrated to dryness. The residue was dissolved in DCM (1000 mL) and washed with water (500 mL × 2). The organics were dried over Na_2SO_4 and concentrated to dryness. The residue was purified by chromtography eluting with petroleum ether/EtOAc (60/1 → 10/1) and material re-purified by reversed phase HPLC to give 4-bromonaphthalen-2-ol (40.0 g, 139 mmol, 17.3 % yield, 77.4% purity) as a gray solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.07 – 8.05 (d, *J*=8.0 Hz, 1H), 7.60 – 7.58 (d, *J*=7.6 Hz, 1H), 7.41 - 7.36 (m, 3H), 7.07 (s, 1H).




[0327] Step D: 3-benzyloxy-1-bromo-naphthalene: A mixture of 4-bromonaphthalen-2-ol (30.0 g, 134 mmol), BnBr (25.3 g, 148 mmol, 17.6 mL) and K_2CO_3 (55.7 g, 403 mmol) in MeCN (500 mL) was heated at 80 °C for 1 hr. The reaction mixture was filtered and concentrated to dryness. The residue was purified by silica gel column eluting with PE/EA (100/1 to 60/1) to give 3-benzyloxy-1-bromo-naphthalene (40.0 g, 128 mmol, 95 % yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ 8.19 – 8.17 (d, *J*=8.0 Hz, 1H), 7.75 – 7.32 (d, *J*=8.8 Hz, 1H), 7.64 - 7.63 (d, *J*=2.4 Hz,1H), 7.52 – 7.37 (m, 7H), 7.23 – 7.21 (d, *J*=2.0 Hz,1H), 5.2 (s, 2H).

Intermediate 49

benzyl 4-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(methylsulfinyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate




[0328] Step A: *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7- carboxylate: To a solution of 1-tert-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (50.0 g, 184 mmol) in MeOH (1.00 L) under nitrogen was added NaOMe (49.8 g, 921 mmol) and 2-methylisothiourea (62.4 g, 331 mmol, H_2SO_4). The reaction mixture was stirred at 25 °C for 16 hours. HCl (2 M) was added to the reaction mixture until pH~5 and then the mixture was concentrated under reduced pressure. The residue was suspended in 300 mL of ethyl acetate and 300 mL of water. The suspension was filtered. The organic phase was washed with water (1 × 300 mL), brine (1× 200 mL), dried over Na_2SO_4, filtered and concentrated to give *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7- carboxylate (51.0 g, 138 mmol, 75.4 % yield, 81.0 % purity) which was used directly in the next reaction. ES+APCI MS m/z 298.2 $[M+H]^+$.




[0329] Step B: *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a solution of *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 171 mmol) in DCM (500 mL) was added DIEA (44.3 g, 343 mmol, 59.9 mL) and Tf_2O (72.6 g, 257 mmol, 42.4 mL) sequentially at 0 °C under nitrogen. The reaction mixture was warmed up to 25 °C and stirred for 16 hours. The reaction mixture was concentrated and the residue purified by column

chromatography eluting with EtOAc/Petroleum 0 → 10% to give *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (46.0 g, 107 mmol, 62.4 % yield). ES+APCI MS m/z 430.2 $[M+H]^+$.




[0330] Step C: tert-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a solution of *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (46.0 g, 107 mmolin DMF (500 mL) was added DIEA (27.7 g, 214 mmol, 37.4 mL) and benzyl piperazine-1-carboxylate (25.9 g, 117 mmol, 22.7 mL). The reaction was heated to 100 °C for one hour under N_2 atmosphere. The reaction mixture was poured into ethyl acetate (300 mL). The mixture was washed with H_2O (300 mL × 3). The organic phase was washed with brine (200 mL), dried over anhydrous Na_2SO_4, concentrated in vacuo. The residue was purified by column chromatography using 0→20% EtOAc/Petroleum as eluent to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 96.9 mmol, 90.5 % yield, 92.0 % purity) ES+APCI MS m/z 500.3 $[M+H]^+$.




[0331] Step D: Benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1 –carboxylate: To a solution of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (25.0 g, 50 mmol) in DCM (50 mL) was added TFA (85.6 g, 750 mmol, 55.6 mL). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure and the

residue was dissolved in 300 mL of ethyl acetate and 300 mL of water and Na_2CO_3 added until pH~8. The organic layer was washed with water (1 × 300 mL), brine(1 × 200 mL) and dried over Na_2SO_4, filtered and concentrated under reduced pressure to give benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1 –carboxylate. The product was used directly to the next step without further purification. ES+APCI MS m/z 400.2 $[M+H]^+$.




[0332] Step E: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of 3-benzyloxy-1-bromo-naphthalene (16.3 g, 52.1 mmol) , benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1 -carboxylate (16.0 g, 40.1 mmol), Cs_2CO_3 (32.6 g, 100 mmol), $Pd_2(dba)_3$ (5.50 g, 6.01 mmol) and RuPhos (3.74 g, 8.01 mmol) in dioxane (300 mL) was degassed with N_2 3 times and the mixture stirred at 85 °C for 5 hour under N_2 atmosphere. The reaction mixture was quenched by addition water (200 mL) at 0 °C, and extracted with EtOAc (3 × 200 mL). The combined organic layers were washed with brine (3 × 150 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluting with 10→20% MeOH/DCM to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-4-yl]piperazine-1-carboxylate (16.0 g, 22.8 mmol, 56.9 % yield, 90.0 % purity ES+APCI MS m/z 632.5 $[M+H]^+$.




[0333] Step F: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (8.00 g, 12.7 mmol) in DCM (200 mL) was added m-CPBA (2.73 g, 12.7 mmol, 80.0 % purity) at 0 °C under nitrogen atmosphere. The reaction mixture was stirred for two hours under 0 °C. The reaction mixture was quenched by addition $Na_2S_2O_3$ (10 mL) at 0 °C, and then diluted with water (100 mL) and extracted with DCM (200 mL). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography eluting with 0→10% MeoH/DCM to benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (3.50 g, 4.92 mmol, 38.8 % yield, 91.0 % purity) ES+APCI MS m/z 648.5 $[M+H]^+$.

Intermediate 50

tert-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate






[0334] Step A: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate: To a stirred solution of *tert*-butyl4-(4-benzyloxycarbonylpiperazin -1-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (14.4 g, 28.9 mmol) in DCM (150 mL) was added m-CPBA solid (17.4 g, 101 mmol) at 0 °C under nitrogen. After stirring at 0 °C for 2 hours, the reaction mixture was diluted with water (300 mL) and basified with saturated $NaHCO_3$ aqueous solution to pH ~ 8 and then extracted with DCM (3 × 200 mL). The combined organic layers were washed with brine (3 × 200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 10/1 to 1/2) to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (11.0 g, 19.7 mmol, 68.6 % yield, 95.4 % purity). ES+APCI MS m/z 532.1 $[M+H]^+$.

Intermediate 51


4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole



[0335] Step A: 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole: To a mixture of 4-bromo-5-methyl-1*H*-indazole (3 g, 14.2 mmol) and 3,4-dihydro-2*H*-pyran (2.39 g, 28.4 mmol, 2.60 mL) in DCM (30 mL) was added TsOH*H_2O (270 mg, 1.42 mmol) and the mixture stirred at 15 °C for 2 hours. After completion, the reaction mixture was concentrated under vacuum and the residue purified by column chromatography using 5→20& EtOAc/Petroleum Ether as eluent to give 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole (4 g, 13.6 mmol, 95.3% yield) as white solid. ^{1}H NMR (400 MHz, chloroform-d) δ 8.01 (s, 1H), 7.47 (d, *J*=8.4 Hz, 1H), 7.25 (d, *J*=8.4 Hz, 1H), 5.70 (dd, *J*=2.8, 9.2 Hz, 1H), 4.05 - 3.96 (m, 1H), 3.79 - 3.70 (m, 1H), 2.66 - 2.44 (m, 4H), 2.25 - 2.04 (m, 2H), 1.84 - 1.56 (m, 3H).

Intermediate 52


4-bromo-5-methoxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole




[0336] 4-bromo-5-methoxy-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole was prepared following Intermediate 51 substituting 4-bromo-5-methoxy-1H-indazole for 4-bromo-5-methyl-1*H*-indazole in Step A. ^{1}H NMR (400 MHz, chloroform-d) δ 8.00 (s, 1H), 7.53 (d, *J*=9.2 Hz, 1H), 7.16 (d, *J*=9.2 Hz, 1H), 5.70 (dd, *J*=2.8, 9.2 Hz, 1H), 4.04 - 3.98 (m, 1H), 3.96 (s, 3H), 2.55 - 2.49 (m, 1H), 2.23 - 2.05 (m, 2H), 1.83 - 1.69 (m, 3H).

Intermediate 53

3-(benzyloxy)-1-bromo-2-methylnaphthalene





[0337] Step A: ethyl 2-methyl-3-oxo-4-phenyl-butanoate. To a dried 250 ml three-necked flask was added ethyl 3-oxo-4-phenyl-butanoate (4.00 g, 19.4 mmol.), THF (50.0 mL), sodium hydride (931 mg, 23.3 mmol) and the reaction stirred for 0.5 hours at 0°C. A solution of methyl iodide (3.03 g, 21.3) was next added drop-wise. After addition was completed, the reaction mixture was warmed to 20 °C and stirred for two hours at 20°C. The reaction mixture was quenched by addition of water (10.0 mL) at 20 °C and then diluted with ethyl acetate (20.0 mL) and the layers separated. The aqueous layer was next extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (30.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether : Ethyl acetate 20:1 to 10:1) to give ethyl 2-methyl-3-oxo-4-phenyl-butanoate (3.60 g, 16.3 mmol, 84.3% yield) as a colorless oil. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.38 - 7.28 (m, 3H), 7.25 - 7.19 (m, 2H), 4.22 - 4.15 (m, 2H), 3.87 (d, J = 2.0 Hz, 2H), 3.65 (q, J = 7.2 Hz, 1H), 1.34 (d, J = 7.2 Hz, 3H), 1.30 - 1.26 (m, 3H).

[0338] Step B: 2-methylnaphthalene-1,3-diol. A solution of ethyl 2-methyl-3-oxo-4-phenyl-butanoate (3.60 g, 16.3 mmol) in concentrated sulfuric acid (19.9 g, 203 mmol) was stirred at 15 °C for 12 hours. The reaction mixture was poured into ice-water (30.0 mL) and the resulting solid collected by filtration and dried under vacuum to afford 2-methylnaphthalene-1,3-diol (1.80 g, 10.3 mmol, 63.2% yield) as a red solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.02 (d, J =

8.0 Hz, 1H), 7.65 - 7.54 (m, 1H), 7.41 (t, J = 7.2 Hz, 1H), 7.36 - 7.31 (m, 1H), 6.80 (s, 1H), 4.29 - 4.20 (s, 2H), 2.41 - 2.24 (s, 3H).

[0339] Step C: 3-methoxy-2-methyl-naphthalen-1-ol. 2-methylnaphthalene-1,3-diol (1.70 g, 9.76 mmol) was added to HCl/MeOH (2 M, 35.0 mL) and the result mixture was stirred at 30 °C for 3 days. The reaction was concentrated in vacuo and the residue purified by Prep-TLC (Petroleum ether : Ethyl acetate 1:1) to give 3-methoxy-2-methyl-naphthalen-1-ol (800 mg, 4.25 mmol, 43.5% yield) as a white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.02 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.44 - 7.38 (m, 1H), 7.37 - 7.31 (m, 1H), 6.79 (s, 1H), 5.14 (s, 1H), 3.94 (s, 3H), 2.29 (s, 3H).

[0340] Step D: (3-methoxy-2-methyl-1-naphthyl)trifluoromethanesulfonate. To a mixture of 3-methoxy-2-methyl-naphthalen-1-ol (800 mg, 4.25 mmol.) and pyridine (504 mg, 6.38 mmol) in DCM (10.0 mL) was added trifluoroacetic anhydride (1.44 g, 5.10 mmol) dropwise at 0°C under N_2 atmosphere. The mixture was warmed to 20°C and stirred for an additional 5 hours. The solvent was removed under vacuum and the residue purified by Prep-TLC (Petroleum ether : Ethyl acetate 1:1) to give (3-methoxy-2-methyl-1-naphthyl)trifluoromethanesulfonate (1.30 g, 4.06 mmol, 95.5% yield) as a white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.97 (d, J = 7.6 Hz, 1H), 7.79 - 7.74 (m, 1H), 7.52 - 7.43 (m, 2H), 7.14 (s, 1H), 3.99 (s, 3H), 2.42 (s, 3H)

[0341] Step E: 1-bromo-3-methoxy-2-methyl-naphthalene : In a sealed tube was added (3-methoxy-2-methyl-1-naphthyl)trifluoromethanesulfonate (466 mg, 1.45 mmol), t-Bu-Brettphos (154 mg, 290 umol), potassium bromide (259 mg, 2.17 mmol), PEG-200 (175 mg), 2-butanone (157 mg, 2.17 mmol) and $Pd_2(dba)_3$ (133 mg, 145 umol) in toluene (10.0 mL) and the mixture de-gassed with N2 for 5 minutes. Next, triisobutylaluminum (431 mg, 2.17 mmol) was added drop-wise at 20 °C. The mixture was heated to 100 °C for 24 hrs. The reaction mixture was poured into water (30.0 mL) and the aqueous layer extracted with ethyl acetate (20.0 mL × 3). The combined organics were washed with brine (30.0 mL), dried over anhydrous sodium sulfate and concentrated in vacuo to give a residue which was pre-purified by column chromatography (Petroleum ether:Ethyl acetate 10:1) and then by Prep-TLC (Petroleum ether : Ethyl acetate 10:1) to give 1-bromo-3-methoxy-2-methyl-naphthalene (700 mg, 2.79 mmol, 64.1% yield) as a


white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.26 - 8.17 (m, 1H), 7.73 - 7.69 (m, 1H), 7.47 - 7.40 (m, 2H), 7.09 (s, 1H), 3.98 - 3.95 (m, 3H), 2.56 (s, 3H).

[0342] Step F: 4-bromo-3-methyl-naphthalen-2-ol: To a solution of 1-bromo-3-methoxy-2-methyl-naphthalene (580 mg, 2.31 mmol) and tetrabutylammonium iodide (2.13 g, 5.78 mmol) in DCM (11.0 mL) cooled to -78 °C was added a solution of BCl_3 (1 M, 5.78 mL) dropwise over a period of 10 minutes while under N_2. The reaction mixture was warmed to 0 °C and stirred for 2 hours at room temperature. Next the solvent was removed under vacuum and the residue was purified by Prep-TLC (Petroleum ether : Ethyl acetate 5:1) to give 4-bromo-3-methyl-naphthalen-2-ol (500 mg, 2.11 mmol, 91.3% yield) as a white solid. ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.26 - 8.15 (m, 1H), 7.63 (dd, J = 3.6, 6.0 Hz, 1H), 7.45 - 7.38 (m, 2H), 7.11 (s, 1H), 5.09 (s, 1H), 2.60 (s, 3H), 1.56 (s, 3H).

[0343] Step G: 3-benzyloxy-1-bromo-2-methyl-naphthalene. To a mixture of 4-bromo-3-methyl-naphthalen-2-ol (265 mg, 1.12 mmol) and benzyl bromide (201 mg, 1.18 mmol) in acetonitrile (3.00 mL) was added potassium carbonate (310 mg, 2.24 mmol) in one portion at 20 °C under N_2. The mixture was next stirred at 60°C for two hours. The solvent was removed under vacuum and the residue purified by Prep-TLC (Petroleum ether : Ethyl acetate 5:1) to give the 3-benzyloxy-1-bromo-2-methyl-naphthalene (250 mg, 695 umol, 31.0% yield, 91.0% purity) as a white solid. ES+APCI MS m/z 327.0, 329.0 $[M+H]^+$.

Intermediate 54


tert-butyl-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate



[0344] Step A: (4-bromo-2-naphthyl) 2,2-dimethylpropanoate. To a solution of 4-bromonaphthalen-2-ol (10 g, 44.8 mmol) and TEA (9.07 g, 89.7 mmol) in DCM (200 mL) was added 2,2-dimethylpropanoyl chloride (8.11 g, 67.2 mmol) at 0°C. The reaction mixture was stirred at 0 °C for 10 min. T reaction mixture was quenched by addition of water (50 mL) and the layers separated. The organic layer was washed with brine (30 mL), dried over Na_2SO_4 filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EA =1:0 to 100:1) to give (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (9 g, 29.3 mmol, 65.4% yield) as a red oil. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.22 (d, *J*=8.0 Hz, 1H), 7.83 - 7.77 (m, 1H), 7.63 - 7.49 (m, 4H), 1.41 (s, 9H).

Intermediate 55

tert-butyl 4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1-carboxylate.



[0345] Step A: 7-benzyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-2,4-diol. To EtOH (600 mL) was added Na (5.56 g, 241 mmol) in portions and the mixture stirred for 1 hour. To this solution was added ethyl 1-benzyl-3-oxo-piperidine-4-carboxylate (30.0 g, 100 mmol) and urea (14.5 g, 242 mmol) and the reaction mixture stirred at 75 °C for 36 hours. The solvent was removed under vacuum and the residue dissolved in water (50 mL) and acidified by addition of HCl (120 mL, 2M) at which point a solid precipitated. The solid was filtered and the filter cake dried under vacuum to give 7-benzyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-2,4-diol (22.0 g, 83.8 mmol). ^{1}HNMR (400MHz, DMSO-d_6) δ = 10.97 (br s, 1H), 10.66 (br s, 1H), 7.55 - 6.95 (m, 5H), 3.81 - 3.50 (m, 2H), 3.26 - 2.91 (m, 2H), 2.77 - 2.58 (m, 2H), 2.34 - 2.09 (m, 2H).


[0346] Step B: 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. To a solution of DIEA (30.1 g, 233 mmol) in $POCl_3$ (330 g, 2.15 mol) was added 7-benzyl-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidine-2,4-diol (20.0 g, 77.7 mmol) and the reaction mixture stirred at 110 °C for 5 hours. Upon completion, the reaction mixture was concentrated under vacuum. The residue was dissolved in DCM (400 mL) and poured into sat. $NaHCO_3$ (200 mL) and the layers separated. The aqueous layer was extracted with DCM (2 × 400 mL). The combined organics were washed with brine (100 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/DCM = 10/1 to 0/1) to give 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (7.70 g, 26.2 mmol). ^{1}HNMR (300MHz, chloroform-d) δ = 7.43 - 7.28 (m, 5H), 3.73 (s, 2H), 3.66 (br s, 2H), 2.84 (br s, 4H).

[0347] Step C: *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl) piperazine-1-carboxylate. To a solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidine (17.3 g, 58.8 mmol) in DMSO (200 mL) was added DIEA (19.0 g, 147 mmol) and *tert*-butyl piperazine-1-carboxylate (11.5 g, 61.7 mmol) and the mixture stirred at 55 °C for 10 hours. The reaction mixture was poured into ethyl acetate (200 mL) and washed with water (3x200mL). The combined organics were washed with brine (200 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give a residue. The residue was purified by trituration from MTBE (200 mL) to give *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl) piperazine-1-carboxylate (24 g, 52.9 mmol). ES+APCI MS m/z 444.2 $[M+H]^+$.

[0348] Step D: *tert*-Butyl 4-[7-benzyl-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl] piperazine-1-carboxylate. A mixture of 3-morpholinopropan-1-ol (11.8 g, 81.1 mmol), *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1- carboxylate (18 g, 40.5 mmol), BINAP (5.05 g, 8.11 mmol), *t*-BuONa (9.74 g, 101 mmol) and $Pd_2(dba)_3$ (3.71 g, 4.05 mmol) in toluene (300 mL) was degassed and purged with N_2 3 times, and the mixture stirred at 110 °C for 3 hours under N_2 atmosphere. The reaction mixture was poured into H_2O (200 mL) and the aqueous layer extracted with ethyl acetate (3x300 mL). The combined organics were washed with brine (200 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 100/1 to 5/1) to give *tert*-Butyl 4-[7-benzyl-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl] piperazine-1-carboxylate (14 g, 22.5 mmol). ES+APCI MS m/z 553.4 $[M+H]^+$.

[0349] Step E: *tert*-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl] piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-benzyl-2-(3-morpholinopropoxy)- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (14 g, 25.3 mmol) in MeOH (1 L) was added dry Pd/C (3 g, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 10 hours. The mixture was filtered and the filtrate concentrated in vacuo to give a residue. The residue was purified by reversed phase flash [water (0.1TFA)/acetonitrile] to give *tert*-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl] piperazine-1-carboxylate (6.5 g, 13.9 mmol). ES+APCI MS m/z 463.4 $[M+H]^+$.


Intermediate 56




[0350] Naphthalen-1-yl trifluoromethanesulfonate. alpha-Naphthol (4 g, 27.74 mmol) was dissolved in DCM (200 mL) in a 3 neck flask. The reaction was cooled to 10°C in a water bath.

N-ethyl-N-isopropylpropan-2-amine (4.846 ml, 27.74 mmol) and trifluoromethanesulfonic anhydride (4.668 ml, 27.74 mmol) were added to the solution dropwise. The reaction was stirred at 10°C for 2 hours. TLC (25% EtOAc, UV vis) showed reaction complete. The organics were with water (2X) and brine (2X). The organics were dried over MgSO4 and concentrated in vacuo. The concentrate was purified using normal phase chromatography on the CombiFlash (0%-12% EtOAc:Hexanes). All fractions containing clean product were combined and conentrated in vacuo to give naphthalen-1-yl trifluoromethanesulfonate (6.77 g, 24.51 mmol, 88.34 % yield).

Intermediate 57




Tert-butyl (S)-2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate



[0351] To a solution of (S)-1-Boc-2-hydroxymethylpiperazine (1.0 g, 4.62 mmol) in DCE (92.47 ml, 4.624 mmol) was added formaldehyde (3.474 ml, 46.24 mmol) (37% in water) followed by sodium triacetoxyborohydride (4.9 g, 23.12 mmol). The mixture was stirred vigorously at room temperature for 2.5hours. The mixture was treated with saturated sodium bicarbonate (30 mL), stirred for 10 min then extracted with DCM (3 x 10 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated. ES+APCI MS m/z 231.1 $[M+H]^+$.


Intermediate 58




Tert-butyl (R)-2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate

[0352] Title compound was prepared as in Intermediate 57, substituting tert-butyl (R)-2-(hydroxymethyl)piperazine-1-carboxylate for (S)-1-Boc-2-hydroxymethylpiperazine. ES+APCI MS m/z 231.1 $[M+H]^+$

Intermediate 59



1-bromo-3-chloro-2-fluoro-5-(methoxymethoxy)benzene




[0353] To a round bottom flask was added THF (8.87 ml, 4.44 mmol) followed by sodium hydride, 60 % dispersion in mineral oil (0.213 g, 5.32 mmol). The mixture was cooled to 0 °C then 3-bromo-5-chloro-4-fluorophenol (1.0 g, 4.44 mmol) was added portionwise. Once the bubbling had ceased the resulting dark mixture was stirred at 0 °C for 30 min. Then chloromethyl methyl ether (0.421 ml, 5.54 mmol) was added and the mixture was warmed to ambient temperature where it was stirred for 2 hr. A saturated aqueous ammonium chloride solution was added and the mixture was extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated. Crude material was chromatographed (0-15% EtOAc in hexanes) to provide product as clear oil.

Intermediate 60


4-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole

SUBSTITUTE SHEET (RULE 26)




[0354] Step A: 4-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole: To a solution of 4-bromo-5-(trifluoromethyl)-1H-indazole (500 mg, 1.89 mmol, 1 *eq*) in DCM (10 mL) was added 3,4-dihydro-2H-pyran (476 mg, 5.66 mmol, 517 uL, 3 *eq*) and $TsOH \cdot H_2O$ (35.9 mg, 188 umol, 0.1 *eq*). The mixture was stirred at 15 °C for 1 hour. The mixture was concentrated. The residue was purified by column chromatography (SiO_2, PE:EA=10:1 to 1:1) to give 4-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole (480 mg, 1.37 mmol, 72.9% yield) as yellow oil.^{1}H NMR (400 MHz, chloroform-d) δ 8.20 (s, 1H), 7.69 - 7.63 (m, 2H), 5.70 (dd, *J*=2.8, 8.8 Hz, 1H), 4.05 - 3.96 (m, 1H), 3.79 - 3.70 (m, 1H), 2.56 - 2.50 (m, 1H), 2.27 - 2.04 (m, 2H), 1.80 - 1.74 (m, 2H), 1.60 - 1.54 (m, 1H).

Intermediate 61



[0355] 8-bromo-6-(methoxymethoxy)quinoline: A stirred suspension of 8-bromoquinolin-6-ol (1.00 g, 4.46 mmol) in DCM (20 mL) was cooled to 0°C and diisopropylethylamine (1.2 mL, 6.7 mmol, 1.5 eq.) was added followed by chloro(methoxy)methane (0.41 mL, 5.4 mmol, 1.2 eq.) dropwise and the reaction mixture was warmed to room temperature overnight. Concentrated aqueous ammonia (0.5 mL, ~5 mmol) was next added and the resulted mixture was stirred for 1hour at room temperature. The mixture was evaporated in vacuo and chromatographed on silica gel, Redisep 40g, using 20% EtOAc/hexane as eluent to give a colorless powder (0.52 g, 44%). ES+APCI MS m/z 268.0, $[M+H]^+$.

Intermediate 62



[0356] To a solution of but-3-enenitrile (80.0 g, 1.19 mol, 96.4 mL, 1.00 eq) in *tert*-butanol (130 mL) and petroleum ether (480 mL) was added a solution of Br_2 (191 g, 1.19 mol, 61.5 mL, 1.00 eq) in *tert*-butanol (130 mL). The mixture was stirred at 10 °C for 4 hours. The mixture was used into next step without any workup.

[0357] To the above mixture (274 mL) was added a solution of *N*,*N*'-dibenzylethane-1,2-diamine (160 g, 445 mmol, 157 mL, 2 HOAc) and Et_3N (178 g, 1.76 mol, 245 mL) in toluene (300 mL). After was stirred at 110 °C for 2 hours, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 3/1) to give 2-(1, 4-dibenzylpiperazin-2-yl)acetonitrile (75.0 g, 246 mmol, two steps 55.7 % yield) as a yellow solid. LCMS [ESI, M+1]: 306.


[0358] ^{1}H NMR (400MHz, chloroform-d) δ = 7.37 - 7.23 (m, 10H), 3.80 (d, *J* = 13.2 Hz, 1H), 3.60 - 3.42 (m, 3H), 3.06 - 2.96 (m, 1H), 2.95 - 2.83 (m, 1H), 2.69 - 2.53 (m, 4H), 2.52 - 2.35 (m, 3H).

[0359] To a solution of 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile (160 g, 524 mmol, 1.00 eq) in dichloroethane (1.50 L) was added 1-chloroethyl carbonochloridate (300 g, 2.10 mol, 4.00 eq) at 15 °C. After stirred at 85 °C for 48 h, the mixture was concentrated under vacuum. The residue was then taken up into methanol (1.50 L) and heated to reflux for 1 hour. The mixture was concentrated. The solid was treated with methyl tert-butyl ether (1.00 L), 2-piperazin-2-

ylacetonitrile (Intermediate 62, 90.0 g, 454 mmol, 86.7 % yield, 2HCl) was obtained as a white solid and used for next step without further purification.

[0360] ^{1}H NMR (400MIIz, DMSO-d6) δ = 10.19 (br s, 2H), 4.01 - 3.73 (m, 1H), 3.69 - 3.41 (m, 4H), 3.32 (dt, *J* = 2.8, 13.2 Hz, 1H), 3.27 - 3.10 (m, 3H).

Intermediate 63



[0361] To a solution of *t*ert-butyl (3*R*)-3-(hydroxymethyl)piperazine-1-carboxylate (80.0 g, 370 mmol, 1.0 *eq*) in Ethyl acetate (1400 mL) was added $NaHCO_3$ (93.2 g, 1.11 mol, 43.2 mL, 3.0 *eq*), H_2O (700 mL) and benzyl carbonochloridate (82.0 g, 481 mmol, 68.4 mL, 1.30 *eq*). The mixture was stirred at 25 °C for 12 hour. After completion, the organic phase was separated, washed with water (500 mL x 2) dried over Na_2SO_4 and filtered. The solvent was removed under vacuum to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=40/1 to 1/1). The product 1-benzyl 4-*t*ert-butyl (2*R*)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate (85.0 g, 235 mmol, 64% yield, 96% purity) was obtained as a yellow oil. LCMS [ESI, M-99]: 251.

[0362] To a solution of 1-benzyl 4-*t*ert-butyl (2*R*)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate (20.0 g, 57.1 mmol, 1.0 *eq*) in 2-Methyltetrahydrofuran (240 mL) was added TEA (17.3 g, 171.23 mmol, 23.8 mL, 3.0 *eq*) and methanesulfonyl chloride (7.74 g, 67.6 mmol, 5.23 mL, 1.18 *eq*). The mixture was stirred at 20 °C for 1 hour. The reaction mixture was quenched by addition H_2O 150 mL at 20 °C. The reaction mixture was extracted with Ethyl acetate (300 mL x 2). The organic layers were washed with H_2O (100 mL), dried over Na_2SO_4, and filtered. The solvent was removed under vacuum. 1-benzyl 4-*t*ert-butyl (2*R*)-2-

SUBSTITUTE SHEET (RULE 26)


(methylsulfonyloxymethyl)piperazine-1,4-dicarboxylate (22.0 g, crude) was obtained as a yellow oil. The crude product was used directly to the next step without further purification.

[0363] To a solution of 1-benzyl 4-tert-butyl (2*R*)-2-(methylsulfonyloxymethyl)piperazine-1,4-dicarboxylate (22.0 g, 51.3 mmol) in DMA (150 mL) was added NaCN (10.4 g, 211 mmol). The mixture was stirred at 60 °C for 12 hour. The solvent was removed under vacuum to give a oil residue. The residue was diluted with H_2O (40.0 mL) and extracted with Ethyl acetate (50.0 mL × 3). The combined organic layers were washed with saturated brine (80.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=40/1 to 5:1) The product 1-benzyl 4-tert-butyl (2*S*)-2-(cyanomethyl)piperazine-1,4-dicarboxylate (18.5 g, 46.4 mmol, two steps yield 72%) was obtained as a yellow oil. LCMS [ESI, M+1]: 360.

[0364] To a solution of 1-benzyl 4-tert-butyl (2*S*)-2-(cyanomethyl)piperazine-1,4-dicarboxylate (18.5 g, 43.3 mmol, 1.00 eq) in dioxane (40.0 mL) was added HCl•dioxane (4 M, 54.1 mL, 5.0 eq). The mixture was stirred at 20 °C for 1 hour. Then the reaction mixture was added $NaHCO_3$ to pH>7, and concentrated under reduced pressure to remove dioxane. The residue was diluted with H_2O (50.0 mL) and extracted with Ethyl acetate (50.0 mL × 3). The combined organic layers were washed with H_2O (20.0 mL) , dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The product benzyl (2*S*)-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 63, 11.5 g, 91.8% purity, 95% yield) was obtained as a yellow oil. LCMS [ESI, M+1]: 260.

[0365] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.37 - 7.31 (m, 5H), 5.14 (s, 2H), 4.49 (br, s, 1H), 3.93 (br, s, 1H), 3.07 - 2.81 (m, 5H), 2.78 - 2.54 (m, 2H).

Intermediate 64



[0366] A mixture of *tert*-butyl 2-methylsulfanyl-4 -(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (3.81 g, 8.87 mmol, 1.0 eq), benzyl(2*S*)-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 63, 2.30 g, 8.87 mmol, 1.0 eq), DIEA (3.44 g, 26.6 mmol, 4.63 mL, 3.0 eq) in DMF (20.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 1 hour under N_2 atmosphere. After completion, the solvent was removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to 1:1) to give *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (3.6 g, 6.16 mmol, 69% yield, 92.2% purity) as a yellow solid. LCMS [ESI, M+1]: 539.


[0367] A mixture of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*pyrido[3,4-d]pyrimidine-7-carboxylate (6.0 g, 11.1 mmol, 1.0 eq), TFA (30.8 g, 270 mmol, 20.0 mL, 24.3 eq) in DCM (20.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 20 °C for 1 hour under N_2 atmosphere. After completion, the reaction mixture was quenched with saturated $NaHCO_3$ solution (500 mL). The mixture was extracted with ethyl acetate (3 × 300 mL) and the organic layer was dried over Na_2SO_4 and filtered. The solvent was removed under vacuum to give benzyl (2*S*)-2-

(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.8 g, crude) as a yellow solid which was used for the next step without further purification.

[0368] A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.8 g), 1-bromonaphthalene (3.8 g, 18.35 mmol, 2.55 mL), $Pd_2(dba)_3$ (1.0 g, 1.09 mmol), RuPhos (1.02 g, 2.19 mmol) and Cs_2CO_3 (12.0 g, 36.8 mmol) in toluene (30.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 12 hours under N_2 atmosphere. After completion, the reaction mixture was filtered. The organic solvent was removed under vacuum to give an oil residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=5/1 to 3:1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfanyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.2 g, 3.31 mmol, 85.3% purity, two steps yield 30%) was obtained as a yellow solid. LCMS [ESI, M+1]: 565.

[0369] A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfanyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.8 g, 3.97 mmol, 1.0 eq), m-CPBA (1.05 g, 5.16 mmol, 1.3 eq) in DCM (4.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0 °C for 1 hour under N_2 atmosphere. After completion, the reaction is quenched by adding saturated Na_2SO_3 solution (50 mL). The mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layer was dried with Na_2SO_4 and filtered. The solvent was removed to give a oil residue. The residue was purified by column chromatography (SiO_2, Metheanol/Ethyl acetate=1/20 to 1:10) to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 1.5 g, 2.35 mmol, 59% yield, 90.8% purity) as a yellow solid. LCMS [ESI, M+1]: 581.

Intermediate 65



[0370] To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl -3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (24.3 g, 45.0 mmol, 1.0 *eq*) in Ethyl acetate (480 mL) was added m-CPBA (8.69 g, 42.8 mmol, 85% purity, 0.95 *eq*) portionwise at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the mixture was diluted with water (50.0 mL) and extracted with ethyl acetate (2 × 300 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile]. The mixture was neutralized with saturated sodium bicarbonate solution, concentrated under vacuum to remove MeCN and extracted with ethyl acetate (3 × 1000 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (22.8 g, 39.3 mmol, 87% yield, 95.8% purity) as a yellow solid.

[0371] ^{1}H NMR (400 MHz, chloroform-d) δ 7.37 - 7.23 (m, 5H), 5.12 (s, 2H), 4.75 - 4.41 (m, 3H), 4.17 - 4.05 (m, 2H), 3.86 (d, J = 11.6 Hz, 1H), 3.81 - 3.62 (m, 1H), 3.46 - 3.18 (m, 3H), 3.10 (d, J = 3.6, 12.0 Hz, 1H), 2.81 (d, J = 3.2 Hz, 3H), 2.77 - 2.56 (m, 4H), 1.42 (s, 9H).

[0372] To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl- 3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (5.0 g, 9.01 mmol, 1.0


eq) and [(2*S*)-1-methylpyrrolidin -2-yl]methanol (1.82 g, 15.8 mmol, 1.88 mL, 1.75 *eq*) in toluene (50.0 mL) was added t-BuONa (1.73 g, 18.0 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added cold water (50.0 mL) and extracted with ethyl acetate (5 × 50.0 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE : EA = 10:1 - EA : MeOH = 5:1) to give *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (2.80 g, 4.62 mmol, 51.0% yield) as yellow solid.

[0373] ^{1}H NMR (400 MHz, chloroform-d) δ 7.44 - 7.35 (m, 5H), 5.21 (s, 2H), 4.73 - 4.54 (m, 2H), 4.44 - 4.33 (m, 2H), 4.22 - 4.10 (m, 2H), 3.41 - 3.93 (m, 1H), 3.82 (br d, J = 11.6 Hz, 2H), 3.39 - 3.22 (m, 3H), 3.11 (br t, J = 7.8 Hz, 1H), 2.99 (d, J = 3.6, 12.8 Hz, 1H), 2.90 - 2.56 (m, 5H), 2.49 (s, 3H), 2.35 - 2.25 (m, 1H), 2.07 - 2.02 (m, 1H), 1.91 - 1.76 (m, 3H), 1.50 (s, 9H).

[0374] To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl -3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (2.40 g, 3.96 mmol, 1.0 *eq*) in DCM (8.0 mL) was added TFA (13.9 g, 122 mmol, 9.0 mL, 30.7 *eq*). The mixture was stirred at 15 °C for 2 hours. After completion, the mixture was concentrated. The residue was added saturated $NaHCO_3$ aqueous (20.0 mL) and extracted with DCM (5 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The product benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 1.40 g, 2.77 mmol, 70% yield) was obtained as yellow solid. LCMS [ESI, M+1]: 506.

Intermediate 66

SUBSTITUTE SHEET (RULE 26)



[0375] Step A: To a solution of 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidine (20.0 g, 65.4 mmol, 1 *eq*) in DCE (200 mL) was added 1-chloroethyl carbonochloridate (28.1 g, 196 mmol, 3 *eq*) at 0 °C. The mixture was stirred at 0 °C for 30 minutes and 70 °C for 15 hours. The mixture was concentrated under vacuum. The residue was dissolved in MeOH (200 mL) and stirred at 70 °C for 0.5 hours. Upon completion, the mixture was concentrated under vacuum. The residue was triturated with methyl *tert*-butyl ether (60 mL). The precipitate was collected by filtration, washed with methyl *tert*-butyl ether (20 mL) and dried under vacuum to give 4-chloro-2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (17.2 g, crude, HCl) as a yellow solid which was used directly in the next step without further purification.

[0376] ^{1}H NMR (400 MHz, methanol-d_4) δ = 4.35 (s, 2H), 3.60 (t, J = 6.4 Hz, 2H), 3.05 (t, J = 6.4 Hz, 2H), 2.55 (s, 3H).

[0377] Step B: To a solution of 4-chloro-2-methylsulfanyl-5,6,7,8-tetrahydropyrido [3,4-d]pyrimidine (16.5 g, crude, HCl) and TEA (20.0 g, 196 mmol, 27.3 mL) in THF (400 mL) was added benzyl carbonochloridate (16.7 g, 98.1 mmol, 13.9 mL) dropwise at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. Upon completion, the mixture was diluted with water (80 mL) and the organic layer was separated. The aqueous phase was extracted with EtOAc (200 mL). The combined organic layers were dried over $MgSO_4$, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 80/1 to 5/1) to give benzyl 4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidine-7-carboxylate (19.6 g, 50.4 mmol, two steps 86% yield, 90% purity) as a yellow oil.

[0378] ^{1}H NMR (300 MHz, chloroform-d) δ = 7.37 (s, 5H), 5.18 (s, 2H), 4.63 (s, 2H), 3.877 (d, *J* = 8.0, 2H), 2.80 (br s, 2H), 2.54 (s, 3H).

[0379] Step C: To a solution of benzyl 4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidine-7-carboxylate (21.5 g, 55.3 mmol, 1.00 *eq*) in DMF (400 mL) was added DIEA (35.7 g, 277 mmol, 48.2 mL, 5.00 *eq*) and 2-[(2*S*)-piperazin-2-yl]acetonitrile (6.92 g, 55.3 mmol, 1.00 *eq*). After stirred at 80 °C for 2 hours, $(Boc)_2O$ (60.4 g, 277 mmol, 63.5 mL, 5.00 *eq*) was added into above mixture and stirred at 80 °C for another 2 hours. Upon completion, the mixture was diluted with water (800 mL) and extracted with EtOAc (2 × 400 mL). The organic layers were washed with brine (300 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 10/1 to 1/1) to give benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (24.3 g, 43.0 mmol, 78% yield, 95% purity) as a yellow solid.

[0380] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.43 - 7.29 (m, 5H), 5.18 (s, 2H), 4.76 - 4.54 (m, 2H), 4.46 (br d, *J* = 18.4 Hz, 1H), 4.08 - 3.69 (m, 4H), 3.53 - 3.35 (m, 1H), 3.34 - 3.03 (m, 2H), 3.03 - 2.89 (m, 1H), 2.81 - 2.55 (m, 4H), 2.50 (s, 3H), 1.51 (s, 9H).

[0381] Step D: To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (24.3 g, 45.1 mmol, 1 *eq*) in EtOAc (480 mL) was added *m*-CPBA (8.70 g, 42.9 mmol, 85% purity, 0.95 *eq*) potionwise at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the


mixture was diluted with water (800 mL). The pH was adjusted to 8 with $NaHCO_3$ and the organic layer was separated. The aqueous phase was extracted with EtOAc (2 × 400 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (EtOAc/MeOH 100/1 to 10/1) to give benzyl 4-[(3*S*)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (20.9 g, 36.4 mmol, 81% yield, 96% purity) as a white solid. LCMS [ESI, M+1]: 555.

[0382] Step E: To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (20.9 g, 37.6 mmol, 1 *eq*) and [(2*S*)-1-methylpyrrolidin-2-yl]methanol (8.67 g, 75.3 mmol, 8.94 mL, 2 *eq*) in toluene (400 mL) was added *t*-BuONa (7.23 g, 75.3 mmol, 2 *eq*) at 0 °C. After stirred at 0 °C for 10 minutes, the mixture was concentrated under vacuum. The residue was diluted with water (200 mL) and extracted with EtOAc (2 × 400 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile]. The mixture was neutralized with saturated sodium bicarbonate solution, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 1000 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidine-7-carboxylate (13.5 g, 20.5 mmol, 54% yield, 92% purity) as a yellow solid. LCMS [ESI, M+1]: 606.

[0383] Step F: To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (3.50 g, 5.78 mmol, 1 *eq*) in MeOH (60.0 mL) was added NH_3/MeOH (60.0 mL), Pd/C (1.00 g, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 4 hours. Upon completion, the catalyst was filtered off and the filtrate was concentrated under vacuum to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 2.33 g, 4.55 mmol, 79% yield, 92% purity) as a yellow solid which was used directly in the next step without further purification.

[0384] ^{1}H NMR (400 MHz, chloroform-d) δ = 4.58 (br s, 1H), 4.34 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.11 (dd, *J* = 6.8, 10.8 Hz, 1H), 4.08 - 3.88 (m, 4H), 3.84 (br d, *J* = 12.8 Hz, 1H), 3.25 - 3.03 (m, 4H), 3.01 - 2.88 (m, 2H), 2.82 - 2.51 (m, 5H), 2.47 (s, 3H), 2.27 (dt, *J* = 7.2, 9.2 Hz, 1H), 2.11 - 1.97 (m, 1H), 1.92 - 1.75 (m, 3H), 1.50 (s, 9H).

Intermediate 67




tert-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate

[0385] Step A: *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7- carboxylate. To a stirred solution of 1-*tert*-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (50.0 g, 184 mmol, 1.00 *eq*) in MeOH (1.00 L) at 25 °C under nitrogen was added NaOMe (49.8 g, 921 mmol, 5.00 *eq*), followed by 2-methylisothiourea (62.4 g, 331 mmol, 1.80 *eq*, H_2SO_4) as a solid. The reaction mixture was stirred at 25 °C for 16 hours. The reaction mixture was acidified with HCl (2 M) until pH~5, and then the mixture was concentrated under reduced pressure to removed MeOH. The residue was suspended in 300 mL of ethyl acetate and 300 mL of water and stirred rapidly. The suspension was filtered and the white solid was collected. The filtrate was separated and the organics washed with water (1 × 300 mL) and brine (1× 200 mL). The organics were isolated, dried over Na_2SO_4, filtered and concentrated to a white solid. *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7- carboxylate (51.0 g, 138 mmol, 75.4 % yield, 81 % purity) was obtained as a white solid and used directly for next step without further purification. LCMS [M+1]: 298.

[0386] ^{1}H NMR (400MHz, chloroform-d) δ = 4.33 (s, 2H), 3.61 (t, *J*=5.6 Hz, 2H), 2.68 - 2.49 (m, 5H), 1.50 (s, 9H).

[0387] Step B: *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy) -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To a stirred suspension of *tert*-butyl 4-hydroxy-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (51.0 g, 171 mmol, 1.00 *eq*) in DCM (500 mL) at 0 °C was added DIEA (44.3 g, 343 mmol, 59.9 mL, 2.00 *eq*), followed by Tf_2O (72.6 g, 257 mmol, 42.4 mL, 1.50 *eq*) under nitrogen. Immediately a brown solution formed. After stirring at 25 °C for 16 hours, the reaction was concentrated to give a brown oil. The brown oil was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 10/1). Title compound *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy) -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (46.0 g, 107 mmol, 62 % yield) was obtained as a yellow solid. LCMS [M+1]: 430.

Intermediate 68




tert-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate

[0388] Step A: *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. A mixture of *tert*-butyl 2-methylsulfanyl-4 -(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate(3.81 g, 8.87 mmol, 1.0 eq), benzyl(2*S*)-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 63, 2.30 g, 8.87 mmol, 1.0 eq), DIEA (3.44 g, 26.6 mmol, 4.63 mL, 3.0 eq) in DMF (20.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 1 hour under N_2 atmosphere. After completion, the solvent was removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to 1:1) to give title compound *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (3.6 g, 6.16 mmol, 69% yield, 92.2% purity) as a yellow solid.

SUBSTITUTE SHEET (RULE 26)

Intermediate 69




1-bromo-8-methylnaphthalene

[0389] Step A: 1-bromo-8-methyl-naphthalene. To a solution of 1,8-dibromonaphthalene (1 g, 3.50 mmol, 1 *eq*) in THF (20 mL) was added MeLi (1.6 M in diethyl ether, 2.62 mL, 1.2 *eq*) at 0°C dropwise. After stirring for 30 minutes at 0°C, iodomethane (3.38 g, 23.8 mmol, 1.48 mL, 6.81 *eq*) was added dropwise. The mixture was warmed up to 25°C and stirred for another 3 hours. The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 45% - 70%, 28 MIN; 40% min). Ttitle compound 1-bromo-8-methyl-naphthalene (340 mg, 1.49 mmol, 43% yield, 97% purity) was obtained as a yellow solid after lyophilisation.

[0390] ^{1}H NMR (400MHz, chloroform-d) δ = 7.75 (dd, *J* = 0.8, 7.2 Hz, 1H), 7.69 (dd, *J* = 0.8, 8.0 Hz, 1H), 7.66 - 7.59 (m, 1H), 7.30 - 7.22 (m, 2H), 7.13 (t, *J* = 8.0 Hz, 1H), 3.05 (s, 3H).

Intermediate 70



1-bromo-8-chloronaphthalene

[0391] Step A: 1*H*-naphtho[1,8-de][1,2,3]triazine. To a solution of naphthalene-1,8-diamine (100 g, 632 mmol, 1 *eq*) in AcOH (200 mL) and EtOH (1000 mL) was added isoamyl nitrite (72.6 g, 619 mmol, 83.4 mL, 0.98 *eq*) dropwise over a period of 2 h with temperature controlled


between 18 and 21 °C under a cold-water bath. After the addition, the resulting red suspension was stirred at 25 °C for 16 hours. The solid was collected by filtration, washed with ethanol (2 × 500 mL) and dried under vacuum. Compound 1*H*-naphtho[1,8-de][1,2,3]triazine (84 g, 496 mmol, 79% yield) was obtained as a red crystalline solid and directly used next step without purification. LCMS [ESI, M+1]: 170.

[0392] Step B: 8-chloronaphthalen-1-amine. To a solution of 1*H*-naphtho[1,8-de][1,2,3]triazine (84 g, 496 mmol, 1 *eq*) in HCl (1.5 L) was added Cu (2.10 g, 33.1 mmol, 234 uL, 0.0665 *eq*). The mixture was stirred at 25 °C for 12 hours. The resulting mixture was diluted with water (500 mL) and heated at 85 °C for 30 mins. The resulting almost clear aqueous solution was filtered, cooled, basified with aqueous ammonia (until blue to litmus paper) and the solution was extracted with ether acetate (2 × 1000 mL). The combined extracts were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 5/1). Compound 8-chloronaphthalen-1-amine (57 g, 259 mmol, 52% yield, 81% purity) was obtained as a red solid. LCMS [ESI, M+1]: 178.

[0393] Step C: 1-bromo-8-chloro-naphthalene. To a solution of 8-chloronaphthalen-1-amine (57 g, 320 mmol, 1 *eq*) and $TsOH•H_2O$ (219 g, 1.16 mol, 3.6 *eq*) in MeCN (1000 mL) was added a solution of $NaNO_2$ (39.8 g, 577 mmol, 1.8 *eq*) and CuBr (138 g, 963 mmol, 29.3 mL, 3 *eq*) in H_2O (120 mL) at - 5 °C, then the reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was added saturated Na_2SO_3 solution (100 mL) and stirred for 15 mins, then extracted with ethyl acetate (1000 mL×3). The combined organic layers were washed with brine (500 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether). Title compound 1-bromo-8-chloro-naphthalene (56 g, 229 mmol, 72% yield, 99% purity) was obtained as white solid.

[0394] ^{1}H NMR (400MHz, chloroform-d) δ = 7.93 (dd, *J* = 1.2, 7.6 Hz, 1H), 7.82 (dd, *J* = 1.2, 8.4, 1H), 7.79 (dd, *J* = 1.2, 8.4, 1H), 7.67 (dd, *J* = 1.2, 7.6 Hz, 1H), 7.37 (t, *J* = 8.0 Hz, 1H), 7.28 (t, *J* = 8.0 Hz, 1H).

Intermediate 71



Int. 71


2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile

[0395] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.5 g, 791 umol, 1 *eq*) in dioxane (5 mL) was added HCl•dioxane (4 M, 5.00 mL, 25.3 *eq*) at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum to give an impure product (500 mg, crude, HCl) as a brown solid. 60 mg of the impure product was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water(0.04% $NH_3•H_2O$ + 10mM NH_4HCO_3) - ACN]; B%: 50% - 80%, 10 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (19.3 mg, 36.1 umol, 34% purification yield, 99.2% purity) as a off-white solid. LCMS [ESI, M+1]:532.

[0396] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.75 (d, *J* = 8.4 Hz, 1H), 7.60 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.52 (dd, *J* = 0.8, 7.2 Hz, 1H), 7.44 (dt, *J* = 3.6, 7.6 Hz, 1H), 7.36 - 7.29 (m, 1H), 7.22 (t, *J* = 6.8 Hz, 1H), 4.46 - 4.34 (m, 2H), 4.15 (td, *J*=6.4, 10.6 Hz, 1H), 4.04 (br d, *J*=12.4 Hz, 0.5H), 3.95 - 3.79 (m, 2H), 3.74 (br d, *J*=12.8 Hz, 0.5H), 3.63 - 3.48 (m, 1H), 3.40 - 2.99 (m, 7H), 2.98 - 2.80 (m, 2H), 2.73 - 2.61 (m, 1H), 2.60 - 2.49 (m, 3H), 2.47 (d, *J*=2.4 Hz, 3H), 2.32 - 2.23 (m, 1H), 2.10 - 1.99 (m, 1H), 1.82 - 1.68 (m, 3H).

Intermediate 72

SUBSTITUTE SHEET (RULE 26)



Int. 72

2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile


[0397] Step A: (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.22 g, 1.98 mmol, 1.0 *eq*), 1-bromo-2,3-dimethyl-benzene (1.10 g, 5.93 mmol, 802 uL, 3.0 *eq*), Cs_2CO_3 (1.93 g, 5.93 mmol, 3 *eq*), RuPhos (185 mg, 396 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (181 mg, 198 umol, 0.1 *eq*) in toluene (8 mL) was de-gassed and then heated to 90 °C for 12 hours under N_2. Upon completion, the mixture was concentrated under vacuum. The residue was diluted with water (20 mL) and extracted with EtOAc (3 × 30 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1 % FA)/acetonitrile]. The collected desired fractions were neutralized with saturated aqueous sodium bicarbonate and concentrated under vacuum to remove MeCN, and then extracted with EtOAc (3 × 50 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (380 mg, 623 umol, 32 % yield, 100 % purity) as a yellow solid. LCMS [ESI, M+1]: 610.

[0398] Step B: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (20 mL) at -70 °C for 30 minutes. A solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (380 mg, 623 umol, 1.0 *eq*) was added the above

solution followed by Pd/C (200 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The reaction was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the catalyst was filtered and the filtrate was concentrated to give title compound 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (230 mg, 459 umol, 74% yield, 95% purity) as a yellow solid.

[0399] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.11 (t, *J* = 8.0 Hz, 1H), 6.96 (d, *J* = 8.0 Hz, 2H), 4.39 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.14 (dd, *J* = 7.2, 9.6 Hz, 1H), 4.02 – 3.95 (m, 3H), 3.84 – 3.78 (m, 1H), 3.31 – 3.19 (m, 1H), 3.17 – 3.04 (m, 5H), 3.04 – 2.95 (m, 1H), 2.89 (dd, *J* = 9.2, 11.6 Hz, 1H), 2.76 – 2.62 (m, 3H), 2.58 – 2.50 (m, 2H), 2.48 (s, 3H), 2.30 (s, 3H), 2.29 - 2.23 (m, 4H), 2.12 - 2.00 (m, 1H), 1.89 - 1.76 (m, 3H).

Intermediate 73



[0400] *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate

[0401] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (1.60 g, 3.96 mmol, 1.0 *eq*), 1-bromo-2,3-dimethyl-benzene (1.61 g, 8.70 mmol, 1.18 mL, 2.20 *eq*), $Pd_2(dba)_3$ (362 mg, 395 umol, 0.10 *eq*), RuPhos (369 mg, 791 umol, 0.20 *eq*) and Cs_2CO_3 (3.87 g, 11.9 mmol, 3.0 *eq*) in toluene (8.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 12 hrs under N_2 atmosphere. The organic solvent was washed with water (20.0 mL). The aqueous phase was extracted with ethyl

acetate (3 × 30.0 mL). Combine extracts were washed with brine (80.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate=3 : 1 to Ethyl acetate : Methanol = 10 : 1). Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (900 mg, 1.59 mmol, 40% yield, 90% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 509.

[0402] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.11 (t, *J* = 15.6 Hz, 1H), 6.95(d, *J* = 8.0 Hz,2H), 4.63 (br s, 1H), 4.10 – 3.93 (m, 4H), 3.89 (br d, *J* = 4.8 Hz, 1H), 3.27 (dd, *J* = 3.6 Hz, *J* = 13.6 Hz, 1H),3.24 – 3.05 (m, 3H), 3.05 – 2.95 (m, 1H), 2.89 – 2.67 (m, 4H), 2.52 (s, 3H), 2.30 (s, 3H), 2.28 (s, 3H), 1.52 (s, 9H).


[0403] Step B: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 983 umol, 1.0 *eq*), 3-chlorobenzenecarboperoxoic acid (200 mg, 983 umol, 1.0 *eq*) in DCM (5.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0 °C for 30 min under N_2 atmosphere. The organic solvent was washed with water (10.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 20.0 mL). Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate=3 : 1 to Ethyl acetate : Methanol = 10 : 1). Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-methylsulfinyl-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (450 mg, 793 umol, 81% yield, 93% purity) was obtained as a yellow solid. LCMS [ESI, M+1]:525.

[0404] Step C: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3- dimethylphenyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.52 mmol, 1.0 *eq*), [(2*S*)-1-methylpyrrolidin-2-yl]methanol (369 mg, 3.20 mmol, 380 uL, 2.10 *eq*), *t*-BuONa (293 mg, 3.05 mmol, 2.0 *eq*) in toluene (10.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0 °C for 30 min under N_2 atmosphere. The


reaction was quenched with water (20.0 mL). The crude mixture was extracted with ethyl acetate (3 × 30.0 mL). Combine extracts were washed with brine (80.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate=5: 1 to Dichloromethane: Methanol=10:1). Title compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (740 mg, 1.22 mmol, 80% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 576.

[0405] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.10 (t, *J* = 15.2 Hz, 1H), 6.95 (d, *J* = 8.0 Hz, 2H), 4.61 (br s, 1H), 4.39 (dd, *J* = 4.8 Hz, *J* = 9.6 Hz,1H), 4.13 – 4.00 (m, 4H), 3.89 (br d, *J* = 12.4 Hz 1H), 3.27 – 3.13 (m, 3H), 3.13 – 2.95 (m, 3H), 2.87 – 2.65 (m, 5H), 2.49 (s, 3H), 2.30 (s, 3H), 2.27 (s, 3H), 2.09 – 2.06 (m, 1H), 2.06 – 2.04 (m, 1H), 1.93 – 1.62 (m, 4H), 1.51 (s, 9H).

EXAMPLE 1



1-(4-(7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0406] Step A: tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: In 2 mL of dimethyl acetamide were combined tert-butyl 4-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.0 g, 3.7 mmol), triethylamine (1.0 mL, 7.4 mmol), and benzyl 1-piperazinecarboxylate (0.86 mL, 4.4 mmol). The reaction vessel was sealed and the reaction mixture was heated to 90 °C with stirring. After 5 hours, the reaction was diluted with brine and extracted with methyl t-butyl ether. The combined organic layers were washed sequentially with saturated ammonium chloride and brine, dried over $MgSO_4$, and concentrated under reduced pressure to a thick oil. The oil was chromatographed (RediSep®, 24 g) eluting with1:1 ethyl acetate/Hexanes to give tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.3 g, 2.9 mmol, 77 % yield). ES+APCI MS m/z 454.2 $[M+H]^+$.

[0407] Step B : Benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-5,8-

dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.58 g, 3.484 mmol) in dichloromethane (11.61 mL, 3.484 mmol) was added trifluoroacetic acid (2.668 mL, 34.84 mmol) and the reaction was stirred at room temperature for 3 hours. The reaction was concentrated under vacuum and the residue was taken up in dichloromethane. The solution was washed with sequentially with 1M NaOH and brine, dried over Na_2SO_4, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Biotage Isolera, 24G Isco RediSep® Gold, 10 to 20% methanol/dichloromethane) to afford the product (1.1 g, 89%) as an off-white foam. ES+APCI MS m/z 354.2 $[M+H]^+$.

[0408] Step C: benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a vial was added tris(dibenzylideneacetone)dipalladium (0) (0.0069 g, 0.0075 mmol), racemic-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (0.0096 g, 0.015 mmol) and toluene (0.62 mL, 0.19 mmol). Argon was bubbled through the mixture for 5 minutes and then the vial was capped and the mixture was heated to 100 °C for 15 minutes. The mixture was cooled to ambient temperature and then sodium tert-butoxide (0.036 g, 0.37 mmol) was added followed by 1-bromo-3-(methoxymethoxy)naphthalene (0.050 g, 0.19 mmol) and benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.13 g, 0.37 mmol). The vial was capped and the mixture heated to 100 °C for 20 hours. The mixture was cooled to ambient temperature, diluted with dichloromethane and filtered through GF/F paper. The filtrate was concentrated and purified by column chromatography (Biotage Isolera, 12G Isco RediSep®, 10-50% ethyl acetate/dichloromethane) to afford the product (0.062 g, 61%) as an off-white foam. ES+APCI MS m/z 540.3 $[M+H]^+$.

[0409] Step D : 7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine: To a solution of benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.061 g, 0.11 mmol) in ethanol (1.1 mL, 0.11 mmol) and tetrahydrofuran (1.1 mL, 0.11 mmol) was added palladium (0.024 g, 0.011 mmol) (Degussa Type, 10 wt.%, 50% H_2O). An atmosphere of H_2 was introduced into the reaction vessel by vacuum, and then the reaction mixture was maintained under an atmosphere of H_2. The mixture was stirred at ambient temperature for 2.5 hours, then diluted with methanol and filtered through GF/F paper.

The colorless filtrate was concentrated under vacuum with toluene to provide an off-white foam (0.048 g, 105%) that was used directly in the next step. ES+APCI MS m/z 406.2 $[M+H]^+$.


[0410] Step E: 1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a suspension of 7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (0.046 g, 0.11 mmol) in dichloromethane (1.1 mL, 0.11 mmol) at ambient temperature was added acryloyl chloride (1.2 mL, 0.12 mmol) (freshly prepared 0.1 M solution in dichloromethane) followed by triethylamine (0.032 mL, 0.23 mmol). The reaction was stirred at ambient temperature for 1 hour. The mixture was concentrated and the product was purified by column chromatography (Biotage Isolera, 12G Isco RediSep®, ethyl acetate) to afford the product (0.042 g, 79%) as an off-white solid foam. ES+APCI MS m/z 460.2 $[M+H]^+$.

[0411] Step F: 1-(4-(7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a solution of 1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (0.034 g, 0.074 mmol) in ethyl acetate (0.74 mL, 0.074 mmol) was added hydrochloric acid (5 to 6 N solution in 2-propanol (0.44 mL, 2.2 mmol). The mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with ethyl acetate (10 mL), filtered through a polypropylene filter and the collected solid was washed with ethyl acetate and hexanes to provide the product as the HCl salt. The impure material was treated with 1 mL of ammonium hydroxide/methanol to quench the acid and the mixture was concentrated. The residue was dissolved in 10% methanol/dichloromethane and purified by column chromatography (Biotage Isolera, 12G Isco RediSep®, 2 to 5% methanol/ethyl acetate) to afford the product (0.008 g, 25%) as an off-white solid. ES+APCI MS m/z 416.2 $[M+H]^+$.

[0412] 1H NMR (CD3OD, 400 MHz) δ 8.49 (s, 1H), 8.07 (app d, J = 8.2 Hz, 1H), 7.61 (app d, J = 8.2 Hz, 1H), 7.35 (m, 1H), 7.25 (m, 1H), 6.80 (m, 3H), 6.23 (dd, J = 16.8, 1.6 Hz, 1H), 5.77 (dd, J = 10.6, 2.0 Hz, 1H), 4.22 (br s, 2H), 3.80 (app t, J = 4.7 Hz, 4H), 3.63 (br s, 4H), 3.35 (br s, 2H), 3.03 (br s, 2H).

EXAMPLE 2


SUBSTITUTE SHEET (RULE 26)



1-(4-(7-(7-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0413] Synthesized according to the method of **Example 1**, using 2-bromo-7-(methoxymethoxy)naphthalene in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 416.1 $[M+H]^+$.


EXAMPLE 3



1-(4-(7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0414] Synthesized according to the method of **Example 1**, using 1-iodonaphthalene in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 400.2 $[M+H]^+$.


EXAMPLE 4



1-(4-(7-(2-fluoro-6-hydroxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0415] Synthesized according to the method of **Example 1**, using 2-bromo-1-fluoro-3-(methoxymethyl)benzene in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 384.2 $[M+H]^+$.


EXAMPLE 5



1-(4-(7-(2-fluoro-5-hydroxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0416] Synthesized according to the method of **Example 1**, using 2-bromo-1-fluoro-4-(methoxymethoxy)benzene in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 384.2 $[M+H]^+$.

EXAMPLE 6



1-(4-(7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0417] Steps A-C: benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Synthesized according to the


method of **Example 1**, Steps A-C, using tert-butyl 4-chloro-6-methyl-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate in place of 4-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate in Step A. ES+APCI MS m/z 430.2 $[M+H]^+$.

[0418] Step D1: benzyl 4-(7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.05 g, 0.09 mmol) in isopropanol (10 mL) was added hydrogen chloride (5-6M in isopropanol) (0.02 mL, 0.09 mmol) and the reaction stirred at room temperature for 1 hour. The reaction was concentrated under vacuum and the concentrate was partitioned between ethyl acetate and water to convert the material to the free base. The combined organic layers were washed with brine, dried over $MgSO_4$ and concentrated under vacuum to give benzyl 4-(7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.005 g, 0.010 mmol, 11% yield). ES+APCI MS m/z 510.3 $[M+H]^+$.

[0419] Step D2: 4-(7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-ol: Prepared according to the method of **Example 1**, Step D.

[0420] Step E: 1-(4-(7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: Prepared according to the method of **Example 1**, Step E.

EXAMPLE 7



1-(4-(7-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one


[0421] Steps A-D: benzyl 4-(7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Synthesized according to General Scheme 1, Steps A-C, using 4-bromo-5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C

[0422] Step D1: benzyl 4-(7-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl 4-(7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.16 g, 0.26 mmol) in dichloromethane (10 mL) was added 2,2,2-trifluoroacetic acid (0.89 g, 7.8 mmol) followed by anisole (0.028 g, 0.26 mmol), and the reaction was stirred at room temperature for 3 hours at room temperature. The reaction was concentrated under vacuum and the concentrated material was taken up in ethyl acetate and washed with basic brine. The combined organic layers were dried over $MgSO_4$ and concentrated under vacuum. The crude material was chromatographed using 0 to 10% methanol/dichloromethane as the eluent to give benzyl 4-(7-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.05g, 38%). ES+APCI MS m/z 484.2 $[M+H]^+$.


[0423] Step D2: 7-(5-methyl-1H-indazol-4-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine: Prepared according to the method of **Example 1**, Step D.

[0424] Step E: 1-(4-(7-(5-methyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: Prepared according to the method of **Example 1**, Step E.

EXAMPLE 8



(S)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0425] Step A: tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: Benzyl 1-piperazinecarboxylate (1.268 mL, 6.575 mmol) and tert-Butyl 2,4-dichloro-5,6-dihydropyrido[3 4-d]pyrimidine-7(8H)-carboxylate (2 g, 6.575 mmol) were dissolved in dimethyl acetamide (10 mL) and treated with N-ethyl-N-isopropylpropan-2-amine (3.445 mL, 19.73 mmol). The reaction mixture was stirred at 85 °C for 2 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, washed with water and brine, dried over $MgSO_4$, filtered and concentrated. The concentrate was purified by chromatography (CombiFlash®, 0%-50% ethyl acetate:Hexanes as the eluent to provide the product (2.69g, 83%). ES+APCI MS m/z 488.2, 490.2 $[M+H]^+$.

[0426] Step B: tert-butyl (S)-4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: Tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-

d]pyrimidine-7(6H)-carboxylate (235 mg, 0.482 mmol), and (S)-1-(dimethylamino)propan-2-ol (497 mg, 4.82 mmol) were added to dioxane (0.5 mL) and heated to 100 °C for 3 days. The reaction was concentrated and the resulting residue was purified by silica gel (Biotage Isolera, 0-12% methanol in dichloromethane) to provide tert-butyl (S)-4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (200 mg, 0.361 mmol, 74.9 % yield). ES+APCI MS m/z 555.3 $[M+H]^+$.

[0427] Step C: benzyl (S)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (200 mg, 0.3606 mmol) in dichloromethane (1202 μL, 0.3606 mmol) was added trifluoroacetic acid (828.3 μL, 10.82 mmol) and the reaction was stirred at room temperature for 3 hours. The reaction was concentrated under vacuum and the residue was taken up in dichloromethane. The solution was washed with 1M NaOH followed by brine and then dried over Na_2SO_4, filtered and concentrated under vacuum. The crude product was purified by column chromatography (Biotage Isolera, 24G Isco RediSep®Gold, 10 to 20% methanol/dichloromethane) to afford the product as an off-white foam (0.135 g, 83%). ES+APCI MS m/z 455.2 $[M+H]^+$.

[0428] Step D : benzyl (S)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a vial was added tris(dibenzylideneacetone)dipalladium (0) (21.8 mg, 0.0238 mmol), racemic-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (30.4 mg, 0.0488 mmol) and toluene (991 μL, 0.297 mmol). Argon was bubbled through the mixture for 5 minutes and then the vial was capped and the mixture was heated to 100 °C for 15 minutes. The mixture was cooled to ambient temperature and sodium tert-butoxide (57.2 mg, 0.595 mmol) was added followed by 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate (100 mg, 0.297 mmol) and benzyl (S)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (135 mg, 0.297 mmol). The vial was capped and the mixture was heated to 100 °C for 18 hours. The mixture was cooled and concentrated. The crude material was purified by silica gel (Biotage Isolera, 0-11% methanol/dichloromethane to

provide benzyl (S)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (68 mg, 0.106 mmol, 35.7 % yield). ES+APCI MS m/z 641.3 $[M+H]^+$.

[0429] Step E: (S)-2-((7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine: To a solution of benzyl (S)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (68 mg, 0.11 mmol) in ethanol (1061 μL, 0.11 mmol) and tetrahydrofuran (1061 μL, 0.11 mmol) was added Palladium (113 mg, 0.053 mmol) (Degussa Type, 10 wt.%, 50% H_2O). An atmosphere of H_2 was introduced by vacuum and then the reaction vessel was maintained under an atmosphere of H_2. The mixture was stirred at ambient temperature for 3 hours. The mixture was diluted with methanol and filtered through GF/F paper. The colorless filtrate was concentrated to provide (S)-2-((7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine (54 mg, 100 % yield) which was used in the next step without purification. ES+APCI MS m/z 507.3 $[M+H]^+$.


[0430] Step F: (S)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a suspension of (S)-2-((7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine (54 mg, 0.11 mmol) in dichloromethane (1066 μL, 0.11 mmol) at ambient temperature was added acryloyl chloride (1279 μL, 0.13 mmol) (freshly prepared 0.1 M solution in DCM) followed by triethylamine (30 μL, 0.21 mmol). The reaction was stirred at ambient temperature for 20 minutes. The mixture was concentrated and the product was purified by column chromatography (Biotage Isolera, 12G Isco RediSep®, 0-15% methanol/dichloromethane) to afford (S)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (51 mg, 0.091 mmol, 85 % yield). ES+APCI MS m/z 561.3 $[M+H]^+$.

[0431] Step G: 1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: (S)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-

tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (51 mg, 0.091 mmol) was added to a vial containing 350 μL of methanol and a few drops of tetrahydrofuran and the reaction vial was capped. HCl (379 μL, 2.3 mmol) (6M aqueous) was added with stirring, and the mixture was heated to 55 °C for 3 hours. The reaction was cooled and concentrated under vacuum. A saturated bicarbonate solution was added and the reaction was extracted with 10% methanol in dichloromethane. The organic layers were combined and concentrated. The resulting residue was purified by silica gel (Biotage Isolera, 4-20% methanol in dichloromethane with 1% concentrated ammonium chloride) to provide the title product (25.3 mg, 54%). ES+APCI MS m/z 517.2 $[M+H]^+$.

[0432] ^{1}H NMR (400 MHz, $CDCl_3$) δ 7.90 (d, 1H, J=8.314Hz), 7.54 (d, 1H, J=8.021), 7.34 (m, 1H), 7.24 (m, 1H). 6.72 (m, 1H), 6.56-6.48 (m, 2H), 6.32 (dd, 1H, J=16.726, 1.858), 5.73 (dd, 1H, J=10.368, 1.858), 5.45 (m, 1H), 4.09-3.94 (m, 2H), 3.63 (bs, 2H), 3.47 (bs, 2H), 3.31 (m, 4H), 3.16 (bs, 2H), 2.84 (m, 1H), 2.60 (bs, 2H), 2.45 (m, 1H), 2.43 (s, 6H), 1.31 (d, 3H, J=6.162 Hz)


EXAMPLE 9



1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0433] Synthesized according to the method of **Example 8**, using 2-(dimethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 503.2 $[M+H]^+$.


EXAMPLE 10



1-(4-(2-(3-(dimethylamino)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0434] Synthesized according to the method of **Example 8**, using 3-(dimethylamino)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 11



1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0435] Synthesized according to the method of **Example 8**, using 1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 12



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(4-methylpiperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0436] Synthesized according to the method of **Example 8**, using 1-methylpiperazine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 514.3 $[M+H]^+$.


EXAMPLE 13



1-(4-(2-(3-(dimethylamino)pyrrolidin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0437] Synthesized according to the method of **Example 8**, using N,N-dimethylpyrrolidin-3-amine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 528.3 $[M+H]^+$.


EXAMPLE 14



(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one

[0438] Synthesized according to the method of **Example 8**, using benzyl (S)-2-methylpiperazine-1-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and using 2-(dimethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 15



(R)-1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl)prop-2-en-1-one

[0439] Synthesized according to the method of **Example 8**, substituting benzyl (R)-2-methylpiperazine-1-carboxylate for benzyl piperazine-1-carboxylate in Step A and 2-(dimethylamino)ethan-1-ol for (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 16



1-(6-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one

[0440] Synthesized according to the method of **Example 8**, using benzyl 2,6-diazaspiro[3.3]heptane-2-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and substituting 2-(dimethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 515.3 $[M+H]^+$.


EXAMPLE 17



1-(4-(2-(4-(dimethylamino)piperidin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0441] Synthesized according to the method of **Example 8**, using N,N-dimethylpiperidin-4-amine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 580.3 $[M+H]^+$.


EXAMPLE 18



1-(6-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one

[0442] Synthesized according to the method of **Example 8**, using benzyl 2,6-diazaspiro[3.3]heptane-2-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and substituting 1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 19



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0443] Synthesized according to the method of **Example 8**, using (R)-1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 20



1-(6-(2-(3-(dimethylamino)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one

[0444] Synthesized according to the method of **Example 8**, using benzyl 2,6-diazaspiro[3.3]heptane-2-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and substituting 3-(dimethylamino)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 21



1-(4-(2-((4-(dimethylamino)butan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0445] Synthesized according to the method of **Example 8**, using 4-(dimethylamino)butan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 531.3 $[M+H]^+$.


EXAMPLE 22



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-4-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0446] Synthesized according to the method of **Example 8**, using 1-methylpiperidin-4-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 23



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-3-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0447] Synthesized according to the method of **Example 8**, using 1-methylpyrrolidin-3-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 515.3 $[M+H]^+$.


EXAMPLE 24



1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0448] Synthesized according to the method of **Example 8**, using 1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, using 1-bromo naphthalene in place of3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in step D, and eliminating Step G. ES+APCI MS m/z 501.3 $[M+H]^+$.


EXAMPLE 25



1-(4-(2-(3-(dimethylamino)propoxy)-7-(1-phenylethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0449] Synthesized according to the method of **Example 8**, using 3-(dimethylamino)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, using (1-bromoethyl)benzene in place of 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in step D, and eliminating Step G. ES+APCI MS m/z 559.3 $[M+H]^+$.


EXAMPLE 26



1-(4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0450] Synthesized according to the method of **Example 8**, using 2-(piperazin-1-yl)ethyl acetate in place of (S)-1-(dimethylamino)propan-2-ol in Step B. After Step D, the following saponification reaction was performed: Benzyl 4-(2-(4-(2-acetoxyethyl)piperazin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate was taken up in THF (5 mL) and 2 M LiOH (1 mL) was added. The mixture was stirred at ambient temperature for 24 hr. Saturated NH_4Cl was added and the reaction was extracted with DCM. The combined organic layers were concentrated and the resulting residue was purified by silica gel (Biotage Isolera Gold, eluting with 0-10% MeOH in DCM) to provide benzyl 4-(2-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. The remainder of the synthesis proceeded as in Example 8, step E. ES+APCI MS m/z 544.3 $[M+H]^+$.


EXAMPLE 27



1-((S)-4-(2-(((R)-1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one

[0451] Synthesized according to the method of **Example 8**, using benzyl (S)-3-methylpiperazine-1-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and using (R)-1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 531.3 $[M+H]^+$.


EXAMPLE 28



(S)-1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one

[0452] Synthesized according to the method of **Example 8**, using benzyl (S)-3-methylpiperazine-1-carboxylate in place of benzyl piperazine-1-carboxylate in Step A and using 2-(dimethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.2 $[M+H]^+$.


EXAMPLE 29



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-morpholinoethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0453] Synthesized according to the method of **Example 8**, using 2-morpholinoethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 545.2 $[M+H]^+$.


EXAMPLE 30



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-morpholino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0454] Synthesized according to the method of **Example 8**, using morpholine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 501.3 $[M+H]^+$.


EXAMPLE 31



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(pyrrolidin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0455] Synthesized according to the method of **Example 8**, using pyrrolidine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 485.2 $[M+H]^+$.


EXAMPLE 32



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(pyrrolidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0456] Synthesized according to the method of Example 8, using (R)-1-(pyrrolidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 543.4 $[M+H]^+$.

EXAMPLE 33



1-(4-(2-(2-(1,1-dioxidothiomorpholino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate


[0457] Step A: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 463.12 μmol, 1.00 eq) and 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanol (166 mg, 926 μmol, 2.00 eq) in toluene (10.0 mL) was added NaOBu-t (133 mg, 1.39 mmol, 3.00 eq), BINAP (57.7 mg, 92.6 μmol, 0.20 eq), $Pd_2(dba)_3$ (42.4 mg, 46.3 μmol, 0.10 eq). The reaction mixture was stirred at 90 °C for 12 hours under N_2. The

reaction mixture was filtered and the filter cake was washed with DCM (3 × 10 mL). The filtrate was concentrated under vacuum. The residue was purified by reverse flash chromatography (40 % MeCN in water (0.1 % TFA) to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 301 μmol, 65.1 % yield) as a brown solid . **ESI** MS m/z 763.5 $[M+H]^+$.

[0458] Step B: 4-[2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: To a solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 249 μmol, 1.00 eq) in MeOH (10.0 mL) was added Pd/C (100 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 40°C for 4 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum to give 4-[2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (90.0 mg, 167 μmol, 67.1 % yield) as a brown solid. **ESI** MS m/z 539.4 $[M+H]^+$.

[0459] Step C: 1-[4-[2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (90.0 mg, 167 μmol, 1.00 eq) and DIEA (64.8 mg, 501 μmol, 87.5 μL, 3.00 eq) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (19.0 mg, 150 μmol, 0.90 eq) at -40 °C. The reaction mixture was stirred at -40 °C for 0.5 h. The reaction mixture was quenched with 1 mL of MeOH and concentrated under vacuum. The residue was purified by preparative HPLC column: Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.1% TFA) -ACN]; B%: 12%-42%,11 min to give 1-[4-[2-[2-(1,1-dioxo-1,4-thiazinan-4-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one trifluoroacetate (32.6 mg, 50.2 μmol, 30.0 % yield, 91.3 % purity) as a brown solid . **ESI** MS m/z 593.5 $[M+H]^+$.


EXAMPLE 34



1-(4-(2-(3-(1,1-dioxidothiomorpholino)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate

[0460] Synthesized according to the method of **Example 33**, using 3-(1,1-dioxo-1,4-thiazinan-4-yl)propan-1-ol in place of 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanol in Step A. **ESI** MS m/z 607.5 $[M+H]^+$.


EXAMPLE 35



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(4-morpholinobutoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate

[0461] Synthesized according to the method of **Example 33**, using 4-morpholinobutan-1-ol in place of 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanol in Step A. **ESI** MS m/z 573.4 $[M+H]^+$.


EXAMPLE 36



(R)-1-(4-(2-((1-(4-acetylpiperazin-1-yl)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0462] Synthesized according to the method of **Example 33**, using 1-[4-[(2*R*)-2-hydroxypropyl]piperazin-1-yl]ethanone in place of 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanol in Step A. **ESI** MS m/z 600.6 $[M+H]^+$.

EXAMPLE 37



1-(4-(2-(2-(4-acetylpiperazin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one


[0463] Step A: benzyl 4-[2-[2-(4-acetylpiperazin-1-yl)ethoxy]-7-(3-benzyloxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanone (277 mg, 1.61 mmol, 2.60 eq) in THF (8.00 mL) was added NaH (49.4 mg, 1.23 mmol, 60 % purity, 2.00 eq) at 0°C.The reaction mixture was stirred at 0 °C for 15 minutes. To the mixture was added benzyl-4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg,

618 μmol, 1.00 eq) in THF (2.00 mL). The reaction mixture was stirred at 0 °C for 20 minutes. The reaction mixture was quenched with saturated NH_4Cl (6 mL) and water (6 mL). The reaction mixture was extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated under vacuum to give benzyl 4-[2-[2-(4-acetylpiperazin-1-yl)ethoxy]-7-(3-benzyloxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (450 mg, 534 μmol, 86.5 % yield, 89.7 % purity) as a brown solid. **ESI** MS m/z 756.3 $[M+H]^+$.

[0464] Step B: 1-[4-[2-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethyl]piperazin-1-yl]ethanone: To a solution of benzyl 4-[2-[2-(4-acetylpiperazin-1-yl)ethoxy]-7-(3-benzyloxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 264 μmol, 1.00 eq) in THF (10.0 mL) was added Pd/C (100 mg, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 40 °C for 12 hours. The reaction mixture was filtered and the filter cake was washed with THF (3 × 5 mL). The filtrate was concentrated under vacuum to give 1-[4-[2-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethyl]piperazin-1-yl]ethanone (80.0 mg, 150 μmol, 56.9 % yield) as a brown solid.

[0465] Step C: 1-[4-[2-[2-(4-acetylpiperazin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[2-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethyl]piperazin-1-yl]ethanone (80.0 mg, 150 μmol, 1.00 eq) and DIEA (58.3 mg, 451 μmol, 78.8 μL, 3.00 eq) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (14.2 mg, 113 μmol, 0.75 eq) at - 40 °C for 0.5 h. The reaction mixture was quenched with MeOH (1 mL) and diluted by DCM (20 mL) next washed with water (5 mL). The combined organic layers were washed with brine (5 mL), dried over Na_2SO_4 and concentrated under vacuum. The reaction mixture was purified by preparative HPLC : Phenomenex Gemini 150*25mm*, 10 μ; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 30%-55%, 10 min to give 1-[4-[2-[2-(4-acetylpiperazin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (13.8 mg, 23.3 μmol, 15.5 % yield, 98.7 % purity) as a yellow solid. **ESI** MS m/z 586.3 $[M+H]^+$.


EXAMPLE 38



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-(piperidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0466] Synthesized according to the method of **Example 37**, using 3-(1-piperidyl)propan-1-ol in place of 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanone in Step A. **ESI** MS m/z 557.5 $[M+H]^+$.


EXAMPLE 39



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-(pyrrolidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0467] Synthesized according to the method of **Example 37**, using 3-pyrrolidin-1-ylpropan-1-ol in place of 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanone in Step A. **ESI** MS m/z 543.3 $[M+H]^+$.


EXAMPLE 40



1-(4-(2-(4-(dimethylamino)butoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0468] Synthesized according to the method of **Example 37**, using 4-(dimethylamino)butan-1-ol in place of 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanone in Step A. **ESI** MS m/z 531.4 $[M+H]^+$.

EXAMPLE 41



1-(4-(7-(3-cyclopropyl-5-hydroxyphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate

[0469] Step A: 4-[7-(3-benzyloxy-5-cyclopropyl-phenyl)-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 805 μmol, 1.00 *eq*) and 1-benzyloxy-3-bromo-5-cyclopropyl-benzene (268 mg, 886 μmol, 1.10 *eq*) in toluene (10.0 mL) was added 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (75.2 mg, 161 μmol, 0.20 *eq*), $Pd_2(dba)_3$ (111 mg, 121 μmol,


0.15 *eq*) and Cs_2CO_3 (656 mg, 2.01 mmol, 2.50 *eq*). The reaction mixture was stirred at 90 °C for 12 hours under N_2. The mixture was added to water (15 mL) and extracted with DCM (2 × 15 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The residue was purified by chromatography (SiO_2, Petroleum ether/Ethyl acetate = 3:1 to Dichloromethane: Methanol = 10:1) to give benzyl 4-[7-(3-benzyloxy-5-cyclopropyl-phenyl)-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 230 μmol, 28.5 % yield, 97.2 % purity) as brown oil. **ESI** MS m/z 719.6 $[M+H]^+$.

[0470] Step B: 3-cyclopropyl-5-[2-(3-morpholinopropoxy)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]phenol To a mixture of benzyl 4-[7-(3-benzyloxy-5-cyclopropyl-phenyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 209 μmol, 1.00 *eq*) in MeOH (10.0 mL) was added Pd/C (150 mg, 10 % purity) and CH_3COOH (25.1 mg, 417.3 μmol, 23.9 μL, 2.00 *eq*). The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 Psi) at 40 °C for 2 hours. The reaction mixture was filtered through Celite® and the filtrate was concentrated. The product 3-cyclopropyl-5-[2-(3-morpholinopropoxy)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]phenol diacetate (80.0 mg, 130 μmol, 62.4 % yield) was obtained as yellow solid. **ESI** MS m/z 495.2 $[M+H]^+$.

[0471] Step C: 1-[4-[7-(3-cyclopropyl-5-hydroxy-phenyl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one To a mixture of 3-cyclopropyl-5-[2-(3-morpholinopropoxy)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]phenol diacetate (80.0 mg, 130 μmol, 1.00 *eq*) in DCM (2.00 mL) was added DIEA (168 mg, 1.30 mmol, 227 μL, 10.0 *eq*) and prop-2-enoyl prop-2-enoate (13.1 mg, 104 μmol, 0.80 *eq*) at -78 °C, the reaction mixture was stirred at -78 °C for 0.5 hour. The reaction mixture was quenched with MeOH (2 eq, 10 mg), then concentrated. The residue was purified by preparative HPLC (Instrument: GX-K; Column: Phenomenex Synergi C18 150*25*, 10 μ; Conditions: water (0.1 % TFA)-ACN; Begin B: 8; End B: 38; Gradient Time (min): 11; 100% B Hold Time (min): 2; FlowRate (mL/min): 25). The isolated product was concentrated by lyophilization. The product 1-[4-[7-(3-cyclopropyl-5-hydroxy-phenyl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-

one trifluoroacetate (21.5 mg, 31.1 μmol, 23.9 % yield, 95.8 % purity) was obtained as yellow solid. **ESI** MS m/z 549.5 $[M+H]^+$.


EXAMPLE 42



1-(4-(7-(2-fluoro-5-hydroxyphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0472] Synthesized according to the method of **Example 41**, using 4-(benzyloxy)-2-bromo-1-fluorobenzene in place of 1-benzyloxy-3-bromo-5-cyclopropyl-benzene in Step A. **ESI** MS m/z 527.4 $[M+H]^+$.

EXAMPLE 43



1-(4-(7-(3-hydroxy-6-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0473] Step A: benzyl 4-[7-(3-methoxy-6-methyl-1-naphthyl)-2- (3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate

(500 mg, 1.01 mmol, 1.00 *eq*), (3-methoxy-6-methyl-1-naphthyl)trifluoromethanesulfonate (483 mg, 1.51 mmol, 1.50 *eq*), Cs_2CO_3 (820 mg, 2.52 mmol, 2.50 *eq*), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (93.9 mg, 201.3 μmol, 0.20 *eq*) and $Pd_2(dba)_3$ (92.2 mg, 100 μmol, 0.10 *eq*) in toluene (3.00 mL) was stirred at 90 °C for 10 hours. The mixture was diluted with ethyl acetate (50.0 mL). The precipitate was removed by filtration, and the filtrate was concentrated under vacuum. The residue was purified by reversed phase column chromatography over silica gel (0.1% TFA water/acetonitrile). The desired fractions were combined and basified with saturated aqueous sodium bicarbonate (2.00 mL), then concentrated under vacuum. The residue was extracted with ethyl acetate (2 × 100 mL). The combined extracts were washed with brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give benzyl 4-[7-(3-methoxy-6-methyl-1-naphthyl)-2- (3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400. mg, 599 μmol, 59.4 % yield, 100 % purity) as a yellow solid. **ESI** MS m/z 667.6 $[M+H]^+$.


[0474] Step B: 4-[3-[[7-(3-methoxy-6-methyl-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine: To a solution of benzyl 4-[7-(3-methoxy-6-methyl-1-naphthyl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (370 mg, 554 μmol, 1.00 *eq*) in MeOH (10.0 mL) was added Pd-C (100 mg, 10 % purity) and AcOH (66.6 mg, 1.11 mmol, 2.00 *eq*) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 40 °C for 2 hours. The reaction mixture was filtered and concentrated in vacuum to provide 4-[3-[[7-(3-methoxy-6-methyl-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (295 mg, 553 μmol, 99.8 % yield) as a yellow solid which was used directly in the next step without purification. **ESI** MS m/z 533.6 $[M+H]^+$

[0475] Step C: 1-[4-[7-(3-methoxy-6-methyl-1-naphthyl)-2-(3-morpholinopropoxy) -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of prop-2-enoyl prop-2-enoate (56.8 mg, 450 μmol, 0.80 *eq*) and DIEA (727 mg, 5.63 mmol, 983 μL, 10.0 *eq*) in DCM (2.00 mL) was added a solution of 4-[3-[[7-(3-methoxy-6-methyl-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (300 mg, 563 μmol, 1.00 *eq*) DCM (1.00 mL) at - 40°C under a nitrogen atmosphere. The mixture was

stirred for 1 hour. The reaction mixture was quenched by addition of MeOH (50 μL) at -40°C, diluted with water (10.0 mL), extracted with DCM(10.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to provide 1-[4-[7-(3-methoxy-6-methyl-1-naphthyl)-2-(3-morpholinopropoxy) -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (270 mg, 460 μmol, 81.7 % yield) **ESI** MS m/z 587.6 $[M+H]^+$.

[0476] Step D: 1-[4-[7-(3-hydroxy-6-methyl-1-naphthyl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[7-(3-methoxy-6-methyl-1-naphthyl)-2- (3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (100 mg, 170 μmol, 1.00 *eq*) in DCM (3.00 mL) was added BBr_3 (213 mg, 852 μmol, 82.1 μL, 5.00 *eq*) at -78 °C. The mixture was stirred at 0 °C for 1 hour. The mixture was cooled to -78 °C and diluted with DCM (20.0 mL), quenched by addition of saturated sodium bicarbonate solution (5.00 mL) and stirred at -78 °C for 10 mins, then warmed to 0 °C. The mixture was extracted with DCM (2 × 15.0 mL), washed with brine (1 × 20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by preparative HPLC (column: Phenomenex Gemini C18 250*50 mm*, 10 μ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 27%-57%, 12 min) to provide 1-[4-[7-(3-hydroxy-6-methyl-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (11.0 mg, 18.6 μmol, 10.9 % yield, 97.0 % purity) as a brown solid. **ESI** MS m/z 573.6 $[M+H]^+$.

EXAMPLE 44



1-(4-(7-(5-methyl-1H-indazol-4-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0477] Step A: benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]- 2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 1.01 mmol, 1.00 *eq*), 2-[(4-bromo-5-methyl-indazol-1-yl)methoxy] ethyl-trimethylsilane (448 mg, 1.31 mmol, 1.30 *eq*), Cs_2CO_3 (822 mg, 2.53 mmol, 2.50 *eq*), $Pd_2(dba)_3$ (138 mg, 151 μmol, 0.15 *eq*) and 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (94.3 mg, 202 μmol, 0.20 *eq*) in toluene (20.0 mL) was degassed and purged with nitrogen 3 times, and stirred at 90 °C for 10 hours under a nitrogen atmosphere. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (3 × 50.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by reversed phase HPLC (0.1% TFA water/acetonitrile) to provide benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]- 2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (420 mg, 554 μmol, 54.9 % yield) as a yellow oil. **ESI** MS m/z 757.6 $[M+H]^+$.


[0478] Step B: *tert*-butyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-2-(3-morpholinopropoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl) indazol-4-yl]-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (370 mg, 488 μmol, 1.00 *eq*) in MeOH (10.0 mL) was added triethylamine (98.9 mg, 977 μmol, 135 μL, 2.00 eq), Pd/C(100 mg, 10 % purity) and *tert*-butoxycarbonyl *tert*-butyl carbonate (213 mg, 977 μmol, 224 μL, 2.00 *eq*) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 40 °C for 2 hours. The reaction mixture was filtrated and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 1:0 to 10:1) to provide *tert*-butyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-2-(3-morpholinopropoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (340 mg, 470 μmol, 96.2 % yield) as a brown oil. **ESI** MS m/z 723.5 $[M+H]^+$.

[0479] Step C: 4-[3-[[7-(5-methyl-1*H*-indazol-4-yl) -4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine trifluoroacetate : To a solution of *tert*-butyl

4-[7-[5-methyl-1- (2-trimethylsilylethoxymethyl)indazol-4-yl]-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 207 μmol, 1.00 *eq*) in DCM (500 μL) was added TFA (354 mg, 3.11 mmol, 230 μL, 15.0 *eq*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated in vacuum to provide 4-[3-[[7-(5-methyl-1*H*-indazol-4-yl) -4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine trifluoroacetate (125 mg, 206 μmol, 99.3 % yield) as a brown oil and used directly in the next step without purification. **ESI** MS m/z 493.4 $[M+H]^+$.

[0480] Step D 1-[4-[7-(5-methyl-1*H*-indazol-4-yl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one : To a mixture of 4-[3-[[7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin -1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine trifluoroacetate (120 mg, 197 μmol, 1.00 *eq*, TFA) and DIEA (255 mg, 1.98 mmol, 345 μL, 10.0 *eq*) in dichloromethane (2.00 mL) was added a solution of prop-2-enoyl prop-2-enoate (19.9 mg, 158 μmol, 0.80 *eq*) dichloromethane (1.00 mL) at -40°C under nitrogen atmosphere. The mixture was stirred for 1 hour. The reaction mixture was quenched by addition of MeOH (50.0 μL) at -40°C, diluted with water (10.0 mL), extracted with dichloromethane (10.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC (column: Phenomenex Gemini 150*25mm*, 10 μ; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 30%-60%,10 min) to provide 1-[4-[7-(5-methyl-1*H*-indazol-4-yl) -2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (19.0 mg, 34.4 μmol, 17.4 % yield, 99.0 % purity) as a white solid. **ESI** MS m/z 547.5 $[M+H]^+$.

EXAMPLE 45



1-((1R,5S)-3-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)prop-2-en-1-one

[0481] Step A: *tert*-butyl 3-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate: To a mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (920 mg, 3.13 mmol, 1.00 *eq*) and *tert*-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (677 mg, 3.19 mmol, 1.02 *eq*) in DMSO (18.0 mL) was added DIEA (1.21 g, 9.39 mmol, 1.64 mL, 3.00 *eq*). The reaction mixture was stirred at 60 °C for 1 hour. The mixture was diluted with extracted with EtOAc (3 × 20 mL), washed with water (10 mL), 1N HCl (5 mL), $NaHCO_3$ (15 mL), and brine (15 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 3-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.30 g, 2.41 mmol, 76.9 % yield, 87.0 % purity) as a brown oil which was used directly in the next step without further purification. **ESI** MS m/z 470.2 $[M+H]^+$.

[0482] Step B: *tert*-butyl 3-[7-benzyl-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate: To a solution of 1-(dimethylamino)propan-2-ol (857 mg, 8.31 mmol, 942 µL, 3.00 *eq*) in THF (40.0 mL) was added NaH (222 mg, 5.54 mmol, 60.0 % purity, 2.00 *eq*) at 15 °C under N_2. After stirring at 15 °C for 0.5 hour, *tert*-butyl 3-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.30 g, 2.77 mmol, 1.00 *eq*) was added. The mixture was stirred at 100 °C for 12 hours in a sealed tube. The reaction was slowly quenched with water (3 mL) and then concentrated under vacuum. The residue was purified by column chromatography (DCM/MeOH 60:1 to 10:1) to give *tert*-butyl 3-[7-benzyl-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (700 mg, 1.07 mmol, 38.8 % yield, 82.4 % purity) as a yellow oil.

[0483] Step C: *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate : To a solution of *tert*-butyl 3-[7-benzyl-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (700 mg, 1.30 mmol, 1.00 *eq*) in MeOH (30.0 mL) was added Pd/C (200 mg) under N_2. The suspension was degassed

under vacuum and purged with hydrogen 4 times. The mixture was stirred under hydrogen (50 psi) at 40 °C for 12 hours. The mixture was concentrated under vacuum. The residue was purified by column chromatography (DCM/MeOH 50:1 to 5:1) to give *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (500 mg, 952 μmol, 73.2 % yield, 85.0 % purity) as a yellow oil.

[0484] Step D: *tert*-butyl 3-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate: $Pd_2(dba)_3$ (84.1 mg, 91.8 μmol, 0.10 *eq*) was added to a solution of *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (410 mg, 918 μmol, 1.00 *eq*), 3-benzyloxy-1-bromo-naphthalene (293 mg, 936 μmol, 1.02 *eq*), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (85.7 mg, 184 μmol, 0.20 *eq*) and Cs_2CO_3 (897 mg, 2.75 mmol, 3.00 *eq*) in dioxane (9.00 mL). The reaction mixture was stirred at 100 °C for 7 hours under N_2 and then concentrated under vacuum. The residue was diluted with water (5 mL) and extracted with DCM (2 × 20 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (DCM/MeOH 100:1 to 20:1) to give *tert*-butyl 3-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (317 mg, 441 μmol, 48.1 % yield, 94.5 % purity) as a yellow oil. **ESI** MS m/z 679.2 $[M+H]^+$.

[0485] Step E: *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate: To a solution of *tert*-butyl 3-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (340 mg, 501 μmol, 1.00 *eq*) in MeOH (6.80 mL) was added Pd/C (120 mg). The suspension was degassed under vacuum and purged with hydrogen 4 times. The mixture was stirred under hydrogen (15 psi) at 40 °C for 1.5 hours. The mixture was concentrated under vacuum to give *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (210 mg, 316 μmol, 63.1 % yield, 88.6 % purity) as a yellow solid which was used directly in the next step

SUBSTITUTE SHEET (RULE 26)


without further purification. **ESI** MS m/z 589.3 $[M+H]^+$.

Step F: 4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate : To a solution of *tert*-butyl 3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (180 mg, 306 μmol, 1.00 *eq*) in DCM (230 μL) was added TFA (349 mg, 3.06 mmol, 226 μL, 10.0 *eq*). The reaction mixture was stirred at 18 °C for 0.5 hour. The mixture was concentrated under vacuum to give 4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate (528 mg, crude) as a red oil which was used directly in the next step without further purification. **ESI** MS m/z 489.2 $[M+H]^+$.

[0486] Step G: 1-[3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]prop-2-en-1-one: To a solution of 4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate (149 mg, 306 μmol, 1.00 *eq*) and DIEA (1.36 g, 10.5 mmol, 1.84 mL, 34.5 *eq*) in DCM (1.50 mL) was added prop-2-enoyl prop-2-enoate (30.9 mg, 245 μmol, 0.80 *eq*) dropwise at - 50 °C. The mixture was stirred at -40 and then -20 °C for 30 minutes. The reaction was quenched with MeOH (19.6 mg) and concentrated under vacuum. The residue was purified by preparative TLC (DCM/MeOH 7:1) to give 1-[3-[2-[2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]prop-2-en-1-one (18.9 mg, 32.8 μmol, 10.7 % yield, 94.3 % purity) as a yellow solid. **ESI** MS m/z 543.3 $[M+H]^+$.

EXAMPLE 46


SUBSTITUTE SHEET (RULE 26)



1-((1R,5S)-8-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-3-yl)prop-2-en-1-one

[0487] Synthesized according to the method of **Example 4**, using tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate in place *tert*-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate in Step A. **ESI** MS m/z 543.4 $[M+H]^+$.

EXAMPLE 47



1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-8-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0488] Step A: ethyl 2-(benzylamino)propanoate: To a solution of ethyl 2-bromopropanoate (30.0 g, 165 mmol, 21.6 mL, 1.00 eq), $BnNH_2$ (23.1 g, 215 mmol, 23.6 mL, 1.30 eq) in MeCN (600 mL) was added K_2CO_3 (45.8 g, 331 mmol, 2.00 eq). The mixture was stirred at 80 °C for 2 hour. The reaction mixture was filtered and the filter cake was washed with DCM (300 mL). The filtrated was concentrated under vacuum. The residue was purified by silica gel

chromatography (diethyl ether:ethyl acetate=10:1 to 4:1) to give ethyl 2-(benzylamino)propanoate (34.0 g, 163 mmol, 98.4 % yield, 99.4 % purity) a colorless oil.

[0489] Step B: ethyl 4-[benzyl-(2-ethoxy-1-methyl-2-oxo-ethyl)amino]butanoate: To a solution of ethyl 2-(benzylamino)propanoate (31.0 g, 150 mmol, 1.00 eq) and ethyl 4-bromobutanoate (87.5 g, 449 mmol, 64.4 mL, 3.00 eq) in MeCN (600 mL) and water (60.0 mL) was added Cs_2CO_3 (97.5 g, 299.12 mmol, 2.00 eq) and KI (4.97 g, 29.9 mmol, 0.20 eq). The reaction mixture was stirred at 80-90 °C for 40 hours. The reaction mixture was filtered and the filter cake was washed with DCM (2 × 100 mL). The filtrate was concentrated under vacuum. The residue was dissolved in DCM (300 mL) and washed with brine (80 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by flash silica gel chromatography (diethyl ether:ethyl acetate = 1:0 to 20:1) to give ethyl 4-[benzyl-(2-ethoxy-1-methyl-2-oxo-ethyl)amino]butanoate (28.0 g, 87.1 mmol, 58.3 % yield) as a yellow oil.

[0490] Step C: ethyl 1-benzyl-2-methyl-3-oxo-piperidine-4-carboxylate: To a solution of ethyl 4-[benzyl-(2-ethoxy-1-methyl-2-oxo-ethyl)amino]butanoate (28.0 g, 87.1 mmol, 1.00 eq) in THF (600 mL) was added tBuOK (19.6 g, 174 mmol, 2.00 eq).The reaction mixture was stirred at 18 °C for 1 hour. The reaction mixture was quenched with water (100 mL) and extracted with MTBE (3 × 300mL) and DCM (2 × 200 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated under vacuum. The crude product was purified by silica gel chromatography (diethyl ether:ethyl acetate=100:1 to 20:1) to give ethyl 1-benzyl-2-methyl-3-oxo-piperidine-4-carboxylate (20.0 g, 58.8 mmol, 67.5 % yield, 81.0 % purity) as a yellow oil. **ESI** MS m/z 276.0 $[M+H]^+$.

[0491] Step D: 7-benzyl-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-2,4-diol: To EtOH (400 mL) was added Na (3.76 g, 163 mmol, 3.88 mL, 2.50 eq). The reaction mixture was stirred at 20 °C for 0.5 hour. To the mixture was added ethyl 1-benzyl-2-methyl-3-oxo-piperidine-4-carboxylate (18.0 g, 65.4 mmol, 1.00 eq) and UREA (9.82 g, 163 mmol, 8.77 mL, 2.50 eq) and the reaction mixture was stirred at 80 °C for 80 hours. The solvent was removed under vacuum. The residue was dissolved in water (100 mL) and washed with MTBE (3 × 50 mL). The aqueous phase was adjusted to pH 6-7 with HCl (15 mL, 12 M). The mixture was filtered and the filter cake was washed with water (30 mL) and dried in vacuum to give 7-benzyl-8-methyl-

6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-2,4-diol (12.0 g, 44.2 mmol, 67.7 % yield, 100 % purity) was obtained as a brown solid. **ESI** MS m/z 272.0 $[M+H]^+$.

[0492] Step E: benzyl-2,4-dichloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine: A mixture of 7-benzyl-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-2,4-diol (5.00 g, 18.4 mmol, 1.00 eq) in $POCl_3$ (305 g, 1.99 mol, 185 mL, 108 eq) was heated to 110 °C for 12 hours. The solvent was removed under vacuum. The residue was dissolved in DCM (500 mL) and poured into saturated $NaHCO_3$ (200 mL) while keeping the pH greater than 7. The organic layer was washed with brine (50 mL), dried over Na_2SO_4.The solution was filtered through a pad of silica gel and the filter cake was washed with DCM (3 × 400 mL). The combined organic layers were concentrated under vacuum to give 7-benzyl-2,4-dichloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine (4.50 g, 14.6 mmol, 79.2 % yield) as a brown oil.

[0493] Step F: 4-(7-benzyl-2-chloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of 7-benzyl-2,4-dichloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine (3.00 g, 9.73 mmol, 1.00 eq) and DIEA (2.52 g, 19.5 mmol, 3.40 mL, 2.00 eq) in dioxane (60.0 mL) was added tert-butyl piperazine-1-carboxylate (1.90 g, 10.2 mmol, 1.05 eq). The reaction mixture was stirred at 60 °C for 12 hours. The solvent was removed under vacuum. The residue was purified by silica gel chromatography (diethyl ether:ethyl acetate = 2:1) to give tert-butyl 4-(7-benzyl-2-chloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (3.30 g, 7.15 mmol, 73.5 % yield, 99.3 % purity) as a yellow solid. **ESI** MS m/z 458.1 $[M+H]^+$.

[0494] Step G: tert-butyl-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of 2-(dimethylamino)ethanol (583 mg, 6.54 mmol, 655 µL, 3.00 eq) in toluene (20.0 mL) was added $Pd(OAc)_2$ (48.9 mg, 218 µmol, 0.10 eq), tert-butyl-4-(7-benzyl-2-chloro-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.00 g, 2.18 mmol, 1.00 eq), Cs_2CO_3 (2.13 g, 6.54 mmol, 3.00 eq) and BINAP (272 mg, 436 µmol, 0.20 eq). The reaction mixture was stirred at 110 °C for 3 hours under N_2. The reaction mixture was concentrated under vacuum. The residue was dissolved in water (10 mL) and extracted with DCM (3 × 40 mL). The combined organic layers were washed with brine, dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (diethyl ether:ethyl acetate =

5:1 to 2:1 then DCM:MeOH = 50:1 to 5:1) to give tert-butyl-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (900 mg, 1.76 mmol, 80.8 % yield) as a brown solid. **ESI** MS m/z 511.2 $[M+H]^+$.


[0495] Step H: tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate :To a solution of tert-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.57 mmol, 1.00 eq) in MeOH (20.0 mL) was added Pd/C (100 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (50 psi) at 40°C for 12 hours. The reaction mixture was filtered and the filter cake was washed with MeOH (3 × 200 mL).The filtrate was concentrated under vacuum to give tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (450 mg, 1.07 mmol, 68.2 % yield) as brown oil which was used for next step without further purification. **ESI** MS m/z 421.3 $[M+H]^+$.

[0496] Step I: tert-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (380 mg, 904 μmol, 1.00 eq) and 3-benzyloxy-1-bromo-naphthalene (311 mg, 994 μmol, 1.10 eq) in dioxane (8.00 mL), Cs_2CO_3 (883 mg, 2.71 mmol, 3.00 eq) and 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (84.3 mg, 181 μmol, 0.20 eq) and $Pd_2(dba)_3$ (82.7 mg, 90.4 μmol, 0.10 eq) were added. The reaction mixture was stirred at 90 °C for 12 h under N_2. The reaction mixture was concentrated under vacuum. The residue was partitioned between DCM (50 mL) and water (20 mL). The reaction mixture was extracted with DCM (50 mL). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (diethyl ether:ethyl acetate = 5:1 then DCM:MeOH =100:1 to 5:1), followed by purification of the isolated product by preparative TLC (DCM: MeOH=10:1) to give tert-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 306 μmol, 33.9 % yield) as brown solid. **ESI** MS m/z 653.4 $[M+H]^+$.

[0497] Step J: 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol bis-trifluoroacetate:To a solution of tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 177 μmol, 1.00 eq) in DCM (130.00 μL) was added TFA (202 mg, 1.78 mmol, 132 μL, 10.00 eq). The reaction mixture was stirred at 20 °C for 1 hour. The solvent was removed under vacuum to provide 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol bis-trifluoroacetate (175.00 mg) as a brown oil which was used in the next step without further purification.

[0498] Step K: 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[2-[2-(dimethylamino)ethoxy]-8-methyl-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol bis-trifluoroacetate (97.4 mg, 141 μmol, 1.00 eq) in DCM (500.00 μL) was added DIEA (222 mg, 1.72 mmol, 300 μL, 12.2 eq) and prop-2-enoyl prop-2-enoate (14.2 mg, 113 μmol, 0.80 eq) at -40 °C. The reaction mixture was stirred at -40 °C for 0.5 h. The reaction mixture was quenched with a drop of MeOH and concentrated under vacuum. The residue was purified by preparative TLC (DCM:MeOH =10:1) and then by preparative HPLC (column: Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.1%TFA)-ACN]; B%: 15%-45%, 13 min) to give 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-8-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (10.7 mg, 20.7 μmol, three steps 6.8 % yield) as a brown oil. **ESI** MS m/z 517.2 $[M+H]^+$.

EXAMPLE 48



1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate

[0499] Step A: ethyl 4-[benzyl-(2-ethoxy-2-oxo-ethyl)amino]pentanoate: A solution of ethyl 4-oxopentanoate (47.0 g, 326 mmol, 46.5 mL, 1.50 *eq*), ethyl 2-(benzylamino)acetate (42.0 g, 217.3 mmol, 1.00 *eq*) and AcOH (13.0 g, 217 mmol, 12.4 mL, 1.00 *eq*) in DCM (800 mL) was stirred at 12-18 °C for 30 min, then cooled at 0-5 °C, $NaBH(OAc)_3$ (138 g, 652 mmol, 3.00 *eq*) was added portion-wise. The mixture was warmed to 10-18 °C and stirred for 16 hours. The reaction mixture was quenched with water (1000 mL) and extracted with DCM (2 × 500 mL). The combined organic phases were dried and concentrated to dryness. The residue was purified by silica gel column eluting with diethyl ether/ethyl acetate (60:1 to 40:1) to provide ethyl 4-[benzyl-(2-ethoxy-2-oxo-ethyl)amino]pentanoate (42.0 g, 91.5 mmol, 42.1 % yield, 70 % purity) as colorless oil. **ESI** MS m/z 322.2 $[M+H]^+$.

[0500] Step B: ethyl 1-benzyl-2-methyl-5-oxo-piperidine-4-carboxylate: A solution of ethyl 4-[benzyl-(2-ethoxy-2-oxo-ethyl)amino]pentanoate (37.00 g, 115.12 mmol, 1.00 *eq*) and t-BuOK (16.8 g, 150 mmol, 1.30 *eq*) in toluene (30.0 mL) was stirred at 25 °C for 5 hours. The reaction was quenched with water (50 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic extracts were dried and concentrated to dryness to provide ethyl 1-benzyl-2-methyl-5-oxo-piperidine-4-carboxylate (14.6 g, 53.0 mmol, 46 % yield) as yellow oil which was used directly in the next step.

[0501] Step C: 7-benzyl-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-2,4-diol: Na (3.05 g, 133 mmol, 3.14 mL, 2.50 *eq*) was dissolved in EtOH (280 mL), and then ethyl 1-benzyl-2-methyl-5-oxo-piperidine-4-carboxylate (14.6 g, 53.0 mmol, 1.00 *eq*) and urea (7.96 g, 133 mmol, 7.11 mL, 2.50 *eq*) were added. The reaction mixture was heated to reflux (78 °C) for 16 hrs under N_2. The reaction mixture was concentrated to dryness. The residue was dissolved in water (100 mL), washed with MTBE (100 mL). The pH of the water phase was adjusted to pH 6-7 with 6N HCl (2 mL). The resulting solid was collected by filtration and dried under vacuum at 60 °C to provide 7-benzyl-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-2,4-diol (5.00 g, 17.1 mmol, 32.3 % yield, 93 % purity) as light yellow solid.

SUBSTITUTE SHEET (RULE 26)

[0502] Step D: 7-benzyl-2,4-dichloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: $POCl_3$ (49.5 g, 323 mmol, 30.0 mL, 58.4 *eq*) and 7-benzyl-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-2,4-diol (1.50 g, 5.53 mmol, 1.00 *eq*) were heated to 100 °C under reflux for 12 hours. The reaction was concentrated to dryness to remove $POCl_3$. The residue was dissolved in DCM (40 mL) and washed with saturated $NaHCO_3$ aqueous /saturated aqueous Na_2CO_3 (1/1, 60 mL). The mixture was filtered and the organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give 7-benzyl-2,4-dichloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (2.08 g, crude) as a brown solid which was used directly in the next step without further purification. **ESI** MS m/z 307.9, 309.9 $[M+H]^+$.

[0503] Step E: 4-(7-benzyl-2-chloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate :To a mixture of 7-benzyl-2,4-dichloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (2.50 g, 8.11 mmol, 1.00 *eq*) and *tert*-butyl piperazine-1-carboxylate (1.54 g, 8.27 mmol, 1.02 *eq*) in dioxane (50.0 mL) was added DIEA (3.14 g, 24.3 mmol, 4.25 mL, 3.00 *eq*). The mixture was stirred at 60 °C for 20 hours. The mixture was concentrated under vacuum. The residue was diluted with water (20 mL) and extracted with DCM (2 × 80 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by automated flash chromatography system (diethyl ether/ethyl acetate 50:1 to 2:1) to give *tert*-butyl 4-(7-benzyl-2-chloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (2.59 g, 5.29 mmol, 65.2 % yield, 93.5 % purity) as a yellow solid.

[0504] Step F: *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of 2-(dimethylamino)ethanol (701 mg, 7.86 mmol, 788 μL, 3.00 *eq*) in THF (45.0 mL) was added NaH (210 mg, 5.24 mmol, 60.0 % purity, 2.00 *eq*) at 15 °C under N_2. After stirring at 15 °C for 0.5 hour, *tert*-butyl 4-(7-benzyl-2-chloro-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.20 g, 2.62 mmol, 1.00 *eq*) was added. The mixture was stirred at 110 °C for 18 hours in a sealed tube. The mixture was concentrated under vacuum. The residue was purified by column chromatography over Al_2O_3 (DCM/MeOH 100:1 to 10:1) to give *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.38 g, 2.36 mmol, 90.3 % yield, 87.5% purity) as a yellow oil. **ESI** MS m/z 511.3 $[M+H]^+$.

[0505] Step G: *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.50 g, 2.94 mmol, 1.00 *eq*) in MeOH (80.0 mL) was added Pd/C (450 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen 4 times. The mixture was stirred under hydrogen (50 psi) at 40 °C for 12 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (DCM/MeOH 40/1 to 10/1) to give *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.15 g, 2.46 mmol, 83.7 % yield, 90.0 % purity) as a yellow oil.

[0506] Step H: *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: $Pd_2(dba)_3$ (109 mg, 119 μmol, 0.10 *eq*) was added to a solution of *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 1.19 mmol, 1.00 *eq*), 3-benzyloxy-1-bromo-naphthalene (410 mg, 1.31 mmol, 1.10 *eq*), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (111 mg, 238 μmol, 0.20 *eq*) and Cs_2CO_3 (1.16 g, 3.57 mmol, 3.00 *eq*) in dioxane (10.0 mL). The reaction mixture was stirred at 90 °C for 12 hours under N_2. The mixture was concentrated under vacuum. The residue was diluted with water (5 mL) and extracted with DCM (2 × 20 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography over Al_2O_3 (DCM/MeOH 100/1 to 10/1) and by preparative TLC (DCM/MeOH 5:1) to give *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (309 mg, 453 μmol, 38.1 % yield, 95.8 % purity) as a yellow oil.


[0507] Step I: *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (340 mg, 521 μmol, 1.00 *eq*) in MeOH (6.80 mL) was added Pd/C (120 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen 4 times. The mixture was stirred under hydrogen (15 psi) at 40 °C for 1.5

hours. The mixture was concentrated under vacuum to give *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 312 μmol, 59.8 % yield, 83.5 % purity) as a pink solid which was used directly in the next step without further purification. **ESI** MS m/z 563.3 $[M+H]^+$.

[0508] Step J: 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate : To a solution of *tert*-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6-methyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 320 μmol, 1.00 *eq*) in DCM (240 μL) was added TFA (365 mg, 3.20 mmol, 237 μL, 10.0 *eq*). The mixture was stirred at 18 °C for 0.5 hour. The mixture was concentrated under vacuum to give 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate (273 mg) as a yellow oil which was used directly in the next step without further purification.

Step K: 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[2-[2-(dimethylamino)ethoxy]-6-methyl-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol trifluoroacetate (148 mg, 320 μmol, 1.00 *eq*) and DIEA (494 mg, 3.83 mmol, 668 μL, 12.0 *eq*) in DCM (500 μL) was added prop-2-enoyl prop-2-enoate (32.3 mg, 256 μmol, 0.80 *eq*) dropwise at - 50 °C. The mixture was stirred at -40 to -20 °C for 30 minutes. The reaction was quenched with MeOH (20.5 mg) and concentrated under vacuum. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.1% TFA)-ACN]; B%: 8%-38%,13 min) to give 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one trifluoroacetate (73.7 mg, 113 μmol, 35.2 % yield, 96.3 % purity) as a yellow solid. **ESI** MS m/z 517.3 $[M+H]^+$.

EXAMPLE 49



1-(4-(2-(2-(3-fluoropyrrolidin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0509] Step A: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate :A mixture of 2-(3-fluoropyrrolidin-1-yl)ethanol (401 mg, 3.01 mmol, 1.60 *eq*), *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-methylsulfonyl- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (1.00 g, 1.88 mmol, 1.00 *eq*), Cs_2CO_3 (1.84 g, 5.64 mmol, 3.00 *eq*), $Pd(OAc)_2$ (42.2 mg, 188 μmol, 0.10 *eq*) and BINAP (234 mg, 376 μmol, 0.20 *eq*) in toluene (50.00 mL) was stirred at 110 °C for 3 hours. The mixture was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 10:1 to 100:1). The desired fractions were collected and concentrated under vacuum to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (1.20 g, 1.07 mmol, 56.8 % yield, 52 % purity) as a yellow solid. **ESI** MS m/z 585.3 $[M+H]^+$.

[0510] Step B: benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-5,6,7,8-tetrahydropyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1- yl)-2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (1.20 g, 2.05 mmol, 1.00 *eq*) in DCM (10.00 mL) was added TFA (3.51 g, 30.8 mmol, 2.28 mL, 15.00 *eq*) at 0 °C. The mixture was warmed to 25 °C and stirred for 16 hours. The mixture was diluted with water (100 mL) and the solution was extracted with ethyl acetate (2 × 100 mL). The water layer was basified with saturated aqueous sodium carbonate solution (50 mL) and then extracted with ethyl acetate (2 × 100 mL). The

combined organic layers were washed with brine (1 × 100 mL), dried over sodium sulfate, and filtered. The filtrate was concentrated under vacuum to provide benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-5,6,7,8-tetrahydropyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.65 mmol, 80.4 % yield) as a yellow gum. **ESI** MS m/z 485.3 $[M+H]^+$.

[0511] Step C: benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (750 mg, 1.55 mmol, 1.00 *eq*), (3-methoxy-1-naphthyl) trifluoromethanesulfonate (949 mg, 3.10 mmol, 2.00 *eq*), 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (144.66 mg, 310.00 μmol, 0.20 *eq*), $Pd_2(dba)_3$ (141.94 mg, 155.00 μmol, 0.10 *eq*) and Cs_2CO_3 (1.52 g, 4.65 mmol, 3.00 *eq*) in toluene (70.00 mL) was stirred at 110 °C for 16 hours. The mixture was concentrated under vacuum and then diluted with ethyl acetate (100 mL) and water (100 mL). The separated organic layer was washed with brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 10:1 to ethyl acetate/methanol 10:1). The desired fractions were collected and concentrated under vacuum to give benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (700 mg, 961 μmol, 62.0 % yield, 88% purity) as a brown solid. **ESI** MS m/z 641.3 $[M+H]^+$.


[0512] Step D: 2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine: A mixture of benzyl 4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7- (3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (700.00 mg, 1.09 mmol, 1.00 *eq*) in MeOH was hydrogenated (15 psi) at 40 °C with dry Pd/C (140 mg,) as a catalyst for 4 hours. The catalyst was filtered through a Celite® pelt and the filtrate was concentrated under vacuum to provide 2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine (500 mg, 987 μmol, 90.6 % yield) as a brown solid.

[0513] Step E: 1-[4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7- (3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5H-

pyrido[3,4-d]pyrimidine (500 mg, 987 μmol, 1.00 *eq*) and DIEA (255 mg, 1.97 mmol, 345 μL, 2.00 *eq*) in dichloromethane (8 mL) was added a solution of prop-2-enoyl prop-2-enoate (124 mg, 987 μmol, 1.00 *eq*) in dichloromethane (2 mL) at - 40 °C under nitrogen atmosphere. The mixture was warmed to 25 °C and stirred for 1 hour. The mixture was diluted with water (20 mL) and dichloromethane (30 mL). The separated organic layer was washed with brine (1 × 30 mL), dried over magnesium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (dichloromethane/methanol 100/1 to 10/1). The desired fractions were collected and concentrated under vacuum to give 1-[4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (450 mg, 714 μmol, 72.4 % yield, 89 % purity) as a yellow solid. **ESI** MS m/z 561.2 $[M+H]^+$.

[0514] Step F: 1-[4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7- (3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[2-[2-(3-fluoropyrrolidin-1-yl) ethoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (400 mg, 713 μmol, 1.00 *eq*) in DCM (2.00 mL) was added BBr_3 (1.30 g, 5.19 mmol, 500 μL, 7.27 *eq*) at -70 °C under nitrogen atmosphere. The mixture was warmed to 0 °C and stirred for 1 hour. The mixture was diluted with dichloromethane (20 mL), and then quenched with saturated aqueous sodium bicarbonate solution (20 mL). The separated organic layer was washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by preparative HPLC (Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.1%TFA)-ACN]; B%: 18%-48%,12 min.) The desired fractions were collected and lyophilized to give 1-[4-[2-[2-(3-fluoropyrrolidin-1-yl)ethoxy]-7- (3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (40.0 mg, 63.7 μmol, 8.92 % yield, 87 % purity) was a yellow solid. **ESI** MS m/z 547.3 $[M+H]^+$.

EXAMPLE 50



1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one

[0515] Step A: 1-tert-butyl 2-methyl4-(7-benzyl-2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin -4-yl)piperazine-1,2-dicarboxylate :To a solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5H-pyrido[3,4-d] pyrimidine (2.00 g, 6.80 mmol, 1.00 eq) in DMSO (40.0 mL) was added DIEA (1.76 g, 13.6 mmol, 2.38 mL, 2.00 eq) and 1-tert-butyl 2-methylpiperazine-1,2-dicarboxylate (1.74 g, 7.14 mmol, 1.05 eq). The mixture was stirred at 55 °C for 16 hours. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na_2SO_4, filtered and concentrated to dryness. The residue was purified by column chromatography (SiO_2, diethyl ether/ethyl acetate = 1:0 to 3:1) to give 1-tert-butyl 2-methyl-4-(7-benzyl-2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin -4-yl)piperazine-1,2-dicarboxylate (3.10 g, 5.70 mmol, 83.8 % yield, 92.3 % purity) as a yellow semisolid. **ESI** MS m/z 502.2 $[M+H]^+$.

[0516] Step B: 1-tert-butyl 2-methyl4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d] pyrimidin-4-yl]piperazine-1,2-dicarboxylate: A mixture of 1-tert-butyl 2-methyl-4-(7-benzyl-2-chloro-6,8-dihydro -5H-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1,2-dicarboxylate (3.00 g, 5.98 mmol, 1.00 eq), 2-(dimethylamino)ethanol (1.07 g, 12.0 mmol, 1.20 mL, 2.00 eq), Cs_2CO_3 (4.87 g, 15.0 mmol, 2.50 eq), $Pd(OAc)_2$ (201 mg, 897 μmol, 0.15 eq) and BINAP (744 mg, 1.20 mmol, 0.20 eq) in toluene (60.0 mL) was degassed and purged with nitrogen 3 times, and then the mixture was stirred at 110 °C for 3 hours under a nitrogen atmosphere. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL), dried over Na_2SO_4, filtered and concentrated to dryness. The residue was purified by column

chromatography (SiO_2, DCM / MeOH = 1:0 to 5:1) to give 1-tert-butyl 2-methyl-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d] pyrimidin-4-yl]piperazine-1,2-dicarboxylate (3.10 g, 4.45 mmol, 80.4 % yield, 86.0 % purity) as a black oil. **ESI** MS m/z 555.3 $[M+H]^+$.

[0517] Step C: 1-tert-butyl 2-methyl4-[2- [2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate:To a solution of 1-tert-butyl 2-methyl-4-[7-benzyl-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (2.33 g, 4.20 mmol, 1.00 eq) in MeOH (50.0 mL) was added Pd/C (233 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (50 psi) at 40 °C for 36 hours. The reaction mixture was filtered and the organic phase was concentrated to dryness to give 1-tert-butyl-2-methyl4-[2- [2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (1.50 g, crude) as a colorless oil, which was used directly in the next step without further purification.

[0518] Step D: 1-tert-butyl2-methyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate: A mixture of 1-tert-butyl-2-methyl4-[2-[2-(dimethylamino)ethoxy] -5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (1.50 g, crude), 3-benzyloxy-1-bromo-naphthalene (1.49 g, 4.76 mmol, 1.30 eq), Cs_2CO_3 (2.98 g, 9.15 mmol, 2.50 eq), $Pd_2(dba)_3$ (503 mg, 549 μmol, 0.15 eq) and 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (342 mg, 732 μmol, 0.20 eq) in dioxane (100 mL) was degassed and purged with nitrogen 3 times, and the mixture was stirred at 85 °C for 5 hours under a nitrogen atmosphere. The reaction mixture was quenched by adding water (50 mL) at 0 °C, and extracted with DCM (3 × 100 mL). The combined organic layers were washed with brine (3 × 150 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM / MeOH = 10:1 to 5:1) to give 1-tert-butyl2-methyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (1.72 g, 2.25 mmol, 53.5 % yield, 91% purity) as a yellow. **ESI** MS m/z 697.3 $[M+H]^+$.

[0519] Step E: methyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-di hydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-2-carboxylate: To a solution of 1-tert-butyl 2-methyl4-[7-(3-benzyloxy-1-naphthyl) -2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (1.32 g, 1.89 mmol, 1.00 eq) in DCM (20.0 mL) was added TFA (4.31 g, 37.8 mmol, 2.80 mL, 20.0 eq) at 0 °C and the reaction mixture was stirred for 2 hours at 25 °C. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in DCM (50 mL) and H_2O (20 mL) and the reaction mixture was adjusted to pH 8 with saturated $NaHCO_3$. The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give methyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-di hydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-2-carboxylate (1.12 g, 1.87 mmol, 69.6 % yield, 70 % purity) as a brown oil, which was used directly in the next step without further purification. **ESI** MS m/z 597.4 $[M+H]^+$.

[0520] Step F: [4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]methanol: A mixture of methyl-4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-2-carboxylate (400 mg, 0.670 mmol) in THF (5.00 mL) was added $LiAlH_4$ (102 mg, 2.68 mmol, 4.00 eq) at 0 °C. The reaction mixture was degassed and purged with nitrogen 3 times, and stirred at 0 °C for 2 hours under a nitrogen atmosphere. The reaction mixture was quenched by addition of $Na_2SO_4 \cdot 10\ H_2O$ (0.5 g) at 0 °C, and then diluted with DCM (50 mL). The combined organic layers were filtered, dried over Na_2SO_4, and concentrated under reduced pressure to give [4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]methanol (280 mg, 0.493 mmol, 73.6 % yield) as a yellow semisolid, which was used directly in the next step without further purification. **ESI** MS m/z 569.3 $[M+H]^+$.

[0521] Step G: 2-[[7-(3-benzyloxy-1-naphthyl)-4-[3-[[tert-butyl(dimethyl)silyl]oxymethyl] piperazin-1-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]-N,N-dimethyl-ethanamine: To a stirred solution of [4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]methanol (250 mg, 440 µmol, 1.00 eq) and NaH (176 mg, 4.40 mmol, 60.0 % purity, 10.0 eq) in THF (10.0 mL) was added tert-


butyldimethylsilyl chloride (232 mg, 1.54 mmol, 189 μL, 3.50 eq) at 0 °C. The mixture was stirred at 25 °C for 12 hours under a nitrogen atmosphere. The reaction mixture was quenched by addition of water (25 mL) at 0 °C and extracted with DCM (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by preparative TLC (SiO_2, DCM/MeOH = 10:1) to give 2-[[7-(3-benzyloxy-1-naphthyl)-4-[3-[[tert-butyl(dimethyl)silyl]oxymethyl] piperazin-1-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]-N,N-dimethyl-ethanamine (128 mg, 180 μmol, 40.9 % yield, 96.0 % purity) as a colorless semisolid. **ESI** MS m/z 683.3 $[M+H]^+$.

[0522] Step H: 1-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-[[tert-butyl(dimethyl)silyl]oxymethyl]piperazin-1-yl]prop-2-en-1-one; To a solution of 2-[[7-(3-benzyloxy-1-naphthyl)-4-[3-[[tert-butyl (dimethyl)silyl]oxymethyl]piperazin-1-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]-N,N-dimethyl-ethanamine (128 mg, 187 μmol, 1.00 eq) and triethylamine (47.4 mg, 469 μmol, 65.0 μL, 2.50 eq) in DCM (5.00 mL) was added prop-2-enoyl prop-2-enoate (35.5 mg, 281 μmol, 1.50 eq) dropwise at - 40 °C and stirred for 30 minutes. The reaction mixture was concentrated under reduced pressure to dryness. The residue was purified by preparative TLC (SiO_2, DCM/MeOH = 10:1) to give 1-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-[[tert-butyl(dimethyl)silyl]oxymethyl]piperazin-1-yl]prop-2-en-1-one (92.0 mg, 101 μmol, 54.0 % yield, 81.0 % purity) as a yellow solid. **ESI** MS m/z 737.3 $[M+H]^+$.

[0523] Step I: 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(hydroxymethyl)piperazin-1-yl]prop-2-en-1-one: A mixture of 1-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-[[tert-butyl(dimethyl)silyl]oxymethyl]piperazin-1-yl]prop-2-en-1-one (92.0 mg, 125 μmol, 1.00 eq) in DCM (8.00 mL) was added BBr_3 (17.0 mg, 67.8 μmol, 6.53 μL, 10.0 eq). The mixture was stirred at - 40 °C for 30 minutes under a nitrogen atmosphere and then concentrated at 25 °C under reduced pressure to dryness. To the residue was added saturated $NaHCO_3$ aqueous (0.5 mL). The solution was adjusted to pH 7 at 0 °C and then MeOH (2.0 mL) was added. The solution was purified by preparative HPLC (column: Phenomenex Synergi

C18 150*25*, 10 μ; mobile phase: [water (0.1 % TFA) - ACN]; B %: 15 % - 45 %, 11 min). The desired fractions were collected and concentrated under reduced pressure to remove MeCN and lyophilized to give 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(hydroxymethyl)piperazin-1-yl]prop-2-en-1-one (6.30 mg, 11.2 μmol, 9.00 % yield, 95.0 % purity) as a yellow solid. **ESI** MS m/z 533.2 $[M+H]^+$.

EXAMPLE 51



1-acryloyl-4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-N,N-dimethylpiperazine-2-carboxamide

[0524] Step A: 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-tert-butoxycarbonyl-piperazine-2-carboxylic acid: To a solution of 1-tert-butyl 2-methyl 4-[7-(3-benzyloxy-1-naphthyl) -2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (300 mg, 431 μmol, 1.00 eq) in THF (4.00 mL) and H2O (1.00 mL) was added NaOH (68.9 mg, 1.72 mmol, 4.00 eq). The mixture was stirred at 25 °C for 12 hours under a nitrogen atmosphere. The reaction mixture was diluted with water (50 mL) and the reaction mixture was adjusted to pH 6 with HCl (6 M) and then extracted with DCM (3 × 50 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness to give 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-tert-butoxycarbonyl-piperazine-2-carboxylic acid (310 mg, crude) as a yellow solid which was used directly in the next step without further purification. **ESI** MS m/z 683.3 $[M+H]^+$.

[0525] Step B: tert-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate A mixture of 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-tert-butoxycarbonyl-piperazine-2-carboxylic acid (310 mg, crude) and DIEA (352 mg, 2.72 mmol, 476 μL) in DCM (10.0 mL) was added portionwise HATU (259 mg, 681 μmol) at 0 °C. After stirring for 30 minutes, N-methylmethanamine (130 mg, 1.59 mmol, 146 μL, HCl) was added in one portion. The reaction mixture was degassed and purged with nitrogen 3 times. After stirring at 25 °C for 12 hours under a nitrogen atmosphere, the reaction mixture was diluted with water (50 mL) at 0 °C and extracted with DCM (3 × 50 mL). The combined organic layers were adjusted to pH 6 with HCl (1 M), washed with brine (3 × 50 mL) and water (3 × 50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness to give tert-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate (345 mg, 428 μmol, two steps 94.2 % yield, 88.0 % purity) as a yellow semi-solid. **ESI** MS m/z 710.3 $[M+H]^+$.


[0526] Step C: tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate: To a solution of tert-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2- (dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate (345 mg, 486 μmol, 1.00 eq) in MeOH (5.00 mL) was added Pd/C (80.0 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (15 psi) at 25 °C for 8 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to dryness to give tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate (197 mg, crude) as a brown solid, which was used directly in the next step without further purification. **ESI** MS m/z 620.3 $[M+H]^+$.

[0527] Step D: 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-N,N-dimethyl-piperazine-2-carboxamide: A mixture of tert-butyl 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(dimethylcarbamoyl)piperazine-1-carboxylate (197 mg, crude) in DCM

(5.00 mL) was added HCl/dioxane (4 M, 1.61 mL) at 0 °C. The reaction mixture was degassed and purged with nitrogen 3 times and stirred at 25 °C for 2 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to dryness. The residue was purified by preparative HPLC (column: Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.05 % HCl) - ACN]; B %: 10 % - 30 %, 7.8 min). The collected water phase was lyophilized to dryness to give 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-N,N-dimethyl-piperazine-2-carboxamide (90.0 mg, 171 μmol, 53.1 % yield, 99.0 % purity) as a brown solid. **ESI** MS m/z 520.2 $[M+H]^+$.

[0528] Step E: 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-N,N-dimethyl-1-prop-2-enoyl-piperazine-2-carboxamide: To a solution of 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-N,N-dimethyl-piperazine-2-carboxamide (70.0 mg, 135 μmol, 1.00 eq) in DMAC (500 μL) was added triethylamine (40.9 mg, 404 μmol, 56.0 μL, 3.00 eq) at 0 °C and then prop-2-enoyl prop-2-enoate (2.55 mg, 20.2 μmol, 0.15 eq) was added. The mixture was stirred at 0 °C for 2 hours under a nitrogen atmosphere. The reaction mixture was filtered and the collected organic phase was purified by preparative HPLC (column: Phenomenex Synergi C18 150*25*, 10 μ; mobile phase: [water (0.1 % TFA)-ACN]; B %: 15 % - 45 %, 12 min). The collected water phase was lyophilized to give 4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-N,N-dimethyl-1-prop-2-enoyl-piperazine-2-carboxamide (10.0 mg, 16.5 μmol, 12.2 % yield, 94.6 % purity) as a yellow semisolid. **ESI** MS m/z 574.2 $[M+H]^+$.

EXAMPLE 52



1-[4-[7-(3-hydroxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one

[0529] Step A: tert-butyl 4-[7-benzyl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro- 5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of 2-(1-piperidyl)ethanol (872 mg, 6.75 mmol, 899 µL, 3.00 eq) in toluene (40.0 mL) was added $Pd(OAc)_2$ (50.5 mg, 225 µmol, 0.10 eq), Cs_2CO_3 (2.20 g, 6.75 mmol, 3.00 eq), BINAP (280 mg, 450 µmol, 0.20 eq) and tert-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.00 g, 2.25 mmol, 1.00 eq). The mixture was stirred at 110 °C for 12 hours under N_2 and then concentrated under vacuum. The residue was diluted with water (10.0 mL), extracted with ethyl acetate (3 × 20 mL), washed with brine (1 × 50 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, DCM /MeOH = 10:1) to give tert-butyl 4-[7-benzyl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro- 5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (700 mg, 1.30 mmol, 58.0 % yield) as a red solid. **ESI** MS m/z 537.3 $[M+H]^+$.

[0530] Step B: tert-butyl 4-[2-[2-(1-piperidyl)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] piperazine-1-carboxylate: To a mixture of tert-butyl 4-[7-benzyl-2-[2-(1-piperidyl)ethoxy]-6,8- dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 1.12 mmol, 1.00 eq) in MeOH (50.0 mL) was added Pd/C (67.2 mg, 10 %). The mixture was stirred at 40 °C for 24 hours at 50 psi under H_2. The mixture was filtered and concentrated under vacuum to give tert-butyl 4-[2-[2-(1-piperidyl)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] piperazine-1-carboxylate (500 mg, crude) as a brown oil and used in the next step without further purification. **ESI** MS m/z 447.3 $[M+H]^+$.

[0531] Step C: tert-butyl 4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of tert-butyl 4-[2-[2-(1-piperidyl)ethoxy]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg) and (3-methoxy-1-naphthyl) trifluoromethanesulfonate (343 mg, 1.12 mmol) in toluene (6.00 mL) was added 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (RuPhos) (52.3 mg, 112 µmol), $Pd_2(dba)_3$ (32.19 mg, 55.98 µmol) and Cs_2CO_3 (548 mg, 1.68 mmol). After stirring at 110 °C for 72 hours under N_2, the mixture was concentrated under vacuum, diluted with water (20.0 mL), extracted with ethyl acetate (3 × 30.0 mL), washed with brine (1

× 50.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 10:1) to give tert-butyl 4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 232 μmoL, two steps, 41.5 % yield) as a yellow solid. **ESI** MS m/z 603.3 $[M+H]^+$.


[0532] Step D: 7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine: A mixture of tert-butyl 4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 199 μmol, 1.00 eq) and TFA (340 mg, 2.99 mmol, 221 μL, 15.0 eq) in DCM (1.00 mL) was stirred at 25 °C for 1 hour. The mixture was concentrated under vacuum to give 7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine bis-trifluoroacetate (145 mg, crude) as a yellow solid which was used into next step without further purification. **ESI** MS m/z 503.3 $[M+H]^+$.

[0533] Step E: 1-[4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-2-[2- (1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine bis-trifluoroacetate (145 mg, crude) and Et_3N (221 mg, 2.18 mmol, 303 μL) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (25.0 mg, 198 μmol) at -78 °C. After stirring at 0 °C for 0.5 h, the mixture quenched with MeOH and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, DCM/MeOH = 10:1) to give 1-[4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (90.0 mg, 162 μmol, two steps 81.5 % yield) a yellow solid. **ESI** MS m/z 557.3 $[M+H]^+$.

[0534] Step F: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8- dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[7-(3-methoxy-1-naphthyl)-2-[2-(1-piperidyl) ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (90.0 mg, 162 μmol, 1.00 eq) in DCM (2.00 mL) was added BBr_3 (405 mg, 1.62 mmol, 156 μL, 10.0 eq) at -78 °C. After stirring at 0 °C for 1 h, the mixture was quenched with saturated sodium bicarbonate solution at -78°C and stirred at 0 °C for 0.5 h. The mixture was extracted with ethyl acetate (3 × 20.0 mL), washed with brine (1 × 40.0 mL),

dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by preparative HPLC (Phenomenex Gemini 150*25mm*, 10 μ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%,10 min) to give 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8- dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (6.19 mg, 10.8 μmol, 6.71 % yield, 95 % purity) as a yellow oil. **ESI** MS m/z 543.2 $[M+H]^+$.

EXAMPLE 53



1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one

[0535] Step A: 1-tert-butyl 3-methyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate :A mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5H-pyrido[3,4-d] pyrimidine (3.00 g, 10.2 mmol, 1.00 eq), 1-tert-butyl-3-methyl piperazine-1,3-dicarboxylate (2.62 g, 10.7 mmol, 1.05 eq), DIEA (3.30 g, 25.5 mmol, 4.45 mL, 2.50 eq) in DMSO (50.0 mL) was degassed and purged with nitrogen 3 times. The mixture was stirred at 100 °C for 12 hours under a nitrogen atmosphere. The reaction mixture was diluted with DCM (200 mL), washed with brine (3 × 50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 10:1 to 3:1) to give 1-tert-butyl 3-methyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (2.10 g, 3.81 mmol, 37.4 % yield, 91.0 % purity) as a yellow oil. **ESI** MS m/z 502.1 $[M+H]^+$.

[0536] Step B: 1-tert-butyl 3-methyl4-(7-benzyl-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate :A mixture of 1-tert-butyl 3-methyl 4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (2.10 g, 4.17 mmol, 1.00 eq), 2-(dimethylamino)ethanol (929 mg, 10.4 mmol, 1.04 mL, 2.50 eq), $Pd(OAc)_2$ (140 mg, 625 μmol, 0.15 eq), BINAP (519 mg, 833 μmol, 0.20 eq) and Cs_2CO_3 (3.39 g, 10.4 mmol, 2.50 eq) in toluene (60.0 mL) was degassed and purged with nitrogen for 3 times. The mixture was stirred at 110 °C for 3 hours under a nitrogen atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 30:1 to 10:1) to give 1-tert-butyl 3-methyl4-(7-benzyl-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (1.30 g, 1.67 mmol, 40.0 % yield, 71.4 % purity) as a yellow solid. **ESI** MS m/z 555.3 $[M+H]^+$.

[0537] Step C: 1-tert-butyl 3-methyl 4-(2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1,3-dicarboxylate :To a solution of 1-tert-butyl 3-methyl 4-(7-benzyl-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (1.30 g, 2.34 mmol, 1.00 eq) in MeOH (15.0 mL) was added Pd/C (300 mg) under N_2. The suspension was degassed under vacuum and purged with hydrogen several times. The mixture was stirred under hydrogen (50 psi) at 45 °C for 48 hours. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to give 1-tert-butyl 3-methyl 4-(2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1,3-dicarboxylate (780 mg, crude) as a colorless oil, which was used directly in the next step without further purification.

[0538] Step D: 1-tert-butyl 3-methyl 4-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate: A mixture of 1-tert-butyl 3-methyl 4-(2-(2-(dimethylamino)ethoxy)- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (780 mg, crude), 3-benzyloxy-1-bromo-naphthalene (684 mg, 2.18 mmol), Pd2(dba)3 (231 mg, 252 μmol), Cs_2CO_3 (1.37 g, 4.20 mmol) and 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl (RuPhos) (157 mg, 336 μmol) in dioxane (20.0 mL) was degassed and purged with nitrogen 3 times. The mixture was stirred at 85 °C for 5 hours under a nitrogen atmosphere. The reaction mixture was

filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 10:1 to 5:1) to give 1-tert-butyl 3-methyl 4-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2- (dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (750 mg, 1.02 mmol, two steps 43.6 % yield, 95.0 % purity) as a yellow solid. ^{1}H NMR (400 MHz, chloroform-d) δ = 8.10 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.58 - 7.31 (m, 8H), 7.00 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 2.0 Hz, 1H), 5.18 (s, 2H), 4.75 (br s, 1H), 4.45 (br d, J = 13.2 Hz, 1H), 4.42 - 4.34 (m, 1H), 4.34 - 4.28 (m, 1H), 4.15 (br s., 2H), 4.13 - 3.91 (m, 1H), 3.85 - 3.70 (m, 5H), 3.49 - 3.33 (m, 2H), 3.31 - 3.07 (m, 2H), 2.99 (br s, 1H), 2.83 - 2.68 (m, 3H), 2.35(s, 6H), 1.48 (s, 9H).

[0539] Step E: methyl 1-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate: To a solution of 1-tert-butyl 3-methyl 4-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1,3-dicarboxylate (200 mg, 287 μmol, 1.00 eq) in DCM (5.00 mL) was added TFA (770 mg, 6.75 mmol, 500 μL, 23.5 eq) at 0 °C. The mixture was stirred at 25 °C for 2 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to dryness. The residue was dissolved in DCM (100 mL) and water (50 mL) and the solution was adjusted to pH 8 with saturated Na_2CO_3 aqueous and then extracted with DCM (3 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give methyl 1-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate (171 mg, 263 μmol, 91.6 % yield, 91.7 % purity) as a yellow solid. **ESI** MS m/z 597.2 $[M+H]^+$.

[0540] Step F: (1-(7-(3-(benzyloxy) naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)methanol: To a mixture of methyl 1-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2- (dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate (171 mg, 287 μmol, 1.00 eq) in THF (5.00 mL) was added $LiAlH_4$ (65.3 mg, 1.72 mmol, 6.00 eq) at 0 °C. After stirring for 2 hours at 25 °C, the reaction mixture was quenched by addition of water (30 mL) at 0 °C, and extracted with DCM (3 × 30 mL). The combined organic layers were washed with brine (3 × 30 mL). The collected organic phase was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give

(1-(7-(3-(benzyloxy) naphthalen-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)methanol (160 mg, 281 μmol, 98.2 % yield, 100 % purity) as a colorless semisolid. **ESI** MS m/z 569.2 $[M+H]^+$.


[0541] Step G: 2-((7-(3-(benzyloxy)naphthalen-1-yl)-4-(2-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylethanamine: To a mixture of (1-(7-(3-(benzyloxy)naphthalen-1-yl)-2-(2-(dimethyl amino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)methanol (160 mg, 281 μmol, 1.00 eq) in THF (5.00 mL) was added NaH (94.0 mg, 2.35 mmol, 60.0 % purity, 8.00 eq) at 0 °C. After stirring for 30 minutes, tert-butyldimethylsilyl chloride (133 mg, 881 μmol, 108 μL, 3.00 eq) was added dropwise. The mixture was stirred at 25 °C for 6 hours under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give 2-((7-(3-(benzyloxy)naphthalen-1-yl)-4-(2-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylethanamine (133 mg, 165 μmol, 56.1 % yield, 84.6 % purity) as a slight yellow solid, which was used directly in the next step without further purification. **ESI** MS m/z 683.2 $[M+H]^+$.

[0542] Step H: 1-(4-(7-(3-(benzyloxy) naphthalene-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-1-yl)prop-2-en-1-one: 1 To a solution of 2-((7-(3-(benzyloxy)naphthalen-1-yl)-4-(2-(((tert-butyl dimethylsilyl)oxy)methyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylethanamine (133 mg, 165 μmol, 1.00 eq) and TEA (39.4 mg, 389 μmol, 54.0 μL, 2.00 eq) in DCM (3.00 mL) was added prop-2-enoyl prop-2-enoate (31.9 mg, 253 μmol, 1.30 eq) at - 40 °C. After stirring at -40 °C for 2 hours, the reaction mixture was quenched with MeOH (1 M) and concentrated under reduced pressure to give 1-(4-(7-(3-(benzyloxy) naphthalene-1-yl)-2-(2-(dimethylamino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-1-yl)prop-2-en-1-one (140 mg, crude) as a yellow solid. **ESI** MS m/z 737.2 $[M+H]^+$.

[0543] Step I: 1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropy rido[3,4-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one: To a solution of 1-(4-(7-(3-(benzyloxy)naphthalen-1-yl) -2-(2-(dimethylamino)ethoxy)-5,6,7,8-

tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(((tert-butyldimethylsilyl)oxy)methyl)piperazin-1-yl)prop-2-en-1-one (140 mg, crude) in DCM (5.00 mL) was added BBr_3 (476 mg, 1.90 mmol, 183 μL) at -40 °C. After stirring for 2 hours at -40 °C under a nitrogen atmosphere, the mixture was concentrated under reduced pressure to dryness. Water (0.5 mL) and MeOH (2.5 mL) were added and the resulting solution was purified by preparative HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (10 mM NH_4HCO_3) - ACN]; B %: 27 % - 57 %, 11 min). The desired fractions were collected and lyophilized to give 1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(hydroxymethyl)piperazin-1-yl)prop-2-en-1-one (4.32 mg, 7.94 μmol, 4.18 % yield, 97.9 % purity) as a white solid. **ESI** MS m/z 533.4 $[M+H]^+$.

EXAMPLE 54



1-[4-[7-(3-amino-1-isoquinolyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one

[0544] Step A: tert-butyl 4-hydroxy-6,8-dihydro-5H-pyrido [3,4-d]pyrimidine-7-carboxylate: To a solution of Na (4.24 g, 184 mmol, 4.37 mL, 2.50 eq) in EtOH (400 mL) was added 1-tert-butyl 4-ethyl 3-oxopiperidine-1,4-dicarboxylate (20.0 g, 73.7 mmol, 1.00 eq) and acetic acid methanimidamide (11.5 g, 111 mmol, 1.50 eq) under N_2. The mixture was stirred at 70 °C for 5 hours. The reaction mixture was adjusted to pH 7 with HCl (1N), extracted with DCM (3 × 200 mL), washed with brine (1 × 400 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give tert-butyl 4-hydroxy-6,8-dihydro-5H-pyrido [3,4-d]pyrimidine-7-carboxylate (16.0 g, 63.7 mmol, 86.4 % yield) as a brown solid. **ESI** MS m/z 274.0 $[M+H]^+$.

[0545] Step B: *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidine-7-carboxylate: To a solution of *tert*-butyl 4-hydroxy-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidine-7-carboxylate (16.0 g, 63.7 mmol, 1.00 eq) in DMF (4.00 mL) was added DBU (29.1 g, 191 mmol, 28.8 mL, 3.00 eq) and benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PYBOP) (39.8 g, 76.4 mmol, 1.20 eq). The mixture was stirred at 25 °C for 1 hour. Benzyl piperazine-1-carboxylate (21.0 g, 95.5 mmol, 18.5 mL, 1.50 eq) was added and the reaction mixture was stirred at 25 °C for 16 hours. The mixture was diluted with ethyl acetate (500 mL) and washed with water (3 × 400 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, diethyl ether/ethyl acetate = 1:1) to give *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidine-7-carboxylate (2.00 g, 4.41 mmol, 6.93 % yield) as a yellow oil. **ESI** MS m/z 454.3 $[M+H]^+$.

[0546] Step C: A mixture of *tert*-butyl 4-(4-benzyloxycarbonylpiperazin-1-yl)- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (1.20 g, 2.65 mmol, 1.00 eq) and TFA (4.53 g, 39.7 mmol, 2.94 mL, 15.0 eq) in DCM (2.00 mL) was stirred at 25 °C for 1 hour. The mixture was concentrated under vacuum. The concentrated material was adjusted to pH 8 with saturated aq. $NaHCO_3$, then extracted with ethyl acetate (3 × 30.0 mL), washed with brine (1 × 100 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d] pyrimidin-4-yl)piperazine-1-carboxylate (800 mg, 2.26 mmol, 85.4 % yield) as a yellow oil. **ESI** MS m/z 354.3 $[M+H]^+$.


[0547] Step D: benzyl 4-[7-[3-(tert-butoxycarbonylamino)-1-isoquinolyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of *tert*-butyl *N*-(1-bromo-3-isoquinolyl)carbamate (330 mg, 1.02 mmol, 1.00 eq), DIEA (264 mg, 2.04 mmol, 357 µL, 2.00 eq) and benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (541 mg, 1.53 mmol, 1.50 eq) in DMSO (3.00 mL) was stirred at 80 °C for 10 hours. The mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (3 × 20 mL). The combined extracts were dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by reverse-phase column (TFA, 0.1 %) to give benzyl 4-[7-[3-(tert-butoxycarbonylamino)-1-isoquinolyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 665 µmol, 65.2 % yield) as a yellow solid. **ESI** MS m/z 596.3 $[M+H]^+$.

[0548] Step E: *tert*-butyl *N*-[1-(4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl) -3-isoquinolyl]carbamate: A mixture of benzyl 4-[7-[3-(tert-butoxycarbonylamino)-1-isoquinolyl]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 403 μmol, 1.00 eq), KOH (36.2 mg, 645 μmol, 1.60 eq) in H_2O (2.40 mL) and n-butyl alcohol (2.40 mL) was stirred at 100 °C for 12 hours. The mixture was diluted with ethyl acetate (3 × 5.00 mL), washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl *N*-[1-(4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl) -3-isoquinolyl]carbamate (150 mg, 325 μmol, 80.7 % yield) as a yellow oil. **ESI** MS m/z 462.3 $[M+H]^+$.

[0549] Step F: 1-(4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl)isoquinolin-3-amine trifluoroacetate: A solution of *tert*-butyl N-[1-(4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl)-3-isoquinolyl]carbamate (150 mg, 325 μmol, 1.00 eq) and TFA (556 mg, 4.87 mmol, 361 μL, 15.0 eq) in DCM (360 μL) was stirred at 25 °C for 1 hours. The mixture was concentrated under vacuum to give 1-(4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl)isoquinolin-3-amine trifluoroacetate (154.52 mg, crude) as a yellow solid which was used into next step without further purification.

[0550] Step G: 1-[4-[7-(3-amino-1-isoquinolyl)-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-(4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-d] pyrimidin-7-yl)isoquinolin-3-amine trifluoroacetate (150 mg, crude) and Et_3N (319 mg, 3.15 mmol, 437 μL) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (31.8 mg, 252 μmol) at -40 °C, then stirred at -40 °C for 0.5 h. The mixture was quenched by adding MeOH (20.22 mg, 630.96 μmol) and concentrated under vacuum. The residue was purified by preparative HPLC (Phenomenex Gemini 150*25mm*, 10 μ; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 26%-56%,10 min) to give 1-[4-[7-(3-amino-1-isoquinolyl)-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (35.4 mg, 82.5 μmol, 26.2 % yield, 96.8 % purity) as a yellow solid. **ESI** MS m/z 416.3 $[M+H]^+$.


EXAMPLE 55



1-(4-(2-(2-(dimethylamino)-3-hydroxypropoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0551] Synthesized according to the method of **Example 8**, using 2-(dimethylamino)propane-1,3-diol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 533.3$[M+H]^+$.


EXAMPLE 56



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-morpholinopropan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0552] Synthesized according to the method of **Example 8**, using (R)-1-morpholinopropan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 559.3 $[M+H]^+$.


EXAMPLE 57



(S)-5-(((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-2-one

[0553] Synthesized according to the method of **Example 8**, using (S)-5-(hydroxymethyl)pyrrolidin-2-one in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 58



(R)-5-(((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-2-one

[0554] Synthesized according to the method of **Example 8**, using (R)-5-(hydroxymethyl)pyrrolidin-2-one in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.2 $[M+H]^+$.


EXAMPLE 59



N-(2-((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)ethyl)acetamide

[0555] Synthesized according to the method of **Example 8**, using N-(2-hydroxyethyl)acetamide in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 60



(R)-1-(4-(2-((1-(dimethylamino)butan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0556] Synthesized according to the method of **Example 8**, using (R)-1-(dimethylamino)butan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 545.3 $[M+H]^+$.


EXAMPLE 61



(S)-6-(((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)piperidin-2-one

[0557] Synthesized according to the method of **Example 8**, using 6-(hydroxymethyl)piperidin-2-one in place of (S)-1-(dimethylamino)propan-2-ol in Step B and the product was separated by chiral chromatography. Peak 2 was given the (S) stereochemistry and this was not confirmed. ES+APCI MS m/z 543.3 $[M+H]^+$.


EXAMPLE 62



(R)-6-(((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)piperidin-2-one

[0558] Synthesized according to the method of **Example 8**, using 6-(hydroxymethyl)piperidin-2-one in place of (S)-1-(dimethylamino)propan-2-ol in Step B and separated by chiral chromatography. Peak 1 was assigned the (R) stereochemistry but this stereochemistry was not confirmed. ES+APCI MS m/z 543.2 $[M+H]^+$.


EXAMPLE 63



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(((R)-1-((R)-3-methoxypyrrolidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0559] Synthesized according to the method of **Example 8**, using (R)-1-((R)-3-methoxypyrrolidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 64



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(((R)-1-((S)-3-methoxypyrrolidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0560] Synthesized according to the method of **Example 8**, using (R)-1-((S)-3-methoxypyrrolidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 65



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(((R)-1-((S)-3-hydroxypyrrolidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0561] Synthesized according to the method of **Example 8**, using (R)-1-((S)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 559.3 $[M+H]^+$.


EXAMPLE 66



(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-3-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0562] Synthesized according to the method of **Example 8**, using (S)-1-methylpiperidin-3-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 67



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-3-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0563] Synthesized according to the method of **Example 8**, using (R)-1-methylpiperidin-3-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 68



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0564] Synthesized according to the method of **Example 8**, using 1-iodonaphthalene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 501.3 $[M+H]^+$.


EXAMPLE 69



1-(4-(7-(isoquinolin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0565] Synthesized according to the method of **Example 1**, using 4-bromoisoquinoline in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 401.2 $[M+H]^+$.


EXAMPLE 70



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(methylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0566] Synthesized according to the method of **Example 8**, using 1-(methylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 503.3 $[M+H]^+$.


EXAMPLE 71



1-(4-(7-(2-hydroxy-1-phenylethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0567] Synthesized according to the method of **Example 1**, using 2-((tert-butyldimethylsilyl)oxy)-1-phenylethyl methanesulfonate in place of 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 394.2 $[M+H]^+$.


EXAMPLE 72



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0568] Synthesized according to the method of **Example 8**, using (1-methylpiperidin-3-yl)methanol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 543.3 $[M+H]^+$.


EXAMPLE 73



1-(4-(2-(2-(dimethylamino)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0569] Synthesized according to the method of **Example 8**, using 2-(dimethylamino)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.2 $[M+H]^+$.


EXAMPLE 74



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0570] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 559.3 $[M+H]^+$.


EXAMPLE 75



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(piperidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0571] Synthesized according to the method of **Example 8**, using (R)-1-(piperidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.3 $[M+H]^+$.


EXAMPLE 76



(R)-1-(4-(7-(3-chloro-5-hydroxy-2-isopropylphenyl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0572] Synthesized according to the method of **Example 8**, using 1-bromo-3-chloro-2-isopropyl-5-(methoxymethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 545.3 $[M+H]^+$.


EXAMPLE 77



1-(4-(2-(2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0573] Synthesized according to the method of **Example 8**, using 2-((1S,4R)-2-azabicyclo[2.2.1]heptan-2-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 555.2 $[M+H]^+$.


EXAMPLE 78



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(5-hydroxy-2-(trifluoromethoxy)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0574] Synthesized according to the method of **Example 8**, using 2-bromo-4-(methoxymethoxy)-1-(trifluoromethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 551.2 $[M+H]^+$.


EXAMPLE 79



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(5-hydroxy-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0575] Synthesized according to the method of **Example 8**, using 2-bromo-4-(methoxymethoxy)-1-(trifluoromethyl)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 535.2 $[M+H]^+$.


EXAMPLE 80



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-methylpiperazin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0576] Synthesized according to the method of **Example 8**, using (4-methylpiperazin-2-yl)methanol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 544.3 $[M+H]^+$.


EXAMPLE 81



1-(2-((4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)ethyl)piperidine-4-carbonitrile

[0577] Synthesized according to the method of **Example 8**, using 1-(2-hydroxyethyl)piperidine-4-carbonitrile in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 568.2 $[M+H]^+$.


EXAMPLE 82



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-(4-methylpiperazin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0578] Synthesized according to the method of **Example 8**, 3-(4-methylpiperazin-1-yl)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 572.4 $[M+H]^+$.


EXAMPLE 83



1-(4-(2-(2-((2-hydroxyethyl)(methyl)amino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0579] Synthesized according to the method of **Example 8**, using 2-((2-((tert-butyldimethylsilyl)oxy)ethyl)(methyl)amino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 533.3 $[M+H]^+$.


EXAMPLE 84



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(2-fluoro-6-hydroxy-3-methylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0580] Synthesized according to the method of **Example 8**, using 2-bromo-3-fluoro-1-(methoxymethoxy)-4-methylbenzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 499.3 $[M+H]^+$.


EXAMPLE 85



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(pyrrolidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0581] Synthesized according to the method of **Example 8**, using 2-(pyrrolidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.2 $[M+H]^+$.


EXAMPLE 86



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(2-hydroxy-5-(trifluoromethoxy)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0582] Synthesized according to the method of **Example 8**, using 2-bromo-1-(methoxymethoxy)-4-(trifluoromethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 551.2 $[M+H]^+$.


EXAMPLE 87



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-fluoro-2-hydroxy-6-methylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0583] Synthesized according to the method of **Example 8**, using 2-bromo-4-fluoro-3-(methoxymethoxy)-1-methylbenzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 499.2 $[M+H]^+$.


EXAMPLE 88



(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(2-methylpiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0584] Synthesized according to the method of **Example 8**, using (S)-2-(2-methylpiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.2 $[M+H]^+$.


EXAMPLE 89



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0585] Synthesized according to the method of **Example 8**, using (1-methylpyrrolidin-3-yl)methanol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 90



1-(4-(7-(5-hydroxy-2-(trifluoromethoxy)phenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0586] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, and using 2-bromo-4-(methoxymethoxy)-1-(trifluoromethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 593.2 $[M+H]^+$.


EXAMPLE 91



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxy-5-(trifluoromethoxy)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0587] Synthesized according to the method of **Example 8**, using 3-bromo-1-(methoxymethoxy)-5-(trifluoromethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 551.2 $[M+H]^+$.


EXAMPLE 92



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(4-methylpiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0588] Synthesized according to the method of **Example 8**, using 2-(4-methylpiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.2 $[M+H]^+$.


EXAMPLE 93



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-morpholinobutan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0589] Synthesized according to the method of **Example 8**, using 4-morpholinobutan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 94



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(5-hydroxy-2-methoxyphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0590] Synthesized according to the method of **Example 8**, using 3-bromo-1-(methoxymethoxy)-4-methoxybenzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 497.2 $[M+H]^+$.


EXAMPLE 95



(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(2-hydroxy-6-methylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0591] Synthesized according to the method of **Example 8**, using 2-bromo-1-(methoxymethoxy)-3-methylbenzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 481.2 $[M+H]^+$.


EXAMPLE 96



1-(4-(7-(5-hydroxy-2-isopropoxyphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0592] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, and using 2-bromo-4-(methoxymethoxy)-1-(isopropoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 567.2 $[M+H]^+$.


EXAMPLE 97



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(2-methylpiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0593] Synthesized according to the method of **Example 8**, using (R)-2-(2-methylpiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.3


EXAMPLE 98



(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(3-methoxypiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0594] Synthesized according to the method of **Example 8**, using (S)-2-(3-methoxypiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.3 $[M+H]^+$.


EXAMPLE 99



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(3-methoxypiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0595] Synthesized according to the method of **Example 8**, using (R)-2-(3-methoxypiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 557.3 $[M+H]^+$.


EXAMPLE 100



1-(4-(2-((1-cyclopropylpiperidin-4-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0596] Synthesized according to the method of **Example 8**, using (1-cyclopropylpiperidin-4-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 555.3 $[M+H]^+$.


EXAMPLE 101



1-(4-(2-(3-(1,4-oxazepan-4-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0597] Synthesized according to the method of **Example 8**, using (3-(1,4-oxazepan-4-yl)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 102



1-(4-(2-(3-(1,4-oxazepan-4-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0598] Synthesized according to the method of **Example 8**, using 2-(diethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 531.3 $[M+H]^+$.


EXAMPLE 103



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(2-methoxyethyl)pyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0599] Synthesized according to the method of **Example 8**, (1-(2-methoxyethyl)pyrrolidin-3-yl)methanol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 104



1-(4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0600] Synthesized according to the method of **Example 8**, using 3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 571.3 $[M+H]^+$.


EXAMPLE 105



1-(4-(7-(5-hydroxy-2-methylphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0601] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, and using 2-bromo-4-(methoxymethoxy)-1-methylbenzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 523.3 $[M+H]^+$.


EXAMPLE 106



1-(4-(7-(4-hydroxy-2-(trifluoromethoxy)phenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0602] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, and using 2-bromo-5-(methoxymethoxy)-1-(trifluoromethoxy)benzene in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 593.2 $[M+H]^+$.


EXAMPLE 107



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-((2-methoxyethyl)(methyl)amino)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0603] Synthesized according to the method of **Example 8**, using 2-((2-methoxyethyl)(methyl)amino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 547.3 $[M+H]^+$.

EXAMPLE 108




1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(4-methoxypiperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0604] Synthesized according to the method of **Example 8**, using 2-(4-methoxypiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.

EXAMPLE 109


SUBSTITUTE SHEET (RULE 26)



1-(4-(2-(2-(4,4-difluoropiperidin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0605] Synthesized according to the method of **Example 8**, using 2-(4,4-difluoropiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 579.2 $[M+H]^+$.


EXAMPLE 110



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0606] Synthesized according to the method of **Example 8**, using (R)-(1-methylpyrrolidin-3-yl)methanol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 529.3 $[M+H]^+$.


EXAMPLE 111



(S)-1-(4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0607] Synthesized according to the method of **Example 8**, using (S)-2-(3-fluoropiperidin-1-yl)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 561.3 $[M+H]^+$.


EXAMPLE 112



1-(4-(7-(3-(difluoromethyl)naphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0608] Synthesized according to the method of **Example 8**, using 3-morpholinopropan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B, and using 1-bromo-3-(difluoromethyl)naphthalene (0.129 g, 0.503 mmol) in place of (3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step D. ES+APCI MS m/z 593.2 $[M+H]^+$.

EXAMPLE 113



4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one

[0609] Step A: tert-butyl 4-(6-fluoropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of 4-chloro-6-fluoropyrido[3,4-d]pyrimidine (1.07 g, 5.83 mmol) in DCM (20 mL) was added N-ethyl-N-isopropylpropan-2-amine (2.09 mL, 11.7 mmol) followed by tert-butyl piperazine-1-carboxylate (1.19 g, 6.41 mmol) and the reaction stirred at room temperature for 2 hours. The reaction mixture was washed with brine, dried over $MgSO_4$ and concentrated *in vacuo* to provide tert-butyl 4-(6-fluoropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate, which was used directly in the next step (1.8 g, 92.6%) **ES+APCI MS** m/z 334.1 $[M+H]^+$.

[0610] Step B: tert-butyl 4-(6-(benzyloxy)pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of phenylmethanol (0.65 g, 6.0 mmol) in DMA (10 mL) was added sodium hydride (0.24 g, 6.0 mmol) in portions while degassing with nitrogen and the reaction mixture was stirred for 30 minutes at room temperature. To the reaction was added tert-butyl 4-(6-fluoropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.0 g, 3.0 mmol) as a solid and the reaction mixture was stirred at room temperature for 3 hours. The reaction was poured into water (300 mL) and the aqueous layer extracted with ethyl acetate. The organic layer was washed with brine, dried over $MgSO_4$ and concentrated *in vacuo*. The crude material was chromatographed using a gradient of 0 to 100% ethyl acetate/DCM as the eluent to give tert-butyl 4-(6-(benzyloxy)pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.4 g, 0.95 mmol, 32 % yield). **ES+APCI MS** m/z 422.2 $[M+H]^+$.

[0611] Step C: tert-butyl 4-(6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of tert-butyl 4-(6-(benzyloxy)pyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.40 g, 0.95 mmol) in 95% ethanol (30 mL) purged with nitrogen

was added Pd/C (0.10 g, 0.95 mmol). The reaction was evacuated with vacuum and backfilled with hydrogen three times. After the third backfill the reaction mixture was stirred at room temperature for 4 hours. The reaction was again degassed with nitrogen, the slurry filtered through Celite® and the filtrate was concentrated in vacuo to give tert-butyl 4-(6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.4g, 126%). ES+APCI MS m/z 334.4 $[M+H]^+$.


[0612] Step D: tert-butyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of tert-butyl 4-(6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.28 g, 0.84 mmol) in dioxanes (4 mL) in a sealed tube was added potassium phosphate (0.36 g, 1.7 mmol), N1,N2-dimethylethane-1,2-diamine (0.074 g, 0.84 mmol) and 1-iodo-3-(methoxymethoxy)naphthalene (0.53 g, 1.7 mmol). The reaction sparged with argon for 20 minutes, followed by addition of copper(I) iodide (0.16 g, 0.84 mmol). The reaction vessel sealed and heated to 100 °C overnight. The reaction was diluted with water and the aqueous layer extracted with ethyl acetate (2 x 150 mL). The organics were washed with brine, dried over $MgSO_4$ and concentrated in vacuo. The material was chromatographed using a gradient of 0 to 100% ethyl acetate/DCM as the eluent to give tert-butyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.30 g, 0.58 mmol, 69 % yield) ES+APCI MS m/z 520.2 $[M+H]^+$.

[0613] Step E: 7-(3-hydroxynaphthalen-1-yl)-4-(piperazin-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one: To a solution of tert-butyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-6-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.30 g, 0.58 mmol) in methanol (10 mL) was added aqueous hydrogen chloride (0.38 mL, 2.3 mmol) and the reaction stirred over night at 50°C. The reaction was concentrated in vacuo to give 7-(3-hydroxynaphthalen-1-yl)-4-(piperazin-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one as the bis HCl salt (0.26g, 100%). ES+APCI MS m/z 376.1 $[M+H]^+$.

[0614] Step F: 4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one: To a slurry of 7-(3-hydroxynaphthalen-1-yl)-4-(piperazin-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one dihydrochloride (0.26 g, 0.58 mmol) in a 1:1 solution of DCM/acetonitrile (10 mL) was added N-ethyl-N-isopropylpropan-2-

amine (0.45 g, 3.5 mmol) and acryloyl chloride (0.052 g, 0.58 mmol) and the reaction stirred at room temperature for 1 hour. The reaction was concentrated *in vacuo* and the material purified by reverse preparative HPLC (using a gradient of 5 to 95% ACN/water) to give 4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one (0.038 g, 0.088 mmol, 15 % yield). ES+APCI MS m/z 430.2 $[M+H]^+$.


EXAMPLE 114



4-(6-acryloyl-2,6-diazaspiro[3.3]heptan-2-yl)-7-(3-hydroxynaphthalen-1-yl)-7,8-dihydropyrido[3,4-d]pyrimidin-6(5H)-one

[0615] Synthesized according to the method of **Example 8**, using tert-butyl 2,6-diazaspiro[3.3]heptane-2-carboxylate hydrochloride (305 mg, 1.54 mmol) in place of tert-butyl piperazine-1-carboxylate (1.19 g, 6.41 mmol) in Step B. ES+APCI MS m/z 442.2 $[M+H]^+$

EXAMPLE 115




1-((S)-4-(2-(((R)-1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one

SUBSTITUTE SHEET (RULE 26)

[0616] Synthesized according to the method of **Example 8**, using benzyl (S)-3-methylpiperazine-1-carboxylate (1.155 g, 4.931 mmol) in place of Benzyl 1-piperazinecarboxylate in step A. ES+APCI MS m/z 531.3 $[M+H]^+$.


EXAMPLE 116



(S)-1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one

[0617] Synthesized according to the method of **Example 8**, using benzyl (S)-3-methylpiperazine-1-carboxylate (1.155 g, 4.931 mmol) in place of Benzyl 1-piperazinecarboxylate in step A. Also, using 2-(dimethylamino)ethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 517.3 $[M+H]^+$.


EXAMPLE 117



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-morpholinoethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0618] Synthesized according to the method of **Example 8**, using 2-morpholinoethan-1-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 545.2 $[M+H]^+$.


EXAMPLE 118



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-morpholino-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0619] Synthesized according to the method of **Example 8**, using morpholine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 501.3 $[M+H]^+$.


EXAMPLE 119



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(pyrrolidin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0620] Synthesized according to the method of **Example 8**, using pyrrolidine in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 485.2 $[M+H]^+$.


EXAMPLE 120



(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(pyrrolidin-1-yl)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0621] Synthesized according to the method of **Example 8**, using (R)-1-(pyrrolidin-1-yl)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 543.4 $[M+H]^+$.

EXAMPLE 121



4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one

[0622] Step A: Tert-butyl 2,4-dichloro-8-oxo-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. To a round bottom flask was added tert-Butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (1.0 g, 3.29 mmol) and EtOAc (16.4 mL). A solution of sodium periodate (2.11 g, 9.86 mmol) in water (16.4 mL) was added. Ruthenium (III) chloride (0.102 g, 0.493 mmol) was added and the mixture was stirred loosely capped and vigorously stirred for 6 h at ambient temperature. The mixture was partitioned between water and EtOAc and the layers were separated. The aqueous layer was extracted further with EtOAc (2 x 20 mL) and the combined extracts were washed with brine and dried over Na_2SO_4, filtered and

concentrated. The crude product was purified via column chromatography (10-30% EtOAc/hexanes, loading with CH_2Cl_2) to afford 0.864 g (82%) of the product as an off-white solid.

[0623] Step B: Tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-8-oxo-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. To a solution of tert-butyl 2,4-dichloro-8-oxo-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.400 g, 1.26 mmol) in CH_2Cl_2 (5.0 mL) was added N,N-Diisopropylethylamine (0.325 g, 2.51 mmol) followed by benzyl 1-piperazinecarboxylate (0.255 mL, 1.32 mmol) and the reaction stirred at ambient temperature for 1.5 h. The reaction mixture was diluted with CH_2Cl_2 (10 mL) and washed with a 0.5M $KHSO_4$ solution (5 mL), followed by a saturated aqueous $NaHCO_3$ solution and brine. The organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product was sonicated in 10 mL MTBE and the resulting solid was isolated by vacuum filtration. The solid was dried in vacuo to provide 0.507 g (80%) of the desired product as an off-white solid which was used directly in the next step. ES+APCI MS m/z 502.1$[M+H]^+$.

[0624] Step C: Benzyl 4-(2-chloro-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. A solution of tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-8-oxo-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.255 g, 0.5080 mmol) in CH_2Cl_2 (1.0 mL) was cooled to 0 °C. Trifluoroacetic acid (0.3890 mL, 5.080 mmol) was added and the mixture was warmed to ambient temperature. After 1 hour the mixture was diluted with CH_2Cl_2 and added to a mixture brine (10 mL) and 3.0 M aqueous NaOH (1.7 mL, 5.080 mmol). The layers were combined and adjusted to pH 8 with saturated aqueous $NaHCO_3$ solution. The layers were separated and the aqueous phase was extracted with 2×10 mL of CH_2Cl_2. The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The title compound (0.223 g, quant.) was obtained as a yellow/orange foam. ES+APCI MS m/z 402.1$[M+H]^+$.

[0625] Step D: Benzyl 4-(2-(3-morpholinopropoxy)-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. To a vial was added N-Hydroxypropanylmorpholine (0.687 g, 4.73 mmol) and benzyl 4-(2-chloro-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.190 g, 0.473 mmol) followed by dioxane (1.6 mL). Cesium carbonate (0.462 g, 1.42 mmol) was added and the mixture was stirred at 65 °C for 15 hours.

The mixture was diluted with $CHCl_3$ and filtered, and the solid was washed with additional $CHCl_3$. The filtrate was concentrated in vacuo and was purified by column chromatography (2-10% MeOH/DCM with 1% NH_4OH) to afford 0.061 g (25%) of the desired product as a thick, colorless oil. ES+APCI MS m/z 511.2$[M+H]^+$.

[0626] Step E: Benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. To a vial was added benzyl 4-(2-(3-morpholinopropoxy)-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.060 g, 0.12 mmol), N,N'-Dimethylethylenediamine (0.010 g, 0.12 mmol) and 1-iodo-3-(methoxymethoxy)naphthalene (0.074 g, 0.24 mmol) followed by dioxane (0.78 mL) and Potassium phosphate tribasic (0.050 g, 0.24 mmol). The reaction was purged with bubbling Ar for 10 min, then Copper (I) Iodide (0.022 g, 0.12 mmol) was added and the vial was sealed. The mixture was heated to 110 °C and stirred for 16 hours. The mixture was cooled to ambient temperature, diluted with water and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried over Na_2SO_4, filtered and concentrated. The mixture was purified via column chromatography (2-8% MeOH/DCM) to afford 0.062 g (76%) of the product as a tan foam. ES+APCI MS m/z 697.3$[M+H]^+$.


[0627] Step F: 7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-4-(piperazin-1-yl)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one. To a solution of benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-8-oxo-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.062 g, 0.089 mmol) in EtOH (0.44 mL) and THF (0.44 mL) was added Palladium on Carbon (0.038 g, 0.018 mmol) (Degussa Type, 10 wt%, 50% H_2O) and then an atmosphere of hydrogen was introduced via vacuum followed by balloon pressure. The mixture was stirred at ambient temperature for 1.5 h, then warmed to 45 °C and stirred for 1 hour. The mixture was diluted with EtOAc and filtered through a nylon filter. The filtrate was concentrated in vacuo providing a light tan foam (0.052g) that was dried overnight and resubmitted to the same reaction conditions above. After stirring at ambient temperature for 5 h additional Pd/C (0.050 g) was added and the reaction was stirred at ambient temperature for another 2 h. The mixture was diluted with EtOAc and filtered through a nylon filter. The solid was washed with EtOAc and MeOH and the filtrate was

concentrated in vacuo providing 0.029 g (58%) of the desired product as a light tan foam. ES+APCI MS m/z 563.3$[M+H]^+$.


[0628] Step G: 4-(4-acryloylpiperazin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one. To a solution of 7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-4-(piperazin-1-yl)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one (0.028 g, 0.050 mmol) in CH_2Cl_2 (0.50 mL) at -78 °C was added Triethylamine (0.014 mL, 0.100 mmol). Acryloyl chloride (0.55 mL, 0.055 mmol, freshly prepared 0.1M CH_2Cl_2) was added and the reaction was then stirred for 0.5 h. The mixture was diluted with $CHCl_3$ and a saturated aqueous NH_4Cl solution was added. The layers were separated and the aqueous layer was extracted with $CHCl_3$ (2 x 10 mL). The combined extracts were dried over Na_2SO_4, filtered and concentrated. The crude product was purified via column chromatography (4-6% MeOH/DCM) to afford 0.018 g (59%) to provide the title compound as a solid off-white foam. ES+APCI MS m/z 617.3$[M+H]^+$.

[0629] Step H: 4-(4-acryloylpiperazin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one. To a solution of 4-(4-acryloylpiperazin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-6,7-dihydropyrido[3,4-d]pyrimidin-8(5H)-one (0.018 g, 0.0292 mmol) in 1/1 MeOH/THF (0.6 mL) was added HCl (0.0486 mL, 0.292 mmol, 6 N Aqueous). The mixture was stirred at 35 °C for 7 hours. The mixture was diluted with brine and adjusted to pH 8 with a saturated aqueous $NaHCO_3$ solution. The mixture was extracted with 10% IPA/$CHCl_3$ (2 x 10 mL) and $CHCl_3$ (10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The crude material was purified via column chromatography (6-10% MeOH/DCM) to afford 0.012 g (71%) of the product as an off-white solid. ES+APCI MS m/z 573.3$[M+H]^+$.

EXAMPLE 122



(R,E)-4-(dimethylamino)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one bis-trifluoroacetate




[0630] Steps A-E: (R)-2-((7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine was synthesized according to the method of Example 8, Step A through Step E, using (R)-1-(dimethylamino)propan-2-ol in place of (S)-1-(dimethylamino)propan-2-ol in Step B.

[0631] Step F: (R)-4-(2-((1-(Dimethylamino)propan-2-yl)oxy)-4-(piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol dihydrochloride: To a solution of (R)-2-((7-(3-(methoxymethoxy)naphthalen-1-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropan-1-amine (75 mg, 0.15 mmol) in DCM (2.9 mL) was added 6N HCl in iPrOH (247 µl, 1.5 mmol) and the mixture was stirred at ambient temperature for 1h. The reaction mixture was concentrated to dryness to provide (R)-4-(2-((1-(Dimethylamino)propan-2-yl)oxy)-4-(piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol dihydrochloride which was used directly in the next stop. ES+APCI MS m/z 463.2 $[M+H]^+$.

[0632] Step G: (R,E)-4-(Dimethylamino)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one bis-trifluoroacetate: A solution of (R)-4-(2-((1-(Dimethylamino)propan-2-yl)oxy)-4-(piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol dihydrochloride (7 mg, 0.01 mmol), HATU (6.2 mg, 0.02 mmol), (2E)-4-(dimethylamino)but-2-enoic acid (2.1 mg, 0.02 mmol), DIEA (6.9 µl, 0.04 mmol) in DCM (131 µl) was stirred at ambient temperature for 1h. The residue was filtered and the filtrate was loaded directly onto a Gilson C18 prep HPLC eluting with 5-95% acetonitrile / water with 0.1% TFA additive. The fractions containing the desired product were concentrated to provide (R,E)-4-(Dimethylamino)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one bis-trifluoroacetate. ES+APCI MS m/z 574.2 $[M+H]^+$.


EXAMPLE 123



1-(4-(2-(2-hydroxy-3-morpholinopropoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0633] Synthesized according to the method of Example 8, using 3-morpholinopropane-1,2-diol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 575.2 $[M+H]^+$.

EXAMPLE 124




(R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(4-fluoro-3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0634] Step A: Benzyl (R)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (221 mg, 0.345 mmol) was placed in ACN (2 mL) and the mixture was cooled to 0 °C. SelectFluor (183 mg, 0.517 mmol) was added and the reaction was stirred at room temperature for 30 minutes. Water was added and the mixture was extracted with DCM. The organic layers were combined and concentrated. The resulting residue was purified by reverse phase chromatography (5-95% ACN:water with 0.1% TFA) to provide benzyl (R)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(4-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate trifluoroacetate (48 mg, 0.0729 mmol, 21.1 % yield).

[0635] Step B: (R)-1-(4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(4-fluoro-3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following Example 33, Steps D-F substituting (R)-4-(2-((1-

(dimethylamino)propan-2-yl)oxy)-7-(4-fluoro-3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate trifluoroacetate for benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. ES+APCI MS m/z 535.2 $[M+H]^+$.

EXAMPLE 125




(R)-1-(4-(7-(4-chloro-3-hydroxynaphthalen-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[0636] Step A: Benzyl (R)-4-(2-((1-(dimethylamino)propan-2-yl)oxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (83 mg, 0.130 mmol) and NCS (21.6 mg, 0.162 mmol) were placed in ACN (2 mL) and stirred at room temperature for 3 hours. Water was added and the mixture was extracted with DCM (3x15 mL). The organic layers were combined and concentrated. The resulting residue was purified by reverse phase chromatography (5-95% ACN:water with 0.1% TFA) to provide benzyl (R)-4-(7-(4-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate trifluoroacetate (17 mg, 0.0252 mmol, 19.4 % yield).

[0637] Step B: (R)-1-(4-(7-(4-chloro-3-hydroxynaphthalen-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following Example 33, Steps D-F substituting (R)-4-(7-(4-chloro-3-(methoxymethoxy)naphthalen-1-yl)-2-((1-(dimethylamino)propan-2-yl)oxy)-5,6,7,8-

tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate trifluoroacetate for benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate and using THF as the solvent in Step D. ES+APCI MS m/z 551.2 $[M+H]^+$.

EXAMPLE 126



1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate

[0638] Step A: benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a slurry of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.20 g, 0.35 mmol) in dioxane in a microwave was added N-ethyl-N-isopropylpropan-2-amine (0.45 g, 3.5 mmol), Cs_2CO_3 (0.34 g, 1.0 mmol) and 2-(pyridin-2-yl)ethan-1-ol (0.43 g, 3.5 mmol) and the reaction heated to 15 °C for 1 hr in the microwave. The reaction was diluted with EtOAc and washed with water, brine, dried over $MgSO_4$ and concentrated in vacuo. The material was chromatographed using a gradient of 0 to 100% EtOAc/DCM as the eluent to give benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.16 g, 0.24 mmol, 70 % yield).


[0639] Step B: 4-(4-(piperazin-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol: To the solid benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.12 g, 0.18 mmol) was added MeOH (20 mL). The


solution was degassed with nitrogen 5 minutes, followed by addition of Pd/C (0.058 g, 0.54 mmol). The reaction vessel was evacuated by vacuum and backfilled with H_2. This procedure was performed three times, and after the third backfill the slurry was left to sir under an atmosphere of hydrogen for 1 hr. The reaction was again degassed with nitrogen for 5 minutes. The slurry was next filtered through Celite® and the Celite® was washed with MeOH (100 mL). The combined organic extracts were concentrated and treated with 10 mL of 1:1 TFA/DCM for 2 hrs. The reaction was again concentrated in vacuo to give 4-(4-(piperazin-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol (0.096 g, 0.20 mmol, 110 % yield).

[0640] Step C: 1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a solution of 4-(4-(piperazin-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl)naphthalen-2-ol (0.096 g, 0.20 mmol) in DCM was added Hunig's Base (0.17 mL, 0.99 mmol) and acryloyl chloride (0.018 g, 0.20 mmol) and the reaction stirred for 30 minutes at room temperature. The reaction was concentrated in vacuo and the crude material was purified by reverse preparative HPLC to give 1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(2-(pyridin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one trifluoroacetate (0.0057 g, 0.011 mmol, 5.3 % yield). **ES+APCI MS** m/z 537.2 $[M+H]^+$.


EXAMPLE 127

(S)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine






[0641] Step A: tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: To a solution of tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (8 g, 26.30 mmol) in DMA (263.0 ml, 26.30 mmol) was added benzyl piperazine-1-carboxylate (5.793 g, 26.30 mmol) and N-ethyl-N-isopropylpropan-2-amine (4.721 ml, 26.30 mmol) and the reaction stirred at room temperature for 2 hours. TLC (20% EtOAc/DCM), UV visualization, showed reaction completion. The reaction was next poured into water and extracted into DCM. The organics were next washed with water (2x), brine, dried over MgSO4 and concentrated in vacuo. The concnetrate was loaded onto a 220g RegiSep column and chromatagraphed on the CombiFlash (0%-10%, EtOAc:DCM). All fractions contiaining desired product were combined and concnetrated to give tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (9.768 g, 20.02 mmol, 76.11 % yield) as a white foam. ES+APCI MS m/z 488.2 $[M+H]^+$.




[0642] Step B: benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-(4-((benzyloxy)carbonyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (9.768 g, 20.02 mmol) was dissolved in

dichloromethane (200.2 ml, 20.02 mmol) and treated with 2,2,2-trifluoroacetic acid (15.33 ml, 200.2 mmol). The reaction mixture stirred at room temp for 4 hours. After completion the reaction was next concentrated in vacuo and taken up in EtOAc and the organics washed with 1M NaOH (2X), brine, dried over MgSO4 and concentrated in vacuo. benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (7.406 g, 19.09 mmol, 95.39 % yield) was used crude in the next reaction. ES+APCI MS m/z 388.2 $[M+H]^+$.




[0643] Step C: benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To the benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate, BINAP (0.275 g, 0.442 mmol) and Pd2(dba)3 (0.203 g, 0.221 mmol) under argon was added toluene (221 ml, 11.1 mmol) and the reaction bubbled with Ar for 10 minutes followed by heating to 100°C for 10 minutes. The reaction was next cooled to room temperature and benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.29 g, 11.1 mmol) and Sodium Tert-Butoxide (2.13 g, 22.1 mmol) were added to the dark solution as solids. Finally, 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate (7.44 g, 22.1 mmol) was added (as the oil) and the reaction heated to 100°C for 1 hour. The reaction was cooled to room temperature and concentrated in vacuo. The concenetrate was dissolved with EtOAc and washed with water and brine. The combined organics were dried over Na2SO4 and concentrated in vacuo. The residue was then loaded on the CombiFlash and chromatographed using 0%-->50% Hexane:EtOAc as eluent. Fractions containing clean product were combined and concentrated in vacuo to afford benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-


yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (2.6 g, 4.53 mmol, 40.9 % yield). ES+APCI MS m/z 574.2 $[M+H]^+$.



[0644] Step D: benzyl (S)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: In a microwave tube benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (300 mg, 0.523 mmol) was dissolved in Dioxane (6532 µl, 0.523 mmol) and treated with cesium carbonate (511 mg, 1.57 mmol), Hunig's base (913 µl, 5.23 mmol) and N-Methyl-L-prolinol (421 mg, 3.66 mmol). The tube was then capped and microwaved at 170°C for 3 hours. The reaction was filtered through GF/F paper. The filtrate was concentrated in vacuo and the residue loaded onto a 12g RegiSep gold column and chromatagraphed on the CombiFlash (0%-15%, DCM:MeOH). All fractions contianing clean product were combined and concentrated in vacuo to give benzyl (S)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (220 mg, 0.337 mmol, 64.5 % yield). ES+APCI MS m/z 653.3 $[M+H]^+$.




[0645] Step E: (S)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine: A solution of benzyl (S)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (220 mg, 0.337 mmol) in EtOH (3370 µl, 0.337 mmol) and THF (3370 µl, 0.337 mmol) was purged with N2 for 5 minutes. To this solution was added Palladium on carbon (179 mg, 0.0843 mmol) (Degussa Type, 10 wt%, 50% H2O), and was immediately capped and purged with N2 for an additional 5 min. The solution then stirred under H2 introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature over night. LC/MS showed reaction completion. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo and (S)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (91 mg, 0.175 mmol, 52.1 % yield) was taken forward as the crude. ES+APCI MS m/z 519.3 $[M+H]^+$.



[0646] Step F: (S)-1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a suspension of (S)-7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (92 mg, 0.18 mmol) in dichloromethane (1774 µl, 0.18 mmol) at ambient temperature was added Acryloyl Chloride (1774 µl, 0.18 mmol) followed by Hunig's base (62 µl, 0.35 mmol). The reaction was then stirred at ambient temperature for 1 hour. The mixture was then concentrated and loaded onto a 4g RegiSep gold column and chromatagraphed on the CombiFlash (0%-15%, DCM:MeOH). All fractions containing clean product were combined and concentrated in vacuo to give (S)-1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-


tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (74 mg, 0.13 mmol, 73% yield). ES+APCI MS m/z 573.3 $[M+H]^+$.



[0647] Step G: (S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: (S)-1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (74 mg, 0.13 mmol) was dissolved in methanol (4307 µl, 0.13 mmol) and treated with hydrogen chloride (1077 µl, 6.5 mmol) (aq). The reaction stirred at 55°C for 1 hour. The reaction mixture was concentrated in vaccuo and was resuspended in 1.5mL of MeOH. The suspension was loaded on to the Gilson (prep HPLC), which was eluted with 5-->95% ACN/0.1% TFA in water/0.1% TFA. All fractions containing clean product were combined and lyophilized overnight to give (S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (26 mg, 0.049 mmol, 38% yield). ES+APCI MS m/z 529.3 $[M+H]^+$.

EXAMPLE 128

1-(4-(2-(3-(dimethylamino)azetidin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0648] Step A: benzyl 4-(2-(3-(dimethylamino)azetidin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.20 g, 0.35 mmol) in dioxanes was added N,N-dimethylazetidin-3-amine hydrochloride (0.24 g, 1.7 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.45 g, 3.5 mmol) and the reaction was heated to 80C for 72 hrs. The reaction was concentrated in vacuo and the residue chromatographed using 0-->20% MeOH/DCM as eluent to give benzyl 4-(2-(3-(dimethylamino)azetidin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.25g, 105%). ES+APCI MS m/z 638.3 $[M+H]^+$.


[0649] 1-(4-(2-(3-(dimethylamino)azetidin-1-yl)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was made according to Example 127 substituting benzyl 4-(2-(3-(dimethylamino)azetidin-1-yl)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate for benzyl (S)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-((1-

methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in step E. ES+APCI MS m/z 514.2 $[M+H]^+$.


EXAMPLE 129

1-[4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one






[0650] Step A: *tert*-butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1-carboxylate: A mixture of BH_3-Me_2S (10 M, 549 uL) and (3*aS*)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-*c*][1,3,2]oxazaborole (1.00 M, 844 uL,) in THF (10 mL) was stirred at 15 °C for 1 hour. To the mixture was added a solution of *tert*-butyl (2*R*)-2-acetylpyrrolidine-1-carboxylate (0.90 g, 4.22 mmol) in THF (10 mL) and the mixture stirred at 15 °C for 1 hour. The mixture was quenched by addition of methanol (2.00 mL) and the reaction concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 50/1 - 5/1) to give *tert*-butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1-carboxylate (0.60 g, 2.79 mmol, 66.0 % yield) as a colorless oil. ^{1}H NMR (400MHz, CD_3OD) δ = 5.18 (br s, 1H), 3.73 (dt, *J* = 4.8, 8.0 Hz, 1H), 3.70 - 3.43 (m, 2H), 3.28 (td, *J* = 6.64, 10.8 Hz, 1H), 1.96 (qd, *J* = 7.2, 12.8 Hz, 1H), 1.89 - 1.68 (m, 2H), 1.62 (br s, *J* = 6.4 Hz, 1H), 1.47 (s, 9H), 1.15 (d, *J* = 6.0 Hz, 3H).




[0651] Step B: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-tert-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.70 g, 1.08 mmol) and *tert*-butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1-carboxylate (349 mg, 1.62 mmol) in THF (10 mL) was added t-BuONa (312 mg, 3.24 mmol) and the mixture stirred at 10 °C for 1 hour. The mixture was diluted with water (10 mL) and the aqueous layer extracted with ethyl acetate (3 × 10 mL). The combined organics were washed brine (20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 3/1) to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-tert-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.35 g, 412 umol, 38.1 % yield) as a yellow solid. ES+APCI MS m/z 799.4 $[M+H]^+$.




[0652] Step C: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)- pyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1- *tert*-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.30 g, 375 umol) and TFA (642 mg, 5.63 mmol, 417 uL) in dichloromethane (0.42 mL) was stirred at 10 °C for 1


hour. The mixture was concentrated under vacuum to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)- pyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (305 mg) LCMS [M+1]: ES+APCI MS m/z 699.2 $[M+H]^+$.



[0653] Step D: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)- pyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.30 g, crude), formaldehyde (210 mg, 1.85 mmol, 192 uL, 37 % water) and AcOH (22.16 mg, 369 umol, 21.1 uL) in methanol (3.00 mL) was stirred at 15 °C for 0.5 hours. To the mixture was added $NaBH_3CN$ (58.0 mg, 923 umol) and the mixture stirred at 15 °C for 48 hours. The mixture was quenched by addition of H_2O (5 mL) at 0 °C, and the aqueous layer extracted with ether acetate (3 × 10 mL). The combined organics were washed with brine (15.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water(0.10 % Formic Acid)/acetonitrile] to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.10 g, 126 umol) as a yellow oil. ES+APCI MS m/z 713.4 $[M+H]^+$.




[0654] Step E: 4-[2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: Ammonia was bubbled into methanol (3 mL) at -78 °C for 30minutes. benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.09 g, 126 umol) and dry 10% Pd/C (0.10 g) were next added added and the mixture stirred at 10 °C for 1 hour under H_2 (15 psi). The reaction was filtered and the filtrate was concentrated under vacuum to give 4-[2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (0.04 g, crude) as a yellow oil. ES+APCI MS m/z 489.2 $[M+H]^+$.



[0655] Step F: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl] ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (0.04 g) and Et_3N (124 mg, 1.23 mmol, 171 uL) in DCM (2.00 mL) at -40 °C was added prop-2-enoyl prop-2-enoate (7.23 mg, 57.3 umol) and the reaction stirred at -40 °C for 0.5 h. The mixture was quenched by addition of methanol (0.10 mL) and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water (0.225%Formic Acid)-ACN]; B%: 10%-37% over 10 minutes) to give 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (9.13 mg, 15.5 umol) as a yellow solid. ES+APCI MS m/z 543.4 $[M+H]^+$.

EXAMPLE 130


1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0656] 1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((*S*)-1-((*S*)-1-methylpyrrolidin-2-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following **Example 129** substituting (3aR)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydro pyrrolo[1,2-c][1,3,2]oxazaborole for (3*aS*)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-*c*][1,3,2]oxazaborole in Step A while also substituting *tert*-butyl (2*S*)-2-acetylpyrrolidine-1-carboxylate for *tert*-butyl (2*R*)-2-acetylpyrrolidine-1-carboxylate in Step A . ES+APCI MS m/z 543.4 $[M+H]^+$.

EXAMPLE 131


1-[4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0657] Step A: (2*R*)-1-[ethyl(methyl)amino]propan-2-ol: (2*R*)-2-methyloxirane (540 mg, 9.31 mmol, 651 uL) was added to *N*-methylethanamine (500 mg, 8.46 mmol, 725 uL) in MeOH (10 mL). The resulting solution was stirred at 80 °C for 3 hours in a sealed tube. Upon completion, the mixture was concentrated under vacuum to give (2*R*)-[ethyl(methyl)amino]propan-2-ol (260 mg, crude) as a light yellow oil which was used directly in the next step without further purification.



[0658] Step B: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of (2*R*)-1-[ethyl(methyl)amino]propan-2-ol (217 mg, 1.85 mmol) in toluene (20 mL) was added benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 617 umol), $Pd_2(dba)_3$ (56.6 mg, 61.8 umol), BINAP (76.9 mg, 124 umol) and NaOtBu (178 mg, 1.85 mmol,) and the mixture de-gassed with N2 for 15 minutes and then heated to 90 °C for 16 hours under N_2. Upon completion, the reaction mixture was filtered and the filtrate concentrated under vacuum. The residue was purified by reversed-phase chormatography to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (110 mg, 153 umol, 24.8 % yield, 97.5 % purity). ES+APCI MS m/z 701.4 $[M+H]^+$.



[0659] Step C: 4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: To a solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 143 umol) in MeOH (3.00 mL) was added HCl/MeOH (4 M, 143 uL), followed by $Pd(OH)_2/C$ (50 mg) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 4 hours. Upon completion, the reaction mixture was filtered and the filtrate concentrated to give 4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (76.0 mg, 125 umol, 87.5 % yield, 90.3 % purity, 2 HCl) which was used directly in the next step without further purification. ES+APCI MS m/z 477.2 $[M+H]^+$.




[0660] Step D: 1-[4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (70 mg, 127 umol, 2 HCl) and DIEA (98.8 mg, 764 umol, 133 uL) in DCM (1.50 mL) was added prop-2-enoyl prop-2-enoate (12.9 mg, 102 umol) dropwise at - 50 °C. The mixture was stirred at -40 to -20 °C for 30 minutes. Upon completion, the mixture was quenched by addition of MeOH (17.0 mg) and concentrated under vacuum. The residue was diluted with water (1 mL) and extracted with DCM (3 × 6 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 48%-78%,10min) to give 1-[4-[2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (9.23 mg, 17.2 umol, 13.5 % yield, 98.7 % purity) as a yellow solid. ES+APCI MS m/z 531.3 $[M+H]^+$.

EXAMPLE 132

1-[4-[2-[(1-cyclohexylpyrrolidin-3-yl)methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[0661] Step A: 1-cyclohexylpyrrolidine-3-carboxylate: To a solution of methyl pyrrolidine-3-carboxylate (1.00 g, 6.04 mmol, HCl) and DIEA (780 mg, 6.04 mmol, 1.05 mL) was added cyclohexanone (652 mg, 6.64 mmol, 686 uL) and HOAc (725 mg, 12.1 mmol, 691 uL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h. To the reaction mixture was added $NaBH(OAc)_3$ (3.84 g, 18.12 mmol) in portions at 0°C.The reaction mixture was stirred at 0 to 15°C for 12 hours. Upon completion, the reaction mixture was quenched by addition of water (5 mL) and organics concentrated under vacuum. The aqueous layer was extracted with DCM (10 mL × 2) and the pH adjusted with sat $NaHCO_3$ (10 mL) and Na_2CO_3 (2 mL) to pH>8. The organic layers were combined, dried over Na_2SO_4 and concentrated under vacuum. The residue was triturated with MTBE/Petroleum Ether (1:3, 20 mL) and the filtrate concentrated under vacuum to give methyl 1-cyclohexylpyrrolidine-3-carboxylate (1.00 g, 4.73 mmol, 78.4 % yield) as brown oil. ES+APCI MS m/z 212.2 $[M+H]^+$.

SUBSTITUTE SHEET (RULE 26)





[0662] Step B: (1-cyclohexylpyrrolidin-3-yl)methanol: To a solution of methyl 1-cyclohexylpyrrolidine-3-carboxylate (1.00 g, 4.73 mmol) in THF (20 mL) was added $LiAlH_4$ (413 mg, 10.9 mmol) at -10 °C. The reaction mixture was stirred at -10 °C for 0.5 hour. The reaction mixture was quenched by addition of saturated Na_2SO_4 (2 mL) and mixture filtered and the filter cake washed with THF (3 × 50 mL).The combined organics were concentrated under vacuum to give : (1-cyclohexylpyrrolidin-3-yl)methanol (800 mg, 4.36 mmol, 92.3 % yield) as a coloress oil. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 3.71 (dd, *J* = 4.1, 10.0 Hz, 1H), 3.53 (dd, *J*=4.4, 10.0 Hz, 1H), 2.90 (dt, *J*=4.4, 8.8 Hz, 1H), 2.74 (dd, *J* = 3.2, 8.8 Hz, 1H), 2.53 (dd, *J* = 6.8, 8.8 Hz, 1H), 2.36 - 2.24 (m, 2H), 2.04 - 1.93 (m, 2H), 1.90 (br s, 2H), 1.78 - 1.64 (m, 3H), 1.61 - 1.52 (m, 1H), 1.33 - 1.12 (m, 5H)

[0663] 1-[4-[2-[(1-cyclohexylpyrrolidin-3-yl)methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting (1-cyclohexylpyrrolidin-3-yl)methanol for (2*R*)-1-[ethyl(methyl)amino]propan-2-ol in Step B. ES+APCI MS m/z 597.4 $[M+H]^+$.

EXAMPLE 133

1-[4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropylamino)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one






[0664] Step A: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropylamino)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 617 umol) and 3-morpholinopropan-1-amine (534 mg, 3.70 mmol, 540 uL) in DMSO (4.00 mL) was heated to 100 °C for 12 hours. Upon completion, the mixture was diluted with water (4 mL) and extracted with EtOAc (3 × 20 mL). The organic layers were washed with brine (30 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography over Al_2O_3 eluting with Ethyl Acetate/Petroleum Ether (20→100%) to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropylamino)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (245 mg, 320 umol, 51.8 % yield, 95.0 % purity) as a yellow oil. ES+APCI MS m/z 728.6 $[M+H]^+$.


[0665] 1-[4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropylamino)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropylamino)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate for benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step C. ES+APCI MS m/z 558.6 $[M+H]^+$.

EXAMPLE 134


(*R*)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-(piperidin-3-ylmethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0666] Step A: *tert*-butyl (3*R*)-3-(hydroxymethyl)piperidine-1-carboxylate: TEA (1.76 g, 17.4 mmol, 2.42 mL) was added to a solution of [(3*R*)-3-piperidyl]methanol (1.0 g, 8.68 mmol) in THF (25.0 mL), followed by the addition of a solution of Boc_2O (1.89 g, 8.68 mmol, 1.99 mL) in THF (5 mL) at 15 °C. The mixture was stirred at 15 °C for 12 hours. The solvent was removed under vacuum and the residue dissolved in ethyl acetate (50 ml) and H_2O (30 mL). The solution was acidified with HCl (6 M) to pH~6 and the layers separated. The organics were washed with brine (3 × 50 mL) and the combined organics concentrated to dryness to give *tert*-butyl (3*R*)-3-(hydroxymethyl)piperidine-1-carboxylate (1.68 g, 7.80 mmol, 89.9% yield, 100% purity) as colorless crystals. ^{1}H NMR (400MHz, chloroform-d) δ = 3.73 (br s, 2H), 3.51 (br d, *J* = 6.8 Hz, 2H), 3.05 (br s, 2H), 1.83 - 1.71 (m, 2H), 1.62 (br s, 1H), 1.46 (s, 9H), 1.44 - 1.37 (m, 1H), 1.35 - 1.22 (m, 1H).




[0667] Step B: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-*tert*-butoxycarbonyl -3-piperidyl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl (3*R*)-3-(hydroxymethyl) piperidine-1-carboxylate (332 mg, 1.54 mmol) in THF (5 mL) was added t-BuONa (223 mg, 2.32 mmol). A solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methyl sulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 772 umol) in THF (5 mL) was next added and the mixture stirred at 0 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure and the residue purified by column chromatography eluting with Petroleum ether/Ethyl Acetate (10/1 to 3/1) to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-*tert*-butoxycarbonyl -3-piperidyl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (510 mg, 628 umol, 81.4% yield, 98.4% purity) as a white solid. ES+APCI MS m/z 799.4 $[M+H]^+$.



[0668] Step C: *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate: A solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-*tert*- butoxycarbonyl-3-piperidyl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg, 313 umol) in MeOH (5 mL) was purgred with NH_3 (10 %, w/w) and then 10% Pd/C (50 mg) was added. The suspension was degassed under vacuum and the mixture stirred under H_2 (15 psi) at 15 °C for 12 hours. The reaction mixture was filtered and concentrated under reduced pressure to dryness to give *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate (126 mg, 211 umol, 67.4% yield, 96.2% purity) as a colorless oil. ES+APCI MS m/z 575.5 $[M+H]^+$.



[0669] Step D: *tert*-butyl(3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoyl piperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate: To a solution of *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl) -4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate (126 mg, 219 umol) and TEA (33.3 mg, 329 umol, 45.8 uL) in DCM (5.0 mL) was added prop-2-enoyl prop-2-enoate (24.9 mg, 197 umol) dropwise at - 40 °C and the reaction stirred for 30 minutes at -40°C. The reaction mixture was quenched by addition MeOH (0.5 mL) and concentrated to dryness. The residue was dissolved into EtOAc (50 mL) and H_2O (20 mL). The resulting solution was acidified with HCl (1 M) to pH~6 and the layers separated. The combined organics were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give *tert*-butyl(3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoyl piperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate (120 mg, 172 umol, 78.5% yield, 90.2% purity) as a yellow oil, which was used directly for next step without further purification. ES+APCI MS m/z 629.6 $[M+H]^+$.




[0670] Step E: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-3-piperidyl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of *tert*-butyl(3*R*)-3-[[7-(3-hydroxy-1-naphthyl) -4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-2-yl]oxymethyl]piperidine-1-carboxylate (120 mg, 191 umol) in DCM (3.0 mL) was added TFA (326 mg, 2.86 mmol, 212 uL) at 0 °C. The mixture was stirred at 15 °C for 2 hours under N_2 atmosphere. The reaction mixture was basified with NH_3 (30 % in water, three drops) and concentrated to dryness. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase:[water (0.225% Formic Acid)-ACN]; B%: 5% - 35%,10 min) to give 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-3-piperidyl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (24.5 mg, 38.9 umol, 20.4% yield) as a yellow solid. ES+APCI MS m/z 529.4 $[M+H]^+$.

EXAMPLE 135

1-[4-[2-[3-(4-acetylpiperazin-1-yl)propoxy] -7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0671] Step A: 1-[4-(3-hydroxypropyl)piperazin-1-yl]ethanone: To a solution of 1-piperazin-1-ylethanone (2.00 g, 15.6 mmol) and K_2CO_3 (4.31 g, 31.2 mmol) in CH_3CN (50.0 mL) was added 3-bromopropan-1-ol (3.25 g, 23.4 mmol). The mixture was stirred at 80 °C for 5 hours. The solid was filtered and the filtrate was evaporated to give 1-[4-(3-hydroxypropyl)piperazin-1-yl]ethanone (2.00 g, 10.7 mmol, 68.8 % yield) as a colorless oil.


[0672] 1-[4-[2-[3-(4-acetylpiperazin-1-yl)propoxy] -7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting 1-[4-(3-hydroxypropyl)piperazin-1-yl]ethanone for benzyl 4-[7-(3-benzyloxy-

1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step C. ES+APCI MS m/z 600.3 $[M+H]^+$.

EXAMPLE 136

1-[4-[7-(3-hydroxy-1-naphthyl)-2-[2-(3-methoxypyrrolidin-1-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[0673] Step A: 2-(3-methoxypyrrolidin-1-yl)ethanol: To a solution of 3-methoxypyrrolidine (450 mg, 3.27 mmol, HCl) and 2-bromoethanol (408 mg, 3.27 mmol) in CH_3CN (10 mL) was added K_2CO_3 (1.36 g, 9.81 mmol). The mixture was stirred at 80 °C for 3 hours. The solid was filtered and the filtrate was evaporated to give 2-(3-methoxypyrrolidin-1-yl)ethanol (450 mg, 3.10 mmol, 94.8 % yield) as a colorless oil.


[0674] Step B: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(3-methoxypyrrolidin-1-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 771 umol), 2-(3-methoxypyrrolidin-1-yl)ethanol (224 mg, 1.54 mmol), and t-BuONa (222 mg, 2.32 mmol) in toluene (10 mL) was stirred at 20 °C for 1 hour under N_2 atmosphere. The mixture was cooled to 0 °C and HCl(2M) was added until pH~7. The mixture was filtered and filtrate was concentrated in vacuum. The residue was purified by column chromatography using 0→10% MeOH/DCM as eluent to give benzyl 4-[7-

(3-benzyloxy-1-naphthyl)-2-[2-(3-methoxypyrrolidin-1-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (110 mg, 147.9 umol, 19.1 % yield) ES+APCI MS m/z 729.2 $[M+H]^+$.

[0675] 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[2-(3-methoxypyrrolidin-1-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(3-methoxypyrrolidin-1-yl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate for benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step C. ES+APCI MS m/z 559.3 $[M+H]^+$.

EXAMPLE 137

1-[4-[7-(3-hydroxy-1-naphthyl)-2-[3-(3-methoxypyrrolidin-1-yl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[0676] Step A: (3-methoxypyrrolidin-1-yl)propan-1-ol: To a solution of 3-methoxypyrrolidine (500 mg, 3.63 mmol, HCl) and 3-bromopropan-1-ol (505 mg, 3.63 mmol) in CH_3CN (10 mL) was added K_2CO_3 (1.51 g, 10.9 mmol). The mixture was stirred at 20 °C for 5 hours. The solid was filtered and the filtrate was evaporated to give 3-(3-methoxypyrrolidin-1-yl)propan-1-ol (540 mg, 3.39 mmol, 93.3 % yield).

[0677] 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[3-(3-methoxypyrrolidin-1-yl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting (3-methoxypyrrolidin-1-yl)propan-1-ol for (2*R*)-1-[ethyl(methyl)amino]propan-2-ol in Step B. ES+APCI MS m/z 573.3 $[M+H]^+$.

EXAMPLE 138

1-[4-[2-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one







[0678] Step A: 2-(3,3-difluoroazetidin-1-yl)ethanol: To a solution of 3,3-difluoroazetidine (500 mg, 3.86 mmol, ***HCl***) and 2-bromoethanol (482 mg, 3.86 mmol, 274 uL) in CH_3CN (10 mL) was added K_2CO_3 (1.60 g, 11.5 mmol) and the reaction stirred at 80 °C for 16 hours. The reaction was filtered and the filtrate evaporated to give 2-(3,3-difluoroazetidin-1-yl)ethanol (300 mg, 2.19 mmol, 56.7 % yield).

[0679] 1-[4-[2-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting give 2-(3,3-difluoroazetidin-1-yl)ethanol for (2*R*)-1-[ethyl(methyl)amino]propan-2-ol in Step B. ES+APCI MS m/z 551.4 $[M+H]^+$.

EXAMPLE 139

1-[4-[2-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[0680] Step A: Methyl 2-(3,3-difluoropyrrolidin-1-yl)acetate: To a suspension of methyl 2-bromoacetate (1.17 g, 7.67 mmol, 723 uL) in DCM (10 mL) cooled to 0 °C was added TEA (1.76 g, 17.4 mmol, 2.42 mL) and 3,3-difluoropyrrolidine (1.00 g, 6.97 mmol, HCl) and the reaction mixture stirred at 20 °C for 16 hours. The reaction was filtered and filtrate was evaporated. The residue was purified by column chromatography with 0.5%-->20% MeOH/DCM as eluent to give methyl 2-(3,3-difluoropyrrolidin-1-yl)acetate (580 mg, 3.24 mmol, 46.4 % yield). ^{1}H NMR (400MHz, chloroform-d) δ = 3.73 (s, 3H), 3.38 (s, 2H), 3.11 (t, *J* = 13.6 Hz, 2H), 2.92 (t, *J* = 6.8 Hz, 2H), 2.36-2.26 (m, 2H).




[0681] Step B: 2-(3,3-difluoropyrrolidin-1-yl)ethanol: To a solution of $LiAlH_4$ (184 mg, 4.86 mmol) in THF (5.0 mL) was added a solution of methyl 2-(3,3-difluoropyrrolidin-1-yl)acetate (580 mg, 3.24 mmol) in THF (5.0 mL) dropwise at 0 °C. The mixture was warmed to 20 °C and stirred for 3 hours. The mixture was quenched by addition of saturated aqueous sodium sulfate solution (1.50 mL). The reaction was filtered and the filtrated was concentrated under vacuum to give 2-(3,3-difluoropyrrolidin-1-yl)ethanol (330 mg, 2.18 mmol, 67.4 % yield) as a

colourless oil. ^{1}H NMR (400MHz, chloroform-d) δ = 3.64 (t, *J* = 5.2 Hz, 2H), 2.97 (t, *J* = 13.2 Hz, 2H), 2.82 (t, *J* = 7.2 Hz, 2H), 2.68 (t, *J* = 5.2 Hz, 2H), 2.49 (br. s, 1H), 2.34-2.24 (m, 2H).

[0682] 1-[4-[2-[2-(3,3-difluoropyrrolidin-1-yl)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 131** substituting 2-(3,3-difluoropyrrolidin-1-yl)ethanol for (2*R*)-1-[ethyl(methyl)amino]propan-2-ol in Step B. ES+APCI MS m/z 565.3 $[M+H]^+$.


EXAMPLE 140

2-[3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidin-1-yl]-*N*,*N*-dimethyl-acetamide




[0683] Step A: methyl 1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidine-3-carboxylate: A solution of methyl pyrrolidine-3-carboxylate (1.00 g, 6.04 mmol, HCl) and NaHCO3 (1.01 g, 12.1 mmol, 470 uL) in ACN (200.0 mL) was stirred at 10 °C for 5 minutes. A solution of 2-bromo-N,N-dimethyl-acetamide (1.00 g, 6.04 mmol) in ACN (5.00 mL) was next added at 10°C and the reaction stirred at 10°C for 6 hours followed by and stirring at 50 °C for 2 hours. The mixture was filtered and and solids washed with DCM (3 × 15 ml). The filtrate was concentrated under vacuum and the residue purified by column chromatography using 0→10%

MeOH/DCM as eluent to to give methyl 1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidine-3-carboxylate (480 mg, 2.02 mmol, 33.4% yield).



[0684] Step B: 2-[3-(hydroxymethyl)pyrrolidin-1-yl]-*N*,*N*-dimethyl-acetamide: To a solution of methyl 1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidine-3-carboxylate (500 mg, 2.33 mmol) in THF (10 mL) was added $LiAlH_4$ (203 mg, 5.36 mmol) at -60 °C and the reaction mixture stirred at -60 °C for 10 minutes. The reaction mixture was quenched by the addition of saturated Na_2SO_4 (0.4 mL) and and the slurry was filtered. The filter cake was washed with THF (3 X 50 mL) and the filtrate concentrated under vacuum to give 2-[3-(hydroxymethyl)pyrrolidin-1-yl]-*N*,*N*-dimethyl-acetamide (400 mg, 2.15 mmol, 92.2% yield) as a brown oil. ES+APCI MS m/z 187.1 $[M+H]^+$.




[0685] Step C: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 772 umol), 2-[3-(hydroxymethyl)pyrrolidin-1-yl]-N,N-dimethyl-acetamide (216 mg, 1.16 mmol) and NaOBu-t (148 mg, 1.54 mmol) in toluene (10 mL) was stirred at 15 °C for 15 minutes. The reaction mixture was purified directly by silica gel chromatography using 20→100% EtOAc/Petroleum Ether to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-

carboxylate (310 mg, 395 umol, 51.1% yield, 98% purity) as a brown solid. ES+APCI MS m/z 770.4 $[M+H]^+$.


[0686] 2-[3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidin-1-yl]-*N*,*N*-dimethyl-acetamide was prepared following **Example 131** substituting benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[1-[2-(dimethylamino)-2-oxo-ethyl]pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate for benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-2-[ethyl(methyl)amino]-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step C. ES+APCI MS m/z 600.3 $[M+H]^+$.

EXAMPLE 141


1-[4-[2-[[1-(2-hydroxyethyl)pyrrolidin-3-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[0687] Step A: methyl pyrrolidine-3-carboxylate: To a solution of 1-(tert-butyl) 3-methyl pyrrolidine-1,3-dicarboxylate (10.0 g, 43.6 mmol) in DCM (50 mL) was added HCl/dioxane (4 M, 109 mL) at 0 °C and stirred at 0 °C for 1 hour. The mixture was concentrated under vacuum to give methyl pyrrolidine-3-carboxylate (7.00 g, crude, HCl) as brown oil. ^{1}H NMR (400MHz, methanol-d_4) δ = 3.77 (s, 3H), 3.56 - 3.53 (m, 2H), 3.41 - 3.37 (m, 3H), 2.40 - 2.24 (m, 2H).



[0688] Step B: methyl 1-(2-benzyloxyethyl)pyrrolidine-3-carboxylate: A solution of methyl pyrrolidine-3-carboxylate (3.0 g, 18.1 mmol, HCl), Cs_2CO_3 (17.7 g, 54.3 mmol) and KI (301 mg, 1.81 mmol) in MeCN (60 mL) was stirred at 15 °C for 5 min. Then a solution of 2-bromoethoxymethylbenzene (4.67 g, 21.7 mmol, 3.43 mL) in ACN (15 mL) was added to the mixture at 15 °C and stirred at 15 °C for 1 hour. The mixture was next warmed to 50 °C and stirred at 50 °C for 12 hours. The reaction mixture was filtered and the filter cake washed with DCM (3 × 30 mL) and the filtrate concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18 250*50mm*10 um;mobile phase: [water(0.1%TFA)-ACN];B%: 10ACN%-40ACN%,30min40%min) to give methyl 1-(2-benzyloxyethyl)pyrrolidine-3-carboxylate (1.48 g, 5.06 mmol, 27.9 % yield, 90.0 % purity) as brown oil. ^{1}H NMR (400MHz, chloroform-d) δ = 7.36 - 7.28 (m, 5H), 4.56 (s, 2H), 3.70 (s, 3H), 3.61 - 3.58 (t, *J*=6.0 Hz, 2H), 3.02 – 3.00 (m, 2H), 2.78 - 2.67 (m, 4H), 2.58 - 2.49 (m, 1H), 2.11 - 2.08 (m, 2H)




[0689] Step C: (1-(2-(benzyloxy)ethyl)pyrrolidin-3-yl)methanol: To the solution of methyl 1-(2-benzyloxyethyl)pyrrolidine-3-carboxylate (1.38 g, 5.24 mmol) in THF (27 mL) was added $LiAlH_4$ (457 mg, 12 mmol) at -10 °C and stirred at -10 °C for 0.5 hour. The reaction mixture was quenched by saturated Na_2SO_4 (1 mL) and filtered, the filter cake was washed with THF (5 × 30 mL), the filtrate was concentrated under vacuum to give (1-(2-(benzyloxy)ethyl)pyrrolidin-3-yl)methanol (1.30 g, 3.31 mmol, 63.3% yield, 60.0 % purity) as brown oil. ES+APCI MS m/z 236.1 $[M+H]^+$.

[0690] 1-[4-[2-[[1-(2-hydroxyethyl)pyrrolidin-3-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared

following **Example 136** substituting (1-(2-(benzyloxy)ethyl)pyrrolidin-3-yl)methanol for 2-(3-methoxypyrrolidin-1-yl)ethanol in Step B. ES+APCI MS m/z 559.3 $[M+H]^+$.

EXAMPLE 142


1-[4-[2-(2-hydroxyethoxy)-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[0691] 1-[4-[2-(2-hydroxyethoxy)-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 136** substituting 2-[*tert*-butyl(dimethyl)silyl]oxyethanol for 2-(3-methoxypyrrolidin-1-yl)ethanol in Step B. ES+APCI MS m/z 476.2 $[M+H]^+$.

EXAMPLE 143


1-[4-[2-(2,3-dihydroxypropoxy)-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[0692] 1-[4-[2-(2,3-dihydroxypropoxy)-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 136** substituting (2,2-dimethyl-1,3-dioxolan-4-yl)methanol for 2-(3-methoxypyrrolidin-1-yl)ethanol in Step B. ES+APCI MS m/z 506.3 $[M+H]^+$.

EXAMPLE 144

(*S*)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-(2-methoxyethyl)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one





[0693] Step A: <u>*tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate</u>: To a slurry of NaH (2.38 g, 59.6 mmol, 60% purity) in THF (50 mL) was added a solution of *tert*-butyl (2*S*)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (10 g, 49.69 mmol) in THF (50 mL) at 0 °C and the mixture was stirred at 10 °C for 1 hour. Bromomethylbenzene (12.8 g, 74.5 mmol, 8.85 mL) was added dropwise at 0 °C and the mixture was stirred at 10 °C for 16 hours. The mixture was quenched by addition of saturated aqueous ammonia chloride solution (20 mL) and then diluted with ethyl acetate (200 mL) and water (100 mL). The separated organic layer was washed with water (100 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 5/1) to give *tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate (8.2 g, 28.06 mmol, 56.5% yield, 99.7% purity) was obtained as a colorless oil. ES+APCI MS m/z 192.1 $[M+H\text{-Boc}]^+$.



[0694] Step B: (2*S*)-2-(benzyloxymethyl)pyrrolidine: To a solution of *tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1- carboxylate (8.2 g, 28.14 mmol) in CH_2Cl_2 (28 mL) was added TFA (43.1 g, 378 mmol, 28.0 mL) dropwise at 0 °C under nitrogen atmosphere. The mixture was stirred at 15 °C for 1 hour. The mixture was concentrated under vacuum. The residue was diluted with dichloromethane (100mL) and then washed with 1M aqueous sodium hydroxide (10 mL) until the aqueous layer reached pH ~ 10. The separated organic layer was washed with brine (2 × 20 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give (2*S*)-2-(benzyloxymethyl)pyrrolidine (4 g, 20.9 mmol, 74.3% yieldLCMS ES+APCI MS m/z 192.2 $[M+H]^+$.




[0695] Step C: (2*S*)-2-(benzyloxymethyl)-1-(2-methoxyethyl)pyrrolidine: A mixture of 1-bromo-2-methoxy-ethane (0.9 g, 6.48 mmol, 608 uL), (2*S*)-2-(benzyloxymethyl)pyrrolidine (1.24 g, 6.48 mmol) and K_2CO_3 (2.68 g, 19.4 mmol) in CH_3CN (20 mL) was stirred at 15 °C for 1 hours and then at 78 °C for 12 hours. The mixture was diluted with ethyl acetate (50 mL) and water (50 mL). The separated organic layer was washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (ethyl acetate/dichloromethane/methanol 1/1/0 to 10/10/2) to give (2*S*)-2-(benzyloxymethyl)-1-(2-methoxyethyl)pyrrolidine (900 mg, 3.61 mmol, 55.7% yield) as a colorless oil. ES+APCI MS m/z 250.2 $[M+H]^+$.




[0696] Step D: (S)-(1-(2-methoxyethyl)pyrrolidin-2-yl)methanol: A solution of (2*S*)-2-(benzyloxymethyl)-1-(2-methoxyethyl)pyrrolidine (900 mg, 3.61 mmol) in MeOH (20 mL) was added 10% Pd/C (721.88 umol) and the slurry stirred under H_2 (50 psi) at 10 °C for 16 hours.

The reaction was filtered and the filtrate concentrated under vacuum to give (S)-(1-(2-methoxyethyl)pyrrolidin-2-yl)methanol (450 mg, 2.83 mmol, 78.30% yield).




[0697] Step E: Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of [(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methanol (245 mg, 1.54 mmol), benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 772 umol), and t-BuONa (223 mg, 2.32 mmol) in THF (5 mL) was stirred at 20 °C for 0.5 hour under N_2 atmosphere. The reaction mixture was poured into H_2O (30 mL) and the aqueous layer extracted with ethyl acetate (3x30 mL). The combined organics were washed with brine (30 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 300/1 to 10:1) to give Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (260 mg, 349 umol, 45.3 % yield). ES+APCI MS m/z 743.4 $[M+H]^+$.




[0698] Step F: *tert*-Butyl 4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a

solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1- (2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 323 umol) and $(Boc)_2O$ (141 mg, 646 umol, 148 uL) in MeOH (150 mL) was added 10% Pd/C (100 mg) under N_2 atmosphere. The suspension was degassed and purged with H_2 3 times. The mixture was stirred under H_2 (15 PSI) at 40 °C for 12 hours. The reaction mixture was filtered and the filtrate concentrated to give *tert*-Butyl 4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (215 mg, crude). ES+APCI MS m/z 619.1 $[M+H]^+$.




[0699] Step G: 4-[2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: To a solution of *tert*-butyl 4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-(2- methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (215 mg, 347 umol) in DCM (500 uL) was added TFA (594 mg, 5.21 mmol, 385 uL) and the mixture stirred at 15 °C for 1 hour. The mixture was concentrated under vacuum to give 4-[2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (219 mg, 346 umol). ES+APCI MS m/z 519.4 $[M+H]^+$.




[0700] Step H: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 4-[2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl] methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (219 mg, 346 umol) and DIEA (447 mg, 3.46 mmol, 603 uL) in dichloromethane (4.00 mL) cooled to - 40 °C was added a solution of prop-2-enoyl prop-2-enoate (34.9 mg, 276.92 umol) in dichloromethane (1.00 mL) under a nitrogen atmosphere. The mixture was stirred at -40 °C for 1 hour. The reaction was quenched by addition of saturated $NaHCO_3$ (2.00 mL) and the mixture poured into ice-water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organics were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 32%-62%, 12 min) to give 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (27 mg, 46.7 umol). ES+APCI MS m/z 573.3 $[M+H]^+$.


EXAMPLE 145

1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one







[0701] Step A: Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1- *tert*-butoxycarbonylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl (2*S*)-2-(hydroxymethyl) pyrrolidine-1-carboxylate (1.24 g, 6.17 mmol) and benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2 g, 3.09 mmol) in THF (50 mL) was added t-BuONa (890 mg, 9.26 mmol) and the reaction stirred at 15 °C for 0.5 hour. The reaction mixture was poured into H_2O (100 mL) and extracted with ethyl acetate (3X100 mL). The combined organics were washed with brine (50 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 100/1 to 1:1) to give Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1- *tert*-butoxycarbonylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.62 g, 2.02 mmol, 65.5 % yield). ES+APCI MS m/z 785.6 $[M+H]^+$.



[0702] Step B: (2*S*)-2-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate: NH_3 was bubbled into MeOH (50 mL) at 15 °C for 30 minutes. To this solution was added benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-tert-butoxycarbonyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.6 g, 2.04 mmol) followed by dry 10 % Pd/C (500 mg) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 1 hour. The mixture was then filtered and the filtrate concentrated under vacuum to give *tert*-butyl (2*S*)-2-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (1.00 g, 1.78 mmol). ES+APCI MS m/z 561.5 $[M+H]^+$.




[0703] Step C: *tert*-butyl (2*S*)-2-[[7-(3-hydroxy-1-naphthyl)-4-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate: To a solution of *tert*-butyl (2*S*)-2-[[7-(3-hydroxy-1-naphthyl)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (800 mg, 1.43 mmol) in DCM (5.00 mL) at at 0 °C was added TFAA (599 mg, 2.85 mmol) and DIEA (737 mg, 5.71 mmol) and the reaction stirred at 0 °C for 0.5 hour. The reaction mixture was poured into H_2O (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organics were washed with brine (30 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl (2*S*)-2-[[7-(3-hydroxy-1-naphthyl)-4-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (1.5 g, crude). ES+APCI MS m/z 657.5 $[M+H]^+$.




[0704] Step D: 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)- pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]ethanone: To a solution of *tert*-butyl (2*S*)-2-[[7-(3-hydroxy-1-naphthyl) -4-[4-(2,2,2-trifluoroacetyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (300 mg,

crude) in DCM (500 uL) was added TFA (521 mg, 4.57 mmol, 338 uL) and the mixture stirred at 15 °C for 1 hour. The mixture was concentrated under vacuum to give 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)- pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]ethanone (306 mg). ES+APCI MS m/z 557.3 $[M+H]^+$.




[0705] Step E: 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]ethanone: To a solution of acetone (132 mg, 2.28 mmol, 167 uL,) and 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]ethanone (306 mg, crude, TFA) in MeOH (5.00 mL) was added AcOH (54.8 mg, 912 umol, 52.2 uL) and $NaBH_3CN$ (115 mg, 1.83 mmol) and the mixture stirred at 15 °C for 16 hours. The reaction mixture was diluted with H_2O (20 mL) and extracted with ethyl acetate (20 mL ×3). The combined organics were washed with brine (10mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]ethanone (300 mg, crude). ES+APCI MS m/z 599.5 $[M+H]^+$.



[0706] Step F: 4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: To a solution of 2,2,2-trifluoro-1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)- 1-isopropylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-


d]pyrimidin-4-yl]piperazin-1-yl]ethanone (300 mg, crude) in MeOH (10 mL) was added K_2CO_3 (346 mg, 2.51 mmol) and the mixture stirred at 15 °C for 1 hour. The reaction mixture was filtered and the filtrate concentrated to give 4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (250 mg). ES+APCI MS m/z 503.3 $[M+H]^+$.




[0707] Step G: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (250 mg, crude) and DIEA (643 mg, 4.97 mmol, 866 uL) in DCM (5.00 mL) cooled to - 40°C was added a solution of prop-2-enoyl prop-2-enoate (50.2mg, 398 umol) in DCM (1 mL) under nitrogen atmosphere. The mixture was stirred at -40 °C for 1 hour. The reaction was quenched by addition of saturated $NaHCO_3$ (2.00 mL). The mixture was poured into ice-water (20 mL) and extracted with DCM (20 mL×2). The combined organics were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 52%-78%, 12min). 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (10 mg, 17.6 umol). ES+APCI MS m/z 557.3 $[M+H]^+$.

EXAMPLE 146


1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0708] Step A: benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-tert-butoxycarbonylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.50 g, 772 umol), *tert*-butyl (3*R*)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (311 mg, 1.54 mmol) and t-BuONa (223 mg, 2.32 mmol) in THF (10 mL) was stirred at 20 °C for 1 hour. The mixture was diluted with water (10 mL) and the aqueous layer extracted with ether acetate (3 × 20 mL). The combined organics were washed with saturated sodium chloride (1 × 30 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 3/1) to give benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-tert-butoxycarbonylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.40 g, 499 umol). ES+APCI MS m/z 785.2 $[M+H]^+$.



[0709] Step B: *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate: NH_3 was bubbled into methanol (10 mL) at -78 °C for 30 minutes. Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-tert-butoxycarbonylpyrrolidin-3-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.25 g, 319 umol) and 10% Pd/C (0.10 g) were added into the mixture and stirred at 10 °C for 1 hour under H_2 (15 psi). The mixture was filtered and concentrated under vacuum to give *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (0.17 g, 303 umol). ES+APCI MS m/z 561.3 $[M+H]^+$.




[0710] Step C: *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate: To a solution of *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (0.17 g, 303 umol) and Et_3N (153 mg, 1.52 mmol, 211 uL) in dichloromethane (4.00 mL) cooled to -40 °C was added prop-2-enoyl prop-2-enoate (26.8 mg, 212 umol) and the mixture stirred at -40 °C for 0.5 h. The mixture was quenched by addition of methanol (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methane = 10/1) to give *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (0.12 g, 189 umol). ES+APCI MS m/z 615.5 $[M+H]^+$.




[0711] Step D: 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: A mixture of *tert*-butyl (3*R*)-3-[[7-(3-hydroxy-1-naphthyl)-4-(4- prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (0.10 g, 163 umol) and TFA (278 mg, 2.44 mmol, 181 uL) in dichloromethane (0.20 mL) was stirred at 10 °C for 1 hour. The mixture was quenched by addition of $NH_3 \cdot H_2O$ and the pH adjusted until the pH = 7. The mixture was purified by prep-HPLC (column: Venusil XBP C8 150*25*10um; mobile phase: [water (0.225%Formic Acid)-ACN]; B%: 15%-45%, 10min) to give 1-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (22.8 mg, 42.9 umol). ES+APCI MS m/z 515.4 $[M+H]^+$.

EXAMPLE 147

2-[4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0712] Step A: (*Z*) and (*E*)-4-bromobut-2-enenitrile: To a solution of but-3-enenitrile (98 g, 1.46 mol, 118 mL) in *tert*-butanol (150 mL) and petroleum ether (575 mL) was added a solution of Br_2 (233 g, 1.46 mol, 75.3 mL) in *tert*-butanol (150 mL) at 15 °C and the reaction stirred for 30 minutes. To the reaction was next added an ethanol solution of sodium ethoxide (100 g, 0.6 mol, 850 mL). The reaction mixture was stirred for 2 hours at the 15 °C. The reaction was next filtered and the filtrate concentrated under vacuum. The residue was purified by column chromatography using 2→20% ethyl acetate/petroleum ether as eluent to give a mixture of (*Z*) and (*E*)-4-bromobut-2-enenitrile (141 g, *E/Z* = 2.5/1, crude) as a slight yellow oil. ^{1}H NMR (400MHz, chloroform-d,) (*E*), δ = 6.79 (td, *J* = 7.2, 16.0 Hz, 1H), 5.63 (d, *J* = 16.0 Hz, 1H), 4.00 (dd, *J* = 1.2, 6.8 Hz, 2H); (*Z*), δ = 6.66 (td, *J* = 8.0, 10.8 Hz, 1H), 5.44 (d, *J* = 10.8 Hz, 1H), 4.16 (dd, *J* = 0.8, 8.0 Hz, 2H).




[0713] Step B: 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile: To a mixture of *N*,*N*'-dibenzylethane-1,2-diamine (115 g, 480 mmol, 113 mL) and TEA (97.0 g, 959 mmol, 133 mL) in toluene (1 L) was added 4-bromobut-2-enenitrile (70 g, crude) dropwise at 0 °C and the reaction stirred at 15 °C for 12 hours. The reaction mixture was filtered and the filtrate concentrated under reduced pressure. The residue was purified by column chromatography using 5→50% EtOAc/Petroleum Ether as eluent to give 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile (82 g, 240 mmol, two steps 37 % yield, 89.3% purity) as a slight yellow semisolid. ES+APCI MS m/z 306.3 $[M+H]^+$. ^{1}H NMR (400MHz, chloroform-d) δ = 7.40 - 7.23 (m, 10H), 3.85 - 3.76 (m, 1H), 3.54 - 3.44 (m, 3H), 3.07 - 2.96 (m, 1H), 2.94 - 2.84 (m, 1H), 2.68 - 2.35 (m, 7H).




[0714] Step C: 2-piperazin-2-ylacetonitrile: To a solution of 2-(1,4-dibenzylpiperazin-2-yl)acetonitrile (164 g, 536 mmol) in DCE (1500 mL) was added 1-chloroethyl

carbonochloridate (306 g, 2.14 mol) dropwise at 0 °C. After addition, the reaction mixture was heated to 85 °C for approximately 48 hours. The dichloroethane was evaporated and the residue was taken up in MeOH (1500 mL) and heated to 70 °C for 1 hour. The reaction mixture was concentrated under reduced pressure and the solids triturated with MTBE (3X3 L) and the solids dried under reduced pressure to give 2-piperazin-2-ylacetonitrile. The crude product was purified by recrystallization with Ethanol and water (8:1, v:v) to give 2-piperazin-2-ylacetonitrile as an off-white solid (53 g, 428 mmol, 40.0 % yield, 96.4% purity, 2 HCl). ES+APCI MS m/z 126.2 $[M+H]^+$. ^1H NMR (400MHz, D_2O) δ = 4.01 - 3.96 (m, 1H), 3.81 - 3.67 (m, 3H), 3.46 - 3.27 (m, 3H), 3.09 (d, J = 6.0 HZ, 2H).




[0715] Step D: 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile: To a mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (1.2 g, 4.08 mmol) and 2-piperazin-2-ylacetonitrile (808 mg, 4.08 mmol, 2HCl) in dioxane (24 mL) was added DIEA (2.64 g, 20.4 mmol, 3.55 mL). The reaction mixture was stirred at 50 °C for 3 hours. Upon completion, the reaction mixture was diluted with water (50 mL) and the aqueous layer extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 and concentrated under vacuum to give 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile (1.56 g, 4.07 mmol, 100% yield) as a brown solid.




[0716] Step E: *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile (1.56 g, 4.07 mmol) was added $(Boc)_2O$


(9.50 g, 43.5 mmol, 10 mL) and the mixture heated to 50 °C for 2 hours. Upon completion, the reaction mixture was purified by silica gel chromatography using 10→50% EtOAc/Petroleum Ether as eluent to give *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.2 g, 2.44 mmol, 59.9% yield, 98.3% purity) as brown solid. ES+APCI MS m/z 483.3 $[M+H]^+$. ^1H NMR (400MHz, CHLOROFORM-d) δ = 7.39 - 7.27 (m, 5H), 4.59 (br s, 1H), 4.06 (br d, J = 13.6 Hz, 2H), 3.90 (br d, J = 11.6 Hz, 1H), 3.74 - 3.49 (m, 4H), 3.29 (dd, J = 4.0, 13.6 Hz, 1H), 3.18 (br s, 1H), 3.10 - 3.00 (m, 1H), 2.85 - 2.55 (m, 6H), 1.53 - 1.45 (m, 9H).



[0717] Step F: *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro -5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of [(2S)-1-methylpyrrolidin-2-yl]methanol (655.74 mg, 5.69 mmol, 676 uLin THF (25 mL) was added NaH (182 mg, 4.55 mmol, 60% purity) at 0 °C and the reaction mixture stirred at 0 °C for 0.5 h. To the mixture was added *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl) piperazine-1-carboxylate (1.1 g, 2.28 mmol) and the reaction mixture stirred at 70 °C for 12 hours in a sealed tube under N_2. Upon completion, the reaction mixture was quenched by addition of saturated NH_4Cl (20 mL) and the aqueous layer extracted with EtOAc (2 × 50 mL). The combined organics were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro -5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.1 g, 1.86 mmol, 81.7% yield, 95% purity) as a brown solid. ES+APCI MS m/z 562.4 $[M+H]^+$.




[0718] Step G: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: Ammonia was bubbled into MeOH (30 mL) for 5 minutes. To this solution was added *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (950 mg, 1.69 mmol) and 10% Pd/C (200 mg). The suspension was degassed under vacuum and purged with H_2 several times and the mixture stirred under H_2 (15 psi) at 40°C for 9 hours. Upon completion, the reaction mixture was filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um;mobile phase: [water(0.225%Formic Acid)-ACN];B%: 15%-40%,30;58%min) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 830 umol, 49.1% yield, 97.8% purity) was obtained as brown oil. ES+APCI MS m/z 472.4 $[M+H]^+$. ^1H NMR (400MHz, CHLOROFORM-d) δ = 4.59 (br s, 1H), 4.43 - 4.28 (m, 1H), 4.18 - 4.09 (m, 1H), 4.07 - 3.90 (m, 4H), 3.88 - 3.78 (m, 1H), 3.21 (br dd, *J* = 3.2, 13.6 Hz, 2H), 3.16 - 3.05 (m, 2H), 3.03 - 2.90 (m, 2H), 2.82 - 2.55 (m, 4H), 2.48 (s, 3H), 2.33 - 2.22 (m, 1H), 2.11 - 2.00 (m, 1H), 1.91 - 1.62 (m, 4H), 1.51 (s, 9H).




[0719] Step H: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution

of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 318 umol), 1-bromonaphthalene (98.8 mg, 477 umol, 66.3 uL), Cs_2CO_3 (311 mg, 954 umol), and RuPhos (29.7 mg, 63.6 umol) in toluene (3 mL) was added $Pd_2(dba)_3$ (29.1 mg, 31.8 umol) and the suspension was degassed under vacuum and purged with N_2 3 times. The reaction mixture was stirred at 100 °C for 12 hours. The mixture was partitioned between water (10 mL) and EtOAc (20 mL) and the layers separated. The aqueous layer was extracted subsequently with EtOAc (3 × 20 mL). The combined organics were washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by reverse flash to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (70 mg, 111 umol, 35.0 % yield, 95.0 % purity) as brown solid. ES+APCI MS m/z 598.6 $[M+H]^+$. ^1H NMR (400 MHz, chloroform-d) δ = 8.21 - 8.20 (m, 1H), 7.87 - 7.85 (m, 1H), 7.61 - 7.59 (d, *J*=8.0 Hz, 1H), 7.51 - 7.49 (m, 2H), 7.45 - 7.41 (t, *J*=7.6 Hz, 1H), 7.15 - 7.13 (d, *J*=7.2 Hz, 1H), 4.63 (br s, 1H), 4.46 (br s, 1H), 4.33 - 4.28 (m, 4H), 4.10 - 4.07 (m, 2H), 3.97 - 3.94 (br d, *J*=11.6 Hz, 1H), 3.46 (br s, 1H), 3.31 - 3.27 (br d, *J*=14.0 Hz, 1H), 3.07 - 3.01 (m, 2H), 2.77 (br s, 3H), 2.55 (br s, 3H), 2.35 (br s, 1H), 1.82 (br s, 7H), 1.52 (s, 9H).



[0720] Step I: 2-[4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (60 mg, 100 umol) in DCM (0.1 mL) was added TFA (154 mg, 1.35 mmol, 0.1 mL) at 15 °C and stirred at 15 °C for 1 hour. The reaction mixture was concentrated under vacuum to give 2-[4-[2-[[(2S)-1-methylpyrrolidin-2-


yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (50 mg) as brown oil.




[0721] Step J: 2-[4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (50 mg, 81.8 umol, TFA) and DIEA (106 mg, 817 umol, 142 uL) in DCM (0.2 mL) was added prop-2-enoyl prop-2-enoate (11.3 mg, 89.9 umol) at 0 °C and the reaction stirred at 0-15 °C for 1.5 hour. The reaction mixture was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um;mobile phase: [water(0.225%Formic Acid)-ACN];B%: 15%-45%,10.5min) to give 2-[4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (9.16 mg, 15.1 umol, 18.5 % yield, 98.7 % purity, Formate) as yellow oil. ES+APCI MS m/z 552.5 $[M+H]^+$. ^{1}H NMR (400 MHz, chloroform-d) δ = 8.45 (br s, 1H), 8.22 - 8.19 (m, 1H), 7.87 - 7.85 (m, 1H), 7.62 - 7.60 (d, *J*=8.0 Hz, 1H), 7.51 - 7.49 (m, 2H), 7.45 - 7.43 (t, *J*=7.6 Hz, 1H), 7.15 - 7.13 (d, *J*=7.2 Hz, 1H), 6.60 (br s, 1H), 6.42 - 6.38 (m, 1H), 5.84 - 5.82 (br d, *J*=10.8 Hz, 1H), 5.08 (br s, 1H), 4.78 - 4.53 (br dd, *J*=6.8, 11.6 Hz, 2H), 4.42 - 4.40 (m, 1H), 4.27 (br s, 2H), 4.21 - 4.18 (br d, *J*=14.0 Hz, 1H), 4.12-3.78 (br d, *J*=12.8 Hz, 2H), 3.68 - 3.07 (m, 7H), 3.05 - 2.84 (m, 3H), 2.77 (d, *J*=1.6 Hz, 3H), 2.71 - 2.64 (m, 1H), 2.26 - 2.17 (m, 1H), 2.11 - 2.03 (m, 1H), 2.02 - 1.88 (m, 2H).

EXAMPLE 148


2-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0722] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol), 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole (188 mg, 636 umol), RuPhos (39.6 mg, 84.8 umol) and Cs_2CO_3 (414 mg, 1.27 mmol) in toluene (6 mL) was added $Pd_2(dba)_3$ (38.8 mg, 42.4 umol) and the reaction stirred at 100 °C for 12 hours under N_2. Upon completion, the mixture was purified directly by silica gel chromatography (PE: EtOAc=3:1 to 0:1) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 149 umol, 35.1% yield, 85.0% purity) as a brown solid. ES+APCI MS m/z 686.6 $[M+H]^+$. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.04 (d, *J* = 2.0 Hz, 1H), 7.33 - 7.29 (m, 2H), 5.70 (dd, *J* = 2.4, 9.2 Hz, 1H), 4.62 (br s, 1H), 4.39 (br s, 1H), 4.34 - 4.28 (m, 2H), 4.20 - 4.14 (m, 1H), 4.05 (br d, *J* = 12.0 Hz, 2H), 3.91 (br d, *J* = 12.4 Hz, 1H), 3.81 - 3.72 (m, 1H), 3.53 (br t, *J* = 4.8 Hz, 2H), 3.27 (br d, *J* = 10.8 Hz, 2H), 3.10 (br d, *J* = 6.8 Hz, 1H), 3.06 - 2.96 (m, 1H), 2.90 - 2.65 (m, 5H), 2.59 (br d, *J* = 10.2 Hz, 1H), 2.50 (s, 3H), 2.43 (s, 3H), 2.35 - 2.26 (m, 1H), 2.23 - 2.15 (m, 1H), 2.11 (br s, 2H), 1.90 - 1.65 (m, 7H), 1.54 (s, 9H).



[0723] Step B: 2-[4-[7-(5-methyl-1H-indazol-4-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 219 umol) in DCM (0.2 mL) was added TFA (616 mg, 5.40 mmol, 0.4 mL) and the reaction mixture stirred at 15 °C for 12 hours. Upon completion, the solvent was removed under vacuum to give 2-[4-[7-(5-methyl-1H-indazol-4-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (159 mg, 218 umol, 99.6% yield, 2TFA) as a red oil.




[0724] Step C: 2-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (159 mg, 218 umol, 2TFA) and DIEA (366 mg, 2.83 mmol, 493 uL) in DCM (4 mL) at -40°C was added prop-2-enoyl prop-2-enoate (24.7 mg, 196 umol,) and the reaction mixture was stirred at -20 °C for 1 hour. Upon completion, the reaction mixture was quenched by addition of water (2 mL) and the aqueous layer separated and back extracted with DCM (2 × 10 mL).The combined organics were concentrated under vacuum and the residue purified by silica gel chromatography (DCM: MeOH=50:1 to 5:1) followed by purification by reverse prep HPCL (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water(0.225%Formic Acid)-ACN];B%: 4%-34%

over 10 minutes) to give 2-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (1.77 mg, 3.10 umol). ES+APCI MS m/z 556.5 $[M+H]^+$. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.00 (s, 1H), 7.18 (br s, 1H), 7.16 - 7.11 (m, 1H), 6.52 (br s, 1H), 6.37 - 6.21 (m, 1H), 5.75 (br d, *J* = 10.4 Hz, 1H), 4.99 (br s, 1H), 4.67 (br dd, *J* = 6.4, 11.6 Hz, 1H), 4.34 (br dd, *J* = 3.9, 11.6 Hz, 1H), 4.24 (s, 2H), 4.11 (br d, *J* = 12.8 Hz, 1H), 3.94 (br s, 1H), 3.57 - 3.40 (m, 4H), 3.29 (br d, *J* = 13.8 Hz, 1H), 3.19 (br s, 1H), 3.02 (br dd, *J*=12.4, 19.7 Hz, 2H), 2.87 (br dd, *J*=8.4, 16.4 Hz, 2H), 2.76 - 2.58 (m, 6H), 2.35 (s, 3H), 2.22 - 2.10 (m, 1H), 2.01 (br d, *J*=8.4 Hz, 1H), 1.89 (br s, 2H).


EXAMPLE 149

2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile




[0725] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 276 umol), 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (120 mg, 303 umol), $Pd_2(dba)_3$ (50.5 mg, 55.1 umol),RuPhos (51.5 mg, 110


umol), Cs_2CO_3 (225 mg, 689 umol) in toluene (3.00 mL) was de-gassed with N_2 and then heated to 90 °C for 12 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated. The residue was purified by prep-TLC (EtOAc/MeOH 8/1) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 169 umol, 61.4 % yield, 95.0 % purity) as a yellow solid. ES+APCI MS m/z 786.3 $[M+H]^+$.



[0726] Step B: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 178 umol) in DCM (3.00 mL) was added 2,6-dimethylpyridine (229 mg, 2.14 mmol) and TMSOTf (238 mg, 1.07 mmol) at 0 °C. The mixture was stirred at 15 °C for 2 hours. Upon completion, the mixture was quenched by addition of MeOH (0.5 mL) and concentrated under vacuum to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude) as a yellow oil which was used directly in the next step without further purification. ES+APCI MS m/z 686.6 $[M+H]^+$.



[0727] Step C: 2-[4-[2-[[(2S)-1-methylpyrrolidin-2- yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (122 mg, 178 umol) and DIEA (138 mg, 1.07 mmol, 186 uL) in DCM (3.00 mL) was added prop-2-enoyl prop-2-enoate (18.0 mg, 143 umol) dropwise at 0 °C. The mixture was stirred at 20 °C for 1.5 hours. Upon completion, the mixture was diluted with water (0.5 mL) and extracted with EtOAc (2 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-TLC (EA/MeOH 10/1) and prep-HPLC (column: Boston pH-lex 150*25 10um;mobile phase: [water(0.1%TFA)-ACN];B%: 39%-69%,10min) to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2- yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (54.0 mg, 43.8 umol). ES+APCI MS m/z 740.6 $[M+H]^+$.





[0728] Step D: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol- 4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (20 mg, 27.0 umol) in DCM (60 uL) was added TFA (30.8 mg, 270 umol). The mixture was stirred at 20 °C for 1 hour. The reaction was not complete so additional TFA (30.8 mg) was added and the reaction stirred at 20 °C for an addtional 0.5 hour. Upon completion, the pH or the mixture was adjusted to 8 by addition of saturated aqueous $NaHCO_3$ (1 mL) and the aqueous layer extracted with EtOAc (2 × 5 mL). The combined organics were washed with brine (3 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was diluted with MeOH (0.5 mL) and $NH_3 \cdot H_2O$ (0.5 mL) added and the mixture stirred at 20 °C for 0.5 hour. The mixture was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um;mobile phase: [water(0.225%Formic Acid)-ACN];B%: 15%-45%,10.5min) to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol- 4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (2.68 mg, 3.99 umol) as a white solid. ES+APCI MS m/z 610.5 $[M+H]^+$. ^1H NMR (400 MHz, chloroform-d) δ = 8.22 (s, 1H), 7.68 (d, *J*=9.2 Hz, 1H), 7.45 (d, *J*=8.8 Hz, 1H), 6.60 (br s, 1H), 6.45 - 6.35 (m, 1H), 5.84 (br d, *J*=11.2 Hz, 1H), 5.09 (br s, 1H), 4.71 - 4.60 (m, 1H), 4.42 - 4.27 (m, 3H), 4.17 (br d, *J*=11.2 Hz, 1H), 4.01 (br d, *J*=12.4 Hz, 2H), 3.78 - 3.31 (m, 5H), 3.23 - 3.03 (m, 2H), 3.02 - 2.75 (m, 4H), 2.71 (s, 3H), 2.66 - 2.57 (m, 1H), 2.27 - 2.12 (m, 1H), 2.10 - 2.03 (m, 3H). ES+APCI MS m/z 610.1 $[M+H]^+$.


EXAMPLE 150

2-(1-acryloyl-4-(2-(((*R*)-1-(dimethylamino)propan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile






[0729] Step A: *tert*-Butyl 4-[7-benzyl-2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (500 mg, 1.04 mmol), (2*R*)-1-(dimethylamino)propan-2-ol (214 mg, 2.07 mmoland sodium tert-butoxide (298 mg, 3.11 mmol) in toluene (20 mL) was added BINAP (129 mg, 207 umol) and $Pd_2(dba)_3$ (94.8 mg, 104 umol) and the mixture was sparged with nitrogen followed by stirring at 90 °C for 5 hr. The mixture was diluted with ethyl acetate (100 mL) and water (100 mL) and the organic layer was separated and dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by reversed phase flash chromatogaphy [water (0.1% Formic Acid water)/acetonitrile]. The desired fractions were collected and neutralized with saturated aqueous sodium carbonate solution (5 mL) and extracted with 10% MeOH/DCM (2 × 50 mL). The combined organics were dried over sodium sulfate, filtered and concentrated under vacuum to give *tert*-Butyl 4-[7-benzyl-2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 480 umol) ES+APCI MS m/z 550.4 $[M+H]^+$.




[0730] Step B: *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-benzyl-2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.1 g, 2.00 mmol) in MeOH (10


mL) was added a solution of NH_3 (792 mg, 46.5 mmol) in MeOH (3.96 g, 123.56 mmol, 5 mL), followed by 10% Pd/C (500 mg). The mixture was stirred at 40 °C for 12 hr under H_2 (15 psi). The reaction was filtered and the filtrate was concentrated under reduced pressure to dryness to give *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (756 mg, crude) was obtained as a yellow solid. ES+APCI MS m/z 460.3 $[M+H]^+$.



[0731] Step C: *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1-methyl- ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (304 mg, 990 umol), *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 761 umol), [2-(2-aminoethyl)phenyl]-chloro-palladium, dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (84.4 mg, 114 umol) and Cs_2CO_3 (620 mg, 1.90 mmolin toluene (10 mL) was purged with N_2 3 times and the mixture stirred at 70 °C for 16 hours under N_2 atmosphere. The reaction mixture was poured into H_2O (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organics were washed with brine (30 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give a residue. The residue was purified by reversed phase flash [water (0.1 % formic acid)/acetonitrile] to give *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1-methyl- ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 303 umol). ES+APCI MS m/z 686.4 $[M+H]^+$.




[0732] Step D: [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2- (dimethylamino)-1-methyl-ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 306 umol) in dichloromethane (300 uL) was added TFA (523 mg, 4.59 mmol, 340 uL) and the mixture stirred at 15 °C for 2 hours. The mixture was concentrated under vacuum to give [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (214 mg, 305 umol). ES+APCI MS m/z 586.4 $[M+H]^+$.



[0733] Step E: [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl- piperazin-1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a mixture of [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (214 mg, 305 umol, TFA) and DIEA (395 mg, 3.06 mmol, 532 uL) in dichloromethane (5.00 mL) cooled to - 40 °C was added a solution of prop-2-enoyl prop-2-enoate (38.6 mg, 305 umol) in dichloromethane (1.00 mL) under nitrogen atmosphere. The mixture was warmed up to 0 °C and stirred for 1 hour. The mixture was concentrated under


vacuum to give a residue. The residue was purified by reversed phase flash [water (0.1% trifluoroacetic acid)\acetonitrile] to give [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl- piperazin-1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (100 mg, 156 umol). ES+APCI MS m/z 640.7 $[M+H]^+$.



[0734] Step F: 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin- 1-yl]-2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (90 mg, 141 umol) in THF (500 uL) cooled to 0 °C was added NaOH (2 M, 281.34 uL*)* and the mixture stirred at 15 °C for 16 hours. The pH of the mixture was adjusted to 7 by addition of a 20 % with formic acid solution. The aqueous solution was next extracted with dichloromethane (3 × 10 mL). The combined organics were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%Formic Acid)-ACN]; B%: 7%-37%, 10 min) to give 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(3-hydroxy-1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (5 mg, 8.82 umol, 6.27 % yield, 98 % purity) ES+APCI MS m/z 556.3 $[M+H]^+$. ^1H NMR (400MHz, methanol-d_4) δ = 8.54 (br s, 0.6 H), 8.07 (d, *J* = 8.4 Hz, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.37 (t, *J* = 7.2 Hz, 1H), 7.30 - 7.21 (m, 1H), 6.91 - 6.72 (m, 3H), 6.29 (br d, *J* = 16.4 Hz, 1H), 5.84 (br d, *J* = 11.2 Hz, 1H), 5.48 (br s, 1H), 5.26 - 4.96 (m, 1H), 4.57 (br s, 1H), 4.24 - 4.09 (m, 4H), 3.74 - 3.54 (m, 1H), 3.48 (m, 2H), 3.22 (m, 2H), 3.10 - 2.86 (m, 5H), 2.78 (br d, *J* = 14.4 Hz, 1H), 2.53 (br s, 6H), 1.37 (dd, *J* = 2.0, 6.4 Hz, 3H).

EXAMPLE 151


2-(1-acryloyl-4-(2-(((*R*)-1-(dimethylamino)propan-2-yl)oxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[0735] (2-(1-acryloyl-4-(2-(((*R*)-1-(dimethylamino)propan-2-yl)oxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile was prepared following **Example 150** substituting 1-bromonaphthalene for (4-bromo-2-naphthyl) 2,2-dimethylpropanoate in Step C and omitting Step F. ES+APCI MS m/z 540.3 $[M+H]^+$. ^1H NMR (400MHz, methanol-d_4) δ = 8.51 (s, 1H), 8.26 - 8.19 (m, 1H), 7.90 - 7.84 (m, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.46 - 7.39 (m, 1H), 7.25 - 7.18 (m, 1H), 6.82 (br s, 1H), 6.30 (br d, J = 17.2 Hz, 1H), 5.84 (br d, J = 10.4 Hz, 1H), 5.62-5.53 (m, 1H), 5.08 (br s, 1H), 4.70 - 4.39 (m, 1H), 4.26 - 4.11 (m, 4H), 3.94 - 3.59 (m, 1H), 3.48 - 3.34 (m, 2H), 3.28-3.18 (m, 3H), 3.13 - 2.92 (s, 5H), 2.79 - 2.61 (s, 6H), 1.48 (dd, J = 2.0, 6.0 Hz, 3H).


EXAMPLE 152

2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile






[0736] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)- 1-methyl-ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.50 g, 1.09 mmol), 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole (482 mg, 1.63 mmol), *t*-BuONa (314 mg, 3.26 mmol) and [2-(2-aminoethyl)phenyl]-chloro-palladium;dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane (80.4 mg, 109 umol) in toluene (30 mL) was stirred at 70 °C for 10 hours. The mixture was diluted with water (10 mL) and the aqueous layer extracted with ethyl acetate (3 × 20 mL). The organic layers were washed with saturated sodium chloride solution (30 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (Formic Acid, 0.1 %.)/acetonitrile] to give *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.40 g, 522 umol, 48.0 % yield) as a yellow solid. ES+APCI MS m/z 674.3 $[M+H]^+$. ^1H NMR (400MHz, chloroform-d) δ = 8.03 (d, J = 1.6 Hz, 1H), 7.31 - 7.27 (m, 2H), 5.68 (dd, J = 2.4, 9.6 Hz, 1H), 5.31 (br s, 1H), 4.61 (br s, 1H), 4.28 (s, 2H), 4.08 - 3.94 (m, 3H), 3.86 (br d, J = 11.6 Hz, 1H), 3.79 - 3.71 (m, 1H), 3.52 (br t, J = 4.8 Hz, 2H), 3.24 (br d, J = 12.8 Hz, 2H), 3.04 - 2.91 (m, 1H), 2.87 - 2.67 (m, 5H), 2.65 - 2.47 (m, 2H), 2.41 (s, 3H), 2.32 (br s, 6H), 2.17 (br d, J = 4.0 Hz, 1H), 2.09 (br s, 1H), 1.77 (br t, J = 10.8 Hz, 3H), 1.52 (s, 9H), 1.36 (d, J = 6.0 Hz, 3H).




[0737] Step B: 2-[4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1*R*)-2- (dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.38 g, 564 umol) in dichloromethane (10 mL) was added TMSOTf (752 mg, 3.38 mmol) and 2,6-dimethylpyridine (725 mg, 6.77 mmol) at 0 °C and the mixture stirred at 10 °C for 1 hour. The mixture was quenched by addition of methanol (0.10 mL) and concentrated under vacuum. The residue was purified by reversed phase chromatography [water (Formic Acid, 0.1 %)/acetonitrile]. The collected fractions were combined and the pH adjusted pH > 7 by addition of saturated sodium bicarbonate solution and the aqueous layer extracted with dichloromethane/methanol (10/1) (3 × 10 mL). The extracts were washed with saturated sodium chloride solution (10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-[4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.30 g, crude) as a yellow solid. ES+APCI MS m/z 574.1 $[M+H]^+$.



[0738] Step C: 2-[4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-

enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7- (5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.20 g, crude) and TEA (176mg, 1.74 mmol, 243 uL) in dichloromethane (1.00 mL) was added prop-2-enoyl prop-2-enoate (44.0 mg, 349 umol) at 0 °C. and the reaction stirred at 0 °C for 0.5 h. The mixture was quenched by addition of methanol (0.10 mL) and concentrated under vacuum. The residue was purified by reversed phase flash [water (Formic Acid, 0.1 %)/acetonitrile]. The collected fractions were combined and the pH adjusted to pH > 7 by addition of saturated sodium bicarbonate solution and the aqueous layer extracted with dichloromethane/methanol (10/1) (3 × 5.00 mL). The extracts were washed with saturated sodium chloride solution (1 × 10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-[4-[2-[(1*R*)-2-(dimethylamino)-1- methyl-ethoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.10 g, 127 umol, two steps 36.6 % yield) as a yellow solid. ES+APCI MS m/z 628.6 $[M+H]^+$.




[0739] Step D: 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: A mixture of 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]- 7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (40 mg, 63.7 umol,) and TsOH (1.10 mg, 6.37 umol) in acetonitrile (3 mL) was stirred at 90 °C for 1 hour. The mixture was quenched by addition of saturated sodium bicarbonate (2 mL) at 0 °C and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methanol = 5/1). The collected desired fractions were concentrated under vacuum to give white solid. The residue was purified by


prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (10mM NH_4HCO_3)-ACN]; B%: 35%-65%, 3min) and (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%Formic Acid)-ACN]; B%: 15%-45%, 10min). The desired fractions were pooled and lyophilizated to give 2-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (2.99 mg, 5.50 umol). ES+APCI MS m/z 544.5 $[M+H]^+$. ^1H NMR (400MHz, chloroform-d) δ = 8.36 (br s, 1H), 8.09 (s, 1H), 7.29 (br s, 1H), 7.24 - 7.20 (m, 1H), 6.62 (br d, *J* = 13.6 Hz, 1H), 6.47 - 6.24 (m, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.50 (br s, 1H), 5.08 (br s, 1H), 4.60 (br s, 1H), 4.31 (s, 2H), 4.12 (br d, *J* = 14.4 Hz, 1H), 3.99 (br d, *J* = 10.8 Hz, 1H), 3.55 (br t, *J* = 5.6 Hz, 2H), 3.42 - 3.29 (m, 1H), 3.10 (br s, 1H), 3.00 - 2.68 (m, 7H), 2.49 (s, 6H), 2.43 (s, 3H), 1.39 (d, *J* = 6.0 Hz, 3H).

EXAMPLE 153

2-[4-[7-(3-hydroxy-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile




[0740] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 773 umol) and 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol (219 mg, 1.39 mmol) in toluene (10 mL) was added tBuONa (111 mg, 1.16 mmol) under N_2. The reaction mixture was stirred at 18 °C for 0.5 hour. Upon completion, the mixture was purified by silica gel chromatography (PE: EtOAc= 3:1 to 0:1 then EA: MeOH=50:1 to 10:1) followed by reversed flash chromatography (50 % to 90 % MeCN in water, base condition) to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 156 umol, 20.5% yield, 97.9% purity) as a brown solid. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.19 - 8.12 (m, 1H), 7.83 - 7.77 (m, 1H), 7.55 - 7.43 (m, 2H), 7.29 (d, *J*=1.6 Hz, 1H), 6.84 (d, *J*=2.0 Hz, 1H), 4.64 (br s, 1H), 4.42 - 4.35 (m, 3H), 4.26 (br d, *J*=5.2 Hz, 2H), 4.12 - 4.03 (m, 3H), 3.96 (br d, *J*=12.8 Hz, 1H), 3.62 (dd, *J*=1.6, 7.6 Hz, 1H), 3.50 (br s, 2H), 3.31 (br d, *J*=13.6 Hz, 3H), 3.11 - 2.97 (m, 2H), 2.94 (br d, *J*=8.8 Hz, 1H), 2.89 - 2.69 (m, 5H), 2.54 (br d, *J*=9.8 Hz, 1H), 2.00 - 1.92 (m, 2H), 1.90 - 1.83 (m, 1H), 1.73 (br d, *J*=10.0 Hz, 1H), 1.53 (s, 9H), 1.41 (s, 9H)




[0741] Step B: 4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: A solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg,

162 umol) in TFA (370 mg, 3.24 mmol, 240 uL) was stirred at 18 °C for 1 hour. Upon completion, the solvent was removed under vacuum to give 4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (140 mg, 161 umol, 99.5% yield, 2TFA) as brown oil.



[0742] Step C: [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a solution of [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (140 mg, 161 umol) and DIEA (167 mg, 1.29 mmol, 225 uL) in DCM (2 mL) was added prop-2-enoyl prop-2-enoate (30.5 mg, 242 umol) at 0°C. The reaction mixture was stirred at 18 °C for 1 hour. Upon completion,the reaction mixture was quenched by addition of water (5 mL) and the aqueous layer extracted with DCM (3 × 10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed flash (Base condition, MeCN/NH_3•H_2O in water: 50 % to 80%) to give [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (60 mg, 86.5 umol, 53.6% yield). ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.22 - 8.13 (m, 1H), 7.84 - 7.78 (m, 1H), 7.56 - 7.45 (m, 2H), 7.31 (d, *J*=2.0 Hz, 1H), 6.86 (d, *J*=2.4 Hz, 1H), 6.62 (br s, 1H), 6.47 - 6.37 (m, 1H), 5.92 - 5.79 (m, 1H), 5.24 - 4.88 (m, 1H), 4.75 (br s, 1H), 4.45 - 4.36 (m, 3H), 4.31 - 4.20 (m, 2H), 4.15 (br d, *J*=13.6 Hz, 1H), 4.10 - 4.01 (m, 2H), 3.64 (dd, *J*=1.6, 7.6 Hz, 2H), 3.51


(br s, 2H), 3.38 (br s, 2H), 3.14 (br s, 1H), 3.08 - 2.73 (m, 7H), 2.56 (br d, *J*=10.0 Hz, 1H), 2.03 - 1.93 (m, 2H), 1.88 (br d, *J*=9.6 Hz, 1H), 1.78 - 1.70 (m, 1H), 1.61 (s, 9H), 1.43 (s, 9H).




[0743] Step D: 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (60 mg, 86.5 umol) in THF (0.5 mL) was added NaOH (2 M, 600 uL). The reaction mixture was stirred at 18 °C for 12 hours. Upon completion, the reaction mixture was acidified by addition of 4 drops of HCOOH (20 % in water) and the aqueous layer was extracted with DCM (5 × 8 mL). The combined organics were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u;mobile phase: [water(0.225%Formic Acid)-ACN];B%: 10%-40%,10min) to give 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (19.8 mg, 28.3 umol, 32.8% yield, 93.8% purity, Formic Acid salt) was obtained as a brown solid. ES+APCI MS m/z 610.5 $[M+H]^+$.

EXAMPLE 154


2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0744] Step A: *tert*-butyl2-(cyanomethyl)-4-[2-methylsulfanyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To the solution of *tert*-butyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (3 g, 7.42 mmol), 1-bromonaphthalene (3.07 g, 14.8 mmol, 2.06 mL) and Cs_2CO_3 (7.25 g, 22.2 mmol) in toluene (60 mL) was added XPhos palladacycle gen 3 (628 mg, 742 umol) under N_2 and the suspension was degassed under vacuum and purged with N_2 several times. The mixture was warmed to 70 °C and stirred at 70 °C for 10 hours. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 × 20 mL). The combined organics were concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (PE: EtOAc from 50:1 to 3:1) to give *tert*-butyl2-(cyanomethyl)-4-[2-methylsulfanyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (3.55 g, 6.02 mmol, 81.2% yield, 90.0 % purity) as brown oil. ES+APCI MS m/z 531.4 $[M+H]^{+}$.




[0745] Step B: *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To the solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.95 g, 5.56 mmol) in DCM (60 mL) was added m-CPBA (1.13 g, 5.56 mmol, 85.0 % purity) at 0 °C and stirred at 0 °C for 1 hour. The reaction mixture was quenched by addition of saturated $Na_2S_2O_3$ (20 mL) at 0°C and layers were separated, and the aqueous layer diluted with water (20 mL) and extracted with EtOAc (60 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash column (ACN/Water (0.1% Formic Acid) = 100 %) to give *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.7 g, 2.80 mmol, 50.3 % yield, 90.0 % purity) as brown solid. . ES+APCI MS m/z 574.4 $[M+H]^+$.




[0746] Step C: *tert*-butyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 549 umol,) and 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol (160 mg, 1.02 mmol) in toluene (6

mL) was added tBuONa (79.1 mg, 823 umol). The reaction mixture was stirred at 18 °C for 0.5 hour. Upon completion, the reaction mixture was purified by silica gel chromatography (PE:EA= 3:1 to 0:1 then EA:MeOH=50:1 to 10:1) to give *tert*-butyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 249 umol, 45.3% yield, 79.6% purity) was obtained as a brown solid. ES+APCI MS m/z 640.5 $[M+H]^+$.



[0747] Step D: 2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: A reaction mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 313 umol) in TFA (770 mg, 6.75 mmol, 500 uL) was stirred at 18 °C for 1 hour. Upon completion the solvent was removed under vacuum to give 2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (271 mg, crude) as a brown oil.





[0748] Step E: 2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-

azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (271 mg, 502 umol) and DIEA (323 mg, 2.50 mmol, 0.435 mL) in DCM (6 mL) was added prop-2-enoyl prop-2-enoate (60 mg, 476 umol) at 0 °C and the reaction mixture stirred at 18 °C for 1 hour. Upon completion, the reaction mixture was quenched by addition of a drop of water and purified by silica gel chromatography (PE: EtOAc=3:1 to 0:1) then prep HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 33%-63%,12min) to give 2-[4-[7-(1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (23.8 mg, 40.0 umol, 7.97% yield) as yellow solid. ES+APCI MS m/z 594.5 $[M+H]^+$.

EXAMPLE 155


(*S*)-1-(4-(7-(5-methyl-1*H*-indazol-4-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0749] Step A: *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (4.15 g, 36.0 mmol, 4.28 mL) in THF (100 mL) was added NaH (2.16 g, 54.06 mmol, 60% purity) in portions at 0 °C. After the mixture was stirred at 0 °C


for 1 hour, a solution of tert-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin -4-yl)piperazine-1-carboxylate (8.0 g, 18.02 mmol) in THF (60 mL) was added and the mixture was stirred at 70 °C for 11 hours. After completion, the reaction mixture was poured into aqueous NH_4Cl (160 mL), and the aqueous layer extracted with EtOAc (2 × 100 mL). The combined organics were dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate/Methanol=10:1) to give *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (4.9 g, 8.70 mmol, 48.3% yield, 92.8% purity) as gray solid. ES+APCI MS m/z 523.2 $[M+H]^+$



[0750] Step B: *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy] -5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.20 g, 4.21 mmol) in MeOH (30 mL) was added $Pd(OH)_2/C$ (700 mg, 10% purity) and the mixture was degassed under vacuum and purged with H_2 several times and the reaction stirred at 40 °C for 12 hours under H_2 (15 Psi). After completion, the reaction mixture was filtered through celite and the filtrate concentrated to give *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy] -5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.80 g, 4.02 mmol, 95.6% yield, 96.7% purity) as black solid. ES+APCI MS m/z 433.1 $[M+H]^+$.




[0751] Step C: *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 462 umol) and 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole (204 mg, 694 umol) in toluene (4 mL) was added $Pd_2(dba)_3$ (63.5 mg, 69.4 umol), RuPhos (43.2 mg, 92.5 umol) and Cs_2CO_3 (301 mg, 925 umol) and the mixture stirred at 110 °C for 12 hours under N_2. After completion, the reaction mixture was partitioned between water (10 mL) and EtOAc and the layers separated. The aqueous layer was subsequently extracted with EtOAc (2 × 10 mL) and the combined organics were dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=5/1 to Ethyl acetate/MeOH=10/1) to give *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 310 umol, 67.1% yield, 83.6% purity) as brown oil. ES+APCI MS m/z 647.6 $[M+H]^+$.



[0752] Step D: 7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: To a mixture of *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 371 umol) in DCM


(1 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL) and the mixture stirred at 15 °C for 1 hour. After completion, the reaction mixture was concentrated to give 7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (250 mg, 309 umol, 83.4% yield, 85.5% purity, 2TFA) as brown solid which was used for the next step without further purification. ES+APCI MS m/z 463.4 $[M+H]^+$.



[0753] Step E: 1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 7-(5-methyl-1H-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (250 mg, 362 umol, 2TFA) in DCM (2 mL) was added DIEA (702 mg, 5.43 mmol, 946 uL) and the mixture cooled to -50 °C. Prop-2-enoyl prop-2-enoate (36.5 mg, 289 umol) was added in portions to the reaction at -50 °C and the mixture stirred at -50 °C for 30 minutes. After completion, the reaction mixture was quenched by addition of MeOH (1 mL) and the mixture concentrated. The residue was taken up in DCM (10 mL) and the organics washed with H_2O (2 × 8 mL). The organics were dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC ((Instrument: gx-l; Column: Phenomenex Gemini C18 250*50mm*10 um; Condition: water (0.05% ammonia hydroxide v/v)-ACN; Begin B: 32; End B: 62; Gradient Time (min): 12; 100%B Hold Time (min): 2; FlowRate (ml/min): 25) to give 1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (48.6 mg, 92.9 umol, 25.7% yield, 98.7% purity) as yellow solid. ES+APCI MS m/z 517.5 $[M+H]^+$.

EXAMPLE 156


(*S*)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(5-(trifluoromethyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0754] (*S*)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(5-(trifluoromethyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following **Example 155** substituting 4-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole (Intermediate 60) for 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole in Step C. ES+APCI MS m/z 571.4 $[M+H]^+$.

EXAMPLE 157

(*S*)-1-(4-(7-(5-methoxy-1*H*-indazol-4-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0755] (*S*)-1-(4-(7-(5-methoxy-1*H*-indazol-4-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following **Example 155** substituting 4-bromo-5-methoxy-1-tetrahydropyran-2-yl-indazole for 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole in Step C. ES+APCI MS m/z 533.4 $[M+H]^+$.

EXAMPLE 158

SUBSTITUTE SHEET (RULE 26)

1-[4-[7-(2-isopropylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0756] Step A: *tert*-butyl 4-[7-(2-isopropylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 462 umol), 1-bromo-2-isopropyl-benzene (120 mg, 601 umol), Cs_2CO_3 (452 mg, 1.39 mmol) and XPHOS PALLADACYCLE GEN 3 (78.3 mg, 92.5 umol) in toluene (4.00 mL) was de-gassed with N_2 and then heated to 100 °C for 10 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated. The crude product was purified by silica gel chromatography eluted with EtOAc/MeOH= 50/1 to 5/1 to give *tert*-butyl 4-[7-(2-isopropylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (84.6 mg, 134 umol, 28.9 % yield, 87.0 % purity) as a yellow solid. ES+APCI MS m/z 551.2 $[M+H]^+$.

[0757] 1-[4-[7-(2-isopropylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 155** substituting *tert*-butyl 4-[7-(2-isopropylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate for *tert*-butyl 4-[2-[[(2*S*)-

1-methylpyrrolidin-2-yl]methoxy]-7-(5-methyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step D. ES+APCI MS m/z 505.6 $[M+H]^+$.

EXAMPLE 159


(*S*)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0758] (*S*)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared following **Example 155** substituting 1-bromo-2-(trifluoromethyl)benzene for 4-bromo-5-methyl-1-tetrahydropyran-2-yl-indazole in Step C. ES+APCI MS m/z 531.5 $[M+H]^+$.


EXAMPLE 160

1-(4-(7-(5-methyl-1*H*-indazol-4-yl)-2-(3-(piperidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0759] Step A: Benzyl 4-[2-methylsulfanyl-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of benzyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d] pyrimidin-4-yl)piperazine-1-carboxylate (3.15 g, 7.88 mmol), 2-[(4-bromo-5-methyl-indazol-1-yl)methoxy]ethyl-trimethyl-silane (3.50 g, 10.2 mmol), Cs_2CO_3 (6.42 g, 19.70 mmol), $Pd_2(dba)_3$ (1.08 g, 1.18 mmol) and RuPhos (735 mg, 1.58 mmol) in toluene (50 mL) was degassed and with N_2 3 times and the mixture stirred at 90 °C for 10 hours under N_2 atmosphere. The reaction mixture was quenched by addition of water (100 mL) and the aqueous layer extracted with ethyl acetate (3 × 100 mL). The combined organics were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced. The residue was purified by column chromatography using 1→33% EtOAc/Petroleum Ether to give benzyl 4-[2-methylsulfanyl-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.30 g, 2.93 mmol, 37.1 % yield). ES+APCI MS m/z 660.3 $[M+H]^+$.




[0760] Step B: benzyl 4-[2-methylsulfinyl-7-[5-methyl-1-(2-trimethylsilyl ethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a stirred solution of benzyl 4-[2-methylsulfanyl-7-[5-methyl-1- (2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.30 g, 3.49 mmol) in DCM (20 mL) was added m-CPBA (601


mg, 3.49 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for 1 hour under N2 atmosphere. The reaction mixture was quenched by addition $Na_2S_2O_3$ (10 mL) at 0 °C, and then diluted with water (100 mL) and the aqueous layer extracted with DCM (200 mL). The combined organics were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography using 1→10% MeOH/DCM as eluent to give benzyl 4-[2-methylsulfinyl-7-[5-methyl-1-(2-trimethylsilyl ethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.00 g, 2.84 mmol, 81.4 % yield). ES+APCI MS m/z 676.3 $[M+H]^+$.



[0761] Step C: benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-2-[3- (1-piperidyl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of benzyl 4-[2-methylsulfinyl-7-[5-methyl-1-(2- trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 739 umol) and 3-(1-piperidyl)propan-1-ol (211 mg, 1.48 mmol) in THF (10 mL) was added t-BuONa (213 mg, 2.22 mmol) portion wise and the mixture stirred at 20 °C for 1 hour under N_2 atmosphere. The mixture was cooled to 0 °C and HCl(2M) was added until the pH~7. The mixture was filtered and filtrate was concentrated in vacuo. The residue was purified by reversed phase flash using water 5→95% 0.5% TFA/water/acetonitrile as eluent to give benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-2-[3- (1-piperidyl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 385. umol, 52.1 % yield). ES+APCI MS m/z 755.4 $[M+H]^+$.



[0762] Step D: 7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-2-(3-(piperidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine: To a solution of benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl) indazol-4-yl]-2-[3-(1-piperidyl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 397 umol) in MeOH (20 mL) was added HCl/MeOH (4 M, 1.99 mL) and $Pd(OH)_2$ (200 mg, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and the filtrate was concentrated to give 7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-2-(3-(piperidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (250 mg, 360 umol, 90.7 % yield).




[0763] Step E: 1-[4-[7-(5-methyl-1H-indazol-4-yl)-2-[3-(1-piperidyl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-2- (3-(piperidin-1-yl)propoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (250 mg, 360 umol, 2HCl) and DIEA (465 mg, 3.60 mmol, 629 uL) in DCM(8.00 mL) was added a solution of prop-2-enoyl prop-2-enoate (36.3 mg, 288 umol) in DCM (2.00 mL) at - 40 °C under nitrogen atmosphere and the reaction stirred for 1 hour. The reaction mixture was quenched by addition $NaHCO_3$(500 uL) at -40°C, and then diluted with water (10 mL) and the aqueous layer extracted with DCM (10 ml). The organics were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, DCM/MeOH 1/0 to 5/1) and further purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225% Formic Acid)-ACN];

B%: 8%-28%, 10min) to give 1-[4-[7-(5-methyl-1H-indazol-4-yl)-2-[3-(1-piperidyl)propoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (16.0 mg, 29.1 umol, 8.07 % yield). ES+APCI MS m/z 545.3 $[M+H]^+$.

EXAMPLE 161


1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[(1-methylpyrrolidin-3-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0764] 1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2-[(1-methylpyrrolidin-3-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 160** substituting (1-methylpyrrolidin-3-yl)methanol for 3-(1-piperidyl)propan-1-ol in Step C. ES+APCI MS m/z 517.4 $[M+H]^+$.


EXAMPLE 162

1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one






[0765] Step A: benzyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of (2*R*)-1-(dimethylamino)propan-2-ol (183 mg, 1.78 mmol) (8.00 mL), benzyl 4-[2-methylsulfinyl-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 592 umol) and NaOtBu (114 mg, 1.18 mmol) in toluene were stirred at 15 °C for 0.5 hour. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by column chromatography over Al_2O_3 (Petroleum Ether/EthylAcetate 10/1 to 0/1) to give benzyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 352 umol). ^{1}H NMR (400 MHz, chloroform-d) δ = 8.08 (s, 1H), 7.46 - 7.39 (m, 5H), 7.38 - 7.33 (m, 2H), 5.76 (s, 2H), 5.43 - 5.33 (m, 1H), 5.24 (s, 2H), 4.35 (s, 2H), 3.72 - 3.67 (m, 4H), 3.64 - 3.56 (m, 4H), 3.55 - 3.47 (m, 4H), 2.87 - 2.80 (m, 2H), 2.74 (dd, *J*=6.8, 12.8 Hz, 1H), 2.49 (s, 3H), 2.47 - 2.40 (m, 1H), 2.36 (s, 6H), 1.42 (d, *J*=6.4 Hz, 3H), 0.98 - 0.92 (m, 2H), 0.00 (s, 9H).




[0766] Step B: *tert*-butyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of benzyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-


d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 280 umol) and $(Boc)_2O$ (122 mg, 559 umol, 129 uL) in MeOH (6.00 mL) was added 10% Pd/C (80 mg) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour and 35 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate concentrated under vacuum to give mixture of *tert*-butyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate and (2*R*)-*N*,*N*-dimethyl-2-[[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine as a mixture (110 mg). ES+APCI MS m/z 681.3 $[M+H]^+$.



[0767] Step C: (2*R*)-*N*,*N*-dimethyl-2-[[7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine: (2*R*)-*N*,*N*-dimethyl-2-[[7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine (TFA) and [4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-5-methyl-indazol-1-yl]methanol. A solution of 110 mg mixture of *tert*-butyl 4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate and (2*R*)-*N*,*N*-dimethyl-2-[[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine in TFA (3.08 g, 27.0 mmol) was stirred at 30 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum to give 260 mg mixture of (2*R*)-*N*,*N*-dimethyl-2-[[7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine and [4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-5-methyl-indazol-1-yl]methanol. ES+APCI MS m/z 451.3 $[M+H]^+$.



[0768] Step D: 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 260 mg mixture of (2*R*)-*N*,*N*-dimethyl-2-[[7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propan-1-amine and [4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-5-methyl-indazol-1-yl]methanol in DCM (1.00 mL) cooled to - 50 °C was added DIEA (594 mg, 4.59 mmol) followed by prop-2-enoyl prop-2-enoate (18.0 mg, 143 umol) dropwise and the mixture was stirred at between -50°C to -40 °C for 30 minutes. Upon completion, the mixture was concentrated under vacuum to give 100 mg mixture of 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one and 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-[1-(hydroxymethyl)-5-methyl-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. ES+APCI MS m/z 505.4 $[M+H]^+$.




[0769] Step E: 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: A mixture of 100 mg of 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one and 1-[4-[2-[(1*R*)-

2-(dimethylamino)-1-methyl-ethoxy]-7-[1-(hydroxymethyl)-5-methyl-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one in THF (22 mL) and water (550 uL) was added NaOH (44.8 mg, 1.12 mmol) and the mixture stirred at 10 °C for 3 hours. Upon completion, the mixture was concentrated under vacuum. The residue was diluted with water (1 mL) and extracted with DCM (3 × 5 mL). The combined organics were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water(0.225% Formic Acid)-ACN];B%: 10%-40%,12min) to give 1-[4-[2-[(1*R*)-2-(dimethylamino)-1-methyl-ethoxy]-7-(5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (16.2 mg, 29.2 umol, 99.0 % purity, Formic Acid Salt) as a off-white solid. ES+APCI MS m/z 505.2 $[M+H]^+$.


EXAMPLE 163

1-(4-(2-(2-(diethylamino)ethoxy)-7-(5-methyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0770] Step A: benzyl 4-[2-[2-(diethylamino)ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a mixture of benzyl 4-[2-methylsulfinyl-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-


yl]piperazine-1-carboxylate (500 mg, 739 umol) and 2-(diethylamino)ethanol (173 mg, 1.48 mmol, 197 uL) in THF (10 mL) was added t-BuONa (213 mg, 2.22 mmol), and the mixture stirred at 20 °C for 1 hour under N_2 atmosphere. The mixture was cooled to 0 °C and HCl (2 M) was added until pH~7. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography using 0→10% MeOH/DCM as eluent to give impure material which was further purified by reversed phase chromatography to give benzyl 4-[2-[2-(diethylamino)ethoxy]-7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (220 mg, 295 umol, 39.9 % yield). ES+APCI MS m/z 729.3 $[M+H]^+$.



[0771] Step B: *N,N*-diethyl-2-[[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethanamine: To a solution of benzyl 4-[2-[2-(diethylamino)ethoxy]-7-[5-methyl-1- (2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 164 umol) in MeOH (10 mL) was added $Pd(OH)_2$ (99.4 mg, 10% purity) and HCl/MeOH (4 M, 823.05 uL) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The mixture was concentrated in vacuo to give *N,N*-diethyl-2-[[7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethanamine (105 mg, 157.24 umol). ES+APCI MS m/z 595.4 $[M+H]^+$.



[0772] Step C: 1-[4-[2-[2-(diethylamino)ethoxy]- 7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of *N*,*N*-diethyl-2-[[7-[5-methyl-1-(2-trimethylsilyl ethoxymethyl)indazol-4-yl]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]ethanamine (105 mg, 158 umol, 2 HCl) and DIEA (204 mg, 1.58 mmol, 276 uL) in DCM (8 mL) at - 40°C was added a solution of prop-2-enoyl prop-2-enoate (15.9 mg, 126.4 umol) in DCM (2 mL) under nitrogen atmosphere and the reaction stirred for 1 hour. The reaction mixture was quenched by addition $NaHCO_3$ (500 uL) at - 40°C, and then diluted with water (10 mL). The aqueous layer was extracted with DCM (10 ml), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography using 0→20% MeOH/DCM as eluent to give 1-[4-[2-[2-(diethylamino)ethoxy]- 7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (60.0 mg, 71.2 umol, 45.0 % yield). ES+APCI MS m/z 649.3 $[M+H]^+$.




[0773] Step D: 1-[4-[2-[2-(diethylamino)ethoxy]-7- (5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[2-[2-(diethylamino)ethoxy]-7-[5-methyl-1- (2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (50 mg, 77.0 umol) in DCM (500 uL) was added TFA (175 mg, 1.54 mmol, 114 uL). The mixture was stirred at 15 °C for 16 hours. The reaction mixture was concentrated under vacuum and the residue purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 32%-62%, 12min) to give 1-[4-[2-[2-(diethylamino)ethoxy]-7- (5-methyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-

4-yl]piperazin-1-yl]prop-2-en-1-one (16.0 mg, 30.2 umol, 39.2 % yield). ES+APCI MS m/z 519.3 $[M+H]^+$.


EXAMPLE 164

1-(4-(7-(5-methyl-1*H*-indazol-4-yl)-2-(2-(piperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)ethanone




[0774] Step A: benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxy methyl)indazol-4-yl]-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of benzyl 4-[2-methylsulfinyl-7-[5-methyl-1- (2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 739 umol) and 2-(1-piperidyl)ethanol (191 mg, 1.48 mmol, 197 uL) in toluene (20 mL) was added t-BuONa (213 mg, 2.22 mmol). The mixture was stirred at 20 °C for 1 hour under N_2 atmosphere. The mixture was cooled to 0 °C and HCl (2 M) was added until pH~7. The mixture was filtered and the filtrate concentrated in vacuo. The residue was purified by column chromatography using 0→10% MeOH/DCM as eluent to give benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxy methyl)indazol-4-yl]-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 404 umol, 54.7 % yield). ES+APCI MS m/z 741.4 $[M+H]^+$.

SUBSTITUTE SHEET (RULE 26)



[0775] Step B: 7-(5-methyl-1*H*-indazol-4-yl)-4- piperazin-1-yl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: A solution of benzyl 4-[7-[5-methyl-1-(2-trimethylsilylethoxymethyl) indazol-4-yl]-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg, 337 umol) in TFA (10 mL) was stirred at 80 °C for 1 hour. The reaction mixture was concentrated under vacuum to give 7-(5-methyl-1*H*-indazol-4-yl)-4- piperazin-1-yl-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (200 mg, 283 umol, 84.1 % yield). ES+APCI MS m/z 477.3 $[M+H]^+$.





[0776] Step C: 1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2- [2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 7-(5-methyl-1*H*-indazol-4-yl)-4-piperazin-1-yl-2- [2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (200 mg, 283 umol, 2TFA) and DIEA (366 mg, 2.84 mmol, 495 uL) in DCM (8 mL) at - 40 °C was added a solution of prop-2-enoyl prop-2-enoate (28.6 mg, 227 umol) DCM (2 mL) under nitrogen atmosphere and the reaction stirred for 1 hour. The reaction mixture was quenched by addition $NaHCO_3$ (500 uL) at - 40°C, and then diluted with water (10 mL) and DCM (10 ml). The separated organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10 um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 30% - 60%, 12min). 1-[4-[7-(5-methyl-1*H*-indazol-4-yl)-2- [2-(1-piperidyl)ethoxy]-6,8-

dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (6.00 mg, 11.1 umol, 3.94 % yield, 99.0 % purity). ES+APCI MS m/z 531.4 $[M+H]^+$.

EXAMPLE 165

1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[0777] Step A: 3-methoxynaphthalen-1-ol: To a solution of naphthalene-1,3-diol (20 g, 125 mmol) in MeOH (150 mL) was added HCl/MeOH (4 M, 250 mL) at 0 °C. The mixture was warmed up to 18 °C and stirred for 36 hours. The mixture was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 1/1). The desired fractions were collected and concentrated under vacuum to give 3-methoxynaphthalen-1-ol (11 g, 62.5 mmol, 50.1% yield, 99% purity) as a light yellow solid. ES+APCI MS m/z 175.1 $[M+H]^+$.

[0778] Step B: 4-bromo-3-methoxy-naphthalen-1-ol: To a solution of 3-methoxynaphthalen-1-ol (0.50 g, 2.87 mmol) in THF (10 mL) was added a solution of NBS (562 mg, 3.16 mmol) in THF (3.00 mL) at 0 °C. After stirring at 0 °C for 2 hours, the mixture was concentrated under vacuum, diluted with H_2O (5 mL), extracted with dichloromethane (3 × 10 mL). The combined extracts were washed with saturated sodium chloride (1 × 20 mL), dried over Na_2SO_4, filtered

and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 3/1) to give 4-bromo-3-methoxy-naphthalen-1-ol (0.43 g, 1.43 mmol, 49.7 % yield) as a yellow solid. ES+APCI MS m/z 253 $[M+H]^+$.

[0779] Step C: 4-bromo-2-fluoro-3-methoxy-naphthalen-1-ol: To a solution of 4-bromo-3-methoxy-naphthalen-1-ol (4.00 g, 15.8 mmol) in acetonitrile (20 mL) was added a solution of 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane;ditetrafluoroborate (6.72 g, 19.0 mmol) in acetonitrile (20 mL) at -40 °C. After stirring at - 40 °C for 1 hour and 10 °C for 3 hours, the mixture was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 3/1) to give 4-bromo-2-fluoro-3-methoxy-naphthalen-1-ol (4.00 g, 10.6 mmol, 67.2 % yield) as a yellow solid. ES+APCI MS m/z 271.0 $[M+H]^+$.

[0780] Step D: 2-fluoro-3-methoxy-naphthalen-1-ol: A mixture of 4-bromo-2-fluoro-3-methoxy-naphthalen-1-ol (2.00 g, 7.38 mmol) and 10% Pd/C (0.01 g) in ethyl acetate (20 mL) was stirred at 10 °C for 1 hour under H_2 at 15 psi. The mixture was filtered and concentrated under vacuum to give 2-fluoro-3-methoxy-naphthalen-1-ol (1.60 g, crude) as yellow oil and used into next step without further purification. ES+APCI MS m/z 193.0 $[M+H]^+$.

[0781] Step E: (2-fluoro-3-methoxy-1- naphthyl) trifluoromethanesulfonate: To a solution of 2-fluoro-3-methoxy-naphthalen-1-ol (1.60 g, crude) and TEA (1.85 g, 18.3 mmol, 2.55 mL) in dichloromethane (30 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (2.35 g, 8.33 mmol, 1.37 mL) at -78 °C for 1 hour. The mixture was quenched with saturated ammonium chloride (30 mL), extracted with ethyl acetate (3 × 20 mL), washed with saturated sodium chloride (1 × 50 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ether acetate = 3/1) to give (2-fluoro-3-methoxy-1- naphthyl) trifluoromethanesulfonate (1.10 g, 2.07 mmol, two steps 24.9 % yield) as a yellow solid. ES+APCI MS m/z 324.9 $[M+H]^+$.

[0782] Step F: *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of *tert*-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.40 g, 865 umol), (2-fluoro-3-methoxy-1-naphthyl) trifluoromethanesulfonate

(561 mg, 1.73 mmol), RuPhos (80.7 mg, 173 umol), $Pd_2(dba)_3$ (79.2 mg, 86.5 umol) and t-BuONa (249 mg, 2.59 mmol) in toluene (10 mL) was stirred at 110 °C for 5 hours under N_2. The mixture was diluted with water (10 mL), extracted with ether acetate (3 × 10 mL). The extracts were washed with saturated sodium chloride (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash chromatography [water (0.1 % Formic Acid)/acetonitrile] to give *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.35 g, 495 umol, 57.2 % yield) as a yellow oil. ES+APCI MS m/z 637.1 $[M+H]^+$.

[0783] Step G: 4-[3-[[7-(2-fluoro-3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine: A mixture of *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2- (3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.40 g, 628. umol) and TFA (1.07 g, 9.42 mmol, 698 uL) in dichloromethane (0.70 mL) was stirred at 10 °C for 1 hour. The mixture was concentrated under vacuum to give 4-[3-[[7-(2-fluoro-3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (0.41 g, crude, TFA) as a yellow oil and used into next step without further purification. ES+APCI MS m/z 537.5 $[M+H]^+$.


[0784] Step H: 1-[4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[3-[[7-(2-fluoro-3-methoxy-1-naphthyl)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (0.41 g, crude, TFA salt) and TEA (635 mg, 6.27 mmol, 873 uL) in dichloromethane (5.0 mL) was added prop-2-enoyl prop-2-enoate (79.1 mg, 627 umol) at - 40 °C. After stirring at – 40 °C for 0.5 h, the mixture was quenched with methanol (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methanol = 10/1) to give 1-[4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (0.25 g, 411 umol, two steps 65.5 % yield) as a yellow oil. ES+APCI MS m/z 591.0 $[M+H]^+$.


[0785] Step I: 1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 1-[4-[7-(2-

fluoro-3-methoxy-1-naphthyl)-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (0.20 g, 339 umol) in dichloromethane (4.00 mL) was added BBr_3 (424 mg, 1.69 mmol, 163 uL) at -78 °C for 0.5 hour and stirred at 0 °C for 2 hours. The mixture was quenched with saturated sodium bicarbonate (5 mL) at -78 °C and stirred at 0 °C for 0.5 h. The mixture was extracted with dichloromethane (3 × 10 mL) and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water(0.225% Formic Acid)-ACN];B%: 13%-45%,7min) to give 1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (35.2 mg, 60.8 umol, 17.9 % yield, 99.4 % purity) as a yellow solid. ES+APCI MS m/z 577.0$[M+H]^+$.

EXAMPLE 166

1-[4-[7-(6-hydroxy-2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[0786] Step A: 4-triisopropylsilyloxyaniline: To a solution of 4-aminophenol (5.00 g, 45.8 mmol, 7.14 mL) in DCM (50.0 mL) was added imidazole (4.06 g, 59.6 mmol). TIPSCl (13.3 g, 68.7 mmol, 14.7 mL) was added to the mixture dropwise. The mixture was stirred at 15 °C for 12 hours. Upon completion, the reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by automated flash chromatography system (PE/EA 100/1 to 3/1) to give 4-triisopropylsilyloxyaniline (9.46 g, 33.9 mmol, 73.9 % yield, 95.0 % purity) as a black oil.

[0787] ^{1}H NMR (400 MHz, chloroform-d) δ = 6.74 - 6.71 (m, 1H), 6.71 - 6.69 (m, 1H), 6.60 - 6.58 (m, 1H), 6.58 - 6.55 (m, 1H), 3.66 - 2.98 (m, 2H), 1.28 - 1.16 (m, 3H), 1.11 - 1.06 (m, 18H)

[0788] Step B: 2,6-dibromo-4-triisopropylsilyloxy-aniline: To a solution of 4-triisopropylsilyloxyaniline (7.30 g, 27.5 mmol) in DCM (73.0 mL) and MeOH (73.0 mL) was added Br_2 (11.0 g, 68.8 mmol, 3.55 mL) in DCM (5 mL) dropwise at 0 °C. The mixture was stirred at 15 °C for 5 hours. Upon completion, the mixture was diluted with sodium sulfite solution (60 mL) and extracted with DCM (3 × 200 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography (PE/EA 50/1 to 1/1) to give 2,6-dibromo-4-triisopropylsilyloxy-aniline (10.8 g, 23.2 mmol, 84.4 % yield, 90.8 % purity) as a brown oil. ES+APCI MS m/z 423.9$[M+H]^+$.

[0789] Step C: *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)acetamide: To a solution of 2,6-dibromo-4-triisopropylsilyloxy-aniline (10.4 g, 24.6 mmol) and CH_3COOH (52 mL) was added acetic anhydride (10.9 g, 107 mmol, 10 mL). The reaction mixture was stirred at 90 °C for 1 hour. Upon completion, water (100 mL) and DCM (200 mL) were added and layers were separated. The aqueous phase was extracted with DCM (100 mL × 2). The combined extracts were washed with 5 % Na_2CO_3 (80 mL), washed with brine (100 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography (PE/EA 50/1 to 1:1) to give *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)acetamide (7.32 g, 14.2 mmol, 57.6 % yield, 90.0 % purity) as a brown solid.

[0790] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.16 (s, 1H), 7.11 (s, 2H), 2.21 (s, 3H), 1.28 - 1.24 (m, 3H), 1.12 - 1.09 (m, 18H).

[0791] Step D: *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)thioacetamide: To a solution of *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)acetamide (7.22 g, 15.5 mmol) in toluene (116 mL) was added LAWESSON'S REAGENT (3.14 g, 7.76 mmol). The mixture was heated to 110 °C for 2 hours. Upon completion, the mixture was concentrated under vacuum. The residue was purified by column chromatography (PE/EA 100/1 to 1/1) *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)thioacetamide (5.41 g, 8.40 mmol, 54.1 % yield, 74.7 % purity) as a yellow oil. ES+APCI MS m/z 481.9$[M+H]^+$.

[0792] Step E: 4-bromo-2-methyl-1,3-benzothiazol-6-ol: CuI (94.2 mg, 494 umol) was added to a solution of *N*-(2,6-dibromo-4-triisopropylsilyloxy-phenyl)thioacetamide (2.38 g, 4.94 mmol), 1,10-phenanthroline (134 mg, 741 umol) and Cs_2CO_3 (4.83 g, 14.8 mmol) in DME (48.0 mL). Then the reaction mixture was stirred at 80 °C for 12 hours under N_2. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (PE/EA 50/1 to 0/1) to give 4-bromo-2-methyl-1,3-benzothiazol-6-ol (1.33 g, 3.54 mmol, 71.7 % yield, 65.0 % purity) as a brown oil.

[0793] ^{1}H NMR (400 MHz, DMSO-d_6) δ = 7.33 (d, *J*=2.4 Hz, 1H), 7.14 (d, *J*=2.4 Hz, 1H), 3.40 - 3.33 (m, 1H), 2.72 (s, 3H).

[0794] Step F: 6-benzyloxy-4-bromo-2-methyl-1,3-benzothiazole: To a mixture of 4-bromo-2-methyl-1,3-benzothiazol-6-ol (1.28 g, 5.24 mmol) and K_2CO_3 (2.17 g, 15.72 mmol) in ACN (26.0 mL) was added BnBr (988 mg, 5.76 mmol, 685 uL). The reaction mixture was stirred at 45 °C for 1 hour. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography (PE/EA 200/1 to 10/1) to give 6-benzyloxy-4-bromo-2-methyl-1,3-benzothiazole (1.10 g, 3.13 mmol, 59.7 % yield, 95.0 % purity) as a light yellow solid. ES+APCI MS m/z 336.2 $[M+H]^+$.

[0795] Step G: benzyl 4-[7-(6-benzyloxy-2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: Benzyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 805 umol), 6-benzyloxy-4-bromo-2-methyl-1,3-benzothiazole (323 mg, 967 umol), RuPhos (75.2 mg, 161 umol), Cs_2CO_3 (787 mg, 2.42 mmol) and $Pd_2(dba)_3$ (73.8 mg, 80.6 umol) in toluene (16 mL) was stirring at 85 °C for 16 hours under N_2. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by column chromatography over Al_2O_3 (PE/EA 10/1 to 0/1) to give benzyl 4-[7-(6-benzyloxy-2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (340 mg, 408 umol, 50.7 % yield, 90.0 % purity) as a yellow oil. ES+APCI MS m/z 750.5$[M+H]^+$.


[0796] Step H: 2-methyl-4-[2-(3-morpholinopropoxy)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-1,3-benzothiazol-6-ol: To a solution of benzyl 4-[7-(6-benzyloxy-

2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (160 mg, 213 umol) in MeOH (4 mL) was added HCl/MeOH (4 M, 533 uL), followed by $Pd(OH)_2/C$ (80 mg, 533 umol) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 8 hours. Upon completion, the reaction mixture was filtered and the filtrate was concentrated to give 2-methyl-4-[2-(3-morpholinopropoxy)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-1,3-benzothiazol-6-ol (110 mg, 126 umol, 59.2 % yield, 68.7 % purity, 2 HCl) as a yellow solid which was used directly in the next step without further purification. ES+APCI MS m/z 526.2$[M+H]^+$.

[0797] Step I: 1-[4-[7-(6-hydroxy-2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 2-methyl-4-[2-(3-morpholinopropoxy)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-1,3-benzothiazol-6-ol (110 mg, 184 umol, 2 HCl) and DIEA (143 mg, 1.10 mmol, 193 uL) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (18.5 mg, 147 umol) dropwise at - 50 °C. The mixture was stirred at -40 - -20 °C for 30 minutes. Upon completion, the mixture was quenched by MeOH (0.5 mL) and concentrated under vacuum. The residue was diluted with water (2 mL) and extracted with DCM (3 × 6 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography over Al_2O_3 (DCM/MeOH 20/1 to 10/1), prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 21%-51%,12min) to give 1-[4-[7-(6-hydroxy-2-methyl-1,3-benzothiazol-4-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (32.4 mg, 55.4 umol, 30.2 % yield, 99.1 % purity) as a yellow solid. ES+APCI MS m/z 580.4$[M+H]^+$.

EXAMPLE 167

1-(4-(7-(5-hydroxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0798] Step A: 2-bromo-4-methoxyaniline: At -10 °C, to a solution of 4-methoxyaniline (100 g, 812 mmol) in THF (3 L) was added *N*-bromosuccinimide (152 g, 853 mmol) in three portions and the mixture was stirred at the same temperature for 30 min. The mixture was concentrated

under reduced pressure. The residue was purified by column chromatography. (petroleum ether/ethyl acetate 15/1) to give 2-bromo-4-methoxyaniline as red oil (30.58 g, 18.6% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.01 (d, *J*=2.4 Hz, 1H), 6.74-6.70 (m, 2H), 3.85-3.74 (m, 2H), 3.73 (s, 3H).

[0799] Step B: 1-(2-amino-3-bromo-5-methoxyphenyl)-2-chloropropan-1-one: To a 0 °C solution of 2-bromo-4-methoxy-aniline (15.0 g, 74.2 mmol) in 1,1-dichloroethane (220 mL) was added boron trichloride (1.00 M, 89.1 mL), 2-chloropropanenitrile (9.97 g, 111 mmol) and titanium tetrachloride (16.9 g, 89.1 mmol). The mixture was heated at 85 °C for 24 hours. The mixture was poured into ice and hydrochloric acid (20%, 300 mL) at 0 °C, concentrated and the residue was refluxed for 0.5 hour. This mixture was basified at 0 °C with sodium hydroxide (saturated aqueous, 120 mL) until pH 4 was attained and then extracted with ethyl acetate (300 mL × 2). The combined organic extracts were washed with brine (200 mL), dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether/ethyl acetate/dichloromethane 50/1/1), to give 1-(2-amino-3-bromo-5-methoxyphenyl)-2-chloropropan-1-one as yellow solid (18.7 g, 86.3% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.37 (d, *J* = 2.8 Hz, 1H), 7.32 (d, *J* = 2.8 Hz, 1H), 6.60 (brs, 2H), 5.25 (q, *J* = 6.4 Hz, 1H), 3.80 (s, 3H), 1.74 (d, *J* = 6.4 Hz, 3H).

[0800] Step C: 7-bromo-5-methoxy-2-methyl-1*H*-indole: To a solution of 1-(2-amino-3-bromo-5-methoxy-phenyl)-2-chloro-propan-1-one (18.7 g, 64.1 mmol) in dioxane (500 mL) and H_2O (50 mL) was added $NaBH_4$ (2.67 g, 70.5 mmol) and this mixture stirred at 100 °C for 15 hours. The mixture was cooled, diluted with hydrochloric acid (aq., 0.10 M, 100 mL) and extracted with dichloromethane (300 mL × 2). The organics were washed with brine (200 mL), dried with anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether/ethyl acetate 25/1) to give 7-bromo-5-methoxy-2-methyl-1*H*-indole as yellow solid (7.01 g, 45.6% yield). ^{1}H NMR (400 MHz, $CDCl_3$) δ = 7.91 (brs, 1H), 7.03-6.91 (m, 2H), 6.23 (d, *J* = 1.2 Hz, 1H), 3.84 (s, 3H), 2.46 (s, 3H).

[0801] Step D: *tert*-butyl 4-(7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-

carboxylate (275 mg, 594 umol) and 7-bromo-5-methoxy-2-methyl-1*H*-indole (130 mg, 540 umol) in 2-methyl-2-butanol (15.0 mL) was added ^{t}BuONa (104 mg, 1.08 mmol) and chloro(2-dicyclohexylphosphino-2',6'-di-^{i}propoxy-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(II) methyl-t-butyl ether adduct (44.1 mg, 54.0 umol). This mixture stirred at 90 °C for 8 hours under a N_2 atmosphere. The mixture was filtered, concentrated under reduced pressure. The residue was purified by prep-TLC (dichloromethane/methanol 10/1), to give *tert*-butyl 4-(7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate as yellow oil (131 mg, 36.8 % yield). ES+APCI MS m/z 622.4$[M+H]^+$.

[0802] Step E: 4-[3-[[7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxy]propyl]morpholine: To a 0 °C solution of *tert*-butyl 4-[7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (131 mg, 211 umol) in dichloromethane (10 mL) was added trifluoroacetic acid (2.00 mL) dropwise and the reaction stirred at 15 °C for 3 hours. The mixture was concentrated under reduced pressure, and the residue was used in the next step without further purification. (126 mg crude product). ES+APCI MS m/z 522.4$[M+H]^+$.


[0803] Step F: 1-(4-(7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a -60 °C solution of 4-[3-[[7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxy]propyl]morpholine (74 mg, 116 umol, trifluoroacetic acid salt) in dichloromethane (5 mL) was added diisopropylethylamine (45.1 mg, 349 umol, 60.8 uL) and the mixture stirred at the same temperature for 10 min. The mixture was quenched with citric acid (aq., 1.00 mL), extracted with dichloromethane (10 mL × 2), washed with brine (15 mL), dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by prep-TLC to give 1-(4-(7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one as yellow solid (31 mg, 39.2 % yield). ES+APCI MS m/z 576.4$[M+H]^+$.


[0804] Step G: 1-(4-(7-(5-hydroxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)- 5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a -78 °C solution of 1-[4-[7-(5-methoxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-

pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (26 mg, 45.2 umol) in dichloromethane (5 mL) was added boron tribromide (56.6 mg, 226 umol, 21.8 uL). The reaction was allowed to warm to 0 °C and stirred for 12 hours. The mixture was neutralized withy $NaHCO_3$ (aq., 3 mL) and extracted with dichloromethane (5 mL × 2), washed with brine (10 mL), dried by anhydrous sodium sulfate, concentrated under vacuum. The residue was purified by prep-HPLC to give 1-(4-(7-(5-hydroxy-2-methyl-1*H*-indol-7-yl)-2-(3-morpholinopropoxy)- 5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one as yellow solid (8.16 mg, 29.1% yield, 90.3% purity). ES+APCI MS m/z 562.5$[M+H]^+$.

EXAMPLE 168

1-(3-(hydroxymethyl)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one





[0805] Step A: *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate: To a solution of *tert*-butyl 3-(hydroxymethyl)piperazine-1-carboxylate (3.50 g, 16.2 mmol) in THF (30 mL) was added NaH (3.24 g, 80.9 mmol, 60.0 % purity) at 0 °C. After stirring for 30 minutes, TBDPSCl (6.67 g, 24.3 mmol, 6.23 mL) was added in one portion. The mixture was warmed to 10 °C and stirred for 12 hours under N_2 atmosphere. The reaction mixture was quenched by addition water at 0 °C, and then extracted with DCM (200 mL). The organic layer was dried with Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 1/0 to 1/2) to give

tert-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (6.34 g, 12.1 mmol, 74.8 % yield, 86.8 % purity) as a colorless oil. ES+APCI MS m/z455.3$[M+H]^+$.

[0806] Step B: *tert*-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)- 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate: A mixture of *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl] piperazine-1-carboxylate (7.25 g, 13.9 mmol), 7-benzyl-2,4-dichloro-6,8-dihydro -5*H*-pyrido[3,4-d]pyrimidine (3.89 g, 13.2 mmol) and DIEA (4.27 g, 33.0 mmol, 5.77 mL) in DMSO (60 mL) was stirred at 55 °C for 24 hours under N_2 atmosphere. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with brine (3 × 150 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 1/0 to 3/1) to give *tert*-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)- 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (4.50 g, 5.91 mmol, 44.7 % yield, 93.5 % purity) as a yellow solid. ES+APCI MS m/z 721.3$[M+H]^+$.

[0807] Step C: *tert*-butyl4-[7-benzyl-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate: A mixture of *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl)-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (2.00 g, 2.81 mmol), 3-morpholinopropan-1-ol (815 mg, 5.62 mmol), $Pd(OAc)_2$ (94.6 mg, 422 umol), BINAP (350 mg, 562 umol) and t-BuONa (674 mg, 7.03 mmol) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was heated to 110 °C and stirred for 3 hours under N_2 atmosphere. After completion, the reaction mixture was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, DCM/MeOH 70/1 to 20/1) to give *tert*-butyl4-[7-benzyl-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (1.50 g, 1.69 mmol, 60.0 % yield, 92.3 % purity) as a yellow solid. ES+APCI MS m/z 821.4$[M+H]^+$.

[0808] Step D: *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-benzyl-2-(3-morpholinopropoxy) -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (1.50 g, 1.83 mmol) in MeOH (20 mL) was added Pd-C (10 %, 1.5 g) under N_2. The suspension was degassed under vacuum

and purged with H_2 several times. The mixture was stirred under H_2 (50 psi) at 50 °C for 24 hours. The reaction mixture was filtered and concentrated under reduced pressure to give *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (988 mg, 1.21 mmol, 66.1 % yield, 89.5 % purity) as a colorless oil, which was used directly for next step without further purification. ES+APCI MS m/z 731.5$[M+H]^+$.

[0809] Step E: *tert*-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate: A mixture of *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl] -4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (731 mg, 1.00 mmol), 3-benzyloxy-1-bromo-naphthalene (783 mg, 2.50 mmol), [2-(2-aminophenyl)phenyl]palladium(1+);dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane;methanesulfonate (169 mg, 200 umol), Cs_2CO_3 (815 mg, 2.50 mmol) in toluene (15 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 60 °C for 24 hours under N_2 atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to dryness and purified by column chromatography (SiO_2, DCM/MeOH = 70/1 to 30/1) to give *tert*-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (250 mg, 188 umol, 18.8 % yield, 72.3 % purity) as a yellow solid. ES+APCI MS m/z 963.4$[M+H]^+$.

[0810] Step F: *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (250 mg, 188 umol) in MeOH (3 mL) was added 10% Pd/C (0.25 g) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 50 °C for 3 hours. After completion, the reaction mixture was filtered and concentrated under reduced pressure to dryness to give *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-

carboxylate (180 mg, 128 umol, 68.1 % yield, 62.0 % purity) as a dark yellow solid, which was used directly for next step without further purification. ES+APCI MS m/z 873.4$[M+H]^+$.


[0811] Step G: 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-(3-morpholinopropoxy)-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: A mixture of *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl] -4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 149 umol), pyridine hydrofluoride (123 mg, 744 umol, 112 uL, 60.0 % purity) in THF (1.5 mL) was stirred at 25 °C for 12 hours under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to dryness. The residue was purified by reverse phase HPLC (TFA condition; MeCN in H_2O; 0 ~ 30 %, flow rate; 40 mL/mins). The desired fractions were concentrated under reduced pressure to give 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-(3-morpholinopropoxy)-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (84 mg, 104 umol, 69.6 % yield, 94.1 % purity, 2TFA) as a yellow semisolid. ES+APCI MS m/z 535.3 $[M+H]^+$.


[0812] Step H: 1-[3-(hydroxymethyl)-4-[7-(3-hydroxy-1- naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-(3- morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (84.0 mg, 114 umol, 2TFA), DIEA (36.9 mg, 285 umol, 49.8 uL) in DCM (3 mL) was added prop-2-enoyl prop-2-enoate (8.63 mg, 68.44 umol) drop wise at -40 °C, and then stirred at -40 °C for 0.5 hours under N_2 atmosphere. The reaction mixture was quenched by addition MeOH (0.5 mL) and concentrated under reduced pressure to dryness. The residue was purified by prep-HPLC (column: Venusil XBP C8 150 * 25 * 10 um; mobile phase: [water (0.225 % Formic Acid)-ACN]; B%: 10% - 40%, 10 min). The desired fractions were collected and lyophilized to dryness to give 1-[3-(hydroxymethyl)-4-[7-(3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (9.75 mg, 14.5 umol, 12.7 % yield, 94.4 % purity, Formic Acid Salt) as a yellow solid. ES+APCI MS m/z 589.3$[M+H]^+$.

EXAMPLE 169

SUBSTITUTE SHEET (RULE 26)


1-[3-(hydroxymethyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one






[0813] Step A: *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate: To a mixture of *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidin-4-yl)-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (495 mg, 694 umol), [(2*S*)-1-methylpyrrolidin-2-yl]methanol (160 mg, 1.39 mmol, 165 uL) and sodium tert-butoxide (200 mg, 2.08 mmol) in toluene (25 mL) was added BINAP (86.5 mg, 139 umol) and $Pd_2(dba)_3$ (63.6 mg, 69.5 umol). The mixture was bubbled with nitrogen atmosphere and stirred at 80 °C for 6 h. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 × 15 mL). The combined organic layers were washed with water (2 × 30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 30/1 to 1:1) to give *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (207 mg, 262 umol, 37.7 % yield) as a yellow solid.^{1}H NMR (400MHz, chloroform-d) δ =7.62 - 7.53 (m, 4H), 7.43 - 7.28 (m, 11H), 4.42 - 4.29 (m, 1H), 4.26 - 3.87 (m, 4H), 3.81 (br d, *J* = 13.2 Hz, 2H), 3.75 – 3.60 (m, 4H), 3.44 (dd, *J* = 1.6, 17.2 Hz, 1H), 3.24 - 3.04 (m, 3H), 2.96 (br s,


1H), 2.75 (br s, 3H), 2.49 (s, 3H), 2.43 - 2.28 (m, 2H), 2.10 - 1.96 (m, 2H), 1.91 - 1.80 (m, 1H), 1.80 - 1.67 (m, 2H), 1.43 (s, 9H), 1.02 - 0.89 (m, 9H).



[0814] Step B: *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: NH_3 was bubbled in methanol (30 mL) at -40 °C for 30 minutes. To a solution of *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (530 mg, 670 umol) in above mixture was added dry 10% Pd/C(0.30 g) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 40°C for 10 hours under 15 psi of H_2. The reaction mixture was filtered and concentrated under reduced pressure to give *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (394 mg, 427 umol, 63.8 % yield) as a yellow solid. ^{1}H NMR (400MHz, chloroform-d) δ = 7.57 (br t, *J* = 6.0 Hz, 4H), 7.43 - 7.33 (m, 6H), 4.43 (br dd, *J* = 5.2, 10.4 Hz, 1H), 4.32 - 4.00 (m, 4H), 3.99 - 3.89 (m, 2H), 3.88 - 3.65 (m, 4H), 3.27 - 2.89 (m, 6H), 2.81 (br d, *J* = 8.4 Hz, 2H), 2.56 - 2.50 (m, 3H), 2.42 (br d, *J* = 16.8 Hz, 2H), 2.13 - 2.03 (m, 1H), 1.88 (br d, *J* = 6.8 Hz, 1H), 1.79 (br d, *J* = 5.2 Hz, 2H), 1.43 (s, 9H), 0.95 (br s, 9H).




[0815] Step C: *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[tert-butyl(diphenyl) silyl]oxymethyl]piperazine-1-carboxylate: A mixture of *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.16 g, 228 umol), 3-benzyloxy-1-bromo-naphthalene (143 mg, 457 umol), [2-(2-aminoethyl)phenyl]-chloro-palladium;dicyclohexyl-[2-(2,4,6- triisopropylphenyl)phenyl]phosphane (16.9 mg, 22.8 umol) and t-BuONa (43.9 mg, 457 umol) in toluene (4 mL) was stirred at 70 °C for 12 hours under N_2. The mixture was diluted with water (5.00 mL) and extracted with ether acetate (3 × 10 mL). The combined organics were washed with saturated sodium chloride (10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (formic acid, 0.1 %)/acetonitrile] to give *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[tert-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (0.15 g, 157 umol, 68.9 % yield) as a yellow solid. ES+APCI MS m/z 933.1$[M+H]^+$.




[0816] Step D: *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: NH_3 was bubbled into methanol (10 mL) at -78 °C for 30 minutes. *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[[tert-butyl(diphenyl)silyl]oxymethyl]piperazine-1-carboxylate (0.10 g, 107 umol) and dry 10% Pd/C (0.01 g) were added and the mixture was stirred at 10 °C for 1 hour under 15 psi of H_2. The slurry was filtered through a pad of celite and the filtrate concentrated under vacuum to give *tert*-butyl 3-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.09 g,

crude) as a yellow oil and used into next step without further purification. ES+APCI MS m/z 843.0 $[M+H]^+$.



[0817] Step E: 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol: A mixture of *tert*-butyl 3-[[tert-butyl(diphenyl)silyl]oxymethyl]-4-[7- (3-hydroxy-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.04 g, crude) and pyridine;hydrofluoride (118 mg, 712 umol, 106 uL) in dichloromethane (2 mL) was stirred at 0 °C for 1 hour and stirred at 10 °C for 12 hours. The pH of the mixture was adjusted to pH>7 by addition of saturated sodium bicarbonate solution (3.00 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methanol = 5/1) to give 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (0.04 g, crude) as a yellow solid. ES+APCI MS m/z 505.2 $[M+H]^+$.





[0818] Step F: 1-[3-(hydroxymethyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[4-[2-(hydroxymethyl)piperazin-1-yl]-2-[[(2*S*)- 1-methylpyrrolidin-2-

yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol (0.02 g, crude) and TEA (40.1 mg, 396 umol, 55.17 uL) in dichloromethane (2 mL) was added prop-2-enoyl prop-2-enoate (999 ug, 7.93 umol) at -40 °C, then the mixture was stirred at -40 °C for 0.5 h. The mixture was quenched by addition of methanol (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methanol = 5/1). The desired fractions were collected and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (10mM NH4HCO3)-ACN]; B%: 38%-68%, 3min). The desired fractions were collected and lyophilized to give 1-[3-(hydroxymethyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (1.08 mg, 1.73 umol). ES+APCI MS m/z 559.5 $[M+H]^+$.

EXAMPLE 170

2-(1-acryloyl-4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile





[0819] Step A: 1-(tert-butyl)2-methyl4-(7-benzyl-2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl) piperazine-1,2-dicarboxylate: To a solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido [3,4-d] pyrimidine (5.00 g, 17.0 mmol) and 1-*tert*-butyl 2-methylpiperazine-1,2- dicarboxylate (4.24 g, 17.3 mmol) in DMSO (80 mL) was added DIEA (5.49 g, 42.5 mmol, 7.42 mL). After stirring at 55 °C for 12 hours, the mixture was diluted with ethyl acetate (100 mL), washed with brine (3 × 150 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, PE/EA = 3/1) to give 1-*tert*-butyl 2-methyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-4-

yl)piperazine-1,2-dicarboxylate (8.00 g, 15.9 mmol, 93.8 % yield) as a yellow oil. ES+APCI MS m/z 502.1$[M+H]^+$.

[0820] Step B: **1**-(tert-butyl) 2-methyl 4-(7-benzyl-2-(2-(dimethylamino)ethoxy) -5,6,7,8-tetrahydropyrido [3,4-d]pyrimidin-4-yl) piperazine-1,2-dicarboxylate**:** A mixture of 1-*tert*-butyl 2-methyl 4-(7-benzyl-2-chloro-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl) piperazine-1,2-dicarboxylate (8.00 g, 15.9 mmol), 2-(dimethylamino)ethanol (2.84 g, 31.9 mmol, 3.19 mL), Cs_2CO_3 (13.0 g, 39.8 mmol), $Pd(OAc)_2$ (537 mg, 2.39 mmol) and BINAP (1.98 g, 3.19 mmol) in toluene (30 mL) was stirred at 110 °C for 3 hours under nitrogen. The mixture was diluted with water (30 mL) and then extracted with ethyl acetate (3 × 50 mL). The extracts were washed with brine (1 × 100 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase HPLC (TFA, 0.1 %) to give 1-*tert*-butyl 2-methyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (6.00 g, 10.8 mmol, 67.9 % yield) as a yellow solid. ES+APCI MS m/z 555.3$[M+H]^+$.

[0821] Step C: 1-*tert*-butyl 2-methyl 4-[2-[2-(dimethylamino)ethoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate**:** A mixture of 1-*tert*-butyl 2-methyl 4-[7-benzyl-2-[2-(dimethylamino) ethoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (6.00 g, 10.8 mmol) and 10% Pd/C (600 mg, 10.8 mmol) in MeOH (100 mL) was stirred at 40 °C for 12 hours under H_2 at 50 psi. The mixture was filtered and the filtrate was concentrated under vacuum to give 1-*tert*-butyl 2-methyl 4-[2-[2-(dimethylamino)ethoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (4.50 g, crude) was obtained as a yellow solid. ES+APCI MS m/z 465.3$[M+H]^+$.

[0822] Step D: 1-*tert*-butyl 2-methyl 4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidin-4-yl]piperazine -1,2-dicarboxylate: A mixture of 1-*tert*-butyl 2-methyl 4-[2-[2-(dimethylamino)ethoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (2.90 g, 6.24 mmol), 3-benzyloxy-1-bromo-naphthalene (2.54 g, 8.12 mmol), $Pd_2(dba)_3$ (857 mg, 936 umol), RuPhos (728 mg, 1.56 mmol) and Cs_2CO_3 (5.08 g, 15.6 mmol) in 1,4-dioxane (150 mL) was stirred at 85 °C for 5 hours under N_2. The mixture was diluted with water (100 mL), extracted with DCM (1 × 200 mL). The extracts were, washed with brine (1 × 300 mL), dried over Na_2SO_4, filtered

and concentrated under vacuum. The residue was purified by reverse phase HPLC (TFA, 0.1 %) to give 1-*tert*-butyl 2-methyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*- pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (3.50 g, 5.02 mmol, two steps 72.5 % yield) as a brown solid. ES+APCI MS m/z 697.3 $[M+H]^+$.

[0823] Step E: *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy] -6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(hydroxymethyl)piperazine- 1-carboxylate: To a solution of 1-*tert*-butyl 2-methyl 4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1,2-dicarboxylate (1.00 g, 1.44 mmol) in THF (10 mL) was added $LiAlH_4$ (219 mg, 5.76 mmol) in portions at -60 °C. After stirring for 2 hours, the mixture was quenched with saturated sodium sulfate solution (0.3 mL), filtered and the filter cake washed with DCM (100 mL). The combined filtrate was concentrated under vacuum to give *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5H-pyrido[3,4-d] pyrimidin-4-yl]-2-(hydroxymethyl)piperazine-1-carboxylate (750 mg, 1.12 mmol, 77.8 % yield) as a yellow solid. ES+APCI MS m/z 669.3 $[M+H]^+$.

[0824] StepF: 2-[4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8-dihydro -5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: A mixture of *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2- (dimethylamino)ethoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(hydroxymethyl) piperazine-1-carboxylate (100 mg, 149 umol), TBAI (11.1 mg, 29.9 umol), 1-(p-tolylsulfonyl)imidazole (79.9 mg, 359 umol), NaCN (0.12 g, 2.45 mmol), and TEA (37.8 mg, 374 umol, 51.8 uL) in DMF was stirred at 155 °C for 6 hours. The mixture was concentrated under vacuum, diluted with water (1 × 5 mL) and then extracted with ethyl acetate(3 × 10 mL). The extracts were washed with brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC column: Phenomenex Gemini C18 250*50mm*10 um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 50%-70%, 28 MIN) to give 2-[4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, 277 umol, 37.1 % yield) as a yellow solid. ES+APCI MS m/z 578.5$[M+H]^+$.


[0825] Step G: 2-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy] -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of


2-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2- (dimethylamino)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60 mg, 104 umol) and DIEA (67.1 mg, 519 umol, 90.7 uL) in DCM (2 mL) was added prop-2-enoyl prop-2-enoate (13.1 mg, 104 umol) at 0 °C. After stirred at 10 °C for 4 hours, the mixture was quenched with MeOH (0.1 mL), then concentrated under vacuum. The residue was purified by column chromatography (SiO_2, DCM/MeOH 10/1) to give 2-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy] -6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (40.0 mg, 63.3 umol, 61.0 % yield) as a yellow oil. ES+APCI MS m/z 632.3$[M+H]^+$.


[0826] Step H: 2-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2- (dimethylamino)ethoxy] -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (30 mg, 47.5 umol) in DCM (2 mL) was added BBr_3 (35.7 mg, 142 umol, 13.7 uL) at -78 °C under 0.5 h. The mixture was warmed up to 0 °C and stirred for 2 hours. The mixture was concentrated under vacuum and then quenched with saturated sodium bicarbonate solution at -78 - 0 °C. The mixture was purified by column chromatography (Al_2O_3, DCM/MeOH = 5/1), then further purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 30%-60%,12min). The desired fractions were collected and lyophilized to give 2-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (810 ug, 1.46 umol, 3.07% yield, 97.5% purity) as a yellow solid. ES+APCI MS m/z 542.5 $[M+H]^+$.

EXAMPLE 171

1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(2-hydroxyethyl)piperazin-1-yl)prop-2-en-1-one







[0827] Step A: Ethyl 2-(3-oxopiperazin-2-yl)acetate: To a solution of diethyl (*E*)-but-2-enedioate (30.2 g, 175 mmol, 28.8 mL) in *i*-PrOH (300 mL) was added ethane-1,2-diamine

(11.0 g, 183 mmol, 12.2 mL). After stiring at 25 °C for 12 hours, the reaction mixture was concentrated under reduced pressure to dryness. The crude white solid was washed with MTBE (500 mL) and dried under vacuum to give ethyl 2-(3-oxopiperazin-2-yl)acetate (26.0 g, 140 mmol, 79.6 % yield, 100 % purity) as a white solid.^{1}H NMR (400 MHz, Chloroform-d) δ = 6.55 (br s, 1H), 4.15 (q, J = 6.8 Hz, 2H), 3.80 - 3.72 (m, 1H), 3.47 (dt, J = 4.8, 11.2 Hz, 1H), 3.36 - 3.22 (m, 1H), 3.18 - 3.08 (m, 1H), 3.07 - 2.95 (m, 2H), 2.76 - 2.70 (m, 1H), 1.25 (t, J = 7.2 Hz, 3H).

[0828] Step B: Ethyl 2-[1-[(4-methoxyphenyl)methyl]-3-oxo- piperazin-2-yl]acetate: To a mixture of ethyl 2-(3-oxopiperazin-2-yl)acetate (23.6 g, 127 mmol) in methanol (400 mL) was added 4-methoxybenzaldehyde (18.9 g, 139 mmol, 16.9 mL) and CH_3COOH (15.2 g, 253 mmol, 14.5 mL) at 0 °C. After stiring at 0 °C for 1 hour, the reaction mixture was cooled to -10 °C. $NaBH_3CN$ (23.9 g, 380 mmol) was added to the mixture in portions and the reaction mixture was warmed up to 15 °C and stiring for another 11 hours. The reaction was quenched by adding water (400 ML) and extracted with DCM (2 × 300 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The residue was re-dissolved with ethyl acetate (300 mL), then washed with 0.5 M HCl solution (2 × 200 mL). The aqueous phase was adjusted to pH 7 ~ 8 with Na_2CO_3 solid, then extracted with DCM (2 × 300 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated to give ethyl 2-[1-[(4-methoxyphenyl)methyl]-3-oxo- piperazin-2-yl]acetate (27.2 g, 87.6 mmol, 69.0 % yield, 98.5 % purity) as colorless oil. ES+APCI MS m/z 307.1 $[M+H]^+$.

[0829] Step C: 2-[1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethanol: To a mixture of ethyl 2-[1-[(4-methoxyphenyl)methyl]-3-oxo- piperazin-2-yl]acetate (27.2 g, 88.8 mmol) in THF (500 mL) was added $LiAlH_4$ (10.1 g, 266 mmol) in portions at 0 °C. After stirring at 0 °C for 1 hour, the reaction mixture was heated to 70 °C and stirred for 11 hours. After completion, the reaction was quenched with sat.Na_2SO_4 aqueous (40 mL), filtered and then concentrated. The product 2-[1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethanol (20 g, crude) was obtained as yellow oil. ES+APCI MS m/z 251.1 $[M+H]^+$.

[0830] Step D: *tert*-butyl-[2-[1-[(4-methoxyphenyl)methyl] piperazin-2-yl]ethoxy]- diphenyl-silane: To a mixture of 2-[1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethanol (20 g, crude) in THF(300 mL) was added NaH (15.9 g, 399 mmol, 60 % purity) at 0 °C in portions, then a

solution of TBDPSCl (65.9 g, 239 mmol, 61.6 mL) in THF (100 mL) was added. The mixture was warmed up to 15 °C and stirred for a further 12 hours. After completion, the reaction was poured into NH_4Cl solution (300 mL), and extracted with DCM (2 × 300 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate 3/1 to Dichloromethane/Methanol 10/1) to give *tert*-butyl-[2-[1-[(4-methoxyphenyl)methyl] piperazin-2-yl]ethoxy]-diphenyl-silane (29.5 g, 59.9 mmol, two steps 35 %, 99.2 % purity) as yellow oil. ES+APCI MS m/z 489.4$[M+H]^+$.

[0831] Step E: *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[(4-methoxyphenyl)methyl] piperazine-1-carboxylate: To a mixture of *tert*-butyl-[2-[1-[(4-methoxyphenyl) methyl] piperazin-2-yl]ethoxy]-diphenyl-silane (11.0 g, 22.5 mmol) in MeOH (200 mL) was added TEA (6.83 g, 67.5 mmol, 9.36 mL) and $(Boc)_2O$ (9.82 g, 45.0 mmol, 10.3 mL). After stirring at 15 °C for 3 hours, the reaction was concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate 1/0 to 5/1) to give *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[(4-methoxyphenyl)methyl] piperazine-1-carboxylate (11.0 g, 18.7 mmol, 82.9 % yield, 100 % purity) as colorless oil. ES+APCI MS m/z 589.4 $[M+H]^+$.

[0832] Step F: *tert*-butyl 3-[2-[*tert*-butyl(diphenyl) silyl]oxyethyl]piperazine-1-carboxylate: To a mixture of *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4- [(4-methoxyphenyl)methyl]piperazine-1-carboxylate (9.00 g, 15.3 mmol) in MeOH (150 mL) was added 10% Pd/C (849 umol). The suspension was degassed under vacuum and purged with H_2 for three times. The mixture was stirred under H_2 (50 Psi) at 40 °C for 18 hours. After completion, the reaction mixture was filtered through a Celite plug and the filtrate was concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 10/1 to 3:1) to give *tert*-butyl 3-[2-[*tert*-butyl(diphenyl) silyl]oxyethyl]piperazine-1-carboxylate (5.80 g, 12.2 mmol, 79.5 % yield, 98.2 % purity) as colorless oil. ES+APCI MS m/z 469.4 $[M+H]^+$.

[0833] Step G: 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethoxy-tert-butyl-diphenyl-silane: A mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidine (4.00 g, 13.6 mmol), *tert*-butyl-[2-[1-[(4-methoxyphenyl)methyl] piperazin-2-yl]ethoxy]-diphenyl-silane (6.98 g, 14.3 mmol)

and DIEA (4.39 g, 34.0 mmol, 5.93 mL) in DMSO (80 mL) was degassed and purged with N_2 for 3 times, and the mixture was heated to at 55 °C and stirred for 12 hours under N_2 atmosphere. The reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine (3 × 200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 1/0 to 3/1) to give 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethoxy-tert-butyl-diphenyl-silane (9.00 g, 11.7 mmol, 86.0 % yield, 97.0 % purity) as a yellow oil. ES+APCI MS m/z 746.4$[M+H]^+$.

[0834] Step H: 2-[[7-benzyl-4-[3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[(4-methoxyphenyl) methyl]piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine: A mixture of 2-(dimethylamino)ethanol (2.39 g, 26.8 mmol, 2.69 mL), 2-[4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-1-[(4-methoxyphenyl)methyl]piperazin-2-yl]ethoxy-*tert*-butyl-diphenyl-silane (8.00 g, 10.7 mmol), $Pd(OAc)_2$ (361 mg, 1.61 mmol), BINAP (1.34 g, 2.14 mmol) and Cs_2CO_3 (8.73 g, 26.8 mmol) in toluene (100 mL) was degassed and purged with N_2 for 3 times. The mixture was heated to 110 °C and stirred for 3 hours under N_2 atmosphere. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM/MeOH 50/1 to 10/1) to give 2-[[7-benzyl-4-[3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[(4-methoxyphenyl) methyl]piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (6.50 g, crude) as a yellow semisolid. ES+APCI MS m/z 799.4 $[M+H]^+$.

[0835] Step I: 2-[4-[7-benzyl-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]piperazin-2-yl]ethanol: 2-[4-[7-benzyl-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]piperazin-2-yl]ethanol: A solution of 2-[[7-benzyl-4-[3-[2-[*tert*-butyl (diphenyl)silyl]oxyethyl] -4-[(4-methoxyphenyl)methyl]piperazin-1-yl] -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (6.50 g, crude) in TFA (80 mL) was stirred at 80 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to dryness and the residue was re-dissolved into DCM (300 mL) and washed with water (200 mL). The water phase was collected and basified with saturated $NaHCO_3$ aqueous to

pH ~ 8 and then extracted with DCM (3 × 200 mL). The combined organic phase was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 2-[4-[7-benzyl-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]piperazin-2-yl]ethanol (3.00 g, crude) as a yellow semisolid, which was used directly for next step without further purification.

[0836] Step J: 2-[[7-benzyl-4-[3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine: A solution of 2-[4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro -5*H*-pyrido[3,4-d]pyrimidin-4-yl] piperazin-2-yl]ethanol (3.0 g, crude) in THF (40 mL) was added NaH (1.36 g, 34.1 mmol, 60.0 % purity) at 0 °C. After stirring for 30 minutes, TBDPSCl (2.81 g, 10.2 mmol, 2.63 mL) was added by portions. The mixture was warmed to 25 °C and stirred for another 2 hours under N_2 atmosphere. The reaction mixture was quenched by addition water (30 mL) at 0 °C and extracted into ethyl acetate(3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness to give 2-[[7-benzyl-4-[3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (6.00 g, crude) as a yellow oil, which was used directly for next step without further purification. ES+APCI MS m/z 679.4 $[M+H]^+$.

[0837] Step K: *tert*-butyl4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate: A mixture of 2-[[7-benzyl-4-[3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl] piperazin-1-yl]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (6.0 g, crude), Boc_2O (18.5 g, 84.8 mmol, 19.5 mL) in MeOH (3 mL) was degassed and purged with N_2 for 3 times. The mixture was heated to 80 °C and stirred for 3 hours under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM /MeOH 1/0 to 10/1) to give *tert*-butyl4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (3.10 g, 3.28 mmol, four steps 30.7 % yield, 82.2 % purity) as a semisolid. ES+APCI MS m/z 779.4 $[M+H]^+$.

[0838] Step L: *tert*-butyl2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl4-[7-benzyl-2-[2-(dimethylamino)ethoxy] -6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (3.10 g, 3.28 mmol, 82.2 % purity) in MeOH (60 mL) was added Pd-C (10 %, 2 g) under N_2. The suspension was degassed under vacuum and purged with H_2 for three times. The mixture was stirred under H_2 (50 psi) at 50 °C for 36 hours. The reaction mixture was filtered and concentrated under reduced pressure to dryness to give *tert*-butyl2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.20 g, 2.75 mmol, 83.8 % yield, 86.0 % purity) as a yellow solid, which was used directly for next step without further purification. ES+APCI MS m/z 689.4 $[M+H]^+$.

[0839] Step M: *tert*-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate: A mixture of *tert*-butyl2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.85 g, 2.69 mmol), 3-benzyloxy-1-bromo-naphthalene (1.09 g, 3.49 mmol), Cs_2CO_3 (2.19 g, 6.71 mmol), [2-(2-aminophenyl)phenyl]palladium(1+); dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane;methanesulfonate (341 mg, 403 umol) in toluene (40 mL) was degassed and purged with N_2 for 3 times, and the mixture was stirred at 65 °C for 10 hours under N_2 atmosphere. After completion, the reaction mixture was filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM/MeOH 1/0 to 10 /1) to give *tert*-butyl4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate(1.85 g, 1.69 mmol, 63.2 % yield, 84.3 % purity) as a yellow solid. ES+APCI MS m/z 922.5 $[M+H]^+$.


[0840] Step N: 1-[4-[7-(3-benzyloxy -1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]prop-2-en-1-one: To a solution of *tert*-butyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2- [2-[tert-

butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (500 mg, 543 umol), 2,6-lutidine (700 mg, 6.51 mmol, 759 uL) in DCM (10 mL) was added TMSOTf (724 mg, 3.26 mmol, 588 uL). After stirring at 40 °C for 2 hours under N_2 atmosphere, the reaction mixture was cooled to -40 °C and prop-2-enoyl prop-2-enoate (137 mg, 1.09 mmol) was added portionwise. The reaction mixture was warmed to 25 °C and stirred for another 12 hours under N_2 atmosphere. After completion, the reaction mixture was purified directly by column chromatography (SiO_2, DCM/MeOH 30/1 to 10/1) to give 1-[4-[7-(3-benzyloxy -1-naphthyl)-2-[2-(dimethylamino)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]prop-2-en-1-one (256 mg, 226 umol, 41.6 % yield, 77.2 % purity) as a semisolid. ES+APCI MS m/z 875.5 $[M+H]^+$.

[0841] Step O: 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-2-(2-hydroxyethyl)piperazin-1-yl]prop-2-en-1-one**:** To a solution of 1-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethyl amino)ethoxy]-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-2-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]prop-2-en-1-one (133 mg, 152 umol) in DCM (5.00 mL) was added BBr_3 (571 mg, 2.28 mmol, 220 uL) dropwise at -40 °C. The reaction mixture was warmed to 0 °C and stirred for 3 hours. The mixture was concentrated under reduced pressure to dryness. The crude material was washed with MTBE (25 mL) and the solid was collected. The solid was washed with saturated $NaHCO_3$ solution (0.5 mL) to pH ~ 8 at 0 °C then dissolved in MeOH (3 mL). The mixture was directly purified by prep-HPLC(column: Boston Green ODS 150*30 5u;mobile phase: [water (0.225 % Formic Acid)-ACN]; B %: 15 % - 39 %, 10 min) to give 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-2-(2-hydroxyethyl)piperazin-1-yl]prop-2-en-1-one (16.7 mg, 28.2 umol, 18.5 % yield, 99.9 % purity, Formic Acid Salt) as a yellow solid. ES+APCI MS m/z 547.3 $[M+H]^+$.

EXAMPLE 172

1-(4-(2-(2-(dimethylamino)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-(2-hydroxyethyl)piperazin-1-yl)prop-2-en-1-one



[0842] Step A: *tert*-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate: A mixture of 7-benzyl-2,4-dichloro- 6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidine (3.04 g, 10.3 mmol), *tert*-butyl3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl] piperazine-1-carboxylate (5.08 g, 10.8 mmol), DIEA (3.34 g, 25.8 mmol, 4.51 mL) in DMSO (60 mL) was degassed and purged with N_2 for 3 times。 The mixture heated to 55 °C and stirred for 16 hours under a N_2 atmosphere. After cooling to room

temperature, the reaction mixture was diluted with water (100 mL) and extracted with ehtyl acetate (3 × 100 mL). The combined organic layers were washed with brine (3 × 100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate 1/0 to 3/1) to give *tert*-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (3.50 g, 4.53 mmol, 43.9 % yield, 94.0 % purity) as a yellow semisolid. ES+APCI MS m/z 726.4 $[M+H]^+$.

[0843] Step B: *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate: A mixture of 2-(dimethylamino)ethanol (1.07 g, 12.1 mmol, 1.21 mL), *tert*-butyl4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-[2- [*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (3.50 g, 4.82 mmol), $Pd(OAc)_2$ (162 mg, 723 umol,), BINAP (600 mg, 964 umol) and Cs_2CO_3 (3.92 g, 12.1 mmol) in toluene (40 mL) was degassed and purged with N_2 for 3 times. The mixture was heated to 110 °C with stirring for 3 hours under N_2 atmosphere. After cooling to the room temperature, the reaction mixture was filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 1/0 to 10/1) to give *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (2.30 g, 2.57 mmol, 53.3 % yield, 87.0 % purity) as a yellow solid. ES+APCI MS m/z 779.5 $[M+H]^+$.

[0844] Step C: *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4- [2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 4-[7-benzyl-2-[2-(dimethylamino)ethoxy] -6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl] piperazine-1-carboxylate (2.30 g, 2.95 mmol) in MeOH (40 mL) was added Pd-C(10%, 1.5 g) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. After stirring under H_2 (50 psi) at 50 °C for 36 hours, the reaction mixture was filtered and concentrated under reduced pressure to give *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-

carboxylate (1.58 g, 1.83 mmol, 61.9 % yield, 79.6 % purity) as a colorless oil, which was used directly for next step without further purification. ES+APCI MS m/z 689.4 $[M+H]^+$.

[0845] Step D: *tert*-butyl4-[7-(3- benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl] piperazine-1-carboxylate: A mixture of *tert*-butyl 3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]-4- [2-[2-(dimethylamino)ethoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl] piperazine-1-carboxylate (1.48 g, 2.15 mmol), 3-benzyloxy-1-bromo-naphthalene (875 mg, 2.80 mmol), Cs_2CO_3 (1.75 g, 5.38 mmol), [2-(2-aminophenyl)phenyl]palladium(1+); dicyclohexyl- [2-(2,4,6-triisopropylphenyl)phenyl]phosphane;methanesulfonate (273 mg, 323 umol) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 65 °C for 24 hours under N_2 atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to dryness. The residue was purified by column chromatography (Al_2O_3, DCM/MeOH = 1/0 to 20/1) to give *tert*-butyl4-[7-(3- benzyloxy-1-naphthyl)-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (1.20 g, 1.07 mmol, 49.7 % yield, 82.0 % purity) as a yellow solid. ES+APCI MS m/z 921.4 $[M+H]^+$.

[0846] Step E: 2-[[7-(3-benzyloxy-1-naphthyl)-4-[2-[2-[*tert*-butyl (diphenyl)silyl]oxyethyl]piperazin-1-yl]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl] oxy]-*N*,*N*-dimethyl-ethanamine: A mixture of *tert*-butyl4-[7-(3-benzyloxy-1-naphthyl)- 2-[2-(dimethyl amino)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d] pyrimidin-4-yl]-3- [2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazine-1-carboxylate (300 mg, 326 umol) and 2,6-lutidine (419 mg, 3.91 mmol, 455 uL) in DCM (10 mL) was added TMSOTf (434 mg, 1.95 mmol, 353 uL) portionwise at 0 °C. The mixture was warmed to 10 °C and stirred for 12 hours under N_2 atmosphere. The reaction mixture was purified directly by column chromatography (Al_2O_3, DCM/MeOH 1/0 to 50/1) to give 2-[[7-(3-benzyloxy-1-naphthyl)-4-[2-[2-[*tert*-butyl (diphenyl)silyl]oxyethyl] piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (210 mg, 229 umol, 70.3 % yield, 89.5 % purity) as a yellow semi-solid. ES+APCI MS m/z 821.5 $[M+H]^+$.

[0847] Step F: 1-[4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8- dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl] oxyethyl]piperazin-1-yl]prop-


2-en-1-one: To a mixture of 2-[[7-(3-benzyloxy-1-naphthyl)- 4-[2-[2-[*tert*-butyl (diphenyl)silyl] oxyethyl]piperazin-1-yl]-6,8- dihydro-5*H*-pyrido[3,4-d] pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (210 mg, 256 umol) and DIEA (49.6 mg, 384 umol, 67.0 uL) in DCM (10 mL) was added prop-2-enoyl prop-2-enoate (33.9 mg, 269 umol) portionwise at – 40 °C under nitrogen atmosphere. After stirring for 30 minutes at the same temperature, the reaction mixture was purified directly by column chromatography (Al_2O_3, DCM/MeOH 1/0 to 50/1) to give 1-[4-[7-(3-benzyloxy-1-naphthyl)-2- [2-(dimethylamino)ethoxy]-6,8-dihydro- 5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]prop-2-en-1-one (221 mg, 214 umol, 83.6 % yield, 84.7 % purity) as a slight yellow semi-solid. ES+APCI MS m/z 875.4 $[M+H]^+$.

[0848] Step G: 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-(2-hydroxyethyl)piperazin-1-yl]prop-2-en-1-one: A mixture of 1-[4-[7-(3-benzyloxy-1-naphthyl)-2-[2-(dimethylamino) ethoxy]-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidin-4-yl]-3-[2-[*tert*-butyl(diphenyl)silyl]oxyethyl]piperazin-1-yl]prop-2-en-1-one (221 mg, 253 umol) in DCM (10 mL) was added BBr_3 (949 mg, 3.79 mmol, 365 uL) at -40 °C. The mixture was stirred at 0 °C for 3 hours under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to dryness. The crude pdt was washed with MTBE (25 mL), saturated $NaHCO_3$ solution (0.5 mL) to pH ~ 8 at 0 °C and dissolved in MeOH (3 mL). The resulting solution was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225 % Formic Acid) - ACN]; B %: 11 % - 41 %, 10 min) to give 1-[4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-(2-hydroxyethyl)piperazin-1-yl]prop-2-en-1-one (26.7 mg, 44.0 umol, 17.4 % yield, 97.8 % purity, Formic Acid Salt) as a yellow solid. ES+APCI MS m/z 547.3 $[M+H]^+$.

EXAMPLE 173

1-(4-(7-(3-hydroxy-2-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one


SUBSTITUTE SHEET (RULE 26)



[0849] 1-(4-(7-(3-hydroxy-2-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was prepared according to the procedure for **Example 165** 1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-(3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one substituting (3-methoxy-2-methyl-1-naphthyl) trifluoromethanesulfonate for (2-fluoro-3-methoxy-1-naphthyl) trifluoromethanesulfonate in step F to give the desired product 1-(4-(7-(3-hydroxy-2-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one as yellow solid (10.4 mg, 13.1% yield, 98.1% purity). ES+APCI MS m/z 573.5 $[M+H]^+$.

EXAMPLE 174

(*R*)-1-(4-(2-((5,5-dimethylpyrrolidin-2-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0850] Step A: tert-Butyl (5*R*)-5-(hydroxymethyl)-2,2-dimethyl-pyrrolidine-1-carboxylate: To a solution of (2*R*)-1-*tert*-butoxycarbonyl-5,5-dimethyl-pyrrolidine- 2-carboxylic acid (500 mg, 2.06 mmol) in anhydrous THF (4 mL) was added BH_3-Me_2S (2 M, 1.23 mL) dropwise at 15 °C. The reaction was heated at 50 °C for 5 minutes. After cooling in an ice-bath, to the mixture was added Methanol (20 mL). The reaction mixture was concentrated under reduced pressure at 25° C. *tert*-Butyl (5*R*)-5-(hydroxymethyl)-2,2-dimethyl-pyrrolidine-1-carboxylate (400 mg, 1.74 mmol, 84.9% yield) was obtained as a white solid.

[0851] ^{1}H NMR (400MHz, methanol-d_4) δ = 3.97 - 3.81 (m, 1H), 3.62 (dd, *J* = 3.6, 10.8 Hz, 1H), 3.45 - 3.33 (m, 1H), 2.02 - 1.79 (m, 3H), 1.79 - 1.67 (m, 1H), 1.49 - 1.41 (m, 12H), 1.32 (s, 3H).

[0852] Step B: Benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2- [[(2*R*)-1-*tert*-butoxycarbonyl-5,5-dimethyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl (5*R*)-5-(hydroxymethyl)-2,2-dimethyl- pyrrolidine-1-carboxylate (212 mg, 926 umol) and benzyl 4-[7-(3-benzyloxy-1-naphthyl) -2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 463 umol,) in THF (10 mL) was added t-BuONa (133 mg, 1.39 mmol). After stirring at 15 °C for 1 hour, the reaction mixture was poured into H_2O (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile]. The desired fractions were collected and concentrated under vacuum. Compound benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2- [[(2*R*)-1-*tert*-butoxycarbonyl-5,5-dimethyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (110 mg, 129 umol, 28.1% yield, 96% purity) was obtained as a yellow solid. ES+APCI MS m/z 813.5 $[M+H]^+$.

[0853] Step C: *tert*-butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-carboxylate: NH_3 was bubbled into MeOH (30 mL) at - 40 °C for 30 minutes. To a solution of benzyl 4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*R*)-1-*tert*-butoxycarbonyl-5,5- dimethyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 246 umol) in above the mixture (NH_3/MeOH) was added dry Pd-C (10%, 100 mg) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. The catalyst was filtered off and the filtrate was concentrated to give the product *tert*-butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-carboxylate (150 mg, 244 umol, 99.4% yield, 96 % purity) as a yellow solid and directly used next step without purification. ES+APCI MS m/z 589.3 $[M+H]^+$.


[0854] Step D: *tert*-Butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-carboxylate: To a mixture of *tert*-butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4- piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-

carboxylate (130 mg, 221 umol) and DIEA (285 mg, 2.21 mmol, 385 uL) in dichloromethane (3 mL) was added a solution of prop-2-enoyl prop-2-enoate (22.3 mg, 176 umol) in dichloromethane (1 mL) at - 40 °C under nitrogen atmosphere. The mixture was stirred at - 40 °C for 1 hour. The reaction was quenched by addition of saturated $NaHCO_3$ (2 mL) aqueous solution. Then the mixture was poured into water (20 mL) and extracted with dichloromethane (20 mL × 2). The combined organics was dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO_2, dichloromethane/methanol = 1/0 to 10/1). *tert*-Butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-carboxylate (140 mg, 217 umol, 98.6 % yield) was obtained as a brown oil. ES+APCI MS m/z 643.6 $[M+H]^+$.

[0855] Step E: 1-[4-[2-[[(2*R*)-5,5-dimethylpyrrolidin-2-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of *tert*-butyl (5*R*)-5-[[7-(3-hydroxy-1-naphthyl)-4- (4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]-2,2-dimethyl-pyrrolidine-1-carboxylate (120 mg, 187 umol) in dichloromethane (200 uL) was added TFA (212 mg, 1.87 mmol, 138 uL). The mixture was stirred at 15 °C for 1 hour. The reaction mixture was concentrated under vacuum, then diluted with dichloromethane (5 mL) and adjusted PH=7 by addition saturated $NaHCO_3$ aqueous solution. The mixture was extracted with dichloromethane (10 mL × 3). The combined organic phase was dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05 % ammonia hydroxide v/v)-ACN]; B%: 45 %-75 %, 12min). 1-[4-[2-[[(2*R*)-5,5-dimethylpyrrolidin-2-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (30 mg, 53.6 umol, 28.7 % yield, 97 % purity) was obtained as yellow solid by lyophilization. ES+APCI MS m/z 543.5 $[M+H]^+$.

EXAMPLE 175


(*S*)-1-(4-(7-(3-hydroxy-2-methylnaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0856] (*S*)-1-(4-(7-(3-hydroxy-2-methylnaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one was synthesized according to the procedure for Example 165 substituting *tert*-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]pipcrazine-1-carboxylate for *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2- (3-morpholinopropoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate and (2-fluoro-3-methoxy-1-naphthyl) trifluoromethanesulfonate for (3-methoxy-2-methyl-1-naphthyl) trifluoromethanesulfonate in Step F. to give 1-[4-[7-(3-hydroxy-2-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (10.2 mg, 17.3 umol, 21.4 % yield, 100 % purity, Formic Acid Salt) as a white solid. ES+APCI MS m/z 543.4 $[M+H]^+$.

EXAMPLE 176

2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0857] Step A: *tert*-butyl (3a*R*)-1-oxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate: To a solution of imidazole (15.7 g, 231 mmol) in DCM (100 mL) was added $SOCl_2$ (8.25 g, 69.4 mmol, 5.03 mL) at 0 °C. The reaction mixture was stirred at 15 °C for 1 hour. To the mixture was added *tert*-butyl (3*R*)-3-(hydroxymethyl)piperazine-1-carboxylate (5 g, 23.1 mmol) in DCM (100 mL) at -70 °C. The reaction mixture was stirred at 15 °C for 12 hour. Upon completion, the reaction mixture was quenched by saturated NH_4Cl (100 mL) and separated, the aqueous layer was extracted with DCM (40 mL).The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl (3a*R*)-1-oxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate (5.8 g, 22.1 mmol, 95.6% yield) as a brown solid.

[0858] Step B: *tert*-butyl (3a*R*)-1,1-dioxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate: To a solution of *tert*-butyl (3a*R*)-1-oxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate (7.5 g, 28.6 mmol) in MeCN (225 mL) was added $NaIO_4$ (7.95 g, 37.2 mmol, 2.06 mL) in water (75 mL) followed by $RuCl_3.H_2O$ (129 mg, 572 umol) at 0 °C. The reaction mixture was stirred at 15 °C for 0.5 hour. Upon completion, the reaction mixture was quenched with saturated NH_4Cl (10 mL) and extracted with EtOAc (20 mL).The organic layer was washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc=3:1 to 1:1) to give *tert*-butyl (3a*R*)-1,1-dioxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate (7 g, 25.2 mmol, 88.0% yield) as a white solid. ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 4.64 (dd, *J*=6.4, 8.0 Hz, 1H), 4.36 - 3.94 (m, 3H), 3.64 (ddt, *J*=3.6, 6.0, 9.2 Hz, 1H), 3.46 (br d, *J*=11.6 Hz, 1H), 3.13 (br s, 1H), 2.96 (dt, *J*=3.2, 11.2 Hz, 2H), 1.48 (s, 9H)

[0859] Step C: *tert*-butyl (3*S*)-3-(cyanomethyl)piperazine-1-carboxylate: To a solution of *tert*-butyl (3a*R*)-1,1-dioxo-3a,4,6,7-tetrahydro-3*H*-oxathiazolo[3,4-a]pyrazine-5-carboxylate (5 g, 18.0 mmol) in DMF (100 mL) was added KCN (1.04 g, 16.0 mmol, 684.94 uL).The reaction mixture was heated to 50 °C for 16 hours. Upon completion, the reaction mixture was quenched by HCl (2 M, 50 mL) and stirred at 15 °C for 1h.The mixture was basidified by NaOH (40 %, 10 mL) and extracted with EtOAc (3 × 100 mL).The organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc=3:1 to 0:1 then EtOAc: MeOH= 100:1 to 10:1) to give *tert*-butyl (3*S*)-3-

(cyanomethyl)piperazine-1-carboxylate (1.1 g, 4.88 mmol, 27.2% yield) as a brown oil.^{1}H NMR (400MHz, CHLOROFORM-d) δ = 4.05 - 3.71 (m, 2H), 3.08 - 2.88 (m, 3H), 2.84 - 2.62 (m, 2H), 2.56 - 2.37 (m, 2H), 1.47 (s, 9H).

[0860] Step D: 2-[(2*S*)-piperazin-2-yl]acetonitrile: A reaction mixture of *tert*-butyl (3*S*)-3-(cyanomethyl)piperazine-1-carboxylate (850 mg, 3.77 mmol) and HCl/dioxane (4 M, 20 mL) was stirred at 15 °C for 1 hour. Upon completion, the solvent was removed under vacuum to give 2-[(2*S*)-piperazin-2-yl]acetonitrile (740 mg, 3.74 mmol, 99.0% yield, 2HCl) as a white solid. ^{1}H NMR (400MHz, METHANOL-d_4) δ = 4.04 - 3.90 (m, 1H), 3.81 - 3.70 (m, 2H), 3.69 - 3.61 (m, 2H), 3.53 - 3.36 (m, 2H), 3.13 (d, *J*=6.4 Hz, 2H).

[0861] Step E: 2-[(2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile: To a mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (1.3 g, 4.42 mmol) and 2-[(2*S*)-piperazin-2-yl]acetonitrile (1.17 g, 5.91 mmol, 2HCl) in dioxane (25 mL) was added DIEA (2.86 g, 22.1 mmol, 3.85 mL). The reaction mixture was stirred at 50 °C for 12 hours. Upon completion, the reaction mixture was diluted with water (50 mL) and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 and concentrated under vacuum to give 2-[(2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile (1.69 g, 4.41 mmol, 100% yield) as a brown solid.

[0862] Step F: *tert*-butyl (2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: A reaction mixture of 2-[(2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl]acetonitrile (1.69 g, 4.41 mmol) and $(Boc)_2O$ (10.3 g, 47.2 mmol, 10.8 mL) was heated to 50 °C for 2 hours. Upon completion, the reaction mixture was purified by silica gel chromatography (PE: EtOAc=10:1 to 1:1) to give *tert*-butyl (2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.1 g, 2.12 mmol, 48.0% yield, 93% purity) as brown solid. ES+APCI MS m/z 483.4 $[M+H]^+$.

[0863] Step G: *tert*-butyl (2*S*)-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of 2-(dimethylamino)ethanol (415 mg, 4.66 mmol, 468 uL)in THF (20 mL) was added NaH (149

mg, 3.73 mmol, 60% purity) 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h. To the mixture was added *tert*-butyl (2*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (900 mg, 1.86 mmol). The reaction mixture was stirred at 70 °C for 12 hours at sealed tube under N_2.Upon completion, the reaction mixture was quenched by water (10 mL) and extracted with EtOAc (3 × 40 mL). The combined organic layers were treated with activated carbon and filtered. The filtrate was concentrated under vacuum to give *tert*-butyl (2*S*)-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 1.12 mmol, 60.1% yield) as a brown solid.

[0864] Step H: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: NH_3 was bubbled into MeOH (20 mL) for 5 min. To the solution was added *tert*-butyl (2*S*)-4-[7-benzyl-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 1.12 mmol) and 10% Pd/C (200 mg).The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40°C for 16 hours. Upon completion, the mixture was filtered and the filter cake was washed with MeOH (3 × 30 mL). The filtrate was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna(2) C18 250*50 10u;mobile phase: [water(0.225% Formic Acid)-ACN];B%: %-%,30MIN;60%min) to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (167 mg, 331 umol, 29.6% yield, 88.3% purity) as a colorless oil. ES+APCI MS m/z 446.3 $[M+H]^+$.

[0865] Step I: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl (2S)-2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 404 umol), (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (248 mg, 808 umol) and Cs_2CO_3 (395 mg, 1.21 mmol) in toluene (6 mL) was added XPHOS Palladacycle Gen 3 (34.20 mg, 40.4 umol). The reaction mixture was stirred at 70 °C for 4 hours under N_2. Upon completion, the reaction mixture was purified by silica gel chromatography (PE:EA= 5:1 to 0:1) to give *tert*-butyl (2*S*)-

2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 272 umol, 67.3% yield, 91.3% purity) as a brown solid. ES+APCI MS m/z 672.0 $[M+H]^+$.

[0866] Step J: [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 298 umol) in DCM (0.3 mL) was added TFA (420 mg, 3.68 mmol, 273 uL). The reaction mixture was stirred at 15 °C for 1 hour. Upon completion, the reaction mixture was concentrated under vacuum to give [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (238 mg, 298 umol, 99.9% yield, 2TFA) as a brown oil.

[0867] Step K: [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a solution of [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (238 mg, 298 umol, 2TFA) and DIEA (308 mg, 2.38 mmol, 415 uL) in DCM (5 mL) was added prop-2-enoyl prop-2-enoate (56.3 mg, 446 umol) at 0 °C. The reaction mixture was stirred at 15 °C for 1hour. Upon completion, the reaction mixture was quenched with a drop of water .The mixture(was purified by silica gel chromatography (PE: EtOAc= 1:1 to 0:1 then EtOAc: MeOH= 50:1 to 3:1) to give [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (300 mg, crude) as a brown oil. ES+APCI MS m/z 626.4 $[M+H]^+$.


[0868] Step L: 2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[2-(dimethylamino)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (300 mg, 479 umol) in THF (3 mL) was added NaOH (2 M, 3 mL) in water.The reaction mixture was stirred at 15 °C for 8 hours. Upon completion, the reaction mixture was acidified by 0.5 mL of formic

acid (20 % in water) to PH=7 and extracted with DCM (5 × 10 mL).The combined organic layers were dried over Na_2SO_4 , filtered and concentrated under vacuum.

[0869] The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u;mobile phase: [water(0.225% Formic Acid)-ACN];B%: 25%-49%,10min) to give 2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (18.3 mg, 30.2 umol, two steps 10.1% yield, 96.7% purity, Formic Acid Salt) as a yellow solid. ES+APCI MS m/z 542.5 $[M+H]^+$.

EXAMPLE 177

2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0870] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 549 umol) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol (126 mg, 1.10 mmol) in toluene (6 mL) was added t-BuONa (79.1 mg, 823 umol) at 18 °C and the reaction mixture stirred at 18 °C for 0.5 hour. To the mixture was then added EtOAc (20 mL) and water (15 mL), then extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by reversed phase flash column (ACN/Water (0.1% Formic Acid) = 42 %) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 331 umol, 60.4 % yield, 99.0 % purity) as yellow solid. ES+APCI MS m/z 598.3$[M+H]^+$.


[0871] Step B: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 334 umol) and TFA (763 mg, 6.69 mmol, 495 uL) was stirred at 18 °C for 1 hour. The reaction mixture was concentrated under vacuum to give 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (250 mg, crude, 2TFA) as brown oil.


[0872] Step C: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (250 mg, 344 umol, 2TFA) and DIEA (356 mg, 2.76 mmol, 480 uL) in DCM (5 mL) was added prop-2-enoyl prop-2-enoate (65.2 mg, 517 umol) at 0 °C and the mixture was stirred at 18 °C for 1.5 hours. The reaction mixture was quenched with water (3 mL) and then extracted with DCM (3 × 6 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini

150*25mm*10um;mobile phase: [water(10mM NH4HCO3)-ACN];B%: 30%-60%,3min) to give 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (9.98 mg, 17.0 umol, 4.94 % yield, 94.1 % purity) as white solid. ES+APCI MS m/z 552.5[M+H]$^+$.

EXAMPLE 178

2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[0873] Step A: 7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-ol: A suspension of MeOH (1000 mL) and Na (22.0 g, 957 mmol, 22.7 mL) was stirred for 30 min. To this mixture was added ethyl 1-benzyl-3-oxo-piperidine-4-carboxylate (50 g, 191 mmoland 2-methylisothiourea (47.9 g, 344 mmol, 0.5 H_2SO_4) at 15 °C. The reaction mixture was stirred at 15 °C for 30 hours. The reaction mixture was acidified by HCl (2 M) (300 mL) until pH=6 and concentrated under reduced pressure. The residue was suspended in 200 mL of water and stirred rapidly. The suspension was filtered and the white solid collected and washed with ethyl acetate. 7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-ol (68 g, 151 mmol, 79.1 % yield, 64.0 % purity) was obtained as a white solid.

[0874] Step B: 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: To a solution of 7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-ol (50 g, 174 mmol) in $CHCl_3$ (1000 mL) was added $POCl_3$ (166 g, 1.08 mol, 100 mL) and the mixture stirred at 80 °C for 13 hours. Upon completion, the reaction mixture was concentrated under vacuum. The residue was diluted with EtOAc (500 mL) and basified using saturated Na_2CO_3 (800 mL) to PH=7. The mixture was extracted with ethyl acetate (3 × 400 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (PE: EA from 100:1 to 80:1) to give 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (21.7 g, 67.4 mmol, 38.7 % yield, 95.0 % purity) as brown oil. ES+APCI MS m/z 306.1$[M+H]^+$.

[0875] Step C: *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (2.6 g, 8.50 mmol) and 2-piperazin-2-ylacetonitrile (1.68 g, 8.50 mmol, 2HCl) in DMSO (52 mL) was added DIEA (5.49 g, 42.5 mmol, 7.40 mL). The mixture was warmed to 80 °C and stirred at 80 °C for 6 hours. To the mixture was added $(Boc)_2O$ (18.5 g, 85.0 mmol, 19.5 mL) and the mixture stirred at 80 °C for 1 hour. Water (150 mL) was added and the mixture was extracted with ethyl acetate (3 × 200 mL). The combined organic phase was washed with brine (200 mL), dried with anhydrous Na_2SO_4, filtered and concentrated in vacuum. The residue was purified by silica gel chromatography (PE: EA from 10:1 to 0:1) to give *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.74 g, 5.26 mmol, 61.9 % yield, 95.0 % purity) as brown solid. ES+APCI MS m/z 495.4$[M+H]^+$.

[0876] Step D: *tert*-butyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.51 g, 5.07 mmol) and DIEA (1.97 g, 15.2 mmol, 2.65 mL) in DCE (50 mL) was added 1-chloroethyl carbonochloridate (1.81 g, 12.7 mmol) at 0 °C, and the mixture stirred at 15 °C for 3 hours. The reaction mixture was concentrated under vacuum. The residue was dissolved in MeOH (50 mL) and the reaction mixture was stirred at 70 °C for 1.5 hours. The mixture was concentrated under vacuum. The residue was purified by prep-HPLC (column:

SUBSTITUTE SHEET (RULE 26)

Phenomenex Synergi Max-RP 250*50mm*10 um;mobile phase: [water(0.225%FA)-ACN];B%: 23%-48%,30;50%min) to give *tert*-butyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.13 g, 2.51 mmol, 49.5 % yield, 90.0 % purity) as pink solid. ES+APCI MS m/z 405.3$[M+H]^+$.

[0877] Step E: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate**:** To a solution of *tert*-butyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (730 mg, 1.80 mmol), (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (832 mg, 2.71 mmol) and Cs_2CO_3 (1.76 g, 5.41 mmol) in toluene (18 mL) was added [2-(2-aminophenyl)phenyl]palladium(1+);dicyclohexyl-[2-(2,4,6-triisopropylphenyl)phenyl]phosphane-methanesulfonate (153 mg, 180 umol), the suspension was degassed under vacuum and purged with N_2 several times. The reaction mixture was stirred at 70 °C for 4 hours. Upon completion, water (20 mL) was added to the mixture. The resulting mixture was extracted with EtOAc (4 × 20 mL). The combined organic layers were washed with brine (40 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure The residue was purified by silica gel chromatography (PE: EtOAc from 30:1 to 0:1) to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (740 mg, 1.15 mmol, 63.7 % yield, 98.0 % purity) as brown solid. ES+APCI MS m/z 631.5$[M+H]^+$.

[0878] Step F: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfinyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 158 umol) in DCM (2 mL) was added m-CPBA (32.2 mg, 158 umol, 85.0 % purity) at 0 °C and the mixture stirred at 0 °C for 1 hours. The reaction mixture was quenched by saturated $Na_2S_2O_3$ (4 mL) at 0°C and separated, then diluted with water (10 mL) and extracted with ethyl acetate (10 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (PE: EA from 10:1 to 0:1) to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfinyl-6,8-

dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (90 mg, 125 umol, 79.0 % yield, 90.0 % purity) as brown solid. ES+APCI MS m/z 647.5[M+H]$^+$.

[0879] Step G: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (560 mg, 866 umol), [(2*R*)-1-methylpyrrolidin-2-yl]methanol (199 mg, 1.73 mmol) in toluene (10 mL) was added t-BuONa (125 mg, 1.30 mmol) at 0 °C and the mixture was stirred at 0 °C for 0.5 hour. The mixture was partitioned between EtOAc (20 mL) and water (15 mL) and separated. Then the aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by reverse phase flash column to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (340 mg, 481 umol, 55.5 % yield, 98.7 % purity) as brown oil. ES+APCI MS m/z 698.4[M+H]$^+$.

[0880] Step H: [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 201 umol) in DCM (0.2 mL) was added TFA (229 mg, 2.01 mmol, 148 uL) at 15 °C and the mixture was stirred at 15 °C for 5 hours. The reaction mixture was concentrated under vacuum to give [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (170 mg, crude, 2TFA) as brown oil.


[0881] Step I: [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate: To a solution of [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (170 mg, 206 umol, 2TFA) and DIEA (213 mg, 1.65 mmol, 287 uL) in


DCM (0.3 mL) was added prop-2-enoyl prop-2-enoate (38.9 mg, 309 umol) at 0 °C and this mixture was stirred at 15 °C for 1 hour. The reaction mixture was quenched by water (0.5 mL), then concentrated under vacuum. The residue (DCM: MeOH=10:1) was purified by silica gel chromatography (from PE: EtOAc=2:1 to EtOAc: MeOH=0:1) to give [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate (170 mg, 182 umol, 88.7 % yield, 70.0 % purity) as brown oil. ES+APCI MS m/z 652.6$[M+H]^+$.

[0882] Step J: 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate (170 mg, 261 umol) in THF (1.5 mL) was added NaOH (2 M, 1.5 mL) and thr reaction was stirred at 15 °C for 6 hours. The reaction mixture was neutralized by HCOOH (20 %, 0.1 mL) to PH=7. The resulting mixture was extracted with DCM (3 × 5 mL), the combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u;mobile phase: [water(0.225% Formic Acid)-ACN];B%:12%-39%,10min) to give 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (6.88 mg, 11.6 umol, 4.44 % yield, 95.6 % purity) as yellow solid. ES+APCI MS m/z 568.5$[M+H]^+$.

EXAMPLE 179

2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[0883] Step A: [(3*R*)-1-methylpyrrolidin-3-yl]methanol: To the solution of *tert*-butyl (3*R*)-3-(hydroxymethyl)pyrrolidine-1-carboxylate (1 g, 4.97 mmol) in THF (40 mL) was added $LiAlH_4$ (377 mg, 9.94 mmol) at 0 °C, then the mixture was warmed to 70 °C and stirred at 70 °C for 4 hours. The reaction mixture was quenched by saturated Na_2SO_4 (3 mL) and filtered, the filter cake was washed with THF (5 × 20 mL). The combined organic phase was concentrated under vacuum to give [(3*R*)-1-methylpyrrolidin-3-yl]methanol (820 mg, crude) as yellow oil. ^1H NMR (400 MHz, chloroform-d) δ = 3.66 - 3.62 (dd, *J*=4.8, 10.0 Hz, 1H), 3.53 - 3.49 (dd, *J*=5.6, 10.0 Hz, 1H), 3.35 - 3.18 (m, 1H), 2.77 - 2.68 (m, 1H), 2.59 - 2.53 (m, 1H), 2.52 - 2.45 (m, 1H), 2.40 - 2.33 (m, 1H), 2.32 (s, 3H), 2.31 - 2.26 (m, 1H), 2.04 - 1.93 (m, 1H), 1.69 - 1.59 (m, 1H)

[0884] Step B: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To the solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 773 umol) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol

(178 mg, 1.55 mmol) in toluene (10 mL) was added t-BuONa (111 mg, 1.16 mmol) and this mixture stirred at 15 °C for 0.5 hour. To the mixture was added ethyl acetate (20 mL) and water (15 mL), then extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by reversed phase flash column (ACN/Water (0.1% Formic Acid) = 42 %) to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 245 umol, 31.7 % yield, 95.0 % purity) as brown solid. ES+APCI MS m/z 698.6$[M+H]^+$.


[0885] Step C: [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: A mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 258 umol) and TFA (588 mg, 5.16 mmol, 382 uL) was stirred at 20 °C for 1.5 hours. The reaction mixture was concentrated under vacuum to give [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (200 mg, crude, 2TFA) as a brown oil.


[0886] Step D: [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate: To the solution of [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(3R)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (200 mg, 242 umol, 2TFA) and DIEA (470 mg, 3.63 mmol, 633 uL) in DCM (0.6 mL) was added prop-2-enoyl prop-2-enoate (30.5 mg, 242 umol) at 0 °C and the reaction stirred at 15 °C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EA= 2:1~0:1 to DCM: MeOH=50:1~1:1) to give [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (630 mg, crude) as brown oil. ES+APCI MS m/z 652.6$[M+H]^+$.

[0887] Step E: 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (630 mg, 966 umol) in THF (3 mL) was added NaOH (2 M, 3 mL) at 18 °C and the mixture stirred at 18 °C for 2 hours. The reaction mixture was neutralized by HCOOH (20 %, 0.5 mL) to PH=7. The resulting mixture was extracted with DCM (3 × 5 mL), the combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water(10mM NH4HCO3)-ACN];B%: 35%-65%,3min) to give 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (9.4 mg, 15.8 umol, 1.64 % yield, 95.5 % purity) as yellow solid. ES+APCI MS m/z 568.5$[M+H]^+$.

EXAMPLE 180

4-(3-(4-(piperazin-1-yl)-7-(5-(trifluoromethyl)-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yloxy)propyl)morpholine





[0888] Step A. 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane: To a solution of 4-bromo-5-(trifluoromethyl)-1H-indazole (650 mg, 2.45 mmol, 1 eq) in DMF (30 mL) was added NaH (117.71 mg, 2.94 mmol, 60% purity, 1.2 eq)at 0 °C. After being stirred at 0 °C for 1 hour, a solution of 2-(chloromethoxy)ethyltrimethyl-silane (531.56 mg, 3.19 mmol, 564.29 uL, 1.3 eq) in DMF (10 mL)was added dropwise. The mixture was warmed to 15 °C and stirred for 2 hours. The mixture was quenched with saturated aqueous ammonium chloride solution (50.0 mL), diluted with water (100.0 mL) and then extracted with ethyl acetate (3 × 100.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate= 10:1). 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (680 mg, 1.70 mmol, 69.44% yield, 99.0% purity)was obtained as a colorless oil. ES+APCI MS m/z 395.0$[M+H]^+$.

[0889] Step B. tert-butyl 4-[2-(3-morpholinopropoxy)-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (444.35 mg, 1.12 mmol, 1.3 eq), tert-butyl 4-[2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 864.71 umol, 1 eq) , RuPhos (80.70 mg, 172.94 umol, 0.2 eq) , $Pd_2(dba)_3$ (118.77 mg, 129.71 umol, 0.15 eq) , and Cs_2CO_3 (845.21 mg, 2.59 mmol, 3 eq) in toluene (40 mL) was degassed and purged with N_2 3 times, and the mixture was stirred at 90 °C for 12 hrs under nitrogen. The reaction mixture was concentrated under reduced pressure to remove toluene. The residue was diluted with water 100 mL and extracted with Ethyl acetate 300 mL (100 mL x 3). The combined organic layers were washed with water 300 mL (100 mL x 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, DCM: CH_3OH = 30:1 to 20:1). tert-butyl 4-[2-(3-morpholinopropoxy)-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 446.87 umol, 51.68% yield, 86.8% purity) was obtained as a yellow solid. ES+APCI MS m/z 773.3$[M+H]^+$.


[0890] Step C. 4-[3-[[4-piperazin-1-yl-7-[5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine: To a solution of tert-butyl-4-[2-(3-morpholinopropoxy)-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5Hpyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 111.72 umol, 1 eq) in DCM (2 mL) was added TFA (254.77 mg, 2.23 mmol, 165.43 uL, 20 eq) at 25°C. The reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was concentrated in vacuum. 4-[3-[[4-piperazin-1-yl-7-[5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (200 mg, crude, TFA) was obtained as a brown color oil. The crude product was used directly to the next step without further purification.ES+APCI MS m/z 547.5$[M+H]^+$.

[0891] Step D. 1-[4-[2-(3-morpholinopropoxy)-7-[5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 4-[3-[[4-piperazin-1-yl-7-[5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxy]propyl]morpholine (200 mg, TFA) and DIEA (600 mg, 4.64 mmol,

808.63 uL) in DCM (2 mL) was added dropwise prop-2-enoyl prop-2-enoate (13 mg, 103.08 umol) at - 50 °C. The mixture was stirred at -50°C for 30 min. The mixture was quenched with water and extacted with ethyl acetate (50 mL), the organic layer was washed with water (1 × 20 mL) and brine (1 × 20 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (FA condition) column: Luna C18 150*25 5u;mobile phase: [water(0.225%FA)-ACN];B%: 15%-36%,10min]. 1-[4-[2-(3-morpholinopropoxy)-7-[5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (18.26 mg, 28.12 mmol, two steps 23%, 99.6% purity, FA) was obtained as a yellow solid. ES+APCI MS m/z 601.4[M+H]$^+$.

EXAMPLE 181

1-(4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0892] Step A. benzyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of 3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1] heptan-5-yl)propan-1-ol (107 mg, 681 umol) in THF (2 mL) was added t-BuONa (98.1 mg, 1.02 mmol) followed by benzyl 4-[2-methylsulfinyl -7-[5-methyl-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 340 umol). The mixture was stirred at 0 °C for 1 hour. The mixture was poured into water (10 mL) and extracted with DCM (2x10 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.1%TFA) - ACN]; B%: 25%-55%, 12min) to give benzyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (110 mg, 143 umol, 42.0 % yield) was obtained as yellow solid. ^{1}H NMR (400 MHz, Chloroform-d) δ 8.08 - 8.01 (m, 1H), 7.45 - 7.43 (m, 4H), 7.37 - 7.31 (m, 3H), 5.76 (s, 2H), 5.24 (s, 2H), 4.76 - 4.63 (m, 1H), 4.60 - 4.45 (m, 3H), 4.42 (s, 2H), 4.36 - 4.24 (m, 1H), 3.96 - 3.83 (m, 2H), 3.79 - 3.65 (m, 8H), 3.64 - 3.53 (m, 6H), 3.12 - 2.92 (m, 1H), 2.90 – 2.77 (m, 2H), 2.48 (s, 3H), 2.44 - 2.41 (m, 1H), 2.36 - 2.12 (m, 3H), 0.98 - 0.93 (m, 2H), 0.01 - -0.03 (m, 9H)


[0893] Step B. *tert*-butyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo [2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (90 mg, 117 umol) and BOC_2O (51.1 mg, 234.1 umol, 53.8 uL) in MeOH (2 mL) was added Pd/C (10 %, 50 mg) under an N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 12 hours. The mixture was filtered and concentrated. The residue was purified by prep-TLC (SiO_2, DCM/MeOH = 10 : 1) to give *tert*-butyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5- methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (30 mg, 40.8 umol). ES+APCI MS m/z 735.6$[M+H]^+$.

[0894] Step C. (1*S*,4*S*)-5-(3-((7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)propyl)-2-oxa-5-azabicyclo[2.2.1]heptane: To a solution of *tert*-butyl 4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo [2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (30 mg, 40.8 umol) in DCM (0.5 mL) was added TFA (770 mg, 6.75 mmol) dropwise. The mixture was stirred at 15 °C for 2 hours. The mixture was concentrated under vacuum to give (1*S*,4*S*)-5-(3-((7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)propyl)-2-oxa-5-azabicyclo[2.2.1]heptane (30 mg, crude). ES+APCI MS m/z 505.5$[M+H]^+$.

[0895] Step D. 1-(4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a solution of (1*S*,4*S*)-5-(3-((7-(5-methyl-1*H*-indazol-4-yl)-4-(piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)propyl)-2-oxa-5-azabicyclo[2.2.1]heptane (20 mg, 39.6 umol, 1 *eq*) and DIEA (30.7 mg, 238 umol, 41.4 uL, 6 *eq*) in DCM (2 mL) was added prop-2-enoyl prop-2-enoate (4.00 mg, 31.7 umol, 0.8 *eq*) at -50 °C. The mixture was stirred at -40 - -20 °C for 0.5 hour. The mixture was concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 35%-65%,12min). The product 1-(4-(2-(3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(5-methyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (6.48 mg, 11.2 umol, two steps 28.3 % yield, 96.8 % purity) was obtained as white solid. ES+APCI MS m/z 559.5$[M+H]^+$.

EXAMPLE 182

2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0896] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate.To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 403 umol), (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (248 mg, 806 umol) and Cs_2CO_3 (394 mg, 1.21 mmol) in toluene (5 mL) was added XPHOS Palladacycle Gen 3 (34.1 mg, 40.29 umol) and the reaction mixture stirred at 70 °C for 4 hours under N_2.Upon completion, the reaction mixture was purified by silica gel chromatography (PE: EA=3:1 to 0:1) to give *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (95 mg, 118 umol). ES+APCI MS m/z 698.4 $[M+H]^+$.

[0897] Step B: [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (40 mg, 57.3 umol) in DCM (0.1 mL) was added TFA (154 mg, 1.35 mmol) at 15 °C. The reaction mixture was stirred at 15 °C for 1 hour. Upon completion, the solvent was removed under vacuum to give [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (47 mg, 56.9 umol).


[0898] Step C: [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate. To a solution of [4-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (47 mg, 56.9 umol) and DIEA (58.9 mg, 455 umol) in DCM (1 mL) was added prop-2-enoyl prop-2-enoate (10.8 mg, 85.4 umol) at 0 °C. The reaction mixture was stirred at 15 °C for 1 hour. Upon completion, the reaction mixture was quenched by addition of a drop of water. The residue was purified by silica gel chromatography (PE: EtOAc=3:1 to EtOAc: MeOH =3:1) to give [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (130 mg, crude). ES+APCI MS m/z 652.5 $[M+H]^+$.

[0899] Step D: 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of [4-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (250 mg, 384 umol) in THF (1.5 mL) was added NaOH (2 M, 1.5 mL) in water. The reaction mixture was stirred at 15 °C for 9 hours. Upon completion, the reaction mixture was acidified by addition of two drops of formic acid (20 % in water) to reach a pH=7 and the aqueous layer extracted with DCM (5 × 10 mL).The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC(column: Boston Green ODS 150*30 5u;mobile phase: [water(0.225%FA)-ACN];B%:

20%-47%,10min) to give 2-[4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (13.1 mg, 21.2 umol). ES+APCI MS m/z 568.5 $[M+H]^+$.

EXAMPLE 183

2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[0900] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 549 umol) and [(2*S*)-1-methylpyrrolidin-2-yl]methanol (126 mg, 1.10 mmol, 130 uL) in toluene (6.00 mL) was added t-BuONa (105 mg, 1.10 mmol). The mixture was stirred at 20 °C for 0.25 hour. Upon completion, the mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (EA/MeOH 50/1 to 10/1) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 427 umol). ES+APCI MS m/z 598.6 $[M+H]^+$.


[0901] Step B: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (270 mg, 452 umol) in DCM (330 uL) was added TFA (515 mg, 4.52 mmol). The mixture was stirred at 20 °C for 0.5 hour and concentrated under vacuum. Then TFA (334 uL) was added. The mixture was stirred at 20 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum to give 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, crude). ES+APCI MS m/z 498.4 $[M+H]^+$.

[0902] Step C: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (276 mg, 451 umol) and DIEA (1.46 g, 11.3 mmol) in DCM (4.00 mL) was added prop-2-enoyl prop-2-enoate (51.2 mg, 406 umol) dropwise at 0 °C. The mixture was stirred at 20 °C for 1 hour. Upon completion, the mixture was diluted with water (0.5 mL) and extracted with EtOAc (2 × 10 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,12min) to give 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (37.1 mg, 66.3 umol). ES+APCI MS m/z 552.4 $[M+H]^+$.

EXAMPLE 184

SUBSTITUTE SHEET (RULE 26)


1-[4-[7-(3-hydroxy-1-naphthyl)-2-(3-hydroxypropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one




[0903] 1-[4-[7-(3-hydroxy-1-naphthyl)-2-(3-hydroxypropoxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one was prepared following **Example 136** substituting 3-[*tert*-butyl(dimethyl)silyl]oxypropan-1-ol for 2-(3-methoxypyrrolidin-1-yl)ethanol in Step B. ES+APCI MS m/z 490.3 $[M+H]^+$.

EXAMPLE 185

1-(4-(2-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0904] Step A: 3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol: To a vial was added (1R,4R)-2-Oxa-5-azabicyclo[2.2.1]heptane HCl salt (0.250 g, 2.522 mmol), CH_3CN (5.04 mL) and 3-Bromo-1-propanol (0.274 mL, 3.026 mmol). Then K_2CO_3 (1.05 g, 7.57 mmol) was added and the mixture was warmed to 50 °C where it stirred for 16 hours. The mixture was then cooled to ambient temperature, diluted with CH_2Cl_2 and filtered and the solid was washed with CH_2Cl_2. The filtrate was then concentrated and the crude oil was purified via column chromatography (5% MeOH/DCM with 0.2% NH_4OH) to afford the product as a colorless oil.

[0905] Step B: 1-(4-(2-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: Synthesized according to the method of Example 127 using the following procedure in place of that outlined in Step D. To a vial was added 3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol (0.171 g, 1.09 mmol) and benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.125 g, 0.218 mmol) followed by dioxane (0.435 mL). Then Cs_2CO_3 (0.213 g, 0.653 mmol) was added and the mixture was heated to 100 °C for 15 hours. The reaction was diluted with CH_2Cl_2, filtered and the residual solid was washed with CH_2Cl_2. The filtrate was then dried over Na_2SO_4, filtered and concentrated. The crude residue was purified by column chromatography (4% MeOH/DCM with 0.2% NH4OH) to afford the product as a yellow foam. ES+APCI MS m/z 571.2 $[M+H]^+$.

EXAMPLE 186


Benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-(morpholinomethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate



[0906] Benzyl 4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-(morpholinomethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Synthesized according to the method of Example 127 using the following procedure in place of that outlined in Step D. To a solution of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.150 g, 0.261mmol) and 3-(4-Morpholinomethyl)-phenylboronic acid pinacol ester hydrochloride (0.266 g, 0.784 mmol) in dioxane (2.61 mL) was added Na_2CO_3 (0.523 mL, 1.0452 mmol, 2.0M Aq). The mixture was degassed by argon bubbling for 5 min. Then Tetrakis(triphenylphosphine)palladium (0) (0.030 g, 0.026 mmol) was added and the mixture was heated to 95 °C where it stirred for 7 hours. The reaction was cooled to ambient temperature and then diluted with CH_2Cl_2 and filtered. The solid was washed with CH_2Cl_2. The filtrate was then dried over Na_2SO_4, filtered and concentrated. The crude residue was purified by column chromatography (30-50% EtOAc/DCM) to afford the product as a yellow foam. ES+APCI MS m/z 591.3 $[M+H]^+$.

EXAMPLE 187


(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0907] (R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting N-Methyl-D-prolinol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 529.3 $[M+H]^+$.

EXAMPLE 188


(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0908] (S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (3S)-(1-Methyl-pyrrolidin-3-yl)-methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 529.2 $[M+H]^+$.

EXAMPLE 189


1-(4-(2-((1-benzylpyrrolidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0909] 1-(4-(2-((1-benzylpyrrolidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (1-Benzylpyrrolidin-3-yl)methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 605.3 $[M+H]^+$.

EXAMPLE 190


1-(4-(2-((1-cyclopropylpyrrolidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0910] 1-(4-(2-((1-cyclopropylpyrrolidin-3-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (1-Cyclopropyl-3-pyrrolidinyl)methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 555.3 $[M+H]^+$.


EXAMPLE 191

1-((2S,6R)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-dimethylpiperazin-1-yl)prop-2-en-1-one







[0911] Step A: Benzyl 4-((3S,5R)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A suspension of benzyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (500 mg, 1.48 mmol), tert-butyl cis-2,6-dimethylpiperazine-1-carboxylate (349 mg, 1.63 mmol) and DIEA (0.26 mL) in *N,N*-dimethylacetamide (1 mL) was stirred at r.t. overnight. The reaction mixture was divided between EtOAc (15 mL) and 1M $NaHCO_3$ (5 mL) and the layers separated. The organic layer was washed with 2M Na_2CO_3 and brine (2 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel Redisep 24g column using 20 to 50% EtOAc in hexane as eluent to give a colorless solid (0.440 g, 58%). ES+APCI MS m/z 516.2 $[M+H]^+$.




[0912] Step B: Benzyl 4-((3S,5R)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)-2-(3-morpholinopropoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of benzyl 4-((3S,5R)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (400 mg, 0.775 mmol), 3-morpholinopropan-1-ol (400 mg, 2.33 mmol, 5 eq.), cesium carbonate (1.26 g, 3.88 mmol, 5 eq.) and dioxane (3 mL) in a 4-mL vial was purged with nitrogen. The vial was capped and the mixture stirred at 110°C for 20h, then at 120°C overnight. The reaction was cooled, diluted with EtOAc (10 mL), filtered through Celite and evaporated in vacuo. The product was purified by chromatography on silica, Redisep 40g, using 2 to 10% MeOH/DCM +0.2% NH_4OH as eluent to give a light-yellow amorphous solid (272 mg, 56%).



[0913] Step C: tert-butyl (2S,6R)-2,6-dimethyl-4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-((3S,5R)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)-2-(3-morpholinopropoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (272 mg, 0.095 mmol), palladium on carbon (50 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (5 mL) and THF (5 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 3 hours. The reaction mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL). The combined organics were evaporated in vacuo and dried under high vacuum over 2 days to give an off-white foam (205 mg, 96%). ES+APCI MS m/z 491.3 $[M+H]^+$.




[0914] Step D: tert-butyl (2S,6R)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-dimethylpiperazine-1-carboxylate: To a stirred suspension of tris(dibenzylideneacetone)dipalladium (0) (19 mg, 0.020 mmol) in dry degassed toluene (0.5 mL) at room temperature under nitrogen was added (+/-)-2,2`-bis(diphenylphosphino)-1,1`-binaphthyl (24 mg, 0.038 mmol). The mixture was then heated to 100 °C for 15 minutes. The resulted dark mixture was cooled to room temperature and solid sodium-t-butoxide (39 mg, 0.41 mmol) was added, followed by a solution of 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate (82 mg, 0.25 mmol) and tert-butyl (2S,6R)-2,6-dimethyl-4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 0.20 mmol) in degassed dry toluene (0.5 mL). The flask was closed and heated with stirring to 100 °C for 30 min. The reaction mixture was cooled and divided between EtOAc (20 mL) and water (10 mL). The organic layer was separated and washed with brine, dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica, Redisep 40g, using 4% MeOH +0.1% NH_4OH in DCM as eluent to give a colorless solid (87 mg, 63%). ES+APCI MS m/z 684.3 $[M+H]^+$.



[0915] Step E: 1-((2S,6R)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-dimethylpiperazin-1-yl)prop-2-en-1-one: Tert-butyl (2S,6R)-4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2,6-dimethylpiperazine-1-carboxylate (87 mg, 0.129 mmol) was dissolved in 1M TFA/DCM. The reaction mixture turned red-brown, then dark-red. LCMS indicated non-selective deprotection of Boc and MOM. After stirring 30 min at room temperature, 0.2 mL of additional TFA was added and the reaction mixture was left at room temperature for another 30 min. The resulted biphasic mixture was vaporated in vacuo, divided betwen water (5 mL) and DCM (10 mL) + NEt_3 (0.5 mL) and the organic layer separated. The organic layer was dried over Na_2SO_4 and evaporated in vacuo. The residue was purified by chromatography on silica, Redisep 40g, using 6% MeOH in DCM +0.2% NH_4OH as eluent to give another residue which was repurified on reverse phase, C18, 5-95% MeCN-H_2O +0.1%TFA to give product assumed to be the bis-salt with TFA (1.35 mg, 1.3%). ES+APCI MS m/z 587.3 $[M+H]^+$.

EXAMPLE 192


(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0916] (R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting 3-Piperidinemethanol,1-methyl-,(3R)- for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 543.3 $[M+H]^+$.

EXAMPLE 193


1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-methylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0917] 1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-methylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (4-methyl-2-morpholinyl)methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 545.3 $[M+H]^+$.

EXAMPLE 194


1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-methylmorpholin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0918] 1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((4-methylmorpholin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting 4-Methyl-3-(hydroxymethyl)morpholine for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 545.2 $[M+H]^+$.

EXAMPLE 195


(R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0919] (R)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (R)-(1-Methylpiperidin-2-yl)methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 543.3 $[M+H]^+$.

EXAMPLE 196


(S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0920] (S)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpiperidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (S)-(1-Methylpiperidin-2-yl)methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 543.2 $[M+H]^+$.

EXAMPLE 197


(S)-1-(4-(2-((1-ethylpyrrolidin-2-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0921] (S)-1-(4-(2-((1-ethylpyrrolidin-2-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting [(2S)-1-Ethyl-2-pyrrolidinyl]methanol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 543.3 $[M+H]^+$.

EXAMPLE 198


(S,E)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one



[0922] S,E)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one. This compound was prepared following **Example 127** substituting trans-Crotonyl chloride for Acryloyl Chloride in Step F. ES+APCI MS m/z 543.2[M+H]$^+$.

EXAMPLE 199

(S,E)-4-(dimethylamino)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one




[0923] (S,E)-4-(dimethylamino)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one. This compound was prepared following Example 127 substituting the following procedure for step F. 7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-4-(piperazin-1-yl)-4a,5,6,7,8,8a-hexahydropyrido[3,4-d]pyrimidine (150 mg, 0.288 mmol) was dissolved in DCM (5 mL) and treated with (2E)-4-(Dimethylamino)but-2-enoic acid (74.4 mg, 0.576 mmol) and Hunig's base (252 µl, 1.44 mmol). To this mixture was added EDC (55.2 mg, 0.288 mmol) and HOBT (38.9 mg, 0.288 mmol) neat as powders. The reaction mixture was stirred at room temperature for 1 hour and heated to 35°C for an additional 3 hours.. The reaction mixture was concentrated in vacuo and purified on the CombiFlash (0%-15% DCM/MeOH w/ 1% NH4OH modifier). All fractions containing clean desired product were combined and concentrated in vacuo to afford (E)-4-(dimethylamino)-1-(4-(7-(3-(methoxymethoxy)naphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-4a,5,6,7,8,8a-hexahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one (105 mg, 0.166 mmol, 57.7 % yield). The product followed the rest of

Example 127 accordingly to give (S,E)-4-(dimethylamino)-1-(4-(7-(3-hydroxynaphthalen-1-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)but-2-en-1-one (14.8 mg, 0.025 mmol, 15.2% yield). ES+APCI MS m/z 586.3$[M+H]^+$.

EXAMPLE 200


(S)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0924] (S)-1-(4-(2-((1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting naphthalen-1-yl trifluoromethanesulfonate for 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step C and not performing step F. ES+APCI MS m/z 513.3 $[M+H]^+$.

EXAMPLE 201


1-((R)-2-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0925] 1-((R)-2-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting (R)-benzyl 2-methylpiperazine-1-carboxylate for benzyl piperazine-1-carboxylate in Step A and substituting naphthalen-1-yl trifluoromethanesulfonate for 3-(methoxymethoxy)naphthalen-1-yl trifluoromethanesulfonate in Step C and not performing step F . ES+APCI MS m/z 527.3 $[M+H]^+$.

EXAMPLE 202


1-((S)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one



[0926] 1-((S)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting benzyl (S)-3-methylpiperazine-1-carboxylate for benzyl piperazine-1-carboxylate in Step A. ES+APCI MS m/z 543.3 $[M+H]^+$.

EXAMPLE 203


1-((S)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one



[0927] 1-((S)-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one. This compound was prepared following **Example 127** substituting benzyl (S)-3-methylpiperazine-1-carboxylate for benzyl piperazine-1-carboxylate in Step A and substituting N-Methyl-D-prolinol for N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 543.3 $[M+H]^+$.


EXAMPLE 204

1-(4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0928] Step A: Benzyl 4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.13 mmol), 1-cyclopropylpiperidin-4-amine (55 mg, 0.39 mmol) and dioxane (0.5 mL) was heated to 120°C for 36h. The reaction mixture was cooled to room temperature, divided between EtOAc (10 mL) and water (3 mL) and the layers separated. The organic layer was washed with brine, dried over Na_2SO_4 and evaporated in vacuo and the residue chromatographed on silica, Redisep 24g, using

6 to 10% MeOH in DCM +0.2% NH_4OH as eluent to give a colorless solid (43 mg, 49%). ES+APCI MS m/z 678.3 $[M+H]^+$.




[0929] Step B: 1-(4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl 4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-(methoxymethoxy)-naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (43 mg, 0.063 mmol), palladium on carbon (20 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (1.5 mL) and THF (1.5 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 3 hours. The mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL). The combined organics were evaporated in vacuo. The residue was dissolved in DCM (5 mL) and cooled on ice-salt bath with stirring. Triethylamine (0.03 mL) was next added at once, followed by acryloyl chloride (10 μL). After 1 min at -5°C the reaction was quenched with NH_4OH (0.05 mL) and evaporated in vacuo. The residue was stirred 5 min with DCM (5 mL), filtered and chromatographed on silica gel, Redisep 12g, using 6 to 20% MeOH in DCM +0.2% NH_4OH as eluent to give a colorless solid (22 mg, 48%). ES+APCI MS m/z 598.3 $[M+H]^+$.




[0930] Step C: 1-(4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a stirred solution of 1-(4-(2-((1-cyclopropylpiperidin-4-yl)amino)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (22 mg, 0.037 mmol) in a mixture of MeOH and THF 1:1 (3 mL) was added 6M aqueous HCl (0.3 mL, 34 eq.) all at once and the resulting solution was heated with stirring at 50°C for 1.5hours. The reaction mixture was cooled to room temperature, divided between EtOAc (15 mL) and 0.5M Na_2CO_3 (10 mL) and the organic layer separated. The combined organics were washed with brine (3 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica, Redisep 12 g, using 8 to 10% MeOH in DCM +0.2 % NH_4OH as eluent to give a colorless solid (15 mg, 74%). ES+APCI MS m/z 554.3 $[M+H]^+$.

EXAMPLE 205


1-(4-(7-(6-hydroxyquinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0931] Step A: Benzyl 4-(7-(6-(methoxymethoxy)quinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a stirred suspension of tris(dibenzylideneacetone)dipalladium (0) (17 mg, 0.019 mmol) in degassed dry

toluene (0.5 mL) under nitrogen at room temperature was added (+/-)-2,2`-bis(diphenylphosphino)-1,1`-binaphthyl (24 mg, 0.038 mmol) and the mixture was heated to 100 °C for 15 minutes. The dark mixture was cooled to room temperature and solid sodium-t-butoxide (36 mg, 0.38 mmol) was then added, followed by a solution of 8-bromo-6-(methoxymethoxy)quinoline (61 mg, 0.23 mmol) and benzyl 4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (94 mg, 0.19 mmol) in degassed dry toluene (0.5 mL). The flask was closed and heated to 100 °C for 1 hour. The reaction mixture was cooled to room temperature, divided between EtOAc (15 mL) and water (5 mL) and the organic layers separated. The organic layer was washed with brine, dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel, Redisep 24g, using 4 to 10% MeOH in dichloromethane (+0.2% NH_4OH) as eluent to give a yellow solid (28 mg, 22%). ES+APCI MS m/z 684.3 $[M+H]^+$.



[0932] Step B: 1-(4-(7-(6-(methoxymethoxy)quinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl 4-(7-(6-(methoxymethoxy)quinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (28 mg, 0.095 mmol), Pd/C (15 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (2 mL) and THF (2 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 2 hours. The reaction mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL) and the combined organics evaporated in vacuo. The resulted solid was dissolved in DCM (5 mL) and cooled in an ice-salt bath with stirring. Triethylamine (0.04 mL, 3 eq.) was then added at once followed by acryloyl chloride (16 µL, 2 eq.). After 1 min at -5°C the reaction was quenched with NH_4OH (0.05 mL) and evaporated in vacuo. The mixture was filtered through a cotton plug,


chromatographed on silica gel, Redisep 12g, using 6 to 10% MeOH in DCM +0.2% NH_4OH as eluent to give another residue which was repurified on reverse phase, C18, 5 to 95% MeCN, +0.1% HCO_2H to give product which was assumed to be the bis-formate salt as a yellow solid (12 mg, 42%). ES+APCI MS m/z 604.2 $[M+H]^+$.




[0933] Step C: 1-(4-(7-(6-hydroxyquinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a stirred solution of 1-(4-(7-(6-(methoxymethoxy)quinolin-8-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (12 mg, 0.017 mmol) in a mixture of MeOH and THF 1:1 (1 mL) was added 6M aqueous HCl (0.1 mL, 35 eq.) at once and the solution was heated with stirring at 50°C for 1.5h. The reaction mixture was cooled to room temperature, divided between EtOAc (15 mL) and 0.5M Na-phosphate buffer with pH 8 (5 mL) and the layers separated. The combined organics were washed with brine (1 mL), dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica, Redisep 12 g, using 7 to 10% MeOH in DCM +0.2 % NH_4OH as eluent to give a residue which was repurified by reverse phase chromatograpy, C18, 5 to 95% MeOH +0.1%TFA,) to give product as the tris TFA salt as a colorless solid (4.87 mg, 31%). ES+APCI MS m/z 560.3 $[M+H]^+$.

EXAMPLE 206


1-(4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0934] Step A: 3-(3-azabicyclo[3.1.0]hexan-3-yl)propan-1-ol. A mixture of 3-azabicyclo[3.1.0]hexane hydrochloride (200 mg, 1.67 mmol), 3-bromopropan-1-ol (166 µL, 1.84 mmol, 1.1 eq.), K_2CO_3 (0.69 g, 5.02 mmol, 3 eq.), NaI (251 mg, 1.67 mmol, 1 eq.) and acetonitrile (2 mL) in a 4-mL vial was flushed with N_2. The vial was capped and stirred at room temperature for 2 days. The mixture was diluted with water (2 mL) and extracted with ether (15 mL). The ether solution was washed with brine, dried over Na_2SO_4 and decanted into a pear-shaped flask and trifluoroacetic acid (128 µL, 1 eq) added and the mixture was concentrated to ~5 mL. The upper etherial layer was decanted and discarded, the residual oily liquid was dried under vacuum overnight. The oily liquid was diluted with water (0.5 mL) then ether (10 mL) was added with stirring followed by 50% NaOH (0.2 mL, 2.5 mmol, 2 eq.). The layers were separated, the organic solution was dried over KOH and carefully concentrated under nitrogen to yield crude 3-(3-azabicyclo[3.1.0]hexan-3-yl)propan-1-ol as colorless oil. Used on the next stage without further purification.




[0935] Step B: Benzyl 4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-(methoxymethoxy)-naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.13 mmol), crude 3-(3-azabicyclo[3.1.0]hexan-3-yl)propan-1-ol (55 mg, 0.39 mmol, 3 eq.), Cs_2CO_3 (213 mg, 0.65 mmol, 5 eq.) and dioxane (0.5 mL) in a 1.7-mL vial was purged with nitrogen. The vial was capped and stirred at 120°C over the weekend. The reaction mixture was cooled, divided between EtOAc (15 mL) and water (5 mL) and the layers separated. The organic layer was washed with brine, dried over Na_2SO_4, evaporated in vacuo and the residue chromatographed on silica gel, Redisep 24g, using 4 to 10%MeOH +1% NH_4OH as eluent to give product. ES+APCI MS m/z 679.3 $[M+H]^+$.



[0936] Step C: 1-(4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl 4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-(methoxymethoxy)-naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (49 mg, 0.072 mmol), palladium on carbon (12 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (1.5 mL) and THF (1.5 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 3 hours. The reaction mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL). The combined organics were evaporated in vacuo. The resulted colorless solid was dissolved in DCM (5 mL), cooled in an ice-salt bath with stirring and triethylamine (0.04 mL, 3 eq.) was added at once followed by addition of acryloyl chloride (16 µL, 2 eq.). After 1 min at -5°C the reaction was quenched with NH_4OH (0.05 mL) and evaporated in vacuo. The crude product was dissolved in


DCM (5 mL), filtered through a cotton plug and chromatographed on silica gel, Redisep 12g, using 6 to 10% MeOH in DCM +0.2% NH_4OH as eluent to give a colorless solid (30 mg, 69%). ES+APCI MS m/z 599.3 $[M+H]^+$.




[0937] Step D: 1-(4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a stirred solution of 1-(4-(2-(3-(3-azabicyclo[3.1.0]hexan-3-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (30 mg, 0.050 mmol) in a mixture of MeOH and THF 1:1 (3 mL) was added 6M aqueous HCl (0.3 mL, 36 eq.) and the solution was heated with stirring at 50°C for 1.5 h. The reaction mixture was cooled to room temperature, divided between EtOAc (20 mL) and 0.5M Na_2CO_3 (5 mL) and the layers separated. The organic layer was washed with brine (1 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica, Redisep 12 g, using 6% MeOH in DCM +0.2 % NH_4OH as eluent to give a colorless solid (20.62 mg, 74%). ES+APCI MS m/z 555.4 $[M+H]^+$.


EXAMPLE 207

(R)-1-(4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0938] Step A: (R)-2-(3-fluoropiperidin-1-yl)ethan-1-ol. A mixture of R-3-fluoropiperidine hydrochloride (209 mg, 1.50 mmol), 2-bromoethan-1-ol (117 μL, 1.65 mmol, 1.1 eq.), K_2CO_3 (0.62 g, 4.5 mmol, 3 eq.), sodium iodide (225 mg, 1.5 mmol, 1 eq.) and acetonitrile (2 mL) in a 4-mL vial was flushed with N_2. The vial was capped and stirred at room temperature for 2 days. The resulted suspension was diluted with water (2 mL) and extracted with ether (15 mL). The ether solution was washed with brine, dried over Na_2SO_4 and decanted into a pear-shaped flask and trifluoroacetic acid (115 μL, 1 eq) was added and the mixture was concentrated to ~5 mL. The upper ethereal layer was decanted, the residual oily liquid was dried under vacuum overnight. The oily liquid was diluted with water (0.5 mL) and ether (10 mL) with stirring, followed by addition of 50% NaOH (0.2 mL, 2.5 mmol, 2 eq.). The layers were separated, the organic solution was dried over KOH, filtered and carefully concentrated under nitrogen to yield crude amino alcohol as a colorless oil (120 mg, 54%).




[0939] Step B: Benzyl (R)-4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.13 mmol), crude (R)-2-(3-fluoropiperidin-1-yl)ethan-1-ol (58 mg, 0.39 mmol), Cs_2CO_3 (213 mg, 0.65 mmol), and dioxane (0.5 mL) in a 1.7-mL vial was purged with nitrogen. The vial was capped and stirred at 110°C for 48 hours. The reaction mixture was cooled, diluted with EtOAc (1 mL), filtered through Celite and the celite washed with EtOAc (2 x 2 mL) and the combined organics

evaporated in vacuo. The residue was chromatographed on silica, Redisep 24g, using 6 %MeOH in DCM +0.2% NH_4OH as eluent to give a colorless solid (30 mg, 34%). ES+APCI MS m/z 685.4 $[M+H]^+$.




[0940] Step C: (R)-1-(4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl (R)-4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-(methoxymethoxy)-naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (30 mg, 0.044 mmol), palladium on carbon (10 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (1.5 mL) and THF (1.5 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 2 hours. The reaction mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL). The combined organics were evaporated in vacuo. The residue was dissolved in DCM (3 mL) and cooled in an ice-salt bath with stirring. Triethylamine (0.02 mL, 3 eq.) was next added at once followed by addition of acryloyl chloride (7 µL, 2 eq.). After 1 min at -10°C the reaction was quenched with NH_4OH (0.03 mL) and evaporated in vacuo. The residue was dissolved in DCM (5 mL), filtered, and chromatographed on silica gel, Redisep 12g, using 6 to 10% MeOH in DCM +0.2% NH_4OH in DCM as eluent to give a colorless solid (22 mg, 83%). ES+APCI MS m/z 605.3 $[M+H]^+$.



[0941] Step D: (R)-1-(4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a stirred solution of (R)-1-(4-(2-(2-(3-fluoropiperidin-1-yl)ethoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (22 mg, 0.036 mmol) in a mixture of MeOH and THF 1:1 (3 mL) was added 6M aqueous HCl (0.3 mL) and the solution was heated with stirring at 50°C for 1.5h. The reaction mixture was cooled to room temperature, divided between EtOAc (20 mL) and 0.5M Na_2CO_3 (5 mL) and the layers separated. The organic layer was washed with brine (1 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel, Redisep 12 g, using 6% MeOH in DCM +0.2 % NH_4OH as eluent to give a colorless solid (16.86 mg, 83%). ES+APCI MS m/z 561.2 $[M+H]^+$.


EXAMPLE 208

1-(4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0942] Step A: 3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propan-1-ol. A mixture of (3R,4S)-3,4-difluoropyrrolidine hydrochloride (200 mg, 1.39 mmol), 3-bromopropan-1-ol (126 µL, 1.39 mmol, 1.0 eq.), potassium carbonate (577 mg, 4.18 mmol, 3 eq.), sodium iodide (209 mg, 1.39 mmol, 1 eq.) and acetonitrile (2 mL) in a 7-mL vial was flushed with N_2. The vial was capped and the reaction mixture was stirred at room temperature for 2 days. The mixture was diluted


with water (2 mL) and extracted with ether (15 mL). The ether solution was washed with brine, dried over Na_2SO_4 and decanted into a pear-shaped flask. Trifluoroacetic acid (107 µL, 1 eq) was next added and the mixture was evaporated and dried in vacuo. The residue was diluted with water (0.5 mL) and washed with ether (5 mL). To the aqueous layer was added diethyl ether (15 mL) followed by 10M NaOH (0.2 mL, 5 mmol) and the mixture was stirred for 1 hour. The organic layer was separated and dried over solid KOH, filtered through a cotton plug and evaporated under N_2 to give a colorless oil (80 mg, 35%) which was used crude in the next reaction.



[0943] Step B: Benzyl 4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(2-chloro-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.13 mmol), crude 2-(4,4-difluoropiperidin-1-yl)ethan-1-ol (65 mg, 0.39 mmol), cesium carbonate (213 mg, 0.65 mmol, 5 eq.) and dioxane (0.5 mL) in a 1.7-mL vial was purged with nitrogen. The vial was capped and stirred at 110°C over the weekend. The reaction mixture was cooled to room temperature and divided between EtOAc (15 mL) and water (5 mL) and the layers separated. The organic layer was washed with brine, dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica, Redisep 24g, using 3% MeOH in DCM as eluent to give a colorless solid (46 mg, 50%). ES+APCI MS m/z 703.3 $[M+H]^+$.



[0944] Step C: 1-(4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl 4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (46 mg, 0.065 mmol), palladium on carbon (15 mg, *Degussa Type, 10 wt%, 50% H_2O*), EtOH (1 mL) and THF (1 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) for 3 hours. The reaction mixture was diluted with EtOH (3 mL), filtered through Celite and the celite washed with EtOH (2 x 2 mL). The combined organics were evaporated in vacuo. The residue was dissolved in DCM (3 mL) and cooled in an ice-salt bath with stirring. Triethylamine (0.02 mL) was next added followed by addition of acryloyl chloride (7 µL, 2 eq.). After 1 min at -10°C the reaction was quenched with NH_4OH (0.03 mL) and evaporated in vacuo. The residue was dissolved in DCM (3 mL), filtered and purified by chromatography on silica gel, Redisep 12g, using 5 % MeOH in DCM as eluent to give a colorless solid (29 mg, 71%). ES+APCI MS m/z 623.3 $[M+H]^+$.





[0945] Step D: 1-(4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: To a stirred solution of 1-(4-(2-(3-((3R,4S)-3,4-difluoropyrrolidin-1-yl)propoxy)-7-(3-(methoxymethoxy)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one (29 mg, 0.047 mmol) in a mixture of MeOH and THF 1:1 (2 mL) was added 6M aqueous HCl (0.2 mL) and the solution was heated with stirring at 50°C for 1.5h. The rection mixture was cooled to room temperature, divided between EtOAc (15 mL) and 0.5M Na_2CO_3 (10 mL) and the layers separated. The organic layer was washed with brine (3 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was purified by

chromatography on silica, Redisep 12 g, using 5% MeOH in DCM as eluent to give a colorless solid (12.87 mg, 48%). ES+APCI MS m/z 579.2 $[M+H]^+$.


EXAMPLE 209

1-(4-(7-(5-methyl-1H-indol-4-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[0946] Step A: 4-bromo-5-methyl-1-(triisopropylsilyl)-1H-indole: A solution of 4-bromo-5-methyl-1H-indole (100 mg, 0.476 mmol) in dry THF (2 mL) under nitrogen was cooled with stirring in an ice-salt bath. Sodium hydride (23 mg 60% in oil, 0.57 mg, 1.2 eq.) was added and the mixture was stirred for 30 min at -5°C, then 1 h at room temperatue (gas evolution ceased). Chlorotriisopropylsilane (0.10 mL, 0.48 mmol, 1 eq.) was next added and the reaction mixture was stirred at r.t. for 2 hours. The reaction was divided between EtOAc (15 mL) and water (10 mL) and the layers separated. The organic layer was washed with water (5 mL), brine (5 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was purified on silica gel using hexanes as eluent to give product. (107 mg, 63%).



[0947] Step B: Benzyl 4-(7-(5-methyl-1-(triisopropylsilyl)-1H-indol-4-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A stirred mixture of tris(dibenzylideneacetone)dipalladium (0) (17 mg, 0.019 mmol) and (+/-)-2,2`-bis(diphenylphosphino)-1,1`-binaphthyl (24 mg, 0.038 mmol) in dry degassed toluene (0.5 mL) under nitrogen was heated to 100 °C for 15 minutes. The mixture was cooled to room temperature and solid sodium-t-butoxide (37 mg, 0.38 mmol) added followed by addition of a solution of 4-bromo-5-methyl-1-(triisopropylsilyl)-1H-indole (90 mg, 0.25 mmol) and benzyl 4-(2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (94 mg, 0.19 mmol) in dry degassed toluene (0.5 mL). The reaction flask was closed and heated to 100 °C overnight. The reaction mixture was cooled to room temperature, divided between EtOAc (15 mL) and water (5 mL) and the layers separated. The organic layer was washed with brine, dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica gel, Redisep 24g, using 3 to 5% MeOH in dichloromethane as eluent to give a light-yellow solid (28 mg, 19%). ES+APCI MS m/z 782.3 $[M]^+$.





[0948] Step C: 1-(4-(7-(5-methyl-1H-indol-4-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: A mixture of benzyl 4-(7-(5-methyl-1-(triisopropylsilyl)-1H-indol-4-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (46 mg, 0.065 mmol), palladium on carbon (35 mg, *Degussa Type, 10 wt%, 50% H_2O*) in EtOH (1 mL) and THF (1 mL) was purged with hydrogen and stirred under H_2 atmosphere (rubber ballon) overnight. The reaction mixture was diluted with dioxane (3 mL), filtered through celite and the celite washed with dioxane (2 x 2 mL). The combined organics were evaporated in vacuo and dried under high vacuum. The residue was dissolved in THF (1 mL) under N_2, then 1M tetra-n-butylammonium

fluoride in THF (0.07 mL, 2 eq.) was added with stirring and the solution stirred at 0°C for 15 minutes. The reaction mixture was divided between ether (15 mL) and water (5 mL) and the layers separated. The organic layer was washed with water (3 mL), brine (3 mL), dried over Na_2SO_4 and evaporated under nitrogen. The crude product was dissolved in DCM (3 mL) and cooled in an ice-salt-dry ice bath (-20°C) with stirring. Triethylamine (10 µL, 2 eq.) was next added followed by acryloyl chloride (2 µL, 0.75 eq.). After 10 min at -20°C the reaction was quenched with NH_4OH (0.03 mL). and evaporated in vacuo. The product was purified by chromatography on silica gel column using 5 % MeOH/DCM + 0.1% NH_4OH as eluent to give a colorless solid (3.69 mg, 19%). ES+APCI MS m/z 546.3 $[M+H]^+$.

EXAMPLE 210


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile






[0949] Step A: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (8.00 g, 26.3 mmol), Hunig's base (22.9 ml, 132 mmol) and 2-(piperazin-2-yl)acetonitrile dihydrochloride (5.21 g, 26.3 mmol) were placed in DMA (75 mL) and stirred at

room temperature for 20 minutes. Water was added to the reaction and the mixture was extracted with EtOAc (3x100 mL). The extracts were combined and washed with water (3x 50 mL), dried with sodium sulfate, filtered and concentrated to provide crude material that was used as is. ES+APCI MS m/z 393.3 $[M+H]^+$.




[0950] Step B: tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (10.5 g, 26.7 mmol) and TEA (5.6 ml, 40.1 mmol) were placed in THF (100 mL) and cooled to 0°C. Benzyl carbonochloridate (5.7 ml, 40.1 mmol) was added and the reaction was stirred at 0°C for 30 minutes. Water was added to the reaction and the mixture was extracted with DCM (3x 50 mL) and the extracts were combined and concentrated. The residue was purified by silica gel (0-60% EtOAc in hexane as eluent) to provide tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (12.9 g, 24.5 mmol, 92 % yield). ES+APCI MS m/z 527.1 $[M+H]^+$.




[0951] Step C: tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: In a


sealed tube tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.50 g, 2.85 mmol) was dissolved in dioxane (1.42 ml, 2.85 mmol) and treated with milled cesium carbonate (1.85 g, 5.69 mmol) and (2S)-1-Ethyl-2-pyrrolidinyl]methanol (1.64 g, 14.2 mmol). The tube was then capped and heated to 90°C for 24hr. The reaction was cooled to room termperature and water was added. The mixture was extracted with DCM (3x 25 mL), and the combined organics concentrated in vacuo. The residue was purified by silica gel (0-12% MeOH in DCM w/0.2% NH4OH as eluent) to give tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (831 mg, 1.37 mmol, 48 % yield). ES+APCI MS m/z 606.2 $[M+H]^+$.




[0952] Step D: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (831 mg, 1.37 mmol) was placed in DCM (15 mL) and TFA (2114 µL, 27.4 mmol) was added and the reaction was stirred at rt for 1hr. The reaction was concentrated. Saturated bicarbonate was added and the mixture was extracted with DCM (3x25 mL). The extracts were combined, dried with sodium sulfate, filtered and concentrated to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (665 mg, 1.32 mmol, 96 % yield) which was used as is. ES+APCI MS m/z 506.2 $[M+H]^+$.



[0953] Step E: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a vial was added cesium carbonate (103 mg, 0.316 mmol), benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (80 mg, 0.158 mmol), Rhuphos Pd G3 (13.2 mg, 0.016 mmol), 1-bromo-2-(trifluoromethyl)benzene (53.4 mg, 0.237 mmol) and 1,4-dioxane (1582 μL, 0.158 mmol) and the vial was degassed with Ar, sealed then heated to 70°C for 24 hours. Water and saturated NH4Cl were added to the reaction and the mixture was extracted with DCM. The organic layer concentrated in vacuo. The resulting residue was purified by silica gel (0-12% MeOH in DCM w/0.2% NH4OH as eluent) to provide benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (20.5 mg, 0.032 mmol, 20 % yield). ES+APCI MS m/z 650.3 $[M+H]^+$.




[0954] Step F: 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (20.5 mg, 0.032 mmol) in EtOH (316 μL, 0.0316 mmol) and THF (316 μL, 0.032 mmol) was added palladium (16.8 mg, 0.008 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure and was stirred for 2 hours. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to provide desired product which was used as is. ES+APCI MS m/z 516.2 $[M+H]^+$.



[0955] Step G: 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (16.3 mg, 0.032 mmol) and triethylamine (13.2 μL, 0.095 mmol) were placed in CH2Cl2 (316 μL, 0.032 mmol) and cooled to 0°C. Acryloyl chloride (632 μL, 0.063 mmol) was added (freshly prepared 0.1M solution in DCM) and the reaction was stirred for 1hour at 0°C. The mixture was concentrated and the resulting residue was purified by reverse phase chromatography (0-50% ACN:water w/ 0.1%TFA) to provide desired product (18.9 mg, 0.027 mmol, 87 % yield). ES+APCI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 211


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethoxy)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0956] Synthesized according to **Example 210**, Steps E-G using 1-bromo-2-(trifluoromethoxy)benzene in place of 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 586.3 $[M+H]^+$.

EXAMPLE 212


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0957] Synthesized according **Example 210**, Steps E-G using 3-bromo-4-(trifluoromethyl)pyridine in place of 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 213

1-(4-(7-(5-hydroxy-2,3-dimethylphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0958] Step A: 3-bromo-4,5-dimethylphenol: In a sealed tube DPPE (0.431 g, 1.08 mmol), 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.73 g, 13.5 mmol), (1,5-Cyclooctadiene)-eta5-indenyl)iridium(I) (0.449 g, 1.08 mmol) and 1-bromo-2,3-dimethylbenzene (1.00 g, 5.40 mmol) were placed in cyclohexane (6 mL) and was heated to 100°C for 50hr. The reaction was concentrated down and brought up in acetone (5 mL) and oxzone (3.32 g, 5.40 mmol) was added and stirred for 10 min. The reaction was quenched with saturated NaHSO3 and was extracted with DCM (3x20 ml). The extracts were washed with brine, water and concentrated. The residue was passed through a plug of silica eluting with DCM to provide 3-bromo-4,5-dimethylphenol (238 mg, 1.18 mmol, 22 % yield).


[0959] Step B: 1-bromo-5-(methoxymethoxy)-2,3-dimethylbenzene: Was prepared according to the preparation for Intermediate 3 substituting the 3-bromo-4,5-dimethylphenol for 2-bromo-3-fluorophenol.

[0960] Step C: 1-(4-(7-(5-hydroxy-2,3-dimethylphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one 2,2,2-trifluoroacetate: was prepared according to Example 1 Steps C-F substituting Intermediate 25 for benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate and 1-bromo-5-(methoxymethoxy)-2,3-dimethylbenzene for 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 537.3 $[M+H]^+$.

EXAMPLE 214

1-(4-(7-(5-hydroxy-2-((trifluoromethyl)thio)phenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one





[0961] Step A: 3-bromo-4-((trifluoromethyl)thio)phenol: In a sealed tube 3-bromophenol (575 mg, 3.32 mmol) and N,4-dimethyl-N-(trifluoromethyl)benzenesulfonamide (1010 mg, 3.99 mmol) were placed in dry DCE (6 mL). Triflic acid (295 μL, 3.32 mmol) was added slowly and the reaction was then heated to 80°C for 18 hours. The reaction was cooled and the solvent was removed under vacuum and the resulting residue was purified by silica gel (0-20% EtOAc in hexanes) to provide 3-bromo-4-((trifluoromethyl)thio)phenol (650 mg, 2.38 mmol, 72 % yield)


[0962] Step B: (2-bromo-4-(methoxymethoxy)phenyl)(trifluoromethyl)sulfane: Was prepared according to the preparation for Intermediate 3 substituting the 3-bromo-4-((trifluoromethyl)thio)phenol for 2-bromo-3-fluorophenol.

[0963] Step C: 1-(4-(7-(5-hydroxy-2-((trifluoromethyl)thio)phenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: Synthesized according to Example 1 Step C-F substituting Intermediate 25 for benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate and (2-bromo-4-(methoxymethoxy)phenyl)(trifluoromethyl)sulfane for 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 609.2 $[M+H]^+$.

SUBSTITUTE SHEET (RULE 26)

EXAMPLE 215


(R)-1-(4-(2-(2-hydroxy-3-morpholinopropoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0964] Title compound was obtained by SFC chiral resolution of **Example 123** using a Phenomenex OZ-H column (4.6mm x250mm, 5u) and eluting with 40-60% MeOH:IPA:DEA (80:20:1) at 4mL/min. Collecting the first eluting peak provided the desired compound where the stereochemistry was arbitrarily assigned. ES+APCI MS m/z 575.2 $[M+H]^+$.

EXAMPLE 216


(S)-1-(4-(2-(2-hydroxy-3-morpholinopropoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0965] Title compound was obtained by SFC chiral resolution of **Example 123** using a Phenomenex OZ-H column (4.6mm x250mm, 5u) and eluting with 40-60% MeOH:IPA:DEA (80:20:1) at 4mL/min. Collecting the second eluting peak provided the desired compound where the stereochemistry was arbitrarily assigned. ES+APCI MS m/z 575.2 $[M+H]^+$.

EXAMPLE 217


1-(4-(2-((1-hydroxy-3-morpholinopropan-2-yl)oxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0966] Synthesized according to the method of **Example 8**, using 3-morpholinopropane-1,2-diol in place of (S)-1-(dimethylamino)propan-2-ol in Step B. ES+APCI MS m/z 575.2 $[M+H]^+$.

EXAMPLE 218

2-(1-acryloyl-4-(2-(((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0967] Step A: benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: In a sealed vial, a solution of benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 0.27 mmol) in dioxane (2712 µL, 0.27 mmol) was sparged with argon and (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate (270 mg, 0.81 mmol), Cs2CO3 (265 mg, 0.81 mmol), Rhuphos Pd G3 (22.7 mg, 0.027 mmol) were sequentially added under argon and

sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 2hr. Water was added and the mixture was extracted with DCM (3x15 mL). The extracts were combined and concentrated and the resulting residue was purified by silica gel (0-40 % EtOAc in hexanes) to provide benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (113 mg, 0.13 mmol, 49 % yield).

[0968] Step B: tert-butyl (2S,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(((4-(3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate: To a solution of benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (113 mg, 0.133 mmol) in EtOH (1.3 mL, 0.133 mmol) and THF (1.3 mL, 0.133 mmol) was added palladium (70.9 mg, 0.033 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature for 2 hours. The mixture was then diluted with 1:1 MeOH and THF and filtered through GF/F paper. The filtrate was then concentrated to provide crude product which was used as is.

[0969] Step C: tert-butyl (2S,4R)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate: tert-butyl (2S,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(((4-(3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate (95 mg, 0.13 mmol) and triethylamine (56 µL, 0.40 mmol) were placed in CH2Cl2 (1331 µL, 0.13 mmol) and cooled to 0°C. Acryloyl chloride (2661 µL, 0.27 mmol) (freshly prepared 0.1M solution in DCM) was added and the reaction was stirred for 30 min at 0°C. Water was added to the reaction and the mixture was extracted with DCM (3x15 mL). The extracts were combined and concentrated to provide crude material which was used as is.

[0970] Step D: 2-(1-acryloyl-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-


yl)acetonitrile. tert-butyl (2S,4R)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (92 mg, 0.12 mmol) was placed in DCM (3 mL) and TFA (92 μL, 1.2 mmol) was added and the reaction was stirred at room temperature for 2 hours. Saturated bicarbonate was added to the reaction and the mixture was extracted with DCM (3x15 mL). The extracts were combined, dried with sodium sulfate, filtered and concentrated to give crude material that was used as is.

[0971] Step E: 2-(1-acryloyl-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-(1-acryloyl-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (80 mg, 0.12 mmol), formaldehyde (45.0 μL, 0.60 mmol) and Na(OAc)3BH (50.8 mg, 0.24 mmol) were placed in THF (2 mL) and stirred for 2 hrs. Saturated bicarbonate was added and the mixture was extracted with 10% MeOH in DCM (3x15 mL). The extracts were combined, dried with sodium sulfate, and concentrated to provide crude material which was used as is.

[0972] Step F: 2-(1-acryloyl-4-(2-(((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate: 2-(1-acryloyl-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (81 mg, 0.119 mmol) was placed in DCM (5 mL) and HCl (594 μL, 2.38 mmol) was added and the reaction was stirred for 1hr. The reaction was concentrated and the material was purified by reverse phase chromatography (0-50% ACN:water with 0.1% TFA) to provide 2-(1-acryloyl-4-(2-(((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (38.9 mg, 0.057 mmol, 48 % yield). ES+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 219


1-(4-(2-((1,4-dimethylpiperazin-2-yl)methoxy)-7-(3-hydroxynaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one




[0973] Title compound was prepared the same as **Example 127**, substituting (1,4-Dimethyl-2-piperazinyl)methanol in place of N-Methyl-L-prolinol in Step D. ES+APCI MS m/z 558.3 $[M+H]^+$.

EXAMPLE 220


2-(1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile






[0974] Step A: benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (4.00 g, 7.59 mmol) in DCM (25.3 ml, 7.59 mmol) was added trifluoroacetic acid (17.4 ml, 227.7 mmol) and the reaction was stirred at room temperature for 3 hours. The reaction was


concentrated to a thick oil. Saturated bicarbonate was added slowly and the mixture was extracted with 10% MeOH in DCM (3x 50 mL). The extracts were combined, dried with sodium sulfate and concentrated to provide the desired product (3.24 g, 7.6 mmol, 100 % yield) which was used as is. ES+APCI MS m/z 506.2 $[M]^+$.




[0975] Step B: benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a round bottomed flask was added cesium carbonate (8.01 g, 24.6 mmol), benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (3.5 g, 8.2 mmol), 1-bromonaphthalene (4.6 ml, 32.8 mmol) and RuPhos Pd G3 (1.0 g, 1.23 mmol) . After evacuating the flask, 1,4-dioxane (82.0 ml, 8.20 mmol) was added through a septum under argon flow. Argon was bubbled through the mixture for 5 minutes and then the mixture was heated to 70°C overnight. The reaction was cooled and water was added and extracted with ethyl acetate and the organics concentrated in vacuo. The yellow solids were dissolved in minimal DCM and purified by silica chromatography (25-60% EtOAc in hexanes) to provide benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.0 g, 3.6 mmol, 44.1 % yield). ES+APCI MS m/z 553.2 $[M]^+$.




[0976] Step C: benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: In a vial benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (120 mg, 0.22 mmol) was dissolved in dioxane (108 μL, 0.217 mmol) and treated with cesium carbonate (141 mg, 0.434 mmol), and (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-2-hydroxymethylpyrrolidine (47.6 mg, 0.217 mmol). The tube was then capped and heated to 90°C for 12hours. The reaction was filtered through GF/F paper and concentrated. The residue was purified by silica chromatography (0-6% MeOH in DCM). ES+APCI MS m/z 736.3 $[M+H]^+$.




[0977] Step D: benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylat: To a solution of benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (125 mg, 0.170 mmol) in DCM (170 μL, 0.170 mmol) was added trifluoroacetic acid (195 μL, 2.55 mmol) and the reaction stirred at RT for 2 hr. The organics were washed with sodium bicarbonate and the aqueous layer was back extracted with DCM. The combined organic layers were concentrated and used without further purification. ES+APCI MS m/z 636.3 $[M+H]^+$.



[0978] Step E: benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (105 mg, 0.1652 mmol) in DCE (3303 µL, 0.1652 mmol) was added formaldehyde (124.1 µL, 1.652 mmol) (37% in water) followed by sodium triacetoxyborohydride (175.0 mg, 0.8258 mmol). The mixture was stirred vigorously at RT for 2.5h. The mixture was treated with saturated sodium bicarbonate (30 mL), stirred for 10 min then extracted with DCM (3 x 10 mL). The combined organic phases were dried over sodium sulfate, filtered and concentrated and used as is in the next reaction. ES+APCI MS m/z 650.3 $[M+H]^+$.




[0979] Step F: 2-(4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (85 mg, 0.13 mmol) in EtOH (1308 µL, 0.13 mmol) and THF (1308 µL, 0.13 mmol) was added palladium (70 mg, 0.033 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H_2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature overnight. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to provide 2-(4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. ES+APCI MS m/z 516.3 $[M+H]^+$.



[0980] Step G: 2-(1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile : To a suspension of 2-(4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (65 mg, 0.126 mmol) in DCM (1261 μL, 0.126 mmol) at 0°C was added acryloyl chloride (2521 μL, 0.252 mmol) (freshly prepared 0.1M solution in DCM) followed by triethylamine (35.1 μL, 0.252 mmol). The reaction was then stirred at 0°C for 45 minutes. The reaction was concentrated and purified by reverse phase chromatography (0-50% CAN:water with 0.1% TFA) to provide the title compound. ES+APCI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 221


2-(1-acryloyl-4-(2-(((2S,4S)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0981] Synthesized according to the method of **Example 220**, Step C-G, using tert-butyl (2S,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate in place of tert-butyl (2S,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate in Step C. ES+APCI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 222


2-(1-acryloyl-4-(2-(((2S,4S)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0982] Title compound was prepared following **Example 220** (Steps C-G), substituting tert-butyl (2S,4S)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate for (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-2-hydroxymethylpyrrolidine in Step C. ES+APCI MS m/z 582.3 $[M+H]^+$.

EXAMPLE 223


2-(1-acryloyl-4-(2-(((S)-4-methylpiperazin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0983] Steps A-F: 2-(1-acryloyl-4-(2-(((S)-4-methylpiperazin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Title compound was prepared following **Example 220** (Steps C-G), substituting tert-butyl (S)-2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate for (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-2-hydroxymethylpyrrolidine in Step C. ES+APCI MS m/z 567.3 $[M+H]^+$.

EXAMPLE 224


2-(1-acryloyl-4-(2-(((R)-4-methylpiperazin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0984] Title compound was prepared following **Example 220** (Steps C-G), substituting tert-butyl (R)-2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate for tert-butyl (S)-2-(hydroxymethyl)-4-methylpiperazine-1-carboxylate in Step C. ES+APCI MS m/z 567.3 $[M+H]^+$.

EXAMPLE 225


2-(1-acryloyl-4-(7-(5-fluoro-2-(trifluoromethoxy)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0985] Title compound was prepared as in **Example 210** Steps E-G, substituting 2-bromo-4-fluoro-1-(trifluoromethoxy)benzene for 1-bromo-2-(trifluoromethyl)benzene in step E. ES+APCI MS m/z 604.3 $[M+H]^+$.

EXAMPLE 226


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0986] Title compound was prepared as in **Example 210** Steps E-G, substituting 3-bromo-2-(trifluoromethyl)pyridine for 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 227


2-(1-acryloyl-4-(7-(2-fluorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0987] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromo-2-fluorobenzene for 1-bromo-2-(trifluoromethyl)benzene in step E. ES+APCI MS m/z 520.3 $[M+H]^+$.

EXAMPLE 228


2-(1-acryloyl-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0988] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromo-2,3-dimethylbenzene for 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 530.3 [M+H]+.

EXAMPLE 229


2-(1-acryloyl-4-(7-(2-chlorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[0989] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromo-2-chlorobenzene for 1-bromo-2-(trifluoromethyl)benzene in step E. ES+APCI MS m/z 536.2 [M]+.

EXAMPLE 230


2-(1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[0990] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromo-3-fluoro-2-(trifluoromethyl)benzene for 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 588.3 [M+H]+.

EXAMPLE 231


2-(1-acryloyl-4-(2-(3-hydroxypropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile






[0991] Step A: benzyl 2-(cyanomethyl)-4-(2-(3-hydroxypropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Title compound was prepared

as in Example 220 Step C, substituting propane-1,3-diol for (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-2-hydroxymethylpyrrolidine. ES+APCI MS m/z 593.3 $[M+H]^+$.




[0992] Step B: benzyl 4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a vial was added benzyl 2-(cyanomethyl)-4-(2-(3-hydroxypropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (77.6 mg, 0.131 mmol), which was dissolved in DCM (655 µL, 0.131 mmol). The mixture was cooled to 0 °C and then triethylamine (36.5 µL, 0.262 mmol) was added followed by 4-(dimethylamino)-pyridine (4.80 mg, 0.04 mmol). Then tert-butyldimethylsilyl chloride (29.6 mg, 0.196 mmol) was added and the mixture was stirred overnight while warming to room temperature. The reaction mixture was poured onto a saturated brine solution (5ml) and the mixture extracted twice with EtOAc (10 mL). The organic phases were dried over sodium sulfate, filtered and concentrated. The crude reaction product was used as is. ES+APCI MS m/z 707.4 [M+H]+.




[0993] Step C: 2-(4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl 4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-

d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (106 mg, 0.150 mmol) in EtOH (1499 μL, 0.150 mmol) and THF (1499 μL, 0.150 mmol) was added palladium (79.8 mg, 0.0375 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H_2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature overnight. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to a colorless solid that was used without further purification. ES+APCI MS m/z 573.3 [M+H]+.



[0994] Step D: 2-(1-acryloyl-4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-(4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (75 mg, 0.131 mmol) in DCM (1309 μL, 0.131 mmol) at -78°C was added acryloyl chloride (2619 μL, 0.262 mmol) (freshly prepared 0.1M solution in DCM) followed by triethylamine (36.5 μL, 0.262 mmol). The reaction was then stirred at 0°C for 30 minutes. The reaction was concentrated and used crude in the next reaction. ES+APCI MS m/z 627.4 [M+H]+.




[0995] Step E: 2-(1-acryloyl-4-(2-(3-hydroxypropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-(1-acryloyl-4-(2-(3-((tert-butyldimethylsilyl)oxy)propoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (90 mg, 0.14 mmol) in DCM (1436 µL, 0.14 mmol) was added hydrochloric acid (4.0 M in 1,4-dioxane) (359 µL, 1.4 mmol) at 0°C. The reaction was stirred for 30 min at which point it was quenched with saturated sodium bicarbonate and extracted into 10% IPA in CHCl3 (3x15 ml). The combined organic layers were concentrated and the residue was purified by reverse phase chromatography (0-95% ACN:H2O with 0.1TFA). ES+APCI MS m/z 513.2 [M+H]+.

[0996]

EXAMPLE 232


1-(4-(7-(3-chloro-2-fluoro-5-hydroxyphenyl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[0997] The title compound was prepared according to **Example 1** Step C-F substituting Intermediate 25 for benzyl 4-(5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate and 1-bromo-3-chloro-2-fluoro-5-(methoxymethoxy)benzene for 1-bromo-3-(methoxymethoxy)naphthalene in Step C. ES+APCI MS m/z 561.2 [M]+.

EXAMPLE 233


2-(1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[0998] 2-(1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. This compound was prepared following **Example 147** substituting (S)-(1-ethylpyrrolidin-2-yl)methanol for N-Methyl-L-prolinol for [(2S)-1-methylpyrrolidin-2-yl]methanol in Step F. ES+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 234

2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile





[0999] Step A: 1-Benzyl 4-(tert-butyl) (R)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate: To a stirred biphasic solution of (R)-1-Boc-3-hydroxymethylpiperazine (5.00 g, 23.1 mmol) and $NaHCO_3$ (5.83 g, 69.4 mmol) in ethyl acetate (46.2 ml) and water (46.2 ml) at 0°C was added benzyl chloroformate (4.95 ml, 34.7 mmol) dropwise. The reaction mixture was stirred at ambient temperature overnight. The reaction mixture was diluted with EtOAc (50.0 ml) and the organic layer was separated, dried (Na_2SO_4) and concentrated. The crude product was purified by flash chromatography eluting with 10-50% EtOAc/hexanes gradient to afford the title compound (7.62 g, 21.7 mmol, 94.1%). **ESI** MS m/z 251.1 [M-Boc+H]+.

[01000] Step B. 1-Benzyl 4-(tert-butyl) (R)-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate: To a solution of 1-benzyl 4-(tert-butyl) (R)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate (1.69 g, 4.83 mmol) and triethylamine (1.01 ml, 7.25 mmol) in CH_2Cl_2 (32.2 ml) at

0°C was added dropwise MsCl (0.561 ml, 7.25 mmol) neat and the resulting mixture was stirred at RT for 10 min. The reaction mixture was poured into a separatory funnel, diluted with ethyl acetate, then washed sequentially with 1N HCl, water, $NaHCO_3$ (sat.), and brine to afford the title compound (1.9 g, ~100%, used as crude material in next step). **ESI** MS m/z 329.1 [M-Boc+H]+.

[01001] Step C. 1-Benzyl 4-(tert-butyl) (S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate: A solution of 1-benzyl 4-(tert-butyl) (R)-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (2.10 g, 4.90 mmol), sodium cyanide (0.480 g, 9.80 mmol) in DMA (49.0 ml) was heated at 55°C for 1day. The reaction was followed by HPLC (15 min method). The mixture was partitioned between EtOAc/brine, and the organic layer was washed with brine (3x), dried over $MgSO_4$ and concentrated. The residue was purified by flash chromatography eluting with 0-100% EtOAc/hexanes gradient to afford the title compound (1.40 g, 3.90 mmol, 79.5%). Aqueous layers were basified and disposed of in cyanide waste stream. **ESI** MS m/z 260.1 [M-Boc+H]+.

[01002] Step D. Benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride: 1-Benzyl 4-(tert-butyl) (S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate (5.32 g, 14.8 mmol) was placed in CH_2Cl_2 (25 mL) and HCl (4.0 N in dioxane, 18.5 ml, 74.0 mmol) was added and the reaction was stirred at ambient temperature for 1d. The reaction mixture was concentrated to afford the title compound (4.3 g, 99%). **ESI** MS m/z 260.1 [M+H]+.

[01003] Step E. tert-Butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A solution of benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate (1.01 g, 3.89 mmol), tert-butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (1.18 g, 3.89 mmol) and DIEA (1.36 ml, 7.79 mmol) in DMSO (19.5 ml) was heated at 50 °C for 1day. The reaction mixture was partitioned between ethyl acetate and brine and the organics separated. The organic phase was washed with brine (3x), dried over $MgSO_4$ and concentrated to afford the title compound (1.63 g, 3.09 mmol, 79.4%). **ESI** MS m/z 527.2 [M+H]+.

[01004] Step F. tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-

carboxylate: In 250 mL heavy-wall round bottom flask with a PTFE screw cap was added a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.64 g, 3.11 mmol) in dioxane (31.1 ml) and the mixture was sparged with argon. To the mixture was added sequentially (S)-(1-methylpyrrolidin-2-yl)methanol (1.08 g, 9.34 mmol), Cs_2CO_3 (3.04 g, 9.34 mmol) and Ruphos-Pd Gen3 catalyst (0.260 g, 0.311 mmol) under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 1day. The reaction mixture was diluted with ethyl acetate and the organics washed with brine (2x). The organic layer was dried over MgSO4 and concentrated to give a residue that was purified by flash chromatography eluting with 0-20% (MeOH + 2% NH_4OH) in DCM to afford the title compound (1.42 g, 2.34 mmol, 75.3%). **ESI** MS m/z 606.3 [M+H]+.

[01005] Step G. Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate bis-trifluoroacetate salt: A solution of tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (38 mg, 0.063 mmol) in CH_2Cl_2 (627 µl) and TFA (242 µl, 3.1 mmol) was stirred at room temperature for 1day. The reaction mixture was concentrated and used as bis-TFA salt in the next reaction (46 mg, 0.063 mmol, 100%). **ESI** MS m/z 506.3 [M+H]+.

[01006] Step H. Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A suspension of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate bistrifluoroacetate salt (46 mg, 0.063 mmol), 1-bromonaphthalene (39.3 mg, 0.190 mmol) and Cs_2CO_3 (61.9 mg, 0.190 mmol) in dioxane (633 µl) was sparged with argon for 5 min. To this mixture was added Ruphos Pd Gen 3 (5.29 mg, 0.006 mmol) and the resulting suspension was sparged for an additional 1 minute with argon. The vial was capped and heated at 100°C for 2h. The reaction mixture was partitioned between EtOAc and water and the aqueous layer was extracted with EtOAc (3x). The combined organic layers were dried over MgSO4 and concentrated. The residue was purified by flash chromatography eluting with 5%


MeOH/1%NH_4OH/CH_2Cl_2 isocratic to afford the title compound (31.9 mg, 0.050 mmol, 79.8%). **ESI** MS m/z 632.3 [M+H]+.

[01007] Step I. 2-((S)-4-(2-(((S)-1-Methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (31 mg, 0.049 mmol) in methanol (981 µl) and THF (981 µl) sparged with nitrogen was added Pd/C (10.4 mg, 0.00491 mmol) and the mixture was stirred under balloon pressure atmosphere of H_2 for 1day. The reaction mixture was filtered through a PTFE syringe filter (25mm) and the filtrate was concentrated to afford the title compound (23.4 mg, 0.047 mmol, 95.8%). **ESI** MS m/z 498.3 [M+H]+.

[01008] Step J. 2-((S)-1-Acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (23.4 mg, 0.047 mmol) in CH_2Cl_2 (470 µl) was added DIEA (41.1 µl, 0.235 mmol) then acryloyl chloride (12 µl, 0.141 mmol). The resulting mixture was stirred at ambient temperature for 15 minutes. The reaction mixture was partitioned between EtOAc and 2N K_2CO_3 and brine. The aqueous layer was extracted with EtOAc (2x). The combined organic layers were dried over $MgSO_4$ and concentrated. The residue was purified by flash chromatography eluting with 5% MeOH / 1% NH_4OH in CH_2Cl_2 to afford the title compound (19.2 mg, 0.035 mmol, 74.0%). **ESI** MS m/z 552.3 [M+H]+.

EXAMPLE 235


2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01009] Step A. 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (25 mg, 0.0502 mmol) from **Example 234** Step I, (2E)-4-(dimethylamino)but-2-enoic acid (13.0 mg, 0.100 mmol), DIEA (43.9 µl, 0.251 mmol) in CH_2Cl_2 (502 µl) was added HATU (28.7 mg, 0.0754 mmol) and the resulting mixture was stirred at ambient temperature for 1hour. The reaction mixture was partitioned between EtOAc and brine. The aqueous layer was extracted with EtOAc (2x). The combined organic layers were dried over $MgSO_4$ and concentrated. The residue was purified by preparative-C18 eluting with 5-95%ACN/H_2O + 0.1% TFA. The desired fractions were partitioned between EA/2M K_2CO_3. The aqueous was extracted with EtOAc (2x). The combined organic layers were dried over $MgSO_4$ and concentrated to afford the title compound (19.0 mg, 0.031 mmol, 62.1%). **ESI** MS m/z 609.4 [M+H]+.

EXAMPLE 236


2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(E-4-(piperidin-1-yl)but-2-enoyl)piperazin-2-yl)acetonitrile



[01010] Step A. 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(E-4-(piperidin-1-yl)but-2-enoyl)piperazin-2-yl)acetonitrile was prepared according to **Example 235**, substituting (2E)-4-(1-piperidinyl)-2-butenoic acid HCl salt, to afford the title compound (30 mg, 0.046 mmol, 92.0%). **ESI** MS m/z 649.3 [M+H]+.

EXAMPLE 237


2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate




[01011] Synthesized according to **Example 234** substituting 1-bromo-2-(trifluoromethyl)benzene for 1-bromonaphthalene. ES+APCI MS m/z 570.3 $[M+H]^+$.


EXAMPLE 238

2-(1-acryloyl-4-(7-(6-methyl-1H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile







[01012] Step A: 7-bromo-6-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole. A solution of 7-bromo-6-methyl-1H-indazole (200 mg, 0.948 mmol) in tetrahydrofuran (2 ml, 0.948 mmol) was cooled with stirring in an ice bath. Sodium hydride (45.5 mg, 1.14 mmol) was added portionwise to the mixture and the reaction was stirred at 0°C for 1hour. (2-(chloromethoxy)ethyl)trimethylsilane (0.201 ml, 1.14 mmol) was next added and the reaction stirred for 2 hours while warming to room temperature. The mixture was divided between EtOAc (20 mL) and water (10 mL) and the layers separated. The organic layer was washed with water (2 x 10 mL), brine (10 mL), dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica gel using 20 to 40% EtOAc/hexanes as eluent to give 7-bromo-6-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole (46 mg, 14%) along with isomer 7-bromo-6-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (214 mg, 66%). ES+APCI MS m/z 341.1 $[M]^+$.



[01013] Step B: Benzyl 2-(cyanomethyl)-4-(7-(6-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (50 mg, 0.099 mmol), 7-bromo-6-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazole (46 mg, 0.13 mmol), Cs_2CO_3 (97 mg, 0.30 mmol), Ruphos Pd G3 (83 mg, 0.099 mmol) and dioxane (1 mL) was purged with nitrogen and stirred at 70°C for 6 hours. The reaction mixture was cooled to room temperature and divided between EtOAc (20 mL) and water (10 mL) and the layers separated. The organic layer was washed with water (5 mL), brine (5 mL), dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica gel, Redisep 24g, using 2 to 20% MeOH/DCM as eluent to give a colorless solid (50 mg, 66%). ES+APCI MS m/z 766.4 $[M]^+$.



[01014] Step C: Benzyl 2-(cyanomethyl)-4-(7-(6-methyl-1H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Neat benzyl 2-(cyanomethyl)-4-(7-(6-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (10 mg, 0.0131 mmol) (10 mg, 0.0131 mmol) was dissolved in trifluoroacetic acid (1 ml, 13.1 mmol) and the yellow-brow solution was stirred at room temperature for 1.5 hours. The reaction mixture was poured into ethyl acetate (20 mL) and the organics washed carefully with 2M Na_2CO_3 (10 mL, 20 mmol), water (2 x 3 mL), brine (5 mL), dried over Na_2SO_4 and evaporated in vacuo to give a yellowish solid (8 mg, 96%). ES+APCI MS m/z 636.3 $[M+H]^+$.




[01015] Step D: 2-(1-acryloyl-4-(7-(6-methyl-1H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A stirred mixture of benzyl 2-(cyanomethyl)-4-(7-(6-methyl-1H-indazol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (16 mg, 0.02517 mmol), methanol (1.5 ml, 0.02517 mmol), tetrahydrofuran (1.815 mg, 0.02517 mmol) and palladium on carbon (10 mg, 5%, *Degussa type E101 NO/W*) was degassed and stirred under hydrogen atmosphere for 1hour. The mixture was

filtered through Celite (2 mL) and the celite washed with THF (3 x 3 mL). The combined organics were concentrated in vacuo to ~0.5 mL, dissolved in DCM (5 mL), cooled to -30°C with stirring in an EtOH-H_2O-CO_2 bath. Triethylamine (0.02 mL, 5 eq.) was next added followed by acryloyl chloride (0.006134 ml, 0.07550 mmol) and the reaction mixture was stirred 1 min at -30°C. The reaction was quenched with NH_4OH (0.03 mL) and concentrated in vacuo. The residue was divided between 1M $NaHCO_3$ (3 mL) and EtOAc (15 mL) and the layers separated. The organic layer was washed with water (3mL), brine (3 mL), dried over Na_2SO_4 and evaporated in vacuo. The product was purified by chromatography on silica gel, Redisep 12g, using 10 to 20% MeOH/DCM +0.2% NH_4OH as eluent to give a colorless solid (5.96 mg, 43%). ES+APCI MS m/z 556.3 $[M+H]^+$.

EXAMPLE 239


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01016] Synthesized according to **Example 210**, Steps E-G using 4-Bromo-3-(trifluoromethyl)pyridine hydrobromide in place of 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 240


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(2,2,2-trifluoroethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01017] Synthesized according to **Example 210**, Steps E-G using 1-bromo-2-(2,2,2-trifluoroethyl)benzene in place of 1-bromo-2-(trifluoromethyl)benzene in Step E. ES+APCI MS m/z 584.3 $[M+H]^+$.

EXAMPLE 241

benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate




[01018] Step A: In a vial, benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 0.198 mmol) was dissolved in dioxane (98.9 µl, 0.198 mmol) and treated with cesium carbonate (129 mg, 0.396 mmol), and 2-Fluoro-3-(trifluoromethyl)pyridine (163 mg, 0.989 mmol) The tube was then capped and heated to 90°C for 12hr. Reaction was filtered through GF/F paper and concentrated. The residue was purified by silica chromatography (0-12% MeOH in DCM).



[01019] Step B: Synthesized according to **Example 210**, Steps F-G using benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in place of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in Step F. ES+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 242

2-(1-(but-2-ynoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01020] At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (603 µL, 0.06 mmol) was added 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.06 mmol) and triethylamine (12.2 mg, 0.12 mmol). The reaction mixture was vigorously stirred while 2-Butynoic acid (6.08 mg, 0.07 mmol) was added in one portion. Next, 1-Propanephosphonic acid cyclic anhydride (26.9 µl, 0.09 mmol) was added to the stirring mixture. The reaction was allowed to stir for 2h at 0°C. Water was added and the reaction extracted with EtOAc (2x 25 mL). The organic layers were washed with saturated LiCl, NaCl, and water (10 mL each wash).

Dried and concentrated to a solid that was purified by reverse phase prep HPLC (5-95% ACN:H2O, with 0.1% TFA) to provide the title compound.

EXAMPLE 243

2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01021] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (1.05 g, 2.60 mmol), 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (1.13 g, 2.86 mmol), RuPhos (484 mg, 1.04 mmol) and Cs_2CO_3 (2.11 g, 6.49 mmol) in toluene (20 mL) was added $Pd_2(dba)_3$ (475 mg, 519 umol) under N_2, the suspension was degassed under vacuum and purged with N_2 several times. The mixture was warmed to 90 °C and stirred at 90 °C for 7 hours. The reaction mixture was filtered and the filter cake was washed with EtOAc (3 × 20 mL). The combined organic layers were concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EA from 30:1 to 4:1) and then by reversed phase flash column (ACN: 100%) to give *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (850 mg, 1.12 mmol, 43.3 % yield, 95.0 % purity) as a yellow solid. ESI MS m/z 719.5 $[M+H]^+$.

[01022] Step B: *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (850 mg, 1.18 mmol) in DCM (17 mL) was added m-CPBA (240 mg, 1.18 mmol, 85.0 % purity) at 0 °C and stirred at 0 °C for 1 hour. The reaction mixture was quenched by saturated $Na_2S_2O_3$ (15 mL) at 0°C and separated, then diluted with water (10 mL) and extracted with EtOAc (30 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 80 %) to give *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (730 mg, 944 umol, 79.8 % yield, 95.0 % purity) as yellow solid. ESI MS m/z 735.5 $[M+H]^+$.

[01023] Step C: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 408 umol) and [(2*R*)-1-methylpyrrolidin-2-yl]methanol (94.0 mg, 816 umol) in toluene (6 mL) was added t-BuONa (58.8 mg, 612 umol) at 15 °C and stirred at 15 °C for 0.5 hour. To the mixture was added EtOAc (15 mL) and water (5 mL), then extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) =54 %) to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (216 mg, 261 umol, 64.0 % yield, 95.0 % purity) as brown solid. ESI MS m/z 786.6$[M+H]^+$.

[01024] Step D: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 242 umol) and 2,6-dimethylpyridine (311 mg, 2.90 mmol, 338 uL) in DCM (4 mL) was added TMSOTf (645 mg, 2.90 mmol, 524 uL) at 0 °C and stirred at 20 °C for 1 hour. The reaction mixture was quenched by MeOH (1 mL), then concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) =40 %). 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (85 mg, 123 umol, 50.8 % yield, 99.0 % purity) was obtained as a white solid. ESI MS m/z 686.5 $[M+H]^+$.


[01025] Step E: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile To a solution of 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-

5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (85.0 mg, 124 umol), DIEA (96.1 mg, 744 umol, 130 uL) in DCM (2 mL) was added prop-2-enoyl prop-2-enoate (23.4 mg, 186 umol) at 0 °C and the mixture stirred at 20 °C for 1 hour. The reaction mixture was quenched by water (2 mL). The resulting mixture was extracted with DCM (3 × 5 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) =48 %) to give 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (45 mg, 54.7 umol, 44.2 % yield, 90.0 % purity) as white solid. ^{1}H NMR (400 MHz, chloroform-d) δ = 8.16 (s, 1H), 7.71 (d, *J*=8.8 Hz, 1H), 7.52 (d, *J*=8.8 Hz, 1H), 6.59 (br s, 1H), 6.45 - 6.36 (m, 1H), 5.84 (br d, *J*=10.4 Hz, 1H), 5.76 (s, 2H), 5.12 (s, 1H), 4.44 - 4.28 (m, 3H), 4.21 - 4.08 (m, 2H), 3.98 (br d, *J*=12.0 Hz, 1H), 3.63 - 3.54 (m, 2H), 3.48 - 3.39 (m, 2H), 3.32 (br s, 1H), 3.10 (br s, 2H), 2.99 - 2.86 (m, 2H), 2.80 (br s, 2H), 2.73 - 2.58 (m, 2H), 2.49 (s, 3H), 2.28 (br s, 1H), 2.05 (br s, 1H), 1.77 (br s, 4H), 0.94 - 0.88 (m, 2H), -0.04 (s, 9H).

[01026] Step F: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile To a solution of 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (45 mg, 60.8 umol) in DCM (0.15 mL) was added TFA (208 mg, 1.82 mmol, 135 uL) and the mixture stirred at 20 °C for 1 hour. The reaction mixture was basified by saturated $NaHCO_3$ (2 mL) to pH=8. The resulting mixture was extracted with DCM: MeOH (10:1) (3 × 5 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um;mobile phase: [water(0.225%FA)-ACN];B%: 10%-40%,10.5min) to give 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (8.2 mg, 12.0 umol, 19.8 % yield, 96.2 % purity, FA) as yellow oil. ESI MS m/z 610.4 $[M+H]^+$.

EXAMPLE 244

2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01027] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 445 umol), 8-bromoisoquinoline (185 mg, 891 umol), RuPhos (41.6 mg, 89.1 umol) and Cs_2CO_3 (435 mg, 1.34 mmol) in toluene (4.5 mL) was added $Pd_2(dba)_3$ (40.8 mg, 44.5 umol) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 12 hours. The mixture was filtered and the filter cake was washed


with EtOAc (3 × 10 mL). The combined organic layers were concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) =20 %) to give *tert*-butyl 2-(cyanomethyl)-4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (160 mg, 240 umol, 54.0 % yield, 90.0 % purity) as brown solid. ESI MS m/z 599.4 $[M+H]^+$.

[01028] Step B: 2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: A solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 317 umol) and TFA (724 mg, 6.35 mmol, 470 uL) was stirred at 20 °C for 1 hour. The reaction mixture was concentrated under vacuum to give 2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (230 mg, crude, 2TFA) as a brown oil.

[01029] Step C: 2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (230 mg, 316 umol, 2TFA) and DIEA (409 mg, 3.17 mmol, 551 uL) in DCM (5 mL) was added prop-2-enoyl prop-2-enoate (47.9 mg, 380 umol) at 0 °C, then the mixture was stirred at 20 °C for 1 hour. Water (5 mL) was added to the mixture. The resulting mixture was extracted with DCM (3 × 5 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water(0.225%FA)-ACN];B%: 1%-20%,10min) to give 2-[4-[7-(8-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (12.5 mg, 19.7 umol, 6.23 % yield, 94.5 % purity, FA) as yellow solid. ESI MS m/z 553.2 $[M+H]^+$.

EXAMPLE 245

2-[4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01030] Step A: (7-methyl-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate: To a solution of 7-methyltetralin-1-one (2.00 g, 12.5 mmol) and DIPEA (4.84 g, 37.5 mmol, 6.52 mL) in DCM (30 mL) was added Tf_2O (5.28 g, 18.7 mmol, 3.09 mL) dropwise at -5 °C. The mixture was stirred at 20 °C for 3 hours. Upon completion, the mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EA 1/0 to 100/1) to give (7-methyl-

3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.53 g, 4.45 mmol, 35.6 % yield, 85.0 % purity) as a yellow oil. ^{1}H NMR (400 MHz, chloroform-d) δ = 7.17 (s, 1H), 7.11 - 7.05 (m, 2H), 6.01 (t, *J* = 4.8 Hz, 1H), 2.83 (t, *J* = 8.0 Hz, 2H), 2.50 (dt, *J* = 4.8, 8.0 Hz, 2H), 2.36 (s, 3H).

[01031] Step B: (7-methyl-1-naphthyl) trifluoromethanesulfonate: A mixture of (7-methyl-3,4-dihydronaphthalen-1-yl)trifluoro methanesulfonate (1.40 g, 4.79 mmol) and DDQ (2.17 g, 9.58 mmol) in dioxane (28 mL) was stirred at 105 °C for 12 hours. Upon completion, the mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EA 1/0 to 100/1) to give (7-methyl-1-naphthyl) trifluoromethanesulfonate (1.10 g, 3.41 mmol, 71.2 % yield, 90.0 % purity) as a yellow oil. ^{1}H NMR (400 MHz, chloroform-d) δ = 7.87 - 7.79 (m, 3H), 7.49 - 7.38 (m, 3H), 2.59 (s, 3H).

[01032] Step C: *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: A mixture of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido [3,4-d]pyrimidine (10 g, 34.0 mmol), 2-piperazin-2-ylacetonitrile (10.1 g, 51.0 mmol, 2 HCl) and DIEA (17.6 g, 136 mmol, 23.7 mL) in dioxane (100 mL) was stirred at 50 °C for 2 hours. Boc_2O (14.8 g, 68.0 mmol, 15.6 mL) was added and the mixture was stirred at 50 °C for 2 hours. The mixture was concentrated under vacuum and the residue was diluted with ethyl acetate (500 mL). The separated organic layer was washed with water (1 × 300 mL), brine (1 × 200 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was triturated with ethyl acetate (100 mL). The precipitate was filtered and the filtered cake was washed with ethyl acetate (50 mL) and dried under vacuum to give a gray solid. The filtrate was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 100/1 to 1/2). The desired fractions were collected and concentrated under vacuum to give solid then combined with above solid to give *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (15 g, 29.10 mmol, 85.6% yield, 93.7% purity) as yellow solid. ESI MS m/z 483.1 $[M+H]^+$.

[01033] Step D: 4-[7-benzyl-2-[(1-methylpyrrolidin-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (1.19 g, 10.4 mmol, 1.23 mL, 2.5 eq) in THF (30.0 mL) was added NaH (331 mg, 8.28 mmol, 60 % purity in mineral oil, 2.00 eq) at 0 °C and the mixture was

stirred at 0 °C for 0.5 h. *tert*-Butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.00 g, 4.14 mmol, 1.00 eq) was added into the mixture and the mixture was stirred at 80 °C for 4 hours. The mixture was poured into ice water (100 mL) and extracted with ether acetate (3 × 150 mL). The organic layers were washed with saturated sodium chloride solution (1 × 200 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 4-[7-benzyl-2-[(1-methylpyrrolidin-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (2.86 g, crude) as a black oil which was used in the next step without further purification. ESI MS m/z 562.3 $[M+H]^+$.

[01034] Step E: *tert*-butyl 2-(cyanomethyl)-4- [2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate: NH_3 was bubbled into methanol (70.0 mL) at -78 °C for 30 minutes. *tert*-Butyl 4-[7-benzyl-2-[(1-methylpyrrolidin-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido [3,4-*d*] pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (2.00 g, crude) and Pd/C (0.20 g, 10% purity) were added into the mixture. The mixture was stirred at 40 °C for 24 hours under H_2 at 15 psi. The mixture was filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (FA, 0.1 %)/ancetonitrile]. The desired fractions were adjusted to pH >7 by saturated sodium bicarbonate solution (5.00 mL) and the aqueous layer extracted with ether acetate (3 × 100 mL). The combined organic layers were washed with brine (1 × 100 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 2-(cyanomethyl)-4- [2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.40 g, 845 umol, two steps 29.4% yield) as a yellow solid. ESI MS m/z 472.2 $[M+H]^+$.

[01035] Step F: *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A solution of *tert*-butyl 2-(cyanomethyl)-4- [2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (185 mg, 392 umol), (7-methyl-1-naphthyl) trifluoromethanesulfonate (159 mg, 549 umol), $Pd_2(dba)_3$ (35.9 mg, 39.2 umol), RuPhos (36.6 mg, 78.5 umol) and Cs_2CO_3 (320 mg, 981 umol) in toluene (30 mL) was de-gassed with N2 and then heated to 90 °C for 12 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by reversed-phase flash


[water(0.1% $NH_3 \cdot H_2O$)/acetonitrile] to give *tert*-butyl 2-(cyanomethyl)-4-[7-(7-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 283 umol, 72.1 % yield, 96.1 % purity) as a yellow solid. ESI MS m/z 612.6 $[M+H]^+$.

[01036] Step G: 2-[4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: A solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(7-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 294 umol) in TFA (671 mg, 5.88 mmol, 436 uL) was stirred at 20 °C for 1 hour. Upon completion the mixture was concentrated under vacuum to give 2-[4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.37 g, crude, TFA) as a yellow oil which was used directly in the next step without further purification.

[01037] Step H: 2-[4-[7-(7-methyl-1-naphthyl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a solution of 2-[4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (189 mg, crude, TFA) and DIEA (976 mg, 7.55 mmol, 1.32 mL) in DCM (4 mL) was added prop-2-enoyl prop-2-enoate (38.1 mg, 302 umol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction was quenched with MeOH (0.5 mL), diluted with water (1 mL) and extracted with DCM (3 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um; mobile phase: [water(0.225%FA) - ACN]; B%: 15% - 45%,10.5 min) to give 2-[4-[7-(7-methyl-1-naphthyl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (13.2 mg, 21.3 umol, two steps 14.2% yield, 98.4% purity, FA) as a yellow solid. ESI MS m/z 566.5 $[M+H]^+$.

EXAMPLE 246


2-[4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile.



[01038] Synthesized according to the method for **Example 147** substituting 1-bromo-4-fluoronaphthalene for 1-bromonaphthalene in step H. ESI MS m/z 570.5 $[M+H]^+$.

EXAMPLE 247


2-(1-acryloyl-4-(2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-7-(quinolin-8-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01039] Synthesized according to the method for **Example 147** substituting 8-bromoquinoline for 1-bromonaphthalene in Step H. ESI MS m/z 553.2 $[M+H]^+$.

EXAMPLE 248

(*S*)-1-(4-(7-(5-isopropyl-1*H*-indazol-4-yl)-2-((1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[01040] Step A: 2-(2-bromo-4-fluoro-phenyl)propan-2-ol: To a solution of 1-(2-bromo-4-fluoro-phenyl)ethanone (10 g, 46.1 mmol) in THF (100 mL) was added MeMgBr (in ether) (3 M, 46.08 mL) at - 50 °C. The mixture was warmed up to 0 °C and stirred for 3 hours. The mixture was quenched with saturated aqueous ammonium chloride solution (10 mL) at - 50 °C. The mixture was warmed up to 15 °C and was then diluted with ethyl acetate (500 mL). The

separated organic layer was washed with water (1 × 500 mL) and brine (1 × 500 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give 2-(2-bromo-4-fluoro-phenyl)propan-2-ol (10 g, 36.5 mmol, 79.2% yield, 85% purity) as a colorless oil.

[01041] Step B: 2-bromo-4-fluoro-1-isopropyl-benzene: To a solution of 2-(2-bromo-4-fluoro-phenyl)propan-2-ol (9 g, 38.6 mmol) in dichloromethane (100 mL) was added Et_3SiH (8.98 g, 77.2 mmol, 12.3 mL) and TFA (65.1 g, 571 mmol, 42.3 mL). The mixture was stirred at 15 °C for 1 hour and then heated to 50 °C for 1 hour. The reaction mixture was concentrated under vacuum and then diluted with ethyl acetate (100 mL). The aqueous layer pH was adjusted to pH = 7 by addition of saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (50 mL × 3). The combined organic phase was washed with brine (30 mL), dried with anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 1/0 to 100/1). The desired fractions were collected and concentrated under vacuum. 2-bromo-4-fluoro-1-isopropyl-benzene (7 g, 32.2 mmol, 83.5 % yield) was obtained as colorless oil. ^{1}H NMR (400MHz, chloroform-d) δ = 7.36-7.27 (m, 2H), 7.09 - 7.02 (m, 1H), 3.46-3.31 (m, 1H), 1.28 (d, J = 6.8 Hz, 6H).

[01042] Step C: 2-bromo-6-fluoro-3-isopropyl-benzaldehyde: To a mixture of 2-bromo-4-fluoro-1-isopropyl-benzene (7 g, 32.2 mmol in THF (100 mL) was added LDA (2 M in toluene, 24.2 mL) at - 70 °C under nitrogen atmosphere. The mixture was stirred for 0.5 hour, and then DMF (7.07 g, 96.7 mmol, 7.44 mL) was added. The mixture was stirred at - 70 °C for 2 hours. The reaction was quenched with water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, PE\EA = 1\0 to 10\1). The desired fractions were collected and concentrated under vacuum to give 2-bromo-6-fluoro-3-isopropyl-benzaldehyde (2.4 g, 9.79 mmol, 30.4 % yield) as a yellow oil. ^{1}H NMR (400MHz, chloroform-d) δ = 10.41 (s, 1H), 7.48 (dd, J = 5.6, 8.8 Hz, 1H), 7.13(t, J = 9.2, 1H), 3.57 - 3.46 (m, 1H), 1.26 (d, J = 7.2 Hz, 6H).

[01043] Step D: 4-bromo-5-isopropyl-1*H*-indazole: 2-bromo-6-fluoro-3-isopropyl-benzaldehyde (2.4 g, 9.79 mmol) in DMSO (3 mL) was added N_2H_4•H_2O (15.4 g, 302 mmol, 15 mL, 98% purity) and the mixture was heated to 110 °C and stirred for 16 hours. The reaction mixture was poured into H_2O (10 mL) and extracted with ethyl acetate (20 mL × 3). The organic

phase was washed with brine (10 mL), dried over anhydrous Na_2SO_4 and concentrated under vacuum to give the residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 5/1) to give 4-bromo-5-isopropyl-1*H*-indazole (650 mg, 2.72 mmol, 27.8 % yield) as a yellow solid. ^{1}H NMR (400MHz, chloroform-d) δ = 10.24 (br s, 1H), 8.08 (d, *J* = 0.8 Hz, 1H), 7.43 (d, *J* = 8.8 Hz, 1H), 7.34 (d, *J* = 8.8 Hz, 1H), 3.56 (td, *J* = 6.8, 13.6 Hz, 1H), 1.29 (d, *J* = 6.8 Hz, 6H).

[01044] Step E: 4-bromo-5-isopropyl-1-tetrahydropyran-2-yl-indazole: To a solution of 3,4-dihydro-2*H*-pyran (457 mg, 5.44 mmol, 497 uL, 2 *eq*) in dichloromethane (15 mL) was added TsOH•H_2O (51.7 mg, 271 umol) and 4-bromo-5-isopropyl-1*H*-indazole (650 mg, 2.72 mmol). The mixture was stirred at 20 °C for 3 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 5/1) and further purificated by reversed phase flash [water (0.1% formic acid)/acetonitrile] to give 4-bromo-5-isopropyl-1-tetrahydropyran-2-yl-indazole (170 mg, 494 umol, 18.2% yield, 94% purity) as a yellow oil. ESI MS m/z 323.0 $[M+H]^+$.

[01045] Step F: *tert*-butyl 4-[7-(5-isopropyl-1-tetrahydropyran-2-yl-indazol- 4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of 4-bromo-5-isopropyl-1-tetrahydropyran-2-yl-indazole (136 mg, 420 umol), *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 323 umol), RuPhos (15.1 mg, 32.4 umol), RuPhos-Pd-G2 (25.1 mg, 32.4 umol) and *t*-BuONa (77.7 mg, 809 umol) in toluene (3 mL) was degassed and purged with N_2 3 times and the mixture was stirred at 90 °C for 12 hours under N_2 atmosphere. The mixture was diluted with ethyl acetate (20 mL) and washed with water (20 mL). The organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, DCM/MeOH = 100/1 to 10/1) and the desired fractions were collected and concentrated under vacuum to give *tert*-butyl 4-[7-(5-isopropyl-1-tetrahydropyran-2-yl-indazol- 4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-


pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (70 mg, 96.5 umol, 29.8% yield, 93% purity) was as a yellow solid. ESI MS m/z 675.3 $[M+H]^+$.

[01046] Step G: 7-(5-isopropyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: To a solution of *tert*-butyl 4-[7-(5-isopropyl-1-tetrahydropyran- 2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (40 mg, 59.3 umol) in dichloromethane (100 uL) was added TFA (101 mg, 889 umol, 65.8 uL). The mixture was stirred at 25 °C for 1 hour. The mixture was concentrated under vacuum to give 7-(5-isopropyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (42 mg, 58.4 umol, 98.6% yield, 2 TFA) as a brown oil which was used in next step directly without purification. ESI MS m/z 491.4 $[M+H]^+$.

[01047] Step H: 1-[4-[7-(5-isopropyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a mixture of 7-(5-isopropyl-1*H*-indazol-4-yl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (42 mg, 58.4 umol) and DIEA (75.5 mg, 584 umol, 102 uL) in dichloromethane (2 mL) was added a solution of prop-2-enoyl prop-2-enoate (7.37 mg, 58.4 umol, 1 *eq*) in dichloromethane (1 mL) at - 40 °C under nitrogen atmosphere. The mixture was stirred at - 40 °C for 1 hour. The reaction was quenched by adding saturated $NaHCO_3$ (2 mL) aqueous solution. Then the mixture was poured into water (20 mL) and extracted with dichloromethane (20 mL × 2). The combined organics were dried over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225%FA) - ACN]; B%: 5% - 38%, 10 min) to give 1-[4-[7-(5-isopropyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (4.5 mg, 7.93 umol, 13.6% yield, 96% purity) as a yellow solid. ESI MS m/z 545.2 $[M+H]^+$.

EXAMPLE 249

1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[01048] Step A: *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.50 g, 1.16 mmol), (2-fluoro-3-methoxy-1-naphthyl) trifluoromethanesulfonate (562 mg, 1.73 mmol), RuPhos (108 mg, 231 umol), $Pd_2(dba)_3$ (106 mg, 116 umol) and *t*-BuONa (333 mg, 3.47 mmol) in toluene (7 mL) was stirred at 110 °C for 3 hours under nitrogen atmosphere. The mixture was cooled and the pH of the aqueous layer adjusted to 7 by addition of saturated sodium bicarbonate solution and the aqueous layer extracted with ether acetate (3 × 20 mL). The combined organic layers were washed with saturated sodium chloride solution, dried over Na_2SO_4, filtered and concentrated

under vacuum. The residue was purified by column chromatography (SiO_2, dichloromethane/methanol = 10/1) and the mixture was concentrated to give *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 274 umol, 11.8 % yield,) as a yellow solid. ESI MS m/z 607.0 $[M+H]^+$.


[01049] Step B: 7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: A mixture *tert*-butyl 4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 330 umol) and TFA (564 mg, 4.94 mmol, 366 uL) in dichloromethane (0.4 mL) was stirred at 10 °C for 1 hour. The mixture was concentrated under vacuum to give 7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (205 mg, crude) as a yellow oil which was used in the next step without further purification. ESI MS m/z 507.0 $[M+H]^+$.

[01050] Step C: 1-[4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (0.20 g, crude) and TEA (399 mg, 3.95 mmol, 549 uL) in dichloromethane (5mL) was added prop-2-enoyl prop-2-enoate (49.8 mg, 394 umol) at -40 °C, then stirred at -40 °C for 0.5 h. The mixture was quenched with methanol (0.10 mL) and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1 % TFA)/acetonitrile]. The aqueous layer pH was to 7 by addition of saturated sodium bicarbonate solution and the aqueous layer extracted with dichloromethane/methanol (10/1) (3 × 10mL). The combined organic layers were washed with saturated sodium chloride (1 × 5mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 1-[4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (0.10 g, 174 umol, 44.1 % yield) as a yellow oil. ESI MS m/z 561.5 $[M+H]^+$.


[01051] Step D: 1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a

solution of 1-[4-[7-(2-fluoro-3-methoxy-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (0.10 g, 174 umol) in dichloromethane (3mL) was added BBr_3 (223 mg, 892 umol, 85.9 uL) at -78 °C. The mixture was stirred at -78 °C for 0.5 h and 0 °C for 2 hours. The mixture was concentrated under vacuum, diluted with dichloromethane (3mL) and water and the aqueous layer pH adjusted to > 7 by addition of saturated sodium bicarbonate solution at -78 - 0 °C. The aqueous layer was next extracted with dichloromethane (3 × 5.00 mL). The combined organics were concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, dichloromethane/methanol = 10/1) and the mixture was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (10mM NH_4HCO_3) - ACN]; B%: 30% - 60%, 3 min) and further purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 20% - 50%, 10 min). The desired fractions were collected and lyophilized to give 1-[4-[7-(2-fluoro-3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (1.59 mg, 2.91 umol, 1.63 % yield, 100 % purity, FA) as a yellow solid. ESI MS m/z 547.2$[M+H]^+$.

EXAMPLE 250



1-[4-[7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



Step A: 4-bromo-5-chloro-1-tetrahydropyran-2-yl-indazole: To a solution of 4-bromo-5-chloro-1*H*-indazole (100 mg, 432.0 umol) in DCM (3 mL) was added $TsOH \cdot H_2O$ (8.22 mg, 43.2 umol) and 3,4-dihydro-2*H*-pyran (72.7 mg, 864 umol, 79.0 uL). The mixture was stirred at 20°C for 2hours. The reaction was washed by water (20 mL) and the aqueous layer extracted with ethyl acetate (20 mL x 2). The combined organics were dried with Na_2SO_4 and the solvent removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 10:1) to give 4-bromo-5-chloro-1-tetrahydropyran-2-yl-indazole (270 mg, 810 umol, 93.8% yield) as a white solid. ESI MS m/z 547.2$[M+H]^+$.

[01052] Step B: tert-butyl-4-[7-(5-chloro-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate: A mixture of tert-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (123 mg, 284.4 umol) , 4-bromo-5-chloro-1-tetrahydropyran-2-yl-indazole (135 mg, 427 umol), $Pd_2(dba)_3$ (26.0 mg, 28.4 umol), RuPhos (20.0 mg, 42.9 umol) and Cs_2CO_3 (278 mg, 853 umol) in dioxane (10 mL) was degassed and purged with N_2 and then the mixture was stirred at 100 °C for 12 hrs under N_2


atmosphere. The reaction was quenched by adding water (20 mL). The mixture was extracted with ethyl acetate (20 mL x 3). The combined organics were dried with Na_2SO_4 and the solvent was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH=10/1) to give tert-butyl-4-[7-(5-chloro-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (130.0 mg, 188.4 umol, 66.3% yield) as a white solid. ESI MS m/z 668.2$[M+H]^+$.

[01053] Step C: 7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine: To a solution of tert-butyl 4-[7-(5-chloro-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (50.0 mg, 74.9 umol) in DCM (2 mL) was added TFA (1.95 mL).The mixture was stirred at 20°C for 1 hr. The organic solvent was removed under vacuum to give 7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (40.0 mg, crude, 2TFA) as a yellow oil which was used directly in the next step without further purification. ESI MS m/z 483.4$[M+H]^+$.

[01054] Step D: 1-[4-[7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one: To a solution of 7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (40.0 mg, 2TFA) and DIEA (50 mg, 387 umol, 67.4 uL) in DCM (3mL) was added dropwise acrylic anhydride (9.0 mg, 71.4 umol) under N_2 atmosphere. The mixture was stirred at -70 °C for 15 mins. The reaction was quenched by adding water (10 mL). The mixture was extracted with ethyl acetate (10 mL x 3). The organic layer was dried with Na_2SO_4 and the solvent removed under vacuum. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225%FA)-ACN];B%: 10%-37%,10 mins) and lyophilized to give 1-[4-[7-(5-chloro-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (11.9 mg, 20.8 umol, two steps 27.3%,100% e.e.) as a yellow solid. ESI MS m/z 537.2 $[M+H]^+$.


EXAMPLE 251

2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01055] Step A: benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate. In a microwave tube benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.362 mmol) was dissolved in dioxane (181 µl, 0.362 mmol) and treated with cesium carbonate (236 mg, 0.723 mmol) and (S)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate (389 mg, 1.81 mmol). The tube was then capped and heated to 90°C for 2 hours. LC/MS showed reaction completion. The reaction was cooled to room temperature and filtered through GF/F paper. The filtrate was concentrated in vacuo and chromatagraphed on the CombiFlash (0%-10% DCM:MeOH). All fractions containing clean product were combined and concentrated to give benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-

(cyanomethyl)piperazine-1-carboxylate (264 mg, 0.361 mmol, 99.7 % yield). ES+APCI MS m/z 732.4 $[M+H]^+$.




[01056] Step B: benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (264 mg, 0.361 mmol) was dissolved in dichloromethane (3607 µl, 0.361 mmol) and treated with TFA (556 µl, 7.21 mmol). The reaction stirred at room temperature for 1 hour. LC/MS showed reaction completion. The reaction was concentrated in vacuo and treated with saturated bicarb. The aqueous layer was extracted with DCM (2X) and the combined organics dried over Na2SO4 and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (210 mg, 0.332 mmol, 92.2 % yield). ES+APCI MS m/z 632.3 $[M+H]^+$.



[01057] Step C: benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-

5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (105 mg, 0.1662 mmol) was dissolved in formic acid (94.05 µl, 2.493 mmol) and treated with Formaldehyde (1868 µl, 24.93 mmol). The reaction mixture stirred at 85°C for 1 hour. LC/MS showed reaction completion. The reaction was cooled to room temperature and treated with saturated bicarb and the mixture was extracted with DCM (2X) and the organics combined and dried over Na2SO4. The combined organics were concentrated in vacuo and chromatagraphed on the CombiFlash (0%-10% DCM:MeOH). All fractions containing clean product were combined and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.1161 mmol, 69.88 % yield). ES+APCI MS m/z 646.4 $[M+H]^+$.





[01058] Step D: 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. A solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (117 mg, 0.181 mmol) in EtOH (1812 µl, 0.181 mmol) and THF (1812 µl, 0.181 mmol) was purged with N_2 for 5 minutes. To this solution was added Palladium (96.4 mg, 0.0453 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 min. The solution was then stirred under H_2 atmosphere for 1 hour. LC/MS showed clean desired product. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (88 mg, 0.172 mmol, 94.9 % yield). ES+APCI MS m/z 512.3 $[M+H]^+$.

[01059] Step E: 2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a suspension of 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (88 mg, 0.17 mmol) in dichloromethane (1720 µl, 0.17 mmol) at ambient temperature was added Acyloyl Chloride (14 µl, 0.17 mmol) followed by Hunig's base (60 µl, 0.34 mmol). The reaction was then stirred at ambient temperature for 30 minutes. LC/MS showed reaction completion. The reaction mixture was concentrated in vacuo. The concentrate was resuspended in a 60:40 mixture of ACN:H2O and purified on the Gilson (prep HPLC) using 5-->95% ACN/0.1% TFA in water/0.1% TFA as eluent. Fractions containing product were combined and free based with saturated bicarb and the organics extracted with DCM. The organics were dried over MgSO4 and concentrated in vacuo to give 2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (14 mg, 0.025 mmol, 14 % yield). ES+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 252

tert-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate





[01060] Step A: (*S*)-pyrrolidin-2-ylmethanol: To a solution of (*S*)-*tert*-butyl 2-(hydroxymethyl) pyrrolidine-1-carboxylate (2 g, 9.94 mmol) in CH_2Cl_2 (40 mL) was added HCl (4 M in dioxane, 49.69 mL) at 0 °C under a nitrogen atmosphere. After stirring at 15 °C for 30 min, the mixture was concentrated under vacuum. (*S*)-pyrrolidin-2-ylmethanol (1.37 g, 9.96 mmol, 100% yield, HCl) was obtained as a yellow solid.

[01061] Step B: [(2*S*)-1-isopropylpyrrolidin-2-yl] methanol: A mixture of [(2*S*)-pyrrolidin-2-yl]methanol (750 mg, 7.41 mmol, 724 uL) and acetone (4.31 g, 74.2 mmol, 5.46 mL) in MeOH (20 mL) was hydrogenated under H_2 (30 psi) with Pd/C (100 mg, 7.41 mmol, 10% purity) at 15 °C for 3 hours. The mixture was filtered and concentrated under vacuum. [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol (0.821 g, 5.73 mmol, 77.3% yield) was obtained as a yellow oil. ^{1}H NMR (400MHz, methanol-d_4) δ = 3.54 (dd, *J* = 4.0, 10.8 Hz, 1H), 3.40 - 3.35 (m, 1H), 2.99 - 2.86 (m, 3H), 2.60 - 2.50 (m, 1H), 1.94 - 1.82 (m, 1H), 1.82 - 1.66 (m, 3H), 1.15 (d, *J* = 6.4 Hz, 3H), 1.08 (d, *J* = 6.4 Hz, 3H).

[01062] Step C: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] piperazine-1-carboxylatete: To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl- 7-(1-naphthyl)-

6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 549 umol) and [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol (157 mg, 1.10 mmol) in THF (5 mL) was added *t*-BuONa (158 mg, 1.65 mmol). After stirring at 20 °C for 0.5 hour, the reaction mixture was neutralized with HCl (1 M) to pH = 7 while holding the solution temperature to 0°C, and then the mixture was concentrated under reduced pressure. The residue was purified by reversed phase flash [water (0.1% TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (200mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (174 mg, 278 umol, 50.7% yield, 100% purity) was obtained as a yellow oil. ESI MS m/z 626.2 $[M+H]^+$.


[01063] Step D: 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile: To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropyl pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (174 mg, 278 umol) in CH_2Cl_2 (5 mL) was added TFA (7.70 g, 67.5 mmol, 5.00 mL) at 0 °C under nitrogen atmosphere. After stirring at 15 °C for 0.5 h, the mixture was concentrated under vacuum. 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (178 mg, crude, TFA) was obtained as a yellow oil. ESI MS m/z 526.1 $[M+H]^+$.

[01064] Step E: 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin- 2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile: To a mixture of 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (178 mg, crude, TFA salt) and DIEA (360 mg, 2.78 mmol, 485 uL) in CH_2Cl_2 (5 mL) was added prop-2-enoyl prop-2-enoate (28.1 mg, 223 umol) at 0 °C. The mixture was stirred at 20 °C for 1 hour. The reaction mixture was quenched with $NaHCO_3$ saturated solution (5 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 25 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA) - ACN]; B%: 27% -

54%, 10 min). 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin- 2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (11.7 mg, 18.3 umol, two steps 6.58% yield, 97.9% purity, FA) was obtained as a brown solid. ESI MS m/z 580.2 $[M+H]^+$.

EXAMPLE 253

2-(1-acryloyl-4-(7-(7-chloronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01065] Step A: (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate: To a mixture of 7-chlorotetralin-1-one (2 g, 11.1 mmol, 1 eq) and DIEA (4.29 g, 33.2 mmol, 5.79 mL) in DCM (35 mL) was added Tf_2O (4.69 g, 16.6 mmol, 2.74 mL) in one portion at 0 °C under N_2. The mixture was stirred at 25 °C for 5 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 50/1). (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (2.25 g, 7.02 mmol, 63.4% yield, 97.6 % purity) was obtained as a colorless oil. ^1H NMR (400MHz, chloroform-d) δ = 7.32 (d, J = 2.0 Hz, 1H), 7.24 (dd, J = 2.0, 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.10 (t, J = 4.8 Hz, 1H), 2.88 - 2.80 (m, 2H), 2.53 (dt, J = 4.8, 8.0 Hz, 2H).

[01066] Step B: (7-chloro-1-naphthyl) trifluoromethanesulfonate: To a mixture of (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.57 g, 5.02 mmol) in dioxane (35 mL) was added DDQ (2.28 g, 10.0 mmol) in one portion under N_2. The mixture was stirred at 25 °C for 30 min, then heated to 105 °C and stirred for 5 hours. The reaction mixture was concentrated under reduced pressure to remove 1,4-dioxane. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 50/1). (7-chloro-1-naphthyl) trifluoromethanesulfonate (1.24 g, 3.94 mmol, 78.5 % yield, 98.7 % purity) was obtained as a colorless oil. ^{1}H NMR (400MHz, chloroform-d) δ = 8.05 (d, J = 2.0 Hz, 1H), 7.87 - 7.83 (m, 2H), 7.57 - 7.47 (m, 3H).

[01067] Title compound was prepared as in **Example 210** Steps E-G, substituting (7-chloro-1-naphthyl) trifluoromethanesulfonate for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 586.1 $[M+H]^+$.

EXAMPLE 254


2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile




[01068] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromo-5-fluoronaphthalene for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 255

2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[01069] Step A: (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate: To the solution of 7-methoxytetralin-1-one (1 g, 5.67 mmol) and DIEA (2.20 g, 17.0 mmol, 2.97 mL) in DCM (15 mL) was added Tf_2O (2.40 g, 8.51 mmol, 1.40 mL) dropwise, then the mixture was stirred at 20 °C for 12 hours. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 100:1) to give (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.7 g, 5.24 mmol, 92.3 % yield, 95.0 % purity) as yellow oil. ^{1}H NMR (400 MHz, chloroform-d) δ = 7.06 (d, *J*=8.4 Hz, 1H), 6.75 (dd, *J*=2.4, 8.4 Hz, 1H), 6.66 (d, *J*=2.4 Hz, 1H), 6.45 (s, 1H), 3.80 (s, 3H), 3.04 - 2.96 (m, 2H), 2.68 (t, *J*=8.4 Hz, 2H).


[01070] Step 2: (7-methoxy-1-naphthyl) trifluoromethanesulfonate: A mixture of (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.7 g, 5.51 mmol) and DDQ (2.50 g, 11.0 mmol) in dioxane (30 mL) was stirred at 105 °C for 12 hours. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 50:1) to give (7-methoxy-1-naphthyl) trifluoromethanesulfonate (1.41 g, 4.14 mmol, 75.1 % yield, 90.0 % purity) as a colourless oil. ^{1}H NMR (400 MHz, chloroform-d) δ =


7.84 (d, *J*=9.2 Hz, 1H), 7.78 (d, *J*=8.8 Hz, 1H), 7.65 (d, *J*=2.4 Hz, 1H), 7.24 - 7.21 (m, 2H), 7.15 (d, *J*=2.4 Hz, 1H), 3.94 (s, 3H).

[01071] Title compound was prepared as in **Example 210** Steps E-G, substituting (7-methoxy-1-naphthyl) trifluoromethanesulfonate for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 582.4 $[M+H]^+$.


EXAMPLE 256

1-(2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one






[01072] Step A: benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A solution of tert-butyl 2-(methoxymethyl)piperazine-1-carboxylate (0.715 g, 3.10 mmol) in N,N-dimethylacetamide (3 ml) was cooled on an ice bath with stirring and solid benzyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.00 g, 2.96 mmol) was added in small portions, followed by DIPEA (0.57 mL, 3.25 mmol, 1.1 eq.). The resulting solution was allowed to warm up to r.t. over 1 hour, and then divided between water (15 mL) and MTBE (50 mL). The organic layer was washed with water (2 x 10 mL), brine (10 mL), dried over Na_2SO_4 and evaporated in vacuo to give a yellow solid (1.54 g, 98%). ES+APCI MS m/z 532.3, $[M+H]^+$.




[01073] Step B: benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of crude benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (500 mg, 0.940 mmol), (S)-(1-methylpyrrolidin-2-yl)methanol (216 mg, 1.88 mmol), Cs_2CO_3 (612 mg, 1.88 mmol) and dioxane (0.5 mL) was flushed with nitrogen. The vial was capped and stirred at 120°C overnight. The reaction mixture was cooled, divided between EtOAc (20 mL) and water (10 mL), the organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The compound was purified by silica gel chromatography, Redisep 40g, eluting with 4 to 10% MeOH/DCM +0.2%NH_4OH to give a yellow solid (197 mg, 34%). ES+APCI MS m/z 611.4 $[M+H]^+$.




[01074] Step C: tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (197 mg, 0.323 mmol), methanol (10 mL) and palladium on carbon (10 mg, 5%, *Degussa type E101 NO/W*) was degassed and stirred under hydrogen atmosphere (balloon) for 1 hour. The reaction mixture was filtered through Celite (2 mL), washed with MeOH (3 x 3 mL), evaporated in

vacuo, and dried by evaporation with toluene in vacuo and under high vacuum to give a colorless solid (150 mg, 98%). ES+APCI MS m/z 477.2 $[M+H]^+$.



[01075] Step D: tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido-[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (150 mg, 0.315 mmol), Cs_2CO_3 (308 mg, 0.944 mmol), dioxane (1 mL), 1-iodonaphthalene (0.0689 ml, 0.472 mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (26.3 mg, 0.0315 mmol) (RuPhos-Pd-G3) was purged with nitrogen, the flask was capped and stirred at 70°C overnight. The reaction mixture was cooled, divided between EtOAc (15 mL) and water (5 mL), the organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The compound was purified by silica gel chromatography, Redisep 40g, using 4 to 10% MeOH +0.5% NH_4OH as eluent to give a colorless solid, 131 mg. ES+APCI MS m/z 603.3 $[M+H]^+$.




[01076] Step E: 1-(2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. Tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-


5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (130 mg, 0.2157 mmol) was dissolved in 1M trifluoroacetic acid in DCM, and the resulted solution was allowed to stay at r.t. for 1h. The reaction mixture was divided between 2M Na_2CO_3 (5 mL) and DCM (15 mL), and the organic layer was evaporated in vacuo. The solid residue was dissolved in DCM (5 mL), cooled on ice-EtOH-CO_2 bath with stirring to -30°C and triethylamine (0.09 ml, 0.64 mmol) was added, followed by acryloyl chloride (0.035 ml, 0.43 mmol). After 1 min at -30°C the reaction mixture was quenched with NH_4OH (0.05 mL) and evaporated in vacuo and dried under high vacuum. The residue was dissolved in DCM (5 mL), filtered through a cotton plug and purified by silica gel chromatography, Redisep 40g, eluting with 5 to 10% MeOH/DCM +0.25% NH_4OH to give a colorless solid (19.6 mg, 16%). ES+APCI MS m/z 557.3, $[M+H]^+$.

EXAMPLE 257

2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01077] Step A: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: In a conical bottom vial, a solution of benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.362 mmol) in dioxane (3616 µl, 0.362 mmol) was sparged with Argon for 5 minutes. (S)-(1-(cyclopropylmethyl)pyrrolidin-2-yl)methanol (168 mg, 1.08 mmol), Cs2CO3 (353 mg, 1.08 mmol), Rhuphos Pd G3 (30.2 mg, 0.0362 mmol) were sequentially added under Argon and sparged for an additional 5 minutes. The reaction mixture was capped and heated at 100°C for 1 hour. LC/MS showed reaction completion. EtOAc was added and washed with brine (2x). The combined organics were dried over Na2SO4 and concentrated in vacuo. The concentrate was purified by flash chromatography eluting with 0-20% DCM/MeOH + 2% NH4OH. All fractions containing clean desired product were combined and concentrated to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (90 mg, 0.134 mmol, 37.0 % yield). ES+APCI MS m/z 672.4 $[M+H]^+$.



[01078] Step B: 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (90 mg, 0.13 mmol) in EtOH (1340 µl, 0.13 mmol) and THF (1340 µl, 0.13 mmol) was purged with N2 for 5 min. To this solution was added Palladium (36 mg, 0.033 mmol) (Degussa Type, 10 wt%, 50% H2O), and was immediately capped and purged with N2 for an additional 5 min. The solution was then stirred under H2 introduced via vacuum followed by balloon pressure. The


mixture was then stirred at ambient temperature for 1 hour. LC/MS showed desired product. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (71 mg, 0.13 mmol, 99 % yield). ES+APCI MS m/z 538.3 $[M+H]^+$.



[01079] Step C: 2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (71 mg, 0.132 mmol) in dichloromethane (1320 µl, 0.132 mmol) at ambient temperature was added Acryloyl Chloride (10.7 µl, 0.132 mmol) followed by Hunig's base (46.1 µl, 0.264 mmol). The reaction was then stirred at ambient temperature for 1 hour. LC/MS showed reaction completion. The reaction mixture was concentrated in vacuo. The concentrate was resuspended in a 60:40 mixture of ACN:H2O and purified on the Gilson (prep HPLC) eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and free based with saturated bicarb and the organics extracted with DCM. The organics were dried over MgSO4 and concentrated in vacuo to give 2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (15.7 mg, 0.0265 mmol, 20.1 % yield). ES+APCI MS m/z 592.4$[M+H]^+$.

EXAMPLE 258


2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01080] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromoisoquinoline for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 553.3 $[M+H]^+$.

EXAMPLE 259

2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile




[01081] Step A: (6-fluoro-1-naphthyl) trifluoromethanesulfonate: To a solution of 6-fluoronaphthalen-1-ol (0.10 g, 617 umol) and DIEA (159 mg, 1.23 mmol, 215 uL) in dichloromethane (3 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (191 mg, 678 umol, 112 uL,) at 0 °C. After stirred at 0 °C for 1 hour, the mixture was diluted with water (5

mL) and extracted with dichloromethane (3 × 5 mL). The organic layers were washed with brine (1 × 5 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 3/1) to give (6-fluoro-1-naphthyl) trifluoromethanesulfonate (0.17 g, 543 umol, 88.1 % yield) as a colourless oil. ^{1}H NMR (400MHz, chloroform-d) δ = 8.10 (dd, *J* = 5.2, 8.8 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 7.58 - 7.50 (m, 2H), 7.48 - 7.40 (m, 2H).

[01082] Title compound was prepared as in **Example 210** Steps E-G, substituting 1(6-fluoro-1-naphthyl) trifluoromethanesulfonate for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 260


2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01083] Title compound was prepared as in **Example 210** Steps E-G, substituting 4-bromoisoquinoline for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 553.1 $[M+H]^+$.

EXAMPLE 261


2-[1-(2-methylprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[01084] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromonaphthalene for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting 2-methylprop-2-enoyl chloride for acryloyl chloride in step G. ESI MS m/z 566.4$[M+H]^+$.

EXAMPLE 262


2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01085] Title compound was prepared as in **Example 210** Steps E-G, substituting 5-bromoisoquinoline for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 553.4 $[M+H]^+$.

EXAMPLE 263


2-[1-[(*E*)-but-2-enoyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[01086] Title compound was prepared as in **Example 210** Steps E-G, substituting 1-bromonaphthalene for 1-bromo-2-(trifluoromethyl)benzene in step E and (*E*)-but-2-enoyl chloride for acryloyl chloride in step G. ESI MS m/z 566.4 $[M+H]^+$.

EXAMPLE 264


2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01087] Title compound was prepared as in **Example 210** Steps E-G, substituting 5-bromoquinoline for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G. ESI MS m/z 553.4 $[M+H]^+$.

EXAMPLE 265


2-(1-acryloyl-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01088] Title compound was synthesized according to Example 210, Steps E-G using 1-bromo-3-methyl-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step E ES+APCI MS m/z 584.3 $[M+H]^+$.

EXAMPLE 266


2-(1-acryloyl-4-(2-(((S)-1-(2-methoxyethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01089] Title compound was synthesized according to Example 147, Steps F-J, using (S)-(1-(2-methoxyethyl)pyrrolidin-2-yl)methanol in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 596.3 $[M+H]^+$.

EXAMPLE 267


2-((S)-1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01090] Title compound was synthesized according to Example 234 using (R)-(1-methylpyrrolidin-2-yl)methanol in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 552.3 $[M+H]^+$.

EXAMPLE 268


2-(1-acryloyl-4-(2-(((2S,4R)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01091] Title compound was synthesized according to **Example 220**, (Steps C-G), using tert-butyl (2S,4R)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate in place of (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-2-hydroxymethylpyrrolidine in Step C. ES+APCI MS m/z 582.3 $[M+H]^+$.

EXAMPLE 269


2-(1-acryloyl-4-(2-(2-(dimethylamino)-2-methylpropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01092] The title compound was synthesized following **Example 147** substituting 2-Dimethylamino-2-methyl-1-propanol for (S)-(1-(cyclopropylmethyl)pyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 554.4 $[M+H]^+$.

EXAMPLE 270


2-(1-acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01093] Title compound was synthesized according to **Example 147**, Steps F-J, using (R)-N-Boc-2-hydroxymethylmorpholine in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 271


2-(1-acryloyl-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01094] Title compound was synthesized according to **Example 147**, Steps F-J, using (S)-N-Boc-2-hydroxymethylmorpholine in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 272


2-(1-acryloyl-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01095] Title compound was synthesized according to **Example 147**, Steps F-J, using tert-butyl (R)-3-(hydroxymethyl)morpholine-4-carboxylate in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 273


2-(1-acryloyl-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01096] Title compound was synthesized according to **Example 147**, Steps F-J, using tert-butyl (S)-3-(hydroxymethyl)morpholine-4-carboxylate in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F. ES+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 274


2-((S)-1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01097] Title compound was synthesized according to **Example 234**, Steps G-J using (R)-(1-methylpyrrolidin-2-yl)methanol in place of (S)-(1-methylpyrrolidin-2-yl)methanol in Step F and 1-bromo-3-fluoro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step H ES+APCI MS m/z 588.3 $[M+H]^+$.

EXAMPLE 275


2-(1-acryloyl-4-(7-(2-fluoro-6-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01098] Title compound was synthesized according to **Example 210**, Steps E-G using 2-bromo-1-fluoro-3-(trifluoromethyl)benzene for 1-bromonaphthalene in Step E. ES+APCI MS m/z 588.3 $[M+H]^+$.

EXAMPLE 276


2-(1-acryloyl-4-(7-(4-fluoro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01099] Title compound was synthesized according to **Example 210**, Steps E-G using 1-bromo-4-fluoro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step E. ES+APCI MS m/z 588.3 $[M+H]^+$.

EXAMPLE 277


2-(1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01100] Title compound was synthesized according to **Example 210**, Steps E-G using 1-bromo-3-chloro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step E and THF in place EtOH/THF in Step F. ES+APCI MS m/z 604.3 $[M+H]^+$.

EXAMPLE 278


2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(quinolin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01101] Title compound was prepared as in **Example 210** Steps E-G, substituting 4-bromoquinoline for 1-bromo-2-(trifluoromethyl)benzene in step E and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.

EXAMPLE 279


2-(1-acryloyl-4-(2-(2-(dimethylamino)ethoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01102] Title compound was prepared as in **Example 210**, substituting N, N-dimethyl-ethanolamine for (2S)-1-Ethyl-2-pyrrolidinyl]methanol in step C and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.

EXAMPLE 280


2-(4-(2-(3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-acryloylpiperazin-2-yl)acetonitrile



[01103] Title compound was prepared as in **Example 210**, substituting 3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol for (2S)-1-Ethyl-2-pyrrolidinyl]methanol in step C and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.

EXAMPLE 281


2-(1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-3-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01104] Title compound was prepared as in **Example 210**, substituting (R)-(1-methylpyrrolidin-3-yl)methanol for (2S)-1-Ethyl-2-pyrrolidinyl]methanol in step C and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.

EXAMPLE 282


2-(1-(3-methylbut-2-enoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01105] Title compound was prepared as in **Example 210**, substituting 1-bromonaphthalene for 1-bromo-2-(trifluoromethyl)benzene in step E and 3-methylbut-2-enoyl chloride for acryloyl chloride in step G.

EXAMPLE 283


2-(1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01106] Title compound was prepared as in **Example 210**, substituting (2R)-1-Ethyl-2-pyrrolidinyl]methanol for (2S)-1-Ethyl-2-pyrrolidinyl]methanol in step C and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.


EXAMPLE 284

2-(1-acryloyl-4-(2-(2-(diethylamino)ethoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01107] Title compound was prepared as in **Example 210**, substituting N, N-diethyl-ethanolamine for (2S)-1-Ethyl-2-pyrrolidinyl]methanol in step C and also substituting prop-2-enoyl prop-2-enoate for acryloyl chloride in step G.

EXAMPLE 285



tert-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate



[01108] Step 1: (*S*)-pyrrolidin-2-ylmethanol. To a solution of (*S*)-*tert*-butyl 2-(hydroxymethyl) pyrrolidine-1-carboxylate (2 g, 9.94 mmol, 1 *eq*) in CH_2Cl_2 (40 mL) was added HCl (4 M in dioxane, 49.69 mL, 20 *eq*) at 0 °C under nitrogen atmosphere. After stirred at 15 °C for 30 min, the mixture was concentrated under vacuum. Compound (*S*)-pyrrolidin-2-ylmethanol (1.37 g, 9.96 mmol, 100% yield, HCl) was obtained as a yellow solid.

[01109] Step 2: [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol. A mixture of [(2*S*)-pyrrolidin-2-yl]methanol (750 mg, 7.41 mmol, 724 uL, 1 *eq*) and acetone (4.31 g, 74.2 mmol, 5.46 mL, 10 *eq*) in MeOH (20 mL) was hydrogenated under H_2 (30 psi) with Pd/C (100 mg, 7.41 mmol, 10% purity, 1 *eq*) as a catalyst at 15 °C for 3 hours. The mixture was filtered and concentrated under vacuum. Compound [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol (0.821 g, 5.73 mmol, 77.3% yield) was obtained as a yellow oil.

[01110] ^{1}H NMR (400MHz, methanol-d_4) δ = 3.54 (dd, J = 4.0, 10.8 Hz, 1H), 3.40 - 3.35 (m, 1H), 2.99 - 2.86 (m, 3H), 2.60 - 2.50 (m, 1H), 1.94 - 1.82 (m, 1H), 1.82 - 1.66 (m, 3H), 1.15 (d, J = 6.4 Hz, 3H), 1.08 (d, J = 6.4 Hz, 3H).

SUBSTITUTE SHEET (RULE 26)

[01111] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 549 umol, 1 *eq*) and [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol (157 mg, 1.10 mmol, 2 *eq*) in THF (5 mL) was added *t*-BuONa (158 mg, 1.65 mmol, 3 *eq*). After stirred at 20 °C for 0.5 hour, the reaction mixture was neutralized with HCl (1 mol/L) to pH = 7 at 0°C, and then the mixture was concentrated under reduced pressure. The residue was purified by reversed phase flash [water (0.1% TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (200mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (174 mg, 278 umol, 50.7% yield, 100% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 626.


[01112] Step B: 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropyl pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (174 mg, 278 umol, 1 *eq*) in CH_2Cl_2 (5 mL) was added TFA (7.70 g, 67.5 mmol, 5.00 mL, 243 *eq*) at 0 °C under nitrogen atmosphere. After stirred at 15 °C for 0.5 h, the mixture was concentrated under vacuum. Compound 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (178 mg, crude, TFA) was obtained as a yellow oil. LCMS [ESI, M+1]: 526.

[01113] Step C: 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin- 2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (178 mg, crude, TFA) and DIEA (360 mg, 2.78 mmol, 485 uL) in CH_2Cl_2 (5 mL) was added prop-2-enoyl prop-2-enoate (28.1 mg, 223 umol) at 0 °C. The mixture was stirred at 20 °C for 1 hour. The reaction mixture was quenched with $NaHCO_3$ saturated solution (5 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 25 mL).


The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA) - ACN]; B%: 27% - 54%, 10 min). Title compound 2-[4-[2-[[(2*S*)-1-isopropylpyrrolidin- 2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (11.7 mg, 18.3 umol, two steps 6.58% yield, 97.9% purity, FA) was obtained as a brown solid. LCMS [ESI, M+1]: 580.

[01114] ^{1}H NMR (400MHz, Acetic acid-*d*4) δ = 8.28 - 8.19 (m, 1H), 8.08 (s, 1H), 7.91 - 7.83 (m, 1H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.56 - 7.47 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 6.94 - 6.71 (m, 1H), 6.38 (br d, *J* = 16.8 Hz, 1H), 5.87 (br d, *J* = 10.4 Hz, 1H), 5.15 (br s, 1H), 4.92 - 4.54 (m, 4H), 4.42 (br d, *J* = 12.0 Hz, 1H), 4.34 (br s, 2H), 4.13 (br s, 2H), 3.95 (br s, 1H), 3.85 - 3.21 (m, 7H), 3.20 - 2.84 (m, 3H), 2.42 - 2.25 (m, 1H), 2.24 - 2.07 (m, 3H), 1.43 (d, *J* = 6.4 Hz, 3H), 1.39 (d, *J* = 6.4 Hz, 3H).

EXAMPLE 286



2-(1-acryloyl-4-(7-(7-chloronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01115] Step 1: (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate. To a mixture of 7-chlorotetralin-1-one (2 g, 11.1 mmol, 1 eq) and DIEA (4.29 g, 33.2 mmol, 5.79 mL, 3 eq) in DCM (35 mL) was added Tf_2O (4.69 g, 16.6 mmol, 2.74 mL, 1.5 eq) in one portion at 0 °C under N_2. The mixture was stirred at 25 °C for 5 hours. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 50/1). Compound (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (2.25 g, 7.02 mmol, 63.4% yield, 97.6 % purity) was obtained as a colorless oil.

[01116] ^1H NMR (400MHz, chloroform-d) δ = 7.32 (d, J = 2.0 Hz, 1H), 7.24 (dd, J = 2.0, 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.10 (t, J = 4.8 Hz, 1H), 2.88 - 2.80 (m, 2H), 2.53 (dt, J = 4.8, 8.0 Hz, 2H).

[01117] Step 2: (7-chloro-1-naphthyl) trifluoromethanesulfonate. To a mixture of (7-chloro-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.57 g, 5.02 mmol, 1 eq) in dioxane (35 mL) was added DDQ (2.28 g, 10.0 mmol, 2 eq) in one portion under N_2. The

mixture was stirred at 25 °C for 30 min, then heated to 105 °C and stirred for 5 hours. The reaction mixture was concentrated under reduced pressure to remove 1,4-dioxane. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 50/1). Compound (7-chloro-1-naphthyl) trifluoromethanesulfonate (1.24 g, 3.94 mmol, 78.5 % yield, 98.7 % purity) was obtained as a colorless oil.

[01118] ^{1}H NMR (400MHz, chloroform-d) δ = 8.05 (d, *J* = 2.0 Hz, 1H), 7.87 - 7.83 (m, 2H), 7.57 - 7.47 (m, 3H).

[01119] Step A: *tert*-butyl 4-[7-(7-chloro-1-naphthyl)-2 -[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1- methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol, 1 eq) and (7-chloro-1-naphthyl) trifluoromethanesulfonate (264 mg, 848 umol, 2 eq) in toluene (20 mL) was added $Pd_2(dba)_3$ (38.8 mg, 42.4 umol, 0.1 eq), RuPhos (39.6 mg, 84.8 umol, 0.2 eq) and Cs_2CO_3 (414 mg, 1.27 mmol, 3 eq) under N_2. The mixture was heated to 110 °C and stirred for 5 hours. The mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (3 × 15.0 mL). The extracts were washed with brine (1 × 20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1 % TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 30 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound *tert*-butyl 4-[7-(7-chloro-1-naphthyl)-2 -[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 316 umol, 74.6% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 632.

[01120] ^{1}H NMR (400MHz, chloroform-d) δ = 8.20 (d, *J* = 2.0 Hz, 1H), 7.80 (d, *J* = 8.8 Hz, 1H), 7.59 (d, *J* = 8.2 Hz, 1H), 7.48 - 7.38 (m, 2H), 7.18 (d, *J* = 7.2 Hz, 1H), 4.63 (br s, 1H), 4.43 (br dd, *J* = 4.8, 10.3 Hz, 1H), 4.29 - 4.16 (m, 3H), 4.09 - 3.89 (m, 2H), 3.42 (br s, 1H), 3.35 – 3.20 (m, 3H), 3.17 - 2.65 (m, 7H), 2.52 (s, 3H), 2.33 (br d, *J* = 7.6 Hz, 1H), 2.14 - 2.06 (m, 1H), 1.88 - 1.71 (m, 4H).


[01121] Step B: 2-[4-[7-(7-chloro-1-naphthyl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl 4-[7-(7-chloro-1-naphthyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 316 umol, 1 eq) in DCM (2.5 mL) was added TFA (541 mg, 4.75 mmol, 351 uL, 15 eq) in one portion at 0 °C under N_2. Then the mixture was stirred at 25 °C for 2 hours. The reaction mixture was concentrated under reduced pressure. Compound 2-[4-[7-(7-chloro-1-naphthyl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (204 mg, 316 umol, 99.8% yield, TFA) was obtained as a brown solid. LCMS [ESI, M+1]: 532.

[01122] Step C: 2-[4-[7-(7-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[7-(7-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (204 mg, 316 umol, 1 eq, TFA) and TEA (160 mg, 1.58 mmol, 220 uL, 5 eq) in DCM (1.5 mL) was added prop-2-enoyl prop-2-enoate (39.8 mg, 316 umol, 1 eq) in one portion at 0 °C. After stirred at 25 °C for 1 h, the reaction mixture was quenched with saturated $NaHCO_3$ solution (1 mL) at 0 °C, then diluted with water (2 mL) and extracted with DCM (5 mL × 3). The combined organic layers were washed with water (5 mL × 1), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Boston Green ODS 150 × 30 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 30% - 54%, 10 min). Title compound 2-[4-[7-(7-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (36.0 mg, 56.1 umol, 17.8% yield, 98.7 % purity, FA) was obtained as a white solid. LCMS [ESI, M+1]: 586.


[01123] ^{1}H NMR (400MHz, chloroform-d) δ = 8.42 (br s, 1H), 8.19 (d, *J* = 1.6 Hz, 1H), 7.80 (d, *J* = 8.8 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.47 - 7.41 (m, 2H), 7.19 (d, *J* = 7.2 Hz, 1H), 6.61 (br s, 1H), 6.40 (br d, *J* = 16.8 Hz, 1H), 5.84 (br d, *J* = 10.8 Hz, 1H), 5.08 (br s, 1H), 4.91 - 4.75 (m, 2H), 4.48 (td, *J* = 4.4, 12.0 Hz, 1H), 4.23 (br s, 3H), 4.07 (br d, *J* = 11.2 Hz, 1H), 3.82 - 3.58 (m, 2H), 3.56 - 3.08 (m, 6H), 3.08 - 2.92 (m, 2H), 2.89 (d, *J* = 1.6 Hz, 3H), 2.85 - 2.70 (m, 2H), 2.28 (qd, *J* = 8.4, 12.5 Hz, 1H), 2.22 - 2.11 (m, 1H), 2.11 - 1.94 (m, 2H).

SUBSTITUTE SHEET (RULE 26)

EXAMPLE 287



2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01124] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of tert-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol, 1.30 *eq*) and 1-bromo-5-fluoro-naphthalene (73.4 mg, 326 umol, 1.0 *eq*) in toluene (5.0 mL) was added Cs_2CO_3 (319 mg, 979 umol, 3.0 *eq*) , $Pd_2(dba)_3$ (29.9 mg, 32.6umol, 0.10

eq) and RuPhos (22.8 mg, 48.9 umol, 0.15 *eq*). The mixture was stirred at 110 °C for 12 hrs. The reaction mixture was concentrated under reduced pressure to remove toluene. The residue was diluted with H_2O (10.0 mL) and extracted with Ethyl acetate (10.0 mL * 3). The combined organic layers were washed with H_2O (10.0 mL), and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water(0.100%formic acid)/acetonitrile]. Compound *tert*-butyl 2-(cyanomethyl)-4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 211 umol, 64.5% yield) was obtained as a white solid. LCMS [ESI, M+1]: 616.


[01125] Step B: 2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of tert-butyl 2-(cyanomethyl)-4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 211 umol, 1.0 *eq*) in DCM (2.0 mL) was added TFA (3.08 g, 27.0 mmol, 2.00 mL, 128 *eq*). The mixture was stirred at 25°C for 1 hr under N_2 atmosphere. The organic solvent was removed under vacuum. Compound 2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude) was obtained as a yellow oil. The crude product was used directly to the next step without further purification. LCMS [ESI, M+1]: 517.

[01126] Step C: 2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, TFA) in DCM (3.0 mL) was added Et_3N (200 mg, 1.98 mmol, 275 uL) and prop-2-enoyl prop-2-enoate (40.0 mg, 317 umol) at 0°C. The mixture was stirred at 20 °C for 2 hrs. The reaction was washed with water (10.0 mL). The crude mixture was extracted with ethyl acetate (20.0 mL*3). Combine extracts were washed with brine (50.0mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u;mobile phase: [water(0.225%FA)-ACN];B%: 26%-53%,10min) and lyophilization. Title compound 2-[4-[7-(5-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-


dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (48.4 mg, 82.6 umol, two steps 40.0% yield, FA) was obtained as a off-white solid. LCMS [ESI, M+1]: 570.

[01127] ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.41 (s, 1H), 7.91 (d, *J* = 7.6 Hz, 1H), 7.80 (d, *J* = 8.4 Hz, 1H), 7.42 (t, *J* = 7.8 Hz, 1H), 7.38-7.32 (m, 1H), 7.13-7.07 (m, 2H), 6.54-6.52 (m, 1H), 6.33 (m, 1H), 5.76 (d, *J* = 10.4 Hz, 1H), 5.10-4.98 (br, 4H), 4.74-4.69 (m, 1H), 4.41-4.36 (m, 1H), 4.16 (m, 3H), 3.99 (d, *J* = 12.0 Hz, 1H), 3.61-3.60 (m, 1H), 3.14-3.29 (m, 4H), 3.11 (br, 2H), 2.92-2.85 (m, 1H), 2.78 (s, 3H), 2.74-2.67 (m, 2H), 2.21-2.16 (m, 1H), 2.09-2.04 (m, 1H), 1.98-1.91 (m, 2H).

EXAMPLE 288



2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01128] Step 1: (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate. To the solution of 7-methoxytetralin-1-one (1 g, 5.67 mmol, 1 *eq*), DIEA (2.20 g, 17.0 mmol, 2.97 mL, 3 *eq*) in DCM (15 mL) was added Tf_2O (2.40 g, 8.51 mmol, 1.40 mL, 1.5 *eq*) dropwise, then the mixture was stirred at 20 °C for 12 hours. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 100:1) to give (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.7 g, 5.24 mmol, 92.3 % yield, 95.0 % purity) as yellow oil.

[01129] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.06 (d, *J*=8.4 Hz, 1H), 6.75 (dd, *J*=2.4, 8.4 Hz, 1H), 6.66 (d, *J*=2.4 Hz, 1H), 6.45 (s, 1H), 3.80 (s, 3H), 3.04 - 2.96 (m, 2H), 2.68 (t, *J*=8.4 Hz, 2H).

[01130] Step 2: (7-methoxy-1-naphthyl) trifluoromethanesulfonate. A mixture of (7-methoxy-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (1.7 g, 5.51 mmol, 1 *eq*) and DDQ (2.50 g, 11.0 mmol, 2 *eq*) in dioxane (30 mL) was stirred at 105 °C for 12 hours. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 50:1) to give (7-methoxy-1-naphthyl) trifluoromethanesulfonate (1.41 g, 4.14 mmol, 75.1 % yield, 90.0 % purity) as a colorless oil.

[01131] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.84 (d, *J*=9.2 Hz, 1H), 7.78 (d, *J*=8.8 Hz, 1H), 7.65 (d, *J*=2.4 Hz, 1H), 7.24 - 7.21 (m, 2H), 7.15 (d, *J*=2.4 Hz, 1H), 3.94 (s, 3H).

[01132] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 200 mg, 424 umol, 1 *eq*), (7-methoxy-1-naphthyl) trifluoromethanesulfonate (260 mg, 848 umol, 2 *eq*), RuPhos (39.6 mg, 84.8 umol, 0.2 *eq*), Cs_2CO_3 (414 mg, 1.27 mmol, 3 *eq*) in toluene (6 mL) was added $Pd_2(dba)_3$ (38.8 mg, 42.4 umol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 12 hours. Water (5 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (5 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 34 %) to give *tert*-butyl 2-(cyanomethyl)-4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 151 umol, 35.7 % yield, 95.0 % purity) as brown solid. LCMS [ESI, M+1]: 628.


[01133] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.69 (d, *J*=9.2 Hz, 1H), 7.63 (d, *J*=8.8 Hz, 1H), 7.17 (dd, *J*=2.4, 9.2 Hz, 1H), 7.09 (d, *J*=2.0 Hz, 1H), 7.03 (d, *J*=2.4 Hz, 1H), 6.96 (dd, *J*=2.4, 8.8 Hz, 1H), 4.61 (br s, 1H), 4.52 - 4.30 (m, 3H), 4.20 (ddd, *J*=3.2, 6.8, 10.4 Hz, 1H), 4.02 (br d, *J*=13.6 Hz, 2H), 3.92 (s, 3H), 3.87 (br d, *J*=13.2 Hz, 1H), 3.76 - 3.68 (m, 1H), 3.55 - 3.43 (m, 1H), 3.25 (br dd, *J*=3.6, 13.6 Hz, 2H), 3.12 (br t, *J*=7.6 Hz, 1H), 3.05 - 2.94 (m, 1H), 2.92 - 2.77 (m, 3H), 2.76 - 2.65 (m, 2H), 2.51 (s, 3H), 2.35 - 2.26 (m, 1H), 2.14 - 2.06 (m, 1H), 1.92 - 1.74 (m, 3H), 1.52 (s, 9H).

[01134] Step B: 2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 159 umol, 1 *eq*) and TFA (363 mg, 3.19 mmol, 236 uL, 20 *eq*) was stirred at 18 °C for 1 hour. The reaction mixture was concentrated under vacuum to give 2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, crude, 2TFA) as brown oil.


[01135] Step C: 2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To the solution of 2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, 159 umol, 1 *eq*, 2TFA), DIEA (205 mg, 1.59 mmol, 276 uL, 10 *eq*) in DCM (2.5 mL) was added prop-2-enoyl prop-2-enoate (24.0 mg, 190 umol, 1.2 *eq*) at 0 °C and stirred at 18 °C for 1 hour. Water (5 mL) was added into the mixture. The resulting mixture was extracted with DCM (3 × 5 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 45%-75%,10min) to give title compound 2-[4-[7-(7-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (10.6 mg, 17.8 umol, two steps 11.2 % yield, 97.6 % purity) as off-white solid. LCMS [ESI, M+1]: 582.

[01136] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (d, *J*=8.8 Hz, 1H), 7.63 (d, *J*=8.8 Hz, 1H), 7.17 (dd, *J*=2.4, 8.8 Hz, 1H), 7.09 (d, *J*=2.0 Hz, 1H), 7.03 (d, *J*=2.4 Hz, 1H), 6.97 (dd, *J*=2.4, 8.8 Hz, 1H), 6.57 (br d, *J*=10.4 Hz, 1H), 6.43 - 6.36 (m, 1H), 5.83 (br d, *J*=10.8 Hz, 1H), 5.09 (br s, 1H), 4.52 - 4.31 (m, 3H), 4.25 - 4.15 (m, 1H), 4.08 (br d, *J*=12.4 Hz, 1H), 3.96 (br s, 1H), 3.92 (s, 3H), 3.72 (br d, *J*=12.4 Hz, 1H), 3.54 (br d, *J*=5.6 Hz, 2H), 3.30 (br d, *J*=12.4 Hz, 1H), 3.22 - 2.95 (m, 3H), 2.93 (d, *J*=8.4 Hz, 1H), 2.86 (br d, *J*=4.8 Hz, 2H), 2.79 - 2.65 (m, 1H), 2.51 (s, 3H), 2.36 - 2.26 (m, 1H), 2.16 - 2.02 (m, 1H), 1.91 - 1.67 (m, 4H).

EXAMPLE 289



2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01137] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(1-isoquinolyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin -2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 424 umol, 1.00 eq), 1-bromoisoquinoline (132 mg, 636 umol, 1.50 eq) and DIEA (109 mg, 848 umol, 148 uL, 2.00 eq) in DMSO (4.00 mL) was stirred at 110 °C for 3 hours. The mixture was

diluted with water (5.00 mL), extracted with ethyl acetate (3 × 5.00 mL). The organic layers were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.10 %)/acetonitrile]. The desired fractions were collected and adjust pH > 7 with saturated sodium bicarbonate solution (6.00 mL), and extracted with ethyl acetate (3 × 20.0 mL). The organic layers were washed brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 2-(cyanomethyl)-4-[7-(1-isoquinolyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.15 g, 233 umol, 54.9 % yield) as a yellow solid. LCMS [ESI, M+1]: 599.

[01138] ^{1}H NMR (400MHz, chloroform-d) δ = 8.17 - 8.11 (m, 2H), 7.78 (d, *J* = 8.0 Hz, 1H), 7.64 (t, *J* = 7.2 Hz, 1H), 7.57 - 7.51 (m, 1H), 7.28 (s, 1H), 4.69 - 4.55 (m, 3H), 4.42 - 4.35 (m, 1H), 4.15 - 4.01 (m, 3H), 3.96 - 3.81 (m, 2H), 3.57 (ddd, *J* = 4.0, 8.0, 16.8 Hz, 1H), 3.27 (dd, *J* = 4.0, 13.6 Hz, 1H), 3.18 - 3.16 (m, 1H), 3.16 - 2.95 (m, 3H), 2.91 - 2.73 (m, 3H), 2.70 - 2.62 (m, 1H), 2.48 (s, 3H), 2.34 - 2.24 (m, 1H), 2.07 - 2.01 (m, 1H), 1.91 - 1.73 (m, 3H), 1.52 (s, 9H).


[01139] Step B: 2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(1-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.15 g, 250.53 umol, 1.00 eq) and TFA (428 mg, 3.76 mmol, 278 uL, 15.0 eq) in dichloromethane (0.40 mL) was stirred at 15 °C for 1 hour. The mixture was concentrated under vacuum to give 2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, crude, TFA) as a black oil and used into next step without further purification. LCMS [ESI, M+1]: 499.

[01140] Step C: 2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, crude, TFA) and TEA (253 mg, 2.50 mmol, 348 uL) in dichloromethane (4.00 mL) was added prop-2-enoyl prop-2-enoate (31.5 mg, 250 umol) at 0°C, then stirred at 15 °C for 1 hour. The mixture was quenched with saturated sodium bicarbonate solution (1.00 mL) and concentrated under vacuum. The residue was


purified by prep-HPLC column: (Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%, FA) - ACN]; B%: 10% - 24%, 7 min) and (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%, FA) - ACN]; B%: 10% - 24%, 7 min). The desired fractions were collected and lyophilized to give title compound 2-[4-[7-(1-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (31.2 mg, 52.1 umol, two steps 20.9 % yield, FA) as a yellow solid. LCMS [ESI, M+1]: 553.

[01141] ^{1}H NMR (400MHz, acetic) δ = 8.44 (d, *J* = 8.4 Hz, 1H), 8.04 - 7.95 (m, 2H), 7.89 (d, *J* = 6.4 Hz, 1H), 7.82 (br t, *J* = 6.8 Hz, 1H), 7.49 (d, *J* = 6.8 Hz, 1H), 6.91 - 6.69 (m, 1H), 6.37 (br d, *J* = 16.4 Hz, 1H), 5.87 (br d, *J* = 9.2 Hz, 1H), 5.10 (br s, 2H), 4.78 (br s, 3H), 4.53 (br d, *J* = 10.8 Hz, 1H), 4.32 (br d, *J* = 12.8 Hz, 1H), 4.13 (br s, 3H), 3.90 (br s, 2H), 3.79 - 3.40 (m, 3H), 3.26 (br s, 3H), 3.12 (br s, 3H), 3.07 - 2.84 (m, 2H), 2.45 - 2.34 (m, 1H), 2.23 - 2.09 (m, 3H).

EXAMPLE 290



2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01142] Insert: (6-fluoro-1-naphthyl) trifluoromethanesulfonate. To a solution of 6-fluoronaphthalen-1-ol (0.10 g, 617 umol, 1.00 eq) and DIEA (159 mg, 1.23 mmol, 215 uL, 2.00 eq) in dichloromethane (3.00 mL) was added trifluoromethylsulfonyl trifluoromethanesulfonate (191 mg, 678 umol, 112 uL, 1.10 eq) at 0 °C. After stirred at 0 °C for 1 hour, the mixture was diluted with water (5.00 mL) and extracted with dichloromethane (3 × 5.00 mL). The organic layers were washed with brine (1 × 5.00 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 3/1) to give (6-fluoro-1-naphthyl) trifluoromethanesulfonate (0.17 g, 543 umol, 88.1 % yield) as a colorless oil.

[01143] ^{1}H NMR (400MHz, chloroform-d) δ = 8.10 (dd, J = 5.2, 8.8 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.58 - 7.50 (m, 2H), 7.48 - 7.40 (m, 2H).

[01144] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(6-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin -2-yl)methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 424 umol, 1.00 eq), (6-fluoro-1-naphthyl) trifluoromethanesulfonate (150 mg, 509 umol, 1.20 eq), RuPhos (39.6

mg, 84.8 umol, 0.20 eq), $Pd_2(dba)_3$ (38.8 mg, 42.4 umol, 0.10 eq) and Cs_2CO_3 (415 mg, 1.27 mmol, 3.00 eq) in toluene (2.00 mL) was stirred at 110 °C for 3 hours under N_2. The mixture was diluted with water (5.00 mL), extracted with ethyl acetate (3 × 5.00 mL). The organic layers were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.10 %)/acetonitrile]. The desired fractions were collected and adjust pH > 7 with saturated sodium bicarbonate solution (5.00 mL), and then extracted with ethyl acetate (3 × 20.0 mL), the organic layers were washed brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 2-(cyanomethyl)-4-[7-(6-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 322 umol, 75.8 % yield) as a yellow solid. LCMS [ESI, M+1]: 616.

[01145] ^{1}H NMR (400MHz, chloroform-d) δ = 8.22 (dd, *J* = 5.6, 9.2 Hz, 1H), 7.57 - 7.52 (m, 1H), 7.48 - 7.42 (m, 2H), 7.29 – 7.24 (m, 1H) 7.10 (d, *J* = 7.6 Hz, 1H), 4.62 (br s, 1H), 4.39 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.31 - 4.22 (m, 2H), 4.14 - 4.00 (m, 3H), 3.95 (br d, *J* = 12.8 Hz, 1H), 3.44 (br s, 1H), 3.35 - 3.25 (m, 2H), 3.23 - 2.90 (m, 4H), 2.86 - 2.63 (m, 4H), 2.49 (s, 3H), 2.33 - 2.24 (m, 1H), 2.13 - 2.00 (m, 1H) 1.89 - 1.74 (m, 3H), 1.53 (s, 9H).


[01146] Step B: 2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(6-fluoro-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.20 g, 322 umol, 1.00 eq) and TFA (556 mg, 4.87 mmol, 361 uL, 15.0 eq) in dichloromethane (0.40 mL) was stirred at 15 °C for 1 hour. The mixture was concentrated under vacuum to give 2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (205 mg, crude, TFA) as a black oil and used into next step without further purification. LCMS [ESI, M+1]: 516.

[01147] Step C: 2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (205 mg, crude, TFA) and TEA (328 mg, 3.24 mmol, 451 uL) in dichloromethane (4.00 mL) was added


prop-2-enoyl prop-2-enoate (40.9 mg, 324 umol) at 0 °C, then stirred at 15 °C for 1 hour. The mixture was quenched with saturated sodium bicarbonate solution (1.00 mL) and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225 %, FA) - ACN]; B%: 17%-44%, 9min). The desired fractions were collected and lyophilized to give title compound 2-[4-[7-(6-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (85.6 mg, 139 umol, 42.8 % yield, FA) as a off-white solid. LCMS [ESI, M+1]: 570.

[01148] ^{1}H NMR (400MHz, acetic) δ = 8.28 (dd, *J* = 5.6, 9.2 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.55 - 7.45 (m, 2H), 7.31 (dt, *J* = 2.4, 8.8 Hz, 1H), 7.18 (d, *J* = 7.2 Hz, 1H), 6.94 - 6.68 (m, 1H), 6.38 (br d, *J* = 16.8 Hz, 1H), 5.87 (br d, *J* = 10.0 Hz, 1H), 5.16 (br s, 1H), 4.84 (br s, 2H), 4.74 - 4.54 (m, 1H), 4.42 (br d, *J* = 12.8 Hz, 1H), 4.33 (br s, 2H), 4.25 - 4.08 (m, 1H), 3.92 (br s, 2H), 3.81 - 3.47 (m, 3H), 3.46 - 3.16 (m, 4H), 3.11 (br s, 3H), 3.08 - 2.87 (m, 3H), 2.46 - 2.32 (m, 1H), 2.25 - 2.11 (m, 3H).

EXAMPLE 291



2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01149] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.15 g, 318 umol, 1.00 eq), 4-bromoisoquinoline (99.3 mg, 477 umol, 1.50 eq), RuPhos (29.7 mg, 63.6 umol, 0.20 eq), $Pd_2(dba)_3$ (29.1 mg, 31.8 umol, 0.10 eq) and Cs_2CO_3 (311 mg, 954 umol, 3.00 eq) in toluene (5.00 mL) was stirred at 110 °C for 3 hours under N_2. The mixture was diluted with water (6.00 mL), extracted with ethyl acetate (3 × 5.00 mL). The organic layers were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.1 %)/acetonitrile]. The desired fractions were collected and adjust pH > 7 with saturated sodium bicarbonate solution (5.00 mL), and extracted with ethyl acetate (3 × 20.0 mL). The combined organic layers were washed brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 2-(cyanomethyl)-4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.17 g, 273 umol, 85.9 % yield) as a yellow solid. LCMS [ESI, M+1]: 599.

[01150] ^{1}H NMR (400MHz, chloroform-d) δ = 9.03 (s, 1H), 8.26 (s, 1H), 8.14 (d, *J* = 8.4 Hz, 1H), 8.00 (d, *J* = 8.0 Hz, 1H), 7.73 (dt, *J* = 1.2, 7.2 Hz, 1H), 7.67 - 7.60 (m, 1H), 4.63 (br s, 1H), 4.44 - 4.31 (m, 3H), 4.15 - 4.03 (m, 2H), 3.95 (br d, *J* = 12.8 Hz, 1H), 3.59 - 3.49 (m, 1H), 3.40 (br d, *J* = 7.2 Hz, 1H), 3.34 - 3.19 (m, 2H), 3.18 - 2.93 (m, 4H), 2.90 - 2.79 (m, 2H), 2.77 - 2.66 (m, 2H), 2.50 (s, 3H), 2.35 - 2.24 (m, 1H), 2.10 - 2.02 (m, 1H), 1.92 - 1.79 (m, 3H), 1.52 (s, 9H).


[01151] Step B: 2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(4-isoquinolyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.15 g, 251 umol, 1.00 eq) and TFA (428 mg, 3.76 mmol, 278 uL, 15.0 eq) in dichloromethane (0.30 mL) was stirred at 15 °C for 0.5 h. The mixture was concentrated under vacuum to give 2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, crude, TFA) as a black oil and used into next step without further purification. LCMS [ESI, M+1]: 499.

[01152] Step C: 2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, crude, TFA) and Et_3N (254 mg, 2.51 mmol, 349 uL) in dichloromethane (2.00 mL) was added prop-2-enoyl prop-2-enoate (31.6 mg, 251 umol) at -40 °C. After stirred at 15 °C for 1 hour, the mixture was quenched with saturated sodium bicarbonate solution (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/1) and prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%, FA) - ACN]; B%: 12%-36%, 10min). The desired fractions were collected and lyophilized to give title compound 2-[4-[7-(4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (28.3 g, 43.4 umol, two steps 17.3 % yield, FA) as a yellow solid. LCMS [ESI, M+1]: 553.


[01153] ^{1}H NMR (400MHz, acetic) δ = 9.45 (s, 1H), 8.51 - 8.36 (m, 3H), 8.17 (br t, *J* = 8.0 Hz, 1H), 8.03 - 7.97 (m, 1H), 6.92 - 6.67 (m, 1H), 6.37 (br d, *J* = 16.0 Hz, 1H), 5.87 (br d, *J*

= 10.0 Hz, 1H), 5.14 (br s, 1H), 4.82 (br s, 2H), 4.66 - 4.48 (m, 3H), 4.40 (br d, *J* = 12.0 Hz, 1H), 4.22 - 3.80 (m, 3H), 3.79 - 3.49 (m, 4H), 3.32 - 3.09 (m, 7H), 3.07 - 2.88 (m, 2H), 2.47 - 2.36 (m, 1H), 2.24 - 2.11 (m, 3H).

EXAMPLE 292



2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01154] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-

carboxylate. *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]- 5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol, 1.00 *eq*), 5-bromoisoquinoline (115 mg, 551 umol, 1.30 *eq*), RuPhos (39.6 mg, 84.8 umol, 0.20 *eq*), Cs_2CO_3 (415 mg, 1.27 mmol, 3.00 *eq*) and $Pd_2(dba)_3$ (38.8 mg, 42.4 umol, 0.10 *eq*) in toluene (6.00 mL) was de-gassed and then heated to 90 °C for 12 hours under N_2. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile] to give *tert*-butyl 2-(cyanomethyl)-4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (217 mg, 344 umol, 81.0% yield, 94.8% purity) as a yellow solid. LCMS [ESI, M+1]: 599.


[01155] Step B: 2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(5-isoquinolyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (217 mg, 362 umol, 1.00 *eq*) in TFA (620 mg, 5.44 mmol, 403 uL, 15.0 *eq*) was stirred at 25 °C for 1 hour. Upon completion, the reaction mixture was concentrated under vacuum to give 2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (222 mg, crude, TFA) as a yellow oil which was used directly in the next step without further purification. LCMS [ESI, M+1]: 499.

[01156] Step C: 2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (222 mg, 362 umol, TFA) and TEA (367 mg, 3.62 mmol, 504 uL) in DCM (4.50 mL) was added prop-2-enoyl prop-2-enoate (45.7 mg, 362 umol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction was quenched by MeOH (0.5 mL), diluted with water (2 mL) and extracted with EtOAc (2 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um;mobile phase: [water (0.225%FA) - ACN]; B%: 4% - 20%, 8 min) and lyophilized to give title compound 2-[4-[7-(5-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-


pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (73.0 mg, 117 umol, two steps 32.2% yield, 95.6% purity, FA) as a yellow solid. LCMS [ESI, M+1]:553.

[01157] ^{1}H NMR (400MHz, Acetic) δ = 9.71 (s, 1H), 8.69 (d, *J* = 6.4 Hz, 1H), 8.53 (d, *J* = 6.8 Hz, 1H), 8.15 (d, *J* = 8.0 Hz, 1H), 7.91 (t, *J* = 7.8 Hz, 1H), 7.78 (d, *J* = 7.2 Hz, 1H), 6.97 - 6.68 (m, 1H), 6.38 (br d, *J* = 16.8 Hz, 1H), 5.87 (br d, *J* = 10.4 Hz, 1H), 5.15 (br s, 1H), 4.81 (br d, *J* = 4.4 Hz, 2H), 4.67 - 4.51 (m, 1H), 4.49 - 4.31 (m, 3H), 4.28 - 4.04 (m, 1H), 3.91 (br s, 2H), 3.78 - 3.64 (m, 1H), 3.63 - 3.37 (m, 4H), 3.36 - 3.20 (m, 1H), 3.11 (br s, 5H), 3.08 - 2.86 (m, 2H), 2.46 - 2.33 (m, 1H), 2.24 - 2.10 (m, 3H).

EXAMPLE 293



2-[1-[(*E*)-but-2-enoyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[01158] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 212 umol, 1.0 *eq*), $Pd_2(dba)_3$ (19.4 mg, 21.2 umol, 0.10 *eq*), RuPhos (14.8 mg, 31.8 umol, 0.15 *eq*) and Cs_2CO_3 (207 mg, 636 umol, 3.0 *eq*) in toluene (3.0 mL) was dropwise added 1-bromonaphthalene (65.9 mg, 318 umol, 44.2 uL, 1.5 *eq*). The reaction mixture was degassed and purged with N_2 for 3 times, and the mixture was stirred at 110 °C for 4 hours under N_2 atmosphere. The reaction was washed with water (20.0 mL). The aqueous phase was extracted with ethyl acetate (20.0 mL × 3). Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by reversed phase flash (C18, 0.1% FA in water, 0-80% MeCN). Compound *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (80.0 mg, 116 umol, 54.6% yield) was obtained as a off-white solid. LCMS [ESI, M+1]: 598.


[01159] Step B: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (80.0 mg, 134 umol, 1.0 *eq*) in DCM (2.0 mL) was added TFA (3.08 g, 27.0 mmol, 2.0 mL, 202 *eq*). The mixture was stirred at 20 °C for 30 min under N_2 atmosphere. The organic solvent was removed under vacuum. The crude product 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, crude, 2TFA)was obtained as a yellow oil and was used into the next step without further purification. LCMS [ESI, M+1]:498.

[01160] Step C: 2-[1-[(*E*)-but-2-enoyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, 152 umol, 2TFA) in DCM (2.00 mL) was added DIEA (100 mg, 774 umol, 135 uL) and (*E*)-but-2-enoyl chloride (35.0 mg, 335 umol, 32.1 uL) at 0 °C. The mixture was stirred at 0 °C for 1 hour. The reaction was


quenched with water (10.0 mL). The crude mixture was extracted with ethyl acetate (20.0 mL × 3). Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u;mobile phase: [water(0.225%FA)-ACN];B%: 20%-50%,10min) and lyophilization. Title compound 2-[1-[(*E*)-but-2-enoyl]-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (13.3 mg, 23.4 umol, 99.7% purity, FA) was obtained as a white solid. LCMS [ESI, M+1]: 566.

[01161] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.37 (s, 1H), 8.14-8.13 (m, 1H), 7.80-7.78 (m, 1H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.46-7.42 (m, 2H), 7.36 (m, 1H), 7.07 (d, *J* = 7.6 Hz, 1H), 6.95-6.90 (m, 1H), 6.22 (d, *J* = 15.6 Hz, 1H), 5.05-4.91 (br, 1H), 4.67-4.63 (m, 1H), 4.37-4.32(m, 1H), 4.24-4.20 (m, 2H), 4.12 (d, *J* = 14.8 Hz, 1H), 3.96 (d, *J* = 11.6 Hz, 1H), 3.51-3.49 (m, 1H), 3.39-3.29 (m, 2H), 3.18-3.12 (m, 7H), 2.90-2.76 (m, 2H), 2.71 (s, 3H), 2.65-2.58 (m, 1H), 2.18-2.12 (m, 1H), 2.00-1.95 (m, 1H), 1.90-1.86 (m, 5H).

EXAMPLE 294



2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01162] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. *tert*-butyl 2-(cyanomethyl)-4-[2-[(1-methylpyrrolidin-2-yl)methoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol, 1.00 *eq*), 5-bromoquinoline (115 mg, 551 umol, 1.30 *eq*), RuPhos (39.6 mg, 84.8 umol, 0.20 *eq*), Cs_2CO_3 (415 mg, 1.27 mmol, 3.00 *eq*) and $Pd_2(dba)_3$ (38.8 mg, 42.4 umol, 0.10 *eq*) in toluene (6.00 mL) was de-gassed and then heated to 90 °C for 12 hours under N_2. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile] to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 315 umol, 74.4% yield, 94.4% purity) as a brown oil. LCMS [ESI, M+1]: 599.


[01163] Step B: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-

pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 334 umol, 1.00 *eq*) in TFA (571 mg, 5.01 mmol, 371 uL, 15.0 *eq*) was stirred at 25 °C for 1 hour. Upon completion, the reaction mixture was concentrated under vacuum to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (204 mg, crude, TFA) as a yellow oil which was used directly in the next step without further purification. LCMS [ESI, M+1]: 499.


[01164] Step C: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (204 mg, 333 umol, 1.00 *eq*, TFA) and TEA (337 mg, 3.33 mmol, 463 uL) in DCM (4.00 mL) was added prop-2-enoyl prop-2-enoate (42.0 mg, 333 umol) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction was quenched with MeOH (0.5 mL), diluted with water (2 mL) and extracted with EtOAc (2 × 5 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (DCM/MeOH 8/1) and prep-HPLC (column: Boston Green ODS 150*30 5u;mobile phase: [water(0.225%FA)-ACN];B%: 7%-34%,10min). The desired fractions were collected and lyophilized to give title compound 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(5-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (49.1 mg, 79.5 umol, two steps 23.9% yield, 96.9% purity, FA) as a yellow solid. LCMS [ESI, M+1]:553.

[01165] ^{1}H NMR (400MHz, Acetic) δ = 9.22 (d, *J* = 4.8 Hz, 1H), 9.15 (d, *J* = 8.4 Hz, 1H), 8.09 (d, *J* = 8.8 Hz, 1H), 7.98 (d, *J* = 8.0 Hz, 1H), 7.96 - 7.90 (m, 1H), 7.50 (d, *J* = 7.6 Hz, 1H), 6.98 - 6.71 (m, 1H), 6.37 (br d, *J* = 17.2 Hz, 1H), 5.88 (br d, *J* = 10.4 Hz, 1H), 5.15 (br s, 1H), 4.81 (br s, 2H), 4.77 - 4.52 (m, 1H), 4.50 - 4.33 (m, 3H), 4.14 (br d, *J* = 12.4 Hz, 1H), 3.91 (br s, 2H), 3.79 - 3.66 (m, 1H), 3.65 - 3.32 (m, 4H), 3.12 (br s, 6H), 3.05 (br d, *J* = 16.8 Hz, 2H), 2.46 - 2.34 (m, 1H), 2.23 - 2.09 (m, 3H).

EXAMPLE 295



2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01166] Step A: [2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl)- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 0.15 g, 318 umol, 1.00 eq), 4-bromoquinoline (99.3 mg, 477 umol, 1.50 eq), RuPhos (29.7 mg, 63.6 umol, 0.20 eq), $Pd_2(dba)_3$ (29.1 mg, 31.8 umol, 0.10 eq) and Cs_2CO_3 (311 mg, 954 umol, 3.00 eq) in toluene (5 mL) was stirred at 100 °C for 3 hours under N_2. The mixture was diluted with water (5.00 mL), extracted with ethyl acetate (3 × 5.00 mL). The organic layers were washed with brine (1 × 10.0 mL),

dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.1 %)/acetonitrile]. The desired fractions were collected and adjust pH > 7 with saturated sodium bicarbonate (5.00 mL) and extracted with ethyl acetate (3 × 20.0 mL). The organic layers were washed brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl)- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.17 g, 269 umol, 84.8 % yield) as a yellow solid. LCMS [ESI, M+1]: 599.

[01167] ^{1}H NMR (400MHz, chloroform-d) δ = 8.77 (d, *J* = 4.8 Hz, 1H), 8.07 (dd, *J* = 8.0, 16.0 Hz, 2H), 7.70 (dt, *J* = 1.2, 7.2 Hz, 1H), 7.56 - 7.50 (m, 1H), 6.92 (d, *J* = 4.8 Hz, 1H), 4.62 (br s, 1H), 4.44 - 4.33 (m, 3H), 4.15 - 4.04 (m, 2H), 3.95 (br d, *J* = 12.0 Hz, 1H), 3.74 - 3.64 (m, 1H), 3.46 (br d, *J* = 7.2 Hz, 1H), 3.37 - 3.21 (m, 2H), 3.18 - 2.93 (m, 4H), 2.93 - 2.79 (m, 2H), 2.72 (br dd, *J* = 6.0, 16.8 Hz, 2H), 2.51 (s, 3H), 2.36 - 2.26 (m, 1H), 2.13 - 2.06 (m, 1H), 1.93 - 1.79 (m, 3H), 1.53 (s, 9H).

[01168] Step B: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl) -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-7-(4-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (165 mg, 276 umol, 1.00 eq) and TFA (471 mg, 4.13 mmol, 306 uL, 15.0 eq) in dichloromethane (0.30 mL) was stirred at 15 °C for 0.5 hour. The mixture was concentrated under vacuum to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl) -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (168 mg, crude, TFA) as a black oil and used into next step without further purification. LCMS [ESI, M+1]: 499.


[01169] Step C: 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(4-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (168 mg, crude, TFA) and Et_3N (277 mg, 2.74 mmol, 382 uL) in dichloromethane (3.00 mL) was added prop-2-enoyl prop-2-enoate (34.6 mg, 274.22 umol) at -40 °C. After stirred at 15 °C for 1 hour, the mixture was quenched with saturated sodium bicarbonate (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/1) and prep-HPLC

(column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%, FA) - ACN]; B%: 1% - 21%, 7 min). The desired fractions were collected and lyophilized to give 2-[4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(4-quinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 295, 23.4 mg, 39.6 umol, two steps 13.4 % yield, 93.6% purity, FA) as a yellow oil. LCMS [ESI, M+1]: 553.


[01170] SFC condition: OD-3S_3_40_3 ML Column: Chiralcel OD-3 100 × 4.6mm I.D., 3 um, mobile phase: 40% methanol (0.05 % DEA) in CO_2, flow rate: 3 mL / min, wavelength: 220 nm.

[01171] ^{1}H NMR (400MHz, acetic) δ = 8.65 (d, *J* = 7.2 Hz, 1H), 8.35 (d, *J* = 8.4 Hz, 1H), 8.15 (s, 1H), 7.99 (t, *J* = 7.2 Hz, 1H), 7.77 (t, *J* = 7.6 Hz, 1H), 7.28 (d, *J* = 6.8 Hz, 1H), 6.74 (dd, *J* = 10.8, 16.8 Hz, 1H), 6.32 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.85 (dd, *J* = 1.2, 10.8 Hz, 1H), 5.01 (br s, 1H), 4.85 - 4.74 (m, 2H), 4.42 (br d, *J* = 14.0 Hz, 1H), 4.35 - 4.19 (m, 3H), 4.16 - 3.76 (m, 4H), 3.66 (br d, *J* = 14.0 Hz, 2H), 3.51 - 3.40 (m, 1H), 3.39 - 3.16 (m, 4H), 3.13 (s, 3H), 3.07 - 2.90 (m, 2H), 2.49 - 2.39 (m, 1H), 2.26 - 2.17 (m, 3H).

EXAMPLE 296



2-[4-[2-[2-(dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01172] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[2- (dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2- methylsulfinyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 266 umol, 1.0 *eq*) and 2-(dimethylamino)ethanol (47.4 mg, 531 umol, 53.3 uL, 2.0 *eq*) in toluene (1.0 mL) was added t-BuONa (51.1 mg, 531 umol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added water (10.0 mL) and extracted with EA (10 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by reversed phase flash column (C18, 0.1% FA in water, 0 - 40% MeCN). The desired fraction was collected and adjusted with saturated $NaHCO_3$ aqueous to pH ~ 7, then concentrated under vacuum. The remained liquid was extracted with EA (10 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The product *tert*-butyl 2-(cyanomethyl)-4-[2-[2-(dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 254 umol, 95.8% yield) was obtained as yellow oil. LCMS [ESI, M+1]: 590.


[01173] Step B: 2-[4-[2-[2-(dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro- 5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl

2-(cyanomethyl)-4-[2-[2- (dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 254 umol, 1.0 *eq*) in DCM (1.0 mL) was added TFA (29.0 mg, 254 umol, 18.8 uL, 1.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was concentrated under vacuum. The residue was added saturated $NaHCO_3$ aqueous (5 mL) and extracted with DCM (10 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated to give 2-[4-[2-[2-(dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro- 5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude) as yellow oil. LCMS [ESI, M+1]: 490.


[01174] Step C: To a solution of 2-[4-[2-[2-(dimethylamino)ethoxy]-7- [2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (125 mg, 255 umol, 1.0 *eq*) and DIEA (198 mg, 1.53 mmol, 267 uL, 6.0 *eq*) in DCM (1.00 mL) was added prop-2-enoyl prop-2-enoate (32.2 mg, 255 umol, 1.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um; mobile phase: [water (0.225%FA)-ACN]; B%: 10%-40%, 10min). Then concentrated and lyophilized. The product 2-[4-[2-[2-(dimethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 296, 30.7 mg, 51.8 umol, 20.3% yield, 99.5% purity, FA) was obtained as white solid. LCMS [ESI, M+1]: 544.

[01175] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.45 (br s, 1H), 7.67 (br d, *J* = 8.0 Hz, 1H), 7.57 (t, *J* = 7.2 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.30 (d, *J* = 7.6 Hz, 1H), 6.71 - 6.49 (m, 1H), 6.47 - 6.29 (m, 1H), 5.82 (br d, *J* = 10.4 Hz, 1H), 5.07 - 4.97 (m, 1H), 4.54 (t, *J* = 5.4 Hz, 2H), 4.12 (br d, *J* = 13.6 Hz, 1H), 4.07 (s, 2H), 3.98 (br d, *J* = 12.0 Hz, 1H), 3.40 - 3.30 (m, 2H), 3.22 - 3.09 (m, 4H), 3.05 (t, *J* = 5.4 Hz, 2H), 2.92 (dd, *J* = 8.0, 16.8 Hz, 1H), 2.86 - 2.81 (m, 1H), 2.79 - 2.70 (m, 2H), 2.56 (s, 6H).

EXAMPLE 297



2-(1-acryloyl-4-(2-(((*R*)-1-methylpyrrolidin-3-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01176] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo [2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 354 umol, 1.0 *eq*) and 3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol (Intermediate 18, 111 mg, 708 umol, 2.0 *eq*) in toluene (3.0 mL) was added t-BuONa (68.1 mg, 708 umol, 2.0 *eq*) at 0 °C, the reaction was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10 mL), then extracted

with EA (2 ×10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash (C18, 60% MeCN in water), the obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, extracted with EA (2 ×10.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated to give *tert*-butyl 2-(cyanomethyl)-4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo [2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 197 umol, 55.7% yield, 99.8% purity) as white solid. LCMS [ESI, M+1]: 658.


[01177] Step B: 2-[4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (70.0 mg, 106 umol, 1.0 *eq*) in DCM (0.5 mL) was added TFA (770 mg, 6.75 mmol, 0.5 mL, 63.5 *eq*). The reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give 2-[4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (83.0 mg, crude, 2TFA) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 558.

[01178] Step C: 2-[4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (83.0 mg, 106 umol, 1.0 *eq*, 2TFA) in DCM (1.0 mL) was added DIEA (81.9 mg, 634 umol, 110 uL, 6.0 *eq*) and prop-2-enoyl prop-2-enoate (13.3 mg, 106 umol, 1.0 *eq*) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (0.5 mL), and concentrated. The residue was purified by prep-HPLC ((Instrument: ACSWH-GX-G; Column: Phenomenex Gemini 150*25mm*10um ; Condition: water (0.225%FA)-ACN; Begin B:12; End B:42; Gradient Time (min): 10.5; 100%B Hold Time (min): 2; FlowRate (ml/min): 2), the


obtained product was concentrated and then under lyophilization. The product 2-[4-[2-[3-[(1*R*,4*R*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 297, 17.6 mg, 26.3 umol, two steps yield 24.9% yield, 98.1% purity, FA) was obtained as yellow solid. LCMS [ESI, M+1]: 612.


[01179] ^{1}H NMR (400 MHz, chloroform-d) δ 7.69 (d, *J* = 7.6 Hz, 1H), 7.59 (t, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.6 Hz, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 6.72 - 6.52 (m 1H), 6.40 (d, *J* = 16.4 Hz,1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.16 - 5.02 (m, 1H), 4.58 - 4.51 (m, 1H), 4.38 (br t, *J* = 5.8 Hz, 2H), 4.21 (br d, *J* = 9.2 Hz, 1H), 4.18 - 4.06 (m, 4H), 3.99 (br d, *J* = 11.6 Hz, 1H), 3.74 (br d, *J* = 8.4 Hz, 1H), 3.42 - 3.29 (m, 2H), 3.27 - 3.04 (m, 6H), 3.04 - 2.61 (m, 6H), 2.28 - 2.07 (m, 3H), 2.04 - 1.92 (m, 1H).

EXAMPLE 298



2-(1-acryloyl-4-(2-(((*R*)-1-methylpyrrolidin-3-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile





[01180] Step A: [(3*R*)-1-methylpyrrolidin-3-yl]methanol. To a solution of *tert*-butyl (3*R*)-3-(hydroxymethyl) pyrrolidine-1-carboxylate (2.0 g, 9.94 mmol, 1.0 *eq*) in THF (30.0 mL) was added $LiAlH_4$ (754 mg, 19.9 mmol, 2.0 *eq*) in portions at 0 °C. After addition, the reaction was stirred at 70 °C for 3 hours. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous (2.4 mL), then extracted with Ethyl acetate (100 mL). The organic layer was dried with Na_2SO_4 and filtrated. The solvent was removed under vacuum to give [(3*R*)-1-methylpyrrolidin-3-yl]methanol (1.0 g, crude) as yellow oil which was used for the next step without further purification.

[01181] ^{1}H NMR (400 MHz, chloroform-d) δ 3.64 (dd, J = 4.8, 10.0 Hz, 1H), 3.52 (dd, J = 5.6, 10.0 Hz, 1H), 2.78 - 2.67 (m, 1H), 2.60 - 2.45 (m, 2H), 2.42 - 2.23 (m, 5H), 2.08 - 1.91 (m, 1H), 1.72 - 1.57 (m, 1H).

[01182] Step B: *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 177 umol, 1.0 *eq*) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol (61.2 mg, 531 umol, 3.0 *eq*) in toluene (1.0 mL) was added t-BuONa (34.0 mg, 354 umol, 2.0 *eq*) at 0 °C,

the reaction was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10.0 mL), then extracted with Ethyl acetate (2 ×10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash (C18, 50% MeCN in water). *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (40.0 mg, 63.4 umol, 35.8% yield, 97.6% purity) was obtained as white solid. LCMS [ESI, M+1]: 616.


[01183] Step C: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (40.0 mg, 64.9 umol, 1.0 *eq*) in DCM (0.5 mL) was added TFA (770 mg, 6.75 mmol, 500 uL, 104 *eq*). The reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (48.0 mg, crude, 2TFA) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 516.

[01184] Step D: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (48.0 mg, 64.6 umol, 1.0 *eq*, 2TFA) in DCM (1.0 mL) was added DIEA (25.0 mg, 194 umol, 33.7 uL, 3.0 *eq*) and prop-2-enoyl prop-2-enoate (8.14 mg, 64.6 umol, 1.0 *eq*) at 0°C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with methanol (0.5 mL), and concentrated. The residue was purified by prep-HPLC ((Instrument: ACSWH-GX-M; Column: Gemini 150*25 5u; Condition: water (0.04% NH_3H_2O)-ACN; Begin B: 60; End B: 81; Gradient Time (min): 10; 100%B Hold Time (min):3; FlowRate (ml/min): 25), the obtained product was concentrated and then under lyophilization to give 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5H-


pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile(5.48 mg, 9.26 umol, 14.4% yield, 96.3% purity) as brown solid. LCMS [ESI, M+1]: 570.

[01185] ^{1}H NMR (400 MHz, chloroform-d) δ 7.61 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 7.6 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 6.54 - 6.44 (m, 1H), 6.32 (dd, J = 1.6, 16.8 Hz, 1H), 5.75 (br d, J = 10.8 Hz, 1H), 5.12 - 4.92 (m, 1H), 4.13 (d, J = 6.8 Hz, 2H), 4.07 - 3.97 (m, 3H), 3.92 - 3.84 (m, 1H), 3.62 - 3.42 (m, 1H), 3.31 - 3.22 (m, 1H), 3.16 - 2.95 (m, 3H), 2.89 - 2.49 (m, 7H), 2.47 - 2.35 (m, 2H), 2.28 (s, 3H), 2.05 - 1.92 (m, 1H), 1.57 - 1.46 (m, 2H).

EXAMPLE 299



2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01186] Step A: *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-[2-(trifluoromethyl)phenyl]-6,8-di hydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-(2- methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (3.70 g, 9.15 mmol, 1.0 *eq*), $Pd_2(dba)_3$ (1.26 g, 1.37 mmol, 0.15 *eq*), RuPhos (854 mg, 1.83 mmol, 0.2 *eq*) and Cs_2CO_3 (7.45 g, 22.9 mmol, 2.50 *eq*) in toluene (74.0 mL) was added 1-bromo-2-(trifluoromethyl)benzene (4.12 g, 18.3 mmol, 2.49 mL, 2.0 *eq*). The mixture was stirred at 100 °C for 12 hours. After completion, the mixture was added water (100 mL) and extracted with Ethyl acetate (100 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash column (C18, 0.1% FA in water, 0-90% MeCN). The product *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7-[2-(trifluoromethyl)phenyl]-6,8-di hydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.90 g, 3.46 mmol, 37.8% yield) was obtained as yellow solid.

[01187] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.69 (d, J = 8.0 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.46 - 7.37 (m, 2H), 7.22 - 7.11 (m, 1H), 4.67 - 4.55 (m, 1H), 4.03 (br d, J = 13.6 Hz, 2H), 3.88 (br d, J = 12.0 Hz, 1H), 3.68 - 3.47 (m, 1H), 3.30 - 3.08 (m, 4H), 3.02 (dt, J = 3.2, 12.4 Hz, 1H), 2.94 - 2.69 (m, 4H), 2.51 (s, 3H), 1.52 (s, 9H).

[01188] Step B: *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2- methylsulfanyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.50 g, 2.46 mmol, 1.0 *eq*) in DCM (15.0 mL) was added m-CPBA (593 mg, 2.75 mmol, 1.12 *eq*, 80% purity) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added saturated $Na_2S_2O_3$ aqueous (30.0 mL) and extracted with ethyl acetate (30.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash column (C18, 0.1% FA in water, 0-90 % MeCN) to give *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.16 g, 2.05 mmol, 83.6% yield) as yellow solid. LCMS [ESI, M+1]:565.

[01189] Step C : *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 354 umol, 1.0 *eq*) in toluene (3.0 mL) was added [(2*R*)-1-methylpyrrolidin-2-yl]methanol (81.6 mg, 708.4 umol, 2.0 *eq*) and t-BuONa (68.1 mg, 708 umol, 2.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 20 min. After completion, the reaction was quenched with water (10.0 mL). The crude mixture was extracted with ethyl acetate (15 mL × 3). The combined organic layer were washed with brine (50.0 mL), dried with Na_2SO_4 and filtrated. The solvent was then removed under vacuum. The residue was purified by reversed phase flash (C18, 0.1% FA in water, 0-80% MeCN). Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 275 umol, 77.7% yield) was obtained as a white solid. LCMS [ESI, M+1]:616.


[01190] ^{1}H NMR (400 MHz, CHLOROFORM-d) 8.08 (s, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.25 - 7.19 (m, 1H), 5.02 - 4.78 (m, 1H), 4.58 - 4.43 (m, 2H), 4.17 (br t, J = 12.5 Hz, 1H), 4.08 - 3.86 (m, 5H), 3.64 - 3.51 (m, 1H), 3.23 (br dd, J = 3.8, 13.8 Hz, 1H), 3.11 - 3.01 (m, 3H), 2.96 (s, 3H), 2.84 - 2.58 (m, 4H), 2.31 - 2.03 (m, 2H), 2.02 - 1.94 (m, 3H), 1.44 (s, 9H), 1.19 (t, J = 7.2 Hz, 1H).

[01191] Step D: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 276 umol, 1.0 *eq*) in DCM (1.50 mL) was added TFA (2.31 g, 20.3 mmol, 1.50 mL, 73.4 *eq*). The mixture was stirred at 20 °C for 15 min under N_2 atmosphere. After completion, the organic solvent was removed under vacuum. The crude product 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (240 mg, crude, 2TFA) was obtained as a yellow oil and used into the next step without further purification. LCMS [ESI, M+1]: 516.


[01192] Step E: 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (240 mg, 2TFA) in DCM (3.0 mL) was added prop-2-enoyl prop-2-enoate (40.0 mg, 317 umol) and DIEA (130 mg, 1.01 mmol, 175 uL) at 0 °C. The mixture was stirred at 0°C for 30 mins. The reaction was quenched with water (20.0 mL). The crude mixture was extracted with ethyl acetate (20.0 mL×3). The combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4 and filtrated. The solvent was then removed under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150×25mm×10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,3min). Compound 2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 299, 10.2 mg, 16.8 umol, 94.3% purity) was obtained as a white solid. LCMS [ESI, M+1]: 570.

[01193] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.68 (d, *J* = 7.2 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.30 (d, *J* = 7.6 Hz, 1H), 6.59 (br s, 1H), 6.40 (d, *J* = 16.4 Hz, 1H), 5.83 (d, *J* = 10.4 Hz, 1H), 5.07 (br s, 1H), 4.85 (d, *J* = 7.1 Hz, 1H), 4.66 - 4.39 (m, 1H), 4.20 (d, *J* = 11.1 Hz, 1H), 4.13 - 3.95 (m, 4H), 3.70 - 3.55 (m, 2H), 3.45-3.20 (m, 2H), 3.16 - 2.99 (m, 3H), 2.98 - 2.91 (m, 4H),2.85 - 2.70 (m, 4H), 2.33 - 2.14 (m, 2H), 2.10 - 2.01 (m, 2H).

EXAMPLE 300



2-[4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01194] Step A: *tert*-butyl 2-(cyanomethyl)- 4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 354 umol, 1.0 *eq*) and 2-(diethylamino)ethanol (83.0 mg, 708 umol, 93.9 uL, 2.0 *eq*) in toluene (3.0 mL) was added t-BuONa (68.1 mg, 708 umol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added water (10.0 mL) and extracted with ethyl acetate (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash column (C18, 0.1% FA in water, 0 - 40% MeCN). The product *tert*-butyl 2-(cyanomethyl)- 4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 291 umol, 82.3% yield) was obtained as a colorless oil. LCMS [ESI, M+1]: 618.


[01195] Step B: 2-(4-(2-(2-(diethylamino)ethoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-(2-(2-(diethylamino)ethoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (180 mg, 291 umol, 1.0 *eq*) in DCM (2.0 mL) was added TFA (33.2 mg, 291 umol, 21.6 uL, 1.0 *eq*) . The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was added ethyl acetate (10.0 mL,)

and adjusted with saturated $NaHCO_3$ solution to pH > 7. The mixture was extracted with ethyl acetate (30 ml × 3) and the organic layer was dried with Na_2SO_4 and filtered. The solvent was removed under vacuum. The product 2-(4-(2-(2-(diethylamino)ethoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (150 mg, crude) was obtained as yellow oil. LCMS [ESI, M+1]: 518.


[01196] Step C: 2-[4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude) in DCM (3.0 mL) was added DIEA (129 mg, 1.0 mmol, 174 uL) and prop-2-enoyl prop-2-enoate (44.1 mg, 0.35 mmol). The mixture was stirred at 0 °C for 1 hour. After completion, the reaction mixture was quenched by addition methanol (10.0 mL) at 20°C. To the reaction mixture, water (10.0 mL) was added, and extracted with DCM (10.0 mL × 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04%NH3H2O)-ACN]; B%: 65%-83%,10min). The product 2-[4-[2-[2-(diethylamino)ethoxy]-7-[2-(trifluoromethyl)phenyl] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 300, 41.6 mg, 72.7 umol, 100% purity, two steps yield 25.0%) was obtained as a white solid. LCMS [ESI, M+1]: 572.

[01197] ^{1}H NMR (400 MHz, CHLOROFORM-d) δ = 7.68 (d, *J* = 7.8 Hz, 1H), 7.58 (t, *J* = 7.4 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.32 - 7.28 (m, 1H), 6.70 - 6.49 (m, 1H), 6.39 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.82 (d, *J* = 10.8 Hz, 1H), 5.08 (br, s, 1H), 4.39 (t, *J* = 6.8 Hz, 2H), 4.14 - 4.00 (m, 3H), 4.02 - 3.84 (m, 1H), 3.32 (br d, *J* = 12.0 Hz, 1H), 3.24 - 3.16 (m, 1H), 3.15 - 3.04 (m, 2H), 2.96 - 2.88 (m, 4H), 2.87 - 2.70 (m, 1H), 2.68 - 2.61 (m, 4H), 1.89 (br s, 3H), 1.07 (t, *J* = 7.0 Hz, 6H).

EXAMPLE 301



2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01198] Step A: *tert*-butyl (5*S*)-5-(hydroxymethyl)-2,2-dimethyl-pyrrolidine-1-carboxylate. To a solution of (2*S*)-1-*tert*-butoxycarbonyl-5,5-dimethyl-pyrrolidine- 2-carboxylic acid (400 mg, 1.64 mmol, 1.00 *eq*) in anhydrous THF (7.00 mL) was added BH_3•Me_2S (10 M, 493 uL, 3.00 *eq*) dropwise at 25 °C. The reaction was heated at 50 °C for 5 minutes. Upon completion, after cooled by an ice-bath, the mixture was quenched with Methanol (10 mL). The reaction mixture was concentrated under reduced pressure to give *tert*-butyl (5*S*)-5-(hydroxymethyl)-2,2-dimethyl-pyrrolidine-1-carboxylate (360 mg, 1.57 mmol, 95.9%) as a colorless oil which was used directly into the next step without further purification.

[01199] Step B: *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a stirred solution of *tert*-butyl 2-methylsulfanyl-4- (trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (20 g, 46.5 mmol, 1.00 *eq*) in DMF (300 mL) was added DIEA (18.1 g, 139 mmol, 24.3 mL, 3 *eq*) and 2-piperazin-2-ylacetonitrile (10.2 g, 51.2 mmol, 495 uL, 1.10 *eq*, 2 HCl). The reaction was heated to 100 °C and stirred for 1 hour under N_2 atmosphere. *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (18.8 g, crude) was obtained and used to next step directly without work-up and purification.

[01200] Step C: *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2- methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (18.8 g, crude) in DMF (200 mL) was added DIEA (12.0 g, 92.9 mmol, 16.2 mL) and benzyl carbonochloridate (11.9 g, 69.7 mmol, 9.91 mL). The mixture was stirred at 50 °C for 1 hour. The reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 30/1 to 3/1). *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (20 g, 31.6 mmol, two steps 68.0% yield, 85% purity) was obtained as a yellow oil. LCMS [ESI, M+1]:539.

[01201] ^{1}H NMR (400MHz, chloroform-d) δ = 7.40 - 7.36 (m, 5H), 5.21 - 5.15 (m, 2H), 4.73 - 4.55 (m, 2H), 4.39 (d, *J* = 18.8 Hz, 1H), 3.97 (d, *J* = 12.8 Hz, 1H), 3.90 - 3.69 (m, 2H), 3.41 - 3.16 (m, 3H), 3.00 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.86 - 2.53 (m, 5H), 2.51 (s, 3H), 1.49 (s, 9H).

[01202] Step D: benzyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (11 g, 20.4 mmol, 1.00 *eq*) in dioxane (100 mL) was added HCl•dioxane (4 M, 102 mL, 20 *eq*). After stirred at 25 °C for 1 hour, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved in 300 mL of ethyl acetate and 300 mL of water and stirred rapidly. Then saturated Na_2CO_3 aqueous solution was added until the pH~9. The organics was washed with water (1 × 300 mL) and brine (1 × 200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. benzyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (8.2 g, 15.2 mmol, 74.2% yield, 81% purity) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]:439.

[01203] Step E: Benzyl 2-(cyanomethyl)-4-[2-methylsulfanyl- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (5.07 g, 11.6 mmol, 1.1 *eq*), 1-bromonaphthalene (2.83 g, 13.7 mmol, 1.90 mL, 1.3 *eq*), Cs_2CO_3 (8.57 g, 26.3 mmol, 2.50 *eq*), $Pd_2(dba)_3$ (1.45 g, 1.58 mmol, 0.15 *eq*) and RuPhos (982 mg, 2.11 mmol, 0.20 *eq*) in dioxane (100 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 85 °C for 5 hours under N_2 atmosphere. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 100/1 to 2/1). Benzyl 2-(cyanomethyl)-4-[2-methylsulfanyl- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (3.6 g, 4.65 mmol, 40.1% yield, 73% purity) was obtained as a yellow oil. LCMS [ESI, M+1]:565.

[01204] Step F: benzyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a stirred solution of benzyl 2-(cyanomethyl)-4-[2-methylsulfanyl-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (3.1 g, 5.49 mmol, 1 *eq*) in methyltetrahydrofuran (50 mL) at 0 °C under nitrogen was added *m*-CPBA (1.18 g, 5.49 mmol, 80% purity, 1 *eq*) neat as a solid. After stirred at 0 °C for 1 hour under N_2 atmosphere, the reaction mixture was quenched by addition 10 % of $Na_2S_2O_3$ (100 mL) aqueous solution at 0°C, and then diluted with water (200 mL) and extracted with ethyl acetate (200 mL). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol = 100/1 to 10/1) and further purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The desired fractions were adjusted pH = 7 by addition saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give benzyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.3 g, 2.19 mmol, 39.9% yield, 98% purity) was obtained as a yellow solid. LCMS [ESI, M+1]:581.

[01205] ^{1}H NMR (400MHz, chloroform-d) δ = 8.22 - 8.13 (m, 1H), 7.92 - 7.83 (m, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.56 - 7.48 (m, 2H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.41 - 7.32 (m, 5H), 7.15 (d, *J* = 7.2 Hz, 1H), 5.22 (s, 2H), 4.70 (br s, 1H), 4.54 - 4.36 (m, 2H), 4.34 - 4.17 (m, 2H), 4.12 - 4.04 (m, 1H), 3.58 - 3.17 (m, 5H), 3.01 (m, 2H), 2.93 (d, *J* = 2.8 Hz, 3H), 2.90 - 2.79 (m, 1H), 2.77 - 2.65 (m, 1H).

[01206] Step G: To a solution of benzyl 2-(cyanomethyl)-4-[2-methylsulfinyl-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (430 mg, 741 umol, 1.00 *eq*) and *tert*-butyl (5*S*)-5-(hydroxymethyl)-2,2-dimethyl-pyrrolidine- 1-carboxylate (340 mg, 1.48 mmol, 2.00 *eq*) in toluene (8.00 mL) was added *t*-BuONa (142 mg, 1.48 mmol, 2.00 *eq*). The mixture was stirred at 20 °C for 0.25 hour. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile] to give benzyl 4-[2-[[(2*S*)-1-*tert*-butoxycarbonyl-5,5-dimethyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-

(cyanomethyl)piperazine-1-carboxylate (250 mg, 318 umol, 43.0% yield, 95.0% purity) as a yellow solid. LCMS [ESI, M+1]: 746.

[01207] Step H: benzyl 2-(cyanomethyl)-4-[2-[[(2*S*)-5,5-dimethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 4-[2-[[(2*S*)-1-*tert*-butoxycarbonyl-5,5-dimethyl- pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 268 umol, 1.00 *eq*) in dioxane (4.00 mL) was added HCl•dioxane (4 M, 4.00 mL, 59.7 *eq*) at 0 °C. The mixture was stirred at 25 °C for 2 hours. Upon completion, the mixture was concentrated under vacuum to give benzyl 2-(cyanomethyl)-4-[2-[[(2*S*)-5,5-dimethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 251 umol, 93.5% yield, 95.0% purity, HCl) as a yellow oil which was used directly into the next step without further purification.

[01208] Step I: benzyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 2-(cyanomethyl)-4-[2-[[(2*S*)-5,5- dimethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 264 umol, 1.00 *eq*, HCl) and formaldehyde (107 mg, 1.32 mmol, 98.2 uL, 5.00 *eq*, 37% in water) in MeOH (3.00 mL) was added CH_3COOH (31.7 mg, 528 umol, 30.2 uL, 2.00 *eq*) and $NaBH_3CN$ (66.3 mg, 1.06 mmol, 4.00 *eq*). The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was quenched with 1 M HCl (0.2 mL), diluted with water (1 mL) and extracted with EtOAc (3 × 6 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile] to give benzyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (96.0 mg, 131 umol, 49.6% yield, 90.0% purity) as a yellow solid.

[01209] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.23 - 8.17 (m, 1H), 7.89 - 7.83 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.46 - 7.42 (m, 1H), 7.42 - 7.33 (m, 5H), 7.14 (d, *J* = 7.2 Hz, 1H), 5.27 - 5.16 (m, 2H), 4.70 (br s, 1H), 4.41 (dd, *J* = 4.4, 10.4 Hz, 1H), 4.34 - 4.22 (m, 2H), 4.20 - 4.01 (m, 3H), 3.95 (br d, *J* = 11.2 Hz, 1H), 3.40 - 3.21 (m, 3H), 3.13 - 2.91 (m,

2H), 2.91 - 2.69 (m, 3H), 2.32 (s, 3H), 2.13 - 1.96 (m, 1H), 1.75 - 1.54 (m, 5H), 1.15 (s, 3H), 0.92 (s, 3H).


[01210] Step J: 2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (6.00 mL) for 3 minutes at - 40 °C. A solution of benzyl 2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.10 g, 152 umol, 1.00 *eq*) in MeOH (6.00 mL) was added to the NH_3 solution and Pd/C (0.05 g, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The reaction was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the catalyst was filtered off and the filtrate was concentrated under vacuum to give 2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (63.0 mg, 103 umol, 68.0% yield, 86.0% purity) as a yellow solid which was used directly into the next step without further purification. LCMS [ESI, M+1]: 526.

[01211] Step K: 2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (75.0 mg, 143 umol, 1.00 *eq*) and TEA (72.2 mg, 713 umol, 99.3 uL, 5.00 *eq*) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (18.0 mg, 143 umol, 1.00 *eq*) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction was quenched with MeOH (0.5 mL), diluted with water (2 mL) and extracted with EtOAc (2 × 5 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-TLC (EtOAc/MeOH 9/1) and prep-HPLC(column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 60% - 90%, 12 min) and lyophilized to give 2-[4-[7-(1-naphthyl)-2-[[(2*S*)-1,5,5-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 301, 14.7 mg, 25.3 umol, 17.8% yield, 100% purity) as a white solid. LCMS [ESI, M+1]:580.


[01212] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.25 - 8.17 (m, 1H), 7.90 - 7.83 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.55 - 7.48 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H),

6.60 (br s, 1H), 6.45 - 6.36 (m, 1H), 5.84 (br d, J = 10.8 Hz, 1H), 5.10 (br s, 1H), 4.44 (br s, 1H), 4.34 - 4.19 (m, 2H), 4.17 - 3.80 (m, 4H), 3.79 - 3.21 (m,4H), 3.19 - 2.63(m, 6H), 2.34 (br s, 3H), 2.15 - 2.03 (m, 1H), 1.69 (br s, 3H), 1.16 (br s, 3H), 0.94 (s, 3H).

EXAMPLE 302



2-[4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-2-piperidyl]acetonitrile



[01213] Insert: (7-fluoro-1-naphthyl) trifluoromethanesulfonate. To a solution of 7-fluoronaphthalen-1-ol (250 mg, 1.54 mmol, 1 *eq*) and DIEA (598 mg, 4.63 mmol, 806 uL, 3 *eq*) in DCM (10 mL) was added Tf_2O (652 mg, 2.31 mmol, 382 uL, 1.5 *eq*) dropwise at -5 °C. The mixture was stirred at 20 °C for 3 hours. After that, the mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 100/1 to 10/1). (7-fluoro-1-naphthyl) trifluoromethanesulfonate (450 mg, 1.53 mmol, 99.2% yield) was obtained as a colourless oil.

[01214] ^{1}H NMR (400MHz, methanol-d_4) δ = 8.08 (dd, *J* = 5.6, 9.2 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.73 - 7.39 (m, 4H).

[01215] Step A: *tert*-Butyl 2-(cyanomethyl)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (182 mg, 386 umol, 1 *eq*), (7-fluoro-1-naphthyl) trifluoromethanesulfonate (227 mg, 772 umol, 2 *eq*), $Pd_2(dba)_3$ (35.3 mg, 38.6 umol, 0.1 *eq*), RuPhos (36.0 mg, 77.2 umol, 0.2 *eq*) and Cs_2CO_3 (377 mg, 1.16 mmol, 3 *eq*) in toluene (20 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 16 hours under N_2 atmosphere. The mixture was quenched with H_2O (30 mL), and then the mixture was diluted with ethyl acetate (20 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 ×100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-Butyl 2-(cyanomethyl)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (158 mg, 257 umol, 66.5% yield, 100% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 616.

[01216] ^{1}H NMR (400MHz, chloroform-d) δ = 7.92 - 7.79 (m, 2H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 1H), 7.30 – 7.25 (m, 1H), 7.19 (d, *J* = 7.2 Hz, 1H), 4.63 (br d, *J* = 2.1 Hz, 1H), 4.40 (br dd, *J* = 4.8, 10.4 Hz, 1H), 4.24 (br s, 2H), 4.20 - 4.00 (m, 4H), 3.95 (br d, *J* =

12.4 Hz, 1H), 3.52 - 3.37 (m, 1H), 3.36 - 3.16 (m, 3H), 3.15 - 2.63 (m, 6H), 2.50 (s, 3H), 2.36 - 2.22 (m, 1H), 2.12 - 2.05 (m, 1H), 1.92 - 1.70 (m, 3H), 1.53 (s, 9H).


[01217] Step B: 2-[4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4- [7-(7-fluoro-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 162 umol, 1 *eq*) in dioxane (10 mL) was added HCl•dioxane (4 M, 1.62 mL, 40 *eq*) at 0 °C under nitrogen atmosphere. The mixture was stirred at 25 °C for 2 hours. After that, the mixture was concentrated under vacuum. 2-[4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, crude, HCl) was obtained as a yellow oil. LCMS [ESI, M+1]: 516.

[01218] Step C: 2-[4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-2-piperidyl]acetonitrile. To a mixture of 2-[4-[7-(7-fluoro-1-naphthyl)-2- [[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, crude, HCl) and DIEA (234 mg, 1.81 mmol, 315 uL) in DMF (5 mL) was added prop-2-enoyl prop-2-enoate (18.3 mg, 145 umol) at 0 °C. After stirred at 25 °C for 1 h, the reaction mixture was quenched by $NaHCO_3$ saturated solution (5 mL), and then extracted with ethyl acetate (2 × 25 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (Ethyl acetate/MeOH = 50/1 to 1/1). The collected liquid was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225% FA) - ACN]; B%: 12% - 42%, 10 min) and (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 55% - 85%,12 min) 2-[4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-2-piperidyl]acetonitrile (EXAMPLE 302, 4.23 mg, 7.19 umol, two steps 4.29% yield, 96.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 570.


[01219] ^{1}H NMR (400MHz, chloroform-d) δ = 7.93 - 7.77 (m, 2H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 1H), 7.32 - 7.25 (m, 1H), 7.19 (d, *J*=7.3 Hz, 1H), 6.59 (br d, *J* = 10.8

Hz, 1H), 6.41 (dd, J = 1.6, 16.8 Hz, 1H), 5.84 (br d, J = 10.4 Hz, 1H), 5.23 - 4.52 (m, 1H), 4.40 (dd, J = 4.8, 10.6 Hz, 1H), 4.24 (br s, 2H), 4.21 - 4.11 (m, 2H), 4.03 (br d, J = 12.0 Hz, 2H), 3.86 - 3.04 (m, 6H), 3.03 - 2.58 (m, 5H), 2.49 (s, 3H), 2.37 - 2.23 (m, 1H), 2.16 - 1.98 (m, 1H), 1.91 - 1.69 (m, 3H).

EXAMPLE 303



2-[4-[7-(1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01220] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a

solution of 2-(1-piperidyl)ethanol (89.0 mg, 689 umol, 91.5 uL, 2.0 *eq*) in toluene (2.0 mL) was added t-BuONa (66.2 mg, 689 umol, 2.0 *eq*) at 0 °C. Then the mixture was added benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 344 umol, 1.0 *eq*), the mixture was stirred at 0 °C for 1 hour. After completion, the mixture was added water (10.0 mL) and extracted with EA (10 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA=10:1 - EA:MeOH=20:1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[2-(1- piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 296 umol, 86% yield, 95.7 % purity) as yellow oil. LCMS [ESI, M+1]: 646.


[01221] Step B: 2-[(2*S*)-4-[7-(1-naphthyl)-2-[2-(1-piperidyl)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (10.0 mL) at -78 °C for 30 minutes. Then benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[2-(1-piperidyl) ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 279 umol, 1.0 eq) and Pd/C (100 mg, 10.0% purity) was added to the above liquid under N_2 atmosphere. The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 0.5 hour. After completion, the mixture was filtered with Celite and concentrated under vacuum. The obtained product was purified by reversed phase flash column (C18, 0.1 % FA in water, 0 - 40% MeCN) to give 2-[(2*S*)-4-[7-(1-naphthyl)-2-[2-(1-piperidyl)ethoxy]- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, 176 umol, 63% yield) as white solid. LCMS [ESI, M+1]: 512.

[01222] Step C: 2-[4-[7-(1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(1-naphthyl)-2-[2-(1-piperidyl) ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, 176 umol, 1.0 *eq*) and DIEA (136 mg, 1.06 mmol, 184 uL, 6.0 *eq*) in DCM (1.0 mL) was added prop-2-enoyl prop-2-enoate (22.2 mg, 176 umol, 1.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (20.0 mg) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 60% - 90%, 12min) to give 2-[4-[7-(1-naphthyl)-2-[2-(1-


piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 303, 11.2 mg, 19.7 umol, 11% yield, 99.5% purity) as white solid. LCMS [ESI, M+1]: 566.

[01223] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.24 - 8.19 (m, 1H), 7.89 - 7.84 (m, 1H), 7.62 (d, *J* = 8.4 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.44 (t, *J* = 8.0 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 6.70 - 6.53 (m, 1H), 6.41 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.19 - 5.01 (m, 1H), 4.47 (br t, *J* = 6.0 Hz, 2H), 4.33 - 4.21 (m, 2H), 4.12 (br d, *J* = 14.0 Hz, 1H), 4.06 - 3.98 (m, 1H), 3.55 - 3.45 (m, 1H), 3.43 - 3.24 (m, 2H), 3.22 - 3.09 (m, 1H), 3.04 - 2.72 (m, 6H), 2.68 - 2.42 (m, 4H), 1.61 - 1.56 (m, 6H), 1.50 - 1.40 (m, 2H).

EXAMPLE 304



2-[4-[2-[[(2*R*)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01224] [(2*R*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl] methanol. A mixture of [(2*R*)-pyrrolidin-2-yl]methanol (0.70 g, 6.92 mmol, 673 uL, 1.00 *eq*), 2-bromoethoxy-*tert*-butyl-dimethyl-silane (1.66 g, 6.92 mmol, 1.00 *eq*) and K_2CO_3 (4.78 g, 34.6 mmol, 5.00 *eq*) in acetonitrile (70.0 mL) was refluxed at 83 °C for 12 hours. Then the mixture was filtered and the filter cake was washed with methanol. The organic layers were concentrated under vacuum to give a residue. The residue was purified by silica gel chromatography (ethyl acetate/methanol = 50/1 to 1/1). Compound [(2*R*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl] methanol (1.40 g, 5.40 mmol, 78.0 % yield, 100% purity) was obtained as a colorless oil.

[01225] ^{1}H NMR (400MHz, chloroform-d) δ = 3.68 (dd, *J* = 5.2, 6.4 Hz, 2H), 3.57 (dd, *J* = 3.6, 10.8 Hz, 1H), 3.42 - 3.25 (m, 1H), 3.23 - 2.96 (m, 2H), 2.95 - 2.82 (m, 1H), 2.72 - 2.61 (m, 1H), 2.48 (td, *J* = 5.2, 12.8 Hz, 1H), 2.40 - 2.27 (m, 1H), 1.90 - 1.77 (m, 1H), 1.77 - 1.62 (m, 3H), 0.83 (s, 9H), 0.00 (s, 6H).

[01226] Step A: benzyl 4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of benzyl 2-(cyanomethyl)-4-[2-

methylsulfinyl-7-(1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 861 umol, 1 eq) and [(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methanol (447 mg, 1.72 mmol, 2 eq) in toluene (10 mL) was added *t*-BuONa (248 mg, 2.58 mmol, 3 eq) in one portion at 25 °C and the mixture was stirred at 25 °C for 0.5 hour. The mixture was acidified with 1 M HCl solution to pH = 8 and the mixture diluted with ethyl acetate (100 mL) and water (10 mL). The separated organic layer was washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (ethyl acetate/methanol 100/1 to 10/1). The desired fractions were collected and concentrated under vacuum to give benzyl 4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (480 mg, 582 umol, 68% yield, 94.1% purity) as a light yellow solid. LCMS [ESI, M+1]: 776.

[01227] ^{1}H NMR (400MHz, chloroform-d) δ = 8.28 - 8.11 (m, 1H), 7.95 - 7.77 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.55 - 7.29 (m, 8H), 7.14 (d, *J* = 7.2 Hz, 1H), 5.29 - 5.15 (m, 2H), 4.70 (br s, 1H), 4.41 - 3.88 (m, 7H), 3.83 - 3.68 (m, 2H), 3.57 - 2.69 (m, 12H), 2.67 - 2.49 (m, 1H), 2.37 (q, *J* = 8.4 Hz, 1H), 2.03 - 1.93 (m, 1H), 1.83 - 1.74 (m, 3H), 1.00 - 0.79 (m, 9H), 0.13 -0.01 (m, 6H).

[01228] Step B: 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in methanol (60.0 mL) at -78 °C for 30 minutes. Benzyl 4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.20 g, 258 umol, 1.00 eq) and Pd/C (0.10 g, 10.0 % purity) was added into the mixture. The mixture was stirred at 20 °C for 1 hour under H_2 at 15 psi. Then the mixture was filtered and concentrated under vacuum to give 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.15 g, crude) as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 642.

[01229] Step C: 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.15 g, crude) and Et_3N (236 mg, 2.34 mmol, 325 uL) in dichloromethane (2.00 mL)was added prop-2-enoyl prop-2-enoate (29.5 mg, 234 umol) at 0 °C. After stirred at 20 °C for 1 hour, the mixture was quenched with saturated sodium bicarbonate solution (0.50 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10) to give 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.10 g, 135 umol, two steps 52.3% yield) as a yellow solid. LCMS [ESI, M+1]: 696.


[01230] ^1H NMR (400MHz, chloroform-d) δ = 8.25 - 8.18 (m, 1H), 7.90 - 7.82 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 6.59 (br d, *J* = 12.0 Hz, 1H), 6.40 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.22 - 4.94 (m, 1H), 4.36 (td, *J* = 3.6, 10.4 Hz, 1H), 4.31 - 4.20 (m, 2H), 4.15 - 4.05 (m, 2H), 4.04 - 3.97 (m, 1H), 3.75 (t, *J* = 6.8 Hz, 2H), 3.63 (br s, 1H), 3.46 (br s, 1H), 3.35 (br d, *J* = 11.2 Hz, 2H), 3.21 - 3.15 (m, 1H), 3.08 - 2.99 (m, 2H), 2.99 - 2.92 (m, 2H), 2.63 - 2.54 (m, 1H), 2.42 - 2.33 (m, 1H), 2.04 - 1.95 (m, 1H), 1.84 - 1.73 (m, 3H), 1.66 (br s, 4H), 0.88 (s, 9H), 0.05 (s, 6H).

[01231] Step D: 2-[4-[2-[[(2*R*)-1-(2-hydroxyethyl) pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A mixture of 2-[4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.09 g, 129 umol, 1 eq) and TBAF (1.00 M in THF, 1.29 mL, 10 eq) in THF (0.10 mL) was stirred at 10 °C for 1 hour. The mixture was concentrated under vacuum. The residue was purified by reverse phase flash [water (FA, 0.1 %)/acetonitrile], column chromatography (Al_2O_3, methanol/ethyl acetate = 1/3) and prep-HPLC (column: Boston pH-lex 150*25 10um; mobile phase: [water (0.10 % TFA) - ACN]; B%: 22% - 52%, 10 min and column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 47% - 77%, 12 min). The desired fractions were collected and


lyophilized to give title compound 2-[4-[2-[[(2*R*)-1-(2-hydroxyethyl) pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (23.9 mg, 41.0 umol, 31.7 % yield, 99.7 % purity) as a white solid. LCMS [ESI, M+1]: 582.

[01232] ^{1}H NMR (400MHz, chloroform-d) δ = 8.25 - 8.18 (m, 1H), 7.89 - 7.83 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 6.59 (br s, 1H), 6.44 - 6.35 (m, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.10 – 4.50 (m, 1H), 4.38 - 4.24 (m, 3H), 4.22 - 4.09 (m, 2H), 4.00 (br d, *J* = 11.5 Hz, 2H), 3.73 - 3.57 (m, 2H), 3.45 (br s, 1H), 3.36 (br d, *J* = 12.0 Hz, 2H), 3.23 - 2.77 (m, 9H), 2.62 (td, J=3.6, 12.4 Hz, 1H), 2.38 - 2.26 (m, 1H), 2.05 - 1.99 (m, 1H), 1.90 - 1.73 (m, 3H).

EXAMPLE 305



3-(4-((*S*)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8*H*)-yl)isonicotinonitrile



[01233] Step A: benzyl 2-(cyanomethyl)-4-[7-(4-cyano- 3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 791 umol, 1.0 *eq*) and 3-bromopyridine-4-carbonitrile (289 mg, 1.58 mmol, 2.0 *eq*) in toluene (10.0 mL) was added Cs_2CO_3 (516 mg, 1.58 mmol, 2.0 *eq*), $Pd_2(dba)_3$ (72.4 mg, 79.1 umol, 0.1 *eq*) and RuPhos (73.8 mg, 158 umol, 0.2 *eq*), the reaction mixture was stirred at 100 °C for 3 hours under N_2. After completion, the reaction mixture was added water (15 mL), then extracted with EA (2 ×15.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether/Ethyl acetate=5/1 to Petroleum ether/Ethyl acetate/Methanol=5/1/0.1) to give benzyl 2-(cyanomethyl)-4-[7-(4-cyano- 3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 266 umol, 34% yield, 80.9% purity) as yellow solid. LCMS [ESI, M+1]: 608.


[01234] Step B: 3-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]pyridine-4-carbonitrile. To a solution of benzyl 2-(cyanomethyl)-4-[7-(4-cyano-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 226 umol, 1.0 *eq*) in MeOH (5.0 mL) was added NH_3•MeOH (49.4 ug, 49.4umol, 5.0 mL) and Pd/C (150 mg,

10% purity), the suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 1 hour. After completion, the reaction was filtered through a Celite, and the filtrate was concentrated. The residue was purified by reversed phase flash (C18, 30% MeCN in water), the obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated until no solvent remained, the solid was then added DCM (10.0 mL) and stirred at 20 °C for 0.5 h, the solid was filtered and the filtrate was concentrated to give 3-[4-[3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methyl pyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]pyridine-4-carbonitrile (35.0 mg, 73.9 umol, 33% yield, 100% purity) as white solid. LCMS [ESI, M+1]: 474.


[01235] Step C: 3-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2- [[(2*S*)-1-methylpyrrolidin-2yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]pyridine-4-carbonitrile. To a mixture of 3-[4-[3-(cyanomethyl)piperazin -1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]pyridine-4-carbonitrile (35.0 mg, 73.9 umol, 1.0 eq) in DCM (1.0 mL) was added DIEA (28.7 mg, 222 umol, 38.6 uL, 3.0 eq) and prop-2-enoyl prop-2-enoate (9.32 mg, 73.9 umol, 1.0 eq) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (0.5 mL), and concentrated. The residue was purified by prep-HPLC ((Instrument: ACSWH-GX-M; Column: Gemini 150*25 5u; Condition: water (0.04%NH_3·H_2O)-ACN; Begin B:32; End B:56; Gradient Time(min): 10; 100%B Hold Time (min):3; FlowRate (ml/min):100), the obtained product was concentrated., and then under lyophilization. The product 3-[4-[3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2- [[(2*S*)-1-methylpyrrolidin-2yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]pyridine-4-carbonitrile (EXAMPLE 305, 13.0 mg, 24.5 umol, 33% yield, 99.3% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 528.

[01236] ^{1}H NMR (400 MHz, chloroform-d) δ 8.52 (s, 1H), 8.33 (d, *J* = 4.8 Hz, 1H), 7.46 (d, *J* = 4.8 Hz, 1H), 6.69 - 6.53 (m, 1H), 6.42 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.85 (br d, *J* = 11.6 Hz, 1H), 5.19 - 5.01 (m, 1H), 4.48 - 4.36 (m, 3H), 4.27 - 4.08 (m, 2H), 4.07 - 3.81 (m, 3H), 3.78 - 3.33 (m, 3H), 3.23 - 2.99 (m, 3H), 2.97 - 2.83 (m, 2H), 2.81 - 2.61 (m, 2H), 2.52 (s, 3H), 2.40 - 2.27 (m, 1H), 2.16 - 1.99 (m, 1H), 1.95 - 1.76 (m, 3H).

EXAMPLE 306



2-((*S*)-1-acryloyl-4-(2-(((2*S*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01237] Step A: [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl] methanol. To a solution of 1-*tert*-butyl 2-methyl (2*S*,4*R*)-4-fluoropyrrolidine-1,2-dicarboxylate (5.0 g, 20.2 mmol, 1.0 *eq*) in THF (100 mL) was added $LiAlH_4$ (1.53 g, 40.4 mmol, 2.0 *eq*) in portions at 0 °C. After the

reaction mixture was stirred at 0 °C for 1 hour under N_2, the reaction mixture was heated to 70 °C and stirred at 70 °C for 2 hours under N_2. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous (4.5 mL), then filtered, the filtrate was concentrated. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether/Ethyl acetate=5/1 to Petroleum ether/Ethyl acetate/Methanol=3/1/0.1) to give [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl] methanol (1.5 g, 11.3 mmol, 56% yield) as yellow oil.

[01238] ^{1}H NMR (400 MHz, chloroform-d) δ 5.24 - 4.97 (m, 1H), 3.73 (dd, *J* = 3.2, 11.2 Hz, 1H), 3.61 - 3.40 (m, 2H), 2.86 - 2.74 (m, 1H), 2.69 (ddd, *J* = 0.8, 2.8, 12.0 Hz, 1H), 2.61 (dd, *J* = 2.4, 12.0 Hz, 1H), 2.41 (s, 3H), 2.18 - 1.98 (m, 2H).

[01239] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 800 mg, 1.38 mmol, 1.0 *eq*) and [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (367 mg, 2.76 mmol, 2.0 *eq*) in toluene (15.0 mL) was added t-BuONa (265 mg, 2.76 mmol, 2.0 *eq*) at 0 °C, the reaction was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (30 mL), then extracted with EA (2 ×15 mL), the combined organic layer was washed with saturated brine (1 × 30 mL), then dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to Petroleum ether/Ethyl acetate/Methanol=3/1/0.1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (720 mg, 997 umol, 72% yield, 90.0% purity) as light yellow solid. LCMS [ESI, M+1]: 650.


[01240] Step C: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (670 mg, 1.03 mmol, 1.0 *eq*) in MeOH (15.0 mL) was added NH_3•MeOH (1.03 mmol, 15.0 mL, 1.0 *eq*) and Pd/C (400 mg, 10% purity), the suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 1 hour. After completion,

the reaction was filtered through a Celite, and the filtrate was concentrated to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, 478 umol, 46% yield, 94.9% purity) as white solid. LCMS [ESI, M+1]: 516.


[01241] Step D: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, 504 umol, 1.0 eq) in DCM (5.0 mL) was added DIEA (196 mg, 1.51 mmol, 263 uL, 3.0 eq) and prop-2-enoyl prop-2-enoate (63.6 mg, 504 umol, 1.0 eq) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5 mL), and concentrated. The residue was purified by prep-HPLC ((Instrument: ACSWH-GX-H; Column: Gemini 150*25 5u; Condition: water (0.05% ammonia hydroxide v/v)-ACN; Begin B:42; End B:72; Gradient Time(min): 12; 100%B Hold Time (min):1.8; FlowRate (ml/min): 25), the obtained product was concentrated., and then under lyophilization. The product 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 306, 65.6 mg, 115 umol, 23% yield, 99.8% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 570.


[01242] ^{1}H NMR (400 MHz, chloroform-d) δ 8.27 - 8.17 (m, 1H), 7.92 - 7.84 (m, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.56 - 7.49 (m, 2H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.17 (d, *J* = 6.8 Hz, 1H), 6.68 - 6.56 (m, 1H), 6.42 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.86 (br d, *J* = 10.4 Hz, 1H), 5.30 - 4.99 (m, 2H), 4.45 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.35 - 4.21 (m, 3H), 4.15 (br d, *J* = 13.6 Hz, 1H), 4.03 (br d, *J* = 11.6 Hz, 2H), 3.70 - 2.72 (m, 11H), 2.68 - 2.56 (m, 1H), 2.54 (s, 3H), 2.41 - 2.27 (m, 1H), 2.10 - 1.90 (m, 1H).

EXAMPLE 307



2-[4-[7-(2-fluoro-3-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8 -dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[01243] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro-3-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 300 mg, 636 umol, 1.00 *eq*), 1-bromo-2-fluoro-3-methoxy-benzene (261 mg, 1.27 mmol, 2.00 *eq*), $Pd_2(dba)_3$ (117 mg, 127 umol, 0.20 *eq*), RuPhos (89.1 mg, 191 umol, 0.30

eq) and Cs_2CO_3 (622 mg, 1.91 mmol, 3.00 *eq*) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 16 hours under N_2 atmosphere. To the reaction mixture was added H_2O (200 mL) and ethyl acetate (250 mL). The separated organic phase was washed with brine (1 × 200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (100 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro-3-methoxy-phenyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 353 umol, 55.4% yield, 100% purity) was obtained as a faint yellow solid. LCMS [ESI, M+1]: 596.

[01244] ^{1}H NMR (400MHz, chloroform-d) δ = 7.00 (dt, *J* = 1.6, 8.4 Hz, 1H), 6.74 - 6.56 (m, 2H), 4.61 (br s, 1H), 4.44 - 4.34 (m, 1H), 4.28 - 4.10 (m, 3H), 4.01 (br d, *J* = 13.6 Hz, 1H), 3.90 (s, 4H), 3.56 - 3.40 (m, 1H), 3.25 (br dd, *J* = 3.6, 13.6 Hz, 2H), 3.12 (br t, *J* = 7.6 Hz, 1H), 2.98 (dt, *J* = 2.8, 12.4 Hz, 1H), 2.89 - 2.63 (m, 5H), 2.50 (s, 3H), 2.35 - 2.26 (m, 1H), 2.21 - 2.06 (m, 3H), 1.90 - 1.68 (m, 3H), 1.60 - 1.42 (m, 9H).


[01245] Step B: 2-[4-[7-(2-fluoro-3-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro-3-methoxy- phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 168 umol, 1.00 *eq*) in DCM (1 mL) was added TFA (1.63 g, 14.3 mmol, 1.06 mL, 85.0 *eq*) at 0 °C under nitrogen atmosphere. The mixture was stirred at 25 °C for 1 h and then the mixture was concentrated under vacuum. 2-[4-[7-(2-fluoro-3-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (210 mg, crude, TFA) was obtained as a yellow oil. LCMS [ESI, M+1]: 496.

[01246] Step C: 2-[4-[7-(2-fluoro-3-methoxy-phenyl) -2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[7-(2-fluoro-3-methoxy-phenyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (102 mg, crude TFA) and DIEA (216 mg, 1.67 mmol, 291 uL) in DCM (3 mL)


was added prop-2-enoyl prop-2-enoate (16.9 mg, 134 umol) at 0 °C. After stirring at 25 °C for 1 hour, the reaction mixture was quenched with saturated $NaHCO_3$ solution (5 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 25 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 38% - 68%, 12 min). 2-[4-[7-(2-fluoro-3-methoxy-phenyl) -2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 307, 7.47 mg, 13.6 umol, two steps 17% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 550.

[01247] ^{1}H NMR (400MHz, chloroform-d) δ = 7.07 - 6.95 (m, 1H), 6.74 - 6.51 (m, 3H), 6.45 - 6.34 (m, 1H), 5.83 (br d, *J* = 10.6 Hz, 1H), 5.08 (br s, 1H), 4.38 (dd, *J* = 4.8, 10.5 Hz, 1H), 4.31 - 4.12 (m, 3H), 4.07 (br d, *J* = 13.6 Hz, 1H), 4.03 - 3.82 (m, 5H), 3.68 - 3.44 (m, 2H), 3.39 - 3.21 (m, 2H), 3.10 (br t, *J* = 7.8 Hz, 2H), 2.95 - 2.61 (m, 5H), 2.48 (s, 3H), 2.33 - 2.23 (m, 1H), 2.13 - 1.99 (m, 1H), 1.92 - 1.62 (m, 3H).

EXAMPLE 308



2-(1-acryloyl-4-(7-(3-fluoro-2-methoxyphenyl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01248] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(3-fluoro-2-methoxy-phenyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 300 mg, 636 umol, 1 eq), 1-bromo-3-fluoro-2-methoxy-benzene (261 mg, 1.27 mmol, 2 eq), $Pd_2(dba)_3$ (117 mg, 127 umol, 0.2 eq), RuPhos (89.1 mg, 191 umol, 0.3 eq) and Cs_2CO_3 (622 mg, 1.91 mmol, 3 eq) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 16 hours under N_2 atmosphere. To the reaction mixture, H_2O (200 mL) and ethyl acetate (250 mL) were added. The organic phase was separated, washed with brine (200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected, neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound *tert*-butyl 2-(cyanomethyl)-4-[7-(3-fluoro-2-methoxy-phenyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 277 umol, 43.6% yield, 97.1% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 596.

[01249] ^{1}H NMR (400MHz, chloroform-d) δ = 6.96 (dt, *J* = 6.0, 8.0 Hz, 1H), 6.83 - 6.69 (m, 1H), 6.83 - 6.68 (m, 1H), 4.60 (br s, 1H), 4.39 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.31 - 4.14 (m, 3H), 4.04 (br d, *J* = 13.6 Hz, 2H), 3.94 (d, *J* = 0.8 Hz, 4H), 3.62 - 3.47 (m, 1H), 3.26 (br dd, *J* = 4.0, 13.6 Hz, 2H), 3.12 (br t, *J* = 7.6 Hz, 1H), 2.99 (dt, *J* = 2.8, 12.0 Hz, 1H), 2.88 - 2.64 (m, 5H), 2.50 (s, 3H), 2.36 - 2.24 (m, 1H), 2.22 - 2.07 (m, 2H), 1.94 - 1.64 (m, 3H), 1.56 - 1.46 (m, 9H).


[01250] Step B: 2-[4-[7-(3-fluoro-2-methoxy- phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl 2-(cyanomethyl)-4-[7-(3-fluoro-2- methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 285 umol, 1 eq) in DCM (2.50 mL) was added TFA (651 mg, 5.71 mmol, 423 uL, 20 eq) in one portion at 0 °C under N_2. After stirred at 25 °C for 2 hours, the reaction mixture was concentrated under reduced pressure to give a residue. The crude product was used directly into the next step without further purification. Compound 2-[4-[7-(3-fluoro-2-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (173 mg, 284 umol, 99.4% yield, TFA) was obtained as a brown solid. LCMS [ESI, M+1]: 496.

[01251] Step C: 2-[4-[7-(3-fluoro-2- methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[7-(3-fluoro-2-methoxy-phenyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (173 mg, 284 umol, 1 eq, TFA) and prop-2-enoyl prop-2-enoate (35.8 mg, 284 umol, 1 eq) in DCM (3 mL) was added TEA (144 mg, 1.42 mmol, 198 uL, 5 eq) in portion at 0 °C under N_2. After stirred at 25 °C for 0.5 hour, the reaction mixture was quenched by adding saturated $NaHCO_3$ (1.5 mL) at 0 °C, and then diluted with water (2 mL) and extracted with DCM (20 mL × 3). The combined organic layers were washed with water (15 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by column chromatography (Al_2O_3, Petroleum ether/Ethyl acetate = 100/1 to MeOH/EA = 1/2). The desired fractions were collected and concentrated under reduced pressure. Then the residue was purified by prep-HPLC (column: Phenomenex Gemini 150 × 25mm × 10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 48% - 78%,


12 min). Title compound 2-[4-[7-(3-fluoro-2- methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 308, 28.2 mg, 50.4 umol, 17.8% yield, 98.1% purity) was obtained as a white solid. LCMS [ESI, M+1]: 550.

[01252] ^{1}H NMR (400MHz, chloroform-d) δ = 6.97 (dt, *J* = 6.0, 8.4 Hz, 1H), 6.83 - 6.76 (m, 1H), 6.72 (d, *J* = 8.0 Hz, 1H), 6.57 (br d, *J* = 12.0 Hz, 1H), 6.40 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.07 (br s, 1H), 4.56 (br s, 1H), 4.39 (br dd, *J* = 5.2, 10.4 Hz, 1H), 4.30 - 4.18 (m, 2H), 4.18 - 4.06 (m, 2H), 4.04 - 3.96 (m, 1H), 3.95 (d, *J* = 0.8 Hz, 3H), 3.73 - 3.46 (m, 2H), 3.38 - 3.22 (m, 2H), 3.16 - 2.99 (m, 2H), 2.96 - 2.59 (m, 5H), 2.50 (s, 3H), 2.36 - 2.22 (m, 1H), 2.16 - 1.98 (m, 1H), 1.94 - 1.68 (m, 3H).

EXAMPLE 309



2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01253] Insert: 1-bromo-8-methyl-naphthalene. To a solution of 1,8-dibromonaphthalene (1 g, 3.50 mmol, 1 *eq*) in THF (20 mL) was added MeLi (1.6 M in diethyl ether, 2.62 mL, 1.2 *eq*) at 0°C dropwise. After stirring for 30 minutes at 0°C, iodomethane (3.38 g, 23.8 mmol, 1.48 mL, 6.81 *eq*) was added dropwise. The mixture was warmed up to 25°C and stirred for another 3 hours. The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 45% - 70%, 28 MIN; 40% min). 1-bromo-8-methyl-naphthalene (340 mg, 1.49 mmol, 43% yield, 97% purity) was obtained as a yellow solid after lyophilisation.

[01254] ^{1}H NMR (400MHz, chloroform-d) δ = 7.75 (dd, *J* = 0.8, 7.2 Hz, 1H), 7.69 (dd, *J* = 0.8, 8.0 Hz, 1H), 7.66 - 7.59 (m, 1H), 7.30 - 7.22 (m, 2H), 7.13 (t, *J* = 8.0 Hz, 1H), 3.05 (s, 3H).

[01255] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of 1-bromo-8-methyl-naphthalene (122 mg, 551 umol, 1.3 *eq*), *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 200 mg, 424 umol, 1 *eq*), Cs_2CO_3 (345 mg, 1.06 mmol, 2.5 *eq*), RuPhos (39.6 mg, 84.8 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (77.7 mg, 84.8 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 110 °C for 3 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 by addition saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give *tert*-butyl 2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 224 umol, 53% yield, 98% purity) as a yellow solid. LCMS [ESI, M+1]: 612.

[01256] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.60 (m, 2H), 7.42 (dd, *J* = 8.0, 16.0 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.16 (m, 2H), 4.61 (br s, 1H), 4.40 (br s, 1H), 4.30 - 4.16 (m, 2H), 4.10 - 3.71 (m, 4H), 3.58-3.45 (m, 1H), 3.43-3.25 (m, 1H), 3.23 - 3.04 (m, 4H), 3.03 - 2.85 (m, 5H), 2.83 - 2.55 (m, 4H), 2.49 (br s, 3H), 2.40 - 2.20 (m, 1H), 2.14 - 2.06 (m, 1H), 1.92 - 1.71 (m, 2H), 1.55 - 1.44 (m, 9H).

[01257] Step B: 2-[4-[7-(8-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (110 mg, 179 umol, 1 *eq*) in DCM (200 uL) was added TFA (307 mg, 2.70 mmol, 199 uL, 15 *eq*). After stirred at 25 °C for 1 hour, the mixture was concentrated under vacuum. 2-[4-[7-(8-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-


4-yl]piperazin-2-yl]acetonitrile (112 mg, 179 umol, 100% yield, TFA) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]: 512.

[01258] Step C: 2-[4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (112 mg, 179 umol, 1 *eq*, TFA) in DCM (2 mL) was added TEA (181 mg, 1.79 mmol, 249 uL, 10 *eq*) at 0°C. And then prop-2-enoyl prop-2-enoate (18.1 mg, 143 umol, 0.8 *eq*) in DCM (1 mL) was added dropwise at 0 °C. The resulting mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL), diluted with water (10 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, Petroleum ether/Ethyl acetate = 10/1 to 1/3) and further purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 55% - 85%, 12 min). Title compound 2-[4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 309, 16.2 mg, 28.4 umol, 16% yield, 99% purity) was obtained as a white solid after lyophilisation. LCMS [ESI, M+1]: 566.


[01259] SFC condition: "OJ-3S_5_5_40_3ML Column: Chiralcel OJ-3 100 × 4.6mm I.D., 3um Mobile phase: ethanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01260] ^{1}H NMR (400MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.0 Hz, 1H), 7.65 (t, *J* = 8.4 Hz, 1H), 7.46 - 7.38 (m, 1H), 7.34 (t, *J* = 6.4 Hz, 1H), 7.27 - 7.17 (m, 2H), 6.68-6.52 (m *J* = 9.9 Hz, 1H), 6.46 - 6.35 (m, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.08 (br s, 1H), 4.59 (br s, 1H), 4.41 - 4.33 (m, 1H), 4.32 - 4.21 (m, 1H), 4.20 - 4.04 (m, 3H), 4.03 - 3.82 (m, 2H), 3.85-3.67 (m, 1H), 3.61 - 3.33 (m, 2H), 3.24 - 2.99 (m, 4H), 2.92 (s, 3H), 2.87 - 2.77 (m, 1H), 2.71 - 2.59 (m, 2H), 2.47 (d, *J* = 4.0 Hz, 3H), 2.34 - 2.20 (m, 1H), 2.13 - 1.98 (m, 1H), 1.85 - 1.74 (m, 3H).

EXAMPLE 310



2-(1-acryloyl-4-(7-(8-chloronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01261] Insert: 1-bromo-8-chloronaphthalene. To a solution of perchloroethane (1.66 g, 6.99 mmol, 792 uL, 1 *eq*) in THF (30 mL) was added *n*-BuLi (2.5 M in hexane, 4.20 mL, 1.5 *eq*) at – 78 °C dropwise. After stirring for an additional 10 minutes at – 78 °C, 1,8-dibromonaphthalene (2 g, 6.99 mmol, 1 *eq*) in THF (10 mL) was added. The mixture was warmed up to 25 °C and stirred for 3 hours. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed

with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um; mobile phase: [water (0.225% FA) - ACN]; B%: 41 ACN%-71 ACN%, 30 min; 50% min). The mixture was adjusted PH = 7 by adding saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 1-bromo-8-chloronaphthalene (850 mg, 3.52 mmol, 50% yield, 100% purity) as a yellow solid.

[01262] ^{1}H NMR (400MHz, chloroform-d) δ = 7.92 (dd, *J* = 1.2, 7.2 Hz, 1H), 7.80 (ddd, *J* = 0.8, 8.0, 12.4 Hz, 2H), 7.67 (dd, *J* = 1.2, 7.6 Hz, 1H), 7.38 (t, *J* = 8.0 Hz, 1H), 7.32 - 7.25 (t, *J* = 8.0 Hz, 1H).

[01263] Step A: *tert*-butyl 4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of 1-bromo-8-chloro-naphthalene (133 mg, 551 umol, 1.3 *eq*), *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 424 umol, 1 *eq*), Cs_2CO_3 (345 mg, 1.06 mmol, 2.5 *eq*), RuPhos (39.6 mg, 84.8 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (77.7 mg, 84.8 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 110 °C for 3 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 by adding saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Compound *tert*-butyl 4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 237 umol, 56% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 632.

[01264] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, *J* = 8.4 Hz, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m,

1H), 4.61 (br s, 1H), 4.51 - 4.33 (m, 2H), 4.22 - 4.15 (m, 1H), 4.10 - 3.77 (m, 4H), 3.57 (br s, 1H), 3.41 - 3.01 (m, 6H), 3.01 - 2.86 (m, 1H), 2.85 - 2.63 (m, 3H), 2.62 - 2.43 (m, 4H), 2.31 (br s, 1H), 2.13 - 2.06 (m, 1H), 1.78 (br s, 2H), 1.52 (s, 9H).


[01265] Step B: 2-[4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 237 umol, 1 *eq*) in DCM (200 uL) was added TFA (405 mg, 3.56 mmol, 263 uL, 15 *eq*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under vacuum. Compound 2-[4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, 236 umol, 100% yield, TFA) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]: 532.

[01266] Step C: 2-[4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (153 mg, 237 umol, 1 eq, TFA) in DCM (2 mL) was added TEA (239 mg, 2.37 mmol, 329 uL, 10 eq) at 0 °C. After addition, the prop-2-enoyl prop-2-enoate (23.9 mg, 189 umol, 0.8 eq) in DCM (1 mL) was added dropwise at 0°C. The resulting mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL) and diluted with water (20 mL), extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 52% - 82%, 12 min). Title compound 2-[4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 310, 37 mg, 61.2 umol, 26% yield, 97% purity) was obtained after loyphilization as a white solid. LCMS [ESI, M+1]: 586.


[01267] SFC condition: "AD-3S_4_40_3ML Column: Chiralpak AD-3 100×4.6mm I.D., 3um Mobile phase: 40% iso-propanol (0.05% DEA) in CO_2 Flow rate: 3mL/min Wavelength: 220nm".

[01268] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.27 - 7.18 (m, 1H), 6.59 (br s, 1H), 6.45 - 6.35 (m, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.07 (s, 1H), 4.84 - 4.25 (m, 3H), 4.22 - 3.72 (m, 5H), 3.71-3.53 (m, 1H), 3.50-3.34 (m, 1H), 3.32 - 2.96 (m, 5H), 2.91 - 2.76 (m, 1H), 2.70 - 2.52 (m, 2H), 2.48 (d, *J* = 2.8 Hz, 3H), 2.33 - 2.20 (m, 1H), 2.13 - 1.96 (m, 1H), 1.86 - 1.72 (m, 3H).

EXAMPLE 311



2-(1-acryloyl-4-(7-(2-fluoronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01269] Step 1: 2-fluoronaphthalen-1-ol. To a solution of naphthalen-1-ol (2 g, 13.9 mmol, 5.00 mL, 1 *eq*) in CH_3CN (50 mL) was added Select-F (4.91 g, 13.9 mmol, 1 *eq*). The mixture was stirred at 20 °C for 3 hours. The mixture was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, PE/EA = 3/1) and further purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225% FA) - ACN]; B%: 40% - 70%, 10min). The mixture was adjusted PH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Compound 2-fluoronaphthalen-1-ol (400 mg, 2.44 mmol, 18% yield, 99% purity) was obtained as a yellow solid.

[01270] ^1H NMR (400MHz, chloroform-d) δ = 8.21 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.52 (t, J = 7.2 Hz, 1H), 7.47(t, J = 7.6 Hz, 1H), 7.39 (dd, J = 5.2, 8.8 Hz, 1H), 7.31 (d, J=9.6 Hz, 1H), 5.58 (br s, 1H).

[01271] Step 2: (2-fluoro-1-naphthyl) trifluoromethanesulfonate. To a solution of 2-fluoronaphthalen-1-ol (400 mg, 2.47 mmol, 1 *eq*) in DCM (10 mL) was added Tf_2O (765 mg,

2.71 mmol, 448 uL, 1.1 *eq*) and DIEA (637 mg, 4.93 mmol, 859 uL, 2 *eq*) at 0 °C. After stirred at 0 °C for 1 hour, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (20 mL × 3). The combined organic layer was washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 50/1 to 3/1). Compound (2-fluoro-1-naphthyl) trifluoromethanesulfonate (500 mg, 1.65 mmol, 67% yield, 97% purity) was obtained as a colorless oil.

[01272] ^{1}H NMR (400MHz, chloroform-d) δ = 8.07 (d, *J* = 8.4 Hz, 1H), 7.95 - 7.85 (m, 2H), 7.70 (t, *J* = 7.6 Hz, 1H), 7.62 - 7.54 (m, 1H), 7.41 (t, *J* = 9.2 Hz, 1H).

[01273] Step A: *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro- 1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of (2-fluoro-1-naphthyl) trifluoromethanesulfonate (243 mg, 827 umol, 1.3 *eq*), *tert*-butyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 636 umol, 1 *eq*), Cs_2CO_3 (518 mg, 1.59 mmol, 2.5 *eq*), RuPhos (59.4 mg, 127 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (116 mg, 127 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 3 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted PH = 7 by adding saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Compound *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro- 1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 155 umol, 25% yield, 96% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 616.

[01274] ^{1}H NMR (400MHz, chloroform-d) δ = 8.33 (br s, 1H), 7.84 (d, *J* = 7.76 Hz, 1H), 7.75-7.64 (m, 1H), 7.57 - 7.41 (m, 2H), 7.25-7.21 (m, 1H), 4.63 (br s, 1H), 4.47 - 4.16 (m, 4H),

4.13 - 3.82 (m, 4H), 3.61 - 3.25 (m, 3H), 3.20 - 2.90 (m, 4H), 2.81 - 2.56 (m, 4H), 2.49 (s, 3H), 2.38 - 2.19 (m, 1H), 2.14 - 2.06 (m, 1H), 1.88-1.69 (m, 2H), 1.53 (s, 9H).


[01275] Step B: 2-[4-[7-(2-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[7-(2-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 162 umol, 1 *eq*) in DCM (200 uL) was added TFA (278 mg, 2.44 mmol, 180 uL, 15 *eq*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under vacuum. Compound 2-[4-[7-(2-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (102 mg, 162 umol, 100% yield, TFA) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]: 516.

[01276] Step C: 2-[4-[7-(2-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[7-(2-fluoro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (102 mg, 197 umol, 1 *eq*, TFA) in DCM (2 mL) was added TEA (200 mg, 1.98 mmol, 275 uL, 10 *eq*) at 0 °C. After addition, the prop-2-enoyl prop-2-enoate (19.9 mg, 158 umol, 0.8 *eq*) in DCM (1 mL) was added dropwise at 0°C. After stirred at 25 °C for 1 hour, the reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL) and diluted with water (20 mL), extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 52% - 82%, 12 min). Title compound 2-[4-[7-(2-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 311, 11 mg, 18.9 umol, 9.6% yield, 98% purity) was obtained after lyophilization as a white solid. LCMS [ESI, M+1]: 570.


[01277] SFC condition: "OD-3S_3_40_3ML Column: Chiralcel OD-3 100×4.6mm I.D., 3um Mobile phase: 40% methanol (0.05% DEA) in CO_2 Flow rate: 3mL/min Wavelength: 220nm".

[01278] ^{1}H NMR (400MHz, chloroform-d) δ = 8.34 (br s, 1H), 7.84 (d, *J* = 8.0 Hz, 1H), 7.69 (dd, *J* = 4.4, 8.8 Hz, 1H), 7.52 (t, *J* = 7.2 Hz, 1H), 7.47 (t, *J* = 6.8 Hz, 1H), 7.29-7.25 (m, 1H), 6.65-6.50 (m, *J* = 10.5 Hz, 1H), 6.40 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.11 (br s, 1H), 4.65 (s, 1H), 4.43 - 3.85 (m, 7H), 3.81 - 3.30 (m, 3H), 3.24 - 2.95 (m, 3H), 2.94 - 2.56 (m, 4H), 2.47 (s, 3H), 2.36 - 2.20 (m, 1H), 2.13 - 1.97 (m, 1H), 1.93 - 1.75 (m, 3H).

EXAMPLE 312



2-[4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01279] Step A: methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxypyrrolidine-2-carboxylate. To a solution of methyl (2*S*,4*R*)-4-hydroxypyrrolidine-2-carboxylate (10 g, 55.1 mmol, 1 eq, HCl) in ethyl acetate (10 mL) were added imidazole (7.50 g, 110 mmol, 2 eq) and TBDPSCl (16.7 g, 60.6 mmol, 15.6 mL, 1.1 eq). The mixture was stirred at 25 °C for 16 hours. The precipitate was filtered off. The filtrate was concentrated under reduced pressure and the residue was dissolved with ethyl acetate (200 mL) and water (100 mL). The organic phase was washed with brine (1 × 100 mL), dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 10/1 to 1/1). The desired fractions were collected and concentrated under vacuum to give methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxypyrrolidine-2-carboxylate (2.9 g, 7.41 mmol, 13% yield, 98% purity) as a colorless oil. LCMS [ESI, M+1]: 384.

[01280] ^{1}H NMR (400MHz, chloroform-d) δ = 7.64 (dt, *J* = 1.2, 7.2 Hz, 4H), 7.47 - 7.35 (m, 6H), 4.40 (td, *J* = 2.4, 4.8 Hz, 1H), 4.07 (t, *J* = 8.0 Hz, 1H), 3.70 (s, 3H), 3.03 - 2.96 (m, 1H), 2.96 - 2.89 (m, 1H), 2.17 - 2.07 (m, 1H), 1.84 - 1.77 (m, 1H), 1.07 (s, 9H).

[01281] Step B: methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxy-1-methyl-pyrrolidine-2-carboxylate. To a solution of methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxypyrrolidine-2-carboxylate (2.7 g, 7.04 mmol, 1 eq) and formaldehyde (37% aqueous, 2.86 g, 35.2 mmol, 2.62 mL, 5 eq) in MeOH (20 mL) was added CH_3COOH (423 mg, 7.04 mmol, 403 uL, 1 eq) and $NaBH_3CN$ (1.77 g, 28.2 mmol, 4 eq). The mixture was stirred at 25 °C for 1 hr. The mixture was diluted with ethyl acetate (200 mL) and washed with water (2 × 100 mL) and brine (1 × 100 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 20/1 to 3/1). The desired fractions were collected and concentrated under vacuum to give methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxy-1-methyl-pyrrolidine-2-carboxylate (2.4 g, 5.71 mmol, 81% yield, 94.6% purity) as a colorless oil. LCMS [ESI, M+1]: 398.

[01282] ^{1}H NMR (400MHz, chloroform-d) δ = 7.63 (ddd, *J* = 1.2, 4.0, 7.6 Hz, 4H), 7.46 - 7.32 (m, 6H), 4.47 - 4.39 (m, 1H), 3.71 (s, 3H), 3.32 (t, *J* = 8.4 Hz, 1H), 3.24 (dd, *J* = 6.0, 9.6 Hz, 1H), 2.43 - 2.40 (m, 1H), 2.40 (s, 3H), 2.23 - 2.00 (m, 2H), 1.07 (s, 9H).

[01283] Step C: [(2*S*, 4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methanol. To a solution of methyl (2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidine-2-carboxylate (2.20 g, 5.53 mmol, 1.00 eq) in THF (40 mL) was added $LiAlH_4$ (840 mg, 22.1 mmol, 4.00 eq) at 0 °C. The mixture was stirred at 0 °C for 1 hour. The mixture was quenched with water (1.00 mL), sodium hydroxide solution (15.0 %, 2.00 mL) and water (3.00 mL). The precipitate was filtered off and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10) to give [(2*S*, 4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methanol (1.70 g, 4.55 mmol, 82% yield) as a colorless oil. LCMS [ESI, M+1]: 370.

[01284] ^{1}H NMR (400MHz, chloroform-d) δ = 7.68 - 7.61 (m, 4H), 7.46 - 7.35 (m, 6H), 4.35 - 4.26 (m, 1H), 3.62 (dd, *J* = 3.2, 10.8 Hz, 1H), 3.34 (dd, *J* = 2.0, 10.8 Hz, 1H), 3.14 (dd, *J* =

5.6, 10.0 Hz, 1H), 2.78 - 2.70 (m, 1H), 2.43 (dd, *J* = 6.0, 9.6 Hz, 1H), 2.33 (s, 3H), 2.02 - 1.93 (m, 1H), 1.92 - 1.84 (m, 1H), 1.06 (s, 9H).

[01285] Step D: *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl (diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl 2-(cyanomethyl)-4-[2-methylsulfinyl -7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.30 g, 531 umol, 1.00 eq) and [(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1- methyl-pyrrolidin-2-yl]methanol (295 mg, 797 umol, 1.50 eq) in THF (5 mL) was added *t*-BuONa (102 mg, 1.06 mmol, 2.00 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the mixture was adjusted to pH = 7 by HCl solution (1.00 M, 0.40 mL) and extracted with ethyl acetate (3 × 10.0 mL). The organic layers were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, petroleum ether/ethyl acetate = 1/3) to give *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl (diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.22 g, 238 umol, 45 % yield) as a white solid. LCMS [ESI, M+1]: 870.

[01286] ^{1}H NMR (400MHz, chloroform-d) δ = 7.68 (br d, *J* = 8.0 Hz, 1H), 7.66 - 7.61 (m, 4H), 7.57 (br t, *J* = 7.2 Hz, 1H), 7.44 - 7.34 (m, 7H), 7.33 - 7.28 (m, 1H), 4.61 (br s, 1H), 4.45 - 4.28 (m, 2H), 4.09 - 3.95 (m, 4H), 3.87 (br d, *J* = 12.8 Hz, 1H), 3.28 - 3.15 (m, 4H), 3.10 (ddd, *J* = 3.6, 7.2, 12.0 Hz, 2H), 3.02 - 2.93 (m, 1H), 2.88 - 2.67 (m, 4H), 2.48 (s, 3H), 2.45 - 2.34 (m, 2H), 2.14 - 2.07 (m, 1H), 1.94 - 1.80 (m, 1H), 1.52 (s, 9H), 1.06 (s, 9H).

[01287] Step E: 2-[4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl) silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.08 g, 91.9 umol, 1.00 eq) and TFA (157 mg, 1.38 mmol, 102 uL, 15.0 eq) in dichloromethane (150 uL) was stirred at 10 °C for 1 hour. The mixture was concentrated under vacuum to give 2-[4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-

dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (81.3 mg, crude, TFA) as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 770.


[01288] Step F: 2-[4-[2-[[(2*S*,4*R*)-4- [*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.08 g, crude, TFA) and Et_3N (91.6 mg, 905 umol, 125.96 uL) in dichloromethane (2.00 mL) was added prop-2-enoyl prop-2-enoate (11.4 mg, 90.5 umol) at -40 °C. After stirred at 20 °C for 0.5 h, the mixture was quenched with water (0.20 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10). The desired fractions were collected and concentrated under vacuum to give 2-[4-[2-[[(2*S*,4*R*)-4- [*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.06 g, 65.5 umol, two steps 72 % yield) as a yellow oil. LCMS [ESI, M/2+1]: 412.

[01289] Step G: 2-[4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl) phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A mixture of 2-[4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl] oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.05 g, 60.7 umol, 1.00 eq) and TBAF (1.00 M, 607 uL, 10.0 eq) in THF (0.50 mL) was stirred at 20 °C for 1 hour. The mixture was concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, ethyl acetate/methanol = 3/1) and reversed phase flash [water (FA, 0.10 %)/acetonitrile], then further purified by prep-HPLC column: Boston pH-lex 150*25 10um; mobile phase: [water(0.10%, TFA) - ACN]; B%: 31%-61%,10 min and column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05 % ammonia hydroxide v/v)- ACN]; B%: 42% - 72%, 12 min. The desired fractions were collected and lyophilized to give title compound 2-[4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl) phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile


(EXAMPLE 312, 3.70 mg, 6.30 umol, 10 % yield, 99.7 % purity) as a white solid. LCMS [ESI, M+1]: 586.

[01290] ^{1}H NMR (400MHz, chloroform-d) δ = 7.69 (d, *J* = 8.0 Hz, 1H), 7.58 (t, *J* = 8.0 Hz, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 7.30 (t, *J* = 8.0 Hz, 1H), 6.57 (br d, *J* = 10.8 Hz, 1H), 6.39 (dd, *J* = 1.6, 16.4 Hz, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.06 (br s, 1H), 4.49 - 4.42 (m, 1H), 4.37 (ddd, *J* = 3.2, 4.8, 10.8 Hz, 1H), 4.25 - 4.17 (m, 1H), 4.15 - 4.06 (m, 3H), 3.97 (br d, *J* = 10.8 Hz, 1H), 3.60 (br s, 1H), 3.43 (dd, *J* = 6.0, 10.0 Hz, 1H), 3.33 (br s, 1H), 3.23 - 3.16 (m, 1H), 3.15 - 3.06 (m, 2H), 3.04 - 2.89 (m, 3H), 2.88 - 2.66 (m, 4H), 2.48 (s, 3H), 2.33 (dd, *J* = 6.0, 10.0 Hz, 1H), 2.13 - 1.93 (m, 2H).

EXAMPLE 313



2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01291] Step A: 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane. To a solution of 4-bromo-5-(trifluoromethyl)-1*H*-indazole (1 g, 3.77 mmol, 1 *eq*) in DMF (45 mL) was added NaH (181 mg, 4.53 mmol, 60.0 % purity, 1.2 *eq*) at 0 °C. After being stirred at 0 °C for 1 hour, a solution of SEM-Cl (818 mg, 4.91 mmol, 868 uL, 1.3 *eq*) in DMF (15 mL) was added dropwise. The mixture was warmed to 20 °C and stirred for 1 hour. The mixture was quenched with saturated aqueous ammonium chloride solution (50 mL), diluted with water (100 mL) and then extracted with ethyl acetate (2 × 50 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 100:1) to give 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (430 mg, 1.03 mmol, 27.4 % yield, 95.0 % purity) as a colorless oil.

[01292] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.18 (s, 1H), 7.74 - 7.66 (m, 1H), 7.63 - 7.56 (m, 1H), 5.76 (s, 2H), 3.59 - 3.49 (m, 2H), 0.93 - 0.86 (m, 2H), -0.01 - -0.08 (m, 9H).

[01293] Step B: *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To the solution of *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (3.59 g, 8.36 mmol, 1 *eq*), 2-piperazin-2-ylacetonitrile (Intermediate 62, 1.99 g, 10.0 mmol, 1.2 *eq*, 2HCl) in DMF (30 mL) was added DIEA (2.16 g, 16.7 mmol, 2.91 mL, 2 *eq*), then the mixture was heated to 80 °C and stirred at 80 °C for 2 hours. Water (80 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (20 mL) and extracted with EtOAc (5 × 60 mL). The combined organic layers were washed with brine (80 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1 % FA) = 40 %) to give *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.37 g, 5.27 mmol, 63.1 % yield, 90.0 % purity) as a brown solid. LCMS [ESI, M+1]: 405.

[01294] Step C: *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To the solution of *tert*-butyl 4-[3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.37 g, 5.86 mmol, 1 *eq*), $NaHCO_3$ (1.48 g, 17.6 mmol, 684 uL, 3 *eq*) in EtOAc (30 mL) and Water (15 mL) was added CbzCl (2.00 g, 11.7 mmol, 1.67 mL, 2 *eq*) dropwise, then the mixture was stirred at 25 °C for 13 hours. The mixture was diluted with EtOAc (15 mL) and extracted with EtOAc (2 × 15 mL). The combined organic layers were washed with brine (15 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc=20:1~0:1) to give *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.91 g, 5.13 mmol, 87.6 % yield, 95.0 % purity) as a yellow solid. LCMS [ESI, M+1]: 539.

[01295] Step D: *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To the solution of *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.91 g, 5.40 mmol, 1 *eq*) in EtOAc (60 mL) and

ACN (20 mL) was added m-CPBA (1.10 g, 5.40 mmol, 85.0 % purity, 1 *eq*) at 0 °C, then the mixture was stirred at 0 °C for 1 hour. The reaction mixture was quenched by saturated $Na_2S_2O_3$ (30 mL) at 0 °C, then extracted with EtOAc (50 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% $NH_3 \cdot H_2O$) = 62 %) to give *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.65 g, 4.73 mmol, 87.6 % yield, 99.0 % purity) as a white solid. LCMS [ESI, M+1]: 555.

[01296] Step E: *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To the solution of *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (2.2 g, 3.97 mmol, 1 *eq*), [(3*R*)-1-methylpyrrolidin-3-yl]methanol (914 mg, 7.93 mmol, 2 *eq*) in toluene (44 mL) was added t-BuONa (572 mg, 5.95 mmol, 1.5 *eq*) at 0 °C, then the mixture was stirred at 0 °C for 0.5 hour. Water (15 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with brine (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 45 %) to give *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (1.64 g, 2.52 mmol, 63.5 % yield, 93.0 % purity) as a white solid. LCMS [ESI, M+1]: 605.

[01297] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.44 - 7.31 (m, 5H), 5.19 (s, 2H), 4.71 - 4.54 (m, 2H), 4.35 (br d, *J*=19.2 Hz, 1H), 4.24 - 4.16 (m, 2H), 4.11 - 3.92 (m, 2H), 3.79 (br d, *J*=12.4 Hz, 2H), 3.28 (br d, *J*=12.8 Hz, 3H), 2.98 (dt, *J*=3.2, 12.4 Hz, 1H), 2.87 - 2.44 (m, 8H), 2.36 (s, 3H), 2.12 - 2.06 (m, 1H), 1.87 (br s, 2H), 1.49 (s, 9H).

[01298] Step F: benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (1.64 g, 2.71 mmol, 1 *eq*) in

dioxane (30 mL) was added HCl/dioxane (4 M, 30 mL, 44.32 *eq*) at 0 °C, then the mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 35.5 %) to give benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (0.95 g, 1.78 mmol, 65.9 % yield, 95.0 % purity) as a white solid. LCMS [ESI, M+1]: 506.

[01299] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.43 - 7.32 (m, 5H), 5.19 (s, 2H), 4.66 (br s, 1H), 4.25 - 4.07 (m, 3H), 4.01 - 3.91 (m, 3H), 3.83 (br d, *J*=13.6 Hz, 1H), 3.38 - 3.18 (m, 2H), 3.16 - 3.07 (m, 1H), 3.03 - 2.92 (m, 2H), 2.81 (br s, 1H), 2.75 - 2.65 (m, 3H), 2.60 (br d, *J*=5.6 Hz, 3H), 2.55 - 2.45 (m, 2H), 2.36 (s, 3H), 2.14 - 1.97 (m, 1H), 1.68 - 1.54 (m, 2H).

[01300] Step G: benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (510 mg, 1.01 mmol, 1 *eq*), 2-[[4-bromo-5-(trifluoromethyl)indazol-1-yl]methoxy]ethyl-trimethyl-silane (399 mg, 1.01 mmol, 1 *eq*), RuPhos (188 mg, 403 umol, 0.4 *eq*) and Cs_2CO_3 (986 mg, 3.03 mmol, 3 *eq*) in toluene (10 mL) was added $Pd_2(dba)_3$ (185 mg, 202 umol, 0.2 *eq*) under N2, the suspension was degassed under vacuum and purged with N_2 several times. The mixture was warmed to 90 °C and stirred at 90 °C for 14 hours. The reaction mixture filtered, the filter cake was washed with EtOAc (2 × 15 mL). The filtrate was concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 55 %) to give benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (365 mg, 423 umol, 41.9 % yield, 95.0 % purity) as a brown solid. LCMS [ESI, M+1]: 820.

[01301] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.15 (s, 1H), 7.70 (d, *J*=8.8 Hz, 1H), 7.52 (d, *J*=8.8 Hz, 1H), 7.42 - 7.33 (m, 5H), 5.76 (s, 2H), 5.24 - 5.16 (m, 2H), 4.70 (br s, 1H), 4.42 - 4.27 (m, 2H), 4.21 (br d, *J*=6.8 Hz, 2H), 4.06 (br d, *J*=10.8 Hz, 1H), 3.90 (br d, *J*=12.4 Hz, 1H), 3.61 - 3.54 (m, 2H), 3.50 - 3.38 (m, 2H), 3.31 (br d, *J*=11.6 Hz, 2H), 3.10 - 2.99 (m, 1H), 2.86

(br s, 2H), 2.81 - 2.66 (m, 4H), 2.65 - 2.57 (m, 1H), 2.56 - 2.44 (m, 2H), 2.36 (s, 3H), 2.12 - 2.06 (m, 1H), 2.04 - 1.96 (m, 1H), 1.69 - 1.56 (m, 1H), 0.95 - 0.87 (m, 2H), -0.03 - -0.10 (m, 9H).


[01302] Step H: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (6 mL) for 5 minutes. To the solution was added benzyl 2-(cyanomethyl)-4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (310 mg, 378 umol, 1 *eq*), Pd/C (150 mg, 10.0 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 28 °C for 1 hour. The mixture filtered, the filtrate was concentrated under vacuum. The residue was used to next step directly without further purification. Compound 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (165 mg, 240 umol, 63.6 % yield, 100 % purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 686.

[01303] Step I: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To the solution of 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (190 mg, 277 umol, 1 *eq*), DIEA (107 mg, 831 umol, 145 uL, 3 *eq*) in DCM (4 mL) was added prop-2-enoyl prop-2-enoate (41.9 mg, 332 umol, 1.2 *eq*) at 0 °C, then the mixture was stirred at 28 °C for 1 hour. The reaction mixture was quenched by Water (1 mL) and extracted with DCM (3 × 4 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was used to next step directly without further purification. Compound 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (230 mg, 233 umol, 84.2 % yield, 75.0 % purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 740.


[01304] Step J: 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To the solution of 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1-(2-trimethylsilylethoxymethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (220 mg, 297 umol, 1 *eq*) in DCM (1 mL) was added TFA (1.70 g, 14.9 mmol, 1.10 mL, 50 *eq*) , the mixture was stirred at 28 °C for 1hour. The reaction mixture was basified by saturated $NaHCO_3$ (12 mL) to PH=8. The resulting mixture was extracted with DCM: MeOH (10:1) (3 × 15 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (EtOAc: MeOH=100:1~10:1), then the residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 44%-74%,12min) to give 2-[4-[2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-7-[5-(trifluoromethyl)-1*H*-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 313, 1.23 mg, 2.01 umol, 6.74e-1% yield, 99.4 % purity) as a white solid. LCMS [ESI, M+1]: 610.

[01305] ^{1}H NMR (400 MHz, methanol-d_4) δ = 8.38 (s, 1H), 7.70 (d, *J*=8.8 Hz, 1H), 7.57 (d, *J*=8.8 Hz, 1H), 6.84 (br s, 1H), 6.31 (br d, *J*=16.8 Hz, 1H), 5.86 (br d, *J*=10.8 Hz, 1H), 5.13 (br s, 1H), 4.62 (br s, 1H), 4.37 - 4.20 (m, 5H), 4.14 (br d, *J*=11.6 Hz, 1H), 3.64 (br s, 1H), 3.50 (br d, *J*=4.8 Hz, 2H), 3.41 - 3.34 (m, 1H), 3.29 - 3.16 (m, 2H), 3.03 (br d, *J*=6.4 Hz, 1H), 2.94 (br s, 2H), 2.88 - 2.80 (m, 1H), 2.80 - 2.72 (m, 1H), 2.69 (br t, *J*=6.8 Hz, 2H), 2.58 - 2.51 (m, 1H), 2.43 (s, 3H), 2.17 - 2.06 (m, 1H), 1.75 - 1.64 (m, 1H).

EXAMPLE 314



2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01306] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl(2*S*)-2-(cyanomethyl) -4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 900 mg, 1.78 mmol, 1.0 *eq*), $Pd_2(dba)_3$ (245 mg, 267 umol, 0.15 *eq*), RuPhos (166 mg, 356 umol, 0.20 *eq*) and Cs_2CO_3 (1.16 g, 3.56 mmol, 2.0 *eq*) in toluene (10.0 mL) was added (3-methoxy-1-naphthyl) trifluoromethanesulfonate (Intermediate 30, 1.09 g, 3.56 mmol, 2.0 *eq*). The mixture was stirred at 100 °C for 5 hours. After completion, the mixture was added water (20.0 mL) and extracted with EA (20 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE : EA = 10:1 - EA : MeOH = 10:1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.0 g, 1.42 mmol, 79% yield, 93.8% purity) as yellow solid.


[01307] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.08 (d, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.48 - 7.32 (m, 7H), 6.91 (d, *J* = 2.0 Hz, 1H), 6.80 (d, *J* = 2.0 Hz, 1H), 5.27 - 5.15 (m, 2H), 4.70 (br s, 1H), 4.51 - 4.33 (m, 1H), 4.30 - 4.03 (m, 5H), 3.94 - 3.87 (m, 3H), 3.53 - 3.40 (m, 1H), 3.32 (br d, *J* = 12.4 Hz, 3H), 3.16 (br t, *J* = 7.6 Hz, 1H), 3.06 (dt, *J* = 3.6, 12.6 Hz, 1H), 2.97 - 2.72 (m, 6H), 2.52 (s, 3H), 2.39 - 2.28 (m, 1H), 2.15 - 2.06 (m, 1H), 1.93 - 1.74 (m, 3H).

[01308] Step B: 2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (50.0 mL) at -60 °C for 30 minutes. Then benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.0 g, 1.51 mmol, 1.0 eq) and Pd/C (1.0 g, 10% purity) was added to the above liquid under N_2 atmosphere. The suspension was degassed and purged with H_2 for 3 times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 2 hours. After completion, the mixture was filtered with Celite and concentrated under vacuum. The product 2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (600 mg, crude) as yellow oil. LCMS [ESI, M+1]: 528.


[01309] Step C: 2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (600 mg, 1.14 mmol, 1.0 *eq*) and DIEA (882 mg, 6.82 mmol, 1.19 mL, 6.0 *eq*) in DCM (6.0 mL) was added prop-2-enoyl prop-2-enoate (143 mg, 1.14 mmol, 1.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (100 mg) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 52%-80%, 12min). to give the title compound 2-[(2*S*)-4-[7-(3-methoxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 314, 90.5 mg, 155 umol, 14.0% yield, 99.5% purity) as white solid. LCMS [ESI, M+1]: 582.

[01310] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.09 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.45 (t, J = 7.2 Hz, 1H), 7.36 (t, J = 7.6 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 6.68 - 6.53 (m, 1H), 6.41 (dd, J = 1.6, 16.8 Hz, 1H), 5.84 (br d, J = 10.4 Hz, 1H), 5.19 - 4.50 (m, 1H), 4.40 (dd, J = 4.8, 10.4 Hz, 1H), 4.31 - 4.08 (m, 4H), 4.07 - 3.85 (m, 5H), 3.79 - 3.41 (m, 2H), 3.41 - 3.22 (m, 2H), 3.20 - 3.04 (m, 2H), 3.02 - 2.75 (m, 4H), 2.72 - 2.65 (m, 1H), 2.49 (s, 3H), 2.33 - 2.24 (m, 1H), 2.11 - 2.01 (m, 1H), 1.90 - 1.71 (m, 3H).

EXAMPLE 315



2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01311] Step A: benzyl (2*S*)-4-[2-[[(2*S*,4*R*) -4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl -7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 0.90 g, 1.55 mmol, 1.00 eq) and [(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin -2-yl]methanol (687 mg, 1.86 mmol, 1.20 eq) in THF (20.0 mL) was added *t*-BuONa (298 mg, 3.10 mmol, 2.00 eq) at 0 °C. After stirred at 25 °C for 1 hour, the mixture was diluted with ethyl acetate (50.0 mL), washed with water (30.0 mL) and brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10) to give benzyl (2*S*)-4-[2-[[(2*S*,4*R*) -4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.90 g, 873 umol, 56 % yield) as a yellow solid. LCMS [ESI, M/2+1]: 443.

[01312] ^{1}H NMR (400MHz, chloroform-d) δ = 8.24 - 8.18 (m, 1H), 7.90 - 7.83 (m, 1H), 7.71 - 7.57 (m, 5H), 7.53 - 7.47 (m, 2H), 7.45 - 7.35 (m, 12H), 7.14 (br d, *J* = 7.6 Hz, 1H), 5.21 (s, 2H), 4.68 (br s, 1H), 4.43 - 4.36 (m, 1H), 4.33 (br dd, *J* = 4.8, 10.8 Hz, 1H), 4.26 (br s, 2H),

4.16 - 4.03 (m, 3H), 3.93 (br d, J = 12.8 Hz, 1H), 3.47 (br s, 1H), 3.30 (br d, J = 10.4 Hz, 3H), 3.17 (br dd, J = 6.0, 10.0 Hz, 1H), 3.11 - 2.96 (m, 3H), 2.84 (br s, 2H), 2.78 - 2.70 (m, 1H), 2.48 - 2.37 (m, 4H), 2.11 (ddd, J = 4.8, 8.4, 12.8 Hz, 1H), 1.96 - 1.82 (m, 1H), 1.06 (s, 9H).

[01313] Step B: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in methanol (50 mL) at -60 °C for 0.5 h. To the mixture was added benzyl (2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl- pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.90 g, 1.02 mmol, 1.00 eq) and Pd/C (0.10 g, 10.0 % purity). After stirred at 20 °C for 1 hour under H_2 at 15 psi, the mixture was filtered and concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (763 mg, crude) as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 752.

[01314] Step C: 2-[(2*S*)-4-[2-[[(2*S*,4*R*) -4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl) silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.76 g, crude) and Et_3N (511 mg, 5.05 mmol, 703 uL) in dichloromethane (5.00 mL) was added prop-2-enoyl prop-2-enoate (127 mg, 1.01 mmol) at -40 °C. After stirred at 20 °C for 1 hour, the mixture was quenched with saturated sodium bicarbonate (0.20 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10) to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*) -4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.50 g, 552 umol, two steps 55% yield) as a yellow oil. LCMS [ESI, M+1]: 806.

[01315] ^{1}H NMR (400MHz, chloroform-d) δ = 8.25 - 8.17 (m, 1H), 7.90 - 7.82 (m, 1H), 7.68 - 7.58 (m, 5H), 7.50 (td, J = 2.4, 5.2 Hz, 2H), 7.46 - 7.35 (m, 7H), 7.14 (d, J = 7.6 Hz, 1H), 6.67 - 6.51 (m, 1H), 6.46 - 6.31 (m, 1H), 5.83 (br d, J = 10.8 Hz, 1H), 5.08 (br s, 1H), 4.43 - 4.31 (m, 2H), 4.27 (br s, 2H), 4.16 - 4.00 (m, 4H), 3.67 - 3.55 (m, 1H), 3.46 (br s, 1H), 3.31 (br dd, J


= 8.4, 14.4 Hz, 2H), 3.17 (br dd, *J* = 6.0, 9.6 Hz, 1H), 3.11 - 2.73 (m, 6H), 2.47 (s, 3H), 2.42 (br dd, *J* = 6.0, 9.6 Hz, 1H), 2.11 (tt, *J* = 4.0, 8.4 Hz, 1H), 1.96 - 1.84 (m, 1H), 1.06 (s, 9H).

[01316] Step D: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A mixture of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.40 g, 496 umol, 1.00 eq), KF (57.7 mg, 992 umol, 23.3 uL, 2.00 eq) and 18-crown-6 (262 mg, 992 umol, 2.00 eq) in THF (10.0 mL) was stirred at 30 °C for 24 hours. The mixture was concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)/acetonitrile]. The desired fractions were adjust pH > 7 by saturated sodium bicarbonate (2.00 mL) and extracted with ethyl acetate (3 × 30.0 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05 % ammonia hydroxide v/v) - ACN]; B%: 37 % - 67 %,12 min). The desired fractions were concentrated and lyophilized to give title compound 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 315, 51.5 mg, 90.7 umol, 18 % yield, 96.3 % purity) as a white solid. LCMS [ESI, M+1]: 568.


[01317] SFC: "AS-3S_3_5_40_3ML Column: Chiralpak AS - 3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05 %, DEA) in CO_2 from 5 % to 40 % Flow rate: 3 mL/min Wavelength: 220nm".

[01318] ^{1}H NMR (400MHz, chloroform-d) δ = 8.26 - 8.17 (m, 1H), 7.91 - 7.83 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.55 - 7.48 (m, 2H), 7.44 (t, *J* = 8.0 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 6.59 (br s, 1H), 6.47 - 6.36 (m, 1H), 5.84 (br d, *J* = 10.8 Hz, 1H), 5.11 (br s, 1H), 4.52 - 4.43 (m, 1H), 4.39 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.34 - 4.20 (m, 3H), 4.15 (br d, *J* = 14.0 Hz, 1H), 4.02 (br d, *J* = 12.0 Hz, 2H), 3.61 (br s, 1H), 3.53 - 3.41 (m, 2H), 3.34 (br s, 2H), 3.12 (br s, 1H), 3.05 - 2.89 (m, 3H), 2.88 - 2.66 (m, 2H), 2.50 (s, 3H), 2.34 (dd, *J* = 5.6, 10.0 Hz, 1H), 2.16 - 1.94 (m, 2H).

EXAMPLE 316



2-((*S*)-1-acryloyl-4-(7-(4-fluoronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01319] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2 -[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 1.0 g, 1.98 mmol, 1.0 *eq*) and 1-bromo-4-fluoro-naphthalene (2.23 g, 9.89 mmol, 5.0 *eq*) in toluene (20.0 mL) was added Cs_2CO_3 (1.93 g, 5.93 mmol, 3.0 *eq*), XPhos-Pd-G3 (335 mg, 396 umol, 0.2 *eq*), the reaction mixture was stirred at 70 °C for 24 hours under N_2.

After completion, the reaction was added water (20.0 mL), extracted with EA (2 × 20.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate: Methanol=20:1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2 -[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (680 mg, 957 umol, 48% yield, 91.4% purity) as white solid. LCMS [ESI, M+1]: 650.


[01320] Step B: 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1 -methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 1.0 mmol, 1.0 *eq*) in MeOH (15 mL) was added NH_3•MeOH (1.0 mmol, 15.0 mL, 1.0 *eq*) and Pd/C (500 mg, 10% purity), the suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 0.5 hour. After completion, the reaction was filtered through a Celite, and the filtrate was concentrated to give 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1 -methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (460 mg, 824 umol, 82% yield, 92.4% purity) as white solid which was used for the next step without further purification. LCMS [ESI, M+1]: 516.

[01321] Step C: 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (460 mg, 892 umol, 1.0 *eq*) in DCM (10 mL) was added DIEA (461 mg, 3.57 mmol, 622 uL, 4.0 *eq*) and prop-2-enoyl prop-2-enoate (113 mg, 892 umol, 1.0 *eq*) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5.0 mL), and concentrated. The residue was purified by prep-HPLC ((Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 53% - 83%, 12 min), the obtained product was concentrated and then under lyophilization. The title compound 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-


dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 316, 100 mg, 175 umol, 20% yield, 100% purity) was obtained as white solid. LCMS [ESI, M+1]: 570.

[01322] ^{1}H NMR (400 MHz, chloroform-d) δ 8.28 - 8.22 (m, 1H), 8.17 - 8.10 (m, 1H), 7.63 - 7.55 (m, 2H), 7.14 - 7.05 (m, 2H), 6.70 - 6.55 (m, 1H), 6.42 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.86 (br d, *J* = 10.4 Hz, 1H), 5.20 - 4.48 (m, 1H), 4.41 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.33 - 4.10 (m, 4H), 4.09 - 3.92 (m, 2H), 3.78 - 3.20 (m, 4H), 3.19 - 3.07 (m, 2H), 3.05 - 2.64 (m, 5H), 2.50 (s, 3H), 2.36 - 2.25 (m, 1H), 2.13 - 2.02 (m, 1H), 1.92 - 1.73 (m, 3H).

EXAMPLE 317



2-((*S*)-1-acryloyl-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01323] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(2,2- dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 880 mg, 1.87 mmol, 1.0 *eq*) and (4-bromo-2-naphthyl)2,2-dimethylpropanoate (Intermediate 54, 745 mg, 2.43 mmol, 1.3 *eq*) in toluene (20.0 mL) was added Cs_2CO_3 (1.22 g, 3.73 mmol, 2.0 *eq*), RuPhos (174 mg, 373 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (171 mg, 187 umol, 0.1 *eq*), the mixture was stirred at 90 °C for 12 hours under N_2. After completion, the reaction mixture was added water (30 mL), then extracted with EA (2 × 20mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate: Methanol=20/1) to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(2,2- dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (750 mg, 774 umol, 41% yield, 72.9% purity) as brown solid. LCMS [ESI, M+1]: 698.

[01324] Step B: [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(2,2-

dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (750 mg, 774 umol, 1.0 *eq*) in DCM (5.0 mL) was added TFA (7.70 g, 67.5 mmol, 5.0 mL, 87.3 *eq*), the reaction mixture was stirred at 20 °C for 1 hour. After completion, the reaction was concentrated to give [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (550 mg, crude, TFA) as brown oil which was used for the next step without further purification. LCMS [ESI, M+1]: 598.


[01325] Step C: [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl- piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate. To a mixture of [4-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl] 2,2-dimethylpropanoate (550 mg, 773 umol, 1.0 *eq*, TFA) in DCM (5 mL) was added TEA (469 mg, 4.64 mmol, 645 uL, 6.0 *eq*) and prop-2-enoyl prop-2-enoate (97.5 mg, 773 umol, 1.0 *eq*) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5.0 mL), and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate/Methanol=10/1) to give [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl- piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate (270 mg, 323 umol, 42% yield, 78.2% purity) as yellow solid. LCMS [ESI, M+1]: 652.

[01326] Step D: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of [4-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]-2-naphthyl]2,2-dimethylpropanoate (270 mg, 323 umol, 1.0 *eq*) in THF (2.0 mL) was added a solution of NaOH (38.8 mg, 969 umol, 3.0 *eq*) in H_2O (2.0 mL), the reaction mixture was stirred at 20 °C for 4 hours. After completion, the reaction mixture was added water (10 mL), then extracted with EA (2 × 10mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex Luna Phenyl-Hexyl 150_30_5um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 35% - 62%, 3min), the obtained product was concentrated, and then under lyophilization. The title


compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 317, 26.6 mg, 46.3 umol, 14% yield, 98.8% purity) was obtained as pink solid. LCMS [ESI, M+1]: 568.

[01327] ^{1}H NMR (400 MHz, chloroform-d) δ 8.01 - 7.93 (m, 1H), 7.64 (br d, J = 8.4 Hz, 1H), 7.41 (br t, J = 7.2 Hz, 1H), 7.33 - 7.29 (m, 2H), 6.88 (s, 1H), 6.66 - 6.50 (m, 2H), 6.39 (br d, J = 16.4 Hz, 1H), 5.84 (br d, J = 10.8 Hz, 1H), 5.04 - 4.89 (br s, 1H), 4.64 - 4.49 (m, 1H), 4.32 - 4.21 (m, 1H), 4.11 (br s, 2H), 4.00 (br d, J = 14.0 Hz, 1H), 3.94 - 3.71 (m, 2H), 3.47 - 3.08 (m, 4H), 2.93 - 2.61 (m, 10H), 2.47 - 2.33 (m, 1H), 2.25 - 2.06 (m, 1H), 2.00 - 1.89 (m, 3H).

EXAMPLE 318



2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01328] Step A: *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate. To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (Intermediate 64, 500 mg, 901 umol, 1.00 *eq*) and [(2*R*)-1-methylpyrrolidin-2-yl]methanol (208 mg, 1.80 mmol, 2.00 *eq*) in toluene (10.0 mL) was added *t*-BuONa (173 mg, 1.80 mmol, 2.00 *eq*). The mixture was stirred at 0 °C for 10 minutes. Upon completion, the mixture was diluted with water (5 mL) and extracted with EtOAc (2 × 30 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1 % FA)/acetonitrile]. The pH was adjusted to 7 with saturated sodium bicarbonate solution and the mixture was extracted with ethyl acetate (2 × 30 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (340 mg, 505 umol, 56% yield, 90.0 % purity) as a yellow solid.

[01329] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.45 - 7.32 (m, 5H), 5.28 - 5.12 (m, 2H), 4.70 - 4.55 (m, 2H), 4.42 - 4.29 (m, 2H), 4.15 - 3.93 (m, 3H), 3.90 - 3.75 (m, 2H), 3.43 - 3.16 (m,

3H), 3.09 (br t, *J* = 7.6 Hz, 1H), 2.98 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.89 - 2.54 (m, 5H), 2.47 (s, 3H), 2.33 - 2.22 (m, 1H), 2.05 - 1.96 (m, 1H), 1.90 - 1.74 (m, 3H), 1.49 (s, 9H).

[01330] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (340 mg, 561 umol, 1.00 *eq*) in dioxane (4.00 mL) was added HCl/dioxane (4 M, 4.00 mL) at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum. The pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution and the mixture was extracted with the mixed solvent (DCM/i-PrOH 2/1, 2 × 9 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (255 mg, 444 umol, 79% yield, 88.0% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 506.

[01331] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 366 umol, 1.00 *eq*), 1-bromo-4-fluoro-naphthalene (247 mg, 1.10 mmol, 3.00 *eq*), RuPhos (68.2 mg, 146 umol, 0.40 *eq*), *t*-BuONa (87.8 mg, 914 umol, 2.50 *eq*) and $Pd_2(dba)_3$ (66.9 mg, 73.1 umol, 0.20 *eq*) in toluene (2.00 mL) was de-gassed and then heated to 90 °C for 15 hours under N_2. Upon completion, the mixture was concentrated under vacuum, diluted with water (3 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1 % FA)/acetonitrile]. The mixture was neutralized with saturated sodium bicarbonate solution, concentrated under vacuum to remove MeCN and extracted with ethyl acetate (3 × 30 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 175 umol, 48 % yield, 95.0 % purity) as a yellow oil.

[01332] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.23 (dd, *J* = 2.0, 4.4 Hz, 1H), 8.16 - 8.08 (m, 1H), 7.60 - 7.52 (m, 2H), 7.44 - 7.33 (m, 5H), 7.14 - 7.02 (m, 2H), 5.28 - 5.16 (m, 2H), 4.69 (br s, 1H), 4.39 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.29 - 4.14 (m, 4H), 4.07 (br s, 1H), 3.95 (br d, *J* = 12.4 Hz, 1H), 3.54 - 3.15 (m, 4H), 3.14 - 3.03 (m, 2H), 3.00 - 2.61 (m, 5H), 2.48 (s, 3H), 2.35 - 2.23 (m, 1H), 1.97 - 2.05 (m, 1H), 1.92 - 1.83 (m, 3H).

[01333] Step D: 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (5.00 mL) for 3 minutes at - 40 °C. To the solution was added a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)- 2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 185 umol, 1.00 *eq*) in MeOH (5.00 mL) and Pd/C (60.0 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The reaction was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the reaction mixture was filtered and the filtrate was concentrated to give 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, 147 umol, 79% yield, 94.6 % purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 516.


[01334] Step E: 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, 155 umol, 1.00 *eq*) and TEA (78.5 mg, 776 umol, 108 uL, 5.00 *eq*) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (19.6 mg, 155 umol, 1.00 *eq*) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction was quenched with MeOH (0.5 mL), diluted with water (2 mL) and extracted with EtOAc (2 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-TLC (EtOAc/MeOH 7/1) and prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 52% - 82%, 12 min). The desired

fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(4-fluoro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 318, 21.0 mg, 36.7 umol, 24% yield, 99.8% purity) as a white solid. LCMS [ESI, M+1]: 570.


[01335] SFC condition: OD-3S_3_40_3ML Column: Chiralcel OD-3 100×4.6mm I.D., 3um Mobile phase: 40% methanol (0.05% DEA) in CO_2, Flow rate: 3mL/min, Wavelength: 220 nm.

[01336] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.33 - 8.22 (m, 1H), 8.16 - 8.08 (m, 1H), 7.62 - 7.52 (m, 2H), 7.14 - 7.02 (m, 2H), 6.59 (br s, 1H), 6.46 - 6.36 (m, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.10 (br s, 1H), 4.87 - 4.33 (m, 2H), 4.30 - 4.10 (m, 4H), 4.09 - 3.78 (m, 2H), 3.77 - 3.23 (m, 2H), 3.22 - 2.53 (m, 8H), 2.48 (s, 3H), 2.34 - 2.23 (m, 1H), 2.13 - 2.00 (m, 1H), 1.92 - 1.76 (m, 3H).

EXAMPLE 319



2-((*S*)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((*R*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01337] Step A: benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of [(2*R*)-1-methylpyrrolidin-2-yl]methanol (1.31 g, 11.4 mmol, 3 *eq*) in THF (10 mL) was added NaH (304 mg, 7.59 mmol, 60% purity in mineral oil, 2 *eq*) at 0 °C, the mixture was stirred at 0 °C for 0.5 hour. Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (2 g, 3.79 mmol, 1 *eq*) was added into the mixture and the mixture was stirred at 80 °C for 3 hours. The reaction mixture was quenched with ice water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The desired fractions were collected and adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (1 g, 1.60 mmol, 42% yield, 97% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 606.

[01338] ^{1}H NMR (400MHz, chloroform-d) δ = 7.43 - 7.31 (m, 5H), 5.19 (s, 2H), 4.75 - 4.64 (m, 1H), 4.59 (br s, 1H), 4.44 (d, *J* = 18.8 Hz, 1H), 4.35 (br s, 1H), 4.21 - 4.11 (m, 1H), 4.07 - 3.64 (m, 4H), 3.43 (br s, 1H), 3.30-3.15 (m, 2H), 3.10 (br t, *J* = 7.6 Hz, 1H), 3.03 - 2.91 (m, 1H), 2.83 - 2.55 (m, 5H), 2.53 - 2.42 (m, 3H), 2.35 - 2.22 (m, 1H), 2.11 - 2.01 (m, 1H), 1.88 - 1.74 (m, 3H), 1.51 (s, 9H).

[01339] Step B: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. NH_3 was bubbled in MeOH (100 mL) at - 60 °C for 30 minutes. To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl] -2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (900 mg, 1.49 mmol, 1 *eq*) in above mixture was added dry Pd/C (500 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The mixture was concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 1.24 mmol, 84% yield, 90% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 472.

[01340] Step C: *tert*-Butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of 1-bromo-3-chloro-2-(trifluoromethyl)benzene (1.32 g, 5.09 mmol, 4 *eq*), *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin -2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 1.27 mmol, 1 *eq*), Cs_2CO_3 (1.04 g, 3.18 mmol, 2.5 *eq*), $Pd_2(dba)_3$ (233 mg, 254 umol, 0.2 *eq*) and RuPhos (118 mg, 254 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 3 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (30 mL), dried over

Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH = 100/1 to 10:1) and further purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted PH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. *tert*-Butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (370 mg, 569 umol, 45% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 650

[01341] ^{1}H NMR (400MHz, chloroform -d) δ = 7.40 (t, *J* = 8.0 Hz, 1H), 7.30 - 7.24 (m, 1H), 7.19 (d, *J* = 8.4 Hz, 1H), 4.61 (br s, 1H), 4.40 (br s, 1H), 4.24 - 4.14 (m, 1H), 4.13 - 3.98 (m, 4H), 3.95 - 3.80 (m, 1H), 3.39 - 2.95 (m, 6H), 2.93 - 2.62 (m, 5H), 2.52 (br s, 3H), 2.32 (br s, 1H), 2.14 - 2.05 (m, 1H), 1.85-1.71 (m, 3H), 1.52 (s, 9H).

[01342] Step D: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl) phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (370 mg, 569 umol, 1 *eq*) in DCM (700 uL) was added TFA (973 mg, 8.54 mmol, 632 uL, 15 *eq*). The mixture was stirred at 25 °C for 1 hour. The mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (377 mg, 567 umol, 99% yield, TFA) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]: 550.


[01343] Step E: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl) phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (377 mg, 567 umol, 1 eq, TFA) in DCM (5 mL) was added TEA (574 mg, 5.68 mmol, 790 uL, 10 eq) at 0 °C. After addition, the prop-2-enoyl prop-2-enoate (57.3 mg, 454 umol, 0.8 eq) in DCM (1 mL) was added dropwise at 0 °C. After stirred at 25°C

for 1 hour, the reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL). Then diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, EA/MeOH = 100/1 to 10:1) and further purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12 min). Title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 319, 95 mg, 154 umol, 27% yield, 98% purity) was obtained as a white solid after lyophilisation. LCMS [ESI, M+1]: 604.


[01344] SFC condition: "OD-3S_3_5_40_3ML Column: Chiralcel OD - 3 100 × 4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01345] ^{1}H NMR (400MHz, chloroform-d) δ = 7.40 (d, *J* = 8.0 Hz, 1H), 7.29-7.25 (m, 1H), 7.19 (d, *J* = 8.0 Hz, 1H), 6.71 - 6.51 (m, 1H), 6.45 - 6.34 (m, 1H), 5.83 (d, *J* = 10.4 Hz, 1H), 5.25-4.52 (m, 1H), 4.38 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.22 - 4.04 (m, 4H), 3.96 (br d, *J* = 11.6 Hz, 2H), 3.74 - 3.02 (m, 5H), 2.99 - 2.61 (m, 6H), 2.48 (s, 3H), 2.35 - 2.23 (m, 1H), 2.14 - 1.97 (m, 1H), 1.92 - 1.79 (m, 3H).

EXAMPLE 320



2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[01346] Step A: benzyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 300 mg, 517 umol, 1.0 *eq*), [(2*S*)-1-isopropylpyrrolidin-2-yl]methanol (148 mg, 1.03 mmol, 2.0 *eq*) in toluene (15.0 mL) was added *t*-BuONa (99.3 mg, 1.03 mmol, 2.0 *eq*) in portions at 0 °C, the reaction mixture was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0 °C for 30 min under N_2 atmosphere. After completion, the organic solvent was washed with water (10.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 20.0 mL). Combined extracts were washed with brine (50.0 mL), dried with Na_2SO_4, the solvent was then removed under vacuum. The residue was purified by reversed phase flash (C18, 0.1% FA in water, 0-60% MeCN). The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8 and then concentrated, the aqueous was extracted with ethyl acetate (3 × 20.0 mL) and the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Compound benzyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 272 umol, 53% yield, 99.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 660.


[01347] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into methanol (20.0 mL) at -60 °C for 30 minutes. Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl] methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 197 umol, 1.0 *eq*) and Pd/C (80.0 mg, 197 umol, 10% purity, 1.0 *eq*) was added to the above mixture, then the mixture was degassed and purged with H_2 for 3 times, and then the mixture was stirred at 25°C for 1 hour under H_2 atmosphere. After completion, the crude mixture was filtered through a pad of celite. The cake was washed with methanol (30.0 mL) and the filtrate was dried under high vacuum. Compound 2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (75.0 mg, 132 umol, 67% yield, 92.6% purity) was obtained as a gray solid. LCMS [ESI, M+1]: 526.

[01348] Step C: 2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 190 umol, 1.0 *eq*) in DCM (5.00 mL) was added DIEA (73.8 mg, 571 umol, 99.4 uL, 3.0 *eq*) and dropwise added prop-2-enoyl prop-2-enoate (36.0 mg, 285 umol, 1.50 *eq*) at 0 °C under N_2 atmosphere. The mixture was stirred at 0 °C for 1 hour. After completion, the reaction was quenched with water (10.0 mL). The crude mixture was extracted with ethyl acetate (3 × 15.0 mL). Combined extracts were washed with brine (30.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Luna Phenyl-Hexyl 150_30_5um; mobile phase: [water (10mM NH_4HCO_3)-ACN]; B%: 52% - 82%, 3min) and lyophilization. Title compound 2-[(2*S*)-4-[2-[[(2*S*)-1-isopropylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 320, 21.3 mg, 36.1 umol, 19% yield, 98.1% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 580.


[01349] ^{1}H NMR (400 MHz, chloroform-d) δ 8.24 - 8.21 (m, 1H), 7.89 - 7.87 (m, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.54 - 7.50 (m, 2H), 7.45 (t, *J* = 7.8 Hz, 1H), 7.16 (d, *J* = 7.2 Hz, 1H), 6.65 - 6.57 (m, 1H), 6.42 (dd, *J* = 1.8, 16.8 Hz, 1H), 5.86 (d, *J* = 10.0 Hz, 1H), 5.16 - 4.51 (m,

1H) , 4.35 - 4.22 (m, 3H), 4.15 -3.95 (m, 4H), 3.68 - 3.47 (m, 1H), 3.42 - 2.77 (m, 11H), 2.58 - 2.52 (m, 1H),1.90 - 1.75 (m, 3H), 1.17 (d, J = 6.4 Hz, 3H), 1.10 (d, J = 6.4 Hz, 3H).

EXAMPLE 321



1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one



[01350] Step A: *tert*-butyl (3*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate. The solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (2 g, 6.80 mmol, 1 *eq*), *tert*-butyl (3*S*)-3-methylpiperazine-1-carboxylate (1.50 g, 7.48 mmol, 1.1 *eq*), DIEA (1.76 g, 13.6 mmol, 2.37 mL, 2 *eq*) in NMP (40 mL) was stirred at 100 °C for 7 hours. Water (80 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (20 mL) and extracted with EtOAc (3 × 80 mL). The combined organic layers were washed with brine (40 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The mixture was filtered and the filter cake was washed with EtOAc (3 × 5 mL). The filtrate was concentrated under vacuum. The residue was triturated with (PE: EtOAc=3:1, 20 mL) and filtered and the filter cake was washed with (PE: EtOAc=3:1, 40 mL). Compound *tert*-butyl (3*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate (1.44 g, 3.14 mmol, 46.2 % yield) was obtained as a white solid. LCMS [ESI, M+1]: 458.

[01351] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.39 - 7.28 (m, 5H), 4.29 - 4.20 (m, 1H), 4.16 - 3.81 (m, 2H), 3.76 (br s, 1H), 3.73 (br s, 1H), 3.68 (s, 2H), 3.61 (d, *J* = 10.4 Hz, 2H), 3.37 - 3.28 (m, 1H), 3.11 (br s, 2H), 2.73 - 2.58 (m, 4H), 1.48 (s, 9H), 1.23 (d, *J* = 6.8 Hz, 3H).

[01352] Step B: *tert*-butyl (3*S*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate. To the solution of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (830 mg, 7.21 mmol, 855 uL, 2.5 *eq*) in THF (25 mL) was added NaH (230 mg, 5.76 mmol, 60% purity, 2 *eq*) at 0 °C and stirred at 0 °C for 0.5 hour. Then *tert*-butyl (3*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate (1.32 g, 2.88 mmol, 1 *eq*) was added to the mixture. The reaction mixture was heated to 70 °C for 12 hours in a tube under N_2. The reaction mixture was quenched by water (10 mL). The resulting mixture was diluted with EtOAc (20 mL) and extracted with EtOAc (3 × 30 mL). The combined organic layers were washed with brine (30 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 40 %) to give *tert*-butyl (3*S*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (1.35 g, 2.39 mmol, 82.9% yield, 95% purity) as a brown solid. LCMS [ESI, M+1]: 537.

[01353] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.40 - 7.27 (m, 5H), 4.37 (br dd, *J* = 5.2, 10.8 Hz, 1H), 4.22 - 4.14 (m, 2H), 4.07 - 3.73 (m, 2H), 3.71 - 3.64 (m, 3H), 3.63 - 3.49 (m, 2H), 3.34 - 3.24 (m, 1H), 3.21 - 2.92 (m, 3H), 2.79 - 2.64 (m, 2H), 2.63 - 2.56 (m, 3H), 2.51 (s, 3H), 2.33 (br d, *J* = 7.6 Hz, 1H), 2.12 - 2.05 (m, 1H), 1.92 - 1.69 (m, 3H), 1.48 (s, 9H), 1.20 (d, *J* = 6.8 Hz, 3H).

[01354] Step C: *tert*-butyl (3*S*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl (3*S*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (1.43 g, 2.66 mmol, 1 *eq*) in MeOH (28 mL) was added $Pd(OH)_2/C$ (500 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 4 hours. The reaction mixture was filtered, the filter cake was washed with MeOH (3 × 20 mL). The filtrate was concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 40 %) to give *tert*-butyl (3*S*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (810 mg, 1.72 mmol, 64.7 % yield, 95.0% purity) as a yellow solid. LCMS [ESI, M+1]: 447.

[01355] Step D: *tert*-butyl (3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate. To the solution of *tert*-butyl (3*S*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 1.12 mmol, 1 *eq*), 2-bromo-1-fluoro-3-methoxy-benzene (459 mg, 2.24 mmol, 2 *eq*) and *t*-BuONa (323 mg, 3.36 mmol, 3 *eq*) in toluene (10 mL) was added BrettPhos-Pd-G3 (304 mg, 336 umol, 0.3 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 16 hours. Water (10 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (from PE: EtOAc 2:1~0:1 to EtOAc: MeOH 1:0~5:1), then the residue purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um;mobile phase:

[water(0.225%FA)-ACN];B%: 32%-57%,30;80%min) to give *tert*-butyl (3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (180 mg, 300 umol, 26.8 % yield, 95.0 % purity) as a brown oil. LCMS [ESI, M+1]: 571.

[01356] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.02 (dt, *J* = 6.4, 8.4 Hz, 1H), 6.75 - 6.65 (m, 2H), 4.36 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.27 (s, 2H), 4.24 - 4.17 (m, 1H), 4.12 - 4.09 (m, 1H), 3.84 (s, 3H), 3.74 - 3.65 (m, 1H), 3.38 - 3.27 (m, 3H), 3.24 - 2.94 (m, 3H), 2.67 (br d, *J* = 4.4 Hz, 3H), 2.48 (s, 3H), 2.32 - 2.23 (m, 1H), 2.08 (br d, *J*=3.2 Hz, 1H), 2.04 - 1.98 (m, 1H), 1.87 - 1.69 (m, 4H), 1.49 (s, 9H), 1.25 - 1.21 (m, 3H).

[01357] Step E: 7-(2-fluoro-6-methoxy-phenyl)-4-[(2*S*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. The solution of *tert*-butyl (3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (210 mg, 368 umol, 1 *eq*) and TFA (839 mg, 7.36 mmol, 545 uL, 20 *eq*) was stirred at 25 °C for 0.5 hour. The reaction mixture was concentrated under vacuum. Compound 7-(2-fluoro-6-methoxy-phenyl)-4-[(2*S*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (260 mg, crude, 2TFA) was obtained as a yellow oil.


[01358] Step F: 1-[(3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one. To the solution of 7-(2-fluoro-6-methoxy-phenyl)-4-[(2*S*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (260 mg, crude, 2TFA), DIEA (481 mg, 3.72 mmol, 648 uL,) in DCM (5 mL) was added prop-2-enoyl prop-2-enoate (46.9 mg, 372 umol) at 0 °C, then the mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched by water (1 mL). The resulting mixture was concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 33 %) to give 1-[(3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one (130 mg, 235 umol, 63.2 % yield, 95.0 % purity) as a white solid. LCMS [ESI, M+1]: 525.

[01359] Step G: 3-bromo-1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]propan-1-one. To a solution of 1-[(3*S*)-4-[7-(2-fluoro-6-methoxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one (80 mg, 152 umol, 1 eq) in PhBr (2 mL) was added BBr_3 (764 mg, 3.05 mmol, 294 uL, 20 eq). The reaction mixture was stirred at 90°C for 12 hours. Upon completion, the reaction mixture was concentrated under vacuum. The residue was quenched with saturated NaHCO3 (2 mL) and extracted with EtOAc (2 × 20 mL).3-bromo-1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]propan-1-one (90 mg, crude) was obtained as a brown oil. The crude product was used for next step without further purification.


[01360] Step H: 1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one. To a solution of 3-bromo-1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]propan-1-one (90 mg, 152 umol, 1 eq) in THF (2 mL) was added TEA (154 mg, 1.52 mmol, 212 uL, 10 eq). The reaction mixture was stirred at 20 °C for 12 hours. Upon completion, the reaction mixture concentrated under vacuum. The residue was purified by prep-TLC (DCM: MeOH= 10:1) then prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 48%-78%,12min) to give title compound 1-[(3*S*)-4-[7-(2-fluoro-6-hydroxy-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazin-1-yl]prop-2-en-1-one (EXAMPLE 321, 10.6 mg, 20.1 umol, 13 % yield, 96.9% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 511.

[01361] ^{1}H NMR (400MHz, Methanol-d_4) δ = 7.17 - 6.97 (m, 1H), 6.93 - 6.76 (m, 1H), 6.71 (d, *J*=8.4 Hz, 1H), 6.61 (dd, *J*=8.8, 11.2 Hz, 1H), 6.29 (br dd, *J*=4.8, 16.4 Hz, 1H), 5.82 (br d, *J*=10.8 Hz, 1H), 4.58 - 4.27 (m, 4H), 4.20 - 4.04 (m, 3H), 4.03 - 3.87 (m, 1H), 3.68 - 3.39 (m, 2H), 3.30 (br s, 2H), 3.25 - 3.05 (m, 2H), 2.82 (br s, 2H), 2.75 (td, *J*=6.8, 13.6 Hz, 1H), 2.51 (s, 3H), 2.36 (q, *J*=9.2 Hz, 1H), 2.13 - 2.08 (m, 1H), 1.89 - 1.78 (m, 2H), 1.77 - 1.67 (m, 1H), 1.28 (br d, *J*=5.2 Hz, 3H).

EXAMPLE 322



2-(1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(4-fluoronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01362] Step A: benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. benzyl 2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (2.00 g, 4.56 mmol, 1.00 *eq.*), 1-bromo-4-fluoro-naphthalene (1.54 g, 6.84 mmol, 1.50 *eq.*), $Pd_2(dba)_3$

(418 mg, 456 umol, 0.100 *eq.*), RuPhos (426 mg, 912 umol, 0.20 *eq.*) and cesium carbonate (4.46 g, 13.7 mmol, 3.00 *eq.*) in toluene (40.0 mL) was de-gassed and then heated to 110 °C for 3 hours under N_2 atmosphere. The reaction mixture was quenched by addition water (20.0 mL) at 20 °C, then diluted with ethyl acetate (30 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (50.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1) to give benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2.00 g, 3.43 mmol, 75.2% yield) as a yellow solid.

[01363] ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.24 (dt, *J*=1.6, 4.8 Hz, 1H), 8.16 - 8.08 (m, 1H), 7.64 - 7.53 (m, 2H), 7.47 - 7.34 (m, 5H), 7.15 - 7.03 (m, 2H), 5.22 (s, 2H), 4.72 (br s, 1H), 4.29 - 4.17 (m, 2H), 4.12 - 4.04 (m, 1H), 3.95 (br d, *J*=12.0 Hz, 1H), 3.51 - 3.19 (m, 3H), 3.14 - 2.68 (m, 5H), 2.54 (s, 3H).

[01364] Step B: benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.06 g, 1.82 mmol, 1.00 *eq.*) in ethyl acetate (33.0 mL) was added m-CPBA (332 mg, 1.64 mmol, 85.0% purity, 0.90 *eq.*) in one portion at 20°C under N_2 atmosphere .The mixture was stirred at 20°C for 5 hours. The reaction was quenched by saturated sodium thiosulfate (20.0 mL) and then extracted with ethyl acetate (20.0 mL×3), the combined organic phase was washed by brine(30.0 mL), concentrated to give benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.00 g, 1.67 mmol, 91.8% yield) as a yellow solid which was used for the next step without further purification. LCMS [M+1]: 599.1.

[01365] Step C: benzyl-2-(cyanomethyl)-4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl 2-(cyanomethyl)-4-[7-(4-fluoro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 835.16 umol, 1.00 *eq.*) and [(2*S*)-1-ethylpyrrolidin-2-yl]methanol (216 mg, 1.67 mmol, 2.00 *eq.*) in toluene (10.0 mL) was

added sodium *tert*-butoxide (120 mg, 1.25 mmol, 1.50 *eq.*) in one portion at 0°C under N_2 atmosphere. The mixture was stirred at 0 °C for 30 min, The reaction mixture was quenched by addition water (10.0 mL) at 0°C, and then diluted with ethyl acetate (10.0 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (20.0 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue which purified by Prep-HPLC (TFA condition) to give benzyl-2-(cyanomethyl)-4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 292 umol, 35.0% yield, 97.0% purity) as a colorless solid. LCMS [M+1]: 664.5.


[01366] Step D: 2-[4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 (g) was bubbled into methanol (2 mL) for 5 min at 0 °C, then added into a solution of benzyl 2-(cyanomethyl)-4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 301umol, 1.00 *eq.*) in methanol (2.00 mL), then Pd/C (100 mg, 10% purity) was added under N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20°C for 1 hours. Filtered and concentrated to give 2-[4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude) as a black solid which used for the next step without further purification. LCMS [M+1]: 530.5.

[01367] Step E: 2-[4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[4-[2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 189 umol, 1.00 *eq.*) and DIEA (73.2 mg, 566 umol, 98.7 uL, 3.00 *eq.*) in DCM (2.00 mL) was added prop-2-enoyl prop-2-enoate (47.6 mg, 378 umol, 2.00 *eq.*) in DCM (1.00 mL) drop-wise at 0 °C under N_2 atmosphere. The mixture was stirred at 20 °C for 30 min, methanol (1.00 mL) was added the reaction mixture and then the solvent was removed to give a residue which purified by Prep-TLC (SiO2, DCM: MeOH = 10:1, one drop of NH_4OH was added) to give a crude product. Then by Prep-HPLC (base condition) to give title compound 2-[4-[2-[[(2*S*)-1-ethylpyrrolidin-2-


yl]methoxy]-7-(4-fluoro-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (14.9 mg, 25.0 umol, 13.2% yield, 97.9% purity) as a white solid. LCMS [M+1]: 584.5.

[01368] ^{1}H NMR (400 MHz, $CDCl_3$) δ = 8.25 (dd, *J*=2.4, 4.8 Hz, 1H), 8.19 - 8.08 (m, 1H), 7.63 - 7.54 (m, 2H), 7.15 - 7.03 (m, 2H), 6.61 (br s, 1H), 6.47 - 6.38 (m, 1H), 5.86 (br d, *J*=10.2 Hz, 1H), 5.12 (br s, 1H), 4.38 (dd, *J*=4.4, 10.6 Hz, 1H), 4.24 (br s, 2H), 4.20 - 4.10 (m, 2H), 4.04 (br d, *J*=12.0 Hz, 2H), 3.76 - 2.67 (m, 12H), 2.52 - 2.37 (m, 1H), 2.32 - 2.21 (m, 1H), 2.09 - 1.97 (m, 1H), 1.90 - 1.74 (m, 3H), 1.16 (t, *J*=7.2 Hz, 3H).

EXAMPLE 323



2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01369] Step A: methyl (2*R*,4*S*)-4-hydroxy-1-methyl-pyrrolidine-2-carboxylate. To a solution of methyl (2*R*,4*S*)-4-hydroxypyrrolidine-2-carboxylate (3 g, 20.7 mmol, 1 *eq*, HCl) and formaldehyde (8.39 g, 103 mmol, 7.69 mL, 37% purity, 5 *eq*) in MeOH (30 mL) was added AcOH (1.24 g, 20.7 mmol, 1.18 mL, 1 *eq*) at 15 °C. After stirring for 30 minutes, $NaBH_3CN$ (3.25 g, 51.7 mmol, 2.5 eq) was added. The mixture was stirred for 16 hours. To the mixture was added saturated aqueous sodium carbonate solution (50 mL), and then extracted with dichloromethane/methanol 10/1 (3 × 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. Methyl (2*R*,4*S*)-4-hydroxy-1-methyl-pyrrolidine-2-carboxylate (2 g, 12.6 mmol, 61% yield) was obtained as a yellow oil.

[01370] Step B: methyl (2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidine- 2-carboxylate. To a solution of methyl (2*R*,4*S*)-4-hydroxy-1-methyl-pyrrolidine -2-carboxylate (1.70 g, 10.7 mmol, 1.00 *eq*) in DMF (10.0 mL) was added imidazole (1.67 g, 24.6 mmol, 2.30 *eq*) and *tert*-butylchlorodiphenylsilane (3.52 g, 12.8 mmol, 3.29 mL, 1.20 *eq*). The mixture was stirred at 20 °C for 10 hours. The mixture was diluted with ethyl acetate (20.0 mL), washed with

brine (3 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/10) to give methyl (2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidine- 2-carboxylate (3.00 g, 7.24 mmol, 68 % yield) as a colorless oil. LCMS [ESI, M+1]: 398.

[01371] ^{1}H NMR (400MHz, chloroform-d) δ = 7.63 (ddd, *J* = 1.6, 3.6, 7.6 Hz, 4H), 7.46 - 7.35 (m, 6H), 4.47 - 4.40 (m, 1H), 3.71 (s, 3H), 3.32 (t, *J* = 8.4 Hz, 1H), 3.25 (dd, *J* = 6.0, 10.0 Hz, 1H), 2.42 (br d, *J* = 5.2 Hz, 1H), 2.40 (s, 3H), 2.18 - 2.01 (m, 2H), 1.07 (s, 9H).

[01372] Step C: [(2*R*,4*S*)-4-[*tert*-butyl (diphenyl)silyl]oxy-1-methyl -pyrrolidin-2-yl]methanol. To a solution of methyl (2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1 -methyl-pyrrolidine-2-carboxylate (1.50 g, 3.77 mmol, 1.00 *eq*) in THF (10.0 mL) was added $LiAlH_4$ (573 mg, 15.1 mmol, 4.00 *eq*) at -40 °C. After stirred at -40 °C for 1 hour, the mixture was quenched with water (0.50 mL), NaOH solution (15.0 %, 1.00 mL), water (1.50 mL). The formed precipitate was filtered off and the filter cake was washed with ethyl acetate (40.0 mL). The filtrate was concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate 1/10) to give [(2*R*,4*S*)-4-[*tert*-butyl (diphenyl)silyl]oxy-1-methyl -pyrrolidin-2-yl]methanol (1.20 g, 3.18 mmol, 84 % yield) as a yellow oil. LCMS [ESI, M+1]: 370.

[01373] ^{1}H NMR (400MHz, chloroform-d) δ = 7.67 - 7.62 (m, 4H), 7.46 - 7.36 (m, 6H), 4.37 - 4.24 (m, 1H), 3.63 (dd, *J* = 3.2, 11.2 Hz, 1H), 3.35 (dd, *J* = 2.0, 10.8 Hz, 1H), 3.15 (dd, *J* = 6.0, 9.6 Hz, 1H), 2.76 (br t, *J* = 8.0 Hz, 1H), 2.44 (dd, *J* = 6.0, 9.6 Hz, 1H), 2.33 (s, 3H), 2.04 - 1.85 (m, 2H), 1.06 (s, 9H).

[01374] Step D: benzyl (2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl -pyrrolidin-2-yl]methanol (305 mg, 827 umol, 1.20 *eq*) in THF (5.00 mL) was added *t*-BuONa (132 mg, 1.38 mmol, 2.00 *eq*) at 0 °C followed by benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 0.40 g, 689 umol, 1.00 eq). After stirring at 0 °C for 0.5 h, the mixture was diluted with ethyl acetate (30.0 mL), washed with

water (1 × 20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, petroleum ether/ethyl acetate = 1/3) to give benzyl (2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.35 g, 328 umol, 48 % yield) as a yellow solid. LCMS [ESI, M/2+1]: 444.

[01375] ^{1}H NMR (400MHz, chloroform-d) δ = 8.24 - 8.18 (m, 1H), 7.90 - 7.84 (m, 1H), 7.69 - 7.59 (m, 5H), 7.52 - 7.48 (m, 2H), 7.44 - 7.36 (m, 12H), 7.14 (d, *J* = 7.2 Hz, 1H), 5.21 (s, 2H), 4.68 (br s, 1H), 4.42 - 4.36 (m, 1H), 4.32 (br dd, *J* = 4.8, 10.4 Hz, 1H), 4.26 (br d, *J* = 6.8 Hz, 2H), 4.17 - 4.06 (m, 3H), 3.98 - 3.88 (m, 1H), 3.47 (br s, 1H), 3.29 (br d, *J* = 10.8 Hz, 3H), 3.16 (br dd, *J* = 6.0, 9.6 Hz, 1H), 3.11 - 2.95 (m, 3H), 2.91 - 2.73 (m, 3H), 2.47 - 2.36 (m, 4H), 2.11 (ddd, *J* = 4.8, 8.4, 13.2 Hz, 1H), 1.95 - 1.82 (m, 1H), 1.06 (s, 9H).

[01376] Step E: 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in methanol (40.0 mL) at -78 °C for 0.5 h. Benzyl (2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.32 g, 361 umol, 1.00 eq) and Pd/C (0.10 g, 10.0 % purity) was added into the mixture. After stirring at 25 °C under H_2 at 15 psi for 1 hour, the mixture was filtered and filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.27 g, crude) as a yellow oil and used into next step without further purification. LCMS [ESI, M/2+1]: 377.

[01377] Step F: 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*- butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.27 g, crude) and TEA (182 mg, 1.80 mmol, 250 uL) in dichloromethane (2.00 mL) was added prop-2-enoyl prop-2-enoate (45.3 mg, 359 umol) at 0 °C. After stirring at 25 °C for 0.5 h, the mixture was quenched with methanol (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography


(Al_2O_3, petroleum ether/ethyl acetate = 1/3) to give 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.16 g, 171 umol, two steps 48 % yield) as a yellow solid. LCMS [ESI, M+1]: 806.

[01378] Step G: 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-hydroxy-1-methyl -pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A mixture of 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-[*tert*-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.16 g, 198 umol, 1.00 eq), KF (46.1 mg, 794 umol, 18.6 uL, 4.00 eq) and 18-crown-6 (210 mg, 794 umol, 4.00 eq) in THF (2.00 mL) was stirred at 40 °C for 12 hours. The mixture was concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)/acetonitrile]. The desired fraction was collected and adjust pH > 7 by saturated sodium bicarbonate (2.00 mL) and then extracted with ethyl acetate (3 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (Phenomenex Gemini 150 * 25mm * 10um; mobile phase: [water (0.05 % ammonia hydroxide v/v) - ACN]; B%: 38%-66%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[2-[[(2*R*,4*S*)-4-hydroxy-1-methyl -pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 323, 36.3 mg, 63.9 umol, 32 % yield, 98.1% purity) as a white solid. LCMS [ESI, M+1]: 568.


[01379] SFC: "OJ-3S_3_5_40_3ML Column: Chiralcel OJ-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01380] ^{1}H NMR (400MHz, chloroform-d) δ = 8.25 - 8.18 (m, 1H), 7.91 - 7.83 (m, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.55 - 7.48 (m, 2H), 7.44 (t, *J* = 8.0 Hz, 1H), 7.15 (d, J=7.2 Hz, 1H), 6.60 (br s, 1H), 6.46 - 6.35 (m, 1H), 5.84 (br d, *J* = 9.6 Hz, 1H), 5.20 - 4.53 (m, 1H), 4.47 (quin, *J* = 5.6 Hz, 1H), 4.41 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.34 - 4.19 (m, 3H), 4.14 (br d, *J* = 13.2 Hz, 1H), 4.02 (br d, *J* = 11.6 Hz, 2H), 3.63 (br s, 1H), 3.46 (br dd, *J* = 6.0, 9.6 Hz, 2H), 3.36 (br s, 2H), 3.12 (br s, 1H), 3.07 - 2.90 (m, 3H), 2.90 - 2.67 (m, 2H), 2.51 (s, 3H), 2.35 (dd, *J* = 5.2, 9.6 Hz, 1H), 2.14 - 2.04 (m, 1H), 2.04 - 1.96 (m, 1H).

EXAMPLE 324



2-[(2*S*)-4-[7-(3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01381] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 300 mg, 593 umol, 1.00 *eq*), 1-bromo-3-methoxy-2-methyl-

benzene (239 mg, 1.19 mmol, 2 *eq*), Cs_2CO_3 (580 mg, 1.78 mmol, 3 *eq*), $Pd_2(dba)_3$ (109 mg, 119 umol, 0.2 *eq*) and RuPhos (83.1 mg, 178 umol, 0.3 *eq*) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 16 hours under N_2 atmosphere. To the reaction mixture was added H_2O (1 × 200 mL) and Ethyl acetate (1 × 250 mL). The organic phase was separated, washed with brine (1 × 200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized to pH = 7 with saturated $NaHCO_3$ solution and extracted with ethyl acetate (100 mL). The extracts were dried over sodium sulfate, filtered and concentrated under vacuum. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (170 mg, 270 umol, 45% yield, 99.2% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 626.

[01382] ^{1}H NMR (400MHz, chloroform-d) δ = 7.43 - 7.33 (m, 5H), 7.16 (t, *J* = 8.0 Hz, 1H), 6.72 (d, *J* = 8.0 Hz, 1H), 6.68 (d, *J* = 8.0 Hz, 1H), 5.20 (s, 2H), 4.80 (br dd, *J* = 6.8, 11.6 Hz, 1H), 4.68 (br s, 1H), 4.45 (br dd, *J* = 4.4, 12.0 Hz, 1H), 4.21 - 4.08 (m, 3H), 4.05 (s, 2H), 3.94 (br d, *J* = 12.8 Hz, 1H), 3.85 (s, 3H), 3.67 - 3.56 (m, 1H), 3.32 (br d, *J* = 11.2 Hz, 3H), 3.24 - 3.01 (m, 3H), 2.95 - 2.67 (m, 8H), 2.32 - 2.10 (m, 5H), 2.00 (br s, 1H).


[01383] Step B: 2-[(2*S*)-4-[7- (3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methoxy -2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (260 mg, 416 umol, 1.00 *eq*), Pd/C (130 mg, 10% purity) and NH_3 in MeOH (50 mL) was degassed and purged with H_2 for 3 times, and then the mixture was stirred at 25 °C for 1 hr under H_2 atmosphere at 15 psi pressure. After that, the catalyst was filtered off and the filtrate was concentrated under vacuum. Compound 2-[(2*S*)-4-[7- (3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 376 umol, 91% yield, 92.4% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 492.

[01384] Step C: 2-[(2*S*)-4-[7-(3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(3-methoxy-2-methyl-phenyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 407 umol, 1.00 eq) and TEA (206 mg, 2.03 mmol, 283 uL, 5.00 eq) in DCM (10 mL) was added prop-2-enoyl prop-2-enoate (41.0 mg, 325 umol, 0.800 eq) at 0 °C. The mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with $NaHCO_3$ saturated solution (5 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 25 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by silica gel chromatography (Ethyl acetate/Methanol = 20/1 to 3/1). The residue was further purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 48% - 78%, 12 min). Title compound 2-[(2*S*)-4-[7-(3-methoxy-2-methyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 324, 35.2 mg, 63.6 umol, 16% yield, 98.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 546.


[01385] SFC condition: "OD-3S_3_40_3ML Column: Chiralcel OD-3 100×4.6mm I.D., 3um, Mobile phase: 40% methanol (0.05% DEA) in CO2 Flow rate: 3mL/min Wavelength: 220nm".

[01386] ^{1}H NMR (400MHz, chloroform-d) δ = 7.17 (t, *J* = 8.4 Hz, 1H), 6.73 (d, *J* = 8.0, 1H) 6.68 (d, *J* = 8.4, 1H), 6.59 (br s, 1H), 6.46 - 6.34 (m, 1H), 5.83 (br d, *J* = 10.0 Hz, 1H), 5.10 (br s, 1H), 4.39 (dd, *J* = 5.2, 10.4 Hz, 1H), 4.20 - 4.09 (m, 2H), 4.06 (s, 2H), 4.02 - 3.92 (m, 2H), 3.85 (s, 3H), 3.59 (br s, 1H), 3.31 (br d, *J* = 12.0 Hz, 1H), 3.22 (br d, *J* = 11.6 Hz, 1H), 3.17 - 3.02 (m, 3H), 3.02 - 2.62 (m, 6H), 2.49 (s, 3H), 2.36 - 2.25 (m, 1H), 2.22 (s, 3H), 2.13 - 1.99 (m, 1H), 1.91 - 1.70 (m, 2H).

EXAMPLE 325



2-(1-acryloyl-4-(7-(7-chloronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01387] Step A: benzyl (2*S*)-2-(cyanomethyl)-4- [7-(2-cyanophenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 320 mg, 633 umol, 1 eq) and 2-bromobenzonitrile (230 mg, 1.27 mmol, 2 eq) in toluene (30 mL) was added Cs_2CO_3 (619 mg, 1.90 mmol, 3 eq), RuPhos (59.1 mg, 127 umol, 0.2 eq), $Pd_2(dba)_3$ (58.0 mg, 63.3 umol, 0.1 eq) in one portion. The mixture was degassed and purged with N_2 for 3 times, then heated to 90 °C and stirred for 5 hours. The reaction mixture

was diluted with water (10 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with water (30 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (5 mL) and extracted with ethyl acetate (100 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4- [7-(2-cyanophenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (139 mg, 210 umol, 33% yield, 91.5% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 607.

[01388] ^{1}H NMR (400MHz, chloroform-d) δ = 7.62 (dd, *J* = 1.2, 7.6 Hz, 1H), 7.56 - 7.49 (m, 1H), 7.42 - 7.33 (m, 5H), 7.09 - 7.00 (m, 2H), 5.21 (s, 2H), 4.68 (br s, 1H), 4.38 (br dd, *J* = 4.8, 10.4 Hz, 1H), 4.26 (s, 2H), 4.19 - 4.01 (m, 3H), 3.92 (br d, *J* = 11.6 Hz, 1H), 3.78 (br d, *J* = 12.0 Hz, 1H), 3.44 - 3.21 (m, 3H), 3.15 - 2.95 (m, 3H), 2.85 - 2.61 (m, 4H), 2.49 (s, 3H), 2.34 - 2.23 (m, 1H), 2.12 - 2.00 (m, 1H), 1.92 - 1.72 (m, 3H).


[01389] Step B: 2-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]benzonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(2- cyanophenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (160 mg, 264 umol, 1 eq) in MeOH (12 mL) was added NH_3•MeOH (20 mL) and Pd/C (20 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to give a residue. The crude product was used directly in the next step without purification. Compound 2-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]benzonitrile (119 mg, crude) was obtained as a green solid. LCMS [ESI, M+1]: 473,

[01390] Step C: 2-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]benzonitrile. To a mixture of 2-[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]benzonitrile (119 mg, crude) and prop-2-enoyl prop-2-enoate (31.8 mg, 252 umol) in DCM (5 mL) was added TEA (127 mg, 1.26


mmol, 175 uL) in portion at 0 °C under N_2. The mixture was heated to 25 °C and stirred for 0.5 hour. The reaction mixture was quenched by addition saturated $NaHCO_3$ (5 mL) at 0 °C, and then extracted with DCM (10 mL × 3). The combined organic layers were washed with water (15 mL × 1), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 43% - 73%, 12 min). Title compound 2-[4-[(3*S*)-3-(cyanomethyl)-4-prop-2-enoyl-piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-7-yl]benzonitrile (EXAMPLE 325, 35.1 mg, 65.1 umol, two steps 25% yield, 97.5% purity) was obtained as a colorless oil. LCMS [ESI, M+1]: 527.

[01391] ^{1}H NMR (400MHz, chloroform-d) δ = 7.62 (d, *J* = 8.0 Hz, 1H), 7.54 (t, *J* = 8.4 Hz, 1H), 7.10 - 7.00 (m, 2H), 6.59 (br s, 1H), 6.45 - 6.34 (m, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.09 (br s, 1H), 4.38 (dd, *J* = 5.2, 10.4 Hz, 1H), 4.27 (s, 2H), 4.21 - 4.08 (m, 2H), 3.99 (br d, *J* = 12.0 Hz, 2H), 3.86 - 3.52 (m, 2H), 3.39 (br s, 2H), 3.18 - 2.99 (m, 3H), 2.97 - 2.59 (m, 5H), 2.49 (s, 3H), 2.37 - 2.21 (m, 1H), 2.17 - 1.98 (m, 1H), 1.94 - 1.79 (m, 2H).

EXAMPLE 326



2-((*S*)-1-acryloyl-4-(7-(7-methylnaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01392] Step A: methyl-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate. To a solution of 7-methyltetralin-1-one (2.5 g, 15.6 mmol, 1.0 *eq*) in DCM (40 mL) was added DIEA (6.05 g, 46.8 mmol, 8.15 mL, 3.0 *eq*) and Tf_2O (6.60 g, 23.4 mmol, 3.86 mL, 1.5 *eq*) in portions at 0 °C, the reaction mixture was stirred at 0 - 20 °C for 3 hours under N_2. After completion, the reaction was added ice water (40 mL) slowly; the organic layer was separated, and then dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=1:0) to give (7-methyl-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (4.0 g, 13.7 mmol, 88% yield) as yellow oil.

[01393] ^1H NMR (400 MHz, chloroform-d) δ 7.18 (s, 1H), 7.12 - 7.06 (m, 2H), 6.02 (t, *J* = 4.8 Hz, 1H), 2.85 (t, *J* = 8.2 Hz, 2H), 2.54 - 2.45 (m, 2H), 2.37 (s, 3H).

[01394] Step B: (7-methyl-1-naphthyl) trifluoromethanesulfonate. To a solution of (7-methyl-3,4-dihydronaphthalen-1-yl) trifluoromethanesulfonate (4.0 g, 13.7 mmol, 1.0 *eq*) in dioxane (80.0 mL) was added DDQ (6.21 g, 27.4 mmol, 2.0 *eq*), the reaction mixture was stirred at 105 °C for 12 hours . After completion, the reaction was concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=1:0). The product (7-

methyl-1-naphthyl) trifluoromethanesulfonate (3.4 g, 11.7 mmol, 86% yield) was obtained as yellow oil.

[01395] ^{1}H NMR (400 MHz, chloroform-d) δ 7.89 - 7.81 (m, 3H), 7.49 - 7.40 (m, 3H), 2.60 (s, 3H).

[01396] Step C: benzyl(2*S*)-2-(cyanomethyl)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 1.20 g, 2.37 mmol, 1.0 *eq*) and (7-methyl-1-naphthyl) trifluoromethanesulfonate (1.03 g, 3.56 mmol, 1.50 *eq*) in toluene (20.0 mL) was added Cs_2CO_3 (1.55 g, 4.75 mmol, 2.0 *eq*), and Xphos-Pd-G3 (301 mg, 356 umol, 0.15 *eq*), the mixture was stirred at 70 °C for 12 hours under N_2. After completion, the reaction mixture was added water (20.0 mL), then extracted with ethyl acetate (2 × 15.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to ethyl acetate: Methanol=20:1). The product benzyl(2*S*)-2-(cyanomethyl)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (820 mg, 1.22 mmol, 51% yield, 95.9% purity) was obtained as brown solid. LCMS [ESI, M+1]: 646.


[01397] Step D: 2-[(2*S*)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (790 mg, 1.22 mmol, 1.0 *eq*) in MeOH (15.0 mL) was added NH_3·MeOH (1.22 mmol, 15.0 mL, 1.0 *eq*) and Pd/C (500 mg, 10% purity), the suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 0.5 hour. After completion, the reaction mixture was filtered through a pad of Celite, and the filter cake was washed with DCM (2 × 20 mL), the filtrate was concentrated. The product 2-[(2*S*)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (490 mg, 934 umol, 76% yield, 97.5%

purity) was obtained as white solid which was used for the next step without further purification. LCMS [ESI, M+1]: 512.


[01398] Step E: 2-[(2*S*)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (490 mg, 958 umol, 1.0 *eq*) in DCM (8.0 mL) was added DIEA (495 mg, 3.83 mmol, 667 uL, 4.0 *eq*) and prop-2-enoyl prop-2-enoate (121 mg, 958 umol, 1.0 *eq*) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5.0 mL), and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Ethyl acetate/Methanol=20/1), the obtained crude product was concentrated and re-purified by prep-HPLC ((column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 57%-87%, 12min), the obtained product was concentrated. and then under lyophilization. Title compound 2-[(2*S*)-4-[7-(7-methyl-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 326, 133 mg, 235 umol, 25% yield, 99.6% purity) was obtained as white solid. LCMS [ESI, M+1]: 566.

[01399] ^{1}H NMR (400 MHz, chloroform-d) δ 8.00 (s, 1H), 7.78 (d, *J* = 8.4 Hz, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.43 - 7.32 (m, 2H), 7.13 (d, *J* = 7.2 Hz, 1H), 6.69 - 6.49 (m, 1H), 6.42 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.85 (br d, *J* = 10.8 Hz, 1H), 5.20 - 4.52 (m, 1H), 4.42 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.36 - 4.24 (m, 2H), 4.22 - 4.10 (m, 2H), 4.06 - 3.95 (m, 2H), 3.76 - 3.22 (m, 4H), 3.21 - 3.07 (m, 2H), 3.04 - 2.63 (m, 5H), 2.56 (s, 3H), 2.51 (s, 3H), 2.35 - 2.26 (m, 1H), 2.14 - 2.02 (m, 1H), 1.92 - 1.75 (m, 3H).

EXAMPLE 327



2-((*S*)-1-acryloyl-4-(2-(((2*S*,4*R*)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01400] Step 1: 1-tert-butyl 2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate. To a solution of 1-*tert*-butyl 2-methyl(2*S*,4*R*)-4- hydroxypyrrolidine-1,2-dicarboxylate (9 g, 36.7 mmol, 1 *eq*) in CH_3CN (150 mL) was added Ag_2O (25.5 g, 110 mmol, 3 *eq*) and CH_3I (54.3 g, 383 mmol, 23.8 mL, 10.4 *eq*). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was filtered and the filter was concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=20/1 to 3:1). Compound 1-tert-butyl 2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (9 g, 34.7 mmol, 95% yield) was obtained as a colorless oil.

[01401] ^{1}H NMR (400MHz, chloroform-d) δ = 3.94 - 3.79 (m, 1H), 3.66 (dd, *J* = 3.2, 11.2 Hz, 1H), 3.44 - 3.34 (m, 2H), 3.28 (s, 3H), 2.92 - 2.53 (m, 2H), 2.40 - 2.25 (m, 4H),, 2.12 - 1.99 (m, 1H), 1.89 - 1.79 (m, 1H).

[01402] Step 2: [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol. To a solution of 1-*tert*-butyl 2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (5 g, 19.28 mmol, 1 *eq*) in THF (100 mL) was added $LiAlH_4$ (2.20 g, 57.8 mmol, 3 *eq*). The mixture was stirred at 80 °C for 2 hours. The reaction mixture was quenched with saturated Na_2SO_4 aqueous solution (6 mL). Then the mixture was filtered and the filter was concentrated. Compound [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (1.8 g, 12.4 mmol, 64% yield) was obtained as a colourless oil and used to next step directly without purification.

[01403] ^1H NMR (400MHz, chloroform-d) δ = 4.43 - 4.23 (m, 1H), 3.45 - 3.90 (m, 1H), 3.78 - 3.69 (m, 3H), 3.68 - 3.43 (m, 2H), 3.32 (s, 3H), 2.43 - 2.24 (m, 1H), 2.12-1.95 (m, 1H), 1.52 - 1.33 (m, 9H).

[01404] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4- methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (600 mg, 4.13 mmol, 3 *eq*) and benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro- 5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.38 mmol, 1 *eq*) in THF (10 mL) was added *t*-BuONa (397 mg, 4.13 mmol, 3 *eq*). The mixture was stirred at 25 °C for 0.5 hour. The reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (20 mL). The organic layers was washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH=200/1 to 20:1). Compound benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4- methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (910 mg, 1.28 mmol, 93% yield, 93% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 662.

[01405] Step B: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in MeOH (80 mL) at - 60 °C for 10 minutes. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1- methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (850 mg, 1.28 mmol, 1 *eq*) in MeOH (30 mL) was added above NH_3•MeOH (20 mL) and dry Pd/C (500 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times.


The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and the filter was concentrated. Compound 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (620 mg, 1.18 mmol, 91% yield) was obtained as a colourless oil and used to next step directly without purification. LCMS [ESI, M+1]: 528.

[01406] Step C: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl- pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (620 mg, 1.18 mmol, 1 *eq*) in dichloromethane (10 mL) was added TEA (1.19 g, 11.7 mmol, 1.64 mL, 10 *eq*) at 0 °C. After addition, and prop-2-enoyl prop-2-enoate (118 mg, 940 umol, 0.8 *eq*) in dichloromethane (1 mL) was added dropwise at 0°C. The resulting mixture was stirred at 25°C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL). Then diluted with water (20 mL) and extracted with dichloromethane (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, EA/MeOH=100/1 to 10:1) and further purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 45% - 75%, 12min). Title compound 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (101 mg, 167 umol, 14% yield, 96.6% purity) was obtained as a white solid by lyophilisation. LCMS [ESI, M+1]: 582.


[01407] SFC condition: Column: Chiralcel OJ-3 100×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

[01408] ^{1}H NMR (400MHz, chloroform-d) δ = 8.26 - 8.17 (m, 1H), 7.91 - 7.82 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.44 (t, *J* = 8.0 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 6.60 (br s, 1H), 6.41 (d, *J* = 16.8 Hz, 1H), 5.84 (br d, *J* = 10.8 Hz, 1H), 5.21 - 4.53 (m, 1H), 4.42 (dd, *J* = 4.4, 10.4 Hz, 1H), 4.34 - 4.17 (m, 3H), 4.13 (br d, *J* = 13.6 Hz, 1H), 4.04 - 3.93 (m, 2H), 3.70 - 3.42 (m, 3H), 3.31 (s, 5H), 3.22 - 2.69 (m, 7H), 2.48 (s, 3H), 2.33 (dd, *J* = 5.6, 9.6 Hz, 1H), 2.14 - 2.04 (m, 1H), 2.02 - 1.91 (m, 1H).

EXAMPLE 328



2-((*S*)-1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01409] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.0 g, 1.98 mmol, 1.0 *eq*) and 1-bromo-3-fluoro-2-(trifluoromethyl)benzene (2.88 g, 11.9 mmol, 6.0 *eq*) in toluene (20.0 mL) was added Cs_2CO_3 (1.29 g, 3.96 mmol, 2.0 *eq*), RuPhos (185 mg, 396 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (272 mg, 297 umol, 0.15 *eq*), the mixture was stirred at 100 °C for 18 hours under N_2. After completion, the reaction mixture was added water (30.0

mL), then extracted with ethyl acetate (2 × 20.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate: Methanol=20:1). The obtained product was then purified by reversed phase flash again (C18, 0.1% FA in MeCN), the obtained product was adjusted with $NaHCO_3$ solid to pH~7, the mixture was extracted with ethyl acetate (2 × 15.0 mL), and the organic layer was dried over Na_2SO_4, filtered and concentrated. The product benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (160 mg, 236 umol, 12% yield, 98% purity) was obtained as brown oil. LCMS [ESI, M+1]: 668.


[01410] Step B: 2-[(2*S*)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl] -2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (460 mg, 689 umol, 1.0 *eq*) in MeOH (10 mL) was added Pd/C (300 mg, 10% purity) and NH_3•MeOH (10 mL), the suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 10 mins. After completion, the reaction was filtered through a pad of Celite, and the filtrate was concentrated to give 2-[(2*S*)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl] -2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (320 mg, 591 umol, 86% yield, 98% purity) as yellow solid. LCMS [ESI, M+1]: 534.

[01411] Step C: 2-[(2*S*)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (320 mg, 599 umol, 1.0 *eq*) in DCM (8.0 mL) was added DIEA (310 mg, 2.40 mmol, 418 uL, 4.0 *eq*) and prop-2-enoyl prop-2-enoate (75.6 mg, 599 umol, 1.0 *eq*) at 0°C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5.0 mL), and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Ethyl acetate/Methanol=20/1), then the obtained product was


concentrated and purified again by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 51%-81%, 12min). Title compound 2-[(2*S*)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (86.8 mg, 145 umol, 24% yield, 98% purity) was obtained as white solid. LCMS [ESI, M+1]: 588.

[01412] ^{1}H NMR (400 MHz, chloroform-d) δ 7.55 - 7.45 (m, 1H), 7.08 (d, *J* = 8.4 Hz, 1H), 7.02 - 6.91 (m, 1H), 6.68 - 6.53 (m, 1H), 6.41 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.85 (br d, *J* = 10.8 Hz, 1H), 5.11 - 4.52 (m, 1H), 4.39 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.17 (dd, *J* = 6.8, 10.4 Hz, 1H), 4.14 - 4.07 (m, 3H), 3.98 (br d, *J* = 11.6 Hz, 1H), 3.72 - 3.52 (m, 1H), 3.42 - 3.25 (m, 2H), 3.23 - 2.58 (m, 9H), 2.49 (s, 3H), 2.35 - 2.25 (m, 1H), 2.13 - 2.01 (m, 1H), 1.91 - 1.73 (m, 3H).

EXAMPLE 329



2-[(2*S*)-4-[2-[[(2*R*)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01413] Insert: [(2*R*)-1-[2-[*tert*- butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methanol. A mixture of [(2*R*)-pyrrolidin-2-yl]methanol (0.50 g, 4.94 mmol, 481 uL, 1.00 eq), 2-bromoethoxy-*tert*-butyl-dimethyl-silane (1.18 g, 4.94 mmol, 1.00 eq) and K_2CO_3 (3.42 g, 24.7 mmol, 5.00 eq) in acetonitrile (30.0 mL) was stirred at 83 °C for 12 hours. The mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 10/1) to give [(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methanol (0.50 g, 1.93 mmol, 39 % yield) as a colorless oil.

[01414] ^{1}H NMR (400MHz, chloroform-d) δ = 3.70 (t, *J* = 6.0 Hz, 2H), 3.60 (dd, *J* = 3.6, 10.8 Hz, 1H), 3.36 (dd, *J* = 3.6, 10.8 Hz, 1H), 3.20 (td, *J* = 4.4, 9.2 Hz, 1H), 2.89 (td, *J* = 6.4, 12.8 Hz, 1H), 2.74 - 2.65 (m, 1H), 2.50 (td, *J* = 5.2, 12.8 Hz, 1H), 2.42 - 2.32 (m, 1H), 1.92 - 1.81 (m, 1H), 1.78 - 1.66 (m, 3H), 0.90 (d, *J* = 0.8 Hz, 9H), 0.07 (d, *J* = 0.4 Hz, 6H).

[01415] Step A: benzyl (2*S*)-4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin -2-yl]methanol (344 mg, 1.33 mmol, 1.10 eq) in THF (10.0 mL) was added *t*-BuONa (232 mg, 2.41 mmol, 2.00 eq) and benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl) -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 0.70 g, 1.21 mmol, 1.00 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the mixture was diluted with ethyl acetate (10.0 mL), washed with water (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, ethyl acetate/petroleum ethyl = 3/1) to give benzyl (2*S*)-4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.60 g, 704 umol, 58% yield) as a yellow solid. LCMS [ESI, M+1]: 776.

[01416] ^{1}H NMR (400MHz, chloroform-d) δ = 8.23 - 8.18 (m, 1H), 7.90 - 7.83 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.46 - 7.34 (m, 6H), 7.14 (d, *J* = 7.2 Hz, 1H), 5.21 (s, 2H), 4.70 (br s, 1H), 4.34 (br dd, *J* = 4.2, 10.6 Hz, 1H), 4.30 - 4.20 (m, 2H), 4.17 - 3.89 (m, 4H), 3.75 (t, *J* = 6.8 Hz, 2H), 3.49 (br d, *J* = 8.4 Hz, 1H), 3.38 - 3.13 (m, 4H), 3.10 - 2.90 (m,

4H), 2.89 - 2.70 (m, 3H), 2.63 - 2.52 (m, 1H), 2.41 - 2.31 (m, 1H), 2.04 - 1.94 (m, 1H), 1.87 - 1.73 (m, 3H), 0.88 (s, 9H), 0.05 (d, J = 1.2 Hz, 6H).

[01417] Step B: 2-[(2*S*)-4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in methanol (50.0 mL) at -78 °C for 10 minutes. Benzyl (2*S*)-4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.60 g, 773 umol, 1.00 eq) and Pd/C (0.1 g, 10 % purity) were added into the above solution. After stirred at 25 °C for 1 hour under H_2 at 15 psi, the catalyst was filtered off and the filter cake was wash with THF (10.0 mL). The filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*R*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.50 g, crude) as a yellow oil and used into next step without further purification. LCMS [ESI, M/2+1]: 321.

[01418] Step C: 2-[(2*S*)-4-[2-[[(2*R*) -1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*)-1-[2-[tert-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.50 g, crude) and TEA (394 mg, 3.89 mmol, 542 uL) in dichloromethane (5.00 mL) was added prop-2-enoyl prop-2-enoate (98.2 mg, 779 umol,) at -40 °C. After stirred at 25 °C for 1 hour, the mixture was quenched with saturated sodium bicarbonate (0.10 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ ethyl acetate = 10/1) to give 2-[(2*S*)-4-[2-[[(2*R*) -1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.35 g, 427 umol, two steps 55 % yield) as a yellow solid. LCMS [ESI, M+1]: 696.


[01419] Step D: 2-[(2*S*)-4-[2-[[(2*R*)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A mixture of 2-[(2*S*)-4-[2-[[(2*R*)-1-[2-*[tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (0.35 g, 503 umol, 1.00 eq), KF (146 mg, 2.51 mmol,

58.9 uL, 5.00 eq) and 18-CROWN-6 (665 mg, 2.51 mmol, 5.00 eq) in THF (5.00 mL) was stirred at 40 °C for 12 hours. The mixture was concentrated under vacuum. The residue was purified by reverse phase flash [water (TFA, 0.10 %)/acetonitrile] and prep-HPLC (column: Phenomenex Gemini 150 * 25mm * 10um; mobile phase: [water (0.05 % ammonia hydroxide v/v) - ACN]; B%: 45% - 75%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[2-[[(2*R*)-1-(2-hydroxyethyl)pyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 329, 146 mg, 245 umol, 49 % yield, 97.7 % purity) as a white solid. LCMS [ESI, M+1]:582.


[01420] SFC condition: " Column: Chiralcel OJ-3 100 × 4.6 mm I.D., 3 um, Mobile phase: methanol (0.05 % DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm".

[01421] ^{1}H NMR (400MHz, chloroform-d) δ =8.29 - 8.18 (m, 1H), 7.95 - 7.82 (m, 1H), 7.61 (d, *J* = 8.0 Hz, 1H), 7.56 - 7.47 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 6.60 (br s, 1H), 6.46 - 6.31 (m, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.19 - 4.47 (m, 1H), 4.38 - 4.22 (m, 3H), 4.21 - 4.09 (m, 2H), 4.02 (br d, *J* = 11.2 Hz, 2H), 3.71 - 3.57 (m, 2H), 3.53 - 3.27 (m, 3H), 3.22 - 2.76 (m, 9H), 2.62 (td, *J* = 3.6, 12.4 Hz, 1H), 2.41 - 2.28 (m, 1H), 2.11 - 1.95 (m, 1H), 1.89 - 1.77 (m, 3H).

EXAMPLE 330



2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01422] Insert: 1-bromo-3-methoxy-2-(trifluoromethyl)benzene. To a solution of MeOH (264 mg, 8.23 mmol, 333 uL, 2.00 *eq*) in DMF (25.0 mL) was added NaH (329 mg, 8.23 mmol, 60% purity in mineral oil, 2.00 *eq*). The solution was mixed at room temperature (25 °C) for 30 minutes after which time 1-bromo-3-fluoro-2-(trifluoromethyl)benzene (1.00 g, 4.12 mmol, 1.00 *eq*) was added. The solution was then stirred at 25 ° C for 0.5 hour. Upon completion, the mixture was diluted with water (50 mL) and extracted with EtOAc (2 × 50 mL). The organic layers were washed with brine (30 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 1/0 to 100/1) to give 1-bromo-3-methoxy-2-(trifluoromethyl)benzene (880 mg, 3.11 mmol, 75% yield, 90.0% purity) as a colorless oil.

[01423] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.34 - 7.27 (m, 2H), 6.99 (br d, J = 7.2 Hz, 1H), 3.91 (s, 3H).

[01424] Step A: (2*S*)-2-(cyanomethyl)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 550 mg, 1.09 mmol, 1.00 *eq*), 1-bromo-3-methoxy-2-(trifluoromethyl)benzene (416 mg, 1.63

mmol, 1.50 *eq*), RuPhos (152 mg, 326 umol, 0.30 *eq*), Cs_2CO_3 (1.06 g, 3.26 mmol, 3.00 *eq*) and $Pd_2(dba)_3$ (149 mg, 163 umol, 0.15 *eq*) in toluene (30.0 mL) was de-gassed and then heated to 90 °C for 12 hours under N_2. Upon completion, the mixture was concentrated under vacuum. The residue was diluted with water (10 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed-phase flash [water (0.1% FA)/acetonitrile]. The collected desired fractions were neutralized with saturated sodium bicarbonate solution, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 100 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 321 umol, 30% yield, 94.9% purity) as a yellow solid. LCMS [ESI, M+1]: 680.

[01425] Step B: 2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl) phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 338 umol, 1.00 *eq*) in MeOH (4.00 mL) was added NH_3/MeOH (7 M, 4.00 mL), Pd/C (70.0 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the catalyst was filtered off and the filtrate was concentrated to give 2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl) phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 242 umol, 72% yield, 88.1% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 546.


[01426] Step C: 2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl) phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 242 umol, 1.00 *eq*) and TEA (122 mg, 1.21 mmol, 168 uL, 5.00 *eq*) in DCM (3.00 mL) was added prop-2-enoyl prop-2-enoate (30.5 mg, 242 umol, 1.00

eq) dropwise at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was quenched with MeOH (0.1 mL) and water (2 mL). Layers were separated. The aqueous phase was extracted with EtOAc (2 × 8 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-TLC (EtOAc/MeOH 7/1) and then prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12 min) and lyophilized to give 2-[(2*S*)-4-[7-[3-methoxy-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 330, 28.2 mg, 45.6 umol, 19% yield, 96.8% purity) as a white solid. LCMS [ESI, M+1]: 600.


[01427] SFC condition: Column: Chiralcel OD-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm.

[01428] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.42 (t, *J* = 8.4 Hz, 1H), 6.84 (d, *J* = 8.0 Hz, 1H), 6.79 (d, *J* = 8.4 Hz, 1H), 6.59 (br s, 1H), 6.46 - 6.34 (m, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.09 (br s, 1H), 4.37 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.21 - 4.02 (m, 4H), 4.01 - 3.77 (m, 5H), 3.75 - 3.21 (m, 3H), 3.20 - 2.98 (m, 3H), 2.97 - 2.56 (m, 5H), 2.48 (s, 3H), 2.35 - 2.23 (m, 1H), 2.12 - 1.98 (m, 1H), 1.91 - 1.72 (m, 3H).

EXAMPLE 331



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile




[01429] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (700 mg, 1.16 mmol, 1.00 *eq*, 2 HCl) and TEA (1.76 g, 17.4 mmol, 2.42 mL, 15.0 *eq*) in anhydrous DCM (17.0 mL) was added prop-2-enoyl prop-2-enoate (146 mg, 1.16 mmol, 1.00 *eq*) at 0 °C. The mixture was stirred for 1 hour at 25 °C. Upon completion, the mixture was quenched with MeOH (1 mL) and water (10 mL). The separated aqueous phase was extracted with EtOAc (2 × 20 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate 2/1 to 0/1) and then prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 52%-82%, 12min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 331, 122 mg, 205 umol, 18% yield, 98.5% purity) as a white solid. LCMS [ESI, M+1]:586.


[01430] SFC condition: Column: Chiralpak AD-3 100 × 4.6 mm I.D., 3 um, Mobile phase: 40% *iso*-propanol (0.05% DEA) in CO_2 Flow rate: 3 mL/min Wavelength: 220 nm.

[01431] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (br d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 7.6, 13.2 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.27 - 7.17 (m, 1H), 6.59 (br s, 1H), 6.45 - 6.33 (m, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.08 (br s, 1H), 4.49 - 4.30 (m, 2H), 4.22 - 3.66 (m, 5H), 3.63 - 3.32 (m, 2H), 3.32 - 2.97 (m, 5H), 2.91 - 2.52 (m, 4H), 2.48 (d, *J* = 2.4 Hz, 3H), 2.36 - 2.21 (m, 1H), 2.12 - 1.96 (m, 1H), 1.86 - 1.70 (m, 3H).

EXAMPLE 332



2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01432] Step A: tert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (450 mg, 751 umol, 1.0 *eq*) and [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (218 mg, 1.50 mmol, 2.0 *eq*) in toluene (20.0 mL) was added *t*-BuONa (144 mg, 1.50 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 10 min. The reaction mixture was quenched by addition H_2O (10.0 mL) at 20 °C, and the reaction mixture was

extracted with EA (20.0 mL × 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 1/1 to EA/MeOH = 10/1). The product *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.30 g, 413 umol, 55 % yield, 93.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 680.


[01433] Step B: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (270 mg, 397 umol, 1.0 *eq*) in DCM (2.0 mL) was added TFA (3.08 g, 27.0 mmol, 2.0 mL, 68.1 *eq*). The mixture was stirred at 20 °C for 10 min. The reaction mixture was concentrated under reduced pressure to give a residue. The product 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude, 2TFA) was obtained as a yellow solid. LCMS [ESI, M+1]: 580.

[01434] Step C: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, 371 umol, 1.0 *eq*, 2TFA) in DCM (3.0 mL) was added DIEA (480 mg, 3.71 mmol, 647 uL, 10.0 *eq*). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was quenched by addition MeOH (10.0 mL) at 20°C, and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 50%-80%, 12 min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilization. Title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (27.6


mg, 43.5 umol, two steps 10% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 634.

[01435] ^{1}H NMR (400MHz, Chloroform-d) δ = 7.44 - 7.37 (m, 1H), 7.32 - 7.40 (m, 1H) 7.19 (d, *J* = 8.4 Hz, 1H), 6.57 (br, d, *J* = 14.1 Hz, 1H), 6.44 - 6.37 (m, 1H), 5.84 (br, d, *J* = 10.8 Hz, 1H), 5.1 (br, s, 1H), 4.45 - 4.35 (m, 1H), 4.19 (br, dd, *J* = 5.9, 10.9 Hz, 1H), 4.10 (s, 3H), 4.00 - 3.90 (m, 2H), 3.75 - 3.4 (m, 2H), 3.40- 3.00 (m, 8H), 3.00 - 2.65 (m, 5H), 2.45 (s, 3H), 2.38 - 2.28 (m, 1H), 2.15 - 2.00 (m, 1H), 2.00 - 1.90 (m, 1H).

EXAMPLE 333



2-[(2*S*)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01436] Insert: (7-fluoro-1-naphthyl) trifluoromethanesulfonate. To a solution of 7-fluoronaphthalen-1-ol (980 mg, 6.04 mmol, 1 *eq*) and DIEA (2.34 g, 18.1 mmol, 3.16 mL, 3 *eq*) in DCM (40 mL) was added Tf_2O (2.56 g, 9.07 mmol, 1.50 mL, 1.5 *eq*) dropwise at - 5 °C. The mixture was stirred at 25 °C for 3 hours. Then the mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 100/1 to 10/1). Compound (7-fluoro-1-naphthyl) trifluoromethanesulfonate (1.63 g, 5.54 mmol, 92% yield) was obtained as a colorless oil.

[01437] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.92 (dd, *J* = 5.6, 9.0 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.70 (dd, *J* = 2.4, 9.9 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.49 - 7.43 (m, 1H), 7.42 - 7.34 (m, 1H).

[01438] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(7-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 330 mg, 463 umol, 1 *eq*), (7-fluoro-1-naphthyl) trifluoromethanesulfonate (273 mg, 927 umol, 2 *eq*), $Pd_2(dba)_3$ (84.9 mg, 92.7 umol, 0.2 *eq*), RuPhos (64.9 mg, 139 umol, 0.3 *eq*) and Cs_2CO_3 (453 mg, 1.39 mmol, 3 *eq*) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N_2 atmosphere. The reaction mixture was added H_2O (1 × 200 mL) and ethyl acetate (1 × 250 mL). The organic phase was separated, washed with brine (1 × 200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized to pH = 7 with saturated $NaHCO_3$ solution, and then extracted with ethyl acetate (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[7-(7-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 308 umol, 100% purity, 67% yield) was obtained as a yellow oil. LCMS [ESI, M+1]: 650.

[01439] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.80 - 7.70 (m, 2H), 7.53 (d, *J* = 8.4 Hz, 1H), 7.36 - 7.24 (m, 6H), 7.24 - 7.16 (m, 1H), 7.10 (d, *J* = 7.2 Hz, 1H), 5.19 - 5.09 (m, 2H), 4.62

(br s, 1H), 4.51 (dd, *J* = 6.0, 11.2 Hz, 1H), 4.26 (dd, *J* = 5.6, 11.3 Hz, 1H), 4.15 (s, 2H), 4.11 - 3.99 (m, 2H), 3.90 (br d, *J* = 12.8 Hz, 1H), 3.38 - 3.11 (m, 5H), 3.08 - 2.95 (m, 2H), 2.93 - 2.71 (m, 3H), 2.70 - 2.62 (m, 1H), 2.60 (s, 3H), 2.53 - 2.42 (m, 1H), 2.15 - 2.02 (m, 1H), 1.96 - 1.75 (m, 3H).

[01440] Step B: 2-[(2*S*)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(7-fluoro-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (810 mg, 1.25 mmol, 1 *eq*), Pd/C (400 mg, 10% purity) and NH_3 in MeOH (7 M, 150 mL) was degassed and purged with H_2 for 3 times, and then the mixture was stirred at 25 °C for 0.5 hr under H_2 atmosphere at 15 psi pressure. The mixture was filtered and concentrated under vacuum. 2-[(2*S*)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (600 mg, 1.16 mmol, 93% yield, 99.4% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 516.

[01441] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.89 - 7.79 (m, 2H), 7.61 (br d, *J* = 8.4 Hz, 1H), 7.40 (t, *J* = 7.8 Hz, 1H), 7.32 - 7.24 (m, 1H), 7.19 (br d, *J* = 7.6 Hz, 1H), 4.51 (dd, *J* = 5.6, 10.9 Hz, 1H), 4.30 - 4.19 (m, 3H), 4.05 (br d, *J* = 12.4 Hz, 1H), 3.88 (br d, *J* = 12.0 Hz, 1H), 3.37 - 3.21 (m, 4H), 3.19 - 3.09 (m, 2H), 3.06 - 2.84 (m, 5H), 2.61 - 2.53 (m, 5H), 2.47 - 2.36 (m, 1H), 2.19 - 2.08 (m, 1H), 1.97 - 1.76 (m, 3H).


[01442] Step C: 2-[(2*S*)-4-[7-(7- fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(7-fluoro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (600 mg, 1.16 mmol, 1 *eq*) and TEA (589 mg, 5.82 mmol, 810 uL, 5 *eq*) in DCM (30 mL) was added prop-2-enoyl prop-2-enoate (117 mg, 931 umol, 0.8 *eq*) at 0 °C. The mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ solution (10 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 30 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (Al_2O_3, Ethyl acetate/Methanol = 20/1 to 3/1). The residue was purified by prep-HPLC (column: waters xbridge 150 * 25 5u;

mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 10 min). Title compound 2-[(2*S*)-4-[7-(7- fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 333, 139 mg, 244 umol, 21% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 570.


[01443] SFC condition: "Column: Chiralpak AD-3 100 × 4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm".

[01444] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.92 - 7.80 (m, 2H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 1H), 7.33 - 7.25 (m, 1H), 7.20 (d, *J* = 7.2 Hz, 1H), 6.62 (br s, 1H), 6.47 - 6.37 (m, 1H), 5.85 (br d, *J* = 10.8 Hz, 1H), 5.27 - 4.52 (m, 1H), 4.41 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.25 (br s, 2H), 4.22 - 4.10 (m, 2H), 4.09 - 3.87 (m, 2H), 3.77 - 3.25 (m, 2H), 3.24 - 3.06 (m, 3H), 3.05 - 2.59 (m, 6H), 2.50 (s, 3H), 2.38 - 2.23 (m, 1H), 2.15 - 2.00 (m, 1H), 1.99 - 1.81 (m, 3H).

EXAMPLE 334



2-(1-acryloyl-4-(7-(7-chloronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01445] Step A: *tert*-butyl (2*R*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate. To a solution of NaH (1.11 g, 27.8 mmol, 60% purity, 1.2 eq) in THF (80 mL) was added a solution of *tert*-butyl (2*R*)-2-(hydroxymethyl)pyrrolidine -1-carboxylate (4.67 g, 23.2 mmol, 1 eq) in THF (20 mL) at 0 °C and the mixture was stirred at 0 °C for 1 hour. BnBr (5.95 g, 34.8 mmol, 4.13 mL, 1.5 eq) was added dropwise at 0 °C and the mixture was stirred at 25 °C for 4 hours. The reaction mixture was quenched with saturated ammonium chloride solution (20 mL) at 0 °C, and then diluted with ethyl acetate (2 × 100 mL). The organic layers were washed with water (1 × 150 mL) and brine (1 × 150 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate = 100/1 to 2/1). Compound *tert*-butyl (2*R*)-2-

(benzyloxymethyl)pyrrolidine-1-carboxylate (5.03 g, 17.3 mmol, 74% yield) was obtained as a colorless oil.

[01446] ^{1}H NMR (400MHz, chloroform-d) δ = 7.37 - 7.14 (m, 5H), 4.47 (br s, 2H), 4.07 - 3.77 (m, 1H), 3.67 - 3.07 (m, 4H), 2.08 - 1.68 (m, 4H), 1.38 (s, 9H).

[01447] Step B: (2*R*)-2- (benzyloxymethyl)pyrrolidine. To a mixture of *tert*-butyl (2*R*)-2-(benzyloxymethyl)pyrrolidine -1-carboxylate (4 g, 13.7 mmol, 1 eq) in dioxane (80 mL) was added HCl/dioxane (4 M, 120 mL, 35 eq). The mixture was stirred at 25 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was used directly into next step without further purification. Compound (2*R*)-2-(benzyloxymethyl)pyrrolidine (3.13 g, crude, HCl) was obtained as a white solid.

[01448] ^{1}H NMR (400MHz, DMSO-d_6) δ = 9.76 (br s, 1H), 9.11 (br s, 1H), 7.43 - 7.23 (m, 5H), 4.55 (s, 2H), 3.75 - 3.61 (m, 3H), 3.13 (br d, *J* = 4.4 Hz, 2H), 2.07 - 1.76 (m, 3H), 1.66 - 1.56 (m, 1H).

[01449] Step C: (2*R*)-2-(benzyloxymethyl)-1- ethyl-pyrrolidine. To a mixture of (2*R*)-2-(benzyloxymethyl)pyrrolidine (3 g, crude, HCl) and iodoethane (2.05 g, 13.2 mmol, 1.05 mL) in CH_3CN (65 mL) was added K_2CO_3 (1.82 g, 13.2 mmol) in portion at 25 °C. The mixture was stirred at 25 °C for 1 h, then heated to 78 °C and stirred for 11 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with water (30 mL × 2), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 100/1 to Ethyl acetate/Methanol = 5/1). Compound (2*R*)-2-(benzyloxymethyl)-1- ethyl-pyrrolidine (2.41 g, 10.4 mmol, two steps 79% yield, 95% purity) was obtained as a brown oil.

[01450] ^{1}H NMR (400MHz, chloroform-d) δ = 7.30 - 7.18 (m, 5H), 4.47 (s, 2H), 3.46 (dd, *J* = 4.8, 9.2 Hz, 1H), 3.30 (dd, *J* = 6.4, 9.2 Hz, 1H), 3.10 (ddd, *J* = 2.4, 6.8, 8.8 Hz, 1H), 2.88 (qd, *J* = 7.6, 12.4 Hz, 1H), 2.62 - 2.49 (m, 1H), 2.24 (qd, *J* = 7.2, 12.4 Hz, 1H), 2.14 - 2.03 (m, 1H), 1.92 - 1.80 (m, 1H), 1.78 - 1.51 (m, 3H), 1.04 (t, *J* = 7.2 Hz, 3H).

[01451] Step D: [(2*R*)-1-ethylpyrrolidin-2-yl]methanol. To a solution of (2*R*)-2-(benzyloxymethyl)-1-ethyl-pyrrolidine (2 g, 9.12 mmol, 1 eq) in MeOH (60 mL) was added HCl/MeOH (4 M, 30 mL, 13.2 eq) to adjusting the pH to 3 ~ 4, and then $Pd(OH)_2/C$ (300 mg, 20% purity) was added under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (50 psi) at 25 °C for 12 hours. The catalyst was filtered and concentrated under reduced pressure to give a residue. The crude product was used directly into the next step without further purification. Compound [(2*R*)-1-ethylpyrrolidin-2-yl]methanol (1.68 g, crude, HCl) was obtained as a yellow solid.

[01452] ^1H NMR (400MHz, methanol-d_4) δ = 3.88 (dd, J = 3.6, 12.4 Hz, 1H), 3.75 - 3.45 (m, 4H), 3.21 - 3.08 (m, 2H), 2.30 - 1.82 (m, 4H), 1.37 (t, J = 7.2 Hz, 3H).

[01453] Step E: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-ethylpyrrolidin -2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. [(2*R*)-1-ethylpyrrolidin-2-yl]methanol (334 mg, 2.01 mmol, 1.95 eq, HCl) was dissolved into saturated sodium carbonate solution (5 mL) and then extracted ethyl acetate (2 × 10 mL). The extracts were dried over sodium sulfate, filtered and concentrated under vacuum. To a mixture of benzyl (2*S*)-2-(cyanomethyl) -4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 600 mg, 1.03 mmol, 1 eq) and the above residue in toluene (35 mL) was added *t*-BuONa (298 mg, 3.10 mmol, 3 eq) in portion at 0 °C under N_2. The mixture was warmed to 25 °C and stirred for 10 min. The reaction mixture was diluted with ethyl acetate (20 mL) and adjusted PH to 8-9 with 2M HCl at 0 °C, then extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with water (15 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (3 ml) and extracted with ethyl acetate (100 mL × 2). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-ethylpyrrolidin -2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 526 umol, 51% yield, 97.1% purity) was obtained as a white solid. LCMS [ESI, M+1]: 646.


[01454] Step F: 2-[(2*S*)-4-[2-[[(2*R*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1- ethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (305 mg, 472 umol, 1 eq) in MeOH (40 mL) and NH_3•MeOH (20 mL) was added Pd/C (300 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 0.5 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was used to next step directly without further purification. Compound 2-[(2*S*)-4-[2-[[(2*R*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (240 mg, crude) was obtained as a green solid. LCMS [ESI, M+1]: 512.

[01455] Step G: 2-[(2*S*)-4-[2-[[(2*R*)-1- ethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[2-[[(2*R*)-1-ethylpyrrolidin-2- yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (240 mg, crude) in DCM (10 mL) was added TEA (237 mg, 2.35 mmol, 326 uL), then prop-2-enoyl prop-2-enoate (59.2 mg, 469 umol) was added in portion at 0 °C under N_2. The mixture was warmed to 25 °C and stirred for 0.5 hour. The reaction mixture was quenched by adding saturated $NaHCO_3$ solution (2 mL) at 0 °C, and then extracted with DCM mL (20 mL × 3). The combined organic layers were washed with brine (15 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, Petroleum ether/Ethyl acetate = 50/1 to Ethyl acetate/Methanol = 5/1) and further purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 59% - 89%, 12 min). Title compound 2-[(2*S*)-4-[2-[[(2*R*)-1-ethylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 334, 44.2 mg, 75.2 umol, two steps 16% yield, 96.4% purity) was obtained as a white solid. LCMS [ESI, M+1]: 566.


[01456] ^{1}H NMR (400MHz, chloroform-d) δ = 8.24 - 8.18 (m, 1H), 7.90 - 7.83 (m, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 6.60 (br s, 1H), 6.47 - 6.35 (m, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.11 (br s, 1H), 4.39 (br d, *J* =

8.4 Hz, 1H), 4.35 - 4.21 (m, 2H), 4.19 - 4.09 (m, 2H) , 4.02 (br d, *J* = 12.4 Hz, 1H), 3.47 (br s, 2H), 3.34 (br s, 2H), 3.26 - 3.07 (m, 3H), 3.05 - 2.63 (m, 5H), 2.44 (br dd, *J* = 6.8, 12.0 Hz, 1H), 2.26 (br d, *J* = 8.0 Hz, 1H), 2.12 - 1.94 (m, 1H), 1.80 (br d, *J* = 4.0 Hz, 4H), 1.15 (br t, *J* = 7.2 Hz, 3H).

EXAMPLE 335



2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01457] Step 1: methyl (2*S*,4*R*)-4-methoxypyrrolidine-2-carboxylate. To a solution of *O*1-*tert*-butyl-*O*2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (5.00 g, 19.3 mmol, 1.0 *eq*) in DCM (5.0 mL) was added TFA (7.70 g, 67.5 mmol, 5.0 mL, 3.50 *eq*). The mixture was stirred at 20 °C for 1 hour. After completion, the mixture was concentrated. The product methyl (2*S*,4*R*)-4-methoxypyrrolidine-2-carboxylate (3.0 g, crude, TFA) was obtained as yellow oil.

[01458] Step 2: methyl (2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidine-2 -carboxylate. To a solution of methyl (2*S*,4*R*)-4-methoxypyrrolidine -2-carboxylate (3.0 g, 11.0 mmol, 1.0 *eq*, TFA) and K_2CO_3 (4.55 g, 32.9 mmol, 3.0 *eq*) in MeCN (30.0 mL) was added iodoethane (1.71 g, 11.0 mmol, 878 uL, 1.0 *eq*) in portions. The mixture was stirred at 25 °C for 1 hour and heated to 78 °C, then stirred at 78 °C for 11 hours. After completion, the mixture was filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA=10:1 - EA:MeOH=10:1) to give methyl (2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidine-2 -carboxylate (1.20 g, 6.41 mmol, two steps 33% yield) as yellow oil.

[01459] ^{1}H NMR (400 MHz, Chloroform-d) δ 4.04 - 3.95 (m, 1H), 3.73 (s, 3H), 3.55 - 3.33 (m, 2H), 3.29 (s, 3H), 2.83 - 2.70 (m, 1H), 2.53 - 2.35 (m, 2H), 2.14 (dd, *J* = 5.6, 8.0 Hz, 2H), 1.09 (t, *J* = 7.2 Hz, 3H).

[01460] Step 3: [(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methanol. To a solution of methyl (2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidine-2-carboxylate (1.20 g, 6.41 mmol, 1.0 *eq*) in THF (15.0 mL) was added $LiAlH_4$ (730 mg, 19.2 mmol, 3.0 *eq*). The mixture was stirred at -78 °C for 1 hour. After completion, the mixture was quenched with saturated Na_2SO_4 aqueous (0.30 mL) and filtered, washed with THF (10.0 mL). The mother liquid was concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA=10:1 - EA;MeOH=5:1) to give [(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methanol (600 mg, 3.77 mmol, 59% yield) as yellow oil.

[01461] ^{1}H NMR (400 MHz, Chloroform-d) δ 3.92 - 3.83 (m, 1H), 3.66 (dd, *J* = 3.2, 10.8 Hz, 1H), 3.49 - 3.35 (m, 2H), 3.30 (s, 3H), 2.89 - 2.76 (m, 2H), 2.40 - 2.27 (m, 2H), 2.07 - 1.97 (m, 1H), 1.93 - 1.82 (m, 1H), 1.08 (t, *J* = 7.2 Hz, 3H).

[01462] Step A: *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl] -2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-

(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methanol (266 mg, 1.67 mmol, 2.00 *eq*) in THF (5.0 mL) was added t-BuONa (241 mg, 2.50 mmol, 3.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. Then *tert*-butyl (2*S*)-4-[7-[3-chloro-2- (trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (500 mg, 835 umol, 1.0 *eq*) was added to the above liquid. After addition, the mixture was stirred at 0°C for 0.5 hour. Upon completion, the mixture was added water (10.0 mL) and extracted with ethyl acetate (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA=20:1 - EA:MeOH=10:1) to give *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl] -2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (440 mg, 513 umol, 62% yield, 81% purity) as yellow solid. LCMS [ESI, M+1]: 694.

[01463] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.41 (t, *J* = 8.0 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 1H), 7.20 (d, *J* = 8.4 Hz, 1H), 4.63 (br s, 1H), 4.42 (br dd, *J* = 4.4, 10.8 Hz, 1H), 4.18 - 4.06 (m, 4H), 4.06 - 3.96 (m, 2H), 4.06 - 3.96 (m, 1H), 3.92 - 3.86 (m, 1H), 3.36 - 3.20 (m, 6H), 3.18 - 2.96 (m, 4H), 2.94 - 2.66 (m, 4H), 2.58 - 2.39 (m, 1H), 2.37 - 2.30 (m, 1H), 2.14 - 2.07 (m, 1H), 2.02 - 1.91 (m, 1H), 1.53 (s, 9H), 1.13 (t, *J* = 7.4 Hz, 3H).


[01464] Step B: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2- (trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (390 mg, 455 umol, 1.0 *eq*) in DCM (1.00 mL) was added TFA (1.54 g, 13.5 mmol, 1.0 mL, 29.7 *eq*). The mixture was stirred at 25 °C for 10 minutes. After completion, the mixture was concentrated under vacuum. The product 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, crude, 2 TFA) was obtained as yellow oil. LCMS [ESI, M+1]: 594.

[01465] Step C: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-


enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, 487 umol, 1.0 *eq*, 2 TFA) in DCM (2.0 mL) was added DIEA (629 mg, 4.87 mmol, 847 uL, 10.0 *eq*) at -30 °C. Then prop-2-enoyl prop-2-enoate (92.0 mg, 730 umol, 1.50 *eq*) was added to the above liquid at -30 °C and the mixture was stirred at -30 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (0.50 mL) and concentrated under vacuum. The title compound was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 50%-80%, 12min) to give 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-1-ethyl-4-methoxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 335, 120 mg, 182 umol, two steps 28% yield, 99% purity) as white solid. LCMS [ESI, M+1]: 648.

[01466] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.42 (t, *J* = 8.0 Hz, 1H), 7.29 (d, *J* = 6.4 Hz, 1H), 7.21 (d, *J* = 8.0 Hz, 1H), 6.68 - 6.55 (m, 1H), 6.42 (dd, *J* = 1.6, 16.4 Hz 1H), 5.85 (br d, *J* = 10.8 Hz, 1H), 5.20 - 4.51 (m, 1H), 4.42 (dd, *J* = 4.4, 10.8 Hz, 1H), 4.19 - 4.04 (m, 4H), 4.04 - 3.72 (m, 3H), 3.70 - 3.41 (m, 2H), 3.39 - 3.22 (m, 5H), 3.20 - 2.79 (m, 7H), 2.76 (br s, 1H), 2.50 - 2.40 (m, 1H), 2.33 (dd, *J* = 5.2, 10.0 Hz, 1H), 2.15 - 2.05 (m, 1H), 2.03 - 1.90 (m, 1H), 1.13 (t, *J* = 7.2 Hz, 3H).

EXAMPLE 336



1-[(2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazin-1-yl]prop-2-en-1-one



[01467] Step A: *tert*-butyl (2*R*, 5*S*)-4-(7-benzyl-2-chloro- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)-2,5-dimethyl-piperazine-1-carboxylate. A soluion of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidine (2.70 g, 9.18 mmol, 1.00 eq), *tert*-butyl (2*R*,5*S*)-2,5-dimethylpiperazine-1 -carboxylate (1.77 g, 8.26 mmol, 0.90 eq) and DIEA (2.37 g, 18.4 mmol, 3.20 mL, 2.00 eq) in NMP (30.0 mL) was stirred at 100 °C for 7 hours. The mixture was diluted with ethyl acetate (50.0 mL), washed with brine (3 × 100 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 3/1) to give *tert*-butyl (2*R*, 5*S*)-4-(7-benzyl-2-chloro- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)-2,5-dimethyl-piperazine-1-carboxylate (2.80 g, 5.69 mmol, 62 % yield) as a yellow solid. LCMS [ESI, M+1]: 472.

[01468] ^{1}H NMR (400MHz, chloroform-d) δ = 7.40 - 7.29 (m, 5H), 4.45 - 4.19 (m, 2H), 3.71 - 3.61 (m, 4H), 3.54 - 3.43 (m, 3H), 3.41 - 3.36 (m, 1H), 2.81 - 2.67 (m, 2H), 2.64 - 2.49 (m, 2H), 1.48 (s, 9H), 1.20 (d, *J* = 6.8 Hz, 3H), 1.17 (d, *J* = 6.8 Hz, 3H).

[01469] Step B: *tert*-butyl (2*R*,5*S*)-4-[7-benzyl-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate. To a solution of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (854 mg, 7.41 mmol, 880 uL, 2.50 eq) in THF (20.0 mL) was added NaH (237 mg, 5.93 mmol, 60.0 % purity, 2.00 eq) at 0 °C. After stirred at 0 °C for 0.5 h, *tert*-butyl (2*R*, 5*S*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)-2,5-dimethyl-piperazine-1-carboxylate (1.40 g, 2.97 mmol, 1.00 eq) was added. The mixture was stirred at 80 °C for 4 hours. The mixture was diluted with water (20.0 mL), extracted with ethyl acetate (3 × 30.0mL), the organic layer was washed with brine (1 × 40.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 1/ 10) to give *tert*-butyl (2*R*,5*S*)-4-[7-benzyl-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (1.55 g, 2.56 mmol, 86 % yield) as a yellow solid. LCMS [ESI, M+1]: 551.

[01470] ^{1}H NMR (400MHz, chloroform-d) δ =7.39 - 7.28 (m, 5H), 4.31 (br dd, *J* = 4.8, 10.4 Hz, 2H), 4.16 - 4.08 (m, 1H), 3.72 - 3.62 (m, 4H), 3.61 - 3.56 (m, 1H), 3.52 - 3.43 (m, 2H), 3.38 (br s, 1H), 3.08 (br t, *J* = 8.0 Hz, 1H), 2.81 - 2.48 (m, 6H), 2.45 (s, 3H), 2.33 - 2.20 (m, 1H), 2.04 - 1.95 (m, 1H), 1.78 - 1.65 (m, 3H), 1.48 (s, 9H), 1.17 (br d, *J* = 6.4 Hz, 6H).

[01471] Step C: *tert*-butyl (2*R*,5*S*)-2,5-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. NH_3 was bubbled in methanol (150 mL) at -78 °C for 15 mins. *tert*-Butyl (2*R*,5*S*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (2.80 g, 5.08 mmol, 1.00 eq) and Pd/C (0.50 g, 10.0 % purity) was added into the mixture. After stirred at 40 °C for 5 hours under H_2 at 15 psi, the mixture was filtered and concentrated under vacuum to give *tert*-butyl (2*R*,5*S*)-2,5-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (2.20 g, crude) as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 461.

[01472] Step D: *tert*-butyl (2*R*,5*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate. A mixture of *tert*-butyl (2*R*,5*S*)-2,5-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.00 g, crude), 3-benzyloxy-1-bromo-naphthalene (1.02 g, 3.26 mmol, 1.50 eq), RuPhos (203 mg, 434 umol), $Pd_2(dba)_3$ (199 mg, 217 umol) and Cs_2CO_3 (2.12 g, 6.51 mmol) in toluene (30.0 mL) was stirred at 110 °C for 5 hours under N_2. The mixture was diluted with water (20.0 mL), extracted with ethyl acetate (3 × 40.0 mL). The organic layer was washed with brine (1 × 50.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)/acetonitrile]. The desired fraction was collected and adjusted pH > 7 by saturated sodium bicarbonate (5.00 mL), and then extracted with ethyl acetate (3 × 30.0 mL). The organic layer was washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl (2*R*,5*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (1.06 g, 1.47 mmol, two steps 68% yield) as a yellow solid. LCMS [ESI, M/2+1]: 347.

[01473] ^{1}H NMR (400MHz, chloroform-d) δ = 8.11 (d, *J* = 8.4 Hz, 1H), 7.77 - 7.71 (m, 1H), 7.52 - 7.40 (m, 5H), 7.39 - 7.33 (m, 2H), 6.99 (d, *J* = 2.0 Hz, 1H), 6.90 (d, *J* = 2.0 Hz, 1H), 5.18 (s, 2H), 4.48 - 4.42 (m, 1H), 4.38 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.32 - 4.25 (m, 1H), 4.20 (br d, *J* = 5.6 Hz, 1H), 4.16 - 4.09 (m, 1H), 3.76 (br s, 1H), 3.70 - 3.61 (m, 1H), 3.60 - 3.52 (m, 1H), 3.45 (br s, 2H), 3.24 (br s, 1H), 3.10 (br t, *J* = 7.6 Hz, 1H), 2.93 (br s, 1H), 2.80 - 2.61 (m, 2H), 2.49 (s, 3H), 2.33 - 2.25 (m, 1H), 2.12 - 2.03 (m, 1H), 1.91 - 1.76 (m, 4H), 1.50 (s, 9H), 1.27 - 1.22 (m, 6H).

[01474] Step E: *tert*-butyl (2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate. A mixture of *tert*-butyl (2*R*,5*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (0.90 g, 1.30 mmol, 1.00 eq) and Pd/C (0.10 g, 10.0 % purity) in methanol (40.0 mL) was stirred at 25 °C for 1 hour under H_2 at 15 psi. The mixture was filtered and concentrated under vacuum to give *tert*-butyl (2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl) -

2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (0.72 g, crude) as a yellow solid which was used into next step without further purification. LCMS [ESI, M+1]: 603.


[01475] Step F: 4-[4-[(2*S*,5*R*)-2,5-dimethylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]naphthalen-2-ol. A mixture of *tert*-butyl (2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazine-1-carboxylate (0.70 g, crude) and TFA (1.99 g, 17.42mmol, 1.29 mL) in dichloromethane (1.20 mL) was stirred at 25 °C for 0.5 h. The mixture was concentrated under vacuum to give 4-[4-[(2*S*,5*R*)-2,5-dimethylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]naphthalen-2-ol (849 mg, crude, 2TFA) as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 503.

[01476] Step G: 1-[(2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazin-1-yl]prop-2-en-1-one. To a solution of 4-[4-[(2*S*,5*R*)-2,5-dimethylpiperazin-1-yl]-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]naphthalen-2-ol (0.84 g, crude, 2TFA) and TEA (1.16 g, 11.5 mmol, 1.60 mL) in dichloromethane (3.00 mL) was added prop-2-enoyl prop-2-enoate (102 mg, 805 umol) at -40 °C. After stirred at -40 °C for 0.5 h, the mixture was quenched with water (0.10 mL) and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% TFA)-acetonitrile] and prep-HPLC (column: Phenomenex Luna Phenyl-Hexyl 150_30_5um; mobile phase: [water (10mM NH_4HCO_3) - ACN]; B%: 45% - 75%, 3 min). The desired fraction was collected and lyophilized to give title compound 1-[(2*R*,5*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2,5-dimethyl-piperazin-1-yl]prop-2-en-1-one (EXAMPLE 336, 55.8 mg, 94.1 umol, three steps 8.2 % yield, 93.9 % purity) as a off-white solid. LCMS [ESI, M+1]:557.


[01477] SFC: "Column: Chiralpak AS-3 50×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm".

[01478] ^{1}H NMR (400MHz, chloroform-d) δ = 7.97 (br d, *J* = 8.0 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.40 - 7.34 (m, 1H), 7.26 (dt, *J* = 1.6, 8.4 Hz, 1H), 6.90 (d, *J* = 1.6 Hz, 1H), 6.65 (br s, 1H), 6.61 - 6.43 (m, 1H), 6.39 - 6.26 (m, 1H), 5.73 (br t, *J* = 8.8 Hz, 1H), 4.83 (br s, 1H), 4.55 (br d, *J* = 5.6 Hz, 1H), 4.43 - 4.04 (m, 4H), 3.91 (br d, *J* = 17.2 Hz, 1H), 3.77 - 3.26 (m, 5H), 3.19 (br t, *J* = 8.0 Hz, 1H), 3.06 - 2.68 (m, 3H), 2.63 (br s, 3H), 2.57 (br d, *J* = 13.2 Hz, 1H), 2.41 - 2.33 (m, 1H), 2.15 - 1.83 (m, 4H), 1.11 - 0.96 (m, 6H).

EXAMPLE 337



2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01479] Step 1: 1-(2-bromo-6-chloro-phenyl) ethanol. Into a flame-dried 100 mL round-bottom flask equipped with a magnetic stir bar and under N_2 was added 2-bromo-6-chloro-benzaldehyde (10.0 g, 45.6 mmol, 1 *eq*) and THF (100 mL). The mixture was cooled to 0 °C and then MeMgBr (3 M in Et_2O, 22.8 mL, 1.5 *eq*) was added dropwise over 20 min. The resulting suspension was stirred at 0 °C for 2 h. The reaction mixture was quenched by dropwise addition of a saturated aqueous NH_4Cl solution (10 mL). The mixture was cooled, poured into a 100 mL separatory funnel containing water (150 mL) and the mixture was extracted with ethyl acetate (2 × 150 mL). The combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate = 100/1 to 10/1). Compound 1-(2-bromo-6-chloro-phenyl) ethanol (8.00 g, 32.6 mmol, 72% yield, 96% purity) was obtained as a yellow oil. LCMS [ESI, M-17]: 219.

[01480] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.46 (br d, *J* = 8.0 Hz, 1H), 7.31 (br d, *J* = 8.0 Hz, 1H), 7.07 - 6.96 (m, 1H), 5.68 - 5.44 (m, 1H), 3.24 (br d, *J* = 8.0 Hz, 1H), 1.61 (d, *J* = 4.4 Hz, 3H).

[01481] Step 2: 1-bromo-3-chloro-2-ethyl-benzene. To a mixture of 1-(2-bromo-6-chloro-phenyl)ethanol (8.00 g, 34.0 mmol, 1 *eq*) in DCE (150 mL) was added $BF_3.Et_2O$ (14.5 g, 102 mmol, 12.6 mL, 3 *eq*) and Et_3SiH (19.8 g, 170 mmol, 27.1 mL, 5 *eq*) in portions at 0 °C. The mixture was stirred at 50 °C for 6 hours. The reaction mixture was washed with saturated $NaHCO_3$ aqueous (2 × 75 mL) and saturated brine (1 × 75 mL), then dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether). The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um;mobile phase: [water (0.225% FA) - ACN]; B%: 65ACN% - 95ACN%, 30 min; 60% min). Compound 1-bromo-3-chloro-2-ethyl-benzene (1.50 g, 6.83 mmol, 20% yield, 100% purity) was obtained as a yellow oil.

[01482] Step A: *tert*-butyl (2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 300 mg, 636 umol, 1 *eq*), 1-bromo-3-chloro-2-

ethyl-benzene (279 mg, 1.27 mmol, 2 *eq*), $Pd_2(dba)_3$ (117 mg, 127 umol, 0.2 *eq*), RuPhos (89.1 mg, 191 umol, 0.3 *eq*) and Cs_2CO_3 (622 mg, 1.91 mmol, 3 *eq*) in toluene (30 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N_2 atmosphere. The reaction mixture was added H_2O (1 × 200 mL) and Ethyl acetate (1 × 250 mL). The organic phase was separated, washed with brine (1 × 200 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized to pH = 7 with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 200 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-butyl (2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (155 mg, 0.254 mmol, 100% purity, 40% yield) was obtained as a yellow solid. LCMS [ESI, M+1]: 610.

[01483] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.20 - 7.16 (m, 1H), 7.13 (t, *J* = 8.0 Hz, 1H), 7.07 - 7.03 (m, 1H), 4.61 (br s, 1H), 4.39 (dd, *J* = 5.2, 10.6 Hz, 1H), 4.16 (dd, *J* = 6.8, 10.4 Hz, 1H), 4.09 - 3.95 (m, 4H), 3.91 (br d, *J* = 13.2 Hz, 1H), 3.26 (dd, *J* = 3.6, 13.7 Hz, 1H), 3.22 - 2.96 (m, 5H), 2.90 (q, *J* = 7.4 Hz, 2H), 2.84 - 2.63 (m, 5H), 2.48 (s, 3H), 2.35 - 2.23 (m, 1H), 2.13 - 2.00 (m, 1H), 1.83 - 1.70 (m, 3H), 1.52 (s, 9H), 1.22 (t, *J* = 7.4 Hz, 3H).

[01484] Step B: 2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(3-chloro-2-ethyl-phenyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (310 mg, 508 umol, 1 *eq*) in DCM (600 uL) was added TFA (869 mg, 7.62 mmol, 564 uL, 15 *eq*) at 0 °C under nitrogen atmosphere. The mixture was stirred at 25 °C for 1 h. After that, the mixture was concentrated under vacuum. 2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (850 mg, crude, 2 TFA) was obtained as a yellow oil. LCMS [ESI, M+1]: 510.


[01485] Step C: 2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl) -2-[[(2*S*)-1-

methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (850 mg, crude, 2 TFA) and prop-2-enoyl chloride (59.8 mg, 660 umol, 53.8 uL) in DCM (8 mL) was added TEA (514 mg, 5.08 mmol, 707 uL) in portion. The mixture was stirred at - 40 °C for 30 min. The reaction mixture was quenched by $NaHCO_3$ saturated solution (2 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 30 mL). The combined organic layers were washed with brine (1 × 30 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (Al_2O_3; Ethyl acetate/Methanol = 20/1 to 3/1). The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04% NH_3·H_2O) - ACN]; B%: 65% - 95%, 10 min). Title compound 2-[(2*S*)-4-[7-(3-chloro-2-ethyl-phenyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 337, 142 mg, 252 umol, two steps 50% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 564.


[01486] SFC condition: " Column: Chiralpak AD-3 100×4.6mm I.D., 3 um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm".

[01487] ^{1}H NMR (400 MHz, dmso-d_6) δ = 7.21 (s, 3H), 6.78 (dd, *J* = 10.4, 16.8 Hz, 1H), 6.15 (dd, *J* = 2.0, 16.8 Hz, 1H), 5.74 (dd, *J* = 2.0, 10.6 Hz, 1H), 4.84 (br s, 1H), 4.28 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.23 - 4.07 (m, 2H), 4.05 - 3.90 (m, 4H), 3.39 (br s, 1H), 3.27 (br dd, *J* = 3.6, 13.6 Hz, 1H), 3.20 - 3.05 (m, 3H), 2.99 - 2.93 (m, 2H), 2.93 - 2.76 (m, 4H), 2.61 - 2.52 (m, 2H), 2.40 - 2.31 (m, 3H), 2.22 (q, *J* = 8.4 Hz, 1H), 2.00 - 1.87 (m, 1H), 1.77 - 1.54 (m, 3H), 1.19 (t, *J* = 7.2 Hz, 3H).

EXAMPLE 338



2-((*S*)-1-acryloyl-4-(7-(8-fluoronaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01488] Insert: 1-bromo-8-fluoro-naphthalene. To a solution of 1,8-dibromonaphthalene (2 g, 6.99 mmol, 1 *eq*) in THF (50 mL) was added *n*-BuLi (2.5 M in hexane, 4.20 mL, 1.5 *eq*) at - 78 °C dropwise. After stirring for 10 minutes at -78 °C, a solution of *N*-(benzenesulfonyl)-*N*-fluoro-benzenesulfonamide (4.41 g, 13.9 mmol, 2 *eq*) in THF (10 mL) was added dropwise. The mixture was warmed up to 25 °C and stirred for 3 hours. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um; mobile phase: [water (0.225% FA) - ACN]; B%: 50% - 75%, 25 min). The mixture was adjusted pH = 7 by addition saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. 1-bromo-8-fluoro-naphthalene (560 mg, 2.46 mmol, 35% yield, 99% purity) was obtained as a yellow solid.

[01489] ^{1}H NMR (400MHz, chloroform-d) δ = 7.81 (d, *J* = 7.2 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.31 (t, *J* = 7.6 Hz, 1H), 7.23 (td, *J* = 0.8, 5.2 Hz, 1H).

[01490] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of 1-bromo-8-fluoro-naphthalene (310 mg, 1.38 mmol, 1.3 *eq*), *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 500 mg, 1.06 mmol, 1 *eq*), Cs_2CO_3 (863 mg, 2.65 mmol, 2.5 *eq*), RuPhos (98.9 mg, 212 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (194 mg, 212 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 3 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The desired fractions were adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (370 mg, 570 umol, 54% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 616.

[01491] ^{1}H NMR (400MHz, chloroform-d) δ = 7.64 (d, *J* = 7.6 Hz, 1H), 7.56 (br d, *J* = 8.8 Hz, 1H), 7.47 - 7.42 (m, 1H), 7.20 - 7.08 (m, 3H), 4.64 (br s, 1H), 4.47 - 4.27 (m, 2H), 4.23 - 4.14 (m, 2H), 4.11 - 3.82 (m, 3H), 3.81 - 3.65 (m, 1H), 3.44 - 3.23 (m, 2H), 3.19 - 3.07 (m, 2H), 3.02 - 2.79 (m, 3H), 2.77 – 2.66 (m, 2H), 2.56 (br s, 1H), 2.50 (s, 3H), 2.34-2.25 (m, 1H), 2.13 - 2.06 (m, 1H), 1.82 - 1.72 (m, 3H), 1.53 (s, 9H).

[01492] Step B: 2-[(2*S*)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7- (8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (370 mg, 600 umol, 1 *eq*) in DCM (600 uL) was added TFA (1.03 g, 9.01 mmol, 667 uL, 15 *eq*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-


yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (378 mg, 600 umol, 99% yield, TFA) was obtained as a yellow oil and used next step directly without purification. LCMS [ESI, M+1]: 516.

[01493] Step C: 2-[(2*S*)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (261 mg, 506 umol, 1 *eq*, TFA) in DCM (5 mL) was added TEA (512 mg, 5.07 mmol, 705 uL, 10 *eq*) at 0 °C. After addition, and prop-2-enoyl prop-2-enoate (51.1 mg, 405 umol, 0.8 *eq*) in DCM (1 mL) was added dropwise at 0 °C. After stirred at 25 °C for 1 hour, the reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 48% - 78%, 12 min). Title compound 2-[(2*S*)-4-[7-(8-fluoro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 338, 93.5 mg, 163 umol, 32% yield, 99.4% purity) was obtained as a white solid. LCMS [ESI, M+1]: 570.


[01494] SFC condition: "OD-3_MeOH (DEA)_40_3mL-35T Column: Chiralcel OD-3 50 ×4.6mm I.D., 3um Mobile phase: 40% methanol (0.05% DEA) in CO_2 Flow rate: 3mL/min Wavelength: 220nm".

[01495] ^{1}H NMR (400MHz, chloroform-d) δ = 7.64 (d, *J* = 8.0 Hz, 1H), 7.56 (d, *J* = 8.4 Hz, 1H), 7.47 - 7.35 (m, 2H), 7.19-7.09 (m, 2H), 6.60 (br s, 1H), 6.40 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.30 - 4.48 (m, 1H), 4.46 - 4.28 (m, 2H), 4.27 - 3.85 (m, 5H), 3.73 (br s, 1H), 3.56 - 2.54 (m, 10H), 2.49 (s, 3H), 2.37 - 2.21 (m, 1H), 2.12 - 1.97 (m, 1H), 1.95 - 1.79 (m, 3H).

EXAMPLE 339



2-((*S*)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((*S*)-1-ethylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01496] Step A: *tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate. To a solution of NaH (1.19 g, 49.6 mmol, 2.0 *eq*) in THF (50.0 mL) was added a solution of *tert*-butyl (2*S*)-2-(hydroxymethyl)pyrrolidine-1- carboxylate (5.00 g, 24.8 mmol, 1.0 *eq*) in THF (50.0 mL)

at 0 °C and the mixture was stirred at 10 °C for 1 hour. Bromomethylbenzene (6.38 g, 37.3 mmol, 4.43 mL, 1.50 *eq*) was added dropwise to the above mixture at 0 °C and the mixture was stirred at 10 °C for 16 hours. After completion, the mixture was quenched with saturated NH_4Cl aqueous (20.0 mL) and diluted with ethyl acetate (50.0 ml). The separated organic layer was washed with brine (1 × 30.0 mL) and dried over sodium sulfate, filtered and concentrated under vacuum. The obtained product was purified by column chromatography (SiO_2, Petroleum ether:Ethyl acetate =10:1 - 3:1) to give *tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate (6.60 g, 10.4 mmol, 42% yield) as yellow oil.

[01497] ^1H NMR (400 MHz, Methanol-d_4) δ 7.44 - 7.26 (m, 5H), 4.53 (s, 2H), 4.00 - 3.85 (m, 1H), 3.61 - 3.39 (m, 2H), 3.38 - 3.33 (m, 2H), 2.04 - 1.77 (m, 4H), 1.50 - 1.36 (m, 9H).

[01498] Step B: (2*S*)-2-(benzyloxymethyl)pyrrolidine. To a solution of *tert*-butyl (2*S*)-2-(benzyloxymethyl)pyrrolidine-1-carboxylate (6.60 g, 22.7 mmol, 1.0 *eq*) in DCM (23.0 mL) was added TFA (34.7 g, 304 mmol, 22.5 mL, 13.4 *eq*) dropwise at 0 °C under nitrogen atmosphere. The mixture was stirred at 15 °C for 1 hour. After completion, the mixture was concentrated under vacuum to give (2*S*)-2-(benzyloxymethyl)pyrrolidine (10.0 g, crude, TFA) as yellow oil. LCMS [ESI, M+1]: 192.

[01499] Step C: (2*S*)-2-(benzyloxymethyl)-1-ethylpyrrolidine. To a solution of (2*S*)-2-(benzyloxymethyl)pyrrolidine (2.0 g, 6.55 mmol, 1.0 *eq*, TFA) and acetaldehyde (1.44 g, 32.8 mmol, 1.84 mL, 5.0 *eq*) in MeOH (30.0 mL) was added CH_3COOH (787 mg, 13.1 mmol, 749 uL, 2.0 *eq*) and $NaBH_3CN$ (1.65 g, 26.2 mmol, 4.0 *eq*). The mixture was stirred at 20 °C for 2 hours. After completion, the pH was adjusted to 3 with 1 M HCl aqueous (15.0 mL) and concentrated under vacuum to remove MeOH. The mixture was extracted with mixed solvent (PE/EA = 10:1, 2 × 60.0 mL). The aqueous phase was adjusted to the pH ~ 9 with saturated Na_2CO_3 aqueous (10.0 mL) and extracted with mixed solvent (EA/MeOH = 10:1, 4 × 60.0 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The obtained product was purified by reversed-phase flash (0.1% TFA condition) to give (2*S*)-2-(benzyloxymethyl)-1-ethylpyrrolidine (707 mg, 3.18 mmol, 49% yield, 99.0% purity) as colorless oil.

[01500] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.36 - 7.31 (m, 4H), 7.31 - 7.26 (m, 1H), 4.58 - 4.54 (s, 2H), 3.52 (dd, *J* = 4.8, 9.2 Hz, 1H), 3.37 (dd, *J* = 6.4, 9.2 Hz, 1H), 3.20 - 3.12 (m, 1H), 3.01 - 2.89 (m, 1H), 2.66 - 2.58 (m, 1H), 2.35 - 2.25 (m, 1H), 2.21 - 2.05 (m, 1H), 2.03 - 1.87 (m, 1H), 1.83 - 1.62 (m, 3H), 1.11 (t, *J* = 7.2 Hz, 3H).

[01501] Step D: [(2*S*)-1-ethylpyrrolidin-2-yl]methanol. To a solution of (2*S*)-2-(benzyloxymethyl)-1-ethyl-pyrrolidine (860 mg, 3.92 mmol, 1.00 *eq*) in MeOH (3.00 mL) was added HCl•MeOH (4 M, 0.80 mL) and $Pd(OH)_2/C$ (300 mg, 20% purity). The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (50 Psi) at 25 °C for 16 hours. After completion, the mixture was filtered and concentrated. The product [(2*S*)-1-ethylpyrrolidin-2-yl]methanol (460 mg, 3.56 mmol, 91% yield) was obtained as white solid. LCMS [ESI, M+1]: 130.

[01502] Step E: *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (400 mg, 668 umol, 1.0 *eq*) and [(2*S*)-1-ethylpyrrolidin-2-yl]methanol (173 mg, 1.34 mmol, 2.0 *eq*) in toluene (8.0 mL) was added t-BuONa (128 mg, 1.34 mmol, 2.0 *eq*) at 0 °C, the reaction was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (30.0 mL), then extracted with EA (2 × 20.0 mL), the combined organic layer was washed with saturated brine (1 × 30.0 mL), then dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=5/1 to Ethyl acetate/Methanol=20/1) to give *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (240 mg, 353 umol, 53% yield, 97.6% purity) as light yellow solid. LCMS [ESI, M+1]: 664.


[01503] Step F: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl) phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (240 mg, 361 umol, 1.0 *eq*) in DCM (2.0 mL) was added

TFA (3.08 g, 27.0 mmol, 2.0 mL, 74.8 *eq*), the mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl) phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (280 mg, crude, 2TFA) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 564.


[01504] Step G: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (280 mg, 496 umol, 1.0 *eq*, 2TFA) in DCM (5.0 mL) was added DIEA (642 mg, 4.96 mmol, 865 uL, 10.0 *eq*) and prop-2-enoyl prop-2-enoate (62.6 mg, 496 umol, 1.0 *eq*) at 0 °C, the reaction mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (5.0 mL), and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Ethyl acetate/Methanol=20/1), then the crude product was concentrated and re-purified by prep-HPLC ((column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%, 12 min), the obtained product was concentrated, and then under lyophilization. The title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-ethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 339, 31.9 mg, 50.2 umol, 10% yield, 97.2% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 618.

[01505] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.37 - 7.29 (m, 1H), 7.23 - 7.18 (m, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 6.58 - 6.46 (m, 1H), 6.32 (dd, *J* = 0.8, 16.4 Hz, 1H), 5.76 (br d, *J* = 10.4 Hz, 1H), 5.11 - 4.37 (m, 1H), 4.28 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.09 - 3.96 (m, 4H), 3.89 (br d, *J* = 12.4 Hz, 2H), 3.69 - 3.41 (m, 1H), 3.33 - 2.51 (m, 12H), 2.38 - 2.28 (m, 1H), 2.20 - 2.11 (m, 1H), 2.00 - 1.80 (m, 3H), 1.06 (t, *J* = 7.2 Hz, 3H).

EXAMPLE 340



2-((*S*)-1-acryloyl-4-(7-(4-methoxypyridin-3-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01506] Step A: tert-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (580 mg, 1.23 mmol, 1.0 *eq*), 3-bromo-4-methoxy-pyridine (694 mg, 3.69 mmol, 3.0 *eq*), $Pd_2(dba)_3$ (113 mg, 123 umol, 0.1 *eq*), RuPhos (115 mg, 246 umol, 0.2 *eq*) and Cs_2CO_3 (1.20 g, 3.69 mmol, 3.0 *eq*) in toluene (25.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N_2 atmosphere. After completion, the organic solvent was removed under vacuum, and washed with water (20.0 mL). The aqueous phase was extracted with ethyl acetate (2 × 30.0 mL). Combined extracts were washed with brine (100 mL), dried

over Na_2SO_4, the solvent was then removed under vacuum. The residue was purified by reversed phase flash HPLC [C18, 0.1% FA in water, 0-70% MeCN]. The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (2 × 50.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 397 umol, 32% yield, 100% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 579.


[01507] Step B: 2-[(2*S*)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 605 umol, 1.0 *eq*) in dioxane (3.0 mL) was added 4M HCl/dioxane (5.0 mL), the mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated, then extracted with DCM (10.0 mL), the organic layer was washed with saturated $NaHCO_3$ aqueous (2 × 10.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated to give 2-[(2*S*)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, crude) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 479.

[01508] Step C: 2-[(2*S*)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, 543 umol, 1.0 *eq*) in DCM (5.0 mL) was added TEA (220 mg, 2.17 mmol, 302 uL, 4.0 *eq*) and prop-2-enoyl chloride (63.9 mg, 706 umol, 57.6 uL, 1.3 *eq*) at -60°C, the reaction mixture was stirred at -60 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (2.0 mL), and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether : Ethyl acetate=3:1 to Ethyl acetate/Methanol=20/1), then the crude product was concentrated and re-purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water


(0.04%NH_3H_2O)-ACN]; B%: 30%-54%,10 min), the obtained product was concentrated, and then under lyophilization Title compound 2-[(2*S*)-4-[7-(4-methoxy-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 340, 83.6 mg, 155 umol, 29% yield, 98.8% purity) was obtained as white solid. LCMS [ESI, M+1]: 533.

[01509] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.25 (d, *J* = 5.2 Hz, 1H), 8.17 (s, 1H), 6.82 (d, *J* = 5.2 Hz, 1H), 6.38 (dd, *J* = 1.2, 16.8 Hz, 1H), 6.44 - 6.33 (m, 1H), 5.82 (br d, *J* = 10.4 Hz, 1H), 5.21 - 4.52 (m, 1H), 4.37 (dd, *J* = 4.8 Hz, 10.4 Hz, 1H), 4.33 - 4.26 (m, 1H), 4.24 - 4.13 (m, 2H), 4.06 (br d, *J*=13.6 Hz, 1H), 4.02 - 3.88 (m, 5H), 3.72 - 3.37 (m, 2H), 3.36 - 3.23 (m, 2H), 3.16 - 3.02 (m, 2H), 2.98 - 2.88 (m, 1H), 2.87 - 2.72 (m, 3H), 2.70 - 2.60 (m, 1H), 2.47 (s, 3H), 2.33 - 2.27 (m, 1H), 2.10 - 1.99 (m, 1H), 1.91 - 1.69 (m, 3H).

EXAMPLE 341



2-((*S*)-1-acryloyl-4-(2-(((*S*)-1-(2-hydroxyethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01510] [(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl] pyrrolidin-2-yl]methanol. To a mixture of [(2*S*)-pyrrolidin-2-yl]methanol (500 mg, 4.94 mmol, 481 uL, 1 eq) and 2-bromoethoxy-*tert*-butyl-dimethyl-silane (1.30 g, 5.44 mmol, 1.1 eq) in MeCN (30 mL) was added K_2CO_3 (3.42 g, 24.7 mmol, 5 eq) in portion under N_2. The mixture was stirred at 50 °C for 12 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, Ethyl acetate/Methanol = 100/1 to 5/1). Compound [(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl] pyrrolidin-2-yl]methanol (437 mg, 1.68 mmol, 34.0% yield) was obtained as a brown oil.

[01511] ^{1}H NMR (400MHz, chloroform-d) δ = 3.71 (dd, *J* = 5.2, 6.4 Hz, 2H), 3.63 - 3.58 (m, 1H), 3.37 (dd, *J* = 3.2, 10.8 Hz, 1H), 3.21 (td, *J* = 4.8, 10.0 Hz, 1H), 2.90 (td, *J* = 6.4, 12.8 Hz, 1H), 2.74 - 2.67 (m, 1H), 2.52 (td, *J* = 5.2, 10.4 Hz, 1H), 2.41 - 2.31 (m, 1H), 1.97 - 1.80 (m, 1H), 1.79 - 1.55 (m, 3H), 0.92 - 0.87 (m, 9H), 0.11 - 0.00 (m, 6H).

[01512] Step A: benzyl (2*S*)-4-[2-[[(2*S*)-1- [2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of [(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl] pyrrolidin-2-yl]methanol (447 mg, 1.72 mmol, 2 eq) in toluene (35 mL) was added *t*-BuONa (248 mg, 2.58 mmol, 3 eq) in portion, then to the solution was added benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 500 mg, 861 umol, 1 eq) at 0 °C. The mixture was warmed to 25 °C and stirred for 1 hour. The reaction mixture was diluted with ethyl acetate 20 mL and adjusted PH to 8-9 with 2M HCl at 0 °C, then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with water (15 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 100/1 to 1/2). Compound benzyl (2*S*)-4-[2-[[(2*S*)-1- [2-[*tert*-butyl(dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (400 mg, 494 umol, 57.4% yield, 95.8% purity) was obtained as a colorless oil. LCMS [ESI, M+1]: 776.

[01513] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl] pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl (dimethyl)silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (380 mg, 490 umol, 1 eq) in MeOH (30 mL) was added Pd/C (230 mg, 490 umol, 10% purity, 1.00 eq) and NH_3•MeOH (25 mL). The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. Compound 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl]oxyethyl] pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (314 mg, 489 umol, 99.9% yield) was obtained as a yellow oil and used directly into the next step without further purification. LCMS [ESI, M+1]: 642.


[01514] Step C: 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (314 mg, 489 umol, 1 eq) in DCM (15 mL) was added TEA (148 mg, 1.47 mmol, 204 uL, 3 eq) and prop-2-enoyl chloride (57.6 mg, 636 umol, 51.9 uL, 1.3 eq) in portion at -40 °C under N_2. The mixture was stirred at -40 °C for 30 min. The reaction mixture was quenched by adding saturated $NaHCO_3$ solution 3 mL at -40 °C, and then extracted with DCM (20 mL × 3). The combined organic layers were washed with brine (15 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, Petroleum ether/Ethyl acetate = 100/1 to 1/3). Compound 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl)silyl] oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (210 mg, 300 umol, 61.4% yield, 99.5% purity) was obtained as a colorless oil. LCMS [ESI, M+1]: 696.

[01515] Step D: 2-[(2*S*)-4-[2-[[(2*S*)-1-(2-hydroxyethyl) pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[2-[[(2*S*)-1-[2-[*tert*-butyl(dimethyl) silyl]oxyethyl]pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (205 mg, 295 umol, 1 eq) in THF (3 mL) was added KF (171 mg, 2.95 mmol, 69.0 uL, 10 eq) and 18-crown-6 (779 mg, 2.95 mmol, 10 eq) in portion. The mixture was stirred at 40 °C for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 45% - 75%, 12 min). Title compound 2-[(2*S*)-4-[2-[[(2*S*)-1-(2-hydroxyethyl) pyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 341, 43.4 mg, 71.6 umol, 24.3% yield, 95.9% purity) was obtained as a white solid. LCMS [ESI, M+1]: 582.


[01516] SFC: "OJ-3S_3_5_40_3ML Column: Chiralcel OJ-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01517] ^{1}H NMR (400MHz, chloroform-d) δ = 8.24 - 8.18 (m, 1H), 7.89 - 7.83 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.44 (t, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 6.8 Hz, 1H), 6.60 (br s, 1H), 6.40 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.84 (br d, *J* = 10.4 Hz, 1H), 5.11 (br s, 1H), 4.36 - 4.22 (m, 3H), 4.16 (dd, *J* = 6.8, 10.4 Hz, 2H), 4.01 (br d, *J* = 11.6 Hz, 1H), 3.72 - 3.55 (m, 3H), 3.53 - 3.26 (m, 3H), 3.24 - 2.68 (m, 10H), 2.62 (td, *J* = 4.0, 12.5 Hz, 1H), 2.39 - 2.28 (m, 1H), 2.07 - 1.96 (m, 1H), 1.90 - 1.75 (m, 3H).

EXAMPLE 342



2-[(2*S*)-1-[(*E*)-4-(dimethylamino)but-2-enoyl]-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[01518] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate. To a solution *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine-7-carboxylate (3.00 g, 5.57 mmol, 1.00 eq) in dioxane (30.0 mL) was added HCl/dioxane (4.00 M, 30.0 mL, 21.6 eq) at 0 °C. After stirred at 25 °C for 1 hour, the mixture was concentrated under vacuum. The residue was diluted with water (4.00 mL), adjusted pH > 8 by saturated sodium bicarbonate (10.0 mL) and extracted with ethyl acetate (3 × 30.0 mL). The extracts were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, methanol/ethyl acetate = 10/1) to give benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (2.10 g, 4.02 mmol, 72% yield) as a yellow solid. LCMS [ESI, M+1]: 439.

[01519] ^{1}H NMR (400MHz, chloroform-d) δ = 7.46 - 7.30 (m, 5H), 5.25 - 5.14 (m, 2H), 4.66 (br s, 1H), 4.14 - 4.05 (m, 1H), 4.04 - 3.90 (m, 3H), 3.84 (br d, *J* = 12.4 Hz, 1H), 3.26 (br d, *J* = 11.6 Hz, 2H), 3.12 (td, *J* = 5.2, 12.4 Hz, 1H), 3.05 - 2.91 (m, 2H), 2.79 (br s, 1H), 2.74 - 2.56 (m, 3H), 2.49 (s, 3H).

[01520] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3- fluoro-2-(trifluoromethyl)phenyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (2.00 g, 4.56 mmol, 1.00 eq), 1-bromo-3-fluoro-2-(trifluoromethyl)benzene (1.66 g, 6.84 mmol, 1.50 eq), $Pd_2(dba)_3$ (418 mg, 456 umol, 0.10 eq), RuPhos (426 mg, 912 umol, 0.20 eq) and Cs_2CO_3 (2.97 g, 9.12 mmol, 2.00 eq) in toluene (30.0 mL) was stirred at 90 °C for 5 hours. The mixture was diluted with water (20.0 mL), extracted with ethyl acetate (3 × 30.0 mL). The organic layers were washed with brine (1 × 40.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)/acetonitrile]. The desired fractions were collected and adjusted pH > 7 by saturated sodium bicarbonate (5.00 mL), extracted with ethyl acetate (3 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3- fluoro-2-(trifluoromethyl)phenyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (2.00 g, 2.90 mmol, 64% yield) as a yellow solid. LCMS [ESI, M+1]: 601.

[01521] ^{1}H NMR (400MHz, chloroform-d) δ = 7.53 - 7.44 (m, 1H), 7.43 - 7.29 (m, 5H), 7.07 (d, *J* = 8.0 Hz, 1H), 7.00 - 6.91 (m, 1H), 5.26 - 5.13 (m, 2H), 4.69 (br s, 1H), 4.16 - 4.10 (m, 3H), 4.04 (br d, *J* = 13.2 Hz, 1H), 3.87 (br d, *J* = 12.4 Hz, 1H), 3.39 - 3.22 (m, 3H), 3.19 - 3.09 (m, 1H), 3.04 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.83 (br s, 2H), 2.76 - 2.67 (m, 2H), 2.51 (s, 3H).

[01522] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2- (trifluoromethyl)phenyl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.90 g, 3.16 mmol, 1.00 eq) in ethyl acetate (50.0 mL) was added m-CPBA (610 mg, 3.01 mmol, 85% purity, 0.95 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the mixture was diluted with water (30.0 mL), adjusted pH > 7 by saturated sodium bicarbonate (10.0 mL) and extracted with ethyl

acetate (3 × 20.0 mL). The organic layers were washed with brine (1 × 40.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 1/3) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.20 g, 1.73 mmol, 55% yield) as a yellow solid. LCMS [ESI, M+1]: 617.

[01523] ^{1}H NMR (400MHz, chloroform-d) δ = 7.55 - 7.47 (m, 1H), 7.44 - 7.33 (m, 5H),, 7.08 (d, *J* = 8.0 Hz, 1H), 7.03 - 6.94 (m, 1H), 5.20 (s, 2H), 4.68 (br s, 1H), 4.31 - 4.09 (m, 4H), 4.02 (br d, J=12.0 Hz, 1H), 3.46 (br d, *J* = 13.2 Hz, 1H), 3.40 - 3.09 (m, 4H), 2.90 (br d, *J* = 2.8 Hz, 6H), 2.74 - 2.64 (m, 1H).

[01524] Step D: benzyl (2*S*)-4-[2-[[(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methanol (145 mg, 392 umol, 1.10 eq) in THF (5.00 mL) was added *t*-BuONa (68.6 mg, 714 umol, 2.00 eq) at 0 °C. Then benzyl (2*S*)-2-(cyanomethyl)-4-[7-[3-fluoro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.22 g, 357 umol, 1.00 eq) was added into the mixture. After stirred at 0 °C for 0.5 h, the mixture was diluted with ethyl acetate (10.0 mL) and water (10.0 mL), and then extracted with ethyl acetate (3 × 10.0 mL). The extracts were washed with brine (1 × 20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, petroleum ether/ethyl acetate = 1/3) to give benzyl (2*S*)-4-[2-[[(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.18 g, 185 umol, 52% yield) as a yellow solid. LCMS [ESI, M/2+1]: 462.

[01525] Step E: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4 -[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled in methanol (30.0 mL) at -78 °C for 15 minutes. Benzyl (2*S*)-4-[2-[[(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy] -7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-

4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (0.18 g, 195 umol, 1.00 eq) and Pd/C (0.10 g, 10% purity) was added into the mixture. After stirred at 40 °C for 1 hour under H_2 at 15 psi, the catalyst was filtered and concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4 -[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.13 g, crude) as a yellow solid. LCMS [ESI, M/2+1]: 395.


[01526] Step F: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile. A mixture of (*E*)-4-bromobut-2-enoic acid (0.50 g, 3.03 mmol, 1.00 eq) and oxalyl dichloride (3.85 g, 30.31 mmol, 2.65 mL, 10.0 eq) in dichloromethane (5 mL) was stirred at 0 °C for 0.5 h and 40 °C for 2 hours. The mixture was concentrated under vacuum. The above residue (93.0 mg, crude) was added into the mixture of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, crude) and Py (80.3 mg, 1.02 mmol, 82.0 uL) in dichloromethane (0.50 mL) at 0 °C. After stirred at 0 °C for 0.5 h, *N*-methylmethanamine (69.4 mg, 508 umol, 77.9 uL) was added and the mixture was stirred at 20 °C for 1 hour. Then the mixture was concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)]. The desired fractions were adjusted pH > 7 by saturated sodium bicarbonate (1 × 5.00 mL) and extracted with ethyl acetate (3 × 10.0 mL). The extracts were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[*tert*-butyl(diphenyl)silyl]oxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (0.06 g, 48.05 umol, two steps 65% yield) was obtained as a yellow oil. LCMS [ESI, M+1]: 899.

[01527] Step G: 2-[(2*S*)-1-[(*E*)-4-(dimethylamino)but-2-enoyl]-4-[7-[3 -fluoro-2-(trifluoromethyl)phenyl] -2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-[tert-butyl(diphenyl)silyl]oxy -1-methyl-pyrrolidin-2-yl]methoxy]-7-[3-fluoro-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-


(dimethylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (0.06 g, 66.7 umol, 1.00 eq), KF (38.8 mg, 667 umol, 15.6 uL, 10.0 eq) and 18-crown-6 (176 mg, 667 umol, 10.0 eq) in THF (0.10 mL) was stirred at 40 °C for 12 hours. The mixture was concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %/acetonitrile)] and prep-HPLC column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 30% - 60%, 12 min. The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-1-[(*E*)-4-(dimethylamino)but-2-enoyl]-4-[7-[3 -fluoro-2-(trifluoromethyl)phenyl] -2-[[(2*S*,4*R*)-4-hydroxy-1-methyl-pyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 342, 4.60 mg, 6.91 umol, 10% yield, 99.2% purity) as a white solid. LCMS [ESI, M+1]:661.

[01528] ^{1}H NMR (400MHz, chloroform-d) δ = 7.52 - 7.44 (m, 1H), 7.07 (d, *J* = 8.4 Hz, 1H), 7.00 - 6.90 (m, 2H), 6.46 (br d, *J* = 15.2 Hz, 1H), 5.07 (br s, 1H), 4.50 - 4.42 (m, 1H), 4.36 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.22 (dd, *J* = 5.6, 10.8 Hz, 1H), 4.16 - 4.06 (m, 3H), 3.96 (br d, *J* = 11.6 Hz, 2H), 3.60 (br s, 1H), 3.43 (dd, *J* = 6.0, 10.0 Hz, 1H), 3.39 - 3.23 (m, 2H), 3.20 - 3.05 (m, 4H), 3.05 - 2.79 (m, 4H), 2.78 - 2.62 (m, 2H), 2.48 (s, 3H), 2.35 - 2.26 (m, 7H), 2.12 - 1.92 (m, 2H).

EXAMPLE 343



(*S*)-7-(2,3-dimethylphenyl)-2-((1-methylpyrrolidin-2-yl)methoxy)-4-(4-(vinylsulfonyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidine




[01529] Step A: 7-(2,3-dimethylphenyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. To a solution of *tert*-butyl 4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 652 umol, 1.0 *eq*) in dioxane (3.0 mL) was added 4M HCl/dioxane (5.0 mL), the mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated, then added DCM (10.0 mL), the organic layer was washed with saturated $NaHCO_3$ aqueous (2 × 10.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated to give 7-(2,3-dimethylphenyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (280 mg, crude) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 437.

[01530] Step B: 7-(2,3-dimethylphenyl)-2-[[(2*S*)-methylpyrrolidin- 2-yl]methoxy]-4-(4-vinylsulfonylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. To a mixture of 7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (280 mg, 641 umol, 1.0 *eq*) in DCM (5.0 mL) was added TEA (195 mg, 1.92 mmol, 268 uL, 3.0 *eq*) and ethenesulfonyl chloride (122 mg, 962 umol, 1.5 *eq*) at -60°C, the reaction mixture was stirred at -60 °C for 0.5 hour. After completion, the reaction mixture was quenched with MeOH (1.0 mL), and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether : Ethyl acetate=3:1~Ethyl acetate/Methanol=20/1), then the crude product was concentrated and repurified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 62%-92%,12min), the obtained product was concentrated, and then under lyophilization. Title compound 7-(2,3-dimethylphenyl)-2-[[(2*S*)-methylpyrrolidin- 2-yl]methoxy]-4-(4-


vinylsulfonylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (EXAMPLE 343, 98.2 mg, 185 umol, 29% yield, 99.3% purity) was obtained as white solid. LCMS [ESI, M+1]: 527.

[01531] ^{1}H NMR (400 MHz, chloroform-d) δ 7.12 (t, *J* = 7.6 Hz, 1H), 7.00 - 6.94 (m, 2H), 6.47 (dd, *J* = 10.0 Hz, 16.8 Hz, 1H), 6.30 (d, *J* = 16.8 Hz, 1H), 6.11 (d, *J* = 10.0 Hz, 1H), 4.39 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.15 (dd, *J* = 6.8, 10.4 Hz, 1H), 4.03 (s, 2H), 3.62 (t, *J* = 4.6 Hz, 4H), 3.30 (t, *J* = 4.6 Hz, 4H), 3.19 - 3.05 (m, 3H), 2.80 - 2.62 (m, 3H), 2.49 (s, 3H), 2.32 - 2.25 (m, 7H), 2.13 - 2.00 (m, 1H), 1.92 - 1.72 (m, 3H).

EXAMPLE 344



2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01532] Step A: benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*R*)-1-methylpyrrolidin-2-yl]methanol (101 mg, 874 umol, 1.2 *eq*) in toluene (15 mL) was added *t*-BuONa (140 mg, 1.46 mmol, 2 *eq*) at 0 °C under 10 minutes. Then to the mixture was added a solution of benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 64, 500 mg, 728 umol, 1 *eq*) in toluene (10 mL) dropwise at 0 °C. After stirred at 0 °C for 0.5 h, the reaction mixture was diluted with H_2O (1 × 7 mL) and Ethyl acetate (1 × 25 mL). The organic phase was separated, washed with brine (1 × 20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3; Petroleum ether/Ethyl acetate = 10/1 to 0/1). Compound benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (390 mg, 489 umol, 67% yield, 92.6% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 738.

[01533] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.09 (d, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 7.50 (d, *J* = 7.2 Hz, 2H), 7.46 - 7.34 (m, 10H), 7.00 (d, *J* = 2.0 Hz, 1H), 6.89 (d, *J* = 2.4 Hz, 1H), 5.24 - 5.15 (m, 4H), 4.70 (br s, 1H), 4.39 (dd, *J* = 4.8, 10.7 Hz, 1H), 4.33 - 4.22 (m, 2H), 4.20 - 4.11 (m, 3H), 3.93 (br d, *J* = 12.0 Hz, 1H), 3.56 - 3.19 (m, 4H), 3.14 - 2.61 (m, 7H), 2.48 (s, 3H), 2.34 - 2.23 (m, 1H), 2.11 - 2.06 (m, 1H), 1.84 - 1.69 (m, 3H).

[01534] Step B: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (100 mL) at -60 °C for 20 minutes. To a solution of benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (360 mg, 488 umol, 1 *eq*) in MeOH (25 mL) was added Pd/C (300 mg, 10% purity) and the above solution (NH_3•MeOH, 25 mL) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25°C for 1 hour. The catalyst was filtered off and concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*)-1-


methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (230 mg, crude) was obtained as a yellow oil. LCMS [ESI, M+1]: 514.

[01535] Step C: 2-[(2*S*)-4-[7-(3-hydroxy-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*R*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (230 mg, crude) and TEA (453 mg, 4.48 mmol, 623 uL) in DCM (8 mL) was added prop-2-enoyl chloride (40.5 mg, 448 umol, 36.5 uL) in portion at -40 °C. The mixture was stirred at -40 °C for 30 min. The reaction mixture was quenched with $NaHCO_3$ saturated solution (2 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 30 mL). The combined organic layers were washed with brine (1 × 30 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (Al_2O_3; Ethyl acetate/Methanol = 20/1 to 3/1). The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 38% - 68%, 12 min). Title compound 2-[(2*S*)-4-[7-(3-hydroxy-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 344, 25.6 mg, 44.8 umol, two steps 9.2% yield, 99.5% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 568.


[01536] SFC condition: "AS-3_MeOH (DEA) _5_40_3mL-35T Column: Chiralpak AS-3 50×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01537] ^{1}H NMR (400 MHz, acetic) δ = 8.08 (d, *J* = 8.4 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.29 (t, *J* = 7.2 Hz, 1H), 6.96 (s, 1H), 6.90 - 6.68 (m, 2H), 6.38 (br d, *J* = 17.6 Hz, 1H), 5.87 (br d, *J* = 10.8 Hz, 1H), 5.17 (br s, 1H), 4.82 (br s, 2H), 4.59 (br s, 1H), 4.45 - 4.25 (m, 3H), 4.21 - 3.61 (m, 4H), 3.60 - 3.19 (m, 5H), 3.17 - 2.83 (m, 7H), 2.45 - 2.31 (m, 1H), 2.23 - 2.10 (m, 3H).

EXAMPLE 345



2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01538] Step A: *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (700 mg, 1.48 mmol, 1.0 *eq*), 4-chloro-3-methyl-pyridine (379 mg, 2.97 mmol, 2.0 *eq*), $Pd_2(dba)_3$ (204 mg, 223 umol, 0.15 *eq*), RuPhos (139 mg, 297 umol, 0.2 *eq*) and Cs_2CO_3 (1.45 g, 4.45 mmol, 3.0 *eq*) in toluene (10.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 12 hrs under N_2 atmosphere. The organic solvent was removed under vacuum, and washed with water (15.0 mL). The aqueous phase was extracted with ethyl acetate

(3×25.0 mL). Combine extracts were washed with brine (60.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by reversed phase flash HPLC [C18, 0.1% FA in water , 0-45% MeCN].The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (3×50.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Compound *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (270 mg, 475 umol, 32% yield, 99.0% purity) was obtained as yellow solid. LCMS [ESI, M+1]:563.


[01539] Step B: 2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 355 umol, 1.0 *eq*) in dioxane (3.0 mL) was added HCl· dioxane (4 M, 3.0 mL, 33.8 *eq*). The mixture was stirred at 25 °C for 30 min under N_2 atmosphere. The organic solvent was removed under vacuum. The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (3×15.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (125 mg, crude) was obtained as a yellow solid and used into the next step without further purification. LCMS [ESI, M+1]:463.

[01540] Step C: 2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (125 mg, crude) in DCM (3.0 mL) was added TEA (137 mg, 1.35 mmol, 188 uL) and prop-2-enoyl chloride (36.7 mg, 405 umol, 33.1 uL) at -60°C. The mixture was stirred at -60 °C for 30 min. The reaction was quenched with methanol (10.0 mL) and the mixture was removed under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 32%-


62%,12min) and lyophilization. Title compound 2-[(2*S*)-4-[7-(3-methyl-4-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 345, 25.3 mg, 48.4 umol, 18% yield, 99% purity) was obtained as a white solid. LCMS [ESI, M+1]:517.

[01541] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.33 – 8.29 (m, 2H), 6.83 (d, *J* = 5.6 Hz, 1H), 6.65 – 6.50 (m, 1H), 6.38 (dd, *J* = 1.6 Hz, *J* = 16.8 Hz,1H), 5.82 (d, *J* = 10.8 Hz 1H), 5.41 (br s, 1H), 4.36 (dd, *J* = 4.8 Hz, *J* = 10.4 Hz,1H), 4.20 – 4.06 (m, 4H), 4.97 (br d, *J* = 11.6 Hz 2H),3.68 – 3.45 (m, 1H), 3.40 – 3.31 (m, 2H),3.26 – 3.15 (m, 1H),3.15 – 3.03 (m, 2H), 2.97 – 2.60 (m, 5H), 2.31 (s, 3H), 2.29 -2.21 (m, 3H) 2.15 – 2.10 (m, 1H), 2.09 – 2.00 (m, 1H) 1.88 – 1.70 (m, 3H).

EXAMPLE 346



2-[4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01542] Step 1: To a solution of (*E*)-4-bromobut-2-enoic acid (1.0 g, 6.06 mmol, 1.0 *eq*) in DCM (5.0 mL) was added $(COCl)_2$ (8.70 g, 68.5 mmol, 6 mL, 11.3 *eq*). The mixture was stirred at 60 °C for 16 hrs under N_2 atmosphere. The organic solvent was removed under vacuum. The crude product (*E*)-4-bromobut-2-enoyl chloride (1.3 g, crude) was obtained as a yellow liquid and used into the next step without further purification.

[01543] Step A: *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.30 g, 2.17 mmol, 1.0 *eq*) and [(2*S*)-1-methylpyrrolidin-2-yl]methanol (500 mg, 4.34 mmol, 515 uL, 2.0 *eq*) in toluene (20.0 mL) was added *t*-BuONa (417 mg, 4.34 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 10 min. The

reaction mixture was quenched by adding saturated brine (30 mL) at 20 °C, and extracted with EA (3 × 30.0 mL). The combined organic layers were washed with saturated brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to EA/MeOH = 10/1). The product *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.10 g, 1.62 mmol, 75% yield, 96% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 650.


[01544] Step B: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 308 umol, 1.0 *eq*) in dioxane (2.0 mL) was added HCl/dioxane (4 M, 2.0 mL, 26.0 *eq*). The mixture was stirred at 25 °C for 30 min under N_2 atmosphere. The organic solvent was removed under vacuum. The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (3 × 20.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (130 mg, crude) was obtained as a yellow solid and used into the next step without further purification. LCMS [ESI, M+1]:551.

[01545] Step C: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 1812 umol, 1.0 *eq*) and PYRIDINE (115 mg, 1.45 mmol, 117 uL, 8.0 *eq*) in DCM (3.0 mL) was added (*E*)-4-bromobut-2-enoyl chloride (133 mg, 727 umol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hr. After the starting material was consumed, morpholine (79.2 mg, 909 umol, 80.0 uL, 5.0 *eq*) was added to the above mixture and stirred at 0 °C for 3.5 hrs. The organic solvent was removed under vacuum. The obtained


product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (3 × 15.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 346, 21.7 mg, 30.6 umol, 16.9% yield, 99% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 703.

[01546] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.40 (t, *J* = 8.0 Hz, *J* = 8.0 Hz 1H), 7.28 (s, 1H), 7.19 (d, *J* = 8.0 Hz, 1H), 7.00 – 6.93(m, 1H), 6.59 (br s, 1H), 6.57 – 6.40 (m, 1H), 5.18 – 5.03 (m, 1H), 4.38 (dd, *J* = 4.8 Hz, *J* = 10.4 Hz,1H), 4.16 (d d, *J* = 6.8 Hz, *J* = 10.4 Hz, 1H), 4.14 - 4.04 (m, 3H), 4. 04 – 3.88 (m, 2H), 3.74 (t, *J* = 4.4 Hz, *J* = 4.8 Hz, 4H), 3.52 (br s, 1H), 3.41 – 3.23 (m, 2H), 3.18 (d, *J* = 5.6 Hz, 3H), 3.12 – 3.08 (m, 2H),2.95 - 2.85 (m, 2H), 2.30 - 2.15 (m, 3H), 2.55 – 2.45 (m, 7H), 2.34 – 2.24 (m, 1H), 2.13 – 2.00 (m, 1H), 1.90 – 1.75 (m, 3H).

EXAMPLE 347



2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-pyrrolidin-1-ylbut-2-enoyl]piperazin-2-yl]acetonitrile



[01547] Insert: (*E*)-4-bromobut-2-enoyl chloride. A solution of (*E*)-4-bromobut-2-enoic acid (1.00 g, 6.06 mmol, 1.00 *eq*) in $(COCl)_2$ (14.5 g, 114 mmol, 10.0 mL, 18.9 *eq*) and DCM (10.0 mL) was stirred at 70 °C for 2 hours. After completion, the mixture was concentrated under vacuum. The product (*E*)-4-bromobut-2-enoyl chloride (1.00 g, crude) was obtained as yellow oil. The crude compound was used directly to the next step without further purification.

[01548] Step A: 2-[(2*S*)-4-[7-[3-chloro -2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (700 mg, 1.08 mmol, 1.0 *eq*) in dioxane (5.0 mL) was added HCl•dioxane (4 M, 7.0 mL, 26.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 2 hours.

After completion, the mixture was concentrated and adjusts with saturated $NaHCO_3$ aqueous to pH~7, then extracted with EA (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The product 2-[(2*S*)-4-[7-[3-chloro -2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, 669 umol, 62% yield, 92% purity) was obtained as yellow oil. LCMS [ESI, M+1]: 550.


[01549] Step B: 2-[(2*S*)-1-[(*E*)-4-bromobut- 2-enoyl]-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 364 umol, 1.00 *eq*) and Pyridine (230 mg, 2.91 mmol, 235 uL, 8.0 *eq*) in DCM (2.0 mL) was added (*E*)-4-bromobut-2-enoyl chloride (267 mg, 1.45 mmol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added water (10.0 mL) and extracted with DCM (10.0 mL × 2). The organic layer was dried over Na_2SO_4, filtered and concentrated. The product 2-[(2*S*)-1-[(*E*)-4-bromobut- 2-enoyl]-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude) was obtained as brown oil.

[01550] Step C: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-pyrrolidin-1-ylbut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of pyrrolidine (306 mg, 4.30 mmol, 359 uL, 10.0 *eq*), K_2CO_3 (297 mg, 2.15 mmol, 5.0 *eq*) and KI (21.4 mg, 129 umol, 0.30 *eq*) in THF (2.0 mL) was added 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, 430 umol, 1.0 *eq*) in portions at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, water (10.0 mL) was added to the mixture and extracted with DCM (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10 um; mobile phase: [water(10mM NH_4HCO_3)-ACN]; B%: 70%-100%,3min) to give title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-


2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-pyrrolidin-1-ylbut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 347, 17.1 mg, 24.5 umol, two steps 7% yield, 99% purity) as yellow oil. LCMS [ESI, M+1]: 687.


[01551] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.41 (t, *J* = 8.0 Hz, 1H), 7.28 (d, *J* = 8.0 Hz, 1H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.06 - 6.95 (m, 1H), 6.47 (br d, *J* = 14.0 Hz, 1H), 5.20 - 4.60 (m, 1H), 4.39 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.22 - 4.07 (m, 4H), 3.97 (br d, *J* = 12.0 Hz, 2H), 3.42 - 3.23 (m, 3H), 3.21 - 3.04 (m, 3H), 2.96 - 2.86 (m, 2H), 2.79 - 2.64 (m, 5H), 2.62 - 2.54 (m, 4H), 2.49 (s, 3H), 2.35 - 2.25 (m, 1H), 2.13 - 2.01 (m, 1H), 1.83 - 1.70 (m, 7H).

EXAMPLE 348



2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[01552] Insert: tert-Butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1- carboxylate. A mixture of BH_3•Me_2S (10 M in DMS, 610 uL, 1.3 *eq*) and (3a*S*)-1-methyl-3,3-diphenyl-3a,4,5,6-tetrahydropyrrolo[1,2-c][1,3,2]oxazaborole (1 M in toluene, 938 uL, 0.2 *eq*) in THF (10 mL) was stirred at 25 °C for 1 hour. Then a solution of *tert*-butyl (2*R*)-2-acetylpyrrolidine-1-carboxylate (1.00 g, 4.69 mmol, 1 *eq*) in THF (10 mL) was added and the mixture stirred at 25 °C for 1 hour. The mixture was quenched with MeOH (4 mL), concentrated under vacuum. The residue was purified by column chromatography (SiO_2, PE/EtOAC = 50/1 to 5/1). t*ert*-Butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1- carboxylate (690 mg, 3.21 mmol, 68% yield) was obtained as a white solid.

[01553] ^{1}H NMR (400 MHz, chloroform-d) δ = 5.19 (br s, 1H), 3.79 - 3.59 (m, 2H), 3.49 (br s, 1H), 3.35 - 3.18 (m, 1H), 2.04 - 1.90 (m, 1H), 1.88 - 1.68 (m, 3H), 1.47 (d, *J* = 0.8 Hz, 9H), 1.20 - 1.11 (m, 3H).

[01554] Step A: benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-*tert*-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*R*)-2-[(1*R*)-1-hydroxyethyl]pyrrolidine-1 -carboxylate (263 mg, 1.22 mmol, 1.2 *eq*) in toluene (15 mL) was added *t*-BuONa (196 mg, 2.04 mmol, 2 *eq*) at 0 °C for 10 minutes. To the mixture was added

benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (700 mg, 1.02 mmol, 1 *eq*) in toluene (15 mL) dropwise at 0 °C. After stirred at 0 °C for 0.5 h, the reaction mixture was added H_2O (1 × 7 mL) and ethyl acetate (1 × 35 mL). The organic phase was separated, washed with brine (1 × 20 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized to pH = 7 with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 100 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-*tert*-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (470 mg, 536 umol, 53% yield, 95.6% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 838.

[01555] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.09 (d, *J* = 8.4 Hz, 1H), 7.73 (d, *J* = 8.0 Hz, 1H), 7.53 - 7.48 (m, 2H), 7.46 - 7.31 (m, 10H), 7.00 (d, *J* = 1.6 Hz, 1H), 6.89 (d, *J* = 2.0 Hz, 1H), 5.78 - 5.44 (m, 1H), 5.30 - 5.08 (m, 4H), 4.70 (br s, 1H), 4.35 - 4.20 (m, 3H), 4.08 - 3.79 (m, 2H), 3.72 - 3.13 (m, 7H), 3.12 - 2.64 (m, 4H), 2.01 - 1.71 (m, 5H), 1.46 (s, 9H), 1.26 - 1.23 (m, 3H).

[01556] Step B: benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-pyrrolidin-2-yl]ethoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*) -1-[(2*R*)-1-*tert*-butoxycarbonylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (450 mg, 537 umol, 1 *eq*) in DCM (600 uL) was added TFA (918 mg, 8.05 mmol, 596 uL, 15 *eq*) at 0 °C under nitrogen atmosphere. The mixture was stirred at 25°C for 1 hour. Then the mixture was concentrated under vacuum. Compound benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-pyrrolidin-2-yl]ethoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (700 mg, crude, TFA) was obtained as a yellow oil.

[01557] Step C: benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of benzyl (2*S*)-4-[7-(3-benzyloxy-1-

naphthyl)-2-[(1*R*)-1- [(2*R*)-pyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (650 mg, 763 umol, 1 *eq*, TFA), formaldehyde (310 mg, 3.81 mmol, 284 uL, 5 *eq*, 37% in water) and AcOH (45.8 mg, 763 umol, 43.6 uL, 1 *eq*) in MeOH (15 mL) was stirred at 25 °C for 0.5 h. Then $NaBH_3CN$ (120 mg, 1.91 mmol, 2.5 *eq*) was added and the mixture was stirred at 25 °C for 1 hour. The mixture was quenched with H_2O (10 mL) at 0 °C, then extracted with ethyl acetate (3 × 15 mL), washed with brine (1 × 15 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized to pH = 7 with saturated $NaHCO_3$ solution and extracted with ethyl acetate (2 × 50 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (260 mg, 339 umol, two steps 68% yield, 97.9% purity) was obtained as a yellow solid.

[01558] Step D: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (100 mL) at – 60 °C for 20 minutes. To a solution of benzyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin -2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (260 mg, 346 umol, 1 *eq*) in MeOH (15 mL) was added Pd/C (200 mg, 10% purity) and above mixture (NH_3•MeOH, 15 mL) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The catalyst was filtered off and concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 300 umol, 87% yield, 88.0% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 528.


[01559] Step E: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1- [(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-

yl]acetonitrile (180 mg, 341 umol, 1 *eq*) and TEA (345 mg, 3.41 mmol, 475 uL, 10 *eq*) in DCM (8 mL) was added prop-2-enoyl chloride (30.9 mg, 341 umol, 27.8 uL, 1 *eq*) in portion at -40 °C and the mixture was stirred at - 40 °C for 30 min. The reaction mixture was quenched with $NaHCO_3$ saturated solution (2 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 30 mL). The combined organic layers were washed with brine (1 × 30 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by column chromatography (Al_2O_3; Ethyl acetate/Methanol = 20/1 to 3/1). The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 42% - 72%, 12 min). Title compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[(1*R*)-1-[(2*R*)-1-methylpyrrolidin-2-yl]ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 348, 23.5 mg, 39.9 umol, 12% yield, 99.0% purity) was obtained as a white solid. LCMS [ESI, M+1]: 582.


[01560] SFC condition: "OJ-3S_3_5_40_3ML Column: Chiralcel OJ-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01561] ^{1}H NMR (400 MHz, methanol-d_4) δ = 8.09 (d, *J* = 8.4 Hz, 1H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.39 (t, *J* = 7.6 Hz, 1H), 7.32 - 7.23 (m, 1H), 6.98 - 6.74 (m, 3H), 6.31 (br d, *J* = 16.4 Hz, 1H), 5.85 (br d, *J* = 10.4 Hz, 1H), 5.27 - 5.15 (m, 1H), 5.11 (br s, 1H), 4.62 (br s, 1H), 4.33 - 4.00 (m, 5H), 3.75 - 3.38 (m, 2H), 3.27 - 2.81 (m, 7H), 2.75 - 2.62 (m, 1H), 2.55 (s, 3H), 2.47 - 2.31 (m, 1H), 2.11 - 1.96 (m, 1H), 1.86 - 1.69 (m, 3H), 1.34 (d, *J* = 6.4 Hz, 3H).

EXAMPLE 349



2-((*S*)-1-acryloyl-4-(7-(3-fluoro-2,6-dimethylphenyl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01562] Step 1: 2-bromo-6-fluoro-3-methyl- benzaldehyde. To a solution of 2-bromo-4-fluoro-1-methyl-benzene (10 g, 52.9 mmol, 1 eq) in THF (200 mL) was added LDA (2 M in toluene, 31.7 mL, 1.2 eq) at -78 °C under nitrogen atmosphere. After stirred at -78 °C for 2 hours, a solution of DMF (4.64 g, 63.5 mmol, 4.88 mL, 1.2 eq) was added at -78 °C. The mixture was warmed up to 25 °C carefully and stirred for 0.5 hours. The mixture was quenched with water (5 mL) and the mixture was diluted with petroleum ether/ethyl acetate (50 mL/5 mL) and water (50 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound 2-bromo-6-fluoro-3-methyl- benzaldehyde (11.5 g, 52.9 mmol, 100% yield) was obtained as a colorless oil.

[01563] Step 2: (2-bromo-6-fluoro-3-methyl-phenyl)methanol. To a solution of 2-bromo-6-fluoro-3-methyl-benzaldehyde (11.5 g, 52.9 mmol, 1 eq) in MeOH (100 mL) was added $NaBH_4$ (2.20 g, 58.2 mmol, 1.1 eq) at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. The

mixture was quenched with water at 0 °C and the mixture was concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 50/1 to 3/1). The desired fractions were collected and concentrated under vacuum. Compound (2-bromo-6-fluoro-3-methyl-phenyl)methanol (8.5 g, 38.4 mmol, 73% yield, 99% purity) was obtained as a white solid. LCMS [ESI, M-17]: 201.

[01564] ^{1}H NMR (400MHz, chloroform-d) δ = 7.20 (dd, J = 6.4, 8.4 Hz, 1H), 6.98 (t, J = 8.8 Hz, 1H), 4.88 (d, J = 2.0 Hz, 2H), 2.41 (s, 3H), 2.35 - 2.11 (m, 1H).

[01565] Step 3: 3-bromo-2-(bromomethyl)-1- fluoro-4-methyl-benzene. To a mixture of (2-bromo-6-fluoro-3-methyl-phenyl)methanol (5 g, 22.8 mmol, 1 *eq*) in THF (100 mL) was added PBr_3 (12.4 g, 45.6 mmol, 2 *eq*) in portions at 0 °C. After stirred at 25 °C for 1 hour, the mixture was concentrated under vacuum. The residue was diluted with ethyl acetate (100 mL) and washed with ice water (1 × 50 mL), 10% aqueous sodium bicarbonate solution (2 × 50 mL) and brine (1× 20 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 10/1). Compound 3-bromo-2-(bromomethyl)-1- fluoro-4-methyl-benzene (5.6 g, 19.9 mmol, 87% yield) was obtained as a colorless oil.

[01566] ^{1}H NMR (400MHz, chloroform-d) δ = 7.20 (dd, J = 6.4, 8.0 Hz, 1H), 6.97 (t, J = 8.8 Hz, 1H), 4.70 (d, J = 2.0 Hz, 2H), 2.41 (s, 3H).

[01567] Step 4: 3-bromo-1-fluoro-2,4-dimethyl-benzene. To a solution of 3-bromo-2-(bromomethyl)-1-fluoro-4- methyl-benzene (5.6 g, 19.9 mmol, 1 *eq*) in DMF (50 mL) was added $NaBH_4$ (1.50 g, 39.7 mmol, 2 *eq*) and $AgNO_3$ (6.75 g, 39.7 mmol, 6.68 mL, 2 *eq*) at 25 °C. The mixture was stirred at 25 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was concentrated under reduced pressure. Compound 3-bromo-1-fluoro-2,4-dimethyl-benzene (2.1 g, 9.93 mmol, 50% yield, 96% purity) was obtained as a colorless oil.

[01568] ^{1}H NMR (400MHz, chloroform-d) δ = 7.05 (dd, *J* = 6.0, 8.4 Hz, 1H), 6.91 (t, *J* = 8.8 Hz, 1H), 2.38 (s, 3H), 2.35 (d, *J* = 2.4 Hz, 3H).


[01569] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 1.06 mmol, 1 *eq*), 3-bromo-1-fluoro-2,4-dimethyl- benzene (430 mg, 2.12 mmol, 2 *eq*), RuPhos-Pd-G3 (177 mg, 212 umol, 0.2 *eq*), Cs_2CO_3 (863 mg, 2.65 mmol, 2.5 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 70 °C for 12 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, ethyl acetate/methanol = 100/1 to 10/1) and further purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Compound *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (20 mg, 28.6 umol, 3% yield, 85% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 594.

[01570] Step B: 2-[(2*S*)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-fluoro- 2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (20 mg, 33.7 umol, 1 *eq*) in DCM (100 uL) was added TFA (57.6 mg, 505 umol, 37.4 uL, 15 *eq*). After stirred at 25 °C for 1 hour, the reaction mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (20.5 mg, 33.7 umol, 100% yield, TFA) was obtained as a yellow oil.


[01571] Step C: 2-[(2*S*)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(3-fluoro-2,6-dimethyl- phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (20.5 mg, 33.7 umol, 1 *eq*, TFA) in DCM (1 mL) was added TEA (34.1 mg, 337 umol, 46.9 uL, 10 *eq*) at - 40 °C. Then prop-2-enoyl chloride (3.05 mg, 33.7 umol, 2.75 uL, 1 *eq*) in DCM (1 mL) was added dropwised and the mixture was stirred at - 40 °C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (0.1 mL) and concentrated under vacuum. The residue was purified by prep-TLC (SiO_2, dichloromethane/methanol = 10/1) and further purified by prep-HPLC (column: Phenomenex Synergi C18 150 * 25 * 10um; mobile phase: [water (0.225% FA) - ACN]; B%: 16% - 43%, 9min). Title compound 2-[(2*S*)-4-[7-(3-fluoro-2,6-dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 349, 0.39 mg, 0.693 umol, 2% yield, 97.3% purity) was obtained as a colorless solid. LCMS [ESI, M+1]: 548.

[01572] ^{1}H NMR (400MHz, chloroform-d) δ = 7.06 - 6.92 (m, 1H), 6.84 (t, *J* = 8.8 Hz, 1H), 6.70 - 6.49 (m, 1H), 6.42 (d, *J* = 15.2 Hz, 1H), 5.85 (d, *J* = 10.4 Hz, 1H), 5.09 (br s, 1H), 4.60 (br s, 1H), 4.39 - 4.27 (m, 1H), 4.25 - 3.83 (m, 5H), 3.75 - 3.22 (m, 5H), 3.19 - 2.47 (m, 10H), 2.34 - 2.21 (m, 6H), 2.21 - 1.89 (m, 4H).

EXAMPLE 350



2-((*S*)-1-acryloyl-4-(7-(3-hydroxynaphthalen-1-yl)-2-(((*R*)-1-methylpyrrolidin-3-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01573] Step A: *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1- naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of 3-benzyloxy-1-bromo-naphthalene (Intermediate 29, 1.01 g, 3.21 mmol, 1.3 *eq*), *tert*-butyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (Intermediate 66, 1 g, 2.47 mmol, 1 *eq*), Cs_2CO_3 (2.01 g, 6.18 mmol, 2.5 *eq*), RuPhos (230 mg, 494 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (452 mg, 494 umol, 0.2 *eq*) in toluene (50 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 5 hours under N_2 atmosphere. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 100/1 to 3/1). Compound *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1- naphthyl)-2-methylsulfanyl-6,8-

dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.2 g, 1.71 mmol, 69% yield, 91% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 637.

[01574] Step B: *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1- naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.2 g, 1.88 mmol, 1 *eq*) in ethyl acetate (50 mL) was added *m*-CPBA (382 mg, 1.88 mmol, 85% purity, 1 *eq*) at 0 °C. After stirred at 0 °C for 0.5 hour, the reaction mixture was quenched with saturated $Na_2S_2O_3$ aqueous solution (20 mL), and then extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH = 100/1 to 10/1). Compound *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (900 mg, 1.30 mmol, 69% yield, 94% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 653.

[01575] Step C: *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-methyl pyrrolidin-3-yl]methoxy]-6,8-*d*ihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (793 mg, 1.22 mmol, 1 *eq*) in toluene (10 mL) was added *t*-BuONa (350 mg, 3.65 mmol, 3 *eq*) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol (420 mg, 3.65 mmol, 3 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 10/1 to 0/1). Compound *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*)-1-methyl pyrrolidin-3-yl]methoxy]-6,8-*d*ihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (700 mg, 944 umol, 78% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 704.

[01576] Step D: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-hydroxy-1-naphthyl)-2- [[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. NH_3 was bubbled into MeOH (100 mL) at - 60 °C for 10 minutes. To a solution of *tert*-butyl (2*S*)-4-[7-(3-benzyloxy-1-naphthyl)-2-[[(3*R*) -1-methylpyrrolidin-3-yl]methoxy]-6,8-*d*ihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (700 mg, 994 umol, 1 *eq*) in MeOH (20 mL) was added dry Pd/C (300 mg, 10% purity) and the above NH_3•MeOH solution (20mL) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The catalyst was filtered off and the filtrate was concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(3-hydroxy-1-naphthyl)-2- [[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 619 umol, 62% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 614.

[01577] ^{1}H NMR (400MHz, chloroform-d) δ = 8.02 (d, *J* = 8.4 Hz, 1H), 7.62 (d, *J* = 8.4 Hz, 1H), 7.38 (t, *J* = 7.2 Hz, 1H), 7.29 (t, *J* = 7.2 Hz, 1H), 6.88 (d, *J* = 2.0 Hz, 1H), 6.70 (d, *J* = 2.0 Hz, 1H), 4.57 (br s, 1H), 4.36 - 4.22 (m, 2H), 4.17 - 4.14 (m, 1H), 4.02 (br d, *J* = 13.6 Hz, 2H), 3.85 (br d, *J* = 12.8 Hz, 1H), 3.47 - 3.08 (m, 3H), 3.07 - 2.64 (m, 12H), 2.56 (s, 3H), 2.27 - 2.14 (m, 1H), 1.89 - 1.75 (m, 1H), 1.52 (s, 9H).


[01578] Step E: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(3- hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 651 umol, 1 *eq*) in DCM (500 uL) was added TFA (743 mg, 6.52 mmol, 482 uL, 10 *eq*). After stirred at 25 °C for 1 hour, the reaction mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (409 mg,

crude, TFA) was obtained as a brown oil and used next step directly without purification. LCMS [ESI, M+1]: 514.


[01579] Step F: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin- 3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (409 mg, 651 umol, 1 *eq*, TFA) in DCM (10 mL) was added TEA (659 mg, 6.52 mmol, 907 uL, 10 *eq*) at 0 °C. After addition, prop-2-enoyl chloride (53.1 mg, 586 umol, 47.8 uL, 0.9 *eq*) in DCM (1 mL) was added dropwise at -40 °C. The resulting mixture was stirred at -40 °C for 0.5 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH = 100/1 to 5/1) and further purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225%FA) - ACN]; B%: 11% - 41%, 10 min). The mixture was adjusted pH = 8 with saturated $NaHCO_3$ aqueous solution and extracted with dichloromethane (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Title compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin- 3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 350, 25.5 mg, 39.9 umol, 6% yield, 89% purity) was obtained as a brown solid. LCMS [ESI, M+1]: 568.

[01580] ^{1}H NMR (400MHz, Acetic acid-d_4) δ = 8.07 (d, *J* = 8.4 Hz, 1H), 7.66 (d, *J* = 8.0 Hz, 1H), 7.39 (t, *J* = 7.2 Hz, 1H), 7.29 (t, *J* = 7.2 Hz, 1H), 6.96 (d, *J* = 2.0 Hz, 1H), 6.87 (d, *J* = 1.6 Hz, 1H), 6.75 (br s, 1H), 6.38 (d, *J* = 16.8 Hz, 1H), 5.87 (d, *J* = 10.0 Hz, 1H), 5.23 - 5.01 (m, 1H), 4.98 - 4.49 (m, 4H), 4.43 (s, 1H), 4.33 (s, 2H), 4.23 - 4.00 (m, 1H), 3.99 - 3.51 (m, 5H), 3.50 - 3.23 (m, 4H), 3.17 - 2.91 (m, 8H), 2.63 - 2.24 (m, 1H).

EXAMPLE 351



2-[(2*S*)-4-[2-(1*H*-imidazol-2-ylmethoxy)-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01581] Step 1: ethyl 1-tetrahydropyran-2-ylimidazole-2-carboxylate. A mixture of ethyl 1*H*-imidazole-2-carboxylate (5 g, 35.7 mmol, 1 *eq*), DHP (33.0 g, 392 mmol, 35.9 mL, 11.0 *eq*) and PTSA•H_2O (400 mg, 2.32 mmol, 6.51e-2 *eq*) in THF (100 mL) was stirred at 60 °C (oil bath temperature) for 16 hours. Upon completion, the mixture was concentrated under vacuum and then diluted with ethyl acetate (100 mL) and water (100 mL). The separated organic layer was

washed with brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 20/1 to 1/1) to give ethyl 1-tetrahydropyran-2-ylimidazole-2-carboxylate (6.2 g, 26.0 mmol, 73% yield, 94% purity) as a light yellow oil.

[01582] ^{1}H NMR (400MHz, chloroform-d) δ = 7.40 (d, *J* = 0.8 Hz, 1H), 7.16 (d, *J* = 0.8 Hz, 1H), 6.21 (dd, *J* = 2.0, 10.0 Hz, 1H), 4.39 (dq, *J* = 0.8, 7.2 Hz, 2H), 4.20 - 4.10 (m, 1H), 3.71 (dt, *J* = 2.8, 11.6 Hz, 1H), 2.13 - 2.03 (m, 1H), 2.03 - 1.88 (m, 1H), 1.80 - 1.55 (m, 4H), 1.42 (t, *J* = 7.2 Hz, 3H).

[01583] Step 2: (1-tetrahydropyran-2-ylimidazol-2-yl)methanol. A solution of ethyl 1-tetrahydropyran-2-ylimidazole-2-carboxylate (2 g, 8.92 mmol, 1 *eq*) in THF (40 mL) was added $LiAlH_4$ (758 mg, 20.0 mmol, 2.24 *eq*) in 3 portions at 0 °C. The mixture was stirred at 0 °C for 1 hour. Upon completion, the mixture was quenched with saturated aqueous Na_2SO_4 (2.89 mL), filtered and the filtrate was concentrated. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 1/0 to 10/1) to give (1-tetrahydropyran-2-ylimidazol-2-yl)methanol (1.57 g, 7.75 mmol, 87% yield, 90% purity) as a yellow oil.

[01584] ^{1}H NMR (400 MHz, methanol-d_4) δ = 7.27 (d, *J* = 1.6 Hz, 1H), 6.89 (d, *J* = 1.2 Hz, 1H), 5.54 (dd, *J* = 2.4, 10.0 Hz, 1H), 4.74 - 4.61 (m, 2H), 4.15 - 3.99 (m, 1H), 3.76 - 3.68 (m, 1H), 2.06 - 1.88 (m, 3H), 1.84 - 1.60 (m, 3H).

[01585] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-methylsulfinyl-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 64, 380 mg, 654 umol, 1 *eq*) and (1-tetrahydropyran-2-ylimidazol-2-yl)methanol (238 mg, 1.31 mmol, 2 *eq*) in toluene (0.4 mL) was added *t*-BuONa (126 mg, 1.31 mmol, 2 *eq*) at 0 °C. The mixture was stirred at 0 °C for 20 minutes. Upon completion, the mixture was concentrated under vacuum. The residue was diluted with water (10 mL) and extracted with EtOAc (2 × 20 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by chromatography (SiO_2, PE/EtOAc 3/1 to 1/3) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazine-1-carboxylate (270 mg, 363.19 umol, 56% yield, 94% purity) as a yellow solid. LCMS [ESI, M+1]: 699.

[01586] Step B: 2-[(2*S*)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. NH_3 was bubbled into MeOH (3 mL) at -40 °C for 10 minutes. A solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2- ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (260 mg, 372 umol, 1 *eq*) in MeOH (3 mL) was added above solution, then Pd/C (100 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 6 times. The reaction was stirred under H_2 (15 psi) at 28 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, 275 umol, 74% yield, 97% purity) as a yellow solid which was used directly into the next step without further purification. LCMS [ESI, M+1]: 565.

[01587] Step C: 2-[(2*S*)-4-[7-(1-naphthyl)-2-[(1- tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2- ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, 283 umol, 1.00 *eq*) and DIEA (73.2 mg, 567 umol, 98.7 uL, 2.00 *eq*) in DCM (3 mL) was added prop-2-enoyl chloride (38.5 mg, 425 umol, 34.7 uL, 1.50 *eq*) dropwise at -40 °C. The mixture was stirred at -40 °C for 10 minutes. Upon completion, to the mixture was added saturated aqueous $NaHCO_3$ (1 mL) and water (3 mL). Layers were separated. The aqueous phase was extracted with EtOAc (2 × 5 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, EtOAc/MeOH 50/1 to 10/1) to give 2-[(2*S*)-4-[7-(1-naphthyl)-2-[(1- tetrahydropyran-2-ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (80 mg, 101 umol, 36% yield, 78% purity) as a yellow solid. LCMS [ESI, M+1]: 619.


[01588] Step D: 2-[(2*S*)-4-[2-(1*H*-imidazol-2- ylmethoxy)-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. A solution of 2-[(2*S*)-

4-[7-(1-naphthyl)-2-[(1-tetrahydropyran-2- ylimidazol-2-yl)methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (67 mg, 84.5 umol, 1 *eq*) and TsOH•H_2O (48.2 mg, 253 umol, 3 *eq*) in MeCN (1.5 mL) was stirred at 60 °C for 3 hours. Upon completion, the mixture was quenched with saturated aqueous $NaHCO_3$ (1 mL) at 0 °C. The residue was purified by reversed-phase flash [water (0.1% NH_3•H_2O)/acetonitrile]. The desired fractions were collected and lyophilized. The crude product was purified by prep-HPLC (column: PhenomenexSynergi C18 150*30mm*4um; mobile phase: [water (0.225%FA) - ACN]; B%: 20% - 50%, 10.5 min). The desired fractions were collected and lyophilized. to give title compound 2-[(2*S*)-4-[2-(1*H*-imidazol-2- ylmethoxy)-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 351, 2.55 mg, 4.22 umol, 5.4% yield, 96% purity, FA) as a white solid. LCMS [ESI, M+1]: 535.


[01589] SFC Condition: Column: Chiralpak AS-3 50×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm

[01590] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.26 - 8.20 (m, 1H), 7.92 - 7.82 (m, 1H), 7.63 (d, *J*=8.4 Hz, 1H), 7.56 - 7.48 (m, 2H), 7.45 (t, *J*=8.0 Hz, 1H), 7.17 (d, *J*=7.2 Hz, 1H), 7.08 - 6.99 (m, 2H), 6.69 - 6.52 (m, 1H), 6.46 - 6.32 (m, 1H), 5.84 (br d, *J*=11.2 Hz, 1H), 5.56 - 5.44 (m, 2H), 5.24 - 4.90 (m, 1H), 4.88 - 4.14 (m, 4H), 4.14 - 3.79 (m, 2H), 3.79 - 3.37 (m, 3H), 3.35 - 2.64 (m, 4H), 2.61 - 2.49 (m, 1H).

EXAMPLE 352



2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01591] 3-bromo-4-cyclopropyl-pyridine. A mixture of 3,4-dibromopyridine (3.0 g, 12.7 mmol, 1.0 *eq*), cyclopropylboronic acid (1.09 g, 12.7 mmol, 1.0 *eq*), $Pd(dppf)Cl_2$ (927 mg, 1.27 mmol, 0.10 *eq*), K_3PO_4 (8.06 g, 38.0 mmol, 3.0 *eq*) in DMF (15.0 mL) and H_2O (3.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 60 °C for 6 hrs under N_2 atmosphere. The organic solvent was washed with water (80.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 100 mL). Combine extracts were washed with brine (300 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether : Ethyl acetate=30 : **1** to 20 **: 1**). Compound 3-bromo-4-cyclopropyl-pyridine (630mg, 3.17 mmol, 25% yield, 99.6% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 198.

[01592] ^1H NMR (400MHz, CHLOROFORM-d) δ = 8.69 – 8.61 (m, 1H), 8.39 – 8.32 (m, 1H), 6.75 – 6.71 (m, 1H), 2.29 – 2.18 (m, 1H), 1.20 – 1.12 (m, 2H), 0.84 – 0.77 (m, 2H).


[01593] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 500 mg, 1.06 mmol, 1.0 *eq*), 3-bromo-4-cyclopropyl-pyridine (315 mg, 1.59 mmol, 1.50 *eq*), $Pd_2(dba)_3$ (97.09 mg, 106 umol, 0.10 *eq*), RuPhos (99.0 mg, 212 umol, 0.20 *eq*) and Cs_2CO_3 (1.04 g, 3.18 mmol, 3.0 *eq*) in toluene (5.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 12 hrs under N_2 atmosphere. The organic solvent was washed with water (15.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 20 mL). Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by reversed phase flash HPLC [C18, 0.1% NH_3•H_2O in water, 0-60% MeCN]. The obtained product was then concentrated, the aqueous was extracted with EA (3 × 50 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 260 umol, 24.5% yield, 85% purity)was obtained as a yellow solid. LCMS [ESI, M+1]:589.

[01594] Step B: 2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (30.0 mg, 43.3 umol, 1.0 *eq*) in dioxane (1.0 mL) was added HCl•dioxane (4 M, 1.0 mL, 92.4 *eq*). The mixture was stirred at 25 °C for 30 min under N_2 atmosphere. The organic solvent was removed under vacuum. The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (3 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (30.0 mg, crude) was obtained as a yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 489.


[01595] Step C: 2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (30.0 mg, 61.4 umol, 1.0 *eq*) in DCM (1.50 mL) was added TEA (31.1 mg, 307 umol, 42.7 uL, 5.0 *eq*) and prop-2-enoyl chloride (8.34 mg, 92.1 umol, 7.51 uL, 1.50 *eq*) at -60°C. The mixture was stirred at -60 °C for 30 min under N_2 atmosphere. The reaction was quenched with methanol (6.0 mL) and was removed under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 33%-63%,12min) and lyophilization. Title compound 2-[(2*S*)-4-[7-(4-cyclopropyl-3-pyridyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 352, 2.71 mg, 4.97 umol, 8.1% yield, 99.5% purity) was obtained as a white solid. LCMS [ESI, M+1]: 543.

[01596] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.29 (s 1H), 8.26 (d, *J*=5.2 Hz, 1H), 6.68 (d, *J*=5.2 Hz, 1H), 6.64 – 6.53 (m, 1H), 6.40 (dd, *J*=0.8 Hz, *J*=16.8 Hz, 1H), 5.52 (d, *J*=10.4 Hz, 1H), 5.07 (br s, 1H), 4.39 (dd, *J*=4.8 Hz, *J*=10.4 Hz, 1H), 4.29 – 4.23 (m, 1H), 4.21 – 4.15 (m, 2H), 4.13 – 4.07 (m, 1H), 4.00 – 3.95 (m, 1H), 3.57 (br s, 1H), 3.44 – 3.24 (m, 4H), 3.17 – 3.03 (m, 2H), 2.94 (dd, *J*=8.8 Hz, *J*=16.8 Hz, 1H), 2.87 – 2.80 (m, 2H), 2.73 – 2.64 (m, 1H), 2.49 (s, 3H), 2.35 – 2.22 (m, 3H), 2.11 – 2.00 (m, 1H), 1.89 – 1.76 (m, 3H),1.17 – 1.11 (m, 2H), 0.90 – 0.77 (m, 3H).

EXAMPLE 353



1-[(3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[01597] Step A: *tert*-butyl (3*R*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate. The solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (1.5 g, 5.10 mmol, 1 *eq*), *tert*-butyl (3*R*)-3-methylpiperazine-1-carboxylate (1.12 g, 5.61 mmol, 1.1 *eq*), DIEA (1.32 g, 10.2 mmol, 1.78 mL, 2 *eq*) in NMP (30 mL) was stirred at 100 °C for 7 hours. Water (90 mL) was added into the mixture. The resulting mixture was diluted with EtOAc (20 mL) and extracted with EtOAc (3 × 50 mL).The combined organic layers were washed with brine (40 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was slurried with (PE: EtOAc = 3:1, 20 mL) and filtered and the filter cake was washed with (PE: EtOAc = 3:1, 40 mL) to give *tert*-butyl (3*R*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate (0.9 g, 1.73 mmol, 34 % yield, 88.0 % purity) as a gray solid. LCMS [ESI, M+1]: 458.

[01598] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.38 - 7.27 (m, 5H), 4.28 - 4.18 (m, 1H), 4.16 - 3.80 (m, 2H), 3.74 (br d, *J* = 13.6 Hz, 1H), 3.68 (s, 2H), 3.65 - 3.52 (m, 2H), 3.41 - 3.27 (m, 1H), 3.21 - 2.89 (m, 2H), 2.74 - 2.58 (m, 4H), 1.48 (s, 9H), 1.23 (d, *J* = 6.8 Hz, 3H).

[01599] Step B: *tert*-butyl (3*R*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate. To the solution of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (566 mg, 4.91 mmol, 583 uL, 2.5 *eq*) in THF (20 mL)

was added NaH (157 mg, 3.93 mmol, 60.0 % purity, 2 *eq*) at 0 °C and stirred at 0 °C for 0.5 hour. Then *tert*-butyl (3*R*)-4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3-methyl-piperazine-1-carboxylate (900 mg, 1.97 mmol, 1 *eq*) was added to the mixture. The reaction mixture was heated to 70 °C for 12 hours in a tube under N_2.The mixture was quenched by Water (15 mL). The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (40 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 35 %) to give *tert*-butyl (3*R*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (680 mg, 1.14 mmol, 58 % yield, 90.0 % purity) as a brown solid. LCMS [ESI, M+1]: 537.

[01600] Step C: *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl (3*R*)-4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-methyl-piperazine-1-carboxylate (680 mg, 1.27 mmol, 1 *eq*) in MeOH (14 mL) was added $Pd(OH)_2/C$ (340 mg, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 4 hours. The reaction mixture was filtered, the filter cake was washed with MeOH (3 × 10 mL), and the fitrate was concentrated under vacuum to give *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (540 mg, 1.09 mmol, 86 % yield, 90.0 % purity) as a brown solid which was used for next step without further purification.

[01601] Step D: *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (520 mg, 1.16 mmol, 1 *eq*), 1-bromonaphthalene (482 mg, 2.33 mmol, 324 uL, 2 *eq*), RuPhos (109 mg, 233 umol, 0.2 *eq*) and Cs_2CO_3 (1.14 g, 3.49 mmol, 3 *eq*) in toluene (11 mL) was added $Pd_2(dba)_3$ (107 mg, 116 umol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 105 °C for 7 hours. Water (10 mL) was added into the

mixture. The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 5:1 to 0:1). Then the residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 61 %). Compound *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (330 mg, 547 umol, 47 % yield, 95.0 % purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 573.

[01602] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.26 - 8.18 (m, 1H), 7.89 - 7.84 (m, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 4.41 (dd, *J* = 5.2, 10.4 Hz, 1H), 4.26 (s, 3H), 4.18 - 4.14 (m, 1H), 4.03 - 3.68 (m, 2H), 3.45 - 3.00 (m, 6H), 2.84 (br s, 2H), 2.69 (br d, *J* = 6.4 Hz, 1H), 2.50 (s, 3H), 2.35 - 2.24 (m, 1H), 2.12 - 2.06 (m, 1H), 1.91 - 1.70 (m, 4H), 1.50 (s, 9H), 1.32 - 1.27 (m, 3H).


[01603] Step E: 4-[(2*R*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. The mixture of *tert*-butyl (3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (330 mg, 576 umol, 1 *eq*) and TFA (657 mg, 5.76 mmol, 427 uL, 10 *eq*) was stirred at 30 °C for 40 mins. The mixture was concentrated under vacuum to give 4-[(2*R*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (340 mg, crude, TFA) as a brown oil which was used for next step without further purification.

[01604] Step F: 1-[(3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To the solution of 4-[(2*R*)-2-methylpiperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (340 mg, crude, TFA), TEA (586 mg, 5.80 mmol, 807 uL) in DCM (6 mL) was added prop-2-enoyl chloride (78.7 mg, 869 umol, 70.9 uL) at -40 °C, the mixture was stirred at -40 °C for 0.5 hour. The mixture was quenched by saturated $NaHCO_3$ (2 mL). The mixture was diluted with EtOAc (5 mL) and extracted with EtOAc (10 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase:


[water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,12min) to give title compound 1-[(3*R*)-3-methyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 353, 85.5 mg, 162 umol, two steps 28 % yield, 99.8 % purity) as a white solid. LCMS [ESI, M+1]: 527.


[01605] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.23 (br d, *J* = 9.2 Hz, 1H), 7.90 - 7.84 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 6.70 - 6.52 (m, 1H), 6.37 (dd, *J* = 1.6, 16.8 Hz, 1H), 5.77 (br d, *J* = 10.0 Hz, 1H), 4.66 - 4.31 (m, 3H), 4.27 (s, 2H), 4.14 (dd, *J* = 6.8, 10.4 Hz, 1H), 4.02 - 3.73 (m, 2H), 3.64 - 3.25 (m, 4H), 3.24 - 2.99 (m, 2H), 2.86 (br s, 2H), 2.74 - 2.63 (m, 1H), 2.49 (s, 3H), 2.34 - 2.24 (m, 1H), 2.13 - 2.00 (m, 1H), 1.90 - 1.74 (m, 3H), 1.28 (br d, *J* = 4.4 Hz, 3H).

EXAMPLE 354



1-[3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[01606] Step A: *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,3-dimethyl-piperazine-1-carboxylate. The solution of 7-benzyl-2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (1.5 g, 5.10 mmol, 1 *eq*) and *tert*-butyl 3,3-dimethylpiperazine-1-carboxylate (4.37 g, 20.4mmol, 4 *eq*) was stirred at 130 °C for 22 hours. The residue was used directly to purify. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 10:1).Then the residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*80mm*10 um;mobile phase: [water (0.225 %FA) - ACN]; B%: 30 %-60 %, 35 min, 60 % min) to give *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,3-dimethyl-piperazine-1-carboxylate (1 g, 2.12 mmol, 42 % yield, 100 % purity) as a yellow solid. LCMS [ESI, M+1]: 472.

[01607] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.39 - 7.28 (m, 5H), 4.01 (t, *J* = 5.6 Hz, 2H), 3.69 (s, 2H), 3.55 - 3.44 (m, 6H), 2.78 - 2.66 (m, 4H), 1.51 (s, 6H), 1.48 (s, 9H).

[01608] Step B: *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,3-dimethyl-piperazine-1-carboxylate. To the solution of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (610 mg, 5.30 mmol, 629 uL, 2.5 *eq*) in THF (20 mL) was added NaH (169 mg, 4.24 mmol, 60 % purity, 2 *eq*) at 0 °C and stirred at 0 °C for 0.5 hour. Then *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl)-3,3-dimethyl-piperazine-1-carboxylate (1 g, 2.12 mmol, 1 *eq*) was added to the mixture. The reaction mixture was heated to 70 °C for 12 hours in a tube under N_2. The reaction mixture was quenched by Water (10 mL). The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna

C18 250*50mm*10 um;mobile phase: [water(0.225%FA)-ACN];B%: 25 %-50 %,30;79 % min) to give *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,3-dimethyl-piperazine-1-carboxylate (980 mg, 1.69 mmol, 80 % yield, 95.0 % purity) as a yellow oil. LCMS [ESI, M+1]: 551.

[01609] Step C: *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl 4-[7-benzyl-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3,3-dimethyl-piperazine-1-carboxylate (980 mg, 1.78 mmol, 1 *eq*) in MeOH (20 mL) was added $Pd(OH)_2/C$ (500 mg, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 4 hours. The mixture was filtered, the filter cake was washed with MeOH (3 × 10 mL). The filtrate was concentrated under vacuum to give *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (780 mg, 1.69 mmol, 95 % yield, 100 % purity) as a colorless oil which was used for next step without further purification. LCMS [ESI, M+1]: 461.

[01610] Step D: *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 868 umol, 1 *eq*), 1-bromonaphthalene (360 mg, 1.74 mmol, 241 uL, 2 *eq*), Cs_2CO_3 (849 mg, 2.61 mmol, 3 *eq*) and RuPhos (81.0 mg, 174 umol, 0.2 *eq*) in toluene (8 mL) was added $Pd_2(dba)_3$ (79.5 mg, 86.8 umol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 95 °C for 8 hours. Water (10 mL) was added into the mixture. The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 10:1 ~ 0:1). Then the residue was purified by reversed phase flash column (ACN/Water (0.1 % FA) = 52 %) to give *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 340 umol, 39 % yield, 95.0 % purity) as a white solid. LCMS [ESI, M+1]: 587.

[01611] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.22 (dd, *J* = 3.2, 6.4 Hz, 1H), 7.87 - 7.82 (m, 1H), 7.58 (d, *J* = 8.4 Hz, 1H), 7.51 - 7.45 (m, 2H), 7.42 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 4.39 - 4.27 (m, 2H), 4.12 - 4.05 (m, 3H), 3.60 - 3.26 (m, 6H), 3.14 (br t, *J* = 7.6 Hz, 1H), 2.79 (br s, 2H), 2.74 - 2.65 (m, 1H), 2.53 (s, 3H), 2.39 - 2.28 (m, 1H), 2.05 - 2.00 (m, 1H), 1.92 - 1.70 (m, 4H), 1.58 (br d, *J* = 4.0 Hz, 6H), 1.49 (s, 9H).


[01612] Step E: 4-(2,2-dimethylpiperazin-1-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. The solution of *tert*-butyl 3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 358 umol, 1 *eq*) and TFA (408 mg, 3.58 mmol, 265 uL, 10 *eq*) was stirred at 30 °C for 0.5 hour. The mixture was concentrated under vacuum to give 4-(2,2-dimethylpiperazin-1-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (210 mg, crude, TFA) as a brown oil which was used for next step without further purification.

[01613] Step F: 1-[3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To the solution of 4-(2,2-dimethylpiperazin-1-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (210 mg, crude, TFA) and TEA (531 mg, 5.24 mmol, 730 uL) in DCM (4 mL) was added prop-2-enoyl chloride (47.5 mg, 524 umol, 42.8 uL) at -40 °C, the mixture was stirred at -40 °C for 0.5 hour. The mixture was quenched by water (2 mL). The mixture was diluted with EtOAc (5 mL) and extracted with EtOAc (10 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05 % ammonia hydroxide v/v)-ACN];B%: 73 %-100 %,12min) to give title compound 1-[3,3-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 354, 104 mg, 189 umol, 53 % yield, 98.6 % purity) as a white solid. LCMS [ESI, M+1]: 541.


[01614] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.26 - 8.18 (m, 1H), 7.85 (dd, *J* = 3.2, 6.4 Hz, 1H), 7.58 (d, *J* = 8.0 Hz, 1H), 7.48 (dd, *J* = 3.2, 6.4 Hz, 2H), 7.42 (t, *J* = 7.6 Hz, 1H), 7.15 (br d, *J* = 7.2 Hz, 1H), 6.65 - 6.52 (m, 1H), 6.48 - 6.33 (m, 1H), 5.79 - 5.70 (m, 1H), 4.37 - 4.26 (m, 2H), 4.21 (br t, *J* = 5.6 Hz, 1H), 4.17 - 4.06 (m, 3H), 3.80 (s, 1H), 3.78 - 3.69 (m, 2H), 3.61

(s, 1H), 3.39 (br s, 2H), 3.13 (br t, J = 7.6 Hz, 1H), 2.80 (br s, 2H), 2.73 - 2.65 (m, 1H), 2.52 (s, 3H), 2.37 - 2.28 (m, 1H), 2.09 - 1.99 (m, 1H), 1.94 - 1.68 (m, 3H), 1.62 (br s, 6H).

EXAMPLE 355



1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[01615] Step A: *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl) piperazine-1-carboxylate. To a solution of 7-benzyl-4-chloro-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (5.0 g, 16.4 mmol, 1.0 *eq*) and *tert*-butyl piperazine-1-carboxylate (4.57 g, 24.5 mmol, 1.50 *eq*) in DMSO (20.0 mL) was added DIEA (6.34 g, 49.1 mmol, 8.54 mL, 3.0 *eq*). The mixture was stirred at 60 °C for 5 hours. After completion, the mixture was added water (200 mL) and extracted with EA (200 mL × 3). The organic layer was washed with brine (500 mL), dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE : EA = 50:1 - 5:1) to give *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl) piperazine-1-carboxylate (7.0 g, 15.4 mmol, 93% yield).as light brown solid. LCMS [ESI, M+1]: 456.

[01616] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.40 - 7.27 (m, 5H), 3.68 (s, 2H), 3.58 (s, 2H), 3.54 - 3.48 (m, 4H), 3.47 - 3.38 (m, 4H), 2.65 (s, 4H), 1.48 (s, 9H).

[01617] Step B: *tert*-butyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate. To a solution of *tert*-butyl 4-(7-benzyl-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (7.0 g, 15.4 mmol, 1.0 *eq*) and DIEA (5.96 g, 46.1 mmol, 8.03 mL, 3.0 *eq*) in DCE (100 mL) was added 1-chloroethyl carbonochloridate (5.49 g, 38.4 mmol, 2.5 *eq*) at 0 °C. The mixture was stirred at 15 °C for 2 hours. Then the mixture was concentrated. The residue was dissolved with MeOH (100 mL) and heated to 70 °C, the reaction mixture was stirred at 70 °C for 1 hour. After completion, the mixture was concentrated under vacuum. The obtained product was purified by reversed phase flash column (C18, 0.1% FA in water , 0-50% MeCN) to give *tert*-butyl 4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (4.6 g, 12.6 mmol, 82% yield) as a yellow solid. LCMS [ESI, M+1]: 366.

[01618] Step C: To a solution of *tert*-butyl 4-(2-methylsulfanyl -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (3.60 g, 9.85 mmol, 1.0 *eq*), (3-methoxy-1-naphthyl) trifluoromethanesulfonate (Intermediate 30, 7.54 g, 24.6 mmol, 2.50 *eq*), RuPhos (919 mg, 1.97 mmol, 0.20 *eq*) and Cs_2CO_3 (9.63 g, 29.6 mmol, 3.0 *eq*) in toluene (30.0 mL) was added $Pd_2(dba)_3$ (1.35 g, 1.48 mmol, 0.15 *eq*). The mixture was degassed under vacuum and purged with N_2 3 times. Then the mixture was stirred at 90 °C for 8 hours. After completion,

the mixture was added water (50.0 mL) and extracted with EA (50.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA = 20:1 - EA:MeOH = 10:1) to give *tert*-butyl 4-[7-(3-methoxy-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (4.60 g, 8.82 mmol, 89% yield) as yellow solid. LCMS [ESI, M+1]: 522.

[01619] Step D: *tert*-butyl 4-[7-(3-methoxy -1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-(3-methoxy-1-naphthyl)- 2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (3.80 g, 7.28 mmol, 1.0 *eq*) in EA (40.0 mL) was added m-CPBA (1.41 g, 6.56 mmol, 0.90 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with saturated $NaHSO_3$ aqueous (30.0 mL) and extracted with EA (50.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by reversed phase flash column (C18, 0.1% FA in water, 0-60 % MeCN) to give *tert*-butyl 4-[7-(3-methoxy -1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (2.70 g, 5.02 mmol, 69% yield) as yellow solid.

[01620] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.07 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.52 - 7.42 (m, 1H), 7.39 - 7.33 (m, 1H), 6.92 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 2.0 Hz, 1H), 4.42 (br s, 2H), 3.93 (s, 3H), 3.61 (br d, J = 4.0 Hz, 8H), 3.52 - 3.34 (m, 2H), 3.08 - 2.81 (m, 5H), 1.50 (s, 9H).

[01621] Step E: *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-(3-methoxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.49 mmol, 1.0 *eq*) and t-BuONa (286 mg, 2.98 mmol, 2.0 *eq*) in toluene (8.0 mL) was added [(2S,4R)-4-fluoro -1-methyl-pyrrolidin-2-yl]methanol (396 mg, 2.98 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 2 hours. After completion, the mixture was added water (10.0 mL) and extracted with EA (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by reversed phase flash column (C18, 0.1 % FA in water , 0-60 % MeCN) to give *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-

naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (670 mg, 1.10 mmol, 74% yield) as yellow solid.


[01622] ^{1}H NMR (400 MHz, Chloroform-d) δ = 8.09 (d, *J* = 8.4 Hz, 1H), 7.75 (d, *J* = 8.0 Hz, 1H), 7.48 - 7.41 (m, 1H), 7.38 - 7.31 (m, 1H), 6.90 (d, *J* = 2.0 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 5.29 - 5.06 (m, 1H), 4.44 (dd, *J* = 4.4, 10.8 Hz, 1H), 4.27 - 4.20 (m, 3H), 3.92 (s, 3H), 3.66 - 3.43 (m, 9H), 3.36 (br s, 2H), 3.11 - 2.99 (m, 1H), 2.85 (br s, 2H), 2.70 - 2.55 (m, 1H), 2.52 (s, 3H), 2.40 - 2.26 (m, 1H), 2.05 - 1.91 (m, 1H), 1.50 (s, 9H).

[01623] Step F: 2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3 -methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. To a solution of *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1 -methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 1.07 mmol, 1.0 *eq*) in DCM (1.50 mL) was added TFA (2.39 g, 21.0 mmol, 1.55 mL, 19.6 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the mixture was concentrated under vacuum. The product 2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3 -methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (780 mg, crude, 2 TFA) as yellow oil. LCMS [ESI, M+1]: 507.


[01624] Step G: 1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To a solution of 2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (780 mg, 1.06 mmol, 1.0 *eq*, 2 TFA) and DIEA (1.65 g, 12.7 mmol, 2.22 mL, 12.0 *eq*) in DCM (8.0 mL) was added prop-2-enoyl prop-2-enoate (201 mg, 1.59 mmol, 1.50 *eq*) at -50 °C. The mixture was stirred at -50 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (1 mL), then concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 46%-76%, 12min) to give title compound 1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 355, 300 mg, 528 umol, two steps 49% yield, 98% purity) as white solid. LCMS [ESI, M+1]: 561.


[01625] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.10 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.49 - 7.42 (m, 1H), 7.40 - 7.32 (m, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 6.61 (dd, J = 10.8, 16.8 Hz, 1H), 6.36 (dd, J = 2.0, 16.8 Hz, 1H), 5.77 (dd, J = 1.6, 10.4 Hz, 1H), 5.28 - 5.07 (m, 1H), 4.44 (dd, J = 4.8, 11.2 Hz, 1H), 4.30 - 4.19 (m, 3H), 3.93 (s, 3H), 3.84 (br s, 2H), 3.72 (br s, 2H), 3.65 - 3.50 (m, 5H), 3.37 (br s, 2H), 3.10 - 3.01 (m, 1H), 2.87 (br s, 2H), 2.70 - 2.55 (m, 1H), 2.52 (s, 3H), 2.42 - 2.26 (m, 1H), 2.07 - 1.90 (m, 1H).

EXAMPLE 356



1-[4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[01626] Step A: [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol. To a solution of *O*1-*tert*-butyl *O*2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (1.8 g, 6.94 mmol, 1.0 *eq*) in THF (30.0 mL) was added $LiAlH_4$ (790 mg, 20.8 mmol, 3.0 *eq*). The mixture was stirred at -40 °C for 1 hour. Then the mixture stirred 80 °C for 2 hours under N_2 atmosphere. The reaction mixture was quenched with saturated Na_2SO_4 aqueous solution (6.0 mL). Then the mixture was filtered and the filter was concentrated. Compound [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (1.1 g, 6.82 mmol, 98% yield, 90% purity) was obtained as a colorless oil and used to next step without further purification.

[01627] ^1H NMR (400 MHz, Chloroform-d) δ 3.90 - 3.82 (m, 1H), 3.66 (dd, *J* = 3.2 Hz, 10.8 Hz, 1H), 3.46 - 3.37 (m, 2H), 3.28 (s, 3H), 2.77 - 2.65 (m, 1H), 2.64 - 2.57 (m, 1H), 2.35 - 2.30 (m, 4H), 2.11 - 2.01 (m, 1H), 1.90 - 1.79 (m, 1H).

[01628] Step B: *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl 4-[7-(3-methoxy-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.49 mmol, 1.0 *eq*), [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (454 mg, 3.12 mmol, 2.1 *eq*), *t*-BuONa (286 mg, 2.98 mmol, 2.0 *eq*) in toluene (5.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 0 °C for 30 mins under N_2 atmosphere. After completion, the reaction mixture was added water (15.0 mL), extracted with ethyl acetate (3 × 20.0 mL). Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4, the solvent was then removed under vacuum. The residue was purified by reversed phase flash HPLC [C18, 0.1% FA in water, 0-60% MeCN]. The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH~8, then concentrated, the aqueous was extracted with EA (3 × 50.0 mL), the combined

organic layer was dried over Na_2SO_4, filtered and concentrated. Compound *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 808 umol, 54% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 619.


[01629] Step C: 2-[[(2*S*,4*R*)-4-methoxy-1-methyl -pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. To a solution of *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (450 mg, 727 umol, 1.0 *eq*) in DCM (6.0 mL) was added TFA (6.93 g, 60.8 mmol, 4.50 mL, 83.6 *eq*). The mixture was stirred at 25 °C for 30 mins. After completion, the organic solvent was removed under vacuum to give 2-[[(2*S*,4*R*)-4-methoxy-1-methyl -pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (540 mg, crude, 2TFA) as yellow oil. The crude product was used into the next step without further purification. LCMS [ESI, M+1]: 519.

[01630] Step D: 1-[4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl] methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To a solution of 2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-methoxy-1-naphthyl)-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (540 mg, 2TFA) in DCM (6.0 mL) was dropwise added prop-2-enoyl prop-2-enoate (130 mg, 1.03 mmol) and DIEA (800 mg, 6.19 mmol, 1.08 mL) under N_2 atmosphere. The mixture was stirred at 0 °C for 30 min. After completion, the reaction was quenched with methanol (10.0 mL) and the mixture was removed under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 48% - 78%, 12 min) and under lyophilization. Title compound 1-[4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl] methoxy]-7-(3-methoxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 356, 112 mg, 196 umol, 99% purity, 18% yield) was obtained as white solid. LCMS [ESI, M+1]: 573.


[01631] ^{1}H NMR (400 MHz, Chloroform-d) δ 8.09 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.48 - 7.44 (m, 1H), 7.38 - 7.34 (m, 1H), 6.91 (d, J = 2.4 Hz, 1H), 6.81 (d, J = 2.4 Hz, 1H), 6.61 (dd, J = 10.4 Hz, 16.8 Hz, 1H), 6.35 (dd, J = 2.0 Hz, 16.8 Hz, 1H), 5.76 (dd, J = 1.6


Hz, 9.6 Hz, 1H), 4.41 (dd, *J* = 4.8 Hz, 10.8 Hz, 1H), 4.24 (s, 2H), 4.22 - 4.16 (m, 1H), 4.00 - 3.94 (m, 1H), 3.92 (s, 3H), 3.83 - 3.67 (m, 4H), 3.62 - 3.48 (m, 4H), 3.47 - 3.42 (m, 1H), 3.40 - 3.33 (m, 2H), 3.30 (s, 3H), 2.94 - 2.82 (m, 3H), 2.47 (s, 3H), 2.33 (dd, *J* = 6.0 Hz, 10.0 Hz, 1H), 2.12 - 2.04 (m, 1H), 2.01 - 1.93 (m, 1H).

EXAMPLE 357



1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one





[01632] Step A: *tert*-butyl 4-[7-benzyl-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (631 mg, 4.74 mmol, 3.76 *eq*) in THF (7.0 mL) was added NaH (126 mg, 3.16 mmol, 60% purity, 2.51 *eq*) at 0 °C. Then the mixture was stirred at 0 °C for 0.5 hr. Then *tert*-butyl 4-(7-benzyl-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (700 mg, 1.26 mmol, 1.0 *eq*) was added to the above mixture. After addition, the mixture was stirred at 70 °C for 12 hrs. After completion, the mixture was quenched with saturated NH_4Cl aqueous (15.0 mL) and extracted with EA (3 × 20.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Dichloromethane: Methanol = 20:1 to 10:1) to give *tert*-butyl 4-[7-benzyl-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (530 mg, 980 umol, 78% yield) as yellow oil. LCMS [ESI, M+1]: 541.

[01633] ^{1}H NMR (400 MHz, Chloroform-*d*) δ 7.24 - 7.13 (m, 5H), 5.08 - 4.91 (m, 1H), 4.23 (dd, *J* = 4.4 Hz, 10.8 Hz, 1H), 4.04 (dd, *J* = 6.0 Hz, 10.8 Hz, 1H), 3.53 (s, 2H), 3.45 - 3.42 (m, 2H), 3.38 - 3.33 (m, 5H), 3.31 - 3.27 (m, 4H), 2.90 - 2.84 (m, 1H), 2.52 - 2.46 (m, 3H), 2.35 (s, 3H), 2.21 - 2.09 (m, 1H), 1.87 - 1.73 (m, 3 H), 1.34 (s, 9H).

[01634] Step B: *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-benzyl-2-[[(2*S*,4R)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (480 mg, 887 umol, 1 *eq*) in MeOH (6.0 mL) was added $Pd(OH)_2$/C (270 mg, 10% purity) under N_2. The suspension was degassed under

vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 Psi) at 20 °C for 2 hours. After completion, the mixture was filtered and concentrated. The residue was purified by column chromatography (SiO_2, EA/MeOH = 20:1 to 10:1). The product *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 706 umol, 79% yield, 91% purity) was obtained as yellow oil. LCMS [ESI, M+1]:451.

[01635] Step C: To a mixture of *tert*-butyl 4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 621 umol, 1.0 *eq*), $Pd_2(dba)_3$ (85.3 mg, 93.2 umol, 0.15 *eq*), RuPhos (58.0 mg, 124.3 umol, 0.2 *eq*) and Cs_2CO3 (404 mg, 1.24 mmol, 2.0 *eq*) in toluene (10.0 mL) was added (4-bromo-2-naphthyl) 2,2-dimethylpropanoate (Intermediate 54, 572 mg, 1.86 mmol, 3.0 *eq*). The mixture was stirred at 110 °C for 5 hrs under N_2. The mixture was quenched with water (15.0 mL) and extracted with EA (3 × 20.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash HPLC (^{18}C, 0.1% FA in water, 0-70% MeCN). The obtained product was adjusted with saturated $NaHCO_3$ aqueous to pH-8, then concentrated, the aqueous was extracted with EA (3 × 40.0 mL), the combined organic layer was dried over Na_2SO4, filtered and concentrated. Compound *tert*-butyl 4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 272 umol, 44% yield, 97% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 677.

[01636] Step D: [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-2-naphthyl]-2,2-dimethylpropanoate. To a mixture of *tert*-butyl 4-[7-[3-(2,2-dimethylpropanoyloxy)-1-naphthyl]-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (110 mg, 162 umol, 1.0 *eq*) in DCM (1.5 mL) was added TFA (2.31 g, 20.2 mmol, 1.5 mL, 124 *eq*) in portions at 25 °C under N_2. The mixture was stirred at 25 °C for 1 hr. After completion, the reaction mixture was concentrated to give [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-2-

naphthyl]-2,2-dimethylpropanoate (200 mg, crude, 2TFA) as yellow solid, which was used into the next step without further purification. LCMS [ESI, M+1]: 577.


[01637] Step E: [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-2-naphthyl]-2,2-dimethylpropanoate. To a mixture of [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-7-yl]-2-naphthyl]-2,2-dimethylpropanoate (200 mg, 2TFA) and TEA (493 mg, 4.87 mmol, 678 uL) in DCM (2.0 mL) was added prop-2-enoyl prop-2-enoate (40.9 mg, 324 umol) in portions at 0 °C under N_2. The mixture was stirred at 0 °C for 1 hr. After completion, the reaction mixture was quenched by MeOH (3.0 mL) at 0 °C, and then concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, EA/MeOH = 20:1 to 10:1). Compound [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-2-naphthyl]-2,2-dimethylpropanoate (100 mg, 153 umol, 97% purity) was obtained as a yellow oil. LCMS [ESI, M+1]:631.

[01638] Step F: 1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. A mixture of [4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-2-naphthyl]-2,2-dimethylpropanoate (39.0 mg, 61.8 umol, 1.0 *eq*) and NaOH (61.8 mg, 1.55 mmol, 25.0 *eq*) in THF (1.5 mL) and H_2O (1.5 mL) was stirred at 25 °C for 14 hours. After completion, the reaction mixture was quenched by water (10.0 mL) and then extracted with EA (3 × 15.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B: 38%-68%, 12min) and lyophilization. Title compound 1-[4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(3-hydroxy-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 357, 10.1 mg, 18.4 umol, 30% yield, 99% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 547.


[01639] SFC Conditions: 100% ee.


[01640] ^{1}H NMR (400 MHz, Chloroform-*d*) δ 8.04 (d, *J* = 8.4 Hz, 1H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.42 (t, *J* = 7.2 Hz, 1 H), 7.30 - 7.34 (m, 1H), 6.88 (d, *J* = 1.6 Hz, 1H), 6.72 (d, *J* = 2.0 Hz, 1H), 6.60 (dd, *J* = 10.4 Hz, 16.8 Hz, 1H), 6.37 (dd, *J* = 1.6 Hz, 16.8 Hz, 1H), 5.79 (dd, *J* = 2.0 Hz, 10.2 Hz, 1H), 5.28 - 5.14 (m, 1H), 4.46 (dd, *J* = 4.8 Hz, 11.2 Hz, 1H), 4.32 (dd, *J* = 5.2 Hz, 11.2 Hz, 1H), 4.18 (s, 2H), 3.82 - 3.68 (m, 2H), 3.66 - 3.55 (m, 4H), 3.52 - 3.42 (m 4H), 3.35 - 3.21 (m, 2H), 3.17 - 3.10 (m, 1H), 2.82 - 2.68 (m, 2H), 2.63 - 2.74 (m, 1H), 2.61 (s, 3H), 2.40 - 2.25 (m, 1H), 2.13 - 1.94 (m, 1H).

EXAMPLE 358



1-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-prop-2-ynyl-piperazin-1-yl]prop-2-en-1-one





[01641] Step A: (2*S*)-2-(*tert*-butoxycarbonylamino)pent-4-ynoic acid. To a suspension of (2S)-2-aminopent-4-ynoic acid (5 g, 44.2 mmol, 1 eq) in THF (15 mL) was added H_2O (15 mL), K_2CO_3 (18.3 g, 133 mmol, 3 eq) and Boc_2O (11.1 g, 50.8 mmol, 11.7 mL, 1.15 eq). Additional water was added to produce a solution which was stirred for 12 hours at 25 °C. The organic solvent was then evaporated and the aqueous solution was washed with *t*-butyl methyl ether, then acidified to pH = 3 with 1N HCl acid. The solution was extracted with ethyl acetate (2 × 100 mL). The solvent was evaporated to give (2*S*)-2-(*tert*-butoxycarbonylamino)pent-4-ynoic acid (8 g, 37.5 mmol, 85% yield) as a colorless oil used without further purification. LCMS [ESI, M+1]: 589.

[01642] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (br d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 8.0, 13.2 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.10 (br s, 1H), 4.49 - 4.33 (m, 2H), 4.21 - 4.01 (m, 3H), 3.96 - 3.79 (m, 2H), 3.60 (br d, *J* = 6.8 Hz, 1H), 3.44 (br d, *J* = 13.6 Hz, 1H), 3.32 - 2.97 (m, 5H), 2.88 - 2.53 (m, 4H), 2.48 (d, *J* = 2.8 Hz, 3H), 2.29 (br d, *J* = 8.8 Hz, 1H), 2.11 - 2.00 (m, 1H), 1.87 - 1.71 (m, 3H).

[01643] Step B: ethyl 2-[benzyl-[(2S)-2-(tert-butoxycarbonylamino)pent- 4-ynoyl]amino]acetate. To a solution of (2*S*)-2-(*tert*-butoxycarbonylamino)pent-4-ynoic acid (7.75 g, 36.4 mmol, 1 eq), ethyl 2-(benzylamino)acetate (7.02 g, 36.4 mmol, 1 eq) and HATU (16.6 g, 43.5 mmol, 1.20 eq) in DMF (50 mL) was added TEA (7.35 g, 72.7 mmol, 10.1 mL, 2.00 eq) at 25 °C. The mixture was stirred at 25 °C for 0.5 h. The mixture was diluted with ethyl acetate (150 mL) and washed with water (3 × 200 mL) and brine (1 × 100 mL). The separated organic layer was washed with water (1 × 100 mL) and brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was used to next step without further purification. Compound ethyl 2-[benzyl-[(2S)-2-(tert-butoxycarbonylamino)pent- 4-ynoyl]amino]acetate (13.7 g, 32.1 mmol, 88.3% yield, 91% purity) was obtained as red oil which become to red solid as standing at 25 °C for 16 hours. LCMS [ESI, M-99]: 289.

[01644] Step C: (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine-2,5-dione. To a solution of ethyl 2-[benzyl-[(2*S*)-2-(*tert*-butoxycarbonylamino) pent-4-ynoyl]amino]acetate (11.7 g, 30.1 mmol, 1 eq) in DCM (40 mL) was added TFA (46.2 g, 405 mmol, 30 mL, 13.5 eq) at 0 °C and the mixture was stirred at 25 °C for 0.5 hour. The mixture was concentrated under vacuum and toluene (30 mL) was added. After stirred at 100 °C for 1 hour, the mixture was concentrated under vacuum. The residue was dissolved into ethyl acetate (200 mL) and basified with saturated aqueous sodium carbonate solution to pH = 8. The separated organic layer was washed with water (1 × 200 mL) and brine (1 × 100 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was triturated with (ethyl acetate/petroleum ether 1/5, 100 mL) and the precipitate was filtered. The filter cake was dried under vacuum. Compound (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine-2,5-dione (5 g, 20.5 mmol, 68% yield, 99.5% purity) was obtained as a white solid. LCMS [ESI, M+1]: 243.

[01645] ^{1}H NMR (400MHz, chloroform-d) δ = 7.46 - 7.20 (m, 5H), 6.59 (br s, 1H), 4.76 (d, *J* = 14.4 Hz, 1H), 4.50 (d, *J* = 14.4 Hz, 1H), 4.20 (br d, *J* = 4.4 Hz, 1H), 4.04 - 3.90 (m, 1H), 3.89 - 3.76 (m, 1H), 2.95 - 2.69 (m, 2H), 2.05 (t, *J* = 2.8 Hz, 1H).

[01646] Step D: (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine. To a mixture of (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine-2,5-dione (5.00 g, 20.6 mmol, 1.00 eq) in THF (50.0 mL) was added $LiAlH_4$ (3.13 g, 82.6 mmol, 4.00 eq) at 25 °C. After stirred at 65 °C for 12 hours, the mixture was filtered off and the filter cake was washed with ethyl acetate (100 mL). The filtrate was

concentrated under vacuum to give (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine (4.10 g, 19.1 mmol, 93% yield) as a yellow oil and used into next step without further purification.

[01647] ^{1}H NMR (400MHz, chloroform-d) δ = 7.37 - 7.24 (m, 5H), 3.55 - 3.47 (m, 2H), 3.03 - 2.86 (m, 3H), 2.85 - 2.78 (m, 1H), 2.73 (br d, *J* = 11.2 Hz, 1H), 2.33 - 2.20 (m, 2H), 2.13 - 2.04 (m, 1H), 2.02 (t, *J* = 2.8 Hz, 1H), 1.90 - 1.83 (m, 1H).

[01648] Step E: *tert*-butyl (2*S*)-4-benzyl-2-prop-2-ynyl-piperazine-1-carboxylate. A mixture of (3*S*)-1-benzyl-3-prop-2-ynyl-piperazine (2.00 g, 9.33 mmol, 1.00 eq), TEA (2.83 g, 28.0 mmol, 3.90 mL, 3.00 eq) and $(Boc)_2O$ (10.2 g, 46.7 mmol, 10.7 mL, 5.00 eq) in THF (20.0 mL) was stirred at 25 °C for 1 hour. The mixture was diluted with water (1 × 20.0 mL), extracted with ethyl acetate (3 × 20.0 mL). The combine organic layer was wash with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 5/1). The desired fractions were collected and concentrated under vacuum to give *tert*-butyl (2*S*)-4-benzyl-2-prop-2-ynyl-piperazine-1-carboxylate (1.50 g, 4.20 mmol, 45% yield, 88% purity) as a colorless oil. LCMS [ESI, M+1]: 315.

[01649] ^{1}H NMR (400MHz, chloroform-d) δ = 7.38 - 7.27 (m, 5H), 4.26 (br s, 1H), 3.99 - 3.74 (m, 1H), 3.59 - 3.45 (m, 2H), 3.08 - 2.89 (m, 2H), 2.79 - 2.68 (m, 2H), 2.62 - 2.53 (m, 1H), 2.11 (dd, *J* = 3.6, 11.2 Hz, 1H), 2.06 - 1.98 (m, 1H), 1.89 (t, *J* = 2.8 Hz, 1H), 1.48 - 1.45 (m, 9H).

[01650] Step F: (2*S*)-2-prop-2-ynylpiperazine. A mixture of *tert*-butyl (2*S*)-4-benzyl-2-prop-2-ynyl-piperazine -1-carboxylate (1.40 g, 4.45 mmol, 1.00 eq), 1-chloro-1-(1-chlorovinyloxy)ethane (2.51 g, 17.8 mmol, 4.00 eq) in DCE (20.0 mL) was stirred at 85 °C for 1 hour. The mixture was concentrated under vacuum. The residue was dissolved in methanol (20.0 mL) and stirred at 65 °C for 1 hour. The mixture was concentrated under vacuum and triturated with petroleum ether (10.0 mL) to give (2*S*)-2-prop-2-ynylpiperazine (0.80 g, crude, 2 HCl) as a yellow solid and used into next step without further purification.

[01651] ^{1}H NMR (400MHz, methanol-d4) δ = 4.56 - 4.44 (m, 1H), 3.88 - 3.80 (m, 1H), 3.79 - 3.73 (m, 1H), 3.62 - 3.34 (m, 4H), 2.87 - 2.76 (m, 3H).

[01652] Step G: 4-benzyloxy-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. A mixture of 4-benzyloxy-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidine (2.00 g, 5.64 mmol, 1.00 eq), 1-bromonaphthalene (1.75 g, 8.46 mmol, 1.18 mL, 1.50 eq), $Pd_2(dba)_3$ (517 mg, 564 umol, 0.10 eq), RuPhos (527 mg, 1.13 mmol, 0.20 eq) and Cs_2CO_3 (3.68 g, 11.3 mmol, 2.00 eq) in toluene (20.0 mL) was stirred at 110 °C for 3 hours under N_2. The mixture was diluted with water (5.00 mL), extracted with ethyl acetate (3 × 5.00 mL). The organic layers were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (TFA, 0.10 %)/acetonitrile]. The desired fraction was collected and adjusted pH > 7 by saturated sodium bicarbonate (5.00 mL), and then extracted with ethyl acetate (3 × 20.0 mL). The combined organic layers were washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 4-benzyloxy-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (1.34 g, 2.78 mmol, 49% yield, 99.6% purity) as a yellow solid. LCMS [ESI, M+1]: 481.

[01653] ^{1}H NMR (400MHz, chloroform-d) δ = 8.22 - 8.16 (m, 1H), 7.89 - 7.82 (m, 1H), 7.59 (d, *J* = 8.0 Hz, 1H), 7.51 - 7.45 (m, 4H), 7.45 - 7.33 (m, 4H), 7.14 (dd, *J* = 0.8, 7.2 Hz, 1H), 5.49 (s, 2H), 4.45 (dd, *J* = 5.6, 10.4 Hz, 1H), 4.27 - 4.18 (m, 3H), 3.55 - 3.24 (m, 2H), 3.12 (br t, *J* = 7.6 Hz, 1H), 2.89 (br s, 2H), 2.76 - 2.65 (m, 1H), 2.50 (s, 3H), 2.35 - 2.24 (m, 1H), 2.14 - 2.06 (m, 1H), 1.91 - 1.78 (m, 3H).

[01654] Step H: 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol. A mixture of 4-benzyloxy-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (1.30 g, 2.70 mmol, 1.00 eq) and Pd/C (0.20 g, 10% purity) in methanol (200 mL) was stirred at 25 °C for 1 hour under H_2 at 15 psi. The catalyst was filtered off and the filtrate was concentrated under vacuum to give 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol (1.00 g, 1.90 mmol, 70% yield, 74% purity) as a yellow solid and used into next step without further purification. LCMS [ESI, M+1]: 391.

[01655] ^{1}H NMR (400MHz, chloroform-d) δ = 8.24 - 8.16 (m, 1H), 7.90 - 7.81 (m, 1H), 7.59 (d, *J* = 8.4 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.42 (t, *J* = 7.6 Hz, 1H), 7.14 (d, *J* = 7.6 Hz, 1H),

4.43 - 4.31 (m, 2H), 4.05 (s, 2H), 3.38 (br s, 2H), 3.18 - 3.10 (m, 1H), 2.79 (br s, 2H), 2.70 - 2.54 (m, 2H), 2.47 (s, 3H), 2.32 (dt, J = 7.2, 9.6 Hz, 1H), 2.02 - 1.96 (m, 1H), 1.91 - 1.75 (m, 3H).

[01656] Step I: [2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesulfonate. To a solution of 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol (0.40 g, 1.02 mmol, 1.00 eq) and TEA (207 mg, 2.05 mmol, 285 uL, 2.00 eq) in dichloromethane (10.0 mL) was added Tf_2O (318 mg, 1.13 mmol, 186 uL, 1.10 eq) at -40 °C. After stirred -40 °C for 0.25 hour, the mixture was diluted with water (3.00 mL) and then extracted with ethyl acetate (3 × 5.00 mL). The extracts wer washed with brine (1 × 5.00 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 10/1). The desired fractions were collected and concentrated under vacuum to give [2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro- 5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesulfonate (0.40 g, 528 umol, 52% yield, 69% purity) as a yellow solid. LCMS [ESI, M+1]: 523.

[01657] Step J: 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-4-[(3*S*)-3-prop-2-ynylpiperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine. A mixture of [2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesulfonate (0.38 g, 727 umol, 1.00 eq), (2*S*)-2-prop-2-ynylpiperazine (350 mg, crude, 2 HCl) and DIEA (939 mg, 7.27 mmol, 1.27 mL, 10.0 eq) in DMF (4.00 mL) was stirred at 100 °C for 0.25 hour. The mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (3 × 10.0 mL). The extracts were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.1%)/acetonitrile]. The desired fractions were collected and lyophilized to give 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-4-[(3*S*)-3-prop-2-ynylpiperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (0.20 g, 336 umol, 46% yield, 99% purity, 2 FA) as a yellow oil. LCMS [ESI, M+1]: 497.


[01658] Step K: 1-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-prop-2-ynyl-piperazin-1-yl]prop-2-en-1-one. To a solution of 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7- (1-naphthyl)-4-[(3*S*)-3-prop-2-ynylpiperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (145 mg, 246 umol, 1.00 eq, 2 FA)

and TEA (374 mg, 3.69 mmol, 514 uL, 15.0 eq) in dichloromethane (4.00 mL) was added prop-2-enoyl chloride (22.3 mg, 246 umol, 20.1 uL, 1.00 eq) at - 40 °C. After stirred at 25 °C for 0.25 h, the mixture was diluted with water (3.00 mL), and then extracted with dichloromethane (3 × 3.00 mL). The extracts were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (10 mM NH_4HCO_3) - ACN]; B%: 57% - 87%, 12 min). The desired fractions were collected and lyophilized to give title compound 1-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-prop-2-ynyl-piperazin-1-yl]prop-2-en-1-one (EXAMPLE 358, 25.6 mg, 46.3 umol, 19% yield, 99.5% purity) as a brown solid. LCMS [ESI, M+1]: 551.


[01659] SFC conditions: "OD-3S_3_40_3ML Column: Chiralcel OD-3 100×4.6mm I.D., 3um, Mobile phase: 40% methanol (0.05% DEA) in CO_2, Flow rate: 3mL/min, Wavelength: 220nm".

[01660] ^{1}H NMR (400MHz, chloroform-d) δ = 8.21 (m, 1H), 7.91 - 7.81 (m, 1H), 7.60 (br d, *J* = 8.0 Hz, 1H), 7.54 - 7.47 (m, 2H), 7.46 - 7.39 (m, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 6.65 (br s, 1H), 6.36 (br d, *J* = 16.8 Hz, 1H), 5.77 (dd, *J* = 2.0, 10.8 Hz, 1H), 5.00 - 4.52 (m, 1H), 4.46 - 4.36 (m, 1H), 4.34 - 3.81 (m, 6H), 3.47 (m, 1H), 3.38 - 3.21 (m, 2H), 3.19 - 2.90 (m, 4H), 2.84 (br s, 1H), 2.73 - 2.52 (m, 3H), 2.48 (s, 3H), 2.34 - 2.24 (m, 1H), 2.10 - 2.03 (m, 1H), 1.90 - 1.70 (m, 4H).

EXAMPLE 359



2-((*S*)-1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01661] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of 1-bromo-8-methyl-naphthalene (Intermediate 69, 507 mg, 1.65 mmol, 1.3 *eq*), *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 600 mg, 1.27 mmol, 1 *eq*), Cs_2CO_3 (1.04 g, 3.18 mmol, 2.5 *eq*), RuPhos (118 mg, 254 umol, 0.2 *eq*) and $Pd_2(dba)_3$ (233 mg, 254 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 2 hours under N_2 atmosphere. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Compound *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (310 mg, 501 umol, 39% yield, 99% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 612.

[01662] ^{1}HNMR (400 MHz, chloroform-d) δ = 7.74 - 7.60 (m, 2H), 7.46 - 7.37 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.16 (m, 2H), 4.61 (br s, 1H), 4.43 - 4.33 (m, 1H), 4.30 - 4.14 (m, 2H), 4.10 - 3.72 (m, 4H), 3.60 - 3.44 (m, 1H), 3.38 (br dd, *J* = 3.6, 13.6 Hz, 1H), 3.24 - 3.04 (m, 4H), 3.03 - 2.84 (m, 5H), 2.82 - 2.53 (m, 4H), 2.52 - 2.42 (m, 3H), 2.29 (br s, 1H), 2.05 - 1.95 (m, 1H), 1.91 - 1.69 (m, 2H), 1.52 (s, 9H).

[01663] Step B: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (310 mg, 506 umol, 1 *eq*) in DCM (500 uL) was added TFA (866 mg, 7.60 mmol, 562 uL, 15 *eq*). The mixture was stirred at 25 °C for 1 hour. The reaction mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (317 mg, 506 umol, 99% yield, TFA) was obtained as a yellow oil and used to next step directly without purification. LCMS [ESI, M+1]: 512.


[01664] Step C: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (317 mg, 506 umol, 1 *eq*, TFA) in DCM (5 mL) was added TEA (512 mg, 5.07 mmol, 705 uL, 10 *eq*) at 0°C. After addition, and prop-2-enoyl prop-2-enoate (51.1 mg, 405 umol, 0.8 *eq*) in DCM (1 mL) was added dropwise at 0°C. The resulting mixture was stirred at 25 °C for 1 hour. The reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (1 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12min). Title compound 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-

yl]acetonitrile (EXAMPLE 359, 60.2 mg, 105 umol, 21% yield, 99.5 % purity) was obtained as a white solid. LCMS [ESI, M+1]: 566.

[01665] SFC condition: "OJ-3S_5_5_40_3ML Column: Chiralcel OJ-3 100×4.6mm I.D., 3um Mobile phase: ethanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[01666] ^{1}H NMR (400MHz, chloroform-d) δ = 7.75 - 7.60 (m, 2H), 7.46 - 7.38 (m, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 6.57 (s, 1H), 6.46 - 6.33 (m, 1H), 5.83 (br d, J = 10.4 Hz, 1H), 5.07 (br s, 1H), 4.64 (br s, 1H), 4.44 - 4.32 (m, 1H), 4.31 - 4.21 (m, 1H), 4.20 - 4.03 (m, 3H), 3.98 - 3.83 (m, 1H), 3.78 - 3.62 (m, 1H), 3.60 - 3.36 (m, 2H), 3.23 - 2.96 (m, 5H), 2.92 (s, 3H), 2.88 - 2.74 (m, 1H), 2.73 - 2.55 (m, 2H), 2.47 (d, J = 4.4 Hz, 3H), 2.35 - 2.21 (m, 1H), 2.13 - 1.97 (m, 1H), 1.90 - 1.74 (m, 3H).

[01667] Alternatively, EXAMPLE 359 may be prepared as follows:



[01668] Step A: *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of *tert*-butyl 2,4-dichloro-6,8-dihydro-5*H*-pyrido [3,4-*d*]pyrimidine-7-carboxylate (18.8 g, 61.7 mmol, 1 *eq*) in DMF (200 mL) was added DIEA (15.9 g, 123 mmol, 21.5 mL, 2 *eq*) and benzyl (2*S*)-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 63, 16.0 g, 61.7 mmol, 1 *eq*). After stirred at 80 °C for 1.5 hour, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with water (200 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 50/1 to 2/1). Compound *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (26 g, 48.8 mmol, 79% yield, 99% purity) was obtained as a white solid. LCMS [ESI, M+1]: 527.

[01669] ^{1}H NMR (400MHz, chloroform-d) δ = 7.43 - 7.34 (m, 5H), 5.20 (s, 2H), 4.73 - 4.60 (m, 2H), 4.45 (d, *J* = 19.2 Hz,, 1H), 4.13 - 4.02 (m, 2H), 3.94 - 3.75 (m, 2H), 3.45 - 3.25 (m, 3H), 3.11 (td, *J* = 3.6, 12.4 Hz, 1H), 2.88 - 2.59 (m, 4H), 1.60 (s, 9H).

[01670] Step B: *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl -3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. A mixture of [(2*S*)-1-methylpyrrolidin-2-yl]methanol (10.5 g, 91.1 mmol, 10.8 mL, 2 eq), *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (24 g, 45.6 mmol, 1 eq), $Pd_2(dba)_3$ (6.18 g, 6.84 mmol, 0.15 eq), RuPhos (4.26 g, 9.12 mmol, 0.2 eq) and Cs_2CO_3 (37.1 g, 114 mmol, 2.5 eq) in toluene (450 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 5 hours under N_2 atmosphere. The reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (500 mL × 3). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, ethyl acetate/methanol = 1/0 to 10/1). Compound *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl -3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (25 g, 35.9 mmol, 79% yield, 87% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 606.

[01671] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (16 g, 26.4 mmol, 1 *eq*) in dioxane (100 mL) was added HCl/dioxane (4 M, 99.1 mL, 15 *eq*). The mixture was stirred at 0 °C for 1 hour. The dioxane was decanted and the solid was collected. The solid residue was diluted with water (50 mL) and dichloromethane (200 mL), then adjusted pH = 8 with saturated Na_2CO_3 aqueous solution and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 13.5 g, 24.5 mmol, 93% yield, 91.6% purity) as a yellow oil and used next step without purification. LCMS [ESI, M+1]: 506.

[01672] ^{1}H NMR (400MHz, chloroform-d) δ = 7.45 - 7.31 (m, 5H), 5.19 (s, 2H), 4.65 (br s, 1H), 4.40 - 4.31 (m, 1H), 4.14 - 4.04 (m, 2H), 4.03 - 3.91 (m, 3H), 3.91 - 3.77 (m, 1H), 3.24 (d, *J* = 13.2 Hz, 2H), 3.16 - 3.05 (m, 2H), 3.04 - 2.89 (m, 2H), 2.81 (br s, 1H), 2.75 - 2.51 (m, 4H), 2.47 (s, 3H), 2.35 - 2.22 (m, 1H), 2.08 - 2.00 (m, 1H), 1.92 - 1.76 (m, 3H).

[01673] Step D: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (10 g, 19.8 mmol, 1 *eq*), 1-bromo-8-methyl-naphthalene (Intermediate 69, 5.68 g, 25.7 mmol, 1.3 *eq*), RuPhos (2.77 g, 5.93 mmol, 0.3 *eq*), Cs_2CO_3 (16.1 g, 49.5 mmol, 2.5 *eq*) and $Pd_2(dba)_3$ (3.62 g, 3.96 mmol, 0.2 *eq*) in toluene (100 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N_2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (500 mL × 3). The combined organic layers

were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (9 g, 12.9 mmol, 33% yield, 93% purity) as a yellow solid. LCMS [ESI, M+1]: 646.

[01674] ^{1}H NMR (400MHz, $C_2D_2Cl_4$) δ = 7.32 (d, *J* = 8.0 Hz, 1H), 7.26 (t, *J* = 8.0 Hz, 1H), 7.08 - 6.93 (m, 7H), 6.91 – 6.78 (m, 2H), 4.81 (s, 2H), 4.30 (s, 1H), 4.13 - 3.95 (m, 1H), 3.88 - 3.33 (m, 6H), 3.22 - 2.87 (m, 2H), 2.86 - 2.65 (m, 4H), 2.65 - 2.42 (m, 5H), 2.41 - 2.32 (m, 1H), 2.30 - 2.13 (m, 2H), 2.07 (d, *J* = 7.2 Hz, 3H), 1.92 (br s, 1H), 1.72 - 1.45 (m, 4H).

[01675] Step E: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (8 g, 12.4 mmol, 1 *eq*) in MeOH (100 mL) was added Pd/C (2 g, 10% purity) and NH_3•MeOH (50 mL, 15%) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The mixture was concentrated under vacuum. Compound 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (5.7 g, 10.0 mmol, 81% yield, 90% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 512.


[01676] ^{1}H NMR (400MHz, chloroform-d) δ = 7.69 (d, *J* = 8.0 Hz, 1H), 7.64 (dd, *J* = 3.2, 7.6 Hz, 1H), 7.40 (td, *J* = 4.4, 7.6 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.19 (m, 2H), 4.46 - 4.34 (m, 1H), 4.25 - 4.03 (m, 2H), 3.97 - 3.69 (m, 3H), 3.49 - 3.44 (m, 1H), 3.39 - 3.07 (m, 5H), 3.06 - 2.83 (m, 6H), 2.76 - 2.63 (m, 1H), 2.62 - 2.51 (m, 3H), 2.48 (d, *J* = 3.2 Hz, 3H), 2.35 - 2.22 (m, 1H), 2.13 - 1.98 (m, 1H), 1.83 - 1.69 (m, 3H).

[01677] Step F: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (6.4 g, 12.5 mmol, 1 *eq*) in dichloromethane (120 mL) was added TEA (19 g, 187 mmol, 26 mL, 15 *eq*)


at -40 °C. After addition, a solution of prop-2-enoyl chloride (1.70 g, 18.8 mmol, 1.53 mL, 1.5 *eq*) in dichloromethane (2 mL) was added dropwise at - 40 °C. After stirred at - 40 °C for 0.5 hour, the reaction mixture was quenched with saturated $NaHCO_3$ aqueous solution (10 mL), then diluted with water (50 mL) and extracted with dichloromethane (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, DCM/MeOH = 100/1 to 10/1) and further purified by prep-HPLC (column: Kromasil 250*50mm*10um; mobile phase: [water (0.225%FA)-ACN]; B%: 20% - 50%, 28 min). The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with dichloromethane (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give title compound 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 359, 2.3 g, 4.03 mmol, 32% yield, 99% purity) as a yellow solid. LCMS [ESI, M+1]: 566.

[01678] ^{1}H NMR (400MHz, chloroform -d) δ = 7.74 - 7.59 (m, 2H), 7.46 - 7.36 (m, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.15 (m, 2H), 6.70 - 6.47 (s, 1H), 6.39 (d, *J* = 16.4 Hz, 1H), 5.82 (d, *J* = 10.4 Hz, 1H), 5.16 - 4.47 (m, 1H), 4.44 - 4.32 (m, 1H), 4.30 - 3.62 (m, 6H), 3.58 - 3.26 (m, 2H), 3.25 - 2.95 (m, 5H), 2.91 (s, 3H), 2.86 - 2.55 (m, 4H), 2.48 (d, *J* = 5.2 Hz, 3H), 2.36 - 2.21 (m, 1H), 2.13 - 2.02 (m, 1H), 1.92 - 1.67 (m, 3H).

EXAMPLE 360



2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01679] Insert: 1-bromo-8-ethyl-naphthalene. To a solution of 1,8-dibromonaphthalene (2.0 g, 6.99 mmol, 1.0 *eq*) and $Pd(dppf)Cl_2$ (367 mg, 501 umol, 7.16 e^{-2} *eq*) in THF (15.0 mL) was added diethyl zinc (1.0 M in toluene, 3.50 mL, 0.50 *eq*) at - 78 °C. The mixture was stirred at -78 - 20 °C for 12 hours. After completion, the reaction mixture was added water (30.0 mL) and extracted with EA (30.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was triturated with PE (60.0 mL) and filtered. The filter cake was washed with PE (10.0 mL × 2), the mother liquid was concentrated. The obtained product was purified by reversed phase flash column (C18, 0.1% FA in water, 0 - 100 % MeCN) to give 1-bromo-8-ethyl-naphthalene (600 mg, 2.45 mmol, 35% yield, 96% purity) as yellow oil.

[01680] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.72 - 7.63 (m, 2H), 7.58 (dd, *J* = 2.4, 7.2 Hz, 1H), 7.30 - 7.23 (m, 2H), 7.13 - 7.04 (m, 1H), 3.43 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H).

[01681] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 300 mg, 636 umol, 1.0 *eq*), t-BuONa (183 mg, 1.91 mmol, 3.0 *eq*), RuPhos (59.4 mg, 127 umol, 0.2 *eq*) and RuPhos-Pd-G3 (106 mg, 127 umol, 0.20 *eq*) in toluene (5.0 mL) was added 1-bromo-8-ethyl-naphthalene (299 mg, 1.27 mmol, 2.0 *eq*). The mixture was stirred at 90 °C for 12 hours. After completion, the reaction mixture was added water (10.0 mL) and extracted with EA (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by reversed phase flash column (C18, 0.1 % FA in water, 0-60 % MeCN) to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 221 umol, 34% yield, 98% purity) as yellow oil. LCMS [ESI, M+1]: 626.


[01682] Step B: 2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8- ethyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 208 umol, 1.0 *eq*) in DCM (1.0 mL) was added TFA (1.54 g, 13.5 mmol, 1.0 mL, 65.0 *eq*). The mixture was stirred at 25 °C for 10 min. After completion, the reaction mixture was concentrated under vacuum. The product 2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude, 2TFA)was obtained as yellow oil. LCMS [ESI, M+1]: 526.

[01683] Step C: 2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg,


199 umol, 1.0 *eq*, 2TFA) and DIEA (309 mg, 2.39 mmol, 416 uL, 12.0 *eq*) in DCM (2.0 mL) was added prop-2-enoyl prop-2-enoate (37.7 mg, 299 umol, 1.50 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (1.0 mL) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 53%-83%, 12min) to give title compound 2-[(2*S*)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 360, 20.0 mg, 33.8 umol, 17% yield, 98% purity) as pink solid. LCMS [ESI, M+1]: 580.

[01684] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.74 - 7.64 (m, 2H), 7.46 - 7.35 (m, 2H), 7.27 - 7.20 (m, 2H), 6.64 - 6.60 (m, 1H), 6.46 - 6.36 (m, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.20 - 4.50 (m, 1H), 4.45 - 4.33 (m, 1H), 4.31 - 4.19 (m, 1H), 4.17 - 3.96 (m, 3H), 3.93 - 3.84 (m, 1H), 3.74 (br d, *J* = 18.0 Hz, 1H), 3.65 - 3.39 (m, 3H), 3.37 - 2.92 (m, 7H), 2.88 - 2.76 (m, 1H), 2.71 - 2.57 (m, 2H), 2.47 (br d, *J* = 4.8 Hz, 3H), 2.34 - 2.23 (m, 1H), 2.11 - 1.98 (m, 1H), 1.80 - 1.72 (m, 3H), 1.17 (t, *J* = 7.4 Hz, 3H).

EXAMPLE 361



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01685] Insert: [(3*R*)-1-methylpyrrolidin-3-yl] methanol. To a solution of *tert*-butyl (3*R*)-3-(hydroxymethyl) pyrrolidine-1-carboxylate (1.0 g, 4.97 mmol, 1.0 *eq*) in THF (20.0 mL) was added $LiAlH_4$ (377 mg, 9.94 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour, then heated to 70 °C and stirred at 70 °C for 2 hours. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous (1.0 mL) and filtered. The filter cake was washed with THF (10.0 mL). Then the mother liquid was concentrated to give [(3*R*)-1-methylpyrrolidin-3-yl] methanol (500 mg, 4.34 mmol, 87% yield) as colorless oil.

[01686] ^1H NMR (400 MHz, Chloroform-d) δ 3.65 (dd, J = 4.8, 10.0 Hz, 1H), 3.52 (dd, J = 5.6, 10.0 Hz, 1H), 3.05 - 2.69 (m, 2H), 2.63 - 2.53 (m, 1H), 2.51 - 2.44 (m, 1H), 2.40 - 2.25 (m, 5H), 2.04 - 1.94 (m, 1H), 1.72 - 1.59 (m, 1H).

[01687] Step A: *tert*-butyl(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(3*R*)-1-methylpyrrolidin-3-yl] methanol (178 mg, 1.55 mmol, 3.0

eq) in toluene (3.0 mL) was added t-BuONa (124 mg, 1.29 mmol, 2.50 *eq*). The mixture was stirred at 0 °C for 0.5 hour. Then *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 516 umol, 1.0 *eq*) was added to the above mixture. After addition, the mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10.0 ml) and extracted with EA (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by reversed phase flash (C18, 0.1% FA in water, 0-60% MeCN) to give *tert*-butyl(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (220 mg, 342 umol, 66% yield, 98% purity) as yellow solid. LCMS [ESI, M+1]: 632.


[01688] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*) -1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (360 mg, 569 umol, 1.0 *eq*) in DCM (1.50 mL) was added TFA (2.31 g, 20.3 mmol, 1.50 mL, 35.6 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*) -1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (450 mg, crude, 2TFA) as yellow oil.

[01689] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*)-1- methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (450 mg, 592 umol, 1.0 *eq*, 2TFA) and DIEA (918 mg, 7.10 mmol, 1.24 mL, 12.0 *eq*) in DCM (4.0 mL) was added prop-2-enoyl prop-2-enoate (112 mg, 888 umol, 1.50 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (1.0 mL) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04% NH_3•H_2O)-ACN]; B%: 70%-82%,10 min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*)-1- methylpyrrolidin-3-yl]methoxy]-6,8-


dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 361, 32.6 mg, 53.8 umol, 9% yield, 97% purity) as gray solid. LCMS [ESI, M+1]: 586.


[01690] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.68 (br d, *J* = 8.0 Hz, 1H), 7.54 (t, *J* = 7.6 Hz, 1H), 7.45 (d, *J* = 7.2 Hz, 1H), 7.41 -7.32 (m, 1H), 7.26 (t, *J* = 8.0 Hz, 1H), 7.18 - 7.11 (m, 1H), 6.60 - 6.43 (m, 1H), 6.32 (br d, *J* = 16.4 Hz, 1H), 5.75 (br d, *J* = 10.8 Hz, 1H), 5.15 - 4.50 (m, 1H), 4.41 - 4.28 (m, 1H), 4.18 - 4.10 (m, 2H), 4.09 - 3.88 (m, 2H), 3.87 - 3.68 (m, 2H), 3.57 - 3.45 (m, 1H), 3.42 - 3.26 (m, 1H), 3.25 - 2.87 (m, 5H), 2.86 - 2.74 (m, 1H), 2.73 - 2.57 (m, 3H), 2.56 - 2.47 (m, 2H), 2.46 - 2.37 (m, 2H), 2.28 (s, 3H), 2.07 - 1.90 (m, 1H). LCMS [ESI, M+1]: 586.

EXAMPLE 362



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[01691] Step A: *tert*-butyl(2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of 2-(1-piperidyl) ethanol (133 mg, 1.03 mmol, 137 uL, 3.0 *eq*) in toluene (2.0 mL) was added t-BuONa (66.2 mg, 688 umol, 2.0 *eq*) at 0 °C. The mixture was stirred at 20 °C for 0.5 hour. Then *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 344 umol, 1.0 *eq*) was added to the above liquid at 0 °C. After addition, the mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (5.0 mL) and extracted with EA (5.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE:EA = 3:1 - EA:MeOH = 10:1) to give *tert*-butyl(2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 221 umol, 64% yield, 95% purity) as yellow oil. LCMS [ESI, M+1]: 646.

[01692] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.61 (t, *J* = 7.8 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.33 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.17 (m, 1H), 4.64 - 4.61 (m, 1H), 4.48 - 4.36 (m, 3H), 4.14 - 3.92 (m, 3H), 3.90 - 3.76 (m, 1H), 3.63 - 3.54 (m, 1H), 3.36 (br dd, *J* = 3.6, 13.6 Hz, 1H), 3.26 - 3.06 (m, 3H), 3.01 - 2.86 (m, 1H), 2.82 - 2.76 (m, 2H), 2.71 (br d, *J* = 6.8 Hz, 1H), 2.64 - 2.58 (m, 1H), 2.58 - 2.50 (m, 4H), 2.48 - 2.42 (m, 1H), 2.06 (d, *J* = 6.4 Hz, 1H), 1.64 - 1.57 (m, 5H), 1.52 (s, 9H).


[01693] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2- (1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 387 umol, 1.0 *eq*) in DCM

(1.0 mL) was added TFA (1.54 g, 13.5 mmol, 1.0 mL, 34.9 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was concentrated under vacuum. The product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2- (1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude, 2TFA) was obtained as yellow oil. LCMS [ESI, M+1]: 546.


[01694] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, 388 umol, 1.0 *eq*, 2TFA) and DIEA (601 mg, 4.65 mmol, 810 uL, 12.0 *eq*) in DCM (2.0 mL) was added prop-2-enoyl prop-2-enoate (73.3 mg, 581 umol, 1.5 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (1.0 mL) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%,12min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 362, 54.0 mg, 88.1 umol, 23% yield, 98% purity) as colorless oil. LCMS [ESI, M+1]: 600.

[01695] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.18 (m, 1H), 6.58 - 6.62 (m, 1H), 6.44 - 6.36 (m, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.15 - 4.55 (m, 1H), 4.51 - 4.36 (m, 3H), 4.20 - 3.97 (m, 2H), 3.95 - 3.75 (m, 2H), 3.66 - 3.54 (m, 1H), 3.51 - 3.37 (m, 1H), 3.34 - 2.97 (m, 4H), 2.94 - 2.67 (m, 4H), 2.65 - 2.57 (m, 1H), 2.55 - 2.48 (m, 4H), 1.65 - 1.60 (m, 4H), 1.49 - 1.39 (m, 2H).

EXAMPLE 363



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01696] Insert: [(2*R*)-4-methylmorpholin-2-yl] methanol. To a solution of *tert*-butyl (2*R*)-2-(hydroxymethyl) morpholine-4-carboxylate (1.50 g, 6.90 mmol, 1.0 *eq*) in THF (20.0 mL) was added $LiAlH_4$ (524 mg, 13.8 mmol, 2.0 *eq*) in portions at 0 °C. The mixture was stirred at 0 °C for 0.5 hour, then heated to 60 °C and stirred at 60 °C for 12 hours. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous (1.50 mL) and filtered. The cake

was washed with THF (20.0 mL × 2). Then the mother liquid was concentrated to give [(2*R*)-4-methylmorpholin-2-yl] methanol (800 mg, 6.10 mmol, 88% yield) as yellow oil.

[01697] ^{1}H NMR (400 MHz, Chloroform-d) δ 3.92 - 3.86 (m, 1H), 3.73 - 3.52 (m, 4H), 2.84 - 2.56 (m, 3H), 2.27 (s, 3H), 2.11 (dt, *J* = 3.6, 11.6 Hz, 1H), 1.93 (t, *J* = 10.8 Hz, 1H).

[01698] Step A: *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*R*)-4-methylmorpholin-2-yl]methanol (203 mg, 1.55 mmol, 3.0 *eq*) in toluene (4.0 mL) was added t-BuONa (99.2 mg, 1.03 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. Then *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 516 umol, 1.0 *eq*) was added to the above mixture. The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10.0 ml) and extracted with EA (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The obtained product was purified by column chromatography (SiO_2, PE: EA=3:1 - EA: MeOH=10:1) to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 366 umol, 71% yield, 95% purity) as yellow oil. LCMS [ESI, M+1]: 648.

[01699] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.75 (d, *J* = 8.0 Hz, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.39 (m, 1H), 7.33 (t, *J* = 7.8 Hz , 1H), 7.26 - 7.17 (m, 1H), 4.68 - 4.53 (m, 1H), 4.48 - 4.31 (m, 2H), 4.29 - 4.19 (m, 1H), 4.16 - 4.01 (m, 3H), 4.00 - 3.82 (m, 4H), 3.79 - 3.69 (m, 1H), 3.63 - 3.53 (m, 1H), 3.36 (br dd, *J* = 3.6, 13.6 Hz, 1H), 3.29 - 3.06 (m, 3H), 3.01 - 2.86 (m, 2H), 2.83 - 2.64 (m, 3H), 2.63 - 2.45 (m, 1H), 2.36 - 2.28 (m, 3H), 2.19 (dt, *J* = 3.6, 11.6 Hz, 1H), 1.52 (s, 9H).


[01700] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-4- methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (240 mg, 370 umol, 1.0 *eq*) in DCM (1.0 mL) was added TFA (1.54 g, 13.5 mmol, 1.0 mL, 36.5 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction

mixture was concentrated to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude, 2TFA) as light red oil. LCMS [ESI, M+1]: 548.


[01701] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, 387 umol, 1.0 *eq*, 2TFA) and DIEA (599 mg, 4.64 mmol, 808 uL, 12.0 *eq*) in DCM (2.0 mL) was added prop-2-enoyl prop-2-enoate (73.1 mg, 580 umol, 1.50 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched with MeOH (1.0 mL) and concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04% $NH_3 \cdot H_2O$)-ACN]; B%: 45%-75%,10 min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*R*)-4-methylmorpholin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 363, 42.7 mg, 70.4 umol, 18% yield, 99% purity) as white solid. LCMS [ESI, M+1]: 602.


[01702] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.55 - 7.50 (m, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.18 (m, 1H), 6.65 - 6.52 (m, 1H), 6.39 (br d, *J* = 16.8 Hz, 1H), 5.83 (br d, *J* = 10.8 Hz, 1H), 5.25 - 4.53 (m, 1H), 4.48 - 4.32 (m, 2H), 4.30 - 4.21 (m, 1H), 4.19 - 4.00 (m, 2H), 3.99 - 3.89 (m, 3H), 3.88 - 3.76 (m, 1H), 3.75 - 3.68 (m, 1H), 3.64 - 3.55 (m, 1H), 3.52 - 3.35 (m, 1H), 3.31 - 2.98 (m, 4H), 2.92 - 2.55 (m, 5H), 2.31 (s, 3H), 2.18 (dt, *J* = 3.2, 11.4 Hz, 1H), 2.02 (dt, *J* = 1.6, 10.8 Hz, 1H).

EXAMPLE 364



2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile





[01703] Step 1: 1-bromo-3-methoxy-2-(trifluoromethyl)benzene. To a solution of MeOH (1.32 g, 41.2 mmol, 1.67 mL, 2 *eq*) in DMF (125 mL) was added NaH (1.65 g, 41.2 mmol, 60.0 % purity, 2 *eq*). The mixture was stirred at 25 °C for 0.5 hour. Then to the mixture was added 1-bromo-3-fluoro-2-(trifluoromethyl)benzene (5 g, 20.6 mmol, 1 *eq*) and stirred at 25 °C for 0.5 hour. The reaction mixture was quenched by ice water (20 mL). Water (300 mL) was added into the mixture and extracted with MTBE (3 × 100 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE) to give 1-bromo-3-methoxy-2-(trifluoromethyl)benzene (5.28 g, 18.6 mmol, 91.0 % yield, 90.0 % purity) as a colorless oil.

[01704] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.34 - 7.28 (m, 2H), 7.01 - 6.97 (m, 1H), 3.91 (s, 3H).

[01705] Step 2: 1-methoxy-3-methyl-2-(trifluoromethyl)benzene. To the solution of 1-bromo-3-methoxy-2-(trifluoromethyl)benzene (5.28 g, 20.7 mmol, 1 *eq*), Cs_2CO_3 (20.2 g, 62.1 mmol, 3 *eq*), methylboronic acid (6.20 g, 104 mmol, 5 *eq*) in dioxane (105 mL) and Water (21 mL) was added Pd(dppf)Cl_2 (2.27 g, 3.11 mmol, 0.15 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 100 °C for 6 hours. Water (50 mL) was added into the mixture. The mixture was diluted with EtOAc (30 mL) and extracted with EtOAc (100 mL). The organic layer was dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE) to give 1-methoxy-3-methyl-2-(trifluoromethyl)benzene (3.2 g, 15.1 mmol, 73.1 % yield, 90.0 % purity) as a yellow oil.

[01706] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.33 (t, *J*=8.0 Hz, 1H), 6.87 (br d, *J*=8.4 Hz, 1H), 6.83 (d, *J*=7.2 Hz, 1H), 3.88 (s, 3H), 2.49 (q, *J*=3.6 Hz, 3H).

[01707] Step 3: 3-methyl-2-(trifluoromethyl)phenol. To the solution of 1-methoxy-3-methyl-2-(trifluoromethyl)benzene (3.2 g, 16.8 mmol, 1 *eq*) in DCE (65 mL) was added BBr_3 (21.1 g, 84.1 mmol, 8.11 mL, 5 *eq*) at -40 °C, the mixture was stirred at -40 - -10 °C for 0.5 hour. The reaction mixture was quenched by Water (100 mL). The mixture was diluted with EtOAc (20 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine (30 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 50:1) to give 3-methyl-2-(trifluoromethyl)phenol (740 mg, 4.08 mmol, 24.2 % yield, 97.0 % purity) as a yellow solid.

[01708] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.29 - 7.24 (m, 1H), 6.87 - 6.77 (m, 2H), 5.95 (q, *J*=6.4 Hz, 1H), 2.46 (q, *J*=2.8 Hz, 3H).

[01709] Step 4: [3-methyl-2-(trifluoromethyl)phenyl] trifluoromethanesulfonate. To the solution of 3-methyl-2-(trifluoromethyl)phenol (600 mg, 3.41 mmol, 1 *eq*), TEA (1.38 g, 13.6 mmol, 1.90 mL, 4 *eq*) in EtOAc (12 mL) was added Tf_2O (1.44 g, 5.11 mmol, 843 uL, 1.5 *eq*) at -40 °C, the mixture was stirred at -40 °C for 0.5 hour. The mixture was quenched by Water (10 mL). The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and

concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc from 1:0 to 100:1) to give [3-methyl-2-(trifluoromethyl)phenyl] trifluoromethanesulfonate (590 mg, 1.82 mmol, 53.0 % yield, 95.0 % purity) as a colorless oil.

[01710] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.53 - 7.47 (m, 1H), 7.33 (d, *J*=7.6 Hz, 1H), 7.29 (d, *J*=8.4 Hz, 1H), 2.57 (q, *J*=2.8 Hz, 3H).

[01711] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 600 mg, 973 umol, 1 *eq*), [3-methyl-2-(trifluoromethyl)phenyl] trifluoromethanesulfonate (450 mg, 1.46 mmol, 1.5 *eq*), Cs_2CO_3 (951 mg, 2.92 mmol, 3 *eq*) and RuPhos (90.8 mg, 195 umol, 0.2 *eq*) in toluene (12 mL) was added $Pd_2(dba)_3$ (89.1 mg, 97.3 umol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 4 hours. Water (15 mL) was added into the mixture. The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (30 mL). The organic layer was washed with brine (20 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (from PE: EtOAc = 5:1 ~ 1:1 to EtOAc: MeOH = 1:0 ~ 20:1). Then the residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 50.0 %) to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 354 umol, 36 % yield, 98.0 % purity) as a yellow oil. LCMS [ESI, M+1]: 664.

[01712] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.41 - 7.35 (m, 6H), 7.18 (d, *J*=8.0 Hz, 1H), 7.07 (d, *J*=7.6 Hz, 1H), 7.10 - 7.04 (m, 1H), 5.20 (s, 2 H), 4.69 (br s, 1H), 4.38 (dd, *J*=5.2, 10.8 Hz, 1H), 4.16 (t, *J*=3.2 Hz, 1H), 4.05 (s, 2H), 3.89 (br d, *J*=12.0 Hz, 1H), 3.30 (br s, 2H), 3.21 - 2.95 (m, 5H), 2.92 - 2.62 (m, 6H), 2.52 (q, *J*=3.6 Hz, 3H), 2.48 (s, 3H), 2.33 - 2.24 (m, 1H), 2.05 - 2.00 (m, 1H), 1.90 - 1.79 (m, 3H).


[01713] Step B: NH_3 was bubbled into MeOH (5 mL) for 5 minutes. To the solution was added benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-

2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 362 umol, 1 *eq*), Pd/C (50 mg, 10.0 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 30 °C for 0.5 hour. The reaction mixture was filtered, the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 336 umol, 93.0 % yield, 99.0 % purity) as a brown oil which was used for next step without further purification. LCMS [ESI, M+1]: 530.


[01714] Step C: 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (170 mg, 321 umol, 1 *eq*) and TEA (97.4 mg, 963 umol, 134 uL, 3 *eq*) in DCM (3.5 mL) was added prop-2-enoyl chloride (43.6 mg, 482 umol, 39.3 uL, 1.5 *eq*) at -40 °C, the mixture was stirred at -40 - 30 °C for 0.5 hour. The reaction mixture was quenched by Water (2 mL) and separated. The aqueous phase was extracted with EtOAc (4 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,12min) to give title compound 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[3-methyl-2-(trifluoromethyl)phenyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 364, 110 mg, 188 umol, 58.0 % yield, 100 % purity) as a white solid. LCMS [ESI, M+1]: 584.

[01715] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.43 - 7.35 (m, 1H), 7.19 (d, *J*=8.4 Hz, 1H), 7.08 (d, *J*=7.6 Hz, 1H), 6.59 (br s, 1H), 6.40 (dd, *J*=1.6, 16.8 Hz, 1H), 5.83 (br d, *J*=10.4 Hz, 1H), 5.09 (br s, 1H), 4.64 (br s, 1H), 4.37 (dd, *J*=4.8, 10.4 Hz, 1H), 4.18 - 4.08 (m, 2H), 4.06 (s, 2H), 3.96 (br d, *J*=12.4 Hz, 1H), 3.60 (br s, 1H), 3.30 (br s, 1H), 3.22 - 3.01 (m, 4H), 2.98 - 2.62 (m, 5H), 2.52 (q, *J*=3.2 Hz, 3H), 2.48 (s, 3H), 2.33 - 2.23 (m, 1H), 2.11 - 1.99 (m, 1H), 1.90 - 1.68 (m, 3H).

EXAMPLE 365



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01716] Insert: 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol. To a solution of (1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptane (500 mg, 3.69 mmol, 1.0 *eq*, HCl), 3-bromopropan-1-ol (513 mg, 3.69 mmol, 333 uL, 1.0 *eq*) in CH_3CN (6.0 mL) was added K_2CO_3 (1.53 g, 11.1 mmol, 3.0 *eq*). The mixture was stirred at 50 °C for 2 hours. After completion, the

reaction mixture was filtered and the filtrate was evaporated. The residue was purified by column chromatography (SiO_2, Ethyl acetate: MeOH = 50: 1 to 20: 1) to give 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol (195 mg, 1.12 mmol, 30% yield, 90% purity) as colorless oil.

[01717] ^{1}H NMR (400 MHz, Chloroform-d) δ 4.42 (s, 1H), 3.99 (d, *J* = 8.0 Hz, 1H), 3.82 (t, *J* = 5.6 Hz, 2H), 3.65 - 3.61 (m, 1H), 3.53 - 3.45 (m, 2H), 2.99 - 2.92 (m, 2H), 2.84 - 2.77 (m, 1H), 2.67 - 2.61 (m, 1H), 1.86 - 1.80 (m, 1H), 1.79 - 1.58 (m, 3H).

[01718] Step A: *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan- 5-yl]propan-1-ol (325 mg, 2.06 mmol, 3.0 *eq*), *t*-BuONa (198 mg, 2.06 mmol, 3.0 *eq*) in toluene (2.0 mL) was added a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 71, Step A, 400 mg, 688 umol, 1.0 *eq*) in toluene (2.0 mL) in portions, the mixture was stirred at 0 °C for 30 min under N_2 atmosphere. After completion, the organic solvent was added water (10.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 10 mL). Combine extracts were washed with brine (20.0 mL), dried with Na_2SO_4, the solvent was then removed under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether : Ethyl acetate=3 : 1 to Ethyl acetate : MeOH =20 : 1) to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (320 mg, 432 umol, 62% yield, 91% purity) as yellow solid. LCMS [ESI, M+1]: 674.


[01719] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (340 mg, 504 umol, 1.0 *eq*) in dioxane (3.0 mL) was added HCl•dioxane (4.0 M, 3.0 mL, 23.8 *eq*). The mixture was stirred at 25 °C for 15 min under N_2 atmosphere. After completion, the organic solvent was removed under vacuum. The obtained

product was adjusted with saturated $NaHCO_3$ aqueous (10 mL), extracted with ethyl acetate (3 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (270 mg, crude) was obtained as yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 574.


[01720] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3- [(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)- 2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (270 mg, 470 umol, 1.0 *eq*) in DCM (4.0 mL) was added TEA (143 mg, 1.41 mmol, 196 uL, 3.0 *eq*) and prop-2-enoyl prop-2-enoate (178 mg, 1.41 mmol, 3.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 30 min under N_2 atmosphere. After completion, the organic solvent was removed under vacuum. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether: Ethyl acetate = 3**:** 1 **to** 1: 1), then the crude product was concentrated and repurified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 45%-75%, 12 min) and under lyophilization. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 365, 43.1 mg, 67.7 umol, 14% yield, 98% purity) was obtained as off-white solid. LCMS [ESI, M+1]: 628.

[01721] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (d, *J* = 9.6 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.50 (d, *J* = 6.4 Hz, 1H), 7.47 - 7.40 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.26 - 7.16 (m, 1H), 6.67 - 6.54 (m, 1H), 6.40 (d, *J* = 16.8 Hz, 1H), 5.82 (d, *J* = 10.8 Hz, 1H), 5.16 - 5.03 (m, 1H), 4.48 - 4.40 (m, 1H), 4.38 - 4.34 (m, 3H), 4.22 - 4.08 (m, 1H), 4.07 - 3.99 (m, 2H), 3.97 - 3.74 (m, 2H), 3.64 - 3.55 (m, 2H), 3.54 - 3.35 (m, 2H), 3.31 - 3.20 (m, 1H), 3.19 - 3.14 (m, 1H), 3.13 - 2.99 (m, 2H), 2.92 (d, *J* = 10.4 Hz, 1H), 2.89 - 2.81 (m, 1H), 2.80 - 2.76 (m, 1H), 2.75 - 2.68 (m, 1H), 2.64 - 2.57 (m, 1H), 2.52 (d, *J*=10.0 Hz, 1H), 1.98 - 1.89 (m, 2H), 1.85 (d, *J* = 9.2 Hz, 1H), 1.74 - 1.70 (m, 2H).

EXAMPLE 366



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01722] Insert: To a solution of *O*1-*tert*-butyl *O*2-methyl (2*S*)-4,4-difluoropyrrolidine-1,2-dicarboxylate (300 mg, 1.13 mmol, 1.0 *eq*) in THF (8.0 mL) was added $LiAlH_4$ (129 mg, 3.39 mmol, 3.0 *eq*). The mixture was stirred at -40 °C for 1 hour. Then the mixture was stirred at 80 °C for 2 hours under N_2 atmosphere. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous solution (6.0 mL), dried with Na_2SO_4. Then the mixture was filtered

and the filtrate was concentrated. [(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl] methanol (165 mg, crude) was obtained as colorless oil and used into the next step without further purification.


[01723] Step A: *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methanol (156 mg, 1.03 mmol, 3.0 *eq*) in toluene (2.0 mL) was added *t*-BuONa (99.2 mg, 1.03 mmol, 3.0 *eq*) at 0 °C and a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 344 umol, 1.0 *eq*) in toluene (1.0 mL) dropwise at 0 °C under N_2. The reaction mixture was stirred at 0 °C for 30 min. After completion, the organic solvent was added water (10.0 mL), extracted with ethyl acetate (3 × 10 mL). Combine extracts were washed with brine (20.0 mL), dried with Na_2SO_4, filtered and the filtrate was concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether : Ethyl acetate = 5 : 1 to 1 : 1) to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (160 mg, 230 umol, 67% yield, 96% purity) as yellow solid. LCMS [ESI, M+1]: 668.

[01724] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (137 mg, 205 umol, 1.0 *eq*) in dioxane (1.0 mL) was added HCl•dioxane (4 M, 1.0 mL, 19.5 *eq*). The mixture was stirred at 25 °C for 15 min under N_2 atmosphere. After completion, the organic solvent was removed under vacuum. The obtained product was adjusted with saturated $NaHCO_3$ aqueous (10 mL), extracted with ethyl acetate (3 × 10 mL), dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, crude) was obtained as yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 568.


[01725] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, 194 umol, 1.0 *eq*) in DCM (3.0 mL) was added TEA (196 mg, 1.94 mmol, 270 uL, 10.0 *eq*) and prop-2-enoyl prop-2-enoate (73.3 mg, 581 umol, 3.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 30 min under N_2 atmosphere. After completion, the reaction mixture was quenched with methanol (6.0 mL) and the mixture was removed under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150×25mm×10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55% - 85%, 12 min) and under lyophilization. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 366, 34.1 mg, 54.5 umol, 28% yield, 99% purity) was obtained as off-white solid. LCMS [ESI, M+1]: 622.

[01726] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.63 (t, *J* = 7.2 Hz, 1H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.42 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.26 - 7.19 (m, 1H), 6.63 - 6.57 (m, 1H), 6.40 (d, *J* = 16.8 Hz, 1H), 5.84 (d, *J* = 10.4 Hz, 1H), 5.02 - 4.98 (m, 1H), 4.49 - 4.37 (m, 2H), 4.31 - 4.22 (m, 1H), 4.19 - 3.97 (m, 2H), 3.96 - 3.89 (m, 1H), 3.88 - 3.77 (m, 1H), 3.76 - 3.65 (m, 1H), 3.64 - 3.55 (m, 1H), 3.52 - 3.37 (m, 2H), 3.36 - 3.10 (m, 3H), 3.07 - 2.95 (m, 2H), 2.94 - 2.80 (m, 1H), 2.79 - 2.48 (m, 4H), 2.47 - 2.45 (m, 3H), 2.36 - 2.24 (m, 1H).

EXAMPLE 367



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile



[01727] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (Intermediate 71, Step A, 200 mg, 316 umol, 1.0 *eq*) in dioxane (1.5 mL) was added HCl•dioxane (4 M, 1.5 mL, 19.0 *eq*). The mixture was stirred at 25 °C for 0.5 hour under N_2 atmosphere. After completion, the organic solvent was removed under vacuum. The obtained product was adjusted with saturated $NaHCO_3$ aqueous (10 mL), extracted with ethyl acetate (3 × 10 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated. The crude product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy] -6,8-dihydro-5*H*-

pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (130 mg, crude) was obtained as yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 532.


[01728] Step B: 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 282 umol, 1.0 *eq*) in DCM (3.0 mL) was added Pyridine (446 mg, 5.64 mmol, 455 uL, 20.0 *eq*) and (*E*)-4-bromobut-2-enoyl chloride (155 mg, 846 umol, 3.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was concentrated. The crude product 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (190 mg, crude) was obtained as yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 680.

[01729] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (190 mg, 280 umol, 1.0 *eq*), KI (9.29 mg, 56.0 umol, 0.20 *eq*) and K_2CO_3 (387 mg, 2.80 mmol, 10.0 *eq*) in DCM (5.0 mL) was added morpholine (146 mg, 1.68 mmol, 148 uL, 6.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was quenched with methanol (10.0 mL) and the mixture was removed under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 60%-90%, 12 min) and then under lyophilization. The title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 367, 31.6 mg, 45.2 umol, 16% yield, 98% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 685.


[01730] ^{1}H NMR (400 MHz, chloroform-d) δ 7.78 - 7.73 (m, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.48 - 7.41 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.26 - 7.18 (m, 1H), 7.02 - 6.91 (m, 1H), 6.55 - 6.42 (m, 1H), 5.15 - 5.01 (m, 1H), 4.47 - 4.34 (m, 2H), 4.20 - 4.13 (m, 1H), 4.12 -


4.04 (m, 1H), 3.95 - 3.79 (m, 2H), 3.78 - 3.65 (m, 5H), 3.62 - 3.63 (m, 1H), 3.52 - 3.36 (m, 1H), 3.30 - 3.14 (m, 4H), 3.13 - 2.97 (m, 3H), 2.88 - 2.77 (m, 1H), 2.73 - 2.53 (m, 3H), 2.52 - 2.46 (m, 7H), 2.34 - 2.22 (m, 1H), 2.11 - 1.99 (m, 1H), 1.88 - 1.70 (m, 3H).

EXAMPLE 368



2-((2S,5S)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile





[01731] Step A: ((2R,5S)-5-methylpiperazin-2-yl)methanol: Cyclo(L-Ala-L-Ser) (400 mg, 2.53 mmol) was diluted with borane-tetrahydrofuran complex (18716 µl, 18.7 mmol), placed under nitrogen and heated to 70°C. After stirring for 12 hours, the reaction was allowed to cool. The reaction was cooled to 0°C in an ice bath followed by the slow dropwise addition of MeOH (5116 µl, 126 mmol) followed by the addition of HCl (1096 µl, 6.58 mmol). After stirring for one hour, the reaction was concentrated to afford ((2R,5S)-5-methylpiperazin-2-yl)methanol (328 mg, 2.52 mmol, 99.6 % yield).

[01732] Step B: tert-butyl (6S,8aR)-6-methyl-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate: ((2R,5S)-5-methylpiperazin-2-yl)methanol (500 mg, 3.84 mmol) was diluted with methanol (5 mL), placed under nitrogen and cooled to 0°C. TEA (2141 µl, 15.4 mmol) was added followed by BOC-Anhydride (2675 µl, 11.5 mmol) (in methanol 5 mL, over 15 minutes). The reaction was kept <10°C for 1 hour and then the ice bath was removed. After 1 additional hour, the reaction was heated to 50°C. After stirring at 50°C for 12 hours, the reaction was concentrated to afford tert-butyl (6S,8aR)-6-methyl-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate (980 mg, 3.82 mmol, 99.6 % yield).

[01733] Step C: tert-butyl (2S,5R)-5-(hydroxymethyl)-2-methylpiperazine-1-carboxylate: Tert-butyl (6S,8aR)-6-methyl-3-oxotetrahydro-3H-oxazolo[3,4-a]pyrazine-7(1H)-carboxylate (980 mg, 3.82 mmol) was diluted with ethanol (10047 µl, 172 mmol) followed by the addition of NaOH (9559 µl, 19.1 mmol). The reaction was placed under nitrogen, heated to 95°C and stirred for 4 hours. TLC (methanol/DCM/NH4OH, 10/89/1) staining with KMNO4 indicated the disappearance of a slightly higher rf spot. The reaction was allowed to cool, and then placed in an ice bath. The pH was adjusted to ~9 with 2N HCl and then extracted twice with DCM. The

DCM was dried over MgSO4, filtered and concentrated to afford tert-butyl (2S,5R)-5-(hydroxymethyl)-2-methylpiperazine-1-carboxylate (850 mg, 3.69 mmol, 96.5 % yield).

[01734] Step D: 1-benzyl 4-(tert-butyl) (2R,5S)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate: Tert-butyl (2S,5R)-5-(hydroxymethyl)-2-methylpiperazine-1-carboxylate (350 mg, 1.52 mmol) was diluted with THF (4 mL), placed under nitrogen and cooled to 0°C. NaOH (1672 µl, 1.67 mmol) was added followed by the addition of benzyl chloroformate (228 µl, 1.52 mmol). After stirring for 2 hours, the reaction was diluted with ethyl acetate and water. The water was extracted two more times and the ethyl acetate was combined, dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-80% ethyl acetate/hexanes to afford 1-benzyl 4-(tert-butyl) (2R,5S)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate (300 mg, 0.823 mmol, 54.2 % yield). ESI+APCI MS m/z 265.1 $[M+H]^+$ (minus boc).

[01735] Step E: 1-benzyl 4-(tert-butyl) (2R,5S)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate: 1-benzyl 4-(tert-butyl) (2R,5S)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate (300 mg, 0.823 mmol) was diluted with DCM (4 mL), placed under nitrogen and cooled to 0°C. DIEA (216 µl, 1.23 mmol) was added followed by the addition of methanesulfonyl chloride (70.1 µl, 0.905 mmol). After stirring for 2 hours at 0°C, the reaction was diluted with DCM and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-50% ethyl acetate/hexanes to afford 1-benzyl 4-(tert-butyl) (2R,5S)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (290 mg, 0.655 mmol, 79.6 % yield).

[01736] Step F: 1-benzyl 4-(tert-butyl) (2S,5S)-2-(cyanomethyl)-5-methylpiperazine-1,4-dicarboxylate: 1-benzyl 4-(tert-butyl) (2R,5S)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (290 mg, 0.655 mmol) was diluted with DMA (4 mL) followed by the addition of NaCN (64.2 mg, 1.31 mmol). The reaction was heated to 55°C and stirred for 12 hours. The reaction was allowed to cool, diluted with MTBE and washed with saturated sodium bicarbonate, water and brine. The MTBE was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-50% ethyl acetate/hexanes to afford 1-benzyl 4-(tert-butyl) (2S,5S)-2-(cyanomethyl)-5-

methylpiperazine-1,4-dicarboxylate (200 mg, 0.536 mmol, 81.7 % yield). ESI+APCI MS m/z 274.2 $[M+H]^+$ (minus boc).

[01737] Step G: benzyl (2S,5S)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate: 1-benzyl 4-(tert-butyl) (2S,5S)-2-(cyanomethyl)-5-methylpiperazine-1,4-dicarboxylate (200 mg, 0.536 mmol) was diluted with DCM (2 mL) followed by the addition of HCl (669 µl, 2.68 mmol). After stirring for 3 hours, the reaction was concentrated to afford benzyl (2S,5S)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (146 mg, 0.534 mmol, 99.7 % yield). ESI+APCI MS m/z 274.1 $[M+H]^+$.

[01738] Step H: tert-butyl 4-((2S,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-Butyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (211 mg, 0.695 mmol) was diluted with DMA (4 mL) followed by the addition of benzyl (2S,5S)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (190 mg, 0.695 mmol) and DIEA (364 µl, 2.09 mmol). The reaction was allowed to stir at ambient temperature for 12 hours. Very little product was detected so the reaction was heated to 75°C for an additional 12 hours. The reaction was allowed to cool, diluted with ethyl acetate and water. The ethyl acetate was washed with water, brine, dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-50% ethyl acetate/hexanes to afford tert-butyl 4-((2S,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (53 mg, 0.0980 mmol, 14.1 % yield). ESI+APCI MS m/z 541.2 $[M+H]^+$.


[01739] Step I: benzyl (2S,5S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate: Tert-butyl 4-((2S,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (53 mg, 0.098 mmol) was diluted with DCM followed by the addition of HCl (122 µl, 0.49 mmol). After stirring for 4 hours, the reaction was concentrated to afford benzyl (2S,5S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (43 mg, 0.098 mmol, 100 % yield). ESI+APCI MS m/z 441.1 $[M+H]^+$.

[01740] Step J: benzyl (2S,5S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate: Benzyl (2S,5S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (43 mg, 0.0975 mmol), 1-iodonaphthalene (124 mg, 0.488 mmol), Cs2CO3 (95.3 mg, 0.293 mmol) and Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (12.5 mg, 0.0146 mmol) were diluted with DMA (600 uL), purged with argon, sealed and heated to 92°C. After stirring for 12 hours, the reaction was allowed to cool, diluted with ethyl acetate and water. The layers were separated and the ethyl acetate was washed with brine, dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-50% ethyl acetate/hexanes to afford benzyl (2S,5S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (26.5 mg, 0.0467 mmol, 47.9 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.


[01741] Step K: 2-((2S,5S)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: benzyl (2S,5S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (26.5 mg, 0.0467 mmol), (s)-(dicyclohexyl(2',6'-diisopropoxy-[1,1'-biphenyl]-2-yl)-l5-phosphanyl)(2'-(methylamino)-[1,1'-biphenyl]-2-yl)palladium(III) methanesulfonate (7.96 mg, 0.00935 mmol) and Cs2CO3 (76.1 mg, 0.234 mmol) were diluted with DMA (300 uL) followed by the addition of N-Methyl-l-prolinol (21.5 mg, 0.187 mmol). The reaction was purged with argon, sealed and heated to 90°C. After stirring for 12 hours, the reaction was allowed to cool, diluted with ethyl acetate and water. The ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford benzyl (2S,5S)-2-(cyanomethyl)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (8 mg, 0.0124 mmol, 26.5 % yield) and 2-((2S,5S)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (10 mg, 0.0195 mmol, 41.8 % yield). ESI+APCI MS m/z 512.3 $[M+H]^+$.


[01742] Step L: 2-((2S,5S)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((2S,5S)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (10 mg, 0.020 mmol) was diluted with DCM (200 uL) followed by the addition of DIEA (6.8 µl, 0.039 mmol). The reaction was placed under nitrogen and cooled to 0°C. acryloyl chloride (1.8 µl, 0.021 mmol) was added and the reaction was stirred for 2 hours. The reaction was poured into a 10% sodium bicarbonate solution and extracted with DCM. The DCM was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound 2-((2S,5S)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 368, 6 mg, 0.011 mmol, 54 % yield). ESI+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 369



2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-acryloylpiperazin-2-yl)acetonitrile





[01743] Step A: tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: Benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (10 g, 34 mmol) was dissolved in DMA (68 ml, 34 mmol). To the solution was next added tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (9.3 g, 30 mmol) followed by Hunig's Base (24 ml, 135 mmol) and the reaction stirred at room temperature for 1 hour. The reaction was next poured into basic water and extracted with MTBE. The organics were washed with additional water, brine, dried over Na_2SO_4 and concentrated in vacuo. The material was chromatographed using 10% to70% EtOAc:Hexane as eluent to give tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (12 g, 23 mmol, 67 % yield). ESI+APCI MS m/z 527.2 $[M+H]^+$.

[01744] Step B: benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1 g, 2 mmol) was dissolved in DCM (19 ml, 2 mmol) and treated with Hydrochloric Acid (4.0 M solution in 1,4-dioxane) (2 ml, 9 mmol). The reaction stirred at room temperature for 1 hour. The reaction was concentrated in vacuo and resuspended in DCM. The suspension was washed with 1M NaOH. The aqueous layer was extracted with DCM (2X). The combined organics were dried over Na2SO4, concentrated in vacuo and taken forward as crude benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.8 g, 2 mmol, 99 % yield). ESI+APCI MS m/z 427.1 $[M+H]^+$.

SUBSTITUTE SHEET (RULE 26)

[01745] Step C: benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tris(dibenzylideneacetone)dipalladium(0) (343 mg, 0.375 mmol) and 2-(Dicyclohexylphosphino)-2',4',6'-tri-i-propyl-1,1'-biphenyl (357 mg, 0.750 mmol) were dissolved in 1,4-dioxane (18740 µl, 1.87 mmol) and purged under Argon for 5 minutes. The reaction stirred at 100°C under argon for an additional 15 min. To the reaction was added benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (800 mg, 1.87 mmol), 1-bromo-8-methylnaphthalene (1243 mg, 5.62 mmol), and cesium carbonate (1832 mg, 5.62 mmol) under Argon. The reaction was capped under Argon and stirred at 100°C over night. The reaction was cooled to room temperature and filtered through GF/F paper. The filtrate was concentrated in vacuo and purified by normal phase chromatography on the CombiFlash eluting with 0%-15% DCM:MeOH(+2% NH_4OH modifier) to give benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (378 mg, 0.667 mmol, 35.6 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.


[01746] Step D: benzyl (S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: In a round bottom flask, a solution of benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.3 g, 0.529 mmol) in dioxane (5.29 ml, 0.529 mmol) was sparged with Argon. 3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol (0.250 g, 1.59 mmol), Cs_2CO_3 (0.517 g, 1.59 mmol), Tris(dibenzylideneacetone)dipalladium (0) (0.0969 g, 0.106 mmol) and 9,9-Dimethyl-4,5-Bis(Dipheyl-Phosphino)Xanthene (0.122g, 0.212mmol) were sequentially added under Argon and sparged for an additional 5 minutes. The reaction mixture was capped and heated at 100°C for 2 hours. The reaction was filtered through GF/F paper and concentrated in vacuo. The concentrate was purified by silica gel eluting with 0-12% MeOH in DCM with 2% NH_4OH to provide benzyl (S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.155 g, 0.225 mmol, 42.6 % yield). ESI+APCI MS m/z 688.3 $[M+H]^+$.

SUBSTITUTE SHEET (RULE 26)

[01747] Step E: 2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (155 mg, 0.225 mmol) in EtOH (2253 µl, 0.225 mmol) and THF (2253 µl, 0.225 mmol) and EtOH (2253 µl, 0.225 mmol) was purged with N_2 for 5 minutes. To this solution was added Palladium (60.0 mg, 0.0563 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 minutes. The solution then stirred under an atmosphere of H_2. The mixture was then diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide 2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (98 mg, 0.177 mmol, 78.5 % yield). This was taken forward as crude. ESI+APCI MS m/z 554.3 $[M+H]^+$.

[01748] Step F: 2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-acryloylpiperazin-2-yl)acetonitrile: To a suspension of 2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (98 mg, 0.177 mmol) in dichloromethane (1770 µl, 0.177 mmol) at ambient temperature was added Acyloyl Chloride (14.4 µl, 0.177 mmol) followed by Hunig's base (61.8 µl, 0.354 mmol). The reaction was then stirred at ambient temperature for 2 hours. The reaction mixture was concentrated in vacuo. The concentrate was resuspended in a 60:40 mixture of ACN: H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-((S)-4-(2-(3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-acryloylpiperazin-2-yl)acetonitrile (EXAMPLE 369, 63.5 mg, 0.104 mmol, 59.0 % yield).ESI+APCI MS m/z 608.3 $[M+H]^+$.


EXAMPLE 370



(S)-2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01749] (S)-2-(1-acryloyl-4-(7-(8-methylnaphthalen-1-yl)-2-(3-morpholinopropoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following EXAMPLE 369 substituting N-Hydroxypropanylmorpholine for 3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol and also substituting Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) for Tris(dibenzylideneacetone)dipalladium (0) and 9,9-Dimethyl-4,5-Bis(Dipheyl-Phosphino)Xanthene in Step D. ESI+APCI MS m/z 596.3 $[M+H]^+$.

EXAMPLE 371




(S)-3-((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide


[01750] (S)-3-((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide: The title

compound was prepared following EXAMPLE 369 substituting 3-Hydroxy-N,N-dimethylpropanamide for 3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propan-1-ol and also substituting Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) for Tris(dibenzylideneacetone)dipalladium (0) and 9,9-Dimethyl-4,5-Bis(Dipheyl-Phosphino)Xanthene in Step D. ESI+APCI MS m/z 568.3 $[M+H]^+$.

EXAMPLE 372




2-((S)-1-((E)-but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01751] Step A: 2-((S)-1-((E)-but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.05863 mmol) and 3-(E)-but-2-enoic acid (6.562 mg, 0.07622 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (20.48 µl, 0.1173 mmol) and 1-propanephosphonic acid cyclic anhydride (52.35 µl, 0.08795 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on

silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound 2-((S)-1-((E)-but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 372, 10 mg, 0.01725 mmol, 29.42 % yield). ESI+APCI MS m/z 580.3 $[M+H]^+$.

EXAMPLE 373




2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01752] Step A: Benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: In a microwave tube benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 0.198 mmol) was dissolved in dioxane (98.9 µl, 0.198 mmol) and treated with cesium carbonate (129 mg, 0.396 mmol), and 2-Fluoro-3-(trifluoromethyl)pyridine (163 mg, 0.989 mmol). The tube was then capped and heated to 90°C for 12hr. The reaction was cooled and filtered through GF/F paper and the filtrate was concentrated. The residue was purified by silica chromatography (0-12% MeOH in DCM with 0.25 % NH4OH) to provide benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (70 mg, 0.11 mmol, 54%).

[01753] Step B: 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. The title compound was prepared following EXAMPLE 375, Steps F-G substituting benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-2-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate for benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in EXAMPLE 375 Step F. ESI+APCI MS m/z 571.3 $[M+H]^+$.


EXAMPLE 374




2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(2,2,2-trifluoroethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01754] 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(2,2,2-trifluoroethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 375**, Steps E-G, substituting 1-bromo-2-(2,2,2-trifluoroethyl)benzene for 4-Bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E. ESI+APCI MS m/z 584.3 $[M+H]^+$.

EXAMPLE 375



2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01755] Step A: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (8.0 g, 26.3 mmol), Hunig's base (22.9 ml, 132 mmol) and 2-(piperazin-2-yl)acetonitrile dihydrochloride (5.21 g, 26.3 mmol) were placed in DMA (75 mL) and stirred at rt for 20min. Water was added and the mixture was extracted with EtOAc (3x100 mL). The extracts were combined and washed with water (3x 50 mL) then was dried with sodium sulfate. The solids were filtered and the filtrate was concentrated to provide crude tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. ESI+APCI MS m/z 337.1 $[M+H]^+$.

[01756] Step B : tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (10.50 g, 26.725 mmol) and TEA (5.5876 ml, 40.088 mmol) were placed in THF (100 mL) and was cooled to 0C. Benzyl carbonochloridate (5.6518 ml, 40.088 mmol) was added and the reaction was stirred at 0C for 30 min. Water was added and the mixture was extracted with DCM (3x 50 mL). The extracts were combined and concentrated. The resulting residue was purified by silica

gel (0-60% EtOAc in hex) to provide tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (12.939 g, 24.551 mmol, 91.865 % yield). ESI+APCI MS m/z 527.2 $[M+H]^+$.

[01757] Step C : tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: In a conical bottom vial, a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (3.28g, 6.22 mmol) in dioxane (62.2 ml, 6.22 mmol) was sparged with argon and (S)-(1-methylpyrrolidin-2-yl)methanol (2.15 g, 18.7 mmol), Cs2CO3 (6.08 g, 18.7 mmol), Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.795 g, 0.934 mmol) were sequentially added under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 18hr. The reaction was cooled and water was added. The mixture was extracted with DCM (3x15mL) and the extracts were combined and concentrated. The resulting residue was purified by silica gel (0-12% MeOH in DCM woth 0.25% NH4OH) to provide tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (2.65 g, 4.37 mmol, 70.3 % yield). ESI+APCI MS m/z 606.3 $[M+H]^+$.

[01758] Step D: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.6 g, 1.0 mmol) was dissolved in dichloromethane (10 ml, 1.0 mmol) and treated with hydrochloric acid (4.0 M solution in 1,4-dioxane (1 ml, 5 mmol) and the reaction was stirred at room temperature for 1 hour. The reaction was next concentrated in vacuo and the material partitioned between EtOAc and basic water and the layers separated. The organics were next washed with brine, dried over Na2SO4 and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.4 g, 0.8 mmol, 80 % yield). ESI+APCI MS m/z 506.2 $[M+H]^+$.


[01759] Step E : benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate : To a vial was added Cesium carbonate (193 mg, 0.593 mmol), benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (60 mg, 0.119 mmol) and Rhuphos Pd G3 (9.92 mg, 0.0119 mmol), and 4-Bromo-3-(trifluoromethyl)pyridine hydrobromide (93.4 mg, 0.356 mmol). the vial was sealed and the1,4-dioxane (1187 µl, 0.119 mmol) added through a septum. Ar was bubbled through the mixture for 5 minutes and then the mixture was heated to 70oC for 7h. the reaction was cooled, filtered through qualitative paper and concentrated. The yellow solids were dissolved in minimal DCM and purified by silica chromatography (0-12% MeOH in DCM) to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (35 mg, 0.0541 mmol, 45.6%). ESI+APCI MS m/z 551.3 $[M+H]^+$.

[01760] Step F: 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (35.2 mg, 0.0541 mmol) in EtOH (541 µl, 0.0541 mmol) and THF (541 µl, 0.0541 mmol) was added Palladium (28.8 mg, 0.0135 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature for 1h. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to provide 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (26.4 mg, 0.0511 mmol, 94.5 % yield).


[01761] Step G : 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (26.4 mg, 0.0511 mmol) in CH2Cl2 (511 µl, 0.0511 mmol) at -78oC was added

acryloyl chloride (1022 µl, 0.102 mmol) (freshly prepared 0.1M solution in DCM) followed by Triethylamine (14.2 µl, 0.102 mmol). The reaction was then stirred at 0°C for 45 minutes. LC-MS indicated product formation. Reaction concentrated and purified by prep HPLC to provide title compound 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 375, 3 mg, 0.00526 mmol, 10.3 % yield). ESI+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 376



2-(1-(but-2-ynoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate



[01762] Step A: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (8.0 g, 26.3 mmol), Hunig's base (22.9 ml, 132 mmol) and 2-(piperazin-2-yl)acetonitrile dihydrochloride (5.21 g, 26.3 mmol) were placed in DMA (75 mL) and stirred at rt for 20min. Water was added and the mixture was extracted with EtOAc (3x100 mL). The extracts were combined and washed with water (3x 50 mL) then was dried with sodium sulfate. The solids were filtered and the filtrate was concentrated to provide crude tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. ESI+APCI MS m/z 337.1 $[M+H]^+$.

[01763] Step B : tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: tert-butyl 2-chloro-4-(3-(cyanomethyl)piperazin-1-yl)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (10.50 g, 26.73 mmol) and TEA (5.59 ml, 40.0 mmol) were placed in THF (100 mL) and was cooled to 0°C. Benzyl carbonochloridate (5.65 ml, 40.0 mmol) was added and the reaction was stirred at 0°C for 30 min. Water was added and the mixture was extracted with DCM (3x 50 mL). The extracts were combined and concentrated. The resulting residue was purified by silica gel (0-60% EtOAc in hex) to provide tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (12.94 g, 24.6 mmol, 92 % yield). ESI+APCI MS m/z 527.2 $[M+H]^+$.

[01764] Step C : tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: In a conical bottom vial, a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (3.28g, 6.22 mmol) in dioxane (62.2 ml, 6.22 mmol) was sparged with argon and (S)-(1-methylpyrrolidin-2-yl)methanol (2.15 g, 18.7 mmol), Cs2CO3 (6.08 g, 18.7 mmol), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.795 g, 0.934 mmol) were sequentially added under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 18hr. The reaction was cooled and water was added. The mixture was extracted with DCM (3x15mL) and the extracts were combined and concentrated. The resulting residue was purified by silica

gel (0-12% MeOH in DCM woth 0.25% NH4OH) to provide tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (2.65 g, 4.37 mmol, 70 % yield). ESI+APCI MS m/z 606.3 $[M+H]^+$.

[01765] Step D: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.6 g, 1.0 mmol) was dissolved in dichloromethane (10 ml, 1.0 mmol) and treated with hydrochloric acid (4.0 M solution in 1,4-dioxane (1 ml, 5 mmol) and the reaction was stirred at room temperature for 1 hour. The reaction was concentrated in vacuo and the material partitioned between EtOAc and basic water and the layers were separated. The organics were washed with brine, dried over Na2SO4 and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.4 g, 0.8 mmol, 80 % yield). ESI+APCI MS m/z 506.2 $[M+H]^+$.


[01766] Step E: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a vial was added cesium carbonate (193 mg, 0.59 mmol), benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (60 mg, 0.12 mmol) and Rhuphos Pd G3 (9.92 mg, 0.012 mmol), and 1-bromonaphthalene (49.8 µl, 0.36 mmol). The vial was sealed and the1,4-dioxane (1187 µl, 0.12 mmol) added through a septum. Ar was bubbled through the mixture for 5 minutes and then the mixture was heated to 70°C for 7h. The reaction was cooled, filtered through qualitative paper and concentrated. The yellow solids were dissolved in minimal DCM and purified by silica chromatography (0-12% MeOH in DCM) to provide benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (28 mg, 0.044 mmol, 37% yield). ESI+APCI MS m/z 632.4 $[M+H]^+$.

[01767] Step F: 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of


benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (45 mg, 0.071 mmol) in EtOH (712 µl, 0.071 mmol) and THF (712 µl, 0.071 mmol) was added palladium (38 mg, 0.018 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature for 1h. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to provide 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.060 mmol, 85 % yield). ESI+APCI MS m/z 498.3 $[M+H]^+$.

[01768] Step G: 2-(1-(but-2-ynoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (603 µl, 0.060 mmol) was added 2-(4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.060 mmol) and triethylamine (12.2 mg, 0.12 mmol). The reaction mixture was vigorously stirred while 2-butynoic acid (6.08 mg, 0.072 mmol) was added in one portion. 1-Propanephosphonic acid cyclic anhydride (26.9 µl, 0.090 mmol) was added slowly to the stirring mixture. The reaction was allowed to stir for 2hr at 0°C. Water was added and the reaction extracted with EtOAc (2x 25 mL). The organic layers were washed with saturated LiCl, NaCl, and water (10 mL each wash). Dried and concentrated to a solid that was purified by prep HPLC (5-95% ACN:H2O, TFA) which provided title compound 2-(1-(but-2-ynoyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate (EXAMPLE 376, 11.2 mg, 0.02 mmol, 33% yield) ESI+APCI MS m/z 564.3 $[M+H]^+$.

EXAMPLE 377



2-((S)-1-acryloyl-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01769] Step A: 2-((S)-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.30 g, 0.54 mmol) in dioxanes was added (S)-(1-methylpiperidin-2-yl)methanol (0.49 g, 3.8 mmol) and Cs_2CO_3 (0.53 g, 1.6 mmol) and the reaction degassed with Argon for 15 minutes, followed by addition of Rhuphos Pd G3 (0.068 g, 0.081 mmol) and the reaction heated to 100°C for overnight. The reaction was cooled and filtered through GFF paper and the filtrate concentrated in vacuo. The residue was next chromatographed using 1→15% MeOH/DCM with 2% Ammonium Hydroxide as eluent to give 2-((S)-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.23 g, 0.45 mmol, 83 % yield). ESI+APCI MS m/z 512.3 $[M+H]^+$.


[01770] Step B: 2-((S)-1-acryloyl-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.23 g, 0.45 mmol) in DCM (20 mL) cooled to 0°C was added N-ethyl-N-isopropylpropan-2-amine (0.16 ml, 0.90 mmol) followed by addition of a solution of acryloyl chloride (0.037 ml, 0.45 mmol) (in 10 mL of DCM) and the reaction stirred at 0°C for 10 minutes. To the reaction was next added 1 mL of methanol and the reaction concentrated in vacuo. The material was next chromatographed 2X using 1→ 10% MeOH/DCM with 2% NH_4OH as eluent to give a solid which was further

purified by reverse prep HPLC using 5→95% ACN/water with 0.1%TFA as modifier to give title compound 2-((S)-1-acryloyl-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 377, 0.030 g, 0.053 mmol, 12 % yield). ESI+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 378



2-((2S,5R)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01771] Step A: 1-benzyl 4-(tert-butyl) (2R,5R)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate: Tert-butyl (2R,5R)-5-(hydroxymethyl)-2-methylpiperazine-1-carboxylate (1.0 g, 4.34 mmol) was dissolved in water (50 mL) followed by addition of EtOAc (6.68 ml, 4.34 mmol) and sodium hydrogen carbonate (1.09 g, 13.0 mmol) and and the reaction stirred 3 minutes. To the reaction was added benzyl carbonochloridate (0.648 ml, 4.56 mmol) in 1 bolus (internal temp from 19 --> 25 C) and the reaction stirred overnight at room temperature. The layers were next separated and the organics washed with brine, dried over $MgSO_4$ and concentrated in vacuo. The residue was chromatographed using10→70% EtOAc/Hex as eluent to give 1-benzyl 4-(tert-butyl) (2R,5R)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate (1.2 g, 3.29 mmol, 75.8 % yield). ESI+APCI MS m/z 265.2 $[M+H\text{-}boc]^+$.

[01772] Step B: 1-benzyl 4-(tert-butyl) (2R,5R)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate: To a solution of 1-benzyl 4-(tert-butyl) (2R,5R)-2-(hydroxymethyl)-5-methylpiperazine-1,4-dicarboxylate (1.2 g, 3.3 mmol) in DCM cooled to 0C was added N-ethyl-N-isopropylpropan-2-amine (0.64 g, 4.9 mmol) and methanesulfonyl chloride (0.30 ml, 3.6 mmol) and the reaction stirred at 0°C for 2 hrs. The organics were next washed with brine, dried over $MgSO_4$ and concentrated in vacuo. The material was next chromatographed using 10→70% EtOAc/hex as eluent to give 1-benzyl 4-(tert-butyl) (2R,5R)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (1.3 g, 2.9 mmol, 89 % yield). ESI+APCI MS m/z 343.1 $[M+H\text{-}boc]^+$.

[01773] Step C: 1-benzyl 4-(tert-butyl) (2S,5R)-2-(cyanomethyl)-5-methylpiperazine-1,4-dicarboxylate: To a solution of 1-benzyl 4-(tert-butyl) (2R,5R)-5-methyl-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (1.3 g, 2.9 mmol) in DMA (20 mL) was added cyanosodium (0.29 g, 5.9 mmol) and the reaction stirred 48hrs at 55°C. The reaction was next diluted with basic water (220 mL) and the aq layer extracted with MTBE. The organics were next washed with water (2x50 mL), brine (50 mL), dried over $MgSO_4$ and concentrated in vacuo. The material was next chromatographed using 10→50% EtOAc/hex as eluent to give 1-benzyl 4-(tert-butyl) (2S,5R)-2-(cyanomethyl)-5-methylpiperazine-1,4-dicarboxylate (0.90 g, 2.4 mmol, 82 % yield). ESI+APCI MS m/z 274.1 $[M+H\text{-}boc]^+$.

[01774] Step D: benzyl (2S,5R)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate hydrochloride: To a solution of 1-benzyl 4-(tert-butyl) (2S,5R)-2-(cyanomethyl)-5-

methylpiperazine-1,4-dicarboxylate (0.90 g, 2.4 mmol) in DCM was added hydrogen chloride (3.0 ml, 12 mmol) and the reaction stirred for 2 hrs at rt (added 5 more eq of HCl at 1 hr). The reaction was next concentrated in vacuo and the material used crude in the next reaction. ESI+APCI MS m/z 274.2 $[M+H]^+$.

[01775] Step E: tert-butyl 4-((2R,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: To the solid benzyl (2S,5R)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate hydrochloride (0.75 g, 2.4 mmol) and tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.74 g, 2.4 mmol) was added DMA (10 mL) followed by Hunig'sBase (1.3 ml, 7.3 mmol) and the reaction stirred overnight at room temperature. The reaction was next poured into water and and the aqueous layer extracted with MTBE. The MTBE layer was washed with water, brine, dried over $MgSO_4$ and concentrated in vacuo. The material was purified by column chromatogrpaphy using 10→70% etoac/hex as eluent to give tert-butyl 4-((2R,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.72 g, 1.3 mmol, 55 % yield). ESI+APCI MS m/z 541.3 $[M+H]^+$.

[01776] Step F: benzyl (2S,5R)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate: To a solution of tert-butyl 4-((2R,5S)-4-((benzyloxy)carbonyl)-5-(cyanomethyl)-2-methylpiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.72 g, 1.3 mmol) in DCM (20 mL) was added hydrogen chloride (1.7 ml, 6.7 mmol) (4 M in dioxanes) and the reaction stirred for 1 hour at room temperature. The reaction was next concentrated in vacuo and the residue partitioned between EtOAc and basic water. The organics were separated and washed with brine, dried over MgSO4 and concentrated in vacuo. The material was used crude in the next rxn. ESI+APCI MS m/z 441.2 $[M+H]^+$.

[01777] Step G: benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of benzyl (2S,5R)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (0.48 g, 1.1 mmol) in dioxanes (40 mL) was added 1-iodonaphthalene (1.4 g, 5.4 mmol) and Cs_2CO_3 (1.1 g, 3.3 mmol) and the reaction degassed with Ar for 15 minutes, followed


by addition of Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.14 g, 0.16 mmol) and the reaction heated to 100°C for 5 hours. The reaction was next cooled and filtered through GFF paper and concentrated in vacuo. The material was next chromatographed using 10→70 etoac/hex as eluent to give benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.8 g, 5.1 mmol, 64 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.

[01778] Step H: 2-((2S,5R)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile :To a solution of benzyl (2S,5R)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)-5-methylpiperazine-1-carboxylate (0.48 g, 0.85 mmol) in dioxanes (40 mL) was added (S)-(1-methylpyrrolidin-2-yl)methanol (0.39 g, 3.4 mmol) and Cs_2CO_3 (1.4 g, 4.2 mmol) and the reaction degassed with Ar for 15 minutes followed by addition of Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.11 g, 0.13 mmol) and the reaction heated to 100°C for overnight. The reaction was next cooled and filtered through GFF paper and concentrated in vacuo. The material was next chromatographed using 1→15% (MeOH +2% NH_4OH)/DCM with to give benzyl (2S,5R)-2-(cyanomethyl)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.20 g, 0.31 mmol, 37 % yield) and 2-((2S,5R)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.14 g, 0.27 mmol, 32 % yield). ESI+APCI MS m/z 512.3 $[M+H]^+$.

[01779] Step I: 2-((2S,5R)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((2S,5R)-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.14 g, 0.274 mmol) cooled to 0°C was added N-ethyl-N-isopropylpropan-2-amine (0.0982 ml, 0.547 mmol) followed by acryloyl chloride (0.0225 ml, 0.274 mmol) and the reaction stirred at 0°C for 10 minutes. 1 mL of methanol was added to the reaction and the

reaction concentrated in vacuo. The material was next purified by gilson reverse prep 2 HPLC 2 times eluting with 5→95% ACN/water with 0.1% TFA as modifier. The combined fractions were partitioned between EtOAc and basic water and the layers separated. The orgnanics were next washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give title compound 2-((2S,5R)-1-acryloyl-5-methyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 378, 0.0118 g, 0.0209 mmol, 7.62 % yield). ESI+APCI MS m/z 566.3 $[M+H]^+$.


EXAMPLE 379



2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01780] 2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 1-bromo-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 570.3 $[M+H]^+$.


EXAMPLE 380



2-(1-acryloyl-4-(2-(((S)-1-(2-methoxyethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile


[01781] 2-(1-acryloyl-4-(2-(((S)-1-(2-methoxyethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 375**, Steps C-G, substituting (S)-(1-(2-methoxyethyl)pyrrolidin-2-yl)methanol for (S)-(1-methylpyrrolidin-2-yl)methanol in Step C and 1-bromonaphthalene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E. ESI+APCI MS m/z 596.3 $[M+H]^+$.

EXAMPLE 381



2-(1-acryloyl-4-(2-(((2S,4R)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile


[01782] Step A: tert-butyl (2S,4R)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-methoxypyrrolidine-1-carboxylate: was prepared following **Example 375**, Steps C-F, substituting tert-butyl (2S,4R)-2-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate for (S)-(1-methylpyrrolidin-2-yl)methanol in Step C and 1-bromonaphthalene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E



[01783] Step B: benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: benzyl 4-(2-(((2S,4R)-1-(tert-butoxycarbonyl)-4-methoxypyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (27.0 mg, 0.04 mmol , formaldehyde (15.7 µl, 0.2 mmol), Na(OAc)3BH (17.7 mg, 0.08 mmol) were placed in THF (2 mL) and stirred for 2 hrs. Saturated bicarbonate was added and the mixture was extracted with 10% MeOH in DCM (3x15 mL). The extracts were combined, dried with sodium sulfate, and concentrated to provide crude material which was used as is.

[01784] Step C: 2-(1-acryloyl-4-(2-(((2S,4R)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile was prepared following **Example 375** Step F and G, subsituting benzyl 2-(cyanomethyl)-4-(2-(((2S,4R)-4-methoxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate for benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in Step F. ESI+APCI MS m/z 582.3 $[M+H]^+$.

EXAMPLE 382




2-((S)-1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01785] 2-((S)-1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps F-J, substituting (R)-(1-

methylpyrrolidin-2-yl)methanol for (S)-(1-methylpyrrolidin-2-yl)methanol in Step F and 1-bromo-3-fluoro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 588.3 $[M+H]^+$.


EXAMPLE 383




2-((S)-1-acryloyl-4-(7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01786] 2-((S)-1-acryloyl-4-(7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 3-bromo-5-fluoro-4-(trifluoromethyl)pyridine for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 589.3 $[M+H]^+$.


EXAMPLE 384



2-((S)-1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01787] Step A: benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.37 g, 10.2 mmol) was placed in DCM (75 mL) and was cooled to 0°C. HCl (12.7 ml, 50.9 mmol) was added and the reaction was warmed to rt and was stirred for 2hr. The reaction was concentrated and was brought up in DCM. Saturated bicarbonate was added and the mixture was extracted with DCM (3x 50 mL). The organic layers were combined, dried, and concentrated to provide benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (4.33 g, 10.1 mmol, 99 % yield) which was used as is.




[01788] Step B: benzyl (S)-4-(2-chloro-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a vial was added cesium carbonate (2.29 g, 7.0 mmol), benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.00 g, 2.3 mmol), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.30 g, 0.35 mmol), 3-bromo-5-fluoro-4-(trifluoromethyl)pyridine (1.29 g, 5.3 mmol) and 1,4-dioxane (15.6 ml, 2.3 mmol) the vial was degassed with Ar and sealed then heated to 90°C for 24 hr. The reaction was cooled and water and saturated NH4Cl was added and the mixture was extracted with DCM. The organic layers


were combined and concentrated. The resulting residue was purified by silica gel (5-75% EtOAc in hexane) to provide benzyl (S)-4-(2-chloro-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (634 mg, 1.1 mmol, 46 % yield).



[01789] Step C: tert-butyl (2S,4R)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate: In a conical bottom vial, a solution of benzyl (S)-4-(2-chloro-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (634 mg, 1.07 mmol) in dioxane (10746 µl, 1.07 mmol) was sparged with argon. Tert-butyl (2S,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate (942 mg, 4.30 mmol), Cs2CO3 (1050 mg, 3.22 mmol), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (137 mg, 0.161 mmol) were sequentially added under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 18hr. The reaction was cooled and water was added. The mixture was extracted with DCM (3x20mL) and the extracts were combined and concentrated. The resulting residue was purified by silica gel (0-10% MeOH) to provide tert-butyl (2S,4R)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate (579 mg, 0.907 mmol, 84 % yield).




[01790] Step D: tert-butyl (2S,4R)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate: Tert-butyl (2S,4R)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate (579 mg, 0.907 mmol), triethylamine (379 µl, 2.72 mmol) were placed in CH2Cl2 (9066 µl, 0.907 mmol) and cooled to 0°C. Acryloyl chloride (6044 µl, 1.81 mmol) was added (freshly prepared 0.3M solution in DCM) and the reaction was stirred for 45 min at 0°C. Water was added and the mixture was extracted with DCM (3x 15 mL). The layers were combined and concentrated to provide crude material that was used as is.




[01791] Step E: 2-((S)-1-acryloyl-4-(7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-2-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: In a sealed vessel tert-butyl (2S,4R)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate (628 mg, 0.91 mmol) was placed in MeOH (2 mL). HCl (756 µl, 4.53 mmol) (6M aqueous) was added and the mixture was stirred at rt for 5hr. Saturated bicarbonate was added slowly to bring the pH

~9. The mixture was extracted with DCM (3x20 mL). The extracts were combined, dried, filtered and concentrated to provide crude material that was used as is.



[01792] Step F: 2-((S)-1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-1-acryloyl-4-(7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-2-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (175 mg, 0.30 mmol), formaldehyde (111 µl, 1.48 mmol), Na(OAc)3BH (125 mg, 0.59 mmol) and were placed in THF (2 mL) and stirred for 2 hrs. Saturated bicarbonate was added and the mixture was extracted with 10% MeOH in DCM (3x15 mL). The extracts were combined, dried with sodium sulfate, and concentrated. The resulting residue was purified by silica gel (4-13% MeOH in DCM with 0.25% NH4OH) to provide 2-((S)-1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (69.7 mg, 0.115 mmol, 39 % yield). ESI+APCI MS m/z 607.2 $[M+H]^+$.


EXAMPLE 385



2-((S)-1-acryloyl-4-(7-(5-chloro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01793] 2-((S)-1-acryloyl-4-(7-(5-chloro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 3-bromo-5-chloro-4-(trifluoromethyl)pyridine for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 605.3 $[M+H]^+$.


EXAMPLE 386



2-((S)-1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-isopropylpyrrolidin-2-yl)methoxy)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01794] 2-((S)-1-acryloyl-4-(2-(((2S,4R)-4-fluoro-1-isopropylpyrrolidin-2-yl)methoxy)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile, was prepared following the prep for **Example 384**, Step F, substituting propan-2-one for formaldehyde in step F. ESI+APCI MS m/z 635.3 $[M+H]^+$.


EXAMPLE 387



2-((S)-1-acryloyl-4-(7-(5-chloro-4-methylpyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01795] 2-((S)-1-acryloyl-4-(7-(5-chloro-4-methylpyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 3-bromo-5-chloro-4-methylpyridine for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 551.2 $[M+H]^+$.


EXAMPLE 388




2-((S)-1-acryloyl-4-(7-(3-fluoro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01796] 2-((S)-1-acryloyl-4-(7-(3-fluoro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 1-bromo-3-fluoro-2-methylbenzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 534.3 $[M+H]^+$.

EXAMPLE 389



2-((S)-1-(but-2-ynoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01797] Step A: 1-benzyl 4-(tert-butyl) (R)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate: To tert-butyl (R)-3-(hydroxymethyl)piperazine-1-carboxylate (76.0 g, 351 mmol) in a 3L flask was added water (500 mL) and the slurry was stirred until the material was completely dissolved. To this mixture was added EtOAc (541ml, 351 mmol) followed by $NaHCO_3$ (88.6 g, 1.05 mol) and the resulting mixture was stirred for 3 min (internal temp = 20°C). To this mixture was added Cbz-Cl (52.5 ml, 369 mmol) over 3 minutes (internal temp from 20°C to 25°C, off-gas seen at this point) and the reaction was stirred for 1d at rt. The reaction mixture was transferrred to a separatory funnel and the organic layer was washed with brine, dried ($MgSO_4$) and concentrated in vacuo. The residue was purified by flash chromatography eluting with 10-70% EtOAc/hex to afford 1-benzyl 4-(tert-butyl) (R)-2-(hydroxymethyl)piperazine-1,4-dicarboxylate (114.6 g, 327.0 mmol, 93% yield). ESI+APCI MS m/z 251.1 $[M\text{-}Boc+H]^+$.

[01798] Step B: 1-benzyl 4-(tert-butyl) (R)-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate: To a solution of 1-benzyl 4-(tert-butyl) (R)-2-(hydroxymethyl)piperazine-1,4-

dicarboxylate (32 g, 91.3 mmol) in CH_2Cl_2 (457 mL, 0.2 M) cooled to 0°C was added DIEA (24.6 ml, 137 mmol) followed by methanesulfonyl chloride (7.77 ml, 100 mmol) over 1 minute and the mixture was stirred at 0°C for 1h. The reaction mixture was transferred to a separatory funnel and washed with 1:1 water/brine (500 mL). The organic layer was collected, dried ($MgSO_4$), and concentrated in vacuo. The residue was purified by flash chromatography eluting with 10-60% EtOAc/hex to afford 1-benzyl 4-(tert-butyl) (R)-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (33 g, 77.0 mmol, 84.3 % yield). ESI+APCI MS m/z 329.1 $[M\text{-Boc}+H]^+$.

[01799] Step C: 1-benzyl 4-(tert-butyl) (S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate : To a solution of 1-benzyl 4-(tert-butyl) (R)-2-(((methylsulfonyl)oxy)methyl)piperazine-1,4-dicarboxylate (12.6 g, 29.4 mmol) in DMA (368 ml, 73.5 mmol) was sparged with argon. To the solution was added sodium cyanide (3.60 g, 73.5 mmol) and the reaction stirred at 55°C for 1d, monitoring by HPLC (long method) to determine reaction completion. The reaction mixture was transferred to a separatory funnel, diluted with 0.5M NaOH (800 mL) then extratced with MTBE (2x). The combined organic layers were next washed with basic water (2x 200 mL), brine (100 mL), dried ($MgSO_4$) and concentrated in vacuo. The residue was purified by flash chromatography eluting with 10-->60% EtOAc/hex as eluent to afford 1-benzyl 4-(tert-butyl) (S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate (7.9 g, 22.0 mmol, 75 % yield). ESI+APCI MS m/z 260.1 $[M\text{-Boc}+H]^+$.

[01800] Step D: benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride: To a solution of 1-benzyl 4-(tert-butyl) (S)-2-(cyanomethyl)piperazine-1,4-dicarboxylate (20.4 g, 56.8 mmol) in DCM (50 mL) was added hydrogen chloride (99.3 ml, 397 mmol) (4.0 M solution in dioxane) and the reaction stirred at rt for 1.5 hrs. The reaction mixture was concentrated in vacuo and dried under vacuum to give benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (16.8 g, 56.8 mmol, 100 % yield) as a foam. ESI+APCI MS m/z 260.1 $[M+H]^+$.

[01801] Step E: tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate : To a solution of benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (16.8 g, 56.8 mmol) in DMA (114 ml, 56.8 mmol) was added tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (15.5 g, 51.1 mmol) followed by DIEA (39.7 ml, 227 mmol) and the reaction

mixture was stirred at RT for 1 hr. The reaction mixture was diluted with 1L of water and extracted with MTBE (2x). The combined organics were washed with water (2x200 mL), brine, dried over $MgSO_4$ and concentrated in vacuo. The residue was purified by flash chromatography eluting with 10-60% EtOAc/hex as eluent to give tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (22.8 g, 43.3 mmol, 76 % yield). ESI+APCI MS m/z 527.2 $[M+H]^+$.

Step F: tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: In 250 mL heavy-wall RBF with a PTFE screw cap, a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.55 g, 10.5 mmol) in dioxane (60.2 ml, 10.5 mmol) was sparged with argon and (S)-(1-methylpyrrolidin-2-yl)methanol (3.64 g, 31.6 mmol), Cs_2CO_3 (10.3 g, 31.6 mmol), Ruphos Pd G3 (0.881 g, 1.05 mmol) were sequentially added and the resulting mixture was sparged with argon for an additional 5 min. The reaction mixture was capped and heated at 100°C for 1d. Upon consumption of starting material, the reaction mixture was cooled to ambient temperature and Cbz-Cl was added as necessary to convert Cbz-hydrolyzed product to title compound. The reaction mixture was then partitioned between EtOAc/10% brine. The aqueous layer was extracted with EtOAc (2x). The combined organic layers were dried (MgSO4) and concentrated. The residue was purified by flash chromatography eluting with a gradient of 1.5%MeOH/0.15% NH_4OH/DCM to 11.25%MeOH/1.125% NH_4OH/DCM (Premix 15%MeOH/1.5%NH_4OH in DCM and ramp from 10-75% of this mixture in DCM) to afford the title compound (4.51 g, 7.45 mmol, 71%). ESI MS m/z 606.3 $[M+H]^+$.

[01802] Step G: benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (7.2 g, 12 mmol) in DCM (1.0 g, 12 mmol) was added HCl (4M in dioxane, 15 ml, 59 mmol). The mixture was stirred at RT for 2h. The reaction mixture was concentrated to the bis HCl salt. The residue was partitioned between DCM / NaHCO3 (sat) and the aqueous layer was extracted with

DCM (3x). The combined organic layers were dried and concentrated to provide the title compound 4.72 g (0.009 mmol, 79%). ESI MS m/z 506.3 $[M+H]^+$.


[01803] Step H: benzyl (S)-2-(cyanomethyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a vial was added cesium carbonate (967 mg, 2.97 mmol), benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (500 mg, 0.989 mmol), Rhuphos Pd G3 (124 mg, 0.148 mmol), 1-bromo-2,3-dimethylbenzene (915 mg, 4.94 mmol) and1,4-dioxane (9889 µl, 0.989 mmol) the vial was degassed with Ar and sealed then heated to 75°C for 24 hr. Water and saturated NH4Cl was added and the mixture was extracted with DCM. The organic layers were combined and concentrated. The resulting residue was purified by silica gel (0-12% MeOH in DCM w/0.25% NH4OH) to provide benzyl (S)-2-(cyanomethyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (505mg, 0.828 mmol, 83.7 % yield). ESI MS m/z 610.4 $[M+H]^+$.

[01804] Step I: 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl (S)-2-(cyanomethyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (505 mg, 0.828 mmol) in EtOH (8282 µl, 0.828 mmol) and THF (8282 µl, 0.828 mmol) was added palladium (441 mg, 0.207 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure. The mixture was then stirred at ambient temperature for 2 hours. The mixture was then diluted with MeOH and THF 1:1 and filtered through GF/F paper. The filtrate was then concentrated to provide crude product which was used as is. ESI MS m/z 476.3 $[M+H]^+$.


[01805] Step J: 2-((S)-1-(but-2-ynoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (4415 µl, 0.4415 mmol) was added 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (210 mg, 0.44 mmol) and triethylamine (122.7 µl, 0.88 mmol). The reaction mixture was vigorously stirred while but-

2-ynoic acid (44.54 mg, 0.53 mmol) was added in one portion. 1-Propanephosphonic acid cyclic anhydride (197.1 µl, 0.66 mmol) was added slowly to the stirring mixture. The reaction was allowed to stir for 2 hr at 0°C. Water was added and the solids were filtered. The solids were purified by silica gel (5-18% MeOH in DCM with 0.25% NH4OH) to provide title compound 2-((S)-1-(but-2-ynoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 389, 144 mg, 0.27 mmol, 60%). . ESI+APCI MS m/z 542.3 $[M+H]^+$.


EXAMPLE 390



2-((S)-1-acryloyl-4-(2-(((2R,3S)-3-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01806] Step A: benzyl (S)-4-(2-(((2R,3S)-1-(tert-butoxycarbonyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: was prepared according to **Example 400**, Step C-E substiuting tert-butyl (2R,3S)-3-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate for (S)-(1-methylpyrrolidin-2-yl)methanol in Step C.



[01807] Step B: 2-((S)-1-acryloyl-4-(2-(((2R,3S)-3-hydroxypyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile tert-butyl (2R,3S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate (363 mg, 0.473 mmol) was placed in MeOH (10 mL). 6M aquous HCl was added and stirred at rt for 6hr. The reaction was cooled to 0°C and saturated bicarbonate was added slowly. The mixture was extracted with DCM (3x20 ml). The extracts were combined, dried, filtered and concentrated to provide crude material that was used as is.

[01808] Step C: 2-((S)-1-acryloyl-4-(2-(((2R,3S)-3-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared according to EXAMPLE 384, Step F substitutitng 2-((S)-1-acryloyl-4-(2-(((2R,3S)-3-hydroxypyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile for 2-((S)-1-acryloyl-4-(7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-2-(((2S,4R)-4-fluoropyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. ESI+APCI MS m/z 568.3 $[M+H]^+$.


EXAMPLE 391



2-((S)-1-(but-2-ynoyl)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01809] 2-((S)-1-(but-2-ynoyl)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared according to **Example 389**, Step H-J, substititing, 1-bromo-8-chloronaphthalene for 1-bromo-2,3-dimethylbenzene in Step H. ESI+APCI MS m/z 598.2 $[M+H]^+$.


EXAMPLE 392




2-((S)-1-(cyclobut-1-ene-1-carbonyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01810] 2-((S)-1-(cyclobut-1-ene-1-carbonyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 389** Step J, substituting cyclobut-1-ene-1-carboxylic acid for but-2-ynoic acid. ESI+APCI MS m/z 556.3 $[M+H]^+$.

EXAMPLE 393




2-((S)-1-acryloyl-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01811] Step A: benzyl (S)-2-(cyanomethyl)-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Benzyl (S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 0.22 mmol), K2CO3 (329 µl, 0.66 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (82.6 mg, 0.658 mmol) and Tetrakis (25.3 mg, 0.022 mmol) were placed in dioxane (731 µl, 0.22 mmol) and heated to 90°C for 18 hr. Water was added and the mixture was extracted with 10% MeOH in DCM (3x15 mL). The extracts were combined and concentrated. The resulting residue was purified by silica gel (2-80% MeOH in DCM with 0.25% NH4OH) to provide benzyl (S)-2-(cyanomethyl)-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.11 mmol, 52 % yield).

[01812] Step B: 2-((S)-1-acryloyl-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step I and J substiuting benzyl (S)-2-(cyanomethyl)-4-(7-(3-methyl-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate for benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in Step I. ESI+APCI MS m/z 584.3 $[M+H]^+$.


EXAMPLE 394




2-((S)-1-acryloyl-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01813] 2-((S)-1-acryloyl-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 234**, Steps H-J, substituting 1-bromo-2,3-dimethylbenzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 530.3 $[M+H]^+$.

EXAMPLE 395



2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



Step A: benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate : In a microwave tube benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.362 mmol) was dissolved in dioxane (181 µl, 0.362 mmol) and treated with cesium carbonate (236 mg, 0.723 mmol) and (S)-tert-butyl 2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate (389 mg, 1.81 mmol). The tube was then capped and heated to 90°C for 2 hours. The reaction was cooled to room temperature and filtered through GF/F paper. The filtrate was concentrated in vacuo and chromatagraphed on the CombiFlash eluting with 0%-10% DCM:MeOH. All fractions containing clean product were combined and concentrated to give benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (264 mg, 0.361 mmol, 99.7 % yield). ESI+APCI MS m/z 732.4 $[M+H]^+$.

Step B: benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (264 mg, 0.361 mmol) was dissolved in dichloromethane (3607 µl, 0.361 mmol) and treated with TFA

(556 µl, 7.21 mmol). The reaction stirred at room temperature for 1 hour. The reaction was concentrated in vacuo and treated with saturated bicarb. The aqueous was extracted with DCM (2X) and the combined organics dried over Na_2SO_4. The organics were concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (210 mg, 0.332 mmol, 92.2 % yield). ESI+APCI MS m/z 632.3 $[M+H]^+$.


Step C: benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Benzyl 2-(cyanomethyl)-4-(2-(((S)-2-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (105 mg, 0.1662 mmol) was dissolved in formic acid (94.05 µl, 2.493 mmol) and treated with Formaldehyde (1868 µl, 24.93 mmol). The reaction mixture stirred at 85°C for 1 hour. The reaction was cooled to room temperature and treated with saturated bicarb. The aqueous was extracted with DCM (2X). The combined organics were dried over Na_2SO_4, concentrated in vacuo and chromatographed on the CombiFlash eluting with 0%-10% DCM:MeOH. All fractions containing clean product were combined and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (75 mg, 0.1161 mmol, 69.88 % yield). ESI+APCI MS m/z 646.3 $[M+H]^+$.

Step D: 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (117 mg, 0.181 mmol) in EtOH (1812 µl, 0.181 mmol) and THF (1812 µl, 0.181 mmol) was purged with N_2 for 5 minutes. To this solution was added Palladium (96.4 mg, 0.0453 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 min. The solution then stirred under an atmosphere of H_2. The mixture was then diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-


4-yl)piperazin-2-yl)acetonitrile (88 mg, 0.172 mmol, 94.9 % yield). ESI+APCI MS m/z 512.3 $[M+H]^+$.

[01814] Step E: 2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-(4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (88 mg, 0.17 mmol) in dichloromethane (1720 µl, 0.17 mmol) at ambient temperature was added Acryloyl Chloride (14 µl, 0.17 mmol) followed by Hunig's base (60 µl, 0.34 mmol). The reaction was then stirred at ambient temperature for 30 minutes. The reaction mixture was then concentrated in vacuo. The concentrate was suspended in a 60:40 mixture of ACN: H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give 2-(1-acryloyl-4-(2-(((S)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (14 mg, 0.025 mmol, 14 % yield). ESI+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 396



2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




Step A: benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: In a conical bottom vial, a solution of benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.362 mmol) in dioxane (3616 µl, 0.362 mmol) was sparged with Argon and (S)-(1-(cyclopropylmethyl)pyrrolidin-2-yl)methanol (168 mg, 1.08 mmol), Cs_2CO_3 (353 mg, 1.08 mmol), Rhuphos Pd G3 (30.2 mg, 0.0362 mmol) were sequentially added under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 1 hour. The reaction mixture was cooled to room temperature. EtOAc was added and washed with brine (2x). The combined organics were dried over Na_2SO_4 and concentrated in vacuo. The concentrate was purified by flash chromatography eluting with 0-20% DCM/MeOH + 2% NH_4OH. All fractions containing clean desired product were combined and concentrated to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (90 mg, 0.134 mmol, 37.0 % yield).. ESI+APCI MS m/z 672.4 $[M+H]^+$.

[01815] Step B : 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (90 mg, 0.13 mmol) in EtOH (1340 µl, 0.13 mmol) and THF (1340 µl, 0.13 mmol) was purged with N_2 for 5 min. To this solution was added Palladium (36 mg, 0.033 mmol) (Degussa Type, 10

wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 min. The solution then stirred under an atmosphere of H_2. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was concentrated in vacuo to provide crude 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (71 mg, 0.13 mmol, 99 % yield). ESI+APCI MS m/z 538.3 $[M+H]^+$.

[01816] Step C : 2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-(4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (71 mg, 0.132 mmol) in dichloromethane (1320 µl, 0.132 mmol) at ambient temperature was added Acryloyl Chloride (10.7 µl, 0.132 mmol) followed by Hunig's base (46.1 µl, 0.264 mmol). The reaction was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo. The concentrate was suspended in a 60:40 mixture of ACN: H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-(1-acryloyl-4-(2-(((S)-1-(cyclopropylmethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 396, 15.7 mg, 0.0265 mmol, 20.1 % yield). ESI+APCI MS m/z 592.4 $[M+H]^+$.


EXAMPLE 397




2-(1-acryloyl-4-(2-(2-(dimethylamino)-2-methylpropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01817] 2-(1-acryloyl-4-(2-(2-(dimethylamino)-2-methylpropoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 396** substituting 2-Dimethylamino-2-methyl-1-propanol for (S)-(1-(cyclopropylmethyl)pyrrolidin-2-yl)methanol in Step A. ESI+APCI MS m/z 554.4 $[M+H]^+$.

EXAMPLE 398



2-((2S)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide



Step A: 2- benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: In a microwave tube benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.362 mmol) was dissolved in dioxane (181 µl, 0.362 mmol) and treated with cesium carbonate (236 mg, 0.723 mmol) and N-tert-Butoxycarbonyl-L-prolinol (364 mg, 1.81 mmol). The tube was then capped and heated to 90°C overnight. The reaction mixture was cooled to room temperature and filtered through GF/F paper and concentrated in vacuo. The concentrate was chromatographed on the CombiFlash eluting with 0%-10% DCM:MeOH. All fractions containing clean product were combined and concentrated to give benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (225 mg, 0.313 mmol, 86.7 % yield). ESI+APCI MS m/z 718.4 $[M+H]^+$.

Step B : benzyl 2-(cyanomethyl)-4-(7-(naphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Benzyl 4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (225 mg, 0.313 mmol) was dissolved in dichloromethane (3134 µl, 0.313 mmol) and treated with TFA (483 µl, 6.27 mmol). The reaction stirred at room temperature for 1 hour. The reaction was concentrated in vacuo and the organics washed with saturated bicarb. The organics were extracted with DCM(3X). The combined organics were dried over Na_2SO_4 and concentrated in vacuo to give benzyl 2-(cyanomethyl)-4-(7-(naphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (111 mg, 0.180 mmol, 57.3 % yield). ESI+APCI MS m/z 618.3 $[M+H]^+$.

Step C : benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(2-(dimethylamino)-2-oxoethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Benzyl 2-(cyanomethyl)-4-(7-(naphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (111 mg, 0.1797 mmol) was dissolved in dichloromethane (1797 µl, 0.1797 mmol) and treated with N-ethyl-N-isopropylpropan-2-amine (156.9 µl, 0.8984 mmol) and Chloroacetyldimethylamine (46.20 µl,


0.4492 mmol). The reaction was stirred at room temperature for 30 minutes. 2 more equivalences of base were added and the reaction stirred for an additional 3 hours. The reaction was concentrated in vacuo and was chromatographed on the CombiFlash eluting with 0%-15% DCM/MeOH + 0.5% NH_4OH modifier. All fractions containing clean desired product were combined and concentrated to give benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(2-(dimethylamino)-2-oxoethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (73 mg, 0.1039 mmol, 57.80 % yield). ESI+APCI MS m/z 703.3 $[M+H]^+$.

Step D : 2-((2S)-2-(((4-(3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide: A solution of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-(2-(dimethylamino)-2-oxoethyl)pyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (73 mg, 0.10 mmol) in EtOH (1039 µl, 0.10 mmol) and THF (1039 µl, 0.10 mmol) was purged with N_2 for 5 minutes. To this solution was added Palladium (28 mg, 0.026 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 minutes. The solution then stirred under an atmosphere of H_2. The mixture was then diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide 2-((2S)-2-(((4-(3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide (43 mg, 0.076 mmol, 73 % yield). ESI+APCI MS m/z 569.3 $[M+H]^+$.

[01818] Step E : 2-((2S)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide: To a suspension of 2-((2S)-2-(((4-(3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide (43 mg, 0.0756 mmol) in dichloromethane (756 µl, 0.0756 mmol) at ambient temperature was added Acryloyl Chloride (6.14 µl, 0.0756 mmol) followed by Hunig's base (26.4 µl, 0.151 mmol). The reaction was then stirred at ambient temperature for 1hour. The reaction mixture was concentrated in vacuo, resuspended in a 60:40 mixture of ACN: H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in

water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give 2-((2S)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide (14.9 mg, 0.0239 mmol, 31.6 % yield). ESI+APCI MS m/z 623.3 $[M+H]^+$.


EXAMPLE 399




2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01819] 2-(1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 396** substituting (3R)-(1-Methyl-pyrrolidin-3-yl)-methanol for (S)-(1-(cyclopropylmethyl)pyrrolidin-2-yl)methanol in Step A. ESI+APCI MS m/z 552.3 $[M+H]^+$.

EXAMPLE 400



2-((S)-1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01820] Step A: benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.0 g, 9.5 mmol) in DCM (50 mL) was added hydrogen chloride (12 ml, 47 mmol, 4 M solution in dioxanes) and the reaction stirred at room temperature for 1 hour. The reaction was next concentrated to a thick slurry and a mixture of EtOAc/water was added. The aqueous layer was basified with 1M NaOH and the aqueous layer extracted with EtOAc (2X). The combined organics were washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (4.0 g, 9.4 mmol, 99 % yield). ESI+APCI MS m/z 427.1 $[M+H]^+$.

[01821] Step B: benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate :To a solution of benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (3.4 g, 8.0 mmol) in dioxanes (40 mL) was added 1-iodonaphthalene (6.0 ml, 40 mmol) and cesium carbonate (5.2 g, 16 mmol) and the reaction degassed with Argon for 15 minutes

followed by addition of Rhuphos Pd G3 (1.00 g, 1.2 mmol) and the reaction heated to 100°C for overnight. The reaction was next filtered through GF/F paper and concentrated in vacuo. The material was next chromatographed using 10-->70 EtOAc/Hexanes as eluent to give benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.8 g, 5.1 mmol, 64 % yield). ESI+APCI MS m/z 553.2 $[M+H]^+$.


[01822] Step C: benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: In a conical bottom vial a solution of benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 0.452 mmol) in dioxane (4520 µl, 0.452 mmol) was sparged with Argon for 5 minutes. (3R)-(1-Ethyl-pyrrolidin-3-yl)-methanol (175 mg, 1.36 mmol), Cs_2CO_3 (442 mg, 1.36 mmol), Rhuphos Pd G3 (37.8 mg, 0.0452 mmol) were sequentially added under Argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 1 hour. The reaction was cooled to room temperature and ethyl acetate was added. The organics were washed with brine (2x), dried over Na_2SO_4 and concentrate in vacuo. The concentrate was purified by flash chromatography eluting with 0-20% (MeOH + 2% NH_4OH)/DCM. All fractions containing clean desired product were combined and concentrated to give benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (118 mg, 0.183 mmol, 40.4 % yield). ESI+APCI MS m/z 646.3 $[M+H]^+$.

[01823] Step D: 2-((S)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (237 mg, 0.367 mmol) in EtOH (3670 µl, 0.367 mmol) and THF (3670 µl, 0.367 mmol) was purged with N_2 for 5 min. To this solution was added Palladium (97.6 mg, 0.0917 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 min. The solution then stirred under an atmosphere of H_2. The mixture was then diluted with MeOH and filtered through


packed celite. The filtrate was then concentrated in vacuo to provide 2-((S)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (155 mg, 0.303 mmol, 82.5 % yield). ESI+APCI MS m/z 512.3 $[M+H]^+$.

[01824] Step E: 2-((S)-1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a suspension of 2-((S)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (226 mg, 0.442 mmol) in dichloromethane (4417 µl, 0.442 mmol) at ambient temperature was added Acyloyl Chloride (35.9 µl, 0.442 mmol) followed by Hunig's base (154 µl, 0.883 mmol). The reaction was stirred at ambient temperature for 2 hours. The reaction mixture was concentrated in vacuo and loaded onto a 12g RediSep Gold column and chromatagraphed on the CombiFlash (0%-15% DCM:MeOH +1% NH_4OH modifier). All fractions containing product were combined and concentrated in vacuo. The concentrate was suspended in a 60:40 mixture of ACN:H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-((S)-1-acryloyl-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 400, 136 mg, 0.240 mmol, 54.4 % yield). ESI+APCI MS m/z 566.2 $[M+H]^+$.

EXAMPLE 401




2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01825] Step A: 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (150 mg, 0.293 mmol), (2E)-4-(Dimethylamino)but-2-enoic acid (75.7 mg, 0.586 mmol), DIEA (256 µl, 1.47 mmol) in DCM (2932 µl, 0.293 mmol) was added HATU (167 mg, 0.440 mmol) and the resulting mixture was stirred at room temperature for 5 hours. The reaction mixture was partitioned between EtOAc and Brine. The aqueous was extracted with EtOAc (2x). The combined organics were dried over Na_2SO_4, and concentrated in vacuo. The concentrate was diluted in 60:40 ACN:H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(2-(((S)-1-ethylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 401, 27.6 mg, 0.0443 mmol, 15.1 % yield). ESI+APCI MS m/z 623.4 $[M+H]^+$.


EXAMPLE 402



2-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide

[01826] 2-((S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)-N,N-dimethylacetamide: The title compound was prepared following **Example 398** substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate for benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate in Step A. ESI+APCI MS m/z 623.3 $[M+H]^+$.

EXAMPLE 403




benzyl (S)-2-(cyanomethyl)-4-(2-((S)-3-(dimethylamino)pyrrolidin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate


[01827] benzyl (S)-2-(cyanomethyl)-4-(2-((S)-3-(dimethylamino)pyrrolidin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: The title compound was prepared following **Example 400** substituting (3S)-(-)-3-

(Dimethylamino)Pyrrolidine for (3R)-(1-Ethyl-pyrrolidin-3-yl)-methanol in Step C. ESI+APCI MS m/z 551.3 $[M+H]^+$.

EXAMPLE 404



2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01828] Step A: 2- tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate In a round bottom flask, a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-

(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5 g, 9.487 mmol) in dioxane (94.87 ml, 9.487 mmol) was sparged with argon and (S)-(1-methylpyrrolidin-2-yl)methanol (3.278 g, 28.46 mmol), Cs_2CO_3 (9.273 g, 28.46 mmol), Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.8078 g, 0.9487 mmol) were sequentially added under Argon and sparged for an additional 5 minutes. The reaction mixture was capped and heated at 100°C over night. The reaction was filtered through GF/F paper and concentrated in vacuo. The concentrate was purified on the Combi Flash (0-12% MeOH in DCM with 2% NH_4OH) to provide tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.425 g, 8.508 mmol, 89.68 % yield). ESI+APCI MS m/z 606.4 $[M+H]^+$.


Step B : benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.4 g, 8.915 mmol) was dissolved in dichloromethane (89.15 ml, 8.915 mmol) and treated with Hydrochloric Acid (4.0M solution in 1,4-dioxane) (11.14 ml, 44.57 mmol). The reaction stirred at room temperature for 1 hour. The reaction was next diluted with more DCM and 1M NaOH and the layers separated. The organics were next washed with brine, dried over Na_2SO_4 and concentrated in vacuo to give benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.364 g, 8.631 mmol, 96.82 % yield).. ESI+APCI MS m/z 506.3 $[M+H]^+$.

Step C : 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: In a round bottom flask, a solution of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.364 g, 8.631 mmol) in dioxane (43.15 ml, 8.631 mmol) was sparged with Argon for 5 minutes. 1-Bromo-2,3-dimethylbenzene (5.851 ml, 43.15 mmol), Cs_2CO_3 (14.06 g, 43.15 mmol), and Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.7348 g, 0.8631 mmol) were sequentially added under Argon

and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C ON. The reaction was cooled to room temperature. Ethyl acetate was added and the reaction filtered through GF/F paper and concentrated in vacuo. The concentrate was purified twice via normal phase chromatography on the CombiFlash using 0-15% MeOH in DCM with 2% NH_4OH as eluent. Fractions containing desired product were collected and concentrated in vacuo to give 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.411 g, 0.8641 mmol, 100.1 % yield). ESI+APCI MS m/z 476.3 $[M+H]^+$.

[01829] Step D : 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (95 mg, 0.200 mmol), (2E)-4-(Dimethylamino)but-2-enoic acid (51.6 mg, 0.399 mmol), DIEA (174 µl, 0.999 mmol) in DCM (1997 µl, 0.200 mmol) was added HATU (114 mg, 0.300 mmol) and the resulting mixture was stirred at room temperature for 5 hours. The reaction mixture was washed with Brine and the aqueous layer extracted with DCM (2x). The combined organic layers were dried over Na_2SO_4, concentrated, diluted in 60:40 ACN:H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5%-95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and free based with saturated bicarb and the organics extracted with DCM. The organics were dried over Na_2SO_4 and concentrated in vacuo to give 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (38 mg, 0.0648 mmol, 32.4 % yield). ESI+APCI MS m/z 587.4 $[M+H]^+$.


EXAMPLE 405



2-((2S)-1-acryloyl-4-(2-(3-(dimethylamino)piperidin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01830] 2-((2S)-1-acryloyl-4-(2-(3-(dimethylamino)piperidin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 400** substituting N,N-Dimethylpiperidin-3-amine for (3R)-(1-Ethyl-pyrrolidin-3-yl)-methanol in Step C. ESI+APCI MS m/z 565.4 $[M+H]^+$.


EXAMPLE 406



2-((S)-1-acryloyl-4-(7-(2-chloro-3-fluorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01831] 2-((S)-1-acryloyl-4-(7-(2-chloro-3-fluorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 234** substituting 1-Bromo-2-chloro-3-fluorobenzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 554.2 $[M+H]^+$.


EXAMPLE 407




2-((S)-1-acryloyl-4-(7-(2,3-difluorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01832] 2-((S)-1-acryloyl-4-(7-(2,3-difluorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 234** substituting 1-Bromo-2,3-difluorobenzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 538.2 $[M+H]^+$.

EXAMPLE 408




2-((S)-1-acryloyl-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)amino)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01833] Step A: benzyl (S)-2-(cyanomethyl)-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)amino)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 0.542 mmol) was dissolved in Dioxane and treated with (S)-(1-methylpyrrolidin-2-yl)methanamine (356 µl, 2.71

mmol). The reaction was stirred at 80°C for 3 hours. The reaction was cooled to room temperature and partitioned between water and EtOAc. The aqueous layer was extracted with EtOAc (2X). The combined organics were washed with water and brine then dried over Na_2SO_4 and filtered. The filtrate was concentrated in vacuo and chromatographed on the CombiFlash eluting with 0%-15% DCM:MeOH + 2% NH_4OH to give benzyl (S)-2-(cyanomethyl)-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)amino)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate acetonitrile (146 mg, 0.231 mmol, 42.7 % yield). ESI+APCI MS m/z 631.3 $[M+H]^+$. The rest of the synthesis for the title compound was done by following **Example 396** Steps B through C. ESI+APCI MS m/z 551.3 $[M+H]^+$.


EXAMPLE 409



(S)-2-(1-acryloyl-4-(7-(naphthalen-1-yl)-2-(2-(piperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01834] (S)-2-(1-acryloyl-4-(7-(naphthalen-1-yl)-2-(2-(piperidin-1-yl)ethoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 400** substituting 1-Piperidineethanol for (3R)-(1-Ethyl-pyrrolidin-3-yl)-methanol in Step C. ESI+APCI MS m/z 556.3 $[M+H]^+$.


EXAMPLE 410



2-((S)-1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01835] 2-((S)-1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 400** substituting (R)-3-(hydoxymethyl)-1-methylpyrrolidine for (3R)-(1-Ethyl-pyrrolidin-3-yl)-methanol in Step C. ESI+APCI MS m/z 552.3 $[M+H]^+$.


EXAMPLE 411



2-(1-acryloyl-4-(7-(3-fluoro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01836] 2-(1-acryloyl-4-(7-(3-fluoro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 375**, Steps E-G, substituiting 1-bromo-3-fluoro-2-methylbenzene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E. ESI+APCI MS m/z 534.3 $[M+H]^+$.


EXAMPLE 412



2-(1-acryloyl-4-(7-(2-fluoro-6-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01837] 2-(1-acryloyl-4-(7-(2-fluoro-6-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 375** Steps E-G, substituiting 2-bromo-1-fluoro-3-(trifluoromethyl)benzene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E. ESI+APCI MS m/z 588.3 $[M+H]^+$.


EXAMPLE 413



2-(1-acryloyl-4-(7-(4-fluoro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01838] 2-(1-acryloyl-4-(7-(4-fluoro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 375** Steps E-G, substituiting 1-bromo-4-fluoro-2-(trifluoromethyl)benzene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E. ESI+APCI MS m/z 588.3 $[M+H]^+$.


EXAMPLE 414




2-(1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01839] 2-(1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 375** Steps E-G, substituting 1-bromo-3-chloro-2-(trifluoromethyl)benzene for 4-bromo-3-(trifluoromethyl)pyridine hydrobromide in Step E and THF for MeOH in Step F. ESI+APCI MS m/z 604.2 $[M+H]^+$.

EXAMPLE 415




2-(1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((2R,4S)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01840] Step A: benzyl 4-(2-chloro-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a vial was added cesium carbonate (4.01 g, 12.3 mmol), benzyl 4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.75 g, 4.10 mmol) and Rhuphos Pd G3 (0.343 g, 0.410 mmol), and 1-bromo-3-fluoro-2-(trifluoromethyl)benzene (4.98 g, 20.5

mmol). The vial was sealed and the1,4-dioxane (41.0 ml, 4.10 mmol) added through a septum. Ar was bubbled through the mixture for 5 minutes and then the mixture was heated to 70°C for 7h. The reaction was cooled, filtered through qualitative paper and concentrated. The yellow solids were dissolved in minimal DCM and purified by silica chromatography (0-12% MeOH in DCM) which provided benzyl 4-(2-chloro-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.3 g, 2.21 mmol, 54% yield.




[01841] Step B: benzyl 4-(2-(((2R,4S)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: A solution of benzyl 4-(2-chloro-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 0.255 mmol) in dioxane (2547 µl, 0.255 mmol) was sparged with argon and (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate (211 mg, 0.637 mmol), Cs2CO3 (249 mg, 0.76 mmol), Rhuphos Pd G3 (21.3 mg, 0.026 mmol) were sequentially added under argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C for 4 hr. The mixture was filtered through GF/F paper, concentrated and the residue was dissolved in DCM and washed with water, aqueous was separated and extracted with DCM (3x15 mL). The extracts were combined and concentrated and the resulting residue was purified by silica gel (0-50 %EtOAc/hex 20CV, 50% EA/hex 2CV, 50-100% EA/hex 10CV) to provide benzyl 4-(2-(((2R,4S)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (95 mg, 0.107 mmol, 42 % yield).

[01842] Step C: tert-butyl (2R,4S)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate: was prepared following the prep for EXAMPLE 375, Step F and G, substituting benzyl 4-(2-(((2R,4S)-1-(tert-butoxycarbonyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate for benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-(trifluoromethyl)pyridin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate in Step F.

[01843] Step D: 2-(1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((2R,4S)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared according to EXAMPLE 390, Step B and C, substituting tert-butyl (2R,4S)-2-(((4-(4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate for tert-butyl (2R,3S)-2-(((4-((S)-4-acryloyl-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidine-1-carboxylate in Step B. .
ESI+APCI MS m/z 604.3 $[M+H]^+$.


EXAMPLE 416



2-(1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((2R,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01844] 2-(1-acryloyl-4-(7-(3-fluoro-2-(trifluoromethyl)phenyl)-2-(((2R,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 415**, Steps B-D substiuting tert-butyl (2R,4R)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate for (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate in Step B. ESI+APCI MS m/z 604.3 $[M+H]^+$.


EXAMPLE 417



2-(1-acryloyl-4-(2-(((2R,4S)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01845] 2-(1-acryloyl-4-(2-(((2R,4S)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 415**, Steps B-D substiuting tert-butyl (2R,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate for (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate in Step B. ESI+APCI MS m/z 606.2 $[M+H]^+$.

EXAMPLE 418




SUBSTITUTE SHEET (RULE 26)

2-(1-acryloyl-4-(2-(((R)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01846] 2-(1-acryloyl-4-(2-(((R)-1,2-dimethylpyrrolidin-2-yl)methoxy)-7-(3-fluoro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 415**, Steps B-D substiuting tert-butyl (R)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate for (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate in Step B. ESI+APCI MS m/z 602.3 $[M+H]^+$.


EXAMPLE 419



2-(1-acryloyl-4-(2-(((2S,4S)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01847] 2-(1-acryloyl-4-(2-(((2S,4S)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared following **Example 415**, Steps A-D substiuting 1-bromonaphthalene for 1-bromo-3-fluoro-2-(trifluoromethyl)benzene in Step A tert-butyl (2S,4S)-4-((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate *for* (2S,4R)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-(hydroxymethyl)pyrrolidine-1-carboxylate in Step B. ESI+APCI MS m/z 568.3 $[M+H]^+$.


EXAMPLE 420



2-((S)-1-acryloyl-4-(7-(3-chloro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01848] 2-((S)-1-acryloyl-4-(7-(3-chloro-2-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step H-J substiuting 1-bromo-3-chloro-2-methylbenzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 550.3 $[M+H]^+$.


EXAMPLE 421



2-((S)-1-acryloyl-4-(7-(2,3-dichlorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01849] 2-((S)-1-acryloyl-4-(7-(2,3-dichlorophenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step H-J substituting 1-bromo-2,3-dichlorobenzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 570.2 $[M+H]^+$.


EXAMPLE 422



2-((S)-1-acryloyl-4-(7-(3-chloro-2-methoxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01850] 2-((S)-1-acryloyl-4-(7-(3-chloro-2-methoxyphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step H-J substituting 1-bromo-3-chloro-2-methoxybenzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 566.2 $[M+H]^+$.

EXAMPLE 423




2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(dimethylamino)but-2-enoyl)piperazin-2-yl)acetonitrile

[01851] Step A: 2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: **Example 234**, Step F-I substiuting (R)-(1-methylpyrrolidin-2-yl)methanol for (S)-(1-methylpyrrolidin-2-yl)methanol in Step F, 1-bromo-3-chloro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I.

[01852] Step B: 2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(dimethylamino)but-2-enoyl)piperazin-2-yl)acetonitrile: N,N'-Diisopropylethylamine (29.5 µl, 0.166 mmol) and O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium PF6 HATU (25.2 mg, 0.066 mmol) were added to a solution of trans-4-dimethylaminocrotonic acid (6.42 mg, 0.05 mmol) and 2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile 2,2,2-trifluoroacetate (22 mg, 0.033 mmol) in dichloromethane (331 µl, 0.033 mmol). The reaction was stirred at rt for 18 hr. The mxiture was washed with brine, extracted with 30% iPrOH/CHCl3 (3x), combined extracts and concentrated. The resulting residue was purified by reverse phase chromatography (5-95% ACN/H2O with 0.1% TFA) then free based using DCM and aqueous bicarb to give title compound 2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(dimethylamino)but-2-enoyl)piperazin-2-yl)acetonitrile (EXAMPLE 423, 10 mg, 0.015 mmol, 46 % yield). ESI+APCI MS m/z 661.3$[M+H]^+$.


EXAMPLE 424



2-((S)-1-acryloyl-4-(7-(4-fluoro-2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01853] 2-((S)-1-acryloyl-4-(7-(4-fluoro-2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step H-J substiuting 1-bromo-4-fluoro-2,3-dimethylbenzene for 1-bromonaphthalene in Step H. ESI+APCI MS m/z 548.3 $[M+H]^+$.


EXAMPLE 425




2-((S)-1-acryloyl-4-(7-(2-chloro-3-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[01854] 2-((S)-1-acryloyl-4-(7-(2-chloro-3-methylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 234**, Step H-J substituting 1-bromo-2-chloro-3-methylbenzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 550.2 $[M+H]^+$.

EXAMPLE 426



2-((S)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01855] Step A: benzyl (S)-2-(cyanomethyl)-4-(2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(methylthio)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (741 mg, 1.38 mmol) in dichloromethane (9171 µl, 1.38 mmol) was treated with hydrochloric acid (1720 µl, 6.88 mmol) at 0°C and stirred for 1h after warming to rt. The mixture was quenched with saturated NaHCO3, the aqueous phase was separated and extracted with DCM (3x). The combined extracts were dried, filtered and concentrated give benzyl (S)-2-(cyanomethyl)-4-(2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (608 mg, 1.39 mmol, 100 % yield). ESI+APCI MS m/z 439.2 $[M+H]^+$.

[01856] Step B: benzyl (S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a vial was added cesium carbonate (1.65 g, 5.06 mmol), benzyl (S)-2-(cyanomethyl)-4-(2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.74 g, 1.69 mmol), and 1-bromo-3-chloro-2-(trifluoromethyl)benzene (0.876 g, 3.37 mmol) in 1,4-dioxane (11.2 ml, 1.69 mmol). The mixture was purged with Ar for 10 min and treated with methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-

1,1'-biphenyl-2-yl)palladium(II) RuPhos Pd G4 (0.215 g, 0.253 mmol). The mixture was purged with Ar for 10 min, the resulting mixture was heated to 100°C for 4 hr. The reaction was concentrated, treated with water, extracted with 30% iPrOH/CHCl3 (3x), dried, filtered and concentrated and the resulting residue was purified by silica gel (2-16% MeOH in DCM with 0.25% NH4OH) to provide benzyl (S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (388 mg, 0.63 mmol, 37 % yield). ESI+APCI MS m/z 617.2 $[M+H]^+$.

[01857] Step C: benzyl (2S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylsulfinyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution of benzyl (S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylthio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (388 mg, 0.566 mmol) in dichloromethane (5659 µl, 0.566 mmol) was added m-chloroperbenzoic acid (117.6 mg, 0.680 mmol) at 0°C. The mixture was stirred at this temp for 90 min. The mixture was quenched with saturated Na2S2O3, the aqueous layers were separated and extracted with EtOAc (3x). The extracts were combined dried, filtered and concentrated. The resulting residue was purified by silica gel (0-100% EA/hex) to give benzyl (2S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylsulfinyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (282 mg, 0.445 mmol, 79 % yield).

[01858] Step D: ((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methanol: To a suspension of methyl (2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidine-2-carboxylate (3.65 g, 13.3 mmol) in tetrahydrofuran (66.7 ml, 13.3 mmol), at 0°C under nitrogen lithium borohydride (13.3 ml, 26.7 mmol) was added slowly. The reaction was allowed to warm to RT and the mixture stirred at rt for 18 h. The reaction mixture was slowly quenched with saturated NH4Cl, diluted with water and extracted twice with EtOAc (20 mL). The combined organic phases were dried, filtered and concentrated and purified by silica gel (0-80% EA/hex) to give ((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methanol (1.8 g, 5.87 mmol, 44 % yield).


[01859] Step E: benzyl (S)-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-chloro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution

of (2S,4R)-1-boc-4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)pyrrolidine (144 mg, 0.587 mmol) and benzyl (2S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(methylsulfinyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate 2,2,2-trifluoroacetate (258 mg, 0.294 mmol) in toluene (2935 µl, 0.294 mmol) was added sodium-t-butoxide (42.3 mg, 0.440 mmol). The reaction was stirred at rt for 1 h. The mixture was washed with water, extracted wtih 30% iPrOH/CHCl3 (3x), combined extracts, dried, filtered and concentrated. The resulting residue was purified by silica gel (0-100% EA/hex 20 CV) to give benzyl (S)-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-chloro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (57 mg, 0.070 mmol, 23 % yield).

[01860] Step F: 2-((S)-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-chloro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl (S)-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-chloro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (56 mg, 0.069 mmol) in THF (688 µl, 0.069 mmol) was added palladium (29 mg, 0.028 mmol) (Degussa Type, 10 wt%, 50% H2O) and then an atmosphere of H2 was introduced via vacuum followed by balloon pressure and was stirred for 6 hr. The mixture was then diluted with MeOH and filtered through GF/F paper. The filtrate was then concentrated to provide desired product which was used as is.

[01861] Step G: 2-((S)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((2S,4R)-4-hydroxy-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared acorrding to EXAMPLE 384 Step D and E substituting 2-((S)-4-(2-(((2S,4R)-4-((tert-butyldimethylsilyl)oxy)-1-methylpyrrolidin-2-yl)methoxy)-7-(3-chloro-2-(trifluoromethyl)phenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile for Tert-butyl (2S,4R)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(5-fluoro-4-(trifluoromethyl)pyridin-3-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-4-fluoropyrrolidine-1-carboxylate in Step D. ESI+APCI MS m/z 620.2 $[M+H]^+$.


EXAMPLE 427



2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(dimethylamino)but-2-enoyl)piperazin-2-yl)acetonitrile

[01862] 2-((S)-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(dimethylamino)but-2-enoyl)piperazin-2-yl)acetonitrile: was prepared according to **Example 234**, substituting (S)-(1-methylpyrrolidin-2-yl)methanol for (R)-(1-methylpyrrolidin-2-yl)methanol in Step A. ESI+APCI MS m/z 661.3$[M+H]^+$.

EXAMPLE 428




2-((S)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile


[01863] 2-((S)-1-acryloyl-4-(7-(3-chloro-2-(trifluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared according to **Example 234**, Step H-J substituting 1-bromo-3-

chloro-2-(trifluoromethyl)benzene for 1-bromonaphthalene in Step H and THF for MeOH in Step I. ESI+APCI MS m/z 604.2 $[M+H]^+$.

EXAMPLE 429



1-(2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[01864] Step A: benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A stirred solution of tert-butyl 2-(methoxymethyl)piperazine-1-carboxylate (0.715 g, 3.10 mmol) in N,N-dimethylacetamide (3 ml, 2.96 mmol) was cooled on an ice bath and then solid benzyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.00 g, 2.96 mmol) was added in small portions followed by addition of DIPEA (0.57 mL, 3.25 mmol). The resulting solution was warmed to r.t. and stirred for 1 hour. The reaction mixture was partitioned between water (15

mL) and MTBE (50 mL) and the layers separated. The organic layer was washed with water (2*10 mL), brine (10 mL), dried over Na_2SO_4 and evaporated in vacuo and used crude in the next reaction.

[01865] Step B : benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of crude benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (500 mg, 0.940 mmol), (S)-(1-methylpyrrolidin-2-yl)methanol (216 mg, 1.88 mmol), Cs_2CO_3 (612 mg, 1.88 mmol) and dioxane (0.5 mL) was flushed with nitrogen, the vial was capped and stirred at 100°C for 2 hours and then at 120°C overnight. The reaction mixture was cooled and partitioned between EtOAc (20 mL) and water (10 mL). The organic layer was separated and washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4 to 10%MeOH/DCM +0.2%NH_4OH as eluent to give product (197 mg, 34%). ESI+APCI MS m/z 611.4 $[M+H]^+$.


[01866] Step C: tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl 4-(4-(tert-butoxycarbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (197 mg, 0.323 mmol), methanol (10 mL) and palladium on carbon (10 mg, 5%, *Degussa type E101 NO/W*) was degassed and stirred under hydrogen atmosphere for 1hour. The mixture was filtered through Celite (2 mL) and the celite washed with MeOH (3X3 mL). The combined filtrates were evaporated in vacuo, azeotroped by evaporation with toluene, and dried under high vacuum to give product (150 mg, 98%). ESI+APCI MS m/z 477.2 $[M+H]^+$.

[01867] Step D: tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (150 mg, 0.315 mmol), Cs_2CO_3 (308 mg, 0.944 mmol), dioxane (1 mL), 1-iodonaphthalene (0.0689 ml, 0.472 mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G3, 0.1 eq., 26.3 mg, 0.0315


mmol) was purged with nitrogen, the flask was capped and and the reaction stirred at 70°C overnight. The reaction mixture was cooled, partitioned between EtOAc (15 mL) and water (5 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4 to 10% MeOH +0.5% NH_4OH as eluent to give product (131 mg, 69%). ESI+APCI MS m/z 603.3 $[M+H]^+$.

[01868] Step E: 1-(2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: Tert-butyl 2-(methoxymethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (130 mg, 0.2157 mmol) was dissolved in 1M TFA/DCM and the solution stirred at r.t. for 1hour. The solution was partitioned between 2M Na_2CO_3 (5 mL) and DCM (15 mL) and the layers separated and the organic layer concentrated in vacuo. The residue was dissolved in DCM (5 mL) and cooled to -30°C with stirring and triethylamine (0.09018 ml, 0.6470 mmol) added followed by addition of acryloyl chloride (0.03504 ml, 0.4313 mmol). After 1 min at -30°C the reaction mixture was quenched with NH_4OH (0.05 mL) and evaporated in vacuo and dried under high vacuum. The residue was dissolved in DCM (5 mL), filtered through a cotton plug and chromatographed on silica gel using 5 to 10% MeOH/DCM +0.25% NH_4OH as eluent to give title compound (EXAMPLE 429, 19.55 mg, 16%). ESI+APCI MS m/z 557.3 $[M+H]^+$.

EXAMPLE 430



2-((S)-1-acryloyl-4-(7-(isoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01869] Step A: benzyl (S)-2-(cyanomethyl)-4-(7-(isoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (125 mg, 0.247 mmol), Cs_2CO_3 (242 mg, 0.742 mmol), 8-bromoisoquinoline (77.2 mg, 0.371 mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G3, 0.1 eq., 20.7 mg, 0.0247 mmol) in 2 mL of dioxane was purged with nitrogen, the flask was capped and stirred at 80°C for 2.5 hours. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH/DCM +0.4% NH_4OH as eluent to give product (100 mg, 64%). ESI+APCI MS m/z 633.3 $[M+H]^+$.


[01870] Step B: 2-((S)-1-acryloyl-4-(7-(isoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a solution of benzyl (S)-2-(cyanomethyl)-4-(7-(isoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 0.1580 mmol) in MeOH-THF (1:1; 3 mL) was added palladium on carbon (30 mg, 5%, *Degussa type E101 NO/W*) and the mixture degassed under vacuum and backfilled with hydrogen and the reaction stirred under hydrogen atmosphere for 2 hours. The reaction was filtered through Celite (2 mL) and the celite washed with EtOH (3*2 mL). The combined organics were evaporated in vacuo The residue was dissolved in DCM (10 mL) and the solution cooled with stirring to -30°C. To the solution was added NEt_3 (0.14 mL) followed by acryloyl chloride (0.02568 ml, 0.3161 mmol) and the reaction mixture stirred at -30°C for 1 minute. The reaction was quenched with addition of NH_4OH (0.05 mL) and concentrated in vacuo. The residue was dissolved in DCM (5

mL), filtered through a cotton plug and chromatographed on silica gel using 6 to 10% MeOH/DCM +0.6% NH_4OH as eluent to give title compound (EXAMPLE 430, 22.19 mg, 25%). ESI+APCI MS m/z 553.3 $[M+H]^+$.

EXAMPLE 431



2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(phthalazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01871] Step A: benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(phthalazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (101 mg, 0.200 mmol), 1-chlorophthalazine (65.8 mg, 0.400 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.0696 ml, 0.400 mmol) in 1,4-dioxane (0.5 ml, 0.200 mmol) was purged with nitrogen, the reaction capped and stirred at 80°C for 16 hours. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (5 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and concentrated in


vacuo. The residue was chromatographed on silica gel using 6% MeOH/DCM +0.6% NH_4OH as eluent to give product (53 mg, 42%). ESI+APCI MS m/z 634.3 $[M+H]^+$.

[01872] Step B: 2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(phthalazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(phthalazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (60 mg, 0.09467 mmol), methanol (2 ml) and palladium on carbon (20 mg, 5%, *Degussa type E101 NO/W*) was degassed under vacuum and backfilled with hydrogen and the reaction stirred under hydrogen atmosphere for 4 hours. The reaction was filtered through Celite (2 mL) and the celite washed with MeOH (3X3 mL). The combined organics were evaporated in vacuo. The residue was dissolved in DCM (5 mL) and cooled to -30°C with stirring. To the solution was next added triethylamine (0.06598 ml, 0.4734 mmol) followed by acryloyl chloride (0.02308 ml, 0.2840 mmol) and the reaction stirred for 5 minutes at -30°C. The reaction was quenched by addition of sat. $NaHCO_3$ (1 mL). The mixture was warmed up to r.t., water was added (2 mL) and the layers were separated. The organics were dried over Na_2SO_4 and evaporated in vacuo and the residue chromatographed on silica gel using 4 to 10% MeOH +0.4% NH_4OH as eluent to give impure product, which was purified on the Gilson reverse prep HPCL eluting with 5 to 95% acetonitrile in water +0.1% TFA. Fractions containing product were partitioned between DCM and sat. Na_2CO_3 and the layers separated. The organics were next washed with brine, dried over Na_2SO_4 and concentrated in vacuo to give title compound (EXAMPLE 431, 1.1 mg, 2%). ESI+APCI MS m/z 554.2 $[M+H]^+$.

EXAMPLE 432



2-((S)-1-acryloyl-4-(2-(((R)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01873] Step A: 2-((S)-4-(2-(((R)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 0.452 mmol), (R)-(1-methylpiperidin-2-yl)methanol (175 mg, 1.36 mmol) and Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (19.2 mg, 0.0226 mmol) in 1,4-dioxane (2 mL) was purged with nitrogen and stirred at 80°C overnight. The reaction mixture was cooled, partitioned between MTBE (20 mL) and water (5 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and concentrated in vacuo. The residue was dissolved in MeOH (5 mL) followed by addition of palladium on carbon (70 mg, 5%, *Degussa type E101 NO/W*). The reaction mixture was degassed under vacuum and backfilled with hydrogen and the reaction stirred under H_2 atmosphere for 1.5 hours. The reaction was filtered through Celite (2 mL) and the Celite was washed with MeOH (3X3 mL) and concentrated in vacuo to give product, which was used crude in the next reaction. ESI+APCI MS m/z 512.3 $[M+H]^+$.


[01874] Step B: 2-((S)-1-acryloyl-4-(2-(((R)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Crude 2-((S)-4-(2-(((R)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (292 mg, 0.57068 mmol) was dissolved in DCM (10 mL) followed by addition of triethylamine (238.63 µl, 1.7120 mmol) and the solution cooled to -30°C. To the reaction was next added acryloyl chloride (92.728 µl, 1.1414 mmol) dropwise and the mixture stirred at -30°C for 10 minutes. EtOH (0.1 mL) was next added and the reaction warmed to 0°C. The mixture was chromtographed directly on silica using

5%MeOH +0.5% NH_4OH/DCM as eluent followed by repurification of the material using the same eluent conditions to give title compound (EXAMPLE 432, 107.47 mg, 33%). ESI+APCI MS m/z 566.3 $[M+H]^+$.

EXAMPLE 433



1-((S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one



[01875] Step A: 4-benzyl 1-(tert-butyl) (S)-2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate: To a the solid (S)-tert-butyl-2-(2-hydroxyethyl)piperazine-1-carboxylate hydrochloride (500 mg, 1.874 mmol) and $NaHCO_3$ (629.8 mg, 7.497 mmol) were added EtOAc and water (10 mL each) and the mixture cooled to 0°C followed by dropwise addition of benzyl carbonochloridate (0.4013 ml, 2.811 mmol) and the reaction mixture stirred overnight while warming to room temperature. The layers were next separated and the organic layer washed with water and brine (5 mL each), dried over Na_2SO_4 and concentrated in vacuo. The material was next chromatographed on silica gel using 20% to 40% EtOAc/hexane as eluent to give product (578 mg, 85%). ESI+APCI MS m/z 256.2 $[M\text{-Boc}+H]^+$.

[01876] Step B: 4-benzyl 1-(tert-butyl) (S)-2-(2-methoxyethyl)piperazine-1,4-dicarboxylate: A stirred solution of 4-benzyl 1-(tert-butyl) (S)-2-(2-hydroxyethyl)piperazine-1,4-dicarboxylate (270 mg, 0.741 mmol) in N,N-dimethylformamide (3 ml, 0.741 mmol) under N_2 was cooled to -20°C followed by addition of sodium hydride (44.4 mg, 1.11 mmol) in one bolus. To the reaction was next added iodomethane (0.138 ml, 2.22 mmol) and the reaction mixture was warmed to r.t. over 1 hour and continued stirring for 1 hour at room temperature. The reaction was quenched by addition of ice (~5g) and the mixture partitioned between MTBE (20 mL) and water (10 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and concentrated in vacuo to give product which was used crude in the next reaction (252 mg, 90%). ESI+APCI MS m/z 279.1 $[M\text{-Boc}+H]^+$.

[01877] Step C: tert-butyl (S)-2-(2-methoxyethyl)piperazine-1-carboxylate: To a mixture of 4-benzyl 1-(tert-butyl) (S)-2-(2-methoxyethyl)piperazine-1,4-dicarboxylate (252 mg, 0.666 mmol) in methanol (5 ml) was added palladium on carbon (50 mg, 5%, *Degussa type E101 NO/W*) and the reaction degassed under vacuum and backfilled with hydrogen and the reaction stirred under hydrogen atmosphere for 3hours. The slurry was filtered through Celite (2 mL) and the Celite washed with MeOH (3X3 mL). The combined organics were concentrated in vacuo and dried under high vacuum to give product (140 mg, 86%). ESI+APCI MS m/z 245.2 $[M+H]^+$.

[01878] Step D: benzyl (S)-4-(4-(tert-butoxycarbonyl)-3-(2-methoxyethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A solution of crude tert-butyl (S)-2-(2-methoxyethyl)piperazine-1-carboxylate (140 mg, 0.573 mmol) and N,N-dimethylacetamide (0.5 ml, 0.573 mmol) was cooled to 0°C and benzyl 2,4-dichloro-5,6-

dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (194 mg, 0.573 mmol) was added in one bolus. The reaction mixture was stirred overnight followed by addition of N-ethyl-N-isopropylpropan-2-amine (0.150 ml, 0.859 mmol) and the reaction stirred at room temperature for for 1 hour. The reaction mixture was partitioned between MTBE (20 mL) and sat. $NaHCO_3$ (5 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and concentrated in vacuo. The residue was chromatographed on silica gel using 2% MeOH/DCM as eluent to give product (190 mg, 61%).

[01879] Step E: benzyl 4-((S)-4-(tert-butoxycarbonyl)-3-(2-methoxyethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of benzyl (S)-4-(4-(tert-butoxycarbonyl)-3-(2-methoxyethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (190 mg, 0.348 mmol), (S)-(1-methylpyrrolidin-2-yl)methanol (120 mg, 1.04 mmol), Cs_2CO_3 (340 mg, 1.04 mmol) and 1,4-dioxane (0.5 ml) under N_2 atmosphere was heated to 120°C for 20 hours. The reaction was cooled, diluted with EtOAc (3 mL), filtered through Celite and concentrated in vacuo. The residue was chromatographed on silica gel using 4 to 8% MeOH/DCM +0.4% NH_4OH as eluent to give product (77 mg, 35%). ESI+APCI MS m/z 625.3 $[M+H]^+$.

[01880] Step F: tert-butyl (S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a mixture of benzyl 4-((S)-4-(tert-butoxycarbonyl)-3-(2-methoxyethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (77 mg, 0.12 mmol) in methanol (5 ml) was added palladium on carbon (20 mg, 5%, *Degussa type E101 NO/W*) and the slurry degassed under vacuum and back filled with hydrogen and the reaction stirred under hydrogen atmosphere overnight. The slurry was filtered through Celite (2 mL) and the celite washed with MeOH (3X3 mL). The combined organics were concentrated in vacuo and azeotroped with toluene (2X2 mL) to give product which was used crude in the next reaction. ESI+APCI MS m/z 491.3 $[M+H]^+$.


[01881] Step G: tert-butyl (S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude tert-butyl (S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (60 mg,

0.122 mmol), Cs_2CO_3 (120 mg, 0.367 mmol), dioxane (2 mL), 1-iodonaphthalene (0.0268 ml, 0.183 mmol) (1.5 eq.) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G3, 0.1 eq., 10.2 mg, 0.0122 mmol) was purged with nitrogen and the reaction capped and stirred at 80°C overnight. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 5% MeOH/DCM +0.5% NH_4OH as eluent to give product (56 mg, 74%). ESI+APCI MS m/z 617.4 $[M+H]^+$.


[01882] Step H: 4-((S)-3-(2-methoxyethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine: To the solid tert-butyl (S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (56 mg, 0.091 mmol) was added hydrogen chloride (0.5 ml, 2.0 mmol) and the reaction stirred at 0°C followed by warming to room temperature for 15 minutes, at which point a solid formed.The organics were decanted and the solids partitioned between between DCM (12 mL) and 2M Na_2CO_3 (1 mL) and the layers separated. The organic layer was dried over K_2CO_3 and concentrated in vacuo to give crude product. ESI+APCI MS m/z 517.3 $[M+H]^+$.

[01883] Step I: 1-((S)-2-(2-methoxyethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one. Crude 4-((S)-3-(2-methoxyethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine (39 mg, 0.07548 mmol) was dissolved in DCM (10 mL) followed by addition of triethylamine (31.56 µl, 0.2264 mmol) and the solution cooled to -40°C and stirred for 5 minutes followed by dropwise addition of acryloyl chloride (12.26 µl, 0.1510 mmol). The reaction mixture was stirred at -30°C for 10 minutes followed by addition of MeOH (0.05 mL). The mixture was warmed up to 0°C and and the organics washed with 0.5M Na_2CO_3. The organic layer was evaporated in vacuo and chromatographed on silica gel using 5%MeOH +0.5% NH_4OH in DCM as eluent to give title compound (EXAMPLE 433, 25.45 mg, 59%). ESI+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 434



2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01884] Step A: 8-(trifluoromethyl)naphthalen-1-yl trifluoromethanesulfonate: To a stirred solution of 8-(trifluoromethyl)naphthalen-1-ol (500 mg, 2.36 mmol) in DCM (10 mL) at 0°C was added N-ethyl-N-isopropylpropan-2-amine (616 µl, 3.53 mmol) followed by dropwise addition of trifluoromethanesulfonic anhydride (475 µl, 2.83 mmol) and the reaction mixture stirred 1 hour while warming to room temperature. The reaction was next diluted with hexane (20 mL) and MTBE (5 mL) and the organics washed with sat. $NaHCO_3$, water and brine (5 mL each),

dried over Na_2SO_4 and concentrated in vacuo. The residue was dissolved in 10% EtOAc/10% DCM in hexane and the material filtered through a silica gel plug. The organics were concentrated and chromatographed on silica gel using 5 to 10% EtOAc/hexane as eluent to give impure material. The solid was finally crystallized from hexane, and the solid washed with small amount of cold hexane to give product (482 mg, 59%).


[01885] Step B: benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (700 mg, 1.38 mmol), Cs_2CO_3 (1353 mg, 4.15 mmol), toluene (7 ml), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq.,116 mg, 0.138 mmol) and 8-(trifluoromethyl)naphthalen-1-yl trifluoromethanesulfonate (715 mg, 2.08 mmol) was purged with nitrogen and the reaction capped and stirred at 90°C for 5 hours. The reaction mixture was cooled, partitioned between EtOAc (50 mL) and water (20 mL) and the layers separated. The organic layer was washed with water and brine (10 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH/DCM +0.4% NH_4OH as eluent to give product (86 mg, 9%). ESI+APCI MS m/z 700.3 $[M+H]^+$.

[01886] Step C: 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (86 mg, 0.123 mmol), methanol (3 ml, 74.2 mmol) and palladium on carbon (30 mg, 5%, Degussa type E101 NO/W) was degassed under vacuum and backfilled with hydrogen and the reaction stirred under H_2 atmosphere for 1 hour. The rection was next filtered through Celite (2 mL) and the Celite washed with MeOH (3X3 mL). The combined organics were concentrated in vacuo to give crude product (60 mg, 86%).


[01887] Step D: 2-((S)-1-acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-

(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (50 mg, 0.08839 mmol) was dissolved in DCM (10 mL) followed by addition of triethylamine (36.96 µl, 0.2652 mmol) and the solution cooled to -40°C and stirred for 5 minute followed by dropwise addition of acryloyl chloride (14.36 µl, 0.1768 mmol). The reaction mixture was stirred at -30°C for 10 minutes followed by addition of 0.01 mL of acryloyl chloride. MeOH (0.05 mL) was next added to reaction and the mixture warmed to 0°C. The reaction was next washed with 0.5M Na_2CO_3 and the organics separated. The organics were evaporated in vacuo and chromatographed on silica gel using 5%MeOH +0.5% NH_4OH in DCM as eluent to give title compound (EXAMPLE 434, 39 mg, 71%).

EXAMPLE 435



2-((S)-1-acryloyl-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01888] Step A: benzyl (S)-2-(cyanomethyl)-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (200 mg, 0.396 mmol), Cs_2CO_3 (387 mg, 1.19 mmol), dioxane (0.5 mL), 7-bromo-2,3-dihydrobenzofuran (118 mg, 0.593 mmol, 1.5 eq.) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq., 33.7 mg, 0.0396 mmol) was purged with nitrogen, the reaction was capped and stirred at 80°C overnight. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and then the layers were separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH/DCM +0.4% NH_4OH as eluent to give product (97 mg, 39%). ESI+APCI MS m/z 624.3 $[M+H]^+$.

[01889] Step B: 2-((S)-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-2-(cyanomethyl)-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (97 mg, 0.16 mmol), methanol (4 ml), THF (4 mL) and palladium on carbon (30 mg, 5%, *Degussa type E101 NO/W*) was degassed under vacuum and backfilled with hydrogen and the reaction stirred under hydrogen atmosphere overnight. The residue was filtered through Celite (1 mL) and the celite was washed with MeOH (3x2 mL). The combined organics were evaporated in vacuo to give crude product. ESI+APCI MS m/z 490.3 $[M+H]^+$.


[01890] Step C: 2-((S)-1-acryloyl-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-((S)-4-(7-(2,3-dihydrobenzofuran-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (69 mg, 0.1409 mmol) in DCM (5 mL) was cooled to -30°C with stirring. Triethylamine (58.93 µl, 0.4228 mmol) was added followed by addition of acryloyl chloride (22.90 µl, 0.2818 mmol) and the reaction stirred for 5 minutes at -30°C. The reaction was next quenched by addition of MeOH (0.05 mL) and the reaction warmed to room temperature. The

organics were washed with 0.5M Na_2CO_3 (4 mL), dried over K_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel in using 5% MeOH +0.5% NH_4OH as eluent to give title compound (EXAMPLE 435, 45.85 mg, 60%). ESI+APCI MS m/z 544.3 $[M+H]^+$.

EXAMPLE 436



2-((S)-1-acryloyl-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01891] Step A: 7-iodo-1-methyl-1H-indole: A stirred solurion of 7-iodo-1H-indole (4.11 ml, 2.06 mmol) in N,N-dimethylformamide (4 ml, 51.9 mmol) was cooled to -20°C and sodium hydride (123 mg, 3.09 mmol) was added in small portions followed by addition of iodomethane (0.256 ml, 4.11 mmol) and the mixture was warmed to room temperature over a 2 hour period. The mixture was partitioned between MTBE (40 mL) and ice-water mixture (20 mL) and the layers separated. The organic layer was washed with water (2X20 mL), brine (10 mL), dried over

Na_2SO_4 and evaporated in vacuo. The solid was washed with MTBE (1 mL). The solid was recrystallized from MTBE to give product (0.31 g, 59%).


[01892] Step B: benzyl (S)-2-(cyanomethyl)-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (200 mg, 0.396 mmol), Cs_2CO_3 (387 mg, 1.19 mmol), dioxane (0.5 mL), 7-iodo-1-methyl-1H-indole (153 mg, 0.593 mmol) (1.5 eq.) and methanesulfonato (2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq., 33.7 mg, 0.0396 mmol) was purged with nitrogen and the reaction capped and stirred at 90°C for 5 hours then overnight at 80°C. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers were separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH/DCM +0.4% NH_4OH as eluent to give product (65 mg, 26%). ESI+APCI MS m/z 635.3 $[M+H]^+$.

[01893] Step C: 2-((S)-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-2-(cyanomethyl)-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (65 mg, 0.10 mmol), methanol (6 ml), and palladium on carbon (30 mg, 5%, *Degussa type E101 NO/W*) was degassed with vacuum and back filled with hyrdogen and the mixture stirred under a hydrogen atmosphere overnight. The slurry was filtered through Celite (1 mL) and the Celite washed with MeOH (3X2 mL). The combined organics were evaporated in vacuo to give crude product. ESI+APCI MS m/z 501.3 $[M+H]^+$.


[01894] Step D: 2-((S)-1-acryloyl-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-((S)-4-(7-(1-methyl-1H-indol-7-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (51 mg, 0.1019 mmol) in DCM (5 mL) was cooled to -30°C with stirring followed by addition of triethylamine (42.60 µl, 0.3056 mmol) and acryloyl chloride (16.55 µl, 0.2037 mmol). After

stirring at 5 minutes at -30°C, the reaction mixture was quenched with MeOH (0.05 mL) and warmed to room temperature. The organics were washed with 0.5M Na_2CO_3 (4 mL), dried over K_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 5% MeOH +0.5% NH_4OH as eluent to give title compound (EXAMPLE 436, 36 mg, 64%). ESI+APCI MS m/z 555.3 $[M+H]^+$.

EXAMPLE 437




2-((S)-1-acryloyl-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01895] Step A: 2-((S)-1-acryloyl-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (50 mg, 0.1013 mmol) in DCM (5 mL) was cooled to -30°C followed by addition of triethylamine (42.35 µl, 0.3039 mmol) and acryloyl chloride (16.46 µl, 0.2026 mmol). After stirring 5 minutes at -30°C the reaction mixture was quenched with MeOH (0.05 mL) and warmed to room temperature. The organics were washed with 0.5M Na_2CO_3 (4 mL), dried over K_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 4%

MeOH + 0.4% NH_4OH as eluent to give title compound (EXAMPLE 437, 34 mg, 61%). ESI+APCI MS m/z 548.3 $[M+H]^+$.

EXAMPLE 438




2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01896] Step A: 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a stirred solution of 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((2S,4R)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (50 mg, 0.1013 mmol) in DCM (1 mL) was added (2E)-4-(Dimethylamino)but-2-enoic acid (26.17 mg, 0.2026 mmol), N-ethyl-N-isopropylpropan-2-amine (0.03529 ml, 0.2026 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57.77 mg, 0.1519 mmol) and the reaction mixture stirred at room temperature for 4 hours. Water (1 mL) was next added and the reaction mixture stirred for 5 minutes. The mixture was partitioned between EtOAc (10 mL) and sat. $NaHCO_3$ (5 mL) and the layers separated. The organic layer was washed with $NaHCO_3$, brine,

dried over K_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 5% MeOH +0.5% NH4OH as eluent to give title compound (EXAMPLE 438, 45 mg, 74%). ESI+APCI MS m/z 605.3 $[M+H]^+$.

EXAMPLE 439



2-(4-acryloyl-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01897] Step A: tert-butyl 4-(4-((benzyloxy)carbonyl)-2-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A stirred solution of 2-(piperazin-2-yl)acetonitrile (0.2 g, 1.278 mmol) in a mixture of DCM (20 mL) and iPrOH (10

mL) was cooled to -30°C and benzyl carbonochloridate (0.2190 ml, 1.534 mmol) was added dropwise and the reaction stirred for 1 hour while warming to room temperature. The organics were evaporated under the slow flow of N_2. The residue was dissolved in N,N-dimethylacetamide (1 ml, 1.278 mmol) followed by addition of N-ethyl-N-isopropylpropan-2-amine (0.3340 ml, 1.917 mmol) and tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (0.3888 g, 1.278 mmol). The reaction mixture was heated to 70°C for 2 hours followed by stirring at room temperature for 4 days. The reaction was partitioned between water (5 mL) and MTBE (20 mL) and the layers were separated. The organics were washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 40 to 100% EtOAc/hexane as eluent to give product (134 mg, 20%). ESI+APCI MS m/z 527.2 $[M+H]^+$.

[01898] Step B: tert-butyl 4-(4-((benzyloxy)carbonyl)-2-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of tert-butyl 4-(4-((benzyloxy)carbonyl)-2-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (134 mg, 0.254 mmol), Cs_2CO_3 (249 mg, 0.763 mmol), methanesulfonato (2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (21.6 mg, 0.0254 mmol), (S)-(1-methylpyrrolidin-2-yl)methanol (146 mg, 1.27 mmol) and 1,4-dioxane (2 ml, 0.254 mmol) was purged with N_2, the reaction capped and stirred at 80°C for 3 hours. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (5 mL) and the layers were separated. The organics were washed with brine (5 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH + 0.4% NH4OH /DCM as eluent to give product (60 mg, 39%). ESI+APCI MS m/z 606.3 $[M+H]^+$.

[01899] Step C: benzyl 3-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Neat (tert-butyl 4-(4-((benzyloxy)carbonyl)-2-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (60 mg, 0.09905 mmol)) was diluted with DCM (0.2 mL). The reaction was cooled to 0°C and 4M HCl in dioxane (0. 50 mL, 20 eq) was added with stirring. The reaction mixture was warmed to room temperature and left in a fridge overnight, at which point a solid precipitated. The liquid phase was decanted and

the solid partitioned between DCM (10 mL) and 2M Na_2CO_3 (0.5 mL) and the layers were separated. The organics were dried over K_2CO_3 and evaporated under N_2 flow. The product was used crude in the next reaction.


[01900] Step D: benzyl 3-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude benzyl 3-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (50 mg, 0.0989 mmol), Cs_2CO_3 (96.7 mg, 0.297 mmol), dioxane (0.5 mL), 1-iodonaphthalene (37.7 mg, 0.148 mmol, 1.5 eq.) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq., 8.42 mg, 0.00989 mmol) was purged with nitrogen and the reaction capped and stirred at 80°C for 2 hours. The reaction mixture was cooled and partitioned between EtOAc (20 mL) and water (5 mL) and the layers separated. The organics were washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica using 4% MeOH/DCM +0.4% NH_4OH as eluent to give impure product, which was purified by reversed prep HPLC chromatogaphy eluting with 5 to 95% MeCN/water +0.1%TFA (first eluted compound). The target fractions were diluted with 2M Na_2CO_3 and the aqueous later extracted with DCM (3X20 mL). The combined extracts were washed with brine (15 mL), dried over K_2CO_3 and evaporated in vacuo to afford product (26 mg, 42%). ESI+APCI MS m/z 632.3 $[M+H]^+$.

[01901] Step E: 2-(1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl 3-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (26 mg, 0.041 mmol), methanol (2 ml), and palladium on carbon (10 mg, 5%, *Degussa type E101 NO/W*) was degassed under vacuum and backfilled with hydorgen and the reaction stirred under a hydrogen atmosphere for 1.5 hour. The reaction was filtered through Celite (2 mL) and the Celite washed with MeOH (3X3 mL). The combined organics were evaporated in vacuo to give product which was used crude in the next reaction. ESI+APCI MS m/z 498.3 $[M+H]^+$.


[01902] Step F: 2-(4-acryloyl-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-

(1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (15 mg, 0.03014 mmol) in DCM (5 mL) was cooled to -30°C with stirring followed by addition of triethylamine (12.60 µl, 0.09043 mmol) and acryloyl chloride (4.898 µl, 0.06028 mmol). After stirring 5 minutes at -30°C, the reaction mixture was quenched by addition of MeOH (0.05 mL) and warmed up to room temperature. The organics were washed with 0.5M Na_2CO_3 (4 mL), dried over Na_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH + 0.4% NH_4OH as eluent to give title compound (EXAMPLE 439, 8.43 mg, 51%). ESI+APCI MS m/z 552.2 $[M+H]^+$.

EXAMPLE 440



2-((S)-1-acryloyl-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01903] Step A: (2R,3R)-3-fluoropyrrolidine-2-carboxylic acid: To the solid (2R, 3R)-1-Boc-3-fluoropyrrolidine-carboxylic acid (400 mg, 1.71 mmol) was added 4M hydrogen chloride (2144 µl, 8.57 mmol) dropwise and the reaction mixture stirred at room temperature for 1.5 hours. The reaction mixture was evaporated in vacuo followed by addition of solid $NaHCO_3$ (173 mg, 2.06 mmol) and methanol (1715 µl, 1.71 mmol) and the suspension stirred at room temperature overnight. To the mixture was added an additional portion of MeOH (10 mL) and the reaction mixture stirred for 30 minutes and was sonicated until full dispersion of semi-solids was acheived. This slurry was used crude in the next reaction.

[01904] Step B: (2R,3R)-3-fluoro-1-methylpyrrolidine-2-carboxylic acid: To a stirred suspension of crude (2R,3R)-3-fluoropyrrolidine-2-carboxylic acid (228 mg, 1.71 mmol) in MeOH (12 mL) was added palladium on carbon (30 mg, 5%, Degussa type E101 NO/W) followed by addition of aqueous formaldehyde (159 µl, 2.14 mmol) and the reaction mixture was degassed with hydrogen and stirred under hydrogen overnight. The reaction mixture was filtered through Celite and the Celite was washed with MeOH (3x2 mL). The combined organics were evaporated in vacuo. The semi-solid was taken up in dioxan and evaporated under N_2 over weekend. The product was used crude in the next reaction.

[01905] Step C: ((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methanol: A stirred suspension of crude 1-Boc-2-(S)-Pyrrolidinedicarboxylic acid, 3-(R)-fluoro- (252 mg, 1.71 mmol) in THF under nitrogen was cooled on to 0°C followed by dropwise addition of 2.4M lithium aluminium hydride (0.999 ml, 2.40 mmol) and the reaction stirred for 30 minutes while warming to room temperature. The reaction was sonicated followed by addition of another portion of lithium aluminium hydride in THF (0.999 ml, 2.40 mmol) and the reaction mixture was stirred at room temperature. The slurry was cooled on to 0°C and quenched with successive addition of water (0.18 mL), 15% NaOH (0.18 mL) and water (0.54 mL). The slurry was diluted with ether (20 mL) and the precipitate separated. The reaction mixture was filtered through Celite and the Celite washed with ether (3X3 mL). To the combined organics was added 4M HCl/dioxane (0.45 mL, 1.1 eq.). The mixture turned from a colorless suspension into a reddish precipitate. The supernatant solution was evaporated in vacuo. The residual red solid was extracted with a minimal amount of water, filtered through a cotton plug and the cotton plug was washed with a small amount of water. The combined water solution was saturated with KOH and

extracted with ether (3X7 mL). The combined extracts were dried over NaOH and evaporated partially under nitrogen to give product as a solution in ether (340 mg as 40% solution in ether, 60%)


[01906] Step D: benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 0.2712 mmol), Cs_2CO_3 (265.1 mg, 0.8137 mmol), 1,4-dioxane (1 ml), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (23.09 mg, 0.02712 mmol) and RuPhos (9.492 mg, 0.02034 mmol) was degassed with nitrogen and stirred at 70°C for 1.5 hours. The reaction mixture was cooled and partitioned between EtOAc (20 mL) and water (5 mL) and the layers were separtaed. The organics were washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 3% MeOH +0.3% NH_4OH in DCM as eluent to give product (108 mg, 61%). ESI+APCI MS m/z 650.3 $[M+H]^+$.

[01907] Step E: 2-((S)-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (108 mg, 0.166 mmol), methanol (5 ml), and palladium on carbon (35 mg, 5%, *Degussa type E101 NO/W*) was degassed under vacuum and backfilled with hydrogen and the reaction stirred under hydrogen atmosphere for 1.5 hours. The reaction mixture was filtered through Celite (2 mL) and the celite was washed with MeOH (3X3 mL). The combined organics were evaporated in vacuo to give the crude product which was used in the next reaction.


[01908] Step F: 2-((S)-1-acryloyl-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-((S)-4-(2-(((2R,3R)-3-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (78 mg, 0.1513 mmol) in DCM (5 mL) was cooled to -30°C followed by addition of triethylamine (63.25 µl, 0.4538 mmol) and acryloyl chloride (24.58 µl, 0.3025 mmol). After

stirring 5 minutes at -30°C, the reaction mixture was quenched with MeOH (0.05 mL) and warmed to room temperature. The mixture was washed with 0.5M Na_2CO_3 (4 mL), dried over Na_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% to 10% MeOH eluent to give title compound (EXAMPLE 440, 63 mg, 73%). ESI+APCI MS m/z 570.3 $[M+H]^+$.

EXAMPLE 441



2-((S)-1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01909] Step A: tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. A mixture of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (500 mg, 0.949 mmol), (D)-

(R)-(1-methylpyrrolidin-2-yl)methanol (328 mg, 2.85 mmol)(3 eq.), Cs_2CO_3 (927 mg, 2.85 mmol), dioxane (1 mL) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G3, 0.1 eq., 79.3 mg, 0.0949 mmol) was purged with nitrogen and the reaction was capped and stirred at 70°C for 5 hours. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers were separated. The organics were washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4 to 10% MeOH +0.5% NH_4OH as eluent to give product (150 mg, 26%). ESI+APCI MS m/z 606.3 $[M+H]^+$.


[01910] Step B: benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A solution of tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (296 mg, 0.489 mmol) in DCM (2.5 mL) was cooled on dry ice followed by addition of 4M HCl in dioxane (1.2 mL)and the reaction stirred for 3 hours while warming to room temperature, at which point a precipitate formed. The liquid layer was decanted and the precipitate was washed with DCM (2 mL). The solid was then stirred with a mixture of DCM (20 mL) and 2M Na_2CO_3 (3 mL) for 1 hour. The layers were separated and the organics was dried over Na_2CO_3, filtered and evaporated in vacuo. The material was used crude in the next reaction. ESI+APCI MS m/z 506.3 $[M+H]^+$.

[01911] Step C: benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (247 mg, 0.489 mmol), Cs_2CO_3 (477 mg, 1.47 mmol), dioxane (2 mL), 1-iodonaphthalene (107 µl, 0.733 mmol, 1.5 eq.) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G3, 0.1 eq., 40.9 mg, 0.0489 mmol) was purged with nitrogen and the reaction was capped and stirred at 80°C overnight. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers separated. The organics were washed with water and brine (5 mL each), dried over


Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 5% MeOH/DCM +0.25% NH_4OH as eluent to give product (216 mg, 70%). ESI+APCI MS m/z 632.3 $[M+H]^+$.

[01912] Step D: 2-((S)-1-acryloyl-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a stirred solution of benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (216 mg, 0.3419 mmol) in MeOH-THF (1:1, 3 mL) was added palladium on carbon (50 mg, 5%, *Degussa type E101 NO/W*) and the mixture was degassed under vacuum, backfilled with hydrogen and the reaction stirred under hydrogen atmosphere for 4 hours. The reaction mixture was filtered through Celite (2 mL) and the celite washed with EtOH (3X2 mL). The combined organics were evaporated in vacuo and the residue dissolved in DCM (10 mL). The solution was cooled with stirring to -30°C followed by addition of NEt_3 (0.28 mL, 1.71 mmol) acryloyl chloride (0.08333 ml, 1.026 mmol) and the reaction stirred at -30°C for 1 minute. The reaction was quenched with addition of NH_4OH (0.05 mL) and warmed to room temperature. The solution was evaporated in vacuo. The residue was dissolved in DCM (10 mL), filtered through a cotton plug and chromatographed on silica gel using 5 to 10% MeOH +0.25% NH_4OH in DCM as eluent to give title compound (EXAMPLE 441, 109 mg, 58%). ESI+APCI MS m/z 552.3 $[M+H]^+$.

EXAMPLE 442



2-((S)-1-acryloyl-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01913] Step A: 5-iodoindolizine: To a stirred solution of indolizine (5.69 ml, 1.71 mmol) and N1,N1,N2,N2-tetramethylethane-1,2-diamine (0.282 ml, 1.88 mmol) in anhydrous tetrahydrofuran (5.7 ml, 1.71 mmol) cooled to -80°C was added a solution of butyllithium (120 mg, 1.88 mmol) dropwise. The reaction mixture was warmed to -20°C and kept at -20°C for 2 hours. The mixture was cooled to -80°C and a solution of iodine (433 mg, 1.71 mmol) in dry THF (3 mL) was added. The reaction mixture was warmed to room temperature and treated with a saturated solution of ammonium chloride. The organic layer was separated and the aqueous layer was extracted with hexane. The combined organics were dried over anhydrous Na_2SO_4 and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using hexane as eluent to give product (216 mg).


[01914] Step B: benzyl (S)-2-(cyanomethyl)-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 0.198 mmol), Cs_2CO_3 (193 mg, 0.593 mmol), dioxane (0.5 mL), 5-iodoindolizine (72.1 mg, 0.297 mmol) (1.5 eq.) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq., 16.8 mg, 0.0198 mmol) was purged with nitrogen and the reaction was capped and stirred at 80°C for 4

hours. The reaction mixture was cooled, partitioned between EtOAc (20 mL) and water (10 mL) and the layers were separated. The organics were washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH/DCM +0.4% NH_4OH as eluent to give product (74 mg, 60%). ESI+APCI MS m/z 621.3 $[M+H]^+$.


[01915] Step C: 2-((S)-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A mixture of benzyl (S)-2-(cyanomethyl)-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (74 mg, 0.12 mmol), methanol (5 ml) and palladium on carbon (20 mg, 5%, *Degussa type E101 NO/W*) was degassed under vacuum and backfilled with hydrogen and the reaction was stirred under a hydrogen atmosphere for 2 hours. The slurry was filtered through Celite (1 mL) and the Celite was washed with MeOH (3X2 mL). The combined organics were evaporated in vacuo to give product which was used crude in the next reaction. ESI+APCI MS m/z 487.3 $[M+H]^+$.

[01916] Step D: 2-((S)-1-acryloyl-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of 2-((S)-4-(7-(indolizin-5-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (50 mg, 0.1027 mmol) in DCM (5 mL) was cooled to -30°C followed by addition of triethylamine (42.96 µl, 0.3082 mmol) and acryloyl chloride (16.70 µl, 0.2055 mmol). After stirring 5 minutes at -30°C the reaction mixture was quenched with sat. $NaHCO_3$ (1 mL) and warmed to room temperature followed by addition of water (2 mL). The layers were separated and the organics were dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH +0.4% NH_4OH as eluent to give title compound (EXAMPLE 442, 33 mg, 59%). ESI+APCI MS m/z 571.3 $[M+H]^+$.

EXAMPLE 443



2-(1-Acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01917] Step A: tert-Butyl (2R)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate: Prepared according to the procedure of **Example 375** Step C, substituting benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (65 mg, 0.118 mmol) and (R)-N-Boc-2-hydroxymethylmorpholine (76.6 mg, 0.353 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (2R)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-

yl)oxy)methyl)morpholine-4-carboxylate (49 mg, 0.0668 mmol, 56.8 % yield). ESI+ MS m/z 734.3 (100%) $[M+H]^+$.


[01918] Step B: Benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride: Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (2R)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (49 mg, 0.067 mmol) to afford benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (45 mg, 0.067 mmol, 100%). ESI+ MS m/z 634.3 (100%) $[M+H]^+$.

Step C: Benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. To a solution of benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (45 mg, 0.067 mmol), formaldehyde (54 mg, 0.67 mmol) (37 wt% in MeOH/water) in DCM (671 µl, 0.067 mmol) and THF (671 µl, 0.067 mmol) was added $NaBH(OAc)_3$ (142 mg, 0.67 mmol) and the resulting mixture was stirred at RT for 15m. The reaction mixture was partitioned between ethyl acetate and 1N NaOH. The aqueous layer was extracted with ethyl acetate (1x). The combined organic layers were dried ($MgSO_4$) and concentrated to give a residue that was purified by flash eluting with a gradient of 25-50% of a 10%MeOH/1%NH4OH/DCM mixture in DCM. The product-containing fractions were concentrated to afford benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (22 mg, 0.034 mmol, 51%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.


[01919] Step D: 2-(4-(2-(((R)-4-Methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (22 mg, 0.034 mmol) to afford 2-(4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (15.9 mg, 0.031 mmol, 91%). ESI+ MS m/z 514.3 (100%) $[M+H]^+$.

[01920] Step E: 2-(1-Acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-(4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (16 mg, 0.031 mmol) to afford title compound 2-(1-acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 443, 8.0 mg, 0.014 mmol, 46%). ESI+ MS m/z 568.3 (100%) $[M+H]^+$.

EXAMPLE 444



2-(1-Acryloyl-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01921] Step A: tert-Butyl (2S)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate: Prepared according to the procedure of **Example 375** Step C, substituting benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (65 mg, 0.118 mmol) and tert-butyl (S)-2-(hydroxymethyl)morpholine-4-carboxylate (76.6 mg, 0.353 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (2S)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (43mg, 0.059 mmol, 49.9 % yield). ESI+ MS m/z 734.3 (100%) $[M+H]^+$.

[01922] Step B: Benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride: Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (2S)-2-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (43 mg, 0.059 mmol) to afford benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (39 mg, 0.058 mmol, 100%). ESI+ MS m/z 634.3 (100%) $[M+H]^+$.


[01923] Step C: Benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (39 mg, 0.067 mmol), to afford benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (17 mg, 0.026 mmol, 45%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.

[01924] Step D: 2-(4-(2-(((S)-4-Methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-


4-yl)piperazine-1-carboxylate (17 mg, 0.026 mmol) to afford 2-(4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (13.5 mg, 0.026 mmol, 100%). ESI+ MS m/z 514.3 (100%) $[M+H]^+$.


[01925] Step E: 2-(1-Acryloyl-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-(4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (13.5 mg, 0.026 mmol) to afford title compound 2-(1-acryloyl-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 444, 9.5 mg, 0.017 mmol, 65%). ESI+ MS m/z 568.3 (100%) $[M+H]^+$.

EXAMPLE 445



2-(1-Acryloyl-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile





[01926] Step A: tert-Butyl (3S)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (65 mg, 0.118 mmol) and tert-butyl (R)-3-(hydroxymethyl)morpholine-4-carboxylate (76.6 mg, 0.353 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (3S)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (80 mg, 0.109 mmol, 92.8 % yield). ESI+ MS m/z 734.3 (100%) $[M+H]^+$.

[01927] Step B: Benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride. Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (3S)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (80 mg, 0.11 mmol) to afford benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (73 mg, 0.11 mmol, 100%). ESI+ MS m/z 634.3 (100%) $[M+H]^+$.


[01928] Step C: Benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl 2-(cyanomethyl)-4-(2-(((S)-morpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-

tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (73 mg, 0.109 mmol), to afford benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (27.6 mg, 0.042 mmol, 39%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.


[01929] Step D: 2-(4-(2-(((S)-4-Methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl 2-(cyanomethyl)-4-(2-(((S)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (27.6 mg, 0.042 mmol) to afford 2-(4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20.2 mg, 0.039 mmol, 100%). ESI+ MS m/z 514.3 (100%) $[M+H]^+$.

[01930] Step E: 2-(1-Acryloyl-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-(4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20.2 mg, 0.0393 mmol) to afford title compound 2-(1-acryloyl-4-(2-(((S)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 445, 15 mg, 0.026 mmol, 67%). ESI+ MS m/z 568.3 (100%) $[M+H]^+$.

EXAMPLE 446



2-(1-Acryloyl-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01931] Step A: tert-Butyl (3R)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl 4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (65 mg, 0.118 mmol) and tert-butyl (S)-3-(hydroxymethyl)morpholine-4-carboxylate (76.6 mg, 0.353 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (3R)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (50 mg, 0.068 mmol, 58.0 % yield). ESI+ MS m/z 734.3 (100%) $[M+H]^+$.

[01932] Step B: Benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride. Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (3R)-3-(((4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (50 mg, 0.068 mmol) to afford benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-3-yl)methoxy)-7-


(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (46 mg, 0.068 mmol, 100%). ESI+ MS m/z 634.3 (100%) $[M+H]^+$.

[01933] Step C: Benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl 2-(cyanomethyl)-4-(2-(((R)-morpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (73 mg, 0.109 mmol), to afford benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (23.0 mg, 0.036 mmol, 52%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.


[01934] Step D: 2-(4-(2-(((R)-4-Methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl 2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (23.0 mg, 0.036 mmol) to afford 2-(4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (18.2 mg, 0.036 mmol, 100%). ESI+ MS m/z 514.3 (100%) $[M+H]^+$.

[01935] Step E: 2-(1-Acryloyl-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-(4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (18.2 mg, 0.036 mmol) to afford title compound 2-(1-acryloyl-4-(2-(((R)-4-methylmorpholin-3-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 446, 14 mg, 0.025 mmol, 69%). ESI+ MS m/z 568.3 (100%) $[M+H]^+$.

EXAMPLE 447



2-((S)-1-Acryloyl-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01936] Step A: Benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (50 mg, 0.090 mmol) and tert-butyl (S)-4,4-difluoro-2-(hydroxymethyl)pyrrolidine-1-carboxylate (64.3 mg, 0.271 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-

tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (15 mg, 0.020 mmol, 22.0 % yield). ESI+ MS m/z 754.3 (100%) $[M+H]^+$.

[01937] Step B: Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride. Prepared according to the procedure of **Example 375** Step D, substituting benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (18 mg, 0.024 mmol) to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (16 mg, 0.023 mmol, 100%). ESI+ MS m/z 654.3 (100%) $[M+H]^+$.


[01938] Step C: Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoropyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (16 mg, 0.023 mmol), to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (16.0 mg, 0.024 mmol, 52%). ESI+ MS m/z 668.3 (100%) $[M+H]^+$.

[01939] Step D: 2-((S)-4-(2-(((S)-4,4-Difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (16.0 mg, 0.024 mmol) to afford 2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8.0 mg, 0.015 mmol, 63%). ESI+ MS m/z 534.3 (100%) $[M+H]^+$.


[01940] Step E: 2-((S)-1-Acryloyl-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-

yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8.0 mg, 0.015 mmol) to afford title compound 2-((S)-1-acryloyl-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 447, 4 mg, 0.007 mmol, 45%). ESI+ MS m/z 588.3 (100%) $[M+H]^+$.

EXAMPLE 448



2-((S)-1-Acryloyl-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01941] Step A: tert-Butyl (R)-6-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (25 mg, 0.045 mmol) and tert-butyl (R)-6-(hydroxymethyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate (33.0 mg, 0.136 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (R)-6-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate (35 mg, 0.0461 mmol, 100 % yield). ESI+ MS m/z 760.3 (100%) $[M+H]^+$.


[01942] Step B: Benzyl (S)-4-(2-(((R)-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride. Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (R)-6-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate (35 mg, 0.046 mmol) to afford benzyl (S)-4-(2-(((R)-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (32 mg, 0.046 mmol, 100%). ESI+ MS m/z 660.3 (100%) $[M+H]^+$.

[01943] Step C: Benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl (S)-4-(2-(((R)-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (32 mg, 0.046 mmol), to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (31 mg, 0.046 mmol, 100%). ESI+ MS m/z 674.3 (100%) $[M+H]^+$.


[01944] Step D: 2-((S)-4-(2-(((R)-4-Methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (31.0 mg, 0.046 mmol) to afford 2-((S)-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (18.0 mg, 0.033 mmol, 72%). ESI+ MS m/z 540.3 (100%) $[M+H]^+$.

[01945] Step E: 2-((S)-1-Acryloyl-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-((S)-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (18.0 mg, 0.033 mmol) to afford title compound 2-((S)-1-acryloyl-4-(2-(((R)-4-methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 448, 5.8 mg, 0.010 mmol, 29%). ESI+ MS m/z 594.3 (100%) $[M+H]^+$.

EXAMPLE 449



2-(1-Acryloyl-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[01946] Step A. Benzyl 2-(cyanomethyl)-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. A mixture of benzyl 2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (30 mg, 0.0593 mmol), 1-Bromo-2-difluoromethylbenzene (36.8 mg, 0.178 mmol), BINAP Palladacycle Gen. 3 (5.9 mg, 0.006 mmol), Cs2CO3 (77.3 mg, 0.237 mmol) in dioxane (593 µl, 0.0593 mmol) was sparged with Ar for 5m then sealed and heated at 100°C for 1d. The reaction mixture was loaded onto a silica gel samplet and purified by flash chromatography eluting with a 1-10% MeOH/DCM (1% NH4OH) gradient to afford benzyl 2-(cyanomethyl)-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (12 mg, 0.019 mmol, 32%). ESI+ MS m/z 632.3 (100%) [M+H]+.

[01947] Step B: 2-((S)-4-(2-(((R)-4-Methyl-7-oxa-4-azaspiro[2.5]octan-6-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl 2-(cyanomethyl)-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-


5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (12.0 mg, 0.019 mmol) to afford 2-(4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (9.5 mg, 0.019 mmol, 100%). ESI+ MS m/z 498.3 (100%) [M+H]+.

[01948] Step C: 2-(1-Acryloyl-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-(4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (9.5 mg, 0.019 mmol) to afford title compound 2-(1-acryloyl-4-(7-(2-(difluoromethyl)phenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 449, 4.2 mg, 0.008 mmol, 40%). ESI+ MS m/z 552.3 (100%) [M+H]+.

EXAMPLE 450



2-((S)-1-Acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01949] Step A: tert-Butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate. Prepared according to the procedure of **Example 443** Step A, substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (95 mg, 0.172 mmol) and (R)-N-Boc-2-hydroxymethylmorpholine (112 mg, 0.515 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (126 mg, 0.172 mmol, 100 % yield). ESI+ MS m/z 734.3 (100%) $[M+H]^+$.

[01950] Step B: Benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride: Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-


yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)morpholine-4-carboxylate (126 mg, 0.172 mmol) to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-morpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate hydrochloride (109 mg, 0.172 mmol, 100%). ESI+ MS m/z 634.3 (100%) $[M+H]^+$.

[01951] Step C: Benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure of **Example 443** Step C, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (109 mg, 0.172 mmol) to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (76 mg, 0.117 mmol, 68%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.


[01952] Step D: 2-((S)-4-(2-(((R)-4-Methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (76 mg, 0.117 mmol) to afford 2-((S)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (57.1 mg, 0.111 mmol, 95%). ESI+ MS m/z 514.3 (100%) $[M+H]^+$.

[01953] Step E: 2-(1-Acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-((S)-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (56 mg, 0.11 mmol) to afford title compound 2-((S)-1-acryloyl-4-(2-(((R)-4-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 450, 50 mg, 0.088 mmol, 81%). ESI+ MS m/z 568.3 (100%) $[M+H]^+$.

EXAMPLE 451



2-((S)-1-Acryloyl-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01954] Step A: tert-Butyl (2R,5R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5-methylmorpholine-4-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (95 mg, 0.172 mmol) and tert-butyl (2R,5R)-2-(hydroxymethyl)-5-methylmorpholine-4-carboxylate (119 mg,

0.515 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (2R,5R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5-methylmorpholine-4-carboxylate (128 mg, 0.171 mmol, 100 % yield). ESI+ MS m/z 748.3 (100%) $[M+H]^+$.


[01955] Step B: Benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-5-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (2R,5R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5-methylmorpholine-4-carboxylate (128 mg, 0.171 mmol) to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-5-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (111 mg, 0.171 mmol, 100%). ESI+ MS m/z 648.3 (100%) $[M+H]^+$.

[01956] Step C: Benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-5-methylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (111 mg, 0.171 mmol), to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (56 mg, 0.085 mmol, 49%). ESI+ MS m/z 662.3 (100%) $[M+H]^+$.


[01957] Step D: 2-((S)-4-(2-(((2R,5R)-4,5-Dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (56 mg, 0.085 mmol) to afford 2-((S)-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (44.3 mg, 0.084 mmol, 99%). ESI+ MS m/z 528.3 (100%) $[M+H]^+$.

[01958] Step E: 2-((S)-1-Acryloyl-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step G, substituting 2-((S)-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (43 mg, 0.081 mmol) to afford title compound 2-((S)-1-acryloyl-4-(2-(((2R,5R)-4,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 451, 32 mg, 0.055 mmol, 68%). ESI+ MS m/z 582.3 (100%) $[M+H]^+$.

EXAMPLE 452



2-((S)-1-Acryloyl-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[01959] Step A: tert-Butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5,5-dimethylmorpholine-4-carboxylate. Prepared according to the procedure of **Example 375** Step C, substituting benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (95 mg, 0.172 mmol) and tert-butyl (R)-2-(hydroxymethyl)-5,5-dimethylmorpholine-4-carboxylate (126 mg, 0.515 mmol), purifying by flash chromatography eluting with 25-100% hex/EtOAc to afford tert-butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5,5-dimethylmorpholine-4-carboxylate (131 mg, 0.172 mmol, 100 % yield). ESI+ MS m/z 762.3 (100%) $[M+H]^+$.

[01960] Step B: Benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-5,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure of **Example 375** Step D, substituting tert-butyl (R)-2-(((4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)-5,5-dimethylmorpholine-4-carboxylate (131 mg, 0.172 mmol) to afford benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-5,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (114 mg, 0.172 mmol, 100%). ESI+ MS m/z 662.3 (100%) $[M+H]^+$.


[01961] Step C: Benzyl (S)-2-(cyanomethyl)-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate. Prepared according to the procedure from **Example 443** step C, substituting benzyl (S)-2-(cyanomethyl)-4-(2-(((R)-5,5-dimethylmorpholin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (114 mg, 0.172 mmol), to afford benzyl (S)-2-(cyanomethyl)-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (77 mg, 0. 114 mmol, 66%). ESI+ MS m/z 676.3 (100%) $[M+H]^+$.

[01962] Step D: 2-((S)-4-(7-(Naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 375** Step F, substituting benzyl (S)-2-(cyanomethyl)-4-


(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (77 mg, 0.114 mmol) to afford 2-((S)-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (47 mg, 0.087 mmol, 77%). ESI+ MS m/z 542.3 (100%) $[M+H]^+$.

[01963] Step E: 2-((S)-1-Acryloyl-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. Prepared according to the procedure of **Example 1** Step G, substituting 2-((S)-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (46 mg, 0.085 mmol) to afford title compound 2-((S)-1-acryloyl-4-(7-(naphthalen-1-yl)-2-(((R)-4,5,5-trimethylmorpholin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 452, 36 mg, 0.060 mmol, 71%). ESI+ MS m/z 582.3 (100%) $[M+H]^+$.

EXAMPLE 453



1-[4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[01964] Step 1: 3-bromo-1,2,4-trimethyl-5-nitro-benzene. To a solution of 1,2,4-trimethyl-5-nitro-benzene (10 g, 60 mmol, 1 *eq*) in DCE (200 mL) was added $FeBr_3$ (358 mg, 1.21 mmol, 0.02 *eq*), Fe (879 mg, 15.7 mmol, 0.26 *eq*) following by Br_2 (11.6 g, 72.6 mmol, 3.74 mL, 1.2 *eq*) dropwise. After stirred at 25 °C for 1 hour, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The crude product was slurried in water and collected by filtration. 3-bromo-1,2,4-trimethyl-5-nitro-benzene (8.6 g, 34.9 mmol, 58% yield, 99% purity) was obtained as a white solid.

[01965] Step 2: 3-bromo-2,4,5-trimethyl-aniline. To a solution of 3-bromo-1,2,4-trimethyl-5-nitro-benzene (5.2 g, 21.3 mmol, 1 *eq*) in EtOH (100 mL) was added Fe (5.95 g, 107

mmol, 5 *eq*) and AcOH (12.8 g, 213 mmol, 12.2 mL, 10 *eq*). The mixture was stirred at 60 °C for 3 hours. Upon completion, the reaction mixture was filtered and the filtrate was concentrated. The residue was purified by reversed phase flash [water (0.1% formic acid)/acetonitrile)]. The desired fractions were collected and neutralized with saturated aqueous $NaHCO_3$, and then concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 100 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give 3-bromo-2,4,5-trimethyl-aniline (3.4 g, 14.3 mmol, 67% yield, 90% purity) as a yellow solid.

[01966] ^{1}H NMR (400 MHz, chloroform-d) δ = 6.51 (s, 1H), 3.56 (br s, 2H), 2.32 (s, 3H), 2.31 (s, 3H), 2.26 (s, 3H).

[01967] Step 3: 4-bromo-5,6-dimethyl-1*H*-indazole. 3-bromo-2,4,5-trimethyl-aniline (200 mg, 934.14 umol, 1 *eq*) was dissolved in trifluoroborane;hydrofluoride (1.69 g, 7.71 mmol, 1.20 mL, 8.25 *eq, 40% in water*) dropwise at 0 °C. A cooled aqueous solution of $NaNO_2$ (96.7 mg, 1.40 mmol, 1.5 *eq*) (in the minimum of water to saturated aqueous). After addition, the mixture was stirred at 0 °C for 1 hour and 25°C for 0.5 hour. $NaNO_2$ (64 mg, in the minimum of water to saturated aqueous) was added at 0 °C and the mixture was stirred at 0 °C for 0.5 hour. Then, the resulting precipitate was filtered, washed with $(i\text{-Pr})_2O$ (40 mL) and concentrated under vacuum which was directly added in one portion under N_2 to a stirred mixture of KOAc (183 mg, 1.87 mmol, 2 *eq*) and 18-CROWN-6 (12.4 mg, 46.7 umol, 0.05 *eq*) in $CHCl_3$ (8 mL). The mixture was stirred at 35 °C for 0.5 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 100/1 to 5/1) to give 4-bromo-5,6-dimethyl-1*H*-indazole (70 mg, 280 umol, 30% yield, 90% purity) as a yellow solid.

[01968] Step 4: 4-bromo-5,6-dimethyl-1-tetrahydropyran- 2-yl-indazole. To a solution of 4-bromo-5,6-dimethyl-1*H*-indazole (290 mg, 1.29 mmol, 1 *eq*) in DCM (6 mL) was added $TsOH{\bullet}H_2O$ (24.5 mg, 129 umol, 0.1 *eq*), followed by DHP (217 mg, 2.58 mmol, 236 uL, 2 *eq*) and MeCN (1 mL). The mixture was stirred at 25 °C for 5 hours. Upon completion, the mixture was quenched with saturated aqueous $NaHCO_3$ solution (5 mL), diluted with water (20 mL). layers were separated and the aqueous phase was extracted with EtOAc (2 × 200 mL). Combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 100/1 to 25/1) to give 4-bromo-5,6-dimethyl-

1-tetrahydropyran- 2-yl-indazole (320 mg, 828 umol, 64% yield, 80% purity) as a yellow oil. LCMS [ESI, M+1]: 309.

[01969] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.94 (s, 1H), 7.33 (s, 1H), 5.66 (dd, *J* = 2.8, 9.2 Hz, 1H), 4.06 - 3.97 (m, 1H), 3.79 - 3.67 (m, 1H), 2.47 (s, 3H), 2.44 (s, 3H), 2.16 (qd, *J* = 4.4, 7.6 Hz, 1H), 2.06 (qd, *J* = 3.2, 13.2 Hz, 1H), 1.83 - 1.64 (m, 4H).

[01970] Step A: *tert*-butyl 4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (385 mg, 890 umol, 1 *eq*), 4-bromo-5,6-dimethyl-1-tetrahydropyran-2-yl-indazole (303 mg, 979 umol, 1.10 *eq*), $Pd_2(dba)_3$ (163 mg, 178 umol, 0.2 *eq*), RuPhos (166 mg, 356 umol, 0.4 *eq*) and Cs_2CO_3 (725 mg, 2.23 mmol, 2.5 *eq*) in toluene (30 mL) was de-gassed and then heated to 90 °C for 8 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (EtOAc/MeOH 100/1 to 5/1) to give *tert*-butyl 4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)- 2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 275 umol, 31% yield, 91% purity) as a yellow solid. LCMS [ESI, M+1]: 661.

[01971] Step B: 7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. To a solution of *tert*-butyl 4-[7-(5,6-dimethyl-1-tetrahydropyran-2- yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (190 mg, 288 umol, 1 *eq*) in DCM (0.4 mL) was added TFA (924 mg, 8.10 mmol, 0.6 mL, 28.2 *eq*). The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum to give 7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (220 mg, crude, 2TFA) as a yellow oil which was used directly into the next step without further purification.


[01972] Step C: 1-[4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To a solution of 7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-4-

piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (200 mg, 284 umol, 1 *eq*, 2 TFA) and TEA (574 mg, 5.68 mmol, 790 uL, 20 *eq*) in DCM (4 mL) was added prop-2-enoyl prop-2-enoate (35.8 mg, 284 umol, 1 *eq*) dropwise at - 40 °C. The mixture was stirred at -40 °C for 30 minutes. Upon completion, the mixture was quenched with MeOH (0.5 mL), diluted with water (5 mL) and then extracted with DCM (2 × 10 mL). The extracts were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 100/1 to 10/1) and prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 35%-65%, 12 min). The desired fractions were collected and lyophilized to give title compound 1-[4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 453, 45.3 mg, 85.2 umol, two steps 30% yield, 99.7% purity) as a white solid. LCMS [ESI, M+1]:531.


[01973] SFC condition: Column: Chiralcel OJ-3 100×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

[01974] ^{1}H NMR (400 MHz, chloroform-d) δ = 10.84 (br s, 1H), 8.02 (s, 1H), 7.13 (s, 1H), 6.59 (dd, *J* = 10.4, 16.8 Hz, 1H), 6.34 (dd, *J* = 1.2, 16.8 Hz, 1H), 5.79 - 5.68 (m, 1H), 4.40 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.26 (s, 2H), 4.17 (dd, *J* = 6.8, 10.4 Hz, 1H), 3.90 - 3.39 (m, 10H), 3.09 (br t, *J* = 7.6 Hz, 1H), 2.89 - 2.62 (m, 3H), 2.47 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H), 2.30 - 2.23 (m, 1H), 2.09 - 1.97 (m, 1H), 1.91 - 1.69 (m, 3H).

Example 454



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01975] Step 1: 4,4-difluoropiperidine. To a solution of *tert*-butyl 4,4-difluoropiperidine-1-carboxylate (2.0 g, 9.04 mmol, 1.0 *eq*) in DCM (0.50 mL) was added TFA (770 mg, 6.75 mmol, 0.50 mL, 7.47 e^{-1} *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was concentrated under vacuum to give the product 4,4-difluoropiperidine (1.50 g, crude, TFA) as yellow oil which was used for the next step without further purification.

[01976] Step 2: 1-(2-benzyloxyethyl)-4,4-difluoro -piperidine. To a solution of 4,4-difluoropiperidine (1.50 g, 6.38 mmol, 1.0 *eq*, TFA) in MeCN (20.0 mL) was added NaOH (765 mg, 19.1 mmol, 3.0 *eq*). The mixture was stirred at 25 °C for 0.5 hour. Then 2-bromoethoxymethylbenzene (1.65 g, 7.65 mmol, 1.21 mL, 1.20 *eq*) and KI (212 mg, 1.28 mmol, 0.20 *eq*) was added to the above liquid, the mixture was stirred at 90 °C for 12 hours. After completion, the reaction mixture was added water (20.0 mL), and then extracted with EA (3 × 20.0 mL). The combined organic layers were dried over by Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate =

10:1 to 0:1) to give 1-(2-benzyloxyethyl)-4,4-difluoro -piperidine (600 mg, 2.35 mmol, two steps 37% yield) as yellow oil.

[01977] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.41 - 7.29 (m, 5H), 4.54 (s, 2H), 3.82 - 3.72 (m, 2H), 3.33 - 2.94 (m, 6H), 2.37 - 2.15 (m, 4H).

[01978] Step 3: 2-(4,4-difluoro-1-piperidyl)ethanol. A solution of 1-(2-benzyloxyethyl)-4,4-difluoro-piperidine (400 mg, 1.57 mmol, 1.0 *eq*) and Pd/C (200 mg, 10% purity) in EtOH (5.0 mL) was stirred under H_2 (15 Psi) atmosphere at 25 °C for 12 hours. After completion, the reaction mixture was filtered through Celite, the filter cake was washed with THF (10.0 mL). The filtrate was collected and concentrated to give the product 2-(4,4-difluoro-1-piperidyl)ethanol (170 mg, 1.03 mmol, 66% yield) as colorless oil. The product was used for the next step without further purification.

[01979] ^{1}H NMR (400 MHz, Chloroform-d) δ 3.84 - 3.70 (m, 2H), 2.98 - 2.89 (m, 4H), 2.86 - 2.80 (m, 3H), 2.24 - 2.11 (m, 4H).

[01980] Step A: *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2- (4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of 2-(4,4-difluoro-1-piperidyl)ethanol (102 mg, 619 umol, 3.0 *eq*) in toluene (3.0 mL) and *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (120 mg, 206 umol, 1.0 *eq*) was added *t*-BuONa (39.7 mg, 413 umol, 2.0 *eq*), the mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10.0 mL) and extracted with EA (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash (C18, 0.1% NH_3•H_2O, 0 - 60% MeCN) to give the product *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2- (4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (90.0 mg, 132 umol, 64% yield) as yellow oil. LCMS [ESI, M+1]: 682.


[01981] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (30.0 mg,

44.0 umol, 1.0 *eq*) in DCM (0.5 mL) was added TFA (770 mg, 6.75 mmol, 0.50 mL, 154 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the mixture was concentrated. The residue was adjusted with saturated $NaHCO_3$ aqueous to pH ~ 7, then extracted with EA (3 × 5.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated to give the product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (26.0 mg, crude) as yellow oil which was used for the next step without further purification. LCMS [ESI, M+1]: 582.


[01982] Step C: 2-[(2*S*)-4-[7- (8-chloro-1-naphthyl)-2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (26.0 mg, 44.7 umol, 1.0 *eq*) and DIEA (69.3 mg, 536 umol, 93.4 uL, 12.0 *eq*) in DCM (1.0 mL) was added prop-2-enoyl prop-2-enoate (8.45 mg, 67.0 umol, 1.50 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched by addition MeOH (1.0 mL), and then concentrated to give a residue. Then the residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 47% - 77%, 12 min) to give title compound 2-[(2*S*)-4-[7- (8-chloro-1-naphthyl)-2-[2-(4,4-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 454, 6.35 mg, 9.82 umol, two steps 22% yield, 98% purity) as white solid. LCMS [ESI, M+1]: 636.

[01983] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (br d, *J* = 8.0 Hz, 1H), 7.63 (t, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.17 (m, 1H), 6.67 - 6.54 (m, 1H), 6.40 (br d, *J* = 16.4 Hz, 1H), 5.83 (br d, *J* = 11.2 Hz, 1H), 5.20 - 4.56 (m, 1H), 4.50 - 4.35 (m, 3H), 4.22 - 4.01 (m, 2H), 3.98 - 3.75 (m, 2H), 3.66 - 3.57 (m, 1H), 3.53 - 3.36 (m, 1H), 3.31 - 2.98 (m, 4H), 2.91 - 2.80 (m, 3H), 2.79 - 2.49 (m, 6H), 2.09 - 1.94 (m, 4H).

EXAMPLE 455



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[01984] Step 1: 1-(2-benzyloxyethyl)-3,3-difluoro-piperidine. To a solution of 3,3-difluoropiperidine (1.0 g, 6.35 mmol, 1.0 *eq*, HCl) in MeCN (6.0 mL) was added NaOH (761 mg, 19.0 mmol, 3.0 *eq*) in one portion at 25 °C. The mixture was stirred at 25 °C for 5 minutes, then 2-bromoethoxymethylbenzene (1.64 g, 7.61 mmol, 1.20 mL, 1.20 *eq*) and KI (211 mg, 1.27 mmol, 0.20 *eq*) was added. The mixture was stirred at 90 °C for 12 hours. After completion, the reaction mixture was added H_2O (15.0 mL), and then extracted with EA (3 × 20.0 mL). The combined organic layers were dried over by Na_2SO_4, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=10:1 to 5:1) to give 1-(2-benzyloxyethyl)-3,3-difluoro-piperidine (1.40 g, 5.48 mmol, 86% yield) as colorless oil.

[01985] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.38 - 7.31 (m, 5H), 4.56 (s, 2H), 3.64 (t, *J* = 5.8 Hz, 2H), 2.79 - 2.73 (m, 4H), 2.55 (t, *J* = 5.4 Hz, 2H), 1.85 - 1.85 (m, 2H), 1.82 - 1.76 (m, 2H).

[01986] Step 2: 2-(3,3-difluoro-1-piperidyl)ethanol. To a solution of 1-(2-benzyloxyethyl)-3,3-difluoro-piperidine (400 mg, 1.57 mmol, 1.0 *eq*) in MeOH (5.0 mL) was added Pd/C (200 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 12 hours. After completion, the reaction mixture was filtered and concentrated to give 2-(3,3-difluoro-1-piperidyl)ethanol (240 mg, 1.45 mmol, 93% yield) as colorless oil. The product was used for the next step without further purification.

[01987] ^{1}H NMR (400 MHz, Chloroform-d) δ 3.64 (t, *J* = 5.4 Hz, 2H), 2.73 (t, *J* = 11.2 Hz, 2H), 2.63 (t, *J* = 5.4 Hz, 2H), 2.54 (t, *J* = 5.2 Hz, 2H), 1.97 - 1.87 (m, 2H), 1.82 - 1.76 (m, 2H).

[01988] Step A: *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (230 mg, 396 umol, 1.0 *eq*), 2-(3,3-difluoro-1-piperidyl)ethanol (196 mg, 1.19 mmol, 3.0 *eq*), *t*-BuONa (114 mg, 1.19 mmol, 3.0 *eq*) in toluene (5.0 mL) was degassed and purged with N_2 for 3 times,

and then the mixture was stirred at 0 °C for 0.5 hour under N_2 atmosphere. After completion, the reaction mixture was quenched by H_2O (5.0 mL) and extracted with EA (3 × 10.0 mL). The combined organic layer was washed with saturated NaCl aqueous solution (20.0 mL), dried over Na_2SO_4, filtered and concentrated to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3:1 to 0:1) to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 344 umol, 87% yield, 94% purity) as yellow oil.

[01989] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.77 (d, *J* = 8.0 Hz, 1H), 7.63 (t, *J* = 8.0 Hz, 1H), 7.54 (d, *J* = 7.2 Hz, 1H), 7.50 - 7.42 (m, 1H), 7.37 - 7.33 (m, 1H), 7.27 - 7.20 (m, 1H), 4.67 - 4.64 (m, 1H), 4.48 - 4.39 (m, 3H), 4.06 (d, *J* = 12.8 Hz, 1H), 4.01 - 3.80 (m, 3H), 3.60 (d, *J* = 4.0 Hz, 1H), 3.37 (dd, *J* = 3.6, 13.6 Hz, 1H), 3.27 - 3.10 (m, 3H), 2.97 - 2.90 (m, 3H), 2.84 - 2.78 (m, 3H), 2.61 - 2.57 (m, 2H), 1.89 - 1.85 (m, 3H), 1.72 - 1.54 (m, 3H), 1.53 (s, 9H).

[01990] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 293 umol, 1.0 *eq*) in DCM (1.50 mL) was added TFA (2.31 g, 20.3 mmol, 1.50 mL, 69.0 *eq*) in one portion at 25 °C under N_2. The mixture was stirred at 25 °C for 0.5 hour. After completion, the mixture was concentrated to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, crude, 2TFA) as yellow solid. The product was used for the next step without further purification. LCMS [ESI, M+1]: 582.


[01991] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, 494 umol, crude, 2TFA) and TEA (727 mg, 7.18 mmol, 1.0 mL) in DCM (2.0 mL) was addedprop-2-enoyl prop-2-enoate (100 mg, 793 umol) in one portion at 0 °C under N_2. The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was quenched by addition

MeOH (3.0 mL) at 0 °C, and then concentrated to give a residue. Then the residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25 mm*10 um; mobile phase: [water (10.0 mM NH_4HCO_3)-ACN]; B%: 57%-87%, 10 min.) and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[2-(3,3-difluoro-1-piperidyl)ethoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 455, 48.4 mg, 75.8umol, 26% yield, 99% purity) as white solid.


[01992] SFC condition: 100%.e.e.

[01993] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.78 (d, *J* = 8.0 Hz, 1H), 7.64 (t, *J* = 7.4 Hz, 1H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.50 - 7.43 (m, 1H), 7.36 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.21 (m, 1H), 6.60 - 6.58 (m, 1H), 6.44 - 6.39 (m, 1H), 5.85 (d, *J* = 10.4 Hz, 1H), 5.10 - 4.66 (m, 1H), 4.49 - 4.40 (m, 3H), 4.18 - 4.08 (m, 2H), 3.94 - 3.89 (m, 1H), 3.85 - 3.73 (m, 1H), 3.63 - 3.60 (m, 1H), 3.50 - 3.41 (m, 1H), 3.33 - 3.02 (m, 4H), 2.94 - 2.76 (m, 6 H), 2.64 - 2.61 (m, 3H), 1.95 - 1.85 (m, 2H), 1.80 - 1.78 (m, 2H). LCMS [ESI, M+1]: 636.

EXAMPLE 456



5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one



[01994] Insesrt Step 1: 2-bromo-3,4-dimethyl -6-nitro-aniline. To a solution of 4,5-dimethyl-2-nitro-aniline (5 g, 30.1 mmol, 1 *eq*) in $CHCl_3$ (100 mL) was added Br_2 (7.21 g, 45.1 mmol, 2.33 mL, 1.5 *eq*) dropwise at 10 °C. The reaction mixture was stirred at 10 °C for 30 mins and 25 °C for 30 mins. After completion, the reaction mixture was washed with saturated with $NaHCO_3$ aqueous (80 mL). The aqueous was extracted with $CHCl_3$ (30 mL). The combined organic phase was dried over Na_2SO_4, filtered through a pad of silica gel, and then concentrated to dryness. 2-bromo-3,4-dimethyl -6-nitro-aniline (7 g, 28.5 mmol, 95% yield, 99.7% purity) was obtained as yellow solid. LCMS [ESI, M+3]: 247

[01995] Step 2: 3-bromo-1,2-dimethyl-4,5-dinitro-benzene. To a solution of 2-bromo-3,4-dimethyl-6-nitro-aniline (7 g, 28.6 mmol, 1 *eq*) in TFA (50 mL) was added hydrogen peroxide (25.9 g, 229 mmol, 22.0 mL, 30% purity, 8.0 *eq*) dropwise at 10 °C. The reaction mixture was stirred at 10 °C for 30 mins and 25 °C for 30mins, and then at 40 °C for another 2 hrs. The reaction mixture was cooled to 5 - 10 °C and then was filtered. The filter cake was washed with PE (3 × 20 mL). The solid was then dried under reduced pressure at 50 °C. 3-bromo-1,2-dimethyl-4,5-dinitro-benzene (5 g, 18.2 mmol, 64% yield) was obtained as yellow solid.

[01996] Step A: *tert*-butyl 4-[7-(2,3-dimethyl-5,6-dinitro-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg, 578 umol, 1 *eq*), 3-bromo-1,2-dimethyl-4,5-dinitro-benzene (318 mg, 1.16 mmol, 2 *eq*), $Pd_2(dba)_3$ (52.9 mg, 57.8 umol, 0.1 *eq*), RuPhos (40.5 mg, 86.7 umol, 0.15 *eq*) and Cs_2CO_3 (377 mg, 1.16 mmol, 2 *eq*) in toluene (25 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2 atmosphere. The reaction mixture was diluted with H_2O (100 mL × 1) and ethyl acetate (100 mL × 2). The separated organic phase was washed with brine (100 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (SiO_2, Ethyl acetate/MeOH = 50/1 to 3/1) and reversed phase falsh [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 100 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-butyl 4-[7-(2,3-dimethyl-5,6-dinitro-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (22.0 mg, 140 umol, 6% yield, 99.7% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 627.

[01997] Step B: *tert*-butyl 4-[7-(2,3-diamino-5,6- dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-(2,3-dimethyl-5,6-dinitro-phenyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (120 mg, 191 umol, 1 *eq*) in MeOH (10 mL) was added Pd/C (24.0 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 for several times. The

mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The catalyst was filtered off and the filtrate was concentrated under vacuum. *tert*-butyl 4-[7-(2,3-diamino-5,6- dimethyl-phenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, crude) was obtained as a yellow solid and used into next step without further purification. LCMS [ESI, M+1]: 567.

[01998] Step C: *tert*-butyl 4-[7-(5,6-dimethyl-2-oxo-1,3-dihydrobenzimidazol-4-yl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-(2,3-diamino-5,6-dimethyl-phenyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 176 umol, 1 *eq*) in THF (10 mL) was added CDI (57.2 mg, 353 umol, 2 *eq*). After stirred at 50 °C for 1 h, CDI (171 mg) was added and the mixture was stirred at 70 °C for further 3 hours. The reaction mixture was quenched with H_2O (3 mL × 1), and then extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Luna C18 150 * 25 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 17% - 47%, 10min). The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution and extracted with ethyl acetate (1 × 30 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. *tert*-butyl 4-[7-(5,6-dimethyl-2-oxo-1,3-dihydrobenzimidazol-4-yl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (20.0 mg, 33.7 umol, two steps 19% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 593.


[01999] Step D: 5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one. To a solution of *tert*-butyl 4-[7-(5,6-dimethyl-2-oxo-1,3- dihydrobenzimidazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (16.0 mg, 27.0 umol, 1 *eq*) in dioxane (2 mL) was added HCl/dioxane (4 M, 101 uL, 15 *eq*) at 0 °C. After stirred at 25 °C for 0.5 h, the mixture was concentrated under vacuum. 5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one (20.0 mg, crude, HCl) was

obtained as a yellow oil and used into next step without further purification. LCMS [ESI, M+1]: 493.


[02000] Step E: 5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one. To a mixture of 5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2- yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one (20.0 mg, 37.8 umol, 1 *eq*, HCl) and TEA (38.3 mg, 378 umol, 52.6 uL, 10 *eq*) in DCM (2 mL) was added prop-2-enoyl prop-2-enoate (4.77 mg, 37.8 umol, 1 *eq*) in portion at -40 °C. After stirred at -40°C for 30 mins, the reaction mixture was quenched with saturated $NaHCO_3$ solution (0.5 mL) at 0 °C, and then extracted with CH_2Cl_2 (2 × 10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 * 25 * 10um; mobile phase: [water (0.225% FA) - ACN]; B%: 10% - 37%, 9min). The desired fractions were collected and concentrated under reduced pressure to remove ACN, and then lyophlizated. Title compound 5,6-dimethyl-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-(4-prop-2-enoylpiperazin-1-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-7-yl]-1,3-dihydrobenzimidazol-2-one (EXAMPLE 456, 3.15 mg, 5.25 umol, two steps 14% yield, 98.8% purity, HCOOH) was obtained as a brown solid. LCMS [ESI, M+1]: 547.

[02001] ^{1}H NMR (400 MHz, methanol-d_4) 6.90 - 6.81 (m, 1H), 6.80 - 6.72 (m, 1H), 6.28 (br d, J = 16.8 Hz, 1H), 5.82 (br d, J = 10.4 Hz, 1H), 4.72 - 4.46 (m, 2H), 4.32 - 4.01 (m, 2H), 3.93 - 3.53 (m, 10H), 3.53 - 3.38 (m, 1H), 3.21 - 3.02 (m, 2H), 2.98 (s, 3H), 2.95 - 2.58 (m, 2H), 2.48 - 2.32 (m, 1H), 2.31 (br s, 3H), 2.29 (br s, 3H), 2.19 - 1.94 (m, 3H).

EXAMPLE 457



1-[4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one



[02002] Step 1: (*E*)-2-(2-bromo-3,4-dimethyl-6-nitro-phenyl)-*N*,*N*-dimethyl- ethenamine. To a solution of 3-bromo-1,2,4-trimethyl-5-nitro-benzene (2 g, 8.19 mmol, 1 *eq*) in DMF (20 mL) was added DMFDMA (5.86 g, 49.2 mmol, 6.53 mL, 6 *eq*). The mixture was stirred at 130 °C for 10 hours. Upon completion, the mixture was concentrated under vacuum to give (*E*)-2-(2-bromo-3,4-dimethyl-6-nitro-phenyl)-*N*,*N*-dimethyl- ethenamine (2.5 g, crude) as a brown oil which was used directly into the next step without further purification.

[02003] Step 2: 4-bromo-5,6-dimethyl-1*H*-indole. To a solution of (*E*)-2-(2-bromo-3,4-dimethyl-6-nitro-phenyl)- *N*,*N*-dimethyl-ethenamine (2.5 g, 8.36 mmol, 1 *eq*) in EtOH (50 mL) was added Fe (2.33 g, 41.8 mmol, 5 *eq*) and AcOH (5.02 g, 83.6 mmol, 4.78 mL, 10 *eq*). The mixture was stirred at 60 °C for 2 hours. Upon completion, the mixture was filtered and the filtrate was concentrated. The mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (50 mL × 2). The combined organic layers were washed

with brine (50 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 1/0 to 50/1) to give 4-bromo-5,6-dimethyl-1*H*-indole (380 mg, 1.46 mmol, two steps yield 18%, 86% purity) as a yellow oil.

[02004] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.12 (br s, 1H), 7.20 - 7.10 (m, 2H), 6.59 - 6.52 (m, 1H), 2.47 (s, 3H), 2.43 (s, 3H).

[02005] Step 3: 2-[(4-bromo-5,6-dimethyl-indol-1-yl)methoxy]ethyl-trimethyl-silane. To a solution of 4-bromo-5,6-dimethyl-1*H*-indole (450 mg, 2.01 mmol, 1 *eq*) in THF (9 mL) was added NaH (161 mg, 4.02 mmol, 60% purity, 2 *eq*) at 0° C. The reaction was stirred at 0 °C for 15 minutes under N_2. The reaction was allowed to warm to 25 °C and stirred for 0.5 hour. The reaction was chilled again to 0° C. And SEM-Cl (502 mg, 3.01 mmol, 533 uL, 1.5 *eq*) in THF (100 uL) was added drop-wise at 0° C. After stirring for 5 minutes, the mixture was allowed to warm to room temperature (25 °C) and stirred for another 5 hours. Upon completion, the mixture was quenched with saturated aqueous ammonium chloride solution (20 mL), diluted with water (10 mL), and then extracted with ethyl acetate (2 × 30 mL). The extracts were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 1/0 to 50/1) to give 2-[(4-bromo-5,6-dimethyl-indol-1-yl)methoxy]ethyl-trimethyl-silane (440 mg, 1.18 mmol, 59% yield, 95% purity) as a yellow oil.

[02006] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.25 (s, 1H), 7.11 (d, *J* = 3.2 Hz, 1H), 6.51 (d, *J* = 2.8 Hz, 1H), 5.43 (s, 2H), 3.52 - 3.40 (m, 2H), 2.47 (s, 3H), 2.46 (s, 3H), 0.92 - 0.87 (m, 2H), -0.01 - -0.08 (m, 9H).

[02007] Step A: *tert*-butyl 4-[7-[5,6-dimethyl-1-(2-trimethylsilylethoxymethyl)indol-4-yl]-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 66, 450 mg, 1.04 mmol, 1 *eq*), 2-[(4-bromo-5,6-dimethyl-indol-1-yl)methoxy]ethyl-trimethyl-silane (406 mg, 1.14 mmol, 1.1 *eq*), $Pd_2(dba)_3$ (191 mg, 208 umol, 0.2 *eq*), RuPhos (194 mg, 416 umol, 0.4 *eq*) and Cs_2CO_3 (847 mg, 2.60 mmol, 2.5 *eq*) in toluene (30 mL) was de-gassed and then heated to 90 °C for 8 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (EtOAc/MeOH 50/1 to

10/1) to give *tert*-butyl 4-[7-[5,6-dimethyl-1-(2-trimethylsilylethoxymethyl)indol-4-yl]-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (106 mg, 135 umol, 13% yield, 90% purity) as a yellow solid. LCMS [ESI, M+1]: 706.

[02008] Step B: *tert*-butyl 4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[7-[5,6-dimethyl-1- (2-trimethylsilylethoxymethyl)indol-4-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (70 mg, 99.2 umol, 1 *eq*) in DMF (0.35 mL) was added TBAF (1 M in THF, 496 uL, 5 *eq*) followed by ethane-1,2-diamine (8.94 mg, 149 umol, 9.95 uL, 1.5 *eq*). The mixture was stirred at 85 °C for 3 hours. Upon completion, the mixture was diluted with EtOAc (3 mL) and water (2 mL). The separated organic layer was dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-TLC (DCM/MeOH 10/1) to give *tert*-butyl 4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (50 mg, 60.8 umol, 61% yield, 70% purity) as a yellow oil. LCMS [ESI, M+1]: 576.

[02009] Step C: 7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. To a solution of *tert*-butyl 4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (45 mg, 78.2 umol, 1 *eq*) in DCM (70 uL) was added TFA (89.1 mg, 782 umol, 57.9 uL, 10 *eq*). The mixture was stirred at 25 °C for 0.5 hour. Upon completion, the mixture was concentrated under vacuum to give 7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (60 mg, crude, 2 TFA) as a yellow oil which was used directly into the next step without further purification.


[02010] Step D: 1-[4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one. To a solution of 7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-4-piperazin-1-yl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (55 mg, 78.2 umol, 1 *eq*, 2 TFA) and TEA (158 mg, 1.56 mmol, 218 uL, 20 *eq*) in DCM (1 mL) was added prop-2-enoyl prop-2-

enoate (9.86 mg, 78.2 umol, 1 *eq*) dropwise at - 40 °C. The mixture was stirred at - 40 °C for 30 minutes. Upon completion, the mixture was quenched with MeOH (0.5 mL), diluted with water (5 mL) and then extracted with DCM (2 × 10 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 100/1 to 10/1) and prep-HPLC (column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.1% TFA)-ACN]; B%: 16%-43%, 12 min). The desired fractions were collected and neutralized with saturated aqueous $NaHCO_3$, extracted with DCM (2 × 15 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give title compound 1-[4-[7-(5,6-dimethyl-1*H*-indol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one (EXAMPLE 457, 9.81 mg, 18.3 umol, two steps 23% yield, 98.8% purity) as a brown solid. LCMS [ESI, M+1]: 530.


[02011] SFC condition: OJ-3S_3_5_40_3ML Column: Chiralcel OJ-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm.

[02012] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.22 (br s, 1H), 7.09 (s, 1H), 7.07 - 7.03 (m, 1H), 6.60 (dd, *J* = 10.8, 16.8 Hz, 1H), 6.53 - 6.48 (m, 1H), 6.34 (dd, *J* = 2.0, 16.9 Hz, 1H), 5.76 (dd, *J* = 2.0, 10.4 Hz, 1H), 4.49 - 4.10 (m, 4H), 3.81 (br s, 2H), 3.76 - 3.38 (m, 8H), 3.13 (br t, *J* = 7.2 Hz, 1H), 3.02 - 2.56 (m, 3H), 2.50 (s, 3H), 2.39 (s, 3H), 2.36 (s, 3H), 2.34 - 2.25 (m, 1H), 2.13 - 2.06 (m, 1H), 1.84 - 1.71 (m, 3H).

EXAMPLE 458



2-((S)-1-(but-2-ynoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02013] Step A: 1-bromo-8-methylnaphthalene: To a solution of 1,8-dibromonaphthalene (33.8 g, 118 mmol) in THF (200 mL) cooled to -78°C was added butyllithium (49.6 ml, 124 mmol) at such a rate that the internal temperature did not exceed -69°C. After complete addition, the reaction was cooled to -78°C, and methyl iodide (14.8 ml, 236 mmol) was added in a bolus such that the internal temp increased to -40°C. After methyl iodide addition, the dry ice/acetone bath was removed and the reaction warmed to room temperature. The reaction was next poured into brine and the aqueous layer extratced with EtOAc (300 mL) and the organics separated. The organics were next dried over MgSO4 and concentrated in vacuo and the residue chromatographed using hexanes as eluent to give a white solid (24 g). The solid was next slurried in IPA (ca. 60 mL) and the slurry heated to 60°C at which point the solids dissolved. The solution was reomoved from heating and cooled to room temperature over 2 hrs. The resulting slurry was filtered and the solids dried in vacuo to give 1-bromo-8-methylnaphthalene (16 g, 72.4 mmol, 61 % yield) >95% purity.

[02014] Step B: benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A solution of xantphos (4.5 g, 7.8 mmol) and Pd2(dba)3 (3.5 g, 3.9 mmol) in dioxane (100 mL) was degassed with Argon for 15 minutes, followed by heating the solution for 20 minutes at 100°C. The solution was cooled to room temperature and benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-


d]pyrimidin-4-yl)piperazine-1-carboxylate (9.8 g, 19 mmol), 1-bromo-8-methylnaphthalene (13 g, 58 mmol) and Cs2CO3 (32 g, 97 mmol), Pd2(dba)3 (3.5 g, 3.9 mmol) were added to the solution and the mixture was degassed for an additional 20 minutes with Argon and the reaction heated to 100°C overnight. The reaction was next cooled to room temperature and filtered through GFF paper and the filtrate was concentrated in vacuo. The residue was next chromatographed 3 times using 1-->10%(MeOH+2% NH4OH)/DCM to give benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (7.8 g, 12 mmol, 62 % yield). ESI+APCI MS m/z 646.3 $[M+H]^+$.

[02015] Step C: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (7.8 g, 12 mmol) in 1:1 EtOH/THF (100 mL) was degassed with N2 for 5 minutes followed by addition of Pd/C (2.6 g, 2.4 mmol). The slurry was next degassed under vacuum and backfilled with H2 (3X). On the third back fill the mixture was stirred under a balloon of hydrogen for overnight. The slurry was again degassed with N2 and the slurry filtered through celite. The combined filtrate was concentrated in vacuo and the solids chromatographed using 1-->10%(MeOH+2% NH4OH)/DCM as eluent to give 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (5.0 g, 9.8 mmol, 81 % yield).


[02016] Step D: 2-((S)-1-(but-2-ynoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (1954 µl, 0.391 mmol) was added 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (200 mg, 0.391 mmol) and triethylamine (136 µl, 0.977 mmol). The reaction mixture was vigorously stirred while but-2-ynoic acid (49.3 mg, 0.586 mmol) was added in one portion. 1-Propanephosphonic acid cyclic anhydride (175 µl, 0.293 mmol) was added slowly to the stirring mixture. The reaction was allowed to stir at rt for 18hr. Water was added and the solids were

filtered. The solids were purified by silica gel (5-18% MeOH in DCM with 0.25% NH4OH) to provide title compound 2-((S)-1-(but-2-ynoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 458, 110 mg, 0.190 mmol, 49 % yield). ESI+APCI MS m/z 578.3 $[M+H]^+$.

EXAMPLE 459




2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02017] Step A: 2-((S)-1-((E)-4-(dimethylamino)but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. A stirred mixture of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (100 mg, 0.1954 mmol), (E)-4-(dimethylamino)but-2-enoic acid

(37.86 mg, 0.2932 mmol) and N,N-dimethylformamide (2 mL, 25.58 mmol) was cooled on ice-salt bath and triethylamine (0.02724 mL, 0.1954 mmol) was added at once, followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide, 50% in EtOAc (0.1745 mL, 0.2932 mmol). The reaction mixture was allowed to warm to r.t. over 5 min, then stirred at r.t. for 3 h. The reaction mixture was partitioned between EtOAc (50 mL) and 0.5 M Na_2CO_3 (20 mL), the organics were separated, the organic layer was washed with water and brine (10 mL each), dried over Na_2SO_4 and evaporated in vacuo. Chromatography on silica gel in 5 to 10% MeOH + 0.5% NH_4OH in DCM afforded crude product that was purified on the reverse phase, Gilson, 5 to 95% MeCN +0.1% TFA in water. The target fractions were combined, basified with 2M Na_2CO_3 and extracted with DCM (3*20 mL). The combined extracts were washed with brine (10 mL), dried over Na_2SO_4 and evaporated in vacuo. The solid residue was dissolved in DCM (3 mL), filtered and evaporated to yield the desired title compound as colorless solid (EXAMPLE 459, 40 mg, 33%). ESI+APCI MS m/z 623.3 $[M+H]^+$.

EXAMPLE 460



2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile



[02018] Step A: benzyl (2*S*)-2-(cyanomethyl)- 4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)- 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 500 mg, 989 umol, 1.0 *eq*), $Pd_2(dba)_3$ (181 mg, 198 umol, 0.20 *eq*), Xantphos (172 mg, 297 umol, 0.30 *eq*) and Cs_2CO_3 (967 mg, 2.97 mmol, 3.0 *eq*) in toluene (5.0 mL) was added 1-bromo-8-methyl-naphthalene (Intermediate 69, 284 mg, 1.29 mmol, 1.30 *eq*). The mixture was stirred at 90 °C for 12 hours. After completion, the reaction mixture was added water (10.0 mL) and extracted with ethyl acetate (10.0 mL × 4). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (C18, 0.1 % in formic acid, 0-70 % acetonitrile) to give the product benzyl (2*S*)-2-(cyanomethyl)- 4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 619 umol, 63% yield) as yellow oil. LCMS [ESI, M+1]: 646.

[02019] Step B: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7- (8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (700 mg, 1.08 mmol, 1.0 *eq*) and NH_3•MeOH (20.0 mL, 30% purity) in methanol (20.0 mL) was added Pd/C (200 mg, 10% purity). The mixture was purged by nitrogen for 3 times. Then the mixture was stirred under hydrogen atmosphere (15 Psi) at 25 °C for 1 hour. After completion, the reaction mixture was filtered through celite, the filter cake was washed with tetrahydrofuran (20.0 mL). The mother liquor was collected and concentrated under vacuum to give the product 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (500 mg, 977 umol, 90% yield) as yellow oil.


[02020] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 (d, *J* = 8.0 Hz, 1H), 7.64 (dd, *J* = 3.2, 7.2 Hz, 1H), 7.43 - 7.37 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.19 (m, 2H), 4.43 - 4.33 (m, 1H), 4.22 (dd, *J* = 6.8, 18.0 Hz, 1H), 4.17 - 4.08 (m, 1H), 4.07 - 3.89 (m, 1H), 3.89 - 3.70 (m, 2H), 3.52 - 3.45 (m, 2H), 3.38 - 3.20 (m, 1H), 3.19 - 3.04 (m, 4H), 3.03 - 2.94 (m, 2H), 2.93 - 2.82 (m, 4H), 2.70 - 2.60 (m, 1H), 2.60 - 2.49 (m, 3H), 2.47 (d, *J* = 2.4 Hz, 3H), 2.31 - 2.22 (m, 1H), 2.11 - 2.00 (m, 1H), 1.88 - 1.76 (m, 3H).

[02021] Step C: 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (250 mg, 489 umol, 1.0 *eq*) and pyridine (309 mg, 3.91 mmol, 316 uL, 8.0 *eq*) in dichloromethane (4.0 mL) was added (*E*)-4-bromobut-2-enoyl chloride (359 mg, 1.95 mmol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give the product 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (330 mg, crude) as yellow oil. The product was used for the next step without further purification. LCMS [ESI, M+1]: 658.


[02022] Step D: 2-[(2*S*)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude) and K_2CO_3 (630 mg, 4.55 mmol, 10.0 *eq*) in dichloromethane (2.0 mL) was added morpholine (238 mg, 2.73 mmol, 241 uL, 6.0 *eq*). The mixture was stirred at 0 °C for 12 hours. After completion, the reaction mixture was added water (10.0 mL) and extracted with ethyl acetate (10.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 50%-80%, 12min) to give the title compound 2-[(2*S*)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-morpholinobut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 460, 48.2 mg, 72.5 umol, 16% yield) as white solid. LCMS [ESI, M+1]: 665.

[02023] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 (br d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.4 Hz, 1H), 7.41 (dd, *J* = 7.6, 15.2 Hz 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 7.02 - 6.91 (m, 1H), 6.55 - 6.39 (m, 1H), 5.23 - 4.47 (m, 1H), 4.40 - 4.33 (m, 1H), 4.31 - 4.19 (m, 1H), 4.19 - 4.09 (m, 2H), 4.07 - 3.83 (m, 2H), 3.81 - 3.64 (m, 5H), 3.59 - 3.40 (m, 2H), 3.24 - 3.13 (m, 4H), 3.12 - 2.94 (m, 3H), 2.92 (s, 3H), 2.86 - 2.76 (m, 1H), 2.75 - 2.54 (m, 3H), 2.50 (br s, 4H), 2.48 - 2.45 (m, 3H), 2.33 - 2.22 (m, 1H), 2.10 - 2.00 (m, 1H), 1.87 - 1.71 (m, 3H).

EXAMPLE 461



2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[02024] Step A: *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of *tert*-butyl 2,4-dichloro-6,8-dihydro-5*H*-pyrido[3,4-*d*] pyrimidine-7-carboxylate (3 g, 9.86 mmol, 1 *eq*) in DMAc (60 mL) was added DIEA (3.82 g, 29.6 mmol, 5.15 mL, 3 *eq*) and 2-piperazin-2-ylacetonitrile (Intermediate 62, 2.15 g, 10.9 mmol, 1.1 *eq*, 2HCl) at 0 °C. The mixture was stirred at 25 °C for 1.5 hrs. Then to the solution was added DIEA (2.55 g, 19.7 mmol, 3.43 mL, 2 *eq*) and benzyl chloroformate (2.52 g, 14.8 mmol, 2.10 mL, 1.5 *eq*) at 0 °C. The mixture was stirred at 25 °C for another 2.5 hrs. To the reaction mixture was added H_2O (40 mL) and ethyl acetate (100 mL). The separated organic phase was washed with 5 % of aqueous citric acid

solution (40 mL × 1), aqueous saturated Na_2CO_3 solution (40 mL × 1) and brine (40 mL × 1), dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give a residue. The residue was triturated with methyl *tert*-butyl ether (25 mL) to give a pure product. *tert*-butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (4.10 g, 7.62 mmol, 79% yield, 98% purity) was obtained as a white solid. LCMS [ESI, M+1]: 527.

[02025] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.43 - 7.29 (m, 5H), 5.17 (s, 2H), 4.71 - 4.55 (m, 2H), 4.48 - 4.37 (m, 1H), 4.21 - 3.97 (m, 2H), 3.92 - 3.67 (m, 2H), 3.40 – 3.20 (m, 3H), 3.09 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.88 - 2.57 (m, 4H), 1.47 (s, 9H).

[02026] SFC condition (40935): Column: Chiralcel OD - 3 50 × 4.6 mm I.D., 3 um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3 mL/min, Wavelength: 220 nm.

[02027] Step B: *tert*-butyl 4-[(3*R*)-4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. *tert*-Butyl 4-[4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]- 2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (2.20 g, 4.17 mmol, 1 *eq*) was separated by SFC (column: OD (250mm * 30mm, 10um); mobile phase: [0.1% NH_3H_2O MeOH]; B%: 40% - 40%, 3.1 min: 180 min). The desired fractions were collected and concentrated under vacuum to give *tert*-butyl 4-[(3*R*)-4-benzyloxycarbonyl-3-(cyanomethyl) piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (940 mg, 1.78 mmol, 43% yield, 99.7% purity) as a white solid. LCMS [ESI, M+1]: 527.

[02028] SFC condition: Column: Chiralcel OD - 3 50 × 4.6 mm I.D., 3 um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3 mL/min, Wavelength: 220 nm.

[02029] Step C: *tert*-Butyl 4-[(3*R*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a mixture of *tert*-butyl 4-[(3*R*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (290 mg, 550 umol, 1 *eq*), [(2*S*)-1-methylpyrrolidin-2-yl]methanol (127 mg, 1.10 mmol, 131 uL, 2 *eq*), $Pd_2(dba)_3$ (60.5 mg, 66.0 umol, 0.12 *eq*), RuPhos (51.4 mg, 110 umol, 0.2 *eq*) and Cs_2CO_3 (448 mg, 1.38 mmol, 2.5

eq) in toluene (20 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 7 hours under N_2 atmosphere. To the reaction mixture was added H_2O (25 mL × 1) and ethyl acetate (25 mL × 2). The separated organic phase was washed with brine (100 mL × 1), dried over sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure. The residue was diluted with ethyl acetate (50 mL) and acidified with aqueous HCl solution (1 mol/L) to pH = 3 ~ 4. To the separated water layer was added ethyl acetate (60 mL) and basified with saturated aqueous Na_2CO_3 solution to pH = 8 ~ 9. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. *tert*-Butyl 4-[(3*R*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (225 mg, 0.36 mmol, 66% yield, 97.7% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 606.

[02030] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.47 - 7.30 (m, 5H), 5.19 (s, 2H), 4.73 - 4.52 (m, 2H), 4.44 - 4.26 (m, 2H), 4.22 - 4.14 (m, 1H), 4.03 - 3.74 (m, 3H), 3.41 - 3.21 (m, 3H), 3.08 (br t, *J* = 7.6 Hz, 1H), 2.97 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.89 - 2.53 (m, 5H), 2.46 (s, 3H), 2.38 - 2.10 (m, 2H), 2.08 - 2.03 (m, 1H), 1.89 - 1.65 (m, 3H), 1.48 (s, 9H).

[02031] SFC condition: Column: Chiralpak AD - 3 50 × 4.6 mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO2 from 5% to 40%, Flow rate: 3 mL/min, Wavelength: 220 nm.

[02032] Step D: benzyl (2*R*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[(3*R*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (620 mg, 1.02 mmol, 1 *eq*) in dioxane (12 mL) was added HCl/dioxane (4 M, 12.4 mL, 48.5 *eq*) at 0 °C. The mixture was stirred at 25 °C for 0.5 h. The liquid was decanted and the residue was concentrated under vacuum. Benzyl (2*R*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (470 mg, crude, HCl) was obtained as a yellow oil which was dissolved into DCM (10 mL). The mixture basified with saturated aqueous sodium carbonate solution to pH = 9. The organic phase was separated, washed with brine (5 mL × 1), filtered and concentrated under reduced pressure to give a residue which was pure enough without further purification. Benzyl (2*R*)-2-

(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 718 umol, 77% yield, 90.8% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 506.

[02033] Step E: benzyl (2*R*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*R*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 415 umol, 1 *eq*), 1-bromo-8-methyl-naphthalene (Intermediate 69, 119 mg, 540 umol, 1.3 *eq*) $Pd_2(dba)_3$ (76.1 mg, 83.1 umol, 0.2 *eq*), Cs_2CO_3 (406 mg, 1.25 mmol, 3 *eq*) and Xantphos (72.1 mg, 125 umol, 0.3 *eq*) in toluene (7 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2 atmosphere. To the reaction mixture was added H_2O (20 mL × 1) and the mixture was extracted with ethyl acetate (20 mL × 2). The extracts were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was diluted with ethyl acetate (50 mL) and acidified to pH = 3 ~ 4 with aqueous HCl solution (1 mol/L). To the water layer was added ethyl acetate (60 mL) and basified to pH = 8 ~ 9 with saturated aqueous Na_2CO_3 solution. The organic phase was separated, dried over sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol 50/1 to 5/1). Benzyl (2*R*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (86 mg, 0.128 mmol, 31% yield, 96.0 purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 646.

[02034] Step E: 2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*R*)-2-(cyanomethyl)-4-[7-(8-methyl- 1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 201 umol, 1 *eq*) in MeOH (15 mL) was added Pd/C (25 mg, 15.5 umol, 10% purity) and NH_3•MeOH (15.5 umol, 15 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 for several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The catalyst was filtered off through a pad of celite. The filtrate was concentrated under vacuum. 2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-


yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 0.183 mmol, 91% yield, 93.5% purity) was obtained as a yellow solid and used into next step without further purification. LCMS [ESI, M+1]: 512.

[02035] Step F: 2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 195 umol, 1 *eq*) and TEA (198 mg, 1.95 mmol, 272 uL, 10 *eq*) in DCM (10 mL) was added prop-2-enoyl chloride (17.7 mg, 195 umol, 15.9 uL, 1 *eq*) in portion. After stirring at - 40 °C for 30 min, the mixture was quenched with MeOH (2 mL) and concentrated under vacuum. The residue was purified by column chromatography (Al_2O_3, Dichloromethane/Methanol = 10/1 to 10/1). The residue was purified by prep-HPLC (column: Luna C18 150 * 25 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 25% - 45%, 7.8 min) and (column: Gemini 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 57% - 87%, 12 min). The desired fractions were concentrated under reduced pressure to remove acetonitrile, and then lyophlizated. Title compound 2-[(2*R*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 461, 17.6 mg, 31.0 umol, 16% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 566.


[02036] SFC condition: Column: Chiralcel OJ-3 50 × 4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3 mL/min, Wavelength: 220 nm.

[02037] ^{1}H NMR (400M Hz, chloroform-d) δ = 7.77 - 7.63 (m, 2H), 7.48 - 7.32 (m, 2H), 7.31 - 7.18 (m, 2H), 6.61 (br s, 1H), 6.48 - 6.37 (m, 1H), 5.85 (br d, *J* = 10.0 Hz, 1H), 5.27 - 4.49 (m, 1H), 4.45 - 4.33 (m, 1H), 4.33 - 4.06 (m, 4H), 4.05 - 3.62 (m, 3H), 3.61 - 3.34 (m, 2H), 3.33 - 2.99 (m, 5H), 2.94 (s, 3H), 2.88 - 2.77 (m, 1H), 2.75 - 2.57 (m, 2H), 2.54 - 2.44 (m, 3H), 2.30 (br d, *J* = 7.2 Hz, 1H), 2.15 – 1.95 (m, 1H), 1.95 - 1.79 (m, 3H).

EXAMPLE 462



2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile



[02038] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 1.27 mmol, 1 *eq*), 4-bromo-5,6-dimethyl-1-tetrahydropyran-2- yl-indazole (511 mg, 1.65 mmol, 1.3 *eq*), RuPhos (237 mg, 509 umol, 0.4 *eq*), Cs_2CO_3 (1.04 g, 3.18 mmol, 2.5 *eq*) and $Pd_2(dba)_3$ (233 mg, 254 umol, 0.2 *eq*) in toluene (20

mL) was de-gassed and then heated to 90 °C for 8 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated aqueous $NaHCO_3$. The mixture was concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 50 mL). The organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (365 mg, 469 umol, 37% yield, 90% purity) as a yellow solid. LCMS [ESI, M+1]: 700.

[02039] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.99 (s, 1H), 7.22 (s, 1H), 5.66 (dd, *J* = 2.8, 9.6 Hz, 1H), 4.61 (br s, 1H), 4.40 (br dd, *J* = 4.8, 10.4 Hz, 1H), 4.26 (br s, 2H), 4.09 - 3.97 (m, 3H), 3.90 (br d, *J* = 11.6 Hz, 1H), 3.80 - 3.71 (m, 1H), 3.50 (br t, *J* = 4.8 Hz, 2H), 3.25 (br s, 2H), 3.09 (br t, *J* = 7.6 Hz, 1H), 2.99 (br t, *J* = 11.2 Hz, 1H), 2.83 - 2.51 (m, 6H), 2.48 (s, 3H), 2.43 (s, 3H), 2.33 (s, 3H), 2.31 - 2.24 (m, 1H), 2.21 - 2.13 (m, 1H), 2.11 - 2.06 (m, 1H), 1.90 - 1.69 (m, 8H), 1.52 (s, 9H).

[02040] Step B: 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1- tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (720 mg, 1.03 mmol, 1 *eq*) in DCM (1 mL) was added TFA (4.62 g, 40.5 mmol, 3 mL, 39.4 *eq*). The mixture was stirred at 20 °C for 4 hours. Upon completion, the mixture was diluted with DCM (10 mL) and neutralized with saturated aqueous $NaHCO_3$. Then the aqueous phase was extracted with EtOAc (2 × 30 mL). The organic layers were combined, dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (880 mg, crude) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 516.


[02041] Step C: (2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-

piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude) and TEA (177 mg, 1.75 mmol, 243 uL) in DCM (4 mL) was added prop-2-enoyl chloride (13.2 mg, 145 umol, 11.9 uL) dropwise at -40 °C. After stirring at -40 °C for 30 minutes, the mixture was quenched with saturated aqueous $NaHCO_3$ (1 mL) and extracted with DCM (2 × 10 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 1/0 to 10/1) followed by prep-HPLC (column: Gemini 200*30 10μ; mobile phase: [water (10 mM NH_4HCO_3) - ACN]; B%: 40%-70%, 6.0 min). The desired fractions were collected and lyophilized to give title compound (2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoyl-piperazin-2-yl]acetonitrile (EXAMPLE 462, 15.6 mg, 27.2 umol, two steps 15% yield, 99.6% purity) as a white solid. LCMS [ESI, M+1]:570.


[02042] SFC condition: Column: Chiralcel OJ-3 100×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

[02043] ^{1}H NMR (400 MHz, chloroform-d) δ = 10.26 (br s, 1H), 8.03 (s, 1H), 7.14 (s, 1H), 6.57 (br d, *J* = 9.6 Hz, 1H), 6.39 (dd, *J* = 1.2, 16.4 Hz, 1H), 5.83 (br d, *J* = 10.4 Hz, 1H), 5.12 - 4.38 (m, 2H), 4.28 (s, 2H), 4.23 - 3.84 (m, 4H), 3.73 - 3.40 (m, 3H), 3.32 (br s, 1H), 3.10 (br t, *J* = 7.6 Hz, 2H), 2.98 - 2.61 (m, 5H), 2.48 (s, 3H), 2.41 (s, 3H), 2.34 (s, 3H), 2.32 - 2.24 (m, 1H), 2.11 - 1.99 (m, 1H), 1.91 - 1.78 (m, 3H).

EXAMPLE 463



(S,E)-3-((4-(3-(cyanomethyl)-4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide



[02044] Step A: tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: Benzyl (S)-2-(cyanomethyl)piperazine-1-carboxylate hydrochloride (10 g, 34 mmol) was dissolved in DMA (68 ml, 34 mmol). To the solution was next added tert-butyl 2,4-dichloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (9.3 g, 30 mmol) followed by Hunig's Base (24 ml, 135 mmol) and the reaction stirred at room temperature for 1 hour. The reaction was next poured into basic water and extracted with MTBE. The organics were washed with additional water, brine, dried over Na_2SO_4 and concentrated in vacuo. The concentrate was then chromatographed using 10→70% EtOAc/Hexane as eluent to give tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (12 g, 67 % yield). ESI+APCI MS m/z 580.3 $[M+H]^+$.

[02045] Step B: benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (1.5 g, 2.8 mmol) was dissolved in DCM (28 ml, 2.8 mmol) and treated with Hydrochloric Acid

Solution (4.0 M in 1,4-dioxane) (3.6 ml, 14 mmol). The reaction was stirred at room temperature for 1 hour. The organics were washed with 1M NaOH. The aqueous layer was extracted with DCM (2X). The combined organics were dried over Na_2SO_4, concentrated in vacuo and taken forward as crude benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.2 g, 99 % yield). ESI+APCI MS m/z 427.2 $[M+H]^+$.

[02046] Step C: benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tris(dibenzylideneacetone)dipalladium(0) (0.51 g, 0.56 mmol) and Xantphos (0.54 g, 1.1 mmol) were dissolved in 1,4-dioxane (28 ml, 2.8 mmol) and purged under Argon for 5 minutes followed by stirring at 100°C under Argon for 15 minutes. The reaction was next cooled to room temperature. To the reaction was added benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.2 g, 2.8 mmol), 1-bromo-8-methylnaphthalene (1.9 g, 8.4 mmol), and Cesium Carbonate (2.7 g, 8.4 mmol) under Argon. The reaction was capped under Argon and stirred at 100°C over night. The reaction was cooled to room temperature and was filtered through GF/F paper. The filtrate was concentrated in vacuo and purified by normal phase chromatography on the CombiFlash using 0% →75% Hexanes/EtOAc as the eluent to give benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.45 g, 28 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.

[02047] Step D: benzyl (S)-2-(cyanomethyl)-4-(2-(3-(dimethylamino)-3-oxopropoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,4-dihydropyrazine-1(2H)-carboxylate: In a microwave tube a solution of benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 0.441 mmol) in dioxane (4408 µl, 0.441 mmol) was sparged with Argon for 5 minutes. 3-Hydroxy-N,N-dimethylpropanamide (155 mg, 1.32 mmol), Cesium Carbonate (431 mg, 1.32 mmol), Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (37.5 mg, 0.0441 mmol) were sequentially added under Argon and the reaction sparged for an additional 5 minutes with Argon. The reaction mixture was capped and heated at 100°C for 1 hour. The reaction was cooled to room temperature and Ethyl Acetate was added. The reaction was filtered


through GF/F paper and the filtrated concentrated in vacuo. The residue was purified by flash chromatography eluting with 0 →20% MeOH + 2% NH_4OH/DCM. All fractions containing clean desired product were combined and concentrated to give benzyl (S)-2-(cyanomethyl)-4-(2-(3-(dimethylamino)-3-oxopropoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-3,4-dihydropyrazine-1(2H)-carboxylate (140 mg, 49.2 % yield). ESI+APCI MS m/z 648.3 $[M+H]^+$.

[02048] Step E: (S)-3-((4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide: A solution of benzyl (S)-2-(cyanomethyl)-4-(2-(3-(dimethylamino)-3-oxopropoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (140 mg, 0.216 mmol) in EtOH (2161 µl, 0.216 mmol) and THF (2161 µl, 0.216 mmol) was purged with N_2 for 5 minutes. To this solution was added Palladium (57.5 mg, 0.0540 mmol) (Degussa Type, 10 wt%, 50% H2O) and the reaction capped and purged with N_2 for an additional 5 minutes. The solution was stirred under one atmosphere of H_2 overnight. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide crude (S)-3-((4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide (111 mg, 100.0 % yield). ESI+APCI MS m/z 514.3 $[M+H]^+$.


[02049] Step F: (S,E)-3-((4-(3-(cyanomethyl)-4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide: To a 25 mL round bottom flask containing dichloromethane (2161 µl, 0.216 mmol) cooled to 0°C was added (S)-3-((4-(3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide (111 mg, 0.216 mmol) and Hunig's base (226 µl, 1.30 mmol). The reaction mixture was vigorously stirred while (E)-4-(dimethylamino)but-2-enoic acid (167 mg, 1.30 mmol) was added in one portion. Next, 1-Propanephosphonic acid cyclic anhydride (772 µl, 1.30 mmol) was added slowly to the stirring mixture. The reaction was stirred for 2 hours at 0°C. The reaction was treated with basic water and the aqueous layer extracted with EtOAc (3X). The combined organics were concentrated in vacuo and purified on the Gilson (prep HPLC) eluting with 5 →95% ACN +0.1% TFA /water+0.1% TFA. Fractions containing product were

combined, diluted with 1M NaOH and the aqueous layer extracted with DCM. The organics were dried over Na_2SO_4 and concentrated in vacuo to give title compound (S,E)-3-((4-(3-(cyanomethyl)-4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)-N,N-dimethylpropanamide (17.6 mg, 13.0 % yield). ESI+APCI MS m/z 625.4 $[M+H]^+$.

EXAMPLE 464



2-((S)-1-acryloyl-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02050] Step A: Benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (200 mg, 0.396 mmol), Cs_2CO_3 (644 mg, 1.98 mmol), 1,8-dibromonaphthalene (339 mg, 1.19 mmol), $Pd_2(dba)_3$ (72.4 mg, 0.0791 mmol) and XANTPHOS (91.6 mg, 0.158 mmol) were diluted with toluene (1582 µl, 0.396 mmol). The reaction was purged with argon, sealed and heated to 100°C. After stirring for 23 hours, the reaction was cooled and diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 1-10% methanol/DCM (1% NH4OH as additive) to afford benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (68 mg, 24.2 % yield). ESI+APCI MS m/z 712.2 $[M+H]^+$.

[02051] Step B: 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (25 mg, 0.035 mmol) was diluted with TFA (2 mL), placed under nitrogen and heated to 90°C. After stirring for 2 hours, the reaction was cooled and concentrated. The material was diluted with DCM and washed with saturated sodium bicarbonate. The DCM was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH as additive) to afford 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8 mg, 39 % yield). ESI-APCI MS m/z 578.2 $[M+H]^+$.


[02052] Step C: 2-((S)-1-acryloyl-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8 mg, 0.014 mmol) was diluted with DCM (200 uL) followed by the addition of acryloyl chloride (1.4 mg, 0.015

mmol) and DIEA (4.8 µl, 0.028 mmol). After stirring for 12 hours, the reaction was diluted with saturated sodium carbonate and extracted twice with DCM. The DCM was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH as additive) to afford title compound 2-((S)-1-acryloyl-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 464, 6 mg, 69 % yield). ESI+APCI MS m/z 632.2 $[M+H]^+$.

EXAMPLE 465



(R)-4-acryloyl-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carbonitrile



[02053] Step A: benzyl (R)-4-(4-(tert-butoxycarbonyl)-2-cyanopiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of benzyl 2,4-dichloro-5,6-dihydropyrido[3,4-d]pyrimidine-7(8H)-carboxylate (700 mg, 2.07 mmol), R-1-N-Boc-3-cyanopiperazine (656 mg, 3.10 mmol), N,N-dimethylacetamide (1 ml) and N-ethyl-N-isopropylpropan-2-amine (0.433 ml, 2.48 mmol) was stirred at 60°C under nitrogen atmosphere for 48 hours. The reaction mixture was cooled, partitioned between MTBE (50 mL) and 0.2M Na_2CO_3 (15 mL) and the layers separated. The organic layer was washed with water and brine (10 mL each), dried over Na_2SO_4 and evaporated in vacuo. The material crystallized upon dilution with MTBE (5 mL). The mother liquor was decanted and the solid was washed with MTBE (2*1 mL) followed by purification on silica gel using in 40 to 60% EtOAc/hexane as eluent to give product (308 mg, 29%). ESI+APCI MS m/z 513.2 $[M+H]^+$.

[02054] Step B: benzyl 4-((R)-4-(tert-butoxycarbonyl)-2-cyanopiperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate: A mixture of benzyl (R)-4-(4-(tert-butoxycarbonyl)-2-cyanopiperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (308 mg, 0.600 mmol), Cs_2CO_3 (587 mg, 1.80 mmol), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 51.1 mg, 0.0600 mmol), (S)-(1-methylpyrrolidin-2-yl)methanol (346 mg, 3.00 mmol) and 1,4-dioxane (4 ml) was purged with N_2 and the vial was capped and reaction stirred at 70°C for 2 hours. The reaction mixture was partitioned between water (5 mL) and EtOAc (20 mL) and the organic layer separated. The organics were washed with water and brine (3 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH + 0.4% NH_4OH/DCM as eluent to give product as a mixture of isomers (214 mg of ~60% purity, 36%). ESI+APCI MS m/z 592.3 $[M+H]^+$.

[02055] Step C: tert-butyl (R)-3-cyano-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of crude benzyl 4-((R)-4-(tert-butoxycarbonyl)-2-cyanopiperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (214 mg, 0.362 mmol), methanol (7 ml, 0.362 mmol), and palladium on carbon (20 mg, 5%, *Degussa type E101 NO/W*) was degassed and stirred under hydrogen atmosphere for 1.5 hours. The reaction mixture was

filtered through Celite (2 mL), the celite washed with MeOH (3*3 mL) and the combined organics evaporated in vacuo to give product which was used crude in the next reaction. ESI+APCI MS m/z 458.3 $[M+H]^+$.


[02056] Step D: tert-butyl (R)-3-cyano-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: A mixture of tert-butyl (R)-3-cyano-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (165 mg, 0.361 mmol), Cs_2CO_3 (352 mg, 1.08 mmol), dioxane (0.5 mL), 1-iodonaphthalene (0.0790 ml, 0.541 mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (RuPhos-Pd-G4, 0.1 eq., 30.7 mg, 0.0361 mmol) was purged with nitrogen, the flask capped and stirred at 70°C for 1.5 hours. The reaction mixture was cooled and partitioned between EtOAc (20 mL) and water (5 mL) and the layers separated. The organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH+0.4% NH_4OH /DCM as eluent to give product (120 mg, 57%). ESI+APCI MS m/z 584.3 $[M+H]^+$.

[02057] Step E: (R)-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carbonitrile: The (tert-butyl (R)-3-cyano-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (120 mg, 0.206 mmol) was dissolved in dichloromethane (0.5 ml) and cooled to 0°C followed by addition of 4M hydrogen chloride (1.03 ml, 4.11 mmol) and the reaction stirred for 1 hr while warming to room temperature. The mixture was evaporated in vacuo and the residue was partitioned between DCM (10 mL) and 2M Na_2CO_3 (0.5 mL) and the layers separated. The organics were dried over Na_2CO_3, filtered and evaporated in vacuo. The material was used crude in the next reaction. ESI+APCI MS m/z 484.2 $[M+H]^+$.

[02058] Step F: (R)-4-acryloyl-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carbonitrile: A solution of (R)-1-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-2-carbonitrile (79 mg, 0.1634 mmol) in DCM (5 mL) was cooled to -30°C with stirring followed by addition of triethylamine (68.31 µl, 0.4901

mmol) and acryloyl chloride (26.54 µl, 0.3267 mmol). After 5 minutes at -30°C, the reaction was quenched by addition of MeOH (0.05 mL) and the reaction warmed to room temperature. The organics were next separated and washed with 0.5M Na_2CO_3 (4 mL), dried over Na_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel using 4% MeOH + 0.4% NH_4OH/DCM as eluent to give title compound (EXAMPLE 465, 17 mg, 19%). ESI+APCI MS m/z 538.3 $[M+H]^+$.


EXAMPLE 466



2-((S)-1-acryloyl-4-(7-(5,6-dimethyl-1H-indol-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02059] 2-((S)-1-acryloyl-4-(7-(5,6-dimethyl-1H-indol-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. The title compound is prepared following **Example 454** substituting Intermediate 66 for *tert*-butyl 4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate in Step A.


EXAMPLE 467



2-((S)-1-acryloyl-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02060] 2-((S)-1-acryloyl-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound is prepared following **Example 447** substituting benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate in **Example 447**, Step A for benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate in **Example 447**, Step A.


EXAMPLE 468



2-((S)-1-acryloyl-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02061] 2-((S)-1-acryloyl-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound is prepared following **Example 447** substituting benzyl (S)-4-(2-chloro-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate in **Example 447**, Step A for benzyl (S)-4-(2-chloro-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate in **Example 447**, Step A.


EXAMPLE 469



(S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[02062] (S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: The title compound is prepared following EXAMPLE 457 substituting EXAMPLE 139, Step B product 2-(3,3-difluoropyrrolidin-1-yl)ethanol for [(2*S*)-1-methylpyrrolidin-2-yl]methanol in preparation of Intermediate 66, Step E and then following EXAMPLE 457 Steps B – D.


EXAMPLE 470




(S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one

[02063] (S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)prop-2-en-1-one: The title compound is prepared following **Example 453** substituting **Example 139**, Step B product 2-(3,3-difluoropyrrolidin-1-yl)ethanol for [(2*S*)-1-methylpyrrolidin-2-yl]methanol in preparation of Intermediate 66, Step E and then following **Example 453** Steps B – C.

EXAMPLE 471



2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3,3-difluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile



[02064] (E)-4-bromobut-2-enoyl chloride. To a solution of (*E*)-4-bromobut-2-enoic acid (500 mg, 3.03 mmol, 1.0 *eq*) in DCM (2.0 mL) was added $(COCl)_2$ (4.35 g, 34.3 mmol, 3.0 mL, 11.3 *eq*).The mixture was stirred at 60 °C for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product (E)-4-bromobut-2-enoyl chloride (500 mg, crude) was obtained as brown oil.

[02065] Step A: *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.30 g, 2.17 mmol, 1.0 *eq*) and [(2*S*)-1-methylpyrrolidin-2-yl]methanol (500 mg, 4.34 mmol, 515 uL, 2.0 *eq*) in toluene (20.0 mL) was added *t*-BuONa (417 mg, 4.34 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 10 min. The reaction mixture was quenched by addition saturated brine (30.0 mL) at 20 °C, and extracted with EA (3×30.0 mL). The combined organic layers were washed with saturated brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to EA/MeOH = 10/1). The product *tert*-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (1.1 g, 1.62 mmol, 75% yield, 96% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 650.


[02066] Step B: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *t*ert-butyl (2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (100 mg, 154 umol, 1.00 *eq*) in dioxane (0.5 mL) was added HCl•dioxane (4 M, 1.00 mL, 26.0 *eq*). The mixture was stirred at 0 °C for 10 min. The reaction mixture was concentrated under reduced pressure to remove dioxane. The residue was diluted with saturated $NaHCO_3$ aqueous (10.0 mL) and extracted with EA (10 mL × 3). The combined organic layers were washed with saturated brine (20.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The crude product 2-[(2*S*)-4-

[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, crude) was obtained as a white solid. LCMS [ESI, M+1]:550.


[02067] Step C: 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3,3-difluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, 145 umol, 1.0 *eq*) in DCM (3.0 mL) was added Py (115 mg, 1.45 mmol, 117 uL, 10.0 *eq*) and (*E*)-4-bromobut-2-enoyl chloride (107 mg, 582 umol, 4.0 *eq*) in DCM (3.0 mL). The mixture was stirred at 0 °C for 1 hour. After the starting material was consumed, then to a solution of 3,3-difluoropyrrolidine (156 mg, 1.45 mmol, 10.0 *eq*) in DCM (6.0 mL) was added the reaction mixture. The mixture was stirred at 0 °C at 2 hours. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 62%-92%,12min). And the residue was concentrated under reduced pressure to remove ACN, and then lyophilization. Title compound 2-[(2*S*)-4-[7-[3-chloro-2-(trifluoromethyl)phenyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3,3-difluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 471, 15.4 mg, 20.8 umol, 14 % yield, 97.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 723.


[02068] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.40 (t, *J*=8.2 Hz, 1H), 7.30 - 7.26 (m, 1H), 7.19 (d, *J* = 8.0 Hz, 1H), 7.05 - 6.90 (m, 1H), 6.60 - 6.40 (m, 1H), 5.08 (br s, 1H), 4.39 (br dd, *J* = 5.2, 10.8 Hz, 1H), 4.17 (br dd, *J*=6.8, 10.8 Hz, 1H), 4.1 (br s, 2H), 4.12 - 4.05 (m, 1H), 3.97 (br d, *J*=10.8 Hz, 2H), 3.70 - 3.53 (m, 1H), 3.35 - 3.25 (m, 3H), 3.17 - 3.07 (m, 2H), 2.96 (br t, *J*=13.2 Hz, 3H), 2.90 - 2.85 (m, 1H), 2.81 (br t, *J* = 6.8 Hz, 3H), 2.75 - 2.65 (m, 2H), 2.50 (s, 3H), 2.40 - 2.27 (m, 3H), 2.15 - 1.95 (m, 1H), 1.95 - 1.72 (m, 5H).

EXAMPLE 472



2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile





[02069] 2-chloroprop-2-enoyl chloride. To a solution of 2-fluoroprop-2-enoic acid (400 mg, 4.44 mmol, 1.0 *eq*) in DCM (1.50 mL) was added $(COCl)_2$ (846 mg, 6.66 mmol, 583 uL, 1.50 *eq*) and DMF (32.5 mg, 444 umol, 34.2 uL, 0.10 *eq*). The mixture was stirred at 25 °C for 2 hours.2-chloroprop-2-enoyl chloride (400 mg, crude) was used for the next step directly.


[02070] Step A: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *t*ert-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 347 umol, 1.0 *eq*) in DCM (2.0 mL) was added TFA (3.08 g, 27.0 mmol, 2.0 mL, 77.8 *eq*). The mixture was stirred at 20 °C for 10 min. The reaction mixture was concentrated under reduced pressure to give a residue. The product 2-[(2*S*)-4-[7-(2,3-

dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude, TFA) was obtained as a yellow solid and used into the next step without further purification.


[02071] Step B: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 339 umol, 1.0 *eq*, TFA) in DCM (2.0 mL) was added DIEA (1.11 g, 8.61 mmol, 1.50 mL, 25.4 *eq*) and 2-fluoroprop-2-enoyl chloride (200 mg, 1.84 mmol, 5.43 *eq*) in DCM (2.0 mL). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-83%, 12min). Title compound 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 472, 120 mg, 217 umol, two steps 62% yield, 98.9% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 548.


[02072] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.11 (t, J=7.8 Hz, 1H), 7.01 - 6.91 (m, 2H), 5.52 - 5.32 (m, 1H), 5.26 (dd, J=3.2, 16.8 Hz, 1H), 5.08 - 4.70 (br s, 1H), 4.39 (dd, *J* = 5.2, 10.4 Hz, 1H), 4.25 - 4.02 (m, 5H), 3.97 (d, *J* = 12.8 Hz, 1H), 3.43 - 3.73 (br s, 1H) 3.32 (d, *J* = 13.2 Hz, 1H), 3.25 - 3.16 (m, 1H), 3.15 - 3.02 (m, 3H), 3.01 - 2.91 (m, 1H), 2.90 -2.80 (m, 2H) 2.79 - 2.60 (m, 2H), 2.49 (s, 3H), 2.31-2.28 (m, 7H), 2.13 - 1.97 (m, 1H), 1.90 - 1.70 (m, 3H).

EXAMPLE 473



2-[(2*S*)-1-(2-chloroprop-2-enoyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile






[02073] 2-chloroacryloyl chloride. A solution of 2-chloroprop-2-enoic acid (400 mg, 3.76 mmol, 1.0 *eq*) and $(COCl)_2$ (715 mg, 5.63 mmol, 493 uL, 1.50 *eq*) in DCM (1.0 mL) was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was not work-up, and used for the next step directly.

[02074] Step A: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 73, 400 mg, 695 umol, 1.0 *eq*) in DCM (0.50 mL) was added TFA (3.08 g, 27.0 mmol, 2.0 mL, 38.9 *eq*). The mixture was stirred at 20 °C for 0.5 hour. After completion, the mixture was concentrated and adjusts with saturated $NaHCO_3$ aqueous to pH~7, then extracted with DCM (5.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The product 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (400 mg, crude) was obtained as yellow oil and used to the next step without further purification.


[02075] Step B: 2-[(2*S*)-1-(2-chloroprop-2-enoyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, 631 umol, 1.0 *eq*) and DIEA (245 mg, 1.89 mmol, 330 uL, 3.0 *eq*) in DCM (1.0 mL) was added 2-chloroprop-2-enoyl chloride (236 mg, 1.89 mmol, 3.0 *eq*) at -78 °C. The mixture was stirred at -78 °C for 0.5 hour. After completion, the mixture was added saturated $NaHCO_3$ aqueous (2.0 mL) and extracted with EA (10.0 mL × 3). The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 53%-83%,12min) to give title compound 2-[(2*S*)-1-(2-chloroprop-2-enoyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 473, 4.72 mg, 8.35 umol, two steps 1% yield, 99.8% purity) as white solid. LCMS [ESI, M+1]: 564.

[02076] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.11 (t, *J* = 7.8 Hz, 1H), 6.98 - 6.94 (m, 2H), 5.86 - 5.78 (m, 1H), 5.77 - 5.72 (m, 1H), 5.15 - 4.78 (m, 1H), 4.45 - 4.30 (m, 1H), 4.21 - 4.12 (m, 1H), 4.10 - 4.03 (m, 3H), 3.96 (br d, *J* = 12.4 Hz, 2H), 3.30 (br dd, *J* = 3.2, 13.6 Hz, 1H), 3.23 - 3.04 (m, 4H), 3.04 - 2.54 (m, 6H), 2.50 (br s, 3H), 2.34 - 2.23 (m, 7H), 2.12 - 2.02 (m, 1H), 1.91 - 1.66 (m, 3H).

EXAMPLE 474



2-((*S*)-1-(4-hydroxybut-2-ynoyl)-4-(2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02077] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 65, 1 g, 1.58 mmol, 1 eq) and 1-bromonaphthalene (655 mg, 3.16 mmol, 440 uL, 2 eq) in toluene (20 mL) was added $Pd_2(dba)_3$ (145 mg, 158 umol, 0.1 eq), RuPhos (148 mg, 316 umol, 0.2 eq), Cs_2CO_3 (1.55 g, 4.75 mmol, 3 eq) in one portion. The mixture was degassed and purged with N_2 for 3 times, then heated to 90 °C and stirred for 2 hours. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with water (50 mL × 1), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (6 mL) and extracted with ethyl acetate (100 mL × 2). The separated organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (515 mg, 726 umol, 45.9% yield, 89.1% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 632.

[02078] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1 g, 1.58 mmol, 1 eq) in MeOH (60 mL) was added Pd/C (500 mg, 10% purity) and NH_3•MeOH (20%, 50 mL) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was concentrated under reduced pressure. Compound 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (680 mg, 1.26 mmol, 80% yield, 92.3% purity) was obtained as a yellow solid which was used directly into the next step without further purification. LCMS [ESI, M+1]: 498.


[02079] ^{1}H NMR (400MHz, chloroform-d) δ = 8.26 - 8.19 (m, 1H), 7.89 - 7.83 (m, 1H), 7.60 (d, *J* = 8.4 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.16 - 7.12 (m, 1H), 4.41 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.26 (s, 2H), 4.16 (dd, *J* = 7.2, 10.8 Hz, 1H), 4.01 (br d, *J* = 12.4 Hz, 1H), 3.95 - 3.82 (m, 1H), 3.44 - 3.21 (m, 3H), 3.18 - 2.97 (m, 4H), 2.95 - 2.76 (m, 3H), 2.74 - 2.63 (m, 1H), 2.55 (dd, *J* = 1.2, 5.6 Hz, 2H), 2.51 - 2.46 (m, 3H), 2.33 - 2.22 (m, 1H), 2.12 - 1.99 (m, 1H), 1.88 - 1.80 (m, 3H).

[02080] Step C: 2-[(2*S*)-1-(4-hydroxybut-2-ynoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid (172 mg, 803 umol, 2 *eq*) and DIEA (155 mg, 1.21 mmol, 210 uL, 3 *eq*) in MeCN (5 mL) was added MsCl (92.1 mg, 803 umol, 62.2 uL, 2 *eq*) at 0 °C. After stirring at 0 °C for 20 minutes, to the mixture was added 2-[(2*S*)-4-[2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 402 umol, 1 *eq*) and the mixture was stirred at 25 °C for 2 hours. Then the reaction mixture was heated to 80 °C and stirred for 10 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 5u; mobile phase: [water (0.225% FA)-ACN]; B%: 25% - 45%, 10 min) and further purified by prep-HPLC (column: Phenomenex


Gemini 150*25mm*10um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 45% - 75%, 12 min). Title compound 2-[(2*S*)-1-(4-hydroxybut-2-ynoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 474, 1.43 mg, 2.39 umol, 1% yield, 96.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 580.

[02081] ^{1}H NMR (400MHz, chloroform-d) δ = 8.22 (d, *J* = 6.8 Hz, 1H), 7.90 - 7.82 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.44 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 5.26 - 4.89 (m, 1H), 4.60 - 4.34 (m, 4H), 4.33 - 4.16 (m, 3H), 4.14 - 3.96 (m, 1H), 3.95 - 3.80 (m, 1H), 3.78 - 3.50 (m, 2H), 3.50 - 3.28 (m, 2H), 3.27 - 3.07 (m, 3H), 3.06 - 2.82 (m, 3H), 2.80 - 2.64 (m, 2H), 2.51 (d, *J*=12.4 Hz, 3H), 2.38 - 2.24 (m, 1H), 2.14 - 2.00 (m, 1H), 1.97 - 1.85 (m, 2H).

EXAMPLE 475




2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile




[02082] Step A: 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of deuterio 2,3,3-trideuterioprop-2-enoate (68.8 mg, 904 umol, 3 eq) and DIEA (234 mg, 1.81 mmol, 315 uL, 6 eq) in MeCN (3 mL) was added MsCl (69.1 mg, 603 umol, 46.7 uL, 2 eq) at 5 °C for 0.5 hour. To the resulting reaction was added 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 301 umol, 1 eq). The reaction mixture was stirred at 5 °C for 1 hour. Then the reaction mixture was heated to 80 °C for 12 hrs. Upon completion, the reaction mixture was quenched by water (0.5 mL). The residue mixture was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 50%-80%,12min) to give title compound 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 475, 34.2 mg, 60.2 umol, 20% yield, 97.7% purity) as a white solid. LCMS [ESI, M+1]: 555.

[02083] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 8.28 - 8.16 (m, 1H), 7.91 - 7.83 (m, 1H), 7.63 (d, *J*=8.0 Hz, 1H), 7.56 - 7.48 (m, 2H), 7.45 (t, *J*=7.6 Hz, 1H), 7.16 (d, *J*=7.2 Hz, 1H), 5.28 - 4.94 (m, 1H), 4.41 (dd, *J*=5.2, 10.8 Hz, 1H), 4.36 - 4.24 (m, 2H), 4.23 - 4.11 (m, 2H), 4.04 (br d, *J*=11.6 Hz, 2H), 3.73 - 3.25 (m, 3H), 3.22 - 2.74 (m, 7H), 2.69 (td, *J*=6.4, 13.2 Hz, 1H), 2.50 (s, 3H), 2.36 - 2.24 (m, 1H), 2.15 - 2.02 (m, 1H), 1.83 - 1.77 (m, 3H).


EXAMPLE 476



2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(E)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile



(*E*)-4-bromobut-2-enoyl chloride



[02084] Insert: (E)-4-bromobut-2-enoyl chloride. A solution of (*E*)-4-bromobut-2-enoic acid (1.0 g, 6.06 mmol, 1.0 *eq*) in $(COCl)_2$ (14.5 g, 114 mmol, 10.0 mL, 18.9 *eq*) and DCM (10.0 mL) was stirred at 70 °C for 2 hours. After completion, the mixture was concentrated under vacuum. The product (*E*)-4-bromobut-2-enoyl chloride (1.0 g, crude) was obtained as yellow oil. The crude compound was used directly to the next step without further purification.

[02085] Step A: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of tert-butyl (2*S*)-2-(cyanomethyl)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-

methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (Intermediate 73, 200 mg, 347 umol, 1.0 *eq*) in dioxane (2.0 mL) was added HCl•dioxane (4.0 M, 2.0 mL, 23.0 *eq*). The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was adjusted pH=7 with saturated of $NaHCO_3$ aqueous solution and extracted with EA (5.0 mL × 3). The combined organic layers were washed with brine (10.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The product 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, crude) was obtained as a yellow solid and used into the next step without further purification.


[02086] Step B: 2-[(2*S*)-1-[(E)-4-bromobut-2-enoyl]-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, 336 umol, 1.0 *eq*) in DCM (6.0 mL) was added Py (532 mg, 6.73 mmol, 543 uL, 20.0 *eq*) and (E)-4-bromobut-2-enoyl chloride (246 mg, 1.35 mmol, 4.0 *eq*) in DCM (2.0 mL). The mixture was stirred at 0 °C for 1 hour. After completion, the reaction mixture was quenched by addition MeOH (5.0 mL) at 0 °C, and then concentrated under reduced pressure to give a residue. The product 2-[(2*S*)-1-[(E)-4-bromobut-2-enoyl]-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude) was obtained as a yellow oil and used into the next step without further purification. LCMS [ESI, M+1]: 622.

[02087] Step C: 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(E)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(E)-4-bromobut-2-enoyl]-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 321 umol, 1.0 *eq*) in DCM (3.0 mL) was added K_2CO_3 (88.8 mg, 642 umol, 2.0 *eq*), KI (2.67 mg, 16.1 umol, 0.05 *eq*) and 3-fluoropyrrolidine (403 mg, 3.21 mmol, 10.0 *eq*, HCl salt). The mixture was stirred at 0 °C for 1 hour. After completion, the reaction mixture was concentrated under reduced pressure to give a


residue. The residue was adjusted pH=7 with saturated of $NaHCO_3$ aqueous solution and extracted with EA (10.0 mL× 3). The combined organic layers were washed with brine (20.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water(0.04%NH3H2O)-ACN];B%: 60%-84%,10min). The residue was concentrated under reduced pressure and then lyophilization to give title compound 2-[(2*S*)-4-[7-(2,3-dimethylphenyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(E)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 476, 123 mg, 193 umol, 56% yield in three steps, 99.2% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 631.

[02088] ^{1}H NMR (400MHz, Chloroform-d) δ 7.16 - 7.07 (m, 1H), 7.02 - 6.92 (m, 3H), 6.59 - 6.41 (m, 1H), 5.31 - 5.10 (m, 1H), 5.09 - 4.46 (m, 1H), 4.38 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.26 - 3.83 (m, 6H), 3.80 - 3.45 (m, 1H), 3.42 - 3.24 (m, 3H), 3.23 - 3.15 (m, 1H), 3.14 - 3.03 (m, 3H), 3.02 - 2.83 (m, 4H), 2.82 - 2.62 (m, 4H), 2.54 - 2.49 (m, 1H), 2.47 (s, 3H), 2.32 - 2.26 (m, 6H), 2.25 - 2.17 (m, 1H), 2.16 - 2.09 (m, 1H), 2.08 - 2.02 (m, 1H), 1.92 - 1.78 (m, 4H).

EXAMPLE 477




2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile




[02089] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile. To the solution of deuterio 2,3,3-trideuterioprop-2-enoate (56.6 mg, 744 umol, 3 *eq*) and DIEA (481 mg, 3.72 mmol, 648 uL, 15 *eq*) in ACN (3 mL) was added MsCl (56.8 mg, 496 umol, 38.4 uL, 2 *eq*) at 5 °C, the mixture was stirred at 5 °C for 0.5 hour. Then to the mixture was added 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 150 mg, 248 umol, 1 *eq*, 2 HCl), the resulting mixture was stirred at 5 °C for 1 hour. Then the mixture was heated to 80 °C and stirred at 80 °C for 12 hours. The mixture was quenched by Water (0.5 mL). The reaction mixture was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um;mobile phase: [water (0.05 % ammonia hydroxide v/v)-ACN];B%: 50 % - 80 %,10 min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2,3,3-trideuterioprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 477, 13.0 mg, 21.6 umol, 9 % yield, 98.2 % purity) as a off-white solid. LCMS [ESI, M+1]: 589.


[02090] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (br d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 8.0, 13.2 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.10 (br s, 1H), 4.49 - 4.33 (m, 2H), 4.21 - 4.01 (m, 3H), 3.96 - 3.79 (m, 2H), 3.60 (br d, *J* = 6.8 Hz, 1H), 3.44 (br d, *J* = 13.6 Hz, 1H), 3.32 - 2.97 (m, 5H), 2.88 - 2.53 (m, 4H), 2.48 (d, *J* = 2.8 Hz, 3H), 2.29 (br d, *J* = 8.8 Hz, 1H), 2.11 - 2.00 (m, 1H), 1.87 - 1.71 (m, 3H).

EXAMPLE 478



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile





[02091] 2-fluoroprop-2-enoyl chloride. To a solution of 2-fluoroprop-2-enoic acid (400 mg, 4.44 mmol, 1 *eq*) in DCM (4 mL) was added $(COCl)_2$ (846 mg, 6.66 mmol, 583 uL, 1.5 *eq*) and DMF (32.5 mg, 444 umol, 34.2 uL, 0.1 *eq*). The mixture was stirred at 25 °C for 2 hrs. The reaction mixture was concentrated under reduced pressure to remove a part of solvent and give a residue in DCM. Compound 2-fluoroprop-2-enoyl chloride (400 mg, crude) was obtained as a yellow liquid and used into the next step without further purification.


[02092] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg,

528 umol, 1 *eq*, HCl) in DCM (5 mL) was added DIEA (1.73 g, 13.4 mmol, 2.33 mL, 25.4 *eq*) and 2-fluoroprop-2-enoyl chloride (286 mg, 2.64 mmol, 5 *eq*) in DCM (5 mL). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al_2O_3, Dichloromethane/Methanol = 10/1 to 10/1). The residue was purified by prep-HPLC (column: Gemini 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 55% - 85%, 12min). The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 * 30mm * 4um; mobile phase: [water (0.225% FA) - ACN]; B%: 20% - 50%, 10.5min). The residue was concentrated under reduced pressure to remove ACN, and then lyophlization. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 478, 24.1 mg, 36.7 umol, 7% yield, 99.1% purity, FA) was obtained as a brown solid.


[02093] SFC condition: "AD - 3S_3_5_40_3ML Column: Chiralpak AD - 3 100 × 4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".

[02094] ^{1}H NMR (400 MHz, Acetic) δ = 7.82 (d, *J* = 8.0 Hz, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.56 (d, *J* = 7.6 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.41 - 7.30 (m, 2H), 5.58 - 5.25 (m, 2H), 5.17 - 4.59 (m, 4H), 4.57 - 4.28 (m, 3H), 4.24 - 3.78 (m, 4H), 3.67 - 3.13 (m, 7H), 3.08 (br d, *J* = 2.4 Hz, 3H), 2.98 (br d, *J* = 6.4 Hz, 1H), 2.83 - 2.61 (m, 1H), 2.45 - 2.29 (m, 1H), 2.24 - 2.08 (m, 3H).

EXAMPLE 479



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile



[02095] Step A: ethyl (*E*)-4-fluorobut-2-enoate. A mixture of ethyl (*E*)-4-bromobut-2-enoate (2.00 g, 10.4 mmol, 1.43 mL, 1.00 eq) and AgF (3.94 g, 31.1 mmol, 674 uL, 3.00 eq) in acetonitrile (20.0 mL) was stirred at 25 °C for 12 hours. The mixture was filtered and washed with THF (10.0 mL), then concentrated under vacuum to give ethyl (*E*)-4-fluorobut-2-enoate (2.50 g, crude) as a yellow oil and used into next step without further purification.

[02096] ^{1}H NMR (400MHz, chloroform-d) δ =7.04 - 6.89 (m, 1H), 6.12 (qd, *J* = 2.0, 16.0 Hz, 1H), 5.14 - 4.94 (m, 2H), 4.22 (q, *J* = 6.8 Hz, 2H), 1.30 (t, *J* = 6.8 Hz, 3H).


[02097] Step B: (*E*)-4-fluorobut-2-enoic acid. A mixture of ethyl (*E*)-4-fluorobut-2-enoate (0.10 g, crude) and NaOH (121 mg, 3.03 mmol) in THF (1.00 mL) and H_2O (1.00 mL) was stirred at 25 °C for 2 hours. The pH value was adjusted to 1~3 by HCl (1N, 5.00 mL), extracted with ethyl acetate (3 × 10.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum to give (*E*)-4-fluorobut-2-enoic acid (0.02 g, 192 mmol, two steps 46%) as a yellow oil and used into next step without further purification.

[02098] ^{1}H NMR (400MHz, chloroform-d) δ = 8.37 - 7.31 (m, 1H), 7.15 - 7.01 (m, 1H), 6.15 (dd, J=1.6, 16.0 Hz, 1H), 5.22 - 4.96 (m, 2H).


[02099] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of (*E*)-4-fluorobut-2-enoic acid (7.32 mg, 70.4 umol, 2 eq) and Py (8.35 mg, 106 umol, 8.52 uL, 3.00 eq) in acetonitrile (1.00 mL) was added MsCl (8.06 mg, 70.4 umol, 5.45 uL, 2.00 eq) at 0 °C. After stirred at 0 °C for 1 hour, 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.02 g, 35.2 umol, 1.00 eq, HCl) was added into the mixture. The mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (5.00 mL), extracted with ethyl acetate (3 × 5.00 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12min). The desired fraction was collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 479, 3.01 mg, 4.82 umol, 14 % yield, 98.9% purity) as a brown solid. LCMS [ESI, M+1]: 618.

[02100] ^{1}H NMR (400MHz, CHLOROFORM-d) δ = 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 7.6, 12.8 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.17 (m, 1H), 7.09 - 6.91 (m, 1H), 6.59 (br d, *J* = 15.6 Hz, 1H), 5.19 - 5.05 (m, 2H), 4.49 - 4.36 (m, 2H), 4.22 - 3.79 (m, 5H), 3.76 - 2.96 (m, 8H), 2.92 - 2.55 (m, 4H), 2.48 (d, *J* = 2.4 Hz, 3H), 2.29 (br d, *J* = 9.6 Hz, 1H), 2.06 (br d, *J* = 10.0 Hz, 1H), 1.83 - 1.71 (m, 3H).

EXAMPLE 480



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile



[02101] Insert: (*E*)-4-bromobut-2-enoyl chloride. To a solution of (*E*)-4-bromobut-2-enoic acid (930 mg, 5.64 mmol, 1.0 eq) in DCM (2.0 mL) was added $(COCl)_2$ (2.90 g, 22.9 mmol, 2.0 mL, 4.05 eq). The mixture was stirred at 60 °C for 12 hours. After completion, the mixture was concentrated under vacuum. The product (*E*)-4-bromobut-2-enoyl chloride (650 mg, crude) was obtained as yellow oil and used directly to the next step without further purification.


[02102] Step A: 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro- 1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 150 mg, 282 umol, 1.0 eq) in DCM (3.0 mL) was added Py (446 mg, 5.64 mmol, 455 uL, 20.0 eq) and (*E*)-4-bromobut-2-enoyl chloride (207 mg, 1.13 mmol, 4.0 eq) in DCM (1.0 mL). The mixture was stirred at 0 °C for 1 hour. After completion, the reaction mixture was concentrated under reduced pressure to give a residue. The product 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro- 1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude) was

obtained as brown oil and used into the next step without further purification. LCMS [ESI, M+1]: 680.


[02103] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 221 umol, 1.0 *eq*) in DCM (10.0 mL) was added K_2CO_3 (366 mg, 2.65 mmol, 12.0 *eq*), KI (1.83 mg, 11.0 umol, 0.05 *eq*) and 3-fluoropyrrolidine (277 mg, 2.21 mmol, 10.0 *eq*, HCl). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was adjusted pH~7 with saturated $NaHCO_3$ aqueous solution and extracted with EA (3 × 10 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04%NH_3•H_2O)-ACN]; B%: 60%-84%, 10 min). The residue was concentrated under reduced pressure and then lyophilization. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoropyrrolidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 480, 9.67 mg, 14.0 umol, 6% yield, 99.2% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 687.

[02104] ^{1}H NMR (400MHz, Chloroform-d) δ 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 7.26 (br d, *J* = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.17 (m, 1H), 7.05 - 6.92 (m, 1H), 6.57 - 6.42 (m, 1H), 5.32 - 5.11 (m, 1H), 5.10 - 4.50 (m, 1H), 4.47 - 4.35 (m, 2H), 4.19 - 4.00 (m, 2H), 3.95 - 3.75 (m, 2H), 3.65 - 3.55 (m, 1H), 3.47 - 3.28 (m, 3H), 3.24 - 3.05 (m, 4H), 3.04 - 2.86 (m, 4H), 2.85 - 2.71 (m, 2H), 2.70 - 2.50 (m, 3H), 2.47 - 2.45 (m, 3H), 2.32 - 2.15 (m, 2H), 2.14 - 2.02 (m, 2H), 1.87 - 1.67 (m, 4H).

EXAMPLE 481



[02105] 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile



[02106] Insert: (*E*)-4-bromobut-2-enoyl chloride. To a solution of (*E*)-4-bromobut-2-enoic acid (1 g, 6.06 mmol, 1.0 *eq*) in DCM (5.0 mL) was added oxalyl dichloride (7.25 g, 57.1 mmol, 5.0 mL, 9.4 *eq*). The mixture was stirred at 60 °C for 12 hours. After completion, the reaction mixture was concentrated under reduced pressure to give (*E*)-4-bromobut-2-enoyl chloride (850 mg, crude) as yellow oil which was used for the next step without further purification.


[02107] Step A: Intermediate 71, 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (310 mg, 414 umol, 1.0 *eq*) in dioxane (4.0 mL) was added HCl/dioxane (4.0 M, 4.0 mL, 39.0 *eq*) at 25 °C. The mixture was stirred at 25 °C for 0.5 hour. After completion, the reaction mixture was quenched by saturated $NaHCO_3$ aqueous solution (20.0 mL), and then extracted with EA (3 × 40.0 mL). The combined organic layers were washed with saturated NaCl aqueous solution (100.0 mL), dried over Na_2SO_4, filtered and concentrated to give a residue 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (250 mg, crude) as yellow solid. The crude product was used into the next step without further purification. LCMS [ESI, M+1]: 532.

[02108] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 150 mg, 282 umol, 1.0 *eq,* crude) in DCM (6.0 mL) was added Py (446 mg, 5.6 mmol, 455 uL, 20.0 *eq*) and (*E*)-4-bromobut-2-enoyl chloride (207 mg, 1.2 mmol, 4.0 *eq,* crude) in DCM (1.0 mL). The mixture was stirred at 0 °C for 1 hour. Then K_2CO_3 (779 mg, 5.6 mmol, 20.0 *eq*), KI (4.6 mg, 28.2 umol, 0.1 *eq*) and 3-fluoroazetidine (472 mg, 4.2 mmol, 15.0 *eq*, HCl) was added at 0 °C. Then the mixture was stirred at 25 °C for 12 hours. After completion, the mixture was filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25 mm*10 um; mobile phase: [water (10.0 mM NH_4HCO_3)-ACN]; B%: 55%-85%, 10 min.) and lyophilization to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 481, 10.8 mg, 15.7 umol, 6% yield, 98% purity) as yellow solid. LCMS [ESI, M+1]: 673.


[02109] SFC Conditions: 100% .e.e.

[02110] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.77 (d, *J* = 8.0 Hz, 1 H), 7.63 (t, *J* = 7.8 Hz, 1 H), 7.54 (d, *J* = 7.2 Hz, 1 H), 7.50-7.43 (m, 1 H), 7.35 (t, *J* = 7.8 Hz, 1 H), 7.26 - 7.21 (m, 1 H), 6.89 (d, *J* = 15.2 Hz, 1 H), 6.42 (d, *J* = 14.8 Hz, 1 H), 5.26-4.62 (m, 1 H), 5.11 (t, *J* = 5.2 Hz, 1 H), 4.80 - 4.37 (m, 2 H), 4.20 - 4.08 (m, 2 H), 3.92 (br d, *J* = 17.6 Hz, 1 H), 3.86 - 3.71 (m, 3 H), 3.60 (s, 1 H), 3.52 - 3.47 (m, 1 H), 3.45 - 3.33 (m , 1 H), 3.28 - 3.21 (m, 3 H), 3.16 - 3.11 (m, 3 H), 3.03 (dd, *J* = 8.4, 16.8 Hz, 1 H), 2.82 - 2.60 (m, 4 H), 2.49 (d, *J* = 2.8 Hz, 3 H), 2.37 - 2.25 (m, 1 H), 2.09 - 2.03 (m, 1 H), 1.86 - 1.83 (m, 1 H), 1.78 - 1.76 (m, 3 H).

EXAMPLE 482



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-[methyl(2,2,2-trifluoroethyl)amino]but-2-enoyl]piperazin-2-yl]acetonitrile




[02111] Insert: (*E*)-4-bromobut-2-enoyl chloride. A solution of (*E*)-4-bromobut-2-enoic acid (600 mg, 3.64 mmol, 1.0 *eq*) in $(COCl)_2$ (10.2 g, 80.0 mmol, 7.0 mL, 22.0 *eq*) and DCM (7.0 mL) was stirred at 70 °C for12 hours. After completion, the reaction mixture was concentrated to give (*E*)-4-bromobut-2-enoyl chloride (500 mg, crude) as yellow oil. The crude product was used for the next step without further purification.

[02112] Step A: 2-[(2*S*)-1-[(*E*)- 4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 188 umol, 1.0 *eq*) and pyridine (119 mg, 1.50 mmol, 121 uL, 8.0 *eq*) in DCM (2.0 mL) was added (*E*)-4-bromobut-2-enoyl chloride (138 mg, 752 umol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (130 mg, crude) as yellow oil. LCMS [ESI, M+1]: 678, 680.


[02113] Step B: 2-[(2*S*)-4-[7- (8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-[methyl(2,2,2-trifluoroethyl)amino]but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl] -4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (128 mg, 189 umol, 1.0 *eq*), K_2CO_3 (130 mg, 943 umol, 5.0 *eq*) and KI (9.39 mg, 56.6 umol, 0.30 *eq*) in DCM (3.0 mL) was added 2,2,2-trifluoro-N-methyl-ethanamine (213 mg, 1.88 mmol, 10.0 *eq*) in portions. The mixture was stirred at 0-25 °C for 12 hours. After completion, the mixture was concentrated under vacuum. The obtained product was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.04% $NH_3 \cdot H_2O$)-ACN]; B%: 70%-100%, 10 min) to give title compound 2-[(2*S*)-4-[7- (8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-[methyl(2,2,2-trifluoroethyl)amino]but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 482, 2.87 mg, 3.84 umol, 2% yield, 95% purity) as white solid. LCMS [ESI, M+1]: 711.

[02114] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (br d, *J* = 7.6 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.18 (m, 1H), 6.95 -6.79 (m, 1H), 6.54 - 6.38 (m, 1H), 5.12 - 4.50 (m, 1H) , 4.48 - 4.35 (m, 2H), 4.24 - 3.99 (m, 3H), 3.96 - 3.78 (m, 2H), 3.77 - 3.64 (m, 1H), 3.61 - 3.53 (m, 1H), 3.52 - 3.34 (m, 3H), 3.33 - 2.97 (m, 7H), 2.92 - 2.76 (m, 1H), 2.75 -2.65 (m, 1H), 2.63 - 2.55 (m, 1H), 2.51 (s, 3H), 2.49 (br d, *J* = 3.2 Hz, 3H), 2.35 - 2.25 (m, 1H), 2.13 - 1.99 (m, 1H), 1.89 - 1.67 (m, 3H).

EXAMPLE 483



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(4-hydroxybut-2-ynoyl)piperazin-2-yl]acetonitrile




[02115] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(4-hydroxybut-2-ynoyl)piperazin-2-yl]acetonitrile. To a solution of 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid (129 mg, 564 umol, 1.50 eq) and DIEA (194 mg, 1.50 mmol, 262 uL, 4.00 eq) in DMF (2.00 mL) was added HATU (214 mg, 564 umol, 1.50 eq) at 0 °C. After stirred at 0 °C for 10 mins, 2-[(2*S*)-4-[7-(8-


chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.20 g, 376 umol, 1.00 eq) was added into the mixture. After stirred at 25 °C for 12 hours, the mixture was diluted with ethyl acetate (10.0 mL), washed with brine (3 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.10 %)/acetonitrile]. The desired fractions were collected, neutralized with saturated sodium bicarbonate (5.00 mL) to pH > 7 and extracted with ethyl acetate (3 × 20.0 mL). The organic layers were washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC column: Phenomenex Synergi C18 150*25*10um; mobile phase: [water (0.225%, FA) - ACN]; B%: 10% - 40%, 10 min. The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(4-hydroxybut-2-ynoyl)piperazin-2-yl]acetonitrile (EXAMPLE 483, 10.1 mg, 15.3 umol, 4.1 % yield, 99.6% purity, FA) as a yellow solid. LCMS [ESI, M+1]: 614.


[02116] ^{1}H NMR (400MHz, Acetic acid-d4) δ = 7.82 (d, *J* = 8.4 Hz, 1H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.56 (d, *J* = 7.6 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 1H), 7.42 - 7.31 (m, 2H), 5.14 - 4.73 (m, 4H), 4.70 - 4.23 (m, 5H), 4.01 - 3.81 (m, 3H), 3.80 - 3.51 (m, 3H), 3.49 - 3.17 (m, 4H), 3.09 (m, 5H), 2.81 - 2.63 (m, 1H), 2.45 - 2.34 (m, 1H), 2.22 - 2.08 (m, 3H).

EXAMPLE 484



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4,4-difluorobut-2-enoyl]piperazin-2-yl]acetonitrile





[02117] Step 1: 4,4-difluoro-3-hydroxy -butanoate. To a solution of ethyl 4,4-difluoro-3-oxo-butanoate (5.00 g, 30.1 mmol, 1.00 eq) in toluene (150 mL) was added $NaBH_4$ (1.20 g, 31.7 mmol, 1.05 eq) at 0 °C. After stirred at 25 °C for 4 hours, the mixture was diluted with water (50.0 mL) at 0 °C and extracted with ethyl acetate (3 × 100 mL). The extracts were washed with brine (1 × 100 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give ethyl 4,4-difluoro-3-hydroxy-butanoate (4.30 g, crude) as a yellow oil and used into next step without further purification.

[02118] ^{1}H NMR (400MHz, DMSO-d6) δ = 6.05 - 5.87 (m, 1H), 5.86 - 5.72 (m, 1H), 4.11 - 4.01 (m, 2H), 2.57 (dd, *J* = 4.0, 15.6 Hz, 1H), 2.38 (dd, *J* = 9.2, 15.6 Hz, 1H), 1.21 - 1.17 (m, 3H).

[02119] Step 2: ethyl (*E*)-4,4-difluorobut-2-enoate. To a solution of ethyl 4,4-difluoro-3-hydroxy-butanoate (3.00 g, crude) in dichloromethane (20.0 mL) was added TEA (1.81 g, 17.8 mmol, 2.48 mL,) and MsCl (3.68 g, 32.1 mmol, 2.49 mL) at 0 °C. After stirred for 4 hours, to the mixture was addded TEA (3.61 g, 35.68 mmol, 4.97 mL, 2 eq) 0 °C. After warmed up to 25 °C and stirred for 12 hours, the mixture was diluted with water (10.0 mL), washed with HCl (1N, 1 × 20.0 mL) and brine (1 × 20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum

to give ethyl (*E*)-4,4-difluorobut-2-enoate (1.40 g, 9.33 mmol, two steps 44 % yield) as a colourless oil and used into next step with further purification.

[02120] ^{1}H NMR (400MHz, chloroform-d) δ = 6.81 (m, 1H), 6.29 (dt, *J* = 2.8, 1.6 Hz, 1H), 6.23 (dd, *J* = 4.0, 55.2 Hz, 1H), 4.25 (q, *J* = 7.2 Hz, 2H), 1.31 (t, *J* = 7.2 Hz, 3H).

[02121] Step 3: (*E*)-4,4-difluorobut-2-enoic acid. A mixture of ethyl (*E*)-4,4-difluorobut-2-enoate (1.30 g, 8.66 mmol, 1.00 eq) and NaOH (1.39 g, 34.6 mmol, 4.00 eq) in THF (5.00 mL) and H_2O (5.00 mL) was stirred at 25 °C for 2 hours. The mixture was acidified with HCl (2N, 20.0 mL) to pH = 1 ~ 3 and extracted with ethyl acetate (3 × 20.0 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give (*E*)-4,4-difluorobut-2-enoic acid (0.35 g, 2.87 mmol, 33% yield) as a yellow solid and used into next step without further purification.


[02122] ^{1}H NMR (400MHz, chloroform-d) δ = 6.92 (m, 1H), 6.32 (dtd, *J* = 0.8, 2.8, 16.8 Hz, 1H), 6.27 (dtd, *J* = 1.2, 54.8 Hz, 4.0, 1H).

[02123] Step A: 2-[(2$_S$)-4-[7-(8-chloro-1-naphthyl)-2-[[(2$_S$)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5$_H$-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4,4-difluorobut-2-enoyl]piperazin-2-yl]acetonitrile. A mixture of (*E*)-4,4-difluorobut-2-enoic acid (68.8 mg, 564 umol, 1.50 eq), EDCI (108 mg, 564 umol, 1.50 eq) and HOBt (50.8 mg, 376 umol, 1.00 eq) in Py (3 mL) was stirred at 0 °C for 15 min, then 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 0.20 g, 376 umol, 1.00 eq) was added into the mixture. After stirred at 0 °C for 1 hour and 25 °C for 1 hour, the mixture was diluted with water (10.0 mL), extracted with ethyl acetate (1 × 10.0 mL). The extracts were washed with brine (1 × 10.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash [water (FA, 0.10 %)/acetonitrile]. The desired fractions were collected and the mixture was neutralized with saturated sodium bicarbonate (5.00 mL), extracted with ethyl acetate (3 × 20.0 mL). The organic layers were washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 55% - 85%, 12 min). The desired fractions were collected and lyophilized to give title


compound 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4,4-difluorobut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 484, 66.9 mg, 104 umol, 28% yield, 98.7% purity) as a yellow solid. LCMS [ESI, M+1]: 636.

[02124] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 7.6, 12.8 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.27 - 7.18 (m, 1H), 6.88 - 6.71 (m, 2H), 6.45 - 6.12 (m, 1H), 5.17 - 4.59 (m, 1H), 4.55 - 4.41 (m, 1H), 4.40 - 4.33 (m, 1H), 4.21 - 3.69 (m, 5H), 3.64 - 3.32 (m, 2H), 3.31 - 2.97 (m, 5H), 2.96 - 2.52 (m, 4H), 2.47 (d, *J* = 1.6 Hz, 3H), 2.33 - 2.23 (m, 1H), 2.11 - 2.00 (m, 1H), 1.90 - 1.77 (m, 3H).

EXAMPLE 485



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[2-(methoxymethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile



[02125] Step 1: 1-(2-(ethoxycarbonyl)allyl)-1,4-diazabicyclo[2.2.2]octan-1-ium bromide. To ethyl 2-(bromomethyl)prop-2-enoate (15 g, 77.7 mmol, 1 *eq*) in THF (5 mL) was added DABCO (10.5 g, 93.6 mmol, 10.3 mL, 1.20 *eq*) and the resulting mixture was stirred at 25 °C for 2 hours. The precipitate was formed and filtered under nitrogen atmosphere. The filter cake was collected to give 1-(2-(ethoxycarbonyl)allyl)-1,4-diazabicyclo[2.2.2]octan-1-ium bromide (15 g, 49.6 mmol, 64% yield) as a light yellow solid which was used directly in the next step without further purification.

[02126] Step 2: ethyl 2-(methoxymethyl)prop-2-enoate. A mixture of 1-(2-(ethoxycarbonyl)allyl)-1,4-diazabicyclo[2.2.2] octan-1-ium bromide (15 g, 49.6 mmol, 1 *eq*) and TEA (10.5 g, 104 mmol, 14.5 mL, 2.09 *eq*) in MeOH (150 mL) was stirred at 25 °C for 16 hours. The solvent was evaporated under vacuum (25 °C). The residue was dissolved into DCM (40 ml) and then washed with 5% aqueous citric acid solution (1 × 40 mL) and saturated sodium bicarbonate aqueous solution (1 × 40 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum at 25 °C to give ethyl 2-(methoxymethyl)prop-2-enoate (5.3 g, 36.8 mmol, 74% yield) as a yellow liquid which was used directly in the next step without further purification.

[02127] Step 3: 2-(methoxymethyl)prop-2-enoic acid. To a solution of ethyl 2-(methoxymethyl)prop-2-enoate (5.1 g, 35.4 mmol, 1 *eq*) in THF (71 mL) was added a solution of NaOH (5.66 g, 142 mmol, 4 *eq*) in H_2O (71 mL) at 5 °C. The mixture was stirred at 25 °C for 2 hours. Upon completion, the THF was evaporated under vacuum. The pH of the mixture was adjusted to 3 with 1 M HCl and extracted with EtOAc (3 × 70 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give 2-(methoxymethyl)prop-2-enoic acid (3.4 g, 26.4 mmol, 75% yield, 90% purity) as a light yellow liquid which was used directly in the next step without further purification.


[02128] ^{1}H NMR (400 MHz, chloroform-d) δ = 6.45 (d, *J* = 1.2 Hz, 1H), 5.98 (q, *J* = 1.6 Hz, 1H), 4.16 (t, *J* = 1.2 Hz, 2H), 3.42 (s, 3H).

[02129] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[2-(methoxymethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-(methoxymethyl)prop-2-enoic acid (175 mg, 1.50 mmol, 2 *eq*) and DIEA (389 mg, 3.01 mmol, 524 uL, 4 *eq*) in DCM (8 mL) was added HATU (429 mg, 1.13 mmol, 1.5 *eq*) at -40 °C. After stirred at -40 °C for 10 minutes, 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 400 mg, 752 umol, 1 *eq*) was added into the mixture. The mixture was stirred at -40 °C for 20 minutes, 0 °C for 0.5 hour and 25 °C for 1 hour. Upon completion, to the mixture was added water (10 mL) and extracted with DCM (2 × 20 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 100/1 to 40/1) and purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[2-(methoxymethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 485, 73.0 mg, 116 umol, 15% yield, 98.9% purity) as a off-white solid. LCMS [ESI, M+1]:630.


[02130] SFC condition: Column: Chiralpak AS-3 100×4.6mm I.D., 3um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm.

[02131] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (br d, *J*= 8 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.45 (td, *J* = 7.6, 13.2 Hz, 1H), 7.37 - 7.30 (m, 1H), 7.26 - 7.17 (m, 1H), 5.51 (s, 1H), 5.32 (br s, 1H), 5.19 - 4.58 (m, 1H), 4.48 - 4.34 (m, 2H), 4.23 - 4.07 (m, 4H), 4.06 - 3.78 (m, 3H), 3.64 - 3.55 (m, 1H), 3.39 (s, 3H), 3.36 - 2.72 (m, 8H), 2.71 - 2.53 (m, 2H), 2.47 (s, 3H), 2.35 - 2.22 (m, 1H), 2.14 - 1.98 (m, 1H), 1.90 - 1.73 (m, 3H).

EXAMPLE 486



2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile



Step A: 2- tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate. In a round bottom flask, a solution of tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5 g, 9.487 mmol) in dioxane (94.87 ml, 9.487 mmol) was sparged with argon and (S)-(1-methylpyrrolidin-2-yl)methanol (3.278 g, 28.46 mmol), Cs_2CO_3 (9.273 g, 28.46 mmol), Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.8078 g, 0.9487 mmol) were sequentially added under Argon and sparged for an additional 5 minutes. The reaction mixture was capped and heated at 100°C overnight. The reaction was filtered through GF/F paper and concentrated in vacuo. The concentrate was purified on the Combi Flash (0-12% MeOH in DCM with 2% NH_4OH) to provide tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.425 g, 8.508 mmol, 89.68 % yield). ESI+APCI MS m/z 606.4 $[M+H]^+$.


Step B : benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (5.4 g, 8.915 mmol) was dissolved in dichloromethane (89.15 ml, 8.915 mmol) and treated with Hydrochloric Acid (4.0M solution in 1,4-dioxane) (11.14 ml, 44.57 mmol). The reaction stirred at room temperature for 1 hour. The reaction was diluted with more DCM and 1M NaOH and the layers separated. The organics were next washed with brine, dried over Na_2SO_4 and concentrated in vacuo to give benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.364 g, 8.631 mmol, 96.82 % yield).. ESI+APCI MS m/z 506.3 $[M+H]^+$.

Step C : 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: In a round bottom flask, a solution of benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (4.364 g, 8.631 mmol) in dioxane (43.15 ml, 8.631 mmol) was sparged with Argon for 5 minutes. 1-Bromo-2,3-

dimethylbenzene (5.851 ml, 43.15 mmol), Cs_2CO_3 (14.06 g, 43.15 mmol), and Methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (0.7348 g, 0.8631 mmol) were sequentially added under Argon and sparged for an additional 5 min. The reaction mixture was capped and heated at 100°C ON. The reaction was cooled to room temperature. Ethyl acetate was added and the reaction filtered through GF/F paper and concentrated in vacuo. The concentrate was purified twice via normal phase chromatography on the CombiFlash using 0-15% MeOH in DCM with 2% NH_4OH as eluent. Fractions containing desired product were collected and concentrated in vacuo to give 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.411 g, 0.8641 mmol, 100.1 % yield). ESI+APCI MS m/z 476.3 $[M+H]^+$.

[02132] Step D : 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (200 mg, 0.420 mmol), 4,4,4-Trifluorocrotonic Acid (118 mg, 0.841 mmol), DIEA (367 µl, 2.10 mmol) in DCM (4205 µl, 0.420 mmol) was added HATU (240 mg, 0.631 mmol) and the resulting mixture was stirred at room temperature for 5 hours. . The reaction mixture was washed with Brine and the aqueous layer extracted with DCM (2x). The combined organic layers were dried over Na_2SO_4, concentrated, diluted in 60:40 ACN:H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and free based with saturated bicarb and the organics extracted with DCM. The organics were dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile (EXAMPLE 486, 28 mg, 0.0468 mmol, 11.1 % yield). ESI+APCI MS m/z 598.3 $[M+H]^+$.


EXAMPLE 487



2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(trifluoromethyl)acryloyl)piperazin-2-yl)acetonitrile

[02133] 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(trifluoromethyl)acryloyl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 486** substituting 2-(Trifluoromethyl)propenoic acid for 4,4,4-Trifluorocrotonic Acid in Step D. ESI+APCI MS m/z 598.3 $[M+H]^+$.


EXAMPLE 488




2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(hydroxymethyl)acryloyl)piperazin-2-yl)acetonitrile

[02134] 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(hydroxymethyl)acryloyl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 486** substituting 2-(hydroxymethyl)prop-2-enoic acid for 4,4,4-Trifluorocrotonic Acid in Step D. ESI+APCI MS m/z 560.3 $[M+H]^+$.

EXAMPLE 489




2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile




[02135] Step A: 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile: To a solution of 2-((S)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (50 mg, 0.1051 mmol) in DCM (1 mL) was added (E)-4-methoxybut-2-enoic acid (24.41 mg, 0.2102 mmol), N-ethyl-N-isopropylpropan-2-amine (0.03662 ml, 0.2102 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium PF_6 (59.96 mg, 0.1577 mmol) and the reaction mixture stirred at room temperature for 4 hours. Water (1 mL) was next added and the reaction mixture stirred for 5 minutes. The mixture was divided between EtOAc (10 mL) and 0.5M $NaHCO_3$ (5 mL) and the layers separated. The organics were washed with brine (3 mL), dried over Na_2SO_4 and evaporated in vacuo. The residue was chromatographed on silica gel using 3% MeOH + 0.3% NH_4OH to 4% MeOH + 0.4% NH_4OH as eluent to give title compound (EXAMPLE 489, 26 mg, 43%). ESI+APCI MS m/z 574.4 $[M+H]^+$.

EXAMPLE 490



2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile




[02136] Step A: benzyl (S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a solution ofbenzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (0.6 g, 1.2 mmol) in dioxanes (10 mL) was added 1-bromo-8-chloronaphthalene (0.37 g, 1.5 mmol) and the reaction degassed with Ar for 15 minutes followed by addition of Cs_2CO_3 (1.2 g, 3.6 mmol), $Pd_2(dba)_3$ (0.22 g, 0.24 mmol) and 2-Dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl (0.11 g, 0.24 mmol) and the reaction heated to 100°C for overnight. The reaction was next filltered through GFF paper and the filtrated concentrated in vacuo. The residue was next chromatographed using 1→10% (MeOH+2% NH_4OH)/DCM to give benzyl (S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.20 g, 0.30 mmol, 25 % yield). ESI+APCI MS m/z 666.2 $[M+H]^+$.


[02137] Step B: 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (0.17 g, 0.255 mmol) in THF (30 mL) was purged with N_2 followed by addition of Pd/C (0.0272 g, 0.255 mmol). The reaction was evacuated by vacuum and backfilled with H_2 3x and the mixture was stirred for 3 days at room temperature. The reaction was again purged with N_2 followed by filtering through celite and the filtrate concentrated in vacuo. The material used crude in the next reaction. ESI+APCI MS m/z 532.2 $[M+H]^+$.

[02138] Step C: 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile :To a solution of 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.055 g, 0.10 mmol) in DCM (20 mL) was added N-ethyl-N-isopropylpropan-2-amine (0.040 g, 0.31 mmol), (E)-4,4,4-trifluorobut-2-enoic acid (0.017 g, 0.12 mmol) and 1-Propanephosphonic acid cyclic anhydride (0.033 g, 0.10 mmol) and the reaction stirred at room temperature for 30 minutes. Next additional TEP3 and acid (0.24 mmol) were added and and the reaction an addition 1 hour. The organics were next washed with 1 N NaOH, brine, dried over $MgSO_4$ and concentrated in vacuo. The material was chromatographed 2x on normal phase silica (1→ 10% (MeOH+2% NH_4OH)/DCM) followed by purification by gilson reverse prep HPLC using 5→95% ACN/water with 0.1% TFA as additive. The PURE fractions were poured into basic water and extracted into EtOAc. The organics were washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give title compound 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile (EXAMPLE 490, 0.0094 g, 0.014 mmol, 14 % yield). ESI+APCI MS m/z 654.2 $[M+H]^+$.

EXAMPLE 491




2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile



[02139] Step A: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (2932 µl, 0.293 mmol) was added 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (150 mg, 0.293 mmol) and Hunig's base (102 µl, 0.586 mmol). The reaction mixture was vigorously stirred while (E)-4,4,4-trifluorobut-2-enoic acid (49.3 mg, 0.352 mmol) was added in one portion. Next, 1-Propanephosphonic acid cyclic anhydride (262 µl, 0.440 mmol) was added slowly to the stirring mixture. The reaction was stirred for 2 hours at 0°C. The reaction was treated with basic water and the aqueous layer extracted with EtOAc (3X). The combined organics were concentrated in vacuo and resuspended in a 60:40 mixture of ACN: H_2O and purified on the Gilson (reverse prep HPLC), eluting with 5-->95% ACN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between saturated

bicarb and DCM. The aqueous layer was extracted with DCM two more times. The organic layers were combined, dried over Na_2SO_4 and concentrated in vacuo to give title compound 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4,4,4-trifluorobut-2-enoyl)piperazin-2-yl)acetonitrile (EXAMPLE 491, 74.5 mg, 0.118 mmol, 40.1 % yield). ESI+APCI MS m/z 634.3 $[M+H]^+$.


EXAMPLE 492



2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(trifluoromethyl)acryloyl)piperazin-2-yl)acetonitrile

[02140] 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-(trifluoromethyl)acryloyl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 491** substituting 2-(trifluoromethyl)acrylic acid for (E)-4,4,4-trifluorobut-2-enoic acid in Step A. ESI+APCI MS m/z 634.2 $[M+H]^+$.


EXAMPLE 493



2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-2-yl)acryloyl)piperazin-2-yl)acetonitrile

[02141] 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-2-yl)acryloyl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 491** substituting 3-(Pyridin-2-yl)acrylic acid for (E)-4,4,4-trifluorobut-2-enoic acid in Step A. ESI+APCI MS m/z 643.3 $[M+H]^+$.


EXAMPLE 494



2-((S)-1-((E)-3-(1-methyl-1H-pyrazol-4-yl)acryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02142] 2-((S)-1-((E)-3-(1-methyl-1H-pyrazol-4-yl)acryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 491** substituting (2E)-3-(1-Methyl-1H-pyrazol-4-yl)acrylic acid for (E)-4,4,4-trifluorobut-2-enoic acid in Step A. ESI+APCI MS m/z 646.4 $[M+H]^+$.


EXAMPLE 495




2-((S)-1-((E)-4,4-difluorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02143] 2-((S)-1-((E)-4,4-difluorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 491** substituting 4,4-Difluorobut-2-enoic acid for (E)-4,4,4-trifluorobut-2-enoic acid in Step A. ESI+APCI MS m/z 616.3 $[M+H]^+$.

EXAMPLE 496




2-((S)-4-(2-(((S)-1-methylpiperidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-3-yl)acryloyl)piperazin-2-yl)acetonitrile




[02144] Step A: To a solution of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (0.12 g, 0.23 mmol) in DCM (10 mL) N-ethyl-N-isopropylpropan-2-amine (0.13 ml, 0.70 mmol), (E)-3-(pyridin-3-yl)acrylic acid (0.070 g, 0.47 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (0.30 g, 0.47 mmol) and the reaction stirred at room temperature for 3 hours. The reaction was next poured into 1N NaOH and the layers separated. The organics were next washed with brine, dried over MgSO4 and concentrated in vacuo. The material was next purified by Gilson reverse prep HPLC eluting with 5→95 ACN/water with 0.1% TFA as modifier. Fractions containing product were pooured into 1N NaOH and the aqueous layer extracted with EtOAc (3X). The combined organics were washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give title compound 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-3-yl)acryloyl)piperazin-2-yl)acetonitrile (EXAMPLE 496, 0.040 g, 0.062 mmol, 27 % yield). ESI+APCI MS m/z 643.3 $[M+H]^+$.

EXAMPLE 497




2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(3-oxocyclopent-1-ene-1-carbonyl)piperazin-2-yl)acetonitrile




[02145] Step A: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(3-oxocyclopent-1-ene-1-carbonyl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.05863 mmol) and 3-oxocyclopent-1-enecarboxylic acid (9.612 mg, 0.07622 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (20.48 µl, 0.1173 mmol) and 1-propanephosphonic acid cyclic anhydride (52.35 µl, 0.08795 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(3-oxocyclopent-1-ene-1-carbonyl)piperazin-2-yl)acetonitrile (EXAMPLE 497, 2.3 mg, 0.003711 mmol, 6.329 % yield). ESI+APCI MS m/z 620.3 $[M+H]^+$.

EXAMPLE 498




2-((S)-1-((E)-4-chlorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02146] Step A: 2-((S)-1-((E)-4-chlorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (30 mg, 0.05863 mmol) and gamma-chlorocrotonic acid (10.60 mg, 0.08795 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (20.48 µl, 0.1173 mmol) and 1-propanephosphonic acid cyclic anhydride (55.84 µl, 0.09381 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound 2-((S)-1-((E)-4-chlorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 498, 4.5 mg, 0.007327 mmol, 12.50 % yield). ESI+APCI MS m/z 614.3 $[M+H]^+$.

EXAMPLE 499



(E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-N,N-dimethyl-4-oxobut-2-enamide




[02147] Step A: Ethyl (E)-4-(dimethylamino)-4-oxobut-2-enoate: Fumaric acid monoethyl ester (442 mg, 3.07 mmol) was diluted with DCM (5 mL) followed by the addition of oxalyl chloride (1533 µl, 3.07 mmol) and 1 drop of DMF. After stirring for 15 minutes, dimethylamine (4600 µl, 9.20 mmol) was added and the reaction was stirred for 3 hours. The reaction was diluted with ethyl acetate and water. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10-70% ethyl acetate/hexanes to afford ethyl (E)-4-(dimethylamino)-4-oxobut-2-enoate (382 mg, 2.23 mmol, 72.8 % yield). ESI+APCI MS m/z 172.1 $[M+H]^+$.

[02148] Step B: (E)-4-(dimethylamino)-4-oxobut-2-enoic acid: Ethyl (E)-4-(dimethylamino)-4-oxobut-2-enoate (382 mg, 2.23 mmol) was diluted with methanol (8 mL) followed by the addition of NaOH (4463 µl, 8.93 mmol). After stirring for 4 hours, the reaction was diluted with 2N HCl (4.5 mL) and extracted with ethyl acetate. The ethyl acetate was dried over MgSO4, filtered and concentrated to afford (E)-4-(dimethylamino)-4-oxobut-2-enoic acid.


[02149] Step C: (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-N,N-dimethyl-4-oxobut-2-enamide: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-

yl)acetonitrile (30 mg, 0.05863 mmol) was diluted with DMF followed by the addition of (E)-4-(dimethylamino)-4-oxobut-2-enoic acid (10.07 mg, 0.07036 mmol), DIEA (20.48 µl, 0.1173 mmol) and 1-propanephosphonic acid cyclic anhydride (52.35 µl, 0.08795 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-N,N-dimethyl-4-oxobut-2-enamide (EXAMPLE 499, 3.7 mg, 0.005810 mmol, 9.910 % yield). ESI+APCI MS m/z 637.3 $[M+H]^+$.

EXAMPLE 500



[02150] (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enamide




[02151] Step A: Ethyl (E)-3-cyanoacrylate: Ethyl cis-(beta-cyano)acrylate (1.0 g, 7.99 mmol) was diluted with ACN (30 mL), placed under nitrogen and heated to reflux for 3 days. The reaction was allowed to cool and then concentrated. The material was purified on silica gel eluting with hexanes to afford ethyl (E)-3-cyanoacrylate (300 mg, 2.40 mmol, 30.0 % yield).


[02152] Step B: (E)-4-amino-4-oxobut-2-enoic acid: Ethyl (E)-3-cyanoacrylate (300 mg, 2.40 mmol) was diluted with HCl (3996 µl, 24.0 mmol). The reaction was placed under nitrogen and heated to 100°C for 4 hours. The reaction was allowed to cool and then concentrated to afford (E)-4-amino-4-oxobut-2-enoic acid (214 mg, 1.86 mmol, 77.6 % yield).

[02153] Step C: (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enamide: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20 mg, 0.039 mmol), HATU (30 mg, 0.078 mmol) and (E)-4-amino-4-oxobut-2-enoic acid (9.0 mg, 0.078 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (14 µl, 0.078 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enamide (EXAMPLE 500, 2.9 mg, 0.0048 mmol, 12 % yield). ESI+APCI MS m/z 609.3 $[M+H]^+$.

EXAMPLE 501



(E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile




[02154] Step A: Ethyl (E)-3-cyanoacrylate: Ethyl cis-(beta-cyano)acrylate (1.0 g, 7.99 mmol) was diluted with ACN (30 mL), placed under nitrogen and heated to reflux for 3 days. The reaction was allowed to cool and then concentrated. The material was purified on silica gel eluting with hexanes to afford ethyl (E)-3-cyanoacrylate (300 mg, 2.40 mmol, 30.0 % yield).

[02155] Step B: (E)-3-cyanoacrylic acid: Ethyl (E)-3-cyanoacrylate (10 mg, 0.080 mmol) was diluted with HCl (133 µl, 0.80 mmol), placed under nitrogen and heated to 100°C. After stirring for 15 minutes the reaction was concentrated to afford (E)-3-cyanoacrylic acid (7.5 mg, 0.077 mmol, 97 % yield).


[02156] Step C: (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20 mg, 0.03909 mmol) and (E)-3-cyanoacrylic acid (5.312 mg, 0.05472 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (13.65 µl, 0.07817 mmol) and 1-propanephosphonic acid cyclic anhydride (34.90 µl, 0.05863 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on

silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound (E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile (EXAMPLE 501, 3.5 mg, 0.005925 mmol, 15.16 % yield). ESI+APCI MS m/z 591.3 $[M+H]^+$.

EXAMPLE 502



(Z)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile




[02157] Step A: (Z)-3-cyanoacrylic acid: Ethyl cis-(beta-cyano)acrylate (50 mg, 0.40 mmol) was diluted with HCl (200 µl, 1.2 mmol), placed under nitrogen and heated to 100°C. After stirring for 1 minute the reaction was cooled and concentrated to afford (Z)-3-cyanoacrylic acid (35 mg, 0.36 mmol, 90 % yield).


[02158] Step B: (Z)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20 mg,


0.03909 mmol) and (Z)-3-cyanoacrylic acid (6.071 mg, 0.06254 mmol) were diluted with DMF (400 uL) followed by the addition of DIEA (13.65 µl, 0.07817 mmol) and 1-propanephosphonic acid cyclic anhydride (39.56 µl, 0.06645 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over MgSO4, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH4OH) to afford title compound (Z)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-enenitrile (EXAMPLE 502, 2.1 mg, 0.003555 mmol, 9.095 % yield). ESI+APCI MS m/z 591.3 $[M+H]^+$.

EXAMPLE 503



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-(dimethylamino)-2-fluoro-but-2-enoyl]piperazin-2-yl]acetonitrile





[02159] Step 1: (*E*)-4-[tert-butoxycarbonyl(methyl)amino]-2-fluoro-but-2-enoic acid. To the solution of ethyl 2-diethoxyphosphoryl-2-fluoro-acetate (2 g, 8.26 mmol, 1.68 mL, 1 eq) and *tert*-butyl *N*-methyl-*N*-(2-oxoethyl)carbamate (2.15 g, 12.4 mmol, 1.5 eq) in THF (40 mL) was added NaH (661 mg, 16.5 mmol, 60% purity, 2 eq). The mixture was stirred at 25 °C for 1.5 hour. Upon completion, the reaction mixture was quenched by saturated NH_4Cl (8 mL) and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50mm*10 um;mobile phase: [water(0.225%FA)-ACN];B%: 20ACN%-50ACN%,30min; 50%min) to give (*E*)-4-[tert-butoxycarbonyl(methyl)amino]-2-fluoro-but-2-enoic acid (820 mg, 3.16 mmol, 38.3% yield, 90% purity) as a brown oil.

[02160] Step A: *tert*-butyl *N*-[(*E*)-4-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazin-1-yl]-3-fluoro-4-oxo-but-2-enyl]-*N*-methyl-carbamate. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 300 mg, 564 umol, 1 eq), (*E*)-4-[tert-butoxycarbonyl(methyl)amino]-2-fluoro-but-2-enoic acid (600 mg, 2.57 mmol, 4.56 eq) and DIEA (729 mg, 5.64 mmol, 982 uL, 10 eq) in DCM (10 mL) was added HATU (643 mg, 1.69 mmol, 3 eq) at 0 °C. The reaction mixture was stirred at 25 °C for 1 hour. Upon

completion, the reaction mixture was quenched by water (3 mL) and extracted with DCM (3 × 8 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed flash chromatography (FA condition: 60 % MeCN in water (0.1% FA)) to give *tert*-butyl *N*-[(*E*)-4-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazin-1-yl]-3-fluoro-4-oxo-but-2-enyl]-*N*-methyl-carbamate (330 mg, 404 umol, 72% yield, 91.5% purity) as a brown solid. LCMS [ESI, M+1]: 747.


[02161] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-2-fluoro-4-(methylamino)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl *N*-[(*E*)-4-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazin-1-yl]-3-fluoro-4-oxo-but-2-enyl]-*N*-methyl-carbamate (300 mg, 401 umol, 1 eq) in DCM (1 mL) was added TFA (915 mg, 8.03 mmol, 594 uL, 20 eq).The reaction mixture was stirred at 25 °C for 1hour. Upon completion, the reaction mixture was diluted by DCM (10 mL) and basified by saturated $NaHCO_3$ (8 mL).The mixture was extracted with DCM (3 × 10 mL).The combined organic layer was dried over Na_2SO_4 and concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-2-fluoro-4-(methylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (240 mg, 356 umol, 89% yield, 95.9% purity) as a brown solid which was used for next step without further purification. LCMS [ESI, M+1]: 647.

[02162] Step C: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-(dimethylamino)-2-fluoro-but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-2-fluoro-4-(methylamino)but-2-enoyl]piperazin-2-yl]acetonitrile (120 mg, 185 umol, 1 eq) and paraformaldehyde (83.5 mg, 927 umol, 5 eq), HCOOH (26.7 mg, 556 umol, 3 eq) in MeOH (5 mL) was added $NaBH_3CN$ (35.0 mg, 556 umol, 3 eq). The reaction mixture was stirred at 25 °C for 12 hours. Upon completion, the reaction mixture was quenched by water (0.5 mL) and filtered. The residue was purified by silica gel chromatography (EA:MeOH:NH_3•H_2O=50:1:0 to 10:1:0.1), then prep-HPLC(column: Phenomenex Gemini 150*25mm*10um;mobile phase:


[water(10mM NH_4HCO_3)-ACN];B%:50%-100%,10min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-(dimethylamino)-2-fluoro-but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 503, 26.7 mg, 40.2 umol, 22% yield, 99.5% purity) as a yellow solid. LCMS [ESI, M+1]: 661.

[02163] ^{1}H NMR (400MHz, chloroform-d) δ = 7.68 (d, *J*=8.0 Hz, 1H), 7.54 (t, *J*=7.2 Hz, 1H), 7.45 (d, *J*=7.2 Hz, 1H), 7.37 (td, *J*=7.6, 12.8 Hz, 1H), 7.26 (t, *J*=8.0 Hz, 1H), 7.19 - 7.08 (m, 1H), 5.81 - 5.60 (m, 1H), 5.04 - 4.41 (m, 1H), 4.40 - 4.25 (m, 2H), 4.16 - 3.91 (m, 3H), 3.88 - 3.71 (m, 2H), 3.66 - 3.46 (m, 2H), 3.36 (br d, *J*=10.8 Hz, 1H), 3.27 - 2.69 (m, 9H), 2.64 - 2.56 (m, 1H), 2.55 - 2.46 (m, 1H), 2.40 (d, *J*=2.4 Hz, 3H), 2.27 - 2.15 (m, 7H), 2.06 - 1.90 (m, 1H), 1.85 - 1.72 (m, 3H).

EXAMPLE 504



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[2-(trifluoromethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile




[02164] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[2-(trifluoromethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-(trifluoromethyl)prop-2-enoic acid (39.5 mg, 282 umol, 1.50 eq), 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy] -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 0.10 g, 188 umol, 1.00 eq) and DIEA (48.6 mg, 376 umol, 65.5 uL, 2.00 eq) in dichloromethane (0.20 mL) was added HATU (107 mg, 282 umol, 1.50 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the mixture diluted with water and the layer was separated. The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (FA, 0.1%)/acetonitrile] and prep HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 56%-86%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[2-(trifluoromethyl)prop-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 504, 13.1 mg, 19.6 umol, 10.5% yield, 97.9% purity) as a white solid. LCMS [ESI, M+1]: 654.

[02165] SFC condition: Column: Chiralcel OJ-3 50×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

[02166] ^{1}H NMR (400MHz, chloroform-*d*) δ = 7.76 (d, *J* = 8.4 Hz, 1H), 7.65 - 7.59 (m, 1H), 7.55 - 7.50 (m, 1H), 7.45 (td, *J* = 7.6, 10.0 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.18 (m, 1H), 6.18 (br s, 1H), 5.86 (br s, 1H), 5.11 (br s, 1H), 4.57 - 4.36 (m, 2H), 4.33 - 4.10 (m, 2H), 4.04 (br d, *J* = 12.8 Hz, 1H), 3.97 - 3.79 (m, 2H), 3.66 - 3.54 (m, 1H), 3.50 - 3.33 (m, 1H), 3.29 - 3.07 (m, 4H), 3.04 - 2.72 (m, 4H), 2.63 - 2.50 (m, 4H), 2.45 - 2.32 (m, 1H), 2.15 - 2.04 (m, 1H), 1.90 (br s, 3H).


EXAMPLE 505




2-((S)-1-((Z)-3-chloroacryloyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02167] 2-((S)-1-((Z)-3-chloroacryloyl)-4-(7-(2,3-dimethylphenyl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Was prepared following **Example 389** Step J, substituting (Z)-3-chloroacrylic acid for but-2-ynoic acid. ESI+APCI MS m/z 564.3 $[M+H]^+$.

EXAMPLE 506




2-((S)-1-((E)-4-fluorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02168] Step A: 2-((S)-1-((E)-4-fluorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (3909 µl, 0.39 mmol) was added 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (200 mg, 0.391 mmol) and triethylamine (136 µl, 0.98 mmol). The reaction

mixture was vigorously stirred while (E)-4-fluorobut-2-enoic acid (61.0 mg, 0.59 mmol) was added in one portion. Next, 1-propanephosphonic acid cyclic anhydride (175 µl, 0.59 mmol) was added slowly to the stirring mixture. The reaction was stirred at room temperature for 18hr. Water was added and the mixture was extracted with EtOAc (3x 15 mL). The extracts were combined and washed with water (1x 10 mL) and concentrated. The residue was purified by silica gel (5-18% MeOH in DCM with 0.25% NH_4OH) to provide title compound 2-((S)-1-((E)-4-fluorobut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 506, 89.3 mg, 0.15 mmol, 38 % yield). ESI+APCI MS m/z 598.3 $[M+H]^+$.

EXAMPLE 507




2-((S)-1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02169] Step A: 2-((S)-1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8 g, 15.63 mmol) was diluted with DMF (78.17 ml, 15.63 mmol), placed under nitrogen and cooled to 0°C. DIEA (6.827 ml, 39.09 mmol) was added followed by the addition of 2-Fluoroacrylic acid (2.112 g, 23.45 mmol) and the dropwise addition of 1-Propanephosphonic acid cyclic anhydride (9.307 ml, 15.63 mmol). The reaction was stirred at 0°C for 6 hours and left to stir for an additional 10 hours warming to ambient temperature. The reaction was poured into a 5% sodium bicarbonate solution and extracted twice with ethyl acetate. The ethyl acetate was washed with water, brine, dried over MgSO4, filtered and concentrated. The material was

purified on silica gel eluting with 1-10% methanol/DCM (1% NH4OH as additive) to afford title compound 2-((S)-1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 507, 6.6 g, 11.31 mmol, 72.32 % yield). ESI+APCI MS m/z 584.3 $[M+H]^+$.


EXAMPLE 508




2-((S)-1-(4-hydroxybut-2-ynoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02170] 2-((S)-1-(4-hydroxybut-2-ynoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: was prepared according to **Example 458**, Step D, substituting 4-((tert-butyldimethylsilyl)oxy)but-2-ynoic acid for but-2-ynoic acid. ESI+APCI MS m/z 594.3 $[M+H]^+$.

EXAMPLE 509



2-((S)-1-((E)-4-(1H-pyrazol-1-yl)but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02171] Step A: (E)-4-(1H-pyrazol-1-yl)but-2-enoic acid. A solution of 4-bromocrotonic acid (100 mg, 0.606 mmol) and pyrazole (37.1 mg, 0.546 mmol) in acetonitrile (1 ml, 19.1 mmol) was heated in a closed vial for 48h to 60°C with stirring. The resulted light-green solution was divided between water (5 mL) and EtOAc (15 mL), the organics were separated, the organic layer was washed with brine, dried over Na_2SO_4 and evaporated in vacuo. The material was chromatographed on silica gel in 2 to 5% MeOH/DCM + 0.2% TFA. The resulting solid was dissolved in minimal amount of 6M HCl and evaporated under slow N_2 flow. This material was used in the next step without further purification.


[02172] Step B: 2-((S)-1-((E)-4-(1H-pyrazol-1-yl)but-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. A stirred mixture of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (42.37 mg, 0.08281 mmol), (E)-4-(1H-pyrazol-1-yl)but-2-enoic acid (12.6 mg, 0.08281 mmol) and N,N-dimethylformamide (1 mL, 12.79 mmol) was cooled on ice-salt bath with stirring, and triethylamine (0.03463 mL, 0.2484 mmol) was added at once, followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide, 50% in EtOAc (0.07395 mL, 0.1242 mmol). The reaction mixture was allowed to warm up to r.t. over 5 min and was stirred at r.t. overnight. The reaction mixture was divided between 0.5M Na_2CO_3 (5 mL) and

EtOAc (10 mL), the organics were separated, the organic layer was washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo. The product was purified by silicia gel chromatography using 5%MeOH +0.5% NH_4OH in DCM to give title compound as a colorless solid (EXAMPLE 509, 11.46 mg, 23%). ESI+APCI MS m/z 646.3 $[M+H]^+$.

EXAMPLE 510



2-((S)-1-((E)-4-hydroxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02173] Step A: (E)-4-hydroxybut-2-enoic acid. To a stirred suspension of 4-bromocrotonic acid (4824 mg, 29.24 mmol) in water (48 mL) a 2M solution of potassium hydroxide (4.921 g, 87.72 mmol) was added dropwise and the resulted solution was heated to reflux for 5 min. The reaction mixture was left under a N_2 stream to cool and concentrate. The residue was cooled on ice bath, acidified with 4M H_2SO_4 to pH 1-2, the resulted suspension was evaporated in vacuo by half and then extracted with EtOAc (3*60 mL). The combined extracts


were dried over Na_2SO_4 and evaporated in vacuo. The material was purified by chromatography using 2 to 5% MeOH +0.2% TFA to afford the target acid as colorless crystals (2.165 g, 73%).

[02174] Step B: 2-((S)-1-((E)-4-hydroxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a stirred solution of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (100 mg, 0.1954 mmol), (2E)-4-hydroxybut-2-enoic acid (39.90 mg, 0.3909 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.06809 ml, 0.3909 mmol) in DCM (5 mL), O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-Tetramethyluronium hexafluorophosphate (111.5 mg, 0.2932 mmol) was added at once and the reaction mixture was stirred at r.t for 4 h. Water (1 mL) was added, the reaction mixture was stirred for 5 min and divided between EtOAc (10 mL) and sat. $NaHCO_3$ (5 mL). The organic layer was separated, washed with $NaHCO_3$, brine (5 mL each), dried over K_2CO_3 and evaporated in vacuo. The residue was chromatographed on silica gel with 5% MeOH +0.5% NH_4OH. Title compound as a colorless solid (EXAMPLE 510, 29 mg, 25%). ESI+APCI MS m/z 596.3 $[M+H]^+$.

EXAMPLE 511




2-((S)-1-((E)-4-methoxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02175] Step A: 2-((S)-1-((E)-4-methoxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. A stirred mixture of 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (250 mg, 0.4886 mmol), (E)-4-methoxybut-2-enoic acid (85.10 mg, 0.7329 mmol) and N,N-dimethylformamide (2 mL, 25.58 mmol) was cooled on an ice-salt bath and triethylamine (0.2043 mL, 1.466 mmol) was added at once, followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide, 50% in EtOAc (0.4363 mL, 0.7329 mmol). The reaction mixture was allowed to warm to r.t. over 5 min, and stirred at r.t. for 2h. The resulted solution was divided between 0.5M Na_2CO_3 (10 mL) and EtOAc (30 mL), the organic layer was separated, washed with water and brine (10 mL each), dried over Na_2SO_4 and evaporated in vacuo. The material was purified by silica gel chromatography using 5% MeOH +0.5% NH_4OH in DCM. The material was further purified by the reverse phase chromatography, Gilson, 25 to 75% MeCN/H_2O + 0.1% TFA. Target fractions were basified with excess of 2M Na_2CO_3 and extracted with DCM (3*50 mL). The combined organic extracts were washed with brine, dried over Na_2SO_4 and evaporated in vacuo. Title compound as a light-yellow solid (EXAMPLE 511, 123 mg, 41%). ESI+APCI MS m/z 610.3 $[M+H]^+$.

EXAMPLE 512



2-[(2*S*)-1-(2-methoxyprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02176] Step A: methyl 2,2-dimethoxypropanoate. To a solution of ethyl 2-oxopropanoate (4.00 g, 34.5 mmol, 3.81 mL, 1.00 eq) and trimethoxymethane (4.75 g, 44.8 mmol, 4.91 mL, 1.30 eq) in methanol (10.0 mL) was added H_2SO_4 (33.8 mg, 344 umol, 18.4 uL, 0.01 eq). After stirred at 65 °C for 4 hours, the pH value was adjusted > 7 by KOH (120 mg in 20.0 mL water) and extracted with ethyl acetate (3 × 20.0 mL). The organic layer was washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was distilled at 60 °C under oil pump to give methyl 2,2-dimethoxypropanoate (4.00 g, 27.0 mmol, 78% yield) as a colourless oil and used into next step without further purification.

[02177] ^{1}H NMR (400MHz, chloroform-d) δ = 3.81 (s, 3H), 3.28 (s, 6H), 1.52 (s, 3H).

[02178] Step B: methyl 2-methoxyprop-2-enoate. To a solution of methyl 2,2-dimethoxypropanoate (2.00 g, 13.5 mmol, 1.00 eq) in DMF (20.0 mL) was added P_2O_5 (1.05 g, 7.42 mmol, 458 uL, 0.55 eq) in portions. After heated to 100 °C for 1 hour, the mixture was diluted with saturated sodium bicarbonate (20.0 mL), extracted with isopropyl ether (3 × 30.0 mL), washed with brine (3 × 40.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was distilled under oil pump to give methyl 2-methoxyprop-2-enoate (0.65 g, 5.60 mmol, 41% yield) as a colorless oil and used into next step without further purification.

[02179] Step C: 2-methoxyprop-2-enoic acid. A mixture of methyl 2-methoxyprop-2-enoate (0.60 g, 5.17 mmol, 1.00 eq) and NaOH (827 mg, 20.7 mmol, 4.00 eq) in H_2O (5.00 mL) and THF (5.00 mL) was stirred at 60 °C for 1 hour. The mixture was adjusted to pH < 3 by concentrated HCl (10.0 mL) and extracted with ethyl acetate (3 × 20.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-methoxyprop-2-enoic acid (0.40 g, 1.96 mmol, 38% yield, 50% purity) as a pink oil and used into next step without further purification.

[02180] ^{1}H NMR (400MHz, chloroform-d) δ = 8.63 (br s, 1H), 5.52 (d, *J* = 2.8 Hz, 1H), 4.75 (d, *J* = 2.8 Hz, 1H), 3.70 (s, 3H).


[02181] Step D: 2-[(2*S*)-1-(2-methoxyprop-2-enoyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.14 g, 274 umol, 1.00 eq), 2-methoxyprop-2-enoic acid (112 mg, 1.09 mmol, 4.00 eq) and DIEA (141 mg, 1.09 mmol, 191 uL, 4.00eq) in dichloromethane (5.00 mL) was added HATU (208 mg, 547umol, 2.00 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the mixture was diluted with water (3.00 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (FA, 0.10%)/acetonitrile] and prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 60% - 90%, 12min). The desired fraction was collected and lyophilized to give title compound 2-[(2*S*)-1-(2-methoxyprop-2-enoyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-

yl]acetonitrile (EXAMPLE 512, 10.27 mg, 17.22 umol, 6.3% yield, 99.9% purity) as a off-white solid. LCMS [ESI, M+1]: 596.


[02182] SFC condition: "IC-3S_3_40_3ML Column: Chiralpak IC-3 100×4.6mm I.D., 3 um, Mobile phase: 40% methanol (0.05% DEA) in CO_2, Flow rate: 3mL/min, Wavelength: 220 nm".

[02183] ^{1}H NMR (400MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.45 - 7.31 (m, 2H), 7.27 - 7.17 (m, 2H), 5.05 - 4.61 (m, 1H), 4.48 (br s, 1H), 4.37 (td, *J* = 4.4, 10.0 Hz, 1H), 4.30 - 3.98 (m, 4H), 3.96 - 3.74 (m, 2H), 3.69 (br s, 3H), 3.59 - 3.28 (m, 2H), 3.27 - 2.93 (m, 6H), 2.92 (s, 3H), 2.88 - 2.51 (m, 4H), 2.47 (d, *J* = 3.2 Hz, 3H), 2.33 - 2.23 (m, 1H), 2.11 - 1.98 (m, 1H), 1.89 - 1.74 (m, 3H).

EXAMPLE 513



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-hydroxybut-2-enoyl]piperazin-2-yl]acetonitrile



[02184] Step 1: ethyl (*E*)-4-hydroxybut-2-enoate. To a solution of (*E*)-4-ethoxy-4-oxo-but-2-enoic acid (1.0 g, 7.29 mmol, 1.0 *eq*) in THF (6.0 mL) was added a solution of BH_3-Me_2S (10.0 M, 692 uL, 0.95 *eq*) in THF (8.0 mL) dropwise over 1 hour at -10°C. The reaction mixture was gradually warmed to 25 °C and stirred for 17 hours. After completion, the reaction mixture was quenched by addition water (30.0 mL) and extracted with Ethyl acetate (30.0 mL×3). The combined organic layers were washed with brine (30.0 mL×2), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. Compound ethyl (*E*)-4-hydroxybut-2-enoate (900 mg, crude) was obtained as colorless oil. The crude product was used directly in the next step without further purification.

[02185] Step 2: (*E*)-4-trityloxybut-2-enoate. A mixture of ethyl (*E*)-4-hydroxybut-2-enoate (900 mg, crude), [chloro(diphenyl)methyl]benzene (2.89 g, 10.4 mmol), DMAP (84.5 mg, 692 umol), TEA (1.4 g, 13.8 mmol, 1.9 mL) in DCM (5.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 25 °C for 1 hour under N_2 atmosphere. After completion, the reaction mixture was quenched by addition H_2O (10.0 mL) and extracted with Ethyl acetate (10.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column

chromatography (SiO_2, Petroleum ether/Ethyl acetate=20:1 to 15:1). Compound ethyl (*E*)-4-trityloxybut-2-enoate (340 mg, 913 umol, 13% yield) was obtained as colorless oil.

[02186] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.38 - 7.35 (m, 6 H), 7.26 - 7.22 (m, 6 H), 7.18 - 7.15 (m, 3 H), 6.88 (dt, *J* = 15.6, 3.6 Hz, 1 H), 6.29 (dt, *J* = 15.6, 2.2 Hz, 1 H), 4.16 (q, *J* = 7.1 Hz, 2 H), 3.72 (dd, *J* = 2.4, 2.0 Hz, 2 H), 1.25 (t, *J* = 7.0 Hz, 3 H).

[02187] Step 3: (E)-4-trityloxybut-2-enoic acid. To a solution of ethyl (*E*)-4-trityloxybut-2-enoate (170 mg, 456 umol, 1.0 *eq*) in MeOH (1.0 mL) was added solution of NaOH (54.5 mg, 1.37 mmol, 3.0 *eq*) in H_2O (0.5 mL) and then the mixture was stirred at 40 °C for 1 hour under N_2 atmosphere. After completion, the reaction mixture was quenched by addition 1M HCl at 0 °C until pH = 5, and then extracted with Ethyl acetate (8.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3:1 to 1:1). Compound (*E*)-4-trityloxybut-2-enoic acid (113 mg, 328 umol, 72% yield) was obtained as a white solid.

[02188] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.38 - 7.36 (m, 6 H), 7.26 - 7.24 (m, 5 H), 7.20 - 7.16 (m, 4 H), 7.0 (dt, *J* = 15.6, 3.6 Hz, 1 H), 6.32 (dt, *J* = 15.6, 2.0 Hz, 1 H), 3.76 (dd, *J* = 3.2, 2.4 Hz, 2 H).

[02189] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (Intermediate 71, 60.0 mg, 113 umol, 1.0 *eq*), (*E*)-4-trityloxybut-2-enoic acid (77.8 mg, 226 umol, 2.0 *eq*) and DIEA (73.0 mg, 564 umol, 98 uL, 5.0 *eq*) in DCM (2.0 mL) was added HATU (64 mg, 169 umol, 1.5 *eq*) in one portion at 0 °C under N_2. The mixture was stirred at 25°C for 1 hour. After completion, the reaction mixture was quenched by addition H_2O (8.0 mL) and then extracted with Ethyl acetate (10.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. Compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (150 mg,


crude) was obtained as a yellow solid, and the crude product was used directly in the next step without further purification. LCMS [ESI, M+1]: 858.

[02190] Step B: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-hydroxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (150 mg, crude) in DCM (1.0 mL) was added TFA (1.0 ml, 13.5 mmol).The mixture was stirred at 25°C for 1 hour. After completion, the reaction mixture was quenched by addition $NaHCO_3$ aqueous solution at 0 °C until pH = 8, and then extracted with Ethyl acetate (10.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25 mm*10 um; mobile phase: [water (0.04% NH_3H_2O + 10 mM NH_4HCO_3)-ACN]; B%: 48%-72%, 10min.) and lyophilization. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-hydroxybut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 513, 8.21 mg, 13.3 umol, 7.6% yield, 99.8% purity) was obtained as a white solid. LCMS [ESI, M+1]: 616.


[02191] SFC condition: 100% e.e.

[02192] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.68 (d, *J* = 8.0 Hz, 1 H), 7.70-7.33 (m, 1 H), 7.49 (dd, *J* = 6.8, 0.8 Hz, 1 H), 7.37 (dt, *J* = 11.98, 7.82 Hz, 1 H), 7.26 (t, *J* = 11.8 Hz, 1 H), 7.19 - 7.11 (m, 1 H), 6.99 (dt, *J* = 14.8, 3.4 Hz, 1 H), 6.56 (br s, 1 H), 5.02-4.57 (m, 1 H), 4.39-4.29 (m, 4 H), 4.12-4.06 (m, 1 H), 4.03-3.99 (m, 2 H), 3.85-3.72 (m, 2 H), 3.67-3.36 (m, 3 H), 3.24-3.09 (m, 2 H), 3.03-2.89 (m, 3 H), 2.73 (br s, 1 H), 2.63-2.61 (m, 1 H), 2.50 (br s, 1 H), 2.41 (s, 3 H), 2.25-2.19 (m, 1 H), 2.03-1.92 (m, 1 H), 1.70-1.60 (m, 3 H).

EXAMPLE 514



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-methoxyprop-2-enoyl)piperazin-2-yl]acetonitrile



[02193] Step 1: methyl 2,2-dimethoxypropanoate. To a solution of ethyl 2-oxopropanoate (4.00 g, 34.5 mmol, 3.81 mL, 1.00 eq) and trimethoxymethane (4.75 g, 44.8 mmol, 4.91 mL, 1.30 eq) in methanol (10.0 mL) was added H_2SO_4 (33.8 mg, 344 umol, 18.4 uL, 0.01 eq). After stirring at 65 °C for 4 hours, the reaction mixture was adjusted to pH value was adjusted > 7 by KOH aqueous (120 mg in 20.0 mL water) and extracted with ethyl acetate (3 × 20.0 mL). The organic layers were washed with brine (1 × 30.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was distilled at 60 °C under vacuum to give methyl 2,2-dimethoxypropanoate (4.00 g, 27.0 mmol, 78% yield) as a colorless oil.

[02194] ^{1}H NMR (400MHz, chloroform-d) δ = 3.81 (s, 3H), 3.28 (s, 6H), 1.52 (s, 3H).

[02195] Step 2: methyl 2-methoxyprop-2-enoate. To a solution of methyl 2,2-dimethoxypropanoate (2.00 g, 13.5 mmol, 1.00 eq) in DMF (20.0 mL) was added P_2O_5 (1.05 g, 7.42 mmol, 458 uL, 0.55 eq) in portions. After stirring at 100 °C for 1 hour, the mixture was diluted with saturated sodium bicarbonate (20.0 mL), extracted with isopropyl ether (3 × 30.0 mL). The extracts were washed with brine (3 × 40.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was distilled under vacuum to give methyl 2-methoxyprop-2-enoate (0.65 g, 5.60 mmol, 41% yield) as a colorless oil which was used to next step without further purification.

[02196] ^{1}H NMR (400MHz, chloroform-d) δ = 5.36 (d, J = 2.8 Hz, 1H), 4.63 (d, J = 2.8 Hz, 1H), 3.81 (s, 3H), 3.66 (s, 3H).

[02197] Step 3: 2-methoxyprop-2-enoic acid. A mixture of methyl 2-methoxyprop-2-enoate (0.60 g, 5.17 mmol, 1.00 eq) and NaOH (827 mg, 20.7 mmol, 4.00 eq) in H_2O (5.00 mL) and THF (5.00 mL) was stirred at 60 °C for 1 hour. The mixture was adjusted to pH < 3 by concentrated HCl (10.0 mL) and extracted with ethyl acetate (3 × 20.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-methoxyprop-2-enoic acid (0.40 g, 1.96 mmol, 38% yield, 50% purity) as a pink oil and used into next step without further purification.

[02198] ^{1}H NMR (400MHz, chloroform-d) δ = 8.63 (br s, 1H), 5.52 (d, J = 2.8 Hz, 1H), 4.75 (d, J = 2.8 Hz, 1H), 3.70 (s, 3H).


[02199] Step A: 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-methoxyprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (0.20 g, 376 umol, 1.00 eq), 2-methoxyprop-2-enoic acid (153 mg, 1.50 mmol, 4.00 eq) and DIEA (194 mg, 1.50 mmol, 262 uL, 4.00 eq) in dichloromethane (5.00 mL) was added HATU (286 mg, 752 umol, 2.00 eq) at 0 °C. After stirred at 0 °C for 0.5 h, the reaction was purified by reversed phase flash [water (FA, 0.1%)/acetonitrile], prep-HPLC (column: Luna C18 150*25 5u;mobile phase: [water(0.225% FA) - ACN]; B%: 25% - 45%, 7.8 min) and further prep-HPLC (column: Waters Xbridge 150*25 5u;mobile phase: [water (0.05% ammonia

hydroxide v/v) - ACN]; B%: 55% - 79%, 10 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-methoxyprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 514, 30.1 mg, 48.9 umol, 13% yield, 100% purity) as a yellow solid. LCMS [ESI, M+1]: 616.


[02200] SFC condition: "AS-3_ MeOH (DEA)_5_40_3mL-35T Column: Chiralpak AS-3 50×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm".

[02201] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.44 (td, *J* = 7.6, 13.6 Hz, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.27 - 7.18 (m, 1H), 5.07 - 4.63 (m, 1H), 4.57 - 4.29 (m, 4H), 4.21 - 3.96 (m, 3H), 3.95 - 3.77 (m, 2H), 3.69 (br s, 3H), 3.59 (br d, *J* = 11.2 Hz, 1H), 3.51 - 3.32 (m, 1H), 3.30 - 3.02 (m, 5H), 2.89 - 2.50 (m, 4H), 2.47 (d, *J* = 2.0 Hz, 3H), 2.32 - 2.23 (m, 1H), 2.11 - 2.00 (m, 1H), 1.89 - 1.72 (m, 3H).

EXAMPLE 515



2-[(2*S*)-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02202] Step A: 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 293 umol, 1.0 *eq*) and pyridine (186 mg, 2.35 mmol, 189 uL, 8.0 *eq*) in dichloromethane (4.0 mL) was added (*E*)-4-bromobut -2-enoyl chloride (215 mg, 1.17 mmol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was concentrated to give the product 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, crude) as yellow oil. The product was used for the next step without further purification. LCMS [ESI, M+1]: 658.

[02203] Step B: 2-[(2*S*)-1-[(*E*)-4-(3- fluoroazetidin-1-yl)but-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 228 umol, 1.0 *eq*) and K_2CO_3 (315 mg, 2.28 mmol, 10.0 *eq*) in acetonitrile (2.0 mL) was added 3-fluoroazetidine (152 mg, 1.37 mmol, 6.0 *eq*, HCl). The mixture was stirred at 0°C for 0.5 hour. After completion, the reaction mixture was added water (5.0 mL) and extracted with ethyl acetate (5.0 mL × 4). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-


ACN]; B%: 60%-90%,12min) to give the title compound 2-[(2*S*)-1-[(*E*)-4-(3- fluoroazetidin-1-yl)but-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 515, 45.0 mg, 66 umol, 29% yield, 96% purity) as white solid. LCMS [ESI, M+1]: 653.

[02204] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 (br d, *J* = 8.0 Hz, 1H), 7.65 (t, *J* = 8.4 Hz, 1H), 7.41 (dd, *J* = 7.6, 15.2 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.18 (m, 2H), 6.92 -6.82 (m, 1H), 6.52 - 6.31 (m, 1H), 5.28 - 5.08 (m, 1H), 5.07 - 4.46 (m, 1H), 4.41 - 4.33 (m, 1H), 4.32 - 4.01 (m, 4H), 4.01 - 3.79 (m, 2H), 3.79 - 3.56 (m, 3H), 3.55 - 3.37 (m, 2H), 3.36 - 3.31 (m, 2H), 3.30 - 3.24 (m, 1H), 3.23 - 3.18 (m, 2H), 3.17 - 3.15 (m, 1H), 3.14 - 3.06 (m, 2H), 3.05 - 2.95 (m, 1H), 2.92 (s, 3H), 2.86 - 2.75 (m, 1H), 2.71 - 2.57 (m, 2H), 2.47 (d, *J* = 4.0 Hz, 3H), 2.33 - 2.22 (m, 1H), 2.11 - 1.99 (m, 1H), 1.88 - 1.67 (m, 3H).

EXAMPLE 516



2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((*R*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02205] Step A: *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. A mixture of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (5.5 g, 10.4 mmol, 1 *eq*), [(2*R*)-1-methylpyrrolidin-2-yl]methanol (2.40 g, 20.9 mmol, 2.25 mL, 2 *eq*), $Pd_2(dba)_3$ (1.91 g, 2.09 mmol, 0.2 *eq*), RuPhos (1.95 g, 4.17 mmol, 0.4 *eq*) and Cs_2CO_3 (8.50 g, 26.1 mmol, 2.5 *eq*) in toluene (100 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 5 hours under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with ethyl acetate (100 mL) and water (50 mL). Then the mixture was acidified to PH ~ 4 with 1 M HCl aqueous solution. The water phase was separated and basified to PH ~ 8 with saturated Na_2CO_3 aqueous solution, then the mixture was extracted with ethyl acetate (50 mL × 2). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (4 g, 5.55 mmol, 53% yield, 84% purity) was obtained as a yellow solid and used to next step without purification.

[02206] ^{1}H NMR (400MHz, chloroform-d) δ = 7.46 - 7.31 (m, 5H), 5.23 (s, 2H), 4.74 - 4.49 (m, 2H), 4.43 - 4.27 (m, 2H), 4.21 - 3.70 (m, 5H), 3.42 - 3.17 (m, 3H), 3.09 (t, *J* = 7.6 Hz, 1H), 2.98 (td, *J* = 3.6, 12.4 Hz, 1H), 2.86 - 2.74 (m, 1H), 2.74 - 2.54 (m, 4H), 2.47 (s, 3H), 2.35 - 2.21 (m, 1H), 2.05 - 1.97 (m, 1H), 1.90 - 1.74 (m, 3H), 1.49 (s, 9H).

[02207] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (3.7 g, 6.11 mmol, 1 *eq*) in dioxane (20 mL) was added HCl/dioxane (4 M, 22.9 mL, 15 *eq*). The mixture was stirred at 0 °C for 1 hour. The liquid was decanted and the solid was collected. The solid residue was diluted with water (50 mL) and dichloromethane (100 mL), then the mixture was basified to pH ~ 8 with saturated Na_2CO_3 aqueous solution and extracted with dichloromethane (100 mL × 3). The combined organic layers were washed with brine (50m L), dried over Na_2SO_4, filtered and concentrated under reduced pressure. Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (2.6 g, 4.89 mmol, 80% yield, 95% purity) was obtained as a yellow solid and used next step without purification. LCMS [ESI, M+1]: 506.

[02208] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (2.3 g, 4.55 mmol, 1 *eq*), 1-bromo-8-methyl-naphthalene (Intermediate 69,1.31 g, 5.91 mmol, 1.3 *eq*), Cs_2CO_3 (3.71 g, 11.4 mmol, 2.5 *eq*), $Pd_2(dba)_3$ (833 mg, 909 umol, 0.2 *eq*) and Xantphos (1.05 g, 1.82 mmol, 0.4 *eq*) in toluene (50 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 6 hours under N_2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/ Methanol = 100/1 to 10/1). Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-

naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.6 g, 2.48 mmol, 54% yield) was obtained as a yellow solid.


[02209] Step D: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1.60 g, 2.48 mmol, 1.00 eq) in MeOH (20.0 mL) and NH_3 (20% w/w in MeOH, 7 mL) was hydrogenated with Pd/C (100 mg, 2.48 mmol, 10% purity, 1.00 eq) as a catalyst under H_2 (4.99 mg, 2.48 mmol, 1.00 eq, 15 psi) at 25 °C for 3 hours. The catalyst was filtered off through a pad of celite and the filtrate was concentrated under vacuum. The crude product was used to next step directly without further purification. 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (1.20 g, 2.35 mmol, 95% yield) was obtained as a light yellow solid. LCMS [ESI, M+1]: 512.

[02210] Step E: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2 -[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (140 mg, 274 umol, 1.00 eq) and 2-fluoroprop-2-enoic acid (73.9 mg, 821 umol, 3.00 eq) in dichloromethane (3.00 mL) was added DIEA (212 mg, 1.64 mmol, 286 uL, 6.00 eq), HATU (312 mg, 821 umol, 3.00 eq) in one portion at 0°C under N_2. After stirring at 0 °C for 30 min, the reaction mixture was diluted with water (10.0 mL) and extracted with dichloromethane (2 × 10.0 mL). The combined organic layers were washed with water (1 × 10.0 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.04% NH_3H_2O + 10 mM NH_4HCO_3) - ACN]; B%: 55% - 85%, 10 min). Title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2 -[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 516, 48.7 mg, 82.1 umol, 30% yield, 98.4% purity) was obtained as a white solid.


[02211] SFC condition: "Column: Chiralcel OJ-3 50 × 4.6 mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3 mL/min, Wavelength: 220 nm".

[02212] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.62 (m, 2H), 7.45 - 7.31 (m, 2H), 7.27 - 7.17 (m, 2H), 5.53 - 5.34 (m, 1H), 5.26 (dd, *J* = 3.6, 17.2 Hz, 1H), 4.88 (br s, 1H), 4.41 - 4.32 (m, 1H), 4.31 - 4.22 (m, 1H), 4.21 - 4.10 (m, 2H), 4.10 - 4.02 (m, 1H), 3.89 (br d, *J* = 18.0 Hz, 1H), 3.78 (d, *J* = 18.4 Hz, 1H), 3.59 - 3.40 (m, 2H), 3.27 - 3.15 (m, 2H), 3.14 - 3.04 (m, 2H), 3.03 - 2.90 (m, 4H), 2.90 - 2.73 (m, 2H), 2.72 - 2.56 (m, 2H), 2.47 (d, *J* = 4.8 Hz, 3H), 2.33 - 2.23 (m, 1H), 2.11 - 1.98 (m, 1H), 1.90 - 1.74 (m, 3H).

EXAMPLE 517



2-((*S*)-1-((*E*)-4-hydroxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((*R*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02213] Step A: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl) -2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-

yl]acetonitrile (120 mg, 234 umol, 1 *eq*), TEA (142 mg, 1.41 mmol, 195 uL, 6 *eq*) and (*E*)-4-trityloxybut-2-enoic acid (96.9 mg, 281 umol, 1.2 *eq*) in ethyl acetate (2 mL) was added T3P (448 mg, 703 umol, 418 uL, 50% purity in EtOAc, 3 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol = 200/1 to 10/1). 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (90 mg, 103 umol, 44% yield, 96% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 838.


[02214] Step B: 2-[(2*S*)-1-[(*E*)-4-hydroxybut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (80 mg, 95.5 umol, 1 *eq*) in dichloromethane (200 uL) was added TFA (218 mg, 1.91 mmol, 141 uL, 20 *eq*). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was diluted with water (5 mL) and basified to pH ~ 8 with $NaHCO_3$ aqueous solution (2 mL). The mixture was extracted with dichloromethane (5 mL × 3). The combined organic layers were washed with brine (3 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 50% - 80%, 12 min). The mixture was collected and lyophlizated. Title compound 2-[(2*S*)-1-[(*E*)-4-hydroxybut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 517, 10.2 mg, 16.8 umol, 18% yield, 98.5% purity) was obtained as a off-white solid. LCMS [ESI, M+1]: 596.

[02215] SFC condition: Column: Chiralcel OD-3 50 × 4.6mm I.D., 3um, Mobile phase: 40% methanol (0.05% DEA) in CO_2, Flow rate: 3mL/min, Wavelength: 220nm.


[02216] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.61 (m, 2H), 7.46 - 7.30 (m, 2H), 7.27 - 7.16 (m, 2H), 7.06 (d, *J* = 14.8 Hz, 1H), 6.62 (br d, *J* = 13.6 Hz, 1H), 5.25 - 4.53 (m, 1H),


4.48 - 4.32 (m, 3H), 4.30 - 3.95 (m, 4H), 3.93 - 3.82 (m, 1H), 3.81 - 3.61 (m, 1H), 3.59 - 3.39 (m, 2H), 3.30 - 2.96 (m, 5H), 2.92 (s, 3H), 2.87 - 2.53 (m, 4H), 2.47 (d, J = 4.0 Hz, 3H), 2.34 - 2.21 (m, 1H), 2.13 - 1.99 (m, 1H), 1.98 - 1.82 (m, 3H).


EXAMPLE 518



2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile







[02217] Step 1: O1-tert-butyl O2-methyl (2*R*,4*R*)-4-fluoropyrrolidine-1,2- dicarboxylate. To a solution of (2*R*,4*R*)-1-tert-butoxycarbonyl-4-fluoro- pyrrolidine-2-carboxylic acid (300 mg, 1.29 mmol, 1.0 *eq*) and K_2CO_3 (533 mg, 3.86 mmol, 3.0 *eq*) in DMF (2.0 mL) was added MeI (4.80 g, 33.8 mmol, 2.11 mL, 26.3 *eq*). The mixture was stirred at 20 °C for 12 hours. After completion, the reaction mixture was added water (5.0 mL) and extracted with ethyl acetate (10.0 ml × 2). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether: Ethyl acetate=10:1-1:1) to give the product O1-tert-butyl O2-methyl (2*R*,4*R*)-4-fluoropyrrolidine-1,2- dicarboxylate (300 mg, 1.21 mmol, 94% yield) as yellow oil.

[02218] ^{1}H NMR (400 MHz, Chloroform-d) δ 5.30 - 5.10 (m, 1H), 4.58 - 4.37 (m, 1H), 3.94 - 3.76 (m, 1H), 3.75 (s, 3H), 3.72 - 3.55 (m, 1H), 2.54 - 2.23 (m, 2H), 1.52 - 1.40 (m, 9H).

[02219] Step 2: [(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol To a solution of O1-tert-butyl O2-methyl (2*R*,4*R*)-4- fluoropyrrolidine-1,2-dicarboxylate. (300 mg, 1.21 mmol, 1.0 *eq*) in THF (3.0 mL) was added $LiAlH_4$ (138 mg, 3.64 mmol, 3.0 *eq*) at -40 °C. The mixture was stirred at this temperature for 1 hour, then heated to 70 °C and stirred at 70 °C for 2 hours. After completion, the reaction mixture was quenched with saturated Na_2SO_4 aqueous (0.30 mL), then filtered. The mother liquor was collected and concentrated under vacuum to give the product [(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (130 mg, 976 umol, 80% yield) as yellow oil.

[02220] ^{1}H NMR (400 MHz, Chloroform-d) δ 5.18 - 4.98 (m, 1H), 3.76 - 3.70 (m, 1H), 3.54 - 3.43 (m, 1H), 3.38 - 3.28 (m, 1H), 2.51 - 2.44 (m, 1H), 2.42 - 2.37 (m, 1H), 2.35 (s, 3H), 2.34 - 2.26 (m, 1H), 2.21 - 2.09 (m, 1H).

[02221] Step A: benzyl(2*S*)-2-(cyanomethyl)-4-[2- [[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl] methanol (103 mg, 773 umol, 2.0 *eq*) and t-BuONa (55.8 mg, 580 umol, 1.50 *eq*) in toluene (2.0 mL) was added benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 387 umol, 1.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (10.0 mL) and extracted with ethyl acetate (10.0 ml × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reversed phase flash HPLC (C18, 0.1 % FA in water, 0 - 60 % MeCN) to give the product benzyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (210 mg, 316 umol, 82% yield) as yellow solid. LCMS [ESI, M+1]:664.

[02222] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 (br d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.6 Hz, 1H), 7.45 - 7.32 (m, 7H), 7.26 - 7.17 (m, 2H), 5.24 - 5.02 (m, 3H), 4.73 - 4.61 (m, 1H), 4.53 - 4.42 (m, 1H), 4.30 - 4.18 (m, 2H), 4.11 - 3.96 (m, 2H), 3.94 - 3.81 (m, 1H), 3.81 - 3.67 (m, 1H), 3.58 - 3.47 (m, 1H), 3.46 - 3.29 (m, 2H), 3.24 - 3.06 (m, 3H), 3.05 - 2.96 (m, 1H), 2.92 (s, 3H), 2.82 - 2.71 (m, 2H), 2.70 - 2.51 (m, 2H), 2.50 - 2.47 (m, 4H), 2.45 - 2.35 (m, 1H), 2.12 - 2.05 (m, 1H).


[02223] Step B: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4- fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 301 umol, 1.0 *eq*) and NH_3•MeOH (2.0 mL, 20% purity) in methanol (4.0 mL) was added Pd/C (80 mg, 10% purity). The mixture was purged by N_2 for 3 times, and then stirred under H_2 atmosphere (15 Psi) at 25 °C for 1 hour. After completion, the reaction mixture was filtered through Celite. The mother liquor was concentrated under vacuum to give the

product 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8- methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (140 mg, 264 umol, 88% yield) as yellow oil. The product was used for the next step directly without further purification. LCMS [ESI, M+1]:664.


[02224] Step C: 2-[(2*S*)-4-[2- [[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, 226 umol, 1.0 *eq*), 2-fluoroprop-2- enoic acid (61.2 mg, 680 umol, 3.0 *eq*) and DIEA (176 mg, 1.36 mmol, 238 uL, 6.0 *eq*) in DCM (3.0 mL) was added HATU (258.44 mg, 679.69 umol, 3 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was added water (5.0 mL) and extracted with ethyl acetate (5.0 mL × 3). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 50%-80%,12min) to give the title compound 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 518, 37.9 mg, 60.1 umol, 27% yield, 96% purity) as white solid. LCMS [ESI, M+1]: 602.

[02225] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 (br d, J = 8.0 Hz, 1H), 7.65 (t, J = 8.2 Hz, 1H), 7.45 - 7.37 (m, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.27 - 7.18 (m, 2H), 5.53 - 5.32 (m, 1H), 5.30 - 5.22 (m, 1H), 5.21 - 5.03 (m, 1H), 4.97 - 4.68 (m, 1H), 4.52 - 4.42 (m, 1H), 4.29 - 4.20 (m, 2H), 4.18 - 4.03 (m, 2H), 3.95 - 3.68 (m, 2H), 3.60 - 3.41 (m, 2H), 3.39 - 3.30 (m, 1H), 3.26 - 3.15 (m, 2H), 3.15 - 2.95 (m, 2H), 2.92 (s, 3H), 2.90 - 2.54 (m, 4H), 2.53 - 2.46 (m, 4H), 2.45 - 2.35 (m, 1H), 2.13 - 1.97 (m, 1H).

EXAMPLE 519



2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02226] Step 1: *O*1-*tert*-butyl *O*2-methyl (2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate. To a solution of *O*1-*tert*-butyl *O*2-methyl (2*R*,4*R*)-4-hydroxypyrrolidine-1,2-dicarboxylate (2.1 g, 8.56 mmol, 1 *eq*) in MeCN (42 mL) was added Ag_2O (5.95 g, 25.7 mmol, 3 *eq*) and CH_3I (7.75 g, 54.6 mmol, 3.40 mL, 6.38 *eq*). The reaction mixture was stirred at 33 °C for 12 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 8/1

to 5/1) to give *O*1-*tert*-butyl *O*2-methyl (2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (1.88 g, 6.89 mmol, 80 % yield, 95.0 % purity) as a colorless oil.

[02227] ^{1}H NMR (400 MHz, chloroform-d) δ = 4.45 - 4.26 (m, 1H), 3.96 - 3.89 (m, 1H), 3.72 (s, 3H), 3.68 - 3.55 (m, 1H), 3.54 - 3.43 (m, 1H), 3.27 (s, 3H), 2.38 - 2.17 (m, 2H), 1.51 - 1.37 (m, 9H).

[02228] Step 2: [(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol. To the solution of *O*1-*tert*-butyl *O*2-methyl (2*R*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (2.98 g, 11.5 mmol, 1 *eq*) in THF (60 mL) was added $LiAlH_4$ (872 mg, 23.0 mmol, 2 *eq*) at 0 °C, the mixture was stirred at 0 °C for 1 hour. Then the reaction mixture was heated to 80 °C and stirred for 2 hours. The mixture was quenched with saturated Na_2SO_4 aqueous (3 mL), then filtered and the filter cake was washed with THF (3 × 20 mL). The filtrate was concentrated under vacuum to give [(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (1.53 g, 10.0 mmol, 87 % yield, 95.0 % purity) as a brown oil which was used for next step without further purification.

[02229] ^{1}H NMR (400 MHz, chloroform-d) δ = 3.82 - 3.76 (m, 1H), 3.69 (dd, *J* = 3.2, 11.2 Hz, 1H), 3.45 (dd, *J* = 1.6, 10.8 Hz, 1H), 3.29 (s, 3H), 3.18 (d, *J* = 10.4 Hz, 1H), 2.62 (br s, 1H), 2.42 (tdd, *J* = 2.8, 6.4, 9.2 Hz, 1H), 2.38 - 2.33 (m, 1H), 2.32 (s, 3H), 2.16 (ddd, *J* = 6.8, 8.8, 14.0 Hz, 1H), 1.92 (tdd, *J* = 1.6, 6.8, 14.0 Hz, 1H).

[02230] Step A: (benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of [(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (1.37 g, 9.42 mmol, 2.8 *eq*) in toluene (40 mL) was added *t*-BuONa (970 mg, 10.1 mmol, 3 *eq*) at 0 °C, then benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2 g, 3.36 mmol, 1 *eq*) was added at 0 °C, the reaction mixture was stirred at 0 °C for 0.5 hour. Water (20 mL) was added into the mixture. The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (2 × 20 mL). The combined organic layers were washed with brine (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 57 %) to give (benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-

yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (1.8 g, 2.53 mmol, 75 % yield, 95.0 % purity)) as a yellow solid. LCMS [ESI, M+1]: 676.

[02231] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.73 - 7.60 (m, 2H), 7.47 - 7.31 (m, 7H), 7.27 - 7.16 (m, 2H), 5.21 (s, 2H), 4.67 (br s, 1H), 4.45 (br dd, *J* = 4.4, 10.0 Hz, 1H), 4.24 - 4.16 (m, 2H), 4.10 - 3.96 (m, 2H), 3.96 - 3.65 (m, 3H), 3.59 - 3.40 (m, 2H), 3.29 (d, *J* = 1.6 Hz, 3H), 3.25 - 3.06 (m, 4H), 3.00 (dt, *J* = 3.6, 12.4 Hz, 1H), 2.91 (s, 3H), 2.81 - 2.55 (m, 4H), 2.45 (d, *J* = 6.0 Hz, 3H), 2.42 - 2.29 (m, 2H), 1.88 - 1.68 (m, 2H).


[02232] Step B: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (2 g, 2.96 mmol, 1 *eq*) and NH_3•MeOH (20 mL, 20 % purity) in MeOH (40 mL) was added Pd/C (1 g, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 0.5 hour. The reaction mixture was filtered, the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (1.29 g, 2.26 mmol, 76 % yield, 95 % purity) as a yellow solid which was used for next step without further purification. LCMS [ESI, M+1]: 542.

[02233] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 277 umol, 1 *eq*), 2-fluoroprop-2-enoic acid (74.8 mg, 831 umol, 3 *eq*) and TEA (336 mg, 1.66 mmol, 462 uL, 50 % purity, 6 *eq*) in EtOAc (3 mL) was added T3P (264 mg, 831 umol, 247 uL, 3 *eq*) at 0 °C, the mixture was stirred at 0 °C for 0.5 hour. Water (4 mL) was added into the mixture. The mixture was extracted with EtOAc (3 × 8 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1 %


FA) = 32 %). Then the residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,12min) to give title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 519, 59.5 mg, 97.0 umol, 35 % yield, 100 % purity) as a white solid. LCMS [ESI, M+1]: 614.

[02234] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.0 Hz, 1H), 7.45 - 7.38 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 5.53 - 5.33 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.88 (br s, 1H), 4.50 - 4.41 (m, 1H), 4.30 - 3.99 (m, 4H), 3.96 - 3.71 (m, 3H), 3.59 - 3.40 (m, 2H), 3.30 (s, 3H), 3.25 - 3.15 (m, 3H), 3.14 - 2.94 (m, 2H), 2.92 (s, 3H), 2.90 - 2.74 (m, 2H), 2.73 - 2.55 (m, 2H), 2.45 (d, *J* = 5.6 Hz, 3H), 2.42 - 2.29 (m, 2H), 1.81 (br dd, *J* = 7.2, 14.4 Hz, 1H).

EXAMPLE 520



2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile



[02235] Step A: benzyl(2*S*)-2-(cyanomethyl)-4- [2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methanol (609.98 mg, 4.04 mmol, 3.0 *eq*) and *t*-BuONa (388 mg, 4.04 mmol, 3.0 *eq*) in toluene (2.0 mL) was dropwise added a solution of benzyl(2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.35 mmol, 1.0 *eq*) in toluene (4.0 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was washed with water (15.0 mL) and extracted with ethyl acetate (3 x 20.0 mL). The Combine extracts were washed with brine (50.0 mL), dried with Na_2SO_4, filtrated and the solvent was removed under vacuum. The residue was purified by reversed phase flash HPLC [C18, 0.1% FA in water , 0-80% MeCN].The obtained product was then concentrated, the aqueous was extracted with Ethyl acetate (3 × 50.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. Compound benzyl(2*S*)-2-(cyanomethyl)-4- [2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (750

mg, 1.08 mmol, 80.1% yield, 98% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 682.

[02236] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. benzyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 953 umol, 1.0 *eq*) and Pd/C (200 mg, 10% purity) was added in MeOH (8.0 mL) and NH_3·MeOH (8.0 mL, 20% purity) then the mixture was degassed and purged with H_2 for 3 times, and then the mixture was stirred at 20 °C for 0.5 hour under H_2 (15 psi) atmosphere. After completion, the crude mixture was filtered through a pad of celite. The cake was washed with MeOH (50.0 mL) and the filtrate dried under high vacuum. Compound 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (420 mg, 736 umol, 77.2% yield, 96% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 548.


[02237] Step C: 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl] -4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (420 mg, 822 umol, 1.0 *eq*) and pyridine (520 mg, 6.57 mmol, 531 uL, 8.0 *eq*) in DCM (6.0 mL) was added (*E*)-4-bromobut-2-enoyl chloride (603 mg, 3.29 mmol, 4.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was concentrated under vacuum. The product 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl] -4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (500 mg, crude) was obtained as yellow oil. The crude product was used directly to the next step without further purification. LCMS [ESI, M+1]: 695.

[02238] Step D: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-[(*E*)-4-bromobut-2-enoyl] -4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-


dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (500 mg, 720 umol, 1.0 *eq*) and K_2CO_3 (995 mg, 7.20 mmol, 10.0 *eq*) in MeCN (12.0 mL) was added 3-fluoroazetidine (482 mg, 4.32 mmol, 6.0 *eq*, HCl) at 0 °C. The mixture was stirred at 20 °C for 1 hour. After completion, the organic solvent was washed with water (10.0 mL). The aqueous phase was extracted with ethyl acetate (3×10 mL). Combine extracts were washed with brine (20.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether : Ethyl acetate = 3:1 to Ethyl acetate : Methanol = 100:1), then the crude product was concentrated and purified by prep-HPLC (column: Waters Xbridge 150×25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-79%,10min];B%: 45%-75%,12min) and lyophilization. Title compound 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-(3-fluoroazetidin-1-yl)but-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 520, 45.8 mg, 66.5 umol, 9.24% yield, 100% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 689.

[02239] ^{1}H NMR (400MHz, chloroform-d) δ = 7.74 - 7.63 (m, 2H), 7.47 - 7.32 (m, 2H), 7.27 - 7.18 (m, 2H), 6.88 (br d, *J* = 15.3Hz, 1H), 6.42 (br d, *J* = 15.4 Hz, 1H), 5.27 - 5.05 (m, 1H), 4.64 (br s, 1H), 4.48 - 4.41 (m, 1H), 4.31 - 4.18 (m, 2H), 4.16 - 3.95 (m, 2H), 3.94 - 3.84 (m, 1H), 3.82 - 3.66 (m, 3H), 3.54 (br d, *J* = 7.6 Hz, 1H), 3.50 - 3.36 (m, 2H), 3.34 (br d, *J* = 3.8 Hz, 2H), 3.30 - 3.24 (m, 1H), 3.24 - 3.08 (m, 4H), 3.07 - 2.95 (m, 2H), 2.92 (s, 3H), 2.86 - 2.76 (m, 1H), 2.76 - 2.57 (m, 3H), 2.57 - 2.47 (m, 1H), 2.46 (d, *J* = 4.5 Hz, 3H), 2.34 - 2.17 (m, 1H).

EXAMPLE 521



2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02240] Step A: 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1- tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (720 mg, 1.03 mmol, 1 *eq*) in DCM (1 mL) was added TFA (4.62 g, 40.5 mmol, 3 mL, 39.4 *eq*). The mixture was stirred at 20 °C for 4 hours. Upon completion, the mixture was diluted with DCM (10 mL) and neutralized with saturated aqueous $NaHCO_3$. Then the aqueous phase was extracted with EtOAc (2 × 30 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum to give 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (880 mg, crude) as a yellow solid which was used directly into the next step without further purification.


[02241] Step B: 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-

2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (500 mg, crude), 2-fluoroprop-2-enoic acid (61.1 mg, 679 umol) and TEA (294 mg, 2.91 mmol, 405 uL) in DMF (10 mL) was added T3P (926 mg, 1.45 mmol, 865 uL, 50% purity in EtOAc) at -40 °C. Then the mixture was stirred at -40 °C for 0.5 hour and 0 °C for another 0.5 hour. Upon completion, the mixture was diluted with water (20 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were washed with brine (50 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated aqueous $NaHCO_3$ and extracted with EtOAc (2 × 70 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4um; mobile phase: [water (0.225%FA)-ACN]; B%: 10%-40%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (EXAMPLE 521, 52.5 mg, 79.8 umol, two steps 15% yield, 96.4% purity, FA) as a white solid. LCMS [ESI, M+1]:588.


[02242] SFC condition: Column: Chiralcel OJ-3 100×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

[02243] ^{1}H NMR (400 MHz, chloroform-d) δ = 8.03 (s, 1H), 7.15 (s, 1H), 5.53 - 5.34 (m, 1H), 5.25 (br dd, *J* = 3.2, 16.8 Hz, 1H), 5.02 - 4.61 (m, 3H), 4.43 (dd, *J* = 4.8, 11.6 Hz, 1H), 4.27 (s, 2H), 4.19 (br d, *J* = 13.2 Hz, 1H), 4.01 (br d, *J* = 12.4 Hz, 1H), 3.68 - 3.56 (m, 1H), 3.55 - 3.50 (m, 2H), 3.49 - 3.21 (m, 3H), 3.14 (br s, 1H), 2.98 (br s, 1H), 2.91 - 2.61 (m, 7H), 2.41 (s, 3H), 2.34 (s, 3H), 2.23 (qd, *J* = 8.4, 12.4 Hz, 1H), 2.14 - 1.95 (m, 3H).

EXAMPLE 522



2-((*S*)-4-(2-(((2*R*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-hydroxybut-2-enoyl)piperazin-2-yl)acetonitrile




[02244] Step A: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl -pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl -pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 378 umol, 1.0 *eq*), (*E*)-4-trityloxybut-2-enoic acid (169 mg, 491 umol, 1.3 *eq*) and DIEA (293 mg, 2.27 mmol, 395 uL, 6.0 *eq*) in DCM (3.0 mL) was added HATU (431 mg, 1.13 mmol, 3.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the mixture was added water (10 mL) and extracted with ethyl acetate (2 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate : Methanol=20:1). The product 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl -pyrrolidin-2-

yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (290 mg, 339 umol, 90% yield) was obtained as yellow solid.


[02245] Step B: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7- (8-methyl-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-4-hydroxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (290 mg, 339 umol, 1.0 eq) in dichloromethane (1.5 mL) was added TFA (2.31 g, 20.3 mmol, 1.5 mL, 59.8 eq), the mixture was stirred at 20 °C for 0.5 hour. After completion, the reaction mixture was concentrated, then added dichloromethane (10.0 mL), the organic layer was washed with saturated $NaHCO_3$ aqueous (2 × 10.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether/Ethyl acetate=3/1 to Ethyl acetate: Methanol=20:1). The crude product was then repurified by prep-HPLC (column: Gemini 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 45%-75%,12 min), the obtained product was concentrated and under lyophilization. Title compound 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7- (8-methyl-1-naphthyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-4-hydroxybut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 522, 61.3 mg, 99.9 umol, 29% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 614.

[02246] ^{1}H NMR (400 MHz, chloroform-d) δ 7.73 - 7.61 (m, 2H), 7.46 - 7.31 (m, 2H), 7.27 - 7.18 (m, 2H), 7.06 (br d, *J* = 14.8 Hz, 1H), 6.62 (br d, *J* = 14.8 Hz, 1H), 5.27 - 4.97 (m, 1H), 4.74 - 4.55 (m, 1H), 4.52 - 4.34 (m, 3H), 4.31 - 4.16 (m, 2H), 4.15 - 3.96 (m, 2H), 3.94 - 3.58 (m, 3H), 3.56 - 3.48 (m, 1H), 3.46 - 3.41 (m, 1H), 3.36 - 3.29 (m, 1H), 3.26 - 3.07 (m, 3H), 3.04 - 2.97 (m, 1H), 2.92 (s, 3H), 2.85 - 2.57 (m, 4H), 2.49 (d, *J* = 4.8 Hz, 3H), 2.45 - 2.34 (m, 1H), 2.29 - 1.91 (m, 2H).

EXAMPLE 523



2-[(2*S*)-1-[(*E*)-4-hydroxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02247] Step A: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 369 umol, 1 *eq*), (*E*)-4-trityloxybut-2-enoic acid (254 mg, 738 umol, 2 *eq*) and TEA (374 mg, 3.69 mmol, 514 uL, 10 *eq*) in EtOAc (4 mL) was added T3P (705 mg, 1.11 mmol, 659 uL, 50 % purity, 3 *eq*) at 0 °C, the mixture was stirred at 0 °C for 0.5 hour. Water (10 mL) was added into the mixture. The mixture was diluted with EtOAc (5 mL) and extracted with EtOAc (15 mL). The organic layer was washed with brine (10

mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 70 %) to give 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (230 mg, 262 umol, 71 % yield, 99 % purity) as a yellow solid.


[02248] Step B: 2-[(2*S*)-1-[(*E*)-4-hydroxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-trityloxybut-2-enoyl]piperazin-2-yl]acetonitrile (230 mg, 265 umol, 1 *eq*) in DCM (2.3 mL) was added TFA (3.54 g, 31.1 mmol, 2.3 mL, 117 *eq*), the mixture was stirred at 15 °C for 1 hour. The reaction mixture was basified with saturated $NaHCO_3$ (30 mL) to PH=7~8, then extracted with DCM (2 × 15 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1% FA) = 32 %). Then the residue was purified by prep-HPLC (column: Gemini 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 37%-67%,12min) to give title compound 2-[(2*S*)-1-[(*E*)-4-hydroxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 523, 41.7 mg, 66.6 umol, 25 % yield, 100 % purity) as a white solid. LCMS [ESI, M+1]: 626.

[02249] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.0 Hz, 1H), 7.45 - 7.38 (m, 1H), 7.37 - 7.31 (m, 1H), 7.27 - 7.17 (m, 2H), 7.07 (br d, *J* = 14.8 Hz, 1H), 6.62 (br d, *J* = 14.0 Hz, 1H), 5.07 (br s, 1H), 4.85 - 4.55 (m, 1H), 4.51 - 4.37 (m, 3H), 4.30 - 3.97 (m, 4H), 3.94 - 3.65 (m, 2H), 3.58 - 3.40 (m, 2H), 3.29 (d, *J* = 1.6 Hz, 3H), 3.25 - 2.96 (m, 5H), 2.92 (s, 3H), 2.86 - 2.54 (m, 4H), 2.45 (d, *J* = 4.8 Hz, 3H), 2.42 - 2.28 (m, 2H), 1.81 (br dd, *J* = 8.9, 13.6 Hz, 1H).

EXAMPLE 524




2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile




[02250] Step A: 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile: A stirred mixture of 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (100 mg, 0.1879 mmol), (*E*)-4-methoxybut-2-enoic acid (32.73 mg, 0.2819 mmol) and N,N-dimethylformamide (1 mL, 12.79 mmol) was cooled to 0°C followed by addition of triethylamine (0.07859 mL, 0.5638 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide, 50% in EtOAc (0.1678 mL, 0.2819 mmol). The reaction mixture was stirred for 2 hours while warming to room temperature. The mixture was partitioned between 0.5M Na_2CO_3 (5 mL) and EtOAc (15 mL) and the organics separated. The organics were next washed with water and brine (5 mL each), dried over Na_2SO_4 and evaporated in vacuo.

The residue was next chromatographed on silica gel using 4%MeOH + 0.4% NH_4OH/DCM as eluent to give impure material which was further purified by Gilson reverse prep HPLC eluting with 5 to 75% ACN+0.1% TFA /H_2O +0.1% TFA. Fractions containing pure product were combined and partitioned between DCM and a saturated solution of Na_2CO_3 and the layers separated. The organics were next washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give pure title compound (EXAMPLE 524, 33 mg, 28%). ESI+APCI MS m/z 630.3 [M^+].

EXAMPLE 525




N-(3-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-3-oxoprop-1-en-2-yl)acetamide



[02251] Step A: N-(3-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-3-oxoprop-1-en-2-yl)acetamide: To a 25 mL round bottom flask containing dichloromethane

(2932 µl, 0.2932 mmol) cooled to 0°C was added 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (150 mg, 0.2932 mmol) and Hunig's base (307.2 µl, 1.759 mmol). The reaction mixture was vigorously stirred while 2-Acetamidoacrylic acid (227.1 mg, 1.759 mmol) was added in one portion. Next, 1-Propanephosphonic acid cyclic anhydride (1047 µl, 1.759 mmol) was added slowly to the stirring mixture. The reaction was stirred for 2 hours at 0°C. The reaction was treated with basic water and the aqueous layer extracted with EtOAc (3X). The combined organics were concentrated in vacuo and purified on the Gilson (prep HPLC) eluting with 5→95% ACN+0.1% TFA /water+0.1% TFA. Fractions containing product were combined and basified with 1M NaOH and the aqueous layer extracted with DCM (2X). The organics were dried over Na_2SO_4 and concentrated in vacuo to give title compound N-(3-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-3-oxoprop-1-en-2-yl)acetamide (EXAMPLE 525, 124.2 mg, 68.03 % yield). ESI+APCI MS m/z 623.3 $[M+H]^+$.

EXAMPLE 526




2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-4-yl)acryloyl)piperazin-2-yl)acetonitrile


[02252] 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-3-(pyridin-4-yl)acryloyl)piperazin-2-yl)acetonitrile: The title compound was prepared following **Example 525** substituting Trans-3-

(4-Pyridyl) Acrylic Acid for 2-Acetamidoacrylic acid in Step A. ESI+APCI MS m/z 643.3 $[M+H]^+$.

EXAMPLE 527



2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02253] 1-bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene. To a solution of 1-bromo-5-fluoro-2-iodo-3-methyl-benzene (2 g, 6.35 mmol, 1 eq) in DMF (40 mL) was added CuI (7.26 g, 38.1 mmol, 6 eq) and methyl 2,2-difluoro-2-fluorosulfonyl-acetate (7.32 g, 38.1 mmol, 4.85 mL, 6 eq). The mixture was stirred at 60 °C for 12 hours. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (20 mL × 3). The organic layer was washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 10/1). 1-bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene (1.3 g, 3.74 mmol, 59% yield, 74% purity) was obtained as a yellow oil.

[02254] ^{1}H NMR (400MHz, chloroform-d) δ = 7.33 (dd, J = 2.4, 7.6 Hz, 1H), 6.95 (dd, J = 2.0, 8.8 Hz, 1H), 2.54 (q, J = 3.6 Hz, 3H).

[02255] 2-bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde. To a mixture of 1-bromo-5-fluoro-3-methyl-2- (trifluoromethyl)benzene (900 mg, 3.50 mmol, 1 eq) in THF (20 mL) was added LDA (2 M in THF, 3.50 mL, 2 eq) at - 60 °C under nitrogen atmosphere. After stirring for 0.5 hour, to the mixture was added DMF (768 mg, 10.5 mmol, 808 uL, 3 eq). The mixture was stirred at - 60 °C for 1 hour. The reaction was quenched with saturated NH_4Cl aqueous solution (10 mL) and then extracted with ethyl acetate (50 mL × 3). The combined organic phase was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 200/1 to 5/1). 2-bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde (700 mg, 2.46 mmol, 70% yield) was obtained as a yellow oil.

[02256] ^{1}H NMR (400MHz, chloroform-d) δ = 10.35 (s, 1H), 7.08 (d, J = 10.4 Hz, 1H), 2.66 - 2.58 (m, 3H).

[02257] 4-bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole. A solution of 2-bromo-6-fluoro-4-methyl-3- (trifluoromethyl)benzaldehyde (600 mg, 2.11 mmol, 1 eq) and hydrazine monohydrate (2.11 g, 42.1 mmol, 2.05 mL, 20 eq) in DMSO (8 mL) was stirred at 60 °C for 2 hours. The mixture was diluted with ethyl acetate (50 mL) and washed with water (3 × 50 mL) and brine (1 × 50 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was used to next step without further purification. 4-

bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole (550 mg, 1.97 mmol, 94% yield) was obtained as a white solid.

[02258] 4-bromo-6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole. To a solution of 4-bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole (500 mg, 1.79 mmol, 1 eq) in DCM (10 mL) was added 4-methylbenzenesulfonic acid hydrate (34.1 mg, 1791 umol, 0.1 eq) 1 followed by a solution of DHP (603 mg, 7.17 mmol, 655 uL, 4 eq) in CH_3CN (2 mL). The mixture was stirred at 25 °C for 16 hours. The mixture was diluted with ethyl acetate (100 mL) and washed with water (2 × 100 mL) and brine (1 × 50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 20/1 to 3/1). The desired fractions were collected and concentrated under vacuum to give 4-bromo-6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole (600 mg, 1.54 mmol, 86% yield, 93% purity) as a light yellow gum. LCMS [MSI, M+1]: 363.


[02259] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 848 umol, 1 eq), 4-bromo-6-methyl-1-tetrahydropyran- 2-yl-5-(trifluoromethyl)indazole (431 mg, 1.19 mmol, 1.4 eq) $Pd_2(dba)_3$ (155 mg, 170 umol, 0.2 eq), RuPhos (158 mg, 339 umol, 0.4 eq) and Cs_2CO_3 (691 mg, 2.12 mmol, 2.5 eq) in toluene (20 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 100 °C for 16 hours under N_2 atmosphere. To the mixture was added H_2O (20 mL × 1) and Ethyl acetate (20 mL × 1). The organic phase was separated, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (Ethyl acetate /Methanol = 50/1 to 2/1). *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 535 umol, 32% yield, 80.7% purity) was obtained as a yellow solid. LCMS [MSI, M+1]: 754.

[02260] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-

yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (470 mg, 503 umol, 1 eq) in DCM (1 mL) was added TFA (2.29 g, 20.1 mmol, 1.49 mL, 40 eq). The mixture was stirred at 25 °C for 1 h. To the mixture was added dichloromethane (5 mL) and basified with saturated aqueous NaHCO3 solution to pH = 8 ~ 9. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure to give 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (420 mg, 453 umol, 90% yield, 61.4% purity) was obtained as a yellow solid and used into next step without further purification. LCMS [MSI, M+1]: 570.

[02261] Step C: 2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(6-methyl-5- (trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a solution of 2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl] methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (380 mg, 410 umol, 1 eq), 2-fluoroprop-2-enoic acid (18.4 mg, 205 umol, 0.5 eq) and TEA (124 mg, 1.23 mmol, 171 uL, 3 eq) in DMF (8 mL) was added T3P (391 mg, 614 umol, 365 uL, 50% purity in DMF, 1.5 eq) at -40 °C. Then the mixture was stirred at -40 °C for 0.5 hour and 0 °C for another 0.5 hour. 2-fluoroprop-2-enoic acid (11 mg) and T3P (100 uL) was added and the mixture was stirred at -40 °C for further 0.5 hour. The mixture was diluted with water (15 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were washed with brine (50 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 22% - 42%, 7.8 min) and (column: Phenomenex Gemini 150*25mm*10um; mobile phase: [water (0.04% NH_3H_2O + 10 mM NH_4HCO_3) - ACN]; B%: 50% - 68%, 12 min). The desired fractions were collected and lyophilize to give title compound 2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (EXAMPLE 527) as white solid.


EXAMPLE 528



2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-(3-fluoroazetidin-1-yl)but-2-enoyl)piperazin-2-yl)acetonitrile

[02262] The title compound is prepared following **Example 520** by modifying Intermediate 66 by substituting (S)-(4,4-difluoro-1-methylpyrrolidin-2-yl)methanol for (1-methylpyrrolidin-2-yl)methanol in Intermediate 66, Step E, modified Intermediate 66 is deprotected using the conditions in Intermediate 71, Step A, then substituted for Intermediate 66 in **Example 520**, Step A.

EXAMPLE 529




2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile

[02263] The title compound was prepared following **Example 467** substituting (E)-4-fluorobut-2-enoic acid for acryloyl chloride using the conditions of **Example 479**, Step C. LCMS [ESI, M+1]: 634.

[02264] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.0 Hz, 1H), 7.66 (t, *J* = 8.0 Hz, 1H), 7.45 - 7.38 (m, 1H), 7.38 - 7.32 (m, 1H), 7.27 - 7.18 (m, 2H), 7.09 - 6.93 (m, 1H), 6.60 (br d, *J* = 14.8 Hz, 1H), 5.32 - 4.93 (m, 3H), 4.64 (br s, 1H), 4.45 (td, *J* = 5.2, 11.2 Hz, 1H), 4.32 - 3.63 (m, 6H), 3.58 - 3.36 (m, 3H), 3.25 - 2.96 (m, 5H), 2.93 (s, 3H), 2.88 - 2.77 (m, 1H), 2.75 - 2.50 (m, 3H), 2.46 (d, *J* = 4.4 Hz, 3H), 2.34 - 2.15 (m, 1H).

[02265] SFC condition: Column: Chiralcel OJ-3 50×4.6mm I.D., 3um, Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40%, Flow rate: 3mL/min, Wavelength: 220nm.

EXAMPLE 530



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile


[02266] The title compound was prepared following **Example 467** substituting 2-fluoroprop-2-enoyl chloride for acryloyl chloride using the conditions of **Example 478**, Step A. LCMS [ESI, M+1]:620.

[02267] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.63 (m, 2H), 7.46 - 7.33 (m, 2H), 7.27 - 7.18 (m, 2H), 5.54 - 5.33 (d, *J* = 47.6 Hz, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.05 - 4.62 (m, 1H), 4.58 - 4.37 (m, 1H), 4.31 - 4.13 (m, 3H), 4.12 - 4.05 (m, 1H), 3.97 - 3.73 (m, 1H), 3.59 -

3.36 (m, 3H), 3.27 - 2.95 (m, 6H), 2.92 (s, 3H), 2.89 - 2.49 (m, 5H), 2.46 (d, J = 4.4 Hz, 3H), 2.34 - 2.17 (m, 1H).

[02268] SFC: "Column: Chiralcel OJ - 3 50×4.6 mm I.D., 3 um Mobile phase: methanol (0.05% DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".


EXAMPLE 531



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02269] The title compound is prepared following **Example 467** substituting (methoxymethyl)prop-2-enoic acid for acryloyl chloride using the conditions of **Example 489**, Step A.


EXAMPLE 532



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-hydroxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02270] The title compound is prepared following **Example 467** substituting 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid for acryloyl chloride using the conditions of **Example 483**, Step A.


EXAMPLE 533



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-fluorobut-2-en-1-one

[02271] The title compound is prepared following **Example 469** substituting (E)-4-fluorobut-2-enoic acid for prop-2-enoyl prop-2-enoate in **Example 479**, Step C.


EXAMPLE 534



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-methoxybut-2-en-1-one

[02272] The title compound is prepared following **Example 469** substituting 2-(methoxymethyl)prop-2-enoic acid for prop-2-enoyl prop-2-enoate in **Example 489**, Step A.


EXAMPLE 535



(S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-2-fluoroprop-2-en-1-one

[02273] The title compound is prepared following **Example 469** substituting 2-fluoroacrylic acid for prop-2-enoyl prop-2-enoate in **Example 478**, Step A.


EXAMPLE 536



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-hydroxybut-2-en-1-one

[02274] The title compound is prepared following **Example 469** substituting 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid for prop-2-enoyl prop-2-enoate in **Example 469**, Step D, and following the procedures of **Example 483**, Step A.


EXAMPLE 537



(S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-2-fluoroprop-2-en-1-one

[02275] The title compound is prepared following **Example 470** substituting (E)-4-fluorobut-2-enoic acid for prop-2-enoyl prop-2-enoate in **Example 478**, Step A.


EXAMPLE 538



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-fluorobut-2-en-1-one

[02276] The title compound is prepared following **Example 470** substituting (E)-4-fluorobut-2-enoic acid for prop-2-enoyl prop-2-enoate in **Example 479**, Step C.


EXAMPLE 539



(S)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-2-fluoroprop-2-en-1-one

[02277] The title compound is prepared following **Example 470** substituting 2-fluoroacrylic acid for prop-2-enoyl prop-2-enoate in **Example 478**, Step A.


EXAMPLE 540



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-methoxybut-2-en-1-one

[02278] The title compound is prepared following **Example 470** substituting 2-(methoxymethyl)prop-2-enoic acid for prop-2-enoyl prop-2-enoate in **Example 489**, Step A.


EXAMPLE 541



(S,E)-1-(4-(2-((4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1H-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-hydroxybut-2-en-1-one

[02279] The title compound is prepared following **Example 470** substituting 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid for prop-2-enoyl prop-2-enoate in **Example 470**, Step C and following the procedures of **Example 483**, Step A.

EXAMPLE 542




2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile

[02280] The title compound was prepared following **Example 468** substituting 2-fluoroprop-2-enoyl chloride for acryloyl chloride using the conditions of **Example 479**, Step C. LCMS [ESI, M+1]: 655.

[02281] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.2 Hz, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.50 - 7.40 (m, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 - 7.18 (m,

1H), 7.08 - 6.94 (m, 1H), 6.60 (br d, J = 14.8 Hz, 1H), 5.26 - 5.03 (m, 2H), 4.90 - 4.58 (m, 1H), 4.52 - 4.38 (m, 2H), 4.31 - 4.21 (m, 1H), 4.19 - 3.98 (m, 2H), 3.97 - 3.72 (m, 2H), 3.66 - 7.56 (m, 1H), 3.53 - 3.37 (m, 2H), 3.34 - 3.11 (m, 3H), 3.07 - 2.92 (m, 2H), 2.89 - 2.79 (m, 1H), 2.77 - 2.48 (m, 4H), 2.47 (d, J = 2.4 Hz, 3H), 2.35 - 2.18 (m, 1H).

EXAMPLE 543




2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02282] The title compound was prepared following **Example 468** substituting 2-fluoroprop-2-enoyl chloride for acryloyl chloride using the conditions of **Example 478**, Step A. LCMS [ESI, M+1]: 640.

[02283] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 7.2 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.45 (td, J = 7.6, 12.4 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.27 - 7.19 (m, 1H), 5.54 - 5.33 (dd, J = 2.8, 47.6 Hz, 1H), 5.26 (dd, J = 3.6, 16.8 Hz, 1H), 4.85 (br s, 1H), 4.51 - 4.38 (m, 2H), 4.31 - 3.77 (m, 4H), 3.69 - 3.54 (m, 1H), 3.41 (m, 2H), 3.35 - 2.48 (m, 11H), 2.47 (d, J = 2.4 Hz, 3H), 2.35 - 2.16 (m, 1H).

[02284] SFC: "Column: Cellucoat 50 × 4.6mm I.D., 3um Mobile phase: methanol (0.05 % DEA) in CO_2 from 5% to 40% Flow rate: 3mL/min Wavelength: 220nm".


EXAMPLE 544



2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02285] The title compound is prepared following **Example 468** substituting (methoxymethyl)prop-2-enoic acid for acryloyl chloride using the conditions of **Example 489**, Step A.


EXAMPLE 545



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-hydroxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02286] The title compound is prepared following **Example 468** substituting 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid for acryloyl chloride using the conditions of **Example 483**, Step A.


EXAMPLE 546



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile

[02287] The title compound is prepared following **Example 527** substituting 2-fluoroprop-2-enoyl chloride for acryloyl chloride using the conditions of **Example 479**, Step C.


EXAMPLE 547



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02288] The title compound is prepared following **Example 527** substituting 2-fluoroprop-2-enoyl chloride for acryloyl chloride using the conditions of **Example 478**, Step A.


EXAMPLE 548



2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-methoxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02289] The title compound is prepared following **Example 527** substituting (methoxymethyl)prop-2-enoic acid for acryloyl chloride using the conditions of **Example 489**, Step A.


EXAMPLE 549



2-((S)-4-(2-(((S)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-((E)-4-hydroxybut-2-enoyl)piperazin-2-yl)acetonitrile

[02290] The title compound is prepared following **Example 527** substituting 4-[*tert*-butyl(dimethyl)silyl]oxybut-2-ynoic acid for acryloyl chloride using the conditions of **Example 483**, Step A.


EXAMPLE 550




2-((S)-4-(7-(5,6-dimethyl-1H-indol-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02291] 2-((S)-1-acryloyl-4-(7-(5,6-dimethyl-1H-indol-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. The title compound is prepared following **Example 466** substituting 2-fluoroacrylic acid for prop-2-enoyl prop-2-enoate as described in **Example 478**, Step A.

EXAMPLE 551



2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-methoxybut-2-enoyl]piperazin-2-yl]acetonitrile




[02292] Step A: 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-methoxybut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 378 umol, 1.0 *eq*), (*E*)-4-methoxybut-2-enoic acid (110 mg, 944 umol, 2.5 *eq*) in DMF (3.0 mL) was added TEA (382 mg, 3.78 mmol, 526 uL, 10.0 *eq*) and T3P (721 mg, 1.13 mmol, 674 uL, 50 % purity, 3.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the organic solvent was washed with water (10.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 10.0 mL). Combine extracts were washed with brine (20.0 mL), dried with Na_2SO_4 and filtrated. The solvent was then removed under vacuum. The residue was purified by column chromatography (Base Al_2O_3, Petroleum ether : Ethyl acetate = 10:1 to 1:1), then the crude product was concentrated and repurified by prep-HPLC (column: Phenomenex Gemini 150×25mm×10um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 48%-78%,9-10min) and lyophilization to give title compound 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-methoxybut-2-enoyl]piperazin-2-yl]acetonitrile (EXAMPLE 551, 50 mg, 79.6 umol, 21% yield, 99.9% purity) was obtained as yellow solid. LCMS [ESI, M+1]: 628.


[02293] ^{1}H NMR (400MHz, Chloroform-d) δ = 7.73 - 7.62 (m, 2H), 7.45 - 7.31 (m, 2H), 7.27 - 7.18 (m, 2H), 7.05 - 6.94 (m, 1H), 6.55 (br d, *J* = 15.0 Hz, 1H), 5.23 - 5.03 (m, 1H), 4.66 (br s, 1H), 4.52 - 4.42 (m, 1H), 4.30 - 4.18 (m, 2H), 4.18 – 3.94 (m, 4H), 3.93 - 3.84 (m, 1H),

3.83 - 3.65 (m, 1H), 3.54 (br d, J = 6.7 Hz, 1H), 3.44 (s, 3H), 3.42 - 3.26 (m, 2H), 3.25 - 3.15 (m, 2H), 3.05 (br dd, J = 8.5, 16.4 Hz, 2H), 2.92 (s, 3H), 2.88 - 2.58 (m, 4H), 2.57 -2.35 (m, 5H), 2.14 - 1.96 (m, 1H).

EXAMPLE 552



2-[(2*S*)-1-[(*E*)-4-methoxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02294] Step A: 2-[(2*S*)-1-[(*E*)-4-methoxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 277 umol, 1 *eq*), (*E*)-4-methoxybut-2-enoic acid (64.3 mg, 554 umol, 2 *eq*) and TEA (280 mg, 2.77 mmol, 385 uL, 10


eq) in DMF (3 mL) was added T3P (529 mg, 831 umol, 494 uL, 50 % purity, 3 *eq*) at 0 °C, the mixture was stirred at 0 °C for 0.5 hour. Water (10 mL) was added into the mixture. The mixture was diluted with EtOAc (5 mL) and extracted with EtOAc (2 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reversed phase flash column (ACN/Water (0.1 % FA) = 35 %). Then the residue was purified by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05 % ammonia hydroxide v/v) - ACN]; B %: 50 % - 74 %,10min) to give title compound 2-[(2*S*)-1-[(*E*)-4-methoxybut-2-enoyl]-4-[2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 552, 37.1 mg, 57.2 umol, 21 % yield, 98.7 % purity) as a white solid. LCMS [ESI, M+1]: 640.

[02295] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.45 - 7.31 (m, 2H), 7.27 - 7.17 (m, 2H), 6.99 (br d, *J* = 14.8 Hz, 1H), 6.55 (br d, *J* = 15.2 Hz, 1H), 5.07 (br s, 1H), 4.51 - 4.40 (m, 1H), 4.31 - 4.04 (m, 5H), 3.95 - 3.68 (m, 3H), 3.63 - 3.47 (m, 2H), 3.44 (s, 3H), 3.42 - 3.35 (m, 1H), 3.30 (d, *J* = 1.2 Hz, 3H), 3.24 - 2.96 (m, 5H), 2.92 (s, 3H), 2.76 (br dd, *J* = 8.0, 16.8 Hz, 1H), 2.72 - 2.52 (m, 3H), 2.45 (d, *J* = 5.2 Hz, 3H), 2.41 - 2.27 (m, 2H), 1.81 (br dd, *J* = 7.2, 14.0 Hz, 1H).

EXAMPLE 553



2-((*S*)-1-((*E*)-4-methoxybut-2-enoyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((*R*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02296] Step A: methyl 3-hydroxy-4-methoxy-butanoate. To a solution of methyl 4-methoxy-3-oxo-butanoate (20 g, 137 mmol, 1.0 *eq*) in toluene (300 mL) was added $NaBH_4$ (5.44 g, 144 mmol, 1.05 *eq*) at 0 °C. Then the mixture was stirred at 20 °C for 4 hours. After completion, the mixture was diluted with water (100 mL) at 0 °C and extracted with ethyl acetate (3 × 100 mL). The extracts were washed with brine (200 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give methyl 3-hydroxy-4-methoxy-butanoate (7.5 g, crude) as yellow oil and used into next step without further purification.

[02297] ^{1}H NMR (400MHz, chloroform-d) δ = 4.23 - 4.15 (m, 1H), 3.70 (s, 3H), 3.44 - 3.38 (m, 2H), 3.37 (s, 3H), 3.04 (br s, 1H), 2.51 (d, *J* = 6.4 Hz, 2H).

[02298] Step B: methyl (*E*)-4-methoxybut-2-enoate. To a solution of methyl 3-hydroxy-4-methoxy-butanoate (7.5 g, crude) in DCM (50.0 mL) was added TEA (5.12 g, 50.6 mmol, 7.05 mL) and MsCl (8.70 g, 75.9 mmol, 5.88 mL) at 0 °C. After stirred for 4 hours, to the mixture was added TEA (10.2 g, 101 mmol, 14.1 mL) 0 °C. The mixture was warmed up to 20°C and stirred for 12 hours. After completion, the mixture was diluted with water (50.0 mL), washed with HCl (1N, 15.0 mL) and brine (20.0 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/0 to 50:1) to give methyl (*E*)-4-methoxybut-2-enoate (1.7 g, 11.8 mmol, two steps 8.6% yield, 90% purity) as yellow oil.

[02299] ^{1}H NMR (400MHz, chloroform-d) δ = 6.93 (td, *J* = 4.3, 15.8 Hz, 1H), 6.04 (td, *J* = 2.0, 15.8 Hz, 1H), 4.06 (dd, *J* = 2.0, 4.3 Hz, 2H), 3.72 (s, 3H), 3.36 (s, 3H).

[02300] Step C: (*E*)-4-methoxybut-2-enoic acid. A mixture of methyl (*E*)-4-methoxybut-2-enoate (300 mg, 2.31 mmol, 1.0 *eq*) and KOH (517 mg, 9.22 mmol, 4.0 *eq*) in MeOH (2.0 mL) and H_2O (2.0 mL) was stirred at 20 °C for 2 hours. After completion, the mixture was acidified with HCl (2N, 5.0 mL) to pH = 1 - 3 and extracted with ethyl acetate (2x20 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give (*E*)-4-methoxybut-2-enoic acid (200 mg, 1.55 mmol, 67.3% yield, 90% purity) as yellow solid.


[02301] ^{1}H NMR (400MHz, chloroform-d) δ = 11.13 (br s, 1H),7.06 (td, *J*= 4.1, 15.7 Hz, 1H), 6.08 (td, *J* = 2.0, 15.7 Hz, 1H), 4.12 (dd, *J* = 2.0, 4.1 Hz, 2H), 3.40 (s, 3H).

[02302] Step D: 2-[(2*S*)-1-[(*E*)-4-methoxybut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 391 umol, 1 *eq*), (*E*)-4-methoxybut-2-enoic acid (113 mg, 977 umol, 2.5 *eq*), TEA (395 mg, 3.91 mmol, 544 uL, 10 *eq*) in DMF (4 mL) was added T3P (746 mg, 1.17 mmol, 697 uL, 50% purity, 3 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.3 hour. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (10 mL × 3). The organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH = 100/1 to 10:1) and further purified by prep-HPLC (column: Boston pH - lex 150*25 10 um; mobile phase: [water (0.1%TFA) - ACN]; B%: 35% - 59%, 8min). The mixture was collected and lyophilized. Title compound 2-[(2*S*)-1-[(*E*)-4-methoxybut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (EXAMPLE 553, 37.5 mg, 60.4 umol, 15% yield, 98.2% purity) was obtained as a white solid. LCMS [ESI, M+1]: 610.


[02303] ^{1}H NMR (400MHz, chloroform-d) δ = 7.77 - 7.57 (m, 2H), 7.46 - 7.37 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 6.99 (br d, *J* = 14.4 Hz, 1H), 6.55 (br d, *J* = 14.8 Hz, 1H), 5.24 - 4.49 (m, 1H), 4.46 - 4.32 (m, 1H), 4.32 - 3.74 (m, 7H), 3.73 - 3.25 (m, 6H), 3.25

- 2.94 (m, 5H), 2.92 (s, 3H), 2.86 - 2.54 (m, 4H), 2.49 (d, J = 5.6 Hz, 3H), 2.38 - 2.23 (m, 1H), 2.11 - 2.00 (m, 1H), 1.93 - 1.65 (m, 3H).

EXAMPLE 554



2-[(2*S*)-1-[(*E*)-4-Methoxybut- 2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl] acetonitrile



[02304] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl) -2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*) -1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (850 mg, 1.80 mmol, 1.0 *eq*), 1-bromo-8-methyl-naphthalene (1.20 g, 5.41 mmol, 3.0 *eq*), $Pd_2(dba)_3$ (330 mg, 360 μmol, 0.20 *eq*), Xantphos (417 mg, 721 μmol, 0.40 *eq*) and Cs_2CO_3 (1.76 g, 5.41 mmol, 3.0 *eq*) in toluene (10.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2. After completion, the reaction was washed with 2 N HCl (2 × 15.0 mL). The aqueous phase was basified with solid $NaHCO_3$ to pH ~ 7 and extracted with ethyl acetate (2 × 50.0 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash HPLC [C18, 0.1% FA in water, 0 - 65% MeCN] and was adjusted with solid $NaHCO_3$ to pH ~ 7 and extracted with ethyl acetate (2 × 150 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. Compound *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl) -2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 1.03 mmol, 57% yield, 97% purity) was obtained as white solid. LCMS [ESI, M+1]: 612.

[02305] ^{1}H NMR (400 MHz, chloroform-d) δ 7.72 - 7.61 (m, 2H), 7.44 - 7.37 (m, 1H), 7.36 - 7.30 (m, 1H), 7.27 - 7.16 (m, 2H), 4.63 - 4.52 (m, 1H), 4.46 - 4.36 (m, 1H), 4.30 - 4.15 (m, 2H), 4.09 - 3.95 (m, 2H), 3.93 - 3.73 (m, 2H), 3.57 - 3.47 (m, 1H), 3.42 - 3.27 (m, 1H), 3.22 - 3.04 (m, 4H), 3.02 - 2.94 (m, 1H), 2.92 (s, 3H), 2.81 - 2.54 (m, 4H), 2.53 - 2.47 (m, 3H), 2.40 - 2.26 (m, 1H), 2.12 - 2.05 (m, 1H), 1.92 - 1.71 (m, 3H), 1.52 (s, 9H).

[02306] Step B: 2-[(2S)-4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of tert-butyl (2S)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 981 μmol, 1.0 eq) in dioxane (3.0 mL) was added HCl/dioxane (4 M, 3.0 mL, 12.2 eq) at 25 °C, and the mixture was stirred at 25 °C for 1 hour. After completion, the reaction mixture was quenched by saturated aqueous $NaHCO_3$ (8.0 mL) at 0 °C, and then diluted with H_2O (5.0 mL) and extracted with ethyl acetate (3 × 15.0 mL). The combined

organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 2-[(2S)-4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (410 mg, crude) as yellow solid which was used into the next step without further purification.


[02307] Step C: 2-[(2*S*)-1-[(*E*)-4-methoxybut- 2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl] acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 293 μmol, 1.0 *eq*), (*E*)-4-methoxybut-2-enoic acid (102 mg, 880 μmol, 3.0 *eq*) in ethyl acetate (3.0 mL) was added TEA (237 mg, 2.35 mmol, 326 μL, 8.0 *eq*) and T3P (560 mg, 880 μmol, 523 μL, 50% purity, 3.0 *eq*) at 0 °C. The mixture was stirred at 20 °C for 1 hour. After completion, water was added (5.0 mL). The organic layer was separated, and the aqueous phase was extracted with ethyl acetate (3 × 10 mL). Combined extracts were washed with brine (20.0 mL), dried with Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (basic Al_2O_3, petroleum ether : ethyl acetate = 3 : 1 to ethyl acetate : methanol = 50 : 1), then the crude product repurified by prep-HPLC (column: Waters Xbridge 150*25 5u;mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN];B%: 50%-77%,10 min) and lyophilization. Compound 2-[(2*S*)-1-[(*E*)-4-methoxybut- 2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl] acetonitrile (38.6 mg, 62.4 μmol, 21% yield, 98% purity) was obtained as white solid. LCMS [ESI, M+1]: 512.

[02308] Step D: 2-[(2*S*)-1-[(*E*)-4-methoxybut- 2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl] acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 293 μmol, 1.0 *eq*), (*E*)-4-methoxybut-2-enoic acid (102 mg, 880 μmol, 3.0 *eq*) in ethyl acetate (3.0 mL) was added TEA (237 mg, 2.35 mmol, 326 μL, 8.0 *eq*) and T3P (560 mg, 880 μmol, 523 μL, 50% purity, 3.0 *eq*) at 0 °C. The mixture was stirred at 20 °C for 1 hour. After completion, water was added (5.0 mL). The organic layer was separated, and the aqueous phase was extracted with ethyl acetate (3 × 10 mL). Combined extracts were washed


with brine (20.0 mL), dried with Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (basic Al_2O_3, petroleum ether : ethyl acetate = 3 : 1 to ethyl acetate : methanol = 50 : 1), then the crude product repurified by prep-HPLC (column: Waters Xbridge 150*25 5u;mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN];B%: 50%-77%,10 min) and lyophilization. Compound 2-[(2*S*)-1-[(*E*)-4-methoxybut- 2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl] acetonitrile (38.6 mg, 62.4 μmol, 21% yield, 98% purity) was obtained as white solid. LCMS [ESI, M+1]: 610.

[02309] ^{1}H NMR (400 MHz, chloroform-d) δ 7.73 - 7.62 (m, 2H), 7.45 - 7.31 (m, 2H), 7.26 - 7.17 (m, 2H), 6.99 (br d, *J* = 15.2 Hz, 1H), 6.55 (br d, *J* = 15.6 Hz, 1H), 5.20 - 4.50 (m, 1H) 4.43 - 4.33 (m, 1H), 4.29 - 3.96 (m, 6H), 3.94 - 3.83 (m, 1H), 3.81 - 3.63 (m, 1H), 3.58 - 3.37 (m, 5H), 3.23 - 2.96 (m, 5H), 2.92 (s, 3H), 2.87 - 2.54 (m, 4H), 2.52 - 2.43 (m, 3H), 2.33 - 2.24 (m, 1H), 2.13 - 2.01 (m, 1H), 1.87 - 1.72 (m, 3H).

EXAMPLE 555



2-((*S*)-1-(2-Fluoroacryloyl)-4-(7-(6-methyl-5- (trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02310] 1-Bromo-5-fluoro-3-methyl-2-(trifluoromethyl)benzene. To a solution of 1-bromo-5-fluoro-2-iodo-3-methyl-benzene (2 g, 6.35 mmol, 1 eq) in DMF (40 mL) was added CuI (7.26 g, 38.1 mmol, 6 eq) and methyl 2,2-difluoro-2-fluorosulfonyl-acetate (7.32 g, 38.1 mmol, 4.85 mL, 6 eq). The mixture was stirred at 60 °C for 12 hours. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (20 mL × 3). The organic layer was washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 1/0 to 10/1). 1-bromo-5-fluoro-3-methyl-2-

(trifluoromethyl)benzene (1.3 g, 3.74 mmol, 59% yield, 74% purity) was obtained as a yellow oil.

[02311] ^{1}H NMR (400MHz, chloroform-d) δ = 7.33 (dd, *J* = 2.4, 7.6 Hz, 1H), 6.95 (dd, *J* = 2.0, 8.8 Hz, 1H), 2.54 (q, *J* = 3.6 Hz, 3H).

[02312] 2-Bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde. To a mixture of 1-bromo-5-fluoro-3-methyl-2- (trifluoromethyl)benzene (900 mg, 3.50 mmol, 1 eq) in THF (20 mL) was added LDA (2 M in THF, 3.50 mL, 2 eq) at - 60 °C under nitrogen. After stirring for 0.5 hour, to the mixture was added DMF (768 mg, 10.5 mmol, 808 µL, 3 eq). The mixture was stirred at - 60 °C for 1 hour. The reaction was quenched with saturated aqueous NH_4Cl (10 mL) and then extracted with ethyl acetate (50 mL × 3). The combined organic phase was washed with brine (10 mL), dried over anhydrous Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 200/1 to 5/1). 2-bromo-6-fluoro-4-methyl-3-(trifluoromethyl)benzaldehyde (700 mg, 2.46 mmol, 70% yield) was obtained as a yellow oil.

[02313] ^{1}H NMR (400MHz, chloroform-d) δ = 10.35 (s, 1H), 7.08 (d, *J* = 10.4 Hz, 1H), 2.66 - 2.58 (m, 3H).

[02314] 4-Bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole. A solution of 2-bromo-6-fluoro-4-methyl-3- (trifluoromethyl)benzaldehyde (600 mg, 2.11 mmol, 1 eq) and hydrazine monohydrate (2.11 g, 42.1 mmol, 2.05 mL, 20 eq) in DMSO (8 mL) was stirred at 60 °C for 2 hours. The mixture was diluted with ethyl acetate (50 mL) and washed with water (3 × 50 mL) and brine (1 × 50 mL). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was used in the next step without further purification. 4-Bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole (550 mg, 1.97 mmol, 94% yield) was obtained as a white solid.

[02315] 4-Bromo-6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole. To a solution of 4-bromo-6-methyl-5-(trifluoromethyl)- 1H-indazole (500 mg, 1.79 mmol, 1 eq) in DCM (10 mL) was added 4-methylbenzenesulfonic acid hydrate (34.1 mg, 1791 µmol, 0.1 eq)followed by a solution of DHP (603 mg, 7.17 mmol, 655 µL, 4 eq) in CH_3CN (2 mL). The mixture was stirred at 25 °C for 16 hours. The mixture was diluted with ethyl acetate (100 mL)

and washed with water (2 × 100 mL) and brine (1 × 50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by column chromatography over silica gel (petroleum ether/ethyl acetate 20/1 to 3/1). The desired fractions were collected and concentrated under vacuum to give 4-bromo-6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazole (600 mg, 1.54 mmol, 86% yield, 93% purity) as a light yellow gum. LCMS [MSI, M+1]: 363.


[02316] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 848 μmol, 1 eq), 4-bromo-6-methyl-1-tetrahydropyran- 2-yl-5-(trifluoromethyl)indazole (431 mg, 1.19 mmol, 1.4 eq) $Pd_2(dba)_3$ (155 mg, 170 μmol, 0.2 eq), RuPhos (158 mg, 339 μmol, 0.4 eq) and Cs_2CO_3 (691 mg, 2.12 mmol, 2.5 eq) in toluene (20 mL) was degassed and purged with N_2 for 3 times, and stirred at 100 °C for 16 hours under N_2. To the mixture was added H_2O (20 mL × 1) and ethyl acetate (20 mL × 1). The organic phase was separated, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel chromatography (ethyl acetate /mmethanol = 50/1 to 2/1). *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 535 μmol, 32% yield, 80.7% purity) was obtained as a yellow solid. LCMS [MSI, M+1]: 754.

[02317] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-Methylpyrrolidin- 2-yl]methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[6-methyl-1-tetrahydropyran-2-yl-5-(trifluoromethyl)indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (470 mg, 503 μmol, 1 eq) in DCM (1 mL) was added TFA (2.29 g, 20.1 mmol, 1.49 mL, 40 eq). The mixture was stirred at 25 °C for 1 h. To the mixture was added dichloromethane (5 mL) and basified with saturated aqueous NaHCO3 to pH = 8 ~ 9. The organic phase was separated, dried over sodium sulfate, filtered and concentrated under reduced


pressure to give 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin- 2-yl]methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (420 mg, 453 μmol, 90% yield, 61.4% purity) as a yellow solid that was used into next step without further purification. LCMS [MSI, M+1]: 570.

[02318] Step C: 2-((*S*)-1-(2-Fluoroacryloyl)-4-(7-(6-methyl-5- (trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a solution of 2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl] methoxy]-7-[6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (380 mg, 410 μmol, 1 eq), 2-fluoroprop-2-enoic acid (18.4 mg, 205 μmol, 0.5 eq) and TEA (124 mg, 1.23 mmol, 171 μL, 3 eq) in DMF (8 mL) was added T3P (391 mg, 614 μmol, 365 μL, 50% purity in DMF, 1.5 eq) at - 40 °C. Then the mixture was stirred at -40 °C for 0.5 hour and 0 °C for another 0.5 hour. 2-Fluoroprop-2-enoic acid (11 mg) and T3P (100 μL) were added and the mixture was stirred at -40 °C for further 0.5 hour. The mixture was diluted with water (15 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were washed with brine (50 mL), dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225% FA) - MeCN]; B%: 22% - 42%, 7.8 min) and (column: Phenomenex Gemini 150*25mm*10μm; mobile phase: [water (0.04% NH_3H_2O + 10 mM NH_4HCO_3) - MeCN]; B%: 50% - 68%, 12 min). The desired fractions were collected and lyophilized to give title compound 2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(6-methyl-5-(trifluoromethyl)-1H-indazol-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile as white solid. LCMS [ESI, M+1]: 642.

EXAMPLE 556



2-[(2S)-1-(2-Fluoroprop-2-enoyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02319] 3-Bromo-1-(methoxymethoxy)naphthalene. To a solution of 4-bromonaphthalen-2-ol (3.50 g, 15.7 mmol, 1.0 eq) in DMF (35.0 mL) was added NaH (941 mg, 23.5 mmol, 60% purity, 1.50 eq). After addition, the mixture was stirred at this temperature for 0.5 hour, and then chloro(methoxy)methane (5.90 g, 73.3 mmol, 5.57 mL, 4.67 eq) was added dropwise at 0 °C. The mixture was warmed to 30 °C and stirred for further 1 hour. After completion, the combined reaction mixture was diluted with water (100 mL) and extracted with EtOAc (3 × 50.0 mL). The combined organic layers were washed with saturated brine (200 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=1/0 to 100/1). Compound 3-bromo-1-(methoxymethoxy)naphthalene (3.50 g, 13.1 mmol, 84% yield) was obtained as a red oil.

[02320] ^{1}H NMR (400 MHz, chloroform-d) δ 8.19 - 8.12 (m, 1H), 7.78 - 7.71 (m, 1H), 7.61 - 7.57 (m, 1H), 7.52 - 7.44 (m, 2H), 7.40 (d, J = 2.0 Hz, 1H), 5.29 (s, 2H), 3.53 (s, 3H).

[02321] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(methoxymethoxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of *t*ert-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (800 mg, 1.70 mmol, 1.0 *eq*) and 1-bromo-3-(methoxymethoxy)naphthalene (680 mg, 2.54 mmol, 1.50 *eq*) in toluene (10.0 mL) was added Cs_2CO_3 (2.21 g, 6.79 mmol, 4.00 *eq*), RuPhos (158 mg, 339 μmol, 0.20 *eq*) and $Pd_2(dba)_3$ (233 mg, 254 μmol, 0.15 *eq*). The mixture was stirred at 90 °C for 6 hours. The reaction mixture was diluted with H_2O 100 mL and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were concentrated under reduced pressure to give a residue. The residue was further purified by reverse phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH=7 with $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 50.0 mL). The combined organic layers were washed with saturated brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Compound *t*ert-butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(methoxymethoxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 426 μmol, 25 % yield) was obtained as a yellow solid. LCMS [ESI, M+1]: 658.

[02322] ^{1}H NMR (400 MHz, chloroform-d) δ 8.09 (d, *J* = 8.0 Hz, 1H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.45 (t, *J* = 7.0 Hz, 1H), 7.40 - 7.34 (m, 1H), 7.16 (d, *J* = 2.0 Hz, 1H), 6.87 (d, *J* = 2.4 Hz, 1H), 5.30 (s, 2H), 4.63 (br s, 1H), 4.40 (dd, *J* = 4.8, 10.4 Hz, 1H), 4.33 - 4.22 (m, 2H), 4.21 - 4.16 (m, 1H), 4.09 - 3.86 (m, 3H), 3.54 (s, 3H), 3.51 - 3.40 (m, 1H), 3.37 - 3.17 (m, 3H), 3.15 - 2.96 (m, 3H), 2.89 - 2.73 (m, 3H), 2.72 - 2.64 (m, 1H), 2.49 (s, 3H), 2.33 - 2.25 (m, 1H), 2.13 - 2.05 (m, 1H), 1.91 - 1.78 (m, 3H), 1.52 (s, 9H).


[02323] Step B: 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *t*ert-butyl (2*S*)-2-(cyanomethyl)-4-[7-[3-(methoxymethoxy)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (260 mg, 395 μmol, 1.0 *eq*) in dioxane (2.0 mL) was added HCl•dioxane (4 M, 98.8 μL, 1.0 *eq*). The mixture was stirred at 20 °C for 1 hour. After completion, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was adjusted pH = 7

with saturated of $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 20.0 mL). The combined organic layers were washed with saturated brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. Compound 2-[(2*S*)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 373 μmol, 94% yield, 96% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 514.


[02324] Step C: 2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2S)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 389 μmol, 1.0 eq) and 2-fluoroprop-2-enoic acid (105 mg, 1.17 mmol, 3.0 eq) in DMF (4.00 mL) was added TEA (158 mg, 1.56 mmol, 217 μL, 4.0 eq) and T3P (743 mg, 1.17 mmol, 695 μL, 50% purity, 3.0 eq) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was diluted with H2O (10.0 mL) and extracted with DCM (3 ×10.0 mL). The combined organic layers were washed with saturated brine (20.0 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Al2O3, petroleum ether/ethyl acetate=10/1 to DCM/ MeOH = 5/1), and the residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10μm;mobile phase: [water(0.04%NH3H2O+10mM NH4HCO3)-MeCN];B%: 45%-75%,12min). Title compound 2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[7-(3-hydroxy-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (50.0 mg, 85.0 μmol, 22% yield, 99.6% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 586.

[02325] ^{1}H NMR (400 MHz, chloroform-d) δ 7.94 (br d, *J* = 8.4 Hz, 1H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.40 (t, *J* = 7.2 Hz, 1H), 7.31 - 7.26 (m, 1H), 6.86 (s, 1H), 6.52 (br s, 1H), 5.51 - 5.29 (m, 1H), 5.25 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.95 - 4.35 (m, 2H), 4.24 (dd, *J* = 4.4, 11.2 Hz, 1H), 4.15 - 3.93 (m, 3H), 3.85 - 3.69 (m, 1H), 3.45 - 3.26 (m, 1H), 3.25 - 3.18 (m, 2H), 3.17 - 2.95 (m, 2H), 2.94 - 2.73 (m, 3H), 2.72 - 2.62 (m, 5H), 2.60 - 2.50 (m, 1H), 2.45 - 2.35 (m, 1H), 2.15 - 2.06 (m, 1H), 2.01 - 1.93 (m, 1H), 1.88 - 1.74 (m, 3H).

EXAMPLE 557



2-[(2S)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02326] Step A: Benzyl 4-[(3*S*)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of [(2*R*)-1-methylpyrrolidin-2-yl]methanol (934 mg, 8.11 mmol, 3.0 *eq*) and *t*-BuONa (780 mg, 8.11 mmol, 3.0 *eq*) in toluene (15.0 mL) was added a solution of benzyl 4-[(3*S*)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (1.5 g, 2.70 mmol, 1.0 *eq*) in toluene (10.0 mL) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for another 0.5 hr. After

completion, the reaction was quenched with water (30.0 mL). The crude mixture was extracted with ethyl acetate (2 × 50.0 mL). Combine extracts were washed with brine (100 mL), dried with Na_2SO_4, the solvent was then removed under vacuum. The residue was purified by reverse phase flash HPLC [C18, 0.1% FA in water, 0 - 65% MeCN] and was acidified with $NaHCO_3$ to pH = 8 and extracted with ethyl acetate (2 × 150 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. Compound benzyl 4-[(3*S*)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (820 mg, 1.26 mmol, 47% yield, 93% purity) was obtained as white solid. LCMS [ESI, M+1]: 606.

[02327] ^{1}H NMR (400MHz, chloroform-d) δ 7.42 - 7.29 (m, 5H), 5.18 (s, 2H), 4.69 (br d, *J* = 18.6 Hz, 1H), 4.59 (br s, 1H), 4.44 (d, *J* = 18.8 Hz, 1H), 4.34 (br s, 1H), 4.05 - 3.69 (m, 4H), 3.42 (br s, 1H), 3.24 (br d, *J* = 13.0 Hz, 2H), 3.09 (br t, *J* = 7.6 Hz, 1H), 3.02 - 2.90 (m, 1H), 2.81 - 2.56 (m, 5H), 2.47 (s, 3H), 2.28 (dt, *J* = 7.2, 9.4 Hz, 1H), 2.05 - 1.99 (m, 1H), 1.89 - 1.67 (m, 4H), 1.51 (s, 9H).

[02328] Step B: tert-Butyl (2S)-2-(cyanomethyl)-4-[2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. NH_3 was bubbled into MeOH (10.0 mL) of at -70 °C for 0.5 hr. Benzyl 4-[(3S)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (820 mg, 1.35 mmol, 1.0 eq) and Pd/C (250 mg, 10% purity) was added to the above mixture and MeOH (10.0 mL), then the mixture was degassed and purged with H_2 3 times, and then the mixture was stirred at 20 °C for 0.5 hr under H_2 (15 psi). After completion, the crude mixture was filtered through a pad of celite. The cake was washed with MeOH (50.0 mL) and the filtrate dried under high vacuum. Compound tert-butyl (2S)-2-(cyanomethyl)-4-[2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 1.27 mmol, 94% yield, 100% purity) was obtained as white solid and used into the next step without further purification. LCMS [ESI, M+1]: 472.

[02329] Step C: tert-Butyl(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. A mixture of tert-butyl (2S)-2-(cyanomethyl)-4-[2-[[(2R)-1-methylpyrrolidin-2-

yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (550 mg, 1.17 mmol, 1.0 eq), 1-bromo-8-chloro-naphthalene (845 mg, 3.50 mmol, 3.0 eq), $Pd_2(dba)_3$ (160 mg, 175 μmol, 0.15 eq), Xantphos (135 mg, 233 μmol, 0.20 eq) and Cs_2CO_3 (1.14 g, 3.50 mmol, 3.0 eq) in toluene (10.0 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 90 °C for 8 hrs under N_2. After completion, the reaction was washed with HCl (2N 2 × 15 mL) aqueous solution. The aqueous phase was basified with $NaHCO_3$ to pH 8 and extracted with ethyl acetate (2 × 50 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash HPLC [C18, 0.1% FA in water, 0 - 65% MeCN] and was acidified with $NaHCO_3$ to pH = 8 and extracted with ethyl acetate (2 × 150 mL). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. Compound tert-butyl(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 930 μmol, 80% yield, 98% purity) was obtained as white solid. LCMS [ESI, M+1]: 632.

[02330] ^{1}H NMR (400MHz, chloroform-d) δ 7.75 (br d, J = 8.2 Hz, 1H), 7.61 (t, J = 8.0 Hz, 1H), 7.52 (d, J = 7.5 Hz, 1H), 7.44 (td, J = 7.8, 15.2 Hz, 1H), 7.33 (t, J = 7.8 Hz, 1H), 7.27 - 7.17 (m, 1H), 4.61 (br s, 1H), 4.48 - 4.34 (m, 2H), 4.10 - 3.91 (m, 3H), 3.90 - 3.78 (m, 1H), 3.63 - 3.53 (m, 1H), 3.34 (br dd, J = 3.6, 13.8 Hz, 1H), 3.30 - 3.01 (m, 5H), 2.95 (dt, J = 3.5, 12.3 Hz, 1H), 2.89 - 2.75 (m, 1H), 2.70 (br s, 2H), 2.57 (br d, J = 14.2 Hz, 1H), 2.53 - 2.46 (m, 3H), 2.35 - 2.25 (m, 1H), 2.13 - 2.06 (m, 1H), 1.93 - 1.66 (m, 3H), 1.52 (s, 9H).


[02331] Step D: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 316 μmol, 1.0 *eq*) in dioxane (2.0 mL) was added HCl/dioxane (4 M, 2.0 mL, 25.3 *eq*). The mixture was stirred at 20 °C for 0.5 hour under N_2. After completion, the organic solvent was removed under vacuum. The obtained product was adjusted with saturated aqueous $NaHCO_3$ to Ph = 8, then concentrated. The aqueous phase was extracted with ethyl acetate (3 × 10.0 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The crude product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-1-

methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (145 mg, 259 μmol, 82% yield, 95% purity) was obtained as yellow solid and used into the next step without further purification. LCMS [ESI, M+1]: 532


[02332] Step E: 2-[(2S)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (125 mg, 235 μmol, 1.0 eq), 2-fluoroprop-2-enoic acid (42.3 mg, 470 μmol, 2.0 eq) in ethyl acetate (2.0 mL) was added TEA (190 mg, 1.88 mmol, 262 μL, 8.0 eq) and T3P (449 mg, 705 μmol, 419 μL, 50% purity, 3.0 eq) at 0 °C. The mixture was stirred at 20 °C for 1 hour. After completion, the organic solvent was washed with water (5.0 mL). The aqueous phase was extracted with ethyl acetate (3 × 10 mL). Theombined organic extracts were washed with brine (20.0 mL), dried with Na_2SO_4 the solvent was then removed under vacuum. The residue was purified by column chromatography (basic Al_2O_3, petroleum ether : ethyl acetate = 3 : 1 to ethyl acetate : methanol = 50 : 1), then the crude product was concentrated and re-purified by prep-HPLC (column: Phenomenex Gemini 150 × 25 mm × 10 μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN];B%: 55% - 85%,11.5 min) and lyophilization. Title compound 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (22.5 mg, 37.1 μmol, 16% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 605.

[02333] ^{1}H NMR (400MHz, chloroform-d) δ 7.76 (br d, J = 8.4 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.51 - 5.32 (m, 1H), 5.26 (br dd, J = 3.2, 16.8 Hz, 1H), 4.90 (br s, 1H), 4.49 - 4.34 (m, 2H), 4.24 - 4.01 (m, 3H), 3.97 - 3.78 (m, 2H), 3.64 - 3.55 (m, 1H), 3.44 (br s, 1H), 3.32 - 2.95 (m, 5H), 2.94 - 2.43 (m, 7H), 2.38 - 2.20 (m, 1H), 2.14 – 1.99 (m, 1H) 1.91 - 1.71 (m, 3H).

EXAMPLE 558



2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((2*R*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02334] Step A: Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of [(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (169 mg, 1.27 mmol, 1.5 *eq*) in toluene (4.0 mL) was added *t*-BuONa (163 mg, 1.69 mmol, 2.0 *eq*) at 0 °C, after the reaction mixture was stirred at 0 °C for 0.5 hour, benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-*d*ihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (470 mg, 847 μmol, 1.0 *eq*) was added to the mixture, the reaction mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was

added to water (10 mL), then extracted with ethyl acetate (2 × 10.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=3/1 to ethyl acetate/methanol=20/1) to give benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (330 mg, 484 μmol, 57% yield, 92% purity) as white solid. LCMS [ESI, M+1]: 624.

[02335] ^{1}H NMR (400 MHz, chloroform-d) δ 7.40 - 7.30 (m, 5H), 5.24 - 5.03 (m, 3H), 4.69 (d, *J* = 18.8 Hz, 1H), 4.61 - 4.53 (m, 1H), 4.51 - 4.38 (m, 2H), 4.23 (dd, *J* = 7.6, 10.4 Hz, 1H), 4.08 - 3.73 (m, 4H), 3.52 - 3.11 (m, 4H), 3.04 - 2.91 (m, 1H), 2.81 - 2.57 (m, 5H), 2.55 - 2.36 (m, 5H), 2.11 - 1.99 (m, 1H), 1.51 (s, 9H).

[02336] Step B: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (330 mg, 529 μmol, 1.0 *eq*) in methanol (3.0 mL) and NH_3.MeOH (529 μmol, 3 mL, 20% purity, 1.0 *eq*) was added Pd/C (50 mg, 529 μmol, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 3 hours. After completion, the mixture was filtered, and the filter cake was washed with THF (2 × 3.0 mL), the filtrate was concentrated. The residue was purified by reverse phase flash chromatography (0.1% FA in MeCN). The mixture was adjusted with $NaHCO_3$ solid to pH~8, then concentrated. The aqueous layer (20.0 mL) was extracted with ethyl acetate (2 × 15.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated to give *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 299 μmol, 58% yield, 98% purity) as white solid. LCMS [ESI, M+1]: 490.

[02337] Step C: *tert*-Butyl(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-

[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 306 μmol, 1.0 *eq*) and 1-bromo-8-chloro-naphthalene (148 mg, 618 μmol, 2.0 *eq*) in toluene (3.0 mL) was added XantPhos (35.5 mg, 61.3 μmol, 0.2 *eq*), $Pd_2(dba)_3$ (42.1 mg, 45.9 μmol, 0.15 *eq*), and Cs_2CO_3 (399 mg, 1.23 mmol, 4.0 *eq*), the reaction mixture was stirred at 90 °C for 12 hours under N_2. After completion, the reaction mixture was filtered through celite, and the filtrate was washed with 1N aqueous HCl (2 × 10.0 mL), the aqueous layer was adjusted to pH~8 with solid Na_2CO_3 , then extracted with ethyl acetate (2 × 15.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash chromatography (0.1% FA in MeCN). The obtained product was adjusted with solid $NaHCO_3$ to pH~8, and concentrated. The aqueous layer (20 mL) was extracted with ethyl acetate (2 × 15.0 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The product *tert*-butyl(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (85 mg, 129 μmol, 43% yield, 98% purity) was obtained as white solid. LCMS [ESI, M+1, M+23]: 650, 672.

[02338] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 8.0 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.26 - 7.17 (m, 1H), 5.24 - 5.03 (m, 1H), 4.67 - 4.55 (m, 1H), 4.52 - 4.36 (m, 2H), 4.23 (dd, *J* = 7.6, 10.4 Hz, 1H), 4.13 - 3.77 (m, 4H), 3.65 - 3.52 (m, 1H), 3.43 - 2.86 (m, 7H), 2.84 - 2.64 (m, 3H), 2.62 - 2.38 (m, 5H), 2.16 - 1.98 (m, 1H), 1.52 (s, 9H).


[02339] Step D: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (85.0 mg, 131 μmol, 1.0 *eq*) in dioxane (1.0 mL) was added 4 M HCl/dioxane (1.0 mL), the reaction mixture was stirred at 20 °C for 4 hours. After completion, the reaction mixture was concentrated, the mixture was added dichloromethane (10 mL), then adjusted with saturated aqueous Na_2CO_3 to pH~8, the organic layer was separated, then dried over Na_2SO_4, filtered and concentrated. The product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90 mg, crude) was obtained as brown solid. LCMS [ESI, M+1]: 550.


[02340] Step E: 2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((2*R*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, 120 μmol, *73% purity,* 1.0 *eq*) and 2-fluoroprop-2-enoic acid (21.7 mg, 241 μmol, 2.0 *eq*) in ethyl acetate (2.0 mL) was added T3P (230 mg, 361 μmol, 215 μL, 50% purity, 3.0 *eq*) and TEA (97.6 mg, 962 μmol, 134 μL, 8.0 *eq*), the reaction mixture was stirred at 20 °C for 1 hour. After completion, water was added (10.0 mL), then the organic layer was separated, the aqueous layer was extracted with ethyl acetate (2 × 10.0 mL). The combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=3/1 to ethyl acetate: methanol=10:1). The crude product was re-purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10μm; mobile phase: [water (0.04%NH_3H_2O + 10mM NH_4HCO_3)-MeCN]; B%: 48%-78%, 12 min), the obtained product was concentrated, and then lyophilized. The product title compound 2-((*S*)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2*R*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (10.9 mg, 17.3 μmol, 14% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 622.

[02341] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.18 (m, 1H), 5.50 - 5.34 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.22 - 5.04 (m, 1H), 4.98 - 4.72 (m, 1H), 4.54 - 4.37 (m, 2H), 4.30 - 4.02 (m, 3H), 3.96 - 3.75 (m, 2H), 3.66 - 3.54 (m, 1H), 3.51 - 2.99 (m, 6H), 2.98 - 2.67 (m, 3H), 2.64 - 2.36 (m, 6H), 2.14 - 1.97 (m, 1H).

EXAMPLE 559



2-[(2*S*)-4-[2-[2-(Dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02342] Step A: 2-[(7-Benzyl-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine. To the solution of 7-benzyl-2-chloro-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine (5 g, 17.3 mmol, 1 *eq*), 2-(dimethylamino)ethanol (3.08 g, 34.5 mmol, 3.46 mL, 2 *eq*), Cs_2CO_3 (5.62 g, 17.3 mmol, 1 *eq*) and BINAP (2.15 g, 3.45 mmol, 0.2 *eq*) in toluene (100 mL) was added $Pd(OAc)_2$ (387 mg, 1.73 mmol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 100 °C for 12 hours. The reaction mixture was filtered. To the filtrate was added HCl (2 M, 200 mL), then separated. The aqueous phase was basified with $NaHCO_3$ and K_2CO_3 to PH = 8~9, then extracted with EtOAc (5 × 80 mL). The combined organic phase was washed with brine (100 mL), dried with anhydrous Na_2SO_4, filtered and concentrated in

vacuum to give 2-[(7-benzyl-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine (4.8 g, 12.6 mmol, 73 % yield, 90 % purity) as a brown oil which was used for next step without further purification.

[02343] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.40 - 7.28 (m, 5H), 4.40 (t, *J* = 6.0 Hz, 2H), 3.96 (s, 3H), 3.69 (s, 2H), 3.50 (s, 2H), 2.76 - 2.69 (m, 4H), 2.62 - 2.56 (m, 2H), 2.32 (s, 6H).

[02344] Step B: 2-[(4-Methoxy-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine. To the solution of 2-[(7-benzyl-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine (4.8 g, 14.0 mmol, 1 *eq*) in MeOH (100 mL) was added $Pd(OH)_2/C$ (2 g, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 18 hours. To the mixture was added HCl/MeOH (4 M, 7.01 mL, 2 *eq*). The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 40 °C for 2 hours. The mixture was filtered, the filter cake was washed with NH_3•MeOH (10 %, 3 × 30 mL). The filtrate was concentrated under vacuum. The residue was dissolved with water (10 mL) and EtOAc (10 mL), then the mixture was basified with K_2CO_3 to pH = 11. The mixture was extracted with EtOAc (8 × 20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum to give 2-[(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine (2.58 g, 8.69 mmol, 62 % yield, 85 % purity) as a brown oil which was used for next step without further purification. LCMS [ESI, M+1]: 253.

[02345] Step C: 2-[[4-Methoxy-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine. To the solution of 2-[(4-methoxy-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-2-yl)oxy]-*N*,*N*-dimethyl-ethanamine (2.28 g, 7.68 mmol, 1 *eq*), 1-bromo-8-methyl-naphthalene (2.55 g, 11.5 mmol, 1.5 *eq*), Cs_2CO_3 (7.51 g, 23.0 mmol, 3 *eq*) and Xantphos (889 mg, 1.54 mmol, 0.2 *eq*) in toluene (70 mL) was added $Pd_2(dba)_3$ (703 mg, 768 μmol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 100 °C for 16 hours. The reaction mixture was filtered, the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 10:1 ~ 0:1 to EtOAc: MeOH = 1:0 ~ 10:1) to give 2-[[4-

methoxy-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (3.2 g, 7.34 mmol, 95 % yield, 90 % purity) as a brown solid. LCMS [ESI, M+1]: 393.

[02346] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.69 (d, *J* = 8.0 Hz, 1H), 7.64 (d, *J* = 7.6 Hz, 1H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.22 (m, 2H), 4.44 (t, *J* = 6.4 Hz, 2H), 4.17 - 4.05 (m, 1H), 4.03 (s, 3H), 3.81 (d, *J* = 17.6 Hz, 1H), 3.57 - 3.48 (m, 1H), 3.20 (dt, *J* = 4.0, 11.2 Hz, 1H), 2.94 - 2.82 (m, 4H), 2.75 (t, *J* = 6.4 Hz, 2H), 2.67 (br d, *J* = 16.4 Hz, 1H), 2.34 (s, 6H).

[02347] Step D: 2-[2-(Dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol. To the solution of EtSH (1.96 g, 31.5 mmol, 2.33 mL, 3.64 *eq*) in DMF (60 mL) was added NaH (693 mg, 17.3 mmol, 60 % purity, 2 *eq*), the mixture was stirred at 10 °C for 0.5 hour. Then 2-[[4-methoxy-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxy]-*N*,*N*-dimethyl-ethanamine (3.4 g, 8.66 mmol, 1 *eq*) in DMF (10 mL) was added, the mixture was heated to 60 °C and stirred for 1 hour. The mixture was poured into ice water (200 mL) and extracted with EtOAc (30 mL). The aqueous phase was acidified with HCl (2 M) to PH = 7~8, then extracted with EtOAc (6 × 80 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was triturated with PE: EtOAc = 5:1 to give 2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol (2.4 g, 6.28 mmol, 72 % yield, 99 % purity) as a white solid. LCMS [ESI, M+1]: 379.

[02348] Step E: [2-[2-(Dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesμLfonate. To the solution of 2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-ol (1 g, 2.64 mmol, 1 *eq*) and TEA (668 mg, 6.61 mmol, 919 μL, 2.5 *eq*) in DCM (20 mL) was added Tf_2O (1.12 g, 3.96 mmol, 654 μL, 1.5 *eq*) at -40 °C, the mixture was stirred at -40 °C for 10 min. To the mixture was added water (10 mL), then separated. The aqueous phase was extracted with EtOAc (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 5:1~0:1) to give [2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-

naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesμLfonate (650 mg, 1.15 mmol, 43% yield, 90 % purity) as a brown oil.


[02349] Step F: 2-[(2*S*)-4-[2-[2-(Dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of [2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl] trifluoromethanesμLfonate (350 mg, 685 μmol, 1 *eq*) and 2-[(2*S*)-piperazin-2-yl]acetonitrile (111 mg, 754 μmol, 1.1 *eq*) in DMAC (4 mL) was added DIEA (177 mg, 1.37 mmol, 239 μL, 2 *eq*), the mixture was stirred at 10 °C for 10 min. The mixture was purified by reversed phase flash column (MeCN/Water (0.1% FA) = 40 %) to give 2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60 mg, 121 μmol, 18 % yield, 98 % purity) as a brown oil. LCMS [ESI, M+1]: 486.

[02350] Step F: 2-[(2*S*)-4-[2-[2-(Dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60 mg, 123 μmol, 1 eq), 2-fluoroprop-2-enoic acid (22.2 mg, 247 μmol, 2 eq) and TEA (100 mg, 988 μmol, 138 μL, 8 eq) in EtOAc (1.2 mL) was added T3P (236 mg, 370 μmol, 220 μL, 50 % purity, 3 eq) at 0 °C, the mixture was stirred at 10 °C for 0.5 hour. Water (5 mL) was added into the mixture. The mixture was extracted with EtOAc (2 × 8 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by Al_2O_3 chromatography (EtOAc: MeOH = 1:0 ~ 20:1). Then the residue was purified by prep-HPLC (column: Gemini 150*25 5μ;mobile phase: [water (0.05 % ammonium hydroxide v/v)-MeCN];B%: 53 % - 83 %, 12 min) to give title compound 2-[(2*S*)-4-[2-[2-(dimethylamino)ethoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (39.5 mg, 70.4 μmol, 57 % yield, 99.4 % purity) as a gray solid. LCMS [ESI, M+1]: 558.

[02351] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.0 Hz, 1H), 7.46 - 7.38 (m, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.18 (m, 2H), 5.52 - 5.33 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.88 (br s, 1H), 4.47 - 4.37 (m, 2H), 4.31 - 4.18 (m, 1H), 4.17 -


4.01 (m, 2H), 3.94 - 3.84 (m, 1H), 3.77 (d, J = 18.0 Hz, 1H), 3.58 - 3.41 (m, 2H), 3.25 - 2.95 (m, 4H), 2.92 (s, 3H), 2.90 - 2.77 (m, 2H), 2.77 - 2.70 (m, 2H), 2.68 - 2.56 (m, 1H), 2.34 (d, J = 3.6 Hz, 6H).

EXAMPLE 560



2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-Fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile

[02352] 1-tert-Butyl-2-methyl (2*S*, 4*R*)-4-fluoropyrrolidine-1,2-dicarboxylate. To a solution of (2*S*,4*R*)-1-*tert*-butoxycarbonyl-4-fluoro-pyrrolidine-2-carboxylic acid (2.0 g, 8.58 mmol, 1.0 *eq*) and Ag_2O (3.97 g, 17.2 mmol, 2.0 *eq*) in CH_3CN (20.0 mL) was added MeI (2.43 g, 17.2 mmol, 1.07 mL, 2.0 *eq*) at 0°C in portions, the reaction mixture was stirred at 15°C for 12 hours. After completion, the reaction mixture was added to water (30.0 mL), then the organic layer was separated, the aqueous phase was extracted with ethyl acetate (30.0 mL×2), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether: ethyl acetate=3:1 to ethyl acetate: methanol=10:1). The product 1-tert-butyl-2-methyl (2*S*, 4*R*)-4-fluoropyrrolidine-1,2-dicarboxylate (1.98 g, 8.01 mmol, 93% yield) was obtained as colorless oil.



[02353] ^{1}H NMR (400 MHz, Chloroform-d) δ 5.29-5.15 (m, 1H), 4.49-4.38 (m, 1H), 3.92-3.74 (m, 1H), 3.68 (s, 3H), 3.60-3.56 (m, 1H), 2.63-2.54 (m, 1H), 2.17-2.05 (m, 1H), 1.44 (d, *J*=18.0 Hz, 9H).

[02354] [(2*S*,4*R*)-4-Fluoro-1-methyl-pyrrolidin-2-yl]methanol. To a solution of 1-*tert*-butyl-2-methyl (2*S*,4*R*)-4-fluoropyrrolidine-1,2-dicarboxylate (1.98 g, 8.0 mmol, 1.0 *eq*) in THF (20.0 mL) was added $LiAlH_4$ (912 mg, 24.0 mmol, 3.0 *eq*) slowly at -40°C, after completion the mixture was stirred at -40°C for 0.5 hour, then the mixture was warmed to 70°C and stirred at this temperature for 3 hours. After completion, the reaction mixture was quenched by addition a solution of Na_2SO_4 (6.0 mL) at 0°C, and then diluted with THF (10.0 mL), then filtered and the solid was washed with ethyl acetate (30.0 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (800 mg, 6.01 mmol, 75% yield) as yellow oil.

[02355] ^{1}H NMR (400 MHz, Chloroform-d) δ 5.13-4.97 (m, 1H), 3.67-3.63 (m, 1H), 3.51-3.37 (m, 2H), 2.95 (s, 1H), 2.74-2.68 (m, 1H), 2.63-2.51 (m, 1H), 2.33 (s, 3H), 2.07-2.02 (m, 1H), 1.99-1.95 (m, 1H).

[02356] Step A: Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. A mixture of [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (480 mg, 3.6 mmol, 2.0 *eq*) and *t*-BuONa (295 mg, 3.1 mmol, 1.7 *eq*) in toluene (8.0 mL) was degassed and purged with N_2 for 3 times and the mixture was stirred at 0°C, then benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (1 g, 1.8 mmol, 1.0 *eq*) in toluene (8.0 mL) was added. The mixture was stirred at 0°C for 0.5 hour under N_2. After completion, the mixture was quenched by addition H_2O (25.0 mL), and then extracted with ethyl acetate (30.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase flash HPLC (^{18}C, 0.1% FA in water, 0-60% MeCN). The obtained product was adjusted with saturated aqueous $NaHCO_3$ to pH~8, then concentrated, the aqueous layer was extracted with ethyl acetate (100.0 mL×3), the combined organic layer was dried over Na_2SO_4, filtered and concentrated to give benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (860 mg, 1.38 mmol, 76% yield, 100% purity) as a white solid. LCMS [ESI, M+1]: 624.

[02357] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.31-7.25 (m, 5H), 5.15-5.02 (m, 3H), 4.63-4.58 (m, 1H), 4.51 (br s, 1H), 4.39-4.31 (m, 2H), 4.16-4.12 (m, 1H), 3.99-3.88 (m, 3H), 3.71 (br d, J = 11.2 Hz, 1H), 3.52-3.41 (m, 1H), 3.36 (br s, 1H), 3.19-3.16 (m, 2H), 2.99-2.86 (m, 2H), 2.71-2.48 (m, 5 H), 2.43 (s, 3H), 2.76-2.17 (m, 1H), 1.96-1.80 (m, 1H), 1.74 (br s, 1H), 1.43 (s, 9H).

[02358] Step B: *tert*-Butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (860 mg, 1.4 mmol, 1.0 *eq*) in MeOH (20.0 mL) and NH_3•MeOH (10.0 mL, 50% w/w) was added Pd/C (200 mg, 10% purity, 1.0 *eq*) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25°C for 1 hour. After completion, the reaction mixture was filtered and

concentrated under reduced pressure to give *tert*-butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (620 mg, crude) as a white solid. The crude product was used into the next step without further purification. LCMS [ESI, M+1]: 490.

[02359] ^{1}H NMR (400 MHz, Chloroform-d) δ 5.16-5.02 (m, 1H), 4.51 (br s, 1H), 4.31 (dd, *J* = 4.8, 11.2 Hz, 1H), 4.13 (dd, *J* = 6.0, 11.2 Hz, 1H), 3.87 (s, 2H), 3.76 (d, *J* = 12.4 Hz, 1H), 3.52-3.41 (m, 1H), 3.14 (dd, *J* = 3.6, 13.6 Hz, 2H), 3.06-3.03 (m, 1H), 2.99-2.88 (m, 3H), 2.74-2.48 (m, 6H), 2.43 (s, 3H), 2.29-2.18 (m, 1H), 1.96-1.80 (m, 1H), 1.68-1.59 (m, 2H), 1.44 (s, 9H).


[02360] Step C: *tert*-Butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (600 mg, 1.2 mol, 1.0 *eq*), 1-bromo-8-methyl-naphthalene (812 mg, 3.7 mmol, 3.0 *eq*), $Pd_2(dba)_3$ (168 mg, 184 μmol, 0.15 *eq*), Cs_2CO_3 (1.2 g, 3.7 mmol, 3.0 *eq*) and Xantphos (142 mg, 246 μmol, 0.2 *eq*) in toluene (5.0 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90°C for 12 hours under N_2. After completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue, and then the residue was dissolved with EA 15.0 mL, then was adjusted with 0.5 M HCl to pH~2. The organic layer was washed with H_2O (**15.0** mL×**3**), then the solid $NaHCO_3$ was added to the combined aqueous phase until pH was reached to 8, after that, the aqueous phase was extracted with ethyl acetate (50.0 mL×3), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash HPLC (^{18}C, 0.1% TFA in water, 0-50% MeCN). The obtained product was adjusted with saturated aqueous $NaHCO_3$ to pH-8, then concentrated, the aqueous layer was extracted with EA (100.0 mL×3), the combined organic layer was dried over Na_2SO_4, filtered and concentrated to give *tert*-butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 467 μmol, 35% yield, 99% purity) as yellow oil. LCMS [ESI, M+1]: 630.

[02361] Step D: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-Fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 318 μmol, 1.0 *eq*) in dioxane (1.5 mL) was added HCl/dioxane (4 M, 2.0 mL, 25.0 *eq*) at 25°C. The mixture was stirred at 25°C for 1 hour. After completion, the reaction mixture was quenched by addition saturated aqueous $NaHCO_3$ (6.0 mL) at 0°C, and then diluted with H_2O 10.0 mL and extracted with EA (15.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude) as yellow oil. The product was used into the next step without further purification. LCMS [ESI, M+1]: 530.


[02362] Step E: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-Fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 283 μmol, 1.0 *eq*) in ethyl acetate (1.0 mL) was added a solution of 2-fluoroprop-2-enoic acid (42.9 mg, 476 μmol, 1.68 *eq*) in ethyl acetate (0.5 mL), then was added TEA (1.93 g, 19 mmol, 2.65 mL, 67.0 *eq*) and T3P (455 mg, 715 μmol, 425 μL, 50% purity, 2.5 *eq*) and the mixture was stirred at 0°C, after that the reaction mixture was warmed to 20°C and stirred for 1 hours. After completion, the reaction mixture was quenched by addition H_2O 10.0 mL, and then extracted with ethyl acetate (15.0 mL×3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150*25mm*10μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN]; B%: 58%-88%, 11.5min) and lyophilization to give title compound 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (50.1 mg, 82.9 μmol, two steps 26% yield, 99.5% purity) as a white solid. LCMS [ESI, M+1]: 602.

[02363] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.72 (d, J = 8.4 Hz, 1H), 7.67 (t, J = 8.0 Hz, 1H), 7.46-7.43 (m, 2H), 7.26-7.21 (m, 2H), 5.50-5.38 (m, 1H), 5.30-5.11 (m, 2H), 4.89 (br s, 1H), 4.45-4.40 (m, 1H), 4.30-4.20 (m, 2H), 4.19-4.13 (m, 1H), 4.10-4.05 (m, 1H), 3.92-3.88 (m, 1H), 3.82-3.77 (m, 1H), 3.62-3.46 (m, 3H), 3.25-3.18 (m, 2H), 3.15-3.09 (m, 1H), 3.08-2.98 (m, 2H), 2.94 (s, 3H), 2.90-2.77 (m, 2H), 2.67-2.56 (m, 2H), 2.51 (d, J = 4.8 Hz, 3H), 2.38-2.27 (m, 1H), 2.07-1.89 (m, 1H).

EXAMPLE 561



2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02364] 1-*tert*-Butyl-2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate. To the solution of (2*S*,4*R*)-1-*tert*-butoxycarbonyl-4-hydroxy-pyrrolidine-2-carboxylic acid (2 g, 8.65 mmol, 1 *eq*) and Ag_2O (6.01 g, 26.0 mmol, 3 *eq*) in MeCN (40 mL) was added CH_3I (10.0 g, 70.8 mmol, 4.41 mL, 8.19 *eq*), the mixture was stirred at 30 °C for 14 hours. To the mixture was added CH_3I (13.2 g, 93.1 mmol, 5.80 mL, 10.8 *eq*), the mixture was stirred at 30 °C for 6 hours. The reaction mixture was filtered, the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (PE: EtOAc = 20:1~10:1) to give 1-*tert*-butyl-2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (1.85 g, 6.99 mmol, 81 % yield, 98 % purity) as a yellow oil.

[02365] [(2*S*,4*R*)-4-Methoxy-1-methyl-pyrrolidin-2-yl]methanol. To the solution of *O*1-*tert*-butyl *O*2-methyl (2*S*,4*R*)-4-methoxypyrrolidine-1,2-dicarboxylate (1.85 g, 7.13 mmol, 1 *eq*) in THF (50 mL) was added $LiAlH_4$ (542 mg, 14.3 mmol, 2 *eq*) at 0 °C, the mixture was stirred at 0 °C for 0.5 hour. Then the mixture was heated to 70 °C and stirred for 3 hours. Then $LiAlH_4$ (542 mg, 14.27 mmol, 2 eq) was added at 10 °C, the mixture was heated to 80 °C and stirred for 6 hours. The reaction mixture was quenched by saturated Na_2SO_4 (5 mL), then filtered. The filter cake was washed with THF (3 × 30 mL). The filtrate was concentrated under vacuum to give [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (840 mg, 5.21 mmol, 73 % yield, 90 % purity) as a yellow oil which was used for next step without further purification.

[02366] ^{1}H NMR (400 MHz, chloroform-d) δ = 3.93 - 3.83 (m, 1H), 3.68 (dd, *J* = 3.2, 11.2 Hz, 1H), 3.48 - 3.36 (m, 2H), 3.30 (s, 3H), 2.67 - 2.58 (m, 1H), 2.40 - 2.30 (m, 4H), 2.08 (td, *J* = 8.0, 13.2 Hz, 1H), 1.90 - 1.79 (m, 1H).

[02367] Step A: Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To the solution of [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methanol (367 mg, 2.52 mmol, 2 *eq*) in toluene (18 mL) was added *t*-BuONa (364 mg, 3.79 mmol, 3 *eq*) at 0 °C, then benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (700 mg, 1.26 mmol, 1 *eq*) was added at 0 °C, the reaction mixture was stirred at 8 °C for 1 hour. Water (30 mL) was added into the mixture. The mixture was diluted with EtOAc (10 mL) and extracted with EtOAc (2 × 30 mL). The combined organic layers were washed with brine (20 mL). The combined

organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash column (MeCN/Water (0.1 % FA) = 30 %) to give benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (450 mg, 694 μmol, 55 % yield, 98 % purity) as a yellow solid. LCMS [ESI, M+1]: 636.

[02368] Step B: *tert*-Butyl-(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (490 mg, 771 μmol, 1 *eq*) and NH_3•MeOH (5 mL, 25 % purity) in MeOH (5 mL) was added Pd/C (100 mg, 10 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. The reaction mixture was filtered, the filter cake was washed with MeOH (3 × 5 mL). The filtrate was concentrated under vacuum to give *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (360 mg, 682 μmol, 88 % yield, 95 % purity) as a yellow solid which was used for next step without further purification.

[02369] Step C: *tert*-Butyl(2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To the solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (360 mg, 718 μmol, 1 *eq*), 1-bromo-8-methyl-naphthalene (238 mg, 1.08 mmol, 1.5 *eq*), Cs_2CO_3 (701 mg, 2.15 mmol, 3 *eq*) and Xantphos (83.0 mg, 143 μmol, 0.2 *eq*) in toluene (8 mL) was added $Pd_2(dba)_3$ (65.7 mg, 71.8 μmol, 0.1 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 12 hours. The reaction mixture was filtered, the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (from PE: EtOAc = 5:1~1:1 to EtOAc: MeOH = 1:0~20:1). Then the residue was purified by reverse phase flash column (ACN/Water (0.1 % FA) = 45 %) to give *tert*-butyl(2*S*)-2-(cyanomethyl)-4-[2-

[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 414 μmol, 58 % yield, 95 % purity) as a brown solid. LCMS [ESI, M+1]: 642.

[02370] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.74 - 7.60 (m, 2H), 7.45 - 7.37 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 4.61 (br s, 1H), 4.39 (ddd, *J* = 4.8, 6.8, 11.2 Hz, 1H), 4.30 - 4.20 (m, 1H), 4.16 - 4.11 (m, 1H), 4.11 - 3.89 (m, 4H), 3.88 - 3.68 (m, 1H), 3.56 - 3.47 (m, 1H), 3.46 - 3.32 (m, 2H), 3.30 (d, *J* = 2.4 Hz, 3H), 3.21 - 3.05 (m, 3H), 3.01 - 2.85 (m, 5H), 2.81 - 2.67 (m, 2H), 2.65 - 2.54 (m, 1H), 2.46 (d, *J* = 4.0 Hz, 3H), 2.35 - 2.26 (m, 1H), 2.11 - 2.05 (m, 1H), 2.00 - 1.88 (m, 1H), 1.52 (s, 9H).


[02371] Step D: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-Methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 436 μmol, 1 *eq*) in dioxane (1 mL) was added HCl/dioxane (4 M, 1.64 mL, 15 *eq*) was stirred at 10 °C for 1 hour. The reaction mixture was concentrated under vacuum. The mixture was basified with saturated $NaHCO_3$ to PH = 8~9 and extracted with EtOAc (3 × 15 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (210 mg, 349 μmol, 80 % yield, 90 % purity) as a yellow solid which was used for next step without further purification. LCMS [ESI, M+1]: 542.

[02372] Step E: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 185 μmol, 1 *eq*), 2-fluoroprop-2-enoic acid (33.2 mg, 369 μmol, 2 *eq*) and TEA (149 mg, 1.48 mmol, 206 μL, 8 *eq*) in EtOAc (2 mL) was added T3P (352 mg, 554 μmol, 329 μL, 50 % purity, 3 *eq*) at 0 °C, the mixture was stirred at 10 °C for 0.5 hour. Water (3 mL) was added into the mixture. The mixture was extracted with EtOAc (2 × 3 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated


under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5μm;mobile phase: [water (0.05 % ammonium hydroxide v/v)-ACN];B%: 52 % - 82 %,12 min) to give title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (28.1 mg, 45.5 μmol, 25 % yield, 99.4 % purity) as a white solid. LCMS [ESI, M+1]: 614.

[02373] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.65 - 7.54 (m, 2H), 7.38 - 7.30 (m, 1H), 7.27 (t, *J* = 7.6 Hz, 1H), 7.19 - 7.10 (m, 2H), 5.46 - 5.26 (m, 1H), 5.18 (br dd, *J* = 3.6, 16.8 Hz, 1H), 4.83 (br s, 1H), 4.37 - 4.27 (m, 1H), 4.23 - 3.94 (m, 4H), 3.92 - 3.85 (m, 1H), 3.84 - 3.76 (m, 1H), 3.70 (br d, *J* = 18.0 Hz, 1H), 3.46 (br d, *J* = 8.8 Hz, 1H), 3.42 - 3.31 (m, 2H), 3.22 (d, *J* = 2.0 Hz, 3H), 3.18 - 3.07 (m, 2H), 3.06 - 2.87 (m, 2H), 2.87 - 2.64 (m, 6H), 2.59 - 2.49 (m, 1H), 2.38 (d, *J* = 4.4 Hz, 3H), 2.24 (ddd, *J* = 3.2, 6.0, 9.6 Hz, 1H), 2.04 - 1.94 (m, 1H), 1.93 - 1.81 (m, 1H).

EXAMPLE 562



2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02374] [(3*R*)-1-Methylpyrrolidin-3-yl]methanol. To the solution of *tert*-butyl (3*R*)-3-(hydroxymethyl)pyrrolidine-1- carboxylate (0.5 g, 2.48 mmol, 1 *eq*) in THF (20 mL) was added $LiAlH_4$ (189 mg, 4.97 mmol, 2 *eq*) at 0 °C, then the mixture was warmed to 70 °C and stirred at 70 °C for 0.5 hour. Upon completion, the reaction mixture was quenched with saturated Na_2SO_4 (1 mL). The precipitate was filtered off and the filter cake was washed with THF (3 × 20 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum to give [(3*R*)-1-methylpyrrolidin-3-yl]methanol (220 mg, 1.72 mmol, 69% yield, 90% purity) as a colorless oil which was used directly in the next step without further purification.

[02375] 1H NMR (400 MHz, chloroform-d) δ = 3.67 - 3.57 (m, 1H), 3.50 (dd, J = 6.0, 10.0 Hz, 1H), 3.45 - 3.18 (m, 1H), 2.70 (dt, *J* = 4.8, 8.8 Hz, 1H), 2.56 - 2.44 (m, 2H), 2.42 - 2.24 (m, 5H), 2.04 - 1.90 (m, 1H), 1.68 - 1.54 (m, 1H).

[02376] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1 *eq*) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol (194 mg, 1.68 mmol, 2 *eq*) in

toluene (10 mL) was added *t*-BuONa (162 mg, 1.68 mmol, 2 *eq*). The mixture was stirred at 0 °C for 10 minutes. Upon completion, the mixture was diluted with water (10 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (EtOAc/MeOH 50/1 to 3/1) to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (290 mg, 427 μmol, 51% yield, 95% purity) as a yellow solid. LCMS [ESI, M+1]: 646.

[02377] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.45 - 7.37 (m, 5H), 7.37 - 7.30 (m, 2H), 7.27 - 7.16 (m, 2H), 5.28 - 5.15 (m, 2H), 4.68 (br s, 1H), 4.30 - 4.01 (m, 6H), 4.00 - 3.73 (m, 2H), 3.56 - 3.31 (m, 2H), 3.26 - 3.06 (m, 3H), 3.05 - 2.94 (m, 2H), 2.91 (s, 3H), 2.82 - 2.70 (m, 4H), 2.70 - 2.57 (m, 2H), 2.47 (d, *J* = 4.4 Hz, 3H), 2.20 - 2.07 (m, 1H), 1.80 - 1.67 (m, 1H).


[02378] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (290 mg, 449 μmol, 1 *eq*) in MeOH (4 mL) was added NH_3•MeOH (2 mL, 15% purity), Pd/C (100 mg, 449 μmol, 10% purity, 1 *eq*) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 279 μmol, 62% yield, 95% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 512.

[02379] Step C: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)- 1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, 235 μmol, 1 *eq*), 2-fluoroprop-2-enoic acid (42.2 mg, 469 μmol, 2 *eq*) and TEA (71.2 mg, 704 μmol, 97.9 μL, 3 *eq*) in DMF (2 mL) was added T3P (224 mg, 352


μmol, 209 μL, 50% purity in EtOAc, 1.5 *eq*) at -40 °C. Then the mixture was stirred at -40 °C for 0.5 hour. Upon completion, the mixture was diluted with water (2 mL) and extracted with the mixed solvent (EtOAc/MeOH 10/1, 5 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 50/1 to 20/1) followed by prep-HPLC (column: Phenomenex Gemini 150*25mm*10μm; mobile phase: [water (10mM NH_4HCO_3) - ACN]; B%: 50%-100%, 10 min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (16.0 mg, 26.5 μmol, 11% yield, 96.5% purity) as off-white solid. LCMS [ESI, M+1]: 584.

[02380] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.74 - 7.61 (m, 2H), 7.45 - 7.38 (m, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.17 (m, 2H), 5.55 - 5.32 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.88 (br s, 1H), 4.33 - 4.02 (m, 5H), 4.01 - 3.65 (m, 2H), 3.61 - 3.36 (m, 2H), 3.27 - 2.97 (m, 4H), 2.92 (s, 3H), 2.90 - 2.74 (m, 2H), 2.74 - 2.56 (m, 4H), 2.55 - 2.42 (m, 2H), 2.36 (d, *J* = 2.4 Hz, 3H), 2.14 - 1.99 (m, 1H), 1.66 - 1.52 (m, 1H).

EXAMPLE 563



2-[(2S)-1-[(E)-4-Fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02381] 2-[(2S)-1-[(E)-4-Fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2S)-4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, 508 μmol, 1.0 eq) in ethyl acetate (1.5 mL) was added a solution of (E)-4-fluorobut-2-enoic acid (106 mg, 1.02 mmol, 2.0 eq) in ethyl acetate (0.5 mL), TEA (206 mg, 2.03 mmol, 283 μL, 4.0 eq) and T3P (647 mg, 1.02 mmol, 605 μL, 50% purity, 2.0 eq), and the mixture was stirred at -40 °C and stirred for 1 hour. After completion, the reaction mixture was quenched by H2O (10.0 mL), and extracted with ethyl acetate (3 × 15.0 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225%FA)-ACN]; B%: 25%-45%, 7.8 min). The obtained product was adjusted to pH~8 with saturated aqueous $NaHCO_3$, then concentrated, the aqueous layer was extracted with ethyl acetate (3 × 20.0 mL), the combined organic layer was dried over Na2SO4, filtered and concentrated to give title compound 2-[(2S)-1-[(E)-4-fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (132 mg, 220 μmol, 43% yield, 99% purity) as a white solid. LCMS [ESI, M+1]: 598.


[02382] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.70 - 7.62 (m, 2H), 7.43 - 7.38 (m, 1H), 7.36 - 7.31 (m, 1H), 7.26 - 7.19 (m, 2H), 7.04 - 6.94 (m, 1H), 6.59 (d, J = 14.4 Hz, 1H), 5.17 - 4.60 (m, 3H), 4.41 - 4.35 (m, 1H), 4.28 - 3.44 (m, 9H), 3.20 - 3.08 (m, 4H), 3.05 - 2.99 (m, 1H),

2.92 (s, 3H), 2.83 - 2.77 (m, 1H), 2.72 - 2.62 (m, 2H), 2.47 (d, J = 4.8 Hz, 3H), 2.32 - 2.25 (m, 1H), 2.09 - 2.01 (m, 1H), 1.88 - 1.70 (m, 3H).

EXAMPLE 564



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02383] Step A: Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[3- [(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a solution of benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-methylsulfinyl-6,8-*d*ihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (800 mg, 1.44 mmol, 1 *eq*) in toluene (20 mL) was added *t*-BuONa (277 mg, 2.88

mmol, 2 *eq*) and 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propan-1-ol (340 mg, 2.16 mmol, 1.5 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase flash [water (0.1 % formic acid)/acetonitrile)]. The mixture was adjusted pH = 7 with saturated aqueous $NaHCO_3$ and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Benzyl 4-[(3*S*)-4-*tert*-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[3- [(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (500 mg, 725 μmol, 50 % yield, 94 % purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 648.

[02384] ^{1}H NMR (400MHz, chloroform-d) δ = 7.44 - 7.30 (m, 5H), 5.19 (s, 2H), 4.79 - 4.53 (m, 2H), 4.51 - 4.30 (m, 4H), 4.09 - 3.71 (m, 5H), 3.67 - 3.58 (m, 1H), 3.54 - 3.36 (m, 2H), 3.32 - 3.12 (m, 2H), 3.04 - 2.87 (m, 2H), 2.85 - 2.46 (m, 7H), 2.00 - 1.89 (m, 2H), 1.85 (d, *J*=9.2 Hz, 1H), 1.72 (d, *J*=9.2 Hz, 1H), 1.51 (s, 9H).

[02385] Step B: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl 4-[(3*S*)-4-tert-butoxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (900 mg, 1.39 mmol, 1 *eq*) in MeOH (30 mL) was added Pd/C (100 mg, 10 % purity)and NH_3•MeOH (20 mL, 25 % purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 20 °C for 1 hour. The catalyst was filtered off and the filtrate was concentrated under vacuum. *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (650 mg, 1.06 mmol, 77 % yield, 84 % purity) was obtained as a yellow solid and used to next step without purification. LCMS [ESI, M+1]: 514.

[02386] Step C: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-

(cyanomethyl)piperazine-1-carboxylate. To the solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 350 μmol, 1 *eq*), 1-bromo-8-chloro-naphthalene (127 mg, 526 μmol, 1.5 *eq*), Cs_2CO_3 (342 mg, 1.05 mmol, 3 *eq*) and RuPhos (65.4 mg, 140 μmol, 0.4 *eq*) in toluene (6 mL) was added $Pd_2(dba)_3$ (64.2 mg, 70.1 μmol, 0.2 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 10 hours. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (from PE: EtOAc = 5:1 ~ 1:1 to EtOAc: MeOH = 1:0~20:1) to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (130 mg, 173 μmol, 50 % yield, 90 % purity) as a brown solid. LCMS [ESI, M+1]: 674.


[02387] Step D: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 222 μmol, 1 *eq*) in dioxane (0.6 mL) was added HCl/dioxane (4 M, 556 μL, 10 *eq*), the mixture was stirred at 10 °C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was dissolved with water (15 mL) and EtOAc (10 mL), then separated. The aqueous phase was basified by $NaHCO_3$ solid to PH = 8~9 and extracted with EtOAc (2 × 15 mL). The combined organic layers were washed with brine (20 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 162 μmol, 73 % yield, 93 % purity) as a brown solid which was used for next step without further purification. LCMS [ESI, M+1]: 574.

[02388] Step E: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To the solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-


pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 174 μmol, 1 *eq*), 2-fluoroprop-2-enoic acid (31.4 mg, 348 μmol, 2 *eq*) and TEA (141 mg, 1.39 mmol, 194 μL, 8 *eq*) in EtOAc (2 mL) was added T3P (332 mg, 522 μmol, 311 μL, 50 % purity, 3 *eq*) at 0 °C, the mixture was stirred at 10 °C for 0.5 hour. Water (3 mL) was added into the mixture. The mixture was extracted with EtOAc (2 × 3 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 10μ 250 mm *50mm;mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN];B%: 45%-75%,12min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (26.5 mg, 41 μmol, 24 % yield, 99.9 % purity) as a white solid. LCMS [ESI, M+1]: 646.

[02389] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.45 (td, *J* = 7.6, 12.4 Hz, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.53 - 5.32 (m, 1H), 5.25 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.12 - 4.64 (m, 1H), 4.49 - 4.31 (m, 4H), 4.21 - 3.98 (m, 3H), 3.95 - 3.76 (m, 2H), 3.68 - 3.55 (m, 2H), 3.52 - 3.36 (m, 2H), 3.33 - 2.97 (m, 4H), 2.95 - 2.66 (m, 5H), 2.64 - 2.49 (m, 2H), 1.93 (m, 2H), 1.84 (br d, *J* = 8.4 Hz, 1H), 1.71 (br d, *J* = 10.0 Hz, 1H).

EXAMPLE 565



2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[3- [(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02390] Step A: *tert*-Butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[3-[(1*S*,4*S*)- 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 681 μmol, 1 *eq*), 1-bromo-8-methyl-naphthalene (226 mg, 1.02 mmol, 1.5 *eq*), Xantphos (78.9 mg, 136 μmol, 0.2 *eq*), $Pd_2(dba)_3$ (62.4 mg, 68.1 μmol, 0.1 *eq*) and Cs_2CO_3 (555 mg, 1.70 mmol, 2.5 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 12 hours under N_2. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 300/1 to 10/1). *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5- azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (270 mg, 379 μmol, 56% yield, 92% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 654.

[02391] ^{1}H NMR (400MHz, chloroform-d) δ = 7.75 - 7.61 (m, 2H), 7.45 - 7.37 (m, 1H), 7.34 (t, *J*=7.2 Hz, 1H), 7.26 - 7.15 (m, 2H), 4.62 (br s, 1H), 4.45 - 4.31 (m, 3H), 4.30 - 4.16 (m, 1H), 4.10 - 3.70 (m, 5H), 3.61 (br d, *J*=7.6 Hz, 1H), 3.57 - 3.44 (m, 2H), 3.43 - 3.25 (m, 1H), 3.24 - 3.05 (m, 3H), 3.03 - 2.86 (m, 5H), 2.84 - 2.67 (m, 4H), 2.66 - 2.48 (m, 2H), 2.00 - 1.88 (m, 2H), 1.84 (d, *J* = 9.6 Hz, 1H), 1.72 (d, *J* = 9.6 Hz, 1H), 1.52 (s, 9H).


[02392] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1] heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(8- methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg, 382 μmol, 1 eq) in dioxane (2 mL) was added HCl/dioxane (4 M, 1.91 mL, 1.00 eq) at 0°C. The mixture was stirred at 0°C for 1 hour. The reaction mixture was concentrated under vacuum. The residue was diluted with water (20 mL), and then the mixture was adjusted pH = 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1] heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (260 mg, crude) was obtained as a yellow oil and used to next step without purification. LCMS [ESI, M+1]: 554.

[02393] Step C: 2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, 216 μmol, 1 *eq*), TEA (87.7 mg, 866 μmol, 121 μL, 4 *eq*) and (*E*)-4-fluorobut-2-enoic acid (45.1 mg, 433 μmol, 2 *eq*) in ethyl acetate (2 mL) was added T3P (276 mg, 433 μmol, 258 μL, 50% purity, 2 *eq*) at -70 °C. The mixture was stirred at -70 °C for 0.5 hour. The reaction mixture was quenched with diluted with HCl (1 N, 1 mL) and then diluted with water (20 mL). The mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue


was purified by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 40%-70%, 10min). The desired fractions were collected and lyophilized. Title compound 2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[3- [(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (14.5 mg, 22.5 μmol, 10% yield, 99.3% purity) was obtained as a white solid. LCMS [ESI, M+1]: 640.

[02394] ^{1}H NMR (400MHz, chloroform-d) δ = 7.70 (d, *J* = 8.4 Hz, 1H), 7.65 (t, *J* = 8.0 Hz, 1H), 7.45 - 7.30 (m, 2H), 7.27 - 7.16 (m, 2H), 7.09 - 6.91 (m, 1H), 6.59 (d, *J* = 15.2 Hz, 1H), 5.29 - 4.48 (m, 3H), 4.44 - 4.31 (m, 3H), 4.29 - 3.72 (m, 6H), 3.71 - 3.40 (m, 4H), 3.28 - 2.96 (m, 4H), 2.95 - 2.88 (m, 4H), 2.87 - 2.56 (m, 5H), 2.52 (d, *J* = 10.0 Hz, 1H), 1.99 - 1.87 (m, 2H), 1.84 (d, *J* = 9.6 Hz, 1H), 1.71 (d, *J* = 9.6 Hz, 1H).

EXAMPLE 566




2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02395] 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 181 μmol, 1 *eq*) and 2-fluoroprop-2-enoic acid (32.5 mg, 361 μmol, 2 *eq*) in DCM (1 mL) was added HATU (137 mg, 361 μmol, 2 *eq*) and DIEA (93.4 mg, 722 μmol, 126 μL, 4 *eq*). After stirred at 0 °C for 0.5 hour, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by TLC (DCM/MeOH = 10/1) and further purified by prep-HPLC (column: Xtimate C18 10μ 250 mm *50mm; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 45%-75%, 12min). The desired fraction was collected and lyophilized. Title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (12 mg, 19.1 μmol, 11% yield, 99.6% purity) was obtained as a white solid. LCMS [ESI, M+1]: 626.


[02396] ^{1}H NMR (400MHz, chloroform-d) δ = 7.63 (d, *J* = 8.0 Hz, 1H), 7.58 (t, *J* = 8.4 Hz, 1H),7.39 - 7.23 (m, 2H), 7.19 - 7.09 (m, 2H), 5.35 (d, *J* = 48.8 Hz, 1H), 5.18 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.04 - 4.40 (m, 1H), 4.37 - 3.89 (m, 7H), 3.86 - 3.61 (m, 2H), 3.59 - 3.32 (m, 4H), 3.20 - 2.40 (m, 14H), 1.95 - 1.81 (m, 2H), 1.78 (d, *J* = 9.6 Hz, 1H), 1.65 (d, *J* = 9.6 Hz, 1H).

EXAMPLE 567



2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-[8-(hydroxymethyl)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile





[02397] 8-Bromonaphthalene-1-carbaldehyde. To a solution of 1,8-dibromonaphthalene (5 g, 17.5 mmol, 1 *eq*) in THF (100 mL) was added n-BμLi (2.5 M, 9.09 mL, 1.3 *eq*) at -70 °C dropwise. After stirring for 30 minutes at -70 °C, DMF (12.8 g, 175 mmol, 13.5 mL, 10 *eq*) was added dropwise. The mixture was warmed up to 12 °C and stirred for another 0.5 hour. Upon completion, the mixture was quenched with saturated aqueous NH_4Cl (20 mL). The separated aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum to give 8-bromonaphthalene-1-carbaldehyde (4.5 g, crude) as a yellow solid which was used directly in the next step without further purification.

[02398] ^{1}H NMR (400 MHz, chloroform-d) δ = 11.4 (s, 1H), 8.04 - 7.92 (m, 2H), 7.90 (d, *J* = 8.0 Hz, 2H), 7.60 - 7.55 (m, 1H), 7.39 (t, *J* = 8.0 Hz, 1H).

[02399] (8-Bromo-1-naphthyl)methanol. To a mixture of 8-bromonaphthalene-1-carbaldehyde (4.5 g, 19.1 mmol) in MeOH (80 mL) was added $NaBH_4$ (2.90 g, 76.6 mmol) in one portion at 0 °C. The mixture was stirred at 0 °C for 30 minutes. Upon completion, to the mixture was added water (1 mL) and the mixture was concentrated under vacuum. The residue was diluted with water (10 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 30/1 to 3/1) to give (8-bromo-1-naphthyl)methanol (3.3 g, 12.5 mmol, two steps 72% yield, 90% purity) as a yellow solid.

[02400] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.92 - 7.82 (m, 3H), 7.71 (d, J = 6.8 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.32 - 7.27 (m, 1H), 5.48 (br s, 2H).

[02401] 2-[(8-Bromo-1-naphthyl)methoxy]tetrahydropyran. To a solution of (8-bromo-1-naphthyl)methanol (0.5 g, 2.11 mmol, 1 *eq*) in DCM (10 mL) was added DHP (355 mg, 4.22 mmol, 386 µL, 2 *eq*), followed by TsOH•H_2O (40.1 mg, 211 µmol, 0.1 *eq*) at 12 °C. The mixture was stirred at 12 °C for 2 hours. Upon completion, the mixture was quenched with saturated aqueous $NaHCO_3$ solution (2 mL) and diluted with water (5 mL). The separated aqueous phase was extracted with EtOAc (10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 500/1 to 100/1) to give 2-[(8-bromo-1-naphthyl)methoxy]tetrahydropyran (560 mg, 1.57 mmol, 74% yield, 90% purity) as a colorless oil.

[02402] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.94 - 7.88 (m, 2H), 7.85 (t, J = 8.4 Hz, 2H), 7.56 - 7.50 (m, 1H), 7.36 - 7.28 (m, 1H), 5.63 (s, 2H), 4.92 (t, J = 3.6 Hz, 1H), 4.07 - 3.97 (m, 1H), 3.69 - 3.61 (m, 1H), 2.08 - 1.76 (m, 4H), 1.75 - 1.65 (m, 2H).

[02403] Step A: Benzyl (2S)-2-(cyanomethyl)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. 2-[(8-bromo-1-naphthyl)methoxy]tetrahydropyran (476 mg, 1.48 mmol, 1.5 eq), benzyl (2S)-2-(cyanomethyl)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8- tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 989 µmol, 1 eq), Cs2CO3 (806 mg, 2.47 mmol, 2.5 eq), (5-diphenylphosphanyl-9,9-dimethyl-

xanthen-4-yl)-diphenyl-phosphane (229 mg, 396 μmol, 0.4 eq) and Pd2(dba)3 (181 mg, 198 μmol, 0.2 eq) in toluene (20 mL) was de-gassed and then heated to 90 °C for 10 hours under N2. Upon completion, the mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected, neutralized with saturated aqueous $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 30 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2S)-2-(cyanomethyl)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 338 μmol, 34% yield, 90% purity) as a yellow solid. LCMS [ESI, M+1]: 746.

[02404] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-Methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 375 μmol, 1 *eq*) in MeOH (6 mL) was added NH_3/MeOH (4 mL, 20% purity), Pd/C (120 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 for several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. Upon completion, the mixture was filtered through a pad of celite and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (200 mg, 294 μmol, 78% yield, 90% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 612.

[02405] Step C: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]- 7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 294 μmol, 1 *eq*), T3P (562 mg, 883 μmol, 525 μL, 50% purity in EtOAc, 3 *eq*) and TEA (238 mg, 2.35 mmol,


328 μL, 8 *eq*) in EtOAc (4 mL) was added 2-fluoroprop-2-enoic acid (53.0 mg, 588 μmol, 2 *eq*) at 0 °C. The mixture was stirred at 15 °C for 0.5 hour. Upon completion, the mixture was diluted with water (4 mL) and extracted with EtOAc (3 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 100 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (160 mg, 227 μmol, 77% yield, 97% purity) as a yellow solid. LCMS [ESI, M+1]: 684.

[02406] Step D: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[7-[8-(hydroxymethyl)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-[8-(tetrahydropyran-2-yloxymethyl)-1-naphthyl]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 219 μmol, 1 *eq*) in DCM (160 μL) was added TFA (250 mg, 2.19 mmol, 162 μL, 10 *eq*). The mixture was stirred at 15 °C for 2 hours. Upon completion, the mixture was diluted with dichloromethane (3 mL) and adjusted pH = 9 with saturated Na_2CO_3 aqueous solution. The separated aqueous phase was extracted with DCM (5 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 42%-72%, 8min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-[8-(hydroxymethyl)-1-naphthyl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (62.0 mg, 103 μmol, 47% yield, 100% purity) as a white solid. LCMS [ESI, M+1]: 600.


[02407] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.84 (d, *J* = 8.0 Hz, 1H), 7.79 (dd, *J* = 3.2, 7.2 Hz, 1H), 7.55 - 7.44 (m, 3H), 7.44 - 7.38 (m, 1H), 5.55 - 5.32 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.21 - 4.94 (m, 2H), 4.89 (br t, *J* = 13.2 Hz, 1H), 4.41 - 3.90 (m, 7H), 3.66 - 3.39 (m,

2H), 3.37 - 3.00 (m, 5H), 3.00 - 2.58 (m, 4H), 2.50 - 2.43 (m, 3H), 2.33 - 2.22 (m, 1H), 2.11 - 1.98 (m, 1H), 1.90 - 1.73 (m, 3H).

EXAMPLE 568



2-[(2*S*)-1-(2-Fluoroprop- 2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02408] Step A: *tert*-Butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2- methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a mixture of *tert*-butyl 2-methylsulfanyl-4-(trifluoromethylsulfonyloxy)- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (20.0 g, 46.6 mmol, 1.00 eq) and benzyl (2*S*)-2-(cyanomethyl)piperazine-1-carboxylate (13.3 g, 51.2 mmol, 1.10 eq) in DMAc (250 mL) was added DIEA (18.1 g, 140 mmol, 24.3 mL, 3 eq) in portion at 0 °C under N_2. The mixture was heated to 50 °C and stirred for 1 hour. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with water (3 × 500 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 1/1). Compound *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3-(cyanomethyl)piperazin-1-yl]-2- methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (23.0 g, 42.7 mmol, 92% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 539.

[02409] Step B: Benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido [3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate. To a mixture of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (23.0 g, 42.7 mmol, 1.00 eq) in dioxane (200 mL) was added HCl/dioxane (4 M, 192 mL, 18.0 eq). After stirred at 20 °C and for 0.5 hour, the reaction mixture was filtered and the filter cake was dissolved in ethyl acetate (200 mL). The pH was adjusted to 8-9 with saturated Na_2CO_3 solution and then diluted with water (20.0 mL). The separated water layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was used into the next step directly without further purification. Compound benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8-tetrahydropyrido [3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (16.1 g, 34.5 mmol, 81% yield, 94% purity) was obtained as a yellow solid.

[02410] ^{1}H NMR (400MHz, chloroform-d) δ = 7.42 - 7.33 (m, 5H), 5.25 - 5.12 (m, 2H), 4.66 (br s, 1H), 4.11 - 4.04 (m, 1H), 4.03 - 3.90 (m, 3H), 3.84 (br d, *J* = 13.6 Hz, 1H), 3.34 -

3.17 (m, 2H), 3.11 (td, *J* = 5.2, 10.4 Hz, 1H), 3.04 - 2.93 (m, 2H), 2.88 - 2.76 (m, 1H), 2.75 - 2.56 (m, 3H), 2.50 (s, 3H).

[02411] Step C: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (16.1 g, 36.7 mmol, 1.00 eq) and 1-bromo-8-methyl-naphthalene (10.6 g, 47.7 mmol, 1.30 eq) in toluene (350 mL) was added $Pd_2(dba)_3$ (6.72 g, 7.34 mmol, 0.20 eq), Xantphos (8.50 g, 14.7 mmol, 0.40 eq) and Cs_2CO_3 (35.9 g, 110 mmol, 3.00 eq). The mixture was degassed and purged with N_2 for 3 times. After stirred at 90 °C for 8 hours, the reaction mixture was diluted with water (1 × 100 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with water (1 × 300 mL) and brine (1 × 300 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 100/1 to 2/1) and concentrated under reduced pressure to give a residue. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (15.3 g, 26.5 mmol, 72% yield) was obtained as a yellow solid.

[02412] ^{1}H NMR (400MHz, chloroform-d) δ = 7.68 - 7.55 (m, 2H), 7.40 - 7.28 (m, 7H), 7.22 (s, 2H), 5.22 - 5.09 (m, 2H), 4.64 (br s, 1H), 4.27 - 4.14 (m, 1H), 4.05 - 3.84 (m, 2H), 3.83 - 3.68 (m, 1H), 3.55 - 3.30 (m, 2H), 3.18 - 3.03 (m, 3H), 3.01 - 2.79 (m, 5H), 2.78 - 2.50 (m, 3H), 2.45 (d, *J* = 4.8 Hz, 3H).

[02413] Step D: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2- methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (13.3 g, 23.0 mmol, 1.00 eq) in EtOAc (200 mL) was added m-CPBA (4.67 g, 23.0 mmol, 85% purity, 1.00 eq) at 0 °C under N_2. After stirring at 0 °C for 30 min, the reaction mixture was quenched with saturated $Na_2S_2O_3$ (100 mL) at 0°C. The separated organic layer was diluted with water (1 × 100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over

anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 0/1). Compound benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (9.60 g, 15.3 mmol, 67% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 595.

[02414] ^{1}H NMR (400MHz, chloroform-d) δ = 7.74 - 7.63 (m, 2H), 7.47 - 7.31 (m, 7H), 7.27 - 7.17 (m, 2H), 5.25 - 5.17 (m, 2H), 4.67 (br s, 1H), 4.48 - 4.21 (m, 2H), 4.10 - 3.88 (m, 2H), 3.66 - 3.46 (m, 2H), 3.42 - 3.04 (m, 4H), 3.02 - 2.83 (m, 6H), 2.81 - 2.60 (m, 1H), 2.81 - 2.60 (m, 3H).

[02415] Step E: *tert*-Butyl (2*S*)-4-[2-[[(2*S*)-1-*tert*- butoxycarbonylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)- 2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1.00 eq) and *tert*-butyl (2*S*)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (338 mg, 1.68 mmol, 2.00 eq) in toluene (10.0 mL) was added *t*-BuONa (242 mg, 2.52 mmol, 3.00 eq) in portion at 0°C under N_2. After stirring at 0 °C for 30 min, the reaction mixture was quenched by adding hydrochloric acid (1 M) 2 mL at 0°C, and water (10 mL). The mixture was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with water (30 mL × 1) and brine (30 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 0/1). Compound *tert*-butyl (2*S*)-4-[2-[[(2*S*)-1-*tert*- butoxycarbonylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (330 mg, 473 μmol, 56% yield) was obtained as a yellow solid.

[02416] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.61 (m, 2H), 7.47 - 7.31 (m, 7H), 7.26 - 7.15 (m, 2H), 5.27 - 5.14 (m, 2H), 4.68 (br s, 1H), 4.42 - 4.17 (m, 3H), 4.07 - 3.73 (m, 3H), 3.58 - 3.29 (m, 5H), 3.25 - 2.88 (m, 8H), 2.86 - 2.51 (m, 3H), 2.03 - 1.76 (m, 4H), 1.44 (d, *J* = 4.8 Hz, 9H).

[02417] Step F: *tert*-Butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-7-(8-methyl-1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a mixture of *tert*-butyl (2*S*)-4-[2-[[(2*S*)-1-*tert*-butoxycarbonylpyrrolidin-2- yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (330 mg, 473 μmol, 1.00 eq) in MeOH (15 mL) was added NH_3•MeOH (15 mL, 20% purity), $Pd(OH)_2/C$ (80 mg, 20% purity) in one portion under N_2. The suspension was degassed under vacuum and purged with H_2 for three times. The mixture was stirred under H_2 (15 psi) at 20°C for 1 hour. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to give a residue. The crude product was used into the next step directly without further purification. Compound *tert*-butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-7-(8-methyl-1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (200 mg, 335 μmol, 71% yield) was obtained as a yellow solid. LCMS [ESI, M+1]: 598.


[02418] Step G: *tert*-Butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop-2-enoyl)piperazin-1-yl]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a mixture of *tert*-butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-7-(8 -methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (190 mg, 318 μmol, 1.00 eq) and 2-fluoroprop-2-enoic acid (42.9 mg, 477 μmol, 1.50 eq) in DCM (15.0 mL) was added DIEA (123 mg, 954 μmol, 166 uL, 3.00 eq) and HATU (181 mg, 477 μmol, 1.50 eq) in one portion at 0°C under N_2. After stirring at 0 °C for 30 min, the reaction mixture was diluted with water (10 mL). The separated organic layer was washed with brine (1 × 10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, DCM: MeOH = 50:1 to 5:1). Compound *tert*-butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop-2-enoyl)piperazin-1-yl]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (210 mg, 292 μmol, 92% yield, 93% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 670.

[02419] Step H: 2-[(2*S*)-1-(2-Fluoroprop- 2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl (2*S*)-2-[[4-[(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop- 2-


enoyl)piperazin-1-yl]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (210 mg, 314 μmol, 1.00 eq) in DCM (5.00 mL) was added TFA (1.07 g, 9.41 mmol, 696 μL, 30.0 eq) in one portion at 20°C under N_2. After stirred at 20 °C for 30 min, the reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150 × 30mm × 4μm; mobile phase: [water(0.225%FA)-ACN];B%: 20%-50%,5 min). Title compound 2-[(2*S*)-1-(2-fluoroprop- 2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (75.5 mg, 122 μmol, 39% yield, 99.8% purity, FA) was obtained as a off-white solid. LCMS [ESI, M+1]: 570.

[02420] ^{1}H NMR (400MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.44 - 7.30 (m, 2H), 7.27 - 7.14 (m, 2H), 6.49 - 5.98 (m, 1H), 5.55 - 5.32 (m, 1H), 5.25 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.58 - 4.42 (m, 2H), 4.36 - 3.87 (m, 5H), 3.86 - 3.67 (m, 1H), 3.64 - 3.37 (m, 2H), 3.35 - 3.26 (m, 2H), 3.25 - 2.94 (m, 4H), 2.92 - 2.70 (m, 5H), 2.66 - 2.51 (m, 1H), 2.18 - 1.81 (m, 4H).

EXAMPLE 569



2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4- [7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02421] (5*S*)-5-(Tetrahydropyran-2- yloxymethyl)pyrrolidin-2-one. To a mixture of (5*S*)-5-(hydroxymethyl)pyrrolidin-2-one (5.00 g, 43.4 mmol, 1.00 eq) and DHP (3.65 g, 43.4 mmol, 3.97 mL, 1.00 eq) in DCM (80.0 mL) was added TsOH.H_2O (826 mg, 4.34 mmol, 0.10 eq). The mixture was stirred at 15 °C for 12 hours. The reaction mixture was washed with brine (30.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 20/1 to 0:1). Compound (5*S*)-5-(tetrahydropyran-2- yloxymethyl)pyrrolidin-2-one (5.70 g, 28.6 mmol, 66% yield) was obtained as a yellow oil.

[02422] ^{1}H NMR (400MHz, chloroform-d) δ = 6.36 - 6.01 (m, 1H), 4.66 - 4.47 (m, 1H), 3.92 - 3.71 (m, 2.5H), 3.64 - 3.43 (m, 2H), 3.24 (dd, *J* = 8.0, 9.6 Hz, 0.5H), 2.42 - 2.10 (m, 3H), 1.86 - 1.64 (m, 3H), 1.62 - 1.48 (m, 4H).

[02423] (5*S*)-1-Methyl-5- (tetrahydropyran-2-yloxymethyl)pyrrolidin-2-one. To a mixture of (5*S*)-5-(tetrahydropyran-2- yloxymethyl)pyrrolidin-2-one (5.60 g, 28.1 mmol, 1.00 eq) in DMF (60.0 mL) was added NaH (1.35 g, 33.7 mmol, 60% purity, 1.20 eq) in portion at -40 °C under N_2. The mixture was stirred at -40 °C for 30 min, then CH_3I (6.58 g, 46.4 mmol, 2.89 mL, 1.65 eq) was added and stirred at 0 °C for 2.5 hours. The reaction mixture was quenched by adding saturated $NaHSO_3$ aqueous solution (30.0 mL) and extracted with EA (3 × 50.0 mL). The combined organic phase was dried over Na_2SO_4 and concentrated to dryness. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 10/1 to 0/1). Compound (5*S*)-1-methyl-5- (tetrahydropyran-2-yloxymethyl)pyrrolidin-2-one (4.40 g, 20.6 mmol, 73% yield) was obtained as a yellow oil.

[02424] ^{1}H NMR (400MHz, chloroform-d) δ = 4.59 (td, *J* = 3.2, 13.6 Hz, 1H), 3.93 - 3.73 (m, 2H), 3.63 - 371 (m, 1H), 3.57 - 3.44 (m, 2H), 2.88 (d, *J* = 4.4 Hz, 3H), 2.54 - 2.40 (m, 1H), 2.38 - 2.24 (m, 1H), 2.07 -2.20 (m, 1H), 1.93 - 1.53 (m, 7H).

[02425] (5*S*)-5-(Hydroxymethyl)-1-methyl-pyrrolidin-2-one. To a mixture of (5*S*)-1-methyl-5-(tetrahydropyran-2- yloxymethyl)pyrrolidin-2-one (2.20 g, 10.3 mmol, 1.00 eq) in DCM (20.0 mL) was added TFA (23.5 g, 206 mmol, 15.3 mL, 20.0 eq). The mixture was stirred at 15 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was used in the next step directly without further purification. Compound (5*S*)-5-(hydroxymethyl)-1-methyl-pyrrolidin-2-one (2.60 g, crude) was obtained as a red oil.

[02426] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*) -1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of (5*S*)-5-(hydroxymethyl)-1-methyl-pyrrolidin-2 -one (543 mg, 4.20 mmol, 5.00 eq) in THF (30.0 mL) was added *t*-BuONa (808 mg, 8.41 mmol, 10.0 eq) in portion at 0 °C under N_2. The mixture was stirred at 0 °C for 30 min, then benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1.00 eq) was added and warmed to 15 °C and stirred for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with water (50 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced

pressure to give a residue. The residue was purified by reverse phase flash [water (0.1% TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (10.0 mL) and extracted with ethyl acetate (50.0 mL × 2). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*) -1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (162 mg, 243 μmol, 29% yield, 99% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 660.


[02427] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 197 μmol, 1.00 eq) in MeOH (2.00 mL) was added NH_3•MeOH (1.00 mL, 20% purity) and Pd/C (35.0 mg, 10% purity). The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was used in the next step directly without further purification. Compound 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (70.0 mg, crude) was obtained as a brown solid. LCMS [ESI, M+1]: 526.

[02428] Step C: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4- [7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)- 1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60.0 mg, 114 μmol, 1.00 eq) and 2-fluoroprop-2-enoic acid (20.6 mg, 228 μmol, 2.00 eq) in EA (1.00 mL) was added TEA (92.4 mg, 913 μmol, 127 uL, 8.00 eq), T_3P (218 mg, 342 μmol, 204 uL, 50% purity, 3.00 eq) in portion at 0 °C under N_2. The mixture was stirred at 0 °C for 30 min. The reaction mixture was diluted with water (5.00 mL) and extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with water (10.0 mL × 1) and brine (10.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Xtimate


C18 150 × 25 mm × 5 um;mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN];B%: 42%-72%,10 min). Title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4- [7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (26.8 mg, 43.9 μmol, two steps 26% yield, 98% purity) was obtained as a white solid. LCMS [ESI, M+1]: 598.

[02429] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.62 (m, 2H), 7.46 - 7.38 (m, 1H), 7.38 - 7.32 (m, 1H), 7.27 - 7.17 (m, 2H), 5.55 - 5.32 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.08 - 4.63 (m, 1H), 4.53 - 4.39 (m, 1H), 4.37 - 4.26 (m, 1H), 4.25 - 4.00 (m, 3H), 3.97 - 3.71 (m, 3H), 3.59 - 3.35 (m, 2H), 3.29 - 2.98 (m, 4H), 2.91 (d, *J* = 5.6 Hz, 8H), 2.69 - 2.58 (m, 1H), 2.57 - 2.45 (m, 1H), 2.42 - 2.29 (m, 1H), 2.28 - 2.14 (m, 1H), 2.06 - 1.91 (m, 1H).

EXAMPLE 570



2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02430] (2*R*)-2-(*tert*-Butoxycarbonylamino)-3-[*tert*-butyl(diphenyl)silyl]oxy-propanoic acid. To a solution of (2*R*)-2-(*tert*-butoxycarbonylamino)-3-hydroxy-propanoic acid (27 g, 132 mmol, 1 *eq*) in DMF (270 mL) was added imidazole (45.4 g, 667 mmol, 5.07 *eq*) at 0 °C under nitrogen. After the solution became clear, TBDPSCl (90.4 g, 329 mmol, 84.5 mL, 2.5 *eq*) was added. The reaction was warmed to 15 °C. After stirring at 15 °C for 24 h, the reaction mixture was concentrated under vacuum, diluted with ether (250 ml) and poured into saturated NaCl (100 mL). The separated organic layer was washed with a mixture of 10% HCl (25 mL) and

saturated NaCl (50 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was diluted with acetonitrile and then white precipitate was formed. The precipitate was filtered and the filter cake was dried under vacuum to give (2*R*)-2-(*tert*-butoxycarbonylamino)-3-[*tert*-butyl(diphenyl)silyl]oxy-propanoic acid (45 g, 90 mmol, 69% yield, 89% purity) as a white solid.

[02431] *tert*-Butyl *N*-[(1*R*)-1-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxo-ethyl]carbamate. To a stirred solution of (2*R*)-2-(*tert*-butoxycarbonylamino)-3-[*tert*-butyl (diphenyl)silyl]oxy-propanoic acid (24 g, 54.1 mmol, 1 *eq*) in DCM (400 mL) at 0 °C was added 2,2-dimethyl-1,3-dioxane-4,6-dione (8.19 g, 56.8 mmol, 1.05 *eq*) and DMAP (16.0 g, 131 mmol, 2.42 *eq*), followed by BOP (25.1 g, 56.8 mmol, 1.05 *eq*) in small portions. The mixture was stirred for 1 hour at 0 °C. Upon completion, the mixture was washed with 1N $KHSO_4$ (2 × 360 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum at room temperature to give *tert*-butyl *N*-[(1*R*)-1-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-2-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxo-ethyl]carbamate (35 g, crude) as a yellow oil which as used directly into the next step without further purification.

[02432] *tert*-Butyl (2*R*)-2-[[*tert*-butyl(diphenyl)silyl]oxymethyl] -3,5-dioxo-pyrrolidine-1-carboxylate. *tert*-butyl *N*-[(1*R*)-1-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-2-(2,2- dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-2-oxo-ethyl]carbamate (35 g, 61.43 mmol, 1 *eq*) was refluxed in EtOAc (600 mL) at 77 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum to give *tert*-butyl (2*R*)-2-[[*tert*-butyl(diphenyl)silyl]oxymethyl] -3,5-dioxo-pyrrolidine-1-carboxylate (30 g, crude) as a yellow oil which used directly in the next step without further purification.

[02433] *tert*-Butyl (2*R*,3*R*)-2-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-3-hydroxy-5-oxo-pyrrolidine-1- carboxylate. *tert*-butyl (2*R*)-2-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-3,5-dioxo-pyrrolidine-1-carboxylate (30 g, 64.2 mmol, 1 *eq*) was dissolved in DCM (480 mL) at 0 °C, followed by $NaBH_4$ (3.78 g, 99.9 mmol, 1.56 *eq*) in small portions. The suspension was stirred at 18 °C for 16 hours. Upon completion, the reaction mixture was poured into water (300 ml) and stirred until no solid remained. The separated organic layer was washed with water (150 mL), dried over Na_2SO_4 filtered and concentrated under vacuum. The residue was purified by

silica gel chromatography (PE/EtOAc 10/1 to 2/1) followed by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN, and then extracted with DCM (2 × 50 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give *tert*-butyl (2*R*,3*R*)-2-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-3-hydroxy-5-oxo-pyrrolidine-1- carboxylate (2.13 g, 3.99 mmol, three steps 7.6% yield, 88% purity) as a yellow solid.

[02434] ^{1}H NMR (400 MHz, DMSO-d_6) δ = 7.72 (dd, *J* = 1.6, 8.0 Hz, 2H), 7.59 (dd, *J* = 1.2, 8.0 Hz, 2H), 7.47 - 7.39 (m, 6H), 5.67 (d, *J* = 4.0 Hz, 1H), 4.57 - 4.46 (m, 1H), 4.09 - 3.97 (m, 2H), 3.83 (dd, *J* = 2.8, 10.0 Hz, 1H), 2.75 - 2.65 (m, 1H), 2.62 - 2.53 (m, 1H), 1.38 (s, 9H), 0.93 (s, 9H).

[02435] *tert*-Butyl (2*R*,3*R*)-2-[[*tert*-butyl (diphenyl)silyl]oxymethyl]-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*R*,3*R*)-2-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-3-hydroxy-5-oxo-pyrrolidine-1-carboxylate (2.55 g, 5.43 mmol, 1 *eq*) in DCM (50 mL) was added DHP (913 mg, 10.9 mmol, 993 µL, 2 *eq*), followed by TsOH•H_2O (103 mg, 543 µmol, 0.1 *eq*) at 20 °C. The mixture was stirred at 20 °C for 16 hours. Upon completion, the mixture was quenched with saturated aqueous $NaHCO_3$ solution (10 mL), diluted with water (5 mL) and extracted with DCM (2 × 40 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (PE/EtOAc 15/1 to 7/1) to give *tert*-butyl (2*R*,3*R*)-2-[[*tert*-butyl (diphenyl)silyl]oxymethyl]-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidine-1-carboxylate (2.62 g, 4.64 mmol, 85% yield, 98% purity) as a yellow solid.

[02436] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.75 (td, *J* = 1.2, 7.6 Hz, 2H), 7.66 (td, *J* = 1.6, 8.0 Hz, 2H), 7.47 - 7.34 (m, 6H), 4.75 - 4.68 (m, 1H), 4.63 - 4.51 (m, 1H), 4.20 - 4.17 (m, 1H), 3.99 - 3.88 (m, 2H), 3.87 - 3.74 (m, 1H), 3.60 - 3.50 (m, 1H), 3.23 - 3.01 (m, 1H), 2.76 (ddd, *J* = 8.8, 10.4, 16.8 Hz, 1H), 2.01 - 1.80 (m, 2H), 1.79 - 1.62 (m, 4H), 1.45 (s, 9H), 1.02 (d, *J* = 8.0 Hz, 9H).

[02437] (4*R*,5*R*)-5-[[*tert*-Butyl(diphenyl) silyl]oxymethyl]-4- tetrahydropyran-2- yloxy-pyrrolidin-2- one. To a solution of *tert*-butyl (2*R*,3*R*)-2-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidine-1-carboxylate (2.62 g, 4.73 mmol, 1 *eq*) in MeCN

(50 mL) was added $Mg(ClO_4)_2$ (211 mg, 946 μmol, 95.6 μL, 0.2 *eq*). The reaction mixture was stirred at 70 °C for 12 hours. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and concentrated under vacuum to give (4*R*,5*R*)-5-[[*tert*-butyl(diphenyl) silyl]oxymethyl]-4- tetrahydropyran-2- yloxy-pyrrolidin-2- one (1.14 g, 2.29 mmol, 48% yield, 91% purity) as a yellow oil. LCMS [ESI, M+1]: 454.

[02438] (4*R*,5*R*)-5-[[*tert*-Butyl(diphenyl)silyl]oxymethyl]-1-methyl-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one. To a solution of (4*R*,5*R*)-5-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one (0.95 g, 2.09 mmol, 1 *eq*) in THF (20 mL) was added NaH (168 mg, 4.19 mmol, 60% purity in mineral oil, 2 *eq*) in portion at 0 °C under N_2. The mixture was stirred at 0 °C for 30 minutes, then CH_3I (594 mg, 4.19 mmol, 261 uL, 2 *eq*) was added. After stirred at 0 °C for another 0.5 hour, the mixture was quenched with water (10 mL) and extracted with EtOAc (2 × 30 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and concentrated under vacuum to give (4*R*,5*R*)-5-[[*tert*-butyl(diphenyl)silyl]oxymethyl]-1-methyl-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one (820 mg, 1.67 mmol, 80% yield, 95% purity) as a brown oil.

[02439] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.75 - 7.70 (m, 2H), 7.70 - 7.65 (m, 2H), 7.48 - 7.36 (m, 6H), 4.68 - 4.60 (m, 1H), 4.59 - 4.48 (m, 1H), 4.07 - 3.77 (m, 2H), 3.77 - 3.66 (m, 1H), 3.65 - 3.56 (m, 1H), 3.55 - 3.40 (m, 1H), 2.89 - 2.79 (m, 3H), 2.79 - 2.53 (m, 2H), 1.90 - 1.69 (m, 2H), 1.68 - 1.53 (m, 4H), 1.09 - 1.03 (m, 9H).

[02440] (4*R*,5*R*)-5- (Hydroxymethyl)-1-methyl-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one. To a mixture of (4*R*,5*R*)-5-[[*tert*-butyl(diphenyl)silyl] oxymethyl]-1- methyl-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one (1.07 g, 2.29 mmol, 1 *eq*) in DMSO (10 mL) was added CsF (1.04 g, 6.86 mmol, 253 μL, 3 *eq*). The mixture was stirred at 65 °C for 2 hours. Upon completion, the mixture was concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 50/1 to 5/1) to give (4*R*,5*R*)-5- (hydroxymethyl)-1-methyl-4-tetrahydropyran-2-yloxy-pyrrolidin-2-one (380 mg, 1.49 mmol, 65% yield, 90% purity) as a yellow oil.

[02441] ^{1}H NMR (400 MHz, chloroform-d) δ = 4.80 - 4.52 (m, 2H), 3.98 - 3.81 (m, 3H), 3.72 - 3.61 (m, 1H), 3.60 - 3.48 (m, 1H), 2.87 (d, *J* = 9.6 Hz, 3H), 2.67 (d, *J* = 7.2 Hz, 1H), 2.60 - 2.46 (m, 1H), 1.86 - 1.74 (m, 2H), 1.67 - 1.51 (m, 4H).

[02442] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*,3*R*)-1-methyl-5-oxo- 3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl) -2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 471 μmol, 1 *eq*) and (4*R*,5*R*)-5-(hydroxymethyl)-1-methyl-4-tetrahydropyran-2-yloxy- pyrrolidin-2-one (140 mg, 612 μmol, 1.3 *eq*) in toluene (6 mL) was added *t*-BuONa (90.5 mg, 942 μmol, 2 *eq*) at 0 °C. After stirred at 0 °C for 10 minutes, the mixture was diluted with water (5 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 20 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*,3*R*)-1-methyl-5-oxo- 3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 258 μmol, 55% yield, 98% purity) as a yellow solid. LCMS [ESI, M+1]: 760.

[02443] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.74 - 7.63 (m, 2H), 7.47 - 7.31 (m, 7H), 7.27 - 7.17 (m, 2H), 5.21 (s, 2H), 4.84 - 4.43 (m, 5H), 4.30 - 3.70 (m, 8H), 3.59 - 3.34 (m, 3H), 3.25 - 2.98 (m, 4H), 2.96 - 2.90 (m, 6H), 2.81 - 2.56 (m, 4H), 1.83 - 1.63 (m, 2H), 1.60 - 1.47 (m, 4H).

[02444] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1- naphthyl)-2-[[(2*R*,3*R*)-1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*,3*R*)-1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 197 μmol, 1 *eq*) in MeOH (3 mL) was added NH_3/MeOH (3 mL, 20% purity), Pd/C (75 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The

mixture was stirred under H_2 (15 psi) at 20 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*,3*R*)-1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 144 μmol, 73% yield, 90% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 626.


[02445] Step C: 2-[(2*S*)-4-[2-[[(2*R*,3*R*)-3-Hydroxy-1-methyl-5-oxo- pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*,3*R*)-1- methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 160 μmol, 1 *eq*) in DCM (100 μL) was added TFA (273 mg, 2.40 mmol, 177 μL, 15 *eq*). The mixture was stirred at 20 °C for 1 hour. Upon completion, the mixture was diluted with DCM (5 mL) and basified with saturated sodium bicarbonate aqueous solution to pH = 8. The separated aqueous layer was extracted with EtOAc (3 × 5 mL). Combined organic layers were dried over $MgSO_4$, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo- pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80 mg, 126 μmol, 79% yield, 85% purity) as a yellow oil which was used directly in the next step without further purification.

[02446] Step D: 2-[(2*S*)-1-(2-Fluoroprop-2-enoyl)-4-[2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo- pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80 mg, 148 μmol, 1 *eq*), TEA (44.8 mg, 443 μmol, 61.7 μL, 3 *eq*) and 2-fluoroprop-2-enoic acid (26.6 mg, 295 μmol, 2 *eq*) in EA (3 mL) was added T3P (141 mg, 222 μmol, 132 uL, 50% purity in EtOAc, 1.5 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the mixture was quenched with saturated $NaHCO_3$ aqueous solution (5 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 1/0 to 10/1) followed by prep-HPLC (column: Xtimate


C18 150*25mm*5um; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 34%-64%, 10min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (11.8 mg, 19.1 μmol, 13% yield, 99.3% purity) as a off-white solid. LCMS [ESI, M+1]: 614.

[02447] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.71 (d, *J* = 8.0 Hz, 1H), 7.69 - 7.63 (m, 1H), 7.41 (q, *J* = 7.6 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.19 (m, 2H), 5.55 - 5.33 (m, 1H), 5.27 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.86 (dd, *J* = 5.6, 12.0 Hz, 1H), 4.79 (dd, *J* = 5.6, 12.0 Hz, 1H), 4.63 - 4.49 (m, 2H), 4.39 - 3.94 (m, 3H), 3.89 - 3.77 (m, 2H), 3.76 - 3.63 (m, 1H), 3.61 - 3.44 (m, 2H), 3.38 - 2.99 (m, 4H), 2.91 (d, *J* = 7.2 Hz, 6H), 2.89 - 2.70 (m, 2H), 2.70 - 2.55 (m, 2H), 2.46 (dt, *J* = 5.2, 16.0 Hz, 1H).

EXAMPLE 571



2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl) -2-((*S*)-pyrrolidin-2-ylmethoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02448] Step A: *tert*-Butyl (2*S*)-2-[(7-benzyl-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl) oxymethyl]pyrrolidine-1-carboxylate. To a solution of 7-benzyl-2-chloro-4-methoxy-6,8-dihydro -5*H*-pyrido[3,4-*d*]pyrimidine (4.00 g, 13.8 mmol, 1.00 *eq*) and *t*ert-butyl (2*S*)-2- (hydroxymethyl)pyrrolidine-1-carboxylate (5.56 g, 27.6 mmol, 2.00 *eq*) in toluene (80.0 mL) was added BINAP (1.72 g, 2.76 mmol, 0.20 *eq*), $Pd(OAc)_2$ (310 mg, 1.38 mmol, 0.10 *eq*) and Cs_2CO_3 (13.5 g, 41 mmol, 3.00 *eq*). The mixture was stirred at 110 °C for 8 hours. After completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was diluted with H_2O (200 mL) and ethyl acetate (200 mL). The mixture was acidified to pH~3 with aqueous HCl (2N). The aqueous phase was separated and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=20/1 to 1/1) to give *tert*-butyl (2*S*)-2-[(7-benzyl-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl) oxymethyl]pyrrolidine-1-carboxylate (3.80 g, 8.26 mmol, 60% yield, 99% purity) as yellow oil. LCMS [ESI, M+1]: 455.

[02449] ^{1}H NMR (400 MHz, chloroform-d) δ 7.37 - 7.27 (m, 5H), 4.50 - 4.35 (m, 1H), 4.25 - 4.16 (m, 1H), 3.98 (s, 3H), 3.69 (s, 2H), 3.50 (s, 2H), 3.43 - 3.33 (m, 2H), 2.76 - 2.72 (m,

2H), 2.62 - 2.57 (m, 2H), 2.04 - 1.90 (m, 3H), 1.85 - 1.76 (m, 1H), 1.61 - 1.54 (m, 1H), 1.45 (s, 9H).

[02450] Step B: *tert*-Butyl (2*S*)-2-[(4-methoxy-5,6,7,8- tetrahydropyrido[3,4-*d*] pyrimidin-2-yl)oxymethyl]pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-[(7-benzyl-4-methoxy-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl)oxymethyl]pyrrolidine-1-carboxylate (3.80 g, 8.36 mmol, 1.00 *eq*) in methanol (100 mL) was added $Pd(OH)_2/C$ (1.00 g, 10.3 mmol, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 three times. The mixture was stirred under H_2 (45 psi) at 40 °C for 24 hours. After completion, the reaction mixture was concentrated under reduced pressure to give a residue. Compound *tert*-butyl (2*S*)-2-[(4-methoxy-5,6,7,8- tetrahydropyrido[3,4-*d*] pyrimidin-2-yl)oxymethyl]pyrrolidine-1-carboxylate (2.70 g, 7.17 mmol, 86% yield, 97% purity) was obtained as yellow oil and used into the next step without further purification. LCMS [ESI, M+1]: 365.

[02451] ^{1}H NMR (400 MHz, chloroform-d) δ 4.54 - 4.35 (m, 1H), 4.25 - 4.10 (m, 2H), 3.98 (s, 3H), 3.86 (s, 2H), 3.48 (s, 1H), 3.43 - 3.33 (m, 2H), 3.13 - 3.04 (m, 2H), 2.56 - 2.46 (m, 2H), 2.10 - 1.93 (m, 3H), 1.87 - 1.82 (m, 1H), 1.45 (s, 9H).

[02452] Step C: *tert*-Butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)-4-methoxy-6,8-dihydro -5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-[(4-methoxy-5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-2-yl)oxymethyl]pyrrolidine-1-carboxylate (2.5 g, 6.86 mmol, 1.0 *eq*) and 1-bromo-8-chloro-naphthalene (3.31 g, 13.7 mmol, 2.0 *eq*) in toluene (50 mL) was added $Pd_2(dba)_3$ (1.26 g, 1.37 mmol, 0.2 *eq*), Cs_2CO_3 (5.59 g, 17.2 mmol, 2.5 *eq*), and RuPhos (1.28 g, 2.74 mmol, 0.4 *eq*), the reaction mixture was stirred at 90 °C for 12 hours under N_2. After completion, the reaction mixture was filtered through celite, and the filtrate was washed with saturated brine (1 × 80 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=10/1 to 3/1). The product *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)-4-methoxy-6,8-dihydro -5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (1.3 g, 2.46 mmol, 36% yield, 99% purity) as light yellow solid. LCMS [ESI, M+1]: 525.

[02453] ^{1}H NMR (400 MHz, chloroform-d) δ 7.74 (d, *J* = 8.4 Hz, 1H), 7.60 (br d, *J* = 8.0 Hz, 1H), 7.51 (d, *J* = 7.6 Hz, 1H), 7.43 (t, *J* = 7.8 Hz, 1H), 7.33 (t, *J* = 7.8 Hz, 1H), 7.23 (br d, *J* = 7.6 Hz, 1H), 4.60 - 4.37 (m, 1H), 4.34 - 4.16 (m, 3H), 4.03 (s, 3H), 3.87 (br d, *J* = 17.2 Hz, 1H), 3.63 - 3.57 (m, 1H), 3.45 - 3.30 (m, 2H), 3.21 - 3.10 (m, 1H), 2.99 (br s, 1H), 2.62 (br d, *J* = 16.8 Hz, 1H), 2.07 - 1.79 (m, 4H), 1.45 (s, 9H).

[02454] Step D: *tert*-Butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)-4-hydroxy-6,8 -dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a solution of NaH (168 mg, 4.19 mmol, 60% purity, 2.0 *eq*) in DMF (15 mL) was added EtSH (391 mg, 6.29 mmol, 465 μL, 3.0 *eq*) in portions at 15 °C After stirring for 0.5 hour, a solution of *tert*-butyl(2*S*)-2-[[7-(8-chloro -1-naphthyl)-4-methoxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (1.1 g, 2.10 mmol, 1.0 *eq*) in DMF (7.0 mL) was added to the mixture, then the reaction mixture was stirred at 60 °C for 1 hour. After completion, the reaction mixture was poured into ice water (10 mL), then the mixture was adjusted with 1N HCl aqueous to pH 7~8, the mixture was filtered, the filter cake was dissolved with dichloromethane (10 mL), washed with saturated brine (2 × 15 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=3/1 to ethyl acetate: methanol=10:1) to give *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)-4-hydroxy-6,8 -dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (670 mg, 1.28 mmol, 61% yield, 98% purity) as yellow solid. LCMS [ESI, M+1]: 511.

[02455] Step E: *tert*-Butyl(2*S*)-2-[[7-(8-chloro-1-naphthyl)-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl) -4-hydroxy-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (640 mg, 1.25 mmol, 1.0 *eq*) in DCM (10 mL) was added TEA (380 mg, 3.76 mmol, 523 μL, 3.0 *eq*),4A molecular sieves (500 mg), and Tf_2O (530 mg, 1.88 mmol, 310 μL, 1.5 *eq*) at -40 °C, and the reaction mixture was stirred at -40 °C for 10 mins. After completion, water was added (10 mL) in portions at -40 °C, then the reaction mixture was warmed to 15 °C and the organic layer was separated and washed with saturated brine (1 × 10 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=10/1 to 3/1). The product *tert*-butyl(2*S*)-2-

[[7-(8-chloro-1-naphthyl)-4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (400 mg, 616 μmol, 49% yield, 99% purity) was obtained as light yellow solid. LCMS [ESI, M+1]: 643.

[02456] Step F: *tert*-Butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl) -4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)- 4-(trifluoromethylsulfonyloxy)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (400 mg, 622 μmol, 1.0 *eq*) in DMAC (4.0 mL) was added 2-[(2*S*)-piperazin-2-yl]acetonitrile (86.5 mg, 622 μmol, 1.0 *eq*) and DIEA (161 mg, 1.24 mmol, 217 μL, 2.0 *eq*), the reaction mixture was stirred at 15 °C for 10 mins. After completion, the reaction mixture was poured into ice water (10 mL), the precipitated solid was filtered, dissolved with ethyl acetate (15 mL), the organic layer was washed with saturated brine (2 × 15 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (0.1% FA condition, 20%-30% MeCN in water), the obtained product was adjusted with $NaHCO_3$ solid to pH~8, then concentrated, the aqueous was extracted with ethyl acetate (2 × 15 mL), the organic layer was washed with saturated brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated. The product *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl) -4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (300 mg, 480 μmol, 77% yield, 99% purity) was obtained as light yellow solid. LCMS [ESI, M+1]: 618.

[02457] ^{1}H NMR (400 MHz, chloroform-d) δ 7.75 (d, J = 8.0 Hz, 1H), 7.61 (br d, J = 8.0 Hz, 1H), 7.52 (d, J = 6.8 Hz, 1H), 7.47 - 7.42 (m, 1H), 7.33 (t, J = 7.8 Hz, 1H), 7.23 (br t, J = 6.2 Hz, 1H), 4.71 - 4.31 (m, 2H), 4.29 - 4.06 (m, 3H), 3.95 - 3.69 (m, 2H), 3.63 - 3.28 (m, 4H), 3.26 - 2.82 (m, 7H), 2.72 - 2.46 (m, 3H), 2.02 - 1.79 (m, 4H), 1.45 (s, 9H).


[02458] Step G: *tert*-Butyl(2*S*)-2-[[7-(8-chloro-1-naphthyl)-4- [(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop-2-enoyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl) -4-[(3*S*)-3-(cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (100 mg, 162 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (29.1 mg, 324 μmol, 2.0 *eq*) in ethyl acetate (1.5 mL) was added TEA (131 mg, 1.29 mmol,

180 μL, 8.0 *eq*) and T3P (309 mg, 485 μmol, 289 μL, 50% purity, 3.0 *eq*) in portions at 0 °C, the reaction mixture was stirred at 0 °C for 1 hour. After completion, water was added (10 ml), then the organic layer was separated, the aqueous phase was extracted with ethyl acetate (2 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified column chromatography (basic Al_2O_3, petroleum ether/ethyl acetate=3/1 to 1/1). The product *tert*-butyl(2*S*)-2-[[7-(8-chloro-1-naphthyl)-4- [(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop-2-enoyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (110 mg, crude) was obtained as light yellow solid. LCMS [ESI, M+1]: 690.


[02459] Step H: 2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl) -2-((*S*)-pyrrolidin-2-ylmethoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile. To a solution of *tert*-butyl (2*S*)-2-[[7-(8-chloro-1-naphthyl)- 4-[(3*S*)-3-(cyanomethyl)-4-(2-fluoroprop-2-enoyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-2-yl]oxymethyl]pyrrolidine-1-carboxylate (90.0 mg, 130.40 μmol, 1.0 *eq*) in dichloromethane (0.5 mL) was added TFA (770 mg, 6.75 mmol, 0.5 mL, 51.8 *eq*), and the reaction mixture was stirred at 20 °C for 1 hour. After completion, the reaction mixture was concentrated, then dissolved with ethyl acetate (10 mL), washed with saturated aqueous Na_2CO_3 (1 × 10 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate=3/1 to ethyl acetate: methanol=10:1), then purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10μm; mobile phase: [water (0.225%FA)-ACN]; B%: 20%-50%, 10 min), the obtained product was concentrated and lyophilized. Title compound 2-((*S*)-4-(7-(8-chloronaphthalen-1-yl) -2-((*S*)-pyrrolidin-2-ylmethoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (24.7 mg, 38.1 μmol, 29% yield, 98% purity, FA) was obtained as off-white solid. LCMS [ESI, M+1]: 590.

[02460] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.0 Hz, 1H), 7.56 - 7.49 (m, 1H), 7.54 - 7.50 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.26 - 7.17 (m, 1H), 5.53 - 5.32 (m, 1H), 5.25 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.89 - 4.52 (m, 1H), 4.64 - 4.45 (m, 2H), 4.42 - 4.23 (m, 2H), 4.17 - 3.92 (m, 4H), 3.89 - 3.78 (m, 2H), 3.51 - 3.42 (m, 1H), 3.35 - 3.05 (m, 5H), 2.95 - 2.73 (m, 2H), 2.62 - 2.51 (m, 1H), 2.21 - 1.84 (m, 4H).

EXAMPLE 572



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*)-1- methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02461] Step A: tert-Butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of (5*S*)-5-(hydroxymethyl)-1-methyl-pyrrolidin-2- one (556 mg, 4.30 mmol, 5.00 eq) in THF (20.0 mL) was added *t*-BuONa (827 mg, 8.60 mmol, 10.0 eq) in portion at 0°C under N_2. The mixture was stirred at 0 °C for 30 min, followed by adding *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (500 mg, 860 μmol,

1.00 eq). The mixture was warmed to 15 °C and stirred for 0.5 hour. The reaction mixture was diluted with ethyl acetate (50.0 mL) and washed with water (30 mL × 2), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase flash [water (0.1% TFA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (10.0 mL) and extracted with ethyl acetate (50.0 mL ×3). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound tert-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (125 mg, 193 μmol, 22% yield) was obtained as a yellow solid.


[02462] ^1H NMR (400MHz, chloroform-d) δ = 7.75 (d, *J* = 8.0 Hz, 1H), 7.61 (dd, *J* = 4.8, 8.0 Hz, 1H), 7.52 (dd, *J* = 0.8, 7.2 Hz, 1H), 7.45 (q, *J* = 8.0 Hz, 1H), 7.37 - 7.28 (m, 1H), 7.23 (br d, *J* = 7.6 Hz, 1H), 4.70 - 4.31 (m, 3H), 4.10 - 3.82 (m, 4H), 3.65 - 3.51 (m, 1H), 3.46 - 2.99 (m, 5H), 2.98 - 2.82 (m, 3H), 2.79 - 2.37 (m, 5H), 2.22 (br d, *J* = 8.0 Hz, 1H), 1.93 - 1.59 (m, 3H), 1.52 (s, 9H).

[02463] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo- pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (100 mg, 155 μmol, 1.00 eq) in dioxane (1.50 mL) was added HCl/dioxane (4 M, 967 μL, 25.0 eq). The mixture was stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was dissolved with ethyl acetate (10.0 mL) and basified to pH = 8 with saturated $NaHCO_3$ solution (3.00 mL), and extracted with ethyl acetate (5.00 mL × 3). The combined organic layers were washed with brine (10.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The crude product was used in the next step directly without further purification. Compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, crude) was obtained as a yellow solid. LCMS [ESI, M+1]: 546.


[02464] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*)-1- methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60.0 mg, 110 μmol, 1.00 eq) and 2-fluoroprop-2-enoic acid (19.8 mg, 220 μmol, 2.00 eq) in EA (1 mL) was added TEA (89.0 mg, 879 μmol, 122 μL, 8.00 eq), T_3P (210 mg, 330 μmol, 196 μL, 50% purity in ethyl acetate, 3.00 eq) in portion at 0 °C under N_2. The mixture was stirred at 0 °C for 30 min. The reaction mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with water (10 mL × 1) and brine (10 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Xtimate C18 150 × 25mm × 5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 35%-65%, 10min). Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1- methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (11.3 mg, 18.2 umol, 17% yield, 99% purity) was obtained as a white solid LCMS [ESI, M+1]: 618.

[02465] ^{1}H NMR (400MHz, chloroform-d) δ = 7.77 (d, *J* = 8.0 Hz, 1H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 6.8 Hz, 1H), 7.46 (td, *J* = 8.0, 10.4 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.20 (m, 1H), 5.52 - 5.34 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.92 (br s, 1H), 4.52 - 4.31 (m, 3H), 4.27 - 3.77 (m, 5H), 3.61 (br d, *J* = 10.8 Hz, 1H), 3.46 (br d, *J* = 12.0 Hz, 1H), 3.36 - 2.94 (m, 5H), 2.92 (s, 3H), 2.90 - 2.79 (m, 1H), 2.64 - 2.48 (m, 2H), 2.41 - 2.31 (m, 1H), 2.28 - 2.17 (m, 1H), 2.05 - 1.95 (m, 1H).

EXAMPLE 573



2-[(2*S*) -4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02466] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,3*R*) -1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (280 mg, 482 μmol, 1 *eq*) and (4*R*,5*R*)-5-(hydroxymethyl)-1-methyl-4- tetrahydropyran-2-yloxy-pyrrolidin-2-one (144 mg, 626 μmol, 1.3 *eq*) in toluene (6 mL) was added *t*-BuONa (92.6 mg, 964 μmol, 2 *eq*). The mixture was stirred at 0 °C for 10 minutes. Upon completion, the mixture was diluted with water (5 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 20 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,3*R*) -1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-

5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (280 mg, 345 μmol, 72% yield, 92% purity) as a yellow solid. LCMS [ESI, M+1]: 746.

[02467] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.76 (br d, *J* = 8.0 Hz, 1H), 7.66 - 7.57 (m, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.50 - 7.41 (m, 1H), 7.37 - 7.31 (m, 1H), 7.27 - 7.18 (m, 1H), 4.88 - 4.69 (m, 1H), 4.68 - 4.47 (m, 4H), 4.46 - 4.35 (m, 1H), 4.11 - 3.74 (m, 6H), 3.65 - 3.48 (m, 2H), 3.44 - 2.99 (m, 5H), 2.96 (dd, *J* = 2.8, 8.4 Hz, 3H), 2.91 - 2.51 (m, 5H), 1.81 - 1.64 (m, 2H), 1.52 (s, 13H).


[02468] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1- naphthyl)-2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,3*R*) -1-methyl-5-oxo-3-tetrahydropyran-2-yloxy-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 268 μmol, 1 *eq*) in DCM (0.15 mL) was added TFA (458 mg, 4.02 mmol, 298 μL, 15 *eq*). The mixture was stirred at 20 °C for 1 hour. Upon completion, the mixture was diluted with DCM (5 mL) and basified with saturated sodium bicarbonate aqueous solution to pH = 8. The separated aqueous layer was extracted with EtOAc (5 × 5 mL). Combined organic layers were dried over $MgSO_4$, filtered and concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 230 μmol, 86% yield, 86% purity) as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 562.

[02469] Step C: 2-[(2*S*) -4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,3*R*)-3- hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 267 umol, 1 *eq*), TEA (81.0 mg, 801 umol, 111 uL, 3 *eq*) and 2-fluoroprop-2-enoic acid (48.1 mg, 534 umol, 2 *eq*) in EtOAc (4 mL) was added T3P (255 mg, 400 umol, 238 uL, 50% purity in EtOAc, 1.5 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the mixture was quenched with saturated $NaHCO_3$ aqueous solution (5 mL) and extracted with EtOAc (2 × 10 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by


chromatography (Al_2O_3, EtOAc/MeOH 1/0 to 20/1) followed by prep-HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 33%-63%, 10min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*) -4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,3*R*)-3-hydroxy-1-methyl-5-oxo-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (22.0 mg, 34.5 umol, 13% yield, 99.6% purity) as a white solid. LCMS [ESI, M+1]: 634.

[02470] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.77 (d, *J* = 8.4 Hz, 1H), 7.64 (dd, *J* = 4.4, 8.0 Hz, 1H), 7.54 (d, *J* = 7.6 Hz, 1H), 7.46 (dt, *J* = 6.0, 8.0 Hz, 1H), 7.35 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.21 (m, 1H), 5.54 - 5.33 (m, 1H), 5.27 (dd, *J* = 2.8, 17.2 Hz, 1H), 4.88 (dd, *J* = 1.6, 12.0 Hz, 1H), 4.80 (dd, *J* = 6.0, 12.0 Hz, 1H), 4.64 - 4.48 (m, 2H), 4.47 - 3.94 (m, 4H), 3.91 - 3.65 (m, 3H), 3.64 - 3.43 (m, 2H), 3.37 - 2.98 (m, 4H), 2.91 (d, *J* = 7.6 Hz, 3H), 2.89 - 2.76 (m, 1H), 2.70 - 2.53 (m, 2H), 2.46 (dt, *J* = 5.2, 16.4 Hz, 1H).

EXAMPLE 574



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02471] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of [(2*S*,4*R*)-4-fluoro- 1-methyl-pyrrolidin- 2-yl]methanol (275 mg, 2.06 mmol, 2.0 *eq*) in toluene (12.0 mL) was added *t*-BuONa (198 mg, 2.06 mmol, 2.0 *eq*) in portions at 0 °C, after stirring at 0 °C for 0.5 hour, *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido [3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 1.03 mmol, 1.0 *eq*) was added, and stirred at 0 °C for 0.5 hour. After completion, water was added (15.0 mL), the resulting mixture was extracted with ethyl acetate (2 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (C18, 0.1%TFA in water, 30%-50% MeCN), the obtained product was adjusted with $NaHCO_3$ solid to pH=8, then concentrated, the aqueous phase was extracted with ethyl acetate (2 × 15 mL), the organic layer was washed with saturated brine (20.0 mL), then dried over Na_2SO_4, filtered and concentrated. The product *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (510 mg, 769 μmol, 75% yield, 98% purity) was obtained as light yellow solid. LCMS [ESI, M+1]: 650.


[02472] ^{1}H NMR (400 MHz, chloroform-d) δ 7.80 - 7.72 (m, 1H), 7.62 (t, *J* = 7.8 Hz, 1H), 7.56 - 7.50 (m, 1H), 7.46 - 7.40 (m, 1H), 7.37 - 7.31 (m, 1H), 7.26 - 7.17 (m, 1H), 5.29 - 5.07 (m, 1H), 4.65 - 4.57 (m, 1H), 4.50 - 4.34 (m, 2H), 4.30 - 4.17 (m, 1H), 4.06 - 3.76 (m, 3H), 3.65 - 3.47 (m, 2H), 3.41 - 2.86 (m, 7H), 2.84 - 2.45 (m, 7H), 2.40 - 2.24 (m, 1H), 2.04 - 1.86 (m, 1H), 1.52 (s, 9H).

[02473] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (500 mg, 769 μmol, 1.0 *eq*) in dioxane (5.0 mL) was added 4N HCl•dioxane (5.0 mL), the reaction mixture was stirred at 15 °C for 1 hour. After completion, the reaction mixture was filtered, and the solid was dissolved with dichloromethane (15.0 mL), the organic layer was washed with saturated brine (1 × 15 mL), dried over Na_2SO_4, filtered and concentrated to give 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (360 mg, 635 μmol, 85% yield, 97% purity) as light yellow solid. LCMS [ESI, M+1]: 550.


[02474] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (120 mg, 218 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (39.3 mg, 436 μmol, 2.0 *eq*) in ethyl acetate (1.2 mL) was added TEA (177 mg, 1.75 mmol, 243 μL, 8.0 *eq*) and T3P (416 mg, 654 μmol, 389 μL, 50% purity, 3.0 *eq*) at 0 °C, the reaction mixture was stirred at 0 °C for 1 hour. After completion, the reaction mixture was added saturated brine (10.0 mL), then extracted with ethyl acetate (2 × 10 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by column chromatography (basic Al_2O_3, petroleum ether/ethyl acetate=3/1 to ethyl acetate / methanol=20/1), the crude product was re-purified by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 45%-75%, 10 min]; B%: 45%-75%, 10 min), the obtained product was concentrated, and lyophilized. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin- 2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (50.9 mg, 81.0 μmol, 37% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 622.

[02475] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (d, J = 8.0 Hz, 1H), 7.62 (t, J = 7.4 Hz, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 - 7.18 (m, 1H), 5.55 - 5.33 (m, 1H), 5.30 - 5.07 (m, 2H), 5.01 - 4.66 (m, 1H), 4.53 - 4.35 (m, 2H), 4.29 - 3.98 (m, 3H), 3.96 - 3.78 (m, 2H), 3.73 - 3.33 (m, 3H), 3.32 - 2.98 (m, 5H), 2.94 - 2.71 (m, 2H), 2.68 - 2.53 (m, 2H), 2.51 (d, J = 2.8 Hz, 3H), 2.39 - 2.23 (m, 1H), 2.08 - 1.87 (m, 1H).

EXAMPLE 575



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02476] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro -1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-

carboxylate. To a solution of [(3*R*)-1-methylpyrrolidin-3-yl]methanol (297 mg, 2.58 mmol, 2.50 *eq*) in toluene (6.0 mL) was added *t*-BuONa (198 mg, 2.06 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. Then *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 1.03 mmol, 1.0 *eq*) was added to the above liquid. After addition, the mixture was stirred at 0 °C for another 0.5 hour. After completion, water was added (20.0 mL) and the resulting mixture extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (C18, 0.1% FA in water, 0-60 % MeCN) to give the compound *tert*-butyl (2*S*)-4-[7-(8-chloro -1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (430 mg, 680 μmol, 66% yield) as yellow solid. LCMS [ESI, M+1]: 632.


[02477] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.75 (d, J = 8.0 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.48 - 7.39 (m, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.26 - 7.15 (m, 1H), 4.67 - 4.55 (m, 1H), 4.50 - 4.35 (m, 1H), 4.27 - 4.17 (m, 2H), 4.08 - 3.75 (m, 4H), 3.65 - 3.50 (m, 1H), 3.39 - 3.02 (m, 5H), 3.00 - 2.86 (m, 1H), 2.81 - 2.64 (m, 4H), 2.62 - 2.46 (m, 4H), 2.35 (s, 3H), 2.15 - 2.05 (m, 1H), 1.52 (s, 9H).

[02478] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl) -2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (400 mg, 632 μmol, 1.0 *eq*) in dioxane (2.0 mL) was added HCl•dioxane (4.0 M, 2.0 mL, 12.6 *eq*). The mixture was stirred at 15 °C for 1 hour. After completion, the reaction mixture was concentrated. The residue was adjusted with saturated aqueous $NaHCO_3$ (10.0 mL) to pH~7, and then extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated to give the compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (240 mg, 451 μmol, 71% yield) as yellow solid which was used for the next step without further purification. LCMS [ESI, M+1]: 532.


[02479] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(3*R*)- 1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80.0 mg, 150 μmol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (27.1 mg, 301 μmol, 2.0 *eq*) and TEA (122 mg, 1.20 mmol, 167 μL, 8.0 *eq*) in ethyl acetate (2.0 mL) was added T3P (287 mg, 451 umol, 268 μL, 50% purity in ethyl acetate, 3.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was quenched with HCl (12.0 M, 60.0 uL in 2.0 mL of water). The mixture was adjusted to pH ~ 8 with saturated aqueous $NaHCO_3$ and extracted with ethyl acetate (3 × 10.0 mL). The combined organic layers were washed with brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10μm; mobile phase: [water (0.225%FA)-ACN]; B%: 25%-45%, 8 min), then concentrated. The aqueous layer was adjusted with saturated aqueous $NaHCO_3$ to pH ~ 8 and extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)- 2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (35.9 mg, 57.5 μmol, 38% yield, 96.8% purity) as white solid. LCMS [ESI, M+1]: 604.


[02480] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.78 - 7.73 (d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.2 Hz, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.27 - 7.18 (m, 1H), 5.54 - 5.32 (m, 1H), 5.30 - 5.21 (m, 1H), 5.04 - 4.75 (m, 1H), 4.48 - 4.36 (m, 1H), 4.27 - 4.17 (m, 2H), 4.16 - 3.96 (m, 2H), 3.89 - 3.75 (m, 1H), 3.64 - 3.55 (m, 1H), 3.51 - 3.32 (m, 1H), 3.30 - 2.98 (m, 4H), 2.96 - 2.67 (m, 4H), 2.66 - 2.46 (m, 4H), 2.37 (d, *J* = 2.0 Hz, 3H), 2.14 - 2.06 (m, 1H), 1.70 - 1.57 (m, 1H).

EXAMPLE 576



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4- methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile





[02481] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy- 1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 516 μmol, 1 *eq*) in toluene (5.00 mL) was added *t*-BuONa (124 mg, 1.29 mmol, 2.5 *eq*) and [(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin- 2-yl]methanol (149 mg, 1.03 mmol, 2 *eq*). The mixture was stirred at 0 °C for 1 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and

concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 100/1 to 10:1). *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy- 1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 265 μmol, 51% yield, 88% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 662.


[02482] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 302 μmol, 1 *eq*) in dioxane (1.00 mL) was added HCl/dioxane (4 M, 1.13 mL, 1.00 *eq*). The mixture was stirred at 20 °C for 1 hour. The reaction mixture was concentrated under vacuum and diluted with water (20 mL). The mixture was adjusted to pH = 8 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, 154.60 μmol, 70% yield, 79% purity) was obtained as a yellow solid and used next step without purification. LCMS [ESI, M+1]: 562.

[02483] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4- methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (110 mg, 195 μmol, 1 eq) in ethyl acetate (1.00 mL) was added 2-fluoroprop-2-enoic acid (35.3 mg, 391 μmol, 2 eq), T3P (374 mg, 587 μmol, 349 μL, 50% purity, 3 eq) and TEA (158 mg, 1.57 mmol, 218 μL, 8 eq). The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 100/1 to 10/1)


and further by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 45% - 75%, 10min). The desired fractions were collected and lyophilized. Title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (17 mg, 26.7 μmol, 14% yield, 99.8% purity) was obtained as a white gum. LCMS [ESI, M+1]: 634.

[02484] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.18 (m, 1H), 5.42 (d, *J* = 49.2 Hz, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.91 (br s, 1H), 4.54 - 4.34 (m, 2H), 4.27 - 4.00 (m, 3H), 3.96 - 3.77 (m, 2H), 3.67 - 3.54 (m, 1H), 3.51 - 3.37 (m, 1H), 3.37 - 2.96 (m, 9H), 2.95 - 2.64 (m, 3H), 2.63 - 2.53 (m, 1H), 2.52 - 2.27 (m, 5H), 1.91 - 1.74 (m, 1H).

EXAMPLE 577



2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-methoxy-1-methyl- pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02485] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-

(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2- yl]methanol (300 mg, 2.06 mmol, 2.0 *eq*) and *t*-BuONa (149 mg, 1.55 mmol, 1.50 *eq*) in toluene (7.0 mL) was added *tert*-butyl(2*S*)-4-[7-(8-chloro-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (600 mg, 1.03 mmol, 1.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, water was added (20.0 mL) and the resulting mixture extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (C18, 0.1 % FA in water, 0-60 % MeCN) to give the compound *tert*-butyl (2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (450 mg, 652 μmol, 63% yield, 96% purity) as yellow solid. LCMS [ESI, M+1]: 662.


[02486] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (br d, *J* = 8.4 Hz, 1H), 7.61 (t, *J* = 7.8 Hz, 1H), 7.52 (d, *J* = 7.6 Hz, 1H), 7.48 - 7.40 (m, 1H), 7.35 (t, *J* = 7.8 Hz, 1H), 7.27 - 7.16 (m, 1H), 4.63 - 4.56 (m, 1H), 4.50 - 4.35 (m, 2H), 4.23 - 4.15 (m, 1H), 4.12 - 3.91 (m, 4H), 3.90 - 3.75 (m, 1H), 3.65 - 3.53 (m, 1H), 3.50 - 3.39 (m, 1H), 3.38 - 3.32 (m, 1H), 3.30 (d, *J* = 2.0 Hz, 3H), 3.28 - 3.06 (m, 3H), 3.02 - 2.85 (m, 2H), 2.83 - 2.64 (m, 2H), 2.62 - 2.52 (m, 1H), 2.47 (d, *J* = 2.8 Hz, 3H), 2.35 - 2.29 (m, 1H), 2.11 - 2.06 (m, 1H), 2.03 - 1.91 (m, 1H), 1.52 (s, 9H).

[02487] Step B: 2-[(2*S*)-4-[7-(8-Chloro -1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (450 mg, 680 μmol, 1.0 *eq*) in dioxane (4.0 mL) was added HCl•dioxane (4 M, 4.0 mL, 23.6 *eq*). The mixture was stirred at 15 °C for 0.5 hour. After completion, the reaction mixture was concentrated. The residue was adjusted with saturated aqueous $NaHCO_3$ (10.0 mL) to pH~7, and then extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated to give 2-[(2*S*)-4-[7-(8-chloro -1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (300 mg, crude) as yellow solid which was used for the next step without further purification. LCMS [ESI, M+1]: 562.


[02488] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, 160 μmol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (28.8 mg, 320 μmol, 2.0 *eq*) and TEA (130 mg, 1.28 mmol, 178 μL, 8.0 *eq*) in EA (3.0 mL) was added T3P (306 mg, 480 μmol, 286 μL, 50% purity, 3.0 *eq*). The mixture was stirred at 0 °C for 1 hour. After completion, water was added (10.0 mL) and the resulting mixture extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 5μ;mobile phase: [water (0.05% ammonium hydroxide v/v)-ACN]; B%: 50%-80%,10 min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*S*,4*R*)-4-methoxy-1-methyl- pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (32.0 mg, 50.3 μmol, 31% yield, 99% purity) as white solid. LCMS [ESI, M+1]: 635.

[02489] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.4 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 7.8 Hz, 1H), 7.26 - 7.17 (m, 1H), 5.54 - 5.32 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.10 - 4.70 (m, 1H), 4.52 - 4.34 (m, 2H), 4.27 - 3.80 (m, 6H), 3.69 - 3.54 (m, 1H), 3.50 - 3.37 (m, 2H), 3.30 (d, *J* = 1.6 Hz, 3H), 3.28 - 3.02 (m, 4H), 2.98 - 2.68 (m, 3H), 2.65 - 2.53 (m, 1H), 2.47 (d, *J* = 2.4 Hz, 3H), 2.37 - 2.28 (m, 1H), 2.13 - 2.03 (m, 1H), 2.02 - 1.90 (m, 1H).

EXAMPLE 578



2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile




[02490] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 840 μmol, 1.00 *eq*) in toluene (10.0 mL) was added *t*-BuONa (202 mg, 2.10 mmol, 2.50 *eq*) and [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (224 mg, 1.68 mmol, 2.00 *eq*). After stirred at 0 °C for 1 hour, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, ethyl acetate/methanol = 100/1 to 10/1). Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (340 mg, 502 μmol, 60% yield, 98% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 664.

[02491] Step B: 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 301 μmol, 1.00 *eq*) in MeOH (15.0 mL) was added Pd/C (30.0 mg, 10% purity) and NH_3/MeOH (5.00 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15psi) at 15 °C for 0.5 hour. The catalyst was filtered off. The filtrate was concentrated under vacuum. 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (159 mg, 294 μmol, 98% yield, 98% purity) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 530.


[02492] Step C: 2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (140 mg, 264 μmol, 1.00 *eq*) and (*E*)-4-fluorobut-2-enoic acid (82.5 mg, 793 μmol, 3.00 *eq*) in ethyl acetate (2.00 mL) was added TEA (160 mg, 1.59 mmol, 220 μL, 6.00 *eq*) and T3P (505 mg, 793 μmol, 472 μL, 50% purity, 3.00 *eq*) at – 70 °C. The mixture was stirred at - 70 °C for 1 hour. The reaction mixture was quenched with HCl (12 N, 130 μL in 2 mL of water) at -70 °C. The mixture was warmed to 0 °C and basified with saturated $NaHCO_3$ aqueous solution to pH = 8 and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water (0.05% ammonium hydroxide v/v) - ACN]; B%: 45% - 75%, 10min). The desired fractions were collected and lyophilized. Title compound 2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl]-4-[2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (34.5 mg, 55.8 umol, 21% yield, 99.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 616.


[02493] ^{1}H NMR (400MHz, chloroform-d) δ = 7.74 - 7.62 (m, 2H), 7.46 - 7.31 (m, 2H), 7.27 - 7.17 (m, 2H), 7.09 - 6.93 (m, 1H), 6.59 (d, *J* = 15.2 Hz, 1H), 5.30 - 4.51 (m, 4H), 4.48 - 4.35 (m, 1H), 4.30 - 3.66 (m, 6H), 3.63 - 3.34 (m, 3H), 3.24 - 2.96 (m, 5H), 2.92 (s, 3H), 2.87 - 2.53 (m, 4H), 2.50 (d, *J* = 4.4 Hz, 3H), 2.40 - 2.22 (m, 1H), 2.10 - 1.86 (m, 1H) (m, 3H).

EXAMPLE 579



2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile





[02494] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl- 1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1 *eq*) in toluene (10 mL) was added *t*-BuONa (242 mg, 2.52 mmol, 3 *eq*) and [(2*R*)-1-methylpyrrolidin-2-yl]methanol (194 mg, 1.68 mmol, 2 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/MeOH = 100/1 to 10/1). benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 338 μmol, 40% yield, 91% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 646.


[02495] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 372 μmol, 1 *eq*) in MeOH (15 mL) was added Pd/C (30 mg, 10% purity) and NH_3•MeOH (5 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. The catalyst was filtered off. The filtrate was concentrated under vacuum. 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 352 μmol, 95% yield) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 512.

[02496] Step C: 2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 195 umol, 1 eq) and (*E*)-4-fluorobut-2-enoic acid (40.7 mg, 391 umol, 2 eq) in EtOAc (2 mL) was added TEA (79.1 mg, 782 umol, 109 uL, 4 eq) and T3P (249 mg, 391

umol, 232 uL, 50% purity in EtOAc, 2 eq) at – 70 °C. The mixture was stirred at -70 °C for 1 hour. The reaction mixture was quenched with HCl (60 uL (12 M) in 2 mL of water). The mixture was adjusted pH = 8 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Luna C18 150*25 5u; mobile phase: [water (0.225% FA) - ACN]; B%: 25% - 45%, 7.8min) and further purified by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 52%-79%, 10 min). The desired fractions were collected and lyophilized. Title compound 2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (16.6 mg, 27.7 umol, 14% yield, 99.6% purity) was obtained as a yellow gum. LCMS [ESI, M+1]: 598.


[02497] ^{1}H NMR (400MHz, chloroform-d) δ = 7.72 - 7.62 (m, 2H), 7.45 - 7.32 (m, 2H), 7.27 - 7.16 (m, 2H), 7.07 - 6.93 (m, 1H), 6.60 (d, *J* = 15.6 Hz, 1H), 5.26 - 4.51 (m, 3H), 4.39 (s, 1H), 4.31 - 3.33 (m, 9H), 3.27 - 2.97 (m, 5H), 2.92 (s, 3H), 2.87 - 2.76 (m, 1H), 2.65 (m, 2H), 2.49 (br d, *J*=4.6 Hz, 3H), 2.29 (m, 1H), 2.15 - 1.96 (m, 1H), 1.92 - 1.67 (m, 3H).

EXAMPLE 580



2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile

SUBSTITUTE SHEET (RULE 26)



[02498] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl- 1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1 *eq*) in toluene (10 mL) was added *t*-BuONa (242 mg, 2.52 mmol, 3 *eq*) and [(2*R*)-1-methylpyrrolidin-2-yl]methanol (194 mg, 1.68 mmol, 2 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, ethyl acetate/MeOH = 100/1 to 10/1). Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 338 μmol, 40% yield, 91% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 646.

[02499] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*R*)-1-


methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 372 μmol, 1 *eq*) in MeOH (15 mL) was added Pd/C (30 mg, 10% purity) and NH_3•MeOH (5 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. The catalyst was filtered off. The filtrate was concentrated under vacuum. 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 352 μmol, 95% yield) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 512.

[02500] Step C: 2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)- 1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 195 μmol, 1 eq) and (*E*)-4-fluorobut-2-enoic acid (40.7 mg, 391 umol, 2 eq) in EtOAc (2 mL) was added TEA (79.1 mg, 782 μmol, 109 μL, 4 eq) and T3P (249 mg, 391 μmol, 232 μL, 50% purity in EtOAc, 2 eq) at – 70 °C. The mixture was stirred at -70 °C for 1 hour. The reaction mixture was quenched with HCl (60 μL (12 M) in 2 mL of water). The mixture was adjusted pH = 8 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Luna C18 150*25 5μ; mobile phase: [water (0.225% FA) - MeCN]; B%: 25% - 45%, 7.8min) and further purified by prep-HPLC (column: Waters Xbridge 150*25 5μ; mobile phase: [water (0.05% ammonium hydroxide v/v) - MeCN]; B%: 52%-79%, 10 min). The desired fractions were collected and lyophilized. Title compound 2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl]-4-[7-(8-methyl-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (16.6 mg, 27.7 μmol, 14% yield, 99.6% purity) was obtained as a yellow gum. LCMS [ESI, M+1]: 628.


[02501] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.62 (m, 2H), 7.45 - 7.32 (m, 2H), 7.27 - 7.17 (m, 2H), 7.08 - 6.93 (m, 1H), 6.60 (br d, *J* = 16.0 Hz, 1H), 5.26 - 4.54 (m, 3H), 4.40 (m, 1H), 4.31 - 3.69 (m, 7H), 3.61 - 3.36 (m, 3H), 3.30 (d, *J* = 2.0 Hz, 3H), 3.24 - 2.96 (m, 4H),

2.92 (s, 3H), 2.91 - 2.55 (m, 4H), 2.47 (d, J = 4.8 Hz, 3H), 2.37 - 2.26 (m, 1H), 2.13 - 2.03 (m, 1H), 2.01 - 1.89 (m, 1H).

EXAMPLE 581



2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02502] Step A: Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl -1-naphthyl)-2-

methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (450 mg, 757 umol, 1 *eq*) and [(3*R*)-1-methylpyrrolidin-3-yl]methanol (131 mg, 1.13 mmol, 1.5 *eq*) in toluene (9 mL) was added *t*-BuONa (145 mg, 1.51 mmol, 2 *eq*). The mixture was stirred at 0 °C for 10 minutes. Upon completion, water was added (15 mL) and the resulting mixture extracted with ethyl acetate (30 mL × 2). The organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 50 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl] methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 455 μmol, 60% yield, 98% purity) as a pink solid.

[02503] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.73 - 7.60 (m, 2H), 7.45 - 7.37 (m, 5H), 7.37 - 7.30 (m, 2H), 7.26 - 7.16 (m, 2H), 5.21 (s, 2H), 4.68 (br s, 1H), 4.30 - 3.78 (m, 7H), 3.59 - 3.29 (m, 2H), 3.25 - 2.94 (m, 4H), 2.91 (s, 3H), 2.82 - 2.62 (m, 4H), 2.62 - 2.53 (m, 2H), 2.53 - 2.42 (m, 2H), 2.35 (s, 3H), 2.05 (s, 1H), 1.66 - 1.51 (m, 1H).


[02504] Step B: 2-[(2*S*)-4-[7-(8-Methyl-1-naphthyl)-2-[[(3*R*)-1- methyl pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 465 μmol, 1 *eq*) in MeOH (4 mL) was added Pd/C (150 mg, 10% purity), NH_3/MeOH (4 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1- methyl pyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (210 mg, 369 μmol, 80% yield, 90% purity) as a pink solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 512.

[02505] Step C: 2-[(2*S*)-1-[(*E*)-4-Fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-


yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (70 mg, 137 μmol, 1 *eq*), TEA (41.5 mg, 410 μmol, 57.1 μL, 3 *eq*) and (*E*)-4-fluorobut-2-enoic acid (28.5 mg, 274 μmol, 2 *eq*) in EtOAc (2 mL) was added T3P (131 mg, 205 μmol, 122 μL, 50% purity in EtOAc, 1.5 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the reaction mixture was quenched with 1 M HCl (0.4 mL) at -40 °C and stirred until no ice remained. The separated aqueous layer was concentrated under vacuum. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*30mm*4μm; mobile phase: [water (0.225%FA)-MeCN]; B%: 20%-50%, 10min). The desired fractions were collected and lyophilized to give title compound 2-[(2*S*)-1-[(*E*)-4-fluorobut-2-enoyl] -4-[7-(8-methyl-1-naphthyl)-2-[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (13.7 mg, 20.8 μmol, 15% yield, 97.7% purity, FA) as a gray solid. LCMS [ESI, M+1]: 598.

[02506] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.66 - 7.59 (m, 1H), 7.59 - 7.51 (m, 1H), 7.32 (td, *J* = 7.6, 11.6 Hz, 1H), 7.26 (t, *J* = 7.6 Hz, 1H), 7.19 - 7.07 (m, 2H), 7.00 - 6.83 (m, 1H), 6.52 (br d, *J*= 14.8 Hz, 1H), 5.21 - 4.31 (m, 3H), 4.29 - 3.96 (m, 3H), 3.94 - 3.53 (m, 7H), 3.45 (br d, *J* = 6.8 Hz, 4H), 3.15 - 2.88 (m, 7H), 2.84 (s, 3H), 2.81 - 2.74 (m, 1H), 2.61 - 2.47 (m, 2H), 2.18 (br s, 1H), 1.85 (br s, 1H).

EXAMPLE 582



2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((2*S*,4*R*)- 4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile




[02507] 2-((*S*)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((2*S*,4*R*)- 4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 327 μmol, 1.0 *eq*) and (*E*)-4-fluorobut-2-enoic acid (102 mg, 982 μmol, 3.0 *eq*) was added TEA (265 mg, 2.62 mmol, 364 μL, 8.0 *eq*) and T3P (833 mg, 1.31 mmol, 778 μL, 50% purity, 4.0 *eq*), the reaction mixture was stirred at -65 °C for 1 hour. After completion, the reaction mixture was quenched with 2 N HCl to pH~7 at -65 °C, then the organic layer was separated, the aqueous phase was extracted with ethyl acetate (2 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified column chromatography (basic Al_2O_3, petroleum ether/ethyl acetate=3/1 to ethyl acetate/methanol=20/1), the crude product was re-purified by prep-HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN]; B%: 50%-80%, 8 min), the obtained product was concentrated, and lyophilized. Title compound 2-((*S*)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2*S*,4*R*)- 4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile (72.2 mg, 113 μmol, 34% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 637.


[02508] ^{1}H NMR (400 MHz, chloroform-d) δ 7.79 - 7.73 (m, 1H), 7.62 (t, *J* = 7.0 Hz, 1H), 7.53 (d, *J* = 7.2 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.18 (m, 1H), 7.08 - 6.93 (m, 1H), 6.59 (br d, *J* = 14.8 Hz, 1H), 5.29 - 5.03 (m, 3H), 4.54 - 4.52 (m, 1H), 4.50 -

4.35 (m, 2H), 4.30 - 3.78 (m, 5H), 3.76 - 3.35 (m, 3H), 3.32 - 2.96 (m, 5H), 2.91 - 2.54 (m, 4H), 2.51 (d, J = 3.2 Hz, 3H), 2.39 - 2.23 (m, 1H), 2.08 - 1.86 (m, 1H).

EXAMPLE 583



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy- 1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile




[02509] 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy- 1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 267 μmol, 1.0 *eq*), (*E*)-4-fluorobut-2-enoic acid (55.6 mg, 534 μmol, 2.0 *eq*) and TEA (108 mg, 1.07 mmol, 149 μL, 4.0 *eq*) in ethyl acetate (4.0 mL) was added T3P (340 mg, 534 μmol, 317 μL, 50% purity, 2.0 *eq*). The mixture was stirred at -70 °C for 1 hour. After completion, the reaction mixture was quenched with HCl


(12 M, 60.0 μL in 2.0 mL of water). The mixture was adjusted to pH~8 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 20.0 mL). The combined organic layers were washed with saturated brine (60.0 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5um; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN]; B%: 50%-80%, 8 min) to give title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*,4*R*)-4-methoxy- 1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (39.6 mg, 60.9 μmol, 23% yield, 99% purity) as white solid. LCMS [ESI, M+1]: 619.

[02510] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.27 - 7.17 (m, 1H), 7.08 - 6.94 (m, 1H), 6.67 - 6.54 (m, 1H), 5.25 - 5.03 (m, 2H), 4.80 - 4.60 (m, 1H), 4.48 - 4.34 (m, 2H), 4.21 - 3.77 (m, 5H), 3.65 - 3.55 (m, 1H), 3.51 - 3.37 (m, 1H), 3.31 - 2.97 (m, 5H), 2.88 - 2.54 (m, 4H), 2.48 (d, *J* = 3.6 Hz, 3H), 2.34 - 2.24 (m, 1H), 2.11 - 2.01 (m, 1H), 1.90 - 1.69 (m, 3H).

EXAMPLE 584




2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2 -[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile




[02511] 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2 -[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 188 μmol, 1.0 *eq*), (*E*)-4-fluorobut-2-enoic acid (39.1 mg, 376 μmol, 2.0 *eq*) and TEA (95.1 mg, 940 μmol, 131 μL, 5.0 *eq*) in ethyl acetate (3.0 mL) was added T3P (179 mg, 282 μmol, 168 μL, 50 % purity, 1.50 *eq*). The mixture was stirred at 0 °C for 0.5 hour. After completion, the reaction mixture was quenched with HCl (12 M, 5.0 eq) at - 40 °C. The mixture was adjusted to pH~8 with saturated aqueous $NaHCO_3$ and extracted with ethyl acetate (3 × 10.0 mL). The combined organic layers were washed with brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25*10μm; mobile phase: [water (0.225%FA)-MeCN]; B%: 30%-50%, 8 min) to give the title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2 -[[(3*R*)-1-methylpyrrolidin-3-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (15.7 mg, 24.9 μmol, 13% yield, 98% purity) as a yellow solid.. LCMS [ESI, M+1]: 619.

[02512] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (d, *J* = 8.4 Hz, 1H), 7.65 - 7.59 (m, 1H), 7.56 - 7.49 (m, 1H), 7.48 - 7.40 (m, 1H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.26 - 7.18 (m, 1H), 7.08 - 6.92 (m, 1H), 6.74 - 6.46 (m, 1H), 5.25 - 4.95 (m, 3H), 4.75 - 4.55 (m, 1H), 4.47 - 4.36 (m, 1H), 4.35 - 4.26 (m, 2H), 4.14 - 3.92 (m, 2H), 3.91 - 3.76 (m, 1H), 3.64 - 3.55 (m, 1H), 3.53 - 3.35 (m, 1H), 3.33 - 3.04 (m, 7H), 3.03 - 2.72 (m, 4H), 2.67 (d, *J* = 4.0 Hz, 3H), 2.64 - 2.51 (m, 1H), 2.31 - 2.19 (m, 1H), 1.98 - 1.85 (m, 1H).

EXAMPLE 585



2-((*S*)-4-(2- (3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile



[02513] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro -1-naphthyl)- 2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a mixture of 3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan -5-yl]propan-1-ol (150 mg, 954 μmol, 1.85 *eq*) in toluene (3.0 mL) was added *t*-BuONa (99.2 mg, 1.03 mmol, 2.0 *eq*) in portions at 0 °C, after stirring at 0 °C for 0.5

hour, *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8-dihydro -5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (300 mg, 516 μmol, 1.0 *eq*) was added to the mixture, and stirred at 0 °C for 0.5 hour. After completion, water was added (15 mL), and the resulting mixture extracted with ethyl acetate (2 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (C18, 0.1%TFA in water, 30%-50% MeCN), the obtained product was adjusted with $NaHCO_3$ solid to pH~8, then concentrated, the aqueous phase was extracted with ethyl acetate (2 × 15 mL), the organic layer was washed with saturated brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated. The product *tert*-butyl (2*S*)-4-[7-(8-chloro -1-naphthyl)- 2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (180 mg, 267 μmol, 52% yield, 100% purity) was obtained as light yellow solid. LCMS [ESI, M+1]: 674.

[02514] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (br d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.52 (d, J = 7.2 Hz, 1H), 7.48 - 7.40 (m, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 - 7.17 (m, 1H), 4.66 - 4.54 (m, 1H), 4.50 - 4.29 (m, 4H), 4.08 - 3.77 (m, 5H), 3.65 - 3.54 (m, 2H), 3.51 - 3.44 (m, 1H), 3.39 - 3.31 (m, 1H), 3.29 - 3.02 (m, 4H), 3.00 - 2.87 (m, 2H), 2.84 - 2.46 (m, 6H), 1.99 - 1.82 (m, 3H), 1.52 (s, 9H).


[02515] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa -5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 222 μmol, 1.0 *eq*) in dioxane (1.0 mL) was added 4 N HCl•dioxane (1.0 mL), the reaction mixture was stirred at 15 °C for 1 hour. After completion, the reaction mixture was concentrated, added dichloromethane (10 mL),then washed with saturated aqueous Na_2CO_3 (1 × 10 mL), the organic layer was dried over Na_2SO_4, filtered and concentrated. The product 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[3-[(1*S*,4*S*)-2-oxa -5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 172 μmol, 77% yield, 98% purity) was obtained as brown oil. LCMS [ESI, M+1]: 574.

[02516] Step C: 2-((*S*)-4-(2- (3-((1*S*,4*S*)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[3-[(1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]propoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.0 mg, 157 μmol, 1.0 *eq*) and (*E*)-4-fluorobut-2-enoic acid (48.9 mg, 470 μmol, 3.0 *eq*) in ethyl acetate (1.0 mL) was added TEA (127 mg, 1.25 mmol, 175 μL, 8.0 *eq*) and T3P (399 mg, 627 μmol, 373 μL, 50% purity, 4.0 *eq*) in portions at -65 °C, the reaction mixture was stirred at -65 °C for 1 hour. After completion, the reaction mixture was quenched with 2 N HCl to pH~7 at -65 °C, then the organic layer was separated, the aqueous phase was extracted with ethyl acetate (2 × 10 mL), the combined organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified column chromatography (basic Al_2O_3, petroleum ether/ethyl acetate=3/1 to ethyl acetate/methanol=20/1), the crude product was re-purified by prep-HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN]; B%: 44%-74%, 8 min), the obtained product was concentrated, and lyophilized. Title compound 2-((*S*)-4-(2- (3-((1*S*,4*S*)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)propoxy)-7-(8-chloronaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile (10.6 mg, 16.0 μmol, 10% yield, 99% purity) was obtained as white solid. LCMS [ESI, M+1]: 660.


[02517] ^{1}H NMR (400 MHz, chloroform-d) δ 7.76 (br d, J = 8.4 Hz, 1H), 7.62 (t, J = 7.4 Hz, 1H), 7.53 (d, J = 7.2 Hz, 1H), 7.49 - 7.41 (m, 1H), 7.34 (t, J = 7.8 Hz, 1H), 7.26 - 7.18 (m, 1H), 7.09 - 6.93 (m, 1H), 6.60 (br d, J = 14.0 Hz, 1H), 5.26 - 5.01 (m, 2H), 4.76 - 7.54 (m, 1H), 4.52 - 4.29 (m, 4H), 4.19 - 3.97 (m, 3H), 3.95 - 3.69 (m, 2H), 3.66 - 3.37 (m, 4H), 3.33 - 2.99 (m, 4H), 2.97 - 2.67 (m, 5H), 2.65 - 2.48 (m, 2H), 2.01 - 1.90 (m, 2H), 1.90 - 1.82 (m, 1H), 1.76 - 1.69 (m, 1H).

EXAMPLE 586

SUBSTITUTE SHEET (RULE 26)



2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile



[02518] Step A: *tert*-Butyl (2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. To a solution of [(2*R*)-1-methylpyrrolidin-2-yl]methanol (99.1 mg, 860 μmol, 2.50 *eq*) in toluene (5.0 mL) was added *t*-BuONa (66.2 mg, 688 μmol, 2.0 *eq*) and *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2-methylsulfinyl-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 344 μmol, 1.0 *eq*) in portions. The mixture was stirred at 0 °C for 0.5 hour. After completion, water was added (20.0 mL) and the resulting

mixture extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash (C18, 0.1 % FA in water, 0-60 % MeCN) to give the compound *tert*-butyl (2*S*)-4-[7-(8-chloro-1- naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 313 μmol, 91% yield, 99% purity) as yellow solid. LCMS [ESI, M+1]: 632.

[02519] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.77 - 7.73 (m, 1H), 7.61 (t, *J* = 7.6 Hz, 1H), 7.54 - 7.50 (m, 1H), 7.49 - 7.39 (m, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.27 - 7.16 (m, 1H), 4.67 - 4.56 (m, 1H), 4.47 - 4.35 (m, 2H), 4.23 - 4.15 (m, 1H), 4.09 - 3.89 (m, 3H), 3.88 - 3.77 (m, 1H), 3.63 - 3.53 (m, 1H), 3.41 - 3.30 (m, 1H), 3.22 - 3.03 (m, 4H), 3.01 - 2.85 (m, 1H), 2.74 - 2.67 (m, 2H), 2.63 - 2.51 (m, 2H), 2.49 (d, *J* = 4.4 Hz, 3H), 2.36 - 2.25 (m, 1H), 2.11 - 2.05 (m, 1H), 1.90 - 1.74 (m, 3H), 1.52 (s, 9H).


[02520] Step B: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-4-[7-(8-chloro-1-naphthyl)-2- [[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 316 μmol, 1.0 *eq*) in dioxane (3.0 mL) was added HCl•dioxane (4.0 M, 3.0 mL, 37.9 *eq*). The mixture was stirred at 15 °C for 0.5 hour. After completion, the reaction mixture was concentrated. The residue was adjusted with saturated aqueous $NaHCO_3$ (10.0 mL) to pH~7, and then extracted with ethyl acetate (3 × 10.0 mL). The organic layer was dried over Na_2SO_4, filtered and concentrated to give the compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, crude) as yellow solid. The product was used for the next step without further purification. LCMS [ESI, M+1]: 532.

[02521] Step C: 2-[(2*S*)-4-[7-(8-Chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl) -2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 188 μmol, 1.0 *eq*) and (*E*)-4-fluorobut-2- enoic acid (39.1 mg, 376 μmol, 2.0 *eq*) in ethyl acetate (2.0 mL) was added TEA (76.1 mg, 752 μmol, 105 μL, 4.0 *eq*)


and T3P (239 mg, 376 μmol, 224 μL, 50% purity, 2.0 *eq*) at -70 °C. The mixture was stirred at -70 °C for 1 hour. After completion, the reaction mixture was quenched with HCl (12.0 M, 60.0 μL in 2.0 mL of water). The mixture was adjusted to pH = 8 with saturated aqueous $NaHCO_3$ and extracted with ethyl acetate (3 × 10.0 mL). The combined organic layers were washed with brine (30.0 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-MeCN]; B%: 598%-89%, 8min) to give the title compound 2-[(2*S*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*R*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (13.97 mg, 22.2 μmol, 12% yield, 98.4% purity) as white solid. LCMS [ESI, M+1]: 619.

[02522] ^{1}H NMR (400 MHz, Chloroform-d) δ 7.76 (br d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.6 Hz, 1H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.49 - 7.40 (m, 1H), 7.34 (t, *J* = 8.0 Hz, 1H), 7.27 - 7.17 (m, 1H), 7.08 - 6.94 (m, 1H), 6.67 - 6.54 (m, 1H), 5.25 - 5.03 (m, 2H), 4.80 - 4.60 (m, 1H), 4.48 - 4.34 (m, 2H), 4.21 - 3.77 (m, 5H), 3.65 - 3.55 (m, 1H), 3.51 - 3.37 (m, 1H), 3.31 - 2.97 (m, 5H), 2.88 - 2.54 (m, 4H), 2.48 (d, *J* = 3.6 Hz, 3H), 2.34 - 2.24 (m, 1H), 2.11 - 2.01 (m, 1H), 1.90 - 1.69 (m, 3H).

EXAMPLE 587



N-((E)-4-((S)-2-(Cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-en-1-yl)-N-methylacetamide




[02523] Step A: Ethyl (E)-4-(N-methylacetamido)but-2-enoate: Ethyl (E)-4-acetamidobut-2-enoate (140 mg, 0.818 mmol) was diluted with DMF (4 mL) followed by the addition of NaH (21.6 mg, 0.900 mmol) and MeI (56.2 µl, 0.900 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the organic layer was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10-70% ethyl acetate/hexanes to afford ethyl (E)-4-(N-methylacetamido)but-2-enoate (120 mg, 0.648 mmol, 79.2 % yield).

[02524] Step B: (E)-4-(N-methylacetamido)but-2-enoic acid: Ethyl (E)-4-(N-methylacetamido)but-2-enoate (20 mg, 0.11 mmol) was diluted with methanol (1 mL) followed by the addition of NaOH (270 µl, 0.54 mmol). After stirring for 4 hours, the reaction was diluted with 2N HCl to pH ~4 and the aqueous layer extracted with ethyl acetate. The ethyl acetate was dried over $MgSO_4$, filtered and concentrated to afford (E)-4-(N-methylacetamido)but-2-enoic acid (15 mg, 0.095 mmol, 88 % yield).


[02525] Step C: N-((E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-en-1-yl)-N-methylacetamide: 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (20 mg, 0.039 mmol) was diluted with DMF followed by the addition of DIEA (13.65 µl, 0.07817 mmol). (E)-4-(N-methylacetamido)but-2-enoic acid (9.83 mg, 0.0625 mmol) was added followed by the addition of 1-Propanephosphonic acid cyclic anhydride (39.6

μl, 0.0664 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH_4OH) to afford N-((E)-4-((S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4-oxobut-2-en-1-yl)-N-methylacetamide (2.1 mg, 0.0032 mmol, 8.2 % yield). ESI+APCI MS m/z 651.4 $[M+H]^+$.

EXAMPLE 588



2-((S)-4-(7-(8-Bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile




[02526] Step A: Benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Benzyl (S)-2-(cyanomethyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (140 mg, 0.277 mmol), 1,8-dibromonaphthalene (238 mg, 0.831 mmol), $Pd_2(dba)_3$ (25.4 mg, 0.0277 mmol), Cs_2CO_3 (451 mg, 1.38 mmol) and XANTPHOS (32.0 mg, 0.0554 mmol) were diluted with toluene (111 µl, 0.277 mmol). The reaction was purged with argon, sealed and heated to 110°C while stirring for 12 hours. The reaction was allowed to cool and diluted with ethyl acetate and water. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 1-10% methanol/DCM (1%NH_4OH) to afford benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (80 mg, 0.113 mmol, 40.7 % yield).

[02527] Step B: 2-((S)-4-(7-(8-Bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (80 mg, 0.11 mmol) was diluted with TFA (2 mL), placed under nitrogen and heated to 90°C. After stirring for 2 hours, the reaction was cooled and concentrated. The material was diluted with DCM and washed with saturated sodium bicarbonate. The DCM was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH_4OH) to afford 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (23 mg, 0.040 mmol, 35 % yield).


[02528] Step C: 2-((S)-4-(7-(8-Bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (23 mg, 0.040 mmol) was diluted with DMF (350 µL) followed by the addition of DIEA (22 µl, 0.13 mmol) and 2-fluoroacrylic acid (5.4 mg, 0.060 mmol). 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-

trioxide (25 mg, 0.040 mmol) was added and the reaction was stirred for 12 hours at room temperature. The reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH_4OH) to afford 2-((S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (9 mg, 0.014 mmol, 35 % yield). ESI+APCI MS m/z 650.2 $[M+H]^+$.

EXAMPLE 589




2-((S)-1-(2-Fluoroacryloyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile




[02529] Step A: 2-((S)-1-(2-Fluoroacryloyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-

yl)acetonitrile (24 mg, 0.042 mmol) was diluted with DMF (400 µL), DIEA (19 µl, 0.11 mmol) was added followed by the addition of 2-fluoroacrylic acid (6.1 mg, 0.068 mmol) and the addition of 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (30 µl, 0.047 mmol). The reaction was stirred at ambient temperature for 10 hours. The reaction was poured into a 5% sodium bicarbonate solution and extracted twice with ethyl acetate. The ethyl acetate was washed with water, brine, dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 1-10% methanol/DCM (1% NH_4OH) to afford 2-((S)-1-(2-fluoroacryloyl)-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(8-(trifluoromethyl)naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (5 mg, 0.0078 mmol, 18 % yield). ESI+APCI MS m/z 638.3 $[M+H]^+$.

EXAMPLE 590



2-((S)-4-(7-(8-Cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile




[02530] Step A: Benzyl (S)-2-(cyanomethyl)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: Benzyl (S)-4-(7-(8-bromonaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (30 mg, 0.042 mmol) and dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct (14 mg, 0.017 mmol) were diluted with cyclopropylzinc bromide (253 µl, 0.13 mmol). The reaction was purged with argon, sealed and heated to 90°C. After stirring for 12 hours, the reaction was allowed to cool and diluted with ethyl acetate and water. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silica gel eluting with 10% methanol/DCM (1% NH_4OH) to afford benzyl (S)-2-(cyanomethyl)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (7 mg, 0.010 mmol, 25 % yield).

[02531] Step B: 2-((S)-4-(7-(8-Cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Benzyl (S)-2-(cyanomethyl)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (9 mg, 0.01 mmol) was diluted with methanol (1 mL) followed by the addition of Pd-C (1 mg, 0.01 mmol). The reaction was equipped with a hydrogen balloon and purged three times followed by stirring under an atmosphere of hydrogen for 4 hours. The solids were collected by filtration , rinsed with methanol and the combined organic phase was concentrated to afford 2-((S)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (7 mg, 0.01 mmol, 97 % yield).

[02532] Step C: 2-((S)-4-(7-(8-Cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (10 mg, 0.019 mmol) was diluted with DMF (500 µL) followed by the addition of DIEA (11 µl, 0.065 mmol), 2-fluoroacrylic acid (2.5 mg, 0.028 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-

trioxatriphosphinane 2,4,6-trioxide (13 μl, 0.020 mmol). After stirring for 12 hours, the reaction was diluted with ethyl acetate and saturated sodium bicarbonate. The layers were separated and the ethyl acetate was dried over $MgSO_4$, filtered and concentrated. The material was purified on silca gel eluting with 10% methanol/DCM (1% NH_4OH) to afford 2-((S)-4-(7-(8-cyclopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (0.9 mg, 0.0015 mmol, 7.9 % yield). ESI+APCI MS m/z 610.3 $[M+H]^+$.


EXAMPLE 591



2-((S)-1-(2-Fluoroacryloyl)-4-(7-(8-isopropylnaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02533] Synthesized in the same fashion as **Example 590** substituting isopropyl zinc bromide for cyclopropyl zinc bromide in step A. ESI+APCI MS m/z 612.3 $[M+H]^+$.


EXAMPLE 592



2-((S)-1-(2-Fluoroacryloyl)-4-(7-(1-methylisoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

[02534] Synthesized in the same fashion as **Example 588** substituting 8-bromo-1-methylisoquinoline for 1,8-dibromonaphthalene in step A. ESI+APCI MS m/z 585.3 $[M+H]^+$.


EXAMPLE 593



2-((S)-4-(7-(5-Chloroisoquinolin-4-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02535] Synthesized in the same fashion as **Example 588** substituting 4-bromo-5-chloroisoquinoline for 1,8-dibromonaphthalene in step A. ESI+APCI MS m/z 605.2 $[M+H]^+$.


EXAMPLE 594



2-((S)-4-(7-(8-Bromoisoquinolin-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02536] Synthesized in the same fashion as **Example 588** substituting 8-bromo-1-chloroisoquinoline for 1,8-dibromonaphthalene in step A. ESI+APCI MS m/z 651.2 $[M+H]^+$.


EXAMPLE 595




2-((S)-4-(7-(1-chloroisoquinolin-8-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02537] Synthesized in the same fashion as **Example 589** substituting 8-bromo-1-chloroisoquinoline for 1,8-dibromonaphthalene in step A. ESI+APCI MS m/z 605.3 $[M+H]^+$.

EXAMPLE 596



2-((S)-4-(2-(((S)-1-Benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02538] Step A: Benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tert-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (3 g, 5.7 mmol) was dissolved in DCM (57 ml, 5.7 mmol) and treated with hydrochloric acid solution (4.0M in 1,4-dioxane) (7.1 ml, 28 mmol). The reaction was stirred at room temperature for 1 hour. The reaction was washed with 1M NaOH. The aqueous phase was extracted with additional DCM (2X), the combined organic phase was dried over $MgSO_4$ and concentrated in vacuo to give benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.4 g, 5.6 mmol, 99 % yield). ESI+APCI MS m/z 427.2 $[M+H]^+$.

[02539] Step B: Benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tris(dibenzylideneacetone)dipalladium(0) (1.030 g, 1.124 mmol) and 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (1.301 g, 2.249 mmol) were dissolved in 1,4-dioxane (56.22 ml, 5.622 mmol) and purged under argon for 5 minutes. The reaction was stirred at 100°C under argon for 15 minutes and the reaction cooled to room temperature. To the reaction was added benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.4 g, 5.622 mmol), 1-bromo-8-methylnaphthalene (3.729 g, 16.87 mmol), and cesium carbonate (5.495 g, 16.87 mmol) under argon. The reaction was capped under argon and stirred at 100°C over night. The reaction was cooled to room temperature and the solids were removed by filtration. The filtrate was concentrated in vacuo and purified by normal phase chromatography (2X) on the CombiFlash using 0→75% Hexanes/EtOAc as the eluent to give benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (2.532 g, 4.465 mmol, 79.42 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.

[02540] Step C: 2-((S)-4-(2-(((S)-1-Benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: In a microwave tube a solution of benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (250 mg, 0.441 mmol) in dioxane (2204 µl, 0.441


mmol) was sparged with argon for 5 minutes. (S)-(-)-1-benzyl-2-pyrrolidinemethanol (169 mg, 0.882 mmol), Cs_2CO_3 (431 mg, 1.32 mmol), methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (37.5 mg, 0.0441 mmol) were sequentially added under argon and the reaction sparged with Ar for an additional 5 minutes. The reaction mixture was capped and heated at 100°C for 2 hours. The reaction was cooled to room temperature and ethyl acetate was added. The solids were removed by filtration, and the filtrate was concentrated and purified by flash chromatography eluting with 0→20% DCM/MeOH + 2% NH_4OH. All fractions containing desired product were combined and concentrated to give 2-((S)-4-(2-(((S)-1-benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (120 mg, 0.204 mmol, 77.2 % yield). ESI+APCI MS m/z 722.4 $[M+H]^+$.

[02541] Step D: 2-((S)-4-(2-(((S)-1-Benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-4-(2-(((S)-1-benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (200 mg, 0.277 mmol) in EtOH (2770 µl, 0.277 mmol) and THF (2770 µl, 0.277 mmol) was purged with N_2 for 5 minutes. To this solution was added palladium (73.7 mg, 0.0693 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 minutes. The solution was then stirred under one atmosphere of H_2 for 1 hour. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide crude 2-((S)-4-(2-(((S)-1-benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (160 mg, 0.272 mmol, 98.3 % yield). ESI+APCI MS m/z 588.4 $[M+H]^+$.

[02542] Step E: 2-((S)-4-(2-(((S)-1-Benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile: To a 25 mL RBF containing dichloromethane (2722 µl, 0.272 mmol) at 0°C was added 2-((S)-4-(2-(((S)-1-benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (160 mg, 0.272 mmol) and Hunig's base (95.1 µl, 0.544 mmol). The reaction


mixture was vigorously stirred while 2-fluoroacrylic acid (98.1 mg, 1.09 mmol) was added in one portion. Next, 1-propanephosphonic acid cyclic anhydride (243 µl, 0.408 mmol) was added slowly to the stirring mixture. The reaction was stirred for 2 hours at 0°C. The reaction was treated with basic water and the aqueous layer extracted with DCM (3X). The combined organic phase was concentrated in vacuo and the residue resuspended in a 60:40 mixture of MeCN:H_2O and purified (prep HPLC), eluting with 5→95% MeCN/0.1% TFA in water/0.1% TFA to give product. Pure fractions were pooled and diluted with EtOAc and 1N NaOH and the layers separated. The combined organic phase was washed with brine, dried over $MgSO_4$ and concentrated in vacuo to give 2-((S)-4-(2-(((S)-1-benzylpyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (8 mg, 0.0121 mmol, 4.45 % yield). ESI+APCI MS m/z 660.4 $[M+H]^+$.

EXAMPLE 597



2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-(2-fluoroethyl)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

MET-110 PCT


HCl
Br
Cs2CO3
HCl
Pd/C, H2, RT
EtOH/THF
NaH, DMF, RT
TBSO
HO
Boc
NC
HN
Cl

[02543] Step A: Benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate : *tert*-butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (2 g, 3.795 mmol) was dissolved in DCM (37.95 ml, 3.795 mmol) and treated with hydrochloric acid solution (4.0 M in 1,4-dioxane) (4.744 ml, 18.97 mmol). The reaction was stirred at room temperature for 1 hour. The reaction was washed with 1M NaOH and the aqueous layer extracted with DCM (2X). The organic phase was combined, dried over Na_2SO_4 and concentrated to give benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.619 g, 3.792 mmol, 99.93 % yield). ESI+APCI MS m/z 427.2 $[M+H]^+$.

[02544] Step B: Benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: Tris(dibenzylideneacetone)dipalladium(0) (0.6946 g, 0.7585 mmol) and 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (0.8778 g, 1.517 mmol) were dissolved in 1,4-dioxane (37.92 ml, 3.792 mmol),purged under argon for 5 minutes and stirred at 100°C under argon for 15 minutes and the reaction cooled to room temperature. To the mixture was added benzyl (S)-4-(2-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (1.619 g, 3.792 mmol), 1-bromo-8-methylnaphthalene (2.515 g, 11.38 mmol), and cesium carbonate (3.707 g, 11.38 mmol) under argon. The reaction was capped under argon and stirred at 100°C over night. The reaction was cooled to room temperature and the solids removed by filtration. The filtrate was concentrated in vacuo and purified by normal phase chromatography (2X) using 0→75% hexanes/EtOAc as the eluent to give benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (958 mg, 1.689 mmol, 44.54 % yield). ESI+APCI MS m/z 567.2 $[M+H]^+$.

[02545] Step C: tert-Butyl (S)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate : In a microwave tube, a solution of benzyl (S)-4-(2-chloro-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-

(cyanomethyl)piperazine-1-carboxylate (250 mg, 0.441 mmol) in dioxane (2204 µl, 0.441 mmol) was sparged with argon for 5 minutes. (S)-(-)-1-(tert-Butoxycarbonyl)-2-pyrrolidinemethanol (222 mg, 1.10 mmol), Cs_2CO_3 (431 mg, 1.32 mmol) and methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-methylamino-1,1'-biphenyl-2-yl)palladium(II) (37.5 mg, 0.0441 mmol) were sequentially added under argon and the reaction sparged with Ar for an additional 5 minutes. The reaction mixture was capped and heated at 100°C for 2 hours. The reaction was cooled to room temperature and ethyl acetate was added. The solids were removed by filtration, the filtrate was concentrated and purified by flash chromatography eluting with 0→20% DCM/MeOH + 2% NH_4OH. All fractions containing desired product were combined and concentrated to give benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (306 mg, 0.418 mmol, 94.8 % yield). ESI+APCI MS m/z 598.3 [M+H]+.

[02546] Step D: Benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: *tert*-Butyl (S)-2-(((4-((S)-3-(cyanomethyl)piperazin-1-yl)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidine-1-carboxylate (93 mg, 0.1556 mmol) was dissolved in dichloromethane (1556 µl, 0.1556 mmol) and treated with Hunig's base (135.9 µl, 0.7779 mmol) and benzyl carbonochloridate (33.31 µl, 0.2334 mmol). The reaction was stirred at room temperature for 2 hours. The reaction was partitioned between DCM and water and the layers separated. The aqueous layer was extracted with DCM (2X). The combined organic phase was dried over Na_2SO_4,concentrated in vacuo and the residue purified by chromatography using 0→15% DCM/MeOH + 2% NH_4OH as eluent. All fractions containing product were combined and concentrated to give benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (367 mg, 0.5014 mmol, 322.3 % yield). ESI+APCI MS m/z 732.4 $[M+H]^+$.

[02547] Step E: Benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-

carboxylate: Benzyl (S)-4-(2-(((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (367 mg, 0.501 mmol) was dissolved in DCM (5014 µl, 0.501 mmol) and treated with TFA (193 µl, 2.51 mmol) and the reaction stirred at room temperature for 1 hour. No reaction was observed. The mixture was concentrated in vacuo and resuspended in DCM. To this was added HCl (4M in Dioxane, 500µL) and the reaction stirred at room temperature for 1 hour. The reaction was concentrated in vacuo and the residue partitioned between 1M NaOH and DCM. The combined organic phase was concentrated in vacuo to give crude benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (192 mg, 0.304 mmol, 60.6 % yield). ESI+APCI MS m/z 632.3 $[M+H]^+$.

[02548] Step F: Benzyl (S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate: To a stirred solution of benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-(((S)-pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (150 mg, 0.23742 mmol) in 2.5 mL of DMF was added sodium hydride (60 % dispersion in mineral oil (8.5465 mg, 0.35614 mmol)). After 15 minutes (2-bromoethoxy)(tert-butyl)dimethylsilane (142.00 mg, 0.59356 mmol) was added and the reaction heated to 75°C for 3.5 hours. The reaction was cooled to room temperature and partitioned between water and EtOAc and the layers separated. The aqueous layer was extracted with EtOAc and the combined organic phase washed with more water and brine, dried over Na_2SO_4 and concentrated in vacuo to give crude benzyl (S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (187 mg, 0.237 mmol, 99.7 % yield). ESI+APCI MS m/z 790.4 $[M+H]^+$.

[02549] Step G: 2-((S)-4-(2-(((S)-1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: A solution of benzyl (S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carboxylate (187 mg,


0.237 mmol) in EtOH (2367 µl, 0.237 mmol) and THF (2367 µl, 0.237 mmol) was purged with N_2 for 5 minutes. To this solution was added palladium (63.0 mg, 0.0592 mmol) (Degussa Type, 10 wt%, 50% H_2O), and was immediately capped and purged with N_2 for an additional 5 minutes. The solution was then stirred under one atmosphere of H_2 overnight. The mixture was diluted with MeOH and filtered through packed celite. The filtrate was then concentrated in vacuo to provide crude 2-((S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (134 mg, 0.204 mmol, 86.3 % yield). ESI+APCI MS m/z 656.4 $[M+H]^+$.

[02550] Step H: 2-((S)-4-(2-(((S)-1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile: At 0°C, to a 25 mL RBF containing N,N-dimethylformamide (2043 µl, 0.204 mmol) was added 2-((S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (134 mg, 0.204 mmol) and Hunig's base (71.4 µl, 0.409 mmol). The reaction mixture was vigorously stirred while 2-fluoroacrylic acid (22.1 mg, 0.245 mmol) was added in one portion. Next, 1-propanephosphonic acid cyclic anhydride (182 µl, 0.306 mmol) was added slowly to the stirring mixture. The reaction was stirred for 1 hour at 0°C. The reaction was treated with aqueous NaOH and the aqueous layer extracted with EtOAc (3X). The combined organic phase was concentrated in vacuo to give crude 2-((S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (120 mg, 0.165 mmol, 80.7 % yield). ESI+APCI MS m/z 728.4 $[M+H]^+$.


[02551] Step I: 2-((S)-1-(2-Fluoroacryloyl)-4-(2-(((S)-1-(2-hydroxyethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: 2-((S)-4-(2-(((S)-1-(2-((tert-butyldimethylsilyl)oxy)ethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (50 mg, 0.069 mmol) was dissolved in dichloromethane (687 µl, 0.069 mmol) and treated with hydrogen

chloride (52 µl, 0.21 mmol) (4M in dioxane). The reaction stirred at room temperature for 1 hour. The reaction was then concentrated in vacuo and resuspended in a 60:40 mixture of MeCN:H_2O and purified (prep HPLC) eluting with 5→95% MeCN/0.1% TFA in water/0.1% TFA. Fractions containing product were combined and partitioned between 1M NaOH and DCM and the layers separated and the aqueous layer extracted with additional DCM. The combined organic phase was dried over Na_2SO_4 and concentrated in vacuo to give 2-((S)-1-(2-fluoroacryloyl)-4-(2-(((S)-1-(2-hydroxyethyl)pyrrolidin-2-yl)methoxy)-7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (2.7 mg, 0.0044 mmol, 6.4 % yield). ESI+APCI MS m/z 614.3 $[M+H]^+$.

EXAMPLE 598




2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-(2-fluoroethyl)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02552] Step A: 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-(2-fluoroethyl)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile: 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-

pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (30 mg, 0.0508 mmol) was dissolved in acetonitrile (508 µl, 0.0508 mmol) and cesium carbonate (19.9 mg, 0.0610 mmol) was added in one portion. To this mixture was then added 1-fluoro-2-iodoethane (3.72 µl, 0.0458 mmol) and the reaction stirred at 60°C over night. The reaction was cooled to room temperature, the solids were removed by filtration, and the filtrate was concentrated in vacuo. The residue was resuspended in 60:40 MeCN:water and purified (prep HPLC), eluting with 5→95% MeCN/0.1% TFA in water/0.1% TFA. Fractions containing desired product were combined and partitioned between EtOAc and 1M NaOH and the layers separated. The aqueous layer was extracted with additional EtOAc (2X). The combined organic phase was dried over Na_2SO_4 and concentrated in vacuo to give 2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-(2-fluoroethyl)pyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile (4.8 mg, 0.00755 mmol, 14.8 % yield). ESI+APCI MS m/z 636.3 $[M+H]^+$.

EXAMPLE 599




2-((S)-1-(2-Fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02553] Step A: tert-Butyl (S)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate: To a solution of tert-butyl (S)-2-(hydroxymethyl)pyrrolidine-1-carboxylate (3.0 g, 14.91 mmol) in DCM (74.53 ml, 14.91 mmol) cooled to 0°C was added N-ethyl-N-isopropylpropan-2-amine (4.01 ml, 22.36 mmol) followed by addition of methanesulfonyl chloride (1.38 ml, 17.89 mmol)


over the course of 1 minute and the reaction stirred at 0°C for 1hr. The reaction was next washed with 1:1 water/brine (10 mL) and the layers separated. The combined organic phase was next dried over $MgSO_4$, filtered and concentrated in vacuo. The material was next purified by chromatography using 0-10% MeOH in DCM as eluent to give tert-butyl (S)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (3.786 g, 13.55 mmol, 90.9 % yield).




[02554] Step B: tert-Butyl (S)-2-(((3-methoxy-3-oxopropyl)thio)methyl)pyrrolidine-1-carboxylate: *tert*-Butyl (S)-2-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (2.00 g, 7.16 mmol) and Cs_2CO_3 (4.665 g, 14.32 mmol) were placed in dioxane (10 mL) and stirred for 3 hours at room temperature. NaOH (0.5M) was added and the mixture was extracted with DCM. The combined organic phase was concentrated and the residue purified by silica gel (0-12% MeOH in DCM with 0.25% NH_4OH) to provide tert-butyl (S)-2-(((3-methoxy-3-oxopropyl)thio)methyl)pyrrolidine-1-carboxylate (2.172 g, 7.16 mmol, 99 % yield).



[02555] Step C: Methyl (S)-3-(((1-methylpyrrolidin-2-yl)methyl)thio)propanoate: To a vial was added tert-butyl (S)-2-(((3-methoxy-3-oxopropyl)thio)methyl)pyrrolidine-1-carboxylate (2.172 g, 7.16 mmol) in formic acid (6.751 ml, 179.0 mmol) followed by addition of formaldehyde (10.76 ml, 143.2 mmol) (37% aqueous). The mixture was then heated to 65 °C and stirred for 18hours. The reaction was cooled and saturated bicarbonate was added slowly and the mixture was extracted with 10% MeOH in DCM (3x20 mL). The extracts were combined, dried over $MgSO_4$ and concentrated. The residue was purified by silica gel (5-20% MeOH in DCM with 0.25% NH4OH) to provide methyl (S)-3-(((1-methylpyrrolidin-2-yl)methyl)thio)propanoate (186 mg, 0.86 mmol, 12 % yield).




[02556] Step D: tert-Butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate,: Methyl (S)-3-(((1-methylpyrrolidin-2-yl)methyl)thio)propanoate (186 mg, 0.854 mmol) was placed in dioxane (5 mL). KOtBu (1708 µl, 1.71 mmol) was added and the mixture was stirred for 30 minutes. *tert*-Butyl (S)-4-(4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-chloro-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (300 mg, 0.569 mmol) was added and the mixture was heated to 80°C for 24 hours. The mixture was cooled, diluted with water and extracted with DCM (3x15 mL). The extracts were combined and concentrated. The residue was purified by silica gel (0-15% MeOH in DCM with 0.25% NH_4OH) to provide tert-butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (72 mg, 0.116 mmol, 20.3 % yield).




[02557] Step E: Benzyl (S)-2-(cyanomethyl)-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: *tert*-Butyl 4-((S)-4-((benzyloxy)carbonyl)-3-(cyanomethyl)piperazin-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,8-dihydropyrido[3,4-d]pyrimidine-7(6H)-carboxylate (72

mg, 0.12 mmol) was placed in DCM (5 mL) and cooled to 0°C. HCl (145 µl, 0.58 mmol) was added and the reaction warmed to room temperature and stirred for 18 hours. The reaction was concentrated and was brought up in DCM. Saturated bicarbonate was added and the mixture was extracted with DCM (3x 20 mL). The organic layers were combined, dried over $MgSO_4$ and concentrated to provide benzyl (S)-2-(cyanomethyl)-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (61 mg, 0.12 mmol).



[02558] Step F: Benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate: To a solution of benzyl (S)-2-(cyanomethyl)-4-(2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (61 mg, 0.12 mmol) in toluene (2 mL) was added 1-bromo-8-methylnaphthalene (78 mg, 0.35 mmol) and the reaction degassed with argon for 15 minutes followed by addition of Cs_2CO_3 (190 mg, 0.58 mmol), $Pd_2(dba)_3$ (21 mg, 0.023 mmol) and Xantphos (27 mg, 0.047 mmol) and the reaction heated to 100°C for 18 hr. The solids were removed by filtration, and the filtrate was concentrated in vacuo. The residue was next purified by chromatography using 1→12%MeOH/DCM with 2% NH_4OH as additive to give benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (54 mg, 0.082 mmol, 70 % yield).




[02559] Step G: 2-((S)-4-(7-(8-Methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: Benzyl (S)-2-(cyanomethyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (54 mg, 0.082 mmol) was placed in DCM (10 mL) and the reaction cooled to 0°C. AcOH (14.01 µl, 0.244 mmol) and TMS-I (69.67 µl, 0.490 mmol) were added and the reaction slowly warmed to room temperature and stirred for 1 hour. Saturated bicarbonate was added and the mixture was extracted with DCM. The extracts were concentrated and the residue purifed by reverse phase chromatography (5-95% MeCN in water with 0.1% TFA). The isolated product was then free based by bring up in DCM and adding saturated bicarbonate. The organic layer was separated, dried over $MgSO_4$ and concentrated to provide 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8 mg, 0.15 mmol, 19%).

[02560] Step H: 2-((S)-1-(2-Fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile: To a 0°C solution of N,N-dimethylformamide (152 µl, 0.015 mmol) was added 2-((S)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (8.0 mg, 0.015 mmol) and triethylamine (7.37 µl, 0.053 mmol). The reaction mixture was vigorously stirred while 2-fluoroacrylic acid (4.10 mg, 0.046 mmol) was added in one portion. Next, 1-propanephosphonic acid cyclic anhydride (13.5 µl, 0.023 mmol) was added slowly to the stirring mixture. The reaction was stirred at room temperature for 20 minutes. Water was added and the mixture was

extracted with DCM and the extracts were concentrated. The residue was purified by silica gel (0-12% MeOH in DCM with 0.25% NH_4OH) to provide 2-((S)-1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-2-((((S)-1-methylpyrrolidin-2-yl)methyl)thio)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (2.3 mg, 0.0038 mmol, 25.3 % yield). ES+APCI MS m/z 600.3 $[M+H]^+$.


EXAMPLE 600




2-((S)-4-(7-(5-Chloro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile

[02561] 2-((S)-4-(7-(5-Chloro-4-(trifluoromethyl)pyridin-3-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile, was prepared according to **Example 359** substituting 3,5-dichloro-4-(trifluoromethyl)pyridine for 1-bromo-8-methylnaphthalene in step A. ES+APCI MS m/z 623.2 $[M+H]^+$.

EXAMPLE 601



2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile



[02562] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]- 7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1 *eq*) and [(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methanol (191 mg, 1.26 mmol, 1.5 *eq*) in toluene (10 mL) was added *t*-BuONa (162 mg, 1.68 mmol, 2 *eq*). The mixture was stirred at 0 °C for 30 minutes. Upon completion, the mixture was diluted with water (10 mL) and extracted with EtOAc (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 100 mL). The

organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]- 7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 418 μmol, 50% yield, 95% purity) as a yellow solid. LCMS [ESI, M+1]: 682.


[02563] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2- yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1- methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (260 mg, 381 μmol, 1 *eq*) in MeOH (4 mL) was added Pd/C (120 mg, 10% purity), NH_3/MeOH (3 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 15 °C for 1 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum to give 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2- yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 296 μmol, 78% yield, 90% purity) as a yellow solid used directly into the next step without further purification. LCMS [ESI, M+1]: 548.

[02564] Step C: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (150 mg, 274 umol, 1 *eq*), TEA (222 mg, 2.19 mmol, 305 uL, 8 *eq*) and (*E*)-4-fluorobut-2-enoic acid (57.0 mg, 548 μmol, 2 *eq*) in EA (3 mL) was added T3P (523 mg, 822 μmol, 489 μL, 50% purity in EA, 3 *eq*) at -70 °C. The mixture was stirred at -70 °C for 1 hour. Upon completion, the reaction mixture was quenched with 1 M HCl (2.2 mL) at -70 °C, stirred until no ice remained. Layers were separated. The organic layer was basified with saturated $NaHCO_3$ aqueous solution to pH = 8 and extracted with ethyl acetate (15 mL × 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, EtOAc/MeOH 1/0 to 20/1) followed by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%, 10min). The desired fractions were collected and lyophilized to give


2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (50.6 mg, 78 μmol, 29% yield, 98% purity) as a white solid. LCMS [ESI, M+1]: 634.

[02565] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.0 Hz, 1H), 7.66 (t, *J* = 8.0 Hz, 1H), 7.45 - 7.38 (m, 1H), 7.38 - 7.32 (m, 1H), 7.27 - 7.18 (m, 2H), 7.09 - 6.93 (m, 1H), 6.60 (br d, *J* = 14.8 Hz, 1H), 5.32 - 4.93 (m, 3H), 4.64 (br s, 1H), 4.45 (td, *J* = 5.2, 11.2 Hz, 1H), 4.32 - 3.63 (m, 6H), 3.58 - 3.36 (m, 3H), 3.25 - 2.96 (m, 5H), 2.93 (s, 3H), 2.88 - 2.77 (m, 1H), 2.75 - 2.50 (m, 3H), 2.46 (d, *J* = 4.4 Hz, 3H), 2.34 - 2.15 (m, 1H).

EXAMPLE 602



2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02566] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 593 umol, 1.0 *eq*), 1-bromonaphthalene (184 mg, 890 μmol, 124 μL, 1.5 *eq*), $Pd_2(dba)_3$ (54.3 mg, 59.3 μmol, 0.1 *eq*), Cs_2CO_3 (483 mg, 1.48 mmol, 2.5 *eq*) and RuPhos (55.4 mg, 119 umol, 0.2 *eq*) in toluene (10 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 3 hours under N_2 atmosphere. Upon completion, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (1 × 50 mL) and the organic layer was separated, dried over sodium sulfate, filtered and concentrated under vacuum. The residue was purified by reverse phase HPLC (0.1% FA condition). The residue was basified with saturated aqueous $NaHCO_3$ solution to pH ~ 8, and then extracted with ethyl acetate (2 × 25 mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated under vacuum. Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 317 μmol, 53% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 632.


[02567] Step B: 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 158 μmol, 1.0 *eq*) in MeOH (10 mL) was added Pd/C (20 mg, 10% purity) and NH_3•MeOH (8 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum. 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (70 mg, crude) was obtained as a yellow oil and used into next steps without further purification. LCMS [ESI, M+1]: 498.

[02568] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-


naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60 mg, 121 umol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (21.7 mg, 241 µmol, 2.0 *eq*) and Et_3N (97.6 mg, 965 umol, 134 uL, 8.0 *eq*) in ethyl acetate (6 mL) was added T3P (230 mg, 362 µmol, 215 µL, 50% purity, 3.0 *eq*) at 0 °C. The mixture was stirred at 0 - 25 °C for 1 hour. Upon completion, the mixture was diluted with water (6 mL). The organic layer was separated, washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, ethyl acetate / methanol = 20 / 1 to 5 / 1). The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 60% - 78%, 10 min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilized. 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (7.23 mg, 12.7 µmol, 11% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 571.

[02569] 1H NMR (400 MHz, chloroform-d) δ = 8.27 - 8.16 (m, 1H), 7.91 - 7.81 (m, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.55 - 7.47 (m, 2H), 7.43 (t, *J* = 7.6 Hz, 1H), 7.15 (d, *J* = 7.2 Hz, 1H), 5.56 - 5.33 (m, 1H), 5.26 (dd, *J* = 3.2, 16.8 Hz, 1H), 4.85 (br s, 1H), 4.41 (dd, *J* = 5.2, 10.8 Hz, 1H), 4.34 - 4.24 (m, 2H), 4.22 - 3.96 (m, 4H), 3.75 - 3.21 (m, 4H), 3.12 (br t, *J* = 6.8 Hz, 2H), 3.04 - 2.92 (m, 2H), 2.87 (m, 2H), 2.70 (m, 1H), 2.50 (s, 3H), 2.38 - 2.23 (m, 1H), 2.15 - 1.99 (m, 1H), 1.94 - 1.73 (m, 3H).

EXAMPLE 603



2-[(2*S*)-4-[2-(cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02570] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-(cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of cyclopentylmethanol (50.5 mg, 504 μmol, 54.6 μL, 3.0 *eq*) and benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 168 μmol, 1.0 *eq*) in toluene (5 mL) was added *t*-BuONa (48.5 mg, 504 umol, 3.0 *eq*) at -10 °C. The mixture was stirred at -10 °C for 0.5 hour. Upon completion, the reaction mixture was quenched with water (5 mL) at -10 °C, and then extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 3/1). The compound benzyl (2*S*)-2-(cyanomethyl)-4-[2-(cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (58 mg, 91.6 μmol, 54% yield, 99.6% purity) was obtained as a white solid. LCMS [ESI, M+1]: 631.

[02571] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.46 - 7.30 (m, 7H), 7.26 - 7.16 (m, 2H), 5.27 - 5.15 (m, 2H), 4.69 (br s, 1H), 4.32 - 3.72 (m, 7H), 3.59 - 3.30 (m, 2H), 3.24 - 2.87 (m, 7H), 2.87 - 2.30 (m, 4H), 1.90 - 1.76 (m, 2H), 1.64 (m, 2H), 1.57 - 1.51 (m, 1H), 1.42 - 1.21 (m, 3H).


[02572] Step B: 2-[(2*S*)-4-[2- (cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-(cyclopentylmethoxy) -7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (58 mg, 92.0 μmol, 1.0 *eq*) in MeOH (3 mL) was added Pd/C (20 mg, 10% purity) and NH_3•MeOH (2 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum. 2-[(2*S*)-4-[2- (cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (34 mg, crude) was obtained as a yellow oil and used into next steps without further purification. LCMS [ESI, M+1]: 497.

[02573] Step C: 2-[(2*S*)-4-[2-(cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-(cyclopentylmethoxy)-7-(8-methyl -1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (30 mg, 60.4 μmol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (16.3 mg, 181 umol, 3.0 *eq*) and Et_3N (55.0 mg, 544 μmol, 75.7 μL, 9.0 *eq*) in EA (2.0 mL) was added T3P (154 mg, 242 umol, 144 uL, 50% purity, 4.0 *eq*) at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was diluted with water (6 mL). The organic layer was separated, washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 20/1 to 1/1). The residue was purified by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 65%-95%, 10 min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilized. 2-[(2*S*)-4-[2-(cyclopentylmethoxy)-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (8.85 mg, 15.3 μmol, two steps 17% yield, 98.2% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 569.


[02574] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.70 (br d, *J* = 8.0 Hz, 1H), 7.67 - 7.61 (m, 1H), 7.46 - 7.36 (m, 1H), 7.36 - 7.31 (m, 1H), 7.27 - 7.17 (m, 2H), 5.56 - 5.32 (m, 1H), 5.25 (dd, *J* = 3.6, 16.8 Hz, 1H), 4.89 (br s, 1H), 4.33 - 3.98 (m, 5H), 3.95 - 3.72 (m, 2H), 3.60 - 3.39

(m, 2H), 3.30 - 2.96 (m, 4H), 2.92 (s, 3H), 2.91 - 2.73 (m, 2H), 2.69 - 2.54 (m, 1H), 2.45 - 2.29 (m, 1H), 1.93 - 1.74 (m, 2H), 1.69 - 1.62 (m, 2H), 1.60 - 1.53 (m, 2H), 1.45 - 1.25 (m, 2H).

EXAMPLE 604



2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02575] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (1 g, 1.98 mmol, 1 *eq*), 4-bromo-5,6-dimethyl-1-tetrahydropyran-2-

yl-indazole (795 mg, 2.57 mmol, 1.3 *eq*), RuPhos (369 mg, 791 umol, 0.4 *eq*), Cs_2CO_3 (1.61 g, 4.94 mmol, 2.5 *eq*) and $Pd_2(dba)_3$ (362 mg, 396 umol, 0.2 *eq*) in toluene (20 mL) was de-gassed and then heated to 90 °C for 8 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with solid $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (900 mg, 1.23 mmol, 62% yield, 100% purity) as a brown solid.

[02576] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.98 (s, 1H), 7.43 - 7.33 (m, 5H), 7.22 (s, 1H), 5.66 (dd, *J* = 2.8, 9.6 Hz, 1H), 5.20 (s, 2H), 4.68 (br s, 1H), 4.39 (dd, *J* = 4.8, 10.0 Hz, 1H), 4.25 (s, 2H), 4.18 - 4.14 (m, 1H), 4.04 (br d, *J* = 12.0 Hz, 2H), 3.95 - 3.84 (m, 1H), 3.75 (dt, *J* = 2.8, 10.8 Hz, 1H), 3.50 (br t, *J* = 5.2 Hz, 2H), 3.30 (br s, 2H), 3.13 - 2.98 (m, 2H), 2.95 - 2.52 (m, 6H), 2.47 (s, 3H), 2.43 (s, 3H), 2.32 (s, 3H), 2.30 - 2.23 (m, 1H), 2.22 - 2.11 (m, 1H), 2.07 (br d, *J* = 3.2 Hz, 1H), 1.89 - 1.63 (m, 8H).

[02577] Step B: 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (0.9 g, 1.23 mmol, 1 *eq*) in MeOH (20 mL) was added NH_3•MeOH (20 mL, 20% purity), Pd/C (0.45 g, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the catalyst was removed by filtering through a plug of celite. The solvent was removed under reduced pressure. 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (620 mg, 1.03 mmol, 84% yield, 100% purity) was obtained as a yellow solid which was used directly in the next step without further purification. LCMS [ESI, M+1]: 600.

[02578] Step C: 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl- indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (600 mg, 1.00 mmol, 1 *eq*) in DMF (8 mL) was added 2-fluoroprop-2-enoic acid (180 mg, 2.00 mmol, 2 *eq*) in EA (4 mL) and TEA (304 mg, 3.00 mmol, 414 µL, 3 *eq*) followed by T3P (955 mg, 1.50 mmol, 892 µL, 50% purity in EtOAc, 1.5 *eq*) at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. Upon completion, the mixture was diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with solid $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (3 × 100 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (380 mg, 554 µmol, 55% yield, 98% purity) as a yellow solid. LCMS [ESI, M+1]: 672.


[02579] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.98 (s, 1H), 7.22 (s, 1H), 5.66 (dd, *J* = 2.4, 9.2 Hz, 1H), 5.51 - 5.32 (m, 1H), 5.25 (br dd, *J* = 3.6, 16.8 Hz, 1H), 5.09 - 4.59 (m, 1H), 4.44 - 4.33 (m, 1H), 4.26 (br s, 2H), 4.19 - 4.14 (m, 1H), 4.05 (br d, *J* = 14.4 Hz, 2H), 4.00 - 3.91 (m, 1H), 3.76 (dt, *J* = 2.4, 11.2 Hz, 1H), 3.59 - 3.39 (m, 3H), 3.37 - 3.21 (m, 1H), 3.14 - 3.02 (m, 2H), 2.90 - 2.52 (m, 6H), 2.48 (s, 3H), 2.43 (s, 3H), 2.33 (s, 3H), 2.29 - 2.23 (m, 1H), 2.22 - 2.08 (m, 2H), 1.90 - 1.69 (m, 8H).

[02580] Step D: 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*- indazol-4-yl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran - 2-yl-indazol-4-yl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (360 mg, 536 µmol, 1 *eq*) in DCM (0.4 mL) was added TFA (1.22 g, 10.7 mmol, 794 µL, 20 *eq*). The mixture was stirred at 25 °C for 2 hours. Upon completion, the mixture was diluted with DCM (10 mL) and


neutralized with saturated $NaHCO_3$ solution. The separated aqueous layer was extracted with DCM (2 × 10 mL). Combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with solid $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with EtOAc (2 × 15 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 40%-70%, 10min). The desired fractions were collected and lyophilized to give 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*- indazol-4-yl)-2-[[(2*S*)-1-methyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (73.3 mg, 120 μmol, 22% yield, 96.6% purity) as a white solid. LCMS [ESI, M+1]: 588.

[02581] ^{1}H NMR (400 MHz, chloroform-d) δ = 9.97 (br s, 1H), 8.04 (s, 1H), 7.15 (s, 1H), 5.55 - 5.31 (m, 1H), 5.26 (dd, *J* = 3.6, 16.8 Hz, 1H), 5.08 - 4.50 (m, 1H), 4.39 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.29 (s, 2H), 4.20 - 3.68 (m, 4H), 3.65 - 3.27 (m, 4H), 3.10 (br t, *J* = 7.8 Hz, 2H), 3.02 - 2.72 (m, 4H), 2.71 - 2.60 (m, 1H), 2.48 (s, 3H), 2.42 (s, 3H), 2.34 (s, 3H), 2.31 - 2.24 (m, 1H), 2.12 - 2.01 (m, 1H), 1.93 - 1.73 (m, 3H).

EXAMPLE 605



2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02582] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-(2-pyridylmethoxy)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of 2-pyridylmethanol (55.1 mg, 504 μmol, 48.7 μL, 3.0 *eq*) and benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-methylsulfinyl-6,8-dihydro- 5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 168 μmol, 1.0 *eq*) in toluene (5.00 mL) was added *t*-BuONa (48.5 mg, 504 μmol, 3.0 *eq*) at - 10 °C. The mixture was stirred at - 10 °C for 0.5 hour. Upon completion, the mixture was quenched with water (5.00 mL) and extracted with ethyl acetate (2 × 10 mL). The combined organic layers were washed with brine (1 × 10 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by column chromatography (SiO_2, petroleum ether/ethyl acetate = 50/1 to 1/1). Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-(2-pyridylmethoxy)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (64.0 mg, 98.8 μmol, 59% yield, 98.8% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 641.


[02583] Step B: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-

d]pyrimidin-4-yl]piperazine-1-carboxylate (64.0 mg, 100 μmol, 1.0 *eq*) in MeOH (3.00 mL) was added Pd/C (20.0 mg, 10% purity) and NH_3•MeOH (2.00 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. Upon completion, the mixture was concentrated under vacuum. The residue was purified by column chromatography (SiO_2, dichloromethane/methanol = 100/1 to 8/1). 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (15.0 mg, 19.3 μmol, 19% yield, 64.9% purity) was obtained as a yellow oil. LCMS [ESI, M+1]: 506.


[02584] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1- naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2- (2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (10.0 mg, 19.8 μmol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (5.34 mg, 59.3 μmol, 3.0 *eq*) and Et_3N (18.0 mg, 178 μmol, 24.8 μL, 9.0 *eq*) in EtOAc (2.00 mL) was added T3P (50.3 mg, 79.1 μmol, 47.1 μL, 50% purity in ethyl acetate, 4.0 *eq*) at 0 °C. The mixture was stirred at 25 °C for 1 hour. Upon completion, the mixture was diluted with water (3.00 mL). The organic layer was separated, washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, ethyl acetate/methanol = 50/1 to 10/1). The residue was purified by prep-HPLC (column: Xtimate C18 150 * 25mm * 5um; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 50% - 80%, 10 min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilized. 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1- naphthyl)-2-(2-pyridylmethoxy)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (1.41 mg, 2.44 umol, 12% yield, 99.8% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 579.

[02585] ^{1}H NMR (400MHz, chloroform-d) δ = 8.61 - 8.55 (m, 1H), 7.74 - 7.62 (m, 3H), 7.55 - 7.48 (m, 1H), 7.45 - 7.32 (m, 2H), 7.26 - 7.17 (m, 3H), 5.52 - 5.48 (m, 2H), 5.47 - 5.33 (m, 1H), 5.25 (dd, *J* = 3.6, 17.2 Hz, 1H), 4.79 (br s, 1H), 4.38 - 3.73 (m, 6H), 3.61 - 3.41 (m, 2H), 3.26 - 3.12 (m, 2H), 3.09 - 2.95 (m, 2H), 2.92 (s, 3H), 2.85 - 2.56 (m, 2H).

EXAMPLE 606



2-((*S*)-4-(7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-(((2*S*,4*R*)-4-fluoro-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02586] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-

carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (5.0 g, 11.4 mmol, 1.0 *eq*), 4-bromo-5,6-dimethyl-1-tetrahydropyran-2-yl-indazole (7.05 g, 22.8 mmol, 2.0 *eq*), $Pd_2(dba)_3$ (2.09 g, 2.28 mmol, 0.2 *eq*), RuPhos (2.13 g, 4.56 mmol, 0.4 *eq*) and Cs_2CO_3 (9.29 g, 28.5 mmol, 2.5 *eq*) in toluene (100 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 20/1 to 2/1) and further purified by reverse phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (4.90 g, 7.20 mmol, 63% yield, 98% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 667.

[02587] ^{1}H NMR (400MHz, chloroform-d) δ = 7.98 (s, 1H), 7.50 - 7.31 (m, 5H), 7.22 (s, 1H), 5.66 (dd, *J*=2.4, 9.6 Hz, 1H), 5.27 - 5.13 (m, 2H), 4.69 (br s, 1H), 4.27 (s, 2H), 4.13 - 3.97 (m, 3H), 3.89 (d, *J* = 11.6 Hz, 1H), 3.81 - 3.68 (m, 1H), 3.51 (t, *J*=5.2 Hz, 2H), 3.30 (br s, 2H), 3.04 (t, *J* = 11.6 Hz, 1H), 2.93 - 2.66 (m, 4H), 2.62 - 2.48 (m, 4H), 2.43 (s, 3H), 2.32 (s, 3H), 2.23 - 2.12 (m, 1H), 2.11 - 2.05 (m, 1H), 1.85 - 1.67 (m, 3H).

[02588] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 749 μmol, 1.0 *eq*) in toluene (10 mL) was added *m*-CPBA (152 mg, 749 μmol, 85% purity, 1.0 *eq*). The mixture was stirred at 0 °C for 1 hour. The mixture was diluted with water (10 mL) and adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution. Then the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced

pressure to give the product. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 539 μmol, 72% yield, 92% purity) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 683.

[02589] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (350 mg, 512 μmol, 1.0 *eq*) in toluene (10 mL) was added *t*-BuONa (148 mg, 1.54 mmol, 3.0 *eq*) and [(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methanol (136 mg, 1.03 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl- indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (280 mg, 372 μmol, 73% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 752.

[02590] Step C: 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran -2-yl-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (230 mg, 306 umol, 1.0 *eq*) in methanol (2.0 mL) was added dry Pd/C (50.0 mg, 10% purity) and NH_3/methanol (1.00 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 0.5 hour.

The mixture was concentrated under vacuum. 2-[(2*S*)-4-[7-(5,6-dimethyl-1-tetrahydropyran -2-yl-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (180 mg, 285 μmol, 93% yield, 98% purity) was obtained as a yellow solid and used next step without purification. LCMS [ESI, M+1]: 618.

[02591] Step D: 2-[(2*S*)-4-[7-(5,6-dimethyl-1H-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl -1-tetrahydropyran-2-yl-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (30 mg, 48.6 μmol, 1.0 *eq*) in dichloromethane (300 uL) was added TFA (221 mg, 1.94 mmol, 144 μL, 40 *eq*). The mixture was stirred at 0 °C for 0.5 hour. The mixture was concentrated under vacuum and diluted with water (10 mL). The mixture was adjusted pH ~ 8 with saturated $NaHCO_3$ aqueous solution and extracted with dichloromethane (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. The residue was purified by prep-HPLC (column: Xtimate C18 150 * 25mm * 5um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 26% - 56%, 1min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[7-(5,6-dimethyl-1H-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (7.08 mg, 13.1 μmol, 27% yield, 98.5% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 534.


[02592] ^{1}H NMR (400MHz, chloroform-d) δ = 10.14 (br s, 1H), 8.04 (d, *J*=0.8 Hz, 1H), 7.14 (s, 1H), 5.32 - 5.03 (m, 1H), 4.44 (dd, *J*=4.4, 11.2 Hz, 1H), 4.33 - 4.19 (m, 3H), 4.00 (br d, *J*=12.8 Hz, 1H), 3.82 (br d, *J*=12.0 Hz, 1H), 3.65 - 3.41 (m, 3H), 3.27 (br d, *J*=6.4 Hz, 1H), 3.17 - 2.95 (m, 4H), 2.90 (br dd, *J*=10.0, 12.4 Hz, 1H), 2.83 - 2.47 (m, 8H), 2.41 (s, 3H), 2.38 - 2.23 (m, 4H), 2.09 - 1.90 (m, 1H).

[02593] Step E: 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-


d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 187 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (25.3 mg, 281 μmol, 1.5 *eq*) in ethyl acetate (2.0 mL) was added T3P (477 mg, 749 μmol, 446 μL, 50% purity in ethyl acetate, 4.0 *eq*) and TEA (114 mg, 1.12 mmol, 156 μL, 6.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 38% - 68%, 10min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[7-(5,6-dimethyl-1*H*-indazol-4-yl)-2-[[(2*S*,4*R*)-4-fluoro-1-methyl-pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (8 mg, 12.8 umol, 7% yield, 96.9% purity) was obtained as a white solid. LCMS [ESI, M+1]: 606.

[02594] ^{1}H NMR (400MHz, chloroform-d) δ = 10.03 (br s, 1H), 8.04 (s, 1H), 7.15 (s, 1H), 5.42 (dd, *J*=6.4 Hz, *J*=47.2 Hz 1H), 5.31 - 5.05 (m, 2H), 5.04 - 3.76 (m, 9H), 3.65 - 3.47 (m, 3H), 3.42 - 3.25 (m, 1H), 3.20 - 2.70 (m, 6H) 2.70 - 2.55 (m, 1H), 2.51 (s, 3H), 2.42 (s, 3H), 2.38 - 2.25 (m, 4H), 2.10 - 1.87 (m, 1H).

EXAMPLE 607



2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(6-methylisoquinolin-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02595] Step A: *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(6-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (250 mg, 530 μmol, 1.0 *eq*), 4-bromo-6-methyl-isoquinoline (235 mg, 1.06 mmol, 2.0 *eq*), RuPhos (98.9 mg, 212 μmol, 0.4 *eq*), $Pd_2(dba)_3$ (97.1 mg, 106 umol, 0.2 *eq*) and Cs_2CO_3 (432 mg, 1.33 mmol, 2.5 *eq*) in toluene (5 mL) was degassed and purged with N_2 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2 atmosphere. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(6-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-

carboxylate (230 mg, 349 μmol, 66% yield, 93% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 613.

[02596] Step B: 2-[(2*S*)-4-[7-(6-methyl-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of *tert*-butyl (2*S*)-2-(cyanomethyl)-4-[7-(6-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (50 mg, 81.6 μmol, 1.0 *eq*) in dioxane (400 μL) was added HCl/dioxane (4 M, 408 uL). The mixture was stirred at 25 °C for 0.3 hour. The mixture was concentrated under vacuum and diluted with water (10 mL). The mixture was adjusted pH ~ 8 with saturated $NaHCO_3$ aqueous solution and extracted with dichloromethane (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue. The residue was purified prep-HPLC (column: Xtimate C18 150 * 25mm * 5um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 28% - 58%, 1 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[7-(6-methyl-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (19 mg, 37 μmol, 45% yield, 99.9% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 513.


[02597] ^{1}H NMR (400MHz, chloroform-d) δ = 8.94 (s, 1H), 8.20 (s, 1H), 7.92 - 7.83 (m, 2H), 7.45 (dd, *J*=1.2, 8.4 Hz, 1H), 4.40 (dd, *J*=4.8, 10.8 Hz, 1H), 4.29 (s, 2H), 4.17 (dd, *J*=6.8, 10.8 Hz, 1H), 4.03 (br d, *J*=12.8 Hz, 1H), 3.86 (br d, *J*=12.4 Hz, 1H), 3.42 (br t, *J*=5.2 Hz, 2H), 3.33 - 3.22 (m, 1H), 3.17 - 2.80 (m, 7H), 2.72 - 2.63 (m, 1H), 2.61 - 2.52 (m, 5H), 2.47 (s, 3H), 2.33 - 2.23 (m, 1H), 2.11 - 2.06 (m, 1H), 1.89 - 1.68 (m, 3H).

[02598] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl) -4-[7-(6-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(6-methyl-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 195 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (35.1 mg, 390 umol, 2.0 *eq*) in ethyl acetate (2 mL) was added T3P (372 mg, 585 μmol, 348 μL, 50% purity in ethyl acetate, 3.0 *eq*) and TEA (158 mg, 1.56 mmol, 217 μL, 8.0 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with


ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 38% - 62%, 10 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-1-(2-fluoroprop-2-enoyl) -4-[7-(6-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (11 mg, 18.6 μmol, 9% yield, 98.9% purity) was obtained as a white solid. LCMS [ESI, M+1]: 585.

[02599] ^{1}H NMR (400MHz, chloroform-d) δ = 8.96 (s, 1H), 8.22 (s, 1H), 7.93 - 7.85 (m, 2H), 7.46 (dd, *J*=1.2, 8.4 Hz, 1H), 5.49 - 5.36 (m, 1H), 5.26 (dd, *J*=3.6, 16.8 Hz, 1H), 4.88 (br s, 1H), 4.50 - 4.29 (m, 3H), 4.27 - 3.96 (m, 4H), 3.61 - 3.30 (m, 4H), 3.22 - 3.06 (m, 2H), 3.04 - 2.77 (m, 4H), 2.75 - 2.65 (m, 1H), 2.59 (s, 3H), 2.49 (s, 3H), 2.31 - 2.29 (m, 1H), 2.15 - 1.97 (m, 1H), 1.80 - 1.77 (m, 3H).

EXAMPLE 608



2-[(2S)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02600] Step A: tert-butyl (2S)-2-(cyanomethyl)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of tert-butyl (2S)-2-(cyanomethyl)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (240 mg, 508.91 μmol, 1 *eq*) , t-BuONa (146.72 mg, 1.53 mmol, 3 *eq*) , RuPhos (47.50 mg, 101.78 umol, 0.2 *eq*) and RuPhos Pd G3 (85.13 mg, 101.78 μmol, 0.2 *eq*) in toluene (5 mL) was added 1-bromo-8-ethyl-naphthalene (239.31 mg, 1.02 mmol, 2 *eq*) . The mixture was stirred at 90 °C for 12 hrs. The mixture was added water (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic layers was dried over Na_2SO_4, filtered and concentrated. The residue was purified by reverse phase flash HPLC (C18, 0.1 % FA in water, 0-45 % MeCN). The product of tert-butyl (2S)-2-(cyanomethyl)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (113 mg, 180.57 μmol, 35.48% yield, 100% purity) was obtained as yellow solid. LCMS [ESI, M+1]:626.

[02601] Step B: 2-[(2S)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro- 5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of tert-butyl (2S)-2-(cyanomethyl)- 4- [7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxylate (103 mg, 164.59 μmol, 1 *eq*) in DCM (2 mL) was added TFA (2 mL) at 25 °C. The reaction mixture was stirred at 25 °C for 0.5 hr. The reaction mixture was quenched by addition saturated $NaHCO_3$ aqueous (20 mL) at 25 °C until pH = 8, and then extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. 2-[(2S)-4-[7-(8-ethyl-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-


yl]methoxy]-6,8- dihydro- 5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (81 mg, crude) was obtained as white solid. LCMS [ESI, M+1]: 526.

[02602] 1H NMR (400 MHz, chloroform-d) δ = 7.66 - 7.55 (m, 2H), 7.37 - 7.25 (m, 2H), 7.25 - 7.20 (m, 1H), 7.19 - 7.14 (m, 1H), 4.36 - 4.26 (m, 1H), 4.21 - 4.02 (m, 2H), 4.00 - 3.62 (m, 3H), 3.56 - 2.73 (m, 11H), 2.65 - 2.34 (m, 7H), 2.26 - 2.14 (m, 1H), 2.02 - 1.88 (m, 1H), 1.82 - 1.62 (m, 4H), 1.13 - 1.02 (m, 3H).


[02603] Step C: 2-[(2S)-4- [7-(8-ethyl- 1-naphthyl) -2-[[(2S) -1- methylpyrrolidin-2-yl] methoxy] -6,8-dihydro - 5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2S)-4-[7-(8-ethyl-1-naphthyl) -2-[[(2S)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (61 mg, 116.04 μmol, 1 *eq*) and 2-fluoroprop-2-enoic acid (20.90 mg, 232.08 μmol, 2 *eq*) in DMF (10 mL) were added TEA (281.81 mg, 2.78 mmol, 387.63 μL, 24 *eq*) and T3P (332.29 mg, 1.04 mmol, 310.55 uL, 9 *eq*) at -40°C. After addition, the mixture was stirred at 0 °C for 2 hrs. The mixture was diluted with water (3×20 mL) and diluted with ethyl acetate (3×20 mL). The organic layer was washed with brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 55%-85%, 10min). The mixture was diluted with water (3×20 mL) and diluted with ethyl acetate (3×20 mL). The organic layer was washed with brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum to give 2-[(2S)-4- [7-(8-ethyl- 1-naphthyl) -2-[[(2S) -1- methylpyrrolidin-2-yl] methoxy] -6,8-dihydro - 5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (7 mg, 11.63 μmol, 10.02% yield, 99.3% purity) was obtained as yellow solid. LCMS [ESI, M+1]:598.

[02604] 1H NMR (400 MHz, chloroform-d) δ = 7.67 - 7.54 (m, 2H), 7.39 - 7.26 (m, 2H), 7.25 - 7.20 (m, 1H), 7.15 (s, 1H), 5.45 - 5.24 (m, 1H), 5.23 - 5.12 (m, 1H), 4.95 - 4.58 (m, 1H), 4.33 - 4.25 (m, 1H), 4.25 - 3.63 (m, 6H), 3.57 - 3.33 (m, 3H), 3.21 - 2.49 (m, 10H), 2.44 - 2.35 (m, 3H), 2.27 - 2.15 (m, 1H), 2.03 - 1.90 (m, 1H), 1.82 - 1.66 (m, 3H), 1.13 - 1.04 (m, 3H).

EXAMPLE 609



2-[(2*S*)-4-[7-(6-fluoro-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02605] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(6-fluoro-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To the mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 791 μmol, 1.0 *eq*), 4-bromo-6-fluoro- isoquinoline (215 mg, 949 μmol, 1.2 *eq*), Cs_2CO_3 (773 mg, 2.37 mmol, 3.0 *eq*) and RuPhos (148 mg, 316 μmol, 0.4 *eq*) in toluene (10 mL) was added

$Pd_2(dba)_3$ (145 mg, 158 μmol, 0.2 *eq*) under N_2. The suspension was degassed under vacuum and purged with N_2 several times. The mixture was stirred under N_2 at 90 °C for 10 hours. The reaction mixture filtered and the filtrate was concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and basified with solid $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with ethyl acetate (2 × 40 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-2-(cyanomethyl)-4-[7-(6-fluoro-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (140 mg, 204 μmol, 26% yield, 95% purity) as a yellow solid.


[02606] Step B: 2-[(2*S*)-4-[7-(6-fluoro-4- isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To the mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(6- fluoro-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (30 mg, 46.1 μmol, 1.0 *eq*) and NH_3•MeOH (0.3 mL, 20% purity) in MeOH (0.3 mL) was added Pd/C (10 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1.5 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 30%-60%,1min). The desired fractions were collected and lyophilized to give 2-[(2*S*)-4-[7-(6-fluoro-4- isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (9.78 mg, 18.9 μmol, 41% yield, 99.9% purity) as a white solid. LCMS [ESI, M+1]: 517.

[02607] ^{1}H NMR (400MHz, chloroform-d) δ = 9.00 (s, 1H), 8.27 (s, 1H), 8.02 (dd, *J*=5.6, 9.2 Hz, 1H), 7.74 (dd, *J*=2.4, 10.4 Hz, 1H), 7.39 (dt, *J*=2.4, 8.8 Hz, 1H), 4.41 (dd, *J*=4.8, 10.4 Hz, 1H), 4.28 (s, 2H), 4.18 (dd, *J*=6.8, 10.4 Hz, 1H), 4.02 (br d, *J*=12.4 Hz, 1H), 3.91 - 3.82 (m, 1H), 3.47 - 3.35 (m, 2H), 3.33 - 3.24 (m, 1H), 3.18 - 3.07 (m, 3H), 3.07 - 2.97 (m, 1H), 2.93 (dd, *J*=9.6, 12.8 Hz, 1H), 2.85 (br s, 2H), 2.73 - 2.64 (m, 1H), 2.56 (dd, *J*=2.4, 6.4 Hz, 2H), 2.49 (s, 3H), 2.34 - 2.24 (m, 1H), 2.13 - 2.00 (m, 1H), 1.91 - 1.76 (m, 3H).


[02608] Step C: 2-[(2*S*)-4-[7-(6-fluoro-4-isoquinolyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To the mixture of 2-[(2*S*)-4-[7-(6-fluoro-4-isoquinolyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80 mg, 155 μmol, 1.0 *eq*), 2-fluoroprop-2-enoic acid (41.8 mg, 464 μmol, 3.0 *eq*) and TEA (235 mg, 2.32 mmol, 323 uL, 15 *eq*) in ethyl acetate (1.5 mL) and DMF (1 mL) was added T3P (493 mg, 774 μmol, 460 uL, 50% purity, 5.0 *eq*) at 0 °C, the mixture was stirred at 25 °C for 1 hour. Water (10 mL) was added into the mixture. The mixture was diluted with ethyl acetate (30 mL) and extracted with ethyl acetate (2 × 5 mL). The combined organic layers were dried over anhydrous Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by prep-HPLC (column: Xtimate C18 150*25mm*5um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 40% - 70%,1min). The desired fractions were collected and lyophilized to give 2-[(2*S*)-4-[7-(6-fluoro-4-isoquinolyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (17.4 mg, 29.3 μmol, 19% yield, 99.2% purity) as a white solid. LCMS [ESI, M+1]: 589.

[02609] ^{1}H NMR (400MHz, chloroform-d) δ = 9.01 (s, 1H), 8.28 (s, 1H), 8.03 (dd, *J*=5.6, 8.8 Hz, 1H), 7.73 (dd, *J*=2.4, 10.4 Hz, 1H), 7.40 (dt, *J*=2.4, 8.8 Hz, 1H), 5.52 - 5.35 (m, 1H), 5.27 (dd, *J*=3.6, 17.2 Hz, 1H), 5.02 - 4.62 (m, 1H), 4.46 - 4.38 (m, 1H), 4.36 - 4.25 (m, 2H), 4.24 - 4.07 (m, 3H), 4.02 (br d, *J*=13.2 Hz, 1H), 3.62 - 3.29 (m, 4H), 3.13 (br s, 2H), 3.03 - 2.93 (m, 2H), 2.91 - 2.77 (m, 2H), 2.72 (br s, 1H), 2.51 (s, 3H), 2.32 (br d, *J*=8.4 Hz, 1H), 2.13 - 2.02 (m, 1H), 1.92 - 1.70 (m, 3H).

EXAMPLE 610



(*S*)-2-(1-(2-fluoroacryloyl)-4-(7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02610] Step A: *tert*-butyl 4-hydroxy-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a mixture of *O*1-tert-butyl *O*4-ethyl 3-oxopiperidine-1,4- dicarboxylate (5.00 g, 18.4 mmol, 1.00 eq) in n-BuOH (30.0 mL) was added acetic acid;methanimidamide (9.59 g, 92.2 mmol, 5.00 eq) in portion. The mixture was stirred at 120 °C for 12 hours. The mixture was concentrated to remove the solvent. The residue was added water (30.0 mL) and filtered. The precipitate was washed with water (30.0 mL) and concentrated. The crude product was used in the next step directly without further purification. Compound *tert*-butyl 4-hydroxy-6,8-dihydro-5*H*- pyrido[3,4-*d*]pyrimidine-7-carboxylate (4.10 g, 16.1 mmol, 87% yield, 98.4% purity) was obtained as a brown solid. LCMS [ESI, M+1]: 196.

[02611] Step B: *tert*-butyl 4-chloro-6,8-dihydro-5*H*-pyrido[3,4- *d*]pyrimidine-7-carboxylate. To a mixture of *tert*-butyl 4-hydroxy-6,8-dihydro-5*H*-pyrido[3,4- *d*]pyrimidine-7-carboxylate (3.30 g, 13.1 mmol, 1.00 eq) in DCE (60.0 mL) was added PPh_3 (6.89 g, 26.3 mmol, 2.00 eq), CCl_4 (6.06 g, 39.4 mmol, 3.79 mL, 3.00 eq) in portion under N_2. The mixture was stirred at 70 °C for 3 hours. The reaction mixture was filtered and concentrated under reduced

pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=20/1 to 1/1). Compound *tert*-butyl 4-chloro-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (2.54 g, 9.42 mmol, 72% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 214.

[02612] Step C: *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3 -(cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate. To a mixture of *tert*-butyl 4-chloro-6,8-dihydro-5*H*-pyrido[3,4- *d*]pyrimidine-7-carboxylate (1.30 g, 4.82 mmol, 1.00 eq) and benzyl (2*S*)-2- (cyanomethyl)piperazine-1-carboxylate (1.00 g, 3.86 mmol, 0.80 eq) in DMAc (30.0 mL) was added DIEA (3.11 g, 24.1 mmol, 4.20 mL, 5.00 eq) under N_2. The mixture was stirred at 100 °C for 2 hours. The reaction mixture was diluted with ethyl acetate (100 mL). The organic layers were washed with water (30 mL × 2) and brine (30 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate=20/1 to 0/1). Compound *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3 -(cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (1.18 g, 2.30 mmol, 48% yield, 96% purity) was obtained as a white solid. LCMS [ESI, M+1]: 493.

[02613] Step D: benzyl (2*S*)-2-(cyanomethyl)-4-(5,6,7,8-tetrahydropyrido[3,4 -*d*]pyrimidin-4-yl) piperazine- 1-carboxylate. To a mixture of *tert*-butyl 4-[(3*S*)-4-benzyloxycarbonyl-3- (cyanomethyl)piperazin-1-yl]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylate (1.20 g, 2.44 mmol, 1.00 eq) in acetonitrile (10.0 mL) was added HCl/dioxane (4.00 M, 12.2 mL, 20.0 eq) in portion at 25 °C under N_2. The mixture was stirred at 25 °C for 30 min. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was used in the next step directly without further purification. Compound benzyl (2*S*)-2-(cyanomethyl)-4-(5,6,7,8-tetrahydropyrido[3,4 -*d*]pyrimidin-4-yl) piperazine- 1-carboxylate (883 mg, 2.16 mmol, 89% yield, 96% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 393.

[02614] Step E: benzyl (2*S*)-2- (cyanomethyl)-4-[7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (300 mg, 764 μmol, 1.00 eq) and 1-bromonaphthalene (317 mg, 1.53 mmol, 212 uL, 2.00 eq) in toluene (15.0 mL) was added $Pd_2(dba)_3$ (140 mg, 153 μmol, 0.20 eq), RuPhos (143 mg, 306

μmol, 0.40 eq) Cs_2CO_3 (747 mg, 2.29 mmol, 3.00 eq) in one portion under N_2. The mixture was stirred at 90 °C for 5 hours. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (20.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (5.00 mL) and extracted with ethyl acetate (50.0 mL × 2). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2- (cyanomethyl)-4-[7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, 289 μmol, 38% yield) was obtained as a yellow solid.

[02615] Step F: 2-[(2*S*)-4-[7-(1-naphthyl)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(1- naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (50.0 mg, 96.4 μmol, 1.00 eq) in MeOH (3.00 mL) was added Pd/C (30.0 mg, 10% purity), NH_3•MeOH (0.50 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 × 25 5 u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 35% - 59%, 10 min). Compound 2-[(2*S*)-4-[7-(1-naphthyl)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (8.63 mg, 22.4 μmol, 23% yield, 99.8% purity) was obtained as a off-white solid. LCMS [ESI, M+1]: 385.


[02616] ^{1}H NMR (400MHz, chloroform-d) δ = 8.63 (s, 1H), 8.26 - 8.19 (m, 1H), 7.91 - 7.84 (m, 1H), 7.62 (d, *J*=8.0 Hz, 1H), 7.54 - 7.48 (m, 2H), 7.45 (t, *J*=7.6 Hz, 1H), 7.17 (d, *J*=7.2 Hz, 1H), 4.35 (s, 2H), 3.99 (br d, *J*=12.8 Hz, 1H), 3.83 (br d, *J*=12.8 Hz, 1H), 3.53 - 3.23 (m, 3H), 3.20 - 3.07 (m, 2H), 3.07 - 2.90 (m, 4H), 2.63 - 2.49 (m, 2H).

[02617] Step G: To a mixture of 2-[(2*S*)-4-[7-(1-naphthyl)-6,8-dihydro-5*H*- yrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60.0 mg, 156 μmol, 1.00 eq) in ethyl acetate (0.60 mL) was added 2-fluoroprop-2-enoic acid (56.2 mg, 624 μmol, 4.00 eq), TEA (253 mg, 2.50 mmol, 348 uL, 16.0 eq) and T3P (596 mg, 936 μmol, 557 uL, 50% purity, 6.00 eq) in portion at 0 °C under N_2. The mixture was stirred at 25 °C for 30 min. The reaction mixture was quenched


by addition water (1.00 mL) at 0 °C, and then extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine (5.00 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 × 25 5 u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 40%-70%, 10 min). Compound 2-[(2*S*)-1-(2- luoroprop-2-enoyl)-4-[7-(1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (15.2 mg, 32.8 μmol, 21% yield, 98.9% purity) was obtained as a white solid. LCMS [ESI, M+1]: 457.

[02618] ^{1}H NMR (400MHz, chloroform-d) δ = 8.67 (s, 1H), 8.26 - 8.18 (m, 1H), 7.91 - 7.84 (m, 1H), 7.63 (d, *J*=8.0 Hz, 1H), 7.56 - 7.49 (m, 2H), 7.45 (t, *J*=7.6 Hz, 1H), 7.18 (d, *J*=6.8 Hz, 1H), 5.54 - 5.34 (m, 1H), 5.27 (dd, *J*=4.0, 17.2 Hz, 1H), 4.91 (br s, 1H), 4.46 - 4.29 (m, 2H), 4.14 (br d, *J*=13.6 Hz, 1H), 3.99 (br d, *J*=13.2 Hz, 1H), 3.63 - 3.32 (m, 4H), 3.16 (br t, *J*=11.2 Hz, 2H), 2.99 (br dd, *J*=8.0, 16.4 Hz, 3H), 2.90 - 2.77 (m, 1H).

EXAMPLE 611



(*S*)-2-(1-(2-fluoroacryloyl)-4-(7-(8-methylnaphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02619] Step A: benzyl (2*S*)-2- (cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (100 mg, 255 μmol, 1.00 eq) and 1-bromo-8-methyl-naphthalene (113 mg, 510 μmol, 10.6 uL, 2.00 eq) in toluene (8.00 mL) was added $Pd_2(dba)_3$ (46.7 mg, 51.0 μmol, 0.20 eq), RuPhos (47.6 mg, 102 μmol, 0.40 eq) Cs_2CO_3 (249 mg, 764 μmol, 3.00 eq) in one portion under N_2. The mixture was stirred at 90 °C for 5 hours. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (20.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (5.00 mL) and extracted with ethyl acetate (50.0 mL × 2). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum. Compound benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (150 mg, crude) was obtained as a yellow solid.

[02620] Step B: 2-[(2*S*)- 4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8- methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (50.0 mg, 93.9 μmol, 1.00 eq) in methanol (1.00 mL) was added NH_3•MeOH (93.9 μmol, 0.2 mL, 20% purity, 1.00 eq), Pd/C (15.0 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 * 25 5u;mobile


phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 38%-62%, 10 min). Compound 2-[(2*S*)- 4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (6.13 mg, 15.3 μmol, 16% yield, 99.5% purity) was obtained as a white solid. LCMS [ESI, M+1]: 399.

[02621] ^{1}H NMR (400MHz, chloroform-d) δ = 8.61 (d, *J*=4.8 Hz, 1H), 7.74 - 7.63 (m, 2H), 7.41 (dt, *J*=2.8, 7.6 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.27 - 7.22 (m, 2H), 4.32 (br d, *J*=18.0 Hz, 1H), 4.07 - 3.92 (m, 1H), 3.92 - 3.86 (m, 1H), 3.86 - 3.67 (m, 1H), 3.56 - 3.48 (m, 1H), 3.30 - 3.24 (m, 1H), 3.24 - 3.18 (m, 1H), 3.18 - 2.96 (m, 4H), 2.94 (d, *J*=2.4 Hz, 3H), 2.92 (br s, 1H), 2.92 - 2.83 (m, 1H), 2.69 - 2.59 (m, 1H), 2.57 - 2.53 (m, 2H).


[02622] Step C: 2-[(2*S*)-1-(2- fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60.0 mg, 151 μmol, 1.00 eq) in ethyl acetate (1.00 mL) was added 2-fluoroprop-2-enoic acid (54.2 mg, 602 μmol, 4.00 eq), TEA (244 mg, 2.41 mmol, 335 uL, 16.0 eq) and T3P (575 mg, 903 μmol, 537 uL, 50% purity, 6.00 eq) in portion at 0 °C under N_2. The mixture was stirred at 25 °C for 30 min. The reaction mixture was quenched by addition water (1.00 mL) at 0 °C, and then extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (5 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 × 25 5 u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 40%-70%, 10 min). Compound 2-[(2*S*)-1-(2- fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (8.97 mg, 18.7 μmol, 12% yield, 98.2% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 492.

[02623] ^{1}H NMR (400MHz, chloroform-d) δ = 8.64 (d, *J*=7.2 Hz, 1H), 7.74 - 7.64 (m, 2H), 7.47 - 7.39 (m, 1H), 7.39 - 7.32 (m, 1H), 7.29 (br d, *J*=1.2 Hz, 1H), 7.26 - 7.19 (m, 1H), 5.53 - 5.33 (m, 1H), 5.26 (dd, *J*=3.6, 17.2 Hz, 1H), 4.87 (br s, 1H), 4.33 (br dd, *J*=14.8, 18.0 Hz, 1H), 4.19 (br d, *J*=13.6 Hz, 1H), 4.12 - 3.97 (m, 2H), 3.95 - 3.84 (m, 1H), 3.61 - 3.42 (m, 2H), 3.27 - 3.04 (m, 4H), 2.92 (d, *J*=2.4 Hz, 3H), 2.89 - 2.62 (m, 3H).

EXAMPLE 612



(*S*)-2-(4-(7-(5-chloroisoquinolin-4-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02624] Step A: benzyl (2*S*)-4-[7-(5-chloro-4-isoquinolyl)-6, 8-dihydro-5*H*- pyrido [3,4-*d*]pyrimidin-4-yl]-2-(*c*yanomethyl)piperazine-1-carboxylate. To a mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(5,6,7,8- tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (300 mg, 764 μmol, 1.00 eq) and 4-bromo-5-chloro-isoquinoline (371 mg, 1.53 mmol, 10.6 μL, 2.00 eq) in toluene (15.0 mL) was added $Pd_2(dba)_3$ (140 mg, 153 μmol, 0.20 eq), RuPhos (143 mg, 306 μmol, 0.40 eq), Cs_2CO_3 (747 mg, 2.29 mmol, 3.00 eq) in one portion under N_2. The mixture was degassed and purged with N_2 3 times and stirred at 90 °C for 5 hours. The reaction mixture was diluted with water (10.0 mL) and extracted with ethyl acetate (20.0 mL × 3). The combined organic layers were washed with brine (20.0 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with saturated $NaHCO_3$ solution (5 mL) and extracted with ethyl acetate (50 mL × 2). The separated organic layer was dried over sodium sulfate, filtered and concentrated under vacuum.

Compound benzyl (2*S*)-4-[7-(5-chloro-4-isoquinolyl)-6, 8-dihydro-5*H*- pyrido [3,4-*d*]pyrimidin-4-yl]-2-(*c*yanomethyl)piperazine-1-carboxylate (130 mg, 223 μmol, 29% yield, 95% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 554.

[02625] Step B: 2-[(2*S*)-4-[7-(5-chloro-4-isoquinolyl) -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-4-[7-(5-chloro-4-isoquinolyl)- 6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(*c*yanomethyl)piperazine-1-carboxylate (30.0 mg, 54.2 μmol, 1.00 eq) in methanol (3.00 mL) was added NH_3•MeOH (0.50 mL, 20% purity), Pd/C (35.0 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 × 25 5 u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 22%-46%, 10 min). Compound 2-[(2*S*)-4-[7-(5-chloro-4-isoquinolyl) -6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (8.51 mg, 20.1 μmol, 37% yield, 99.4% purity) was obtained as a white solid. LCMS [ESI, M+1]: 420.


[02626] ^{1}H NMR (400MHz, chloroform-d) δ = 9.02 (s, 1H), 8.60 (d, *J*=4.4 Hz, 1H), 8.35 (d, *J*=1.6 Hz, 1H), 7.91 (dd, *J*=1.2, 8.4 Hz, 1H), 7.75 (dd, *J*=1.2, 7.2 Hz, 1H), 7.50 (t, *J*=7.6 Hz, 1H), 4.54 (br d, *J*=17.2 Hz, 1H), 4.06 - 3.61 (m, 4H), 3.41 - 3.08 (m, 5H), 3.07 - 2.85 (m, 2H), 2.72 - 2.59 (m, 1H), 2.58 - 2.49 (m, 2H).

[02627] Step C: 2-[(2*S*)-4-[7-(5-chloro-4-isoquinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a mixture of 2-[(2*S*)-4-[7-(5-chloro-4-isoquinolyl)-6,8- dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (60.0 mg, 143 μmol, 1.00 eq) in ethyl acetate (0.80 mL) was added 2-fluoroprop-2-enoic acid (25.7 mg, 286 μmol, 2.00 eq), TEA (86.8 mg, 857 μmol, 119 uL, 6.00 eq) and T3P (273 mg, 429 μmol, 255 uL, 50% purity, 3.00 eq) in portion at 0 °C under N_2. The mixture was stirred at 25 °C for 30 min. The reaction mixture was quenched by addition water (1.00 mL) at 0 °C, and then extracted with ethyl acetate (10.0 mL × 3). The combined organic layers were washed with brine (5.00 mL × 1), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge 150 × 25 5 u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 22%-


52%, 10 min). Compound 2-[(2*S*)-4-[7-(5-chloro-4-isoquinolyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (7.88 mg, 16.0 μmol, 11% yield, 100% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 492.

[02628] ^{1}H NMR (400MHz, chloroform-d) δ = 9.04 (d, *J*=3.6 Hz, 1H), 8.65 (d, *J*=6.4 Hz, 1H), 8.35 (d, *J*=11.6 Hz, 1H), 7.96 - 7.88 (m, 1H), 7.76 (dd, *J*=1.2, 7.2 Hz, 1H), 7.56 - 7.47 (m, 1H), 5.55 - 5.33 (m, 1H), 5.26 (dd, *J*=3.2, 16.8 Hz, 1H), 5.03 - 4.70 (m, 1H), 4.55 (br dd, *J*=6.4, 18.0 Hz, 1H), 4.23 - 3.84 (m, 4H), 3.69 (br d, *J*=6.4 Hz, 1H), 3.50 (br d, *J*=13.6 Hz, 1H), 3.35 - 3.19 (m, 3H), 3.16 - 3.00 (m, 1H), 2.97 - 2.61 (m, 3H).

EXAMPLE 613



2-((*S*)-4-(2-(((*S*)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile



[02629] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-(2-methylsulfanyl -5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (5.0 g, 11.4 mmol, 1.0 *eq*), 4-bromo-5,6-dimethyl-1-tetrahydropyran-2-yl-indazole (7.05 g, 22.8 mmol, 2.0 *eq*), $Pd_2(dba)_3$ (2.09 g, 2.28 mmol, 0.2 *eq*), RuPhos (2.13 g, 4.56 mmol, 0.4 *eq*) and Cs_2CO_3 (9.29 g, 28.5 mmol,

2.5 *eq*) in toluene (100 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 90 °C for 8 hours under N_2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 20/1 to 2/1) and further purified by reverse phase flash [water (0.1% formic acid)/acetonitrile)]. The mixture was adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (4.90 g, 7.20 mmol, 63% yield, 98% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 667.

[02630] ^{1}H NMR (400MHz, chloroform-d) δ = 7.98 (s, 1H), 7.50 - 7.31 (m, 5H), 7.22 (s, 1H), 5.66 (dd, *J*=2.4, 9.6 Hz, 1H), 5.27 - 5.13 (m, 2H), 4.69 (br s, 1H), 4.27 (s, 2H), 4.13 - 3.97 (m, 3H), 3.89 (d, *J* = 11.6 Hz, 1H), 3.81 - 3.68 (m, 1H), 3.51 (t, *J*=5.2 Hz, 2H), 3.30 (br s, 2H), 3.04 (t, *J* = 11.6 Hz, 1H), 2.93 - 2.66 (m, 4H), 2.62 - 2.48 (m, 4H), 2.43 (s, 3H), 2.32 (s, 3H), 2.23 - 2.12 (m, 1H), 2.11 - 2.05 (m, 1H), 1.85 - 1.67 (m, 3H).

[02631] Step B: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfanyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 749 μmol, 1.0 *eq*) in toluene (10 mL) was added *m*-CPBA (152 mg, 749 μmol, 85% purity, 1.0 *eq*). The mixture was stirred at 0 °C for 1 hour. The mixture was diluted with water (10 mL) and adjusted pH ~ 7 with saturated $NaHCO_3$ aqueous solution. Then the mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 539 μmol, 72% yield, 92% purity) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 683.

[02632] Step C: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (900 mg, 1.32 mmol, 1.0 *eq*) in toluene (20 mL) was added *t*-BuONa (379 mg, 3.95 mmol, 3.0 *eq*) and [(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methanol (398 mg, 2.64 mmol, 2.0 *eq*). The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1). Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (630 mg, 793 μmol, 60% yield, 97% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 770.

[02633] Step D: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6- dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl) -4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (400 mg, 519 μmol, 1.0 *eq*) in methanol (2 mL) was added dry Pd/C (50 mg, 10% purity) and NH_3/methanol (1 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25°C for 0.5 hour. The mixture was concentrated under vacuum. 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6- dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (330 mg, 519 μmol, 99% yield) was obtained as a yellow solid and used next step directly without purification. LCMS [ESI, M+1]: 636.

[02634] Step E: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl -pyrrolidin-2-

yl]methoxy]-7-(5,6-dimethyl-1-tetrahydropyran-2-yl-indazol-4-yl)-6,8-*d*ihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (50 mg, 78.6 μmol, 1.0 *eq*) in dichloromethane (50 uL) was added TFA (359 mg, 3.15 mmol, 233 μL, 40 *eq*). The mixture was stirred at 0 °C for 0.5 hour. The mixture was concentrated under vacuum and diluted with water (10 mL). The mixture was adjusted pH ~ 8 with saturated $NaHCO_3$ aqueous solution and extracted with dichloromethane (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the product. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 30% - 60%, 10 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (7.29 mg, 13.2 μmol, 17% yield, 99.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 552.


[02635] ^{1}H NMR (400MHz, chloroform-d) δ = 9.95 (br s, 1H), 8.04 (s, 1H), 7.15 (s, 1H), 4.48 (dd, *J*=4.4, 10.8 Hz, 1H), 4.33 - 4.19 (m, 3H), 4.00 (br d, *J*=11.6 Hz, 1H), 3.83 (br d, *J*=11.6 Hz, 1H), 3.51 (t, *J*=5.2 Hz, 2H), 3.42 (dt, *J*=5.6, 11.7 Hz, 1H), 3.26 (br s, 1H), 3.17 - 2.95 (m, 4H), 2.94 - 2.85 (m, 1H), 2.84 - 2.62 (m, 3H), 2.61 - 2.49 (m, 3H), 2.47 (s, 3H), 2.42 (s, 3H), 2.35 (s, 3H), 2.32 - 2.18 (m, 1H).

[02636] Step F: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro- 1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 181 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (24.5 mg, 272 μmol, 1.5 *eq*) in DMF (2 mL) was added T3P (461 mg, 725 μmol, 431 μL, 50% purity in ethyl acetate, 4.0 *eq*) and TEA (147 mg, 1.45 mmol, 202 uL, 8.0 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 ×30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl


acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 38% - 68%, 10 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (11 mg, 17.5 μmol, 10% yield, 99.2% purity, 100% ee) was obtained as a off-white solid. LCMS [ESI, M+1]: 624.

[02637] ^{1}H NMR (400MHz, chloroform-d) δ = 10.27 - 9.49 (s, 1H), 8.04 (s, 1H), 7.16 (s, 1H), 5.55 - 5.34 (m, 1H), 5.26 (dd, *J*=3.6, 16.8 Hz, 1H), 4.86 (br s, 1H), 4.46 (dd, *J*=4.8, 10.8 Hz, 1H), 4.34 - 3.88 (m, 6H), 3.66 - 3.25 (m, 5H), 3.19 - 2.62 (m, 7H), 2.60 - 2.45 (m, 4H), 2.42 (s, 3H), 2.35 (s, 3H), 2.32 - 2.19 (m, 1H).

EXAMPLE 614



2-((*S*)-4-(2-(((*S*)-4,4-difluoro-1-methylpyrrolidin-2-yl)methoxy)-7-(5,6-dimethyl-1*H*-indazol-4-yl)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)-1-((*E*)-4-fluorobut-2-enoyl)piperazin-2-yl)acetonitrile




[02638] Step A: 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl- pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 181 μmol, 1.0 *eq*) and (*E*)-4-fluorobut-2-enoic acid (28.3 mg, 272 μmol, 1.5 *eq*) in DMF (2 mL) was added T3P (461 mg, 725 μmol, 431 uL, 50% purity in ethyl acetate, 4.0 *eq*) and TEA (147 mg, 1.45 mmol, 202 uL, 8.0 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Xtimate C18 150 * 25mm * 5um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 40% - 70%, 10 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[2-[[(2*S*)-4,4-difluoro-1-methyl-pyrrolidin-2-yl]methoxy]-7-(5,6-dimethyl-1*H*-indazol-4-yl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-[(*E*)-4-fluorobut-2-enoyl]piperazin-2-yl]acetonitrile (12 mg, 18.3 μmol, 10% yield, 97.3% purity, 95% ee) was obtained as a white solid. LCMS [ESI, M+1]: 638.


[02639] ^{1}H NMR (400MHz, chloroform-d) δ = 10.06 (br s, 1H), 8.05 (s, 1H), 7.17 (s, 1H), 7.07 - 6.97 (m, 1H), 6.61 (br d, *J*=14.8 Hz, 1H), 5.20 – 5.07 (m, 3H), 4.48 (dd, *J*=4.8, 11.2 Hz, 1H), 4.31 - 4.27 (m, 3H), 4.20 - 3.80 (m, 3H), 3.55 (br t, *J*=5.2 Hz, 3H), 3.49 - 3.27 (m, 2H), 3.13


(br s, 1H), 3.05 - 2.63 (m, 6H), 2.62 - 2.46 (m, 4H), 2.43 (s, 3H), 2.36 (s, 3H), 2.33 - 2.21 (m, 1H).

EXAMPLE 615



2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile





[02640] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methanol (217 mg, 1.51 mmol, 68.2 μL, 3 *eq*) and benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2- methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 504 μmol, 1 *eq*) in toluene (15 mL) was added *t*-BuONa (145 mg, 1.51 mmol, 3 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the mixture was quenched with water (10 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with brine (1 × 50 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase flash [water (0.1% FA) / acetonitrile]. The desired fractions were collected and neutralized with saturated Na_2CO_3 solution (10 mL) and extracted with ethyl acetate (3 × 50 mL). The separated organic layers were dried over sodium sulfate, filtered and concentrated under vacuum. Benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (180 mg, 267 μmol, 53% yield, 99.8% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 675.

[02641] ^{1}H NMR (400MHz, chloroform-d) δ = 7.73 - 7.60 (m, 2H), 7.27 (s, 9H), 5.21 (s, 2H), 4.68 (br s, 1H), 4.47 - 4.34 (m, 1H), 4.30 - 4.15 (m, 2H), 4.13 - 4.04 (m, 1H), 3.95 - 3.69 (m, 2H), 3.56 - 3.34 (m, 2H), 3.28 - 2.48 (m, 13H), 2.47 - 2.33 (m, 3H), 2.22 - 2.11 (m, 1H), 1.88 (br dd, *J*=8.4, 12.6 Hz, 1H), 1.56 (ddd, *J*=4.6, 7.8, 12.6 Hz, 1H), 1.16 (d, *J*=4.0 Hz, 3H), 1.10 - 0.98 (m, 3H).


[02642] Step B: 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1- naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (130 mg, 193 μmol, 1 *eq*) in MeOH (4 mL) was added NH_3•MeOH (2 mL, 15% purity) and Pd/C (26 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 0.5 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethyl pyrrolidin-2-yl]methoxy]-6,8-dihydro-

5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 159 μmol, 85.9% purity) was obtained as a yellow solid which was used into next step without further purification. LCMS [ESI, M+1]: 540.


[02643] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*) -1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90 mg, 143 μmol, 1 *eq*), 2-fluoroprop-2-enoic acid (38.7 mg, 430 μmol, 3 *eq*) and Et_3N (130 mg, 1.29 mmol, 179 uL, 9 *eq*) in ethyl acetate (15 mL) was added T3P (365 mg, 573 μmol, 341 uL, 50% purity in ethyl acetate, 4 *eq*) at 0 °C. The mixture was stirred at 0 °C for 1 hour. Upon completion, the mixture was diluted with water (3 mL). The organic layer was separated, washed with brine (1 × 10 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, ethyl acetate/methanol = 20/1 to 10/1). The residue was purified by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 62% - 89%, 10min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilization. 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(8-methyl-1-naphthyl)-2-[[(2*S*)-1,4,4-trimethylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (12.7 mg, 20.6 μmol, 99.7% purity) was obtained as a white solid. LCMS [ESI, M+1]: 612.

[02644] ^{1}H NMR (400MHz, chloroform-d) δ = 7.79 - 7.56 (m, 2H), 7.51 - 7.31 (m, 2H), 7.27 - 7.08 (m, 2H), 5.65 - 5.08 (m, 2H), 4.85 (br s, 1H), 4.49 - 4.32 (m, 1H), 4.30 - 3.96 (m, 4H), 3.95 - 3.71 (m, 1H), 3.59 - 3.35 (m, 2H), 3.28 - 2.54 (m, 13H), 2.42 (br s, 3H), 2.16 (br d, *J*=8.8 Hz, 1H), 1.96 - 1.81 (m, 1H), 1.63 - 1.45 (m, 1H), 1.15 (br s, 3H), 1.06 (br s, 3H).

EXAMPLE 616



2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile



[02645] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*S*) -1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. To a solution of [(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methanol (326 mg, 2.52 mmol, 68.2 uL, 3 *eq*) and benzyl (2*S*)-2-(cyanomethyl)-4-[7-(8-methyl-1-naphthyl) -2-methylsulfinyl-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (500 mg, 841 μmol, 1 *eq*) in toluene (20 mL) was added *t*-BuONa (242 mg, 2.52 mmol, 3 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon completion, the mixture was quenched with water (10 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over Na_2SO_4, filtered and concentrated under vacuum. The residue was purified by reverse phase HPLC (0.1% FA condition). The residue was basified with saturated aqueous $NaHCO_3$ solution to pH = 8 and extracted with ethyl acetate (3 × 50 mL). The organic phase was separated, dried over sodium sulfate, filtered and concentrated under vacuum. benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*S*) -1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-

1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (328 mg, 461 μmol, 55% yield, 92.7% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 661.

[02646] Step B: 2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methoxy] -7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*,4*S*) -1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (100 mg, 151 μmol, 1 *eq*) in MeOH (4 mL) was added NH_3•MeOH (2 mL, 20% purity) and Pd/C (20 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 0.5 hour. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by prep - HPLC (column: Phenomenex Synergi C18 150 * 30mm * 4um; mobile phase: [water (0.225% FA) - ACN]; B%: 13% - 43%, 10min). After that, the residue was purified by prep - HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 55% - 85%, 10min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilization. 2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methoxy] -7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (13.9 mg, 26.4 μmol, 17% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 526.


[02647] ^{1}H NMR (400MHz, chloroform-d) δ = 7.69 (d, *J*=8.2 Hz, 1H), 7.64 (dd, *J*=2.6, 7.6 Hz, 1H), 7.40 (dt, *J*=4.0, 7.8 Hz, 1H), 7.36 - 7.31 (m, 1H), 7.26 - 7.19 (m, 2H), 4.43 (dt, *J*=4.8, 10.2 Hz, 1H), 4.28 - 4.11 (m, 2H), 4.07 - 3.70 (m, 3H), 3.48 (br d, *J*=11.8 Hz, 1H), 3.38 - 2.82 (m, 11H), 2.80 - 2.64 (m, 2H), 2.61 - 2.53 (m, 3H), 2.49 (t, *J*=8.6 Hz, 1H), 2.42 (d, *J*=2.4 Hz, 3H), 2.35 - 2.15 (m, 2H), 1.39 - 1.25 (m, 1H), 1.08 (d, *J*=6.8 Hz, 3H).

[02648] Step C: 2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl] methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (100 mg, 190 μmol, 1 *eq*), 2-fluoroprop-2-enoic acid (51.4 mg, 571 μmol, 3 *eq*) and Et_3N (173 mg, 1.71 mmol, 238 uL, 9 *eq*) in DMF (10 mL) was added T3P (484 mg, 761 μmol, 452 uL, 50% purity, 4 *eq*) at 0 °C. The mixture was stirred at 0 °C for 0.5 hour. Upon


completion, the residue was diluted with water (10 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (1 × 20 mL), dried over sodium sulfate, filtered and concentrated under vacuum. The mixture was purified by column chromatography (SiO_2, Dichloromethane/Methanol = 10/1). After that, the residue was purified by prep - HPLC (column: Xtimate C18 150 * 25mm * 5um; mobile phase: [water (0.05% ammonia hydroxide v / v) - ACN]; B%: 60% - 90%, 10min). The residue was concentrated under reduced pressure to remove ACN, and then lyophilization. 2-[(2*S*)-4-[2-[[(2*S*,4*S*)-1,4-dimethylpyrrolidin-2-yl]methoxy]-7-(8-methyl-1-naphthyl)-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile (22.2 mg, 37.1 μmol, 19% yield, 99.8% purity) was obtained as a white solid. LCMS [ESI, M+1]: 598.

[02649] ^{1}H NMR (400MHz, chloroform-d) δ = 7.72 - 7.61 (m, 2H), 7.45 - 7.37 (m, 1H), 7.37 - 7.31 (m, 1H), 7.26 - 7.17 (m, 2H), 5.53 - 5.32 (m, 1H), 5.26 (dd, *J*=3.6, 16.8 Hz, 1H), 4.86 (br s, 1H), 4.48 - 4.35 (m, 1H), 4.30 - 3.99 (m, 4H), 3.95 - 3.73 (m, 1H), 3.60 - 3.39 (m, 2H), 3.29 - 2.94 (m, 5H), 2.93 - 2.67 (m, 7H), 2.66 - 2.56 (m, 1H), 2.55 - 2.47 (m, 1H), 2.43 (d, *J*=4.6 Hz, 3H), 2.35 - 2.13 (m, 2H), 1.36 - 1.25 (m, 1H), 1.09 (dd, *J*=3.0, 6.8 Hz, 3H).

EXAMPLE 617



2-((*S*)-1-(2-fluoroacryloyl)-4-(7-(3-methylisoquinolin-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazin-2-yl)acetonitrile



[02650] Step A: benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate. A mixture of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*) -1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 593 μmol, 1.0 *eq*), 4-bromo-3-methyl-isoquinoline (198 mg, 890 μmol, 1.5 *eq*), Cs_2CO_3 (483 mg, 1.48 mmol, 2.5 *eq*), BINAP-Pd-G3 (118 mg, 119 μmol, 0.2 *eq*) in dioxane (6 mL)was degassed and purged with N_2 3 times. The mixture was heated at 110 °C for 12 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate /Methanol=100/1 to 10:1). benzyl (2*S*)-2-(cyanomethyl)-4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (200 mg, 303 μmol, 51% yield, 98% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 647.

[02651] Step B: 2-[(2*S*)-4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a

solution of benzyl (2*S*)-2-(cyanomethyl) -4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (50 mg, 77.3 μmol, 1.0 *eq*) in methanol (2 mL) was added dry Pd/C (10 mg, 10% purity) and NH_3/MeOH (1 mL, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 0.5 hour. The mixture was concentrated under vacuum. The residue was purified by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 30% - 60%, 10min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (7.81 mg, 14.9 μmol, 19% yield, 98.3% purity) was obtained as a yellow solid. LCMS [ESI, M+1]: 513.


[02652] ^{1}H NMR (400MHz, chloroform-d) δ = 9.07 (s, 1H), 8.14 (d, *J*=8.4 Hz, 1H), 7.97 (d, *J*=8.0 Hz, 1H), 7.65 (dt, *J*=1.2, 7.6 Hz, 1H), 7.58 - 7.47 (m, 1H), 4.41 (br dd, *J*=4.8, 10.4 Hz, 1H), 4.3 (s, 2H), 4.16 (dd, *J*=6.8, 10.8 Hz, 1H), 4.10 - 3.93 (m, 1H), 3.91 - 3.77 (m, 1H), 3.57 - 3.37 (m, 2H), 3.36 - 3.21 (m, 1H), 3.18 - 2.85 (m, 6H), 2.75 - 2.61 (m, 5H), 2.56 (br d, *J*=6.8 Hz, 2H), 2.48 (s, 3H), 2.33 - 2.22 (m, 1H), 2.12 - 1.98 (m, 1H), 1.94 - 1.80 (m, 3H).

[02653] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl) -4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(3-methyl-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (80 mg, 156 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (28.1 mg, 312 μmol, 2.0 *eq*) in DMF (2 mL) was added T3P (297 mg, 468 μmol, 278 μL, 50% purity in ethyl acetate, 3.0 *eq*) and TEA (126 mg, 1.25 mmol, 173 μL, 8.0 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150 * 25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 35% - 65%, 10min). The desired fraction was collected and lyophilized. 2-[(2*S*)-1-(2-fluoroprop-2-enoyl) -4-[7-(3-methyl-4-isoquinolyl)-2-[[(2*S*)-1-


methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (12 mg, 19.9 μmol, 13% yield, 97.4% purity, 100% ee) was obtained as a yellow solid. LCMS [ESI, M+1]: 585.

[02654] ^{1}H NMR (400MHz, chloroform-d) δ = 9.08 (s, 1H), 8.26 - 8.04 (m, 1H), 7.97 (br d, *J*=7.6 Hz, 1H), 7.73 - 7.60 (m, 1H), 7.58 - 7.49 (m, 1H), 5.42 (d, *J*=47.6 Hz, 1H), 5.27 (dd, *J*=3.6, 16.8 Hz, 1H), 4.85 (br s, 1H), 4.45 - 3.92 (m, 7H), 3.83 - 3.25 (m, 4H), 3.22 - 2.59 (m, 10H), 2.49 (s, 3H), 2.36 - 2.24 (m, 1H), 2.13 - 1.99 (m, 1H), 1.92 - 1.76 (m, 3H).

EXAMPLE 618



(*S*)-benzyl-2-(cyanomethyl)-4-(7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrr olidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate



[02655] Step A: (*S*)-benzyl-2-(cyanomethyl)-4-(7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrr olidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate. To a solution of benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1- methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 0.59 mmol, 1.0 eq) in toluene (10.0 mL) was added 4-bromo-7-fluoro-isoquinoline (268 mg, 1.19 mmol, 2.0 eq), RuPhos (111 mg, 237 μmol, 0.40 eq), Cs_2CO_3 (483 mg, 1.48 mmol, 2.5 eq) and $Pd_2(dba)_3$ (109 mg, 118 μmol, 0.20 eq) at 25 °C, the mixture was stirred at 90 °C for 16 hours. The reaction mixture was diluted with water (5.0 mL) and extracted with ethyl acetate (3 × 5.0 mL). The combined organic layers were washed with brine (3 × 5.0 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Petroleum ether/Ethyl acetate = 1/1 to Petroleum ether/Ethyl acetate/EtOH (2% NH_3H_2O) = 4/3/1). Then the crude product was purified by reversed-phase HPLC (0.1% FA condition). The desired fractions were collected and concentrated under vacuum to give (*S*)-benzyl-2-(cyanomethyl)-4-(7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrr olidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl)piperazine-1-carboxylate (105 mg, 160 μmol, 27% yield, 99% purity) as a yellow solid. LCMS [M+1]: 651.

[02656] ^{1}H NMR (400 MHz, chloroform -*d*) δ = 2.04 - 2.08 (m, 4 H), 2.69 (d, *J*=5.64 Hz, 1 H), 2.73 (d, *J*=5.52 Hz, 1 H), 2.81 - 2.85 (m, 3 H), 2.87 - 3.02 (m, 3 H), 3.09 - 3.19 (m, 1 H), 3.32 - 3.45 (m, 3 H), 3.45 - 3.55 (m, 1 H), 3.57 - 3.68 (m, 1 H), 3.99 (br d, *J*=12.52 Hz, 1 H), 4.09 - 4.17 (m, 1 H), 4.28 - 4.34 (m, 1 H), 4.31 (m, 1 H), 4.46 (dd, *J*=11.84, 4.31 Hz, 1 H), 4.63 - 4.74 (m, 1 H), 4.80 (br dd, *J*=11.32, 6.82 Hz, 1 H), 5.20 - 5.23 (m, 2H), 5.30 - 5.32 (m, 2 H), 7.35 - 7.42 (m, 5 H), 7.47 - 7.53 (m, 1 H), 7.60 (dd, *J*=8.68, 2.56 Hz, 1 H), 8.16 (dd, *J*=9.24, 5.25 Hz, 1 H), 8.22 - 8.25 (m, 1 H), 8.95 - 9.00 (m, 1 H).

[02657] Step B: 2-((*S*)-4-(7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile. To a solution of (*S*)-benzyl 2-(cyanomethyl)-4- (7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazine-1-carboxylate (30.0 mg, 46.1 μmol, 1.0 eq) in MeOH (1.0 mL) was added NH_3/MeOH (46.1 μmol, 1.5 mL, 15% purity, 1.0 eq) and Pd/C (20.0 mg, 46.1 μmol, 10% purity, 1.0 eq) under N_2. The

suspension was degassed under vacuum and purged with H_2 (93.1 ug, 46.1 μmol, 1.0 eq) several times. The mixture was stirred under H_2 (15 psi) at 25 °C for 1 hour. The reaction mixture was filtered through a celite and washed with MeOH (20 mL). The filtrate was concentrated under reduced pressure at 45 °C to give a residue. The residue was purified by prep-HPLC (basic condition) (column: Xtimate C18 150*25 mm*5 um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 43%-73%, 10 min). The desired fraction was collected and lyophilized. 2-((*S*)-4-(7-(7-fluoroisoquinolin-4-yl)-2-(((*S*)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile (7 mg, 13.3 μmol, 28.8% yield, 98% purity) was obtained as a yellow solid. LCMS [M+1]: 517.


[02658] ^{1}H NMR (400 MHz, chloroform-d) δ = 1.75 - 1.90 (m, 3 H), 1.99 - 2.13 (m, 1 H), 2.24 - 2.34 (m, 1 H), 2.45 - 2.51 (m, 3 H), 2.53 - 2.58 (m, 2 H), 2.64 - 2.74 (m, 1 H), 2.80 - 2.88 (m, 2 H), 2.89 - 2.96 (m, 1 H), 2.97 - 3.06 (m, 1 H), 3.07 - 3.18 (m, 3 H), 3.22 - 3.33 (m, 1 H), 3.38 - 3.48 (m, 2 H), 3.82 - 3.89 (m, 1 H), 4.03 (br d, *J*=12.36 Hz, 1 H), 4.18 (dd, *J*=10.56, 6.69 Hz, 1 H), 4.30 (s, 2 H), 4.40 (dd, *J* = 10.64, 4.75 Hz, 1 H), 7.49 (ddd, *J*=9.16, 8.35, 2.63 Hz, 1 H), 7.60 (dd, *J*=8.76, 2.50 Hz, 1 H), 8.17 (dd, *J*= 9.24, 5.38 Hz, 1 H), 8.24 (s, 1 H), 8.96 (s, 1 H).

[02659] Step C: 2-[(2*S*)-4-[7-(7-fluoro-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile. To a solution of 2-[(2*S*)-4-[7-(7-fluoro-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (90.7 mg, 175 μmol, 1.0 *eq*) and 2-fluoroprop-2-enoic acid (31.6 mg, 351 μmol, 2.0 *eq*) in DMF (2 mL) was added T3P (335 mg, 526 μmol, 313 μL, 50% purity in ethyl acetate, 3.0 *eq*) and TEA (142 mg, 1.40 mmol, 195 μL, 8.0 *eq*) at 0°C. The mixture was stirred at 0 °C for 0.5 hour. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2, Ethyl acetate/Methanol=100/1 to 10/1) and further purification by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (0.05% ammonia hydroxide v/v) - ACN]; B%: 32% - 59%, 10 min). The desired fraction was collected and lyophilized. 2-[(2*S*)-4-[7-(7-fluoro-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-1-(2-fluoroprop-


2-enoyl)piperazin-2-yl]acetonitrile (8 mg, 13.4 μmol, 7.6% yield, 98.3% purity, 100% ee) was obtained as a white solid. LCMS [M+1]: 589.

[02660] ^{1}H NMR (400MHz, chloroform-d) δ = 8.97 (s, 1H), 8.24 (s, 1H), 8.16 (dd, *J*=5.2, 9.2 Hz, 1H), 7.60 (dd, *J*=2.4, 8.8 Hz, 1H), 7.54 - 7.40 (m, 1H), 5.55 - 5.33 (m, 1H), 5.27 (dd, *J*=3.6, 16.8 Hz, 1H), 4.87 (br s, 1H), 4.44 - 3.94 (m, 7H), 3.72 - 3.28 (m, 4H), 3.22 - 3.06 (m, 2H), 3.04 - 2.93 (m, 2H), 2.93 - 2.74 (m, 2H), 2.72 - 2.66 (m, 1H), 2.49 (s, 3H), 2.36-2.24 (m, 1H), 2.13 - 2.03 (m, 1H), 1.92 - 1.76 (m, 3H).

EXAMPLE 619



2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(5-methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile



[02661] Step A: benzyl (2*S*)-4-[7-(1-chloro-5- methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate. Benzyl (2*S*)-2-(cyanomethyl)-4-[2-[[(2*S*)-1-methylpyrrolidin-2-yl] methoxy]-5,6,7,8-tetrahydropyrido[3,4-*d*]pyrimidin-4-yl]piperazine-1-carboxylate (300 mg, 593 μmol, 1.0 *eq*), 4-bromo-1-chloro-5-methyl-isoquinoline (198 mg, 771 μmol, 1.3 *eq*), $Pd_2(dba)_3$ (109 mg, 119 μmol, 0.2 *eq*) and Cs_2CO_3 (483 mg, 1.48 mmol, 2.5 *eq*), XantPhos (137 mg, 237 μmol, 0.4 *eq*) in toluene (10 mL) was de-gassed and then heated to 95 °C for 10 hours under N_2. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, petroleum ether/ethyl acetate 2/1 to 0/1) followed by reversed phase flash [water (0.1% FA)/acetonitrile]. The desired fractions were collected and neutralized with solid $NaHCO_3$, concentrated under vacuum to remove MeCN and extracted with ethyl acetate (2 × 15 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum to give benzyl (2*S*)-4-[7-(1-chloro-5- methyl-4-isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (150 mg, 209 μmol, 35% yield, 95% purity) as a yellow solid. LCMS [ESI, M+1]: 681.

[02662] 1H NMR (400 MHz, chloroform-d) δ = 8.27 (d, *J* = 8.0 Hz, 1H), 8.08 - 7.99 (m, 1H), 7.60 - 7.51 (m, 2H), 7.44 - 7.36 (m, 5H), 5.25 - 5.17 (m, 2H), 4.74 - 4.60 (m, 1H), 4.41 - 4.32 (m, 1H), 4.28 - 4.14 (m, 2H), 4.08 - 3.88 (m, 2H), 3.83 (br d, *J* = 17.6 Hz, 1H), 3.61 - 3.51 (m, 1H), 3.50 - 3.36 (m, 1H), 3.31 - 2.94 (m, 6H), 2.91 (d, *J* = 2.4 Hz, 3H), 2.81 - 2.59 (m, 4H), 2.46 (d, *J* = 4.0 Hz, 3H), 2.33 - 2.21 (m, 1H), 2.06 - 1.97 (m, 1H), 1.92 - 1.72 (m, 3H).


[02663] Step B: 2-[(2*S*)-4-[7-(5-methyl-4- isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of benzyl (2*S*)-4-[7-(1-chloro-5-methyl-4-isoquinolyl) -2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carboxylate (130 mg, 191 μmol, 1 *eq*) in MeOH (3 mL) was added NH_3•MeOH (2 mL, 20% purity), Pd/C (65 mg, 10% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 25 °C for 2 hours. Upon completion, the catalyst was removed by filtering through a plug of celite. The solvent was removed under reduced pressure to give 80 mg of crude product. Taking 20 mg of the crude product was

purified by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 28%-58%, 10min). The desired fractions were collected and lyophilized to give 2-[(2*S*)-4-[7-(5-methyl-4- isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (10.8 mg, 21.0 μmol, 44% yield, 99.9% purity) as a yellow solid. LCMS [ESI, M+1]: 513.


[02664] Step C: 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(5-methyl-4-isoquinolyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile. To a solution of 2-fluoroprop-2-enoic acid (24.6 mg, 273 μmol, 2.0 *eq*) and DIEA (70.6 mg, 546 μmol, 95.1 μL, 4.0 *eq*) in DCM (1.4 mL) was added HATU (77.9 mg, 205 μmol, 1.5 *eq*) at 0 °C. After stirring at 0 °C for 20 minutes, 2-[(2*S*)-4-[7-(5-methyl-4- isoquinolyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (70 mg, 137 μmol, 1.0 *eq*) was added into the mixture. The mixture was stirred at 25 °C for 40 minutes. Upon completion, the mixture was diluted with water (2 mL) and extracted with dichloromethane (6 × 5 mL). The organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by chromatography (Al_2O_3, petroleum ether/ethyl acetate 1/1 to ethyl acetate/methanol 10/1) followed by prep-HPLC (column: Waters Xbridge 150*25 5u; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 35%-65%, 10min). The desired fractions were collected and lyophilized to give 2-[(2*S*)-1-(2-fluoroprop-2-enoyl)-4-[7-(5-methyl-4-isoquinolyl)-2- [[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-*d*]pyrimidin-4-yl]piperazin-2-yl]acetonitrile (20.6 mg, 34.3 μmol, 25% yield, 97.3% purity) as a white solid. LCMS [ESI, M+1]: 585.

[02665] ^{1}H NMR (400 MHz, chloroform-d) δ = 9.03 (d, *J* = 6.0 Hz, 1H), 8.30 (d, *J* = 16.8 Hz, 1H), 7.83 (br d, *J* = 7.6 Hz, 1H), 7.55 - 7.44 (m, 2H), 5.54 - 5.32 (m, 1H), 5.31 - 5.18 (m, 1H), 5.09 - 4.48 (m, 1H), 4.43 - 4.34 (m, 1H), 4.32 - 4.07 (m, 4H), 4.06 - 3.81 (m, 2H), 3.64 - 3.42 (m, 2H), 3.35 - 3.26 (m, 1H), 3.25 - 2.96 (m, 4H), 2.92 (d, *J* = 2.8 Hz, 3H), 2.90 - 2.73 (m, 2H), 2.72 - 2.61 (m, 2H), 2.51 - 2.42 (m, 3H), 2.34 - 2.23 (m, 1H), 2.13 - 1.99 (m, 1H), 1.92 - 1.73 (m, 3H).

EXAMPLE 620



1-[4-[7- (8-chloro-1-naphthyl) -2-[[(2S)-1- methylpyrrolidin- 2- yl] methoxy] -6,8 –dihydro -5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepan-1-yl]-2-fluoro-prop-2-en-1-one



[02666] Step A: *tert*-butyl 4-benzyl -6-fluoro -1,4 – diazepane-1-carboxylate. *tert*-butyl 4-benzyl -6-fluoro -1,4 – diazepane-1-carboxylate. To a solution of tert-butyl (3R)-4-benzyl- 3-(hydroxymethyl) piperazine -1-carboxylate (1.5 g, 4.90 mmol, 1 *eq*) in DCM (40 mL) was added DAST (3.95 g, 24.48 mmol, 3.23 mL, 5 *eq*) drop-wise at 0 °C, and the mixture was stirred at 20 °C for 5 hrs. The mixture was added sat, $NaHCO_3$ (30 mL) and extracted with ethyl acetate (30 mL×2). The organic layer was dried over Na_2SO_4, filtered, concentrated. The residue was purified by silica gel column chromatography (PE: EA=20~5:1) to give *tert*-butyl 4-benzyl -6-fluoro -1,4 – diazepane-1-carboxylate (980 mg, 3.18 mmol, 64.91% yield) as yellow oil. LCMS [ESI, M+1]: 309.

[02667] Step B: *tert*-butyl 6-fluoro-1, 4-diazepane-1-carboxylate. To a solution of tert-butyl 4-benzyl-6-fluoro-1,4-diazepane-1-carboxylate (900.00 mg, 2.92 mmol, 1 *eq*) and Pd/C (200 mg, 2.92 mmol, 10% purity, 1 *eq*) and $Pd(OH)_2$ (179.92 mg, 1.28 mmol, 4.39e-1 *eq*) in MeOH (20 mL) and the mixture was stirred at 40 °C for 12 hrs under H_2 (50 psi). The mixture was filtered, concentrated to give *tert*-butyl 6-fluoro-1, 4-diazepane-1-carboxylate (630 mg, 2.89 mmol, 98.90% yield) as colorless oil.

[02668] Step C: [7-(8- chloro -1- naphthyl) -2- [[(2S) -1-methylpyrrolidin-2-yl]methoxy] -6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl] trifluoromethanesulfonate. To a solution of 7-(8-chloro-1-naphthyl)-2 -[[(2S)-1 –methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-ol (700 mg, 1.65 mmol, 1 *eq*) and TEA (500.09 mg, 4.94 mmol, 687.88 µL, 3 *eq*) , 4A molecular sieves (500 mg) in DCM (7 mL) was added Tf_2O (697.18 mg, 2.47 mmol, 407.71 µL, 1.5 *eq*) at - 40 °C, and stirred at 0 °C for 30 min. The mixture was added water (2 mL) and extracted with DCM (5mL). The organic layer was dried over Na_2SO_4, filtered, concentrated. The residue was purified by silica gel column chromatography (PE: EA=10~1:1) to give [7-(8-chloro-1-naphthyl)-2-[[(2S) -1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido [3,4-d]pyrimidin-4-yl] trifluoromethanesulfonate (470 mg, 843.83 µmol, 51.22% yield) as red oil. LCMS [ESI, M+1]: 557.

[02669] Step D: *tert*-butyl 4-[7-(8- chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl] methoxy]-6,8 -dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepane-1-carboxylate. To solution of [7-(8-chloro-1-naphthyl)-2- [[(2S)-1-methylpyrrolidin-2-yl] methoxy] -6,8-dihydro- 5H-pyrido[3,4-d] pyrimidin-4 -yl], trifluoromethanesulfonate (440 mg, 789.97 µmol, 1

eq) and *tert*-butyl-6 –fluoro-1, 4-diazepane-1-carboxylate (258.64 mg, 1.18mmol, 1.5 *eq*) in DMAC (5 mL) was added DIEA (306.29 mg, 2.37 mmol, 412.79 μL, 3 *eq*) , and the mixture was stirred at 25 °C for 30 min. The mixture was purified by reverse silica gel column chromatography column (0.001 FA) to give *tert*-butyl 4-[7-(8- chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin -2-yl] methoxy]-6,8 -dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepane-1-carboxylate (260 mg, 415.88 μmol, 52.65% yield) as yellow solid. LCMS [ESI, M+1]: 625.

[02670] Step E: 7-(8-chloro-1-naphthyl)-4-(6-fluoro-1 ,4-diazepan-1-yl) -2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine. To a solution of *tert*-butyl 4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepane-1-carboxylate (240.00 mg, 383.89 μmol, 1 *eq*) in DCM (3 mL) was added TFA (12.32 g, 108.05 mmol, 8.00 mL, 281.45 *eq*) , and the mixture was stirred at 20 °C for 30 min. The mixture was concentrated, and added DCM (10 mL), washed with sat.Na_2CO_3 (5 mL). The organic layer was dried over Na_2SO_4, filtered, concentrated to give 7-(8-chloro-1- naphthyl)-4-(6-fluoro-1,4-diazepan-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8- dihydro-5Hpyrido[3,4-d] pyrimidine (200 mg, crude) as yellow solid. Some of this material (160 mg, 304.73 μmol) was used directly in the next step. 40 mg of crude product was purified by prep-HPLC (purified by prep-HPLC (column: Shim-pack C18 150*25*10um; mobile phase: [water (0.225%FA)-ACN];B%: 4%-34%,10min) , then residue was prep-HPLC (column: Xtimate C18 150*25mm*5um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 60%-90%,10min) to give 7-(8-chloro-1-naphthyl)-4-(6-fluoro-1 ,4-diazepan-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine (9 mg, 16.99 μmol). LCMS [ESI, M+1]: 523.


[02671] ^{1}H NMR (400MHz, chloroform-d) δ =7.76 (d, *J*=8.07 Hz, 1 H) 7.61 (t, *J*=8.38 Hz, 1 H) 7.52 (br d, *J*=7.46 Hz, 1 H) 7.44 (dt, *J*=15.86, 7.90 Hz, 1 H) 7.34 (t, *J*=7.76 Hz, 1 H) 7.25-7.18 (dd, *J*=7.46 Hz, 1 H) 4.80 - 5.24 (m, 1 H) 4.31 - 4.46 (m, 2 H) 4.08 - 4.30 (m, 2 H) 3.71 - 4.04 (m, 3 H) 3.50 - 3.68 (m, 2 H) 2.81 - 3.37 (m, 7 H) 2.46 - 2.73 (m, 5 H) 2.25 - 2.35 (m, 1 H) 2.01 - 2.14 (m, 1 H) 1.82 - 1.91 (m, 3 H).

[02672] Step F: 1-[4-[7- (8-chloro-1-naphthyl)-2-[[(2S)-1- methylpyrrolidin- 2- yl] methoxy]-6,8 –dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepan-1-yl] -2-fluoro-


prop-2-en-1-one. To a solution of 7-(8-chloro-1-naphthyl) -4-(6-fluoro-1,4-diazepan-1-yl)-2-[[(2S)-1 –methylpyrrolidin -2-yl]methoxy]- 6,8-dihydro -5H-pyrido [3,4-d] pyrimidine (150.00 mg, 285.68 μmol, 1 *eq*) and 2-fluoroprop -2-enoic acid (51.45 mg, 571.36 μmol, 2 *eq*) in EA (2 mL) was added T3P (50 M, 17.14 μL, 3 *eq*) and TEA (231.27 mg, 2.29 mmol, 318.11 μL, 8 *eq*) at - 40 °C , and the mixture was stirred at -40 °C for 30 min. The mixture was diluted with water (2 mL) and extracted with ethyl acetate (2 mL×2). The organic layer was dried over Na_2SO_4, filtered, concentrated. The residue was purified by prep- HPLC (column: Shim-pack C18 150*25*10um;mobile phase: [water(0.225%FA)-ACN];B%: 18%-48%, 10min) to give 1-[4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1- methylpyrrolidin- 2- yl] methoxy]-6,8 –dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-6-fluoro-1,4-diazepan-1-yl] -2-fluoro- prop-2-en-1-one (90 mg, 140.78 μmol, 49.28% yield, 93.4% purity) as yellow solid. LCMS [ESI, M+1]: 597.

[02673] ^{1}H NMR (400MHz, chloroform-d) δ = 7.76 (d, *J*=8.19 Hz, 1 H) 7.58 - 7.66 (m, 1 H) 7.50 - 7.56 (m, 1 H) 7.38 - 7.50 (m, 1 H) 7.31 - 7.37 (m, 1 H) 7.24 - 7.16 (m, 1 H) 4.90 - 5.55 (m, 3 H) 4.32 - 4.48 (m, 2 H) 3.48 - 4.27 (m, 11 H) 3.21 - 3.43 (m, 1 H) 2.80 - 3.16 (m, 2 H) 2.44 - 2.73 (m, 5 H) 2.25 - 2.36 (m, 1 H) 2.00 - 2.14 (m, 1 H) 1.77 - 1.91 (m, 3 H).

EXAMPLE 621



1-[(3*R*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazin-1-yl]-2-fluoro-prop-2-en-1-one



[02674] Step A: *tert*-butyl (3*R*)-4-benzyl-3-(hydroxymethyl)piperazine-1-carboxylate. A reaction mixture of *tert*-butyl (3*R*)-3-(hydroxymethyl)piperazine-1-carboxylate (10 g, 46.2 mmol, 1 eq), BnBr (8.70 g, 50.9 mmol, 6.04 mL, 1.1 eq) and TEA (7.02 g, 69.36 mmol, 9.65 mL, 1.5 eq) in MeCN (100 mL) was heated to 80 °C for 12 hours. Upon completion, the reaction mixture was concentrated under vacuum. The residue was dissolved into water (30 mL) and ethyl acetate (50 mL).The mixture was extracted with ethyl acetate (3 × 50 mL).The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, and concentrated under vacuum. The residue was purified by silica gel chromatography (petroleum ether: ethyl acetate=5:1 to 3:1). *tert*-butyl (3*R*)-4-benzyl-3-(hydroxymethyl)piperazine-1-carboxylate (9 g, 29.4 mmol, 64% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]: 307.

[02675] ^{1}H NMR (400 MHz, chloroform-d) δ = 7.28 - 7.20 (m, 5H), 3.95 (br d, J = 13.2 Hz, 1H), 3.79 (dd, J = 5.6, 11.6 Hz, 1H), 3.61 (br dd, J = 3.2, 13.6 Hz, 1H), 3.52 (br dd, J = 4.0,

11.2 Hz, 2H), 3.35 (br d, J = 13.3 Hz, 2H), 3.09 (br s, 1H), 2.77 - 2.65 (m, 1H), 2.51 (br s, 1H), 2.20 (ddd, J = 3.2, 8.4, 12.0 Hz, 1H), 1.38 (s, 9H).

[02676] Step B: *tert*-butyl (3*R*)-4-benzyl-3-formyl-piperazine-1-carboxylate. DMSO (13.8 g, 176 mmol, 13.8 mL, 6.0 eq) was added to a to -65 °C solution of $(COCl)_2$ (11.2 g, 88.1 mmol, 7.71 mL, 3.0 eq) in dichloromethane (90 mL). After 10 min, a solution of *tert*-butyl (3*R*)-4-benzyl-3-(hydroxymethyl)piperazine-1-carboxylate (9 g, 29.4 mmol, 1 eq) in dichloromethane (40 mL) was slowly introduced over 15 minutes. After stirring at -65 °C for 1 hour, TEA (29.7 g, 294 mmol, 40.9 mL, 10.0 eq) was added. The mixture was warmed to 28 °C over 30 min and then stirred for another 30 min at that temperature. Upon completion, the reaction mixture was quenched with water (5 mL) and separated. The organic layer was dried over Na_2SO_4 and concentrated under vacuum. *tert*-butyl (3*R*)-4-benzyl-3-formyl-piperazine-1-carboxylate (8.9 g, 29 mmol) was obtained as a yellow oil which was used for next step without further purification.

[02677] Step C: *tert*-butyl (3*R*)-4-benzyl-3-(difluoromethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (3*R*)-4-benzyl-3-formyl-piperazine-1-carboxylate (8.9 g, 29.2 mmol, 1.0 eq) in dichloromethane (180 mL) was added DAST (9.43 g, 58.5 mmol, 7.73 mL, 2 eq) at 0 °C. The reaction mixture was stirred at 0°C for 2 hours. Upon completion, the reaction mixture was quenched by saturated $NaHCO_3$ (150 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with brine (60 mL) and concentrated under vacuum. The residue (Petroleum ether: Ethyl acetate=5:1) was purified by silica gel chromatography (Petroleum ether: Ethyl acetate=1:0 to 10:1). *tert*-butyl (3*R*)-4-benzyl-3-(difluoromethyl)piperazine-1-carboxylate (1.5 g, 4.48 mmol, two steps 15% yield, 97.5% purity) was obtained as a yellow oil. LCMS [ESI, M+1]:327.

[02678] Step D: *tert*-butyl (3*R*)-3-(difluoromethyl)piperazine-1-carboxylate. To a solution of *tert*-butyl (3*R*)-4-benzyl-3-(difluoromethyl)piperazine-1-carboxylate (1.5 g, 4.60 mmol, 1.0 eq) in MeOH (10 mL) was added Pd/C (150 mg, 10% purity), $Pd(OH)_2$/C (150 mg, 20% purity) under N_2. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (50 psi) at 40°C for 12 hours. Upon completion, the mixture was filtered and the filtrate was concentrated under vacuum. *tert*-butyl (3*R*)-3-(difluoromethyl)piperazine-1-carboxylate (1.0 g, 4.23 mmol, 92% yield) was obtained as a yellow oil which was used for next step without further purification.

[02679] 1H NMR (400 MHz, chloroform-d) δ = 5.91 - 5.43 (m, 1H), 4.17 - 3.78 (m, 2H), 3.13 - 2.66 (m, 5H), 1.48 (s, 9H).

[02680] Step E: [7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl] trifluoromethanesulfonate. To a solution of 7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-ol (1.0 g, 2.35 mmol, 1 eq), 4A molecular sieve (1.0 g) and TEA (953 mg, 9.41 mmol, 1.31 mL, 4.0 eq) in dichloromethane (20 mL) was added Tf_2O (996 mg, 3.53 mmol, 582 uL, 1.5 eq) at -40 °C and stirred for 0.5 hours. Upon completion, the reaction mixture was quenched by water (15 mL). The mixture was filtered through a pad of celite. The filtrate separated and the aqueous layers were extracted with dichloromethane (30 mL). The organic layers were washed with brine (10 mL), dried over Na_2SO_4 and concentrated under vacuum. The mixture was purified by silica gel chromatography (SiO_2, Petroleum ether: Ethyl acetate = 5:1 to 0:1) to give [7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl] trifluoromethanesulfonate (1.0 g, 1.63 mmol, 69 % yield, 91% purity) as a brown oil. LCMS [ESI, M+1]:557.

[02681] Step F: *tert*-butyl (3*R*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazine-1-carboxylate. A reaction mixture of [7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl] trifluoromethanesulfonate (1.0 g, 1.80 mmol, 1.0 eq) and *tert*-butyl (3*R*)-3-(difluoromethyl)piperazine-1-carboxylate (780 mg, 3.30 mmol, 1.84 eq) was stirred at 90 °C for 5 hours. Upon completion, the reaction mixture was dissolved in MeCN (5 mL). The reaction mixture was purified by reversed-phase flash [water (0.1% FA)/acetonitrile]. The fractions were basidified by solid $NaHCO_3$ to pH >7 and concentrated under vacuum. The aqueous layer was extracted with Ethyl acetate (3 × 20 mL) and concentrated under vacuum. The residue was purified by prep-TLC (dichloromethane :MeOH=7:1) to give *tert*-butyl (3*R*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazine-1-carboxylate (80 mg, 122 μmol, 7 % yield, 98% purity) as a brown oil. LCMS [ESI, M+1]: 643.

[02682] Step G: 7-(8-chloro-1-naphthyl)-4-[(2*R*)-2-(difluoromethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine. To a solution

of *tert*-butyl (3*R*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazine-1-carboxylate (20 mg, 31.1 μmol, 1 eq) in dichloromethane (0.05 mL) was added TFA (70.9 mg, 622 μmol, 46.0 μL, 20 eq). The reaction mixture was stirred at 25 °C for 1 hour. Upon completion, the reaction mixture was quenched by saturated Na_2CO_3 (4 mL) and extracted with dichloromethane: MeOH(10: 1, 3 × 8 mL).The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by Prep-HPLC(column: Waters Xbridge 150*25 5u;mobile phase: [water(10mM NH4HCO3)-ACN];B%: 43%-73%,10min). The fractions were concentrated and lyophilized. 7-(8-chloro-1-naphthyl)-4-[(2*R*)-2-(difluoromethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (4.22 mg, 7.77 μmol, 25% yield, 100% purity) was obtained as a white solid. LCMS [ESI, M+1]:543.

[02683] 1H NMR (400 MHz, chloroform-d) δ = 7.81 - 7.74 (m, 1H), 7.66 - 7.59 (m, 1H), 7.56 - 7.52 (m, 1H), 7.50 - 7.40 (m, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.28 - 7.16 (m, 1H), 6.69 - 6.09 (m, 1H), 4.68 - 4.54 (m, 1H), 4.51 - 4.34 (m, 2H), 4.30 - 4.11 (m, 1H), 4.07 - 3.68 (m, 2H), 3.63 - 3.46 (m, 2H), 3.44 - 3.31 (m, 2H), 3.30 - 3.21 (m, 1H), 3.20 - 2.97 (m, 4H), 2.92 - 2.83 (m, 1H), 2.78 - 2.67 (m, 1H), 2.58 - 2.49 (m, 3H), 2.38 - 2.26 (m, 1H), 2.15 - 2.02 (m, 1H), 1.94 - 1.73 (m, 3H).

[02684] Step H: 1-[(3*R*)-4-[7-(8-chloro-1-naphthyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazin-1-yl]-2-fluoro-prop-2-en-1-one. To a solution of 7-(8-chloro-1-naphthyl)-4-[(2*R*)-2-(difluoromethyl)piperazin-1-yl]-2-[[(2*S*)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5*H*-pyrido[3,4-d]pyrimidine (45 mg, 82.9 μmol, 1.0 eq), 2-fluoroprop-2-enoic acid (22.4 mg, 249 μmol, 3.0 eq) in Ethyl acetate (1 mL) was added 4A molecular sieve (100 mg). After stirring at 25 °C for 0.5 hour, TEA (126 mg, 1.24 mmol, 173 μL, 15 eq) and T3P (211 mg, 331 μmol, 197 μL, 50% purity, 4 eq) was added at 0 °C. The mixture was stirred at 25 °C for 0.5 hour. Upon completion, the reaction mixture was quenched by water (1 mL) and extracted with Ethyl acetate (3 × 5 mL). The combined organic layers were dried over Na_2SO_4 and concentrated under vacuum. The residue was purified by column (Al_2O_3, Petroleum ether :Ethyl acetate= 3:1 to 0:1), followed by prep-HPLC (column: Waters Xbridge 150*25 5u;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%: 55%-85%,10min) to give 1-[(3*R*)-4-[7-(8-chloro-1-





naphthyl)-2-[[(2*S*)-1-methylpyrrolidin -2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-(difluoromethyl)piperazin-1-yl]-2-fluoro-prop-2-en-1-one (5.98 mg, 9.72 μmol, 11% yield, 99.4% purity) as a white solid. LCMS [ESI, M+1]: 615.











[02685] 1H NMR (400 MHz, chloroform-d) δ = 7.81 - 7.75 (m, 1H), 7.67 - 7.61 (m, 1H), 7.55 (td, J = 1.2, 7.6 Hz, 1H), 7.51 - 7.41 (m, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.28 - 7.17 (m, 1H), 6.48 - 5.83 (m, 1H), 5.47 - 5.31 (m, 1H), 5.27 - 5.19 (m, 1H), 4.88 - 4.65 (m, 1H), 4.59 - 4.31 (m, 4H), 4.21 - 4.10 (m, 1H), 4.04 - 3.76 (m, 2H), 3.69 - 3.44 (m, 3H), 3.33 - 2.92 (m, 4H), 2.75 - 2.64 (m, 1H), 2.61 - 2.52 (m, 1H), 2.49-2.48 (m, 3H), 2.36 - 2.25 (m, 1H), 2.13 - 2.02 (m, 1H), 1.88 - 1.72 (m, 3H).









[02686] EXAMPLES 622 – 678 listed in Table 1 are prepared using commercially available intermediates and/or those intermediates disclosed herein following the methods outlined in the general reactions schemes and the teachings of the exemplified Examples.











Table 1











EXAMPLES 622 – 678









Example No.	Structure	Example No.	Structure
622		650	
623		651	








624		652	
625		653	
626		654	
627		655	
628		656	

629		657	
630		658	
631		659	
632		660	

633		661	
634		662	
635		663	
636		664	
637		665	

638		666	
639		667	
640		668	
641		669	
642		670	

643		671	
644		672	
645		673	
646		674	

647		675	
648		676	
649		677	
		678	

EXAMPLE A

KRas G12C Modification Assay

[02687] This Example illustrates that exemplary compounds of the present invention covalently bind to KRas G12C using a LCMS assay to detect a covalent adduct of the exemplary compound and KRAS G12C.

[02688] The protein concentration of GDP-loaded K-Ras (1-169) G12C, C51S,C80L,C118S and GTP-loaded K-Ras (1-169) G12C,C51S,C80L,C118S,Q61H was adjusted to 2 μM in K-Ras Assay Buffer (25 mM HEPES,150 mM NaCl, 5 mM $MgCl_2$, and 10 mM Octyl β-glucopyranoside at pH 7.5). A 10 μL aliquot of each protein solution was then transferred to a 384 well microtiter plate. Initial compound stocks were generated at fifty times their desired final assay concentration in DMSO.

[02689] Exemplary compounds of Formula (I) were diluted 25-fold into K-Ras Assay Buffer to a final of two times their final concentration. A 10 μL aliquot of each diluted compound solution was then added to each of the protein solutions in the microtiter plate to initiate reaction. Typical final compound concentrations were 3.0, 5.0 and 25.0 μM. At each time point, the reactions were quenched with 20 μL of a 25 mM acetic acid solution. Usual assay endpoints were 15, 180 and 1440 minutes. Once all reactions were quenched, the plates were heat sealed and the samples were injected into a LC/MS system for data acquisition.

[02690] Data collection took place on an Agilent 6520 Q-TOF Accurate Mass Spectrometer. Samples were injected in their liquid phase onto a C-3 reverse phase column to remove assay buffer and prepare the samples for mass spectrometer. The proteins were eluted from the column using an acetonitrile gradient and fed directly into the mass analyzer. Initial raw data analysis took place in Agilent MassHunter software immediately post data acquisition.

[02691] Raw data analysis of the intact protein was exclusively a deconvolution of the multiple charge states of each protein in solution using a maximum entropy deconvolution provided in Mass Hunter. To minimize complexity, only the data over limited mass ranges were considered for analysis, with a minimum of one Dalton mass step intervals. The heights of all masses identified during raw data analysis were exported to be further analyzed in Spotfire® data analysis software.

[02692] Final data analysis was a multistep process in the Spotfire® data analysis software package. Briefly, each protein mass was calculated as a percent of the total signal of that

sample, that percentage was then normalized to the percentage of signal of the protein in the absence of reactive compounds. Those normalized signals were reported as normalized percent of control (POC). An increased POC value indicates a compound that displays a higher degree of modification at a given condition compared to other compounds under the same conditions. The results for exemplary compounds of Formula (I) and Formula (II) tested at 5 μM concentration for 3 hours are shown in Table 2. Key: "A" ≤ 25% POC; "B" > 25% POC - ≤ 50% POC; "C" > 50% POC and ND = not determined.

Table 2

Inhibition of KRas G12C Activity by Exemplary Compounds

Example No.	POC	Example No.	POC
1	B	291	C
2	A	292	A
3	A	293	C
4	A	294	C
5	A	295	A
6	B	296	C
7	A	297	C
8	B	298	C
9	C	299	C
10	C	300	C
11	C	301	C
12	C	302	C
13	C	303	C
14	C	304	C
15	C	305	C
16	C	306	C
17	B	307	C
18	C	308	C
19	C	309	C
20	C	310	C
21	C	311	C
22	C	312	C
23	C	313	C
24	A	314	C
25	A	315	C
26	C	316	C
27	C	317	C
28	C	318	C
29	C	319	C

30	A	320	C
31	B	321	B
32	C	322	C
33	B	323	C
34	A	324	C
35	C	325	C
36	C	326	C
37	C	327	C
38	C	328	C
39	C	329	C
40	C	330	C
41	A	331	C
42	A	332	C
43	C	333	C
44	C	334	C
45	A	335	C
46	A	336	C
47	C	337	C
48	C	338	C
49	B	339	C
50	C	340	C
51	A	341	C
52	C	342	C
53	C	343	C
54	A	344	C
55	C	345	C
56	C	346	C
57	C	347	C
58	C	348	C
59	C	349	C
60	C	350	C
61	C	351	C
62	C	352	C
63	C	353	C
64	C	354	C
65	C	355	A
66	C	356	C
67	C	357	A
68	A	358	C
69	A	359	C
70	C	360	C
71	A	361	C
72	C	362	C
73	C	363	C
74	C	364	C

75	C	365	C
76	C	366	C
77	C	367	C
78	C	368	C
79	A	369	C
80	C	370	C
81	C	371	C
82	C	372	C
83	C	373	C
84	A	374	C
85	C	375	C
86	A	376	C
87	A	377	C
88	C	378	C
89	C	379	C
90	C	380	C
91	A	381	C
92	C	382	C
93	C	383	C
94	A	384	C
95	A	385	C
96	A	386	C
97	C	387	C
98	C	388	C
99	C	389	C
100	C	390	C
101	C	391	C
102	C	392	C
103	C	393	C
104	C	394	C
105	B	395	C
106	A	396	C
107	C	397	C
108	C	398	C
109	C	399	C
110	C	400	C
111	C	401	C
112	A	402	C
113	C	403	C
114	B	404	C
115	C	405	C
116	C	406	C
117	C	407	C
118	A	408	C
119	B	409	C

120	C	410	C
121	C	411	C
122	C	412	C
123	A	413	C
124	C	414	C
125	A	415	C
126	C	416	C
127	C	417	C
128	C	418	C
129	C	419	C
130	C	420	C
131	C	421	C
132	C	422	C
133	C	423	C
134	C	424	C
135	C	425	C
136	C	426	C
137	C	427	C
138	C	428	C
139	C	429	C
140	C	430	C
141	C	431	C
142	C	432	C
143	C	433	C
144	C	434	C
145	C	435	C
146	B	436	C
147	C	437	C
148	C	438	C
149	B	439	C
150	C	440	C
151	B	441	C
152	C	442	C
153	C	443	C
154	C	444	C
155	C	445	C
156	C	446	C
157	C	447	C
158	C	448	C
159	C	449	C
160	C	450	C
161	C	451	C
162	B	452	C
163	C	453	C
164	C	454	C

165	C	455	C
166	B	456	C
167	B	457	C
168	C	458	C
169	C	459	C
170	C	460	C
171	C	461	C
172	C	462	C
173	C	463	C
174	C	464	C
175	C	465	C
176	C	466	C
177	C	467	N.D.
178	C	468	N.D.
179	C	469	N.D.
180	C	470	N.D.
181	C	471	C
182	C	472	C
183	C	473	C
184	C	474	C
185	C	475	C
186	B	476	C
187	C	477	C
188	C	478	C
189	C	479	C
190	C	480	C
191	C	481	C
192	C	482	C
193	C	483	C
194	C	484	C
195	C	485	A
196	C	486	C
197	C	487	A
198	C	488	B
199	C	489	C
200	C	490	C
201	B	491	C
202	C	492	A
203	C	493	C
204	C	494	C
205	C	495	C
206	C	496	C
207	C	497	C
208	C	498	C
209	C	499	C

210	C	500	C
211	C	501	C
212	C	502	C
213	C	503	C
214	C	504	C
215	C	505	C
216	C	506	C
217	C	507	C
218	C	508	C
219	C	509	C
220	C	510	C
221	C	511	C
222	C	512	A
223	C	513	C
224	C	514	A
225	C	515	N.D.
226	C	516	N.D.
227	A	517	N.D.
228	C	518	N.D.
229	C	519	N.D.
230	C	520	N.D.
231	C	521	N.D.
232	C	522	N.D.
233	C	523	N.D.
234	C	524	C
235	C	525	B
236	C	526	C
237	C	527	N.D.
238	C	529	C
239	C	530	C
240	C	542	C
241	C	543	C
242	C	554	C
243	C	555	C
244	C	556	C
245	C	557	C
246	C	558	C
247	C	559	C
248	C	560	C
249	C	561	C
250	C	562	C
251	C	563	C
252	C	564	C
253	C	565	C
254	C	566	C

255	A	567	C
256	C	568	C
257	C	569	N.D
258	C	570	N.D
259	C	571	C
260	C	572	C
261	A	573	N.D.
262	A	574	C
263	C	575	C
264	C	576	C
265	C	577	C
266	C	578	C
267	C	579	C
268	C	580	C
269	C	581	C
270	C	582	C
271	C	583	C
272	C	584	N.D.
273	C	585	C
274	C	586	C
275	C	587	A
276	C	588	C
277	C	589	C
278	C	590	B
279	C	591	B
280	C	592	C
281	C	593	C
282	A	594	A
283	C	595	C
284	C	596	C
285	C	597	C
286	C	598	C
287	C	599	C
288	A	600	C
289	C		
290	C		

EXAMPLE B

Inhibition of KRas G12C-dependent Cell Growth

[02693] This Example illustrates that exemplary compounds of the present invention inhibit the growth of tumor cell lines that express KRas G12C.

[02694] The cellular inhibition of KRAs G12C by exemplary compounds of the present invention was determined by measuring the amount of a downstream marker of KRas activity, phosphorylated ERK ("Phospho-ERK").

[02695] NCI-H358 cells (ATCC CRL-5807) express KRas G12C and were grown in RPMI medium supplemented with 10% fetal bovine serum, penicillin/streptomycin and 10 mM HEPES. Cells were plated in poly-D-Lysine coated 96-well plates at a concentration of 50,000 cells/well and allowed to attach for 8-12 hours. Diluted compounds were then added at a final concentration of 0.5 % DMSO. After 3 hours, the medium was removed, 150 μL of 4% formaldehyde was added and the plates were incubated for 20 minutes. The plates were washed with PBS, and permeabilized using 150 μL of ice cold 100% methanol for 10 minutes. Non-specific antibody binding to the plates was blocked using 100 μL Licor Blocking Buffer (Li-Cor Biotechnology, Lincoln NE) for 1 hour at room temperature. Positive control samples and samples lacking cells were parallel processed with test samples as standards.

[02696] The amount Phospho-ERK was determined using an antibody specific for the phosphorylated form of ERK and compared to the amount of GAPDH. Primary antibodies used for detection were added as follows: Phospho-ERK (Cell Signaling cs9101) diluted 1:500 and GAPDH (Millipore MAB374) diluted 1:5000 in Licor block + 0.05% Tween 20. The plates were incubated for 2 hours at room temperature. The plates were washed with PBS + 0.05% Tween 20.

[02697] Secondary antibodies used to visualize primary antibodies were added as follows: Anti-rabbit-680 diluted 1:1000 and Anti-mouse-800 diluted 1:1000 in Licor Block + 0.05% Tween 20 and incubated for 1 hour at room temperature. The plates were washed with PBS + 0.05% Tween 20. A 100 μL aliquot of PBS was added to each well and the plates were read on a LICOR AERIUS plate reader.

[02698] The pERK(Thr202/Tyr204) signal was normalized with the GAPDH signal and percent of DMSO control values were calculated. IC_{50} values were generated using a 4 parameter fit of the dose response curve. The results for exemplary compounds of Formula (I)

Formula (II) are shown in Table 3. Key: "A" ≥ 0.0001 - ≤ 1 μM; "B" > 1 μM and ND = not determined.

Table 3

Inhibition of KRas G12C-mediated Cell Proliferation by Exemplary Compounds

Example No.	IC_{50}	Example No.	IC_{50}
1	B	301	A
2	B	302	A
3	B	303	A
4	B	304	A
5	B	305	B
6	B	306	A
7	B	307	B
8	B	308	A
9	B	309	A
10	B	310	A
11	A	311	A
12	B	312	A
13	B	313	A
14	B	314	A
15	B	315	A
16	B	316	A
17	B	317	A
18	B	318	A
19	A	319	A
20	B	320	A
21	A	321	B
22	B	322	A
23	B	323	A
24	B	324	A
25	B	325	B
26	B	326	A
27	A	327	A
28	A	328	A
29	B	329	A
30	B	330	A
31	B	331	A
32	A	332	A
33	B	333	A
34	B	334	A
35	B	335	A
36	B	336	A

37	B	337	A
38	A	338	A
39	A	339	A
40	A	340	B
41	B	341	A
42	B	342	A
43	B	343	B
44	B	344	A
45	B	345	B
46	B	346	A
47	B	347	A
48	B	348	A
49	B	349	A
50	B	350	A
51	B	351	A
52	A	352	A
53	B	353	B
54	B	354	B
55	A	355	B
56	A	356	B
57	B	357	A
58	B	358	A
59	B	359	A
60	B	360	A
61	B	361	A
62	B	362	A
63	B	363	A
64	A	364	A
65	B	365	A
66	B	366	A
67	A	367	A
68	B	368	B
69	B	369	A
70	B	370	A
71	B	371	A
72	A	372	A
73	B	373	B
74	A	374	B
75	A	375	B
76	B	376	A
77	A	377	A
78	B	378	A
79	B	379	A
80	B	380	A
81	B	381	A

82	A	382	A
83	B	383	A
84	B	384	A
85	B	385	A
86	B	386	A
87	B	387	A
88	A	388	A
89	A	389	B
90	A	390	A
91	B	391	A
92	A	392	B
93	B	393	A
94	B	394	A
95	B	395	A
96	B	396	A
97	A	397	A
98	B	398	A
99	B	399	A
100	B	400	A
101	A	401	A
102	A	402	A
103	A	403	A
104	A	404	A
105	B	405	A
106	B	406	A
107	B	407	B
108	A	408	B
109	B	409	A
110	A	410	A
111	A	411	A
112	B	412	A
113	B	413	A
114	B	414	A
115	A	415	A
116	A	416	A
117	B	417	A
118	B	418	A
119	B	419	A
120	A	420	A
121	B	421	A
122	B	422	A
123	B	423	A
124	B	424	A
125	B	425	A
126	B	426	A

127	A	427	A
128	B	428	A
129	A	429	B
130	A	430	A
131	A	431	B
132	A	432	A
133	B	433	B
134	B	434	A
135	A	435	A
136	B	436	A
137	B	437	A
138	B	438	A
139	B	439	B
140	B	440	A
141	B	441	A
142	B	442	A
143	B	443	A
144	A	444	A
145	A	445	A
146	B	446	B
147	A	447	A
148	A	448	A
149	A	449	A
150	A	450	A
151	B	451	A
152	A	452	A
153	A	453	A
154	A	454	A
155	A	455	A
156	A	456	B
157	B	457	A
158	B	458	A
159	B	459	A
160	B	460	A
161	B	461	A
162	B	462	A
163	B	463	A
164	B	464	A
165	B	465	B
166	B	466	A
167	B	467	N.D.
168	B	468	N.D.
169	A	469	N.D.
170	A	470	N.D.
171	B	471	B

172	B	472	A
173	B	473	A
174	B	474	A
175	A	475	A
176	A	476	A
177	A	477	A
178	A	478	A
179	A	479	A
180	A	480	A
181	B	481	A
182	A	482	A
183	A	483	A
184	B	484	A
185	A	485	A
186	B	486	A
187	A	487	A
188	A	488	B
189	B	489	A
190	A	490	A
191	B	491	A
192	A	492	A
193	A	493	A
194	B	494	B
195	B	495	A
196	A	496	A
197	A	497	A
198	B	498	A
199	B	499	A
200	B	500	A
201	B	501	A
202	A	502	A
203	A	503	B
204	B	504	A
205	B	505	B
206	A	506	A
207	B	507	A
208	B	508	A
209	B	509	A
210	A	510	A
211	A	511	A
212	A	512	B
213	B	513	A
214	B	514	B
215	B	515	N.D.
216	B	516	A

217	B	517	A
218	A	518	A
219	B	519	A
220	A	520	A
221	A	521	A
222	A	522	A
223	A	523	A
224	A	524	A
225	A	525	A
226	A	526	A
227	A	527	A
228	A	528	B
229	A	529	A
230	A	530	A
231	A	542	A
232	B	543	A
233	A	554	A
234	A	555	A
235	A	556	A
236	A	557	A
237	A	558	A
238	A	559	A
239	B	560	A
240	B	561	A
241	B	562	A
242	A	563	A
243	A	564	A
244	A	565	A
245	A	566	A
246	A	567	B
247	B	568	A
248	B	569	B
249	A	570	B
250	B	571	A
251	A	572	B
252	A	573	B
253	A	574	A
254	A	575	A
255	B	576	A
256	B	577	A
257	A	578	A
258	B	579	A
259	A	580	A
260	A	581	A
261	B	582	A

262	B	583	A
263	A	584	A
264	B	585	A
265	A	586	A
266	A	587	B
267	A	588	A
268	A	589	A
269	A	590	B
270	A	591	B
271	A	592	B
272	A	593	A
273	B	594	B
274	A	595	A
275	A	596	A
276	A	597	A
277	A	598	A
278	A	599	B
279	A	600	A
280	A	601	A
281	A	602	A
282	B	603	B
283	A	604	A
284	A	605	B
285	A	606	A
286	A	607	A
287	A	608	A
288	B	609	A
289	B	610	B
290	A	611	B
291	A	612	B
292	B	613	A
293	A	614	A
294	B	615	A
295	B	616	A
296	A	617	B
297	A	618	B
298	A	619	A
299	A	620	N.D.
300	A	621	B

EXAMPLE C

Improved In Vitro Stability of Compounds Having Substitutions at R^A or R^B in Whole Blood

[02699] This Example illustrates that exemplary compounds of the present invention comprising substitutions at R^A or at least one R^B exhibit improved whole blood stability compared to compounds in which R^A and both R^B substituents are hydrogen.

[02700] Materials: The following reagents were used as received: acetonitrile (HPLC grade, Burdick & Jackson, Madison, WI), phosphate buffered saline (PBS), pH 7.4 (Sigma-Aldrich, Co., St. Louis, MO), water (HPLC grade, JT Baker, Phillipsburg, NJ), DMSO (EM Science, Merck KGaA, Darmstadt, Germany) and isopropanol (IPA, reagent grade, EMD Chemicals, Gibbstown, NJ). Propantheline and esmolol (Sigma-Aldrich) were used as the positive control compounds in the assay. Diazepam (Sigma-Aldrich) was used as an internal standard for quantitation. Human whole blood was obtained from BioIVT (Westbury, NY) and was of the male gender. All other reagents and solvents were of the highest analytical grade supplied by Sigma (St. Louis, MO) and were used as received.

[02701] Blood Incubations: The in vitro stability of representative KRas G12C inhibitor compounds of the present invention in the presence whole blood was conducted in the following manner. Esmolol or propantheline, which are known to undergo ester hydrolysis by esterases in blood and plasma, were used as the positive controls in the assays. A 10 mM stock solution of propantheline, esmolol, or a compound of the present invention in DMSO was diluted to 500 μM with DMSO. Aliquots of whole blood (600 μL), in triplicate, were placed in the appropriate wells of a polypropylene 96-deep well plate (Axygen Scientific, Union City, CA). The blood was diluted to 50% using PBS, pH 7.4 (600 μL). The diluted blood was pre-incubated for 15 minutes at 37 °C. Each well was dosed with 12 μL of the 500 μM DMSO stock simultaneously for a final test concentration of 5 μM. The plates were mixed at 600 rpm for 10 seconds on a plate shaker (IKA MTS 2/4 Digital Microtiter Shaker, VWR). Aliquots of 100 μL from each well of whole blood were transferred to three separate 96-deep well plates labeled 0, 60, or 240 minutes. At the end of each designated time point, the red blood cells were lysed with 100 μL of water, mixed at 600 rpm for one minute, and stopped with 800 μL of acetonitrile containing IS (0.625 μM diazepam). The plates were mixed on the plate shaker at 600 rpm for one minute and spun in a centrifuge at 2095 x *g* for 7 minutes at room temperature using an Allegra benchtop centrifuge (Beckman Coulter, Fullerton, CA). Supernatant (100 μL) was transferred to a shallow 96-well plate (Costar) using a liquid sample handling system (Apricot, Perkin-Elmer, Boston,

MA). The addition of 100 μL of water was added to each sample of supernatant for a final volume of 200 μL. The plates were sealed and the contents of each well were analyzed by LC-MS/MS.

[02702] Analytical quantitation: The LC-MS/MS system was comprised of an HTS-PAL autosampler (Leap Technologies, Carrboro, NC), an HP1200 HPLC (Agilent, Palo Alto, CA), and an API4000 triple quadrupole mass spectrometer (PE Sciex, a division of Applied Biosystems, Foster City, CA). Chromatographic separation of the analyte and internal standard was achieved at room temperature using a C18 column (Kinetex®, 30 x 3.0 mm, 2.6 μm particle size, Phenomenex, Torrance, CA) in conjunction with gradient conditions using mobile phases A (aqueous 0.1% formic acid with 1% isopropyl alcohol) and B (0.1% formic acid in acetonitrile). The total run time, including re-equilibration, for a single injection was 2 minutes. Mass spectrometric detection of the analytes was accomplished using the ESI^+ ionization mode. Ion current was optimized during infusion of a stock solution of propantheline, esmolol, or the representative test compound. Analyte responses, including the IS were measured by multiple reaction monitoring (MRM) of transitions unique to each compound.

[02703] Calculations: Data were acquired and peak areas were calculated for test compounds and the internal standard using Analyst 1.6.2 software (Sciex). The mean peak area ratios were calculated by averaging the peak area ratios (n=3) of each test compound and the IS for each sample.

[02704] Peak area tables were exported to BioAssay Enterprise (CambridgeSoft, Cambridge, MA), where the average analyte-to-internal standard peak area ratios were used to calculate percent remaining (%REM) and half-life ($t_{1/2}$). Percent remaining (f) was calculated by determining the ratio of the peak area ratio at each time point to the peak area ratio of the time-zero samples. The $t_{1/2}$ was determined dividing ln(2) by k_m. The rate of loss of test compound (k_m) was determined by linear regression of -ln(f(t)) versus time. The regression used the form "y=mx", therefore the model forced an intercept of 100% remaining and assumed that the metabolism followed first order kinetics.

[02705] The positive control compounds, propantheline or esmolol, and representative KRas G12C inhibitor compounds of the present invention were incubated in the presence of

human whole blood at 37 °C over a 240-minute incubation period. The half-life of propantheline, esmolol, and each test compound after 240 minutes of incubation at 37 °C is shown in Table 4. Key: A ≤ 200 min; B > 200 min - ≤ 1000 min; C > 1000 min - ≤ 2000 min;and D > 2000 min

Table 4

In Vitro Stability of Exemplary KRas G12C inhibitors in Human Whole Blood

Example No.	Compound Half-life
propantheline	A
235	D
236	B
331	B
359	B
367	C
372	D
478	D
479	D
480	D
481	D
482	D
484	A
485	D
490	A
491	A
495	B
498	D
501	A
502	B
504	A
506	C

507	D
509	D
510	C
511	D
512	D
513	C
514	D
515	D
516	D
517	C
524	D
552	D
557	D
579	C


[02706] Results: As expected, positive control propantheline displayed a short half life of 98 min. In comparison, the half life of exemplary KRas G12C inhibitor compounds comprising substitutions at R^A or R^B in human whole blood was, in some instances, increased by greater than 3-fold or greater than 4-fold compared to unsubstituted compounds, e.g., Examples 331 and 359, resulting in greatly improved pharmacodynamic and pharmacokinetic properties of these compounds resulting in greater in vivo stability and increased bioavailability.

[02707] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

CLAIMS

WE CLAIM:

1. A compound of formula (II):



Formula (II)

or a pharmaceutically acceptable salt thereof:

wherein:

X is a 4-12 membered saturated or partially saturated monocyclic, bridged or spirocyclic ring, wherein the saturated or partially saturated monocyclic ring is optionally substituted with one or more R^8;

Y is a bond, O, S or NR^5;

R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ or $-SO_2C(R^A)$ ------ $C(R^B)_p$;

R^2 is hydrogen, alkyl, hydroxyalkyl, dihydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, -Z-NR^5R^{10}, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, or heteroarylalkyl, wherein each of the Z, heterocyclyl, heterocyclylalkyl, aryl, heteroaryl, and heteroarylalkyl may be optionally substituted with one or more R^9;

each Z is C1 – C4 alkylene;

each R^3 is independently C1 – C3 alkyl, oxo, haloalkyl, hydroxyl or halogen;

L is a bond, -C(O)-, or C1 – C3 alkylene;

R^4 is hydrogen, cycloalkyl, heterocyclyl, aryl, aralkyl or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, aralkyl and heteroaryl may be optionally substituted with one or more R^6, R^7 or R^8;

each R^5 is independently hydrogen or C1 – C3 alkyl;

R^6 is cycloalkyl, heterocyclyl, heterocyclylalkyl, aryl, or heteroaryl, wherein each of the cycloalkyl, heterocyclyl, aryl, or heteroaryl may be optionally substituted with one or more R^7;

each R^7 is independently halogen, hydroxyl, C1 – C6 alkyl, cycloalkyl, alkoxy, haloalkyl, amino, cyano, heteroalkyl, hydroxyalkyl or Q-haloalkyl, wherein Q is O or S;

R^8 is oxo, C1 – C3 alkyl, C2 – C4 alkynyl, heteroalkyl, cyano, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-N(R^5)_2$, wherein the C1 – C3 alkyl may be optionally substituted with cyano, halogen, $-OR^5$, $-N(R^5)_2$, or heteroaryl;

each R^9 is independently hydrogen, oxo, acyl, hydroxyl, hydroxyalkyl, cyano, halogen, C1 – C6 alkyl, aralkyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, alkoxy, dialkylaminyl, dialkylamidoalkyl, or dialkylaminylalkyl, wherein the C1 – C6 alkyl may be optionally substituted with cycloalkyl;

each R^{10} is independently hydrogen, acyl, C1 – C3 alkyl, heteroalkyl or hydroxyalkyl;

R^{11} is haloalkyl;

R^A is absent, hydrogen, deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl;

each R^B is independently hydrogen, deuterium, cyano, C1 – C3 alkyl, hydroxyalkyl, heteroalkyl, C1 – C3 alkoxy, halogen, haloalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)$C1 – C3 alkyl, heteroaryl, heteroarylalkyl, dialkylaminylalkyl, or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl, wherein the heteroaryl or the heteroaryl portion of the heteroarylalkyl is optionally substituted with one or more R^7;

or when $\overset{\text{------}}{=\!=}$ is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 4-8 membered partially saturated cycloalkyl substituted with oxo;


m is zero or an integer between 1 and 2;

p is one or two; and wherein,

when $\overset{\text{- - - - - -}}{\equiv}$ is a triple bond then R^A is absent, p equals one and R^B is hydroxyalkyl,

or when $\overset{\text{- - - - - -}}{\equiv}$ is a double bond then R^A is present, R^B is present and p equals two, wherein when R^A is hydrogen or C1 – C3 alkyl, at least one R^B is deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl, $-CH_2NHC(O)C1$ – C3 alkyl or heterocyclylalkyl, wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl; or when each R^B is hydrogen, then R^A is deuterium, cyano, halogen, haloalkyl, $-C(O)N(R^5)_2$, hydroxyalkyl or heteroalkyl.

2. The compound of claim 1, wherein R^1-X is:



wherein the piperazinyl ring is optionally substituted with R^8.

3. The compound of claim 2, wherein R^1 is $-C(O)C(R^A)\overset{\text{- - - - - -}}{\equiv}C(R^B)_p$.

4. The compound of claim 3, wherein $\overset{\text{- - - - - -}}{\equiv}$ is a triple bond and R^A is absent, p is one and R^B is hydroxyalkyl or C1 – C3 alkoxy.

5. The compound of claim 3, wherein $\overset{\text{- - - - - -}}{\equiv}$ is a double bond and R^A is hydrogen, p is two and at least one R^B is independently deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or C1 – C3 alkyl.

6. The compound of claim 5, wherein the at least one R^B is halogen.

7. The compound of claim 5, wherein the at least one R^B is haloalkyl.

8. The compound of claim 5, wherein the at least one R^B is $-ZNR^5R^{11}$.

9. The compound of claim 8, wherein Z is methylene, R^5 is methyl and R^{11} is trifluoromethyl.

10. The compound of claim 5, wherein the at least one R^B is cyano.

11. The compound of claim 5, wherein the at least one R^B is hydroxyalkyl.

12. The compound of claim 5, wherein the at least one R^B is heteroalkyl.

13. The compound of claim 12, wherein the heteroalkyl is methoxymethyl.

14. The compound of claim 5, wherein the at least one R^B is $-C(O)N(R^5)_2$, wherein each R^5 is hydrogen.

15. The compound of claim 5, wherein the at least one R^B is $-C(O)N(R^5)_2$, wherein each R^5 is C1 – C3 alkyl.

16. The compound of claim 5, wherein the at least one R^B is heteroaryl optionally substituted with one or more R^7.

17. The compound of claim 16, wherein the heteroaryl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each substituted with one or more R^7.

18. The compound of claim 5, wherein the at least one R^B is heteroarylalkyl optionally substituted with one or more R^7.


19. The compound of claim 18, wherein the heteroaryl portion of the heteroarylalkyl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl, each optionally substituted with one or more R^7.

20. The compound of claim 5, wherein the at least one R^B is heterocyclylalkyl substituted with one or more R^7.

21. The compound of claim 20, wherein the heterocyclyl portion of the heterocyclylalkyl is azetindinyl, pyrrolidinyl, piperidinyl piperazinyl or morpholinyl, each substituted with one or more groups independently selected from halogen, hydroxyl, alkoxy or C1 – C3 alkyl.

22. The compound according to any of claims 5-21, wherein the double bond is in the E configuration..

23. The compound according to any of claims 5-21, wherein the double bond is in the Z configuration..

24. The compound of claim 5, wherein  is a double bond and p is two, each R^B is hydrogen, and R^A is deuterium, cyano, halogen, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl.

25. The compound of claim 24, wherein R^A is halogen.

26. The compound of claim 24, wherein R^A is haloalkyl.

27. The compound of claim 24, wherein R^A is cyano.

28. The compound of claim 24, wherein R^A is heteroalkyl.


29. The compound of claim 28, wherein the heteroalkyl is methoxymethyl.


30. The compound of claim 28, wherein the heteroalkyl is alkoxy.

31. The compound of claim 24, wherein R^A is $-C(O)N(R^5)_2$, wherein each R^5 is hydrogen.

32. The compound of claim 24, wherein R^A is hydroxyalkyl.

33. The compound of claim 2, wherein is a double bond and p is two, one R^B is hydrogen, the second R^B is dialkylaminylalkyl, and R^A is halogen.

34. The compound of claim 2, wherein  is a double bond and p is two, each R^B is deuterium, and R^A is deuterium.

35. The compound of claim 2, wherein when  is a double bond and p is two, one R^B is hydrogen and R^A and one R^B and the carbon atoms to which they are attached form a 5-8 membered partially saturated cycloalkyl substituted with oxo.

36. The compound of according to any one of claims 2-35, wherein Y is O.

37. The compound according to any one of claims 2-36, wherein R^2 is selected from the group consisting of hydroxyalkyl, alkylaminylalkyl, dialkylaminylalkyl, $-ZNR^5R^{10}$, heterocyclyl and heterocyclylalkyl, wherein each of the Z, heterocyclyl or heterocyclylalkyl are independently optionally substituted with R^9.

38. The compound of claim 37, wherein R^2 is heterocyclylalkyl optionally substituted with one or more R^9.

39. The compound of claim 38, wherein the heterocyclyl of the heterocyclylalkyl is independently azetidinyl, methylazetidinyl, ethylazetidinyl, isopropylazetidinyl, difluoroazetidinyl, cyclopropylazetidinyl, tertrahydropyranylazetidinyl, tetrahydropyranyl, pyrrolidinyl, methylpyrrolidinyl, dimethylpyrrolidinyl, isopropylpyrrolidinyl, cycloalkylalkylpyrrolidinyl, hydroxypyrrolindinyl, fluoropyrrolidinyl, difluoropyrrolidinyl, (N-methyl)fluoropyrrolidinyl, (N-methyl)difluoropyrrolidinyl, methoxyethylpyrrolidinyl, (N-methyl)methoxypyrrolidinyl, piperazinyl, dimethylaminylpyrrolidinyl, pyrrolidinone, methylpyrrolidinone, morpholinyl, methylmorpholinyl, ethylmorpholinyl, isopropylmorpholinyl, oxetanyl, 1,4-oxazepanyl, piperdinyl, methylpiperidinyl acylpiperdinyl, cyanopiperdinyl, cycloalkylpiperdinyl, halopiperdinyl, dihalopiperdinyl, fluoropiperdinyl, difluoropiperdinyl, alkoxypiperdinyl, pyrrolidonyl, piperidinonyl, tetrahydropyrrolizinyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, oxa-5-azabicyclo[2.2.1]heptan-5-yl, or azabicyclo[2.2.1]heptan-2-yl.

40. The compound of claim 39, wherein the (N-methyl)difluoropyrrolidinyl is 3,3-difluoro-1-methylpyrrolidinyl.

41. The compound of claim 39, wherein the heterocyclyl is N-methylpyrrolidinyl.

42. The compound of claim 37, wherein R^2 is dialkylaminylalkyl optionally substituted with one or more R^9.

43. The compound according to any one of claims 2-42, wherein R^4 is aryl optionally substituted with one or more R^7.

44. The compound of claim 43, wherein the aryl is selected from the group consisting of phenyl and naphthyl optionally substituted with one or more R^7.

45. The compound of claim 44, wherein the phenyl and the naphthyl are each optionally substituted with one or more R^7 selected from the group consisting of halogen, hydroxyl, C1- C6 alkyl, haloalkyl, Q-haloalkyl, and alkoxy.

46. The compound of claim 45, wherein R^7 is selected from the group consisting of halogen, haloalkyl, methyl, isopropyl, methoxy, Q-haloalkyl, hydroxyl and cyano.

47. The compound according to any one of claims 2-42, wherein R^4 is heteroaryl.

48. The compound according to any one of claims 2-42, wherein R^4 is aralkyl optionally substituted with one or more R^7.

49. The compound according to any one of claims 2-48, wherein m is zero.

50. The compound according to any one of claims 2-49, wherein L is a bond.


51. The compound according to any one of claims 2-50, wherein R^8 is heteroalkyl, C2-C4 alkynyl, or C1 – C3alkyl optionally substituted with -OR^5, cyano or heteroaryl.


52. The compound of claim 51, wherein R^8 is C1 – C3 alkyl optionally substituted with cyano.


53. The compound of claim 51, wherein R^8 is cyanomethyl.

54. The compound according to any one of claims 51-53, wherein X is substituted with one R^8.


55. The compound of claim 1, wherein the compound is:










,



,











,






















,

,

,

,

,

,






















,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,



,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,














































,

,

,

,

,

,

,

,

,












,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,










































,

,

,

,

,

,

,

,

,





56. The compound of claim 1, wherein the compound is of Formula II-A:



Formula II-A

wherein the piperazinyl ring is optionally substituted with R^8, where R^1, R^3, R^4, R^5, R^8, R^{10}, L and m are as defined in claim 1 and R^{11} is hydrogen, methyl or hydroxyalkyl.

57. The compound of claim 56, wherein R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ and ------ is a double bond and R^A is hydrogen, p is two and at least one R^B is independently deuterium, cyano.

halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, -ZNR^{5}R^{11}, -C(O)N(R^5)$_2$, -NHC(O)C1 – C3 alkyl or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy or C1 – C3 alkyl.

58. The compound of claim 56, wherein R^1 is –C(O)C(R^A) ------ C(R^B)$_p$ and ------ is a double bond, each R^B is hydrogen, and R^A is deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, -C(O)N(R^5)$_2$, or hydroxyalkyl.

59. The compound according to any of claims 57-58, wherein R^5 and R^{10} are each C1 – C3 alkyl.


60. The compound of claim 59, wherein R^{11} is methyl.

61. The compound of claim 59, wherein R^8 is heteroalkyl, C2-C4 alkynyl, or C1 – C3 alkyl optionally substituted with -OR^5, cyano or heteroaryl.

62. The compound according to any one of claims 54-61, wherein L is a bond, and R^4 is aryl or heteroaryl, each optionally substituted with one or more R^6, R^7 or R^8.

63. The compound of claim 62, wherein the aryl or heteroaryl are substituted with one or more R^7 independently selected from hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy.

64. The compound of claim 1, wherein the compound is of Formula II-B:



Formula II-B

where the piperazinyl ring is optionally substituted with R^8, and R^1, R^3, R^4, R^8, L and m are as defined in claim 1.

65. The compound of claim 64, wherein R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ and ------ is a double bond and R^A is hydrogen, p is two and at least one R^B is independently deuterium, cyano, halogen, haloalkyl, hydroxyalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, $-ZNR^5R^{11}$, $-C(O)N(R^5)_2$, -NHC(O)C1 – C3 alkyl or heterocyclylalkyl wherein the heterocyclyl portion is substituted with one or more substituents independently selected from halogen, hydroxyl, alkoxy and C1 – C3 alkyl.

66. The compound of claim 64, wherein R^1 is $-C(O)C(R^A)$ ------ $C(R^B)_p$ and ------ is a double bond, each R^B is hydrogen, and R^A is deuterium, cyano, halogen, C1 - C-3 alkyl, haloalkyl, heteroalkyl, $-C(O)N(R^5)_2$, or hydroxyalkyl.

67. The compound according to any one of claims 65-66, wherein R^2 is heterocyclylalkyl optionally substituted with one or more R^9.

68. The compound of claim 67, wherein the heterocyclyl portion of the heterocyclylalkyl is pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 1,4-oxazepanyl, thiomorpholinyl-1,1-dioxide, 3-azabicyclo[3.1.0]hexanyl, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, or azabicyclo[2.2.1]heptan-2-yl, each optionally substituted with one or more R^9.

69. The compound of claim 68, wherein each R^9 is independently acyl, oxo, halogen, cyano, C1 – C6 alkyl, hydroxyalkyl, heteroalkyl, cycloalkyl, aralkyl or dialkylamidoalkyl.

70. The compound of claim 69, wherein each R^9 is independently C1-C6 alkyl, heteroalkyl, or halogen.

71. The compound according to any one of claims 65-70, wherein the heterocyclyl is pyrrolidinyl optionally substituted with one or more R^9.

72. The compound of claim 71, wherein the heterocyclyl is 3,3-difluoro-1-methylpyrrolidinyl.

73. The compound of claim 72, wherein R^8 is heteroalkyl, C2-C4 alkynyl, or C1 – C3alkyl optionally substituted with $-OR^5$, cyano or heteroaryl.

74. The compound of claim 73, wherein R^8 is C1-C3 alkyl optionally substituted with cyano.

75. The compound according to any one of claims 65-74, wherein L is a bond and R^4 is aryl or heteroaryl, each optionally substituted with one or more R^6, R^7 or R^8.

76. The compound of claim 75, wherein the aryl or heteroaryl are substituted with one or more R^7 independently selected from hydroxyl, amino, halogen, C1 – C3 alkyl, haloalkyl, Q-haloalkyl, cycloalkyl and alkoxy.

77. The compound according to any one of claims 75-76, wherein R^4 is aryl optionally substituted with one or more R^6 or R^7.

78. The compound according to claim 77, wherein R^4 is phenyl or naphthyl, each optionally substituted with one or more R^6 or R^7.

79. The compound according to claim 77, wherein R^4 is optionally substituted with one or more R^7 independently selected from halogen, C1-C6 alkyl, and haloalkyl.

80. The compound according to any one of claims 65-79, wherein m is zero.

81. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of Formula (II), Formula II-A or Formula II-B according to any one of claims 1-80, and a pharmaceutically acceptable excipient.

82. A method for inhibiting KRas G12C activity in a cell, comprising contacting the cell in which inhibition of KRas G12C activity is desired with an effective amount of a compound of Formula (II), Formula II-A or Formula II-B according to any one of claims 1-80, pharmaceutically acceptable salts thereof or pharmaceutical compositions containing the compound of Formula (II), Formula II-A or Formula II-B, or pharmaceutically acceptable salt thereof.

83. A method for treating cancer comprising administering to a patient having cancer a therapeutically effective amount of a compound of Formula (II), Formula II-A or Formula II-B, or a pharmaceutically acceptable salt thereof according to any one of claims 1-80, alone or combined with a pharmaceutically acceptable carrier, excipient or diluents.

84. The method of claim 83, wherein the therapeutically effective amount of the compound is between about 0.01 to 100 mg/kg per day.

85. The method of claim 84, wherein the therapeutically effective amount of the compound is between about 0.1 to 50 mg/kg per day.

86. The method of claim 83, wherein the cancer is selected from the group consisting of Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Biliary tract: gall bladder carcinoma, ampullary carcinoma, cholangiocarcinoma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial `carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous

cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma.

87. The method of claim 86, wherein the cancer wherein the cancer is a KRas G12C-associated cancer.

88. The method of claims 83-87, wherein the cancer is non-small cell lung cancer.

89. A method for treating cancer in a patient in need thereof, the method comprising (a) determining that the cancer is associated with a KRas G12C mutation (e.g., a KRas G12C-associated cancer); and (b) administering to the patient a therapeutically effective amount of a compound of Formula (II), Formula II-A or Formula II-B or a pharmaceutically acceptable salt thereof according to any one of claims 1-80, or a pharmaceutical composition thereof.